PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	SC	GA	UT	PM	OA	HC	HP	DAJ	Goodman, SR; Smiley, RM; Negron, MA; Freedman, PA; Landau, R				Goodman, Stephanie R.; Smiley, Richard M.; Negron, Maria A.; Freedman, Paula A.; Landau, Ruth			A Randomized Trial of Breakthrough Pain During Combined Spinal-Epidural Versus Epidural Labor Analgesia in Parous Women	ANESTHESIA AND ANALGESIA			English	Article							NEURAXIAL ANALGESIA; DURAL PUNCTURE; BUPIVACAINE; ANESTHESIA; LIDOCAINE; MECHANISM; MORPHINE; NEEDLE	BACKGROUND: There is controversy regarding the benefits and risks of combined spinal-epidural compared with epidural analgesia (CSE, EPID) for labor analgesia. We hypothesized that CSE would result in fewer patient requests for top-up doses compared to EPID. METHODS: One-hundred ASA physical status I or II parous women at term in early labor (<5 cm cervical dilation) requesting analgesia were randomized in double-blind fashion to the EPID group (epidural bupivacaine 2.5 mg/mL, 3 mL, followed by bupivacaine 1.25 mg/mL, 1.0 mL with fentanyl 50 mu g) or the CSE group (intrathecal bupivacaine 2.5 mg with fentanyl 2 mu g). Both groups received identical infusions of bupivacaine 0.625 mg/mL with fentanyl 2 mu g/mL at 12 mL/h. The primary outcome variable was the number of top-up doses requested to treat breakthrough pain. RESULTS: There was no significant difference between the two groups in the percentage of patients requesting top-up doses (44%, CSE vs 51% EPID; 95% confidence interval of the difference -280% to +14%) nor in the need for multiple top-up doses (1.4% CSE vs 15%, EPID). Visual analog scale scores were lower in the CSE group compared to the EPID group at 10 min after initiation of analgesia [median 0 cm (0, 0) vs 4 cm (1, 6) respectively, P < 0.001] and at 30 min [0 cm (0, 0) vs 0 cm (0, 1), respectively, P = 0.03]. CONCLUSIONS: We did not find a difference in the need for top-up doses in parous patients; however, CSE provided better analgesia in the first 30 min compared to EPID.	[Goodman, Stephanie R.] Columbia Univ, Med Ctr, Dept Anesthesiol, New York, NY 10032 USA	Goodman, SR (reprint author), Columbia Univ, Med Ctr, Dept Anesthesiol, 630 W 168th St,PH-5, New York, NY 10032 USA.	srg24@columbia.edu			Department of Anesthesiology, Columbia University	Supported by Department of Anesthesiology, Columbia University.	BERNARDS CM, 1994, ANESTHESIOLOGY, V80, P853, DOI 10.1097/00000542-199404000-00019; BLUMGART CH, 1992, BRIT J ANAESTH, V69, P457, DOI 10.1093/bja/69.5.457; Bucklin BA, 2002, REGION ANESTH PAIN M, V27, P23, DOI 10.1053/rapm.2002.29111; Dunn SM, 1998, ANESTH ANALG, V87, P331, DOI 10.1097/00000539-199808000-00018; Hepner DL, 2000, CAN J ANAESTH, V47, P232, DOI 10.1007/BF03018918; Hess PE, 2001, ANESTH ANALG, V93, P414; MacArthur C, 2001, LANCET, V358, P19; Norris MC, 2001, ANESTHESIOLOGY, V95, P913, DOI 10.1097/00000542-200110000-00020; Pan PH, 2004, INT J OBSTET ANESTH, V13, P227, DOI 10.1016/j.ijoa.2004.04.008; Polley LS, 2000, ANESTHESIOLOGY, V93, P122, DOI 10.1097/00000542-200007000-00022; Sia A. T., 2003, SMJ Singapore Medical Journal, V44, P464; SIMMONS SW, 2007, [No title captured], V3, DOI DOI 10.1002/14651858.CD003401.PUB2; Stienstra R, 1996, ANESTH ANALG, V83, P382, DOI 10.1097/00000539-199608000-00031; Stocks GM, 2001, ANESTHESIOLOGY, V94, P593, DOI 10.1097/00000542-200104000-00011; Swenson JD, 1996, ANESTH ANALG, V83, P523, DOI 10.1097/00000539-199609000-00014; Thomas JA, 2005, ANESTHESIOLOGY, V103, P1046, DOI 10.1097/00000542-200511000-00019; Tsen LC, 1999, ANESTHESIOLOGY, V91, P920, DOI 10.1097/00000542-199910000-00010; Vandermassen G, 2004, EUR J WOMENS STUD, V11, P9, DOI 10.1177/1350506804039812; Vartis A, 1998, ANAESTH INTENS CARE, V26, P256, DOI 10.1177/0310057X9802600304; Wong CA, 2005, NEW ENGL J MED, V352, P655, DOI 10.1056/NEJMoa042573	20	26	29	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	JAN	2009	108	1					246	251		10.1213/ane.0b013e31818f896f			6	Anesthesiology	Anesthesiology	387PB	WOS:000261963000038	19095858	Green Accepted			2020-06-30	J	Vasisht, N; Gever, LN; Tagarro, I; Finn, AL				Vasisht, Niraj; Gever, Larry N.; Tagarro, Ignacio; Finn, Andrew L.			Formulation Selection and Pharmacokinetic Comparison of Fentanyl Buccal Soluble Film with Oral Transmucosal Fentanyl Citrate A Randomized, Open-Label, Single-Dose, Crossover Study	CLINICAL DRUG INVESTIGATION			English	Article							BREAKTHROUGH PAIN; CANCER-PATIENTS; BIOAVAILABILITY; ABSORPTION; TITRATION; TABLET; TRIAL; OTFC	Background and Objectives: BioErodible MucoAdhesive (BEMA (R)) is a new transmucosal drug delivery system designed to improve and ease the administration of drugs by this route. The first product that uses this novel delivery system contains fentanyl and is intended for the treatment of breakthrough pain in opioid-tolerant patients with cancer. The generic name is fentanyl buccal soluble film (FBSF). The objectives of this study were to compare the pharmacokinetic profile of FBSF formulations at three different pHs (pH 6, pH 7.25 and pH 8.5) and to understand the differences in the pharmacokinetics of fentanyl from FBSF compared with that of oral transmucosal fentanyl citrate (OTFC). Methods: This was a randomized, open-label, single-dose, four-period, Latin-square crossover study consisting of a 9-day inpatient treatment period. The study was conducted at a phase I clinical research unit in Austin, TX, USA. Twelve healthy subjects were enrolled, nine males and three females, between the ages of 21 and 44 years. Each subject received four 800 mu g doses of fentanyl: single doses of the three FBSF formulations (pH 6, pH 7.25 and pH 8.5) and OTFC, with concurrent naltrexone. Plasma fentanyl concentrations were measured over a 48-hour period after each study dose. Pharmacokinetic parameters were calculated and compared. Results: Peak plasma fentanyl concentrations (C-max) and overall fentanyl systemic exposure (area under the plasma concentration-time curve from time zero extrapolated to infinity [AUC(infinity)]) for each of the three FBSF formulations were greater than for OTFC. The pH 7.25 FBSF formulation provided the earliest time to reach C-max (t(max)) the highest C-max value and the greatest AUC(infinity) value. Compared with OTFC, peak plasma fentanyl concentrations with pH 7.25 FBSF were significantly higher (mean C-max 1.67 vs 1.03 ng/mL; p < 0.05). Overall exposure was also greater with pH 7.25 FBSF than with OTFC (mean AUC(infinity) 14.5 vs 10.3 ng . h/mL). Conclusions: All three FBSF formulations produced greater peak plasma concentrations and overall exposure to fentanyl than OTFC. In particular, the pH 7.25 FBSF formulation showed the most favourable pharmacokinetic profile of the three FBSF formulations. In comparison with OTFC, the pH 7.25 FBSF formulation produced the fastest and most efficient fentanyl delivery and was selected for further clinical development.	[Vasisht, Niraj; Finn, Andrew L.] BioDelivery Sci Int Inc, Raleigh, NC 27607 USA; [Gever, Larry N.] Meda Pharmaceut Inc, Somerset, NJ USA; [Tagarro, Ignacio] Meda Pharmaceut, Madrid, Spain	Finn, AL (reprint author), BioDelivery Sci Int Inc, 801 Corp Ctr Dr,Suite 210, Raleigh, NC 27607 USA.	afinn@bdsinternational.com			BioDelivery Sciences International	Funding for the design and conduct of this study, and for the collection, management and analysis of the resulting data, was provided by BioDelivery Sciences International. Funding for the preparation of the manuscript was provided by Meda Pharmaceuticals. Drs Vasisht and Finn are employees and shareholders of BioDelivery Sciences International. Drs Gever and Tagarro are employees of Meda Pharmaceuticals.; The authors would like to thank Lew Fredane (Meda Pharmaceuticals), Bill Wheeler (Meda Pharmaceuticals) and Bill Wargin (PK-PM Associates, LLC) for their assistance with and input into this manuscript.	BENNETT D, 2005, [No title captured], V30, P296; *BIODELIVERY SCI I, 2005, DAT FIL; *CEPH INC, 2007, ACT PACK INS; *CEPH INC, 2007, FENT PACK INS; Chandler S, 1999, Am J Hosp Palliat Care, V16, P489, DOI 10.1177/104990919901600213; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Darwish M, 2007, J CLIN PHARMACOL, V47, P343, DOI 10.1177/0091270006297749; Darwish M, 2006, CLIN PHARMACOKINET, V45, P843, DOI 10.2165/00003088-200645080-00006; Davies AN, 2006, BRIT J HOSP MED, V67, P414, DOI 10.12968/hmed.2006.67.8.21960; Durfee S, 2006, AM J DRUG DELIV, V4, P1, DOI DOI 10.2165/00137696-200604010-00001; Farrar JT, 1998, JNCI-J NATL CANCER I, V90, P611, DOI 10.1093/jnci/90.8.611; Food and Drug Administration, 2003, GUID IND BIOAV BIOEQ; Gordon D, 2008, J PALLIAT MED, V11, P633, DOI 10.1089/jpm.2008.9922; Hanks GW, 2004, PALLIATIVE MED, V18, P698, DOI 10.1191/0269216304pm966oa; McCarberg BH, 2007, PAIN MED, V8, pS8; Mercadante S, 2002, CANCER, V94, P832, DOI 10.1002/cncr.10249; *METR LIF INS CO, 1999, METR HEIGHT WEIGHT T; Mystakidou Kyriaki, 2005, J Opioid Manag, V1, P36; Payne R, 2007, PAIN MED, V8, pS3; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, PAIN, V79, P303, DOI 10.1016/S0304-3959(98)00179-1; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Slatkin Neal E, 2007, J Support Oncol, V5, P327; STREISAND JB, 1995, ANESTHESIOLOGY, V82, P759, DOI 10.1097/00000542-199503000-00018; STREISAND JB, 1991, ANESTHESIOLOGY, V75, P223, DOI 10.1097/00000542-199108000-00009	25	28	29	0	5	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	1173-2563	1179-1918		CLIN DRUG INVEST	Clin. Drug Invest.		2009	29	10					647	654		10.2165/11315300-000000000-00000			8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	497XT	WOS:000270099100003	19715381				2020-06-30	J	Zesiewicz, TA; Hauser, RA; Freeman, A; Sullivan, KL; Miller, AM; Halim, T				Zesiewicz, Theresa A.; Hauser, Robert A.; Freeman, Alan; Sullivan, Kelly L.; Miller, Amber M.; Halim, Tariq			Fentanyl-Induced Bradykinesia and Rigidity After Deep Brain Stimulation in a Patient With Parkinson Disease	CLINICAL NEUROPHARMACOLOGY			English	Review						fentanyl; Parkinson disease; rigidity; deep brain stimulation	SUBTHALAMIC NUCLEUS STIMULATION; PROPOFOL-INDUCED DYSKINESIAS; MUSCLE-RELAXANTS; ANESTHESIA; ALFENTANIL; REMIFENTANIL; SURGERY; RAT; DEXMEDETOMIDINE; MECHANISMS	A 58-year-old man with advanced Parkinson disease underwent battery replacement for a deep brain stimulator and experienced severe bradykinesia and rigidity postoperatively for 36 hours. The patient was administered fentanyl as an anesthetic during the procedure and as an analgesic periodically during the day after surgery. The severe bradykinesia and rigidity persisted despite reactivation of the deep brain stimulator and immediate reinstitution of Parkinson disease medications, but resolved completely several hours after discontinuation of fentanyl.	[Zesiewicz, Theresa A.; Hauser, Robert A.; Sullivan, Kelly L.; Miller, Amber M.; Halim, Tariq] Univ S Florida, Natl Parkinsons Fdn, Ctr Excellence,Neurosci Program, Dept Mol Therapeut,Dept Neurol,Parkinsons Dis & M, Tampa, FL 33612 USA; [Freeman, Alan] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA	Zesiewicz, TA (reprint author), Univ S Florida, Natl Parkinsons Fdn, Ctr Excellence,Neurosci Program, Dept Mol Therapeut,Dept Neurol,Parkinsons Dis & M, 12901 Bruce B Downs Blvd,MDC Box 55, Tampa, FL 33612 USA.	tzesiewi@hsc.usf.edu	Sullivan, Kelly/I-5659-2012; Hauser, Robert/I-5372-2012				BENTHUYSEN JL, 1986, ANESTHESIOLOGY, V64, P440, DOI 10.1097/00000542-198604000-00005; Boucai L, 2004, BRIT J NEUROSURG, V18, P213, DOI 10.1080/02688690410001732625; Bpharm SR, 2003, CAN J ANAESTH, V50, P32, DOI 10.1007/BF03020183; COMSTOCK MK, 1981, ANESTH ANALG, V60, P362; Dagtekin O, 2006, ANESTH ANALG, V103, P784, DOI 10.1213/01.ANE.0000227157.50757.AE; Davies RG, 2005, BRIT J ANAESTH, V95, P424, DOI 10.1093/bja/aei579; Deogaonkar A, 2006, ANESTHESIOLOGY, V104, P1337, DOI 10.1097/00000542-200606000-00029; DERYCK M, 1983, EXP NEUROL, V79, P54, DOI 10.1016/0014-4886(83)90378-3; Esselink RAJ, 2004, NEUROLOGY, V62, P201, DOI 10.1212/01.WNL.0000103235.12621.C3; Furuya R, 1998, ANESTHESIOLOGY, V89, P261, DOI 10.1097/00000542-199807000-00035; Goetz CG, 2005, MOVEMENT DISORD, V20, P523, DOI 10.1002/mds.20464; Guridi J, 1999, NEUROSURGERY, V45, P278, DOI 10.1097/00006123-199908000-00017; Harrison C, 1998, BRIT J ANAESTH, V81, P20; Hertel F, 2006, NEUROSURGERY, V59, P1138; Joshi GP, 2002, J CLIN ANESTH, V14, P494, DOI 10.1016/S0952-8180(02)00404-X; KERZ T, 1992, ANAESTHESIST, V41, P426; Khalil SN, 1998, J CLIN ANESTH, V10, P469, DOI 10.1016/S0952-8180(98)00072-5; Khatib R, 2008, J NEUROSURG ANESTH, V20, P36, DOI 10.1097/ANA.0b013e318157a15a; Klemola UM, 2000, ACTA ANAESTH SCAND, V44, P465, DOI 10.1034/j.1399-6576.2000.440419.x; Krauss JK, 1996, ANESTH ANALG, V83, P420, DOI 10.1097/00000539-199608000-00037; Lang E, 1996, ANESTHESIOLOGY, V85, P721, DOI 10.1097/00000542-199610000-00006; Maltete D, 2004, ARCH NEUROL-CHICAGO, V61, P390, DOI 10.1001/archneur.61.3.390; NEGUS SS, 1993, J PHARMACOL EXP THER, V264, P739; PASERO C, 1999, PAIN CLIN MANUAL, P161; Peckys D, 1999, NEUROSCIENCE, V88, P1093, DOI 10.1016/S0306-4522(98)00251-6; RONKEN E, 1993, J NEUROCHEM, V61, P1634, DOI 10.1111/j.1471-4159.1993.tb09797.x; Rozet I, 2006, ANESTH ANALG, V103, P1224, DOI 10.1213/01.ane.0000239331.53085.94; SANFORD TJ, 1994, J CLIN ANESTH, V6, P473, DOI 10.1016/0952-8180(94)90087-6; Sarne Y, 1996, NEUROCHEM RES, V21, P1353, DOI 10.1007/BF02532376; Slaughter A, 2002, AM J NURS, V102, P75, DOI 10.1097/00000446-200205000-00040; *THOMPS PDR, 2006, PHYS DESK REF; Thompson JP, 1996, BRIT J ANAESTH, V76, P341; Venuti F S, 1989, Minerva Anestesiol, V55, P259; Yamada K, 2007, PARKINSONISM RELAT D, V13, P101, DOI 10.1016/j.parkreldis.2006.07.008	34	18	20	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0362-5664	1537-162X		CLIN NEUROPHARMACOL	Clin. Neuropharmacol.	JAN-FEB	2009	32	1					48	50		10.1097/WNF.0b013e31817e23e3			3	Clinical Neurology; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	406HK	WOS:000263285400010	19471184				2020-06-30	J	Walter, C; Felden, L; Lotsch, J				Walter, Carmen; Felden, Lisa; Loetsch, Joern			Bioequivalence Criteria for Transdermal Fentanyl Generics Do These Need a Relook?	CLINICAL PHARMACOKINETICS			English	Article							AVAILABLE RESERVOIR FORMULATION; RESPIRATORY DEPRESSION; COMPARATIVE PHARMACODYNAMICS; DRUG-INTERACTIONS; DELIVERY-SYSTEM; CANCER PAIN; PHARMACOKINETICS; PATIENT; ALFENTANIL; INFUSION	With the increasing appearance of transdermal fentanyl generics since 2004 when patent protection of the reference Duragesic (R) expired, opportunities to switch between different generics have arisen. Transdermal fentanyl is subject to bioequivalence regulation because only approximately 92% of the dose is absorbed as a result of the need to maintain a diffusion gradient from plaster to skin. Considering the high potency of fentanyl and the potential dangerous adverse effects of full V opioid receptor agonists, we assessed evidence suggesting a revision of the confidence limits of bioequivalence of 80-125%. A few cases have been reported where a prescribed ascension in transdermal fentanyl dosing triggered respiratory depression. Values of concentration that produce a 50% effective response for decreasing the ventilatory volume lie within the plasma concentration range of 1.4-2.5 ng/mL during transdermal fentanyl analgesia. However, an exchange of the reference with a generic with higher bioavailability would trigger respiratory depression only in extreme situations and is clinically supported by only a single case report. Experimental or clinical evidence is required to provide the necessary database for final judgement of bioequivalent limits of fentanyl generics. At present, the evidence is not sufficient to advise other bioequivalence criteria than those previously applied to transdermal fentanyl.	[Walter, Carmen; Felden, Lisa; Loetsch, Joern] Goethe Univ Frankfurt, Inst Clin Pharmacol, Pharmazentrum Frankfurt, ZAFES, D-60590 Frankfurt, Germany	Lotsch, J (reprint author), Goethe Univ Frankfurt, Inst Clin Pharmacol, Pharmazentrum Frankfurt, ZAFES, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	j.loetsch@em.uni-frankfurt.de		Lotsch, Jorn/0000-0002-5818-6958			BENTLEY JB, 1982, ANESTH ANALG, V61, P968; *BFARM, 2008, NEUES AUT IDEM REG I; Bleeker CP, 2001, EUR J PAIN-LONDON, V5, P325, DOI 10.1053/eujp.2000.0220; Breivik H, 2006, EUR J PAIN, V10, P287, DOI 10.1016/j.ejpain.2005.06.009; BROWN DL, 1985, CHEST, V88, P779, DOI 10.1378/chest.88.5.779; Byard Roger W, 2005, J Clin Forensic Med, V12, P29, DOI 10.1016/j.jcfm.2004.10.007; Carter KA, 2003, AM J HEALTH-SYST PH, V60, P191, DOI 10.1093/ajhp/60.2.191; Cashman JN, 2004, BRIT J ANAESTH, V93, P212, DOI 10.1093/bja/aeh180; Donner B, 1996, PAIN, V64, P527, DOI 10.1016/0304-3959(95)00180-8; FISET P, 1995, ANESTHESIOLOGY, V83, P459, DOI 10.1097/00000542-199509000-00004; Frolich M, 2001, ANESTH ANALG, V93, P647; GARRIOTT JC, 1983, J TOXICOL-CLIN TOXIC, V19, P987, DOI 10.3109/15563658208992530; GERBER N, 1993, J PEDIATR-US, V123, P322, DOI 10.1016/S0022-3476(05)81713-5; Gharagozlou Parham, 2003, BMC Pharmacol, V3, P1, DOI 10.1186/1471-2210-3-1; GOETZ AM, 1994, CRIT CARE MED, V22, P1579; HABERER JP, 1982, BRIT J ANAESTH, V54, P1267, DOI 10.1093/bja/54.12.1267; Henney JE, 1999, JAMA-J AM MED ASSOC, V282, P1995, DOI 10.1001/jama.282.21.1995-a; HILL HF, 1990, PAIN, V43, P69, DOI 10.1016/0304-3959(90)90051-E; *HLTH CAN THER PRO, 2006, GUID IND BIOCQ REQ C; *INT NARC CONTR BO, 2006, STAT INF NARC DRUGS; *J CIL GMBH, 2006, DUR SMAT FACH PRESCR; Koehntop DE, 1997, PHARMACOTHERAPY, V17, P746; Kuhlman JJ, 2003, J ANAL TOXICOL, V27, P499, DOI 10.1093/jat/27.7.499; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; Lotsch J, 2006, CLIN PHARMACOKINET, V45, P1051; Lotsch J, 2002, ANESTHESIOLOGY, V97, P814; Lotsch J, 2002, CLIN PHARMACOKINET, V41, P31, DOI 10.2165/00003088-200241010-00004; Luckenbill K, 2008, J ANAL TOXICOL, V32, P639, DOI 10.1093/jat/32.8.639; Marier JF, 2007, BRIT J CLIN PHARMACO, V63, P121, DOI 10.1111/j.1365-2125.2006.02758.x; Marier JF, 2006, J CLIN PHARMACOL, V46, P642, DOI 10.1177/0091270006286901; Martin TL, 2006, J ANAL TOXICOL, V30, P603, DOI 10.1093/jat/30.8.603; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; MCCLAIN DA, 1980, CLIN PHARMACOL THER, V28, P106, DOI 10.1038/clpt.1980.138; Mildh LH, 2001, ANESTH ANALG, V93, P939, DOI 10.1097/00000539-200110000-00028; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; Newshan G, 1998, J PAIN SYMPTOM MANAG, V16, P277; NWAKAMA PE, 2006, 12 ANN FDA SCI FOR A; *ORTHOMCNEALJANSSE, DUR FULL PRESCR INF; Piquet CY, 1998, ANN PHARMACOTHER, V32, P653, DOI 10.1345/aph.17182; Regnard C, 2003, PALLIATIVE MED, V17, P714, DOI 10.1191/0269216303pm838cr; Schwabe U, 2008, ARZNEIVERORDNUNGS RE, P232; SCOTT JC, 1991, ANESTHESIOLOGY, V74, P34, DOI 10.1097/00000542-199101000-00007; SCOTT JC, 1985, ANESTHESIOLOGY, V62, P234, DOI 10.1097/00000542-198503000-00005; SCOTT JC, 1987, J PHARMACOL EXP THER, V240, P159; SHAFER SL, 1990, ANESTHESIOLOGY, V73, P1091, DOI 10.1097/00000542-199012000-00005; SHAFER SL, 1991, ANESTHESIOLOGY, V74, P53, DOI 10.1097/00000542-199101000-00010; SOUTHAM MA, 1995, ANTI-CANCER DRUG, V6, P29, DOI 10.1097/00001813-199504003-00005; THIRSTRUP S, 2005, BIOEQUIVALENCE LABEL; *UK NHS INF CTR, PRESCR COST AN ENGL; VARVEL JR, 1989, ANESTHESIOLOGY, V70, P928, DOI 10.1097/00000542-198906000-00008; VOIGT R, 2006, PHARMAZEUTISCHE TECH, P461; Woodall KL, 2008, J FORENSIC SCI, V53, P222, DOI 10.1111/j.1556-4029.2007.00597.x; Yassen A, 2007, CLIN PHARMACOL THER, V81, P50, DOI 10.1038/sj.clpt.6100025	53	3	3	0	4	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	0312-5963	1179-1926		CLIN PHARMACOKINET	Clin. Pharmacokinet.		2009	48	10					625	633		10.2165/11317200-000000000-00000			9	Pharmacology & Pharmacy	Pharmacology & Pharmacy	505CN	WOS:000270666000001	19743885				2020-06-30	J	Taghizadeh, SM; Soroushnia, A; Mirzadeh, H; Barikani, M				Taghizadeh, Seyed Mojtaba; Soroushnia, Arezou; Mirzadeh, Hamid; Barikani, Mehdi			Preparation and In Vitro Evaluation of a New Fentanyl Patch Based on Acrylic/Silicone Pressure-Sensitive Adhesive Blends	DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY			English	Article						fentanyl; patch; central composite design; blend; pressure-sensitive adhesive	CRYSTALLIZATION; INDOMETHACIN; DELIVERY; SURFACE	In this study, the influence of the ratio of silicone (Si) to acrylic pressure-sensitive adhesive (PSA), polyvinyl pyrrolidone (PVP), and lauryl alcohol (LA) % (wt/wt) on the properties of a drug in adhesive patch containing 4% (wt/wt) fentanyl as model drug was evaluated. The dependent variables selected were drug solubility, in vitro drug release in the platforms as well as adhesion properties including peel strength and tack value. By using the central composite design of Design Expert software, it was found that the effect of each factor was different, yet all had influenced dependent variables significantly (p .05). Quadratic model generated for various response variables using backward regression analysis was found to be statistically significant (p .05). It was deduced that the presence of PVP and Si displayed similar trends on drug solubility and release. Each role played by Si with LA and PVP in release rate was separately investigated, and it was found that the presence of PVP and LA in lowering the amount of drug released was more dominant compared with that of Si. The release patterns at the early and later stages follow the Higuchi and semiempirical models, respectively. Effect of PVP as well as Si and LA were similar on tack value. The influence of LA compared to peeling characteristics of Si system was more pronounced.	[Mirzadeh, Hamid] Iran Polymer & Petrochem Inst, Dept Polymer Biomat, Fac Sci, Tehran, Iran; [Taghizadeh, Seyed Mojtaba; Soroushnia, Arezou] Iran Polymer & Petrochem Inst, Novel Drug Delivery Syst, Fac Sci, Tehran, Iran; [Barikani, Mehdi] Iran Polymer & Petrochem Inst, Dept Polyurethane, Fac Sci, Tehran, Iran	Mirzadeh, H (reprint author), Iran Polymer & Petrochem Inst, Dept Polymer Biomat, Fac Sci, POB 14965-115, Tehran, Iran.	h.mirzadeh@ippi.ac.ir	Mirzadeh, Hamid/L-5856-2019	Mirzadeh, Hamid/0000-0002-9821-1759; Barikani, Mehdi/0000-0002-6553-982X			Aymonier A, 2003, J COLLOID INTERF SCI, V268, P341, DOI 10.1016/S0021-9797(03)00701-X; BAGHERI H, 2006, J PHARM BIOMED ANAL, V43, P1763; Ben-Zion O, 2003, J APPL POLYM SCI, V87, P2130, DOI 10.1002/app.11587; BOSTEDT KT, 2004, [No title captured], Patent No. 2004001882; Chau KW, 2004, J POLYM SCI POL PHYS, V42, P3013, DOI 10.1002/polb.20187; COLAS ARL, 2005, Patent No. 6846508; del Consuelo ID, 2007, J CONTROL RELEASE, V122, P135, DOI 10.1016/j.jconrel.2007.05.017; DUNBAR D, 2000, [No title captured], Patent No. 6162456; FORD JL, 1986, PHARM ACTA HELV, V61, P69; Goulding T. M., 1994, HDB ADHESIVE TECHNOL, P549; Guyot M, 2000, INT J PHARM, V204, P171, DOI 10.1016/S0378-5173(00)00494-4; HUYNH NH, 2004, J PHARM BIOMED ANAL, V37, P1095; Jovanovic R, 2004, MACROMOL MATER ENG, V289, P467, DOI 10.1002/mame.200300355; Kandavilli S., 2002, PHARM TECHNOL, P62; Kim JS, 2007, CHEM PHARM BULL, V55, P936, DOI 10.1248/cpb.55.936; Kiortsis S, 2005, EUR J PHARM BIOPHARM, V59, P73, DOI 10.1016/j.ejpb.2004.05.004; Lau C, 2002, POLYMER, V43, P823, DOI 10.1016/S0032-3861(01)00641-3; Lin SB, 2007, J ADHES SCI TECHNOL, V21, P605, DOI 10.1163/156856107781192274; Mehdizadeh Amir, 2006, Acta Pharmaceutica (Zagreb), V56, P219; Mehdizadeh Amir, 2004, Acta Pharmaceutica (Zagreb), V54, P301; MILLER KJ, 2006, [No title captured], Patent No. 20060210617; Miranda J, 1999, Patents, Patent No. [US5958446 A, 5958446]; MIRANDA J, 2001, [No title captured], Patent No. 6221383; Moon SH, 2005, REV SCI INSTRUM, V76, DOI 10.1063/1.1906105; MULLER W, 2004, Patent No. 20040234583; Papadokostaki KG, 1998, J CONTROL RELEASE, V54, P251, DOI 10.1016/S0168-3659(97)00158-2; ROY SD, 1991, J PHARM SCI, V85, P491; SEKIKAWA H, 1978, CHEM PHARM BULL, V26, P118; Singh B, 2006, AAPS PHARMSCITECH, V7, DOI 10.1208/pt070103; Sloan PA, 1998, J PAIN SYMPTOM MANAG, V16, P102, DOI 10.1016/S0885-3924(98)00044-X; STEFANO FJE, 2003, Patent No. 03097008; Tan HS, 1999, PHARM SCI TECHNOL TO, V2, P60, DOI 10.1016/S1461-5347(99)00119-4; Taylor LS, 1997, PHARMACEUT RES, V14, P1691, DOI 10.1023/A:1012167410376; Yang H, 2006, POLYMER, V47, P3889, DOI 10.1016/j.polymer.2006.02.081; YOSHIOKA M, 1995, J PHARM SCI, V84, P983, DOI 10.1002/jps.2600840814	35	12	12	1	21	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0363-9045	1520-5762		DRUG DEV IND PHARM	Drug Dev. Ind. Pharm.		2009	35	4					487	498	PII 906181123	10.1080/03639040802448638			12	Chemistry, Medicinal; Pharmacology & Pharmacy	Pharmacology & Pharmacy	419ET	WOS:000264202600011	19043820				2020-06-30	J	Maragalkis, LL; Chaiwarith, R; Srinivasan, A; Torriani, FJ; Avdic, E; Lee, A; Ross, TR; Carroll, KC; Perl, TM				Maragalkis, Lisa L.; Chaiwarith, Romanee; Srinivasan, Arjun; Torriani, Francesca J.; Avdic, Edina; Lee, Andrew; Ross, Tracy R.; Carroll, Karen C.; Perl, Trish M.			Sphingomonas paucimobilis Bloodstream Infections Associated with Contaminated Intravenous Fentanyl	EMERGING INFECTIOUS DISEASES			English	Article							COMPOUNDING PHARMACY; OUTBREAK; CHAPTER-797; BACTEREMIA; FDA	Nationally distributed medications from compounding pharmacies, which typically adhere to less stringent quality-control standards than pharmaceutical manufacturers, can lead to multistate outbreaks. We investigated a cluster of 6 patients in a Maryland hospital who had Sphingomonas paucimobilis bloodstream infections in November 2007. Of the 6 case-patients, 5 (83%) had received intravenous fentanyl within 48 hours before bacteremia developed. Cultures of unopened samples of fentanyl grew S. paucimobilis; the pulsed-field gel electrophoresis pattern was indistinguishable from that of the isolates of 5 case-patients. The contaminated fentanyl lot had been prepared at a compounding pharmacy and distributed to 4 states. Subsequently, in California, S. paucimobilis bacteremia was diagnosed for 2 patients who had received intravenous fentanyl from the same compounding pharmacy. These pharmacies should adopt more stringent quality-control measures, including prerelease product testing, when compounding and distributing large quantities of sterile preparations.	[Maragalkis, Lisa L.] Johns Hopkins Univ, Div Infect Dis, Sch Med, Dept Hosp Epidemiol & Infect Control, Baltimore, MD 21287 USA; [Chaiwarith, Romanee] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD 21287 USA; [Srinivasan, Arjun] Ctr Dis Control & Prevent, Atlanta, GA USA; [Torriani, Francesca J.] Univ Calif San Diego, San Diego, CA 92103 USA	Maragalkis, LL (reprint author), Johns Hopkins Univ, Div Infect Dis, Sch Med, Dept Hosp Epidemiol & Infect Control, 600 N Wolfe St,Osler 425, Baltimore, MD 21287 USA.	lmaraga1@jhmi.edu			Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [1 K01 CI000300, 1 R01 C1000530]	We thank Beryl Rosenstein, Margaret Garrett, Jeff Natterman, Alex Shangraw, Ernest Feroli, Teresa Wakefield, Kimberly Eskey, Mark Romagnoli, and members of the Microbiology Laboratory, Risk Management, Facilities, Pharmacy, and Security Departments of The Johns Hopkins Hospital; we also thank Laura Herrera, Mary Grace Munoz, and David Blythe.; L.L.M. was supported by grants 1 K01 CI000300 and 1 R01 C1000530 from the Centers for Disease Control and Prevention.; Dr Maragakis is an assistant professor of medicine in the Division of Infectious Diseases at the Johns Hopkins University School of Medicine. She is also an associate hospital epidemiologist at The Johns Hopkins Hospital. Her research interest is healthcare-associated grani-negative infections.	Adams WE, 2006, J CATARACT REFR SURG, V32, P1238, DOI 10.1016/j.jcrs.2006.01.094; Anonymous, 2005, Morbidity and Mortality Weekly Report, V54, P269; [Anonymous], 2000, Am J Health Syst Pharm, V57, P1150; Candy TA, 2006, AM J HEALTH-SYST PH, V63, P1336, DOI 10.2146/ajhp050447; *CDCP, 2002, MMWR-MORBID MORTAL W, V51, P1109; Civen R, 2006, CLIN INFECT DIS, V43, P831, DOI 10.1086/507336; GALSON S, 2003, STATEMENT SENATE COM; Harteker L. R., 2001, AM J HEALTH-SYST PH, V58, P640; Harteker L. R., 2001, AM J HEALTH-SYST PH, V58, P643; Harteker LR, 2001, AM J HEALTH-SYST PH, V58, P638, DOI 10.1093/ajhp/58.8.638; Held MR, 2006, PEDIATRICS, V118, pE212, DOI 10.1542/peds.2005-2617; Hsueh PR, 1998, CLIN INFECT DIS, V26, P676, DOI 10.1086/514595; Kastango ES, 2004, AM J HEALTH-SYST PH, V61, P1928, DOI 10.1093/ajhp/61.18.1928; Kilic A, 2007, JPN J INFECT DIS, V60, P394; Lemaitre D, 1996, J HOSP INFECT, V32, P199, DOI 10.1016/S0195-6701(96)90146-2; McHale J., 2006, Morbidity and Mortality Weekly Report, V55, P961; Morris AM, 2003, AM J HEALTH-SYST PH, V60, P2567, DOI 10.1093/ajhp/60.24.2567; Patel PR, 2006, JAMA-J AM MED ASSOC, V296, P2005, DOI 10.1001/jama.296.16.2005; Pegues DA, 2006, CLIN INFECT DIS, V43, P838, DOI 10.1086/507341; Perola O, 2002, J HOSP INFECT, V50, P196, DOI 10.1053/jhin.2001.1163; Perz JF, 2005, J CLIN MICROBIOL, V43, P5316, DOI 10.1128/JCM.43.10.5316-5318.2005; Schweitzer SO, 2008, NEW ENGL J MED, V358, P1773, DOI 10.1056/NEJMp0802041; Sunenshine RH, 2007, CLIN INFECT DIS, V45, P527, DOI 10.1086/520664; Tenover FC, 1997, INFECT CONT HOSP EP, V18, P426; *US FDA, 2002, GUID FDA STAFF IND C; *US FDA, 2008, FDA REG COMP DRUGS; *US FDA, 2004, [No title captured]; US Food and Drug Administration, REP LTD FDA SURV COM; *US PHARM, 2008, GUID PHARM COMP STER; Wood AJJ, 2008, NEW ENGL J MED, V358, P1774, DOI 10.1056/NEJMp0802227	30	37	41	0	2	CENTERS  DISEASE CONTROL & PREVENTION	ATLANTA	1600 CLIFTON RD, ATLANTA, GA 30333 USA	1080-6040	1080-6059		EMERG INFECT DIS	Emerg. Infect. Dis	JAN	2009	15	1					12	18		10.3201/eid1501.081054			7	Immunology; Infectious Diseases	Immunology; Infectious Diseases	393AG	WOS:000262342700003	19116043	DOAJ Gold, Green Published			2020-06-30	J	Tanabe, T; Fukusaki, M; Fujinaga, A; Ando, Y; Yamashita, K; Terao, Y; Sumikawa, K				Tanabe, Takahiro; Fukusaki, Makoto; Fujinaga, Arihiro; Ando, Yuko; Yamashita, Kazunori; Terao, Yoshiaki; Sumikawa, Koji			Landiolol, a new ultra-short-acting beta(1)-blocker, reduces anaesthetic requirement during sevoflurane/N2O/fentanyl anaesthesia in surgical patients	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article						adrenergic beta antagonists; anaesthesia inhalational; landiolol; sevoflurane	BISPECTRAL INDEX; TRACHEAL INTUBATION; NITROUS-OXIDE; SWINE MODEL; ESMOLOL; ISOFLURANE; SEVOFLURANE; ANTAGONIST; ALFENTANIL; TITRATION	Background and objective It is known that esmolol, a short-acting beta(1)-blocker, reduces anaesthetic requirement. In this study, we evaluated whether a low dose of landiolol, a new ultra-short-acting beta(1)-blocker, can reduce the sevoflurane requirement. Methods Twenty-five patients undergoing hip surgery were randomly divided into two groups. Group A (n = 13) received landiolol (bolus injection of 0.031 mg.kg(-1) and continuous infusion at a rate of 0.01 mg.kg(-1).min(-1)). Group B (n = 12) received physiological saline. Landiolol and physiological saline were started before the induction of anaesthesia and continued until the end of anaesthesia. Anaesthesia was maintained with sevoflurane, 60% N2O and fentanyl. Sevoflurane concentration was controlled to keep the bispectral index at approximately 50. The end-tidal sevoflurane concentration and haemodynamics were measured during anaesthesia. Results The average end-tidal sevoflurane concentration in group A was significantly lower than that in group B (1.2 +/- 0.30 vs. 1.8 +/- 0.3%, P<0.01). Maximum values of systolic arterial pressure showed no difference between the groups, whereas the maximum value of heart rate in group A was significantly less than that in group B (61 +/- 10 vs. 76 +/- 14 beats min(-1), P<0.05). Conclusion The results suggest that a low dose of landiolol significantly reduces the intraoperative sevoflurane requirement during sevoflurane/N2O/fentanyl anaesthesia in patients undergoing hip surgery. Eur J Anaesthesiol 26:39-42 (c) 2009 European Society of Anaesthesiology.	[Tanabe, Takahiro; Fukusaki, Makoto; Fujinaga, Arihiro; Ando, Yuko; Yamashita, Kazunori; Terao, Yoshiaki] Nagasaki Rosai Hosp, Dept Anesthesia, Setogoshi, Sasebo 8570134, Japan; [Sumikawa, Koji] Nagasaki Univ, Sch Med, Dept Anesthesiol, Nagasaki 852, Japan	Tanabe, T (reprint author), Nagasaki Rosai Hosp, Dept Anesthesia, 2-12-25 Setogoshi, Setogoshi, Sasebo 8570134, Japan.	tanestht@yahoo.co.jp		Ando, Yukio/0000-0001-7115-9105			Andrzejowski J, 2000, ANAESTHESIA, V55, P761, DOI 10.1046/j.1365-2044.2000.01532.x; Berridge CW, 1996, J NEUROSCI, V16, P6999; Chia YY, 2004, BRIT J ANAESTH, V93, P799, DOI 10.1093/bja/aeh268; Coloma M, 2001, ANESTH ANALG, V92, P352, DOI 10.1213/00000539-200102000-00014; Fragen RJ, 1996, J CLIN ANESTH, V8, P352, DOI 10.1016/0952-8180(96)00082-7; FUHRMAN TM, 1992, J CLIN ANESTH, V4, P444, DOI 10.1016/0952-8180(92)90216-N; GOLD MI, 1989, ANESTH ANALG, V68, P101, DOI 10.1213/00000539-198902000-00005; IGUCHI S, 1992, CHEM PHARM BULL, V40, P1462; Johansen AW, 1998, ANESTH ANALG, V87, P671; Johansen JW, 1997, ANESTHESIOLOGY, V86, P364, DOI 10.1097/00000542-199702000-00011; Johansen JW, 2000, J CLIN ANESTH, V12, P433, DOI 10.1016/S0952-8180(00)00187-2; Johnson IAT, 1999, ANAESTH INTENS CARE, V27, P221; Kurita T, 2006, BRIT J ANAESTH, V96, P602, DOI 10.1093/bja/ael069; Kurita T, 2007, ANESTH ANALG, V105, P656, DOI 10.1213/01.ane.0000278085.62563.b5; Leslie J B, 1990, J Clin Anesth, V2, P215, DOI 10.1016/0952-8180(90)90099-O; Menigaux C, 2002, BRIT J ANAESTH, V89, P857, DOI 10.1093/bja/aef275; MILLER DR, 1991, CAN J ANAESTH, V38, P849, DOI 10.1007/BF03036959; Nakashima M., 2000, RINSHO IYAKU, V16, P1531; Oda Y, 2005, ANESTH ANALG, V100, P733, DOI 10.1213/01.ANE.0000154441.22654.11; Pavlin DJ, 2001, ANESTH ANALG, V93, P613, DOI 10.1097/00000539-200109000-00017; Rampil IJ, 1998, ANESTHESIOLOGY, V89, P980, DOI 10.1097/00000542-199810000-00023; Tsunekawa K, 1997, XENOBIO METAB DISPOS, V12, P31; TSUNEKAWA K, 1997, YAKUBUTUDOUTAI, V12, P5; Wong J, 2002, CAN J ANAESTH, V49, P13, DOI 10.1007/BF03020413; YOSHIYA O, 1997, RINSHO IYAKU, V13, P4949	25	6	7	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0265-0215	1365-2346		EUR J ANAESTH	Eur. J. Anaesth.	JAN	2009	26	1					39	42		10.1097/EJA.0b013e328318c6a9			4	Anesthesiology	Anesthesiology	396TY	WOS:000262615300007	19122550				2020-06-30	J	Firestone, M; Goldman, B; Fischer, B				Firestone, Michelle; Goldman, Brian; Fischer, Benedikt			Fentanyl use among street drug users in Toronto, Canada: Behavioural dynamics and public health implications	INTERNATIONAL JOURNAL OF DRUG POLICY			English	Article						Prescription opioids; Fentanyl; Canada; Non-medical use; Public health; Prevention	OPIOID ANALGESICS; UNITED-STATES; HEPATITIS-C; ABUSE; DEATHS; MISUSE; INJECTION; TRENDS	Prescription opioids (POs) are playing an increasingly central role in street drug use and related harms in North America. One distinct PO substance of interest is Fentanyl (Duragesic (R)), a potent opioid analgesic designed for transdermal time-release application. Studies from Europe and North America have documented the sizeable overdose and mortality burden associated with the non-medical use of this drug, This study explores practices and risk dynamics associated with Fentanyl abuse, also considering public health implications. Semi-structured interviews were conducted with 25 regular street-entrenched illicit PO users in Toronto, Canada, a sub-sample of which were recent Fentanyl users. Results showed that while relatively rare on the illicit PO market in Toronto, Fentanyl is a highly desired, sought after and relatively expensive PO drug among street users. In addition, the new 'matrix' patch technology implemented for Fentanyl since 2005 is a limited safeguard against abuse as simple extraction methods are utilized by street users. Finally, distinct risk behaviours relevant for public health emerge due to the high black market costs of Fentanyl and the extraction techniques applied, potentially facilitating high risks for infectious disease (e.g., HCV, HIV) transmission and/or overdose. Consequently, prevalence and practices of Fentanyl use by street users require closer monitoring, targeted interventions and further research regarding risks and outcomes. (C) 2008 Elsevier B.V. All rights reserved.	[Firestone, Michelle; Fischer, Benedikt] Ctr Addict & Mental Hlth, Toronto, ON, Canada; [Goldman, Brian] Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada; [Goldman, Brian; Fischer, Benedikt] Univ Toronto, Toronto, ON, Canada; [Fischer, Benedikt] Ctr Addict Res British Columbia, Victoria, BC, Canada	Fischer, B (reprint author), Univ Victoria, CARBC, POB 1700 STN CSC, Victoria, BC V8W 2Y2, Canada.	bfischer@uvic.ca		Fischer, B/0000-0002-2186-4030			Compton WM, 2006, DRUG ALCOHOL DEPEN, V81, P103, DOI 10.1016/j.drugalcdep.2005.05.009; FISCHER B, CONT DRUG P IN PRESS; Fischer B, 2007, ADDICTION, V102, P499, DOI 10.1111/j.1360-0443.2006.01738.x; Fischer B, 2006, CAN MED ASSOC J, V175, P1385, DOI 10.1503/cmaj.060729; Fischer B, 2006, CAN J PUBLIC HEALTH, V97, P384, DOI 10.1007/BF03405347; Gilson AM, 2004, J PAIN SYMPTOM MANAG, V28, P176, DOI 10.1016/j.jpainsymman.2004.01.003; Havens JR, 2007, DRUG ALCOHOL DEPEN, V87, P98, DOI 10.1016/j.drugalcdep.2006.07.008; Hurwitz W, 2005, PAIN MED, V6, P152, DOI 10.1111/j.1526-4637.2005.05024.x; *INT NARC CONTR BO, 2006, NARC DRUGS EST WORLD; Kronstrand R, 1997, FORENSIC SCI INT, V88, P185, DOI 10.1016/S0379-0738(97)00068-6; Kuhlman JJ, 2003, J ANAL TOXICOL, V27, P499, DOI 10.1093/jat/27.7.499; LEHMANN KA, 1992, J PAIN SYMPTOM MANAG, V7, pS8, DOI 10.1016/0885-3924(92)90048-M; Martin TL, 2006, J ANAL TOXICOL, V30, P603, DOI 10.1093/jat/30.8.603; Mathei C, 2006, J VIRAL HEPATITIS, V13, P560, DOI 10.1111/j.1365-2893.2006.00725.x; Paulozzi LJ, 2006, PHARMACOEPIDEM DR S, V15, P618, DOI 10.1002/pds.1276; Reeves MD, 2002, MED J AUSTRALIA, V177, P552, DOI 10.5694/j.1326-5377.2002.tb04951.x; Sung HE, 2005, J ADOLESCENT HEALTH, V37, P44, DOI 10.1016/j.jadohealth.2005.02.013; Tharp AM, 2004, AM J FOREN MED PATH, V25, P178, DOI 10.1097/01.paf.0000127398.67081.11; Thorpe LE, 2002, AM J EPIDEMIOL, V155, P645, DOI 10.1093/aje/155.7.645	19	27	27	0	19	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0955-3959	1873-4758		INT J DRUG POLICY	Int. J. Drug Policy	JAN	2009	20	1					90	92		10.1016/j.drugpo.2008.02.016			3	Substance Abuse	Substance Abuse	395TN	WOS:000262546500011	18508256				2020-06-30	J	Okutomi, T; Saito, M; Mochizuki, J; Amano, K; Hoka, S				Okutomi, T.; Saito, M.; Mochizuki, J.; Amano, K.; Hoka, S.			A double-blind randomized controlled trial of patient-controlled epidural analgesia with or without a background infusion following initial spinal analgesia for labor pain	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Article	Annual Meeting of the American-Society-of-Anesthesiologists	OCT 14-18, 2006	Chicago, IL	Amer Soc Anesthesiologists		Background infusion; Combined-spinal epidural analgesia; Labor analgesia; Patient-controlled epidural analgesia	LOCKOUT INTERVAL; DURAL PUNCTURE; PCEA; BUPIVACAINE; SUFENTANIL; DELIVERY	Background: Patient-controlled epidural analgesia (PCEA) combined with spinal analgesia is an option for pain relief in labor. However, the effect of a CBI on the analgesic requirements of laboring women is still debated. This double-blind study investigated the effect of CBI with PCEA following spinal analgesia on the local anesthetic requirements of parturients during labor. Methods: Sixty-six nulliparous women were randomly assigned to a standard PCEA protocol (5-mL demand bolus, 10-min lockout) with or without a CBI of 6 mL/h. The epidural solution consisted of 0.1% ropivacaine with fentanyl 2 mu g/mL. Labor analgesia was initiated in both groups with intrathecal bupivacaine 2.5 mg plus fentanyl 25 mu g. The number of demands per hour and the hourly dose of ropivacaine were calculated for both groups. Results: The median [range] number of analgesic boluses per hour in the PCEA group that were demanded: 2.4 [0.8-12.2] and delivered: 1.6 [0.8-2.6], were significantly greater than those in the PCEA+CBI group: 0.7 [0.4-4.2] and 0.6 [0.2-1.3] (P 0.05). However, the hourly ropivacaine dose in the PCEA group (7.9 [3.9-13.2] mg/h) was not significantly different from that in the PCEA+CBI group (8.4 [6.0-12.5] mg/h). Conclusion: In laboring nulliparous patients provided initial labor analgesia with spinal anesthesia, the use of a continuous background infusion decreases PCEA demand dosing, but not the total hourly amount of ropivacame and fentanyl used. (C) 2008 Elsevier Ltd. All rights reserved.	[Okutomi, T.] Kitasato Univ, Dept Anesthesiol, Kanagawa 2288555, Japan; [Mochizuki, J.; Amano, K.] Kitasato Univ, Sch Med, Dept Obstet & Gynecol, Kanagawa 2288555, Japan	Okutomi, T (reprint author), Kitasato Univ, Dept Anesthesiol, 1-15-1 Kitasato, Kanagawa 2288555, Japan.	toshiyukiokutomi@hotmail.com					Beaubien G, 2000, REGION ANESTH PAIN M, V25, P254, DOI 10.1016/S1098-7339(00)90007-5; Boselli E, 2004, ANESTHESIOLOGY, V100, P968, DOI 10.1097/00000542-200404000-00030; Bremerich DH, 2005, INT J OBSTET ANESTH, V14, P114, DOI 10.1016/j.ijoa.2004.12.005; Carvalho B, 2005, INT J OBSTET ANESTH, V14, P223, DOI 10.1016/j.ijoa.2005.02.003; CURRY PD, 1994, PAIN, V57, P125, DOI 10.1016/0304-3959(94)90116-3; Eriksson SL, 2003, ACTA ANAESTH SCAND, V47, P1085, DOI 10.1034/j.1399-6576.2003.00207.x; FERRANTE FM, 1991, ANESTH ANALG, V73, P547; FERRANTE FM, 1994, ANESTH ANALG, V79, P80; GAMBLING DR, 1993, CAN J ANAESTH, V40, P211, DOI 10.1007/BF03037032; Halpern S, 2005, CURR OPIN ANESTHESIO, V18, P247, DOI 10.1097/01.aco.0000169229.75938.c8; Lyons GR, 2007, ANESTH ANALG, V104, P412, DOI 10.1213/01.ane.0000252458.20912.ef; Missant C, 2005, ANAESTH INTENS CARE, V33, P452, DOI 10.1177/0310057X0503300405; PAECH MJ, 1992, ANAESTH INTENS CARE, V20, P15, DOI 10.1177/0310057X9202000103; Petry J, 2000, Acta Anaesthesiol Belg, V51, P163; RAWAL N, 1988, ACTA ANAESTH SCAND, V32, P61, DOI 10.1111/j.1399-6576.1988.tb02689.x; Saito Miwako, 2005, J Anesth, V19, P208, DOI 10.1007/s00540-005-0316-2; Sezer OA, 2007, INT J OBSTET ANESTH, V16, P226, DOI 10.1016/j.ijoa.2007.02.007; Sia AT, 2007, ANESTH ANALG, V104, P673, DOI 10.1213/01.ane.0000253236.89376.60; Stratmann G, 2005, INT J OBSTET ANESTH, V14, P200, DOI 10.1016/j.ijoa.2004.12.008; Thomas JA, 2005, ANESTHESIOLOGY, V103, P1046, DOI 10.1097/00000542-200511000-00019; van der Vyver M, 2002, BRIT J ANAESTH, V89, P459, DOI 10.1093/bja/aef217; Vartis A, 1998, ANAESTH INTENS CARE, V26, P256, DOI 10.1177/0310057X9802600304	22	18	18	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-289X			INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	JAN	2009	18	1					28	32		10.1016/j.ijoa.2008.06.006			5	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	398MR	WOS:000262736700006	19022653				2020-06-30	J	Desai, S; Leong, SB; Yvonne, L; Sia, A				Desai, S.; Leong, S. B.; Yvonne, L.; Sia, A.			Chronobiology of parturients receiving neuraxial labour analgesia with ropivacaine and fentanyl: a prospective cohort study	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Article						Chronobiology; Analgesic techniques; Combined spinal-epidural technique; Analgesia; Obstetric; Pain mechanism; Pregnancy; Measurement techniques; Visual analogue scale	BETA-ENDORPHIN; PREGNANCY; DURATION	Background: The circadian variation in biologic rhythm has been known to affect labour pain. The duration of action of ropivacaine or fentanyl used in treatment of labour pain has been demonstrated to vary with different times of the day. The aim of this Study is to find whether the need for epidural supplementation for breakthrough pain is significantly affected by the time of day, in patients who are on a Continuous epidural infusion of these drugs. Methods: In this prospective cohort Study, parturients With spontaneous onset of labour were given a combined spinal-epidural technique With Spinal ropivacaine 2 mg + fentanyl 15 mu g followed by an epidural infusion of ropivacaine 0.1-0.125%, with fentanyl 2 mu g/mL at 10 ml/hour. A total of 1657 patients were divided into four groups: (1) morning: analgesia request: 7:01 to 13:00, delivery before 19:00; (2) afternoon: analgesia request: 13:01 to 19:00, delivery before 1:00; (3) evening: analgesia request: 19:01 to 1:00, delivery before 7:00 and (4) night: analgesia request: 1:00 to 7:00, delivery before 13:00. Pain scores before epidural analgesia, need for additional epidural supplementation, side effects and patient satisfaction scores were compared between the groups. Results: The pain scores before epidural analgesia were significantly higher in evening and night groups than in morning and afternoon groups (6.95 +/- 2.4, 7.38 +/- 2.2 compared to 6.67 +/- 2.5, 6.49 +/- 2.7 respectively, P < 0.001). Incidence of breakthrough pain, side effects and parturient satisraction scores were not significantly different between groups. Conclusion: Parturients With labour onset and neuraxial analgesia request in the evening and night experienced higher pain scores. However, no significant differences in the incidence of breakthrough pain or the quality of analgesia were observed with the provision of commonly used concentrations of ropivacaine with fentanyl via continuous epidural infusion. (C) 2008 Elsevier Ltd. All rights reserved.	[Desai, S.; Leong, S. B.; Yvonne, L.; Sia, A.] KK Women & Childrens Hosp, Dept Womens Anaesthesia, Singapore 229899, Singapore		sameeranaes@gmail.com					Aya AGM, 1999, CAN J ANAESTH, V46, P665, DOI 10.1007/BF03013955; Aya AGM, 2004, BRIT J ANAESTH, V93, P451, DOI 10.1093/bja/aeh223; BRUGUEROLLE B, 1987, J PHARM PHARMACOL, V39, P148, DOI 10.1111/j.2042-7158.1987.tb06966.x; BRUGUEROLLE B, 1988, J PHARM PHARMACOL, V40, P592, DOI 10.1111/j.2042-7158.1988.tb05314.x; BRUGUEROLLE B, 1988, ANN REV CHRONOPHARMA, V5, P223; BRUGUEROLLE B, 1988, ANN REV CHRONOPHARMA, V5, P227; Chassard D, 2005, ANESTHESIOLOGY, V103, P454, DOI 10.1097/00000542-200509000-00004; Debon R, 2004, ANESTHESIOLOGY, V101, P978, DOI 10.1097/00000542-200410000-00024; Debon R, 2002, ANESTHESIOLOGY, V96, P542, DOI 10.1097/00000542-200203000-00006; Dodd JM, 2006, OBSTET GYNECOL, V108, P350, DOI 10.1097/01.AOG.0000227746.35565.d9; Lindow SW, 1996, CLIN ENDOCRINOL, V45, P443, DOI 10.1046/j.1365-2265.1996.8290840.x; Pan PH, 2005, ANESTHESIOLOGY, V103, P595, DOI 10.1097/00000542-200509000-00023; RAISANEN I, 1988, EUR J OBSTET GYN R B, V27, P13, DOI 10.1016/S0028-2243(88)80005-4	13	6	8	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-289X	1532-3374		INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	JAN	2009	18	1					43	47		10.1016/j.ijoa.2008.07.012			5	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	398MR	WOS:000262736700009	19046873				2020-06-30	J	Wokovich, AM; Brown, SA; Shen, M; Doub, WH; Cai, B; Sadrieh, N; Chen, ML; Machado, S; Buhse, LF				Wokovich, Anna M.; Brown, Stanley A.; Shen, Meiyu; Doub, William H.; Cai, Bing; Sadrieh, Nakissa; Chen, Mei Ling; Machado, Stella; Buhse, Lucinda F.			Evaluation of Substrates for 90 degrees Peel Adhesion-A Collaborative Study. II. Transdermal Drug Delivery Systems	JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART B-APPLIED BIOMATERIALS			English	Article						adhesion; peel; transdermal system; patch; skin		In a previous study on peel adhesion for medical tapes, it was shown that a stainless steel (SS) substrate better discriminated among medical tapes than a high-density polyethylene (HDPE) substrate. The objective of this study was to determine if a SS substrate would also better distinguish among transdermal drug delivery systems (TDDSs). Five TDDSs (Vivelle Dot (R), Climara (R), Catapres-TTS (R), Duragesic (R)), and Mylan Fentanyl) were evaluated on three different substrates (SS, HDPE, and human cadaver skin). All measurements were made using a dwell time of similar to 3 min, a peel angle of 90 degrees, and a peel speed of 300 mm/min. Differences among TDDSs were greater for SS than for HDPE, using the F statistic for testing for differences among TDDSs means as a measure of heterogeneity, thereby indicating greater discrimination by SS. (c) 2008 Wiley Periodicals, Inc.*J Biomed Maier Res Part B: Appl Biomater 88B: 61-65, 2009	[Wokovich, Anna M.; Doub, William H.; Buhse, Lucinda F.] US FDA, Ctr Drug Evaluat & Res, St Louis, MO USA; [Brown, Stanley A.] US FDA, Ctr Devices & Radiol Hlth, Rockville, MD 20857 USA; [Shen, Meiyu; Sadrieh, Nakissa; Chen, Mei Ling; Machado, Stella] US FDA, Ctr Drug Evaluat & Res, Silver Spring, MD USA; [Cai, Bing] US FDA, Ctr Drug Evaluat & Res, Rockville, MD 20857 USA	Wokovich, AM (reprint author), US FDA, Ctr Drug Evaluat & Res, St Louis, MO USA.	anna.wokovich@fda.hhs.gov					*ASTM, 2002, D3330D3330M ASTM; Auchter G, 1999, HDB PRESSURE SENSITI, P444; CAI B, 2006, FDA SCI FOR WASH CON; Minghetti P, 1999, DRUG DEV IND PHARM, V25, P1, DOI 10.1081/DDC-100102135; Minghetti P, 2004, AM J DRUG DELIV, V3, P193; Peel Satas D, 1999, HDB PRESSURE SENSITI, P62; Pressure Sensitive Tape Council, 2004, TEST METH PRESS SENS; Spencer TS, 1990, POLYM MAT SCI ENG, V63, P337; Steven-Fountain AJ, 2002, INT J ADHES ADHES, V22, P423, DOI 10.1016/S0143-7496(02)00018-0; Ulman K, 1999, HDB PRESSURE SENSITI, P724; WOKOVICH AM, 2005, FDA SCI FOR WASH CON; Wokovich AM, 2006, EUR J PHARM BIOPHARM, V64, P1, DOI 10.1016/j.ejpb.2006.03.009	12	6	6	0	6	WILEY-LISS	HOBOKEN	DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA	1552-4973			J BIOMED MATER RES B	J. Biomed. Mater. Res. Part B	JAN	2009	88B	1					61	65		10.1002/jbm.b.31149			5	Engineering, Biomedical; Materials Science, Biomaterials	Engineering; Materials Science	386PO	WOS:000261895300007	18546200				2020-06-30	J	Alonso, A; Molenberghs, G; Renard, D; Darstein, C				Alonso, Ariel; Molenberghs, Geert; Renard, Didier; Darstein, Christelle			Evaluation of Biomarkers for Pharmacological Activity	JOURNAL OF BIOPHARMACEUTICAL STATISTICS			English	Article						Biomarkers; Crossover; Optimization; Surrogate marker		In recent years the cost of drug development has increased the demands on efficiency in the selection of suitable drug candidates. Biomarkers for efficacy and safety could be a plausible strategy to improve this selection process. In the present work, we focus on the study and evaluation of different physiological variables as biomarkers for pharmacological activity. We proposed three different approaches using multivariate and univariate techniques. We note that even though one could argue that the multivariate procedure is more powerful than the other alternatives, the univariate methods also offer a great flexibility to answer interesting scientific questions. The three approaches were used to analyze a crossover study involving an opioid antagonist.	[Alonso, Ariel; Molenberghs, Geert] Hasselt Univ, Ctr Stat, B-3590 Diepenbeek, Belgium; [Renard, Didier] Novartis Pharma AG, Exploratory Dev, Clin Informat Sci, Basel, Switzerland; [Darstein, Christelle] Lilly Corp Ctr, Lilly Serv SA, Program Phase Stat, Indianapolis, IN USA	Alonso, A (reprint author), Hasselt Univ, Ctr Stat, B-3590 Diepenbeek, Belgium.	ariel.alonso@uhasselt.be			Belgian Government (Belgian Science Policy)Belgian Federal Science Policy Office [P6/03]	Ariel Alonso and Geert Molenberghs gratefully acknowledge financial support from the Interuniversity Attraction Pole Research Network P6/03 of the Belgian Government (Belgian Science Policy). All authors are grateful to Eli Lilly & Company for graciously providing the data.	Atkinson AJ, 2001, CLIN PHARMACOL THER, V69, P89, DOI 10.1067/mcp.2000.113989; BURZYKOWSKI T, 2005, EVALUATION SURROGATE; Burzykowski T, 2006, PHARM STAT, V5, P173, DOI 10.1002/pst.207; Jones B, 2003, DESIGN ANAL CROSS OV; Lesko LJ, 2001, ANNU REV PHARMACOL, V41, P347, DOI 10.1146/annurev.pharmtox.41.1.347; SUICO J, 2005, CLIN PHARMACOL THER, V77, P28; Temple Robert J., 1995, P3	7	4	4	0	0	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1054-3406	1520-5711		J BIOPHARM STAT	J. Biopharm. Stat.		2009	19	2					256	272	PII 908656491	10.1080/10543400802622386			17	Pharmacology & Pharmacy; Statistics & Probability	Pharmacology & Pharmacy; Mathematics	406JS	WOS:000263291400003	19212878				2020-06-30	J	Amann, M; Proctor, LT; Sebranek, JJ; Pegelow, DF; Dempsey, JA				Amann, Markus; Proctor, Lester T.; Sebranek, Joshua J.; Pegelow, David F.; Dempsey, Jerome A.			Opioid-mediated muscle afferents inhibit central motor drive and limit peripheral muscle fatigue development in humans	JOURNAL OF PHYSIOLOGY-LONDON			English	Article							SOMATOSENSORY CORTEX SI; C-FIBER INPUT; SKELETAL-MUSCLE; EXERCISE PERFORMANCE; GROUP-III; NEUROMUSCULAR FATIGUE; PROGRESSIVE EXERCISE; MUSCULAR-CONTRACTION; ARTERIAL OXYGENATION; INTRATHECAL FENTANYL	We investigated the role of somatosensory feedback from locomotor muscles on central motor drive (CMD) and the development of peripheral fatigue during high-intensity endurance exercise. In a double-blind, placebo-controlled design, eight cyclists randomly performed three 5 km time trials: control, interspinous ligament injection of saline (5K(Plac), L3-L4) or intrathecal fentanyl (5K(Fent), L3-L4) to impair cortical projection of opioid-mediated muscle afferents. Peripheral quadriceps fatigue was assessed via changes in force output pre- versus postexercise in response to supramaximal magnetic femoral nerve stimulation (Delta Q(tw)). The CMD during the time trials was estimated via quadriceps electromyogram (iEMG). Fentanyl had no effect on quadriceps strength. Impairment of neural feedback from the locomotor muscles increased iEMG during the first 2.5 km of 5K(Fent) versus 5K(Plac) by 12 +/- 3% (P < 0.05); during the second 2.5 km, iEMG was similar between trials. Power output was also 6 +/- 2% higher during the first and 11 +/- 2% lower during the second 2.5 km of 5K(Fent) versus 5K(Plac) (both P < 0.05). Capillary blood lactate was higher (16.3 +/- 0.5 versus 12.6 +/- 1.0%) and arterial haemoglobin O-2 saturation was lower (89 +/- 1 versus 94 +/- 1%) during 5K(Fent) versus 5K(Plac). Exercise-induced Delta Q(tw) was greater following 5K(Fent) versus 5K(Plac) (-46 +/- 2 versus -33 +/- 2%, P < 0.001). Our results emphasize the critical role of somatosensory feedback from working muscles on the centrally mediated determination of CMD. Attenuated afferent feedback from exercising locomotor muscles results in an overshoot in CMD and power output normally chosen by the athlete, thereby causing a greater rate of accumulation of muscle metabolites and excessive development of peripheral muscle fatigue.	[Amann, Markus] Univ Zurich, Inst Physiol, CH-8057 Zurich, Switzerland; [Amann, Markus] ETH, Inst Exercise Physiol, Zurich, Switzerland; [Amann, Markus; Pegelow, David F.; Dempsey, Jerome A.] Univ Wisconsin, Sch Med, John Rankin Lab Pulm Med, Madison, WI USA; [Proctor, Lester T.; Sebranek, Joshua J.] Univ Wisconsin, Sch Med, Dept Anaesthesiol, Madison, WI USA	Amann, M (reprint author), Univ Zurich, Inst Physiol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	markus.amann@physiol.biol.ethz.ch		Amann, Markus/0000-0002-4012-8880	National Heart, Lung, and Blood Institute (NHLBI)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL-15469]; American Heart AssociationAmerican Heart Association	This research was supported by a National Heart, Lung, and Blood Institute (NHLBI) RO1 grant (HL-15469). Markus Amann is the recipient of a Postdoctoral Fellowship from the American Heart Association. We thank Mrs Cynthia E. Bird and Mrs Rose E. Voelker for valuable assistance with lactate assessment and EMG data analyses.	Adreani CM, 1997, J APPL PHYSIOL, V82, P1811; Allen DG, 2008, PHYSIOL REV, V88, P287, DOI 10.1152/physrev.00015.2007; Allen DG, 2008, J APPL PHYSIOL, V104, P296, DOI 10.1152/japplphysiol.00908.2007; Almeida TF, 2004, BRAIN RES, V1000, P40, DOI 10.1016/j.brainres.2003.10.073; Amann M, 2004, MED SCI SPORT EXER, V36, P613, DOI 10.1249/01.MSS.0000122076.21804.10; AMANN M, 2008, J APPL PHYSIOL, DOI DOI 10.1152/JAPPLPHYSIOL90456; Amann M, 2008, J APPL PHYSIOL, V104, P861, DOI 10.1152/japplphysiol.01008.2007; Amann M, 2008, MED SCI SPORT EXER, V40, P574, DOI [10.1249/mss.0b013e31815e728f, 10.1249/MSS.0b013e31815e728f]; Amann M, 2008, J PHYSIOL-LONDON, V586, P161, DOI 10.1113/jphysiol.2007.141838; Amann M, 2007, AM J PHYSIOL-REG I, V293, pR2036, DOI 10.1152/ajpregu.00442.2007; Amann M, 2007, J PHYSIOL-LONDON, V581, P389, DOI 10.1113/jphysiol.2007.129700; Amann M, 2006, J PHYSIOL-LONDON, V575, P937, DOI 10.1113/jphysiol.2006.113936; Amann M, 2006, J APPL PHYSIOL, V101, P119, DOI 10.1152/japplphysiol.01596.2005; ARENDTNIELSEN L, 1985, ELECTROEN CLIN NEURO, V60, P130, DOI 10.1016/0013-4694(85)90019-7; Borg G, 1998, BORGS PERCEIVED EXER; Calbet JAL, 2003, J APPL PHYSIOL, V94, P668, DOI 10.1152/japplphysiol.00128.2002; Caquelard F, 2000, CLIN SCI, V98, P329, DOI 10.1042/CS19990263; Duhamel TA, 2004, J APPL PHYSIOL, V97, P188, DOI 10.1152/japplphysiol.00958.2003; ENOKA RM, 1992, J APPL PHYSIOL, V72, P1631; Farina D, 2004, J APPL PHYSIOL, V96, P1486, DOI 10.1152/japplphysiol.01070.2003; Fitts RH, 2008, J APPL PHYSIOL, V104, P551, DOI 10.1152/japplphysiol.01200.2007; Gandevia SC, 2001, PHYSIOL REV, V81, P1725; GOURLAY GK, 1989, PAIN, V38, P253, DOI 10.1016/0304-3959(89)90210-8; Grant GJ, 1996, J CLIN ANESTH, V8, P99, DOI 10.1016/0952-8180(95)00174-3; HANDWERKER HO, 1972, BRAIN RES, V36, P437, DOI 10.1016/0006-8993(72)90751-2; Harms CA, 1998, J PHYSIOL-LONDON, V507, P619, DOI 10.1111/j.1469-7793.1998.619bt.x; HILL JM, 1990, J APPL PHYSIOL, V68, P2466; HOGAN MC, 1984, J APPL PHYSIOL, V57, P507; Hogan MC, 1999, J APPL PHYSIOL, V86, P1367; KALLIOMAKI J, 1993, BRAIN RES, V622, P271, DOI 10.1016/0006-8993(93)90828-B; Kalliomaki J, 1998, PAIN, V77, P323, DOI 10.1016/S0304-3959(98)00115-8; Katayama K, 2007, AM J PHYSIOL-REG I, V292, pR1279, DOI 10.1152/ajpregu.00554.2006; Keenan KG, 2005, J APPL PHYSIOL, V98, P120, DOI 10.1152/japplphysiol.00894.2004; KNIFFKI KD, 1978, EXP BRAIN RES, V31, P511; Kufel TJ, 2002, MUSCLE NERVE, V25, P438, DOI 10.1002/mus.10047; LALLEY PM, 2008, RESP PHYSL IN PRESS; Lepers R, 2002, J APPL PHYSIOL, V92, P1487, DOI 10.1152/japplphysiol.00880.2001; MARK RF, 1958, J PHYSIOL-LONDON, V142, P544, DOI 10.1113/jphysiol.1958.sp006035; Martin PG, 2008, J PHYSIOL-LONDON, V586, P1277, DOI 10.1113/jphysiol.2007.140426; MENSE S, 1977, J PHYSIOL-LONDON, V267, P75, DOI 10.1113/jphysiol.1977.sp011802; MERTON PA, 1954, J PHYSIOL-LONDON, V123, P553, DOI 10.1113/jphysiol.1954.sp005070; Nybo L, 2004, PROG NEUROBIOL, V72, P223, DOI 10.1016/j.pneurobio.2004.03.005; Petersen NT, 2003, J NEUROSCI, V23, P7974; POMEROY G, 1986, BRAIN RES, V381, P385, DOI 10.1016/0006-8993(86)90095-8; Romer LM, 2007, AM J PHYSIOL-REG I, V292, pR598, DOI 10.1152/ajpregu.00269.2006; ROTTO DM, 1988, J APPL PHYSIOL, V64, P2306; Sandiford SD, 2005, AM J PHYSIOL-REG I, V289, pR441, DOI 10.1152/ajpregu.00652.2004; SCHOUENBORG J, 1986, BRAIN RES, V397, P86, DOI 10.1016/0006-8993(86)91371-5; Shannon MT, 1998, J CLIN ANESTH, V10, P452, DOI 10.1016/S0952-8180(98)00058-0; Standl TG, 2001, ANESTHESIOLOGY, V94, P230, DOI 10.1097/00000542-200102000-00011; Strojnik V, 1998, J APPL PHYSIOL, V84, P344; Swenson JD, 2001, REGION ANESTH PAIN M, V26, P306, DOI 10.1053/ramp.2001.25069; Ummenhofer WC, 2000, ANESTHESIOLOGY, V92, P739, DOI 10.1097/00000542-200003000-00018; YANG JF, 1983, ARCH PHYS MED REHAB, V64, P417	54	233	233	3	32	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3751	1469-7793		J PHYSIOL-LONDON	J. Physiol.-London	JAN 1	2009	587	1					271	283		10.1113/jphysiol.2008.163303			13	Neurosciences; Physiology	Neurosciences & Neurology; Physiology	390GH	WOS:000262151800032	19015193	Green Published			2020-06-30	J	Alves, HC; Valentim, AM; Olsson, IAS; Antunes, LM				Alves, H. C.; Valentim, A. M.; Olsson, I. A. S.; Antunes, L. M.			Intraperitoneal anaesthesia with propofol, medetomidine and fentanyl in mice	LABORATORY ANIMALS			English	Article						Propofol; medetomidine; fentanyl; intraperitoneal; anaesthesia; mice	RESPIRATORY DEPRESSION; LABORATORY-ANIMALS; ATIPAMEZOLE; XYLAZINE; AGONISTS; RATS; CARDIOPULMONARY; REVERSAL; MOUSE; MODEL	Fast recoveries are essential when looking for a safe anaesthetic protocol to use on mice. Propofol is a short-acting anaesthetic agent, which provides a smooth, fast recovery. A recent study carried out in our laboratory showed that the intraperitoneal (i.p.) administration of propofol combined with a fast-acting opioid does not provide a sufficiently stable anaesthesia. In this experiment, we hypothesized that the additional application of medetomidine would increase muscle relaxation and analgesia. Fifty-four male CD1 mice, divided into six groups of five and three groups of eight, were used to test nine different combinations of propofol, medetomidine and fentanyl administered i.p. and reversed with atipamezole 30 min after induction. These combinations were composed in the following manner: propofol 75 mg/kg, medetomidine 1 and 2 mg/kg and fentanyl 0.1, 0.15 and 0.2 mg/kg. The depth of anaesthesia, loss of righting reflex, loss of pedal withdrawal reflex, pulse rate and respiratory rate were recorded along with the duration and quality of the recovery. The combination of propofol and medetomidine provided a predictable induction, hypnosis and muscle relaxation, but surgical anaesthesia. (loss of pedal withdrawal reflex) was not achieved. The addition of fentanyl increased analgesia leading to surgical anaesthesia. We concluded that a combination of 75/1/0.2 mg/kg of propofol, medetomidine and fentanyl, respectively, is a safe, easy and reversible technique for i.p. anaesthesia in mice, providing a surgical window of 15 min and restraint for 30 min with a fast recovery.	[Alves, H. C.; Valentim, A. M.; Antunes, L. M.] Univ Tras Os Montes, CECAV UTAD, Ctr Estudos Ciencias Anim & Vet, P-5000801 Vila Real, Portugal; [Alves, H. C.; Valentim, A. M.; Olsson, I. A. S.] Univ Porto, IBMC, Lab Anim Sci, P-4150180 Oporto, Portugal	Alves, HC (reprint author), Univ Tras Os Montes, CECAV UTAD, Ctr Estudos Ciencias Anim & Vet, Apartado 1013, P-5000801 Vila Real, Portugal.	heber.alves@sapo.pt	Lima, Marta/C-7042-2009; Valentim, Ana/C-3389-2013; Olsson, Anna/C-1792-2008	Valentim, Ana/0000-0003-1428-0691; Olsson, Anna/0000-0002-4369-8723; Antunes, Luis/0000-0002-9757-6879	POCTI; FEDEREuropean Union (EU) [POCTI/I CVT/59056/2004]	Portuguese Foundation for Science and Technology funded by POCTI, co-fanded by FEDER, under project POCTI/I CVT/59056/2004; and Dr Silvia Gradfin for assistance with the English review.	Alves HC, 2007, LAB ANIM-UK, V41, P329, DOI 10.1258/002367707781282767; ANTUNES LM, 2001, VET ANAESTH ANALG, V28, P1; Arras M, 2001, COMPARATIVE MED, V51, P443; Becker A, 2003, PROG NEURO-PSYCHOPH, V27, P687, DOI 10.1016/S0278-5846(03)00080-0; Bryant CE, 1996, RES VET SCI, V60, P267, DOI 10.1016/S0034-5288(96)90052-1; Cruz JI, 1998, LAB ANIM-UK, V32, P18, DOI 10.1258/002367798780559383; Das RG, 2007, LAB ANIM-UK, V41, P312; ENGLAND GCW, 1989, ACTA VET SCAND, P179; ERHARDT W, 1984, RES EXP MED, V184, P159, DOI 10.1007/BF01852390; FISCHER M, 1992, ANAESTHESIST, V41, P15; FLECKNELL AP, 1996, LAB ANIMAL ANAESTHES, P7; Flecknell P, 1997, LAB ANIMAL, V26, P21; GARDNER DJ, 1995, LAB ANIM SCI, V45, P199; Green CJ, 1979, LAB ANIMAL HDB; Hacker SO, 2005, CONTEMP TOP LAB ANIM, V44, P7; Hans P, 2006, CURR OPIN ANESTHESIO, V19, P498, DOI 10.1097/01.aco.0000245274.69292.ad; HU C, 1992, LAB ANIM-UK, V26, P15, DOI 10.1258/002367792780809075; KANTO JH, 1988, INT J CLIN PHARM TH, V26, P41; Lalley PM, 2003, AM J PHYSIOL-REG I, V285, pR1287, DOI 10.1152/ajpregu.00199.2003; Leal T, 2006, LAB ANIM-UK, V40, P43, DOI 10.1258/002367706775404480; MALEC D, 1977, POL J PHARMACOL PHAR, V29, P177; MAZE M, 1991, ANESTHESIOLOGY, V74, P581, DOI 10.1097/00000542-199103000-00029; MCEWAN AI, 1993, ANESTHESIOLOGY, V78, P864, DOI 10.1097/00000542-199305000-00009; MEERT TF, 1994, ANESTHESIOLOGY, V81, P677, DOI 10.1097/00000542-199409000-00022; MOHAMMAD FK, 1993, PHARMACOL RES, V27, P81, DOI 10.1006/phrs.1993.1008; MUGE DK, 1994, VET REC, V135, P43, DOI 10.1136/vr.135.2.43; NILSFORS L, 1989, ACTA VET SCAND, P155; Sahbaie P, 2006, ANESTH ANALG, V103, P620, DOI 10.1213/01.ane.0000229714.09553.8c; Sinclair MD, 2003, CAN VET J, V44, P885; SMITH W, 1993, LAB ANIM, V27, P30, DOI 10.1258/002367793781082377; STOTT DG, 1991, BRIT J ANAESTH, V67, P603, DOI 10.1093/bja/67.5.603; Taylor R, 2000, CONTEMP TOP LAB ANIM, V39, P14; Tendillo FJ, 1996, LAB ANIM SCI, V46, P215; VIRTANEN R, 1989, ACTA VET SCAND, P29; WILLETTE RN, 1987, J PHARMACOL EXP THER, V240, P352	35	23	24	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0023-6772	1758-1117		LAB ANIM-UK	Lab. Anim.	JAN	2009	43	1					27	33		10.1258/la.2008.007036			7	Veterinary Sciences; Zoology	Veterinary Sciences; Zoology	402CE	WOS:000262991000004	19001064	Bronze			2020-06-30	J	Koivusalo, AI; Korpela, R; Wirtavuori, K; Piiparinen, S; Rintala, RJ; Pakarinen, MP				Koivusalo, Antti I.; Korpela, Reijo; Wirtavuori, Kari; Piiparinen, Satu; Rintala, Risto J.; Pakarinen, Mikko P.			A Single-Blinded, Randomized Comparison of Laparoscopic Versus Open Hernia Repair in Children	PEDIATRICS			English	Article						children; inguinal hernia repair; laparoscopy; outcome; complications	INGUINAL-HERNIA; CLINICAL-TRIAL; OPEN APPENDECTOMY; RECURRENCE RATE; HERNIORRHAPHY; SURGERY	OBJECTIVE. The role of laparoscopic surgery in pediatric inguinal hernia repair is unclear. We aimed to compare day-case laparoscopic hernia repair with open repair. METHODS. A prospective, single-blinded randomized study in children aged 4 months to 16 years with unilateral inguinal hernia was performed. The primary outcome measure was the time to normal daily activities after surgery. Secondary outcome measures included postoperative pain, time in the operation room, results, and complications. RESULTS. Eighty-nine patients were enrolled (laparoscopic hernia repair: 47, open repair: 42). The mean number of days to normal activity after laparoscopic hernia repair and open repair was 2.4 and 2.5, respectively. Thirty-seven (79%) patients with laparoscopic hernia repair and 20 (42%) with open repair required rescue analgesia postoperatively. The median pain score in the second postoperative morning was significantly higher after laparoscopic hernia repair. The median times in the operation room for laparoscopic hernia repair and open repair were 63 and 38 minutes, respectively. Surgical and cosmetic results were similar at up to 2 years' follow-up. CONCLUSIONS. Recovery and outcome were similar after open repair and laparoscopic hernia repair in children. Laparoscopic hernia repair was associated with increased theater time and postoperative pain. Pediatrics 2009;123:332-337	[Koivusalo, Antti I.; Rintala, Risto J.; Pakarinen, Mikko P.] Univ Helsinki, Hosp Children & Adolescents, Pediat Surg Sect, Helsinki, Finland; [Korpela, Reijo; Wirtavuori, Kari; Piiparinen, Satu] Univ Helsinki, Hosp Children & Adolescents, Sect Pediat Anesthesiol, Helsinki, Finland	Koivusalo, AI (reprint author), Stenbackinkatu 11 000290,LNS HUS,POB 281, Helsinki, Finland.	koivusalo@hus.fi	Rintala, RJ/J-6471-2019; Pakarinen, Mikko/AAD-8834-2019	Rintala, Risto/0000-0002-1460-1857			Arvidsson D, 2005, BRIT J SURG, V92, P1085, DOI 10.1002/bjs.5137; Butler RE, 2007, SURG ENDOSC, V21, P387, DOI 10.1007/s00464-006-9123-6; Chan KL, 2005, SURG ENDOSC, V19, P927, DOI 10.1007/s00464-004-8224-3; Chan KL, 2007, J PEDIATR SURG, V42, P1993, DOI 10.1016/j.jpedsurg.2007.08.014; Eklund A, 2006, BRIT J SURG, V93, P1060, DOI 10.1002/bjs.5405; Glick P, 2006, PEDIAT SURG, V2, P1172; Gorsler CM, 2003, SURG ENDOSC, V17, P571, DOI 10.1007/s00464-002-8947-y; Koivusalo A, 2007, SURG ENDOSC, V21, P2147, DOI 10.1007/s00464-007-9318-5; Koivusalo A, 2006, J PEDIATR SURG, V41, P323, DOI 10.1016/j.jpedsurg.2005.11.007; Koivusalo A, 2006, SURG ENDOSC, V20, P960, DOI 10.1007/s00464-005-0424-y; Korpela R, 1999, ANESTHESIOLOGY, V91, P442, DOI 10.1097/00000542-199908000-00019; Lejus C, 1996, ANESTHESIOLOGY, V84, P801, DOI 10.1097/00000542-199604000-00006; Lintula H, 2001, BRIT J SURG, V88, P510, DOI 10.1046/j.1365-2168.2001.01723.x; MAUNUKSELA EL, 1987, CLIN PHARMACOL THER, V42, P137, DOI 10.1038/clpt.1987.123; McCormack K, 2005, HEALTH TECHNOL ASSES, V9, P1; O'Dwyer P, 1999, LANCET, V354, P185; Ron O, 2007, BRIT J SURG, V94, P804, DOI 10.1002/bjs.5856; Schier F, 2006, J PEDIATR SURG, V41, P1081, DOI 10.1016/j.jpedsurg.2006.02.028; Schier F, 2002, J PEDIATR SURG, V37, P395, DOI 10.1053/jpsu.2002.30842; Sozubir Selami, 2006, Hernia, V10, P74, DOI 10.1007/s10029-005-0047-1; Valusek PA, 2006, J LAPAROENDOSC ADV S, V16, P650, DOI 10.1089/lap.2006.16.650	21	73	80	0	5	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	JAN	2009	123	1					332	337		10.1542/peds.2007-3752			6	Pediatrics	Pediatrics	388UZ	WOS:000262046400051	19117900				2020-06-30	J	Stevens, CW; Martin, KK; Stahlheber, BW				Stevens, Craig W.; Martin, Kristin K.; Stahlheber, Brad W.			Nociceptin produces antinociception after spinal administration in amphibians	PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR			English	Article						Nociceptin; Nociceptin receptor; Opioid receptor; Antinociception; Amphibian	OPIOID RECEPTOR; ORPHANIN FQ/NOCICEPTIN; ANALGESIC POTENCY; FQ RECEPTOR; PHARMACOLOGICAL CHARACTERIZATION; ADRENERGIC AGENTS; ORL1 RECEPTOR; PAIN; MU; KAPPA	Nociceptin, also known as orphanin FQ, is a opioid-like neuropeptide that mediates its effects at the nociceptin receptor, a member of the G protein-coupled receptor superfamily. In mammals, nociceptin produces analgesia after spinal administration, however the role of nociceptin and nociceptin receptors in the modulation of noxious stimuli in non-mammalian species has not been examined. In an amphibian pain model using the acetic acid test with Rana pipiens, nociceptin and nociceptin(1-13) amide produced dose-dependent antinociception (1-100 nmol), blocked by the nociceptin antagonist, [Nphe(1)]-nociceptin(1-13) amide (30 nmol), but not the opioid antagonist, naltrexone (100 nmol/g, s.c.). Conversely, the antinociceptive effects of mu, delta, and kappa opioid receptor agonists were not blocked by the nociceptin antagonist. Nociceptin and nociceptin(1-13) amide were the least potent of the opioid agonists tested. These studies demonstrate that spinal nociceptin receptors and not opioid receptors mediate the antinociceptive effect of nociceptin. Considered with previous findings, these behavioral data supports a role for nociceptin inhibition of spinal nociception in amphibians and perhaps all vertebrates. (C) 2008 Elsevier Inc. All rights reserved.	[Stevens, Craig W.; Martin, Kristin K.; Stahlheber, Brad W.] OSU Ctr Hlth Sci, Dept Physiol & Pharmacol, Coll Osteopath Med, Tulsa, OK 74107 USA	Stevens, CW (reprint author), OSU Ctr Hlth Sci, Dept Physiol & Pharmacol, Coll Osteopath Med, 1111 W 17th St, Tulsa, OK 74107 USA.	cw.stevens@okstate.edu			U.S. National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NIDAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [012448]	Supported in part by a research grant from the U.S. National Institutes of Health, NIDA 012448 (CWS) and a Summer medical student scholarship from the Auxiliary to the Oklahoma Osteopathic Association (BWS). This paper is dedicated to the memory of Peace Corps Nepal volunteer, Phil Cyr, who was killed in the line of duty.	Benyhe S, 1999, BIOCHEM BIOPH RES CO, V260, P592, DOI 10.1006/bbrc.1999.0907; Bloms-Funke P, 2000, PEPTIDES, V21, P1141, DOI 10.1016/S0196-9781(00)00252-7; BRENNER GM, 1994, J PHARMACOL EXP THER, V270, P540; Butour JL, 1997, EUR J PHARMACOL, V321, P97, DOI 10.1016/S0014-2999(96)00919-3; Calo' G, 2002, CLIN EXP PHARMACOL P, V29, P223, DOI 10.1046/j.1440-1681.2002.03633.x; Calo' G, 2000, BRIT J PHARMACOL, V129, P1183, DOI 10.1038/sj.bjp.0703169; Candeletti S, 2000, LIFE SCI, V66, P257; Corradini L, 2001, BRAIN RES, V905, P127, DOI 10.1016/S0006-8993(01)02520-3; Danielson PB, 2001, J BIOL CHEM, V276, P22114, DOI 10.1074/jbc.M011741200; Darland T, 1998, TRENDS NEUROSCI, V21, P215, DOI 10.1016/S0166-2236(97)01204-6; Dooley CT, 2000, PEPTIDES, V21, P949, DOI 10.1016/S0196-9781(00)00231-X; Fawzi AB, 1997, EUR J PHARMACOL, V336, P233, DOI 10.1016/S0014-2999(97)01227-2; Gunduz O, 2006, EUR J PHARMACOL, V539, P39, DOI 10.1016/j.ejphar.2006.03.075; Hamamoto DT, 2000, BRAIN RES, V862, P217, DOI 10.1016/S0006-8993(00)02138-7; Hawes BE, 2000, PEPTIDES, V21, P961, DOI 10.1016/S0196-9781(00)00232-1; Henderson G, 1997, TRENDS PHARMACOL SCI, V18, P293, DOI 10.1016/S0165-6147(97)90645-3; Ko MCH, 2006, J PHARMACOL EXP THER, V318, P1257, DOI 10.1124/jpet.106.106120; Ikeda K, 1997, MOL BRAIN RES, V45, P117, DOI 10.1016/S0169-328X(96)00252-5; Inoue M, 2003, J PHARMACOL EXP THER, V305, P495, DOI 10.1124/jpet.102.046326; JANSSEN PAJ, 1963, ARZNEIMITTEL-FORSCH, V13, P502; King MA, 1997, NEUROSCI LETT, V223, P113, DOI 10.1016/S0304-3940(97)13414-0; Lai CC, 1997, NEUROSCIENCE, V81, P887, DOI 10.1016/S0306-4522(97)00251-0; Lambert DG, 2008, NAT REV DRUG DISCOV, V7, P694, DOI 10.1038/nrd2572; Lu JT, 2001, REGUL PEPTIDES, V101, P81, DOI 10.1016/S0167-0115(01)00263-4; MEUNIER JC, 1995, NATURE, V377, P532, DOI 10.1038/377532a0; Meunier JC, 1997, EUR J PHARMACOL, V340, P1, DOI 10.1016/S0014-2999(97)01411-8; Mika J, 2003, NEUROSCI LETT, V348, P190, DOI 10.1016/S0304-3940(03)00786-9; Mogil JS, 2001, PHARMACOL REV, V53, P381; Mohan S, 2006, EUR J PHARMACOL, V534, P89, DOI 10.1016/j.ejphar.2006.01.011; MOLLEREAU C, 1994, FEBS LETT, V341, P33, DOI 10.1016/0014-5793(94)80235-1; MOSBERG HI, 1983, P NATL ACAD SCI-BIOL, V80, P5871, DOI 10.1073/pnas.80.19.5871; Nazzaro C, 2007, PEPTIDES, V28, P663, DOI 10.1016/j.peptides.2006.11.004; Obara I, 2005, PAIN, V116, P17, DOI 10.1016/j.pain.2005.03.012; Pettersson LME, 2002, BRAIN RES, V945, P266, DOI 10.1016/S0006-8993(02)02817-2; PEZALLA PD, 1983, BRAIN RES, V273, P297, DOI 10.1016/0006-8993(83)90854-5; Pheng LH, 2000, EUR J PHARMACOL, V397, P383, DOI 10.1016/S0014-2999(00)00300-9; REINSCHEID RK, 1995, SCIENCE, V270, P792, DOI 10.1126/science.270.5237.792; Salvadori S, 1999, FARMACO, V54, P810, DOI 10.1016/S0014-827X(99)00108-1; Schuligoi R, 1997, NEUROSCI LETT, V224, P136, DOI 10.1016/S0304-3940(97)13453-X; Stevens CW, 2007, NEUROSCI LETT, V419, P189, DOI 10.1016/j.neulet.2007.04.014; Stevens CW, 2007, BRAIN RES BULL, V71, P628, DOI 10.1016/j.brainresbull.2006.12.001; Stevens CW, 1997, EUR J PHARMACOL, V331, P15, DOI 10.1016/S0014-2999(97)01026-1; Stevens CW, 2004, BRAIN RES REV, V46, P204, DOI 10.1016/j.brainresrev.2004.07.003; Stevens CW, 1996, J PHARMACOL EXP THER, V276, P440; STEVENS CW, 1994, J PHARMACOL EXP THER, V269, P1086; Stevens CW, 2001, CONTEMP TOP LAB ANIM, V40, P23; Stevens CW, 1996, EUR J PHARMACOL, V316, P205, DOI 10.1016/S0014-2999(96)00681-4; STEVENS CW, 1992, LIFE SCI, V50, P901, DOI 10.1016/0024-3205(92)90167-N; Suaudeau C, 1998, FUND CLIN PHARMACOL, V12, P420, DOI 10.1111/j.1472-8206.1998.tb00966.x; VONVOIGTLANDER PF, 1983, J PHARMACOL EXP THER, V224, P7; Walthers EA, 2005, J MOL ENDOCRINOL, V34, P247, DOI 10.1677/jme.1.01687; Wang JL, 1999, REGUL PEPTIDES, V79, P159, DOI 10.1016/S0167-0115(98)00161-X; Wang YQ, 1999, EUR J PHARMACOL, V376, pR1, DOI 10.1016/S0014-2999(99)00399-4; Xu IS, 2002, LIFE SCI, V70, P1151, DOI 10.1016/S0024-3205(01)01496-5; Xu XJ, 2000, PEPTIDES, V21, P1031, DOI 10.1016/S0196-9781(00)00234-5; Yamamoto T, 1997, NEUROSCIENCE, V81, P249, DOI 10.1016/S0306-4522(97)00166-8; Yamamoto T, 1999, PROG NEUROBIOL, V57, P527, DOI 10.1016/S0301-0082(98)00067-7; Yamamoto T, 2006, J PHARMACOL EXP THER, V318, P206, DOI 10.1124/jpet.105.100859; Zaveri N, 2001, EUR J PHARMACOL, V428, P29, DOI 10.1016/S0014-2999(01)01282-1; Zeilhofer HU, 2003, J PHARMACOL EXP THER, V306, P423, DOI 10.1124/jpet.102.046979; Zhu CB, 1997, NEUROSCI LETT, V235, P37, DOI 10.1016/S0304-3940(97)00704-0	61	11	13	0	8	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0091-3057			PHARMACOL BIOCHEM BE	Pharmacol. Biochem. Behav.	JAN	2009	91	3					436	440		10.1016/j.pbb.2008.08.022			5	Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy	Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy	402LF	WOS:000263014500026	18804120	Green Accepted			2020-06-30	J	Lim, Y; Ocampo, CE; Supandji, M; Teoh, WHL; Sia, AT				Lim, Yvonne; Ocampo, Cecilia E.; Supandji, Mia; Teoh, Wendy H. L.; Sia, Alex T.			A Randomized Controlled Trial of Three Patient-Controlled Epidural Analgesia Regimens for Labor	ANESTHESIA AND ANALGESIA			English	Article							BACKGROUND INFUSION; BOLUS; PCEA	BACKGROUND: Patient-controlled epidural analgesia (PCEA) is a safe and effective mode of maintaining labor analgesia; however, the ideal PCEA regimen is controversial. METHODS: In this prospective, randomized, double-blind study, we examined the analgesic efficacy of demand-only PCEA and PCEA with background infusion. We recruited 300 nulliparous parturients. Analgesia was initiated with intrathecal ropivacaine 2 mg and fentanyl 15 mu g and maintained with epidural ropivacame 0.1% with fentanyl 2 mu g/mL. Parturients were randomized to one of three groups. Group 0: demand-only PCEA, bolus of 5 mL, lockout interval of 15 min. Group 5: background infusion of 5 mL/h, bolus of 5 mL, lockout interval of 12 min. Group 10: background infusion of 10 mL/h, bolus of 5 mL, lockout interval of 10 min. The maximum dose of all groups was 20 mL/h. The primary outcome was incidence of breakthrough pain. Secondary outcomes included intrapartum pain scores, neuraxial blockade characteristics, side effects, the total and hourly volume of ropivacaine, neonatal outcomes, and obstetric outcomes. RESULTS: The incidence of breakthrough pain and the maximum visual analog scale (0-100 mm scale) pain scores were higher in Group 0 versus Groups 5 and 10 (43% vs 17% and 11%, P < 0.001 and 37 +/- 28 vs 22 +/- 26 and 16 +/- 25 [mean +/- SD], P < 0.001), respectively. Group 10 had a longer duration of effective analgesia compared with Group 0 (mean 895 min, 95% CI 823-966 vs 565 min, 95%, CI 454-677, P < 0.001) and increased ropivacaine consumption, and was associated with a longer duration of the second stage of labor. CONCLUSION: Demand-only PCEA (5-mL bolus, 15-min lockout interval) resulted in less local anesthetic consumption but an increased incidence of breakthrough pain, higher pain scores, shorter duration of effective analgesia, and lower maternal satisfaction, when compared with PCEA with background infusion (5-mL bolus, 10-12-min lockout interval, and 5-10 mL/h infusion).	[Lim, Yvonne; Ocampo, Cecilia E.; Supandji, Mia; Teoh, Wendy H. L.; Sia, Alex T.] KK Womens & Childrens Hosp, Dept Woman Anesthesia, Singapore 229899, Singapore	Supandji, M (reprint author), KK Womens & Childrens Hosp, Dept Woman Anesthesia, 100 Bukit Timah Rd, Singapore 229899, Singapore.	miasupandji@gmail.com		Teoh, Wendy/0000-0001-9594-3009			Bernard JM, 2000, ANESTH ANALG, V90, P328, DOI 10.1097/00000539-200002000-00017; Boselli E, 2004, ANESTHESIOLOGY, V100, P968, DOI 10.1097/00000542-200404000-00030; Bremerich DH, 2005, INT J OBSTET ANESTH, V14, P114, DOI 10.1016/j.ijoa.2004.12.005; Campbell DC, 2004, ANESTHESIOLOGY, V101, pA1204; Carvalho B, 2005, INT J OBSTET ANESTH, V14, P223, DOI 10.1016/j.ijoa.2005.02.003; D'Angelo R, 2003, CLIN OBSTET GYNECOL, V46, P623, DOI 10.1097/00003081-200309000-00015; FERRANTE FM, 1994, ANESTH ANALG, V79, P80; Halonen P, 2004, ACTA ANAESTH SCAND, V48, P732, DOI 10.1111/j.0001-5172.2004.00413.x; Hodnett ED, 2002, AM J OBSTET GYNECOL, V186, pS160, DOI 10.1067/mob.2002.121141; Lim Y, 2006, ANAESTHESIA, V61, P339, DOI 10.1111/j.1365-2044.2006.04535.x; LIM Y, 2006, MED SCI MONITOR, V18, P9; Missant C, 2005, ANAESTH INTENS CARE, V33, P452, DOI 10.1177/0310057X0503300405; PAECH MJ, 1992, ANAESTH INTENS CARE, V20, P15, DOI 10.1177/0310057X9202000103; Petry J, 2000, Acta Anaesthesiol Belg, V51, P163; Stewart KI, 2004, ANESTHESIOLOGY, V100, pB10; Stratmann G, 2005, INT J OBSTET ANESTH, V14, P200, DOI 10.1016/j.ijoa.2004.12.008; van der Vyver M, 2002, BRIT J ANAESTH, V89, P459, DOI 10.1093/bja/aef217	17	32	35	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	DEC	2008	107	6					1968	1972		10.1213/ane.0b013e3181887ffb			5	Anesthesiology	Anesthesiology	376PZ	WOS:000261196800033	19020146				2020-06-30	J	Yu, XR; Huang, YG; Ju, X; Wang, HL				Yu Xuerong; Huang Yuguang; Ju Xia; Wang Hailan			Ketamine and Lornoxicam for Preventing a Fentanyl-Induced Increase in Postoperative Morphine Requirement	ANESTHESIA AND ANALGESIA			English	Article							ACUTE OPIOID TOLERANCE; LOW-DOSE KETAMINE; NITRIC-OXIDE; REMIFENTANIL; HYPERALGESIA; ANALGESIA; PAIN; RATS; ANESTHESIA; INFUSION	BACKGROUND: N-methyl-D-aspartate receptor antagonists and nonsteroidal anti-inflammatory drugs are believed to prevent opioid-induced hyperalgesia and/or acute opioid tolerance, which could cause an increase in postoperative opioid requirement. In this randomized, double-blind, placebo-controlled study, we investigated whether co-administration of ketamine or lornoxicam and fentanyl could prevent the increase of postoperative morphine requirement induced by fentanyl alone. METHODS: Ninety females undergoing total abdominal hysterectomy with spinal anesthesia were randomly assigned to six groups consisting of placebo (normal saline, C), fentanyl (three bolus of 1 mu g . kg(-1), F), ketamine (infusion of 15 mu g . kg(-1) . min(-1), K), ketamine and fentanyl (infusion of 15 mu g . kg(-1) . min(-1) ketamine plus three bolus of 1 mu g . kg(-1) fentanyl, FK), lornoxicam (one bolus of 8 mg, L), and lornoxicam and fentanyl (one bolus of 8 mg lornoxicam plus three bolus of 1 mu g . kg(-1) fentanyl, FL). Cumulative morphine consumption, pain score, and adverse effects were recorded at 1, 3, 6, 12, 24, and 48 h postoperatively. RESULTS: Cumulative morphine consumption in Group F was significantly more than that in Group C at 3, 6, and 12 h postoperatively (P < 0.05). Postoperative cumulative morphine consumption was similar in Groups C, K, FK, L, and FL. No differences in postoperative pain scores were observed among groups. More patients in Groups K and FK had hallucinations during and/or after surgery than those in Group C (P < 0.05). CONCLUSIONS: Our data suggest that the increase of postoperative morphine requirements induced by intraoperative administration of fentanyl could be prevented by ketamine or lornoxicam.	[Yu Xuerong; Huang Yuguang] Beijing Union Med Coll Hosp, Dept Anesthesiol, Beijing, Peoples R China	Huang, YG (reprint author), Beijing Union Med Coll Hosp, Dept Anesthesiol, Shuaifuyuan 1,Dongcheng Dist, Beijing, Peoples R China.	yxr3l3@yahoo.com.cn					BABEY AM, 1994, NEUROPHARMACOLOGY, V33, P1463, DOI 10.1016/0028-3908(94)90050-7; Celerier E, 2000, ANESTHESIOLOGY, V92, P465, DOI 10.1097/00000542-200002000-00029; Chia YT, 1999, CAN J ANAESTH, V46, P872, DOI 10.1007/BF03012978; Crawford MW, 2006, ANESTH ANALG, V102, P1662, DOI 10.1213/01.ane.0000216036.95705.c2; De Kock M, 2001, PAIN, V92, P373, DOI 10.1016/S0304-3959(01)00278-0; Dunbar SA, 2000, ANESTH ANALG, V91, P417, DOI 10.1097/00000539-200008000-00035; Eisenach JC, 2000, ANESTHESIOLOGY, V92, P308, DOI 10.1097/00000542-200002000-00009; Ganne O, 2005, EUR J ANAESTH, V22, P426, DOI 10.1017/S0265021505000724; Guignard B, 2000, ANESTHESIOLOGY, V93, P409, DOI 10.1097/00000542-200008000-00019; Guignard B, 2002, ANESTH ANALG, V95, P103, DOI 10.1097/00000539-200207000-00018; KISSIN I, 1991, ANESTHESIOLOGY, V74, P166, DOI 10.1097/00000542-199101000-00025; Kissin I, 2000, ANESTH ANALG, V91, P110, DOI 10.1097/00000539-200007000-00021; Kissin I, 2000, ANESTH ANALG, V91, P1483, DOI 10.1097/00000539-200012000-00035; Larcher A, 1998, NEUROSCIENCE, V84, P583, DOI 10.1016/S0306-4522(97)00556-3; Laulin JP, 2002, ANESTH ANALG, V94, P1263, DOI 10.1097/00000539-200205000-00040; Lauretti GR, 1998, ANESTH ANALG, V86, P117, DOI 10.1097/00000539-199801000-00023; Li XQ, 2001, MOL BRAIN RES, V86, P56, DOI 10.1016/S0169-328X(00)00260-6; Luginbuhl M, 2003, ANESTH ANALG, V96, P726, DOI 10.1213/01.ANE.0000048086.58161.18; MAO JR, 1995, PAIN, V62, P259, DOI 10.1016/0304-3959(95)00073-2; Parris WCV, 1996, CAN J ANAESTH, V43, P867, DOI 10.1007/BF03013041; Sakai M, 1998, BRIT J PHARMACOL, V123, P890, DOI 10.1038/sj.bjp.0701661; SALVEMINI D, 1994, J CLIN INVEST, V93, P1940, DOI 10.1172/JCI117185; Schmid RL, 1999, PAIN, V82, P111, DOI 10.1016/S0304-3959(99)00044-5; Troster A, 2006, ANESTHESIOLOGY, V105, P1016; Wong CS, 2000, BRIT J ANAESTH, V85, P747, DOI 10.1093/bja/85.5.747	25	22	27	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	DEC	2008	107	6					2032	2037		10.1213/ane.0b013e3181888061			6	Anesthesiology	Anesthesiology	376PZ	WOS:000261196800042	19020155				2020-06-30	J	He, N; Xue, FS; Xu, YC; Liao, X; Xu, XZ				He, Nong; Xue, Fu S.; Xu, Ya C.; Liao, Xu; Xu, Xiu Z.			Awake orotracheal intubation under airway topical anesthesia using the Bonfils in patients with a predicted difficult airway	CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Letter							FIBERSCOPE		[He, Nong; Xu, Xiu Z.] Peking Univ, Shougang Hosp, Beijing 100871, Peoples R China; [Xue, Fu S.; Xu, Ya C.; Liao, Xu] Chinese Acad Med Sci, Plast Surg Hosp, Beijing 100037, Peoples R China; [Xue, Fu S.; Xu, Ya C.; Liao, Xu] Peking Union Med Coll, Beijing 100021, Peoples R China	He, N (reprint author), Peking Univ, Shougang Hosp, Beijing 100871, Peoples R China.	fruitxue@yahoo.com.cn					Abramson SI, 2008, ANESTH ANALG, V106, P1215, DOI 10.1213/ane.0b013e318167cc7c; Byhahn C, 2008, CAN J ANAESTH, V55, P232, DOI 10.1007/BF03021507; Hagberg Carin A, 2002, Anesthesiol Clin North Am, V20, P907, DOI 10.1016/S0889-8537(02)00023-8; Liao X, 2008, CAN J ANAESTH, V55, P655, DOI 10.1007/BF03021442; Xue FS, 2007, CAN J ANAESTH, V54, P951, DOI 10.1007/BF03026803	5	5	5	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0832-610X			CAN J ANAESTH	Can. J. Anaesth.-J. Can. Anesth.	DEC	2008	55	12					881	882		10.1007/BF03034064			2	Anesthesiology	Anesthesiology	387GR	WOS:000261940200018	19050098	Bronze			2020-06-30	J	Shapiro, FE				Shapiro, Fred E.			Anesthesia for outpatient cosmetic surgery	CURRENT OPINION IN ANESTHESIOLOGY			English	Article						aesthetic facial surgery; breast surgery; combination gynecologic procedures; cosmetic surgery; dexmedetomidine; lidocaine; operating room fire prevention	OPERATING-ROOM FIRES; BREAST SURGERY; PARAVERTEBRAL BLOCK; LOCAL-ANESTHESIA; DEXMEDETOMIDINE; SAFETY; MANAGEMENT; SEDATION; EFFICACY; CARE	Purpose of review American Society of Aesthetic Plastic Surgery statistics show outpatient cosmetic procedures increased from 3 to 11 million (1997-2007), an increase of 457%, and $13 billion was spent. Exponential growth, complexity of cases and patients, and media attention to high-profile untoward events are accompanied with concerns for patient safety and development of safer anesthesia practices. Recent findings Improved safety and efficacy in aesthetic facial surgery include oral sedation and local anesthesia, addition of dexmedetomidine to intravenous anesthesia, and defining the 'safest' dose of lidocaine with epinephrine. A nasopharyngeal tube can be used to deliver a concentration of oxygen commensurate with recent American Society of Anesthesiologists Task Force Practice Advisory for the prevention and management of operating room fires. Analgesia for breast surgery including instillation of bupivicaine, paravertebral block, and combination dexamethasone with nonsteroidal anti-inflammatory drugs can decrease narcotic requirement and recovery time. Risks of combined gynecologic and plastic surgical procedures are not greater than those seen with either procedure alone. A coordinated team approach for patient management is essential. Pulmonary embolism remains the greatest cause of mortality. Summary The methods presented improve patient safety. The number of cosmetic procedures will continue to grow exponentially and evolve additional patient safety concerns. This larger population is the foundation for prospective trials to develop evidence-based anesthesia for cosmetic surgery.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Anesthesiol Crit Care & Pain Med, Boston, MA 02215 USA	Shapiro, FE (reprint author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Anesthesiol Crit Care & Pain Med, 330 Brookline Ave F-407, Boston, MA 02215 USA.	fshapiro@bidmc.harvard.edu					Arain SR, 2002, ANESTH ANALG, V95, P461, DOI 10.1097/00000539-200208000-00042; Bhananker SM, 2006, ANESTHESIOLOGY, V104, P228, DOI 10.1097/00000542-200602000-00005; Breivik EK, 1999, CLIN PHARMACOL THER, V66, P625, DOI 10.1053/cp.1999.v66.103629001; Caplan RA, 2008, ANESTHESIOLOGY, V108, P786; Cinnella G, 2007, PLAST RECONSTR SURG, V119, P2263, DOI 10.1097/01.prs.0000260754.59310.38; Cooter RD, 2007, AESTHET PLAST SURG, V31, P666, DOI 10.1007/s00266-006-0230-5; Culliford AT, 2007, PLAST RECONSTR SURG, V120, P840, DOI 10.1097/01.prs.0000277647.42662.29; Ebert TJ, 2000, ANESTHESIOLOGY, V93, P382, DOI 10.1097/00000542-200008000-00016; Haeck PC, 2009, PLAST RECONSTR SURG, V124, p6S, DOI [10.1097/PRS.0b013e3181b8e880, 10.1097/01.prs.0000308480.33644.56]; Hall JE, 2000, ANESTH ANALG, V90, P699, DOI 10.1097/00000539-200003000-00035; Harley DH, 2008, AESTHET PLAST SURG, V32, P77, DOI 10.1007/s00266-007-9014-9; Kjetil H, 2007, ANESTH ANALG, V105, P481, DOI 10.1213/01.ane.0000267261.61444.69; Klein SM, 2000, ANESTH ANALG, V90, P1402, DOI 10.1097/00000539-200006000-00026; Kryger ZB, 2007, INT J GYNECOL OBSTET, V99, P257, DOI 10.1016/j.ijgo.2007.05.028; Meneghetti SC, 2007, PLAST RECONSTR SURG, V120, P1701, DOI 10.1097/01.prs.0000282729.23202.da; Pusch F, 1999, ACTA ANAESTH SCAND, V43, P770, DOI 10.1034/j.1399-6576.1999.430714.x; Ramon Y, 2007, THER DRUG MONIT, V29, P644, DOI 10.1097/FTD.0b013e3180eaa10a; SaRego MM, 1997, ANESTH ANALG, V85, P1020, DOI 10.1097/00000539-199711000-00012; SHAPIRO FE, 2007, MANUAL OFFICE BASED, P55; Taghinia AH, 2008, PLAST RECONSTR SURG, V121, P269, DOI 10.1097/01.prs.0000293867.05857.90; 2002, ANESTHESIOLOGY, V4, P1004	21	12	13	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0952-7907	1473-6500		CURR OPIN ANESTHESIO	Curr. Opin. Anesthesiol.	DEC	2008	21	6					704	710		10.1097/ACO.0b013e328318694f			7	Anesthesiology	Anesthesiology	398ES	WOS:000262716000003	18997521				2020-06-30	J	Borland, ML; Clark, LJ; Esson, A				Borland, Meredith Louise; Clark, Lisa-Jayne; Esson, Amanda			Comparative review of the clinical use of intranasal fentanyl versus morphine in a paediatric emergency department	EMERGENCY MEDICINE AUSTRALASIA			English	Article						emergency; intranasal fentanyl; paediatric; time to analgesia	POSTOPERATIVE PAIN MANAGEMENT; RANDOMIZED CONTROLLED-TRIAL; INTRAVENOUS MORPHINE; ANALGESIA	Comparison of intranasal fentanyl (INF) and parenteral morphine in children in an ED. Primary objective was to compare time to analgesia from presentation, with secondary objectives to assess patient profiles, specifics of opiate analgesics used plus rate of i.v. access for analgesia alone. Tertiary paediatric ED. Retrospective review of case notes identified through controlled drug register. Patients who received INF and/or parenteral morphine between 1 January and 31 March 2005 (before introduction of fentanyl) and in corresponding months in 2006 and 2007 were included. A total of 617 patients were included. Geometric mean time to analgesia was statistically different for INF versus morphine in 2006 (31.2 min, SD 2.6 vs 55.6 min, SD 2.4) and in 2007 (23.7 min, SD 2.8 vs 53.1 min, SD 3.1) (both P < 0.000). Mean initial dose of INF in 2007 was 1.46 mg/kg (SD 0.11) compared with 1.32 mg/kg (SD 0.36) in 2006. Mean total dose in 2007 was 2.14 mg/kg (SD 0.93), increased from 1.60 mg/kg (SD 0.56) in 2006. INF was used most commonly for fractures and morphine for abdominal pain. The i.v. access for opiate analgesia decreased from 161/161 (100%) in 2005 to 99/237 (41.8%) in 2007. Use of INF in our paediatric ED setting was associated with a significantly reduced time to analgesia for patients requiring immediate analgesia compared with parenteral morphine. Since the introduction of an INF protocol to our department in mid-2005, INF use has increased, with a corresponding decrease in the use of morphine and a reduction in i.v. access for analgesia.	[Borland, Meredith Louise] Princess Margaret Hosp Children, Emergency Dept, Perth, WA 6840, Australia; [Borland, Meredith Louise] Univ Western Australia, Sch Paediat & Child Hlth, Perth, WA, Australia	Borland, ML (reprint author), Princess Margaret Hosp Children, Emergency Dept, GPO D184, Perth, WA 6840, Australia.	meredith.borland@health.wa.gov.au					Beale J P, 2001, Eur J Emerg Med, V8, P271, DOI 10.1097/00063110-200112000-00004; Borland M, 2007, ANN EMERG MED, V49, P335, DOI 10.1016/j.annemergmed.2006.06.016; Borland ML, 2005, BURNS, V31, P831, DOI 10.1016/j.burns.2005.05.001; Lim Stephen C. B., 2003, Journal of Pharmacy Practice and Research, V33, P59; Manjushree R, 2002, CAN J ANAESTH, V49, P190; Rickard C, 2007, AM J EMERG MED, V25, P911, DOI 10.1016/j.ajem.2007.02.027; STRIEBEL HW, 1993, ANAESTHESIA, V48, P753, DOI 10.1111/j.1365-2044.1993.tb07583.x; STRIEBEL HW, 1992, ANESTHESIOLOGY, V77, P281, DOI 10.1097/00000542-199208000-00010	8	48	48	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1742-6731	1742-6723		EMERG MED AUSTRALAS	Emerg. Med. Australas.	DEC	2008	20	6					515	520		10.1111/j.1742-6723.2008.01138.x			6	Emergency Medicine	Emergency Medicine	390FV	WOS:000262150600012	19125831				2020-06-30	J	Zeyneloglu, P; Pirat, A; Candan, S; Kuyumcu, S; Tekin, I; Arslan, G				Zeyneloglu, P.; Pirat, A.; Candan, S.; Kuyumcu, S.; Tekin, I.; Arslan, G.			Dexmedetomidine causes prolonged recovery when compared with midazolam/fentanyl combination in outpatient shock wave lithotripsy	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article						DEXMEDETOMIDINE; ANAESTHESIA RECOVERY PERIOD; LITHOTRIPSY; SEDATION; AMBULATORY CARE	SEDATION; PROPOFOL; REMIFENTANIL; ANESTHESIA; SUFENTANIL; INFUSION; SURGERY	Background and objectives: Analgesia and sedation are usually required during extracorporeal shock wave lithotripsy. In the present study, the recovery time and effectiveness of sedation and analgesia of dexmedetomidine me was compared with a midazolam/fentanyl combination in outpatient extracorporeal shock wave lithotripsy. Methods: Forty-nine patients scheduled for outpatient extracorporeal shock wave lithotripsy were randomly assigned to two groups: a dex group (n = 25; dexmedetomidine 1 mu g kg(-1) loading dose followed by dexmedetomidine 0.2 mu g kg(-1) h(-1)) and a control group (n = 24; midazolam 0.05 mg kg(-1) and fentanyl 1 mu g k(-1) h(-1)) and a control group (n = 24; midazolam 1 mg), and patients' satisfaction rates were recorded. Results: The two groups were similar regarding patient characteristics and procedure-related details (P>0.05). Recovery time was significantly prolonged in the dex group when compared with the control group (116.4 +/- 39.3 vs. 50.8 +/- 19.8 min, respectively, P < 0.001). The percentage of patients requiring rescue doses of fentanyl and the applied doses were significantly higher in the dex group than in the control group (96% vs. 67%, P = 0.01; and 69.0 +/- 31.7 vs. 38.8 +/- 42.9 mu g, respectively, P = 0.007). More patients in the dex group received rescue midazolam (96% vs. 58%, P = 0.002). More patients in the control group were highly satisfied with their sedarion/analgesia (83% vs. 56%, P = 0.038). Conclusion: Dexmedetomidine was associated with a longer recovery time than a midazolam/fentanyl combination when used for sedation and analgesia during Outpatient extracorporeal shock wave lithotripsy in this study. The incidence of rescue sedative and analgesic need was also significantly higher when demedetomidine was used.	[Zeyneloglu, P.; Pirat, A.; Candan, S.; Kuyumcu, S.; Arslan, G.] Baskent Univ, Fac Med, Dept Anaesthesiol, TR-06490 Ankara, Turkey; [Tekin, I.] Baskent Univ, Fac Med, Dept Urol, TR-06490 Ankara, Turkey	Pirat, A (reprint author), Baskent Univ Hastanesi, Anesteziyol Anabilim Dali, 10 Sok 45 Bahcelievler, TR-06490 Ankara, Turkey.	arashp@baskent-ank.edu.tr					ALDRETE JA, 1970, ANESTH ANAL CURR RES, V49, P924; Alhashemi JA, 2006, BRIT J ANAESTH, V96, P722, DOI 10.1093/bja/ael080; Alhashemi JA, 2006, CAN J ANAESTH, V53, P449, DOI 10.1007/BF03022616; Alhashemi JA, 2004, CAN J ANAESTH, V51, P342, DOI 10.1007/BF03018237; Arain SR, 2002, ANESTH ANALG, V95, P461, DOI 10.1097/00000539-200208000-00042; Beloeil H, 2002, BRIT J ANAESTH, V89, P567, DOI 10.1093/bja/aef202; Bhana N, 2000, DRUGS, V59, P263, DOI 10.2165/00003495-200059020-00012; But AK, 2006, ACTA ANAESTH SCAND, V50, P1207, DOI 10.1111/j.1399-6576.2006.01136.x; CHERNIK DA, 1990, J CLIN PSYCHOPHARM, V10, P244; Coursin D B, 2001, Curr Opin Crit Care, V7, P221, DOI 10.1097/00075198-200108000-00002; Eaton MP, 1997, REGION ANESTH, V22, P515; Guler G, 2005, ACTA ANAESTH SCAND, V49, P1088, DOI 10.1111/j.1399-6576.2005.00780.x; Hall JE, 2000, ANESTH ANALG, V90, P699, DOI 10.1097/00000539-200003000-00035; Ho AMH, 2005, BRIT J ANAESTH, V95, P773, DOI 10.1093/bja/aei263; Jalowiecki P, 2005, ANESTHESIOLOGY, V103, P269, DOI 10.1097/00000542-200508000-00009; Joo HS, 2001, ANESTH ANALG, V93, P1227, DOI 10.1097/00000539-200111000-00037; Kamibayashi T, 2000, ANESTHESIOLOGY, V93, P1345, DOI 10.1097/00000542-200011000-00030; Kaygusuz K, 2008, ANESTH ANALG, V106, P114, DOI 10.1213/01.ane.0000296453.75494.64; Koroglu A, 2006, ANESTH ANALG, V103, P63, DOI 10.1213/01.ane.0000219592.82598.AA; Mason KP, 2006, ANESTH ANALG, V103, P57, DOI 10.1213/01.ane.0000216293.16613.15; Medina HJ, 2005, ANESTH ANALG, V101, P365, DOI 10.1213/01.ANE.0000159379.54705.84; MONK TG, 1994, ANESTH ANALG, V79, P506; Moyer M K, 1988, AANA J, V56, P121	23	33	35	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0265-0215	1365-2346		EUR J ANAESTH	Eur. J. Anaesth.	DEC	2008	25	12					961	967		10.1017/S0265021508004699			7	Anesthesiology	Anesthesiology	377WK	WOS:000261282500002	18538051				2020-06-30	J	Cai, QQ; Huang, HQ; Sun, XF; Xia, ZJ; Li, YH; Lin, XB; Gun, Y				Cai, Qingqing; Huang, Huiqiang; Sun, Xiaofei; Xia, Zhongjun; Li, Yuhong; Lin, Xubin; Gun, Ying			Efficacy and safety of transdermal fentanyl for treatment of oral mucositis pain caused by chemotherapy	EXPERT OPINION ON PHARMACOTHERAPY			English	Review						chemotherapy; mucositis; non-cancerous pain; transdermal fentanyl	BONE-MARROW-TRANSPLANTATION; STEM-CELL TRANSPLANTATION; CHRONIC NONCANCER PAIN; LONG-TERM TREATMENT; CANCER PAIN; CONTROLLED ANALGESIA; MANAGEMENT; MORPHINE; TRIAL; SYSTEM	Background/objective: We investigated the efficacy and safety of transdermal fentanyl for severe mucositis pain caused by chemotherapy. Methods: Thirty-two patients who had moderate to severe pain using the Numeric Rating Scale (NRS) were enrolled in this study. The analgesic effect, quality of life and side effects were evaluated after the administration of transdermal fentanyl. Results: The median NRS score was reduced from 6 (range 4 - 9) before treatment to 4 (range 0 - 9), 2.5 (range 0 - 8), 2 (range 0 - 8), 2 (range 0 - 6) and 0 (range 0 - 5) on days 3, 5, 7, 10 and 15, respectively, after treatment (p < 0.001). The patients' quality of life also improved significantly (p < 0.01). The side effects of treatment were mild, and disappeared within several days. Conclusions: Transdermal fentanyl is an effective, convenient and well-tolerated treatment for severe mucositis pain caused by chemotherapy that can improve patients' quality of life.	[Cai, Qingqing; Huang, Huiqiang; Sun, Xiaofei; Xia, Zhongjun; Li, Yuhong; Lin, Xubin; Gun, Ying] Sun Yat Sen Univ, Ctr Canc, Dept Med Oncol, State Key Lab Oncol So China, Guangzhou 510060, Guangdong, Peoples R China	Huang, HQ (reprint author), Sun Yat Sen Univ, Ctr Canc, Dept Med Oncol, State Key Lab Oncol So China, 651 E Dongfeng Rd, Guangzhou 510060, Guangdong, Peoples R China.	huang_sysu@163.com					Allan L, 2001, BRIT MED J, V322, P1154, DOI 10.1136/bmj.322.7295.1154; ALLEN E, 1994, DIAGNOSTIC STAT MANU; [Anonymous], QLQC30 EORTC; Cancer Therapy Evaluation Program, 2003, COMM TERM CRIT ADV E; Clark AJ, 2004, CURR MED RES OPIN, V20, P1419, DOI 10.1185/030079904X2114; Coda BA, 1997, PAIN, V72, P333, DOI 10.1016/S0304-3959(97)00059-6; Darwish M, 2007, CLIN DRUG INVEST, V27, P605, DOI 10.2165/00044011-200727090-00002; Demarosi F, 2004, BONE MARROW TRANSPL, V33, P1247, DOI 10.1038/sj.bmt.1704515; Donner B, 1996, PAIN, V64, P527, DOI 10.1016/0304-3959(95)00180-8; Donner B, 1998, J PAIN SYMPTOM MANAG, V15, P168, DOI 10.1016/S0885-3924(97)00361-8; Eisen D, 1997, SEMIN CUTAN MED SURG, V16, P265, DOI 10.1016/S1085-5629(97)80015-6; Farrar JT, 2008, CLIN THER, V30, P974, DOI 10.1016/j.clinthera.2008.05.011; Finkel JC, 2005, CANCER-AM CANCER SOC, V104, P2847, DOI 10.1002/cncr.21497; Gourlay G K, 2001, Lancet Oncol, V2, P165, DOI 10.1016/S1470-2045(00)00258-8; Grond S, 1997, PAIN, V69, P191, DOI 10.1016/S0304-3959(96)03254-X; Hanks GW, 2004, PALLIATIVE MED, V18, P698, DOI 10.1191/0269216304pm966oa; HUANG H, 2001, CHIN J CLIN ONCOL, V28, P681; Jeal W, 1997, DRUGS, V53, P109, DOI 10.2165/00003495-199753010-00011; Kim JG, 2005, TRANSPL P, V37, P4488, DOI 10.1016/j.transproceed.2005.11.038; Kostler WJ, 2001, CA-CANCER J CLIN, V51, P290, DOI 10.3322/canjclin.51.5.290; Minkowitz HS, 2007, PAIN MED, V8, P657, DOI 10.1111/j.1526-4637.2006.00257.x; Mystakidou K, 2002, ONCOLOGY-BASEL, V62, P9, DOI 10.1159/000048241; PAYNE R, 1995, ANTI-CANCER DRUG, V6, P50, DOI 10.1097/00001813-199504003-00009; Peterson DE, 2008, ANN ONCOL, V19, P122, DOI 10.1093/annonc/mdn109; Pico JL, 1998, ONCOLOGIST, V3, P446; Pillitteri LC, 1998, BONE MARROW TRANSPL, V22, P495, DOI 10.1038/sj.bmt.1701370; Radtke Michelle L, 2005, J Oncol Pharm Pract, V11, P121, DOI 10.1191/1078155205jp159oa; Sloan PA, 1998, J PAIN SYMPTOM MANAG, V16, P102, DOI 10.1016/S0885-3924(98)00044-X; Stiff P, 2001, BONE MARROW TRANSPL, V27, pS3, DOI 10.1038/sj.bmt.1702863; Strupp C, 2000, ONCOL REP, V7, P659; Tawfik MO, 2004, CURR MED RES OPIN, V20, P259, DOI 10.1185/030079903125003026; Vielvoye-Kerkmeer APE, 2000, J PAIN SYMPTOM MANAG, V19, P185, DOI 10.1016/S0885-3924(99)00152-9; WORTHINGTON HV, 2007, COCHRANE DB SYST REV; Zucker TP, 1998, PAIN, V75, P305, DOI 10.1016/S0304-3959(98)00009-8	34	8	8	0	2	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1465-6566	1744-7666		EXPERT OPIN PHARMACO	Expert Opin. Pharmacother.	DEC	2008	9	18					3137	3144		10.1517/14656560802504508			8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	388KJ	WOS:000262018400001	19040334				2020-06-30	J	Kouvaras, E; Asprodini, EK; Asouchidou, I; Vasilaki, A; Kilindris, T; Michaloudis, D; Koukoutianou, I; Papatheodoropoulos, C; Kostopoulos, G				Kouvaras, E.; Asprodini, E. K.; Asouchidou, I.; Vasilaki, A.; Kilindris, T.; Michaloudis, D.; Koukoutianou, I.; Papatheodoropoulos, C.; Kostopoulos, G.			Fentanyl treatment reduces GABAergic inhibition in the CA1 area of the hippocampus 24 h after acute exposure to the drug	NEUROPHARMACOLOGY			English	Article						Hippocampus; Fentanyl; GABA; Inhibition; Electrophysiology; Immunohistochemistry	ACUTE OPIOID DEPENDENCE; LONG-TERM POTENTIATION; NALOXONE-PRECIPITATED WITHDRAWAL; GLUTAMIC-ACID DECARBOXYLASE; PYRAMIDAL CELLS; IN-VITRO; RAT HIPPOCAMPUS; MORPHINE-WITHDRAWAL; SYNAPTIC INHIBITION; MESSENGER-RNA	The effect of in vivo fentanyl treatment on synaptic transmission was studied in the CA1 area of the rat hippocampus. Animals were treated either with saline or fentanyl (4 x 80 mu g/kg, s.c./15 min). Intracellular in vitro recordings were obtained, 24 h after treatment, from CA1 pyramidal neurons. No difference in pyramidal neuron basic membrane properties or postsynaptic membrane excitability was observed between neurons from saline- and fentanyl-treated animals. The peak amplitude of fast (f-) and slow (s-) components of IPSPs elicited in standard ACSF and the peak amplitude and rate of rise of isolated f- and s-IPSPs elicited in the presence of antagonists (CNQX, 10 mu M; AP-5, 10 mu M; CGP 55845, 1 mu M; and bicuculline methochloride, 10 mu M), in response to various stimulus intensities, was smaller in fentanyl-treated animals. Conversely, the rising slope of excitatory responses was similar in neurons from saline- and fentanyl-treated animals. Furthermore, in fentanyl-treated animals, lower stimulus strengths were required to elicit subthreshold excitatory responses of the same amplitude suggesting that acute exposure to fentanyl increases susceptibility of pyramidal neurons to presynaptic stimulation. GABA immunohistochemistry revealed lower GABA content in processes and neuronal somata suggesting diminished GABA release onto pyramidal neurons. We conclude that acute in vivo exposure to fentanyl is sufficient to induce long-lasting reduction in GABA-mediated transmission, rather, than enhanced excitatory transmission or modulation of the intrinsic excitability of pyramidal neurons. These findings provide evidence regarding the mechanisms involved in the early stages of tolerance development towards the analgesic effects of opioids. (C) 2008 Elsevier Ltd. All rights reserved.	[Kouvaras, E.; Asprodini, E. K.; Asouchidou, I.; Vasilaki, A.; Koukoutianou, I.] Univ Thessaly, Sch Med, Pharmacol Lab, Fac Hlth Sci, Larisa 41222, Greece; [Kilindris, T.] Univ Thessaly, Sch Med, Lab Med Phys, Larisa 41222, Greece; [Papatheodoropoulos, C.; Kostopoulos, G.] Univ Patras, Sch Med, Physiol Lab, GR-26110 Patras, Greece; [Michaloudis, D.] Univ Thessaly, Sch Med, Anesthesiol Clin, Larisa 41222, Greece	Asprodini, EK (reprint author), Univ Thessaly, Sch Med, Pharmacol Lab, Fac Hlth Sci, 22 Papakiriazi St, Larisa 41222, Greece.	easpro@med.uth.gr	Vasilaki, Anna/AAD-3200-2020	Vasilaki, Anna/0000-0002-0852-4883; Papatheodoropoulos, Costas/0000-0002-7860-9583	Greek Ministry of EducationGreek Ministry of Development-GSRT; NOVARTIS Pharma AG, Basel, Switzerland	This work was supported by Greek Ministry of Education grant "PYTHAGORAS II". CGP35348 was kindly provided by Dr. M. Pozza, NOVARTIS Pharma AG, Basel, Switzerland.	Asensio VJ, 2006, EUR J PHARMACOL, V539, P49, DOI 10.1016/j.ejphar.2006.04.001; AZARALOSA JL, 1994, PSYCHOPHARMACOLOGY B, V114, P71; BICKEL WK, 1988, J PHARMACOL EXP THER, V244, P126; BJORKMAN S, 1993, J PHARMACOKINET BIOP, V21, P255, DOI 10.1007/BF01059779; Bowers G, 1998, J NEUROSCI, V18, P5938; CAPOGNA M, 1993, J PHYSIOL-LONDON, V470, P539, DOI 10.1113/jphysiol.1993.sp019874; Celerier E, 2004, NEUROPHARMACOLOGY, V46, P264, DOI 10.1016/j.neuropharm.2003.08.008; Celerier E, 2000, ANESTHESIOLOGY, V92, P465, DOI 10.1097/00000542-200002000-00029; DAVIES SN, 1989, PROC R SOC SER B-BIO, V236, P373, DOI 10.1098/rspb.1989.0028; DINGLEDINE R, 1981, J NEUROSCI, V1, P1022; Drake CT, 1999, BRAIN RES, V849, P203, DOI 10.1016/S0006-8993(99)01910-1; Fan Y, 2005, J NEUROPHYSIOL, V93, P1326, DOI 10.1152/jn.00734.2004; Fukuda T, 1998, J COMP NEUROL, V395, P177, DOI 10.1002/(SICI)1096-9861(19980601)395:2<177::AID-CNE3>3.0.CO;2-#; Gol A, 1966, Tex Med, V62, P76; Gray J. A., 2000, NEUROPHYSIOLOGY ANXI; GUERRA D, 1987, DRUG ALCOHOL DEPEN, V20, P261, DOI 10.1016/0376-8716(87)90036-6; Guo M, 2005, NEUROSCI LETT, V381, P12, DOI 10.1016/j.neulet.2005.01.071; HAAS HL, 1980, J PHYSIOL-LONDON, V308, P315, DOI 10.1113/jphysiol.1980.sp013473; Harris AC, 2005, PSYCHOPHARMACOLOGY, V178, P353, DOI 10.1007/s00213-005-2155-0; Harris AC, 2004, PSYCHOPHARMACOLOGY, V176, P266, DOI 10.1007/s00213-004-1889-4; HEBBEN N, 1985, BEHAV NEUROSCI, V99, P1031, DOI 10.1037/0735-7044.99.6.1031; HOUSER CR, 1994, HIPPOCAMPUS, V4, P530, DOI 10.1002/hipo.450040503; HUG CC, 1981, ANESTHESIOLOGY, V55, P369, DOI 10.1097/00000542-198110000-00006; Liu JA, 2004, PHARMACOL BIOCHEM BE, V79, P101, DOI 10.1016/j.pbb.2004.06.006; LUPICA CR, 1992, BRAIN RES, V593, P226, DOI 10.1016/0006-8993(92)91312-3; Mansouri FA, 1999, BRAIN RES, V815, P419, DOI 10.1016/S0006-8993(98)01148-2; Mao JR, 2002, PAIN, V100, P213, DOI 10.1016/S0304-3959(02)00422-0; MCKENNA JE, 1992, PAIN, V49, P105, DOI 10.1016/0304-3959(92)90195-H; McKenna JE, 2001, EXP NEUROL, V172, P92, DOI 10.1006/exnr.2001.7777; MOISES HC, 1994, J NEUROSCI, V14, P5903; Murphy DD, 1998, J NEUROSCI, V18, P2550; MURPHY MR, 1983, ANESTHESIOLOGY, V59, P537, DOI 10.1097/00000542-198312000-00009; NICOLL RA, 1980, NATURE, V287, P22, DOI 10.1038/287022a0; Papatheodoropoulos C, 2002, BRAIN RES, V948, P117, DOI 10.1016/S0006-8993(02)02958-X; Poon N, 2006, SYNAPSE, V59, P125, DOI 10.1002/syn.20223; Pu L, 2002, J NEUROSCI, V22, P1914, DOI 10.1523/JNEUROSCI.22-05-01914.2002; RAYNOR K, 1994, MOL PHARMACOL, V45, P330; Salmanzadeh F, 2003, BRAIN RES, V965, P108, DOI 10.1016/S0006-8993(02)04144-6; Schulteis G, 2004, PSYCHOPHARMACOLOGY, V175, P463, DOI 10.1007/s00213-004-1843-5; Shaw-Lutchman TZ, 2002, J NEUROSCI, V22, P3663; SIGGINS GR, 1981, P NATL ACAD SCI-BIOL, V78, P5235, DOI 10.1073/pnas.78.8.5235; SINCLAIR JG, 1986, NEUROSCI LETT, V68, P47, DOI 10.1016/0304-3940(86)90227-2; Song P, 2001, NEUROSCI RES, V39, P281, DOI 10.1016/S0168-0102(00)00226-1; Stumm RK, 2004, J COMP NEUROL, V469, P107, DOI 10.1002/cne.10997; Svoboda KR, 1998, J NEUROSCI, V18, P7084; SWEARENGEN E, 1989, NEUROPHARMACOLOGY, V28, P689, DOI 10.1016/0028-3908(89)90152-4; Vasilaki A, 2001, INVEST OPHTH VIS SCI, V42, P1600; Wei F, 2000, J CELL BIOL, V149, P1325, DOI 10.1083/jcb.149.7.1325; WHITEGBADEBO D, 1994, PHARMACOL BIOCHEM BE, V47, P559, DOI 10.1016/0091-3057(94)90159-7; WIGSTROM H, 1983, NATURE, V301, P603, DOI 10.1038/301603a0; WIMPEY TL, 1990, NEUROSCI LETT, V110, P349, DOI 10.1016/0304-3940(90)90872-7; Xu NJ, 2003, J NEUROSCI, V23, P4775; ZIEGLGANSBERGER W, 1979, SCIENCE, V205, P415, DOI 10.1126/science.451610	53	10	11	1	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	DEC	2008	55	7					1172	1182		10.1016/j.neuropharm.2008.07.025			11	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	377ZV	WOS:000261291800011	18706433				2020-06-30	J	Voronov, P; Tobin, MJ; Billings, K; Cote, CJ; Iyer, A; Suresh, S				Voronov, Polina; Tobin, Michael J.; Billings, Kathleen; Cote, Charles J.; Iyer, Aditya; Suresh, Santhanam			Postoperative pain relief in infants undergoing myringotomy and tube placement: comparison of a novel regional anesthetic block to intranasal fentanyl - a pilot analysis	PEDIATRIC ANESTHESIA			English	Article						myringotomy tube; postoperative analgesia; nerve of Arnold block; intranasal fentanyl	SEVOFLURANE ANESTHESIA; CHILDREN; ACETAMINOPHEN	Aim: The aim of this study was to investigate the use of a novel regional anesthetic technique for the management of pain in the postoperative period in infants and children undergoing myringotomy and tube placement. Methods: After institutional review board (IRB) approval was obtained, 200 children were randomized in this double blind, prospective, randomized controlled trial to receive either a nerve block of the auricular branch of the Vagus (Nerve of Arnold) with 0.2 ml of 0.25% bupivacaine or receive intranasal fentanyl 2 mcg.kg(-1) after induction of general anesthesia. Patients were monitored in the recovery room for analgesia, need for additional analgesia, incidence of nausea and vomiting, and time to discharge from the hospital. Additional analgesics administered in the PACU, surgical short-stay unit as well as at home were also recorded. Results: There was no difference in the pain scores between groups (P = 0.53); there was no difference in the amount of rescue medications between groups (P = 0.86); there was no difference in the incidence of nausea and vomiting between groups (P = 0.34); there was no difference in the time to discharge between groups (P = 0.5). Conclusions: This pilot study demonstrates the efficacy of a peripheral nerve block for management of postoperative pain in infants and children undergoing myringotomy and tube placement. This may be a viable alternative for postoperative pain control in this population. Future multi-center, randomized controlled trials may be necessary to validate the efficacy of this block in infants and children.	[Voronov, Polina; Suresh, Santhanam] Northwestern Univ, Childrens Mem Hosp, Feinberg Sch Med, Chicago, IL 60611 USA; [Tobin, Michael J.] Shriners Hosp Children, Oak Pk, IL USA; [Billings, Kathleen] Northwestern Univ, Childrens Mem Hosp, Div Pediat Otolaryngol, Feinberg Sch Med, Chicago, IL 60611 USA; [Cote, Charles J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02115 USA; [Iyer, Aditya] Northwestern Univ, Childrens Mem Hosp, Feinberg Sch Med, Chicago, IL 60611 USA	Suresh, S (reprint author), 2300 Childrens Plaza, Chicago, IL 60614 USA.	ssuresh@childrensmemorial.org					Bennie RE, 1998, ANESTHESIOLOGY, V89, P385, DOI 10.1097/00000542-199808000-00015; Bhananker SA, 2006, CAN J ANAESTH, V53, P1111, DOI 10.1007/BF03022879; Breschan C, 2007, PEDIATR ANESTH, V17, P347, DOI 10.1111/j.1460-9592.2006.02101.x; Buttner W, 2000, PAEDIATR ANAESTH, V10, P303, DOI 10.1046/j.1460-9592.2000.00530.x; Galinkin JL, 2000, ANESTHESIOLOGY, V93, P1378, DOI 10.1097/00000542-200012000-00006; Suresh S, 2002, ANESTH ANALG, V94, P859, DOI 10.1097/00000539-200204000-00015; WATCHA MF, 1992, CAN J ANAESTH, V39, P649, DOI 10.1007/BF03008224	7	14	14	0	3	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1155-5645			PEDIATR ANESTH	Pediatr. Anesth.	DEC	2008	18	12					1196	1201		10.1111/j.1460-9592.2008.02789.x			6	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	367GM	WOS:000260540500008	19076574				2020-06-30	J	Apiliogullari, S; Duman, A; Gok, F				Apiliogullari, Seza; Duman, Ates; Gok, Funda			Do infants need higher intrathecal fentanyl doses than older children? - reply	PEDIATRIC ANESTHESIA			English	Letter									[Duman, Ates] Selcuk Univ, Fac Med, Dept Anaesthesia & Intens Care, Konya, Turkey		sapiliogullari@yahoo.com					Batra YK, 2008, PEDIATR ANESTH, V18, P613, DOI 10.1111/j.1460-9592.2008.02613.x; LIU S, 1995, ANESTH ANALG, V80, P730, DOI 10.1097/00000539-199504000-00014	2	1	1	0	1	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1155-5645			PEDIATR ANESTH	Pediatr. Anesth.	DEC	2008	18	12					1248	1248		10.1111/j.1460-9592.2008.02751.x			1	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	367GM	WOS:000260540500044	18717793				2020-06-30	J	Kim, SY; Kim, EM; Nam, KH; Chang, DJ; Nam, SH; Kim, KJ				Kim, So Yeon; Kim, Eun Mi; Nam, Kee-Hyun; Chang, Dong Jin; Nam, Sun Ho; Kim, Ki Jun			Postoperative Intravenous Patient-Controlled Analgesia in Thyroid Surgery: Comparison of Fentanyl and Ondansetron Regimens With and Without the Nonsteriodal Anti-Inflammatory Drug Ketorolac	THYROID			English	Article							CERVICAL PLEXUS BLOCK; PARATHYROID SURGERY; GENERAL-ANESTHESIA; CESAREAN-SECTION; CONTROLLED TRIAL; PAIN RELIEF; KETOPROFEN; EFFICACY; NAUSEA; MORPHINE	Background: Nonsteroidal anti-inflammatory drugs (NSAIDs), through synergistic action with opioids, can reduce postoperative nausea and vomiting via intravenous patient-controlled analgesia (PCA). We compared the efficacy of three PCA regimens. Methods: Patients (n = 135) undergoing thyroidectomy were randomly allocated to three PCA regimens. All groups received 12 mg ondansetron (a serotonin 5-HT3 receptor antagonist). In addition, Group I received the opioid fentanyl, 15 mu g/kg. Group II received fentanyl 12.5 mu g/kg and the NSAID ketorolac, 1.5 mu g= kg, and Group III received fentanyl 10 mu g/kg and ketorolac 3 mu g/kg. Pain scores, nausea and vomiting, and dizziness were assessed 1, 6, 12, and 24 hours postoperatively. Results: Pain scores were similar among the three groups. However, postoperative nausea and vomiting was significantly lower in groups II and III (p < 0.05) than group I. Postoperative dizziness was significantly lower in group III than groups I and II (p < 0.05). Conclusions: The NSAID ketorolac when combined with lower doses of the opioid fentanyl and the same dose of ondansetron is associated with the same analgesic efficacy but less nausea and vomiting after thyroid surgery. A higher ratio of NSAID to opioid, when used as reported here, is associated with less postoperative dizziness.	[Kim, So Yeon; Kim, Eun Mi; Chang, Dong Jin; Nam, Sun Ho; Kim, Ki Jun] Yonsei Univ, Coll Med, Dept Anesthesiol & Pain Med, Anesthesia & Pain Res Inst, Seoul 120752, South Korea; [Nam, Kee-Hyun] Yonsei Univ, Coll Med, Dept Surg, Seoul 120752, South Korea	Kim, KJ (reprint author), Yonsei Univ, Coll Med, Dept Anesthesiol & Pain Med, Anesthesia & Pain Res Inst, CPO Box 8044, Seoul 120752, South Korea.	kkj6063@yumc.yonsei.ac.kr		Nam, Kee-Hyun/0000-0002-6852-1190; Kim, So Yeon/0000-0001-5352-157X; Kim, Ki Jun/0000-0003-1950-7998			Aunac S, 2002, ANESTH ANALG, V95, P746, DOI 10.1097/00000539-200209000-00039; Bagul A, 2005, THYROID, V15, P1245, DOI 10.1089/thy.2005.15.1245; BALLANTYNE JC, 1993, J CLIN ANESTH, V5, P182, DOI 10.1016/0952-8180(93)90013-5; Basto ER, 2001, ANESTH ANALG, V92, P1052; BEAVER WT, 1981, ARCH INTERN MED, V141, P293, DOI 10.1001/archinte.141.3.293; Bergamaschi R, 1998, AM J SURG, V176, P71, DOI 10.1016/S0002-9610(98)00099-3; Bliss RD, 2000, WORLD J SURG, V24, P891, DOI 10.1007/s002680010173; CONNELLY CS, 1991, ARCH INTERN MED, V151, P1963, DOI 10.1001/archinte.151.10.1963; DAHL JB, 1991, BRIT J ANAESTH, V66, P703, DOI 10.1093/bja/66.6.703; Daou R, 1997, Chirurgie, V122, P408; Defechereux T, 1999, J ALTERN COMPLEM MED, V5, P509, DOI 10.1089/acm.1999.5.509; Defechereux T, 2000, ANN CHIR, V125, P539, DOI 10.1016/S0003-3944(00)00238-8; Defechereux T, 1997, ANN CHIR, V51, P647; DOTTRENS M, 1992, BRIT J ANAESTH, V69, P9, DOI 10.1093/bja/69.1.9; EGBERT AM, 1990, ARCH INTERN MED, V150, P1897, DOI 10.1001/archinte.150.9.1897; Eti Z, 2006, ANESTH ANALG, V102, P1174, DOI 10.1213/01.ane.0000202383.51830.c4; FERRANTE FM, 1990, PATIENT CONTROLLED A, P3; Gan TJ, 2002, JAMA-J AM MED ASSOC, V287, P1233, DOI 10.1001/jama.287.10.1233; GOZAL Y, 1994, ACTA ANAESTH SCAND, V38, P813, DOI 10.1111/j.1399-6576.1994.tb04010.x; GRASS JA, 1930, ANESTH ANALG, V101, pS44; Han DW, 2006, THYROID, V16, P599, DOI 10.1089/thy.2006.16.599; HARMER M, 1983, BRIT MED J, V286, P680, DOI 10.1136/bmj.286.6366.680; Herbland A, 2006, REGION ANESTH PAIN M, V31, P34, DOI 10.1016/j.rapm.2005.10.008; HOMMERIL JL, 1994, BRIT J ANAESTH, V72, P383, DOI 10.1093/bja/72.4.383; HOPF HW, 1994, ARCH SURG-CHICAGO, V129, P128; HOWELL PR, 1995, CAN J ANAESTH, V42, P41, DOI 10.1007/BF03010570; Jokela R, 2002, ACTA ANAESTH SCAND, V46, P519, DOI 10.1034/j.1399-6576.2002.460508.x; Karamanlioglu B, 2003, EUR J ANAESTH, V20, P490, DOI 10.1097/00003643-200306000-00013; Kokki H, 1998, BRIT J ANAESTH, V81, P870; LEHMANN K A, 1988, Acta Anaesthesiologica Belgica, V39, P11; LIPPMANN M, 1993, ANESTH ANALG, V76, P1170, DOI 10.1213/00000539-199305000-00060; MCCORMACK K, 1994, PAIN, V59, P9, DOI 10.1016/0304-3959(94)90045-0; McHardy FE, 1999, ANAESTHESIA, V54, P444, DOI 10.1046/j.1365-2044.1999.00780.x; MCQUAY HJ, 1989, PAIN, V37, P7, DOI 10.1016/0304-3959(89)90147-4; Motamed C, 2006, EUR J ANAESTH, V23, P665, DOI 10.1017/S0265021506000391; Niemi TT, 1997, ACTA ANAESTH SCAND, V41, P1353, DOI 10.1111/j.1399-6576.1997.tb04657.x; OSBORNE RJ, 1986, BRIT MED J, V292, P1548, DOI 10.1136/bmj.292.6535.1548; ROBINSON SL, 1991, ANAESTHESIA, V46, P580, DOI 10.1111/j.1365-2044.1991.tb09663.x; RORARIUS MGF, 1993, ACTA ANAESTH SCAND, V37, P616, DOI 10.1111/j.1399-6576.1993.tb03776.x; Rushton ARA, 1997, BRIT J HOSP MED, V57, P105; SECHZER P H, 1968, Anesthesiology (Hagerstown), V29, P209, DOI 10.1097/00000542-196801000-00104; SHAHA A, 1988, SURGERY, V104, P1109; Sonner JM, 1997, J CLIN ANESTH, V9, P398, DOI 10.1016/S0952-8180(97)00069-X; Sun R, 1997, ANESTH ANALG, V84, P331, DOI 10.1097/00000539-199702000-00016; SUNSHINE A, 1987, CLIN PHARMACOL THER, V42, P374, DOI 10.1038/clpt.1987.166; Tang J, 1998, ANESTH ANALG, V86, P274, DOI 10.1097/00000539-199802000-00010; TauzinFin P, 1996, ANN FR ANESTH, V15, P41, DOI 10.1016/0750-7658(96)89401-9; Tramer MR, 1997, ANESTHESIOLOGY, V87, P1277, DOI 10.1097/00000542-199712000-00004; Vach B, 2002, Rozhl Chir, V81, P519; Walder B, 2001, ACTA ANAESTH SCAND, V45, P795, DOI 10.1034/j.1399-6576.2001.045007795.x	50	19	24	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1050-7256	1557-9077		THYROID	Thyroid	DEC	2008	18	12					1285	1290		10.1089/thy.2008.0007			6	Endocrinology & Metabolism	Endocrinology & Metabolism	381GB	WOS:000261522600008	18976162				2020-06-30	J	Davies, AN; Dickman, A; Reid, C; Stevens, AM; Zeppetella, G				Davies, Andrew N.; Dickman, Andrew; Reid, Colette; Stevens, Anna-Marie; Zeppetella, Giovambattista			Breakthrough cancer pain	BRITISH MEDICAL JOURNAL			English	Letter									[Davies, Andrew N.; Stevens, Anna-Marie] Royal Marsden NHS Fdn Trust, Sutton SM2 5PT, Surrey, England; [Dickman, Andrew] Marie Curie Palliat Care Inst, Liverpool, Merseyside, England; [Reid, Colette] Gloucestershire Hosp NHS Trust, Gloucester, England; [Zeppetella, Giovambattista] St Clare Hospice, Hastingwood, England	Davies, AN (reprint author), Royal Marsden NHS Fdn Trust, Sutton SM2 5PT, Surrey, England.	andrew.davies@rmh.nhs.uk					BAILEY F, 2006, CANC RELATED BREAKTH, P43; Cormie PJ, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a2154; DAVIES AN, EUR J PAIN; Gomez-Batiste X, 2002, J PAIN SYMPTOM MANAG, V24, P45, DOI 10.1016/S0885-3924(02)00421-9; Zeppetela G, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004311.pub2	5	8	8	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 25	2008	337								a2689	10.1136/bmj.a2689			2	Medicine, General & Internal	General & Internal Medicine	385QA	WOS:000261827500013	19033342				2020-06-30	J	Cho, JE; Kim, JY; Kim, JE; Chun, DH; Jun, NH; Kil, HK				Cho, J. E.; Kim, J. Y.; Kim, J. E.; Chun, D. H.; Jun, N. H.; Kil, H. K.			Epidural sufentanil provides better analgesia from 24 h after surgery compared with epidural fentanyl in children	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article							PREOPERATIVE ANXIETY; POSTOPERATIVE PAIN; BUPIVACAINE; ROPIVACAINE; INFUSION; LABOR; PHARMACOKINETICS; DELIVERY; MORPHINE	Background: Studies comparing epidural fentanyl and sufentanil in adults reported a similar analgesic effect with variable side effects. We hypothesized that epidural fentanyl and sufentanil will have a similar analgesic effect in children undergoing urological surgery. Methods: Sixty-four children undergoing urological surgery were randomized into two groups: fentanyl in ropivacaine (fentanyl group, n=32) and sufentanil in ropivacaine (sufentanil group, n=32). After anaesthesia, an epidural catheter was inserted at the L2-3, L3-4 or L4-5 interspace. For post-operative pain relief, a solution consisting of fentanyl 0.1 mcg/kg/ml or sufentanil 0.015 mcg/kg/ml in 1.5 mg/ml ropivacaine was infused at a rate of 2 ml/h. To assess post-operative pain, the faces pain scale and the face, legs, activity, cry, consolability score were recorded at 1, 6, 24, 48 and 72 h after surgery. The incidence of adverse effects such as hypoxia, sedation, pruritus, nausea and/or vomiting was also evaluated. Results: Pain scores demonstrated no significant difference between the groups. The need for rescue analgesia during 24-72 h was higher in the fentanyl group than in the sufentanil group (6/32 vs. 0/32, P=0.012). The incidence of pruritus was higher in the sufentanil group compared with that in the fentanyl group (5/32 vs. 0/32). Conclusions: Epidural sufentanil provides better analgesia from 24 h after surgery compared with epidural fentanyl in infants and children undergoing urological surgery. The incidence of pruritus in the sufentanil group was higher than that in the fentanyl group.	[Kil, H. K.] Yonsei Univ, Coll Med, Anesthesia & Pain Res Inst, Dept Anesthesiol & Pain Med, Seoul 120752, South Korea; [Kim, J. Y.; Kil, H. K.] Yonsei Univ, Coll Med, Anesthesiol & Pain Res Inst, Seoul 120752, South Korea	Kil, HK (reprint author), Yonsei Univ, Coll Med, Anesthesia & Pain Res Inst, Dept Anesthesiol & Pain Med, Sungsanno 250, Seoul 120752, South Korea.	hkkil@yuhs.ac		Kim, Ji Young/0000-0001-5822-0338			Axelsson K, 2005, ACTA ANAESTH SCAND, V49, P1191, DOI 10.1111/j.1399-6576.2005.00715.x; Bichel T, 2000, PAEDIATR ANAESTH, V10, P609, DOI 10.1111/j.1460-9592.2000.00557.x; Birmingham PK, 2003, ANESTH ANALG, V96, P686, DOI 10.1213/01.ANE.0000047209.18191.9E; Bosenberg A, 2003, PAEDIATR ANAESTH, V13, P708, DOI 10.1046/j.1460-9592.2003.01142.x; Bosenberg AT, 2005, PEDIATR ANESTH, V15, P739, DOI 10.1111/j.1460-9592.2004.01550.x; Butkovic D, 2007, BRIT J ANAESTH, V98, P677, DOI 10.1093/bja/aem055; CODA BA, 1994, ANESTHESIOLOGY, V81, P1149, DOI 10.1097/00000542-199411000-00008; COHEN S, 1993, ANESTHESIOLOGY, V78, P486, DOI 10.1097/00000542-199303000-00012; Cohen S, 1996, CAN J ANAESTH, V43, P341, DOI 10.1007/BF03011711; Curtis Sarah J, 2007, BMC Pediatr, V7, P27, DOI 10.1186/1471-2431-7-27; GELLER E, 1993, ANESTH ANALG, V76, P1243, DOI 10.1213/00000539-199376060-00011; GOURLAY GK, 1989, PAIN, V38, P253, DOI 10.1016/0304-3959(89)90210-8; Herman NL, 1998, J CLIN ANESTH, V10, P670, DOI 10.1016/S0952-8180(98)00113-5; Kain ZN, 2006, PEDIATRICS, V118, P651, DOI 10.1542/peds.2005-2920; Kokki H, 1999, ACTA ANAESTH SCAND, V43, P775, DOI 10.1034/j.1399-6576.1999.430715.x; Kokki H, 2002, ACTA ANAESTH SCAND, V46, P647, DOI 10.1034/j.1399-6576.2002.460603.x; Le Guen H, 2001, J CLIN ANESTH, V13, P98, DOI 10.1016/S0952-8180(01)00221-5; Lejus C, 2000, BRIT J ANAESTH, V85, P615, DOI 10.1093/bja/85.4.615; Lejus C, 2001, PAEDIATR ANAESTH, V11, P327, DOI 10.1046/j.1460-9592.2001.00659.x; Manworren Renee C B, 2003, Pediatr Nurs, V29, P140; Rolfseng OK, 2002, EUR J ANAESTH, V19, P812, DOI 10.1017/S026502150200131X; STEVENS RA, 1993, ANESTH ANALG, V76, P323; Svedberg KO, 2002, J CLIN PHARM THER, V27, P39, DOI 10.1046/j.1365-2710.2002.00386.x; Wright KD, 2007, BEHAV MODIF, V31, P52, DOI 10.1177/0145445506295055	24	11	14	0	4	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0001-5172			ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	NOV	2008	52	10					1360	1363		10.1111/j.1399-6576.2008.01796.x			4	Anesthesiology	Anesthesiology	361ME	WOS:000260131000010	19025528				2020-06-30	J	Marc, I; Rainville, P; Masse, B; Verreault, R; Vaillancourt, L; Vallee, E; Dodin, S				Marc, Isabelle; Rainville, Pierre; Masse, Benoit; Verreault, Rene; Vaillancourt, Lucie; Vallee, Estelle; Dodin, Sylvie			Hypnotic analgesia intervention during first-trimester pregnancy termination: an open randomized trial	AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY			English	Article; Proceedings Paper	International Congress on Complementary Medicine Research	MAY 11-13, 2007	Munich, GERMANY			anxiety; hypnosis; pain; pregnancy termination; randomized clinical trial	HYPNOSIS REDUCES DISTRESS; MEDICAL PROCEDURES; PAIN MANAGEMENT; SURGICAL ABORTION; BREAST BIOPSY; SEDATION; LORAZEPAM; CHILDREN; ANXIETY	OBJECTIVE: The purpose of this study was to determine whether hypnotic analgesia can reduce the need for intravenous sedation analgesia without increasing pain and anxiety levels during abortion. STUDY DESIGN: A cohort of 350 women who were scheduled for surgical abortion (< 14 weeks' gestation) were assigned randomly to a standard care group or a group that received a standardized hypnotic analgesia intervention 20 minutes before and throughout the surgical procedure. Primary outcome was the difference between the 2 groups: (1) the proportion who received sedation (yes/no) during the surgical procedure and (2) self-assessments of pain and anxiety during suction evacuation of uterus content. RESULTS: Women who underwent hypnosis required less intravenous sedation analgesia (108/172 women; 63%) than the control group (149/175 women; 85%; P < .0001) and self-reported no difference in pain, but not in anxiety, levels during suction evacuation. CONCLUSION: Hypnotic interventions can be effective as an adjunct to pharmacologic management of acute pain during abortion.	[Marc, Isabelle; Vallee, Estelle; Dodin, Sylvie] Univ Laval, Res Ctr, Quebec City, PQ, Canada; [Vaillancourt, Lucie] Univ Laval, Dept Family Planning, Quebec City, PQ, Canada; [Marc, Isabelle] Univ Laval, Dept Pediat, Quebec City, PQ, Canada; [Dodin, Sylvie] Univ Laval, Dept Obstet & Gynecol, Quebec City, PQ, Canada; [Verreault, Rene] Univ Laval, Hop St Francois Assise, Quebec City, PQ, Canada; [Verreault, Rene] Univ Laval, Hop St Sacrement, Dept Epidemiol, Geriatr Res Unit, Quebec City, PQ, Canada; [Rainville, Pierre] Univ Montreal, Fac Med Dent, Dept Stomatol, Montreal, PQ, Canada; Fred Hutchinson Canc Res Ctr, Stat Ctr HIV AIDS Res & Prevent, Seattle, WA 98104 USA	Marc, I (reprint author), Univ Laval, Res Ctr, Quebec City, PQ, Canada.		Rainville, Pierre/M-5480-2015	Rainville, Pierre/0000-0001-9801-757X; Masse, Benoit/0000-0002-4944-8098			Allen RH, 2006, CONTRACEPTION, V74, P407, DOI 10.1016/j.contraception.2006.06.002; Ashburn MA, 2004, ANESTHESIOLOGY, V100, P1573; BELANGER E, 1989, PAIN, V36, P339, DOI 10.1016/0304-3959(89)90094-8; Benotsch EG, 2000, ANN BEHAV MED, V22, P199, DOI 10.1007/BF02895114; Bryant RA, 2003, INT J CLIN EXP HYP, V51, P382, DOI 10.1076/iceh.51.4.382.16407; Butler LD, 2005, PEDIATRICS, V115, pE77, DOI 10.1542/peds.2004-0818; Enqvist B, 1997, ACTA ANAESTH SCAND, V41, P1028, DOI 10.1111/j.1399-6576.1997.tb04831.x; Faymonville ME, 1997, PAIN, V73, P361, DOI 10.1016/S0304-3959(97)00122-X; Jensen MP, 2005, INT J CLIN EXP HYP, V53, P170, DOI 10.1080/00207140590927536; Jensen MP, 1998, CLIN J PAIN, V14, P343, DOI 10.1097/00002508-199812000-00012; Keder LM, 2003, AM J OBSTET GYNECOL, V189, P418, DOI 10.1067/S0002-9378(03)00107-8; Kulier R, 2001, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002900; Lang EV, 2006, PAIN, V126, P155, DOI 10.1016/j.pain.2006.06.035; Lang EV, 2000, LANCET, V355, P1486, DOI 10.1016/S0140-6736(00)02162-0; Lang EV, 2002, RADIOLOGY, V222, P375, DOI 10.1148/radiol.2222010528; LIU JP, 2000, ENCY BIOPHARMACEUTIC, P515; Marc I, 2008, INT J CLIN EXP HYP, V56, P214, DOI 10.1080/00207140701849593; Marc I, 2007, CONTRACEPTION, V75, P52, DOI 10.1016/j.contraception.2006.07.012; MCCONKEY KM, 1986, INT J CLIN EXP HYP, V34, P311, DOI 10.1080/00207148608406996; Montgomery GH, 2002, INT J CLIN EXP HYP, V50, P17, DOI 10.1080/00207140208410088; MORGAN AH, 1979, AM J CLIN HYPN, V21, P134; Murphy DF, 1988, CLIN J PAIN, V3, P197, DOI [10.1097/00002508-198712000-00003, DOI 10.1097/00002508-198712000-00003]; Price DD, 1999, PAIN, V83, P147, DOI 10.1016/S0304-3959(99)00081-0; PRICE DD, 1980, PAIN, V8, P137, DOI 10.1016/0304-3959(88)90001-2; Price DD, 2006, PAIN, V124, P238, DOI 10.1016/j.pain.2006.04.021; Rainville P, 1997, SCIENCE, V277, P968, DOI 10.1126/science.277.5328.968; RAKEL D, 2006, APS B, V16, P3; Rawling MJ, 2001, AM J OBSTET GYNECOL, V185, P103, DOI 10.1067/mob.2001.115860; SMITH GM, 1979, AM J OBSTET GYNECOL, V133, P489, DOI 10.1016/0002-9378(79)90282-5; Sullivan MJL, 1995, PSYCHOL ASSESSMENT, V7, P524, DOI 10.1037/1040-3590.7.4.524; Weisman SJ, 1998, ARCH PEDIAT ADOL MED, V152, P147; Wiebe E, 2003, CONTRACEPTION, V67, P219, DOI 10.1016/S0010-7824(02)00516-4; Wong CYG, 2002, HUM REPROD, V17, P1222, DOI 10.1093/humrep/17.5.1222	33	25	25	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9378	1097-6868		AM J OBSTET GYNECOL	Am. J. Obstet. Gynecol.	NOV	2008	199	5							469.e1	10.1016/j.ajog.2008.01.058			9	Obstetrics & Gynecology	Obstetrics & Gynecology	367XL	WOS:000260585800006	18377854				2020-06-30	J	Pariaut, R; Moise, NS; Koetje, BD; Flanders, JA; Hemsley, SA; Farver, TB; Gilmour, RE; Gelzer, ARM; Kraus, MS; Otani, NF				Pariaut, Romain; Moise, N. Sydney; Koetje, Bethany D.; Flanders, James A.; Hemsley, Shari A.; Farver, Thomas B.; Gilmour, Robert E., Jr.; Gelzer, Anna R. M.; Kraus, Marc S.; Otani, Niels F.			Evaluation of atrial fibrillation induced during anesthesia with fentanyl and pentobarbital in German Shepherd Dogs with inherited arrhythmias	AMERICAN JOURNAL OF VETERINARY RESEARCH			English	Article							ISOLATED SHEEP HEART; VENTRICULAR ARRHYTHMIAS; EXPERIMENTAL-MODELS; SUDDEN-DEATH; ORGANIZATION; FREQUENCIES; MECHANISMS; ALTERNANS; DIAGNOSIS; DYNAMICS	Objective-To determine the type of atrial fibrillation induced by use of 2 pacing protocols during fentanyl and pentobarbital anesthesia before and after administration of atropine and to determine the organization of electrical activity in the left and right atria during atrial fibrillation in German Shepherd Dogs. Animals-7 German Shepherd Dogs. Procedures-Extrastimulus and pacedown protocols were performed before and after atropine administration. Monophasic action potential spectral entropy and mean dominant frequency were calculated during atrial fibrillation. Results-Atrial fibrillation occurred spontaneously in 6 of 7 dogs. All 7 dogs had atrial fibrillation induced. Sustained atrial fibrillation occurred in 13 of 25 (52%) episodes induced by the extrastimulus protocol and in 2 of 12 episodes of atrial fibrillation induced by pacedown. After atropine administration, sustained atrial fibrillation did not occur, and the duration of the nonsustained atrial fibrillation (6 episodes in 2 dogs of 1 to 26 seconds) was significantly shorter than before atropine administration (25 episodes in 7 dogs of 1 to 474 seconds). The left atrium (3.67 +/- 0.08) had lower spectral entropy than the right atrium (3.81 +/- 0.03), indicating more electrical organization in the left atrium. The mean dominant frequency was higher in the left atrium in 3 dogs. Conclusions and Clinical Relevance-Atrial fibrillation developed spontaneously and was induced in German Shepherd Dogs under fentanyl and pentobarbital anesthesia. Electrical activity was more organized in the left atrium than in the right atrium as judged by use of spectral entropy. (Am J Vet Res 2008:69:1434-1445)	[Pariaut, Romain; Moise, N. Sydney; Koetje, Bethany D.; Flanders, James A.; Hemsley, Shari A.; Gelzer, Anna R. M.; Kraus, Marc S.] Cornell Univ, Coll Vet Med, Dept Clin Sci, Ithaca, NY 14853 USA; [Gilmour, Robert E., Jr.; Otani, Niels F.] Cornell Univ, Coll Vet Med, Dept Biomed Sci, Ithaca, NY 14853 USA; [Farver, Thomas B.] Univ Calif Davis, Sch Vet Med, Dept Populat Hlth & Reprod, Davis, CA 95616 USA	Moise, NS (reprint author), Cornell Univ, Coll Vet Med, Dept Clin Sci, Ithaca, NY 14853 USA.						Barbaro V, 2000, PACE, V23, P192, DOI 10.1111/j.1540-8159.2000.tb00800.x; Barbaro V, 2000, PACE, V23, pVIII; EULER DE, 1987, AM J PHYSIOL, V253, pH863; Everett TH, 2006, AM J PHYSIOL-HEART C, V291, pH2911, DOI 10.1152/ajpheart.01128.2005; Gelzer ARM, 2000, J CARDIOVASC ELECTR, V11, P773, DOI 10.1111/j.1540-8167.2000.tb00049.x; Griffioen KJS, 2004, BRAIN RES, V1007, P109, DOI 10.1016/j.brainres.2004.02.010; Jalife J, 2002, CARDIOVASC RES, V54, P204, DOI 10.1016/S0008-6363(02)00223-7; Jalife J, 2003, J INTERV CARD ELECTR, V9, P85, DOI 10.1023/A:1026251517004; Koller ML, 2005, CIRCULATION, V112, P1542, DOI 10.1161/CIRCULATIONAHA.104.502831; Liu LL, 1997, AM J PHYSIOL-HEART C, V273, pH805; Mansour M, 2001, CIRCULATION, V103, P2631; MCGUIRK SM, 1985, VET CLIN N AM-EQUINE, V1, P353, DOI 10.1016/S0749-0739(17)30760-5; Menaut Pierre, 2005, J Vet Cardiol, V7, P75, DOI 10.1016/j.jvc.2005.07.002; Moe G K, 1968, J Electrocardiol, V1, P145; Moise N Sydney, 2005, J Vet Cardiol, V7, P143, DOI 10.1016/j.jvc.2005.09.004; MOISE NS, 1994, J AM COLL CARDIOL, V24, P233, DOI 10.1016/0735-1097(94)90568-1; Moise NS, 1999, CARDIOVASC RES, V44, P37, DOI 10.1016/S0008-6363(99)00198-4; Moise NS, 1997, J AM VET MED ASSOC, V210, P403; Moise NS, 1996, J CARDIOVASC ELECTR, V7, P217, DOI 10.1111/j.1540-8167.1996.tb00519.x; Narayan SM, 2002, CIRCULATION, V106, P1968, DOI 10.1161/01.CIR.0000037062.35762.B4; Nattel S, 2002, NATURE, V415, P219, DOI 10.1038/415219a; Ng J, 2006, HEART RHYTHM, V3, P1295, DOI 10.1016/j.hrthm.2006.07.027; POWELL GE, 1979, J PHYS A-MATH GEN, V12, P2053, DOI 10.1088/0305-4470/12/11/017; Rezek IA, 1998, IEEE T BIO-MED ENG, V45, P1186, DOI 10.1109/10.709563; Rishniw M, 1996, AM J VET RES, V57, P337; Sarmast F, 2003, CARDIOVASC RES, V59, P863, DOI 10.1016/S0008-6363(03)00540-6; Skanes AC, 1998, CIRCULATION, V98, P1236, DOI 10.1161/01.CIR.98.12.1236; Waldo AL, 2003, J CARDIOVASC ELECTR, V14, pS267, DOI 10.1046/j.1540-8167.2003.90401.x; Wilber DJ, 2002, J CARDIOVASC ELECTR, V13, P1280, DOI 10.1046/j.1540-8167.2002.01280.x; Wu TJ, 2001, J AM COLL CARDIOL, V38, P1757, DOI 10.1016/S0735-1097(01)01606-0	30	6	6	0	1	AMER VETERINARY MEDICAL ASSOC	SCHAUMBURG	1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173-4360 USA	0002-9645			AM J VET RES	Am. J. Vet. Res.	NOV	2008	69	11					1434	1445		10.2460/ajvr.69.11.1434			12	Veterinary Sciences	Veterinary Sciences	366LU	WOS:000260483800007	18980425				2020-06-30	J	Cappiello, E; O'Rourke, N; Segal, S; Tsen, LC				Cappiello, Eric; O'Rourke, Nollag; Segal, Scott; Tsen, Lawrence C.			A Randomized Trial of Dural Puncture Epidural Technique Compared with the Standard Epidural Technique for Labor Analgesia	ANESTHESIA AND ANALGESIA			English	Article							INTRATHECAL SUFENTANIL; ANESTHESIA; NEEDLE; BUPIVACAINE; PRESSURE; SPREAD	BACKGROUND: We designed this prospective, double-blind, randomized study to examine whether a dural puncture without intrathecal drug administration immediately before epidural drug administration would improve labor analgesia when compared to a traditional epidural technique without prior dural puncture. METHODS: Eighty nulliparous parturients with cervical dilation less than 5 cm were randomly assigned to receive a standardized epidural technique, with or without a single dural puncture with a 25-gauge (G) Whitacre spinal needle. After successful placement of the needle(s) and the epidural catheter, 12 mL of bupivacaine 2.5 mg/mL was administered through the epidural catheter and a patient-controlled epidural infusion of bupivacaine 1.25 mg/mL + fentanyl 2 mu g/mL was initiated. The presence of sacral analgesia (SI) and pain scores were compared between groups. RESULTS: In demographically similar groups, parturients with prior dural puncture had more frequent blockade of the S1 dermatome (absolute risk difference [95% confidence interval] 22% [6-39]), more frequent visual analog scale scores < 10/100 at 20 min (absolute risk difference 20% [1-38]), and reduced one-sided analgesia (absolute risk difference [95% CI] 17% [2-330]). The highest median sensory level (T10) was no different between groups. CONCLUSIONS: Dural puncture with a 25-G spinal needle immediately before the initiation of epidural analgesia improves the sacral spread, onset, and bilateral pain relief produced by analgesic concentrations of bupivacaine with fentanyl in laboring nulliparous patients.	[Cappiello, Eric; O'Rourke, Nollag; Segal, Scott; Tsen, Lawrence C.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA	Tsen, LC (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, 75 Francis St,CWN-L1, Boston, MA 02115 USA.	ltsen@zeus.bwh.harvard.edu	Segal, Scott/S-4157-2019	Segal, Scott/0000-0002-7647-6422; Tsen, Lawrence/0000-0002-1964-723X	Department of Anesthesiology, Perioperative and Pain Medicine; Brigham and Women's Hospital	Supported by the Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital.	BERNARDS CM, 1994, ANESTHESIOLOGY, V80, P853, DOI 10.1097/00000542-199404000-00019; Cook TM, 2000, ANAESTHESIA, V55, P42, DOI 10.1046/j.1365-2044.2000.01157.x; Eappen S, 1998, INT J OBSTET ANESTH, V7, P220, DOI 10.1016/S0959-289X(98)80042-3; Grocott HP, 1996, ANESTHESIOLOGY, V85, P1086, DOI 10.1097/00000542-199611000-00017; Leighton BL, 1996, ANESTH ANALG, V83, P526, DOI 10.1097/00000539-199609000-00015; MacArthur C, 2002, ANESTHESIOLOGY, V97, P1567; Mardirosoff C, 2002, BJOG-INT J OBSTET GY, V109, P274, DOI 10.1016/S1470-0328(02)01380-0; Norris MC, 2000, INT J OBSTET ANESTH, V9, P3, DOI 10.1054/ijoa.1999.0301; PAUL DL, 1989, BRIT J ANAESTH, V62, P368, DOI 10.1093/bja/62.4.368; Roux M, 1999, ANN FR ANESTH, V18, P487, DOI 10.1016/S0750-7658(99)80122-1; Segal S, 1999, ANESTHESIOLOGY, V91, P90, DOI 10.1097/00000542-199907000-00016; Suzuki N, 1996, ANESTH ANALG, V82, P1040, DOI 10.1097/00000539-199605000-00028; Thomas JA, 2005, ANESTHESIOLOGY, V103, P1046, DOI 10.1097/00000542-200511000-00019; Tsen LC, 2006, EXPERT REV MED DEVIC, V3, P499, DOI 10.1586/17434440.3.4.499; Tsen LC, 1999, ANESTHESIOLOGY, V91, P920, DOI 10.1097/00000542-199910000-00010; Van de Velde M, 2004, ANESTH ANALG, V98, P1153, DOI 10.1213/01.ANE.0000101980.34587.66; Van de Velde M, 2001, ANAESTH INTENS CARE, V29, P595, DOI 10.1177/0310057X0102900605; Wong CA, 2005, NEW ENGL J MED, V352, P655, DOI 10.1056/NEJMoa042573	18	56	60	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	NOV	2008	107	5					1646	1651		10.1213/ane.0b013e318184ec14			6	Anesthesiology	Anesthesiology	365HT	WOS:000260397200031	18931227				2020-06-30	J	Ganesh, A; Adzick, NS; Foster, T; Cucchiaro, G				Ganesh, Arjunan; Adzick, N. Scott; Foster, Travis; Cucchiaro, Giovanni			Efficacy of Addition of Fentanyl to Epidural Bupivacaine on Postoperative Analgesia after Thoracotomy for Lung Resection in Infants	ANESTHESIOLOGY			English	Article							REGIONAL ANESTHESIA; CONTINUOUS-INFUSION; CAUDAL MORPHINE; HUMAN NEONATE; PAIN RELIEF; CHILDREN; SURGERY; MANAGEMENT; STRESS; INJECTION	Background: The authors evaluated the efficacy of adding fentanyl to epidural bupivacaine in infants up to 6 months of age after a thoracotomy in a prospective, randomized, double-blind study. The primary outcome was the total amount of rescue doses of intravenous nalbuphine in the first 24 h after surgery. Secondary outcomes included (1) time to first rescue dose of nalbuphine, (2) pain scores, and (3) behavior scores., Methods: Thirty-two infants were randomly assigned to receive an epidural infusion containing 0.1% bupivacaine (group B; n = 16) or 0.1% bupivacaine and 2 mu g/ml fentanyl (group BF; n = 16). Patients were evaluated up to 24 h after surgery for pain; amount of analgesic rescues and time to first rescue; pain scores; behavior scores (five-item behavior score); and complication, including respiratory depression, oxygen requirement, vomiting, and urinary retention. Results: The two groups had similar demographics. Nalbuphine consumption (P = 0.001) and pain scores (P < 0.001) in the first 24 h were significantly decreased in group BF compared with group B. The time to first analgesic rescue was significantly longer in group BF (P = 0.005). The five-item behavior score was significantly better in group BF than in group B (P = 0.01). The incidence of side effects, the time to first successful feeding, and the time to discharge were similar in both groups. Conclusions: Addition of 2 mu g/ml epidural fentanyl to 0.1% bupivacaine results in improved postthoracotomy analgesia without any increase in side effects, compared with 0.1% bupivacaine, in infants up to 6 months of age.	[Ganesh, Arjunan] Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care Med, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Dept Surg, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Philadelphia, PA 19104 USA	Ganesh, A (reprint author), Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care Med, 34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	ganesha@email.chop.edu					AGARWAL R, 1992, ANESTH ANALG, V75, P284; Anand KJS, 2006, PEDIATRICS, V117, pS9, DOI 10.1542/peds.2005-0620C; ANAND KJS, 1987, LANCET, V1, P62; ANAND KJS, 1987, NEW ENGL J MED, V317, P1321, DOI 10.1056/NEJM198711193172105; ANAND KJS, 1985, HORM RES, V22, P115, DOI 10.1159/000180083; ANAND KJS, 1988, J PEDIATR SURG, V23, P297, DOI 10.1016/S0022-3468(88)80193-3; ANAND KJS, 1985, J PEDIATR SURG, V20, P41, DOI 10.1016/S0022-3468(85)80390-0; Bailey PD, 2005, J PEDIATR SURG, V40, P1118, DOI 10.1016/j.jpedsurg.2005.03.053; BERDE CB, 1992, ANESTH ANALG, V75, P164; Blanco D, 1996, REGION ANESTH, V21, P442; BOSENBERG AT, 1988, ANESTHESIOLOGY, V69, P265; Horak E, 2003, CLIN PEDIATR, V42, P251, DOI 10.1177/000992280304200309; JACQZAIGRAIN E, 1994, LANCET, V344, P646, DOI 10.1016/S0140-6736(94)92085-0; KRANE EJ, 1987, ANESTH ANALG, V66, P647; KRANE EJ, 1988, ANESTH ANALG, V67, P79; KRECHEL SW, 1995, PAEDIATR ANAESTH, V5, P53, DOI 10.1111/j.1460-9592.1995.tb00242.x; Lejus C, 2001, PAEDIATR ANAESTH, V11, P327, DOI 10.1046/j.1460-9592.2001.00659.x; Lemons JA, 2000, PEDIATRICS, V105, P454; Lin YC, 1999, PAEDIATR ANAESTH, V9, P139, DOI 10.1046/j.1460-9592.1999.9220313.x; Lovstad RZ, 2001, ACTA ANAESTH SCAND, V45, P482, DOI 10.1034/j.1399-6576.2001.045004482.x; MCCLOSKEY JJ, 1992, ANESTH ANALG, V75, P287; PURCELLJONES G, 1987, ANAESTHESIA, V42, P1316, DOI 10.1111/j.1365-2044.1987.tb05283.x; Raghavendran S, 2001, ANESTH ANALG, V93, P348, DOI 10.1097/00000539-200108000-00022; RASCH DK, 1990, CAN J ANAESTH, V37, P359, DOI 10.1007/BF03005591; TOBIAS JD, 1993, CAN J ANAESTH, V40, P879, DOI 10.1007/BF03009262; TOBIAS JD, 1993, CAN J ANAESTH, V40, P1065, DOI 10.1007/BF03009478; TRUOG R, 1989, CLIN PERINATOL, V16, P61; TYLER DC, 1989, J PEDIATR SURG, V24, P469, DOI 10.1016/S0022-3468(89)80404-X; VALLEY RD, 1991, ANESTH ANALG, V72, P120; WOLF AR, 1993, BRIT J ANAESTH, V70, P10, DOI 10.1093/bja/70.1.10	30	9	9	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-3022			ANESTHESIOLOGY	Anesthesiology	NOV	2008	109	5					890	894		10.1097/ALN.0b013e31818aa6cb			5	Anesthesiology	Anesthesiology	366XL	WOS:000260516800022	18946302	Bronze			2020-06-30	J	Agarwal, A; Gautam, S; Gupta, D; Agarwal, S; Singh, PK; Singh, U				Agarwal, A.; Gautam, S.; Gupta, D.; Agarwal, S.; Singh, P. K.; Singh, U.			Evaluation of a single preoperative dose of pregabalin for attenuation of postoperative pain after laparoscopic cholecystectomy	BRITISH JOURNAL OF ANAESTHESIA			English	Article						analgesia, postoperative; analgesia, pre-emptive; analgesics non-opioid; pain, postoperative	CONTROLLED-TRIAL; GABAPENTIN; SURGERY; CONVALESCENCE	Background. Postoperative pain is the dominating complaint and the primary reason for prolonged convalescence after laparoscopic cholecystectomy. We have evaluated the efficacy of a single preoperative dose of pregabalin for attenuating postoperative pain and fentanyl consumption after laparoscopic cholecystectomy. Methods. Sixty adults (16-60 yr), ASA physical status I and II, of either sex undergoing elective laparoscopic cholecystectomy were included in this prospective, randomized placebo controlled, double-blind study. Subjects were divided into two groups of 30 each to receive either a matching placebo or pregabalin 150 mg, administered orally 1 h before surgery. Postoperative pain (static and dynamic) was assessed by a 100 mm visual analogue scale, where 0, no pain; 100, worst imaginable pain. Subjects received patient-controlled i.v. fentanyl analgesia during the postoperative period. Results were analysed by Student's t-test, chi(2) test, Mann-Whitney U-test, and Fisher's exact test. Results. Postoperative pain (static and dynamic) and postoperative patient-controlled fentanyl consumption were reduced in the pregabalin group compared with the placebo group (P < 0.05). Side-effects were similar in both groups. Conclusions. A single preoperative oral dose of pregabalin 150 mg is an effective method for reducing postoperative pain and fentanyl consumption in patients undergoing laparoscopic cholecystectomy.	[Agarwal, A.; Gautam, S.; Gupta, D.; Agarwal, S.; Singh, P. K.] Sanjay Gandhi Postgrad Inst Med Sci, Dept Anaesthesiol, Lucknow 226014, Uttar Pradesh, India; [Singh, U.] Sanjay Gandhi Postgrad Inst Med Sci, Dept Biostat, Lucknow 226014, Uttar Pradesh, India	Agarwal, A (reprint author), Sanjay Gandhi Postgrad Inst Med Sci, Dept Anaesthesiol, Type 5 B-11, Lucknow 226014, Uttar Pradesh, India.	aagarwal@sgpgi.ac.in					Ben-Menachem E, 2004, EPILEPSIA, V45, P13, DOI 10.1111/j.0013-9580.2004.455003.x; Bisgaard T, 2001, PAIN, V90, P261, DOI 10.1016/S0304-3959(00)00406-1; Bisgaard T, 2005, SCAND J GASTROENTERO, V40, P1358, DOI 10.1080/00365520510023675; Bisgaard T, 2001, EUR J SURG, V167, P84; Bisgaard T, 2001, ARCH SURG-CHICAGO, V136, P917, DOI 10.1001/archsurg.136.8.917; Bryans JS, 1999, MED RES REV, V19, P149, DOI 10.1002/(SICI)1098-1128(199903)19:2<149::AID-MED3>3.0.CO;2-B; Callesen T, 1998, Ugeskr Laeger, V160, P2095; Dahl JB, 2004, ACTA ANAESTH SCAND, V48, P1130, DOI 10.1111/j.1399-6576.2004.00484.x; Dooley DJ, 2000, J PHARMACOL EXP THER, V295, P1086; DUBOIS F, 1990, ANN SURG, V211, P60, DOI 10.1097/00000658-199001000-00010; Fassoulaki A, 2002, ANESTH ANALG, V95, P985, DOI 10.1097/00000539-200210000-00036; Fink K, 2002, NEUROPHARMACOLOGY, V42, P229, DOI 10.1016/S0028-3908(01)00172-1; Frampton JE, 2004, DRUGS, V64, P2813, DOI 10.2165/00003495-200464240-00006; Gottschalk A, 2001, AM FAM PHYSICIAN, V63, P1979; Hill CM, 2001, EUR J PAIN, V5, P119, DOI 10.1053/eujp.2001.0235; Jokela R, 2008, BRIT J ANAESTH, V100, P834, DOI 10.1093/bja/aen098; Jokela R, 2008, PAIN, V134, P106, DOI 10.1016/j.pain.2007.04.002; Kavoussi R, 2006, EUR NEUROPSYCHOPHARM, V16, pS128, DOI 10.1016/j.euroneuro.2006.04.005; Kong VKF, 2007, BRIT J ANAESTH, V99, P775, DOI 10.1093/bja/aem316; Lau H, 2001, ARCH SURG-CHICAGO, V136, P1150, DOI 10.1001/archsurg.136.10.1150; Paech MF, 2007, ANESTH ANALG, V105, P1449, DOI 10.1213/01.ane.0000286227.13306.d7; Pandey CK, 2004, CAN J ANAESTH, V51, P358, DOI 10.1007/BF03018240; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; Reuben SS, 2006, ANESTH ANALG, V103, P1271, DOI 10.1213/01.ane.0000237279.08847.2d; Turan A, 2004, ANESTHESIOLOGY, V100, P935, DOI 10.1097/00000542-200404000-00025; WALL PD, 1988, PAIN, V33, P289, DOI 10.1016/0304-3959(88)90286-2; WOLF CJ, 1993, ANESTH ANALG, V77, P362; WOOLF CJ, 1983, NATURE, V306, P686, DOI 10.1038/306686a0	28	135	142	0	1	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0007-0912			BRIT J ANAESTH	Br. J. Anaesth.	NOV	2008	101	5					700	704		10.1093/bja/aen244			5	Anesthesiology	Anesthesiology	361MN	WOS:000260131900016	18716003	Bronze			2020-06-30	J	Lauwick, S; Kim, DJ; Michelagnoli, G; Mistraletti, G; Feldman, L; Fried, G; Carli, F				Lauwick, Severine; Kim, Do Jun; Michelagnoli, Giuliano; Mistraletti, Giovanni; Feldman, Liane; Fried, Gerald; Carli, Franco			Intraoperative infusion of lidocaine reduces postoperative fentanyl requirements in patients undergoing laparoscopic cholecystectomy	CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Article							INTRAVENOUS LIDOCAINE; BOWEL FUNCTION; HOSPITAL STAY; PAIN; RECOVERY; ANESTHESIA; ANALGESIA	Background: Lidocaine has been shown to inhibit neural conduction and to have anti-inflammatory properties. The purpose of this study was to determine whether intraoperative lidocaine infusion reduces opioid consumption in the postanesthesia care unit (PACU). Methods: Fifty patients were enrolled in this prospective, randomized and observer-blinded study. At induction of anesthesia the control group (n = 25) received fentanyl 3 mu g.kg(-1) while the lindocaine group received fentanyl 1.5 mu g.kg(-1) and a bolus of lidocaine 1.5 mg.kg(-1) followed by a continuous infusion of lidocaine 2 mg.kg(-1).hr(-1). General anesthesia included propofol, rocuronium, and desflurane titrated to maintain blood pressure and heart rate within set parameters, and the bispectral index between 35 and 50. No supplemental opioids were given during surgery. All patients received acetaminophen, ketorolac, dexamethasone, droperidol and local anesthetics in the skin incision. Patients received fentanyl and ondansetron in the PACU. The primary outcome variable was the amount of fentanyl required in the PACU to establish and to maintain visual analogue scale pain scores < 3. Results: Most patients received fentanyl for pain relief in the PACU, but the cumulative mean dose was lower in the lidocaine group compared to the control group (98 +/- 54 mu g, vs 154 +/- 99 mu g, respectively, P = 0.018). Lidocaine infusion reduced by 10% the amount of desflurane required (P = 0.0 12). White-Song scores > 12 were attained by all patients in both groups within 30 min of their arrival in the PACU. Median time from arrival to the PACU to discharge home was similar in both groups, 167.5 min in the control group vs 180 min in the lidocaine group (P = 0.649). Conclusion: Intraoperative lidocaine infusion reduces opioid consumption in the PACU and intraoperative requirements of desflurane.	[Lauwick, Severine; Kim, Do Jun; Michelagnoli, Giuliano; Mistraletti, Giovanni; Carli, Franco] McGill Univ, Ctr Hlth, Dept Anesthesia, Montreal, PQ H3G 1A4, Canada; [Feldman, Liane; Fried, Gerald] McGill Univ, Ctr Hlth, Dept Surg, Montreal, PQ H3G 1A4, Canada; [Feldman, Liane; Fried, Gerald] McGill Univ, Ctr Hlth, Steinberg Bernstein Ctr Minimally Invas Surg, Montreal, PQ H3G 1A4, Canada	Carli, F (reprint author), McGill Univ, Ctr Hlth, Dept Anesthesia, 1650 Cedar Ave,Room D10-144, Montreal, PQ H3G 1A4, Canada.	franco.carli@mcgill.ca	Mistraletti, Giovanni/O-5859-2017; garcia, waynice np/K-3914-2015	Mistraletti, Giovanni/0000-0001-8322-1623; 	McGill University Health Centre	This work was supported by internal funds, Department of Anesthesia, McGill University Health Centre. None of the authors has any conflict of interest related to this Study.	Bisgaard T, 2006, ANESTHESIOLOGY, V104, P835, DOI 10.1097/00000542-200604000-00030; Bisgaard T, 2001, PAIN, V90, P261, DOI 10.1016/S0304-3959(00)00406-1; Collins G, 2007, OIL GAS J, V105, P62; Groudine SB, 1998, ANESTH ANALG, V86, P235, DOI 10.1097/00000539-199802000-00003; Herroeder S, 2007, ANN SURG, V246, P192, DOI 10.1097/SLA.0b013e31805dac11; HIMES RS, 1977, ANESTHESIOLOGY, V47, P437, DOI 10.1097/00000542-197711000-00010; Hollmann MW, 2005, ANESTHESIOLOGY, V103, P1066, DOI 10.1097/00000542-200511000-00022; Hollmann MW, 2000, ANESTHESIOLOGY, V93, P858, DOI 10.1097/00000542-200009000-00038; Hollmann MW, 2001, ANESTHESIOLOGY, V95, P113, DOI 10.1097/00000542-200107000-00021; Kaba A, 2007, ANESTHESIOLOGY, V106, P11, DOI 10.1097/00000542-200701000-00007; Kehlet H, 2005, SURG ENDOSC, V19, P1396, DOI 10.1007/s00464-004-2173-8; Koppert W, 2004, ANESTH ANALG, V98, P1050, DOI 10.1213/01.ANE.0000104582.71710.EE; Lau H, 2002, WORLD J SURG, V26, P1117, DOI 10.1007/s00268-002-6264-1; Martin F, 2008, ANESTHESIOLOGY, V109, P118, DOI 10.1097/ALN.0b013e31817b5a9b; Ness TJ, 2000, ANESTHESIOLOGY, V92, P1685, DOI 10.1097/00000542-200006000-00028; Pypendop BH, 2005, ANESTH ANALG, V100, P97, DOI 10.1213/01.ANE.0000139350.88158.38; Song D, 1999, J CLIN ANESTH, V11, P364, DOI 10.1016/S0952-8180(99)00061-6; Watt-Watson Judy, 2004, J Nurs Manag, V12, P153; White PF, 1999, ANESTH ANALG, V88, P1069, DOI 10.1097/00000539-199905000-00018; White PF, 2002, ANESTH ANALG, V94, P577, DOI 10.1097/00000539-200203000-00019; Wu CT, 2005, ANESTH ANALG, V100, P448, DOI 10.1213/01.ANE.0000142551.92340.CC	21	50	53	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0832-610X			CAN J ANAESTH	Can. J. Anaesth.-J. Can. Anesth.	NOV	2008	55	11					754	760		10.1007/BF03016348			7	Anesthesiology	Anesthesiology	374LJ	WOS:000261044600005	19138915	Bronze			2020-06-30	J	Kim, H; Czuczman, G; Nicholson, W; Pham, L; Richman, J				Kim, Hyun S.; Czuczman, Gregory J.; Nicholson, Wanda K.; Pham, Luu D.; Richman, Jeffrey M.			Pain Levels Within 24 Hours After UFE: A Comparison of Morphine and Fentanyl Patient-Controlled Analgesia	CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY			English	Article						Patient-controlled analgesia; Pain; Post-uterine artery embolization pain; Post-uterine fibroid embolization pain; Uterine artery embolization; Uterine fibroid embolization	UTERINE ARTERY EMBOLIZATION; ACRYL GELATIN MICROSPHERES; SHORT-TERM OUTCOMES; UTEROOVARIAN ANASTOMOSES; POSTOPERATIVE PAIN; AFRICAN-AMERICAN; LEIOMYOMATA; SEVERITY; RECOVERY; FIBROIDS	The purpose of this study was to assess the presence and severity of pain levels during 24 h after uterine fibroid embolization (UFE) for symptomatic leiomyomata and compare the effectiveness and adverse effects of morphine patient-controlled analgesia (PCA) versus fentanyl PCA. We carried out a prospective, nonrandomized study of 200 consecutive women who received UFE and morphine or fentanyl PCA after UFE. Pain perception levels were obtained on a 0-10 scale for the 24-h period after UFE. Linear regression methods were used to determine pain trends and differences in pain trends between two groups and the association between pain scores and patient covariates. One hundred eighty-five patients (92.5%) reported greater-than-baseline pain after UFE, and 198 patients (99%) required IV opioid PCA. One hundred thirty-six patients (68.0%) developed nausea during the 24-h period. Seventy-two patients (36%) received morphine PCA and 128 (64%) received fentanyl PCA, without demographic differences. The mean dose of morphine used was 33.8 +/- 26.7 mg, while the mean dose of fentanyl was 698.7 +/- 537.4 mu g. Using this regimen, patients who received morphine PCA had significantly lower pain levels than those who received fentanyl PCA (p < 0.0001). We conclude that patients develop pain requiring IV opioid PCA within 24 h after UFE. Morphine PCA is more effective in reducing post-uterine artery embolization pain than fentanyl PCA. Nausea is a significant adverse effect from opioid PCA.	[Kim, Hyun S.] Johns Hopkins Sch Med, Div Vasc & Intervent Radiol, Russell H Morgan Dept Radiol & Radiol Sci, Baltimore, MD 21287 USA; [Kim, Hyun S.; Czuczman, Gregory J.] Johns Hopkins Univ, Sch Med, Russell H Morgan Dept Radiol & Radiol Sci, Baltimore, MD 21205 USA; [Kim, Hyun S.; Nicholson, Wanda K.] Johns Hopkins Univ, Sch Med, Dept Gynecol & Obstet, Baltimore, MD 21205 USA; [Pham, Luu D.] Johns Hopkins Univ, Sch Med, Dept Biostat, Baltimore, MD 21205 USA; [Richman, Jeffrey M.] Johns Hopkins Univ, Sch Med, Dept Anesthesiol, Baltimore, MD 21205 USA	Kim, H (reprint author), Johns Hopkins Sch Med, Div Vasc & Intervent Radiol, Russell H Morgan Dept Radiol & Radiol Sci, 600 N Wolfe St,Blalock 545, Baltimore, MD 21287 USA.	sikhkim@jhmi.edu					Andrews RT, 2004, J VASC INTERV RADIOL, V15, P115, DOI 10.1097/01.RVI.0000109408.52762.35; Bruno J, 2004, J VASC INTERV RADIOL, V15, P801, DOI 10.1097/01.RVI.0000136983.45640.E4; Cano A, 2006, J PAIN, V7, P459, DOI 10.1016/j.jpain.2006.01.445; Cooper LA, 2003, ANN INTERN MED, V139, P907, DOI 10.7326/0003-4819-139-11-200312020-00009; Edwards RR, 2001, PSYCHOSOM MED, V63, P316, DOI 10.1097/00006842-200103000-00018; GINSBERG B, 1995, PAIN, V62, P95, DOI 10.1016/0304-3959(94)00255-D; Goodwin SC, 1999, J VASC INTERV RADIOL, V10, P1159, DOI 10.1016/S1051-0443(99)70213-7; Goodwin SC, 2003, J VASC INTERV RADIOL, V14, pS467; Green CR, 2004, J PAIN, V5, P171, DOI 10.1016/j.jpain.2004.02.227; Hehenkamp WJK, 2006, CARDIOVASC INTER RAD, V29, P179, DOI 10.1007/s00270-005-0195-9; HORNER RD, 1995, MILBANK Q, V73, P443, DOI 10.2307/3350374; Hovsepian DM, 2006, J VASC INTERV RADIOL, V17, P665, DOI 10.1097/01.RVI.0000208986.80383.4C; HOWELL PR, 1995, CAN J ANAESTH, V42, P41, DOI 10.1007/BF03010570; Keyoung JA, 2001, J VASC INTERV RADIOL, V12, P1065, DOI 10.1016/S1051-0443(07)61592-9; Kim HS, 2006, J VASC INTERV RADIOL, V17, P965, DOI 10.1097/01.RVI.0000220425.23309.15; Kim HS, 2006, J VASC INTERV RADIOL, V17, P783, DOI 10.1097/01.RVI.0000209342.02567.C2; Kim T, 2007, CURR OPIN OPHTHALMOL, V18, P39, DOI 10.1097/ICU.0b013e328012166e; Nagao Tomoya, 2005, Japanese Journal of Anesthesiology, V54, P156; ORSINI LF, 1984, RADIOLOGY, V153, P113, DOI 10.1148/radiology.153.1.6473771; Portenoy RK, 2004, J PAIN, V5, P317, DOI 10.1016/j.jpain.2004.05.005; Pron G, 2003, J VASC INTERV RADIOL, V14, P1243, DOI 10.1097/01.RVI.0000092664.72261.F9; Pron G, 2003, FERTIL STERIL, V79, P120, DOI 10.1016/S0015-0282(02)04538-7; Rasuli P, 2004, J VASC INTERV RADIOL, V15, P1423, DOI 10.1097/01.RVI.0000137406.09852.A4; Ravina J-H, 2003, Gynecol Obstet Fertil, V31, P597, DOI 10.1016/S1297-9589(03)00188-7; Rosenquist RW, 2003, REGION ANESTH PAIN M, V28, P279, DOI 10.1016/S1098-7339(03)00035-X; Roth AR, 2000, J VASC INTERV RADIOL, V11, P1047, DOI 10.1016/S1051-0443(07)61337-2; Ryu RK, 2003, CARDIOVASC INTER RAD, V26, P375, DOI 10.1007/s00270-003-0045-6; Siskin GP, 1999, J VASC INTERV RADIOL, V10, P891, DOI 10.1016/S1051-0443(99)70133-8; Spies JB, 2005, OBSTET GYNECOL, V106, P933, DOI 10.1097/01.AOG.0000182582.64088.84; Spies JB, 2003, J VASC INTERV RADIOL, V14, P1219, DOI 10.1097/01.RVI.0000092661.72261.AS; Spies JB, 2001, OBSTET GYNECOL, V98, P29, DOI 10.1016/S0029-7844(01)01382-5; Walker WJ, 2002, BJOG-INT J OBSTET GY, V109, P1262, DOI 10.1016/S1470-0328(02)01949-3; Woodhouse A, 1996, PAIN, V64, P115, DOI 10.1016/0304-3959(95)00082-8; Worthington-Kirsch R, 2005, OBSTET GYNECOL, V106, P52, DOI 10.1097/01.AOG.0000165828.68787.a9; Zhan SH, 2005, EUR RADIOL, V15, P1752, DOI 10.1007/s00330-005-2686-0	35	19	21	0	5	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0174-1551	1432-086X		CARDIOVASC INTER RAD	Cardiovasc. Interv. Radiol.	NOV	2008	31	6					1100	1107		10.1007/s00270-008-9430-5			8	Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging	Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging	370MN	WOS:000260766400008	18797963				2020-06-30	J	Mercadante, S; Porzio, G; Ferrera, P; Fulfaro, F; Alelli, F; Verna, L; Villari, P; Ficorella, C; Gebbia, V; Riina, S; Casuccio, A; Mangione, S				Mercadante, Sebastiano; Porzio, Giampiero; Ferrera, Patrizia; Fulfaro, Fabio; Alelli, Federica; Verna, Lucilla; Villari, Patrizia; Ficorella, Corrado; Gebbia, Vittorio; Riina, Salvatore; Casuccio, Alessandra; Mangione, Salvatore			Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management	EUROPEAN JOURNAL OF PAIN			English	Article						Cancer pain; Morphine; Methadone; Fentanyl; Costs	QUALITY-OF-LIFE; EAPC RECOMMENDATIONS; IMMEDIATE-RELEASE; EFFICACY; OPIOIDS; CONSTIPATION; OXYCODONE; SAFETY; TRIAL; RATS	Purpose: The aim of this study was to compare the analgesic and adverse effects, doses, as well as cost of opioid drugs, supportive drug therapy and other analgesic drugs in patients treated with oral sustained-release morphine, transdermal fentanyl, and oral methadone. Patients and methods: One hundred and eight cancer patients, no longer responsive to opioids for moderate pain, were selected to randomly receive initial daily doses of 60 mg of oral sustained-release morphine, 15 mg of oral methadone, or 0.6 mg (25 mu g/h) of transdermal fentanyl. Oral morphine was used as breakthrough pain medication during opioid titration. Opioid doses, pain intensity, adverse effects, symptomatic drugs, were recorded at week intervals of 4 weeks. Costs of opioid therapy, supportive drugs, and other analgesic drugs were also evaluated. Results: Seventy patients completed the 4 weeks period of study. Five, five, and four patients, treated with oral morphine, transdermal fentanyl, and oral methadone, respectively, required opioid switching. No differences in pain and symptom intensity were observed. Opioid escalation index was significantly lower in patients receiving methadone (p < 0.0001), although requiring up and down changes in doses. At the doses used, methadone was significantly less expensive (p < 0.0001), while the use and costs of supportive drugs and other analgesics were similar in the three groups. No relevant differences in adverse effects were observed among the groups during either the titration phase and chronic treatment. Conclusion: All the three opioids used as first-line therapy were effective, well tolerated and required similar amounts of symptomatic drugs or co-analgesics. Methadone was significantly less expense, but required more changes, up and down, of the doses, suggesting that dose titration of this drug requires major clinical expertise. (C) 2008 European Federation of Chapters of the International Association for the Study of Pain. Published by Elsevier Ltd. All rights reserved.	[Mercadante, Sebastiano; Ferrera, Patrizia; Villari, Patrizia; Riina, Salvatore] La Maddalena Canc Ctr, Pain Relief & Palliat Care Unit, I-90146 Palermo, Italy; [Mercadante, Sebastiano; Mangione, Salvatore] Univ Palermo, Palliat Med Anesthesia & Intens Care Dept, I-90133 Palermo, Italy; [Porzio, Giampiero; Fulfaro, Fabio; Alelli, Federica; Verna, Lucilla; Ficorella, Corrado] Univ Palermo, Dept Oncol, I-90133 Palermo, Italy; [Gebbia, Vittorio] La Maddalena Canc Ctr, Dept Oncol, I-90146 Palermo, Italy; [Casuccio, Alessandra] Univ Palermo, Dept Clin Neurosci, I-90133 Palermo, Italy	Mercadante, S (reprint author), La Maddalena Canc Ctr, Pain Relief & Palliat Care Unit, Via San Lorenzo 312, I-90146 Palermo, Italy.	terapiadeldolore@lamaddalenanet.it	casuccio, alessandra/B-1730-2013; VERNA, Lucilla/M-3998-2017	casuccio, alessandra/0000-0002-5676-9535; Porzio, Giampiero/0000-0002-9875-9220; AIELLI, Federica/0000-0003-2785-0702; Gebbia, Vittorio/0000-0001-8848-5951; VERNA, Lucilla/0000-0002-2046-3980			Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; Asche Carl V, 2006, J Pain Palliat Care Pharmacother, V20, P15, DOI 10.1300/J354v20n03_04; Bruera E, 2004, J CLIN ONCOL, V22, P185, DOI 10.1200/JCO.2004.03.172; BRUERA E, 1999, PAIN UPDATED REV, P1; Clark AJ, 2004, CURR MED RES OPIN, V20, P1419, DOI 10.1185/030079904X2114; Connor M, 2004, BRIT J PHARMACOL, V143, P685, DOI 10.1038/sj.bjp.0705938; DECONNO F, 1996, J CLIN ONCOL, V14, P1836; Donner B, 1996, PAIN, V64, P527, DOI 10.1016/0304-3959(95)00180-8; Fortner BV, 2003, J PAIN SYMPTOM MANAG, V25, P9, DOI 10.1016/S0885-3924(02)00597-3; Gagnon B, 1999, J PAIN SYMPTOM MANAG, V18, P120, DOI 10.1016/S0885-3924(99)00049-4; Gharagozlou Parham, 2003, BMC Pharmacol, V3, P1, DOI 10.1186/1471-2210-3-1; Grond S, 1997, PAIN, V69, P191, DOI 10.1016/S0304-3959(96)03254-X; Guest JF, 2005, CURR MED RES OPIN, V21, P271, DOI 10.1185/030079904X20312; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; Hashimoto T, 2006, ANESTHESIOLOGY, V105, P574, DOI 10.1097/00000542-200609000-00023; Klepstad P, 2003, PAIN, V101, P193, DOI 10.1016/S0304-3959(02)00328-7; Mancini I L, 2000, J Palliat Med, V3, P49, DOI 10.1089/jpm.2000.3.49; Mazzoccato C, 2001, J PALLIAT MED, V115, P261; Mercadante S, 1998, J CLIN ONCOL, V16, P3656, DOI 10.1200/JCO.1998.16.11.3656; Mercadante S, 2005, J CLIN ONCOL, V23, P5229, DOI 10.1200/JCO.2005.13.128; MERCADANTE S, 2007, EUR J PAIN; Mystakidou K, 2001, ANTICANCER RES, V21, P2225; Neighbors DM, 2001, J PAIN SYMPTOM MANAG, V21, P129, DOI 10.1016/S0885-3924(00)00247-5; PARONIS CA, 1992, J PHARMACOL EXP THER, V262, P1; Payne R, 1998, J CLIN ONCOL, V16, P1588, DOI 10.1200/JCO.1998.16.4.1588; Radbruch L, 2000, PALLIATIVE MED, V14, P111, DOI 10.1191/026921600671594561; Ripamonti C, 2006, SUPPORT CARE CANCER, V14, P400, DOI 10.1007/s00520-005-0918-0; Salzman RT, 1999, J PAIN SYMPTOM MANAG, V18, P271, DOI 10.1016/S0885-3924(99)00079-2; Sloan JA, 1998, J CLIN ONCOL, V16, P3662, DOI 10.1200/JCO.1998.16.11.3662; Ventafridda V, 1986, J Pain Symptom Manage, V1, P203, DOI 10.1016/S0885-3924(86)80042-2; Watanabe S, 1996, CANCER TREAT REV, V22, P131, DOI 10.1016/S0305-7372(96)90075-4; Weschules DJ, 2006, PAIN MED, V7, P320, DOI 10.1111/j.1526-4637.2006.00184.x	32	84	91	4	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1090-3801	1532-2149		EUR J PAIN	Eur. J. Pain	NOV	2008	12	8					1040	1046		10.1016/j.ejpain.2008.01.013			7	Anesthesiology; Clinical Neurology; Neurosciences	Anesthesiology; Neurosciences & Neurology	362AA	WOS:000260169400010	18353696				2020-06-30	J	Thomasy, SM; Mama, KR; Stanley, SD				Thomasy, Sara M.; Mama, Khursheed R.; Stanley, Scott D.			Comparison of Liquid Chromatography-Mass Spectrometry and Radioimmunoassay for Measurement of Fentanyl and Determination of Pharmacokinetics in Equine Plasma	JOURNAL OF ANALYTICAL TOXICOLOGY			English	Article							HORSES; METABOLITE; RECEPTOR		[Thomasy, Sara M.; Stanley, Scott D.] Univ Calif Davis, Sch Vet Med, Calif Anim Hlth & Food Safety Lab, KL Maddy Equine Analyt Chem Lab, Davis, CA 95616 USA; [Mama, Khursheed R.] Colorado State Univ, Coll Vet Med & Biomed Sci, Dept Clin Sci, Ft Collins, CO 80523 USA	Stanley, SD (reprint author), Univ Calif Davis, Sch Vet Med, Calif Anim Hlth & Food Safety Lab, KL Maddy Equine Analyt Chem Lab, Davis, CA 95616 USA.	sdstanley@ucdavis.edu			Veterinary Scientist Training Program; Achievement Rewards for College Scientists Scholarship	This study was supported by the Veterinary Scientist Training Program Grant and Achievement Rewards for College Scientists Scholarship.	FRINCKE JM, 1980, DRUG METAB DISPOS, V8, P425; GIBALDI M, 1982, PHARMACOKINETICS; HENDERSON GL, 1981, P W PHARMACOL SOC, V24, P137; Ilkiw JE, 1999, CLIN TECH SMALL AN P, V14, P27, DOI 10.1016/S1096-2867(99)80024-3; KOSTERLITZ HW, 1980, BRIT J PHARMACOL, V68, P333, DOI 10.1111/j.1476-5381.1980.tb10422.x; LEHMANN K A, 1988, Acta Anaesthesiologica Belgica, V39, P11; Maxwell LK, 2003, EQUINE VET J, V35, P484, DOI 10.2746/042516403775600415; Russo C. I., 2002, P 14 INT C RAC AN VE, P413; SCHNEIDER E, 1986, N-S ARCH PHARMACOL, V334, P267, DOI 10.1007/BF00508781; Thomasy SM, 2007, EQUINE VET J, V39, P54, DOI 10.2746/042516407X153011; Thomasy SM, 2006, BRIT J ANAESTH, V97, P232, DOI 10.1093/bja/ael116; Thomasy SM, 2007, VET ANAESTH ANALG, V34, P351, DOI 10.1111/j.1467-2995.2006.00337.x; WATTS VW, 1990, J ANAL TOXICOL, V14, P266, DOI 10.1093/jat/14.5.266; YAMAOKA K, 1978, J PHARMACOKINET BIOP, V6, P165, DOI 10.1007/BF01117450	14	9	11	0	2	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-4760	1945-2403		J ANAL TOXICOL	J. Anal. Toxicol.	NOV-DEC	2008	32	9					754	759		10.1093/jat/32.9.754			6	Chemistry, Analytical; Toxicology	Chemistry; Toxicology	377TK	WOS:000261273300005	19021930	Bronze			2020-06-30	J	von Dossow, V; Luetz, A; Haas, A; Sawitzki, B; Wernecke, KD; Volk, HD; Spies, CD				von Dossow, V.; Luetz, A.; Haas, A.; Sawitzki, B.; Wernecke, K. D.; Volk, H. D.; Spies, C. D.			Effects of Remifentanil and Fentanyl on the Cell-mediated Immune Response in Patients Undergoing Elective Coronary Artery Bypass Graft Surgery	JOURNAL OF INTERNATIONAL MEDICAL RESEARCH			English	Article						OPIOID; INFLAMMATION; CARDIOPULMONARY BYPASS; SUPPRESSOR OF CYTOKINE SIGNALLING-3; CELL-MEDIATED IMMUNE RESPONSE	CARDIOPULMONARY BYPASS; CARDIAC-SURGERY; INFLAMMATORY RESPONSE; TRANSCRIPTION FACTORS; MORPHINE; EXPRESSION; CYTOKINES; DIFFERENTIATION; PROCALCITONIN; INTERLEUKIN-6	This prospective randomized pilot study compared the influence of fentanyl-based versus remifentanil-based anaesthesia on cytokine responses and expression of the suppressor of cytokine signalling (SOCS)-3 gene following coronary artery bypass graft surgery. Forty patients were assigned to receive anaesthesia with either intravenous remifentanil (0.3 - 0.6 mu g/kg per min; n = 20) or intravenous fentanyl (5 - 10 mu g/kg per h; n = 20). Levels of interleukin (IL)-6, IL-10, tumour necrosis factor-alpha and interferon-gamma (IFN-gamma) and the expression of SOCS-3 were measured pre- and post-operatively. The data from 33 of the patients were analysed. The IFN-gamma/IL-10 ratio after concanavalin A stimulation in whole blood cells on postoperative day 1 and SOCS-3 gene expression on post-operative day 2 were significantly lower in the remifentanil group than in the fentanyl group. The time in the intensive care unit was also significantly lower in the remifentanil group. These findings suggest that remifentanil can attenuate the exaggerated inflammatory response that occurs after cardiac surgery with cardiopulmonary bypass. Further clinical trials are required to define the influence of choice of intra-operative opioid on postoperative outcome.	[von Dossow, V.; Luetz, A.; Haas, A.; Spies, C. D.] Campus Virchow Klinikum, Dept Anaesthesiol & Intens Care Med, D-13353 Berlin, Germany; [Sawitzki, B.; Volk, H. D.] Charite, Inst Med Immunol, D-13353 Berlin, Germany; [Wernecke, K. D.] SoStAna GmbH, D-10387 Berlin, Germany; [von Dossow, V.; Luetz, A.; Haas, A.; Spies, C. D.] Charite, Charite Campus Mitte, D-13353 Berlin, Germany	Spies, CD (reprint author), Campus Virchow Klinikum, Dept Anaesthesiol & Intens Care Med, Augustenburger Pl 1, D-13353 Berlin, Germany.	claudia.spies@charite.de	Sawitzki, Birgit/S-2307-2016	Luetz, Alawi/0000-0001-8814-1809; Sawitzki, Birgit/0000-0001-8166-8579			Adamik B, 2000, INTENS CARE MED, V26, P1259, DOI 10.1007/s001340000610; Agnello D, 2003, J CLIN IMMUNOL, V23, P147, DOI 10.1023/A:1023381027062; Alexander WS, 2004, ANNU REV IMMUNOL, V22, P503, DOI 10.1146/annurev.immunol.22.091003.090312; Bathke A, 2003, RECENT ADVANCES AND TRENDS IN NONPARAMETRIC STATISTICS, P109, DOI 10.1016/B978-044451378-6/50008-9; BRAUN J, 2003, CHECK UP ANESTHESIOL, P95; BURNNER E, 2002, NONPARAMETRIC ANAL L; CALAFIORE AM, 1995, ANN THORAC SURG, V59, P398, DOI 10.1016/0003-4975(94)00843-V; DANDONA P, 1994, J CLIN ENDOCR METAB, V79, P1605, DOI 10.1210/jc.79.6.1605; Ely EW, 1999, AM J RESP CRIT CARE, V159, P439, DOI 10.1164/ajrccm.159.2.9805120; Engoren M, 2001, ANESTH ANALG, V93, P859, DOI 10.1097/00000539-200110000-00011; Franke A, 2005, EUR J CARDIO-THORAC, V28, P569, DOI 10.1016/j.ejcts.2005.07.007; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; HALLE E, 2003, CHECK UP ANESTHESIOL, P446; Hein OV, 2006, ANN THORAC SURG, V81, P880, DOI 10.1016/j.athoracsur.2005.09.077; Hirai Shinji, 2003, Ann Thorac Cardiovasc Surg, V9, P365; Ilangumaran S, 2004, SEMIN IMMUNOL, V16, P351, DOI 10.1016/j.smim.2004.08.015; JOHANSEN JW, 2000, CURR ANESTHESIOL REP, V2, P369; Laffey JG, 2002, ANESTHESIOLOGY, V97, P215; Levy MM, 2003, CRIT CARE MED, V31, P1250, DOI 10.1097/01.CCM.0000050454.01978.3B; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mazarakou G, 2005, J NEUROCHEM, V93, P918, DOI 10.1111/j.1471-4159.2005.03069.x; Murphy GS, 2007, ANESTH ANALG, V104, P1334, DOI 10.1213/01.ane.0000264108.47280.f5; Nair MPN, 1997, CLIN DIAGN LAB IMMUN, V4, P127, DOI 10.1128/CDLI.4.2.127-132.1997; Paparella D, 2002, EUR J CARDIO-THORAC, V21, P232, DOI 10.1016/S1010-7940(01)01099-5; Pappalardo F, 2004, EUR J CARDIO-THORAC, V25, P548, DOI 10.1016/j.ejcts.2003.11.034; PETERSON PK, 1987, J CLIN INVEST, V80, P824, DOI 10.1172/JCI113140; Qian YN, 2005, BRIT J ANAESTH, V95, P277, DOI 10.1093/bja/aei574; Roy S, 1996, NEUROCHEM RES, V21, P1375, DOI 10.1007/BF02532379; Roy S, 2004, J NEUROIMMUNOL, V147, P78, DOI 10.1016/j.jneuroim.2003.10.016; Sablotzki A, 2003, EUR J MED RES, V8, P71; Sander M, 2006, ANESTH ANALG, V102, P1623, DOI 10.1213/01.ane.0000215998.21739.48; Stefano GB, 2005, MED SCI MONITOR, V11, pMS35; TURNER JS, 1991, CRIT CARE MED, V19, P1266; Vincent JL, 1998, CRIT CARE MED, V26, P1793, DOI 10.1097/00003246-199811000-00016; Weiss S, 2007, AM J TRANSPLANT, V7, P1584, DOI 10.1111/j.1600-6143.2007.01799.x; Yang XP, 2005, J HEPATOL, V43, P704, DOI 10.1016/j.jhep.2005.02.048	36	22	22	0	1	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0300-0605	1473-2300		J INT MED RES	J. Int. Med. Res.	NOV-DEC	2008	36	6					1235	1247		10.1177/147323000803600610			13	Medicine, Research & Experimental; Pharmacology & Pharmacy	Research & Experimental Medicine; Pharmacology & Pharmacy	388MU	WOS:000262024700010	19094432	Bronze, Green Published			2020-06-30	J	Girgin, NK; Gurbet, A; Turker, G; Bulut, T; Demir, S; Kilic, N; Cinar, A				Girgin, N. K.; Gurbet, A.; Turker, G.; Bulut, T.; Demir, S.; Kilic, N.; Cinar, A.			The Combination of Low-dose Levobupivacaine and Fentanyl for Spinal Anaesthesia in Ambulatory Inguinal Herniorrhaphy	JOURNAL OF INTERNATIONAL MEDICAL RESEARCH			English	Article						LEVOBUPIVACAINE; FENTANYL; ANAESTHETICS; INGUINAL HERNIA; HERNIORRHAPHY; SPINAL ANAESTHESIA; NERVE BLOCK RECOVERY	INTRATHECAL BUPIVACAINE; ROPIVACAINE; LIDOCAINE	This study investigated whether the addition of 25 mu g intrathecal fentanyl to levobupivacaine spinal anaesthesia for outpatient inguinal herniorrhaphy allows a sub-anaesthetic levobupivacaine dose to be used. Forty patients were assigned to receive 5 mg levobupivacaine 0.5% mixed with 25 mu g fentanyl (group LF) or 7.5 mg levobupivacaine 0.5% (group L). The highest sensory block levels achieved were T7 (range T5 - T9) and T6 (range T4 - T9) in groups LF and L, respectively. The times to two-segment regression, S2 regression, ambulation, urination and discharge were all significantly shorter in group LF than group L. These results indicate that, for outpatient inguinal herniorrhaphy, intrathecal fentanyl combined with low-dose levobupivacaine provides good quality spinal anaesthesia and minimizes the need for intra-operative analgesia. This protocol is well suited for the outpatient setting because it features rapid recovery of full motor power, sensory function and bladder function.	[Girgin, N. K.; Gurbet, A.; Turker, G.; Bulut, T.; Demir, S.; Kilic, N.; Cinar, A.] Uludag Univ, Fac Med, Dept Anaesthesiol & Reanimat, TR-16059 Bursa, Turkey	Girgin, NK (reprint author), Uludag Univ, Fac Med, Dept Anaesthesiol & Reanimat, TR-16059 Bursa, Turkey.	nkelebek@uludog.edu.tr	Erdost, Hale Aksu/S-2847-2016; Girgin, Nermin Kelebek/AAH-7250-2019	TURKER, YUNUS GURKAN/0000-0002-3019-581X; GURBET, ALP/0000-0002-6503-8232			Alley EA, 2002, ANESTH ANALG, V94, P188, DOI 10.1097/00000539-200201000-00036; Breebaart MB, 2003, BRIT J ANAESTH, V90, P309, DOI 10.1093/bja/aeg078; Casati A, 2004, ANESTH ANALG, V99, P1387, DOI 10.1213/01.ANE.0000132972.61498.F1; Chilvers CR, 1997, ANESTH ANALG, V84, P65, DOI 10.1097/00000539-199701000-00012; Gautier PE, 1999, ANESTHESIOLOGY, V91, P1239, DOI 10.1097/00000542-199911000-00013; Gupta A, 2003, ACTA ANAESTH SCAND, V47, P13, DOI 10.1034/j.1399-6576.2003.470103.x; Kehlet H, 2003, ACTA ANAESTH SCAND, V47, P1, DOI 10.1034/j.1399-6576.2003.470101.x; KEHLET H, 2003, [No title captured], V49, P143; Korhonen AM, 2006, CURR OPIN ANESTHESIO, V19, P612, DOI 10.1097/ACO.0b013e32801042c7; MAVES TJ, 1992, ANESTHESIOLOGY, V76, P91, DOI 10.1097/00000542-199201000-00014; McDonald SB, 1999, ANESTHESIOLOGY, V90, P971, DOI 10.1097/00000542-199904000-00007; Mulroy MF, 2001, REGION ANESTH PAIN M, V26, P252, DOI 10.1053/rapm.2001.22997; SALINAS FV, 2001, [No title captured], V16, P195; WANG C, 1993, ANESTHESIOLOGY, V79, P766, DOI 10.1097/00000542-199310000-00019	14	9	10	0	2	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0300-0605	1473-2300		J INT MED RES	J. Int. Med. Res.	NOV-DEC	2008	36	6					1287	1292		10.1177/147323000803600616			6	Medicine, Research & Experimental; Pharmacology & Pharmacy	Research & Experimental Medicine; Pharmacology & Pharmacy	388MU	WOS:000262024700016	19094438				2020-06-30	J	Arabin, B; Kuizenga, K; Zveren, DV; Eyck, JV				Arabin, Birgit; Kuizenga, Karel; Zveren, Diny V.; Eyck, Jim V.			Long-term epidural block treatment in patients with early threatening preterm delivery and vaginal fetal engagement	JOURNAL OF PERINATAL MEDICINE			English	Article						Epidural anesthesia; outcome of preterm infants; pain during labor; preterm delivery; prolongation of pregnancy	INTENSIVE-CARE; BIRTH; BABIES; AGE	We report on an exceptional therapy with epidural anesthesia and tunnelling of the peridural catheter over a time period of 2-14 days in patients with threatening early preterm labor, intact membranes and vaginal engagement of the infants (4 singleton, 8 twin and 2 triplet pregnancies). A combination of bupivacaine (0.125%) and fentanyl (2 mu g/mL) was used up to a maximum of 20 mL/h during the treatment period. Long-term follow-up of the infants was normal in 19/20 infants. The advantages, such as prolongation of pregnancy without maternal pain and disadvantages such as the risk of fetal and maternal infection and of sudden delivery are discussed. The online version of the Journal (see http://dx.doi.org/10.1515/jpm.2008.081_supp-1) allows video illustrations of a triplet pregnancy, in which the first triplet was born after one week of epidural anesthesia and the pregnancy continued under epidural anesthesia for the remaining two triplets staying with intact membranes in the vagina (delayed interval delivery) for six more days. The results of this pilot series suggest that prolongation of these pregnancies under epidural anesthesia might be an option in exceptional cases when viability is questionable or when corticosteroid therapy is desired before final delivery. Further evaluation of this strategy is needed but only in tertiary centers with 24-h presence of qualified obstetric and neonatal care and intensive surveillance.	[Arabin, Birgit; Eyck, Jim V.] Isala Kliniken, Dept Perinatol, Zwolle, Netherlands; [Kuizenga, Karel] Isala Kliniken, Dept Anaesthesiol, Zwolle, Netherlands; [Zveren, Diny V.] Isala Kliniken, Dept Neonatol, Zwolle, Netherlands	Arabin, B (reprint author), Inst Dev Res, Clara Angela Fdn, A Herrenhausenstr 44, D-58455 Witten, Germany.	clara-angela@wxs.nl					Ancel PY, 2006, PEDIATRICS, V117, P828, DOI 10.1542/peds.2005-0091; Arabin B, 1999, Matern Child Health J, V3, P81, DOI 10.1023/A:1021801326561; ARABIN BBK, 2006, NTOG, V119, P21; Aram L, 2001, ANESTH ANALG, V92, P1432; Berghella V, 2005, OBSTET GYNECOL, V106, P181, DOI 10.1097/01.AOG.0000168435.17200.53; BERNAL AL, 2007, BMC PREGNANCY CHI S1, V7, pS2, DOI DOI 10.1186/1471-2393-7-S1-S2; Goldenberg RL, 2008, LANCET, V371, P75, DOI 10.1016/S0140-6736(08)60074-4; Levene M, 2004, ACTA PAEDIATR, V93, P149, DOI 10.1080/08035250310007745; Marlow N, 2005, NEW ENGL J MED, V352, P9, DOI 10.1056/NEJMoa041367; MELSEN NC, 1988, ANAESTHESIA, V43, P126; Wilson-Costello D, 2007, PEDIATRICS, V119, P37, DOI 10.1542/peds.2006-1416; Zeitlin J, 2005, EUR J OBSTET GYN R B, V118, P272, DOI 10.1016/j.ejogrb.2004.09.007	12	3	3	0	0	WALTER DE GRUYTER GMBH	BERLIN	GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY	0300-5577	1619-3997		J PERINAT MED	J. Perinat. Med.	NOV	2008	36	6					543	547		10.1515/JPM.2008.081			5	Obstetrics & Gynecology; Pediatrics	Obstetrics & Gynecology; Pediatrics	381CK	WOS:000261512500013	18662140				2020-06-30	J	Karvonen, S; Salomaki, T; Olkkola, KT				Karvonen, Sisko; Salomaki, Timo; Olkkola, Klaus T.			Efficacy of Oral Paracetamol and Ketoprofen for Pain Management after Major Orthopedic Surgery	METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY			English	Article						Postoperative pain; Analgesics; Paracetamol; Ketoprofen; Opioids	PATIENT-CONTROLLED ANALGESIA; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; RANDOMIZED CONTROLLED-TRIALS; POSTOPERATIVE PAIN; ACETAMINOPHEN; MORPHINE; METAANALYSIS; CONSUMPTION	The hypothesis of this study was that oral paracetamol or ketoprofen can reduce opioid consumption and the adverse effects of opioids after major orthopedic surgery. Sixty patients who had elective total hip replacement surgery took part in this double-blind, randomized, placebo-controlled study. The total doses were paracetamol 4 g and ketaprofen 300 mg. After the surgery, analgesia was provided with a patient-controlled analgesia device: 0.05-mg bolus doses of fentanyl i.v. for 5 min, followed by a lockout interval of 5 min, with a maximum of 0.3 mg in any 1-h period. Pain (measured by visual analog scale), respiratory rate, peripheral arteriolar oxygen saturation, heart rate, blood pressure and side effects were recorded every 4 h for a period of 20 h. The mean pain scores were similar among the groups. Patients in the ketoprofen group consumed a mean of 22% less fentanyl (P < 0.05) in a 20-h period than the placebo group, and 28% less than the patients in the paracetamol group (P < 0.05). Oral ketoprofen (300 mg) decreased fentanyl consumption by 22% in the 20-h period immediately following major orthopedic surgery; fentanyl consumption was unaffected by paracetamol (4 g). The frequency of adverse effects was not reduced by using adjunctive nonopioid analgesics.	Oulu Univ, Hosp Kajaanintie, Dept Anesthesiol, Turku, Finland; Turku Univ Hosp, Dept Anesthesiol Intens Care Emergency Care & Pai, FIN-20520 Turku, Finland	Salomaki, T (reprint author), Oulu Univ Hosp, Dept Anesthesiol, Kajaanintie 50, FI-90220 Oulu, Finland.	timo.salomaki@ppshp.fi		Olkkola, Klaus/0000-0001-7872-8665			Anderson BJ, 2001, EUR J CLIN PHARMACOL, V57, P559, DOI 10.1007/s002280100367; Elia N, 2005, ANESTHESIOLOGY, V103, P1296, DOI 10.1097/00000542-200512000-00025; FORREST JAH, 1982, CLIN PHARMACOKINET, V7, P93, DOI 10.2165/00003088-198207020-00001; Hahn TW, 2003, ACTA ANAESTH SCAND, V47, P138, DOI 10.1034/j.1399-6576.2003.00046.x; Hein A, 1999, ACTA ANAESTH SCAND, V43, P248, DOI 10.1034/j.1399-6576.1999.430302.x; Hyllested M, 2002, BRIT J ANAESTH, V88, P199, DOI 10.1093/bja/88.2.199; Kaplowitz N, 2004, HEPATOLOGY, V40, P23, DOI 10.1002/hep.20312; Kehlet H, 2002, AM J SURG, V183, P630, DOI 10.1016/S0002-9610(02)00866-8; Korpela R, 1999, ANESTHESIOLOGY, V91, P442, DOI 10.1097/00000542-199908000-00019; Korpela R, 1999, ACTA ANAESTH SCAND, V43, P245, DOI 10.1034/j.1399-6576.1999.430301.x; Kvalsvik O, 2003, ACTA ANAESTH SCAND, V47, P451, DOI 10.1034/j.1399-6576.2003.00080.x; LAITINEN J, 1992, ANESTHESIOLOGY, V76, P194, DOI 10.1097/00000542-199202000-00006; Marret E, 2005, ANESTHESIOLOGY, V102, P1249, DOI 10.1097/00000542-200506000-00027; Remy C, 2005, BRIT J ANAESTH, V94, P505, DOI 10.1093/bja/aei085; Schug SA, 1998, ANESTH ANALG, V87, P368, DOI 10.1097/00000539-199808000-00024; SWEETMAN SC, 2002, COMPLETE DRUG REFERE; Watkins PB, 2006, JAMA-J AM MED ASSOC, V296, P87, DOI 10.1001/jama.296.1.87	17	4	4	0	4	PROUS SCIENCE, SAU-THOMSON REUTERS	BARCELONA	398 PROVENCA, 08025 BARCELONA, SPAIN	0379-0355	2013-0155		METHOD FIND EXP CLIN	Methods Find. Exp. Clin. Pharmacol.	NOV	2008	30	9					703	706		10.1358/mf.2008.30.9.1316919			4	Pharmacology & Pharmacy	Pharmacology & Pharmacy	413GG	WOS:000263780300005	19229379				2020-06-30	J	Tao, J; Nunery, W; Kresovsky, S; Lister, L; Mote, T				Tao, Jeremiah; Nunery, William; Kresovsky, Seth; Lister, Linda; Mote, Thomas			Efficacy of Fentanyl or Alfentanil in Suppressing Reflex Sneezing After Propofol Sedation and Periocular Injection	OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY			English	Article							BLOCK; REMIFENTANIL	Purpose: A sneeze reflex may occur after propofol sedation and during periocular injections. Unexpected movement from sneezing can result in needle injury to the globe or optic nerve, or hematoma. We investigate the efficacy of concomitant fentanyl or alfentanil in reducing sneezing following propofol and during periocular injections. Methods: Our prospective, randomized study included 81 adult patients Undergoing Conscious sedation prior to periocular injection of local anesthesia. All patients received propofol and were randomized to propofol only (25 patients), propofol plus midazolam (14 patients), propofol plus opioid (31 patients), propofol plus midazolam and opioid (I I patients). Periocular injection of local anesthetic was given in the usual manner. The main outcome measure was sneezing. Patients were also assessed for cardiorespiratory parameters, analgesia, and adverse side effects of sedatives. Results: Of the patients who received no opioid, 17 of 39 (43.6%) sneezed. Of the patients who received an opioid, 0 of 42 sneezed (p < 0.0001 by Fisher exact two-tailed test). Among Subjects receiving no opioids, midazolam was associated with a higher incidence of the sneeze reflex, but this was not quite statistically significant (p = 0.09). No adverse cardiorespiratory events were noted and analgesia was universally adequate. Conclusions: Fentanyl or alfentanil suppressed sneezing after propofol sedation and eyelid anesthetic injection. These medications may prevent needle injury.	[Tao, Jeremiah] Univ Calif Irvine, Dept Ophthalmol, Irvine, CA 92697 USA; [Nunery, William] Oculofacial Plast & Orbital Surg LLC, Indianapolis, IN USA; [Kresovsky, Seth] Indiana Univ, Dept Ophthalmol, Indiana, PA USA; [Lister, Linda; Mote, Thomas] Anesthesia Consultants Indianapolis, Indiana, PA USA	Tao, J (reprint author), Univ Calif Irvine, Dept Ophthalmol, 118 Med Surge 1, Irvine, CA 92697 USA.	j.tao@uci.edu					ABRAMIAN AK, 1995, J TECH ACOUST, V2, P3; Boezaart AP, 2001, J CLIN ANESTH, V13, P422, DOI 10.1016/S0952-8180(01)00296-3; FORRESTER JM, 1985, HUM HERED, V35, P113, DOI 10.1159/000153527; Lopatka CW, 2001, ANESTHESIOLOGY, V95, P1533, DOI 10.1097/00000542-200112000-00044; MEHARDY FE, 2000, CAN J ANAESTH, V47, P211; Miner JR, 2005, ACAD EMERG MED, V12, P491, DOI 10.1197/j.aem.2005.01.011; PEROUTKA SJ, 1984, NEW ENGL J MED, V310, P599; Rewari V, 2002, ANAESTH INTENS CARE, V30, P433, DOI 10.1177/0310057X0203000405; SANTIAGO TV, 1985, J APPL PHYSIOL, V59, P1675; Wessels IF, 1999, OPHTHALMIC SURG LAS, V30, P208; White JM, 1999, ADDICTION, V94, P961, DOI 10.1046/j.1360-0443.1999.9479612.x; Yee JB, 1996, J CLIN ANESTH, V8, P623, DOI 10.1016/S0952-8180(96)00137-7	12	13	13	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0740-9303			OPHTHAL PLAST RECONS	Ophthalmic Plast. Reconstr. Surg.	NOV-DEC	2008	24	6					465	467		10.1097/IOP.0b013e31818ab3ca			3	Ophthalmology; Surgery	Ophthalmology; Surgery	378AT	WOS:000261294200008	19033843				2020-06-30	J	Bryan, M; De La Rosa, N; Hill, AM; Amadio, WJ; Wieder, R				Bryan, Margarette; De La Rosa, Nila; Hill, Ann Marie; Amadio, William J.; Wieder, Robert			Influence of Prescription Benefits on Reported Pain in Cancer Patients	PAIN MEDICINE			English	Article						Medicaid; Uninsured; Charity Care; Long-Acting Opiates; Pain; Pain Regimen	PHYSICIAN	To identify associations between prescription coverage and cancer pain and its sequelae in indigent patients. A retrospective chart review at UMDNJ-University Hospital. Charts from 20 patients with Medicaid and 20 patients categorized as Self-pay/Charity Care were analyzed for the influence of insurance coverage on reported pain at the time of a hospital discharge and at three subsequent clinic visits. Patient and disease characteristics, pain regimens, doses, reported pain and its impact were determined. The groups were statistically indistinguishable except for age and ethnicity. The Medicaid group was younger and had a majority of African Americans while the Self-pay/Charity Care patients had a majority of Hispanics. Lower doses of transdermal fentanyl were prescribed to Self-pay/Charity Care patients. Self-pay/Charity Care patients tended to report higher pain levels, but this was statistically significant only at the second clinic visit. The clinical significance of differences in pain intensity was reflected in differences in unscheduled visits and admissions. Adherence to pain regimens improved in the Medicaid group and diminished in the Self-pay/Charity Care group, but the differences did not achieve statistical significance. Lack of funds as the reason for non-adherence was only given by Self-pay/Charity Care patients. Indigent patients without prescription coverage trended toward reporting more cancer pain, received lower doses of transdermal fentanyl, and trended to lower adherence to pain regimens due to financial reasons. The trends observed in this pilot study will guide the design of a hypothesis-driven regression analysis.	[Bryan, Margarette; Wieder, Robert] Univ Med & Dent New Jersey, New Jersey Med Sch, Univ Hosp Canc Ctr, Div Med Oncol, Newark, NJ 07103 USA; [De La Rosa, Nila] Hackensack Univ, Med Ctr, Hackensack, NJ USA; [Hill, Ann Marie] State New Jersey Commiss Canc Res, Trenton, NJ USA; [Amadio, William J.] Rider Univ, Lawrenceville, NJ 08648 USA	Wieder, R (reprint author), Univ Med & Dent New Jersey, New Jersey Med Sch, Univ Hosp Canc Ctr, Div Med Oncol, 185 S Orange Ave,Canc Ctr H1216, Newark, NJ 07103 USA.	wiederro@umdnj.edu			State of New Jersey Commission on Cancer Research [06-1051]	Supported by the State of New Jersey Commission on Cancer Research grant # 06-1051 (MB).	Bartfield JM, 1997, PAIN, V73, P209, DOI 10.1016/S0304-3959(97)00107-3; Bernabei R, 1998, JAMA-J AM MED ASSOC, V279, P1877, DOI 10.1001/jama.279.23.1877; Cleeland CS, 1997, ANN INTERN MED, V127, P813, DOI 10.7326/0003-4819-127-9-199711010-00006; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Edwards RR, 2003, PAIN, V101, P155, DOI 10.1016/S0304-3959(02)00324-X; Green CR, 2003, PAIN MED, V4, P277, DOI 10.1046/j.1526-4637.2003.03034.x; *NAT COMPR CAN NET, 2007, NETW CLIN PRACT GUID; TODD KH, 1994, JAMA-J AM MED ASSOC, V271, P925, DOI 10.1001/jama.271.12.925	9	6	6	0	1	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1526-2375			PAIN MED	Pain Med.	NOV-DEC	2008	9	8					1148	1157		10.1111/j.1526-4637.2008.00427.x			10	Anesthesiology; Medicine, General & Internal	Anesthesiology; General & Internal Medicine	375HZ	WOS:000261106100025	18346057	Bronze			2020-06-30	J	Simion, C; Corcoran, J; Iyer, A; Suresh, S				Simion, Carmen; Corcoran, Julia; Iyer, Aditya; Suresh, Santhanam			Postoperative pain control for primary cleft lip repair in infants: is there an advantage in performing peripheral nerve blocks?	PEDIATRIC ANESTHESIA			English	Article						cleft lip repair in infants; infraorbital nerve block; fentanyl; analgesia; feeding	CHILDREN; ANALGESIA; SURGERY	Background: Primary cleft lip repair is performed in infants under 1 year of age. The efficacy of an infraorbital nerve block vs intravenous fentanyl was compared in our prospective, randomized controlled trial. Methods: Forty-six infants scheduled for primary cleft lip repair were prospectively randomized to one of two groups: group F that received 2 mcg.kg(-1) of fentanyl intravenously and an infraorbital nerve block with 0.5 ml on each side of preservative-free normal saline, and, group B that received bilateral infraorbital nerve blocks with 0.5 ml on each side of 0.25% bupivacaine and 2 ml of preservative-free saline solution intravenously after induction of anesthesia but prior to surgical incision. Patients were observed by a blinded observer for (i) pain scores using neonatal infant pain score; (ii) need for rescue medication in the anesthesia care unit (PACU), in the short stay unit (SSU) and at home and (iii) feeding parameters including difficulty in feeding, time to first feeding and volume of feeds in the PACU, SSU and at home. Results: There were no significant differences in pain scores between the two groups over time (P = 0.98); there were no differences between groups in the number of rescue medications in the PACU, in the SSU as well as at home; however, the time to first rescue medication was greater in the block group compared with the fentanyl group (P = 0.07). There were no significant differences in feeding volumes between groups in the PACU (P = 0.46), SSU (P = 0.57) and at home (P = 0.15). There were no differences in time to initiate feeding between the two groups (P = 0.81). However, there was difficulty with feeding in the block groups compared with the fentanyl group (P = 0.01). Conclusions: The infraorbital nerve block can be effectively used for pain control in infants undergoing primary cleft lip repair. Although children undergoing a nerve block experienced minor difficulties in feeding, there were no differences in feeding volumes or other feeding parameters. This study has shed light into postoperative outcomes besides pain control on children undergoing cleft lip repairs.	[Simion, Carmen; Iyer, Aditya; Suresh, Santhanam] Childrens Mem Hosp, Dept Pediat Anesthesiol, Chicago, IL 60614 USA; [Simion, Carmen; Corcoran, Julia; Suresh, Santhanam] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; [Corcoran, Julia] Childrens Mem Hosp, Div Plast Surg, Chicago, IL 60614 USA	Suresh, S (reprint author), Childrens Mem Hosp, Dept Pediat Anesthesiol, 2300 Childrens Plaza, Chicago, IL 60614 USA.	ssuresh@childrenmemorial.org					ANAND KJS, 1985, J PEDIATR SURG, V20, P41, DOI 10.1016/S0022-3468(85)80390-0; BOSENBERG AT, 1995, BRIT J ANAESTH, V74, P506, DOI 10.1093/bja/74.5.506; Lynch M T, 1994, Acad Emerg Med, V1, P514; Mcheik JN, 2006, INT J PEDIATR OTORHI, V70, P1785, DOI 10.1016/j.ijporl.2006.06.004; Prabhu KPK, 1999, SCAND J PLAST RECONS, V33, P83, DOI 10.1080/02844319950159668; Rajamani A, 2007, PEDIATR ANESTH, V17, P133, DOI 10.1111/j.1460-9592.2006.02032.x; Suresh S, 2006, REGION ANESTH PAIN M, V31, P211, DOI 10.1016/j.rapm.2005.11.017; Suresh S, 2002, ANESTH ANALG, V94, P859, DOI 10.1097/00000539-200204000-00015; Taddio A, 1997, LANCET, V349, P599, DOI 10.1016/S0140-6736(96)10316-0	9	19	19	0	4	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	1155-5645			PEDIATR ANESTH	Pediatr. Anesth.	NOV	2008	18	11					1060	1065		10.1111/j.1460-9592.2008.02721.x			6	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	356ZW	WOS:000259817100008	18950330				2020-06-30	J	Elakkumanan, LB; Punj, J; Talwar, P; Rajaraman, P; Pandey, R; Darlong, V				Elakkumanan, Lenin Babu; Punj, Jyotsna; Talwar, Praveen; Rajaraman, Prabhu; Pandey, R.; Darlong, V.			An atypical presentation of fentanyl rigidity following administration of low dose fentanyl in a child during intraoperative period	PEDIATRIC ANESTHESIA			English	Letter							ANESTHESIA; VENTILATION; DIFFICULT; CLOSURE		[Elakkumanan, Lenin Babu; Punj, Jyotsna; Talwar, Praveen; Rajaraman, Prabhu; Pandey, R.; Darlong, V.] All India Inst Med Sci, Dept Anesthesiol & Crit Care, New Delhi 110029, India	Elakkumanan, LB (reprint author), All India Inst Med Sci, Dept Anesthesiol & Crit Care, New Delhi 110029, India.	jyotsna_punj@yahoo.com					Abrams JT, 1996, ANESTH ANALG, V83, P629, DOI 10.1097/00000539-199609000-00034; Bennett JA, 1997, ANESTHESIOLOGY, V87, P1070, DOI 10.1097/00000542-199711000-00010; BOWDLE TA, 1994, ANESTH ANALG, V78, P783; Fahnenstich H, 2000, CRIT CARE MED, V28, P836, DOI 10.1097/00003246-200003000-00037; Muller P, 2000, AM J PERINAT, V17, P23, DOI 10.1055/s-2000-7289; STREISAND JB, 1993, ANESTHESIOLOGY, V78, P629, DOI 10.1097/00000542-199304000-00003	6	6	6	0	0	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	1155-5645			PEDIATR ANESTH	Pediatr. Anesth.	NOV	2008	18	11					1115	1117		10.1111/j.1460-9592.2008.02602.x			4	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	356ZW	WOS:000259817100026	18950344				2020-06-30	J	Nagel, K; Willan, AR; Lappan, J; Korz, L; Buckley, N; Barr, RD				Nagel, Kim; Willan, Andrew R.; Lappan, Janie; Korz, Linda; Buckley, Norman; Barr, Ronald D.			Pediatric oncology sedation trial (POST): A double-blind randomized study	PEDIATRIC BLOOD & CANCER			English	Article						double-blind; oncology; pediatric; randomized; sedation	INTRATHECAL CHEMOTHERAPY; INTRAVENOUS ANESTHESIA; PROPOFOL; PREVENTION; CHILDREN	Background. There is limited evidence to support the use of an anti-emetic with the administration of intra-thecal chemotherapy. Nor is there adequate clarity on analgesic strategies for children with cancer undergoing painful procedures. Procedures. A double-blind, randomized, placebo-controlled, factorial trail was performed in children with acute lymphoblastic leukemia undergoing combined bone marrow aspirations and lumbar punctures during maintenance therapy. The study was designed to measure the effect of adding ondansetron and fentanyl to a standard combination of midazola and propofol. Results. During the first 12 hr following the procedures, patients experienced significantly less vomiting/retching and less disruption of activity while receiving ondansetron, and recorded significantly lower pain scores while receiving fentanyl. Conclusions. This study provides evidence that the addition of an analgestic (fentanyl) and an anti-emetic (ondansetron) to the combination of a sedative (midazolam) and an anesthetic (propofol) is of measurable benefit in children who undergo procedures that are painful and risk the consequence of nausea and vomiting.	[Barr, Ronald D.] McMaster Univ, Hlth Sci Ctr, Hamilton, ON L8N 3Z5, Canada; [Nagel, Kim; Lappan, Janie; Barr, Ronald D.] McMaster Childrens Hosp, Hamilton, ON, Canada; [Willan, Andrew R.] Hosp Sick Children, Res Inst, Toronto, ON M5G 1X8, Canada; [Korz, Linda; Buckley, Norman] Dept Anesthesia, Hamilton, ON, Canada	Barr, RD (reprint author), McMaster Univ, Hlth Sci Ctr, Room 3N27,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	rbarr@mcmaster.ca					[Anonymous], 1985, PEDIATRICS, V76, P317; *COMM DRUGS, 1992, PEDIATRICS, V89, P110; Holdsworth MT, 1998, SUPPORT CARE CANCER, V6, P132, DOI 10.1007/s005200050147; Jagoda AS, 1998, ANN EMERG MED, V31, P663, DOI 10.1016/S0196-0644(98)70216-1; Jayabose S, 2001, J PEDIAT HEMATOL ONC, V23, P290, DOI 10.1097/00043426-200106000-00011; Krauss B, 2000, NEW ENGL J MED, V342, P938, DOI 10.1056/NEJM200003303421306; LARSSON S, 1992, ACTA ANAESTH SCAND, V36, P182, DOI 10.1111/j.1399-6576.1992.tb03448.x; Mace Sharon E, 2004, J Emerg Nurs, V30, P447; MARGOLIN JF, 2006, PRINCIPLES PRACTICE, P538; MARTIN TM, 1993, ANESTH ANALG, V76, P144; MCDOWALL RH, 1995, J CLIN ANESTH, V7, P273, DOI 10.1016/0952-8180(95)00017-C; Parker RI, 2001, J PEDIAT HEMATOL ONC, V23, P578, DOI 10.1097/00043426-200112000-00005; WHALEY L, 1987, FACES PAIN RATING SC, P1070; White PF, 2004, NEW ENGL J MED, V350, P2511, DOI 10.1056/NEJMe048099	14	12	15	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1545-5009	1545-5017		PEDIATR BLOOD CANCER	Pediatr. Blood Cancer	NOV	2008	51	5					634	638		10.1002/pbc.21669			5	Oncology; Hematology; Pediatrics	Oncology; Hematology; Pediatrics	351ZS	WOS:000259465400016	18649369				2020-06-30	J	Hollman, GA; Schultz, MM; Eickhoff, JC; Christenson, DK				Hollman, Gregory A.; Schultz, Meredith M.; Eickhoff, Jens C.; Christenson, Devon K.			Propofol-fentanyl versus propofol alone for lumbar puncture sedation in children with acute hematologic malignancies: Propofol dosing and adverse events	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						propofol; fentanyl; pediatric oncology; procedural sedation	LARYNGEAL MASK AIRWAY; PEDIATRIC ONCOLOGY; PAINFUL PROCEDURES; ANESTHESIA; ALFENTANIL; DISTRESS; ADOLESCENTS; REQUIREMENT; MIDAZOLAM; INSERTION	Objective: We sought to determine whether the combination of propofol and fentanyl results in lower propofol doses and fewer adverse cardiopulmonary events than propofol and placebo for lumbar puncture in children with acute hematologic malignancies. Design: Randomized, controlled, double blind, crossover study. Setting: Pediatric Sedation Program. Patients: Children with acute leukemia or lymphoma receiving sedation for lumbar puncture. Interventions: Each patient received two sedations in random order, one with propofol/placebo and one with propofol/fentanyl. The study investigator and patient/parent were blinded to placebo or fentanyl. Data collected included patent age and diagnosis, propofol dose and adverse events. Adverse events included oxygen saturation < 94%, airway obstruction, apnea, hypotension, and bradycardia (< 5% mean for age). Logistic regression analysis was used to assess probability of adverse events and the Wilcoxon Signed Rank and McNemar's tests were used for paired comparisons. Measurements and Main Results: Twenty-two patients were enrolled. Fourteen patients were male and eight were female. Each patient was studied twice for a total of 44 sedations. The median age was 5.0 yrs (range, 2.2-17.2 yrs). All procedures were successfully completed. The median total dose of propofol was 5.05 mg/kg (range, 2.4-10.2 mg/kg) for propofol/placebo vs. 3.00 mg/kg (range 1.4-10.5 mg/kg) for propofol/fentanyl (p < 0.001). Twelve adverse events occurred in 11 of 22 patients (50.0%) propofol/placebo compared with 6 of 22 (18.2%) propofol/fentanyl (p = 0.02). The most common adverse event was hypotension. Conclusions: The combination of propofol and fentanyl vs. propofol alone for lumbar puncture sedation in children with acute hematologic malignancies resulted in lower propofol doses and fewer adverse events. (Pediatr Crit Care Med 2008; 9:616-622)	[Hollman, Gregory A.; Schultz, Meredith M.; Eickhoff, Jens C.; Christenson, Devon K.] Univ Wisconsin, Childrens Hosp, Dept Pediat, Madison, WI 53706 USA	Hollman, GA (reprint author), Univ Wisconsin, Childrens Hosp, Dept Pediat, Madison, WI 53706 USA.	ghollman@pediatrics.wisc.edu			National Center for Research Resources, Clinical Research Centers Program, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR03186]	Supported, in part, by a grant M01RR03186, National Center for Research Resources, Clinical Research Centers Program, National Institutes of Health.	Barnes C, 2002, J PAEDIATR CHILD H, V38, P170, DOI 10.1046/j.1440-1754.2002.00761.x; Cechvala MM, 2008, J PEDIAT HEMATOL ONC, V30, P142, DOI 10.1097/MPH.0b013e31815d8953; Disma N, 2005, EUR J ANAESTH, V22, P848, DOI 10.1017/S0265021505001432; Eastwood PR, 2005, ANESTHESIOLOGY, V103, P470, DOI 10.1097/00000542-200509000-00007; ELLIS JA, 1994, J PAIN SYMPTOM MANAG, V9, P96, DOI 10.1016/0885-3924(94)90162-7; FRADET C, 1990, PAIN, V40, P53, DOI 10.1016/0304-3959(90)91050-S; Gottschling S, 2005, J PEDIAT HEMATOL ONC, V27, P471, DOI 10.1097/01.mph.0000179238.37647.91; Goyagi T, 2003, ACTA ANAESTH SCAND, V47, P771, DOI 10.1034/j.1399-6576.2003.00123.x; Hain RDW, 2001, ARCH DIS CHILD, V85, P12, DOI 10.1136/adc.85.1.12; Hertzog JH, 2000, PEDIATRICS, V106, P742, DOI 10.1542/peds.106.4.742; Howard SC, 2002, JAMA-J AM MED ASSOC, V288, P2001, DOI 10.1001/jama.288.16.2001; Jayabose S, 2001, J PEDIAT HEMATOL ONC, V23, P290, DOI 10.1097/00043426-200106000-00011; Kain ZN, 1997, ANESTH ANALG, V85, P783, DOI 10.1097/00000539-199710000-00012; KATZ ER, 1980, J CONSULT CLIN PSYCH, V48, P356, DOI 10.1037/0022-006X.48.3.356; KAUFFMAN RE, 1992, PEDIATRICS, V89, P1110; Kazak AE, 1996, J PEDIATR PSYCHOL, V21, P195, DOI 10.1093/jpepsy/21.2.195; Klein Scott M, 2003, Pediatr Crit Care Med, V4, P78, DOI 10.1097/00130478-200301000-00016; KRAUSS B, 1999, PEDIAT PROCEDURAL SE; Lichtenbelt BJ, 2004, CLIN PHARMACOKINET, V43, P577, DOI 10.2165/00003088-200443090-00002; Litman RS, 2002, ANESTHESIOLOGY, V96, P342, DOI 10.1097/00000542-200202000-00019; Ljungman G, 1999, ACTA PAEDIATR, V88, P623, DOI 10.1080/08035259950169279; MCGRATH P J, 1990, Journal of Psychosocial Oncology, V8, P109, DOI 10.1300/J077v08n02_06; POCOCK SJ, 1982, BIOMETRICS, V38, P152; PUI CH, 1998, BLOOD, V92, P441; Reber A, 1999, ANESTHESIOLOGY, V90, P1617, DOI 10.1097/00000542-199906000-00018; SCOTT JC, 1985, ANESTHESIOLOGY, V62, P234, DOI 10.1097/00000542-198503000-00005; SHORT TG, 1992, BRIT J ANAESTH, V69, P162, DOI 10.1093/bja/69.2.162; Tanaka M, 2003, BRIT J ANAESTH, V90, P14, DOI 10.1093/bja/aeg018; VanNatta ME, 2006, AM J GASTROENTEROL, V101, P2209, DOI 10.1111/j.1572-0241.2006.00760.x; Vuyk J, 1997, ANESTHESIOLOGY, V87, P1549, DOI 10.1097/00000542-199712000-00033; Vuyk J, 1996, ANESTHESIOLOGY, V84, P288, DOI 10.1097/00000542-199602000-00006; Weisman SJ, 1998, ARCH PEDIAT ADOL MED, V152, P147; ZELTZER L K, 1990, Pediatrics, V86, P826	33	20	20	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1529-7535			PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	NOV	2008	9	6					616	622		10.1097/PCC.0b013e31818e3ad3			7	Critical Care Medicine; Pediatrics	General & Internal Medicine; Pediatrics	372UX	WOS:000260928600010	18838923	Green Accepted			2020-06-30	J	Sirohi, S; Dighe, SV; Walker, EA; Yoburn, BC				Sirohi, Sunil; Dighe, Shveta V.; Walker, Ellen A.; Yoburn, Byron C.			The analgesic efficacy of fentanyl: Relationship to tolerance and mu-opioid receptor regulation	PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR			English	Article						fentanyl; opioid agonist; analgesia; efficacy; tolerance; mu-opioid receptor; receptor downregulation	PROTEIN-COUPLED RECEPTORS; AGONIST EFFICACY; BETA-ARRESTIN; IN-VIVO; PHARMACOLOGICAL AGONISM; INTRINSIC EFFICACY; RELATIVE EFFICACY; OPERATIONAL MODEL; PERTUSSIS TOXIN; RAT THALAMUS	This study determined if fentanyl analgesic efficacy predicts the magnitude of tolerance and mu-opioid receptor regulation. To estimate efficacy, mice were injected i.p.with saline or clocinnamox (CCAM), an irreversible mu-opioid receptor antagonist, (0.32-25.6 mg/kg) and 24 h later fentanyl cumulative dose-response studies were conducted. CCAM dose dependently shifted the fentanyl dose-response function to the right. The apparent efficacy (7) of fentanyl, based on the operational model of agonism, was estimated as 58, indicating that fentanyl is a high analgesic efficacy agonist. Next, mice were infused with fentanyl (1, 2 or 4 mg/kg/day) for 7 days. Controls were implanted with placebo pellets. At the end of 7 days, morphine cumulative dose-response studies or g-opioid receptor saturation binding studies were conducted. Fentanyl infusions dose dependently decreased morphine potency with the highest fentanyl dose reducing morphine potency by approximate to 6 fold. Chronic infusion with fentanyl (4 mg/kg/day) significantly reduced mu-opioid receptor density by 28% without altering affinity whereas lower infusion doses had no effect Taken together, the present results strengthen the proposal that opioid analgesic efficacy predicts mu-opioid receptor regulation and the magnitude of tolerance. (c) 2008 Elsevier Inc. All rights reserved.	[Sirohi, Sunil; Dighe, Shveta V.; Yoburn, Byron C.] St Johns Univ, Coll Pharm & Allied Hlth Profess, Dept Pharmaceut Sci, Queens, NY 11439 USA; [Walker, Ellen A.] Temple Univ, Sch Pharm, Dept Pharmaceut Sci, Philadelphia, PA 19140 USA	Yoburn, BC (reprint author), St Johns Univ, Coll Pharm & Allied Hlth Profess, Dept Pharmaceut Sci, 8000 Utopia Pkwy, Queens, NY 11439 USA.	yoburnb@stjohns.edu	SIROHI, SUNIL/E-1891-2012	SIROHI, SUNIL/0000-0001-7246-9295	National Institute on Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA 19959]	The authors are very grateful to H.H. Rajinder Singh Ji. Dr. M.T. Turnock provided continuous encouragement during this study. Supported in part by a grant from the National Institute on Drug Abuse (DA 19959, to BCY).	ADAMS JU, 1990, J PHARMACOL EXP THER, V255, P1027; Barrett AC, 2003, J PHARMACOL EXP THER, V305, P1061, DOI 10.1124/jpet.102.047068; BLACK JW, 1983, PROC R SOC SER B-BIO, V220, P141, DOI 10.1098/rspb.1983.0093; BLACK JW, 1985, BRIT J PHARMACOL, V84, P561, DOI 10.1111/j.1476-5381.1985.tb12941.x; Bohn LM, 2004, MOL PHARMACOL, V66, P106, DOI 10.1124/mol.66.1.106; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURKE TF, 1994, J PHARMACOL EXP THER, V271, P715; Chan K, 1995, EUR J PHARMACOL, V287, P135, DOI 10.1016/0014-2999(95)00488-2; Clark MJ, 2006, J PHARMACOL EXP THER, V317, P858, DOI 10.1124/jpet.105.096818; Debic HH, 2005, J NEUROSCI, V25, P7847, DOI 10.1523/JNEUROSCI.5045-04.2005; Duttaroy A, 1997, PHARMACOL BIOCHEM BE, V58, P67, DOI 10.1016/S0091-3057(96)00463-7; DUTTAROY A, 1995, ANESTHESIOLOGY, V82, P1226, DOI 10.1097/00000542-199505000-00018; Ferguson S S, 1998, Adv Pharmacol, V42, P420; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Finney DJ, 1973, PROBIT ANAL; FURCHGOTT RF, 1967, ANN NY ACAD SCI, V144, P882, DOI 10.1111/j.1749-6632.1967.tb53817.x; FURCHGOTT RF, 1966, ADV DRUG RES, V3, P21; Galandrin S, 2006, MOL PHARMACOL, V70, P1575, DOI 10.1124/mol.106.026716; Keith DE, 1998, MOL PHARMACOL, V53, P377; Kenakin T, 2002, ANNU REV PHARMACOL, V42, P349, DOI 10.1146/annurev.pharmtox.42.091401.113012; Kenakin T, 2007, TRENDS PHARMACOL SCI, V28, P407, DOI 10.1016/j.tips.2007.06.009; Kieffer BL, 1999, TRENDS PHARMACOL SCI, V20, P19, DOI 10.1016/S0165-6147(98)01279-6; Koch T, 2005, MOL PHARMACOL, V67, P280, DOI 10.1124/mol.104.004994; LEFF P, 1990, J PHARMACOL METHOD, V23, P225, DOI 10.1016/0160-5402(90)90066-T; Mailman RB, 2007, TRENDS PHARMACOL SCI, V28, P390, DOI 10.1016/j.tips.2007.06.002; Martini L, 2007, CURR OPIN NEUROBIOL, V17, P556, DOI 10.1016/j.conb.2007.10.004; Motulsky H, 2004, FITTING MODELS BIOL; PARONIS CA, 1992, J PHARMACOL EXP THER, V262, P1; Patel CN, 2003, SYNAPSE, V50, P67, DOI 10.1002/syn.10246; Patel MB, 2002, MOL PHARMACOL, V62, P1464, DOI 10.1124/mol.62.6.1464; Pawar M, 2007, EUR J PHARMACOL, V563, P92, DOI 10.1016/j.ejphar.2007.01.059; Peckham EM, 2006, J PHARMACOL EXP THER, V316, P1195, DOI 10.1124/jpet.105.094276; Rodriguez-Munoz M, 2007, MOL PAIN, V3, DOI 10.1186/1744-8069-3-19; Selley DE, 1997, MOL PHARMACOL, V51, P87; Selley DE, 1998, J PHARMACOL EXP THER, V285, P496; SHAH S, 1994, PHARMACOL BIOCHEM BE, V49, P773, DOI 10.1016/0091-3057(94)90101-5; Stafford K, 2001, PHARMACOL BIOCHEM BE, V69, P233, DOI 10.1016/S0091-3057(01)00525-1; Waldhoer M, 2004, ANNU REV BIOCHEM, V73, P953, DOI 10.1146/annurev.biochem.73.011303.073940; Walker EA, 2001, PSYCHOPHARMACOLOGY, V154, P131, DOI 10.1007/s002130000620; Whistler JL, 1999, NEURON, V23, P737, DOI 10.1016/S0896-6273(01)80032-5; Whistler JL, 1998, P NATL ACAD SCI USA, V95, P9914, DOI 10.1073/pnas.95.17.9914; YOBURN BC, 1993, J PHARMACOL EXP THER, V265, P314; Zernig G, 1996, J PHARMACOL TOXICOL, V35, P223, DOI 10.1016/1056-8719(96)00053-6; ZERNIG G, 1995, LIFE SCI, V57, P2113, DOI 10.1016/0024-3205(95)02204-V; Zheng H, 2008, MOL PHARMACOL, V73, P178, DOI 10.1124/mol.107.039842	45	25	25	0	7	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0091-3057			PHARMACOL BIOCHEM BE	Pharmacol. Biochem. Behav.	NOV	2008	91	1					115	120		10.1016/j.pbb.2008.06.019			6	Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy	Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy	355NN	WOS:000259715700017	18640146	Green Accepted			2020-06-30	J	Gorelick, DA; Kim, YK; Bencherif, B; Boyd, SJ; Nelson, R; Copersino, ML; Dannals, RF; Frost, JJ				Gorelick, David A.; Kim, Yu Kyeong; Bencherif, Badreddine; Boyd, Susan J.; Nelson, Richard; Copersino, Marc L.; Dannals, Robert F.; Frost, J. James			Brain mu-opioid receptor binding: relationship to relapse to cocaine use after monitored abstinence	PSYCHOPHARMACOLOGY			English	Article						cocaine; mu-opioid receptor; positron emission tomography; relapse; carfentanil; frontal cortex; temporal cortex	MESSENGER-RNA LEVELS; OUTCOME PREDICTORS; NUCLEUS-ACCUMBENS; DRUG-ADDICTION; VALIDITY; DOPAMINE; SEVERITY; ALCOHOL; CORTEX; REWARD	Rationale Cocaine users have increased regional brain muopioid receptor (mOR) binding which correlates with cocaine craving. The relationship of mOR binding to relapse is unknown. Objective To evaluate regional brain mOR binding as a predictor of relapse to cocaine use is the objective of the study. Materials and methods Fifteen nontreatment-seeking, adult cocaine users were housed on a closed research ward for 12 weeks of monitored abstinence and then followed for up to 1 year after discharge. Regional brain mOR binding was measured after 1 and 12 weeks using positron emission tomography (PET) with [C-11] carfentanil (a selective mOR agonist). Time to first cocaine use (lapse) and to first two consecutive days of cocaine use (relapse) after discharge was based on self-report and urine toxicology. Results A shorter interval before relapse was associated with increased mOR binding in frontal and temporal cortical regions at 1 and 12 weeks of abstinence (Ps < 0.001) and with a lesser decrease in binding between 1 and 12 weeks (Ps < 0.0008). There were significant positive correlations between mOR binding at 12 weeks and percent days of cocaine use during first month after relapse (Ps < 0.002). In multiple linear regression analysis, mOR binding contributed significantly to the prediction of time to relapse (R-2 = 0.79, P< 0.001), even after accounting for clinical variables. Conclusions Increased brain mOR binding in frontal and temporal cortical regions is a significant independent predictor of time to relapse to cocaine use, suggesting an important role for the brain endogenous opioid system in cocaine addiction.	[Gorelick, David A.] NIDA, IRP, Baltimore, MD 21224 USA; [Gorelick, David A.; Boyd, Susan J.; Nelson, Richard; Copersino, Marc L.] Natl Inst Drug Abuse, Intramural Res Program, NIH, Baltimore, MD USA; [Kim, Yu Kyeong; Bencherif, Badreddine; Dannals, Robert F.; Frost, J. James] Johns Hopkins Univ, Sch Med, Dept Radiol & Radiol Sci, Baltimore, MD USA	Gorelick, DA (reprint author), NIDA, IRP, 251 Bayview Blvd,Suite 200, Baltimore, MD 21224 USA.	dgorelic@mail.nih.gov			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; National Institute on Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA); NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 DA-09479]	This work was supported by the Intramural Research Program of the National Institutes of Health, National Institute on Drug Abuse and NIH grant RO1 DA-09479 to JJF.	[Anonymous], 1994, DIAGN STAT MAN MENT; Azaryan AV, 1996, NEUROCHEM RES, V21, P1411, DOI 10.1007/BF02532382; Azaryan AV, 1996, J NEUROCHEM, V66, P443; Bauer LO, 1997, DRUG ALCOHOL DEPEN, V44, P1, DOI 10.1016/S0376-8716(96)01311-7; Brady KT, 2002, EXP CLIN PSYCHOPHARM, V10, P276, DOI 10.1037//1064-1297.10.3.276; BRANCH AD, 1992, MOL BRAIN RES, V14, P231, DOI 10.1016/0169-328X(92)90178-E; BROWN J, 1992, BRIT J ADDICT, V87, P1013; Bush G, 2002, P NATL ACAD SCI USA, V99, P523, DOI 10.1073/pnas.012470999; Ciraulo DA, 2003, PSYCHIAT CLIN N AM, V26, P381, DOI 10.1016/S0193-953X(02)00106-5; Cone EJ, 2003, J ANAL TOXICOL, V27, P386, DOI 10.1093/jat/27.7.386; Daglish MRC, 2003, EUR NEUROPSYCHOPHARM, V13, P453, DOI 10.1016/j.euroneuro.2003.08.006; Daunais JB, 1997, PHARMACOL BIOCHEM BE, V57, P471, DOI 10.1016/S0091-3057(96)00432-7; DEROGATIS LR, 1983, SCL 90R ADM SCORING; Donovan DM, 1996, ADDICTION, V91, pS29, DOI 10.1111/j.1360-0443.1996.tb02325.x; Elkashef A, 2003, ADDICT BIOL, V8, P123, DOI 10.1080/1355621031000117356; Endres CJ, 2003, NUCL MED BIOL, V30, P177, DOI 10.1016/S0969-8051(02)00411-0; FROST JJ, 1985, J COMPUT ASSIST TOMO, V9, P231, DOI 10.1097/00004728-198503000-00001; Gianoulakis C, 2004, CURR TOP MED CHEM, V4, P39, DOI 10.2174/1568026043451573; Goldstein RZ, 2002, AM J PSYCHIAT, V159, P1642, DOI 10.1176/appi.ajp.159.10.1642; Gorelick DA, 2005, BIOL PSYCHIAT, V57, P1573, DOI 10.1016/j.biopsych.2005.02.026; GORELICK DA, 2003, PRINCIPLES ADDICTION, P785; Grusser SM, 2004, PSYCHOPHARMACOLOGY, V175, P296, DOI 10.1007/s00213-004-1828-4; Guardia J, 2000, AM J PSYCHIAT, V157, P127, DOI 10.1176/ajp.157.1.127; Hamid R, 1999, SUBST USE MISUSE, V34, P1585, DOI 10.3109/10826089909039416; HAMMER RP, 1989, SYNAPSE, V3, P55, DOI 10.1002/syn.890030108; HARRISON LD, 1995, J DRUG ISSUES, V25, P91, DOI 10.1177/002204269502500107; Hersh D, 1999, J CONSULT CLIN PSYCH, V67, P37, DOI 10.1037/0022-006X.67.1.37; Hser YI, 1999, AM J DRUG ALCOHOL AB, V25, P81, DOI 10.1081/ADA-100101847; Kalivas PW, 2003, PSYCHOPHARMACOLOGY, V168, P44, DOI 10.1007/s00213-003-1393-2; Kampman KM, 2002, ADDICT BEHAV, V27, P251, DOI 10.1016/S0306-4603(01)00171-X; Karila L, 2008, INT J NEUROPSYCHOPH, V11, P425, DOI 10.1017/S1461145707008097; Knapp WP, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003023.pub2; Kosten TR, 2006, NEUROPSYCHOPHARMACOL, V31, P644, DOI 10.1038/sj.npp.1300851; LaForge KS, 2003, BRAIN RES BULL, V59, P353, DOI 10.1016/S0361-9230(02)00927-9; Logan J, 1996, J CEREBR BLOOD F MET, V16, P834, DOI 10.1097/00004647-199609000-00008; Maisto SA, 2006, CLIN PSYCHOL REV, V26, P229, DOI 10.1016/j.cpr.2005.11.009; McKay JR, 1999, DRUG ALCOHOL DEPEN, V56, P67, DOI 10.1016/S0376-8716(99)00013-7; MCLELLAN AT, 1985, J NERV MENT DIS, V173, P412, DOI 10.1097/00005053-198507000-00005; McMahon RC, 2001, J SUBST ABUSE TREAT, V21, P77, DOI 10.1016/S0740-5472(01)00187-8; Milby JB, 2004, PSYCHOL ADDICT BEHAV, V18, P250, DOI 10.1037/0893-164X.18.3.250; Nelson DB, 1998, J DRUG ISSUES, V28, P483, DOI 10.1177/002204269802800210; Palij M, 1996, J ADDICT DIS, V15, P13, DOI 10.1300/J069v15n04_02; Patkar A, 2004, PSYCHOPHARMACOLOGY, V176, P74, DOI 10.1007/s00213-004-1856-0; Patkar AA, 2003, J ADDICT DIS, V22, P79, DOI 10.1300/J069v22n01_06; Poling J, 2007, AM J DRUG ALCOHOL AB, V33, P191, DOI 10.1080/00952990701199416; Preston KL, 2002, J ANAL TOXICOL, V26, P393, DOI 10.1093/jat/26.7.393; Prichep LS, 1999, DRUG ALCOHOL DEPEN, V54, P35, DOI 10.1016/S0376-8716(98)00147-1; Przewlocka B, 1995, EUR NEUROPSYCHOPHARM, V5, P465; Reiber C, 2002, DRUG ALCOHOL DEPEN, V68, P35, DOI 10.1016/S0376-8716(02)00103-5; Robbins TW, 2002, NEUROBIOL LEARN MEM, V78, P625, DOI 10.1006/nlme.2002.4103; ROBINS LN, 1982, PSYCHOL MED, V12, P855, DOI 10.1017/S0033291700049151; Rohsenow DJ, 2007, J STUD ALCOHOL DRUGS, V68, P641, DOI 10.15288/jsad.2007.68.641; Simpson DD, 2002, ARCH GEN PSYCHIAT, V59, P538, DOI 10.1001/archpsyc.59.6.538; SOBELL LC, 1992, MEASURING ALCOHOL CONSUMPTION, P41; UNTERWALD EM, 1992, BRAIN RES, V584, P314, DOI 10.1016/0006-8993(92)90912-S; Unterwald EM, 2001, BRAIN RES, V900, P103, DOI 10.1016/S0006-8993(01)02269-7; UNTERWALD EM, 1994, NEUROREPORT, V5, P1613, DOI 10.1097/00001756-199408150-00018; Volkow ND, 2002, NEUROBIOL LEARN MEM, V78, P610, DOI 10.1006/nlme.2002.4099; Weiss RD, 2003, AM J PSYCHIAT, V160, P1320, DOI 10.1176/appi.ajp.160.7.1320; Williams ZM, 2004, NAT NEUROSCI, V7, P1370, DOI 10.1038/nn1354; Yuferov V, 1999, BRAIN RES BULL, V48, P109, DOI 10.1016/S0361-9230(98)00155-5; Zubieta JK, 1996, NAT MED, V2, P1225, DOI 10.1038/nm1196-1225	62	37	37	1	7	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0033-3158	1432-2072		PSYCHOPHARMACOLOGY	Psychopharmacology	NOV	2008	200	4					475	486		10.1007/s00213-008-1225-5			12	Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	353PD	WOS:000259579100003	18762918	Green Accepted			2020-06-30	J	Lima-Rodriguez, JR; Garcia-Gil, FA; Garcia-Garcia, JJ; Rocha-Camarero, G; Martin-Cancho, MF; Luis-Fernandez, L; Crisostomo, V; Uson-Gargallo, J; Carrasco-Jimenez, MS				Lima-Rodriguez, J. R.; Garcia-Gil, F. A.; Garcia-Garcia, J. J.; Rocha-Camarero, G.; Martin-Cancho, M. F.; Luis-Fernandez, L.; Crisostomo, V.; Uson-Gargallo, J.; Carrasco-Jimenez, M. S.			Effects of Premedication With Tiletamine/Zolazepam/Medetomidine During General Anesthesia Using Sevoflurane/Fentanyl in Swine Undergoing Pancreas Transplantation	TRANSPLANTATION PROCEEDINGS			English	Article; Proceedings Paper	5th Congress of the Andalusian-Society-of-Organ-and-Tissue-Transplantation	MAR 05-07, 2008	Malaga, SPAIN	Andalusian Soc Organ & Tissue Transplantat, ASTELLAS, NOVARTIS, ROCHE			BISPECTRAL INDEX; MEDETOMIDINE; ISOFLURANE; MIDAZOLAM	Objective. To assess cardiac and hemodynamic responses and body temperature during long-term general anesthesia using sevoflurane/fentanyl after premedication with a tiletamine/zolazepam/medetomidine combination in swine undergoing experimental pancreas transplantation. Materials and methods. Twelve Landrace female pigs of means weight 46.4 +/- 5.1 kg were premedicated by intramuscular administration of tiletamine/zolazeparn (3.5 mg/kg), medetomidine (0.03 mg/kg), and atropine (0.02 mg/kg), before anesthesia with 0.75 minimum alveolar concentration sevoflurane and continuous intravenous fentanyl infusion (5.7 +/- 0.7 mu/kg/h). Assessment of heart rate, arterial blood pressure, and temperature in pigs undergoing allogenic pancreas transplant surgery were registered at the start of anesthesia (T0), as well as at 60 (T60), 120 (T120), and 180 (T180) minutes after TO, and finally at the end of anesthesia (T anesthesia end), when we switched off the sevoflurane vaporizer. Analysis of variance was used to determine differences between times with P <.05 considered significant. Results are given as mean values standard deviations. Results. Arterial blood pressure significantly decreased from T120 to the end of anesthesia, while a significantly decreased heart rate was only evident at T60. Body temperature decreased significantly from T60 to the end of anesthesia. These decreases, however, lacked clinical relevance; all parameters were within normal range. No major anesthetic complications were observed in this study. Conclusions. The administration of a tiletamine/zolazepam/medetomidine combination as premedication in swine subjected to pancreas transplantation allowed for a safe reduction of sevoflurane/fentanyl requirements during long-term general anesthesia. Despite arterial blood pressure and body temperature evidencing a decrease during anesthetic maintenance, all parameters remained within normal range values.	[Lima-Rodriguez, J. R.; Martin-Cancho, M. F.; Luis-Fernandez, L.; Crisostomo, V.; Uson-Gargallo, J.] Minimally Invas Surg Ctr Jesus Uson, Caceres, Spain; [Garcia-Gil, F. A.; Garcia-Garcia, J. J.] Univ Zaragoza, Lozano Blesa Hosp, Dept Surg, E-50009 Zaragoza, Spain; [Carrasco-Jimenez, M. S.] Univ Cadiz, Fac Med, Puerto Real Hosp, Dept Anesthesiol, Cadiz, Spain; [Rocha-Camarero, G.] Univ Cadiz, Fac Med, Puerto Real Hosp, Univ Extremadura, Cadiz, Spain	Garcia-Gil, FA (reprint author), Univ Zaragoza, Dept Surg, Domingo Miral S-N, E-50009 Zaragoza, Spain.	agarciagil@telefonica.net		Crisostomo, Veronica/0000-0003-1740-7029			Charney DS, 2004, AM J PSYCHIAT, V161, P1, DOI 10.1176/appi.ajp.161.1.1; DAVID ER, 2001, WORLD J SURG, V25, P487; Garcia-Gil FA, 2006, TRANSPL P, V38, P2595, DOI 10.1016/j.transproceed.2006.08.030; Gruessner AC, 2005, CLIN TRANSPLANT, V19, P433, DOI 10.1111/j.1399-0012.2005.00378.x; KO JCH, 1993, LAB ANIM SCI, V43, P476; KO JCH, 1995, LAB ANIM SCI, V45, P290; LIMA JR, 1998, APRENDIZAJE APLICACI, P85; MANOHAR M, 1984, J PHARMACOL EXP THER, V231, P640; Martin F, 2003, PROSTATECTOMIA RADIC, P47; MARTIN MF, 1998, APRENDIZAJE APLICACI, P27; Martin-Cancho MF, 2004, AM J VET RES, V65, P409, DOI 10.2460/ajvr.2004.65.409; Martin-Cancho MF, 2003, AM J VET RES, V64, P866, DOI 10.2460/ajvr.2003.64.866; MUIR WW, 2000, HDB VET ANESTHESIA, P19; NISHIMURA R, 1993, J VET MED SCI, V55, P687, DOI 10.1292/jvms.55.687; NISHIMURA R, 1993, J VET MED SCI, V55, P717, DOI 10.1292/jvms.55.717; Robertson RP, 2000, DIABETES CARE, V23, P112, DOI 10.2337/diacare.23.1.112; SAKAGUCHI M, 1992, J VET MED SCI, V54, P643, DOI 10.1292/jvms.54.643; SAKAGUCHI M, 1992, J VET MED SCI, V54, P1183, DOI 10.1292/jvms.54.1183; Smith A.C., 1997, AM COLL LAB, P313; Steffey E.P., 1996, LUMB JONES VET ANEST, P297; Sutherland DER, 2001, ANN SURG, V233, P463, DOI 10.1097/00000658-200104000-00003; SUTHERLAND DER, 1998, CURR OPIN ORGAN TRAN, V3, P242; SWINDLE MM, 1984, LAB ANIM SCI, V34, P383; Tendillo FJ, 1996, LAB ANIM SCI, V46, P215; Tendillo FJ, 1991, RES SURG S, V7, P17; Thurmon J. C., 1988, Veterinary Medicine, V83, P841; TRACY CH, 1988, VET MED-US, V83, P104; VONGANTER M, 1990, BERL MUNCH TIERARZTL, V103, P341; WARD GS, 1974, LAB ANIM SCI, V24, P737	29	8	8	1	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0041-1345	1873-2623		TRANSPL P	Transplant. Proc.	NOV	2008	40	9					3001	3006		10.1016/j.transproceed.2008.09.042			6	Immunology; Surgery; Transplantation	Immunology; Surgery; Transplantation	375QQ	WOS:000261128800045	19010173				2020-06-30	J	Covey-Crump, GL; Murison, PJ				Covey-Crump, Gwen L.; Murison, Pamela J.			Fentanyl or midazolam for co-induction of anaesthesia with propofol in dogs	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article						anaesthesia; co-induction; dog; fentanyl; midazolam; propofol	ACEPROMAZINE-BUTORPHANOL; INDUCTION; INJECTION; CATS; PHARMACOKINETICS; PREMEDICATION; SPEED; AGENT	Objective Propofol may cause adverse effects (e.g. apnoea, hypotension) at induction of anaesthesia. Co-induction of anaesthesia may reduce propofol requirements. The effect of fentanyl or midazolam on propofol dose requirements and cardiorespiratory parameters was studied. Study design Randomized, controlled, blinded clinical study. Animals Sixty-six client owned dogs (35 male, 31 female, ASA I-II, age 6-120 months, body mass 4.7-48.0 kg) were selected. Methods Pre-medication with acepromazine (0.025 mg kg(-1)) and morphine (0.25 mg kg(-1)) was administered by intramuscular injection. After 30 minutes group fentanyl-propofol (FP) received fentanyl (2 mu g kg(-1)), group midazolam-propofol (MP) midazolam (0.2 mg kg(-1)) injected over 30 seconds via a cephalic catheter and in a third group, control-propofol (CP), the IV catheter was flushed with an equivalent volume of heparinized saline. Anaesthesia was induced 2 minutes later, with propofol (4 mg kg(-1)minute(-1)) administered to effect. After endotracheal intubation anaesthesia was maintained with a standardized anaesthetic protocol. Pulse rate, respiratory rate (RR) and mean arterial pressure (MAP) were recorded before the co-induction agent, before induction, and 0, 2 and 5 minutes after intubation. Apnoea >= 30 seconds was recorded and treated. Sedation after pre-medication, activity after the co-induction agent, quality of anaesthetic induction and endotracheal intubation were scored. Results Propofol dose requirement was significantly reduced in FP [2.90 mg kg(-1)(0.57)] compared to CP [3.51 mg kg(-1) (0.74)] and MP [3.58 mg kg(-1)(0.49)]. Mean pulse rate was higher in MP than in CP or FP (p = 0.003). No statistically significant difference was found between groups in mean RR, MAP or incidence of apnoea. Activity score was significantly higher (i.e. more excited) (p = 0.0001), and quality of induction score was significantly poorer (p = 0.0001) in MP compared to CP or FP. Intubation score was similar in all groups. Conclusions and clinical relevance Fentanyl decreased propofol requirement but did not significantly alter cardiovascular parameters. Midazolam did not reduce propofol requirements and caused excitement in some animals.	[Covey-Crump, Gwen L.; Murison, Pamela J.] Univ Bristol, Sch Vet, Bristol BS40 5DU, Avon, England	Covey-Crump, GL (reprint author), Univ Bristol, Sch Vet, Langford House, Bristol BS40 5DU, Avon, England.	gwen.covey-crump@bristol.ac.uk		Covey-Crump, Gwen/0000-0002-5541-0168			BENSHLOMO I, 1993, ANAESTHESIA, V48, P111; Bufalari A, 1997, NEW ZEAL VET J, V45, P129, DOI 10.1080/00480169.1997.36012; CLAEYS MA, 1988, BRIT J ANAESTH, V60, P3, DOI 10.1093/bja/60.1.3; COURT MH, 1992, J VET PHARMACOL THER, V15, P343, DOI 10.1111/j.1365-2885.1992.tb01026.x; Davies C., 1991, Journal of Veterinary Anaesthesia, V18, P48; Driver IK, 1996, ANAESTHESIA, V51, P782, DOI 10.1111/j.1365-2044.1996.tb07897.x; GEEL JK, 1991, J S AFR VET ASSOC, V62, P118; GILLIES GWA, 1989, ANAESTHESIA, V44, P386, DOI 10.1111/j.1365-2044.1989.tb11333.x; Hall L., 2001, VET ANAESTHESIA, P77; Harris C E, 1988, Anaesthesia, V43 Suppl, P32, DOI 10.1111/j.1365-2044.1988.tb09065.x; Hughes JML, 1999, VET SURG, V28, P513, DOI 10.1111/j.1532-950X.1999.00513.x; ILKIW JE, 1994, CAN J VET RES, V58, P248; Kojima K, 2002, AM J VET RES, V63, P1671, DOI 10.2460/ajvr.2002.63.1671; MORGAN DWT, 1989, VET REC, V124, P31, DOI 10.1136/vr.124.2.31; Murison PJ, 2001, J SMALL ANIM PRACT, V42, P71, DOI 10.1111/j.1748-5827.2001.tb01995.x; MURPHY PJ, 1994, ANAESTHESIA, V49, P105, DOI 10.1111/j.1365-2044.1994.tb03363.x; Nolan A. M., 1991, Journal of Veterinary Anaesthesia, V18, P30; PETRIE A, 1999, STAT VET ANIMAL SCI, P157; ROLLY G, 1985, BRIT J ANAESTH, V57, P743, DOI 10.1093/bja/57.8.743; SEBEL PS, 1989, ANESTHESIOLOGY, V71, P260, DOI 10.1097/00000542-198908000-00015; SHORT TG, 1992, BRIT J ANAESTH, V69, P162, DOI 10.1093/bja/69.2.162; SMITH JA, 1993, J AM VET MED ASSOC, V202, P1111; Stegmann GF, 2001, J S AFR VET ASSOC, V72, P214; WATKINS SB, 1987, VET REC, V120, P326, DOI 10.1136/vr.120.14.326; WATNEY GCG, 1992, AM J VET RES, V53, P2320; WEAVER BMQ, 1990, VET REC, V126, P617	26	45	45	0	20	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1467-2987	1467-2995		VET ANAESTH ANALG	Vet. Anaesth. Analg.	NOV	2008	35	6					463	472		10.1111/j.1467-2995.2008.00408.x			10	Veterinary Sciences	Veterinary Sciences	361QA	WOS:000260141000002	18565204				2020-06-30	J	Anderson, MK; Day, TK				Anderson, Marlo K.; Day, Thomas K.			Effects of morphine and fentanyl constant rate infusion on urine output in healthy and traumatized dogs	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article						fentanyl; morphine; trauma; urine production	RENAL-FUNCTION; ANTIDIURETIC-HORMONE; INTRAVENOUS-INFUSION; HISTAMINE-RELEASE; FLUID THERAPY; ANESTHESIA; ANALGESIA; PAIN; HALOTHANE; EXCRETION	Objective To determine whether healthy and traumatized dogs receiving a constant rate infusion (CRI) of either morphine or fentanyl have decreased urine production. Study design Prospective randomized controlled study. Animal population Eighteen privately owned previously healthy dogs that had undergone trauma were included. Twenty-three privately owned healthy dogs were used as the controls. Methods Traumatized dogs were randomized into one of two groups. Group Tmorphine received a CRI of morphine (0.12 mg kg(-1) hour(-1)) and group Tfentanyl received a CRI of fentanyl (3 mu g kg(-1) hour(-1)) both administered in lactated Ringer's solution (LRS) at a rate of 60 mL kg(-1) day(-1). Control healthy dogs were randomized into one of three groups. The LRS control group (CLRS) (n = 8) received LRS at a rate of 60 mL kg(-1) day(-1). Group Cmorphine (n = 8) and group Cfentanyl (n = 7) received the same infusions as Tmorphine and Tfentanyl, respectively. Collected data were identical for all groups and consisted of measuring total fluid administered, urine output, and urine specific gravity (USG) for a 24-hour period. An analysis of variance (ANOVA) was used for statistical analysis and a p < 0.05 was considered statistically significant. Results Urine output was significantly decreased (p < 0.05) in all groups compared with the LRS control group. The end mean USG was significantly lower (p = 0.003) in the LRS control group compared with all other groups. Conclusions There was a decrease in urine output with a CRI of morphine or fentanyl in both healthy and traumatized dogs. Clinical relevance Decreased urine output caused by an opioid effect might lead to improper assessments of renal function and urine production.	[Anderson, Marlo K.; Day, Thomas K.] Louisville Vet Specialty & Emergency Serv, Louisville, KY USA	Anderson, MK (reprint author), 203 English Stn Way, Louisville, KY 40245 USA.	zoovet2be@hotmail.com					Ambrisko TD, 2005, AM J VET RES, V66, P406, DOI 10.2460/ajvr.2005.66.406; Bengtsson BOS, 2003, ACTA PAEDIATR, V92, P251; BENTINCKSMITH J, 1989, CURRENT VET THERAPY, P1335; BIDWAI AV, 1976, CAN ANAESTH SOC J, V23, P296, DOI 10.1007/BF03005705; BIDWAI AV, 1975, ANESTH ANALG, V54, P357; Das UG, 2001, PEDIATRICS, V108, P1012, DOI 10.1542/peds.108.4.1012; de Bodo RC, 1944, J PHARMACOL EXP THER, V82, P74; DIBARTOLA SP, 1980, J AM ANIM HOSP ASSOC, V16, P537; DIBARTOLA SP, 2006, FLUID ELECTROLYTE AC, P340; DUKE HN, 1951, Q J EXP PHYSIOL CMS, V36, P149, DOI 10.1113/expphysiol.1951.sp000968; DURANT PAC, 1988, ANESTHESIOLOGY, V68, P325, DOI 10.1097/00000542-198803000-00002; ECOFFEY C, 1984, ACTA ANAESTH SCAND, V28, P245, DOI 10.1111/j.1399-6576.1984.tb02052.x; FUJIMOTO S, 1978, JPN J PHARMACOL, V28, P49, DOI 10.1254/jjp.28.49; Guedes AG, 2006, VET ANAESTH ANALG, V33, P28, DOI 10.1111/j.1467-2995.2005.00218.x; GUTKOWSKA J, 1993, EUR J PHARMACOL, V242, P7, DOI 10.1016/0014-2999(93)90003-Z; Guyton AC, 2006, TXB MED PHYSL, P348; HANDLEY CA, 1952, ARCH INT PHARMACOD T, V90, P185; Hansen B, 2002, J VET EMERG CRIT CAR, V12, P235, DOI 10.1046/j.1435-6935.2002.t01-1-00050.x; HARUKUNI I, 1995, ANESTH ANALG, V81, P1169, DOI 10.1097/00000539-199512000-00009; Haskins, 2005, MANUAL SMALL ANIMAL, P71; Hauptman JG, 2000, AM J VET RES, V61, P1273, DOI 10.2460/ajvr.2000.61.1273; Hellyer PW, 1998, COMP CONT EDUC PRACT, V20, P140; HUIDOBRO F, 1979, EUR J PHARMACOL, V59, P55, DOI 10.1016/0014-2999(79)90024-4; ISHIHARA H, 1978, CAN ANAESTH SOC J, V25, P312, DOI 10.1007/BF03005655; KING LG, 2005, P 11 INT VET EM CRIT, P799; KITTLESON MD, 1998, [No title captured]; Kokko H, 2002, PHARMACOTHERAPY, V22, P1188, DOI 10.1592/phco.22.13.1188.33526; KONO K, 1981, ANESTH ANALG, V60, P552; Lamont LA, 2000, VET CLIN N AM-SMALL, V30, P703, DOI 10.1016/S0195-5616(08)70003-2; LEJUS C, 1994, BRIT J ANAESTH, V72, P156, DOI 10.1093/bja/72.2.156; LIU WS, 1977, CAN ANAESTH SOC J, V24, P371, DOI 10.1007/BF03005110; Lucas AN, 2001, J AM VET MED ASSOC, V218, P884, DOI 10.2460/javma.2001.218.884; Marik PE, 2001, CRIT CARE MED, V29, P1635, DOI 10.1097/00003246-200108000-00024; Masilamani S, 2000, KIDNEY, P595; Mathews KA, 2000, VET CLIN N AM-SMALL, V30, P729, DOI 10.1016/S0195-5616(08)70004-4; OCONNOR WJ, 1977, J PHYSIOL-LONDON, V264, P229, DOI 10.1113/jphysiol.1977.sp011665; PAPPER S, 1964, CLIN PHARMACOL THER, V5, P205; Pascoe PJ, 2000, VET CLIN N AM-SMALL, V30, P757, DOI 10.1016/S0195-5616(08)70005-6; PHILBIN DM, 1976, CAN ANAESTH SOC J, V23, P290, DOI 10.1007/BF03005704; Quandt JE, 2005, COMP CONT EDUC PRACT, V27, P433; RADOSEVICH PM, 1984, J CLIN INVEST, V74, P1473, DOI 10.1172/JCI111560; RATHBUN RC, 1983, PHARMACOL BIOCHEM BE, V19, P863, DOI 10.1016/0091-3057(83)90094-1; Robertson SA, 2001, AM J VET RES, V62, P1922, DOI 10.2460/ajvr.2001.62.1922; ROBINSON EP, 1988, AM J VET RES, V49, P1699; ROSS LA, 1989, VET CLIN N AM-SMALL, V19, P343, DOI 10.1016/S0195-5616(89)50034-2; RUDLOFF E, 2004, P 10 INT VET EM CRIT, P473; SMARICK SD, 2006, P 11 INT VET EM CRIT, P101; SMITH RC, 1964, VET MED, V59, P743; TONNESEN AS, 1990, MONITORING ANESTHESI, P575; Wagner AE, 2002, J AM VET MED ASSOC, V221, P72, DOI 10.2460/javma.2002.221.72; WAGNER AE, 2002, HDB VET PAIN MANAGEM, P164; WALDROP JE, 2005, P 11 INT VET EM CRIT, P481; WINGFIELD WE, 2002, VET ICU BOOK, P453; WRIGHT EM, 1990, EXPT ANIMAL BIOMEDIC, P205	54	10	10	1	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1467-2987	1467-2995		VET ANAESTH ANALG	Vet. Anaesth. Analg.	NOV	2008	35	6					528	536		10.1111/j.1467-2995.2008.00413.x			9	Veterinary Sciences	Veterinary Sciences	361QA	WOS:000260141000010	18565200				2020-06-30	J	Goicoechea, C; Sanchez, E; Cano, C; Jagerovic, N; Martin, MI				Goicoechea, Carlos; Sanchez, Eva; Cano, Carolina; Jagerovic, Nadine; Martin, Maria Isabel			Analgesic activity and pharmacological characterization of N-[1-phenylpyrazol-3-yl]-N-[1-(2-phenethyl)-4-piperidyl] propenamide, a new opioid agonist acting peripherally	EUROPEAN JOURNAL OF PHARMACOLOGY			English	Article						opioid; peripheral effect; analgesia; tolerance; dependence	GUINEA-PIG ILEUM; FENTANYL ANALOGS; VISCERAL PAIN; VAS-DEFERENS; DOUBLE-BLIND; IN-VIVO; MORPHINE; ANTINOCICEPTION; DEPENDENCE; RECEPTORS	We previously reported the synthesis of three new opioid agonists as well as their in vitro and in vivo activity [Giron, R., Abalo, R, Goicoechea, C., Martin, M.I., Callado, L.F., Cano, C., Goya, R, Jagerovic, N. 2002. Synthesis and opioid activity of new fentanyl analogs. Life Sci. 71,1023-1034]. One of them, N-[1-phenylpyrazol-3-yl]-N-[1-(2-phenethyl)-4-piperidyl)] propenamide (IQMF-4), showed an interesting antinociceptive activity. Intraperitoneally (i.p.) administered, it was as effective as fentanyl or morphine, being less potent than fentanyl but more so than morphine. The aim of the present work was to evaluate its antinociceptive effect by different routes of administration, using the hot plate test, and to investigate possible side effects, such as tolerance and withdrawal, in vitro, using the myenteric plexus-longitudinal muscle strip preparation from guinea pig ileum, and in vivo, using the hot plate test. IQMF-4 was more potent than morphine when administered per as (p.o.), but less potent when administered intracerebroventricularly (i.c.v.). By both routes, fentanyl is more potent that IQMF-4. When IQMF-4 was administered i.p., naloxone methiodide, a peripherally acting antagonist, was able to completely block its antinociceptive effect, whereas, after i.c.v. administration, the blockade was only partial. An interesting feature of the new compound is that it induces tolerance in vitro but not in vivo. Moreover, though in vitro withdrawal was not different from fentanyl or morphine, in vivo withdrawal symptoms were significantly less frequent in mice treated with IQMF-4 than in those treated with morphine or fentanyl. Although more assays are required, these results show that IQMF-4 appears to be a potent analgesic compound with an interesting peripheral component, and reduced ability to induce dependence. (C) 2008 Elsevier B.V. All rights reserved.	[Goicoechea, Carlos; Sanchez, Eva; Martin, Maria Isabel] Univ Rey Juan Carlos, Fac Ciencias Salud, Area Farmacol, Unidad Farmacol, Madrid 28922, Spain; [Cano, Carolina; Jagerovic, Nadine] Consejo Super Invest Cient, Inst Quim Med, Barcelona, Spain	Goicoechea, C (reprint author), Univ Rey Juan Carlos, Fac Ciencias Salud, Area Farmacol, Unidad Farmacol, Avda Atenas S-N, Madrid 28922, Spain.	carlos.goicoechea@urjc.es	Sanchez-Robles, Eva M/H-2600-2015; Goicoechea, Carlos/H-6890-2015	Sanchez-Robles, Eva M/0000-0002-2740-2750; Goicoechea, Carlos/0000-0002-6226-6934; Jagerovic, Nadine/0000-0003-2642-6969	Spanish government SAF [2003-08003-C02-01]	Thanks are due to Dr. Shannon Shields for English language revision. This work was supported by a grant by Spanish government SAF: 2003-08003-C02-01.	Abalo R, 2007, LIFE SCI, V80, P2436, DOI 10.1016/j.lfs.2007.04.004; Al-Khrasani M, 2007, BRAIN RES BULL, V74, P369, DOI 10.1016/j.brainresbull.2007.07.008; ALFARO MJ, 1990, BRIT J PHARMACOL, V101, P958, DOI 10.1111/j.1476-5381.1990.tb14187.x; AMBACHE N, 1969, J PHYSL, V200, P50; Arias A, 2006, DRUG ALCOHOL DEPEN, V83, P262, DOI 10.1016/j.drugalcdep.2005.11.024; Bileviciute-Ljungar I, 2006, J PHARMACOL EXP THER, V317, P220, DOI 10.1124/jpet.105.096032; Eisenberg E, 2006, EUR J PAIN, V10, P667, DOI 10.1016/j.ejpain.2005.10.007; EISENBERG RM, 1982, LIFE SCI, V31, P1531, DOI 10.1016/0024-3205(82)90043-1; Essawi MYH, 1999, PHARMAZIE, V54, P307; GEBHART GF, 1971, ARCH INT PHARMACOD T, V191, P96; GILLAN MGC, 1979, BRIT J PHARMACOL, V66, P601, DOI 10.1111/j.1476-5381.1979.tb13700.x; GINZTLER AR, 1980, BRAIN RES, V182, P224; Giron R, 2002, LIFE SCI, V71, P1023, DOI 10.1016/S0024-3205(02)01798-8; Ji YP, 2006, AM J PHYSIOL-REG I, V291, pR307, DOI 10.1152/ajpregu.00824.2005; Kumar V, 2005, BIOORG MED CHEM LETT, V15, P1091, DOI 10.1016/j.bmcl.2004.12.018; Langford R, 2006, ARTHRITIS RHEUM-US, V54, P1829, DOI 10.1002/art.21884; LESLIE FM, 1987, PHARMACOL REV, V39, P197; Lizasoain I, 1996, EUR J PHARMACOL, V299, P41, DOI 10.1016/0014-2999(95)00851-9; Menendez L, 2003, NEUROREPORT, V14, P867, DOI 10.1097/01.wnr.0000069963.11849.af; MORGAN J P, 1985, Advances in Alcohol and Substance Abuse, V5, P163; Mystakidou K, 2006, DRUG DELIV, V13, P269, DOI 10.1080/10717540500394661; Pugsley MK, 2002, PHARMACOL THERAPEUT, V93, P51, DOI 10.1016/S0163-7258(02)00165-1; Ray SB, 2004, J BIOSCIENCES, V29, P51; RUSSELL NJW, 1987, NEUROSCI LETT, V76, P107, DOI 10.1016/0304-3940(87)90201-1; SCHAUMANN W, 1955, BRIT J PHARM CHEMOTH, V10, P456, DOI 10.1111/j.1476-5381.1955.tb00105.x; SCHULZ R, 1976, LIFE SCI, V19, P1117, DOI 10.1016/0024-3205(76)90246-0; Stafford K, 2001, PHARMACOL BIOCHEM BE, V69, P233, DOI 10.1016/S0091-3057(01)00525-1; STEIN C, 1989, J PHARMACOL EXP THER, V248, P1269; Tamayo AC, 2004, SUPPORT CARE CANCER, V12, P613, DOI 10.1007/s00520-004-0649-7; Varrassi G, 1999, ACTA ANAESTH SCAND, V43, P51, DOI 10.1034/j.1399-6576.1999.430112.x; Viscusi ER, 2006, SURG ENDOSC, V20, P64, DOI 10.1007/s00464-005-0104-y; Wenk HN, 2006, J NEUROPHYSIOL, V95, P2083, DOI 10.1152/jn.00394.2005; ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4	33	10	10	0	6	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0014-2999			EUR J PHARMACOL	Eur. J. Pharmacol.	OCT 24	2008	595	1-3					22	29		10.1016/j.ejphar.2008.07.052			8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	358DZ	WOS:000259898300004	18706410				2020-06-30	J	Messenger, DW; Murray, HE; Dungey, PE; van Vlymen, J; Sivilotti, MLA				Messenger, David W.; Murray, Heather E.; Dungey, Paul E.; van Vlymen, Janet; Sivilotti, Marco L. A.			Subdissociative-dose Ketamine versus Fentanyl for Analgesia during Propofol Procedural Sedation: A Randomized Clinical Trial	ACADEMIC EMERGENCY MEDICINE			English	Article; Proceedings Paper	Annual Scientific Assembly of the Canadian-Association-of-Emergency-Physicians	JUN, 2007	Victoria, CANADA	Canadian Assoc Emergency Phys		conscious sedation; hypnotics and sedatives; ketamine; fentanyl; propofol; emergency medicine	EMERGENCY-DEPARTMENT; COMBINATION; ANESTHESIA; MIDAZOLAM; PAIN; PHARMACOKINETICS; PHARMACODYNAMICS; CONSCIOUSNESS; DISLOCATION; REDUCTION	Objectives: The authors sought to compare the safety and efficacy of subdissociative-dose ketamine versus fentanyl as adjunct analgesics for emergency department (ED) procedural sedation and analgesia (PSA) with propofol. Methods: This double-blind, randomized trial enrolled American Society of Anesthesiology (ASA) Class I or II ED patients, aged 14-65 years, requiring PSA for orthopedic reduction or abscess drainage. Subjects received 0.3 mg/kg ketamine or 1.5 mu g/kg fentanyl intravenously (IV), followed by IV propofol titrated to deep sedation. Supplemental oxygen was not routinely administered. The primary outcomes were the frequency and severity of cardiorespiratory events and interventions, rated using a composite intrasedation event rating scale. Secondary outcomes included the frequency or specific scale component events, propofol doses required to achieve and maintain sedation, times to sedation and recovery, and physician and patient satisfaction. Results: Sixty-three patients were enrolled. Of patients who received fentanyl, 26/31 (83.9%) had an intrasedation event versus 15/32 (46.9%) of those who received ketamine. Events prospectively rated as moderate or severe were seen in 16/31 (51.6%) of fentanyl subjects versus 7/32 (21.9%) of ketamine subjects. Patients receiving fentanyl had 5.1 (95% confidence interval [CI] = 1.9 to 13.6; p < 0.001) times the odds of having a more serious intrasedation event rating than patients receiving ketamine. There were no significant differences in secondary outcomes, apart from higher propofol doses in the ketamine arm. Conclusions: Subdissociative-dose ketamine is safer than fentanyl for ED PSA with propofol and appears to have similar efficacy. ACADEMIC EMERGENCY MEDICINE 2008; 15:877-886 (C) 2008 by the Society for Academic Emergency Medicine	[Messenger, David W.; Murray, Heather E.; Dungey, Paul E.; Sivilotti, Marco L. A.] Queens Univ, Dept Emergency Med, Kingston, ON, Canada; [Messenger, David W.] Queens Univ, Crit Care Program, Kingston, ON, Canada; [van Vlymen, Janet] Queens Univ, Dept Anesthesiol, Kingston, ON, Canada	Messenger, DW (reprint author), Queens Univ, Dept Emergency Med, Kingston, ON, Canada.	david.messenger@queensu.ca		Sivilotti, Marco/0000-0001-6641-1118			Akin A, 2005, J CLIN ANESTH, V17, P187, DOI 10.1016/j.jclinane.2004.06.019; Akin A, 2005, PEDIATR CARDIOL, V26, P553, DOI 10.1007/s00246-004-0707-4; Badrinath S, 2000, ANESTH ANALG, V90, P858, DOI 10.1213/00000539-200004000-00016; Blankstein KC, 2006, J ORAL MAXIL SURG, V64, P691, DOI 10.1016/j.joms.2005.11.038; BOND K, 2008, 109 CAN AG DRUGS TEC; Burton JH, 2006, ACAD EMERG MED, V13, P500, DOI 10.1197/j.aem.2005.12.017; Burton JH, 2006, ACAD EMERG MED, V13, P24, DOI 10.1197/j.aem.2005.08.011; Burton JH, 2002, ANN EMERG MED, V40, P496, DOI 10.1067/mem.2002.126607; Campbell Sam G, 2006, CJEM, V8, P85; CHERNIK DA, 1990, J CLIN PSYCHOPHARM, V10, P244; CLAEYS MA, 1988, BRIT J ANAESTH, V60, P3, DOI 10.1093/bja/60.1.3; Deitch K, 2007, ANN EMERG MED, V49, P1, DOI 10.1016/j.annemergmed.2006.06.013; Doufas AG, 2004, ANESTHESIOLOGY, V101, P1112, DOI 10.1097/00000542-200411000-00010; Frazee BW, 2005, AM J EMERG MED, V23, P190, DOI 10.1016/j.ajem.2004.05.008; Frey K, 1999, ANESTH ANALG, V89, P317, DOI 10.1097/00000539-199908000-00013; FRIEDBERG BL, 1993, PLAST RECONSTR SURG, V91, P196, DOI 10.1097/00006534-199301000-00047; Frizelle HP, 1997, ANESTH ANALG, V84, P1318, DOI 10.1097/00000539-199706000-00026; GILL SS, 1990, BRIT J ANAESTH, V65, P760, DOI 10.1093/bja/65.6.760; Godambe SA, 2003, PEDIATRICS, V112, P116, DOI 10.1542/peds.112.1.116; Gottschalk A, 2001, AM FAM PHYSICIAN, V63, P1979; GREEN SM, 1990, ANN EMERG MED, V19, P1024, DOI 10.1016/S0196-0644(05)82568-5; Green SM, 2007, ANN EMERG MED, V49, P31, DOI 10.1016/j.annemergmed.2006.09.020; HUG CC, 1993, ANESTH ANALG, V77, pS21; Hwang J, 2005, ACTA ANAESTH SCAND, V49, P1334, DOI 10.1111/j.1399-6576.2005.00842.x; Iwakiri H, 2003, ANESTH ANALG, V96, P1651, DOI 10.1213/01.ANE.0000062772.28479.2B; Kim KM, 2007, ANESTHESIOLOGY, V106, P924, DOI 10.1097/01.anes.0000265151.78943.af; Kohrs R, 1998, ANESTH ANALG, V87, P1186, DOI 10.1097/00000539-199811000-00039; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; Lichtenbelt BJ, 2004, CLIN PHARMACOKINET, V43, P577, DOI 10.2165/00003088-200443090-00002; Loh G, 2007, ANN PHARMACOTHER, V41, P485, DOI 10.1345/aph.1H522; Marshall SI, 1997, CURR OPIN ANAESTH, V10, P445, DOI [DOI 10.1097/00001503-1997112000-00011, 10.1097/00001503-1997112000-00011]; Mertens MJ, 2004, ANESTHESIOLOGY, V100, P795, DOI 10.1097/00000542-200404000-00008; Messenger DW, 2007, CAN J EMERG MED, V9, P186; Miner JR, 2007, ANN EMERG MED, V50, P182, DOI 10.1016/j.annemergmed.2006.12.017; Miner JR, 2007, ACAD EMERG MED, V14, P170, DOI 10.1197/j.aem.2006.10.101; Miner JR, 2007, ANN EMERG MED, V49, P15, DOI 10.1016/j.annemergmed.2006.06.042; Miner JR, 2005, ACAD EMERG MED, V12, P491, DOI 10.1197/j.aem.2005.01.011; Miner JR, 2005, ACAD EMERG MED, V12, P190, DOI 10.1197/j.aem.2004.10.004; Miner JR, 2003, ACAD EMERG MED, V10, P931, DOI 10.1197/S1069-6563(03)00310-5; Miner JR, 2003, ACAD EMERG MED, V10, P638, DOI 10.1197/aemj.10.6.638; Miner JR, 2002, ACAD EMERG MED, V9, P275, DOI 10.1197/aemj.9.4.275; Mortero RF, 2001, ANESTH ANALG, V92, P1465; MURRAY HE, 2007, ACAD EMERG MED, V14, pSA59; Slavik VC, 2007, PHARMACOTHERAPY, V27, P1588, DOI 10.1592/phco.27.11.1588; SMITH C, 1994, ANESTHESIOLOGY, V81, P820, DOI 10.1097/00000542-199410000-00008; Struys MMRF, 2007, ANESTHESIOLOGY, V107, P386, DOI 10.1097/01.anes.0000278902.15505.f8; TVERSKOY M, 1994, ANESTH ANALG, V78, P205, DOI 10.1213/00000539-199402000-00002; Upton RN, 2005, ANESTHESIOLOGY, V103, P344, DOI 10.1097/00000542-200508000-00018; Vardi A, 2002, CRIT CARE MED, V30, P1231, DOI 10.1097/00003246-200206000-00010; WHITE PF, 1982, ANESTHESIOLOGY, V56, P119, DOI 10.1097/00000542-198202000-00007; WHITEHEAD J, 1993, STAT MED, V12, P2257, DOI 10.1002/sim.4780122404; Willman EV, 2007, ANN EMERG MED, V49, P23, DOI 10.1016/j.annemergmed.2006.08.002; Zed PJ, 2007, CAN J EMERG MED, V9, P421	53	60	61	0	2	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	1069-6563			ACAD EMERG MED	Acad. Emerg. Med.	OCT	2008	15	10					877	886		10.1111/j.1553-2712.2008.00219.x			10	Emergency Medicine	Emergency Medicine	359FO	WOS:000259972000001	18754820				2020-06-30	J	Miner, JR				Miner, James R.			The Surgical Stress Response, Preemptive Analgesia, and Procedural Sedation in the Emergency Department	ACADEMIC EMERGENCY MEDICINE			English	Editorial Material							POSTOPERATIVE PAIN; GENERAL-ANESTHESIA; FORMALIN TEST; PROPOFOL; SURGERY; KETAMINE; MORPHINE; RAT; SENSITIZATION; MECHANISMS		Hennepin Cty Med Ctr, Dept Emergency Med, Minneapolis, MN 55415 USA	Miner, JR (reprint author), Hennepin Cty Med Ctr, Dept Emergency Med, Minneapolis, MN 55415 USA.	jimminer@hotmail.com	Miner, James/AAI-4801-2020				ABRAM SE, 1993, ANESTHESIOLOGY, V78, P713, DOI 10.1097/00000542-199304000-00015; AHO M, 1990, ANESTHESIOLOGY, V72, P797, DOI 10.1097/00000542-199005000-00004; *AM SOC AN, STAT SAF US PROP; Bassett KE, 2003, ANN EMERG MED, V42, P773, DOI 10.1016/S0196-0644(03)00619-X; CAMPBELL JN, 1979, J NEUROPHYSIOL, V42, P1669; Carli F, 2006, MINERVA ANESTESIOL, V72, P395; CARLI F, 1991, ACTA ANAESTH SCAND, V35, P329, DOI 10.1111/j.1399-6576.1991.tb03299.x; CARLI F, 1990, BRIT J ANAESTH, V65, P373, DOI 10.1093/bja/65.3.373; COLLIS R, 1995, BRIT J ANAESTH, V74, P396, DOI 10.1093/bja/74.4.396; CROZIER TA, 1987, ANESTHESIOLOGY, V66, P628, DOI 10.1097/00000542-198705000-00006; DAHL JB, 1994, ACTA ANAESTH SCAND, V38, P557, DOI 10.1111/j.1399-6576.1994.tb03951.x; Dahl V, 1996, ACTA ANAESTH SCAND, V40, P847, DOI 10.1111/j.1399-6576.1996.tb04544.x; Dahl V, 2000, ANESTH ANALG, V90, P1419, DOI 10.1097/00000539-200006000-00031; DESBOROUGH JP, 1991, BRIT J ANAESTH, V67, P390, DOI 10.1093/bja/67.4.390; DICKENSON AH, 1987, PAIN, V30, P349, DOI 10.1016/0304-3959(87)90023-6; Frazee BW, 2005, AM J EMERG MED, V23, P190, DOI 10.1016/j.ajem.2004.05.008; GOTO T, 1994, ANESTHESIOLOGY, V80, P409, DOI 10.1097/00000542-199402000-00021; Gottschalk A, 2001, AM FAM PHYSICIAN, V63, P1979; HYLDEN JLK, 1989, PAIN, V37, P229, DOI 10.1016/0304-3959(89)90135-8; KEHLET H, 1989, BRIT J ANAESTH, V63, P189, DOI 10.1093/bja/63.2.189; Kern SE, 2004, ANESTHESIOLOGY, V100, P1373, DOI 10.1097/00000542-200406000-00007; MANGANO DT, 1992, ANESTHESIOLOGY, V76, P342, DOI 10.1097/00000542-199203000-00004; MCQUAY HJ, 1988, PAIN, V33, P291, DOI 10.1016/0304-3959(88)90287-4; Messenger DW, 2008, ACAD EMERG MED, V15, P877, DOI 10.1111/j.1553-2712.2008.00219.x; Miner JR, 2007, ACAD EMERG MED, V14, P170, DOI 10.1197/j.aem.2006.10.101; Miner JR, 2005, ACAD EMERG MED, V12, P491, DOI 10.1197/j.aem.2005.01.011; Miner JR, 2003, ACAD EMERG MED, V10, P931, DOI 10.1197/S1069-6563(03)00310-5; Pena BMG, 1999, ANN EMERG MED, V34, P483, DOI 10.1016/S0196-0644(99)80050-X; Rogers MJ, 1999, J ENDODONT, V25, P381, DOI 10.1016/S0099-2399(06)81176-3; ROYTBLAT L, 1993, ANESTH ANALG, V77, P1161; TJOLSEN A, 1992, PAIN, V51, P5, DOI 10.1016/0304-3959(92)90003-T; TVERSKOY M, 1994, ANESTH ANALG, V78, P205, DOI 10.1213/00000539-199402000-00002; Vinson DR, 2002, ANN EMERG MED, V39, P592, DOI 10.1067/mem.2002.123695; WHITE PF, 1982, ANESTHESIOLOGY, V56, P119, DOI 10.1097/00000542-198202000-00007; WILMORE DW, 1991, NEW ENGL J MED, V325, P695, DOI 10.1056/NEJM199109053251005; WILSON RJT, 1994, ANAESTHESIA, V49, P591; WOOLF CJ, 1991, BRIT MED BULL, V47, P523, DOI 10.1093/oxfordjournals.bmb.a072490; WOOLF CJ, 1991, PAIN, V44, P293, DOI 10.1016/0304-3959(91)90100-C; YAMAMOTO T, 1992, ANESTHESIOLOGY, V77, P757, DOI 10.1097/00000542-199210000-00021	39	11	11	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1069-6563	1553-2712		ACAD EMERG MED	Acad. Emerg. Med.	OCT	2008	15	10					955	958		10.1111/j.1553-2712.2008.00249.x			4	Emergency Medicine	Emergency Medicine	359FO	WOS:000259972000012	18851717				2020-06-30	J	Siddik-Sayyid, SM; Taha, SK; Azar, MS; Hakki, MA; Yaman, RA; Baraka, AS; Aouad, MT				Siddik-Sayyid, S. M.; Taha, S. K.; Azar, M. S.; Hakki, M. A.; Yaman, R. A.; Baraka, A. S.; Aouad, M. T.			Comparison of three doses of epidural fentanyl followed by bupivacaine and fentanyl for labor analgesia	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article							SUFENTANIL; ANESTHESIA; INFUSION	Background: Epidural fentanyl 100 mu g after lidocaine-epinephrine test dose has been shown to provide adequate analgesia in early labor. This investigation determines the effect of three different bolus doses of epidural fentanyl on duration and quality of analgesia during early first stage of labor. Methods: In this prospective, double-blind study, 103 laboring nulliparous at cervical dilation < 5 cm were enrolled. After an epidural test dose of lidocaine (60 mg) with epinephrine (15 mu g), parturients received, randomly, bolus of epidural fentanyl 50, 75, or 100 mu g, followed by a continuous infusion of epidural bupivacaine 0.0625% and fentanyl 3 mu g/ml at a rate of 10 ml/h. Pain scores and maternal sedation, pruritus, nausea, and vomiting were recorded 10, 20, and 30 min after fentanyl, and every 30 min thereafter until first request for additional analgesia. Results: Adequate analgesia was achieved in 87% (28/32), 94% (35/38), and 94% (31/33) in the fentanyl 50, 75, and 100 mu g groups within 20 min. Mean duration of analgesia before re-dosing was significantly longer in fentanyl 100 and 75 mu g groups (185.6 +/- 82.9 and 188.5 +/- 82.2 min, respectively) as compared with fentanyl 50 mu g group (133.6 +/- 46.2 min, P < 0.016). There was no difference in the incidence of maternal side effects or neonatal Apgar scores among the three groups. Conclusions: After a test dose of lidocaine-epinephrine, the three epidural fentanyl doses produced similar effective labor analgesia. However, epidural fentanyl 75 mu g followed by epidural infusion of dilute bupivacaine and fentanyl produced longer duration of analgesia than fentanyl 50 mu g followed by the same infusion, with no further prolongation when the dose of fentanyl was increased up to 100 mu g.	[Siddik-Sayyid, S. M.; Taha, S. K.; Azar, M. S.; Hakki, M. A.; Yaman, R. A.; Baraka, A. S.; Aouad, M. T.] Amer Univ Beirut, Dept Anesthesiol, Med Ctr, Beirut, Lebanon	Aouad, MT (reprint author), Amer Univ Beirut, Dept Anesthesiol, Med Ctr, POB 11-0236, Beirut, Lebanon.	mm01@aub.edu.lb					Beilin Y, 2005, ANESTHESIOLOGY, V103, P1211, DOI 10.1097/00000542-200512010-00016; BREEN TW, 1993, ANESTH ANALG, V77, P919; Bromage P R, 1965, Acta Anaesthesiol Scand Suppl, V16, P55; Capogna G, 2003, ANESTH ANALG, V96, P1178, DOI 10.1213/01.ANE.0000054003.03645.CF; CARRIE LES, 1981, ANAESTHESIA, V36, P965, DOI 10.1111/j.1365-2044.1981.tb08658.x; CHANEY MA, 1995, CAN J ANAESTH, V42, P891, DOI 10.1007/BF03011037; Connelly NR, 2000, ANESTH ANALG, V91, P374, DOI 10.1097/00000539-200008000-00026; Connelly NR, 2003, ANESTH ANALG, V96, P1799, DOI 10.1213/01.ANE.0000061583.77068.0B; Connelly NR, 2001, ANESTH ANALG, V93, P1001, DOI 10.1097/00000539-200110000-00041; Gaiser RR, 2000, REGION ANESTH PAIN M, V25, P223, DOI 10.1016/S1098-7339(00)90002-6; HALONEN PM, 1993, ACTA ANAESTH SCAND, V37, P774, DOI 10.1111/j.1399-6576.1993.tb03808.x; HUGHES SC, 1984, ANESTH ANALG, V63, P319; JUSTINS DM, 1982, BRIT J ANAESTH, V54, P409, DOI 10.1093/bja/54.4.409; Roelants F, 2006, ANESTH ANALG, V103, P1534, DOI 10.1213/01.ane.0000244595.03322.52; Vercauteren M, 1997, PHARMACOL BIOCHEM BE, V58, P237, DOI 10.1016/S0091-3057(97)00011-7; VERTOMMEN JD, 1991, ANESTHESIOLOGY, V74, P809, DOI 10.1097/00000542-199105000-00002; Wong CA, 2004, INT J OBSTET ANESTH, V13, P19, DOI 10.1016/S0959-289X(03)00106-7	17	5	5	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	OCT	2008	52	9					1285	1290		10.1111/j.1399-6576.2008.01765.x			6	Anesthesiology	Anesthesiology	348MW	WOS:000259215600016	18823470				2020-06-30	J	Chang, DJ; Kweon, TD; Nam, SB; Lee, JS; Shin, CS; Park, CH; Han, DW				Chang, D. J.; Kweon, T. D.; Nam, S. B.; Lee, J. S.; Shin, C. S.; Park, C. H.; Han, D. W.			Effects of fentanyl pretreatment on the QTc interval during propofol induction	ANAESTHESIA			English	Article							Q-T INTERVAL; HEART-RATE; ARTERIAL-PRESSURE; ANESTHETIC INDUCTION; TRACHEAL INTUBATION; PROLONGATION; ALFENTANIL; RESPONSES; SUXAMETHONIUM; HUMANS	Prolongation of the corrected QT (QTc) interval is associated with various anaesthetic drugs. The QTc prolongation may become more exacerbated during laryngoscopy and intubation, which is possibly caused by sympathetic stimulation. The aim of this study was to investigate the effects of fentanyl on the QTc interval during propofol induction in healthy patients. The patients were randomly allocated to receive either fentanyl (n = 25) or saline (n = 25) before induction. The QTc interval was significantly prolonged immediately after intubation in control group compared to preceding values, but it did not change in the fentanyl group. The number of patients with the prolonged QTc interval exceeding 20 ms immediately after intubation compared to the baseline values was 14 in the control group and seven in the fentanyl group. In conclusion, pretreatment with fentanyl 2 mu g.kg(-1) significantly attenuated QTc prolongation associated with laryngoscopy and tracheal intubation during propofol induction.	[Han, D. W.] Yonsei Univ, Coll Med, Dept Anaesthesiol & Pain Med, Seoul 120749, South Korea; Yonsei Univ, Coll Med, Anaesthesia & Pain Res Inst, Seoul 120749, South Korea	Han, DW (reprint author), Yonsei Univ, Coll Med, Dept Anaesthesiol & Pain Med, Seoul 120749, South Korea.	hanesth@yuhs.ac		Nam, Sang Beom/0000-0002-9704-1866; Han, Dong Woo/0000-0002-8757-663X; Kweon, Tae Dong/0000-0002-5451-1856; Lee, Jong Seok/0000-0002-7945-2530; SHIN, CHEUNG SOO/0000-0001-7829-8458			ABILDSKOV JA, 1976, AM HEART J, V92, P210, DOI 10.1016/S0002-8703(76)80256-6; BLAIR JR, 1989, ANESTHESIOLOGY, V71, P565, DOI 10.1097/00000542-198910000-00015; BLAIR JR, 1987, ANESTHESIOLOGY, V67, P442, DOI 10.1097/00000542-198709000-00033; CRAMPTON R, 1979, CIRCULATION, V59, P769, DOI 10.1161/01.CIR.59.4.769; Desai M, 2003, BRIT J CLIN PHARMACO, V55, P511, DOI 10.1046/j.1365-2125.2003.01791.x; Fridericia LS, 2003, ANN NONINVAS ELECTRO, V8, P343, DOI 10.1046/j.1542-474X.2003.08413.x; GALLOWAY PA, 1985, ANESTH ANALG, V64, P612; HYNYNEN M, 1986, BRIT J ANAESTH, V58, P1252, DOI 10.1093/bja/58.11.1252; Katchman AN, 2002, J PHARMACOL EXP THER, V303, P688, DOI 10.1124/jpet.102.038240; KAY B, 1985, ANAESTHESIA, V40, P960, DOI 10.1111/j.1365-2044.1985.tb10550.x; Kleinsasser A, 2000, ANESTH ANALG, V90, P25, DOI 10.1097/00000539-200001000-00006; KORPINEN R, 1995, ACTA ANAESTH SCAND, V39, P809, DOI 10.1111/j.1399-6576.1995.tb04175.x; Kuenszberg E, 2000, EUR J ANAESTH, V17, P662, DOI 10.1046/j.1365-2346.2000.00739.x; LINDGREN L, 1991, ACTA ANAESTH SCAND, V35, P355, DOI 10.1111/j.1399-6576.1991.tb03305.x; LINDGREN L, 1993, BRIT J ANAESTH, V70, P306, DOI 10.1093/bja/70.3.306; LISCHKE V, 1994, ACTA ANAESTH SCAND, V38, P144, DOI 10.1111/j.1399-6576.1994.tb03856.x; MCCONACHIE I, 1989, BRIT J ANAESTH, V63, P558, DOI 10.1093/bja/63.5.558; MEDAK R, 1983, BRIT J ANAESTH, V55, P361, DOI 10.1093/bja/55.4.361; Michaloudis DG, 1996, EUR J ANAESTH, V13, P364, DOI 10.1046/j.1365-2346.1996.00022.x; Morganroth J, 2007, CLIN PHARMACOL THER, V81, P108, DOI 10.1038/sj.clpt.6100010; MOSS AJ, 1986, JAMA-J AM MED ASSOC, V256, P2985; MOSS AJ, 1993, AM J CARDIOL, V72, pB23, DOI 10.1016/0002-9149(93)90036-C; MOSS AJ, 1971, NEW ENGL J MED, V285, P903, DOI 10.1056/NEJM197110142851607; SAARNIVAARA L, 1984, ACTA ANAESTH SCAND, V28, P644, DOI 10.1111/j.1399-6576.1984.tb02137.x; SAARNIVAARA L, 1990, ACTA ANAESTH SCAND, V34, P276, DOI 10.1111/j.1399-6576.1990.tb03085.x; SAARNIVAARA L, 1983, ACTA ANAESTH SCAND, V27, P126, DOI 10.1111/j.1399-6576.1983.tb01921.x; SCHEININ B, 1989, BRIT J ANAESTH, V62, P385, DOI 10.1093/bja/62.4.385; SCHMELING WT, 1991, ANESTH ANALG, V72, P137, DOI 10.1213/00000539-199102000-00001; Shah RR, 2002, BRIT J CLIN PHARMACO, V54, P188, DOI 10.1046/j.1365-2125.2002.01627.x; TOMORI Z, 1969, J PHYSIOL-LONDON, V200, P25, DOI 10.1113/jphysiol.1969.sp008680; WILTON NCT, 1987, ANESTH ANALG, V66, P357; Wisely NA, 2002, EUR J ANAESTH, V19, P853, DOI 10.1017/S0265021502001370	32	44	48	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0003-2409	1365-2044		ANAESTHESIA	Anaesthesia	OCT	2008	63	10					1056	1060		10.1111/j.1365-2044.2008.05559.x			5	Anesthesiology	Anesthesiology	345BA	WOS:000258969800003	18616522				2020-06-30	J	Lu, CH; Man, KM; Ou-Yang, HY; Chan, SM; Ho, ST; Wong, CS; Liaw, WJ				Lu, Chueng-He; Man, Kee-Ming; Ou-Yang, Hsin-Yi; Chan, Shun-Ming; Ho, Shung-Tai; Wong, Chih-Shung; Liaw, Wen-Jinn			Composite auditory evoked potential index versus bispectral index to estimate the level of sedation in paralyzed critically ill patients: A prospective observational study	ANESTHESIA AND ANALGESIA			English	Article							CLINICAL-PRACTICE GUIDELINES; INTENSIVE-CARE-UNIT; ICU PATIENTS; MUSCLE-RELAXANT; ARX INDEX; ANESTHESIA; PROPOFOL; INDUCTION; ADULT; CONSCIOUSNESS	BACKGROUND: Electromyographic activity (EMG) has been reported to elevate the Bispectral Index (BIS) in patients not receiving neuromuscular blockade while under sedation in the intensive care unit (ICU). We investigated the change of the composite A-line autoregressive index (AAI) and BIS after administration of muscle relaxants in sedated surgical ICU patients. METHODS: We prospectively investigated 38 patients who required administration of a muscle relaxant while continuously sedated with midazolam hydrochloride and fentanyl citrate to achieve a Ramsay Sedation Scale value equal to 5. BIS, EMG activity of BIS (EMG-BIS), signal quality index of BIS, AAI, EMG activity of AAI (EMG-AAI), and acceleromyography at the adductor pollicis muscle were recorded simultaneously every 5 min for 30 min before and after neuromuscular blockade. Student's t-test, the Wilcoxon's signed ranks test, and the Spearman test were calculated using the standard statistics software SPSS 10.0 (SPSS Inc., Chicago, IL). RESULTS: After administration of a Muscle relaxant, BIS (58.61 +/- 7.45 vs 44.68 +/- 6.65, P < 0.001), EMG-BIS (37.33 +/- 7.15 vs 27.24 +/- 1.51, P < 0.001), AAI (34.11 +/- 10.96 vs 15.97 +/- 6.69, P < 0.001), and EMG-AAI (59.58 +/- 9.57 vs 1.00 +/- 0.00, P < 0.001) decreased significantly. Significant correlations between BIS and EMG-BIS (r(s) = 0.75, P < 0.001) and AAI and EMG-AAI (r(s) = 0.87, P < 0.001) were also found during the baseline period. CONCLUSIONS: This study demonstrated that, in sedated ICU patients, BIS and AAI markedly decreased after administration of myorelaxant, and the decreased BIS and AAI values after neuromuscular blockade were correlated to those usually seen in the state of surgical anesthesia, respectively.	[Lu, Chueng-He; Chan, Shun-Ming; Ho, Shung-Tai; Wong, Chih-Shung; Liaw, Wen-Jinn] Triserv Gen Hosp, Surg Intens Care Unit, Dept Anesthesiol, Natl Def Med Ctr, Taipei 114, Taiwan; [Ou-Yang, Hsin-Yi] Tungs Taichung MetroHarbor Hosp, Dept Anesthesiol, Taichung, Taiwan; [Man, Kee-Ming] Triserv Gen Hosp, Dept Nursing, Natl Def Med Ctr, Taipei 114, Taiwan	Liaw, WJ (reprint author), Triserv Gen Hosp, Surg Intens Care Unit, Dept Anesthesiol, Natl Def Med Ctr, 325,Sec 2,Chenggong Rd, Taipei 114, Taiwan.	siculiaw@mail.ndmctsgh.edu.tw			Ministry of National Defense [DOD 95-07-04, TSGH-C95-2-S05]; Tri-Service General Hospital [TSGH-C95-2-S04]	Supported by Ministry of National Defense grant DOD 95-07-04, and grant TSGH-C95-2-S05 and partly from the Tri-Service General Hospital, grant TSGH-C95-2-S04.	Absalom AR, 2001, BRIT J ANAESTH, V87, P778, DOI 10.1093/bja/87.5.778; Dahaba AA, 2004, ANESTH ANALG, V99, P781, DOI 10.1213/01.ANE.0000132997.19872.BC; De Deyne C, 1998, INTENS CARE MED, V24, P1294, DOI 10.1007/s001340050765; Deogaonkar A, 2004, CRIT CARE MED, V32, P2403, DOI 10.1097/01.CCM.0000147442.14921.A5; Doi M, 2005, INTENS CARE MED, V31, P41, DOI 10.1007/s00134-004-2516-x; Edmonds H L Jr, 1985, Int J Clin Monit Comput, V1, P201, DOI 10.1007/BF01720184; Ely EW, 2004, INTENS CARE MED, V30, P1537, DOI 10.1007/s00134-004-2298-1; Frenzel D, 2002, INTENS CARE MED, V28, P178, DOI 10.1007/s00134-001-1183-4; Gan TJ, 1997, ANESTHESIOLOGY, V87, P808, DOI 10.1097/00000542-199710000-00014; Jacobi J, 2002, CRIT CARE MED, V30, P119, DOI 10.1097/00003246-200201000-00020; Johansen JW, 2000, ANESTHESIOLOGY, V93, P1336, DOI 10.1097/00000542-200011000-00029; Kim DW, 2001, ANESTH ANALG, V93, P1170; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; Kress JP, 2003, AM J RESP CRIT CARE, V168, P1457, DOI 10.1164/rccm.200303-455OC; Lehmann A, 2003, ANESTH ANALG, V96, P336, DOI 10.1097/00000539-200302000-00008; Litvan H, 2002, ANESTHESIOLOGY, V97, P351, DOI 10.1097/00000542-200208000-00011; Lu CH, 2005, ACTA ANAESTH SCAND, V49, P1063, DOI 10.1111/j.1399-6576.2005.00726.x; Nasraway SA, 2005, CRIT CARE MED, V33, P685, DOI 10.1097/01.CCM.0000155994.45687.64; Nasraway SA, 2002, CRIT CARE MED, V30, P117, DOI 10.1097/00003246-200201000-00019; Nasraway SA, 2002, CRIT CARE MED, V30, P1483, DOI 10.1097/00003246-200207000-00014; Rampil IJ, 1998, ANESTHESIOLOGY, V89, P980, DOI 10.1097/00000542-199810000-00023; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; Riker RR, 2001, INTENS CARE MED, V27, P853, DOI 10.1007/s001340100912; Schmidt GN, 2003, ANESTH ANALG, V97, P139, DOI 10.1213/01.ANE.0000065546.78919.82; Simon L, 2002, PAEDIATR ANAESTH, V12, P36, DOI 10.1046/j.1460-9592.2002.00727.x; Thornton C, 1998, BRIT J ANAESTH, V81, P771, DOI 10.1093/bja/81.5.771; Tonner PH, 2005, CRIT CARE MED, V33, P580, DOI 10.1097/01.ccm.0000156291.04287.7F; Vivien B, 2003, ANESTHESIOLOGY, V99, P9, DOI 10.1097/00000542-200307000-00006; Walder B, 2001, INTENS CARE MED, V27, P107, DOI 10.1007/s001340000761; Weber F, 2004, ANESTHESIOLOGY, V101, P294, DOI 10.1097/00000542-200408000-00008; Wenningmann I, 2006, BRIT J ANAESTH, V97, P666, DOI 10.1093/bja/ael223	31	11	13	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	OCT	2008	107	4					1290	1294		10.1213/ane.0b013e31818061ae			5	Anesthesiology	Anesthesiology	352UE	WOS:000259522100036	18806042				2020-06-30	J	Bhagat, H; Dash, HH; Bithal, PK; Chouhan, RS; Pandia, MP				Bhagat, Hemant; Dash, Hari H.; Bithal, Parmod K.; Chouhan, Rajendra S.; Pandia, Mihir P.			Planning for early emergence in neurosurgical patients: A randomized prospective trial of low-dose anesthetics	ANESTHESIA AND ANALGESIA			English	Article							SUPRATENTORIAL INTRACRANIAL SURGERY; TRACHEAL EXTUBATION; CARDIOVASCULAR-RESPONSES; HEMODYNAMIC-RESPONSES; CRANIOTOMY; FENTANYL; HYPERTENSION; REMIFENTANIL; ISOFLURANE; LIDOCAINE	BACKGROUND: For early detection of a cerebral complication, rapid awakening from anesthesia is essential after craniotomy. Systemic hypertension is a major drawback associated with fast tracking, which may predispose to formation of intracranial hematoma. Although various drugs have been widely evaluated, there are limited data with regards to use of anesthetics to blunt emergence hypertension. We hypothesized that use of low-dose anesthetics during craniotomy closure facilitates early emergence with a decrease in hemodynamic consequences. METHODS: Three emergent techniques were evaluated in 150 normotensive adult patients operated for supratentorial tumors under standard isoflurane anesthesia. At the time of dural Closure, the patients were randomized to receive low-close propofol (3 mg center dot kg(-1) center dot h(-1)), fentanyl (1.5 mu g center dot kg(-1) center dot h(-1)) or isoflurane (end-tidal concentration of 0.2%) until the beginning of skin closure. Nitrous oxide was discontinued after head dressing. RESULTS: Median time to emergence was 6 min with propofol, 4 min with fentanyl, and 5 min with isoflurane (P = 0.008). More patients had hypertension in the pre-extubation compared with extubation or postextubation phase (P = 0.009). Comparing the three groups, fewer patients required esmolol with fentanyl use overall, and in the pre-extubation phase (P = 0.01). Significant midline shift in the preoperative cerebral imaging scans was found to be an independent risk factor for emergence hypertension. CONCLUSIONS: Pain during surgical closure may be an important cause of sympathetic stimulation leading to emergence hypertension. The use of low-closes of fentanyl during craniotomy Closure is more advantageous than propofol or isoflurane for early emergence in neurosurgical patients and is the most effective technique for preventing early postoperative hypertension.	[Bhagat, Hemant; Dash, Hari H.; Bithal, Parmod K.; Chouhan, Rajendra S.; Pandia, Mihir P.] All India Inst Med Sci, Ctr Neurosci, Dept Neuroanesthesiol, New Delhi 110029, India	Bhagat, H (reprint author), All India Inst Med Sci, CN Ctr, Dept Neuroanesthesiol, Room 709A, New Delhi 110029, India.	drhemantbhagat@rediffmail.com; dr.harihardash@gmail.com					Basali A, 2000, ANESTHESIOLOGY, V93, P48, DOI 10.1097/00000542-200007000-00012; Bilotta F, 2007, EUR J ANAESTH, V24, P122, DOI 10.1017/S0265021506001244; Bruder N, 1999, J NEUROSURG ANESTH, V11, P282, DOI 10.1097/00008506-199910000-00009; Bruder Nicolas J, 2002, Curr Opin Anaesthesiol, V15, P477, DOI 10.1097/00001503-200210000-00001; Conti J, 1998, BRIT J ANAESTH, V80, P834, DOI 10.1093/bja/80.6.834; DARJIE HJ, 1976, BR J CLIN PHARM, V3, P751; Enlund M, 2002, ACTA ANAESTH SCAND, V46, P345, DOI 10.1034/j.1399-6576.2002.460402.x; Fujii Y, 1999, CAN J ANAESTH, V46, P952, DOI 10.1007/BF03013130; GAL TJ, 1975, BRIT J ANAESTH, V47, P70, DOI 10.1093/bja/47.1.70; Gauthier A, 2002, ANESTH ANALG, V95, P1384, DOI 10.1097/00000539-200211000-00052; GEFKE K, 1983, ACTA ANAESTH SCAND, V27, P111, DOI 10.1111/j.1399-6576.1983.tb01917.x; Guy J, 1997, ANESTHESIOLOGY, V86, P514, DOI 10.1097/00000542-199703000-00002; Inagaki Yoshimi, 1997, Anesthesia and Analgesia, V85, P328, DOI 10.1097/00000539-199708000-00016; Kross RA, 2000, ANESTH ANALG, V91, P904, DOI 10.1097/00000539-200010000-00024; Kulkarni A, 2004, ANAESTH INTENS CARE, V32, P413, DOI 10.1177/0310057X0403200319; Magni G, 2005, J NEUROSURG ANESTH, V17, P134, DOI 10.1097/01.ana.0000167447.33969.16; MUZZI DA, 1990, ANESTH ANALG, V70, P68; NISHINA K, 1995, ACTA ANAESTH SCAND, V39, P85, DOI 10.1111/j.1399-6576.1995.tb05597.x; Ogasawara K, 2000, SURG NEUROL, V54, P155, DOI 10.1016/S0090-3019(00)00281-0; Talke P, 2002, ANESTH ANALG, V95, P430, DOI 10.1097/00000539-200208000-00036; TODD MM, 1993, ANESTHESIOLOGY, V78, P1005, DOI 10.1097/00000542-199306000-00002; YUKIOKA H, 1985, ANESTH ANALG, V64, P1189	22	13	16	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	OCT	2008	107	4					1348	1355		10.1213/ane.0b013e31817f9476			8	Anesthesiology	Anesthesiology	352UE	WOS:000259522100045	18806051				2020-06-30	J	Foster, D; Upton, R; Christrup, L; Popper, L				Foster, David; Upton, Richard; Christrup, Lona; Popper, Lars			Pharmacokinetics and pharmacodynamics of intranasal versus intravenous fentanyl in patients with pain after oral surgery	ANNALS OF PHARMACOTHERAPY			English	Article						acute pain; fentanyl; intranasal administration; pharmacokinetic-dynamic modeling	POSTOPERATIVE ANALGESIA; BREAKTHROUGH PAIN; DOUBLE-BLIND; MANAGEMENT; CROSSOVER; ADULTS; QUANTITATION; ALFENTANIL; ANESTHESIA; EFFICACY	BACKGROUND: Fentanyl, a short-acting synthetic opioid, has a pharmacokinetic profile suited to fast relief of brief episodic pain. OBJECTIVE: To characterize the pharmacokinetic-pharmacodynamic correlation of intranasal and intravenous fentanyl in opioid-naive patients undergoing third molar extraction. METHODS: A double-blind, double-dummy, crossover design study was conducted, with patients randomized to receive 1 of 4 fentanyl doses (75, 100, 150, or 200 mu g) by both the intravenous and intranasal routes. Venous fentanyl concentrations were determined for up to 180 minutes and pain scores were recorded up to 240 minutes postdose. Duration of effect and time to rescue medication were also recorded. RESULTS: The pharmacokinetics; of intravenous fentanyl reflected a 2-compartment model with a clearance of approximately 1.5 L/min. There was moderate (<50%) between-subject variability (BSV; %CV [coefficient of variation]) in the systemic kinetics of fentanyl. Bioavailability of intranasal fentanyl was 89%, following first-order absorption, with a lag of approximately 5 minutes and a half-life of approximately 6.5 minutes. Interpatient absorption variability was approximately 30% BSV for all absorption parameters. Intranasal versus intravenous administration led to a delayed mean fentanyl time to maximum concentration (13 vs 6 min) and lower maximum concentration (1.2 vs 2.0 ng/mL). Analgesic effect lagged behind the venous fentanyl concentration, with a half-life of approximately 2.5 minutes as described by a fractional sigmoid maximum drug effect dynamic model. The concentration-analgesia relationship was steep, With a 50% effective concentration of 0.46 ng/mL (Hill coefficient 3.5). Intranasal onset and offset of analgesia were slightly delayed, principally due to the delay and lag in systemic absorption, with slightly lower peak analgesic effect, compared with intravenous fentanyl. Duration of effect was directly related to intranasal fentanyl dose, with pain scores returning to predose values at approximately 120 minutes (75 mu g) to approximately 240 minutes (200 mu g) after a single dose. CONCLUSIONS: Intranasal fentanyl showed kinetic and dynamic properties that are desirable for the management of acute, episodic (breakthrough) pain.	[Christrup, Lona] Univ Copenhagen, Fac Pharmaceut Sci, Dept Pharmacol & Pharmacotherapy, DK-2100 Copenhagen, Denmark; [Foster, David] Sansom Inst, Sch Pharm & Med Sci, Adelaide, SA, Australia; [Upton, Richard] Univ Adelaide, Royal Adelaide Hosp, Discipline Anaesthesia & Intens Care, Adelaide, SA, Australia	Christrup, L (reprint author), Univ Copenhagen, Fac Pharmaceut Sci, Dept Pharmacol & Pharmacotherapy, 2 Univ Pk, DK-2100 Copenhagen, Denmark.	llc@farma.ku.dk	Foster, David J R/D-1172-2011; Upton, Richard N/G-4727-2011	Upton, Richard N/0000-0001-9996-4886; Foster, David/0000-0002-7345-4084; Christrup, Lona/0000-0002-4128-7373	Nycomed Pharma, Denmark	This study (Study FT-001-IN) was sponsored by Nycomed Pharma, Denmark.	Anderson BJ, 1999, ANESTHESIOLOGY, V90, P411, DOI 10.1097/00000542-199902000-00014; [Anonymous], 2004, ETH PRINC MED RES IN; Borland Meredith L, 2002, Emerg Med (Fremantle), V14, P275, DOI 10.1046/j.1442-2026.2002.00344.x; Borland ML, 2005, BURNS, V31, P831, DOI 10.1016/j.burns.2005.05.001; Christrup LL, 2008, CLIN THER, V30, P469, DOI 10.1016/j.clinthera.2008.03.001; Dale O, 2002, ACTA ANAESTH SCAND, V46, P759, DOI 10.1034/j.1399-6576.2002.460702.x; Davison A.C., 1997, BOOTSTRAP METHODS TH; Finn J, 2004, BURNS, V30, P262, DOI 10.1016/j.burns.2003.10.017; Galinkin JL, 2000, ANESTHESIOLOGY, V93, P1378, DOI 10.1097/00000542-200012000-00006; LEMMENS HJM, 1994, CLIN PHARMACOL THER, V56, P261, DOI 10.1038/clpt.1994.136; Lim Stephen C. B., 2003, Journal of Pharmacy Practice and Research, V33, P59; Manjushree R, 2002, CAN J ANAESTH, V49, P190; Paech MJ, 2003, ANAESTHESIA, V58, P740, DOI 10.1046/j.1365-2044.2003.03286.x; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; SCOTT JC, 1991, ANESTHESIOLOGY, V74, P34, DOI 10.1097/00000542-199101000-00007; SCOTT JC, 1985, ANESTHESIOLOGY, V62, P234, DOI 10.1097/00000542-198503000-00005; SCOTT JC, 1987, J PHARMACOL EXP THER, V240, P159; STANSKI DR, 1984, J PHARMACOKINET BIOP, V12, P223, DOI 10.1007/BF01059279; STREIBEL HW, 1996, J CLIN ANESTH, V8, P4; Striebel H W, 1993, Schmerz, V7, P122, DOI 10.1007/BF02527870; Striebel HW, 1996, ANESTH ANALG, V83, P548, DOI 10.1097/00000539-199609000-00019; Toussaint S, 2000, CAN J ANAESTH, V47, P299, DOI 10.1007/BF03020941; Wong P, 2003, ANAESTHESIA, V58, P818, DOI 10.1046/j.1365-2044.2003.03295_24.x; Zeppetella G, 2000, PALLIATIVE MED, V14, P57, DOI 10.1191/026921600668793500; Zeppetella G, 2000, J PAIN SYMPTOM MANAG, V20, P253, DOI 10.1016/S0885-3924(00)00180-9	25	59	62	0	8	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1060-0280	1542-6270		ANN PHARMACOTHER	Ann. Pharmacother.	OCT	2008	42	10					1380	1387		10.1345/aph.1L168			8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	353DI	WOS:000259545900002	18728103				2020-06-30	J	Agarwal, A; Yadav, G; Gupta, D; Singh, PK; Singh, U				Agarwal, A.; Yadav, G.; Gupta, D.; Singh, P. K.; Singh, U.			Evaluation of intra-operative tramadol for prevention of catheter-related bladder discomfort: a prospective, randomized, double-blind study	BRITISH JOURNAL OF ANAESTHESIA			English	Article						complications, catheter-related bladder discomfort; pharmacology, tramadol	RECEPTOR-INDUCED RESPONSES; EFFICACY; TOLTERODINE; OXYBUTYNIN; PAIN	Background. Catheter-related bladder discomfort (CRBD) is defined as an urge to void or discomfort in the supra-pubic region; reported postoperatively in patients who have had urinary catheterization intra-operatively. We have evaluated tramadol, a centrally acting opioid analgesic with muscarinic receptor antagonist properties for prevention of CRBD. Methods. Fifty-four adults (18-60 yr), ASA physical status I and II of either sex, undergoing elective percutaneous nephro-lithomy were randomly divided into two groups of 27 each. Control (C) group received normal saline (NS; 2 ml), whereas Tramadol (T) group received tramadol 1.5 mg kg(-1). All medications were diluted in 2 ml NS and administered 30 min before extubation. Intra-operatively, urinary catherization was performed with a 16 Fr Foley's catheter, and the balloon was inflated with 10 ml distilled water. The CRBD was assessed at 0, 1, 2, and 6 h after patient's arrival in the post-anaesthesia care unit along with total postoperative fentanyl requirement. Severity of CRBD was graded as none, mild, moderate and severe. Data were analysed by one-way anova, Z-test, and Fisher's exact test. P < 0.05 was considered significant. Results. Incidence and severity of CRBD was reduced in T group compared with C group at all time points (P < 0.05). Postoperative pain as assessed by visual analogue scale and total postoperative fentanyl requirement (mu g kg(-1)) was also reduced in the T group [176 (sd 26.5)] compared with C group [210 (34.6)] (P < 0.05). Conclusions. Tramadol 1.5 mg kg(-1) administered i.v. 30 min before extubation decreases the incidence and severity of CRBD and postoperative fentanyl requirement.	[Agarwal, A.; Yadav, G.; Gupta, D.; Singh, P. K.] Sanjay Gandhi Postgrad Inst Med Sci, Dept Anaesthesiol, Lucknow 226014, Uttar Pradesh, India; [Singh, U.] Sanjay Gandhi Postgrad Inst Med Sci, Dept Biostat, Lucknow 226014, Uttar Pradesh, India	Agarwal, A (reprint author), Sanjay Gandhi Postgrad Inst Med Sci, Dept Anaesthesiol, Lucknow 226014, Uttar Pradesh, India.	aagarwal@sgpgi.ac.in					Agarwal A, 2006, BRIT J ANAESTH, V96, P587, DOI 10.1093/bja/ael048; Agarwal A, 2006, BRIT J ANAESTH, V96, P377, DOI 10.1093/bja/ael003; Agarwal A, 2005, ANESTH ANALG, V101, P1065, DOI 10.1213/01.ane.0000167775.46192.e9; Agarwal A, 2007, ANESTH ANALG, V105, P1454, DOI 10.1213/01.ane.0000281154.03887.2b; Andersson KE, 2004, UROLOGE A, V43, P552, DOI 10.1007/s00120-004-0565-y; Budd K, 1999, BRIT J ANAESTH, V82, P493; Pehrson R, 2003, EUR UROL, V44, P495, DOI 10.1016/S0302-2838(03)00353-1; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; Scott LJ, 2000, DRUGS, V60, P139, DOI 10.2165/00003495-200060010-00008; Shiga Y, 2002, ANESTH ANALG, V95, P1269, DOI 10.1097/00000539-200211000-00031; Shiraishi M, 2001, J PHARMACOL EXP THER, V299, P255; Singh SK, 2008, NEUROUROL URODYNAM, V27, P65, DOI 10.1002/nau.20465; Tauzin-Fin P, 2007, BRIT J ANAESTH, V99, P572, DOI 10.1093/bja/aem232; Wilder-Smith CH, 1999, ANESTHESIOLOGY, V91, P639, DOI 10.1097/00000542-199909000-00013	14	52	58	0	4	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0007-0912			BRIT J ANAESTH	Br. J. Anaesth.	OCT	2008	101	4					506	510		10.1093/bja/aen217			5	Anesthesiology	Anesthesiology	348HP	WOS:000259201900011	18653496	Bronze			2020-06-30	J	Zollner, C; Mousa, S; Klinger, A; Forster, M; Schafer, M				Zoellner, Christian; Mousa, Shaaban; Klinger, Astrid; Foerster, Michael; Schaefer, Michael			Topical fentanyl in a randomized, double-blind study in patients with corneal damage	CLINICAL JOURNAL OF PAIN			English	Article						corneal erosion; opioid receptor; pain; nerve fibers; topical application	RAT SENSORY NEURONS; INTRAVESICAL MORPHINE ANALGESIA; PRIMARY AFFERENT NEURONS; OPIOID RECEPTOR-BINDING; INFLAMMATORY PAIN; BETA-ENDORPHIN; MESSENGER-RNA; SPINAL-CORD; MODEL; SKIN	Objectives: Corneal damage causes severe pain. This study investigated whether peripheral opioid receptors are present in the human cornea and assessed the efficacy of topical fentanyl in patients with corneal erosion. Methods: Immunohistochemical staining experiments were performed to examine the presence of both mu and delta-receptors on peripheral nerve fibers within human corneal tissue. In a randomized, double-blind clinical trial dexpanthenol (n = 20) or dexpanthenol plus 10 mu g fentanyl (n = 20) were topically applied every 4 hours to the eye of patients with a surgical intervention of corneal damage and subjective pain intensity was determined by a numerical rating scale. Results: Immunohistochemical staining identified peripheral nerve fibers in human cornea expressing both mu and delta-opioid receptors. In patients with corneal damage the ophthalmic intervention in local anesthesia decreased the subjective pain intensity significantly. At 4-hour intervals after the ophthalmic intervention, moderate pain intensity levels were not altered by the application of dexpanthenol with or without fentanyl. At 24 hours pain intensity dropped significantly, most likely owing to a natural decrease in pain, because the erosion was almost healed. Discussion: Both mu and delta-receptors are localized on nerve fibers within the cornea, which are accessible for topical opioid treatment. However, our formulation and dose of topical fentanyl in combination with dexpanthenol did not show any benefit in relieving pain from corneal erosion. Future studies are planned to determine the optimal protocol and dose of topical opioid treatment.	[Zoellner, Christian; Mousa, Shaaban; Klinger, Astrid; Schaefer, Michael] Charite Univ Med Berlin, Klin Anasthesiol & Operat Intes Med, D-12200 Berlin, Germany; [Foerster, Michael] Charite Univ Med Berlin, Klin Augenheilkunde, D-12200 Berlin, Germany	Zollner, C (reprint author), Charite Univ Med Berlin, Klin Anasthesiol & Operat Intes Med, Campus Benjamin Franklin,Hindenburgdamm 30, D-12200 Berlin, Germany.	christian.zoellner@charite.de	Schafer, Michael/AAB-1395-2020		Deutsche Forschungsgemeinschaft (DFG)German Research Foundation (DFG)	Supported by "Klinische Forschergruppe Grant" KFO 100 from the Deutsche Forschungsgemeinschaft (DFG).	ANDREEV N, 1994, NEUROSCIENCE, V58, P793, DOI 10.1016/0306-4522(94)90456-1; ANTONIJEVIC I, 1995, J NEUROSCI, V15, P165; Bertschy C, 1999, PROG UROL, V9, P474; Brack A, 2004, ANESTHESIOLOGY, V100, P149, DOI 10.1097/00000542-200401000-00024; Charlton E, 1995, Pain, V63, P277, DOI 10.1016/0304-3959(95)90040-3; CHAST F, 1991, J PHARM SCI, V80, P911, DOI 10.1002/jps.2600801002; Chen JJ, 1997, MOL PHARMACOL, V51, P666; Craft RM, 1995, J PHARMACOL EXP THER, V275, P1535; Dale O, 2002, ACTA ANAESTH SCAND, V46, P759, DOI 10.1034/j.1399-6576.2002.460702.x; Duckett JW, 1997, J UROLOGY, V157, P1407, DOI 10.1016/S0022-5347(01)65001-8; Ebner Fritz, 2002, Am J Clin Dermatol, V3, P427, DOI 10.2165/00128071-200203060-00005; Egger SF, 1999, OPHTHALMOLOGICA, V213, P246, DOI 10.1159/000027429; Endres-Becker J, 2007, MOL PHARMACOL, V71, P12, DOI 10.1124/mol.106.026740; Fristad I, 2006, ARCH ORAL BIOL, V51, P273, DOI 10.1016/j.archoralbio.2005.08.007; Gobbels M, 1996, KLIN MONATSBL AUGENH, V209, P84; Gold MS, 1996, NEUROSCI LETT, V212, P83, DOI 10.1016/0304-3940(96)12791-9; HASELMANN G, 1952, OPHTHALMOLOGICA, V123, P357, DOI 10.1159/000301205; INGRAM SL, 1994, NEURON, V13, P179, DOI 10.1016/0896-6273(94)90468-5; Jagerovic N, 2002, BIOORGAN MED CHEM, V10, P817, DOI 10.1016/S0968-0896(01)00345-5; JONES MA, 1991, J COMP NEUROL, V313, P132, DOI 10.1002/cne.903130110; Jongkamonwiwat N, 2003, HEARING RES, V181, P85, DOI 10.1016/S0378-5955(03)00175-8; Kolesnikov YA, 2000, J PHARMACOL EXP THER, V295, P546; Krajnik M, 1999, PAIN, V80, P121, DOI 10.1016/S0304-3959(98)00211-5; Lee YS, 2007, BIOORG MED CHEM LETT, V17, P2161, DOI 10.1016/j.bmcl.2007.01.114; Likar R, 1997, ANESTH ANALG, V84, P1313, DOI 10.1097/00000539-199706000-00025; Likar R, 1998, PAIN, V76, P145, DOI 10.1016/S0304-3959(98)00036-0; Long TD, 2001, J BURN CARE REHABIL, V22, P118, DOI 10.1097/00004630-200103000-00006; Mousa SA, 2000, J NEUROIMMUNOL, V108, P160, DOI 10.1016/S0165-5728(00)00284-8; Mousa SA, 2001, J NEUROIMMUNOL, V115, P71, DOI 10.1016/S0165-5728(01)00271-5; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; Muller LJ, 2003, EXP EYE RES, V76, P521, DOI 10.1016/S0014-4835(03)00050-2; Mystakidou Kyriaki, 2005, Am J Hosp Palliat Care, V22, P228, DOI 10.1177/104990910502200313; PEYMAN GA, 1994, BRIT J OPHTHALMOL, V78, P138, DOI 10.1136/bjo.78.2.138; Puehler W, 2004, NEUROSCIENCE, V129, P473, DOI 10.1016/j.neuroscience.2004.06.086; ROZSA AJ, 1982, PAIN, V14, P105, DOI 10.1016/0304-3959(82)90092-6; SCHAFER MKH, 1994, NEUROSCI LETT, V167, P137, DOI 10.1016/0304-3940(94)91046-4; SCHROEDER JE, 1993, J NEUROSCI, V13, P867; Shaqura MA, 2004, J PHARMACOL EXP THER, V308, P712, DOI 10.1124/jpet.103.057257; Stein C, 2003, NAT MED, V9, P1003, DOI 10.1038/nm908; STEIN C, 1995, ANN MED, V27, P219, DOI 10.3109/07853899509031962; STEIN C, 1995, NEW ENGL J MED, V332, P1685, DOI 10.1056/NEJM199506223322506; Stiles J, 2003, AM J VET RES, V64, P813, DOI 10.2460/ajvr.2003.64.813; TERVO K, 1982, INVEST OPHTH VIS SCI, V23, P671; Twillman RK, 1999, J PAIN SYMPTOM MANAG, V17, P288, DOI 10.1016/S0885-3924(98)00140-7; Valenta C, 2001, DRUG DEV IND PHARM, V27, P57, DOI 10.1081/DDC-100000128; Wenk HN, 2003, PAIN, V105, P455, DOI 10.1016/S0304-3959(03)00260-4; Wenk HN, 1999, J COMP NEUROL, V408, P567, DOI 10.1002/(SICI)1096-9861(19990614)408:4<567::AID-CNE10>3.0.CO;2-Q; Zagon IS, 2000, INVEST OPHTH VIS SCI, V41, P73; Zague V, 2005, J Cosmet Dermatol, V4, P29; Zollner C, 2003, MOL PHARMACOL, V64, P202, DOI 10.1124/mol.64.2.202	50	23	23	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0749-8047			CLIN J PAIN	Clin. J. Pain	OCT	2008	24	8					690	696		10.1097/AJP.0b013e318175929e			7	Anesthesiology; Clinical Neurology	Anesthesiology; Neurosciences & Neurology	354UP	WOS:000259664800007	18806534				2020-06-30	J	Smith, I; Walley, G; Bridgman, S				Smith, I.; Walley, G.; Bridgman, S.			Omitting fentanyl reduces nausea and vomiting, without increasing pain, after sevoflurane for day surgery	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article; Proceedings Paper	Annual Congress of the Association-of-Anaesthetists-of-Great-Britain-and-Ireland	SEP, 2006	Aberdeen, SCOTLAND	Assoc Anaesthetists Great Britain & Ireland		surgery ambulatory; postoperative nausea and vomiting; sevoflurane; anaesthesia inhalational; fentanyl; pain acute and postoperative	DAY-CASE ANESTHESIA; POSTOPERATIVE NAUSEA; GYNECOLOGICAL SURGERY; GENERAL-ANESTHESIA; PROPOFOL; RECOVERY; INDUCTION; DEXAMETHASONE; REMIFENTANIL; METAANALYSIS	Background and objective: Despite advantages of induction and maintenance of anaesthesia with sevoflurane, postoperative nausea and vomiting occurs frequently. Fentanyl is a commonly used supplement that may contribute to this, although it may also improve analgesia. Methods: This double-blind study examined the incidence and severity of postoperative nausea and vomiting and pain in the first 24 h after sevoflurane anaesthesia in 216 adult day surgery patients. Patients were randomly allocated to either receive or not receive 1 mu g kg(-1) fentanyl, while a third group received dexamethasone in addition to fentanyl. Results: Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting, but did reduce the incidence of vomiting and/or moderate to severe nausea prior to discharge from 20% and 17% with fentanyl and fentanyl-dexamethasone, respectively, to 59% (P = 0.013). Antiemetic requirements were reduced from 24% and 31% to 7% (P = 0.0012). Dexamethasone had no significant effect on the incidence or severity of postoperative nausea and vomiting. Combining the two fentanyl groups revealed further significant benefits from the avoidance of opioids, reducing postoperative nausea and vomiting and nausea prior to discharge from 35% and 33% to 22% and 19% (P = 0.049 and P = 0.035), respectively, while nausea in the first 24 h was decreased from 42% to 27% (P = 0.034). Pain severity and analgesic requirements were unaffected by the omission of fentanyl. Fentanyl did reduce minor intraoperative movement but had no sevoflurane-sparing effect and increased respiratory depression, hypotension and bradycardia. Conclusion: As fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery.	[Smith, I.] Univ Hosp N Staffordshire, Directorate Anaesthesia, Dept Anaesthesia, Stoke On Trent ST4 6QG, Staffs, England; [Walley, G.; Bridgman, S.] Univ Hosp N Staffordshire, Dept Postgrad Med, Stoke On Trent ST4 6QG, Staffs, England	Smith, I (reprint author), Univ Hosp N Staffordshire, Directorate Anaesthesia, Dept Anaesthesia, Newcastle Rd, Stoke On Trent ST4 6QG, Staffs, England.	damsmith@btinternet.com					Apfel CC, 1999, ANESTHESIOLOGY, V91, P693, DOI 10.1097/00000542-199909000-00022; Apfel CC, 2004, NEW ENGL J MED, V350, P2441, DOI 10.1056/NEJMoa032196; Ashworth J, 1998, ANESTH ANALG, V87, P312, DOI 10.1097/00000539-199808000-00014; BORGEAT A, 1992, ANESTH ANALG, V74, P539; Coloma M, 2001, ANESTH ANALG, V92, P352, DOI 10.1213/00000539-200102000-00014; Dashfield AK, 1998, ANAESTHESIA, V53, P1062, DOI 10.1046/j.1365-2044.1998.00571.x; FISHER DM, 1994, ANESTHESIOLOGY, V81, P795, DOI 10.1097/00000542-199410000-00003; Fisher DM, 1999, ANESTHESIOLOGY, V90, P355, DOI 10.1097/00000542-199902000-00003; Fleischmann E, 1999, ANESTH ANALG, V88, P930, DOI 10.1097/00000539-199904000-00046; FREDMAN B, 1995, ANESTH ANALG, V81, P823, DOI 10.1097/00000539-199510000-00028; Gan Tong J., 1997, P347; Ghatge S, 2003, ACTA ANAESTH SCAND, V47, P917, DOI 10.1034/j.1399-6576.2003.00196.x; Henzi I, 2000, ANESTH ANALG, V90, P186, DOI 10.1097/00000539-200001000-00038; Joo HS, 2000, ANESTH ANALG, V91, P213, DOI 10.1097/00000539-200007000-00040; Liu K, 1999, ANESTH ANALG, V89, P1316, DOI 10.1213/00000539-199911000-00046; Matute E, 2002, ANESTH ANALG, V94, P1217, DOI 10.1097/00000539-200205000-00031; Nathan N, 1998, CAN J ANAESTH, V45, P1148, DOI 10.1007/BF03012454; RUSSELL D, 1995, BRIT J ANAESTH, V75, P562, DOI 10.1093/bja/75.5.562; SHAKIR AAK, 1997, J 1 DAY SURG, V6, P10; Smith I, 1998, ACTA ANAESTH SCAND, V42, P219; Smith I, 1997, Acta Anaesthesiol Belg, V48, P161; Smith I, 1999, ANAESTHESIA, V54, P745, DOI 10.1046/j.1365-2044.1999.00953.x; Smith I, 2001, PHARMACOECONOMICS, V19, P469, DOI 10.2165/00019053-200119050-00003; Smith I, 1999, BRIT J ANAESTH, V83, P564; SMITH I, 2000, J ONE DAY SURG, V10, P12; SMITH I, 2005, FDN ANESTHESIA, P311; SMITH I, 2005, LEES SYNOPSIS ANAEST, P581; Sukhani R, 1996, ANESTH ANALG, V83, P975, DOI 10.1097/00000539-199611000-00013; Thwaites A, 1997, BRIT J ANAESTH, V78, P356; Tramer M, 1996, BRIT J ANAESTH, V76, P186; Vandermeulen Erik P., 1997, P565; YOGENDRAN S, 1995, ANESTH ANALG, V80, P682, DOI 10.1097/00000539-199504000-00006	32	17	18	0	1	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	0265-0215			EUR J ANAESTH	Eur. J. Anaesth.	OCT	2008	25	10					790	799		10.1017/S026502150800464X			10	Anesthesiology	Anesthesiology	355MR	WOS:000259713500003	18544179				2020-06-30	J	Negus, SS; Schrode, K; Stevenson, GW				Negus, S. Stevens; Schrode, Katrina; Stevenson, Glenn W.			Mu/Kappa Opioid Interactions in Rhesus Monkeys: Implications for Analgesia and Abuse Liability	EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY			English	Article						mu opioid agonist; kappa opioid agonist; antinociception; self-administration; drug interaction	SQUIRREL-MONKEY; KAPPA-OPIOIDS; DRUG DISCRIMINATION; THERMAL NOCICEPTION; ANTAGONIST ACTIVITY; SALVIA-DIVINORUM; MU-RECEPTOR; AGONIST; ANTINOCICEPTION; MORPHINE	Mu opioid receptor agonists are clinically valuable as analgesics: however. their use is limited by high abuse liability. Kappa opioid agonists also produce antinociception. but they do not produce mu agonist-like abuse-related effects. suggesting that they may enhance the antinociceptive effects and/or attenuate the abuse-related effects of mu agonists. To evaluate this hypothesis, the present Study examined interactions between the mu agonist fentanyl and the kappa agonist U69,593 in three behavioral assays in rhesus monkeys. In an assay of schedule-controlled responding, monkeys responded under a fixed-ratio 30 (FR 30) schedule of food presentation. Fentanyl and U69.593 each produced rate-decreasing effects when administered alone. and mixtures of 0.22:1. 0.65:1, and 1.96:1 U69,593/fentanyl Usually produced subadditive effects. In an assay of thermal nociception, tail withdrawal latencies were measured from water heated to 50 degrees C. Fentanyl and U69.593 each produced dose-dependent antinociception, and effects were additive for all Mixtures. In an assay of drug self-administration. rhesus monkeys responded for intravenous drug injection, and both dose and FR values were manipulated. Fentanyl maintained self-administration, whereas U69.593 did not. Addition of U69,593 to fentanyl produced a proportion-dependent decrease in rates of fentanyl self-adminstration. Moreover, addition of U69.593 increased the sensitivity of fentanyl self-administration to increases in the FR value. Taken together, these results suggest that simultaneous activation of run and kappa receptors, either with a mixture of selective drubs or with a single drug that targets both receptors. may reduce abuse liability without reducing analgesic effects relative to selective Ion agonists administered alone.	[Negus, S. Stevens; Schrode, Katrina; Stevenson, Glenn W.] Harvard Univ, McLean Hosp, Sch Med, Alcohol & Drug Abuse Res Ctr, Belmont, MA 02178 USA; [Stevenson, Glenn W.] Univ New England, Dept Psychol, Biddeford, ME USA	Negus, SS (reprint author), VA Commonwealth Univ, Dept Pharmacol & Toxicol, POB 980613,410 N 12th St, Richmond, VA 23298 USA.	ssnegus@vcu.edu			NIDAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [R01-DA1 1460]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA	This work Was Supported by Grant R01-DA1 1460 from NIDA, NIH. We thank Ashley Bear for expert technical assistance.	Arnold JM, 1997, PHARMACOL BIOCHEM BE, V57, P441, DOI 10.1016/S0091-3057(96)00445-5; Berger B, 2006, BRIT J PHARMACOL, V148, P795, DOI 10.1038/sj.bjp.0706782; BERTALMIO AJ, 1987, J PHARMACOL EXP THER, V243, P591; Butelman ER, 1998, J PHARMACOL EXP THER, V285, P595; BUTELMAN ER, 1995, J PHARMACOL EXP THER, V272, P845; CRAFT RM, 1992, J PHARMACOL EXP THER, V260, P327; CRAFT RM, 1992, J PHARMACOL EXP THER, V260, P334; DYKSTRA LA, 1990, J PHARMACOL EXP THER, V254, P245; DYKSTRA LA, 1987, J PHARMACOL EXP THER, V242, P413; DYKSTRA LA, 1985, BEHAVIORAL PHARM CUR, P111; EMMERSON PJ, 1994, J PHARMACOL EXP THER, V271, P1630; Emmerson PJ, 1996, J PHARMACOL EXP THER, V278, P1121; FUNADA M, 1993, NEUROPHARMACOLOGY, V32, P1315; GERAK LR, 1994, J PHARMACOL EXP THER, V271, P993; Gonzalez D, 2006, DRUG ALCOHOL DEPEN, V85, P157, DOI 10.1016/j.drugalcdep.2006.04.001; GUTSTEIN H, 2005, PHARMACOL BASIS THER, P547; HURSH SR, 1995, J EXP ANAL BEHAV, V64, P373, DOI 10.1901/jeab.1995.64-373; MALMBERG AB, 1993, ANESTHESIOLOGY, V79, P270, DOI 10.1097/00000542-199308000-00012; Manchikanti Laxmaiah, 2007, Pain Physician, V10, P399; MANSOUR A, 1988, TRENDS NEUROSCI, V11, P308, DOI 10.1016/0166-2236(88)90093-8; Meisch RA, 2000, EXP CLIN PSYCHOPHARM, V8, P333, DOI 10.1037//1064-1297.8.3.333; Mello NK, 1998, J PHARMACOL EXP THER, V286, P812; Miranda HF, 2007, NEUROPHARMACOLOGY, V52, P291, DOI 10.1016/j.neuropharm.2006.07.025; MUCHA RF, 1985, PSYCHOPHARMACOLOGY, V86, P274, DOI 10.1007/BF00432213; NARITA M, 1993, JPN J PHARMACOL, V62, P15, DOI 10.1254/jjp.62.15; NEGUS SS, 1990, PSYCHOPHARMACOLOGY, V102, P465, DOI 10.1007/BF02247126; NEGUS SS, 1993, J PHARMACOL EXP THER, V267, P896; Negus SS, 1999, J PHARMACOL EXP THER, V290, P1132; Negus SS, 2002, J PAIN, V3, P218, DOI 10.1054/jpai.2002.124734; NEGUS SS, 1991, J PHARMACOL EXP THER, V256, P149; ONeill SJ, 1997, J PHARMACOL EXP THER, V282, P271; PFEIFFER A, 1986, SCIENCE, V233, P774, DOI 10.1126/science.3016896; PICK CG, 1992, J PHARMACOL EXP THER, V262, P1044; PRESTON KL, 1991, DRUG ALCOHOL DEPEN, V28, P49, DOI 10.1016/0376-8716(91)90053-2; Prisinzano TE, 2005, LIFE SCI, V78, P527, DOI 10.1016/j.lfs.2005.09.008; Remmers AE, 1999, J PHARMACOL EXP THER, V288, P827; Sivachenko Andrey, 2006, Curr Drug Discov Technol, V3, P269, DOI 10.2174/157016306780368117; Stevenson GW, 2005, J PHARMACOL EXP THER, V314, P221, DOI 10.1124/jpet.104.082685; Stevenson GW, 2003, J PHARMACOL EXP THER, V307, P1054, DOI 10.1124/jpet.103.056515; TALLARIDA R, 2000, DRUG SYNERGISM DOSE; TANG AH, 1985, PSYCHOPHARMACOLOGY, V85, P309, DOI 10.1007/BF00428193; Todtenkopf MS, 2004, PSYCHOPHARMACOLOGY, V172, P463, DOI 10.1007/s00213-003-1680-y; Verborgh CML, 1997, ACTA ANAESTH SCAND, V41, P895, DOI 10.1111/j.1399-6576.1997.tb04806.x; Vivian JA, 1999, J PHARMACOL EXP THER, V290, P259; VONVOIGTLANDER PF, 1983, J PHARMACOL EXP THER, V224, P7; Walsh SL, 2001, PSYCHOPHARMACOLOGY, V157, P151, DOI 10.1007/s002130100788; WESSINGER WD, 1986, NEUROSCI BIOBEHAV R, V10, P103, DOI 10.1016/0149-7634(86)90021-7; Winger G, 2002, J PHARMACOL EXP THER, V301, P690, DOI 10.1124/jpet.301.2.690; WOODS JH, 1982, FED PROC, V41, P221; WOOLVERTON WL, 1987, NEUROBEHAVIORAL PHAR, P275; Xi ZX, 1998, J PHARMACOL EXP THER, V284, P151	51	31	32	0	1	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	1064-1297	1936-2293		EXP CLIN PSYCHOPHARM	Exp. Clin. Psychopharmacol.	OCT	2008	16	5					386	399		10.1037/a0013088			14	Psychology, Biological; Psychology, Clinical; Pharmacology & Pharmacy; Psychiatry	Psychology; Pharmacology & Pharmacy; Psychiatry	365KB	WOS:000260403800004	18837635	Green Accepted			2020-06-30	J	Luckenbill, K; Thompson, J; Middleton, O; Kloss, J; Apple, F				Luckenbill, Kristin; Thompson, Jonathan; Middleton, Owen; Kloss, Julie; Apple, Fred			Fentanyl Postmortem Redistribution: Preliminary Findings Regarding the Relationship Among Femoral Blood and Liver and Heart Tissue Concentrations	JOURNAL OF ANALYTICAL TOXICOLOGY			English	Article									[Luckenbill, Kristin; Kloss, Julie; Apple, Fred] Hennepin Cty Med Ctr, Minneapolis, MN 55415 USA; [Luckenbill, Kristin; Apple, Fred] Univ Minnesota, Sch Med, Minneapolis, MN 55415 USA; [Thompson, Jonathan; Middleton, Owen] Hennepin Cty Med Examiners Off, Minneapolis, MN 55415 USA	Apple, F (reprint author), Hennepin Cty Med Ctr, Clin Labs P4,701 Pk Ave, Minneapolis, MN 55415 USA.	apple004@umn.edu					Anderson DT, 2000, J ANAL TOXICOL, V24, P627, DOI 10.1093/jat/24.7.627; APPLE FS, 1988, AM J CLIN PATHOL, V89, P794, DOI 10.1093/ajcp/89.6.794; CALIS KA, 1992, CLIN PHARMACY, V11, P22; Crandall CS, 2006, J ANAL TOXICOL, V30, P651, DOI 10.1093/jat/30.9.651; CURRY AS, 1960, TOXICOL APPL PHARM, V2, P602, DOI 10.1016/0041-008X(60)90026-0; Dalpe-Scott M, 1995, CAN SOC FORENSIC SCI, V28, P113; GEE DJ, 1972, FORENSIC TOXICOLOGY, P37; Halliburton J R, 1988, AANA J, V56, P229; HARGRAVE SA, 1979, BRIT J ANAESTH, V51, P567; HUDSON RJ, 1986, ANESTHESIOLOGY, V64, P334, DOI 10.1097/00000542-198603000-00006; Kuhlman JJ, 2003, J ANAL TOXICOL, V27, P499, DOI 10.1093/jat/27.7.499; POKLIS A, 1995, J TOXICOL-CLIN TOXIC, V33, P439, DOI 10.3109/15563659509013752; Thompson JG, 2007, J FORENSIC SCI, V52, P978, DOI 10.1111/j.1556-4029.2007.00481.x; VANROOY HH, 1981, J CHROMATOGR, V223, P85, DOI 10.1016/S0378-4347(00)80070-5; Yarema MC, 2005, CLIN TOXICOL, V43, P235, DOI 10.1081/CLT-200058950; 2008, MERCK INDEX      MAR	16	27	27	0	5	PRESTON PUBL INC	NILES	7800 MERRIMAC AVE PO BOX 48312, NILES, IL 60648 USA	0146-4760			J ANAL TOXICOL	J. Anal. Toxicol.	OCT	2008	32	8			SI		639	643		10.1093/jat/32.8.639			5	Chemistry, Analytical; Toxicology	Chemistry; Toxicology	360SO	WOS:000260078200016	19007515	Bronze			2020-06-30	J	Larsson, MH; Bayati, A; Lindstrom, E; Larsson, H				Larsson, M. H.; Bayati, A.; Lindstrom, E.; Larsson, H.			Involvement of kappa-opioid receptors in visceral nociception in mice	NEUROGASTROENTEROLOGY AND MOTILITY			English	Article						CRD; mouse; kappa-opioid receptors; visceral sensitivity	IRRITABLE-BOWEL-SYNDROME; NOXIOUS COLORECTAL DISTENSION; ATTENUATE RESPONSES; COLONIC DISTENSION; AFFERENT-FIBERS; AGONIST; PAIN; RATS; SENSITIVITY; HYPERSENSITIVITY	It has been shown that the behavioural responses to chemically evoked visceral nociception are increased in transgenic mice lacking the kappa-opioid receptor (KOR). The aim of the present study was to evaluate the contribution of KOR in mechanically evoked visceral pain by performing colorectal distension (CRD) and monitoring the subsequent visceromotor response (VMR) in control mice (KOR(+/+)) and in mice lacking KOR (KOR(-/-)). Pseudo-affective visceral pain responses were evoked in conscious mice using increasing (10-80 mmHg) and repeated (12 x 55 mmHg) phasic CRD paradigms. The resulting VMR was determined by monitoring the electromyographic activity of the abdominal muscle. The increasing and repeated CRD paradigms, respectively, evoked similar responses in both KOR(+/+) and KOR(-/-) mice. The selective KOR-agonists U-69593 (5 and 25 mg kg(-1), s.c.) and asimadoline (25 mg kg(-1), s.c.) significantly decreased the VMR in KOR(+/+) mice, while having no effect in KOR(-/-) mice. In contrast, the selective mu-opioid receptor agonist fentanyl significantly reduced the VMR in both types of mice and appeared more efficacious in KOR(-/-) mice. The opioid receptor antagonist naloxone (0.3-30 mg kg(-1) s.c.) did not affect the response to CRD in C57BL/6 mice at any dose tested. In conclusion, the data confirm that the KOR agonists used in this study inhibit the VMR to CRD in mice by acting via KOR receptors. In addition, the data suggest that the endogenous opioid system is not likely to modulate the VMR to mechanically evoked visceral pain in mice.	[Larsson, M. H.; Lindstrom, E.; Larsson, H.] AstraZeneca R&D, Dept Integrat Pharmacol, S-43183 Molndal, Sweden; [Bayati, A.] AstraZeneca R&D, Dept Discovery Med & Epidemiol, S-43183 Molndal, Sweden	Larsson, MH (reprint author), AstraZeneca R&D, Dept Biosci, S-43183 Molndal, Sweden.	marie.h.larsson@astrazeneca.com					Abrahamson MH, 2000, GASTROENTEROLOGY, V118, pA379, DOI 10.1016/S0016-5085(00)83624-0; BARBER A, 1994, BRIT J PHARMACOL, V113, P1317, DOI 10.1111/j.1476-5381.1994.tb17142.x; Burton MB, 1998, J PHARMACOL EXP THER, V285, P707; DANZEBRINK RM, 1995, PAIN, V63, P39, DOI 10.1016/0304-3959(94)00275-J; Delvaux M, 1999, GASTROENTEROLOGY, V116, P38, DOI 10.1016/S0016-5085(99)70226-X; Delvaux M, 2004, ALIMENT PHARM THER, V20, P237, DOI 10.1111/j.1365-2036.2004.01922.x; Greenwood-Van Meerveld B, 2004, NEUROGASTROENT MOTIL, V16, P46, DOI 10.1111/j.1743-3150.2004.00555.x; Gschossmann JM, 2002, NEUROGASTROENT MOTIL, V14, P403, DOI 10.1046/j.1365-2982.2002.00345.x; Kamp EH, 2003, AM J PHYSIOL-GASTR L, V284, pG434, DOI 10.1152/ajpgi.00324.2002; Larsson M, 2003, NEUROGASTROENT MOTIL, V15, P371, DOI 10.1046/j.1365-2982.2003.00418.x; Lembo T, 2000, PAIN, V87, P137, DOI 10.1016/S0304-3959(00)00282-7; Martinez V, 1999, PAIN, V81, P179, DOI 10.1016/S0304-3959(99)00008-1; MERTZ H, 1995, GASTROENTEROLOGY, V109, P40, DOI 10.1016/0016-5085(95)90267-8; Naliboff BD, 1997, GUT, V41, P505, DOI 10.1136/gut.41.4.505; NESS TJ, 1988, BRAIN RES, V450, P153, DOI 10.1016/0006-8993(88)91555-7; RITCHIE J, 1973, GUT, V14, P125, DOI 10.1136/gut.14.2.125; Sengupta JN, 1996, GASTROENTEROLOGY, V111, P968, DOI 10.1016/S0016-5085(96)70064-1; Simonin F, 1998, EMBO J, V17, P886, DOI 10.1093/emboj/17.4.886; Soulard CD, 1996, J PHARMACOL EXP THER, V279, P1379; Su X, 2000, J NEUROPHYSIOL, V83, P963; Su X, 1997, J NEUROPHYSIOL, V78, P1003; Szarka LA, 2007, CLIN GASTROENTEROL H, V5, P1268, DOI 10.1016/j.cgh.2007.07.011; Tammpere A, 2005, PAIN, V116, P220, DOI 10.1016/j.pain.2005.04.012; Thompson WG, 1999, GUT, V45, P43; Verma-Gandhu M, 2006, GASTROENTEROLOGY, V130, P1721, DOI 10.1053/j.gastro.2006.01.045; Verne GN, 2001, PAIN, V93, P7, DOI 10.1016/S0304-3959(01)00285-8	26	14	14	0	0	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1350-1925			NEUROGASTROENT MOTIL	Neurogastroenterol. Motil.	OCT	2008	20	10					1157	1164		10.1111/j.1365-2982.2008.01161.x			8	Gastroenterology & Hepatology; Clinical Neurology; Neurosciences	Gastroenterology & Hepatology; Neurosciences & Neurology	348VD	WOS:000259237300011	18643891				2020-06-30	J	Liu, J; Pan, H; Gold, MS; Derendorf, H; Bruijnzeel, AW				Liu, Jiang; Pan, Hao; Gold, Mark S.; Derendorf, Hartmut; Bruijnzeel, Adrie W.			Effects of fentanyl dose and exposure duration on the affective and somatic signs of fentanyl withdrawal in rats	NEUROPHARMACOLOGY			English	Article						Fentanyl; mu-Opioid receptor; Dependence; Withdrawal; Reward; Rats	BRAIN REWARD FUNCTION; EXTRACORPOREAL MEMBRANE-OXYGENATION; OPIATE WITHDRAWAL; TRANSDERMAL FENTANYL; PHYSICAL-DEPENDENCE; OPIOID ANALGESICS; MEDICAL USE; NICOTINE WITHDRAWAL; CELLULAR MECHANISMS; CANCER PAIN	Fentanyl is a potent mu-opioid receptor agonist that is widely used for the treatment of chronic pain. The aim of the present study was to investigate the effect of the dose of fentanyl and the exposure duration on the affective and somatic signs of fentanyl withdrawal in rats. Fentanyl and saline were chronically administered via osmotic minipumps. A discrete-trial intracranial self-stimulation procedure was used to provide a measure of brain reward function and somatic signs were recorded from a checklist of opioid abstinence signs. The opioid receptor antagonist naloxone elevated the brain reward thresholds of the rats chronically treated with high doses of fentanyl (0.3 and 0.6 mg/kg/day), but not those of rats treated with low doses of fentanyl (0.006 and 0.06 mg/kg/day). Fentanyl had a dose-dependent effect on the naloxone-induced elevations in brain reward thresholds. On a similar note, the discontinuation of the administration of high doses of fentanyl was associated with elevations in brain reward thresholds and the discontinuation of the administration of low doses of fentanyl did not lead to an elevation in brain reward thresholds. The results also demonstrated that the duration of fentanyl administration does not affect naloxone-induced elevation in brain reward thresholds. In contrast, the somatic withdrawal syndrome gradually developed over time; maximum somatic signs were observed 120 h after pump implantation. These studies suggest that the magnitude and duration of the negative affective signs of fentanyl withdrawal depend on the dose of fentanyl administered and not on the duration of fentanyl administration. Published by Elsevier Ltd.	[Gold, Mark S.; Bruijnzeel, Adrie W.] Univ Florida, Coll Med, Dept Psychiat, McKnight Brain Inst, Gainesville, FL 32610 USA; [Liu, Jiang; Pan, Hao; Derendorf, Hartmut] Univ Florida, Coll Pharm, Dept Pharmaceut, Gainesville, FL 32610 USA	Bruijnzeel, AW (reprint author), Univ Florida, Coll Med, Dept Psychiat, McKnight Brain Inst, 100 S Newell Dr,POB 100256, Gainesville, FL 32610 USA.	awbruijn@ufl.edu	Derendorf, Hartmut/B-4628-2012	Derendorf, Hartmut/0000-0003-4016-1370	Department of Psychiatry at the University of FloridaUniversity of Florida; Flight Attendant Medical Research Institute (FAMRI) Young Clinical Scientist Award	This work was partially funded by developmental funds from the Department of Psychiatry at the University of Florida and a Flight Attendant Medical Research Institute (FAMRI) Young Clinical Scientist Award to AWB. The authors would like to thank Melissa Prado and Shani Isaac for excellent technical assistance.	ARNOLD JH, 1990, ANESTHESIOLOGY, V73, P1136, DOI 10.1097/00000542-199012000-00011; Bailey CP, 2005, CURR OPIN PHARMACOL, V5, P60, DOI 10.1016/j.coph.2004.08.012; Barr AM, 2005, NEUROSCI BIOBEHAV R, V29, P675, DOI 10.1016/j.neubiorev.2005.03.012; Bleeker CP, 2001, EUR J PAIN-LONDON, V5, P325, DOI 10.1053/eujp.2000.0220; BOZARTH MA, 1984, SCIENCE, V224, P516, DOI 10.1126/science.6324347; Bruijnzeel AW, 2007, NEUROPSYCHOPHARMACOL, V32, P955, DOI 10.1038/sj.npp.1301192; Bruijnzeel AW, 2007, PSYCHOPHARMACOLOGY, V191, P931, DOI 10.1007/s00213-006-0670-2; Bruijnzeel AW, 2006, BIOL PSYCHIAT, V59, P477, DOI 10.1016/j.biopsych.2005.07.020; Bruijnzeel AW, 2005, BRAIN RES REV, V49, P505, DOI 10.1016/j.brainresrev.2005.01.007; Cryan JF, 2003, BIOL PSYCHIAT, V54, P49, DOI 10.1016/S0006-3223(02)01730-4; Delfs JM, 2000, NATURE, V403, P430, DOI 10.1038/35000212; Dominguez KD, 2003, ANN PHARMACOTHER, V37, P473, DOI 10.1345/aph.1C324; Easterling KW, 1997, J PHARMACOL EXP THER, V281, P188; Epping-Jordan MP, 1998, NATURE, V393, P76; Franck L, 1995, Neonatal Netw, V14, P39; Franck L S, 1998, Am J Crit Care, V7, P364; Franck Linda S, 2004, Intensive Crit Care Nurs, V20, P344, DOI 10.1016/j.iccn.2004.07.008; GELLERT VF, 1978, J PHARMACOL EXP THER, V205, P536; Gilson AM, 2004, J PAIN SYMPTOM MANAG, V28, P176, DOI 10.1016/j.jpainsymman.2004.01.003; GOURLAY GK, 1988, ANESTH ANALG, V67, P329; Gracy KN, 2001, NEUROPSYCHOPHARMACOL, V24, P152, DOI 10.1016/S0893-133X(00)00186-X; HIGGINS GA, 1994, PHARMACOL BIOCHEM BE, V48, P1, DOI 10.1016/0091-3057(94)90489-8; Joranson DE, 2000, JAMA-J AM MED ASSOC, V283, P1710, DOI 10.1001/jama.283.13.1710; KOKKINIDIS L, 1990, PHARMACOL BIOCHEM BE, V36, P463, DOI 10.1016/0091-3057(90)90242-A; Koob GF, 1997, PHARMACOL BIOCHEM BE, V57, P513, DOI 10.1016/S0091-3057(96)00438-8; KORNETSKY C, 1979, FED PROC, V38, P2473; Kronstrand R, 1997, FORENSIC SCI INT, V88, P185, DOI 10.1016/S0379-0738(97)00068-6; Kuhlman JJ, 2003, J ANAL TOXICOL, V27, P499, DOI 10.1093/jat/27.7.499; LEUSCHEN MP, 1993, J THORAC CARDIOV SUR, V105, P885; Lilleng PK, 2004, J FORENSIC SCI, V49, P1364; Linneman PK, 2000, J BURN CARE REHABIL, V21, P519, DOI 10.1097/00004630-200021060-00008; MAGUIRE P, 1992, EUR J PHARMACOL, V213, P219, DOI 10.1016/0014-2999(92)90685-W; MALDONADO R, 1993, BRAIN RES, V605, P128, DOI 10.1016/0006-8993(93)91364-X; Meert TF, 2005, PHARMACOL BIOCHEM BE, V80, P309, DOI 10.1016/j.pbb.2004.12.002; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; Narita M, 2001, PHARMACOL THERAPEUT, V89, P1, DOI 10.1016/S0163-7258(00)00099-1; Nestler EJ, 2004, TRENDS PHARMACOL SCI, V25, P210, DOI 10.1016/j.tips.2004.02.005; NIEMEGEERS CJE, 1976, ARZNEIMITTEL-FORSCH, V26, P1551; Novak S, 2004, PAIN MED, V5, P59, DOI 10.1111/j.1526-4637.2004.04001.x; SCHULTEIS G, 1995, P NATL ACAD SCI USA, V92, P5880, DOI 10.1073/pnas.92.13.5880; SCHULTEIS G, 1994, J PHARMACOL EXP THER, V271, P1391; Skaer TL, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-24; Suzuki T, 1997, PHARMACOL BIOCHEM BE, V57, P293, DOI 10.1016/S0091-3057(96)00319-X; TAYLOR JR, 1988, PSYCHOPHARMACOLOGY, V96, P121, DOI 10.1007/BF02431544; Twite Mark D, 2004, Pediatr Crit Care Med, V5, P521, DOI 10.1097/01.PCC.0000144710.13710.2E; Van Ree JM, 1999, PHARMACOL REV, V51, P341; VANDAELE PGH, 1976, ARZNEIMITTELFORSCH, V26, P1521; VARVEL JR, 1989, ANESTHESIOLOGY, V70, P928, DOI 10.1097/00000542-198906000-00008	48	11	12	1	9	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	OCT	2008	55	5					812	818		10.1016/j.neuropharm.2008.06.034			7	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	361VF	WOS:000260154600023	18634811				2020-06-30	J	Matsuura, N; Shibukawa, Y; Kato, M; Ichinohe, T; Suzuki, T; Kaneko, Y				Matsuura, Nobuyuki; Shibukawa, Yoshiyuki; Kato, Motoichiro; Ichinohe, Tatsuya; Suzuki, Takashi; Kaneko, Yuzuru			Ketamine, not fentanyl, suppresses pain-related magnetic fields associated with trigeminally innervated area following CO2 laser stimulation	NEUROSCIENCE RESEARCH			English	Article						Magnetoencephalography; Secondary somatosensory area; CO2 laser; Ketamine; Fentanyl; Somatosensory-evoked magnetic field	RECEPTOR ANTAGONIST KETAMINE; PRIMARY SOMATOSENSORY CORTEX; LOW-DOSE KETAMINE; HUMAN BRAIN; MAGNETOENCEPHALOGRAPHY; PERCEPTION; ACTIVATION	A variety of pharmacological agents are clinically used to treat pain-related diseases, including in the orofacial region. The effects of analgesics upon cerebral sites responsible for pain perception have yet to be determined. The aim of the present study was to examine the effects of ketamine, an N-methyl-D-aspartate (NMDA) antagonist, and fentanyl, a narcotic analgetic, on pain-related somatosensory-evoked magnetic fields (pain-SEFs) induced by CO2 laser stimulation of the trigeminally innervated area. Two peaks with latencies of approximately 120 and 200 ms were observed in pain-SEFs after CO2 laser stimulation. Peaks with approximately 120 ms latency were detected in the bilateral secondary somatosensory cortices. Amplitude of pain-SEFs after CO2 laser stimulation increased in an intensity-dependent manner. Ketamine suppressed amplitude and prolonged latency of pain-SEFs, whilst fentanyl did not. This suggests that ketamine inhibits NMDA receptor-mediated neurotransmission in a pain input pathway to the cerebral cortex, thereby exerting an analgesic effect. Fentanyl, which acts via opioid receptors, is believed to act differently to ketamine in the pain input process. (C) 2008 Elsevier Ireland Ltd and the Japan Neuroscience Society. All rights reserved.	[Shibukawa, Yoshiyuki; Suzuki, Takashi] Tokyo Dent Coll, Dept Physiol, Mihama Ku, Chiba 2618502, Japan; [Matsuura, Nobuyuki; Shibukawa, Yoshiyuki; Kato, Motoichiro; Ichinohe, Tatsuya; Suzuki, Takashi; Kaneko, Yuzuru] Tokyo Dent Coll, Brain Res Lab, Oral Hlth Sci Ctr, Chiba 2618502, Japan; [Matsuura, Nobuyuki; Ichinohe, Tatsuya; Kaneko, Yuzuru] Tokyo Dent Coll, Dept Dent Anesthesiol, Chiba 2618502, Japan; [Kato, Motoichiro] Keio Univ, Sch Med, Dept Neuropsychiat, Tokyo 1608582, Japan	Shibukawa, Y (reprint author), Tokyo Dent Coll, Dept Physiol, Mihama Ku, 1-2-2 Masago, Chiba 2618502, Japan.	yshibuka@tdc.ac.jp			Ministry of Education, Culture, Sports, Science and Technology (MEXT) of JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [HRC3A07, HRC6A01, HRC6A03, HRC6A08]; MEXT of JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT); Dean of Tokyo Dental College	This work was supported in part by grants (HRC3A07 and HRC6A01 to TI, HRC6A03 to YS, and HRC6A08 to MN) for the High-Tech Research Center Project from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan. YS is a recipient of a grant-in-aid (nos. 18592050 and 20592187) for Scientific Research from the MEXT of Japan and a Grant from the Dean of Tokyo Dental College. The author would like to greatly thank Prof. Tatsuya Ishikawa for his valuable comments on this manuscript, and Associate Prof. Jeremy Williams, Tokyo Dental College, for his editing of the English.	ANIS NA, 1983, BRIT J PHARMACOL, V79, P565, DOI 10.1111/j.1476-5381.1983.tb11031.x; Apkarian AV, 2005, EUR J PAIN, V9, P463, DOI 10.1016/j.ejpain.2004.11.001; Bessho H, 2007, J DENT RES, V86, P265, DOI 10.1177/154405910708600313; BROMM B, 1991, REV NEUROL-FRANCE, V147, P625; Bromm B, 1984, PAIN MEASUREMENT MAN, P3; Casey KL, 1996, J NEUROPHYSIOL, V76, P571; Coghill RC, 1999, J NEUROPHYSIOL, V82, P1934; EIDE PK, 1994, PAIN, V58, P347, DOI 10.1016/0304-3959(94)90129-5; HAMALAINEN M, 1993, REV MOD PHYS, V65, P413, DOI 10.1103/RevModPhys.65.413; HUSKISSON EC, 1974, LANCET, V2, P1127, DOI 10.1016/S0140-6736(74)90884-8; Inui K, 2003, EUR J NEUROSCI, V18, P2859, DOI 10.1111/j.1460-9568.2003.02995.x; Inui K, 2003, NEUROSCIENCE, V120, P235, DOI 10.1016/S0306-4522(03)00261-6; ISHII T, 1993, J BIOL CHEM, V268, P2836; Kakigi R, 2003, NEUROSCI RES, V45, P255, DOI 10.1016/S0168-0102(02)00230-4; KAKIGI R, 1995, NEUROSCI LETT, V192, P45, DOI 10.1016/0304-3940(95)11604-U; Kanda M, 2000, BRAIN RES, V853, P282, DOI 10.1016/S0006-8993(99)02274-X; Kato Y, 2006, PSYCHIAT RES-NEUROIM, V146, P91, DOI 10.1016/j.pscychresns.2005.10.003; KENTON B, 1980, NEUROSCI LETT, V17, P301, DOI 10.1016/0304-3940(80)90040-3; Kohrs R, 1998, ANESTH ANALG, V87, P1186, DOI 10.1097/00000539-199811000-00039; Kubo K, 2008, J DENT RES, V87, P358, DOI 10.1177/154405910808700409; MATHISEN LC, 1995, PAIN, V61, P215, DOI 10.1016/0304-3959(94)00170-J; MAURSET A, 1989, PAIN, V36, P37, DOI 10.1016/0304-3959(89)90109-7; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; Nikolajsen L, 1996, PAIN, V67, P69, DOI 10.1016/0304-3959(96)03080-1; Oga K, 2002, PSYCHIAT CLIN NEUROS, V56, P355, DOI 10.1046/j.1440-1819.2002.01023.x; Ploner M, 1999, J NEUROPHYSIOL, V81, P3100; Rabben T, 2000, METHOD FIND EXP CLIN, V22, P185; Rabben T, 2001, EUR J PAIN-LONDON, V5, P233, DOI 10.1053/eujp.2001.0232; ROYTBLAT L, 1993, ANESTH ANALG, V77, P1161; Shibukawa Y, 2004, J DENT RES, V83, P572, DOI 10.1177/154405910408300712; Shibukawa Y, 2007, PAIN, V128, P180, DOI 10.1016/j.pain.2006.10.006; STANNARD CF, 1993, PAIN, V54, P227, DOI 10.1016/0304-3959(93)90214-A; TADDESE A, 1995, SCIENCE, V270, P1366, DOI 10.1126/science.270.5240.1366; Uusitalo MA, 1997, MED BIOL ENG COMPUT, V35, P135, DOI 10.1007/BF02534144; Wang XH, 2007, EXP BRAIN RES, V180, P481, DOI 10.1007/s00221-007-0878-3; Watanabe S, 1998, BRAIN TOPOGR, V10, P255, DOI 10.1023/A:1022218906322; Yamasaki H, 1999, COGNITIVE BRAIN RES, V8, P73, DOI 10.1016/S0926-6410(99)00003-8	37	5	6	0	0	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0168-0102	1872-8111		NEUROSCI RES	Neurosci. Res.	OCT	2008	62	2					105	111		10.1016/j.neures.2008.06.006			7	Neurosciences	Neurosciences & Neurology	361VH	WOS:000260154800005	18655812				2020-06-30	J	Heit, HA; Gilson, AM				Heit, Howard A.; Gilson, Aaron M.			DEA: Revisited	PAIN MEDICINE			English	Letter									[Heit, Howard A.] Georgetown Univ, Sch Med, Washington, DC 20057 USA; [Gilson, Aaron M.] Univ Wisconsin, Sch Med & Publ Hlth, Pain & Policy Studies Grp, US Program, Madison, WI 53706 USA	Heit, HA (reprint author), Georgetown Univ, Sch Med, Washington, DC 20057 USA.							0	0	0	0	0	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	1526-2375			PAIN MED	Pain Med.	OCT	2008	9	7					924	926		10.1111/j.1526-4637.2008.00520.x			3	Anesthesiology; Medicine, General & Internal	Anesthesiology; General & Internal Medicine	350ZM	WOS:000259392500018	18950444	Bronze			2020-06-30	J	Holtsman, M				Holtsman, Mark			Commentary on Dr. Heit and Dr. Gilson's letter to the Drug Enforcement Administration. Does your pharmacist interpret a new federal standard in a manner that can make your patient suffer in pain?	PAIN MEDICINE			English	Editorial Material									[Holtsman, Mark] Univ Calif Davis, Med Ctr, Sacramento, CA 95817 USA								0	1	1	0	0	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1526-2375			PAIN MED	Pain Med.	OCT	2008	9	7					927	927		10.1111/j.1526-4637.2008.00519.x			1	Anesthesiology; Medicine, General & Internal	Anesthesiology; General & Internal Medicine	350ZM	WOS:000259392500019	18950445	Bronze			2020-06-30	J	Landau, R; Kern, C; Columb, MO; Smiley, RM; Blouin, JL				Landau, Ruth; Kern, Christian; Columb, Malachy O.; Smiley, Richard M.; Blouin, Jean-Louis			Genetic variability of the mu-opioid receptor influences intrathecal fentanyl analgesia requirements in laboring women	PAIN			English	Article						OPRM 1; 304A/G; A118G; Combined spinal-epidural; Fentanyl; Genetic variability; Human; Labor; Pain; Pharmacogenetics; Polymorphism; Pregnancy; Up-down sequential allocation	SINGLE-NUCLEOTIDE POLYMORPHISM; EPIDURAL BUPIVACAINE; PAIN SENSITIVITY; MORPHINE CONSUMPTION; A118G POLYMORPHISM; ASSOCIATION; SUFENTANIL; OPRM1; MORPHINE-6-GLUCURONIDE; CHLOROPROCAINE	Labor initiates one of the most intensely painful episodes in a woman's life. Opioids are used to provide analgesia with substantial interindividual variability in efficacy. p-Opioid receptor (mu OR, OPRM1) genetic variants may explain differences in response to opioid analgesia. We hypothesized that OPRM1 304A/G polymorphism influences the median effective dose (ED50) of intrathecal fentanyl via combined spinal-epidural for labor analgesia. Nulliparous women were prospectively recruited around 35 weeks gestation (n = 224), and genotyped for 304A/G polymorphism. Those requesting neuraxial labor analgesia were enrolled in one of the two double-blinded trials: Up-down sequential allocation (SA, n = 50) and a separate confirmatory random-dose allocation trial (RA, n = 97). Effective analgesia from intrathecal fentanyl was defined by >= 60 min analgesia with verbal rating score <= 1 (scale 0-10) and was compared between mu OR 304A homozygotes (Group A) and women carrying at least one 304G allele (Group G). OPRM1 304G allele frequency f(-) was 0.18. Using SA, intrathecal fentanyl ED50 was 26.8 mu g (95% Cl 22.7-30.9) in Group A and 17.7 mu g (95% Cl 13.4-21.9) in Group G (p < 0.001; 304A homozygosity increased the ED50 1.5-fold). RA confirmed that 304A homozygosity significantly increases intrathecal fentanyl ED50 (27.4 mu g in Group A and 12.8 mu g in Group G [P < 0.002; 2.1-fold]). We demonstrate for the first time that the mu OR 304G variant significantly reduces intrathecal fentanyl ED50 for labor analgesia, suggesting women with the G variant may be more responsive to opioids and require less analgesic drugs. These findings for intrathecal fentanyl pharmacogenetics may have implications for patients receiving opioids in other settings. (C) 2008 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.	[Landau, Ruth] Univ Hosp Geneva, Anesthesiol Serv, Dept Anesthesia, CH-1211 Geneva 14, Switzerland; [Landau, Ruth; Smiley, Richard M.] Columbia Univ Coll Phys & Surg, Dept Anesthesiol, New York, NY 10032 USA; [Columb, Malachy O.] Univ Hosp S Manchester Wythenshawe, Dept Anaesthesia, Manchester, Lancs, England; [Blouin, Jean-Louis] Univ Hosp Geneva, Dept Genet Med & Lab, CH-1211 Geneva 14, Switzerland	Landau, R (reprint author), Univ Hosp Geneva, Anesthesiol Serv, Dept Anesthesia, Rue Micheli du Crest 24, CH-1211 Geneva 14, Switzerland.	ruth.landau@hcuge.ch	Columb, Malachy/F-9588-2016	Columb, Malachy/0000-0001-7837-4262	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD048805-04, R01 HD048805]		Aveline C, 2002, ANESTH ANALG, V95, P735, DOI 10.1097/00000539-200209000-00037; Befort K, 2001, J BIOL CHEM, V276, P3130, DOI 10.1074/jbc.M006352200; Beyer A, 2004, J NEUROCHEM, V89, P553, DOI 10.1111/j.1471-4159.2004.02340.x; Bond C, 1998, P NATL ACAD SCI USA, V95, P9608, DOI 10.1073/pnas.95.16.9608; Campa D, 2008, CLIN PHARMACOL THER, V83, P559, DOI 10.1038/sj.clpt.6100385; Capogna G, 1998, BRIT J ANAESTH, V80, P11; Capogna G, 2001, ANESTHESIOLOGY, V94, P740, DOI 10.1097/00000542-200105000-00009; Carvalho B, 2006, ANESTH ANALG, V103, P1283, DOI 10.1213/01.ane.0000239224.48719.28; Chong RY, 2006, NEUROPSYCHOPHARMACOL, V31, P204, DOI 10.1038/sj.npp.1300856; Chou WY, 2006, ACTA ANAESTH SCAND, V50, P787, DOI 10.1111/j.1399-6576.2006.01058.x; Chou WY, 2006, ANESTHESIOLOGY, V105, P334, DOI 10.1097/00000542-200608000-00016; COLUMB MO, 1995, ANESTH ANALG, V81, P833, DOI 10.1097/00000539-199510000-00030; Columb MO, 1997, INT J OBSTET ANESTH, V6, P39, DOI 10.1016/S0959-289X(97)80050-7; Coulbault L, 2006, CLIN PHARMACOL THER, V79, P316, DOI 10.1016/j.clpt.2006.01.007; Diatchenko L, 2005, HUM MOL GENET, V14, P135, DOI 10.1093/hmg/ddi013; Diatchenko L, 2006, PAIN, V125, P216, DOI 10.1016/j.pain.2006.05.024; DIXON WJ, 1983, INTRO STAT ANAL, P428; Fillingim RB, 2005, J PAIN, V6, P159, DOI 10.1016/j.jpain.2004.11.008; Flores CM, 2001, PHARMACOGENOMICS, V2, P177, DOI 10.1517/14622416.2.3.177; Gelernter J, 1999, MOL PSYCHIATR, V4, P476, DOI 10.1038/sj.mp.4000556; Hernandez-Avila CA, 2003, AM J MED GENET B, V118B, P60, DOI 10.1002/ajmg.b.10054; Hess PE, 2001, ANESTH ANALG, V93, P414; Janicki PK, 2006, ANESTH ANALG, V103, P1011, DOI 10.1213/01.ane.0000231634.20341.88; Kim HS, 2004, PAIN, V109, P488, DOI 10.1016/j.pain.2004.02.027; Klepstad P, 2004, ACTA ANAESTH SCAND, V48, P1232, DOI 10.1111/j.1399-6576.2004.00517.x; Kroslak T, 2007, J NEUROCHEM, V103, P77, DOI 10.1111/j.1471-4159.2007.04738.x; LaCroix-Fralish ML, 2007, PAIN, V131, DOI 10.1016/j.pain.2007.04.041; Landau R, 2004, ANESTHESIOLOGY, V100, P1030, DOI 10.1097/00000542-200404000-00042; Lotsch J, 2002, PHARMACOGENETICS, V12, P3, DOI 10.1097/00008571-200201000-00002; Lotsch J, 2002, ANESTHESIOLOGY, V97, P814; Lyons G, 1998, BRIT J ANAESTH, V81, P899; Margas W, 2007, J NEUROPHYSIOL, V97, P1058, DOI 10.1152/jn.01007.2006; Nelson KE, 2002, ANESTHESIOLOGY, V96, P1070, DOI 10.1097/00000542-200205000-00007; Nielsen CS, 2008, PAIN, V136, P21, DOI 10.1016/j.pain.2007.06.008; Ohel I, 2007, PAIN, V132, pS104, DOI 10.1016/j.pain.2007.05.007; Panni MK, 2003, ANESTHESIOLOGY, V98, P957, DOI 10.1097/00000542-200304000-00024; Polley LS, 1996, ANESTH ANALG, V83, P987, DOI 10.1097/00000539-199611000-00015; Polley LS, 2002, ANESTHESIOLOGY, V96, P1123, DOI 10.1097/00000542-200205000-00015; Polley LS, 1998, ANESTHESIOLOGY, V89, P626, DOI 10.1097/00000542-199809000-00011; Polley LS, 1999, ANESTHESIOLOGY, V90, P944, DOI 10.1097/00000542-199904000-00003; Polley LS, 2000, ANESTHESIOLOGY, V93, P122, DOI 10.1097/00000542-200007000-00022; Romberg RR, 2005, ANESTHESIOLOGY, V102, P522, DOI 10.1097/00000542-200503000-00008; Skarke C, 2004, CLIN CHEM, V50, P640, DOI 10.1373/clinchem.2003.027607; Van de Velde M, 2004, ANESTH ANALG, V98, P1153, DOI 10.1213/01.ANE.0000101980.34587.66; Viscomi CM, 1997, ANESTH ANALG, V84, P1108, DOI 10.1097/00000539-199705000-00028; Wand GS, 2002, NEUROPSYCHOPHARMACOL, V26, P106, DOI 10.1016/S0893-133X(01)00294-9; WANG JB, 1994, FEBS LETT, V338, P217, DOI 10.1016/0014-5793(94)80368-4; Xin LL, 2002, AAPS PHARMSCI, V4; Zubieta JK, 2003, SCIENCE, V299, P1240, DOI 10.1126/science.1078546	49	97	101	1	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0304-3959	1872-6623		PAIN	Pain	SEP 30	2008	139	1					5	14		10.1016/j.pain.2008.02.023			10	Anesthesiology; Clinical Neurology; Neurosciences	Anesthesiology; Neurosciences & Neurology	361WV	WOS:000260159200002	18403122	Green Accepted			2020-06-30	J	Ebrahimzadeh, H; Yamini, Y; Gholizade, A; Sedighi, A; Kasraee, S				Ebrahimzadeh, H.; Yamini, Y.; Gholizade, A.; Sedighi, A.; Kasraee, S.			Determination of fentanyl in biological and water samples using single-drop liquid-liquid-liquid microextraction coupled with high-performance liquid chromatography	ANALYTICA CHIMICA ACTA			English	Article						single-drop liquid-liquid-liquid; microextraction; high-performance liquid; chromatography; fentanyl; plasma; urine; water	SPECTROMETRIC SCREENING METHOD; PHASE MICROEXTRACTION; GAS-CHROMATOGRAPHY; MASS-SPECTROMETRY; HUMAN PLASMA; MAJOR METABOLITES; AROMATIC-AMINES; LC-MS/MS; URINE; NORFENTANYL	A single-drop liquid-liquid-liquid microextraction (LLLME) method coupled with high-performance liquid chromatography (HPLC) was developed for the determination of fentanyl in biological (plasma and urine) and wastewater samples. Fentanyl is a potent synthetic narcotic analgesic administered in the form of a transdermal patch for the management of chronic pain. Fentanyl was extracted from 0.01 M NaOH solution (donor phase) into a thin layer of organic phase (100 mu L), then back-extracted into 5 mu L of the acidic acceptor microdrop (1 x 10(-3) M HClO4) immersed in the organic membrane from the tip of a 25-mu L HPLC syringe. After the extraction, the microdrop was withdrawn into the syringe and injected directly into a HPLC system for analysis. The parameters influencing the extraction efficiency including the organic solvent and its volume, acceptor microdrop volume, composition of the donor and acceptor phases, stirring rate, temperature, salt addition and pre- and back-extraction times were investigated and optimized. At the most appropriate conditions (100 CL of n-octane, 3.6 mL of the donor phase maintained at 0.01 M NaOH, 5 mu L of 1 x 10(-3) M HClO4 as the acceptor microdrop, stirring rate of 1000 rpm for pre-extraction and 700 rpm for back-extraction, 30 degrees C, no salt addition, 30 min for pre-extraction and 20 min for back-extraction), an enrichment factor (EF) of 355 was obtained. The limit of detection (LOD) was 0.1 ng mL(-1) (based on S/N = 3) and intra- and inter-day relative standard deviations less than 9% were obtained. The calibration graph was linear within the range of 0.5-1000ng mL(-1) with the correlation coefficient (r) of 0.9999. Finally, the feasibility of the proposed method was evaluated by extraction and determination of fentanyl in plasma, urine and wastewater samples and satisfactory results were obtained. (c) 2008 Published by Elsevier B.V.	[Ebrahimzadeh, H.; Gholizade, A.; Sedighi, A.; Kasraee, S.] Shahid Beheshti Univ, Dept Chem, Tehran, Iran; [Yamini, Y.] Tarbiat Modares Univ, Dept Chem, Tehran, Iran	Ebrahimzadeh, H (reprint author), Shahid Beheshti Univ, Dept Chem, Tehran, Iran.	h-ebrahim@sbu.ac.ir		Yamini, Yadollah/0000-0002-2484-9477			Bagheri H, 2007, J PHARMACEUT BIOMED, V43, P1763, DOI 10.1016/j.jpba.2006.12.016; BAILEY PL, 1990, ANESTHESIOLOGY, V73, P826, DOI 10.1097/00000542-199011000-00005; Bansal R, 1996, J LIQ CHROMATOGR R T, V19, P353, DOI 10.1080/10826079608001220; Barwick VJ, 1997, TRAC-TREND ANAL CHEM, V16, P293, DOI 10.1016/S0165-9936(97)00039-3; BOVILL JG, 1980, BRIT J ANAESTH, V52, P795, DOI 10.1093/bja/52.8.795; Choi HS, 2001, J CHROMATOGR B, V765, P63, DOI 10.1016/S0378-4347(01)00405-4; Coopman V, 2007, FORENSIC SCI INT, V169, P223, DOI 10.1016/j.forsciint.2006.03.018; Ebrahimzadeh H, 2008, J CHROMATOGR B, V863, P229, DOI 10.1016/j.jchromb.2008.01.005; Fryirsa B, 1997, J CHROMATOGR B, V688, P79, DOI 10.1016/S0378-4347(97)88058-9; Gupta PK, 2007, ANAL BIOANAL CHEM, V388, P579, DOI 10.1007/s00216-007-1279-y; HAMMARGREN WR, 1988, J ANAL TOXICOL, V12, P183, DOI 10.1093/jat/12.4.183; He Y, 2006, J CHROMATOGR A, V1133, P35, DOI 10.1016/j.chroma.2006.08.047; Ho TS, 2002, J CHROMATOGR A, V963, P3, DOI 10.1016/S0021-9673(02)00215-7; Huynh NH, 2005, J PHARMACEUT BIOMED, V37, P1095, DOI 10.1016/j.jpba.2004.09.024; Jeannot MA, 1997, ANAL CHEM, V69, P235, DOI 10.1021/ac960814r; Koch DE, 2004, J PHARMACEUT BIOMED, V34, P577, DOI 10.1016/S0731-7085(03)00652-6; Kumar K, 1996, J PHARMACEUT BIOMED, V14, P667, DOI 10.1016/0731-7085(95)01685-6; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; MCCLAIN DA, 1980, CLIN PHARMACOL THER, V28, P106, DOI 10.1038/clpt.1980.138; PHIPPS JA, 1983, J CHROMATOGR, V272, P392, DOI 10.1016/S0378-4347(00)86145-9; Poklis A, 2004, J ANAL TOXICOL, V28, P422, DOI 10.1093/jat/28.6.422; Portier EJG, 1999, J CHROMATOGR B, V723, P313, DOI 10.1016/S0378-4347(98)00518-0; Shariati S, 2007, J CHROMATOGR B, V855, P228, DOI 10.1016/j.jchromb.2007.05.003; Valaer AK, 1997, J CHROMATOGR SCI, V35, P461, DOI 10.1093/chromsci/35.10.461; Van Nimmen NFJ, 2004, J CHROMATOGR B, V804, P375, DOI 10.1016/j.jchromb.2004.01.044; Van Nimmen NFJ, 2004, J CHROMATOGR A, V1035, P249, DOI 10.1016/j.chroma.2004.02.074; VANROOY HH, 1981, J CHROMATOGR, V223, P85, DOI 10.1016/S0378-4347(00)80070-5; Weng ND, 2002, J PHARMACEUT BIOMED, V28, P1115, DOI 10.1016/S0731-7085(02)00002-X; Yazdi AS, 2005, TALANTA, V66, P664, DOI 10.1016/j.talanta.2004.12.026; Zhao LM, 2001, J CHROMATOGR A, V931, P95, DOI 10.1016/S0021-9673(01)01199-2; Zhu LY, 2002, J CHROMATOGR A, V963, P231, DOI 10.1016/S0021-9673(02)00547-2	31	43	46	1	30	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0003-2670	1873-4324		ANAL CHIM ACTA	Anal. Chim. Acta	SEP 26	2008	626	2					193	199		10.1016/j.aca.2008.07.047			7	Chemistry, Analytical	Chemistry	358PT	WOS:000259930700010	18790121				2020-06-30	J	Vettorello, M; Colombo, R; De Grandis, CE; Costantini, E; Raimondi, F				Vettorello, M.; Colombo, R.; De Grandis, C. E.; Costantini, E.; Raimondi, F.			Effect of fentanyl on heart rate variability during spontaneous and paced breathing in healthy volunteers	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article							MIDAZOLAM SEDATION; GENERAL-ANESTHESIA; SPINAL-ANESTHESIA; POWER; INDUCTION; HYPOTENSION; PRESSURE; PROPOFOL; DIAZEPAM; MARKER	Background: Many studies have been conducted to assess the effects of fentanyl on the autonomic nervous system (ANS) by heart rate variability (HRV) analysis, but disagreement on the results is still present due to confounding influences introduced by concomitant administration of other drugs or opioid-related transitory respiratory depression. We performed a single-drug controlled-breathing study on healthy volunteers to assess the impact of fentanyl on ANS. Methods: HRV as a measure of sympathovagal balance was prospectively analyzed with an autoregressive model in 11 subjects during spontaneous and paced breathing (PB) at 20 breaths/min both before and after fentanyl 1 mcg/kg administration. HRV total power, sympathovagal balance (low-frequency/high-frequency ratio) and normalized spectral powers were considered (LFnu, HFnu). Results: Fentanyl led to a reduction of LFnu (from 55.2 +/- 23.3 to 43.2 +/- 24.1, P < 0.05) without HFnu increase during PB. A decrease in R-R interval variance (from 3345.6 +/- 3333.4 to 1806.9 +/- 1328.6 ms(2), P < 0.05) was shown after fentanyl administration during spontaneous but not PB. PB alone decreased the HRV total power and R-R interval variance. Conclusions: Low-dose fentanyl administration in healthy volunteers leads to sympathetic and overall ANS modulation decrease, with a trend toward vagal activation.	[Vettorello, M.; Colombo, R.; De Grandis, C. E.; Costantini, E.; Raimondi, F.] Luigi Sacco Univ Hosp Milan, Intens Care Unit Dept, I-20157 Milan, Italy	Vettorello, M (reprint author), Luigi Sacco Univ Hosp Milan, Intens Care Unit Dept, Via GB Grassi 74, I-20157 Milan, Italy.	marco.vettorello@fastwebnet.it	Colombo, Riccardo/AAK-9081-2020	Colombo, Riccardo/0000-0002-9616-803X			AKAIKE H, 1970, ANN I STAT MATH, V22, P203, DOI 10.1007/BF02506337; Boardman A, 2002, PHYSIOL MEAS, V23, P325, DOI 10.1088/0967-3334/23/2/308; Camm AJ, 1996, CIRCULATION, V93, P1043, DOI 10.1016/0044-8486(94)90048-5; Cammann H, 2002, COMPUT METH PROG BIO, V68, P15, DOI 10.1016/S0169-2607(01)00154-7; Feldman R, 2007, DEV PSYCHOPATHOL, V19, P1, DOI 10.1017/S0954579407070010; FLACKE JW, 1985, ANESTH ANALG, V64, P1053; Fujiwara Y, 2007, ACTA ANAESTH SCAND, V51, P1161, DOI 10.1111/j.1399-6576.2007.01435.x; GALLETLY DC, 1994, BRIT J ANAESTH, V72, P177, DOI 10.1093/bja/72.2.177; Galletly DC, 1996, BRIT J ANAESTH, V76, P503; Haney MF, 2007, ACTA ANAESTH SCAND, V51, P1289, DOI 10.1111/j.1399-6576.2007.01517.x; Hanss R, 2007, ACTA ANAESTH SCAND, V51, P1297, DOI 10.1111/j.1399-6576.2007.01455.x; HOPF HB, 1995, ANESTHESIOLOGY, V82, P609, DOI 10.1097/00000542-199503000-00002; Huang CJ, 2006, ACTA ANAESTH SCAND, V50, P542, DOI 10.1111/j.1399-6576.2006.001016.x; MONTANO N, 1994, CIRCULATION, V90, P1826, DOI 10.1161/01.CIR.90.4.1826; PAGANI M, 1991, CIRCULATION, V83, P43; PAGANI M, 1986, CIRC RES, V59, P178, DOI 10.1161/01.RES.59.2.178; Parati G, 2006, J APPL PHYSIOL, V101, P676, DOI 10.1152/japplphysiol.00446.2006; Pinna GD, 2006, AM J PHYSIOL-HEART C, V290, pH424, DOI 10.1152/ajpheart.00438.2005; Porta A, 2006, P IEEE, V94, P805, DOI 10.1109/JPROC.2006.871774; Poyhonen M, 2004, ACTA ANAESTH SCAND, V48, P93, DOI 10.1111/j.1399-6576.2004.00272.x; Riznyk L, 2005, PHARMACOL REP, V57, P128; Stark R, 2000, PSYCHOPHYSIOLOGY, V37, P302, DOI 10.1111/1469-8986.3730302; STORELLA RJ, 1995, ANESTH ANALG, V81, P1292, DOI 10.1097/00000539-199512000-00030; TANEYAMA C, 1993, ANESTH ANALG, V77, P44; Win NN, 2005, ANESTH ANALG, V101, P97, DOI 10.1213/01.ANE.0000156204.89879.5C; Zickmann B, 1996, J CARDIOTHOR VASC AN, V10, P609, DOI 10.1016/S1053-0770(96)80138-8	26	14	14	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	SEP	2008	52	8					1064	1070		10.1111/j.1399-6576.2008.01713.x			7	Anesthesiology	Anesthesiology	339QX	WOS:000258593200006	18840105				2020-06-30	J	Schapermeier, U; Hopf, HB				Schaepermeier, U.; Hopf, H. -B.			Fentanyl-induced cough does not depend on injection speed: a randomized study	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article							RAPID-SEQUENCE INTUBATION; INTRAVENOUS LIDOCAINE; BOLUS	Background: The aim of the study was to investigate whether the incidence of cough after intravenous fentanyl depends on the speed of injection. Methods: With ethics committee approval, 476 ASA class I-III nonsmoking patients free of bronchial hyperreactivity and respiratory tract infection undergoing general anaesthesia for elective surgery were randomized to either 1.5 mu g/kg fentanyl injected over 2, 5 or 10 s or placebo (saline) via a periphereal intravenous cannula. The primary endpoint was the incidence of cough within 5 min after completion of injection. Results: The study was terminated for futility after enrollment of 476 patients because an interim analysis yielded an incidence of cough of 3%, 3% and 6% in the three fentanyl groups, respectively, and of 2% in the placebo group, with no difference between groups (P = 0.374, chi(2) test for cough between fentanyl and placebo groups). Conclusions: Under the conditions of our study, the incidence of cough after 1.5 mu g/kg fentanyl injected intravenously over 2, 5 or 10 s was between 3% and 6%, unrelated to the speed of injection and not different from placebo.	[Schaepermeier, U.] Asklepios Klin Langen, Dept Anaesthesia & Perioperat Med, D-63225 Langen, Germany; Univ Frankfurt, Acad Teaching Hosp, Frankfurt, Germany	Hopf, HB (reprint author), Asklepios Klin Langen, Dept Anaesthesia & Perioperat Med, Rontgenstr 20, D-63225 Langen, Germany.	h-b.hopf@asklepios.com					Agarwal A, 2003, CAN J ANAESTH, V50, P297, DOI 10.1007/BF03017801; BOHRER H, 1990, ANAESTHESIA, V45, P18, DOI 10.1111/j.1365-2044.1990.tb14496.x; Gindre S, 2002, ANN FR ANESTH, V21, P760, DOI 10.1016/S0750-7658(02)00795-5; Horng HC, 2007, ACTA ANAESTH SCAND, V51, P862, DOI 10.1111/j.1399-6576.2007.01335.x; Lin CS, 2004, CAN J ANAESTH, V51, P654, DOI 10.1007/BF03018421; Lin JA, 2005, ANESTH ANALG, V101, P670, DOI 10.1213/01.ANE.0000159161.31276.DB; Lui PW, 1996, CAN J ANAESTH, V43, P1216; Pandey CK, 2005, CAN J ANAESTH, V52, P172, DOI 10.1007/BF03027724; Pandey CK, 2004, ANESTH ANALG, V99, P1696, DOI 10.1213/01.ANE.0000136967.82197.82; PHUA WT, 1991, CAN J ANAESTH, V38, P330, DOI 10.1007/BF03007623; POCOCK S, 1998, CLIN TRIALS PRACTICA, P123; Reynolds SF, 2005, CHEST, V127, P1397, DOI 10.1378/chest.127.4.1397	12	11	15	0	1	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0001-5172			ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	SEP	2008	52	8					1071	1075		10.1111/j.1399-6576.2008.01721.x			5	Anesthesiology	Anesthesiology	339QX	WOS:000258593200007	18840106				2020-06-30	J	Sng, BL; Pay, LL; Sia, ATH				Sng, B. L.; Pay, L. L.; Sia, A. T. H.			Comparison of 2% lignocaine with adrenaline and fentanyl, 0.75% ropivacaine and 0.5% levobupivacaine for extension of epidural analgesia for urgent caesarean section after low dose epidural infusion during labour	ANAESTHESIA AND INTENSIVE CARE			English	Article						epidural anaesthesia; obstetric anaesthesia; local anaesthesic; lignocaine; ropivacaine; levobupivacaine	BUPIVACAINE 0.5-PERCENT; EXTRADURAL ANESTHESIA; TOP-UP; BLOCKADE; 0.1-PERCENT; LIDOCAINE; TOXICITY	Low dose local anaesthetic and fentanyl epidural solutions are commonly 'topped-up' for urgent caesarean section. However; the block characteristics associated with newer local anaesthetics such as ropivacaine 0.75% and levobupivacaine 0.5% have not been fully determined. In a randomised double-blinded controlled clinical trial, we compared 2% lignocaine with adrenaline and fentanyl (LAF), 0.75% ropivacaine and 0.5% levobupivacaine for extension of low dose epidural analgesia for urgent caesarean section in 90 Asian parturients. There was no significant difference in the median, interquartile range, time to T4 loss of sensation to cold between LAF (9.5, 7.0 to 13.3 minutes), 0.75% ropivacaine (10.0, 7.0 to 15.0 minutes) and 0.5% levobupivacaine (10.0, 7.0 to 15.0 minutes). No woman required conversion to general anaesthesia. The supplementation rate did not differ between groups. Levobupivacaine provided a longer duration of sensory block compared to LAF, but a similar duration to 0.75% ropivacaine. Under the conditions of this study there was no significant difference in time to surgical readiness (defined as loss of sensation to cold to T4) between LAF, 0.75% ropivacaine and 0.5% levobupivacaine groups. Ropivacaine and levobupivacaine are suitable alternatives for extending epidural analgesia for urgent caesarean section.	[Sng, B. L.; Pay, L. L.; Sia, A. T. H.] KK Womens & Childrens Hosp, Dept Womens Anaesthesia, Singapore 229899, Singapore	Sng, BL (reprint author), KK Womens & Childrens Hosp, Dept Womens Anaesthesia, 100 Bukit Timah Rd, Singapore 229899, Singapore.						Bremerich DH, 2004, ANAESTHESIST, V53, P637, DOI 10.1007/s00101-004-0706-0; Cacciapuoti A, 2002, Minerva Anestesiol, V68, P599; Casati A, 2005, BEST PRACT RES-CLIN, V19, P247, DOI 10.1016/j.bpa.2004.12.003; Chen DT, 2002, MED CARE, V40, P20, DOI 10.1097/01.MLR.0000023952.15394.88; CROSSLEY AWA, 1994, ANAESTHESIA, V49, P205; DATTA S, 1995, ANESTHESIOLOGY, V82, P1346, DOI 10.1097/00000542-199506000-00004; DICKSON MAS, 1994, ANAESTHESIA, V49, P636; Dony P, 2000, ANESTH ANALG, V91, P1489, DOI 10.1097/00000539-200012000-00036; Faccenda KA, 2003, REGION ANESTH PAIN M, V28, P394, DOI 10.1016/S1098-7339(03)00223-2; Fernandez-Guisasola J, 2001, ANESTH ANALG, V92, P1261, DOI 10.1097/00000539-200105000-00034; FERNANDO R, 1991, BRIT J ANAESTH, V67, P699, DOI 10.1093/bja/67.6.699; Foster RH, 2000, DRUGS, V59, P551, DOI 10.2165/00003495-200059030-00013; Goring-Morris J, 2006, INT J OBSTET ANESTH, V15, P109, DOI 10.1016/j.ijoa.2005.11.005; GRIFFIN RP, 1995, BRIT J ANAESTH, V74, P512, DOI 10.1093/bja/74.5.512; Ivani G, 2001, Minerva Anestesiol, V67, P20; KATZ JA, 1990, REGION ANESTH, V15, P250; Lam DTC, 2001, ANAESTHESIA, V56, P790; Levy DM, 2006, ANAESTHESIA, V61, P786, DOI 10.1111/j.1365-2044.2006.04711.x; LIU PL, 1983, ANESTH ANALG, V62, P375; Lucas DN, 2000, BRIT J ANAESTH, V84, P494; Lucas DN, 1999, ANAESTHESIA, V54, P1173, DOI 10.1046/j.1365-2044.1999.01108.x; Malhotra S, 2007, ANAESTHESIA, V62, P667, DOI 10.1111/j.1365-2044.2007.05096.x; Orbach-Zinger S, 2006, ACTA ANAESTH SCAND, V50, P1014, DOI 10.1111/j.1399-6576.2006.01095.x; PAECH MJ, 1988, ANAESTH INTENS CARE, V16, P187, DOI 10.1177/0310057X8801600210; Pan PH, 2004, INT J OBSTET ANESTH, V13, P227, DOI 10.1016/j.ijoa.2004.04.008; Regan KJ, 2008, ANAESTHESIA, V63, P136, DOI 10.1111/j.1365-2044.2007.05319.x; Russell IF, 2004, INT J OBSTET ANESTH, V13, P146, DOI 10.1016/j.ijoa.2003.12.007; Sanders RD, 2004, ANAESTHESIA, V59, P988, DOI 10.1111/j.1365-2044.2004.03753.x; Vladimirov M, 2000, ANESTHESIOLOGY, V93, P744, DOI 10.1097/00000542-200009000-00024; YEE I, 1993, CAN J ANAESTH, V40, P722, DOI 10.1007/BF03009768	30	9	10	0	2	AUSTRALIAN SOC ANAESTHETISTS	EDGECLIFF	P O BOX 600, EDGECLIFF, NSW 2027, AUSTRALIA	0310-057X			ANAESTH INTENS CARE	Anaesth. Intensive Care	SEP	2008	36	5					659	664		10.1177/0310057X0803600505			6	Anesthesiology; Critical Care Medicine	Anesthesiology; General & Internal Medicine	357FW	WOS:000259832700005	18853583	Bronze			2020-06-30	J	Stait, ML; Leslie, K; Bailey, R				Stait, M. L.; Leslie, K.; Bailey, R.			Dreaming and recall during sedation for colonoscopy	ANAESTHESIA AND INTENSIVE CARE			English	Article						colonoscopy; sedation; dreaming; recall	GENERAL-ANESTHESIA; AWARENESS; PROPOFOL; RISK	Dreaming is reported by one in five patients who are interviewed on emergence front general anaesthesia, but the incidence, predictors and consequences of dreaming during procedural sedation are not known. In this prospective observational study, 200 patients presenting for elective colonoscopy under intravenous sedation were interviewed oil emergence to determine the incidences of dreaming and recall. Sedation technique was left to the discretion of the anaesthetist. The incidence of dreaming was 25.5%. Patients reporting dreaming were younger than those who did not report dreaming. Doses of midazolam and fentanyl were similar between dreamers and non-dreamers, however propofol doses were higher in patients who reported dreams than those who did not. Patients reported short, simple dreams about everyday life - no dream suggested near miss recall of the procedure. Frank recall of the procedure was reported by 4% of the patients, which was consistent with propofol doses commensurate with light general anaesthesia. The only significant predictor of recall was lower propofol dose. Satisfaction with care was generally high, however, dreamers were more satisfied with their care than non-dreamers.	[Stait, M. L.; Leslie, K.] Royal Melbourne Hosp, Dept Anaesthesia & Pain Management, Melbourne, Vic, Australia; [Leslie, K.] Univ Melbourne, Dept Pharmacol, Melbourne, Vic, Australia; [Bailey, R.] Albury Base Hosp, Dept Anaesthesia, Albury, NSW, Australia	Stait, ML (reprint author), Royal Melbourne Hosp, Dept Anaesthesia & Pain Management, Melbourne, Vic, Australia.			Leslie, Kate/0000-0001-8512-3517			*AUSTR NZ COLL AN, 2008, PS9 AUSTR NZ COLL AN; Brandner B, 1997, ANAESTHESIA, V52, P750, DOI 10.1111/j.1365-2044.1997.161-az0171.x; BRICE DD, 1970, BRIT J ANAESTH, V42, P535, DOI 10.1093/bja/42.6.535; Clarke AC, 2002, MED J AUSTRALIA, V176, P158, DOI 10.5694/j.1326-5377.2002.tb04345.x; Hellwagner K, 2003, EUR J ANAESTH, V20, P282, DOI 10.1097/00003643-200304000-00002; Hobson J. A., 2002, DREAMING INTRO SCI S; Kasmacher H, 1996, ANAESTHESIST, V45, P146, DOI 10.1007/s001010050249; Leslie K, 2005, ANAESTHESIA, V60, P239, DOI 10.1111/j.1365-2044.2004.04087.x; Leslie K, 2007, BEST PRACT RES-CLIN, V21, P403, DOI 10.1016/j.bpa.2007.05.003; Leslie K, 2007, ANESTHESIOLOGY, V106, P33, DOI 10.1097/00000542-200701000-00010; MARSCH SCU, 1992, EUR J ANAESTH, V9, P331; Myles PS, 2004, LANCET, V363, P1757, DOI 10.1016/S0140-6736(04)16300-9; National Health and Medical Research Council of Australia, 2005, CLIN PRACT GUID PREV; Pace-Schott EF, 2001, J SLEEP RES, V10, P129, DOI 10.1046/j.1365-2869.2001.00249.x; Padmanabhan U, 2008, ANAESTH INTENS CARE, V36, P436, DOI 10.1177/0310057X0803600316; Ranta SOV, 1998, ANESTH ANALG, V86, P1084, DOI 10.1097/00000539-199805000-00035; Sandin RH, 2000, LANCET, V355, P707, DOI 10.1016/S0140-6736(99)11010-9; Swann A, 2007, EMERG MED J, V24, P322, DOI 10.1136/emj.2006.040923	18	14	14	0	1	AUSTRALIAN SOC ANAESTHETISTS	EDGECLIFF	P O BOX 600, EDGECLIFF, NSW 2027, AUSTRALIA	0310-057X			ANAESTH INTENS CARE	Anaesth. Intensive Care	SEP	2008	36	5					685	690		10.1177/0310057X0803600509			6	Anesthesiology; Critical Care Medicine	Anesthesiology; General & Internal Medicine	357FW	WOS:000259832700009	18853587	Bronze			2020-06-30	J	Westeren-Punnonen, S; Ypparila-Wolters, H; Partanen, J; Nieminen, K; Hyvarinen, A; Kokki, H				Westeren-Punnonen, Susanna; Ypparila-Wolters, Heidi; Partanen, Juhani; Nieminen, Kari; Hyvarinen, Antti; Kokki, Hannu			Somatosensory evoked potentials by median nerve stimulation in children during thiopental/sevoflurane anesthesia and the additive effects of ketoprofen and fentanyl	ANESTHESIA AND ANALGESIA			English	Article							NITROUS-OXIDE; SEVOFLURANE ANESTHESIA; ISOFLURANE ANESTHESIA; SPINAL-CORD; DESFLURANE; MIDAZOLAM; ETOMIDATE; RESPONSES	BACKGROUND: Somatosensory evoked potentials (SEPs) are used to determine the spinal cord and brain function during surgical procedures. in general, SEPS are sensitive to volatile anesthetics, but little is known about the effects of anesthesia maintenance with sevoflurane on SEPs in children. Analgesics are often provided during anesthesia, and supplementary drugs may also affect the SEPs. In this prospective clinical trial of 27 healthy, 3- to 8-yr-old children, we evaluated the effects of sevoflurane anesthesia after IV induction with benzodiazepine and barbiturate on median nerve SEP. In addition, the effects of two analgesics (ketoprofen and fentanyl) on SEPs were evaluated. METHODS: Median nerve SEPs were recorded before premedication with midazolam 0.1 mg /kg IV, and at three separate times during anesthesia maintenance with sevoflurane 2% end-tidal concentration in air/oxygen (after 15 min of sevoflurane inhalation), supplemented with/without ketoprofen 1 mg/kg (after 25 min) and fentanyl 1 mu g/kg (after 35 min). RESULTS: Compared with baseline measurements, an increase both in N20 latency (P = 0.015) and in central conduction time (P = 0.001) was noted during anesthesia maintenance with sevoflurane. The administration of analgesics did not have an influence on the N20 latency or central conduction time. In children 5 to 8 yr of age, the mean cortical N20-P25 amplitude was decreased (P = 0.008). In addition, in older children, the N20-P25 amplitude decreased after the co-administration of ketoprofen and fentanyl compared with the values measured before the analgesics (P = 0.03). These decreases were not seen in the younger children. DISCUSSION: in children, anesthesia maintenance with 2% sevoflurane prolongs median SEP latencies in a manner that is similar to those reported for other volatile anesthetics. However, SEP monitoring can be done with sevoflurane inhalation but, the dosage should be adjusted due to interindividual variabilty. Co-administration of ketoprofen, and fentanyl did not affect the SEP latencies, but post hoc analysis suggested that older children had a decrease in cortical amplitudes.	[Westeren-Punnonen, Susanna; Ypparila-Wolters, Heidi; Partanen, Juhani] Kuopio Univ Hosp, Dept Clin Neurophysiol, FI-70211 Kuopio, Finland; [Partanen, Juhani] Helsinki Univ Hosp, Jorvi Hosp, Dept Clin Neurophysiol, Espoo, Finland; [Ypparila-Wolters, Heidi] VTT Informat Technol, Tampere, Finland; [Nieminen, Kari; Kokki, Hannu] Kuopio Univ Hosp, Dept Anesthesiol & Intens Care, FI-70211 Kuopio, Finland; [Hyvarinen, Antti] Kuopio Univ Hosp, Dept Otorhinolaryngol, FI-70211 Kuopio, Finland; [Kokki, Hannu] Univ Kuopio, Dept Pharmacol & Toxicol, FIN-70211 Kuopio, Finland	Westeren-Punnonen, S (reprint author), Kuopio Univ Hosp, Dept Clin Neurophysiol, POB 1777, FI-70211 Kuopio, Finland.	susanna.westeren-punnonen@kuh.fi			Kuopio University Hospital	Supported by funds from the Kuopio University Hospital but not from external sources.	Banoub M, 2003, ANESTHESIOLOGY, V99, P716, DOI 10.1097/00000542-200309000-00029; Boisseau N, 2002, BRIT J ANAESTH, V88, P785, DOI 10.1093/bja/88.6.785; Brosius KK, 2001, PAEDIATR ANAESTH, V11, P585, DOI 10.1046/j.1460-9592.2001.00734.x; Cohen IT, 2002, ANESTH ANALG, V94, P1178, DOI 10.1097/00000539-200205000-00023; da Costa VV, 2001, ANAESTHESIA, V56, P202; GILMORE RL, 1985, ELECTROEN CLIN NEURO, V62, P241, DOI 10.1016/0168-5597(85)90002-4; Goa K L, 1999, Paediatr Drugs, V1, P127, DOI 10.2165/00128072-199901020-00005; HELMERS SL, 1994, J PEDIATR ORTHOPED, V14, P592, DOI 10.1097/01241398-199409000-00007; INOMATA S, 1994, ANESTHESIOLOGY, V80, P93, DOI 10.1097/00000542-199401000-00016; Jantti V, 1998, EVOKED POTENTIAL, V108, P320, DOI 10.1016/S0168-5597(98)00005-7; KOHT A, 1988, ANESTH ANALG, V67, P435; Kokki Hannu, 2003, Paediatr Drugs, V5, P103, DOI 10.2165/00148581-200305020-00004; LOUGHNAN BL, 1987, ANAESTHESIA, V42, P195, DOI 10.1111/j.1365-2044.1987.tb02999.x; MASON DG, 1992, BRIT J ANAESTH, V69, P562, DOI 10.1093/bja/69.6.562; MCPHERSON RW, 1986, ANESTHESIOLOGY, V65, P584, DOI 10.1097/00000542-198612000-00004; *NAT AG MEDS, DRUG CONS 2005; Nieminen K, 2002, BRIT J ANAESTH, V89, P853, DOI 10.1093/bja/aef290; PINTO F, 1990, ACTA ANAESTH SCAND, V34, P389, DOI 10.1111/j.1399-6576.1990.tb03108.x; PORKKALA T, 1994, ACTA ANAESTH SCAND, V38, P206, DOI 10.1111/j.1399-6576.1994.tb03874.x; Schindler E, 1998, J NEUROSURG ANESTH, V10, P218; SCHUBERT A, 1987, CAN J ANAESTH, V34, P35, DOI 10.1007/BF03007679; SLOAN TB, 1990, BRIT J ANAESTH, V64, P590, DOI 10.1093/bja/64.5.590; Sloan TB, 2002, J CLIN NEUROPHYSIOL, V19, P430, DOI 10.1097/00004691-200210000-00006; SLOAN TB, 1989, BRIT J ANAESTH, V63, P51, DOI 10.1093/bja/63.1.51; Sloan TB, 1998, J CLIN NEUROPHYSIOL, V15, P217, DOI 10.1097/00004691-199805000-00005; TANIGUCHI M, 1992, NEUROSURGERY, V31, P891, DOI 10.1227/00006123-199211000-00010; VANDESTEEN A, 1991, NEUROLOGY, V41, P913, DOI 10.1212/WNL.41.6.913; Vaughan DJA, 2001, BRIT J ANAESTH, V86, P59, DOI 10.1093/bja/86.1.59; *WORLD MED ASS DEC, 2005, [No title captured]	29	3	5	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	SEP	2008	107	3					799	805		10.1213/ane.0b013e31817f0f07			7	Anesthesiology	Anesthesiology	341GP	WOS:000258702500015	18713887				2020-06-30	J	Yamauchi, M; Asano, M; Watanabe, M; Iwasaki, S; Furuse, S; Namiki, A				Yamauchi, Masanori; Asano, Makoto; Watanabe, Masanori; Iwasaki, Soushi; Furuse, Shingo; Namiki, Akiyoshi			Continuous low-dose ketamine improves the analgesic effects of fentanyl patient-controlled analgesia after cervical spine surgery	ANESTHESIA AND ANALGESIA			English	Article							POSTOPERATIVE PAIN; MORPHINE; TOLERANCE; MANAGEMENT; COMBINATIONS; INFUSION; RELIEF; RATS	BACKGROUND: The effects of fentanyl with ketamine for postoperative pain are unknown. We investigated the adjuvant effects of ketamine for fentanyl patient-controlled analgesia. METHODS: Cervical and lumbar spine surgery patients were divided into three groups: ketamine 1 mg/kg followed by 42 and 83 mu g . kg(-1) . h(-1) in ketamine-1 and ketamine-2 group, respectively, and a control group. Postoperative patient-controlled analgesia fentanyl was administered with a background infusion. RESULTS: Pain scores and analgesia requirement in the ketamine-2 group were significantly lower than those of the control group after cervical surgery. Ketamine partially improved the analgesic effects of fentanyl after lumbar surgery. CONCLUSION: Small-dose ketamine improved the analgesic effects of fentanyl after cervical Surgery.	[Yamauchi, Masanori; Watanabe, Masanori; Iwasaki, Soushi; Furuse, Shingo; Namiki, Akiyoshi] Sapporo Med Univ, Sch Med, Dept Anesthesiol, Sapporo, Hokkaido 0608543, Japan; [Asano, Makoto] Oji Gen Hosp, Dept Anesthesia, Tomakomai, Japan	Yamauchi, M (reprint author), Sapporo Med Univ, Sch Med, Dept Anesthesiol, S1 W16 Chuo Ku, Sapporo, Hokkaido 0608543, Japan.	yamauchi@sapmed.ac.jp					Burstal R, 2001, ANAESTH INTENS CARE, V29, P246, DOI 10.1177/0310057X0102900304; Chia YT, 1999, CAN J ANAESTH, V46, P872, DOI 10.1007/BF03012978; Himmelseher S, 2005, ANESTHESIOLOGY, V102, P211, DOI 10.1097/00000542-200501000-00030; Javery KB, 1996, CAN J ANAESTH, V43, P212, DOI 10.1007/BF03011736; Kim SI, 2000, BRIT J ANAESTH, V85, P898, DOI 10.1093/bja/85.6.898; Kissin I, 2000, ANESTH ANALG, V91, P1483, DOI 10.1097/00000539-200012000-00035; LAITINEN J, 1992, ANESTHESIOLOGY, V76, P194, DOI 10.1097/00000542-199202000-00006; Laulin JP, 2002, ANESTH ANALG, V94, P1263, DOI 10.1097/00000539-200205000-00040; MARSHALL H, 1985, BMJ-BRIT MED J, V291, P19, DOI 10.1136/bmj.291.6487.19; MARSHALL H, 1999, BRIT J ANAESTH, V83, P393; Menigaux C, 2001, ANESTH ANALG, V93, P606, DOI 10.1097/00000539-200109000-00016; Pelissier T, 2003, EUR J PHARMACOL, V477, P23, DOI 10.1016/S0014-2999(03)02192-7; Reeves M, 2001, ANESTH ANALG, V93, P116; Richebe P, 2005, ANESTHESIOLOGY, V102, P421, DOI 10.1097/00000542-200502000-00028; Roussier M, 2006, BRIT J ANAESTH, V96, P492, DOI 10.1093/bja/ael025; Schmid RL, 1999, PAIN, V82, P111, DOI 10.1016/S0304-3959(99)00044-5; Schnoebel R, 2005, BRIT J PHARMACOL, V146, P826, DOI 10.1038/sj.bjp.0706385; Suzuki M, 1999, ANESTH ANALG, V89, P98, DOI 10.1097/00000539-199907000-00017; Sveticic G, 2003, ANESTHESIOLOGY, V98, P1195, DOI 10.1097/00000542-200305000-00023	19	29	36	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	SEP	2008	107	3					1041	1044		10.1213/ane.0b013e31817f1e4a			4	Anesthesiology	Anesthesiology	341GP	WOS:000258702500053	18713926				2020-06-30	J	Shabanov, PD; Lebedev, AA				Shabanov, P. D.; Lebedev, A. A.			Expression of mRNA for Corticotropin-Releasing Hormone and Vasopressin in the Hypothalamus and Amygdala of Rats after Administration of Narcogenic	BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE			English	Article						corticotropin-releasing hormone; vasopressin; stress; brain limbic brain structures; mRNA expression	SELF-STIMULATION; CORTICOLIBERIN	Male Wistar rats received intraperitoneal injections of physiological saline (control), phenamine, fentanyl, ethanol, sodium ethaminal, or dexamethasone in increasing concentrations for 4 days. Forced administration of these drugs provided gradual load of the organism and prevented the development of tolerance. Such approach is extensively used for the development of drug addiction or several manifestations of this state. Expression of corticotropin-releasing hormone mRNA in the amygdala was maximum after administration of dexamethasone (0.46 arb. units vs. beta-actin), but was much lower in experiments with sodium ethaminal and fentanyl (0.07 and 0.037 arb. units, respectively). In the hypothalamus, enhanced mRNA expression was observed after injection of sodium ethaminal, ethanol, and fentanyl (0.8, 0.37, and 0.039 arb. units, respectively). Phenamine did not increase mRNA expression in the amygdala and hypothalamus. Expression of vasopressin mRNA was not detectable in brain structures of animals from various groups. Our results indicate that the hypothalamic reinforcement system provides a similar response to narcogens, whereas the extended amygdala includes elements of both reinforcement and stress reactivity.	[Shabanov, P. D.; Lebedev, A. A.] SM Kirov Mil Med Acad, Russian Minist Def, Dept Pharmacol, St Petersburg, Russia	Shabanov, PD (reprint author), SM Kirov Mil Med Acad, Russian Minist Def, Dept Pharmacol, St Petersburg, Russia.	shabanov@mail.rcom.ru			Russian Foundation for Basic ResearchRussian Foundation for Basic Research (RFBR) [07-04-00549a]	This work was supported by the Russian Foundation for Basic Research (grant No. 07-04-00549a).	Lebedev A A, 2001, Ross Fiziol Zh Im I M Sechenova, V87, P911; LEBEDEV AA, 2006, PSIKHOFARMAKOL BIOL, V6, P1204; SAMBROCK J, 1989, MOL CLONING LAB MANU, V2, P1418; Sarnyai Z, 2001, PHARMACOL REV, V53, P209; Shabanov P. D., 2006, Eksperimental'naya i Klinicheskaya Farmakologiya, V69, P44; Shabanov P. D., 2007, Eksperimental'naya i Klinicheskaya Farmakologiya, V70, P6; Shabanov P. D., 2006, Eksperimental'naya i Klinicheskaya Farmakologiya, V69, P3; Shabanov P. D., 2006, Eksperimental'naya i Klinicheskaya Farmakologiya, V69, P14; SHABANOV PD, 1989, MEMORY DISORDERS THE; SHABANOV PD, 2006, NARKOLOGIYA, V5, P17; SHABANOV PD, 2006, NEYRONAUKI, V2, P4; SHABANOV PD, 2002, DOPAMINE BRAIN REINF; SHALYAPINA VG, 2005, BASES NEUROENDOCRINO	13	0	0	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0007-4888			B EXP BIOL MED+	Bull. Exp. Biol. Med.	SEP	2008	146	3					317	320		10.1007/s10517-008-0271-7			4	Medicine, Research & Experimental	Research & Experimental Medicine	400CH	WOS:000262845100014	19240849				2020-06-30	J	Ledowski, T; Manopas, A; Lauer, S				Ledowski, T.; Manopas, A.; Lauer, S.			Bronchial mucus transport velocity in patients receiving desflurane and fentanyl vs. sevoflurane and fentanyl	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article						anaesthesia inhalational; desflurane; sevoflurane; mucus; bronchial; transport; velocity	LARYNGEAL MASK AIRWAY; IN-VITRO; ISOFLURANE; ANESTHESIA; PROPOFOL; REMIFENTANIL; REACTIVITY; CLEARANCE; CILIA	Background and objective: Sevoflurane has been shown to distinctly reduce bronchial mucus transport velocity, an essential determinant of mucociliary clearance and pulmonary complications. However, sevoflurane is regarded as one of the least irritant volatile anaesthetics, especially when compared with desflurane. Hence, the aim of this double-blind, randomized, controlled trial was to assess differences in bronchial mucus transport velocity between sevoflurane and desflurane. Methods: Twenty patients listed for general surgery were randomized to receive either maintenance of anaesthesia with desflurane and fentanyl, or sevoflurane and fentanyl. Thirty minutes after tracheal intubation, bronchial mucus transport velocity was assessed by fibreoptic observation of the movement of methylene blue dye applied to the dorsal surface of the right main bronchus. Results: Both agents distinctly reduced bronchial mucus transport velocity when compared with previous studies, but the degree of impairment did not significantly differ between the investigated groups (median [25%/75% percentile]): desflurane 1.5 [0.5/4.2] vs. sevoflurane 1.3 [0.3/2.9] mm min(-1), P = 0.343). Conclusions: Desflurane is commonly regarded as more irritant to the airway, but as far as bronchial mucus transport velocity is concerned, the choice between sevoflurane and desflurane does not seem to matter.	[Ledowski, T.; Manopas, A.; Lauer, S.] Royal Perth Hosp, Dept Anaesthesia & Pain Med, Perth, WA 6000, Australia	Ledowski, T (reprint author), Royal Perth Hosp, Dept Anaesthesia & Pain Med, Wellington St Campus, Perth, WA 6000, Australia.	thomas.ledowski@health.wa.gov.au					Arain SR, 2005, ANESTHESIOLOGY, V103, P495, DOI 10.1097/00000542-200509000-00011; Cervin A, 1998, BRIT J ANAESTH, V80, P475, DOI 10.1093/bja/80.4.475; Keller C, 1998, ANESTH ANALG, V86, P1280, DOI 10.1097/00000539-199806000-00028; Klock PA, 2001, ANESTHESIOLOGY, V94, P963, DOI 10.1097/00000542-200106000-00008; Knowles MR, 2002, J CLIN INVEST, V109, P571, DOI 10.1172/JCI200215217; KONRAD F, 1994, CHEST, V105, P237, DOI 10.1378/chest.105.1.237; KONRAD FX, 1993, J CLIN ANESTH, V5, P375, DOI 10.1016/0952-8180(93)90100-S; Ledowski T, 2006, ANAESTHESIA, V61, P747, DOI 10.1111/j.1365-2044.2006.04714.x; Ledowski T, 2006, ANESTH ANALG, V102, P1427, DOI 10.1213/01.ane.0000204317.78586.07; Raphael JH, 1996, BRIT J ANAESTH, V76, P854; Raphael JH, 1996, BRIT J ANAESTH, V76, P116; Raphael JH, 1997, BRIT J ANAESTH, V79, P473, DOI 10.1093/bja/79.4.473; SACKNER MA, 1973, J APPL PHYSIOL, V34, P495; TerRiet MF, 2000, BRIT J ANAESTH, V85, P305, DOI 10.1093/bja/85.2.305; Wanner A, 1996, AM J RESP CRIT CARE, V154, P1868, DOI 10.1164/ajrccm.154.6.8970383	15	9	10	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0265-0215			EUR J ANAESTH	Eur. J. Anaesth.	SEP	2008	25	9					752	755		10.1017/S0265021508004304			4	Anesthesiology	Anesthesiology	343VO	WOS:000258883600010	18471329				2020-06-30	J	Lee, HJ; Kwon, JY; Shin, SW; Kim, CH; Baek, SH; Balk, SW; Kim, HK; Kim, KH				Lee, H. -J.; Kwon, J. -Y; Shin, S. -W.; Kim, C. -H.; Baek, S. -H.; Balk, S. -W.; Kim, H. -K.; Kim, K. -H.			Preoperatively administered ramosetron oral disintegrating tablets for preventing nausea and vomiting associated with patient-controlled analgesia in breast cancer patients	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article						breast surgery; oral administration; postoperative nausea and vomiting; premedication; ramosetron	MIDDLE-EAR SURGERY; POSTOPERATIVE NAUSEA; PROPHYLACTIC ONDANSETRON; PHARMACOLOGICAL PROFILE; ANTIEMETIC EFFICACY; THERAPEUTIC AGENT; DOUBLE-BLIND; GRANISETRON; CHILDREN; METOCLOPRAMIDE	Background and objectives: The purpose of this study was to investigate the acceptability and therapeutic efficacy of a preoperative single administration of long-acting 5-hydroxytryptamine type 3 (5-HT3) receptor antagonist in an orally disintegrating tablet formulation, ramosetron, in breast cancer patients. Methods: Two hundred and forty women, ASA I-II, aged 24-60 yr, undergoing elective breast cancer surgery, were randomized. A standardized anaesthetic technique was used. Patients were assigned to receive one of three treatment regimens (n = 80 in each group): no prophylactic antiemetics (Group A), single prophylactic intravenous injection of ramosetron 0.1 mg at the completion of surgery (Group B) or preoperatively oral administration of 0.1 mg of ramosetron (Group C). Episodes of nausea and vomiting, the use of rescue antiemetic treatment, degree of pain, adverse events and level of satisfaction were recorded. Results: The overall incidence of nausea and vomiting during the first 24h after the recovery in Groups B (27.8%) and C (25%) was decreased significantly compared with Group A (75.3%). The frequency of the use of rescue antiemetics was Significantly lower in Group C (5.0%) compared with Groups A (53.2%) and B (15.2%). The patients in Group C were more satisfied with control of postoperative nausea and vomiting than others. Conclusion: Preoperative oral administration of ramosetron at a dose of 0.1 mg is an acceptable and effective way of reducing the incidence of postoperative nausea and vomiting in breast cancer patients.	[Lee, H. -J.; Kwon, J. -Y; Shin, S. -W.; Baek, S. -H.; Balk, S. -W.; Kim, H. -K.; Kim, K. -H.] Pusan Natl Univ, Dept Anesthesia & Pain Med, Sch Med, Med Res Inst, Pusan 602739, South Korea; [Kim, C. -H.] Pusan Natl Univ, Dept Dent Anesthesia & Pain Med, Sch Med, Pusan 602739, South Korea	Kwon, JY (reprint author), Pusan Natl Univ, Dept Anesthesia & Pain Med, Sch Med, Med Res Inst, 1-10 Ami Dong, Pusan 602739, South Korea.	lhjksk@pusan.ac.kr			Medical Research Institute, Pusan National University, Busan, Korea	This study was supported by a grant from Medical Research Institute, Pusan National University, Busan, Korea. The authors have no conflicts of interest that are directly relevant to the content of this study.	ALEXANDER R, 1995, ANAESTHESIA, V50, P1086, DOI 10.1111/j.1365-2044.1995.tb05958.x; Apfel CC, 1999, ANESTHESIOLOGY, V91, P693, DOI 10.1097/00000542-199909000-00022; Bauer KP, 2004, J CLIN ANESTH, V16, P177, DOI 10.1016/j.jclinane.2003.07.003; BLAND JM, 1995, BRIT MED J, V310, P170, DOI 10.1136/bmj.310.6973.170; Cohen IT, 2005, ANESTH ANALG, V101, P59, DOI 10.1213/01.ANE.0000154186.03161.35; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; COHEN MM, 1994, ANESTH ANALG, V78, P7; Dresner M, 1998, BRIT J ANAESTH, V81, P384, DOI 10.1093/bja/81.3.384; Fu YR, 2004, CRIT REV THER DRUG, V21, P433, DOI 10.1615/CritRevTherDrugCarrierSyst.v21.i6.10; Fujii Y, 2003, CLIN THER, V25, P3100, DOI 10.1016/S0149-2918(03)90094-4; Fujii Y, 2002, EUR J SURG, V168, P583, DOI 10.1080/11024150201680002; Fujii Y, 2000, ANESTH ANALG, V90, P472, DOI 10.1097/00000539-200002000-00043; Fujii Y, 2001, BRIT J OPHTHALMOL, V85, P670, DOI 10.1136/bjo.85.6.670; Fujii Y, 2001, EUR J SURG, V167, P184; Fujii Yoshitaka, 2004, Am J Ther, V11, P278, DOI 10.1097/01.mjt.0000101829.94820.8f; Gan TJ, 1996, ANESTHESIOLOGY, V85, P1036, DOI 10.1097/00000542-199611000-00011; Gombar S, 2007, ACTA ANAESTH SCAND, V51, P621, DOI 10.1111/j.1399-6576.2007.01296.x; Hartsell T, 2005, ANESTH ANALG, V101, P1492, DOI 10.1213/01.ANE.0000181007.01219.38; Hirata T., 2007, Inflammopharmacology, V15, P5, DOI 10.1007/s10787-006-1537-1; Hirata T, 2008, J PHARMACOL SCI, V106, P264, DOI 10.1254/jphs.FP0071943; Hirata T, 2007, J PHARMACOL SCI, V104, P263, DOI 10.1254/jphs.FP0070620; Jokela R, 2002, ACTA ANAESTH SCAND, V46, P519, DOI 10.1034/j.1399-6576.2002.460508.x; KAZEMIKJELLBERG F, 2001, BMC ANESTHESIOL, V1, P2, DOI DOI 10.1186/1471-2253-1-2; NAKAMURA E, 1995, DRUG METAB PHARMACOK, V10, P808; Noda K, 2002, J INT MED RES, V30, P211, DOI 10.1177/147323000203000301; Paech MJ, 2007, ANESTH ANALG, V104, P808, DOI 10.1213/01.ane.0000258768.76093.16; Reihner E, 2000, EUR J ANAESTH, V17, P197, DOI 10.1046/j.1365-2346.2000.00627.x; Sadhasivam S, 1999, ANESTH ANALG, V89, P1340, DOI 10.1097/00000539-199912000-00002; Sanjay OP, 2004, ANESTH ANALG, V99, P339; Sun R, 1997, ANESTH ANALG, V84, P331, DOI 10.1097/00000539-199702000-00016; Tang J, 1998, ANESTH ANALG, V86, P274, DOI 10.1097/00000539-199802000-00010; Tantipalakorn Charuwan, 2004, Journal of the Medical Association of Thailand, V87, P119; Tramer MR, 2007, ANAESTHESIST, V56, P679, DOI 10.1007/s00101-007-1199-4; WALDER AD, 1994, ANAESTHESIA, V49, P804; Wang JJ, 2000, ANESTH ANALG, V91, P136, DOI 10.1097/00000539-200007000-00025; White LA, 2001, ANAESTHESIA, V56, P365, DOI 10.1046/j.1365-2044.2001.01708-5.x	36	16	18	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0265-0215	1365-2346		EUR J ANAESTH	Eur. J. Anaesth.	SEP	2008	25	9					756	762		10.1017/S0265021508004262			7	Anesthesiology	Anesthesiology	343VO	WOS:000258883600011	18426627				2020-06-30	J	Ojanpera, I; Gergov, M; Liiv, M; Riikoja, A; Vuori, E				Ojanpera, Ilkka; Gergov, Merja; Liiv, Milana; Riikoja, Aime; Vuori, Erkki			An epidemic of fatal 3-methylfentanyl poisoning in Estonia	INTERNATIONAL JOURNAL OF LEGAL MEDICINE			English	Article						3-methylfentanyl; fatal poisoning; post-mortem; blood concentration; designer drug	FENTANYL-RELATED DEATHS; TRANSDERMAL FENTANYL; GAS-CHROMATOGRAPHY; BLOOD; DRUGS; ABUSE; CIRCUMSTANCES; OVERDOSE; MISUSE; PATCH	An exceptional epidemic of poisonings due to the highly potent opioid designer drug 3-methylfentanyl (TMF) was revealed among Estonian drug users in 2005-2006 by post-mortem forensic toxicology. Quantitative analysis of cis-TMF, trans-TMF, and fentanyl was performed by liquid chromatography-tandem mass spectrometry. Comprehensive toxicological analysis was performed using a multi-technique approach. The number of TMF-related fatal accidental poisonings identified was 46 and 71 for 2005 and 2006, respectively. The proportion of male victims was 91.5% and the mean age of all victims was 26 years at death. TMF was used predominantly by intravenous injection. There was no significant difference in the blood concentrations of cis-TMF and trans-TMF between pure TMF poisonings and mixed TMF poisonings. The mean combined concentration of TMF stereoisomers among pure TMF cases (1.9 mu g/l) was more than ten times lower than the mean fentanyl concentration in fentanyl-related fatalities. Concomitant use of other drugs involved alcohol, amphetamines, benzodiazepines, and cannabis, but very rarely other opioids.	[Ojanpera, Ilkka; Gergov, Merja; Vuori, Erkki] Univ Helsinki, Dept Forens Med, FIN-00014 Helsinki, Finland; [Liiv, Milana; Riikoja, Aime] Estonian Bur Forens Med, EE-10150 Tallinn, Estonia	Ojanpera, I (reprint author), Univ Helsinki, Dept Forens Med, POB 40, FIN-00014 Helsinki, Finland.	ilkka.ojanpera@helsinki.fi		Ojanpera, Ilkka/0000-0001-5790-1473			Alho H, 2007, DRUG ALCOHOL DEPEN, V88, P75, DOI 10.1016/j.drugalcdep.2006.09.012; Anderson DT, 2000, J ANAL TOXICOL, V24, P627, DOI 10.1093/jat/24.7.627; Boddiger D, 2006, LANCET, V368, P569, DOI 10.1016/S0140-6736(06)69181-2; Drasch G, 2008, INT J LEGAL MED, V122, P115, DOI 10.1007/s00414-007-0178-2; Drummer OH, 2005, THER DRUG MONIT, V27, P738, DOI 10.1097/01.ftd.0000179853.16846.a9; *EMB US MOSC, 2007, INT NARC CONTR STRAT; *EUR, 2007, AMPH TYP STIM EUR UN; HAMMARGREN WR, 1988, J ANAL TOXICOL, V12, P183, DOI 10.1093/jat/12.4.183; HENDERSON GL, 1983, P W PHARMACOL SOC, V26, P287; HENDERSON GL, 1988, J FORENSIC SCI, V33, P569; HENDERSON GL, 1991, J FORENSIC SCI, V36, P422; HIBBS J, 1991, JAMA-J AM MED ASSOC, V265, P1011, DOI 10.1001/jama.265.8.1011; Hoiseth G, 2007, INT J LEGAL MED, V121, P403, DOI 10.1007/s00414-006-0139-1; Huynh NH, 2005, J PHARMACEUT BIOMED, V37, P1095, DOI 10.1016/j.jpba.2004.09.024; Jones AW, 2005, J FORENSIC SCI, V50, P1215; Jones AW, 1999, J STUD ALCOHOL, V60, P400, DOI 10.15288/jsa.1999.60.400; Kaferstein H, 2000, FORENSIC SCI INT, V113, P353, DOI 10.1016/S0379-0738(00)00224-3; Koski A, 2005, INT J LEGAL MED, V119, P344, DOI 10.1007/s00414-005-0528-x; Kuhlman JJ, 2003, J ANAL TOXICOL, V27, P499, DOI 10.1093/jat/27.7.499; Lilleng PK, 2004, J FORENSIC SCI, V49, P1364; MARTIN M, 1991, ANN EMERG MED, V20, P158, DOI 10.1016/S0196-0644(05)81216-8; Martin TL, 2006, J ANAL TOXICOL, V30, P603, DOI 10.1093/jat/30.8.603; Ojanpera I, 2006, AM J FOREN MED PATH, V27, P328, DOI 10.1097/01.paf.0000188097.78132.e5; OOLE K, 2006, NATL REPORT EMCDDA R; Pelander A, 2003, ANAL CHEM, V75, P5710, DOI 10.1021/ac030162o; Quaglio G, 2001, ADDICTION, V96, P1127, DOI 10.1046/j.1360-0443.2001.96811276.x; Rasanen I, 2003, J CHROMATOGR B, V788, P243, DOI 10.1016/S1570-0232(02)01012-7; Sorokin VI SE, 1994, MICROGRAM, V27, P221; TALU A, 2004, REPORT EMCDDA REPORT; Teske J, 2007, INT J LEGAL MED, V121, P147, DOI 10.1007/s00414-006-0137-3; Tharp AM, 2004, AM J FOREN MED PATH, V25, P178, DOI 10.1097/01.paf.0000127398.67081.11; Thompson JG, 2007, J FORENSIC SCI, V52, P978, DOI 10.1111/j.1556-4029.2007.00481.x; U.S. Department of Justice D.E.A., 2007, FED REGISTER, V72, P20039; VANBEVER WF, 1974, J MED CHEM, V17, P1047, DOI 10.1021/jm00256a003; Warner-Smith M, 2001, ADDICTION, V96, P1113, DOI 10.1046/j.1360-0443.2001.96811135.x	35	39	41	0	19	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0937-9827	1437-1596		INT J LEGAL MED	Int. J. Legal Med.	SEP	2008	122	5					395	400		10.1007/s00414-008-0230-x			6	Medicine, Legal	Legal Medicine	343JC	WOS:000258848400006	18386033				2020-06-30	J	Ayoglu, H; Yapakci, O; Ugur, MB; Uzun, L; Altunkaya, H; Ozer, Y; Uyanik, R; Cinar, F; Ozkocak, I				Ayoglu, Hilal; Yapakci, Osman; Ugur, Mehmet Birol; Uzun, Lokman; Altunkaya, Hanife; Ozer, Yetki; Uyanik, Rahsan; Cinar, Fikret; Ozkocak, Isit			Effectiveness of dexmedetomidine in reducing bleeding during septoplasty and tympanoplasty operations	JOURNAL OF CLINICAL ANESTHESIA			English	Article						Dexmedetomidine; Controlled hypotension; Surgery; Otorhinolaryngology	ENDOSCOPIC SINUS SURGERY; MIDDLE-EAR MICROSURGERY; CLONIDINE PREMEDICATION; CONTROLLED HYPOTENSION; ORTHOGNATHIC SURGERY; BLOOD-LOSS; DELIBERATE HYPOTENSION; SODIUM-NITROPRUSSIDE; ANESTHESIA; RESPONSES	Study Objective: To determine the effect of dexmedetomidine on intraoperative bleeding during septoplasty and tympanoplasty operations. Design: Randomized. placebo-controlled study. Setting: Univesity medical center. Patients: 80 ASA physical status I and II patients, aged 18 to 05 years, 40 of whom were scheduled for septoplasty and 40 to undergo tympanoplasty operations. Interventions: Patients undergoing septoplasty (S) and tympanoplasty (T) operations were randomly divided into 4 groups. Dexmedetomidine (D) was administered to Group SD and Group TD first as a bolus close of one mu g kg(-1), then intraoperative maintenance was supplied with dexmedetomidine 0.7 mu g kg(-1) hour(-1). Groups S and T (controls) were given identical amounts of saline. If systolic blood pressure measurements are greater than 20% preoperative values, then fentanyl one mu g kg(-1) was given. Measurements: Intraoperative blood loss was determined with suction volumes and gauze counting. Bleeding was rated according to a 6-point scale. Hemodynamic parameters and fentanyl administration were recorded. Main Results: Group SI) had less bleeding and lower bleeding scores (P < 0.05). In addition, this group received less intraoperative fentanyl (P < 0.05). The only significant difference between Groups TD and T was the amount of intraoperative fentanyl given (35.4 +/- 58.8 vs 110.0 +/- 81.0 mu g) (P < 0.05). Conclusion: Dexmedetomidine reduces bleeding, bleeding, scores, and intraoperative fentanyl consumption during general anesthesia in septoplasty operations. (C) 2008 Elsevier Inc. All rights reserved.	[Ayoglu, Hilal; Yapakci, Osman; Altunkaya, Hanife; Ozer, Yetki; Uyanik, Rahsan; Ozkocak, Isit] Karaelmas Univ, Fac Med, Dept Anaesthesiol & Reanimat, Zonguldak, Turkey; [Ugur, Mehmet Birol; Uzun, Lokman; Cinar, Fikret] Karaelmas Univ, Fac Med, Dept Otorhinolaryngol Surg, Zonguldak, Turkey	Ayoglu, H (reprint author), Karaelmas Univ, Fac Med, Dept Anaesthesiol & Reanimat, Zonguldak, Turkey.	periayogluzku@yahoo.com	Uzun, Lokman/S-7689-2016	Uzun, Lokman/0000-0003-0304-3789; Ugur, Mehmet Birol/0000-0003-2784-015X			BOEZAART AP, 1995, CAN J ANAESTH, V42, P373, DOI 10.1007/BF03015479; Caverni V, 2005, J CRANIOFAC SURG, V16, P531, DOI 10.1097/01.SCS.0000159084.60049.E6; Cincikas Darius, 2003, Medicina (Kaunas), V39, P852; Durmus M, 2007, EUR J ANAESTH, V24, P447, DOI 10.1017/S0265021506002122; Ebert TJ, 2000, ANESTHESIOLOGY, V93, P382, DOI 10.1097/00000542-200008000-00016; FROMME GA, 1986, ANESTH ANALG, V65, P683; Jacobi KE, 2000, J CLIN ANESTH, V12, P202, DOI 10.1016/S0952-8180(00)00145-8; Lee J, 1999, BRIT J ANAESTH, V82, P639; Marchal JM, 2001, ACTA ANAESTH SCAND, V45, P627, DOI 10.1034/j.1399-6576.2001.045005627.x; MAROOF M, 1994, CAN J ANAESTH, V41, P164, DOI 10.1007/BF03009819; Newton MC, 1996, BRIT J ANAESTH, V76, P352; Praveen K, 2001, BRIT J ORAL MAX SURG, V39, P138, DOI 10.1054/bjom.2000.0593; Precious DS, 1996, J ORAL MAXIL SURG, V54, P680, DOI 10.1016/S0278-2391(96)90679-5; SIMPSON P, 1992, BRIT J ANAESTH, V69, P498, DOI 10.1093/bja/69.5.498; Talke P, 1997, ANESTH ANALG, V85, P1136, DOI 10.1097/00000539-199711000-00033; Talke PO, 2000, ANESTH ANALG, V91, P793, DOI 10.1097/00000539-200010000-00006; Talke PO, 2001, ANESTH ANALG, V93, P271, DOI 10.1097/00000539-200108000-00006; TESTA LD, 1995, J CLIN ANESTH, V7, P326, DOI 10.1016/0952-8180(95)00010-F; Tobias JD, 2002, PAEDIATR ANAESTH, V12, P171, DOI 10.1046/j.1460-9592.2002.00805.x; TOIVONEN J, 1990, ACTA ANAESTH SCAND, V34, P653, DOI 10.1111/j.1399-6576.1990.tb03166.x; WARD CF, 1980, HEAD NECK SURG, V2, P185, DOI 10.1002/hed.2890020304; WELFRINGER P, 1992, ANN FR ANESTH, V11, P125, DOI 10.1016/S0750-7658(05)80001-2; White PF, 2005, ANESTH ANALG, V101, pS5, DOI 10.1213/01.ANE.0000177099.28914.A7; WOODCOCK TE, 1988, BRIT J ANAESTH, V60, P388, DOI 10.1093/bja/60.4.388	24	39	46	1	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180			J CLIN ANESTH	J. Clin. Anesth.	SEP	2008	20	6					437	441		10.1016/j.jclinane.2008.04.008			5	Anesthesiology	Anesthesiology	361NK	WOS:000260134200007	18929284				2020-06-30	J	Karacalar, S; Ture, H; Sanhasan, B				Karacalar, Serap; Tuere, Hatice; Sanhasan, Binnur			Unilateral spinal anesthesia in two centenarian patients	JOURNAL OF CLINICAL ANESTHESIA			English	Article						Anesthesia; Spinal; Unilateral; Bupivacaine; Centenarian patients; Fentanyl; Geriatrics	INTRATHECAL MORPHINE; BUPIVACAINE; SURGERY; RATES	The use of unilateral spinal block with a specific hyperbaric mixture of bupivacaine and fentanyl in two centenarian women is presented. This technique was very effective in restricting sympathetic block, and it provided satisfactory analgesia and hemodynamic stability. (C) 2008 Elsevier Inc. All rights reserved.	[Karacalar, Serap; Tuere, Hatice; Sanhasan, Binnur] Ondokuz Mayis Univ, Dept Anaesthesiol, Sch Med, TR-55139 Samsun, Turkey	Karacalar, S (reprint author), Ondokuz Mayis Univ, Anestezi & Reanimasyon AD, TR-55139 Kurupelit, Samsun, Turkey.	skaracalar@yahoo.com					Casati A, 1998, CAN J ANAESTH, V45, P850, DOI 10.1007/BF03012218; Casati A, 1999, REGION ANESTH PAIN M, V24, P214, DOI 10.1016/S1098-7339(99)90130-X; Casati A, 2001, Minerva Anestesiol, V67, P855; Casati A, 2003, EUR J ANAESTH, V20, P640, DOI 10.1097/00003643-200308000-00009; COVERT CR, 1989, CAN J ANAESTH, V36, P311, DOI 10.1007/BF03010771; Donati A, 2005, Minerva Anestesiol, V71, P75; FavarelGarrigues JF, 1996, ANESTH ANALG, V82, P312, DOI 10.1097/00000539-199602000-00017; Gouma DJ, 2000, ANN SURG, V232, P786, DOI 10.1097/00000658-200012000-00007; Kaya M, 2004, REGION ANESTH PAIN M, V29, P17, DOI 10.1016/j.rapm.2003.09.006; KLEINMAN W, 2002, LANGES CLIN ANESTHES, P253; KUSINIEMI KS, 1997, REG ANESTH PAIN MED, V22, P534; MAVES TJ, 1992, ANESTHESIOLOGY, V76, P91, DOI 10.1097/00000542-199201000-00014; NAGLE CJ, 1991, ANAESTHESIA, V46, P599, DOI 10.1111/j.1365-2044.1991.tb09690.x; Sen Selda, 2007, J Clin Monit Comput, V21, P103, DOI 10.1007/s10877-006-9062-8; TEJWANI GA, 1992, ANESTH ANALG, V74, P726; Vemuri C, 2004, J SURG RES, V118, P26, DOI 10.1016/j.jss.2004.02.007; WANG C, 1993, ANESTHESIOLOGY, V79, P766, DOI 10.1097/00000542-199310000-00019	17	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	SEP	2008	20	6					452	454		10.1016/j.jclinane.2008.04.011			3	Anesthesiology	Anesthesiology	361NK	WOS:000260134200010	18929287				2020-06-30	J	Pinna, MAC; Vargas, RM; Moralo, MJR; Correas, MAS				Cuervo Pinna, Miguel Angel; Mota Vargas, Rafael; Redondo Moralo, Maria Jose; Sanchez Correas, Miguel Angel			Pharmacologic intervention for cancer-related dyspnea	JOURNAL OF CLINICAL ONCOLOGY			English	Letter							CHLORPROMAZINE		[Cuervo Pinna, Miguel Angel; Mota Vargas, Rafael; Redondo Moralo, Maria Jose; Sanchez Correas, Miguel Angel] Palliat Care Team Badajoz, Reg Palliat Care Program Extremadura, Badajoz, Spain	Pinna, MAC (reprint author), Palliat Care Team Badajoz, Reg Palliat Care Program Extremadura, Badajoz, Spain.						Allard P, 1999, J PAIN SYMPTOM MANAG, V17, P256, DOI 10.1016/S0885-3924(98)00157-2; Ben-Aharon I, 2008, J CLIN ONCOL, V26, P2396, DOI 10.1200/JCO.2007.15.5796; MAN GCW, 1986, CHEST, V90, P832, DOI 10.1378/chest.90.6.832; MCIVER B, 1994, J PAIN SYMPTOM MANAG, V9, P341, DOI 10.1016/0885-3924(94)90193-7; Navigante AH, 2006, J PAIN SYMPTOM MANAG, V31, P38, DOI 10.1016/j.jpainsymman.2005.06.009; ONEILL PA, 1985, BRIT J CLIN PHARMACO, V19, P793, DOI 10.1111/j.1365-2125.1985.tb02716.x; Pinna MAC, 2008, MED PALIATIVA, V15, P143	7	3	3	0	1	AMER SOC CLINICAL ONCOLOGY	ALEXANDRIA	2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA	0732-183X			J CLIN ONCOL	J. Clin. Oncol.	SEP 1	2008	26	25					4225	4225		10.1200/JCO.2008.18.3566			1	Oncology	Oncology	350KB	WOS:000259350200032	18757344				2020-06-30	J	Gurbet, A; Turker, G; Girgin, NK; Aksu, H; Bahtiyar, NH				Gurbet, A.; Turker, G.; Girgin, N. K.; Aksu, H.; Bahtiyar, N. H.			Combination of Ultra-low Dose Bupivacaine and Fentanyl for Spinal Anaesthesia in Out-patient Anorectal Surgery	JOURNAL OF INTERNATIONAL MEDICAL RESEARCH			English	Article						ANORECTAL SURGERY; INTRATHECAL; BUPIVACAINE; FENTANYL; ULTRA-LOW DOSE	INTRATHECAL FENTANYL; SUBARACHNOID FENTANYL; PROLONGING RECOVERY; CESAREAN DELIVERY; LIDOCAINE; MORPHINE; BLOCK	This study investigated whether the addition of 25 mu g fentanyl to an ultra-low (sub-an aesthetic) dose of intrathecal bupivacaine provides adequate anaesthesia for out-patient anorectal surgery, without increasing side-effects or delaying hospital discharge. Patients were randomly allocated to receive 2.5 mg 0.5% bupivacaine plus 25 mu g fentanyl (group BF, n = 18) or 5 mg 0.5% bupivacaine alone (group B, n = 17). There were no significant differences in intra-operative outcomes, but mean recovery and discharge times were significantly shorter in group BF. There were no between-group differences in hypotension, bradycardia or respiratory depression and post-operative complications were comparable, apart from pruritus which was significantly more frequent in group BF. Fewer patients requested analgesic medication in the early post-operative period in group BF than in group B. In conclusion, 25 mu g intrathecal fentanyl added to ultra-low dose (2.5 mg) bupivacaine provided good-quality spinal anaesthesia and reduced post-operative analgesic requirement in patients undergoing ambulatory anorectal surgery.	[Gurbet, A.; Turker, G.; Girgin, N. K.; Aksu, H.; Bahtiyar, N. H.] Uludag Univ, Dept Anaesthesiol & Reanimat, Fac Med, TR-16059 Bursa, Turkey	Gurbet, A (reprint author), Uludag Univ, Dept Anaesthesiol & Reanimat, Fac Med, TR-16059 Bursa, Turkey.	agurbet@uludag.edu.tr	Girgin, Nermin Kelebek/AAH-7250-2019	TURKER, YUNUS GURKAN/0000-0002-3019-581X; GURBET, ALP/0000-0002-6503-8232			AKERMAN B, 1988, ANESTH ANALG, V67, P943; BELZARENA SD, 1992, ANESTH ANALG, V74, P653; BenDavid B, 1997, ANESTH ANALG, V85, P560, DOI 10.1097/00000539-199709000-00014; Chilvers CR, 1997, ANESTH ANALG, V84, P65, DOI 10.1097/00000539-199701000-00012; Choi DH, 2000, REGION ANESTH PAIN M, V25, P240, DOI 10.1016/S1098-7339(00)90005-1; ETCHES RC, 1989, CAN J ANAESTH, V36, P165, DOI 10.1007/BF03011441; Goel S, 2003, EUR J ANAESTH, V20, P294, DOI 10.1097/00003643-200304000-00004; Gudaityte Jurate, 2004, Medicina (Kaunas), V40, P101; HUNT CO, 1989, ANESTHESIOLOGY, V71, P535, DOI 10.1097/00000542-198910000-00009; Li ST, 2000, ANESTHESIOLOGY, V93, P1225, DOI 10.1097/00000542-200011000-00015; LIU S, 1995, ANESTH ANALG, V80, P730, DOI 10.1097/00000539-199504000-00014; Lu JK, 1997, ANESTH ANALG, V85, P372, DOI 10.1097/00000539-199708000-00023; MAROOF M, 1995, CAN J ANAESTH, V42, P691, DOI 10.1007/BF03012666; MAVES TJ, 1992, ANESTHESIOLOGY, V76, P91, DOI 10.1097/00000542-199201000-00014; SINGH H, 1995, CAN J ANAESTH, V42, P987, DOI 10.1007/BF03011070; SMITH LE, 1986, SOUTHERN MED J, V79, P163, DOI 10.1097/00007611-198602000-00007; VARRASSI G, 1992, ANAESTHESIA, V47, P558, DOI 10.1111/j.1365-2044.1992.tb02323.x; WANG C, 1993, ANESTHESIOLOGY, V79, P766, DOI 10.1097/00000542-199310000-00019	18	14	16	1	6	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0300-0605	1473-2300		J INT MED RES	J. Int. Med. Res.	SEP-OCT	2008	36	5					964	970		10.1177/147323000803600512			7	Medicine, Research & Experimental; Pharmacology & Pharmacy	Research & Experimental Medicine; Pharmacology & Pharmacy	360VB	WOS:000260085000012	18831889				2020-06-30	J	Gross, DP; Bhambhani, Y; Haykowsky, MJ; Rashiq, S				Gross, Douglas P.; Bhambhani, Yagesh; Haykowsky, Mark J.; Rashiq, Saifudin			Acute opioid administration improves work-related exercise performance in patients with chronic back pain	JOURNAL OF PAIN			English	Article						narcotic analgesia; functional capacity evaluation; work-related function; lumbar spine; work ability	FUNCTIONAL-CAPACITY EVALUATION; LIFT CAPACITY; RELIABILITY; PREVALENCE; CLAIMANTS; EFFICACY; RETURN	We studied the impact of acute opioid administration on work-related exercise performance in patients with chronic back pain. A double-blinded, random-order, placebo-controlled, crossover trial was conducted. Subjects were predominately men (63%), with a mean age of 49 years. Subjects performed a continuous lifting and lowering test to voluntary fatigue at a load equivalent to 33% of their predetermined maximal lifting load twice: Once after receiving a single intravenous dose of 1 mu g/kg fentanyl (a narcotic analgesic) and once after saline placebo. Of the 30 subjects undergoing testing, 3 subjects were unable to complete testing due to medication-induced nausea. Subjects lifted on average 29.4 +/- 17.9 kg under the influence of fentanyl versus 25.6 +/- 3.1 kg with placebo (effect size = 0.23). Time to fatigue was higher in the fentanyl group (312 +/- 251.4 vs 231 +/- 199.9 seconds, effect size = 0.40), and these subjects also performed more total work (7004 +/- 5144 vs 4748 +/- 3147 J, effect size = 0.72). Opioid analgesia improves lifting performance in the short term in individuals with chronic back pain. Longer trials of the effectiveness of opioid analgesia as an adjunct to functional restoration programs are recommended. Perspective: This article presents the results of a clinical trial showing that acute opioid administration improves work-related exercise performance in individuals with chronic back pain. Longer trials of the effectiveness of opioid analgesia as an adjunct to functional restoration programs are recommended. (C) 2008 by the American Pain Society.	[Gross, Douglas P.; Haykowsky, Mark J.] Univ Alberta, Dept Phys Therapy, Edmonton, AB T6G 2G4, Canada; [Bhambhani, Yagesh] Univ Alberta, Dept Occupat Therapy, Edmonton, AB T6G 2G4, Canada; [Rashiq, Saifudin] Univ Alberta, Dept Anesthesiol & Pain Med, Edmonton, AB T6G 2G4, Canada	Gross, DP (reprint author), Univ Alberta, Dept Phys Therapy, 2-50 Corbett Hall, Edmonton, AB T6G 2G4, Canada.	dgross@ualberta.ca	Gross, Douglas P./AAF-6997-2020	Gross, Douglas P./0000-0002-2427-6277	University of AlbertaUniversity of Alberta	Supported by the University of Alberta	Airaksinen O, 2006, EUR SPINE J, V15, pS192, DOI 10.1007/s00586-006-1072-1; Alpert J, 1991, J Occup Rehabil, V1, P13, DOI 10.1007/BF01073277; BIERINGSORENSEN F, 1984, SPINE, V9, P106, DOI 10.1097/00007632-198403000-00002; Collins JJ, 2005, J OCCUP ENVIRON MED, V47, P547, DOI 10.1097/01.jom.0000166864.58664.29; Deshpande A, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004959.pub3; FINCH E, 2002, PHYS REHABILITATION; Gross DP, 2006, J OCCUP REHABIL, V16, P53, DOI 10.1007/s10926-005-9008-x; Gross DP, 2005, PHYS THER, V85, P315, DOI 10.1093/ptj/85.4.315; Gross DP, 2004, SPINE, V29, P914, DOI 10.1097/00007632-200404150-00019; Gross DP, 2004, J OCCUP REHABIL, V14, P165, DOI 10.1023/B:JOOR.0000022759.30446.4f; Gross DP, 2003, J OCCUP REHABIL, V13, P287, DOI 10.1023/A:1026276822721; Guzman J, 2002, COCHRANE DB SYST REV, V1, P1, DOI DOI 10.1002/14651858.CD000963; Hodselmans AP, 2007, J REHABIL MED, V39, P133, DOI 10.2340/16501977-0014; Kalso E, 2005, CURR MED RES OPIN, V21, P1819, DOI 10.1185/030079905X65303; Kalso E, 2004, PAIN, V112, P372, DOI 10.1016/j.pain.2004.09.019; Kell RT, 2006, SPINE, V31, P2630, DOI 10.1097/01.brs.0000240647.57959.72; Kell RT, 2003, EUR J APPL PHYSIOL, V90, P1, DOI 10.1007/s00421-002-0776-0; Lauridsen HH, 2006, BMC MUSCULOSKEL DIS, V7, DOI 10.1186/1471-2474-7-82; Lechner D, 1991, WORK, V1, P37; Martell BA, 2007, ANN INTERN MED, V146, P116, DOI 10.7326/0003-4819-146-2-200701160-00006; MATHESON LN, 1995, SPINE, V20, P2119, DOI 10.1097/00007632-199510000-00010; Matheson LN, 2002, PHYS THER, V82, P249, DOI 10.1093/ptj/82.3.249; MAYER TG, 1988, SPINE, V13, P998, DOI 10.1097/00007632-198809000-00006; Moore RA, 2005, ARTHRITIS RES THER, V7, pR1046, DOI 10.1186/ar1782; Rashiq S, 2003, PAIN, V106, P119, DOI 10.1016/S0304-3959(03)00299-9; Reneman MF, 2007, J OCCUP REHABIL, V17, P247, DOI 10.1007/s10926-007-9078-z; Schonstein E, 2003, SPINE, V28, pE391, DOI 10.1097/01.BRS.0000092482.76386.97; SIMMONDS MJ, 2001, J PAIN S1, V2, P12; Stewart WF, 2003, JAMA-J AM MED ASSOC, V290, P2443, DOI 10.1001/jama.290.18.2443; THOMAS S, 1992, CAN J SPORT SCI, V17, P338; TROUP JDG, 1987, SPINE, V12, P645, DOI 10.1097/00007632-198709000-00003; *US DEP HHS, 1981, PUBL US DEP HLTH HUM; van Tulder MW, 2006, EUR SPINE J, V15, pS64, DOI 10.1007/s00586-005-1048-6	33	11	11	0	4	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	1526-5900			J PAIN	J. Pain	SEP	2008	9	9					856	862		10.1016/j.jpain.2008.04.006			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	347WN	WOS:000259172200011	18562250				2020-06-30	J	Kress, HG; Von der Laage, D; Hoerauf, KH; Nolte, T; Heiskanen, T; Peterson, R; Lundorff, L; Sabatowski, R; Krenn, H; Rosland, JH; Saedder, EA; Jensen, NH				Kress, Hans G.; Von der Laage, Dorothea; Hoerauf, Klaus H.; Nolte, Thomas; Heiskanen, Tarja; Peterson, Rasmus; Lundorff, Lena; Sabatowski, Rainer; Krenn, Herbert; Rosland, Jan H.; Saedder, Eva A.; Jensen, Niels-Henrik			A randomized, open, parallel group, multicenter trial to investigate analgesic efficacy and safety of a new transdermal fentanyl patch compared to standard opioid treatment in cancer pain	JOURNAL OF PAIN AND SYMPTOM MANAGEMENT			English	Article						transdermal fentanyl; noninferiority; opioid treatment; quality of life; safety; matrix technology	RELEASE ORAL MORPHINE; QUALITY-OF-LIFE; TTS-FENTANYL; NAIVE PATIENTS; DELIVERY SYSTEMS; MANAGEMENT; TERM; GUIDELINES; PREFERENCE; INTENSITY	A new 72-hour transdermal fentanyl matrix patch has been designed, which has a 35%-50% reduction of the absolute fentanyl content compared with other currently available transdermal fentanyl patches that are using the matrix technology. The new patch has previously been shown to be pharmacokinetically bioequivalent to the marked fentanyl patch. To determine noninferiority in efficacy in cancer patients and to compare safety, a clinical trial comparing the new fentanyl patch with standard oral or transdermal opioid treatment was planned. The design was an open, parallel group, multicenter trial, in which 220 patients were randomized to receive either the fentanyl patch or standard opioid treatment for 30 days. The primary efficacy variable, pain intensity (PI) on a 0-10-point numerical rating scale, was recorded once daily. The primary endpoint was the relative area under the curve of PI expressed as a percentage of the maximum possible PI area under the curve. Any adverse events were recorded; four tolerability endpoints, constipation, nausea, daytime drowsiness, and sleeping disturbances, were assessed daily. Noninferiority was shown; the upper 95% confidence interval limits os the mean difference in relative PI area under the curve between the fentanyl patch and standard opioid treatment were less than 10% for both the intention-to-treat and per-protocol populations. Scores for the tolerability endpoints were similar in the treatment groups. The new fentanyl matrix patch with a lower drug load was found noninferior and as safe as established standard oral and transdermal opioid treatment.	[Saedder, Eva A.] Nycomed Grp, DK-4000 Roskilde, Denmark; [Kress, Hans G.] Med Univ AKH, Dept Anesthesiol B, Vienna, Austria; [Hoerauf, Klaus H.] Med Univ AKH, Dept Anesthesiol A, Vienna, Austria; [Von der Laage, Dorothea] Univ Hosp Aachen, Dept Anaesthesiol, Aachen, Germany; [Nolte, Thomas] Schmerz & Pallialivzent Wiesbaden, Wiesbaden, Germany; [Nolte, Thomas] Univ Helsinki, Cent Hosp, Helsinki, Finland; [Peterson, Rasmus] Esbjerg Cent Hosp, Pain Clin Palliat Team, Esbjerg, Denmark; [Lundorff, Lena] Herning Hosp, Palliat Team, Herning, Denmark; [Peterson, Rasmus] Univ Cologne, Dept Anaesthesiol & Postoperat Intens Care, Cologne, Germany; [Krenn, Herbert] Hosp Hietzing, Interdisciplinary Pain Clin, Vienna, Austria; [Rosland, Jan H.] Haraldsplass Diaconate Hosp, Sunniva Hosp, Bergen, Norway; [Jensen, Niels-Henrik] Herlev Univ Hosp, Ctr Multidisciplinary Pain, DK-2730 Herlev, Denmark	Saedder, EA (reprint author), Nycomed Grp, Langebjerg1,POB 88, DK-4000 Roskilde, Denmark.	saedder@mail.dk	Saedder, Eva Aggerholm/AAI-8590-2020; Sabatowski, Rainer/K-3475-2019	Sabatowski, Rainer/0000-0003-2228-3147; Saedder, Eva/0000-0003-4905-1004	Nycomed Group, Roskilde, Denmark	The work was supported by the Nycomed Group, Roskilde, Denmark.	AHMEDZAI S, 1994, J DRUG DEV, V6, P93; Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; Allan L, 2005, SPINE, V30, P2484, DOI 10.1097/01.brs.0000186860.23078.a8; Allan L, 2001, BRIT MED J, V322, P1154, DOI 10.1136/bmj.322.7295.1154; Baik SW, 2003, J KOREAN MED SCI, V18, P733, DOI 10.3346/jkms.2003.18.5.733; BERNER B, 1994, CLIN PHARMACOKINET, V26, P121, DOI 10.2165/00003088-199426020-00005; Breitbart W, 2000, ONCOLOGY-NY, V14, P695; *COMM MED PROD HUM, 2000, CPMPICH36496 COMM ME; *COMM MED PROD HUM, 2002, CPMPEWP61200 COMM ME; Dellemijn PLI, 1998, J PAIN SYMPTOM MANAG, V16, P220, DOI 10.1016/S0885-3924(98)00070-0; Donner B, 1996, PAIN, V64, P527, DOI 10.1016/0304-3959(95)00180-8; Donner B, 1998, J PAIN SYMPTOM MANAG, V15, P168, DOI 10.1016/S0885-3924(97)00361-8; DOWNIE WW, 1978, ANN RHEUM DIS, V37, P378, DOI 10.1136/ard.37.4.378; Elsner F, 1999, SCHMERZ, V13, P273, DOI 10.1007/s004820050210; Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9; Freynhagen R, 2005, J PAIN SYMPTOM MANAG, V30, P289, DOI 10.1016/j.jpainsymman.2005.03.015; Genf World Health Organization, 1986, CANC PAIN REL; GROND S, 1991, J PAIN SYMPTOM MANAG, V6, P411, DOI 10.1016/0885-3924(91)90039-7; GUPTA SK, 1992, J PAIN SYMPTOM MANAG, V7, pS17, DOI 10.1016/0885-3924(92)90049-N; Heiskanen T, 1997, PAIN, V73, P37, DOI 10.1016/S0304-3959(97)00072-9; Jeal W, 1997, DRUGS, V53, P109, DOI 10.2165/00003495-199753010-00011; JENSEN MP, 1986, PAIN, V27, P117, DOI 10.1016/0304-3959(86)90228-9; KARNOFSKY DA, 1948, CANCER-AM CANCER SOC, V1, P634, DOI 10.1002/1097-0142(194811)1:4<634::AID-CNCR2820010410>3.0.CO;2-L; Kato K, 2004, YAKUGAKU ZASSHI, V124, P287, DOI 10.1248/yakushi.124.287; Korte W, 1996, J PAIN SYMPTOM MANAG, V11, P139, DOI 10.1016/0885-3924(95)00162-X; KREMER E, 1981, PAIN, V10, P241, DOI 10.1016/0304-3959(81)90199-8; MARIER JF, 2006, J CLIN PHARMACOL, V46, P1; Mystakidou K, 2004, CANCER NURS, V27, P127, DOI 10.1097/00002820-200403000-00005; Mystakidou K, 2004, J PAIN, V5, P119, DOI 10.1016/j.jpain.2003.12.003; Mystakidou K, 2003, INT J CANCER, V107, P486, DOI 10.1002/ijc.11416; Mystakidou K, 2002, ONCOLOGY-BASEL, V62, P9, DOI 10.1159/000048241; Payne R, 1998, J CLIN ONCOL, V16, P1588, DOI 10.1200/JCO.1998.16.4.1588; Radbruch L, 2000, PALLIATIVE MED, V14, P111, DOI 10.1191/026921600671594561; Radbruch L, 2001, PALLIATIVE MED, V15, P309, DOI 10.1191/026921601678320296; RANADE VV, 1991, J CLIN PHARMACOL, V31, P401, DOI 10.1002/j.1552-4604.1991.tb01895.x; Skaer TL, 2004, DRUGS, V64, P2629, DOI 10.2165/00003495-200464230-00002; Tawfik MO, 2004, CURR MED RES OPIN, V20, P259, DOI 10.1185/030079903125003026; *US DRUG ADM, AL HEALTHC PROF FENT; *US FDA, SAF AL DRUGS BIOL ME; van Seventer R, 2003, CURR MED RES OPIN, V19, P457, DOI 10.1185/030079903125002045; VENTAFRIDDA V, 1990, P451; Vielvoye-Kerkmeer APE, 2000, J PAIN SYMPTOM MANAG, V19, P185, DOI 10.1016/S0885-3924(99)00152-9; WEINGART WA, 1985, CLIN PHARMACY, V4, P53; Wong J O, 1997, Acta Anaesthesiol Sin, V35, P25; Zhukovsky DS, 1999, J PAIN SYMPTOM MANAG, V18, P53, DOI 10.1016/S0885-3924(99)00024-X	45	32	35	1	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0885-3924			J PAIN SYMPTOM MANAG	J. Pain Symptom Manage.	SEP	2008	36	3					268	279		10.1016/j.jpainsymman.2007.10.023			12	Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology	Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology	348LD	WOS:000259211100006	18538974	Bronze			2020-06-30	J	Hashimoto, M; Johkura, K; Ichikawa, T; Kojima, A; Nishimura, S; Shinonaga, M				Hashimoto, Mizuki; Johkura, Ken; Ichikawa, Teruo; Kojima, Akio; Nishimura, Satoshi; Shinonaga, Masamichi			Conservative treatment of ruptured vertebrobasilar dissecting aneurysm	NEUROLOGICAL SCIENCES			English	Article						dissecting aneurysm; vertebrobasilar artery; subarachnoid hemorrhage; fentanyl; conservative treatment	VERTEBRAL ARTERY DISSECTION; SUBARACHNOID HEMORRHAGE; MANAGEMENT; FENTANYL	Ruptured vertebrobasilar dissecting aneurysm is usually treated surgically because rebleeding negatively affects outcome. However, the risk of rebleeding decreases markedly once several hours have passed from the initial bleeding. Moreover, surgery-related complications are not rare. We describe seven patients with ruptured vertebrobasilar dissecting aneurysm. To prevent rebleeding during the acute stage, we treated all seven patients conservatively with fentanyl instead of emergency surgery. During the follow-up period (mean 20 months), no patient suffered rebleeding. Conservative treatment with fentanyl administration may be a good option for management of ruptured vertebrobasilar dissecting aneurysm during the acute stage.	[Johkura, Ken] Hiratsuka Kyosai Hosp, Dept Neurol, Hiratsuka, Kanagawa 2548502, Japan; [Johkura, Ken] Hiratsuka Kyosai Hosp, Stroke Ctr, Hiratsuka, Kanagawa 2548502, Japan; [Hashimoto, Mizuki; Ichikawa, Teruo; Kojima, Akio; Nishimura, Satoshi; Shinonaga, Masamichi] Hiratsuka Kyosai Hosp, Dept Neurosurg, Hiratsuka, Kanagawa 2548502, Japan	Johkura, K (reprint author), Hiratsuka Kyosai Hosp, Dept Neurol, 9-11 Oiwake, Hiratsuka, Kanagawa 2548502, Japan.	johkura-k@kkr.hiratsuka.kanagawa.jp					Anxionnat R, 2003, NEUROSURGERY, V53, P289, DOI 10.1227/01.NEU.0000073417.01297.93; AOKI N, 1990, STROKE, V21, P1628, DOI 10.1161/01.STR.21.11.1628; Hunt W E, 1974, Clin Neurosurg, V21, P79; Iihara K, 2002, J NEUROSURG, V97, P259, DOI 10.3171/jns.2002.97.2.0259; KITANAKA C, 1994, J NEUROSURG, V80, P667, DOI 10.3171/jns.1994.80.4.0667; Mizutani T, 2004, NEUROSURGERY, V54, P342, DOI 10.1227/01.NEU.0000103449.80484.7E; MIZUTANI T, 1995, NEUROSURGERY, V36, P905, DOI 10.1227/00006123-199505000-00003; ONO J, 2002, JPN J NEUROSURG, V11, P265; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; POKLIS A, 1995, J TOXICOL-CLIN TOXIC, V33, P439, DOI 10.3109/15563659509013752; POZZATI E, 1991, J NEUROSURG, V75, P69, DOI 10.3171/jns.1991.75.1.0069; Sugiu K, 2005, NEURORADIOLOGY, V47, P158, DOI 10.1007/s00234-005-1341-4; WILLENS JS, 1993, HEART LUNG, V22, P239; Yamada M, 2004, J NEUROSURG, V101, P25, DOI 10.3171/jns.2004.101.1.0025; Yamaura A, 1988, SURG CEREB STROKE, V26, P87; Zhao WY, 2007, ACTA NEUROCHIR, V149, P585, DOI 10.1007/s00701-007-1161-x	16	10	14	0	1	SPRINGER-VERLAG ITALIA SRL	MILAN	VIA DECEMBRIO, 28, MILAN, 20137, ITALY	1590-1874	1590-3478		NEUROL SCI	Neurol. Sci.	SEP	2008	29	4					241	244		10.1007/s10072-008-0974-6			4	Clinical Neurology; Neurosciences	Neurosciences & Neurology	351CX	WOS:000259403200008	18810598				2020-06-30	J	Kaye, AD; Hoover, JM; Kaye, AJ; Ibrahim, IN; Fox, C; Bajwa, A; Anwar, M; Fields, AM; Baluch, A; Huffman, S; Chilian, W				Kaye, A. D.; Hoover, J. M.; Kaye, A. J.; Ibrahim, I. N.; Fox, C.; Bajwa, A.; Anwar, M.; Fields, A. M.; Baluch, A.; Huffman, S.; Chilian, W.			Morphine, opioids, and the feline pulmonary vascular bed	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						lung; opioid receptor; vasodepressor; morphine; fentanyl; sufentanil; remifentanil; meperidine; histamine receptor	REMIFENTANIL; FENTANYL; CAT	Background: Opioid-induced vasodepressor responses have been reported in a variety of species and laboratory models. The aim of this study was to ascertain the relative potencies of different clinically relevant opioids compared with traditional vasodepressor agents in the feline pulmonary vascular bed. A second aim was to study the effects of morphine and to identify the receptors involved in the mediation or the modulation of these effects. Methods: This was a prospective vehicle-controlled study involving an intact chest preparation of adult mongrel cats. The effects of various opioids, morphine, fentanyl, remifentanil, sufentanil, and meperidine were compared with other vasodepressor agents. Additionally, the effects of L-N(5)-(1-iminoethyl) ornithine hydrochloride (L-NIO) (nitric oxide synthase inhibitor), nimesulide [selective cyclooxygenase (COX)-2 inhibitor], glibenclamide (ATP-sensitive K 1 channel blocker), naloxone (non-selective opioid receptor antagonist), and diphenhydramine (histamine H(1)-receptor antagonist) were investigated on pulmonary arterial responses to morphine and other selected agonists in the feline pulmonary vascular bed. The systemic pressure and lobar arterial perfusion pressure were continuously monitored, electronically averaged, and recorded. Results: In the cat pulmonary vascular bed of the isolated left lower lobe, morphine, remifentanil, fentanyl, sufentanil, and meperidine induced a dose-dependent moderate vasodepressor response and it appeared that sufentanil was the most potent on a nanomolar basis. The effects of morphine were not significantly altered after administration of L-NIO, nimesulide, and glibenclamide. However, the vascular responses to morphine were significantly attenuated following administration of naloxone and diphenhydramine. Conclusion: The results of the present study suggest that sufentanil appears to have slightly more potency and morphine the least of the five opioid agonists studied on a nanomolar basis. Morphine-induced vasodilatory responses appeared to be mediated or modulated by both opioid receptor and histamine-receptor-sensitive pathways.	[Kaye, A. D.; Kaye, A. J.; Ibrahim, I. N.; Bajwa, A.; Fields, A. M.; Huffman, S.] Louisiana State Univ, Sch Med, Dept Anesthesiol, New Orleans, LA 70112 USA; [Kaye, A. D.] Louisiana State Univ, Sch Med, Dept Pharmacol, New Orleans, LA 70112 USA; [Hoover, J. M.] Mayo Clin, Dept Neurosurg, Rochester, MN USA; [Fox, C.] Tulane Univ Med Ctr Hosp & Clin, Dept Anesthesiol, New Orleans, LA USA; [Anwar, M.] Yale Univ, Dept Anesthesiol, New Haven, CT USA; [Baluch, A.] NE Ohio Univ, Dept Physiol & Pharmacol, Rootstown, OH USA; [Chilian, W.] Univ Miami, Dept Anesthesiol, Miami, FL USA	Kaye, AJ (reprint author), Louisiana State Univ, Sch Med, Dept Anesthesiol, 2020 Gravier St,Suite 775, New Orleans, LA 70112 USA.	akaye@lsuhsc.edu					Brill S, 2003, EUR J ANAESTH, V20, P682, DOI 10.1097/00003643-200309000-00002; FIORAMONTI J, 2002, GUT               S1, V51, P91; Goodsell DS, 2004, ONCOLOGIST, V9, P717, DOI 10.1634/theoncologist.9-6-717; Inan S, 2004, EUR J PHARMACOL, V486, P61, DOI 10.1016/j.ejphar.2003.12.010; Kaye AD, 2006, ANESTH ANALG, V102, P118, DOI 10.1213/01.ane.0000184826.02943.70; KAYE AD, 2001, EUR J PHARMACOL, V534, P159; Kaye Alan D, 2006, Am J Ther, V13, P478, DOI 10.1097/01.mjt.0000178338.43545.3a; Kaye AD, 2006, J CARDIOTHOR VASC AN, V20, P691, DOI 10.1053/j.jvca.2005.10.003; REISINE T, 2001, GOODMAN GILMANS PHAR, P357; ROSOW CE, 1982, ANESTHESIOLOGY, V56, P93, DOI 10.1097/00000542-198202000-00003; Sahin N., 2002, Autonomic & Autacoid Pharmacology, V22, P103, DOI 10.1046/j.1474-8673.2002.00249.x; Snedecar GW, 1967, STATISTICAL METHODS, P258; TANOBE K, 2003, MASUI, V8, P840; Tuncer S, 2003, PAIN CLINIC, V15, P321, DOI 10.1163/156856903767650862; Waldhoer M, 2004, ANNU REV BIOCHEM, V73, P953, DOI 10.1146/annurev.biochem.73.011303.073940; Wood JD, 2004, NEUROGASTROENT MOTIL, V16, P17, DOI 10.1111/j.1743-3150.2004.00554.x	16	8	8	0	6	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0001-5172			ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	AUG	2008	52	7					931	937		10.1111/j.1399-6576.2008.01595.x			7	Anesthesiology	Anesthesiology	323VB	WOS:000257475400009	18477088				2020-06-30	J	Dey, M; Madill, SA; Pagano, D; Matthews, TD				Dey, M.; Madill, S. A.; Pagano, D.; Matthews, T. D.			Transient visual loss secondary to retinitis pigmentosa and opioid-induced miosis	ANAESTHESIA			English	Letter									[Dey, M.] Birmingham & Midland Eye Ctr, Birmingham, W Midlands, England; Queen Elizabeth Hosp, Birmingham, W Midlands, England; Princess Alexandra Eye Pavil, Edinburgh, Midlothian, Scotland	Dey, M (reprint author), Birmingham & Midland Eye Ctr, Birmingham, W Midlands, England.	moloydey2003@yahoo.com	PAGANO, DUILIO/K-6287-2014	PAGANO, DUILIO/0000-0003-3987-9262			GOTTLOB KP, 1987, ADV OPHTHALMOL, V67, P335; *J CIL PTY LTD, [No title captured]; Williams EL, 2002, ANESTHESIOL CLIN N A, V20, P605	3	0	0	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0003-2409	1365-2044		ANAESTHESIA	Anaesthesia	AUG	2008	63	8					888	888		10.1111/j.1365-2044.2008.05618.x			1	Anesthesiology	Anesthesiology	323VE	WOS:000257475700023	18699908				2020-06-30	J	Domino, EF				Domino, Edward F.			Dr. Paul: Views through the piperidine ring	ANESTHESIA AND ANALGESIA			English	Letter									Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA	Domino, EF (reprint author), Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA.	efdabcde@umuich.edu					Stanley TH, 2008, ANESTH ANALG, V106, P451, DOI 10.1213/ane.0b013e3181605add	1	1	1	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	AUG	2008	107	2					723	724		10.1213/ane.0b013e31817c737d			2	Anesthesiology	Anesthesiology	333QV	WOS:000258168300055	18633058				2020-06-30	J	Budnyk, SA				Budnyk, Samuel A.			Judgment and risk to patient in study design	ANESTHESIA AND ANALGESIA			English	Letter									Destin Surg Ctr, Dept Anesthesiol, Destin, FL USA	Budnyk, SA (reprint author), Destin Surg Ctr, Dept Anesthesiol, Destin, FL USA.	sbudnyk949@aol.com					Mandel JE, 2008, ANESTH ANALG, V106, P434, DOI 10.1213/01.ane.0000297300.33441.32; MOLLER JT, 1991, BRIT J ANAESTH, V66, P437, DOI 10.1093/bja/66.4.437; SEVERINGHAUS JW, 1989, J CLIN MONITOR, V5, P72, DOI 10.1007/BF01617877	3	1	1	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	AUG	2008	107	2					724	725		10.1213/ane.0b013e31817c7393			2	Anesthesiology	Anesthesiology	333QV	WOS:000258168300057	18633059				2020-06-30	J	Rang, ST; Field, J; Irving, C				Rang, Simon T.; Field, Jennifer; Irving, Cohn			Scrotonin toxicity caused by an interaction between fentanyl and paroxetine	CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Article							MONOAMINE-OXIDASE INHIBITORS; SEROTONIN SYNDROME; ANALGESICS; SURGERY; PATIENT	Purpose: To report a case of serotonin toxicity, presenting in the postoperative period, caused by an interaction between paroxetine (a selective serotonin reuptake inhibitor, SSRI) and fentanyl (a phenylpiperidine opioid). Serotonin toxicity precipitated by fentanyl is unusual and has not previously been described in combination with SSRIs in the perioperative setting. Clinical features: A 60-yr-old woman, established on paroxetine for depression, underwent excision of a chest wall myxofibrosarcoma and chest wall reconstruction. Fentanyl was administered for intraoperative and postoperative analgesia (I mg intraoperatively, and 2.5 mg by infusion in the first 36 hr, postoperatively). She developed a vague affectation, intermittent agitation, bilateral hyper-reflexia, inducible clonus, and a period of hypertension, suggestive of serotonin toxicity. There was complete resolution after cessation of fentanyl and paroxetine. Conclusion: The co-administration of SSRIs and fentanyl may precipitate serotonin toxicity. There must be consideration of this unusual interaction when administering fentanyl to patients established on SSRIs. Physicians should be vigilant of the features of serotonin toxicity developing in such patients.	[Rang, Simon T.] Royal Marsden Hosp, Dept Anaesthesia, London SW3 6JJ, England	Rang, ST (reprint author), Royal Marsden Hosp, Dept Anaesthesia, Fulham Rd, London SW3 6JJ, England.	simonrang@gmail.com					Ailawadhi S, 2007, J CLIN PHARM THER, V32, P199, DOI 10.1111/j.1365-2710.2007.00813.x; BODNER RA, 1995, NEUROLOGY, V45, P219, DOI 10.1212/WNL.45.2.219; Bpharm SR, 2003, CAN J ANAESTH, V50, P32, DOI 10.1007/BF03020183; CODD EE, 1995, J PHARMACOL EXP THER, V274, P1263; Dunkley EJC, 2003, QJM-INT J MED, V96, P635, DOI 10.1093/qjmed/hcg109; ELGANZOURI AR, 1985, ANESTH ANALG, V64, P592; Fraser J, 1999, INTENS CARE MED, V25, P548; GILLMAN P, PSYCHO TROPICAL RES; Gillman PK, 1999, J PSYCHOPHARMACOL, V13, P100, DOI 10.1177/026988119901300111; Gillman PK, 2005, BRIT J ANAESTH, V95, P434, DOI 10.1093/bja/aei210; Graudins A, 1998, J Emerg Med, V16, P615, DOI 10.1016/S0736-4679(98)00057-2; Hegerl U, 1998, EUR ARCH PSY CLIN N, V248, P96, DOI 10.1007/s004060050024; INSLER SR, 1994, ANESTH ANALG, V78, P593; Lane R, 1997, J CLIN PSYCHOPHARM, V17, P208, DOI 10.1097/00004714-199706000-00012; Nisijima K, 2003, NEUROCHEM INT, V43, P155, DOI 10.1016/S0197-0186(02)00213-9; NOBLE WH, 1992, CAN J ANAESTH, V39, P1061, DOI 10.1007/BF03008376; STAHL SM, 2000, [No title captured]; STERNBACH H, 1991, AM J PSYCHIAT, V148, P705	18	27	27	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0832-610X			CAN J ANAESTH	Can. J. Anaesth.-J. Can. Anesth.	AUG	2008	55	8					521	525		10.1007/BF03016672			5	Anesthesiology	Anesthesiology	338FK	WOS:000258491400006	18676387	Bronze			2020-06-30	J	Uzumcugil, F; Canbay, O; Celebi, N; Karagoz, AH; Ozgen, S				Uzuemcuegil, F.; Canbay, O.; Celebi, N.; Karagoz, A. H.; Ozgen, S.			Comparison of dexmedetomidine-propofol vs. fentanyl-propofol for laryngeal mask insertion	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article						dexmedetomidine; laryngeal masks; propofol; fentanyl; cardiovascular responses	AIRWAY INSERTION; TRACHEAL INTUBATION; REQUIREMENT; SEVOFLURANE; ISOFLURANE; ANESTHESIA	Background and objectives: There have been many studies to find the optimum anaesthetics to provide excellent conditions for laryngeal mask insertion. We compared the effects of dexmedetomidine administered before propofol, on laryngeal mask insertion with fentanyl combined with propofol. Methods: In all, 52 patients, ASA I-II, scheduled to have minor urological procedures were randomized into two groups. Group F received 1 mu g kg(-1) fentanyl (in 10 mL normal saline) and Group D received 1 mu g kg(-1) dexmedetomidine (in 10 mL normal saline). We used 1.5 mg kg(-1) propofol for induction and 5096 N2O and 1.5% sevoflurane in oxygen for maintenance. We observed jaw mobility (1: fully relaxed; 2: mild resistance; 3: tight but opens; 4: closed), coughing or movement (1: none; 2: one or two coughs; 3: three or more coughs; 4: bucking/movement) and other events such as spontaneous ventilation, breath holding, expiratory stridor and lacrimation. In each category, scores < 2 were acceptable for laryngeal mask insertion. Results: More patients developed apnoea and their apnoea times were longer in Group F than Group D (P < 0.001). Respiratory rates increased in Group D (P < 0.001). Adverse events during laryngeal mask insertion were similar. The reductions in systolic and mean blood pressures were greater in Group F (systolic: P < 0.05, mean: P < 0.01). Emergence times were shorter in Group F than in Group D (P < 0.001). Conclusion: Dexmedetomidine, when used before propofol induction provides successful laryngeal mask insertion comparable to fentanyl, while preserving respiratory functions more than fentanyl.	[Uzuemcuegil, F.; Canbay, O.; Celebi, N.; Karagoz, A. H.; Ozgen, S.] Hacettepe Univ, Sch Med, Dept Anesthesiol & Reanimat, Ankara, Turkey	Uzumcugil, F (reprint author), Hacettepe Univ, Sch Med, Dept Anesthesiol & Reanimat, Ankara, Turkey.	filizd@hacettepe.edu.tr					Avitsian R, 2005, J NEUROSURG ANESTH, V17, P97, DOI 10.1097/01.ana.0000161268.01279.ba; BELLEVILLE JP, 1992, ANESTHESIOLOGY, V77, P1125, DOI 10.1097/00000542-199212000-00013; Driver IK, 1996, ANAESTHESIA, V51, P782, DOI 10.1111/j.1365-2044.1996.tb07897.x; Ebert TJ, 2000, ANESTHESIOLOGY, V93, P382, DOI 10.1097/00000542-200008000-00016; Gal TJ, 2005, MILLERS ANESTHESIA, P1617; Goh PK, 2005, ANAESTH INTENS CARE, V33, P223, DOI 10.1177/0310057X0503300211; Goyagi T, 2003, ACTA ANAESTH SCAND, V47, P771, DOI 10.1034/j.1399-6576.2003.00123.x; Guler G, 2005, ACTA ANAESTH SCAND, V49, P1088, DOI 10.1111/j.1399-6576.2005.00780.x; Guler G, 2005, PEDIATR ANESTH, V15, P762, DOI 10.1111/j.1460-9592.2004.01541.x; Hemmerling TM, 2004, CAN J ANAESTH, V51, P728, DOI 10.1007/BF03018434; Hsu YW, 2004, ANESTHESIOLOGY, V101, P1066, DOI 10.1097/00000542-200411000-00005; Janssens M, 1993, Intensive Care World, V10, P99; Kodaka M, 2004, BRIT J ANAESTH, V92, P238, DOI 10.1093/bja/aeh033; Lawrence CJ, 1997, ANAESTHESIA, V52, P736, DOI 10.1111/j.1365-2044.1997.169-az0303.x; Leong Wai May, 2005, J Anesth, V19, P112, DOI 10.1007/s00540-004-0300-2; Liou Cher-Ming, 2004, Acta Anaesthesiol Taiwan, V42, P209; Mahajan VA, 2007, EUR J ANAESTH, V24, P505, DOI 10.1017/S0265021506001980; Maroof M, 2005, CAN J ANAESTH, V52, P776, DOI 10.1007/BF03016576; Muzi M, 1996, ANESTHESIOLOGY, V85, P536, DOI 10.1097/00000542-199609000-00012; SCHEININ B, 1992, BRIT J ANAESTH, V68, P126, DOI 10.1093/bja/68.2.126; Siddik-Sayyid SM, 2005, ANESTH ANALG, V100, P1204, DOI 10.1213/01.ANE.0000148166.29749.3B; Suzuki Kenji S, 2002, J Anesth, V16, P97, DOI 10.1007/s005400200001; Tanaka M, 2003, BRIT J ANAESTH, V90, P14, DOI 10.1093/bja/aeg018; Taylor IN, 1998, ANAESTHESIA, V53, P222, DOI 10.1046/j.1365-2044.1998.00316.x; Turan A, 2006, EUR J ANAESTH, V23, P234, DOI 10.1017/S0265021505002243; WILKINS CJ, 1992, ANESTH ANALG, V75, P794; Yazicioglu H, 2005, ACTA ANAESTH BELG, V56, P171	27	22	28	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0265-0215	1365-2346		EUR J ANAESTH	Eur. J. Anaesth.	AUG	2008	25	8					675	680		10.1017/S0265021508004213			6	Anesthesiology	Anesthesiology	331WK	WOS:000258043100010	18400141				2020-06-30	J	Ryu, JH; Kim, JH; Park, KS; Do, SH				Ryu, Jung-Hee; Kim, Jae-Hun; Park, Kum-Suk; Do, Sang-Hwan			Remifentanil-propofol versus fentanyl-propofol for monitored anesthesia care during hysteroscopy	JOURNAL OF CLINICAL ANESTHESIA			English	Article						fentanyl; hysteroscopy; monitored anesthesia care; propofol; remifentanil	POSTOPERATIVE ANALGESIA; LOCAL-ANESTHESIA; SURGERY; ALFENTANIL; MORPHINE; NAUSEA; EFFICACY	Study Objective: To compare the efficacy of remifentanil-propofol with that of fentanyl-propofol for monitored anesthesia care during hysteroscopy. Design: Prospective, randomized study. Setting: Operating room and postanesthesia care unit of a university hospital. Patients: 30 ASA physical status I and II adult patients undergoing hysteroscopic procedures. Interventions: After propofol infusion, patients received a bolus of remifentanil (group R, 0.5 mu g/kg) or fentanyl (group F, 1 mu g/kg) 4 minutes before starting the procedure and then received a continuous infusion of remifentanil (group R, 0.05 mu g/kg per min) or bolus doses of fentanyl (group F, 0.5 mu g/kg). Measurements and Main Results: Patients in group R had lower pain scores than patients in group F (0-0 vs 0-7, P < 0.05) and more stable blood pressures (74 +/- 15 vs 85 +/- 9 mmHg, P < 0.05) one minute after the start of the procedure. However, no differences were observed in other variables (recovery profiles and satisfaction scores). Conclusion: Remifentanil seems to be a safe and effective analgesic adjunct for monitored anesthesia care of hysteroscopic surgery. (C) 2008 Elsevier Inc. All rights reserved.	[Do, Sang-Hwan] Seoul Natl Univ, Bundang Hosp, Dept Anesthesiol & Pain Med, Songnam 463707, Gyeonggi Do, South Korea; [Ryu, Jung-Hee; Kim, Jae-Hun; Park, Kum-Suk; Do, Sang-Hwan] Seoul Natl Univ, Coll Med, Dept Anesthesiol & Pain Med, Songnam 463707, Gyeonggi Do, South Korea; [Ryu, Jung-Hee; Kim, Jae-Hun; Park, Kum-Suk] Seoul Natl Univ Hosp, Dept Anesthesiol & Pain Med, Seoul 110744, South Korea	Do, SH (reprint author), Seoul Natl Univ, Bundang Hosp, Dept Anesthesiol & Pain Med, Songnam 463707, Gyeonggi Do, South Korea.	shdo@snu.ac.kr	Do, Sang Hwan/J-5461-2012; Ryu, Jung-Hee/J-5554-2012				Avramov MN, 1997, ANESTH ANALG, V85, P566, DOI 10.1097/00000539-199709000-00015; Beers RA, 2000, ANESTH ANALG, V91, P1420, DOI 10.1097/00000539-200012000-00022; BOSEK V, 1992, J CLIN ANESTH, V4, P480, DOI 10.1016/0952-8180(92)90223-N; Dilger JA, 2004, CAN J ANAESTH, V51, P20, DOI 10.1007/BF03018541; FEELEY TW, 2005, ANESTHESIA, P2708; Fletcher D, 2000, ANESTH ANALG, V90, P666, DOI 10.1097/00000539-200003000-00029; Fung D, 2005, ANESTH ANALG, V100, P1637, DOI 10.1213/01.ANE.0000154203.00434.23; Gan TJ, 1997, ANESTHESIOLOGY, V87, P779, DOI 10.1097/00000542-199710000-00010; Gesztesi Z, 2000, ANESTH ANALG, V90, P567, DOI 10.1097/00000539-200003000-00013; Glass PSA, 1999, ANESTH ANALG, V89, pS7; Gold MI, 1997, ANESTHESIOLOGY, V87, P51, DOI 10.1097/00000542-199707000-00007; Gupta JK, 2004, SURG ENDOSC, V18, P1099, DOI 10.1007/s00464-003-9144-3; Hassan L, 2005, BEST PRACT RES CL OB, V19, P681, DOI 10.1016/j.bpobgyn.2005.06.008; KAPILA A, 1995, ANESTHESIOLOGY, V83, P968, DOI 10.1097/00000542-199511000-00009; Mingus ML, 1998, J CLIN ANESTH, V10, P46, DOI 10.1016/S0952-8180(97)00220-1; Numazaki M, 2005, CAN J ANAESTH, V52, P333, DOI 10.1007/BF03016073; REGO MS, 1998, CURRENT OPINION ANES, V11, P601; RIGG JRA, 1976, CAN ANAESTH SOC J, V23, P370, DOI 10.1007/BF03005917; Rosow CE, 1999, ANESTH ANALG, V89, pS1; SERVIN F, 1999, ANESTH ANALG       S, V89, pS32; Sutton C, 2006, BEST PRACT RES CL OB, V20, P105, DOI 10.1016/j.bpobgyn.2005.10.002; Tramer M, 1997, BRIT J ANAESTH, V78, P247; Yarmush J, 1997, ANESTHESIOLOGY, V87, P235, DOI 10.1097/00000542-199708000-00009	23	13	15	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	AUG	2008	20	5					328	332		10.1016/j.jclinane.2007.12.015			5	Anesthesiology	Anesthesiology	349GH	WOS:000259268800002	18761238				2020-06-30	J	Xu, ZY; Wang, X; Si, YY; Wu, JC; Zuo, YX; Xue, FS; Liu, J				Xu, Zhi Y.; Wang, Xiao; Si, Yong Y.; Wu, Jun C.; Zuo, Yun X.; Xue, Fu S.; Liu, Jin			Intravenous remifentanil and propofol for gastroscopy	JOURNAL OF CLINICAL ANESTHESIA			English	Article						remifentanil; propofol; gastroscopy	CONTINUOUS-INFUSION; ANESTHESIA; ALFENTANIL	Study Objectives: To evaluate the efficiency and safety of intravenous (IV) remifentanil and propofol for gastroscopy in healthy adults. Design: Randomized, double-blinded study. Setting: Endoscopy Center, West China Hospital, Sichuan University (Chengdu, People's Republic of China). Patients: 199 adult ASA physical status I and II patients. Interventions: Patients were randomly allocated to either the fentanyl group (n = 99) or the remifentanil group (n = 100). Patients received either fentanyl 0.5 mu g/kg or rennifentanil 0.5 mu g/kg, followed by a bolus injection of one mg/kg of propofol. The subsequent doses of propofol were 0.5 mg/kg when the patient was conscious or body movement appeared. Measurements: Noninvasive blood pressure, heart rate, arterial pulse oxygen saturation, and respiratory rate were recorded before gastroscopy and at two-minute intervals until the end of the gastroscopy procedure. Patients were asked to evaluate their level of cognition using the Digit-Symbol Substitution Test score before gastroscopy and at 10 minutes after discontinuation of the drug injection. Main Results: Recovery time was significantly shorter in the remifentanil group than in the fentanyl group (P < 0.05). Postoperative Digit-Symbol Substitution Test scores were significantly higher in the remifentanil group than in the fentanyl group (P < 0.01). Total dosage of propofol given in the remifentanil group was significantly less than it was in the fentanyl group (P < 0.01). Frequency of apnea was significantly higher in the remifentanil group (P < 0.05). There were no significant differences in frequency of hypoxemia, bag ventilation, or body movement between the two groups (P > 0.05). Conclusions: intravenous remifentanil and propofol were more efficient for gastroscopy than IV fentanyl and propofol. (C) 2008 Elsevier Inc. All rights reserved.	[Xu, Zhi Y.; Wang, Xiao; Si, Yong Y.; Zuo, Yun X.; Liu, Jin] Sichuan Univ, W China Hosp, Dept Anesthesiol, Chengdu 610041, Peoples R China; [Wu, Jun C.] Sichuan Univ, W China Hosp, Dept Gastroenterol, Endoscopy Ctr, Chengdu 610041, Peoples R China; [Xue, Fu S.] Chinese Acad Med Sci, Plast Surg Hosp, Dept Anesthesiol, Beijing, Peoples R China; [Xue, Fu S.] Peking Union Med Coll, Beijing 100041, Peoples R China	Wang, X (reprint author), Sichuan Univ, W China Hosp, Dept Anesthesiol, Chengdu 610041, Peoples R China.	gege_0011@hotmail.com					AMIN HM, 1995, J PHARMACOL EXP THER, V274, P34; BOUVET L, 2006, ACTA ANAESTH SCAND, V50, P736; Davis PJ, 1997, ANESTH ANALG, V84, P982, DOI 10.1097/00000539-199705000-00007; Egan TD, 2004, BRIT J ANAESTH, V92, P335, DOI 10.1093/bja/aeh075; Glaisyer HR, 2005, ANESTH ANALG, V100, P959, DOI 10.1213/01.ANE.0000147667.06156.DF; Henson L C, 1994, Ann Acad Med Singapore, V23, P125; Keidan I, 2001, PAEDIATR ANAESTH, V11, P297, DOI 10.1046/j.1460-9592.2001.00662.x; Luebbe N, 1998, EUR J ANAESTH, V15, P292, DOI 10.1017/S0265021598000568; Peacock JE, 1998, BRIT J ANAESTH, V80, P509, DOI 10.1093/bja/80.4.509; Rego MMS, 1999, ANESTH ANALG, V88, P518	10	14	15	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	AUG	2008	20	5					352	355		10.1016/j.jclinane.2008.03.006			4	Anesthesiology	Anesthesiology	349GH	WOS:000259268800007	18761243				2020-06-30	J	Juergens, CP; Lo, S; French, JK; Leung, DYC				Juergens, Craig P.; Lo, Sidney; French, John K.; Leung, Dominic Y. C.			Vaso-vagal reactions during femoral arterial sheath removal after percutaneous coronary intervention and impact on cardiac events	INTERNATIONAL JOURNAL OF CARDIOLOGY			English	Letter						vaso-vagal; percutaneous coronary intervention; myocardial infarction; stent		We determined whether vaso-vagal syncope during sheath removal after percutaneous coronary intervention leads to a higher incidence of major adverse cardiac events including acute stent thrombosis, in 611 patients who participated in our previous trial assessing the impact of intravenous sedation and local anaesthesia at this time on patient comfort. A total of 35 (5.7%) patients experienced a vaso-vagal reaction. Major adverse cardiac events at day 30 occurred in 5.7% of patients experiencing vaso-vagal syncope and 7.1% of those who did not (p=1.00) with no case of stent thrombosis in the vaso-vagal group. Whilst unpleasant for patients, we conclude that vaso-vagal syncope during sheath removal after percutaneous coronary intervention is not associated with increased adverse cardiac events in the stent era. (c) 2007 Elsevier Ireland Ltd. All rights reserved.	Liverpool Hosp, Dept Cardiol, Liverpool, NSW 1871, Australia; Univ New S Wales, Sydney, NSW 2052, Australia	Juergens, CP (reprint author), Liverpool Hosp, Dept Cardiol, Locked Bag 7103, Liverpool, NSW 1871, Australia.	C.Juergens@unsw.edu.au	Juergens, Craig/R-2919-2019	Leung, Dominic/0000-0002-5626-7236			Ang CK, 2007, INT J CARDIOL, V116, P321, DOI 10.1016/j.ijcard.2006.04.045; Barbiere C C, 1994, Crit Care Nurse, V14, P90; Boss B J, 1988, J Neurosci Nurs, V20, P245; Fulton T R, 2000, Am J Crit Care, V9, P125; Juergens CP, 2004, CATHETER CARDIO INTE, V63, P166, DOI 10.1002/ccd.20161; LANDAU C, 1993, AM J CARDIOL, V73, P95; MAGER A, 1994, AM J CARDIOL, V74, P1085, DOI 10.1016/0002-9149(94)90456-1	7	7	9	0	1	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0167-5273			INT J CARDIOL	Int. J. Cardiol.	JUL 4	2008	127	2					252	254		10.1016/j.ijcard.2007.02.059			3	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	312HV	WOS:000256661000017	17467820				2020-06-30	J	Koch, S; Ahlburg, P; Spangsberg, N; Brock, B; Tonnesen, E; Nikolajsen, L				Koch, S.; Ahlburg, P.; Spangsberg, N.; Brock, B.; Tonnesen, E.; Nikolajsen, L.			Oxycodone vs. fentanyl in the treatment of early post-operative pain after laparoscopic cholecystectomy: a randomised double-blind study	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						laparoscopic cholecystectomy; post-operative pain; oxycodone; fentanyl	CHRONIC-PANCREATITIS; MORPHINE; OPIOIDS; ANALGESIA	Background: It has been suggested that oxycodone is superior to other opioids in the treatment of visceral pain. We therefore compared the effect of intravenous (i.v.) oxycodone and i.v. fentanyl on post-operative abdominal (visceral) pain after outpatient laparoscopic cholecystectomy. Methods: Seventy-eight patients were randomised to intra- and post-operative pain treatment with either oxycodone (n=39) or fentanyl (n=39). The patients received 10 mg oxycodone/100 mu g fentanyl at the end of anaesthesia. In the post-anaesthetic care unit (PACU), 5 mg oxycodone/50 mu g fentanyl was administered to patients with moderate pain [3-5 on a numeric rating scale (NRS)], and 10 mg oxycodone/100 mu g fentanyl was administered to patients with severe pain (>5 on an NRS). The following measures were recorded: intensity of pain at arrival, after 30, 60 and 90 min and at discharge from the PACU; total consumption of oxycodone/fentanyl; nausea; vomiting; sedation and pressure tolerance thresholds. Results: The median intra- and post-operative consumption of oxycodone was 15 mg (range: 10-40 mg) and the consumption of fentanyl was 200 mu g (range: 100-500 mu g). The intensity of abdominal pain was significantly lower in the oxycodone group at arrival (P < 0.05), after 30, 60 and 90 min, and at discharge from the PACU (P < 0.01). There was a strong tendency towards more side effects with oxycodone. Conclusions: Oxycodone provided better analgesia but also more side effects, suggesting that the doses used in the present study may not be equipotent.	[Nikolajsen, L.] Aarhus Univ Hosp, Danish Pain Res Ctr, DK-8000 Aarhus C, Denmark; [Koch, S.; Ahlburg, P.; Spangsberg, N.; Tonnesen, E.; Nikolajsen, L.] Aarhus Univ Hosp, Dept Anaesthesiol, DK-8000 Aarhus C, Denmark; [Brock, B.] Aarhus Univ Hosp, Dept Clin Pharmacol, DK-8000 Aarhus C, Denmark	Nikolajsen, L (reprint author), Aarhus Univ Hosp, Danish Pain Res Ctr, Norrebrogade 44,Bldg 1A, DK-8000 Aarhus C, Denmark.	nikolajsen@dadlnet.dk		Nikolajsen, Lone/0000-0002-2705-7088; Nikolajsen, Lone/0000-0002-5261-806X			ARMITAGE P, 2001, STAT METHODS MED RES; Bisgaard T, 2001, PAIN, V90, P261, DOI 10.1016/S0304-3959(00)00406-1; Bisgaard T, 2005, SCAND J GASTROENTERO, V40, P1358, DOI 10.1080/00365520510023675; Burton MB, 1998, J PHARMACOL EXP THER, V285, P707; De Schepper HU, 2004, NEUROGASTROENT MOTIL, V16, P383, DOI 10.1111/j.1365-2982.2004.00513.x; Eisenach JC, 2003, PAIN, V101, P89, DOI 10.1016/S0304-3959(02)00259-2; Hanley MA, 2006, CLIN J PAIN, V22, P25, DOI 10.1097/01.ajp.0000148628.69627.82; KALSO E, 1991, ACTA ANAESTH SCAND, V35, P642, DOI 10.1111/j.1399-6576.1991.tb03364.x; KALSO E, 1990, CLIN PHARMACOL THER, V47, P639, DOI 10.1038/clpt.1990.85; Kalso E, 2007, PAIN, V132, P227, DOI 10.1016/j.pain.2007.09.027; Lau H, 2001, ARCH SURG-CHICAGO, V136, P1150, DOI 10.1001/archsurg.136.10.1150; Pereira J, 2001, J PAIN SYMPTOM MANAG, V22, P672, DOI 10.1016/S0885-3924(01)00294-9; Ross FB, 1997, PAIN, V73, P151, DOI 10.1016/S0304-3959(97)00093-6; Silvasti M, 1998, ACTA ANAESTH SCAND, V42, P576, DOI 10.1111/j.1399-6576.1998.tb05169.x; Staahl C, 2007, SCAND J GASTROENTERO, V42, P383, DOI 10.1080/00365520601014414; Staahl C, 2006, PAIN, V123, P28, DOI 10.1016/j.pain.2006.02.006	16	40	54	1	12	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0001-5172			ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	JUL	2008	52	6					845	850		10.1111/j.1399-6576.2008.01643.x			6	Anesthesiology	Anesthesiology	312PQ	WOS:000256683700020	18477082				2020-06-30	J	Schmerler, BL; Cohen, DM; Leder, MS; Bonsu, BK				Schmerler, Betsy L.; Cohen, Daniel M.; Leder, Marc S.; Bonsu, Bema K.			Procedural sedation for fracture reduction in children with hyperactivity	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article							ATTENTION-DEFICIT/HYPERACTIVITY DISORDER	Objective: Children with attention-deficit/hyperactivity disorder (ADHD) have a higher rate of more severe injuries than the general population. However, their ADHD may cause them to respond differently to procedural sedation required for treatment. The purpose of this article is to compare procedural sedation for children with and without ADHD. Methods: Retrospectively, 44 patients with ADHD and 41 controls sedated with fentanyl and midazolam for forearm-fracture reduction in the emergency department (ED) at a children's hospital were identified. Drug dosages, vital signs, and sedation scores were compared. Results: Drug dosages, vital signs, and sedation scores did not significantly differ between cases and controls. Mean ED visit duration was significantly longer for patients with ADHD than for controls as was sedation duration. Conclusions: Children with and without ADHD were equally sedated with the same total drug dosages. The differences in sedation duration and visit duration warrant further investigation. (C) 2008 Elsevier Inc. All rights reserved.	[Schmerler, Betsy L.] Columbus Childrens Hosp, Sect Emergency Med, Dept Pediat, Div Pediat Emergency Med, Columbus, OH 43205 USA	Schmerler, BL (reprint author), Columbus Childrens Hosp, Sect Emergency Med, Dept Pediat, Div Pediat Emergency Med, Columbus, OH 43205 USA.	schmerlerb@pediatrics.ohio-state.edu					BAREN M, 2002, CONT PEDIAT, V19, P125; DiScala C, 1998, PEDIATRICS, V102, P1415, DOI 10.1542/peds.102.6.1415; KAPLAN BJ, 1987, J DEV BEHAV PEDIATR, V8, P305; Leibson CL, 2001, JAMA-J AM MED ASSOC, V285, P60, DOI 10.1001/jama.285.1.60; Marshall W R, 1999, Spec Care Dentist, V19, P259, DOI 10.1111/j.1754-4505.1999.tb01395.x; MERRITT KA, 1994, PEDIATRICS, V94, P17; Pitetti RD, 2003, ARCH PEDIAT ADOL MED, V157, P1090, DOI 10.1001/archpedi.157.11.1090; Rapport MD, 2002, CLIN PSYCHOL REV, V22, P1107, DOI 10.1016/S0272-7358(02)00129-0; Rocha EM, 2003, J PEDIATR PSYCHOL, V28, P47, DOI 10.1093/jpepsy/28.1.47; Wallace M R, 1989, Pediatr Nurs, V15, P118	10	8	8	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0735-6757	1532-8171		AM J EMERG MED	Am. J. Emerg. Med.	JUL	2008	26	6					661	664		10.1016/j.ajem.2007.10.001			4	Emergency Medicine	Emergency Medicine	329TV	WOS:000257894400004	18606317				2020-06-30	J	Grond, S; Jage, J; Van Aken, H				Grond, S.; Jage, J.; Van Aken, H.			Postoperative pain management. Application of an iontophoretic patient-activated transdermal system	ANAESTHESIST			German	Article						iontophoresis; transdermal; postoperative; pain management; opioids	PLACEBO-CONTROLLED TRIAL; CONTROLLED ANALGESIA; MORPHINE; PHARMACOKINETICS; EFFICACY; SAFETY; PCTS; SURGERY; ADULTS	Intravenous patient-controlled analgesia (i.v. PCA) for parenteral postoperative pain control is considered standard therapy as patients can individually titrate the amount of analgesic as needed. Iontophoretic patient-activated transdermal systems (IPATS) are a new non-invasive pre-programmed method for postoperative pain control. By pressing the dosing button a 40 mu g dose of fentanyl is delivered over a 10 min period via iontophoresis through the intact skin. Several comparative randomized controlled trials have demonstrated that IPATS provide postoperative pain control equivalent to i.v. PCA with morphine. Thus, IPATS is a new method in the management of acute postoperative pain which increases patient mobility and reduces time and effort of care as well as the risk of programming errors. In this review the efficacy, pharmacokinetics, handling and process cost-effectiveness of IPATS are discussed.	[Grond, S.] Klinikum Lippe Detmold, Klin Anasthesiol & Operat Intens Med, Detmold, Germany; [Jage, J.] Johannes Gutenberg Univ Mainz, Anasthesiol Klin, Mainz, Germany; [Van Aken, H.] Univ Munster, Klin & Poliklin Anasthesiol & Operat Intens Med, D-4400 Munster, Germany	Grond, S (reprint author), Klinikum Lippe Detmold, Klin Anasthesiol & Operat Intens Med, Rontgenstr 18, Detmold, Germany.	stefan.grond@klinikum-lippe.de					*ALZA CORP, 2002, DAT FIL; ANNEMANS L, 2005, EC EVALUATION FENTAN; Apfelbaum JL, 2003, ANESTH ANALG, V97, P534, DOI 10.1213/01.ANE.0000068822.10113.9E; BALLANTYNE JC, 1993, J CLIN ANESTH, V5, P182, DOI 10.1016/0952-8180(93)90013-5; Batheja Priya, 2006, Expert Opin Drug Deliv, V3, P127; Campbell L, 1998, Br J Nurs, V7, P1364; Campbell L., 1998, BR J NURS, V7, P1372; Camu F, 1998, ANESTH ANALG, V87, P890, DOI 10.1097/00000539-199810000-00027; Chelly JE, 2005, EXPERT OPIN PHARMACO, V6, P1205, DOI 10.1517/14656566.6.7.1205; Chelly JE, 2004, ANESTH ANALG, V98, P427, DOI 10.1213/01.ANE.0000093314.13848.7E; EBERHART L, 2007, DTSCH AN C 5 8 05 20; Etches RC, 1999, SURG CLIN N AM, V79, P297, DOI 10.1016/S0039-6109(05)70384-4; Grond S, 2007, BRIT J ANAESTH, V98, P806, DOI 10.1093/bja/aem102; Gupta SK, 2005, CLIN PHARMACOKINET, V44, P25, DOI 10.2165/00003088-200544001-00005; Hartrick CT, 2006, REGION ANESTH PAIN M, V31, P546, DOI 10.1016/j.rapm.2006.08.011; HOFMANN F, 2005, 11 WORLD C PAIN 11 2, P1716; Hudcova J, 2006, COCHRANE DB SYST REV, DOI 10.1002/146518583.CD003348.pub2; Kehlet H, 1997, BRIT J ANAESTH, V78, P606; Lehmann KA, 1999, EUR SURG RES, V31, P112, DOI 10.1159/000008629; Minkowitz HS, 2007, PAIN MED, V8, P657, DOI 10.1111/j.1526-4637.2006.00257.x; Panchal SJ, 2007, ANESTH ANALG, V105, P1437, DOI 10.1213/01.ane.0000281442.36582.81; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; Power I, 2007, BRIT J ANAESTH, V98, P4, DOI 10.1093/bja/ael314; Sathyan G, 2005, CLIN PHARMACOKINET, V44, P7, DOI 10.2165/00003088-200544001-00003; Sathyan S, 2005, CLIN PHARMACOKINET, V44, P17, DOI 10.2165/00003088-200544001-00004; Simanski C, 2006, SCHMERZ, V20, P327, DOI 10.1007/s00482-005-0451-6; Vicente KJ, 2003, CAN J ANAESTH, V50, P328, DOI 10.1007/BF03021027; Viscusi ER, 2006, ANESTH ANALG, V102, P188, DOI 10.1213/01.ane.0000183649.58483.77; Viscusi ER, 2004, JAMA-J AM MED ASSOC, V291, P1333, DOI 10.1001/jama.291.11.1333; Viscusi ER, 2007, ANESTH ANALG, V105, P1428, DOI 10.1213/01.ane.0000281913.28623.fd; WARFIELD CA, 1995, ANESTHESIOLOGY, V83, P1090, DOI 10.1097/00000542-199511000-00023	31	2	2	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0003-2417			ANAESTHESIST	Anaesthesist	JUL	2008	57	7					704	710		10.1007/s00101-008-1369-z			7	Anesthesiology	Anesthesiology	331BU	WOS:000257988500008	18551260				2020-06-30	J	Wittmann, M; Schaaf, T; Peters, I; Wirz, S; Urban, BW; Barann, M				Wittmann, Maria; Schaaf, Thomas; Peters, Ineke; Wirz, Stefan; Urban, Bernd W.; Barann, Martin			The effects of fentanyl-like Opioids and hydromorphone on human 5-HT3A receptors	ANESTHESIA AND ANALGESIA			English	Article							MORPHINE; ANTAGONISTS; PREVENTION; EMESIS	BACKGROUND: 5-HT3 receptors are involved in various physiologic functions, including the modulation of emesis. 5-HT3 antagonists are clinically widely used as potent antiemetics. Emesis is also a side effect of opioid analgesics. Intriguingly, the natural opioid morphine shows specific interactions with human 5-HT3 receptors at clinically relevant concentrations. In the present study, we investigated whether this is a general effect of opioids, even when they are structurally diverse. Therefore, another morphine (phenanthrene-type) derivative, hydromorphone, and fentanyl including its (4-anilinopiperidine-type) derivatives were tested. METHODS: Whole-cell patches from human embryonic kidney-293 cells, stably transfected with the human 5-HT3A receptor cDNA, were used to determine the opioid effects on the 5-HT (3 mu M)-induced currents using the patch clamp technique (voltage-clamp). RESULTS: None of the fentanyl derivatives affected currents through the 5-HT3A receptor (3 mu M 5-HT) significantly in the clinically relevant nanomolar concentration range (IC50 values >30 mu M). In contrast, hydromorphone was considerably more potent (IC50 = 5.3 mu M), slowing the current activation- and desensitization-kinetics significantly (at 3 mu M by a factor of 1.9 and 2.4, respectively), similar to morphine. At concentrations much higher than clinically relevant, but within the range predicted,from Meyer-Overton correlations for nonspecific interactions, the fentanyl derivatives all showed at least a tendency to suppress current amplitudes, but they had diverse, effects on the activation- and desensitization-kinetics of 5-HT3A receptors. CONCLUSIONS: Only morphine and hydromorphone, but not the fentanyl derivatives, reduced 5-HT-induced current amplitudes and slowed current kinetics near clinically relevant concentrations'. The high potencies of morphine and hydromorphone, when compared to their lipophilicities, suggest a specific interaction with 5-HT3A receptors. In contrast, the effects of fentanyl-type opioids appear to be of unspecific nature. Because the rank order of opioid potencies for human 5-HT3A receptors is opposite of that for opioid receptors, the site involved is structurally different from opioid receptor binding sites. In agreement with recent data on different phenols, a phenolic OH-group (which morphine and hydromorphone possess) may contribute to specific interactions of morphine and hydromorphone with the 5-HT3A receptor. Future clinical studies could test whether corresponding differences in emetogenicity between different classes of opioids will be found.	Univ Kliniken Bonn, Klin & Poliklin Anasthesiol & Operat Intens Med, Bonn, Germany	Barann, M (reprint author), Univ Bonn, Dept Anesthesia & Intens Care Med, Sigmund Freud Str 25, D-53127 Bonn, Germany.	martin.barann@ukb.uni-bonn.de	Wittmann, Maria/I-2125-2018	Wittmann, Maria/0000-0003-4786-7712			Apfel CC, 2004, NEW ENGL J MED, V350, P2441, DOI 10.1056/NEJMoa032196; Barann M, 2008, ANESTH ANALG, V106, P846, DOI 10.1213/ane.0b013e318162ca7c; BARASH PG, 2001, HDB CLIN ANESTHESIA; FAN P, 1995, MOL PHARMACOL, V47, P491; FLACKE JW, 1985, ANESTH ANALG, V64, P897; GADDUM JH, 1957, BRIT J PHARM CHEMOTH, V12, P323, DOI 10.1111/j.1476-5381.1957.tb00142.x; GREENSHAW AJ, 1993, BEHAV PHARMACOL, V4, P479; GYERMEK L, 1995, J CLIN PHARMACOL, V35, P845, DOI 10.1002/j.1552-4604.1995.tb04129.x; HECK M, 2004, [No title captured]; Karim F, 1996, BIOCHEM PHARMACOL, V52, P685, DOI 10.1016/0006-2952(96)00346-2; KOOYMAN AR, 1993, BRIT J PHARMACOL, V108, P287, DOI 10.1111/j.1476-5381.1993.tb12795.x; Manzke T, 2003, SCIENCE, V301, P226, DOI 10.1126/science.1084674; Minami M, 2003, PHARMACOL THERAPEUT, V99, P149, DOI 10.1016/S0163-7258(03)00057-3; Shoji A, 1999, J CLIN ONCOL, V17, P1926, DOI 10.1200/JCO.1999.17.6.1926; Tetko IV, 2002, J CHEM INF COMP SCI, V42, P1136, DOI 10.1021/ci025515j; Urban BW, 2006, PHARMACOL THERAPEUT, V111, P729, DOI 10.1016/j.pharmthera.2005.12.005; Wittmann M, 2006, ANESTH ANALG, V103, P747, DOI 10.1213/01.ane.0000229706.84471.4d	17	10	10	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	JUL	2008	107	1					107	112		10.1213/ane.0b013e31817342c2			6	Anesthesiology	Anesthesiology	318MX	WOS:000257097100018	18635474				2020-06-30	J	Rehberg, B; Ryll, C; Hadzidiakos, D; von Dincklage, F; Baars, JH				Rehberg, Benno; Ryll, Christiane; Hadzidiakos, Daniel; von Dincklage, Falk; Baars, Jan H.			Variability comparison of the composite auditory evoked potential index and the bispectral index during propofol-fentanyl anesthesia	ANESTHESIA AND ANALGESIA			English	Article							CEREBRAL STATE; SPECTRAL EDGE; DEPTH; PERFORMANCE; ENTROPY	BACKGROUND: Monitors of hypnotic depth help anesthesiologists to guide the anesthetic. The performance of different monitors depends on several factors, index variability at a steady state of hypnotic depth being one. We compared the recently introduced AAI1.6 with the established bispectral index (BIS), regarding index variability during stable values of propofol effect-site concentration. METHODS: After ethics committee approval and written informed consent, anesthesia was performed in 40 patients with propofol as the target controlled infusion and fentanyl. Variability of 131 and AAI1.6 was calculated during periods of constant predicted propofol effect compartment concentration and constant levels of surgical stimulation as the median absolute deviation (MAD) from the median value. A variability index was calculated as 1.48*MAD/(threshold - median value), with threshold being the division line between awake and asleep. Threshold crossing time was used to evaluate the performance in predicting return of consciousness. RESULTS: Variability index, however, was significantly larger for the AAI1.6, despite similar absolute variability measured as MAD. Lightening of anesthesia before recovery could be noticed earlier using the BIS than the AAI1.6, although consciousness was detected with a significantly higher Pk-value by the AAI1.6. CONCLUSION: Variability in relation to the difference between the median index value during anesthesia and the threshold necessary to detect consciousness with high sensitivity is higher for the AAI1.6 than for the BIS. This, as well as the steeper concentration-response function found for AAI1.6, impairs the performance of the AAI1.6 in predicting imminent return of consciousness during decreasing propofol concentrations. However, it makes AAI1.6 well suited to detect consciousness when it has occurred.	[Rehberg, Benno; Ryll, Christiane; Hadzidiakos, Daniel; von Dincklage, Falk; Baars, Jan H.] Charite Univ Med Berlin, Dept Anesthesiol, D-10117 Berlin, Germany	Rehberg, B (reprint author), Charite Univ Med Berlin, Dept Anesthesiol, Charite Campus Mitte,Schumannstr, D-10117 Berlin, Germany.	rehberg@charite.de	Rehberg, Benno/AAF-3897-2019	Rehberg, Benno/0000-0002-3145-1555; von Dincklage, Falk/0000-0002-1543-4544			Billard V, 1997, CLIN PHARMACOL THER, V61, P45, DOI 10.1016/S0009-9236(97)90181-8; BRICE DD, 1970, BRIT J ANAESTH, V42, P535, DOI 10.1093/bja/42.6.535; Bruhn J, 2003, ANESTHESIOLOGY, V98, P621, DOI 10.1097/00000542-200303000-00008; Bruhn J, 2002, ANESTHESIOLOGY, V96, P54, DOI 10.1097/00000542-200201000-00015; Doi M, 1997, BRIT J ANAESTH, V78, P180; Drummond JC, 2000, ANESTHESIOLOGY, V93, P876, DOI 10.1097/00000542-200009000-00039; GREENWALD SD, 2006, ANESTHESIOLOGY, V105, pA1027; HADZIDIAKOS D, 2006, EUR J ANAESTH, P1; Huber P. J., 2004, ROBUST STAT; Jensen EW, 2006, ANESTHESIOLOGY, V105, P28, DOI 10.1097/00000542-200607000-00009; Jensen EW, 1996, METHOD INFORM MED, V35, P256; Manyam SC, 2007, ANESTHESIOLOGY, V106, P472, DOI 10.1097/00000542-200703000-00011; Niedhart DJ, 2006, ANESTHESIOLOGY, V104, P242, DOI 10.1097/00000542-200602000-00007; Pilge S, 2006, ANESTHESIOLOGY, V104, P488, DOI 10.1097/00000542-200603000-00016; Schneider G, 2005, ANESTHESIOLOGY, V103, P934, DOI 10.1097/00000542-200511000-00006; Schnider TW, 1998, ANESTHESIOLOGY, V88, P1170, DOI 10.1097/00000542-199805000-00006; Smith WD, 1996, ANESTHESIOLOGY, V84, P38, DOI 10.1097/00000542-199601000-00005; Vanluchene ALG, 2004, ANESTHESIOLOGY, V101, P34, DOI 10.1097/00000542-200407000-00008; VARVEL JR, 1992, J PHARMACOKINET BIOP, V20, P63, DOI 10.1007/BF01143186; Vereecke HEM, 2005, ANESTHESIOLOGY, V103, P500, DOI 10.1097/00000542-200509000-00012	20	10	10	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	JUL	2008	107	1					117	124		10.1213/ane.0b013e31816f1965			8	Anesthesiology	Anesthesiology	318MX	WOS:000257097100020	18635476				2020-06-30	J	Hayashi, H; Kawaguchi, M; Yamamoto, Y; Inoue, S; Koizumi, M; Ueda, Y; Takakura, Y; Furuya, H				Hayashi, Hironobu; Kawaguchi, Masahiko; Yamamoto, Yuri; Inoue, Satoki; Koizumi, Munehisa; Ueda, Yurito; Takakura, Yoshinori; Furuya, Hitoshi			The application of tetanic stimulation of the unilateral tibial nerve before transcranial stimulation can augment the amplitudes of myogenic motor-evoked potentials from the muscles in the bilateral upper and lower limbs	ANESTHESIA AND ANALGESIA			English	Review							DIRECT ELECTRICAL-STIMULATION; NEUROMUSCULAR BLOCKADE; GENERAL-ANESTHESIA; CORTEX; ISOFLURANE; RESPONSES; PROPOFOL; SINGLE; COUNT; EXCITABILITY	BACKGROUND: Recently, we reported a new technique to augment motor-evoked potentials (MEPs) under general anesthesia, posttetanic MEP (p-MEP), in which tetanic stimulation of the peripheral nerve before transcranial stimulation enlarged amplitudes of MEPs from the muscle innervated by the nerve subjected to tetanic stimulation. In the present study, we tested whether tetanic stimulation of the left tibial nerve can also augment amplitudes of MEPs from the muscles which are not innervated by the nerve subjected to tetanic stimulation. METHODS: Thirty patients undergoing spinal surgery under propofol-fentanyl anesthesia with partial neuromuscular blockade were examined. For conventional MEP (c-MEP) recording, transcranial stimulation with train-of-five pulses was delivered to C3-4, and the compound muscle action potentials were bilaterally recorded from the abductor pollicis brevis, abductor hallucis (AH), tibialis anterior, and soleus muscles. For p-MEP recording, tetanic stimulation (50 Hz, 50 mA of stimulus intensity) with a duration of 5 s was applied to the left tibial nerve at the ankle 1 s before transcranial stimulation. Transcranial stimulation and recording of compound muscle action potentials were performed in the same manner as c-MEP recording. Amplitudes of c-MEP and p-MEP were compared using Wilcoxon's signed rank test. RESULTS: Amplitudes of p-MEPs from the left AH muscle innervated by the left tibial nerve with tetanic stimulation were significantly larger compared with those of c-MEPs. Amplitudes of p-MEPs from the bilateral abductor pollicis brevis and soleus muscles and right AH and tibialis anterior muscles, which were not innervated by the left tibial nerve with tetanic stimulation, were also significantly larger compared with those of c-MEPs. CONCLUSION: In patients under propofol and fentanyl anesthesia with partial neuromuscular blockade, the application of tetanic stimulation to the left tibial nerve augmented the amplitudes of MEPs from the muscles without tetanic nerve stimulation and those with stimulation.	[Hayashi, Hironobu; Kawaguchi, Masahiko; Yamamoto, Yuri; Inoue, Satoki; Furuya, Hitoshi] Nara Med Univ, Dept Anesthesiol, Nara 6348522, Japan; [Koizumi, Munehisa; Ueda, Yurito; Takakura, Yoshinori] Nara Med Univ, Dept Orthopaed Surg, Nara 6348522, Japan	Kawaguchi, M (reprint author), Nara Med Univ, Dept Anesthesiol, 840 Shijo Cho, Nara 6348522, Japan.	drjkawa@naramed-u.ac.jp		Hayashi, Hironobu/0000-0002-4352-0423			ALI HH, 1976, ANESTHESIOLOGY, V45, P216, DOI 10.1097/00000542-197608000-00009; Andersson G, 1999, CLIN NEUROPHYSIOL, V110, P720, DOI 10.1016/S1388-2457(98)00049-2; GWINNUTT CL, 1988, BRIT J ANAESTH, V61, P547, DOI 10.1093/bja/61.5.547; Hamdy S, 1998, NAT NEUROSCI, V1, P64, DOI 10.1038/264; Kaelin-Lang A, 2002, J PHYSIOL-LONDON, V540, P623, DOI 10.1113/jphysiol.2001.012801; Kakimoto M, 2005, ANESTHESIOLOGY, V102, P733, DOI 10.1097/00000542-200504000-00007; KALKMAN CJ, 1995, ANESTHESIOLOGY, V83, P270, DOI 10.1097/00000542-199508000-00006; KALKMAN CJ, 1993, ACTA ORTHOP SCAND, V64, P114, DOI 10.3109/17453679308994549; Kawaguchi M, 2000, SPINE, V25, P974, DOI 10.1097/00007632-200004150-00013; Kawaguchi M, 1996, ANESTH ANALG, V82, P593, DOI 10.1097/00000539-199603000-00029; Kawaguchi M, 1998, J NEUROSURG ANESTH, V10, P131, DOI 10.1097/00008506-199807000-00001; Kawaguchi M, 1996, ANESTHESIOLOGY, V85, P1176, DOI 10.1097/00000542-199611000-00027; Kawaguchi Masahiko, 2004, J Anesth, V18, P18, DOI 10.1007/s00540-003-0201-9; Lotto ML, 2004, J NEUROSURG ANESTH, V16, P32, DOI 10.1097/00008506-200401000-00008; Luft AR, 2002, EXP BRAIN RES, V142, P562, DOI 10.1007/s00221-001-0952-1; RIDLEY SA, 1988, BRIT J ANAESTH, V60, P31, DOI 10.1093/bja/60.1.31; Saitoh Y, 1999, BRIT J ANAESTH, V83, P340, DOI 10.1093/bja/83.2.340; Sloan TB, 2002, J CLIN NEUROPHYSIOL, V19, P430, DOI 10.1097/00004691-200210000-00006; TANIGUCHI M, 1993, NEUROSURGERY, V32, P219, DOI 10.1227/00006123-199302000-00011; Ubags LH, 1998, NEUROSURGERY, V43, P90, DOI 10.1097/00006123-199807000-00058; WALI F A, 1988, Acta Anaesthesiologica Belgica, V39, P35; Yamamoto Y, 2008, ANESTH ANALG, V106, P930, DOI 10.1213/ane.0b013e3181617508; Yamamoto Y, 2007, ANESTH ANALG, V104, P1488, DOI 10.1213/01.ane.0000261518.62873.91; Yamamoto Y, 2006, ANESTH ANALG, V102, P1715, DOI 10.1213/01.ane.0000208992.83093.5c	24	8	9	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	JUL	2008	107	1					215	220		10.1213/ane.0b013e318177082e			6	Anesthesiology	Anesthesiology	318MX	WOS:000257097100034	18635490				2020-06-30	J	VanLooy, JW; Schumacher, RE; Bhatt-Mehta, V				VanLooy, J. W.; Schumacher, Robert E.; Bhatt-Mehta, Varsha			Efficacy of a premedication algorithm for nonemergent intubation in a neonatal intensive care unit	ANNALS OF PHARMACOTHERAPY			English	Article						algorithm; neonatal intensive care; nonemergent intubation; premedication	CHEST-WALL RIGIDITY; NASOTRACHEAL INTUBATION; INTRACRANIAL-PRESSURE; CONTROLLED-TRIAL; PAIN; PRETERM; FENTANYL; ATROPINE; CIRCUMCISION; RESPONSES	BACKGROUND: Preventing significant oxygen desaturation and hypotension through adequate analgesia and sedation during nonemergent intubation in neonated is desirable. However, in many neonatal intensive care units, elective intubations occur without adequate premedication. There is significant variations in the choice of premedication agent(s) and doses, and an ideal regimen for use during nonemergent intubation has not been developed. OBJECTIVE: To evaluate the efficacy of an algorithm developed for analgesia and sedation during nonemergent intubation in neonates. METHODS: Prospectively collected continuous quality improvement data on a premediation algorithm for nonemergent intubation were analyzed following institutional review board approval. Midazolam 0.1 mg/kg and fentanyl 2 mu g/kg (if the patient was not already receiving morphine for sedation) were administered prior to nonemergent intubation. Heart rate, oxygen saturation, respiration rate, mean arterial pressure, and pain scores were recorded at baseline prior to medication administration, during the procedure, and for 2 hours after the procedure. Data during laryngoscopy and until the time of tube taping were obtained from the bedside cardiorespiratory monitor. Additional fentanyl was allowed for more than 3 intubation attempts and rocuronium 0.6 mg/kg was allowed for more than 5 attempts. The physiological changes that occured over time were compared with baseline. The number of attempts made, time ti intubation, and medications used are presented. RESULTS: Ninety evaluable patients were included. Mean +/- SD birth weight and postnatal age at treatment were 2040 +/- 961 g and 14 +/- 17 days, respectively. Heart rate decreased and oxygen saturation increased significantly (160 vs 154 beats/min, p = 0.01; 96.4% vs 93.8%, p = 0.002, respectively) from baseline to completion of the procedure; however, mean arterial pressure showed no significant difference (44.9 vs 44.7 mm Hg; p = 0.85; n = 68). The number of attempts at intubation were recorded for 66 patients; of those, 52 required 3 or fewer attempts for successful intubation (median, 2). The time to successful intubation was 7.2 +/- 5.6 minutes (recorded in 45 pts). Average fentanyl and midazolam doses were 1.92 +/- 0.53 mu g/kg and 0.096 +/- 0.026 mg/kg, respectively. No patient received rocuronium. CONCLUSIONS: A systematic approach to premedication during nonemergent intubation successfully prevented acute physiological changes.	[VanLooy, J. W.] St Lukes Reg Med Ctr, Boise, ID USA; [Bhatt-Mehta, Varsha] Univ Michigan, Dept Pediat, Coll Pharm, Ann Arbor, MI 48109 USA	Bhatt-Mehta, V (reprint author), Univ Michigan Hlth Syst, CS Mott Childrens Hosp F5790, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	varsham@umich.edu					ANAND KJS, 1989, PEDIATR CLIN N AM, V36, P795; ANAND KJS, 1987, NEW ENGL J MED, V317, P1321, DOI 10.1056/NEJM198711193172105; BARRINGTON KJ, 1989, CRIT CARE MED, V17, P1293, DOI 10.1097/00003246-198912000-00009; Barrington KJ, 1998, AM J PERINAT, V15, P213, DOI 10.1055/s-2007-993928; Bhutada A, 2000, ARCH DIS CHILD-FETAL, V82, pF34, DOI 10.1136/fn.82.1.F34; Dempsey EM, 2006, ARCH DIS CHILD-FETAL, V91, pF279, DOI 10.1136/adc.2005.087213; DEWILDT SN, 1961, CLIN PHARMACOL THER, V70, P525; DURAND M, 1989, CRIT CARE MED, V17, P506, DOI 10.1097/00003246-198906000-00004; Fahnenstich H, 2000, CRIT CARE MED, V28, P836, DOI 10.1097/00003246-200003000-00037; FRIESEN RH, 1987, ANESTH ANALG, V66, P874; Grunau RE, 1998, J CHILD PSYCHOL PSYC, V39, P587, DOI 10.1111/1469-7610.00354; Hummel P, 2008, J PERINATOL, V28, P55, DOI 10.1038/sj.jp.7211861; KELLY MA, 1984, J PEDIATR-US, V105, P303, DOI 10.1016/S0022-3476(84)80137-7; Lemyre Brigitte, 2004, BMC Pediatr, V4, P20, DOI 10.1186/1471-2431-4-20; Naulaers G, 1997, ARCH DIS CHILD-FETAL, V77, pF61, DOI 10.1136/fn.77.1.F61; NEIDHART P, 1989, ACTA ANAESTH SCAND, V33, P1, DOI 10.1111/j.1399-6576.1989.tb02849.x; NINAN A, 1986, AM J PERINAT, V3, P94, DOI 10.1055/s-2007-999841; Oei J, 2002, J PAEDIATR CHILD H, V38, P146, DOI 10.1046/j.1440-1754.2002.00726.x; PERLMAN JM, 1983, PEDIATRICS, V72, P329; Peters JWB, 2005, PAIN, V114, P444, DOI 10.1016/j.pain.2005.01.014; Rapp HJ, 2004, PEDIATR ANESTH, V14, P329, DOI 10.1046/j.1460-9592.2003.01216.x; Roberts KD, 2006, PEDIATRICS, V118, P1583, DOI 10.1542/peds.2006-0590; Saarenmaa E, 2000, J PEDIATR-US, V136, P767, DOI 10.1067/mpd.2000.105366; Sarkar S, 2006, J PERINATOL, V26, P286, DOI 10.1038/sj.jp.7211499; Shah V, 2002, CLIN PERINATOL, V29, P535, DOI 10.1016/S0095-5108(02)00019-2; Silva YPE, 2007, ARCH DIS CHILD-FETAL, V92, P293, DOI 10.1136/adc.2006.105262; TADDIO A, 1995, LANCET, V345, P291, DOI 10.1016/S0140-6736(95)90278-3; Taddio A, 1997, LANCET, V349, P599, DOI 10.1016/S0140-6736(96)10316-0; Vaughn R L, 1981, Anesth Prog, V28, P50	29	15	16	0	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1060-0280	1542-6270		ANN PHARMACOTHER	Ann. Pharmacother.	JUL-AUG	2008	42	7-8					947	955		10.1345/aph.1K665			9	Pharmacology & Pharmacy	Pharmacology & Pharmacy	334WT	WOS:000258253000004	18594052				2020-06-30	J	Sessler, DI; Ben-Eliyahu, S; Mascha, EJ; Parat, MO; Buggy, DJ				Sessler, Daniel I.; Ben-Eliyahu, Shamgar; Mascha, Edward J.; Parat, Marie-Odile; Buggy, Donal J.			Can regional analgesia reduce the risk of recurrence after breast cancer? Methodology of a multicenter randomized trial	CONTEMPORARY CLINICAL TRIALS			English	Article						anesthesia; breast neoplasm; regional analgesia; epidural; regional anesthesia; paravertebral; surgery	ENDOTHELIAL GROWTH-FACTOR; KILLER-CELL ACTIVITY; GENERAL-ANESTHESIA; PARAVERTEBRAL BLOCK; TUMOR-CELLS; HEMATOGENOUS DISSEMINATION; NK ACTIVITY; SURGERY; ANGIOGENESIS; METASTASIS	Surgery is the primary and most effective treatment of breast cancer, but minimal residual disease is probably unavoidable. Whether residual disease results in clinical metastases depends on numerous factors, including anti-tumor cell mediated immunity and angiogenic and growth signals in sites of residual disease. At least three perioperative factors adversely affect these: 1) the neuroendocrine stress response to surgery, 2) volatile anesthetics, and 3) opioids. Animal studies indicate that regional anesthesia and optimum postoperative analgesia independently reduce the metastatic burden in animals inoculated with breast adenocarcinoma cells following surgery. Retrospective studies in humans also suggest that regional analgesia may reduce recurrence risk after cancer surgery. We will test the hypothesis that local or metastatic recurrence after breast cancer surgery is lower in patients randomized to paravertebral or high-thoracic epidural analgesia combined with sedation or light anesthesia than in patients given intraoperative volatile anesthesia and postoperative opioid analgesia. In a Phase 111, multi-center trial, Stage 1-3 patients having mastectomics for cancer will be randomly assigned to thoracic epidural or paravertebral anesthesia/analgesia, or to sevoflurane anesthesia and morphine analgesia. The primary outcome will be cancer recurrence. Enrolling 1100 patients over 5 years will provide 85% power for detecting a 30% treatment effect at an alpha of 0.05. We plan four equally spaced interim analyses, each evaluating efficacy and futility. Confirming our hypothesis will indicate that a small modification to anesthetic management, one that can be implemented with little risk or cost, will reduce the risk of cancer recurrence - a complication that is often ultimately lethal. (c) 2008 Elsevier Inc. All rights reserved.	[Sessler, Daniel I.; Mascha, Edward J.; Parat, Marie-Odile] Cleveland Clin, Dept Outcomes Res, Cleveland, OH 44195 USA; [Ben-Eliyahu, Shamgar] Tel Aviv Univ, Neuroimmunol Res Unit, IL-69978 Tel Aviv, Israel; [Mascha, Edward J.] Cleveland Clin, Dept Quantitat Hlth Sci, Cleveland, OH 44195 USA; [Buggy, Donal J.] Mater Misericordiae Univ Hosp, Dept Anaesthesia, Dublin, Ireland; [Parat, Marie-Odile] Cleveland Clin, Ctr Anesthesia Res, Cleveland, OH 44195 USA	Sessler, DI (reprint author), Cleveland Clin, Dept Outcomes Res, 9500 Euclid Ave,P77, Cleveland, OH 44195 USA.	DS@OR.org	Parat, Marie-Odile/G-4410-2010; Sessler, Daniel/D-3504-2011; Ben-Eliyahu, Shamgar/AAE-5444-2020	Parat, Marie-Odile/0000-0003-4895-7381; Sessler, Daniel/0000-0001-9932-3077; Ben-Eliyahu, Shamgar/0000-0003-3832-0678; Buggy, Donal/0000-0003-3922-4397			*AM PAIN SOC, 2003, [No title captured]; Antoni MH, 2006, NAT REV CANCER, V6, P240, DOI 10.1038/nrc1820; Bar-Yosef S, 2001, ANESTHESIOLOGY, V94, P1066, DOI 10.1097/00000542-200106000-00022; Beilin B, 1996, ANESTH ANALG, V82, P492, DOI 10.1097/00000539-199603000-00011; Ben-Eliyahu S, 1999, INT J CANCER, V80, P880; Ben-Eliyahu S, 2000, BRIT J CANCER, V83, P1747, DOI 10.1054/bjoc.2000.1563; BenEliyahu S, 1996, BRIT J CANCER, V74, P1900, DOI 10.1038/bjc.1996.651; Brand JM, 1997, CLIN IMMUNOL IMMUNOP, V83, P190, DOI 10.1006/clin.1997.4351; Buggy DJ, 1999, BMJ-BRIT MED J, V319, P530, DOI 10.1136/bmj.319.7209.530; CANNER PL, 1991, CONTROL CLIN TRIALS, V12, P359, DOI 10.1016/0197-2456(91)90016-F; Chae BK, 1998, SURG TODAY, V28, P727, DOI 10.1007/BF02484619; Coveney E, 1998, ANN SURG, V227, P496, DOI 10.1097/00000658-199804000-00008; Denis MG, 1997, INT J CANCER, V74, P540, DOI 10.1002/(SICI)1097-0215(19971021)74:5<540::AID-IJC11>3.0.CO;2-A; Eden P, 2004, EUR J CANCER, V40, P1837, DOI 10.1016/j.ejca.2004.02.025; ESCHWEGE P, 1995, LANCET, V346, P1528, DOI 10.1016/S0140-6736(95)92054-4; Exadaktylos AK, 2006, ANESTHESIOLOGY, V105, P660, DOI 10.1097/00000542-200610000-00008; FOLKMAN J, 1995, MOL MED, V1, P120, DOI 10.1007/BF03401559; FOSS OP, 1966, SURGERY, V59, P691; Greengrass R, 1996, CAN J ANAESTH, V43, P858, DOI 10.1007/BF03013039; Gupta K, 2002, CANCER RES, V62, P4491; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; HWANG IK, 1990, STAT MED, V9, P1439, DOI 10.1002/sim.4780091207; Hynson J M, 1992, J Clin Anesth, V4, P194, DOI 10.1016/0952-8180(92)90064-8; Kairaluoma PM, 2004, ANESTH ANALG, V99, P1837, DOI 10.1213/01.ANE.0000136775.15566.87; Karmakar MK, 2001, ANESTHESIOLOGY, V95, P771, DOI 10.1097/00000542-200109000-00033; KEHLET H, 1998, NEURAL BLOCKADE ANAE; Kurz A, 1996, NEW ENGL J MED, V334, P1209, DOI 10.1056/NEJM199605093341901; Lutgendorf SK, 2003, CLIN CANCER RES, V9, P4514; MARKOVIC SN, 1993, ANESTHESIOLOGY, V78, P700, DOI 10.1097/00000542-199304000-00013; Melamed R, 2005, BRAIN BEHAV IMMUN, V19, P114, DOI 10.1016/j.bbi.2004.07.004; Melamed R, 2003, ANESTH ANALG, V97, P1331, DOI 10.1213/01.ANE.0000082995.44040.07; NAIR VN, 1984, TECHNOMETRICS, V26, P265, DOI 10.2307/1267553; Najarian MM, 2003, AM SURGEON, V69, P213; O'Riain SC, 2005, ANESTH ANALG, V100, P244, DOI 10.1213/01.ANE.0000143336.37946.7D; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Page GG, 1997, BREAST CANCER RES TR, V45, P159, DOI 10.1023/A:1005826403235; Page GG, 2001, PAIN, V90, P191, DOI 10.1016/S0304-3959(00)00403-6; ROCHON J, 1995, J AM STAT ASSOC, V90, P292, DOI 10.2307/2291153; Rochon J, 1996, J ROY STAT SOC B MET, V58, P205; Sacerdote P, 2000, ANESTH ANALG, V90, P1411, DOI 10.1097/00000539-200006000-00028; Saphner T, 1996, J CLIN ONCOL, V14, P2738, DOI 10.1200/JCO.1996.14.10.2738; Schlagenhauff B, 2000, MELANOMA RES, V10, P165, DOI 10.1097/00008390-200010020-00009; Shakhar G, 2003, ANN SURG ONCOL, V10, P972, DOI 10.1245/ASO.2003.02.007; SHAPIRO J, 1981, J CLIN INVEST, V68, P678, DOI 10.1172/JCI110303; Sheffield C W, 1994, Wound Repair Regen, V2, P48, DOI 10.1046/j.1524-475X.1994.20108.x; SHEFFIELD CW, 1994, ACTA ANAESTH SCAND, V38, P201, DOI 10.1111/j.1399-6576.1994.tb03873.x; Smyth MJ, 2001, NAT IMMUNOL, V2, P293, DOI 10.1038/86297; Sood AK, 2006, CLIN CANCER RES, V12, P369, DOI 10.1158/1078-0432.CCR-05-1698; Wada H, 2007, ANESTHESIOLOGY, V106, P499, DOI 10.1097/00000542-200703000-00014; WEITZ CR, 1995, ANN SURG, V222, P19; Wenisch C, 1996, ANESTH ANALG, V82, P810, DOI 10.1097/00000539-199604000-00023; Wong IHN, 1999, CLIN CANCER RES, V5, P4021; Yang EV, 2006, CANCER RES, V66, P10357, DOI 10.1158/0008-5472.CAN-06-2496; YEAGER MP, 1995, ANESTHESIOLOGY, V83, P500, DOI 10.1097/00000542-199509000-00008; Zetter BR, 1998, ANNU REV MED, V49, P407, DOI 10.1146/annurev.med.49.1.407	56	103	110	0	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1551-7144	1559-2030		CONTEMP CLIN TRIALS	Contemp. Clin. Trials	JUL	2008	29	4					517	526		10.1016/j.cct.2008.01.002			10	Medicine, Research & Experimental; Pharmacology & Pharmacy	Research & Experimental Medicine; Pharmacology & Pharmacy	317IY	WOS:000257014600009	18291727				2020-06-30	J	Manral, L; Gupta, PK; Ganesan, K; Malhotra, RC				Manral, Laxmi; Gupta, Pradeep Kumar; Ganesan, Kumaran; Malhotra, Ramesh Chandra			Gas chromatographic retention indices of fentanyl and analogues	JOURNAL OF CHROMATOGRAPHIC SCIENCE			English	Article							PHARMACOLOGICAL EVALUATION		[Manral, Laxmi; Gupta, Pradeep Kumar; Ganesan, Kumaran; Malhotra, Ramesh Chandra] Def Res & Dev Estab, Gwalior 474002, MP, India	Malhotra, RC (reprint author), Def Res & Dev Estab, Gwalior 474002, MP, India.	rcmalhotra06@yahoomail.com					DAGOSTINO PA, 1985, J CHROMATOGR, V331, P47, DOI 10.1016/0021-9673(85)80005-4; Farkas O, 2004, CHEMOMETR INTELL LAB, V72, P173, DOI 10.1016/j.chemolab.2004.01.012; FERNANDEZSANCHE.JA, 1990, J CHROMATOGR, P498; HWANG DR, 1986, J LABELLED COMPD RAD, V23, P277, DOI 10.1002/jlcr.2580230306; Janssen PAJ, 1965, US patent, Patent No. 3164600; KOVATS E, 1958, HELV CHIM ACTA, V41, P1915, DOI 10.1002/hlca.19580410703; KUDZMA LV, 1989, J MED CHEM, V32, P2534, DOI 10.1021/jm00132a007; LALINDE N, 1990, J MED CHEM, V33, P2876, DOI 10.1021/jm00172a032; MAROZZI E, 1982, J ANAL TOXICOL, V6, P185, DOI 10.1093/jat/6.4.185; Micovic IV, 2000, BIOORG MED CHEM LETT, V10, P2011, DOI 10.1016/S0960-894X(00)00394-2; MICOVIC IV, 1996, J CHEM SOC P1, V1, P2041; PATTISON JB, 1973, [No title captured]; PERRIGO BJ, 1985, J CHROMATOGR, V341, P81, DOI 10.1016/S0378-4347(00)84011-6; Poole C.F., 1991, CHROMATOGRAPHY TODAY; SUZUKI S, 1989, J CHROMATOGR, V475, P400, DOI 10.1016/S0021-9673(01)89694-1; TARJAN G, 1989, J CHROMATOGR, V472, P1, DOI 10.1016/S0021-9673(00)94099-8; VANDENDOOL H, 1963, J CHROMATOGR, V11, P463, DOI 10.1016/S0021-9673(01)80947-X; Zhu SK, 2007, J CHROMATOGR A, V1150, P28, DOI 10.1016/j.chroma.2006.09.026	18	4	4	0	5	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0021-9665	1945-239X		J CHROMATOGR SCI	J. Chromatogr. Sci.	JUL	2008	46	6					551	+		10.1093/chromsci/46.6.551			6	Biochemical Research Methods; Chemistry, Analytical	Biochemistry & Molecular Biology; Chemistry	323TC	WOS:000257470300017	18647479	Bronze			2020-06-30	J	Batra, YK; Lokesh, VC; Panda, NB; Rajeev, S; Rao, KLN				Batra, Yatindra Kumar; Lokesh, Vanajakshi C.; Panda, Nidhi Bidyut; Rajeev, Subramanyam; Rao, Katragadda L. N.			Dose-response study of intrathecal fentanyl added to bupivacaine in infants undergoing lower abdominal and urologic surgery	PEDIATRIC ANESTHESIA			English	Article						anesthesia : regional; spinal : infants; opioids : fentanyl; surgery : lower abdominal and urologic	SPINAL-ANESTHESIA; LOCAL-ANESTHETICS; HYPERBARIC BUPIVACAINE; POSTOPERATIVE PAIN; SURGICAL ANALGESIA; CHILDREN; CLONIDINE; BLOCK; DURATION; SEDATION	Background: Intrathecal (IT) adjuncts often are used to enhance the duration of spinal bupivacaine. Fentanyl is a spinal analgesic that could be a useful adjunct, and enhances the duration and quality of sensory block in adult surgical and obstetric population. However, no data exist to assess the dose-response characteristics of IT fentanyl when added to bupivacaine in infants. Methods: Fifty-eight infants undergoing lower abdominal and urologic procedures were randomized into four groups to receive plain 0.5% hyperbaric bupivacaine F0 (< 5 kg = 0.5 mg.kg(-1); 5-10 kg = 0.4 mg.kg(-1)). Groups F0.25, F0.5, and F1 groups received bupivacaine added with 0.25, 0.5, and 1 mu g.kg(-1) of fentanyl, respectively. Duration of spinal anesthesia (SA) as assessed by the recovery of hip flexion in the postoperative period was the primary variable analyzed. In addition, the duration of analgesia in the postoperative period, rescue postoperative analgesic requirements and hemodynamic changes were recorded. Results: Fifty-six infants were studied. The four groups were similar for age, weight, duration of surgery, onset of sensory, motor block, and the highest level of analgesia attained. The addition of 1 mu g.kg(-1) fentanyl (F1) significantly increased the duration of SA (74.27 +/- 6.1 min) compared to the control group (51.21 +/- 5.2 min) (P = 0.001). Postoperative pain-free interval was prolonged (P = 0.004) and significantly less rescue analgesics were required after 1 mu g.kg(-1) IT fentanyl (P = 0.032). These parameters did not show any significant difference among groups F0, F0.25, and F0.5. Conclusions: The addition of 1 mu g.kg(-1) IT fentanyl to spinal bupivacaine prolonged the duration of spinal block in infants undergoing lower abdominal and urologic procedures.	[Batra, Yatindra Kumar; Lokesh, Vanajakshi C.; Panda, Nidhi Bidyut; Rajeev, Subramanyam] Postgrad Inst Med Educ & Res, Dept Anaesthesia & Intens Care, Chandigarh 160012, India; [Rao, Katragadda L. N.] Postgrad Inst Med Educ & Res, Dept Paediat Surg, Chandigarh 160012, India	Batra, YK (reprint author), Postgrad Inst Med Educ & Res, Dept Anaesthesia & Intens Care, Chandigarh 160012, India.	ykbatra@glide.net.in					ABAJIAN JC, 1984, ANESTH ANALG, V63, P359; Atallah MM, 2006, ACTA ANAESTH SCAND, V50, P798, DOI 10.1111/j.1399-6576.2006.01063.x; ATTIA J, 1987, Anesthesiology (Hagerstown), V67, pA532, DOI 10.1097/00000542-198709001-00532; BARRIER G, 1989, INTENS CARE MED, V15, pS37, DOI 10.1007/BF00260883; Berde C, 2004, PEDIATR ANESTH, V14, P387, DOI 10.1111/j.1460-9592.2004.01336.x; Constant I, 1998, BRIT J ANAESTH, V80, P294; Curatolo M, 1998, ACTA ANAESTH SCAND, V42, P910, DOI 10.1111/j.1399-6576.1998.tb05349.x; FOSEL T, 1994, ANAESTHESIST, V43, P26, DOI 10.1007/s001010050030; Ganesh A, 2007, ANESTH ANALG, V104, P271, DOI 10.1213/01.ane.0000252418.05394.28; Goodarzi M, 1998, PAEDIATR ANAESTH, V8, P131, DOI 10.1046/j.1460-9592.1998.00737.x; Gross JB, 2002, ANESTHESIOLOGY, V96, P1004; Jain K, 2004, INT J OBSTET ANESTH, V13, P215, DOI 10.1016/j.ijoa.2004.04.006; JONES SEF, 1984, BRIT J ANAESTH, V56, P137, DOI 10.1093/bja/56.2.137; Kaabachi O, 2002, ANN FR ANESTH, V21, P617, DOI 10.1016/S0750-7658(02)00704-9; MAHE V, 1988, ANESTHESIOLOGY, V68, P601, DOI 10.1097/00000542-198804000-00020; Palmer CM, 1998, ANESTHESIOLOGY, V88, P355, DOI 10.1097/00000542-199802000-00014; Pirat A, 2002, ANESTH ANALG, V95, P1207, DOI 10.1097/00000539-200211000-00017; Rochette A, 2004, ANESTH ANALG, V98, P56, DOI 10.1213/01.ANE.0000093229.17729.6C; Seewal R, 2007, REGION ANESTH PAIN M, V32, P20, DOI 10.1016/j.rapm.2006.09.007; Tobias JD, 2000, PAEDIATR ANAESTH, V10, P367, DOI 10.1046/j.1460-9592.2000.00499.x; Tobias JD, 2000, PAEDIATR ANAESTH, V10, P5, DOI 10.1046/j.1460-9592.2000.00460.x; WEBSTER AC, 1991, CAN J ANAESTH, V38, P281, DOI 10.1007/BF03007615; Weiss M, 2007, PEDIATR ANESTH, V17, P867, DOI 10.1111/j.1460-9592.2007.02273.x; Williams RK, 2006, ANESTH ANALG, V102, P67, DOI 10.1213/01.ANE.0000159162.86033.21	24	14	14	1	1	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1155-5645			PEDIATR ANESTH	Pediatr. Anesth.	JUL	2008	18	7					613	619		10.1111/j.1460-9592.2008.02613.x			7	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	308HL	WOS:000256379200007	18482234				2020-06-30	J	Van Oud-Alblas, HJB; Bosenberg, AT; Tibboel, D				Van Oud-Alblas, Heleen J. Blusse; Bosenberg, Adrian T.; Tibboel, Dick			Awareness in children: another two cases	PEDIATRIC ANESTHESIA			English	Article						anesthesia; pediatrics; awareness	GENERAL-ANESTHESIA	Intraoperative awareness is an anesthesia complication and occurs when a patient becomes conscious during a procedure performed under general anesthesia and subsequently has recall of these events. Awareness is well described phenomenon in adults, with an incidence of 0.1-0.2 % for low-risk surgical procedures. Recent studies have shown that awareness in children is more common than in adults. However, causes and the long-term psychological impact of awareness in children are unknown. We report on two cases of intraoperative awareness in children in an attempt to throw further light on this complex problem.	[Van Oud-Alblas, Heleen J. Blusse] Erasmus Univ, Med Ctr, Sophia Childrens Hosp, Dept Anaesthesiol, Rotterdam, Netherlands; [Van Oud-Alblas, Heleen J. Blusse; Tibboel, Dick] Erasmus Univ, Med Ctr, Sophia Childrens Hosp, Dept Paediat Surg, Rotterdam, Netherlands; [Bosenberg, Adrian T.] Univ Cape Town, Fac Hlth Sci, Dept Anaesthesia, ZA-7925 Cape Town, South Africa	Van Oud-Alblas, HJB (reprint author), Erasmus MC, Dept Anaesthesiol, Dr Molewaterpl 60, NL-3015 GJ Rotterdam, Netherlands.	h.blussevanoudalblas@erasmusmc.nl					BRICE DD, 1970, BRIT J ANAESTH, V42, P535, DOI 10.1093/bja/42.6.535; Davidson AJ, 2006, PEDIATR ANESTH, V16, P374, DOI 10.1111/j.1460-9592.2006.01877.x; Davidson AJ, 2005, ANESTH ANALG, V100, P653, DOI 10.1213/01.ANE.0000150604.73481.00; Davidson AJ, 2007, BEST PRACT RES-CLIN, V21, P415, DOI 10.1016/j.bpa.2007.05.001; Davis PJ, 2005, ANESTH ANALG, V100, P650, DOI 10.1213/01.ANE.0000150601.15068.2D; Ekman A, 2004, ACTA ANAESTH SCAND, V48, P20, DOI 10.1111/j.1399-6576.2004.00260.x; JONES JG, 1994, BRIT J ANAESTH, V73, P31, DOI 10.1093/bja/73.1.31; Lopez U, 2007, ANAESTHESIA, V62, P778, DOI 10.1111/j.1365-2044.2007.05133.x; MOERMAN N, 1993, ANESTHESIOLOGY, V79, P454, DOI 10.1097/00000542-199309000-00007; Myles PS, 2004, LANCET, V363, P1757, DOI 10.1016/S0140-6736(04)16300-9; Sadhasivam S, 2006, ANESTH ANALG, V102, P383, DOI 10.1213/01.ANE.0000184115.57837.30; Sandin RH, 2000, LANCET, V355, P707, DOI 10.1016/S0140-6736(99)11010-9	12	9	10	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645	1460-9592		PEDIATR ANESTH	Pediatr. Anesth.	JUL	2008	18	7					654	657		10.1111/j.1460-9592.2008.02576.x			4	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	308HL	WOS:000256379200013	18482243				2020-06-30	J	Disma, N; Astuto, M; Di Giorgio, A; Russo, G				Disma, Nicola; Astuto, Marinella; Di Giorgio, Angelo; Russo, Giovanna			Scurvy: a disease of anesthetic interest? Scurvy and anesthesia	PEDIATRIC ANESTHESIA			English	Letter									[Disma, Nicola; Astuto, Marinella] Univ Catania, Dept Anaesthesia, Catania, Italy; [Di Giorgio, Angelo] Univ Catania, Dept Pediat, Catania, Italy; [Russo, Giovanna] Univ Catania, Div Pediat Haematol Oncol, Catania, Italy	Disma, N (reprint author), Univ Catania, Dept Anaesthesia, Catania, Italy.	nicoladisma@tin.it	astuto, marinella/AAP-6994-2020; Russo, Giovanna/AAC-6659-2019; Disma, Nicola/AAA-8868-2020	astuto, marinella/0000-0002-9365-1309; Russo, Giovanna/0000-0001-9369-7473; Disma, Nicola/0000-0002-2960-9333			Akikusa J, 2003, J PAEDIATR CHILD H, V39, P75, DOI 10.1046/j.1440-1754.2003.00093.x; DAVIES DP, 2004, CURR PAEDIAT, V14, P83, DOI DOI 10.1016/J.CUPE.2003.11.006; Halligan TJ, 2005, ORAL SURG ORAL MED O, V100, P688, DOI 10.1016/j.tripleo.2005.04.023; Pimentel L, 2003, AM J EMERG MED, V21, P328, DOI 10.1016/S0735-6757(03)00083-4; Weinstein M, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.3.e55	5	1	1	0	0	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1155-5645			PEDIATR ANESTH	Pediatr. Anesth.	JUL	2008	18	7					672	673		10.1111/j.1460-9592.2008.02513.x			3	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	308HL	WOS:000256379200020	18331553				2020-06-30	J	Unal, Y; Dogan, AT; Ozkose, Z; Koksal, F				Unal, Yusuf; Dogan, Alper Tunga; Ozkose, Zerrin; Koksal, Ferda			Anesthetic management of a patient with Seckel syndrome and implanted pacemaker	PEDIATRIC ANESTHESIA			English	Letter									[Unal, Yusuf; Dogan, Alper Tunga; Ozkose, Zerrin; Koksal, Ferda] Gazi Univ, Fac Med, Dept Anesthesiol & Reanimat, Ankara, Turkey	Unal, Y (reprint author), Gazi Univ, Fac Med, Dept Anesthesiol & Reanimat, Ankara, Turkey.	yunal71@yahoo.com	Ozkose, Zerrin/AAF-3419-2019	Ozkose Satirlar, Zerrin/0000-0002-1623-1503			Gurkan Y, 2006, PEDIATR ANESTH, V16, P359, DOI 10.1111/j.1460-9592.2005.01798.x; Rajamani A, 2005, PEDIATR ANESTH, V15, P338, DOI 10.1111/j.1460-9592.2005.01428.x; ROZNER MA, 2006, KAPLANS CARDIAC ANES, P827; Ucar B, 2004, CLIN DYSMORPHOL, V13, P53, DOI 10.1097/00019605-200401000-00017	4	3	3	1	2	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1155-5645			PEDIATR ANESTH	Pediatr. Anesth.	JUL	2008	18	7					676	677		10.1111/j.1460-9592.2008.02517.x			3	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	308HL	WOS:000256379200023	18616496				2020-06-30	J	Smania, MC; Piva, JP; Garcia, PCR				Smania, Maria Cristina; Piva, Jefferson Pedro; Garcia, Pedro Celiny R.			Dexmedetomidine in anesthesia of children submitted to videolaparoscopic appendectomy: A double-blind, randomized and placebo-controlled study	REVISTA DA ASSOCIACAO MEDICA BRASILEIRA			English	Article						dexmedetomidine; alpha adrenoceptor agonist; laparoscopy; pediatric anesthesia; appendectomy	BISPECTRAL INDEX; PEDIATRIC-PATIENTS; ISOFLURANE ANESTHESIA; LAPAROSCOPIC SURGERY; PROPOFOL; INDUCTION; AGONISTS; INFANTS	OBJECTIVES. To evaluate the hemodynamic responses to nociceptive stimuli in children submitted to videolaparoscopic appendectomy under balanced anesthesia with isoflurane and dexmedetomidine. METHODS. Randomized, double-blind and placebo-controlled study involving 26 children submitted to videolaparoscopic appendectomy carried out at Hospital Sao Lucas (PUCRS) between May 2004 and February 2005. Patients were assigned to two groups: (a) Dexmedetomidine group (n= 13): infusion of 1 mu g/kg over 10 minutes and maintenance dose of 0.5 mu g/kg/ h) as an adjuvant to inhaled isoflurane anesthesia; (b) Control group (n= 13): normal saline infusion at a similar rate and volume of the dexmedetomidine infusion. During the different surgical and anesthetic periods, groups were compared regarding heart rate, systolic and diastolic arterial blood pressures as well as need of supplemental fentanyl infusion. Student's t test, ANOVA, and Finner's procedure were used for statistical analysis. RESULTS. During the strongest nociceptive stimuli (airway access and abdominal catheter placement), the heart rate and systolic blood pressure increased significantly (p < 0.001) in the control group compared to the dexmedetomidine group. Compared to baseline levels, the hemodynamic responses to nociceptive stimuli were more stable when dexmedetomidine was used in combination with inhaled isoflurane anesthesia. The need for supplemental doses of fentanyl and the hemodynamic parameters were similar for both groups. CONCLUSION. Dexmedetomidine combined with inhaled isoflurane for anesthesia of children submitted to videolaparoscopic appendectomy, efficiently blocks the hemodynamic responses to nociceptive stimuli. When compared to placebo, the use of dexmedetomidine did not change the need for supplemental doses of fentanyl for maintenance of hemodynamic parameters during the intraoperative period.	Pontificia Univ Catolica Rio Grande do Sul, Hosp Sao Lucas, Div Anesthesia, Porto Alegre, RS, Brazil; Pontificia Univ Catolica Rio Grande do Sul, Sch Med, Dept Pediat, Porto Alegre, RS, Brazil	Smania, MC (reprint author), Rua Sao Vicente 117,Apto 301, BR-90630180 Porto Alegre, RS, Brazil.	mcsmania.ez@terra.com.br	Garcia, Pedro Celiny/G-4659-2012	Garcia, Pedro Celiny/0000-0002-1863-0727			Aantaa R, 1997, ANESTHESIOLOGY, V86, P1055, DOI 10.1097/00000542-199705000-00008; AHO M, 1992, ANESTH ANALG, V75, P940; Aladangady N, 2004, ARCH DIS CHILD-FETAL, V89, pF344, DOI 10.1136/adc.2003.039008; Ard J, 2003, J NEUROSURG ANESTH, V15, P263, DOI 10.1097/00008506-200307000-00015; BRUNO F, 2005, PIVA CELINY MED INTE, P317; CABRAL AS, 2005, CELINY MED INTENSIVA, P563; Denman WT, 2000, ANESTH ANALG, V90, P872, DOI 10.1213/00000539-200004000-00018; Ebert TJ, 2000, ANESTHESIOLOGY, V93, P382, DOI 10.1097/00000542-200008000-00016; Gueugniaud PY, 1998, ANESTH ANALG, V86, P290, DOI 10.1097/00000539-199802000-00012; HANNALLAH RS, 1991, ANESTHESIOLOGY, V74, P217, DOI 10.1097/00000542-199102000-00004; HOCHBERG Y, 1988, BIOMETRIKA, V75, P800, DOI 10.2307/2336325; HOLL JW, 1994, PEDIAT ANESTHESIA, P637; Iannuzzi M, 2005, BRIT J ANAESTH, V94, P492, DOI 10.1093/bja/aei075; Ibacache ME, 2004, ANESTH ANALG, V98, P60, DOI 10.1213/01.ANE.0000094947.20838.8E; JORIS JL, 1993, ANESTH ANALG, V76, P1067; Kagawa K, 1997, ANESTHESIOLOGY, V87, P963, DOI 10.1097/00000542-199710000-00032; Kamibayashi T, 2000, ANESTHESIOLOGY, V93, P1345, DOI 10.1097/00000542-200011000-00030; Kaul HL, 2002, INDIAN J ANAESTH, V46, P323; Khan ZP, 1999, BRIT J ANAESTH, V83, P372; Khan ZP, 1999, ANAESTHESIA, V54, P146, DOI 10.1046/j.1365-2044.1999.00659.x; Koroglu A, 2005, BRIT J ANAESTH, V94, P821, DOI 10.1093/bja/aei119; Morimoto Y, 2004, ANESTH ANALG, V98, P1336, DOI 10.1213/01.ANE.0000105867.17108.B6; PRYSROBERTS C, 1987, BRIT J ANAESTH, V59, P1341, DOI 10.1093/bja/59.11.1341; SCHEININ B, 1992, BRIT J ANAESTH, V68, P126, DOI 10.1093/bja/68.2.126; Scholz J, 2000, Curr Opin Anaesthesiol, V13, P437, DOI 10.1097/00001503-200008000-00007; Serlin S, 2004, PEDIATR ANESTH, V14, P532, DOI 10.1111/j.1460-9592.2004.01317.x; SIKER D, 1994, PEDIAT ANESTHESIA, P83; STANSKI DR, 1994, ANESTHESIA, P1127; Tan LH, 2003, ANESTH ANALG, V97, P461, DOI 10.1213/01.ANE.0000066357.63011.75; TOBAIS JD, 2002, PAEDIA ANAESTHES, V12, P171; Tobias JD, 2003, SOUTH MED J, V96, P871, DOI 10.1097/01.SMJ.0000053557.75799.09; Tobias JD, 2007, PEDIATR CRIT CARE ME, V8, P115, DOI 10.1097/01.PCC.0000257100.31779.41; Tobias Joseph D, 2002, Best Pract Res Clin Anaesthesiol, V16, P115, DOI 10.1053/bean.2001.0211; VIANNA PTG, 2001, REV BRAS ANESTESIOL, V51, P418; Wedgewood J, 2001, PAEDIATR ANAESTH, V11, P391, DOI 10.1046/j.1460-9592.2001.00519.x; Whyte SD, 2004, ANESTH ANALG, V98, P1644	36	11	12	0	2	ASSOC MEDICA BRASILEIRA	SAO PAULO	RUA SAO CARLOS DO PINHAL 324, CAIXA POSTAL 8904, SAO PAULO, SP, BRAZIL	0104-4230			REV ASSOC MED BRAS	Rev. Assoc. Med. Bras.	JUL-AUG	2008	54	4					308	313		10.1590/S0104-42302008000400015			6	Medicine, General & Internal	General & Internal Medicine	333JQ	WOS:000258149200015	18719788	DOAJ Gold, Green Published			2020-06-30	J	Pain, L; Oberling, P; Mainsongeon, M; Moulinoux, JP; Simonnet, G				Pain, Laure; Oberling, Philippe; Mainsongeon, Maud; Moulinoux, Jacques Philippe; Simonnet, Guy			Delayed aversive effects of high-dose fentanyl prevention by a polyamine-deficient diet	BEHAVIOURAL BRAIN RESEARCH			English	Article						fentanyl; affect; aversion; place conditioning; polyamines	OPIOID-INDUCED HYPERALGESIA; NMDA RECEPTOR ANTAGONIST; PLACE PREFERENCE; AFFECTIVE STATE; EXPOSURE; DRUG; SENSITIVITY; ANALGESICS; WITHDRAWAL; PARADIGM	The present study aimed to examine the effects of an acute administration of the mu-opioid receptor fentanyl on affect as assessed by place-conditioning procedure in rats. We determined the affective properties of fentanyl not only immediately following its administration, but also 24 h later. Experiments were performed using the dose of fentanyl (240 gamma/kg; four injections of 60 gamma/(ml kg) every 15 min, subcutaneously) for which secondary hyperalgesia has been previously described. Our results show that the acute administration of fentanyl. display biphasic affective properties, with early rewarding and 24-h delayed aversive components. The 24-h delayed aversive effects of fentanyl were not observed in animals submitted to a polyamine-deficient diet, suggesting an NMDA-dependent mechanism. (c) 2008 Elsevier B.V. All rights reserved.	[Pain, Laure] INSERM, U666, GRERCA, Fac Med, F-67085 Strasbourg, France; [Pain, Laure] Hop Univ Strasbourg, Fac Med, F-67085 Strasbourg, France; [Oberling, Philippe] Univ Strasbourg, UMR 7521, CNRS, ULP, Strasbourg, France; [Oberling, Philippe] Univ Strasbourg, Inst Physiol, Strasbourg, France; [Mainsongeon, Maud] Univ Victor Segalen, Ctr Hosp Univ Bordeaux, Bordeaux 2, France; [Moulinoux, Jacques Philippe] Univ Rennes 1, F-35014 Rennes, France	Pain, L (reprint author), INSERM, U666, GRERCA, Fac Med, 11 Rue Humann, F-67085 Strasbourg, France.	Laurepain@aol.com					Angst MS, 2006, ANESTHESIOLOGY, V104, P570, DOI 10.1097/00000542-200603000-00025; Bespalov AY, 2001, NEUROSCI BIOBEHAV R, V25, P343, DOI 10.1016/S0149-7634(01)00018-5; Celerier E, 2000, ANESTHESIOLOGY, V92, P465, DOI 10.1097/00000542-200002000-00029; Chizh BA, 2001, TRENDS PHARMACOL SCI, V22, P636, DOI 10.1016/S0165-6147(00)01863-0; Estebe JPC, 2006, ANESTH ANALG, V102, P1781, DOI 10.1213/01.ane.0000205755.43562.2b; FINLAY JM, 1988, PSYCHOPHARMACOLOGY, V96, P534, DOI 10.1007/BF02180036; Gaboriau F, 2003, ANAL BIOCHEM, V318, P212, DOI 10.1016/S0003-2697(03)00214-8; Gold MS, 2006, J ADDICT DIS, V25, P15, DOI 10.1300/J069v25n01_04; HALL G, 1980, PSYCHOL BULL, V88, P535, DOI 10.1037/0033-2909.88.2.535; Kergozien S, 1996, LIFE SCI, V58, P2209, DOI 10.1016/0024-3205(96)00215-9; Koob GF, 2001, NEUROPSYCHOPHARMACOL, V24, P97, DOI 10.1016/S0893-133X(00)00195-0; Lohmann AB, 2001, PEDIATR RES, V49, P50, DOI 10.1203/00006450-200101000-00013; Mao JR, 2002, PAIN, V100, P213, DOI 10.1016/S0304-3959(02)00422-0; Morgan AD, 2002, PHARMACOL BIOCHEM BE, V72, P873, DOI 10.1016/S0091-3057(02)00774-8; Pain L, 1996, ANESTHESIOLOGY, V85, P121, DOI 10.1097/00000542-199607000-00017; Pain L, 1997, ANESTHESIOLOGY, V87, P935, DOI 10.1097/00000542-199710000-00029; PCHELINTSEV MV, 1991, PHARMACOL BIOCHEM BE, V39, P873, DOI 10.1016/0091-3057(91)90046-5; Popik P, 2003, BEHAV PHARMACOL, V14, P237, DOI 10.1097/00008877-200305000-00008; Richebe P, 2005, ANESTHESIOLOGY, V102, P421, DOI 10.1097/00000542-200502000-00028; RIVAT CP, 2007, PAIN            0925; Schulteis G, 1997, PSYCHOPHARMACOLOGY, V129, P56, DOI 10.1007/s002130050162; Simonnet G, 2003, NEUROREPORT, V14, P1, DOI 10.1097/00001756-200301200-00001; SOLOMON RL, 1974, PSYCHOL REV, V81, P119, DOI 10.1037/h0036128; Suzuki T, 2000, LIFE SCI, V67, P383, DOI 10.1016/S0024-3205(00)00639-1; TRAYNELIS SF, 1995, SCIENCE, V268, P873, DOI 10.1126/science.7754371; Tzschentke TM, 1998, PROG NEUROBIOL, V56, P613, DOI 10.1016/S0301-0082(98)00060-4; WIDERSMITH OH, 2006, ANESTHESIOLOGY, V104, P601; Yamakura T, 1999, PROG NEUROBIOL, V59, P279, DOI 10.1016/S0301-0082(99)00007-6	28	6	6	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	JUN 26	2008	190	1					119	123		10.1016/j.bbr.2008.02.010			5	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	299PF	WOS:000255766800014	18378328				2020-06-30	J	Markman, JD				Markman, John D.			Not so fast: The reformulation of fentanyl and breakthrough chronic non-cancer pain	PAIN			English	Editorial Material							RANDOMIZED-TRIAL; OPIOID THERAPY; CANCER PAIN; MORPHINE; ASSOCIATION; PREVALENCE; ABUSE		Univ Rochester, Sch Med & Dent, Neuromed Pain Management Ctr & Translat Pain Res, Rochester, NY 14642 USA	Markman, JD (reprint author), Univ Rochester, Sch Med & Dent, Neuromed Pain Management Ctr & Translat Pain Res, 601 Elmwood Ave,Box 670, Rochester, NY 14642 USA.	john_markman@urmc.rochester.edu					Ballantyne JC, 2003, NEW ENGL J MED, V349, P1943, DOI 10.1056/NEJMra025411; BENNETT D, 2005, [No title captured], V30, P296; Caraceni A, 2004, PALLIATIVE MED, V18, P177, DOI 10.1191/0269216304pm890oa; CHIA Y, 1999, CAN J ANESTH, V46, P862; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Compton WM, 2006, DRUG ALCOHOL DEPEN, V81, P103, DOI 10.1016/j.drugalcdep.2005.05.009; Gilron I, 2005, PAIN, V113, P191, DOI 10.1016/j.pain.2004.10.008; Kamboj SK, 2005, PAIN, V117, P388, DOI 10.1016/j.pain.2005.06.022; Laulin JP, 2002, ANESTH ANALG, V94, P1263, DOI 10.1097/00000539-200205000-00040; Mao JR, 2002, PAIN, V100, P213, DOI 10.1016/S0304-3959(02)00422-0; Mercadante S, 2002, CANCER, V94, P832, DOI 10.1002/cncr.10249; Moulin DE, 1996, LANCET, V347, P143, DOI 10.1016/S0140-6736(96)90339-6; Odrcich M, 2006, PAIN, V120, P207, DOI 10.1016/j.pain.2005.10.007; Petzke F, 1999, J PAIN SYMPTOM MANAG, V17, P391, DOI 10.1016/S0885-3924(99)00023-8; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 2006, J PAIN, V7, P583, DOI 10.1016/j.jpain.2006.02.003; Wasan AD, 2005, PAIN, V117, P450, DOI 10.1016/j.pain.2005.08.006; Zacny J, 2003, DRUG ALCOHOL DEPEN, V69, P215, DOI 10.1016/S0376-8716(03)00003-6	18	16	17	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0304-3959	1872-6623		PAIN	Pain	JUN 15	2008	136	3					227	229		10.1016/j.pain.2008.03.011			3	Anesthesiology; Clinical Neurology; Neurosciences	Anesthesiology; Neurosciences & Neurology	318PX	WOS:000257105200001	18384960				2020-06-30	J	Sabatowski, R				Sabatowski, R.			Driving ability under opioids: current assessment of published studies	DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT			German	Review						Driving ability; opioid treatment; Vienna test system; cognitive ability; psychomotor functions; oxycodone-fentanyl	LONG-TERM TREATMENT; RELEASE MORPHINE; PAIN; PERFORMANCE		Univ Klinikum Carl Gustav Carus, Anasthesiol Klin, Univ Schmerz Centrum, D-01307 Dresden, Germany	Sabatowski, R (reprint author), Univ Klinikum Carl Gustav Carus, Anasthesiol Klin, Univ Schmerz Centrum, Fetscherstr 74, D-01307 Dresden, Germany.	rainer.sabatowski@uniklinikum-dresden.de	Sabatowski, Rainer/K-3475-2019	Sabatowski, Rainer/0000-0003-2228-3147			Dagtekin O, 2007, ANESTH ANALG, V105, P1442, DOI 10.1213/01.ane.0000281078.65585.1e; Gaertner J, 2006, ACTA ANAESTH SCAND, V50, P664, DOI 10.1111/j.1399-6576.2006.01027.x; Jamison RN, 2003, J PAIN SYMPTOM MANAG, V26, P913, DOI 10.1016/S0885-3924(03)00310-5; Kamboj SK, 2005, PAIN, V117, P388, DOI 10.1016/j.pain.2005.06.022; Sabatowski R, 2003, J PAIN SYMPTOM MANAG, V25, P38, DOI 10.1016/S0885-3924(02)00539-0; Tassain V, 2003, PAIN, V104, P389, DOI 10.1016/S0304-3959(03)00047-2; Veldhuijzen DS, 2006, PAIN, V122, P28, DOI 10.1016/j.pain.2005.12.019	7	10	10	0	4	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0012-0472	1439-4413		DEUT MED WOCHENSCHR	Dtsch. Med. Wochenschr.	JUN 13	2008	133	24		2			S25	S28		10.1055/s-2008-1081067			4	Medicine, General & Internal	General & Internal Medicine	321TJ	WOS:000257329100002	18548365				2020-06-30	J	Wade, CL; Schuster, DJ; Domingo, KM; Kitto, KF; Fairbanks, CA				Wade, Carrie L.; Schuster, Daniel J.; Domingo, Kristine M.; Kitto, Kelley F.; Fairbanks, Carolyn A.			Supraspinally-administered agmatine attenuates the development of oral fentanyl self-administration	EUROPEAN JOURNAL OF PHARMACOLOGY			English	Article						NMDA; NOS; neuroprotection; intracerebroventricular	NMDA RECEPTOR ANTAGONISTS; INDUCED PLACE PREFERENCE; LONG-TERM POTENTIATION; NITRIC-OXIDE SYNTHASE; ENDOGENOUS LIGAND; OPIOID ANALGESIA; IN-VIVO; MORPHINE; RATS; BRAIN	The decarboxylation product of arginine, agmatine, has effectively reduced or prevented opioid-induced tolerance and dependence when given either systemically (intraperitoneally or subcutaneously) or centrally (intrathecally or intracerebroventricularly). Systemically administered agmatine also reduces the escalation phase of intravenous fentanyl self-administration in rats. The present study assessed whether centrally (intracerebroventricular, i.c.v.) delivered agmatine could prevent the development of fentanyl self-administration in mice. Mice were trained to respond under a fixed-ratio 1 (FR1) schedule for either fentanyl (0.7 mu g/70 mu l, p.o.) or food reinforcement. Agmatine (10 nmol/5 mu l), injected i.c.v. 12-14 h before the first session and every other evening (12-14 h before session) for 2 weeks, completely attenuated oral fentanyl self-administration (but not food-maintained responding) compared to saline-injected controls. When agmatine was administered after fentanyl self-administration had been established (day 8) it had no attenuating effects on bar pressing. This dose of agmatine does not decrease locomotor activity as assessed by rotarod. The present findings significantly extend the previous observation that agmatine prevents opioid-maintained behavior to a chronic model of oral fentanyl self-ad ministration as well as identifying a supraspinal site of action for agmatine inhibition of drug addiction. (c) 2008 Elsevier B.V. All rights reserved.	[Fairbanks, Carolyn A.] Univ Minnesota, Dept Pharmaceut, Minneapolis, MN 55455 USA; [Wade, Carrie L.; Kitto, Kelley F.; Fairbanks, Carolyn A.] Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA; [Schuster, Daniel J.; Domingo, Kristine M.; Kitto, Kelley F.; Fairbanks, Carolyn A.] Univ Minnesota, Dept Neurosci, Minneapolis, MN 55455 USA	Fairbanks, CA (reprint author), Univ Minnesota, Dept Pharmaceut, 9-177 Weaver Densford Hall,308 Harvard St S E, Minneapolis, MN 55455 USA.	carfair@umn.edu			NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [F31 DA021054, R21 DA015387, F31 DA021054-01, K01 DA000509, K01 DA000509-05, K01DA-00509, R21DA-15387, R21 DA015387-02]		Aricioglu F, 2003, ANN NY ACAD SCI, V1009, P147, DOI 10.1196/annals.1304.016; Aricioglu F, 2004, NEUROSCI LETT, V354, P153, DOI 10.1016/j.neulet.2003.10.010; AriciogluKartal F, 1997, LIFE SCI, V61, P1775, DOI 10.1016/S0024-3205(97)00801-1; AUGUET M, 1995, JPN J PHARMACOL, V69, P285, DOI 10.1254/jjp.69.285; Benrath J, 2005, BRIT J ANAESTH, V95, P518, DOI 10.1093/bja/aei215; Colpaert FC, 2001, PAIN, V91, P33, DOI 10.1016/S0304-3959(00)00413-9; Demady DR, 2001, MOL PHARMACOL, V59, P24; Fairbanks CA, 2000, P NATL ACAD SCI USA, V97, P10584, DOI 10.1073/pnas.97.19.10584; Fairbanks CA, 1997, J PHARMACOL EXP THER, V282, P1408; Feng YZ, 2005, NEUROSCI LETT, V390, P129, DOI 10.1016/j.neulet.2005.08.008; Galea E, 1996, BIOCHEM J, V316, P247, DOI 10.1042/bj3160247; Gilad GM, 1996, J NEUROCHEM, V67, P1992; Goracke-Postle CJ, 2006, NEUROREPORT, V17, P13, DOI 10.1097/01.wnr.0000192739.38653.aa; Goracke-Postle CJ, 2007, J NEUROCHEM, V102, P1738, DOI 10.1111/j.1471-4159.2007.04647.x; HALEY JE, 1992, NEURON, V8, P211, DOI 10.1016/0896-6273(92)90288-O; HALEY TJ, 1957, BRIT J PHARM CHEMOTH, V12, P12, DOI 10.1111/j.1476-5381.1957.tb01354.x; HERMAN BH, 1995, NEUROPSYCHOPHARMACOL, V13, P269, DOI 10.1016/0893-133X(95)00140-9; Iyer RK, 2002, MOL GENET METAB, V75, P209, DOI 10.1006/mgme.2001.3277; Kiss JP, 2000, BRAIN RES BULL, V52, P459, DOI 10.1016/S0361-9230(00)00282-3; Kitto KF, 2006, EUR J PHARMACOL, V536, P133, DOI 10.1016/j.ejphar.2006.01.053; KITTO KF, 1992, NEUROSCI LETT, V148, P1, DOI 10.1016/0304-3940(92)90790-E; Kivastik T, 1996, PHARMACOL BIOCHEM BE, V53, P1013, DOI 10.1016/0091-3057(95)02092-6; Kolesnikov Y, 1996, EUR J PHARMACOL, V296, P17, DOI 10.1016/0014-2999(95)00669-9; KUPERS R, 1995, PAIN, V60, P137, DOI 10.1016/0304-3959(94)00106-O; LI G, 1994, SCIENCE, V263, P966, DOI 10.1126/science.7906055; Ma YY, 2006, EXP NEUROL, V200, P343, DOI 10.1016/j.expneurol.2006.02.117; Martin S, 2003, BRAIN RES, V973, P205, DOI 10.1016/S0006-8993(03)02482-X; Mistry SK, 2002, AM J PHYSIOL-GASTR L, V282, pG375, DOI 10.1152/ajpgi.00386.2001; Morgan AD, 2002, PHARMACOL BIOCHEM BE, V72, P873, DOI 10.1016/S0091-3057(02)00774-8; Myers WA, 2000, J COMP NEUROL, V418, P373; Nguyen HOX, 2003, ANN NY ACAD SCI, V1009, P82, DOI 10.1196/annals.1304.009; Ohno M, 2002, CURR BIOL, V12, P654, DOI 10.1016/S0960-9822(02)00767-4; Papp M, 2002, NEUROPSYCHOPHARMACOL, V27, P727, DOI 10.1016/S0893-133X(02)00349-4; Parsons CG, 1999, NEUROPHARMACOLOGY, V38, P735, DOI 10.1016/S0028-3908(99)00019-2; Parsons CG, 1999, NEUROPHARMACOLOGY, V38, P85, DOI 10.1016/S0028-3908(98)00161-0; Piletz JE, 2003, ANN NY ACAD SCI, V1009, P64, DOI 10.1196/annals.1304.007; Raasch W, 2002, BRIT J PHARMACOL, V135, P663, DOI 10.1038/sj.bjp.0704513; Reis DJ, 1998, J AUTONOM NERV SYST, V72, P80, DOI 10.1016/S0165-1838(98)00091-5; REYNOLDS IJ, 1990, BRIT J PHARMACOL, V101, P178, DOI 10.1111/j.1476-5381.1990.tb12109.x; Roberts J., 2007, THESIS; Roberts JC, 2005, J PHARMACOL EXP THER, V314, P1226, DOI 10.1124/jpet.105.086173; Sahraei H, 2004, PHARMACOL BIOCHEM BE, V77, P111, DOI 10.1016/j.pbb.2003.10.008; Semenova S, 1999, EUR J PHARMACOL, V378, P1, DOI 10.1016/S0014-2999(99)00431-8; Yang XC, 1999, J PHARMACOL EXP THER, V288, P544	44	13	13	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0014-2999	1879-0712		EUR J PHARMACOL	Eur. J. Pharmacol.	JUN 10	2008	587	1-3					135	140		10.1016/j.ejphar.2008.04.007			6	Pharmacology & Pharmacy	Pharmacology & Pharmacy	314PR	WOS:000256821800020	18495108	Green Accepted			2020-06-30	J	Malkawi, AH; Al-Ghananeem, AM; Crooks, PA				Malkawi, Ahmad H.; Al-Ghananeem, Abeer M.; Crooks, Peter A.			Development of a GC-MS assay for the determination of fentanyl pharmacokinetics in rabbit plasma after sublingual spray delivery	AAPS JOURNAL			English	Article						breakthrough pain; fentanyl; GC-MS; spray; sublingual delivery	GAS-CHROMATOGRAPHY; ABSORPTION CHARACTERISTICS; CLINICAL PHARMACOKINETICS; LIQUID-CHROMATOGRAPHY; DRUG-DELIVERY; ALFENTANIL; BIOAVAILABILITY; SYSTEM		[Malkawi, Ahmad H.; Al-Ghananeem, Abeer M.; Crooks, Peter A.] Univ Kentucky, Coll Pharm, Lexington, KY 40536 USA	Crooks, PA (reprint author), Univ Kentucky, Coll Pharm, Lexington, KY 40536 USA.	pcrooks@email.uky.edu					Al-Ghananeem AM, 2007, DRUG DEV IND PHARM, V33, P577, DOI 10.1080/03639040600943848; Al-Ghananeem AM, 2006, AAPS PHARMSCITECH, V7, DOI 10.1208/pt070123; BJORKMAN S, 1988, J CHROMATOGR-BIOMED, V433, P95, DOI 10.1016/S0378-4347(00)80588-5; Bredenberg S, 2003, EUR J PHARM SCI, V20, P327, DOI 10.1016/j.ejps.2003.07.002; CAMPISTRON G, 1988, CLIN CHEM, V34, P2157; DEWELL WM, 1993, AM J HOSP PHARM, V50, P2374, DOI 10.1093/ajhp/50.11.2374; HALL GM, 1980, BRIT J ANAESTH, V52, P561, DOI 10.1093/bja/52.6.561; HANKS G, 1998, [No title captured]; HARRIS D, 1992, J PHARM SCI-US, V81, P1, DOI 10.1002/jps.2600810102; KINTZ P, 1989, J CHROMATOGR-BIOMED, V489, P459, DOI 10.1016/S0378-4347(00)82930-8; KUMAR K, 1987, J CHROMATOGR-BIOMED, V419, P464, DOI 10.1016/0378-4347(87)80317-1; LAGANIERE S, 1993, CLIN CHEM, V39, P2206; Mannila J, 2006, LIFE SCI, V78, P1911, DOI 10.1016/j.lfs.2005.08.025; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; MCCLAIN DA, 1980, CLIN PHARMACOL THER, V28, P106, DOI 10.1038/clpt.1980.138; MOCK DL, 1986, ANESTH ANALG, V65, P5102; MOORE JM, 1986, ANAL CHEM, V58, P1656, DOI 10.1021/ac00121a013; Mystakidou K, 2004, IN VIVO, V18, P633; PORTENOY RK, 1993, ANESTHESIOLOGY, V78, P36, DOI 10.1097/00000542-199301000-00007; Portenoy RK, 1999, LANCET, V353, P1695, DOI 10.1016/S0140-6736(99)01310-0; RATHBONE MJ, 1996, DRUGS PHARM SCI, V74, P121; SCHUTTLER J, 1984, ANESTHESIOLOGY, V61, P315, DOI 10.1097/00000542-198409000-00010; SLATTERY PJ, 1985, DRUGS, V30, P539, DOI 10.2165/00003495-198530060-00005; STREISAND JB, 1991, ANESTHESIOLOGY, V75, P223, DOI 10.1097/00000542-199108000-00009; TSUCHIYA M, 1991, JPN J ANESTHESIOL, V40, P644; VARVEL JR, 1989, ANESTHESIOLOGY, V70, P928, DOI 10.1097/00000542-198906000-00008; WANG WL, 1993, FORENSIC SCI INT, V61, P65, DOI 10.1016/0379-0738(93)90250-E; WEINBERG DS, 1988, CLIN PHARMACOL THER, V44, P335, DOI 10.1038/clpt.1988.159; WOESTENBORGHS RJH, 1987, ANESTHESIOLOGY, V67, P85, DOI 10.1097/00000542-198707000-00015; Zhang H, 2002, CLIN PHARMACOKINET, V41, P661, DOI 10.2165/00003088-200241090-00003	30	19	20	1	6	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1550-7416			AAPS J	AAPS J.	JUN	2008	10	2					261	267		10.1208/s12248-008-9031-x			7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	347IK	WOS:000259133600004	18459057	Green Published			2020-06-30	J	Thomas, S; Winecker, R; Pestaner, JP				Thomas, Sandra; Winecker, Ruth; Pestaner, Joseph P.			Unusual fentanyl patch administration	AMERICAN JOURNAL OF FORENSIC MEDICINE AND PATHOLOGY			English	Article						fentanyl; overdose; patch; fatal	ABUSE	Fentanyl is an extremely potent narcotic analgesic that is becoming more popular as a drug of abuse. Because of. the unique way in which the drug is packaged and delivered, the potential for unusual methods of abuse exists. We report the first case of true fentanyl patch ingestion in the medical literature. Initially, though unusual, cases of fentanyl ingestion were thought to have been reported, but further investigation of the literature revealed that in other case reports the patches had been held in the mouth and chewed. Because no reports of swallowing the patch had been published, suicide was initially a strong consideration in this case; however, further investigation showed that the decedent and his brother enjoyed swallowing the patches for quick "highs." Cases such as these serve to remind medical examiners and law enforcement officials of the value of performing thorough death investigations by performing complete autopsies with toxicological testing and correlating with investigation information to form an opinion with regard to the cause and manner of death.	[Thomas, Sandra; Pestaner, Joseph P.] E Carolina Univ, Brody Sch Med, Dept Pathol & Lab Med, Greenville, NC 27834 USA; [Thomas, Sandra] Pitt Cty Mem Hosp, Greenville, NC USA; [Winecker, Ruth] Off Chief Med Examiner N Carolina, Chapel Hill, NC USA	Thomas, S (reprint author), E Carolina Univ, Brody Sch Med, Dept Pathol & Lab Med, 600 Moye Blvd, Greenville, NC 27834 USA.	thomassa@mail.ecu.edu					Anderson DT, 2000, J ANAL TOXICOL, V24, P627, DOI 10.1093/jat/24.7.627; Barrueto F, 2004, VET HUM TOXICOL, V46, P30; DONALD E, DRUGS ABUSE; Gourlay G K, 2001, Lancet Oncol, V2, P165, DOI 10.1016/S1470-2045(00)00258-8; HENDERSON GL, 1991, J FORENSIC SCI, V36, P422; Kramer Christopher, 1998, Journal of the American Osteopathic Association, V98, P385; Kuhlman JJ, 2003, J ANAL TOXICOL, V27, P499, DOI 10.1093/jat/27.7.499; PRESNELL SE, 2004, NAME M; PUGH MB, 2000, [No title captured]; Purucker M, 2000, ANN EMERG MED, V35, P314, DOI 10.1016/S0196-0644(00)70091-6; SNELL KS, 2002, P AM ACAD FOR SCI AT, V8; 2005, FENTANYL MONOGRAPHS, P1122	12	13	14	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0195-7910			AM J FOREN MED PATH	Am. J. Forensic Med. Pathol.	JUN	2008	29	2					162	163		10.1097/PAF.0b013e3181651b66			2	Medicine, Legal; Pathology	Legal Medicine; Pathology	306QH	WOS:000256262400013	18520485				2020-06-30	J	Tufanogullari, B; White, PF; Peixoto, MP; Kianpour, D; Lacour, T; Griffin, J; Skrivanek, G; Macaluso, A; Shah, M; Provost, DA				Tufanogullari, Burcu; White, Paul F.; Peixoto, Mariana P.; Kianpour, Daniel; Lacour, Thomas; Griffin, James; Skrivanek, Gary; Macaluso, Amy; Shah, Mary; Provost, David A.			Dexmedetomidine infusion during laparoscopic bariatric surgery: The effect on recovery outcome variables	ANESTHESIA AND ANALGESIA			English	Article							INCREASING PLASMA-CONCENTRATIONS; ABDOMINAL HYSTERECTOMY; VASCULAR-SURGERY; ANESTHESIA; PREMEDICATION; REQUIREMENTS; ISOFLURANE; ANALGESIA; EFFICACY; PATIENT	BACKGROUND: Dexmedetomidine (Dex), an alpha(2) agonist, has well-known anesthetic and analgesic-sparing effects. We designed this prospective, randomized, double-blind, and placebo-controlled dose-ranging study to evaluate the effect of Dex on both early and late recovery after laparoscopic bariatric surgery. METHODS: Eighty consenting ASA II-III morbidly obese patients were randomly assigned to I of 4 treatment groups: (1) control group received a saline infusion during surgery, (2) Dex 0.2 group received an infusion of 0.2 mu g . kg(-1) . h(-1) IV, (3) Dex 0.4 group received an infusion of 0.4 mu g . kg . h(-1) IV, and (4) Dex 0.8 group received an infusion of 0.8 mu g . kg(-1) . h(-1) IV. Mean arterial blood pressure values were maintained within +/- 25% of the preinduction baseline values by varying the inspired desflurane concentration. Perioperative hemodynamic variables, postoperative pain scores, and the need for "rescue" analgesics and antiemetics were recorded at specific intervals. Follow-up evaluations were performed on postoperative days (PODs) 1, 2, and 7 to assess severity of pain, analgesic requirements, patient satisfaction with pain management, quality of recovery, as well as resumption of dietary intake and recovery of bowel function. RESULTS: Dex infusion, 0.2, 0.4, and 0.8 mu g . kg(-1) . h(-1), reduced the average end-tidal desflurane concentration by 19, 20, and 22%, respectively. However, it failed to facilitate a significantly faster emergence from anesthesia. Although the intraoperative hemodynamic values were similar in the four groups, arterial blood pressure values were significantly reduced in the Dex 0.2, 0.4, and 0.8 groups compared with the control group on admission to the postanesthesia care unit (PACU) (P < 0.05). The length of the PACU stay was significantly reduced in the Dex groups (81 +/- 31 to 87 +/- 24 vs 104 +/- 33 min in the control group, P < 0.05). The amount of rescue fentanyl administered in the PACU was significantly less in the Dex 0.2, 0.4, and 0.8 groups versus control group (113 +/- 85, 108 +/- 67, and 120 +/- 78 vs 187 +/- 99 mu g, respectively, P < 0.05). The percentage of patients requiring antiemetic therapy was also reduced in the Dex groups (30, 30, and 10% vs 70% in the control group). However, the patient-controlled analgesia morphine requirements on PODs 1 and 2 were not different among the four groups. Pain scores in the PACU, and on PODs 1., 2, and 7, in the three Dex groups were not different from the control group. Finally, quality of recovery scores and times to recovery of bowel function and hospital discharge did not differ among the four groups. CONCLUSIONS: Adjunctive use of an intraoperative Dex infusion (0.2-0.8 mu g . kg(-1) . h(-1)) decreased fentanyl use, antiemetic therapy, and the length of stay in the PACU. However, it failed to facilitate late recovery (e.g., bowel function) or improve the patients' overall quality of recovery. When used during bariatric surgery, a Dex infusion rate of 0.2 mu g . kg(-1) . h(-1) is recommended to minimize the risk of adverse cardiovascular side effects.	[Tufanogullari, Burcu; White, Paul F.; Peixoto, Mariana P.; Kianpour, Daniel; Lacour, Thomas; Griffin, James; Skrivanek, Gary; Macaluso, Amy; Shah, Mary] Univ Texas SW Med Ctr Dallas, Dept Anesthesiol & Pain Management, Dallas, TX 75390 USA; [Provost, David A.] Univ Texas SW Med Ctr Dallas, Dept Surg, Dallas, TX 75390 USA	White, PF (reprint author), Univ Texas SW Med Ctr Dallas, Dept Anesthesiol & Pain Management, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	paul.white@utsouthwestern.edu					Aantaa R, 1997, ANESTHESIOLOGY, V86, P1055, DOI 10.1097/00000542-199705000-00008; AANTAA RE, 1990, ANESTH ANALG, V70, P407; AHO M, 1992, ANESTH ANALG, V75, P940; AHO M, 1991, ANESTHESIOLOGY, V74, P997, DOI 10.1097/00000542-199106000-00005; Angst MS, 2004, ANESTHESIOLOGY, V101, P744, DOI 10.1097/00000542-200409000-00024; Arain SR, 2004, ANESTH ANALG, V98, P153, DOI 10.1213/01.ANE.0000093225.39866.75; Arain SR, 2002, ANESTH ANALG, V95, P461, DOI 10.1097/00000539-200208000-00042; Bisgaard T, 2006, ANESTHESIOLOGY, V104, P835, DOI 10.1097/00000542-200604000-00030; Ebert T, 2004, ANESTHESIOLOGY, V101, P568, DOI 10.1097/00000542-200409000-00003; Ebert TJ, 2000, ANESTHESIOLOGY, V93, P382, DOI 10.1097/00000542-200008000-00016; ERKOLA O, 1994, ANESTH ANALG, V79, P646; Feld JM, 2006, J CLIN ANESTH, V18, P24, DOI 10.1016/j.jclinane.2005.05.009; Guler G, 2005, ACTA ANAESTH SCAND, V49, P1088, DOI 10.1111/j.1399-6576.2005.00780.x; Gurbet A, 2006, CAN J ANAESTH, V53, P646, DOI 10.1007/BF03021622; Hall JE, 2000, ANESTH ANALG, V90, P699, DOI 10.1097/00000539-200003000-00035; Hofer RE, 2005, CAN J ANAESTH, V52, P176, DOI 10.1007/BF03027725; Ingersoll-Weng E, 2004, ANESTHESIOLOGY, V100, P738, DOI 10.1097/00000542-200403000-00040; Jalonen J, 1997, ANESTHESIOLOGY, V86, P331; KALLIO A, 1989, CLIN PHARMACOL THER, V46, P33, DOI 10.1038/clpt.1989.103; Myles PS, 1999, ANESTH ANALG, V88, P83, DOI 10.1097/00000539-199901000-00016; Paris A, 2005, CURR OPIN ANESTHESIO, V18, P412, DOI 10.1097/01.aco.0000174958.05383.d5; Ramsay MAE, 2004, ANESTHESIOLOGY, V101, P787; Ramsay MAE, 2006, J CLIN ANESTH, V18, P452, DOI 10.1016/j.jclinane.2006.02.004; TALKE P, 1995, ANESTHESIOLOGY, V82, P620, DOI 10.1097/00000542-199503000-00003; Talke P, 2000, ANESTH ANALG, V90, P834, DOI 10.1213/00000539-200004000-00011; Talke P, 1997, ANESTH ANALG, V85, P1136, DOI 10.1097/00000539-199711000-00033; Tanskanen PE, 2006, BRIT J ANAESTH, V97, P658, DOI 10.1093/bja/ael220; White PF, 2007, ANESTH ANALG, V104, P1380, DOI 10.1213/01.ane.0000263034.96885.e1	28	160	178	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	JUN	2008	106	6					1741	1748		10.1213/ane.0b013e318172c47c			8	Anesthesiology	Anesthesiology	303XU	WOS:000256075200021	18499604				2020-06-30	J	Larson, MD				Larson, Merlin D.			Mechanism of opioid-induced pupillary effects	CLINICAL NEUROPHYSIOLOGY			English	Article						opioids; pupil; pupillary reflex dilation; pupilloconstrictor nucleus	ROSTRAL VENTROMEDIAL MEDULLA; LIGHT REFLEX; GENERAL-ANESTHESIA; NOXIOUS-STIMULATION; PERIAQUEDUCTAL GRAY; DILATION; MORPHINE; BLOCK; RAT; CAT	Objective: This study tested the hypothesis that increased activity in the pupilloconstrictor nucleus by the addition of ambient light and by the administration of fentanyl, sufficient to block pupillary reflex dilation, constricts the pupil of anesthetized patients. Methods: Pupil diameter was measured in 10 anesthetized patients during noxious stimulation above an epidural block level, in darkness and then with light directed into the left eye. Two measurements were taken from the right eye separated by 5 min. Following the second measurement, fentanyl (1 mcg/kg) was administered and the measures in light and dark were repeated. The effect of light and fentanyl on pupil size and pupillary reflex dilation were analyzed. Results: An increase in light directed into the left eye constricted the pupil from 2.15 +/- 0.38 to 1.87 +/- 0.40 mm before fentanyl. Fentanyl did not constrict the pupil either in darkness or light but it did decrease pupillary reflex dilation by 49%. Conclusions: The miotic pupil during general anesthesia is not maximally constricted. Increased excitation of the pupilloconstrictor nucleus does not account for blockade of pupillary reflex dilation after fentanyl administration during desflurane anesthesia. Significance: This study does not support the hypothesis that opioid effects on the human pupil are brought about by a direct excitatory action on the pupilloconstrictor nucleus. (c) 2008 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.	Univ Calif San Francisco, Dept Anesthesia & Perioperat Care, San Francisco, CA 94143 USA	Larson, MD (reprint author), Univ Calif San Francisco, Dept Anesthesia & Perioperat Care, 521 Parnassus Ave,POB 0648, San Francisco, CA 94143 USA.	larsonm@anesthesia.ucsf.edu					BARBARO NM, 1989, SOMATOSENS MOT RES, V6, P413, DOI 10.3109/08990228909144684; BEHBEHANI MM, 1990, NEUROSCIENCE, V38, P373, DOI 10.1016/0306-4522(90)90035-3; BELANI KG, 1993, ANESTHESIOLOGY, V79, P23, DOI 10.1097/00000542-199307000-00006; BERLUCCHI G, 1964, Arch Ital Biol, V102, P230; BONVALLET M, 1963, Arch Ital Biol, V101, P174; BREMER F, 1935, COMPTE RENDU SOC BIO, V18, P1235; CHENG ZF, 1986, BRAIN RES, V375, P57, DOI 10.1016/0006-8993(86)90958-3; Christie MJ, 2000, CLIN EXP PHARMACOL P, V27, P520, DOI 10.1046/j.1440-1681.2000.03291.x; DANIEL M, 1995, ANESTH ANALG, V81, P372, DOI 10.1097/00000539-199508000-00028; DUGGAN AW, 1983, PHARMACOL REV, V35, P219; FIELDS HL, 1988, PROG BRAIN RES, V77, P245; FONTANA F, 2001, NELLA STAMPERIA JAAC, P1; GLANTZ SA, 2002, [No title captured]; Gray AT, 1997, ARCH NEUROL-CHICAGO, V54, P579, DOI 10.1001/archneur.1997.00550170055014; Gutstein H.B., 2006, GOODMAN GILMANS PHAR; HEINRICHER MM, 1994, NEUROSCIENCE, V63, P279, DOI 10.1016/0306-4522(94)90022-1; Ichinohe N, 2001, AUTON NEUROSCI-BASIC, V94, P42, DOI 10.1016/S1566-0702(01)00342-3; Larson MD, 2007, BRIT J ANAESTH, V98, P263, DOI 10.1093/bja/ael335; LARSON MD, 1991, ANESTHESIOLOGY, V75, P62, DOI 10.1097/00000542-199107000-00011; Larson MD, 2004, J APPL PHYSIOL, V97, P725, DOI 10.1152/japplphysiol.00098.2004; Larson MD, 1997, ANESTHESIOLOGY, V87, P849, DOI 10.1097/00000542-199710000-00019; Larson MD, 1996, ANESTHESIOLOGY, V85, P748, DOI 10.1097/00000542-199610000-00009; Larson MD, 2003, ANESTH ANALG, V97, P1652, DOI 10.1213/01.ANE.0000090011.19809.93; Larson MD, 1997, REGION ANESTH, V22, P461, DOI 10.1016/S1098-7339(97)80034-X; Larson MD, 2001, BRIT J CLIN PHARMACO, V51, P27, DOI 10.1046/j.1365-2125.2001.01311.x; LARSON MD, 1993, ANESTHESIOLOGY, V79, P42, DOI 10.1097/00000542-199307000-00009; LARSON MD, 1993, ANESTH ANALG, V76, P1072; Larson MD, 2006, ANESTHESIOLOGY, V105, P632, DOI 10.1097/00000542-200609000-00041; LEE HK, 1975, J PHARMACOL EXP THER, V192, P415; LOEWENFELD I, 1993, PUPIL ANATOMY PHYSL; LOEWENFELD IE, 1958, DOC OPTHALMOL, V12, P184; LOWENSTEIN O, 1964, ANN NY ACAD SCI, V117, P142, DOI 10.1111/j.1749-6632.1964.tb48169.x; MARTIN WR, 1961, J PHARMACOL EXP THER, V133, P262; MORGAN MM, 1992, NEUROSCIENCE, V47, P863, DOI 10.1016/0306-4522(92)90036-2; MURRAY RB, 1983, LIFE SCI, V33, P495, DOI 10.1016/0024-3205(83)90123-6; OKUDERA T, 1978, MT SINAI J MED, V45, P305; PICKWORTH WB, 1985, J PHARMACOL EXP THER, V234, P603; POSNER JB, 2007, PLUM POSNERS DIAGNOS, P167; ROSSI G. F., 1957, ARCH SCI BIOL BOLOGNA, V41, P46; SHARPE LG, 1985, BRAIN RES BULL, V15, P329, DOI 10.1016/0361-9230(85)90159-5; SILLITO AM, 1970, J PHYSIOL-LONDON, V211, P767, DOI 10.1113/jphysiol.1970.sp009303; SMITH J D, 1970, Brain Research, V24, P219, DOI 10.1016/0006-8993(70)90102-2; Sotomayor R, 2005, J NEUROSCI RES, V81, P132, DOI 10.1002/jnr.20537	43	32	32	0	5	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1388-2457	1872-8952		CLIN NEUROPHYSIOL	Clin. Neurophysiol.	JUN	2008	119	6					1358	1364		10.1016/j.clinph.2008.01.106			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	309ZP	WOS:000256499000018	18397839				2020-06-30	J	Lightdale, JR; Valim, C; Newburg, AR; Mahoney, LB; Zgleszewski, S; Fox, VL				Lightdale, Jenifer R.; Valim, Clarissa; Newburg, Adrienne R.; Mahoney, Lisa B.; Zgleszewski, Steven; Fox, Victor L.			Efficiency of propofol versus midazolam and fentanyl sedation at a pediatric teaching hospital: a prospective study	GASTROINTESTINAL ENDOSCOPY			English	Article							GI ENDOSCOPY; OUTPATIENT COLONOSCOPY; GENERAL-ANESTHESIA; DEEP SEDATION; MEPERIDINE; GASTROENTEROLOGIST; EXPERIENCE; NURSES; TRIAL; SUITE	Background: Many pediatric endoscopists are adopting propofol in their practices, with the expectation that propofol will increase their overall efficiency. Objective and Setting: To compare the efficiency of propofol versus midazolam and fentanyl by measuring elapsed times between initial intravenous administration and patient discharge at a pediatric teaching hospital. Design: Endoscopy times were prospectively collected for consecutive patients who were undergoing either anesthesiologist-administered propofol or endoscopist-administered midazolam and fentanyl. The effect of the type of sedation on these times was assessed by using multiple linear regression by adjusting for other candidate predictors, including concomitant use of other sedatives, endotracheal intubation by anesthesiologists, and the presence of fellow trainees. Main Outcome Measurements: Time to onset of sedation (time sedation started to scope in), procedure time (endoscope in to endoscope out), discharge time (endoscope out to hospital discharge), and total time (sedation started to hospital discharge). Results: The times for 134 children (mean age 12 +/- 5 years) to receive propofol sedation were compared with those of 195 children (13 5 years) who received midazolam and fentanyl. Midazolam and fentanyl cases disproportionately included EGDs (P < .001) and patients who were classified as American Society of Anesthesiologists I (P < .03). Patients who received propofol had shorter times until sedated, similar procedure times, longer discharge times, and comparable total times. Multivariate analyses confirmed that fellow participation prolonged the procedure times (P < .0001), and endotracheal intubation prolonged propofol times (P < 01), but adjusting for these did not change the comparison results. Conclusions: Anesthesiologist-administered propofol sedation in a pediatric teaching endoscopy unit may not lead to faster hospital times when compared with endoscopist-administered midazolam and fentanyl. These results are not explained by controlling for patient characteristics, the presence of a trainee, the sedative doses, or endotracheal intubation for air-way management.	[Lightdale, Jenifer R.; Newburg, Adrienne R.; Mahoney, Lisa B.; Fox, Victor L.] Harvard Univ, Sch Publ Hlth, Div Gastroenterol, Boston, MA 02115 USA; [Zgleszewski, Steven] Harvard Univ, Sch Publ Hlth, Dept Anesthesiol, Boston, MA 02115 USA; [Valim, Clarissa] Harvard Univ, Sch Publ Hlth, Childrens Hosp, Dept Biostat, Boston, MA 02115 USA; [Lightdale, Jenifer R.; Valim, Clarissa] Harvard Univ, Sch Publ Hlth, Clin Res Program, Boston, MA 02115 USA	Lightdale, JR (reprint author), Childrens Hosp, Div Gastroenterol & Nutr, 300 Longwood Ave, Boston, MA 02115 USA.				AHRQ HHSUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [K08 HS013675]		*AM SOC AN, [No title captured]; APFELBAUM JL, 1993, ANESTH ANALG, V77, pS10; Barbi E, 2003, ARCH PEDIAT ADOL MED, V157, P1097, DOI 10.1001/archpedi.157.11.1097; CHUANG E, 1995, GASTROINTEST ENDOSC, V42, P156, DOI 10.1016/S0016-5107(95)70073-0; Cohen LB, 2003, GASTROINTEST ENDOSC, V58, P725, DOI 10.1016/S0016-5107(03)02010-8; Eyres R, 2004, PEDIATR ANESTH, V14, P374, DOI 10.1111/j.1460-9592.2004.01333.x; Faulx AL, 2005, GASTROINTEST ENDOSC, V62, P9, DOI 10.1016/S0016-5107(05)00518-3; Gozal D, 2004, J PEDIATR-US, V145, P47, DOI 10.1016/j.jpeds.2004.01.044; Jung M, 2000, ENDOSCOPY, V32, P233, DOI 10.1055/s-2000-96; Kaddu R, 2002, GASTROINTEST ENDOSC, V55, P27, DOI 10.1067/mge.2002.120386; KANTO J, 1989, CLIN PHARMACOKINET, V17, P308, DOI 10.2165/00003088-198917050-00002; Khoshoo V, 2003, J PEDIATR GASTR NUTR, V37, P146, DOI 10.1097/00005176-200308000-00012; Koshy G, 2000, AM J GASTROENTEROL, V95, P1476; Lugay M, 1996, Gastroenterol Nurs, V19, P194, DOI 10.1097/00001610-199611000-00002; Mamula P, 2007, GASTROINTEST ENDOSC, V65, P203, DOI 10.1016/j.gie.2006.05.002; Pavlin DJ, 1998, ANESTH ANALG, V87, P816, DOI 10.1097/00000539-199810000-00014; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; Reimann FM, 2000, ENDOSCOPY, V32, P239, DOI 10.1055/s-2000-134; Rex DK, 2005, GASTROENTEROLOGY, V129, P1384, DOI 10.1053/j.gastro.2005.08.014; Rudner R, 2003, GASTROINTEST ENDOSC, V57, P657, DOI 10.1067/mge.2003.207; Schuttler J, 2000, ANESTHESIOLOGY, V92, P727, DOI 10.1097/00000542-200003000-00017; Seifert H, 2000, ALIMENT PHARM THERAP, V14, P1207; Sipe BW, 2002, GASTROINTEST ENDOSC, V55, P815, DOI 10.1067/mge.2002.124636; TOLIA V, 1990, DEV PHARMACOL THERAP, V14, P141, DOI 10.1159/000480912; Ulmer BJ, 2003, CLIN GASTROENTEROL H, V1, P425, DOI 10.1016/S1542-3565(03)00226-X; Vargo JJ, 2002, GASTROENTEROLOGY, V123, P8, DOI 10.1053/gast.2002.34232; Walker JA, 2003, AM J GASTROENTEROL, V98, P1744, DOI 10.1016/S0002-9270(03)00496-9; Wengrower D, 2004, SCAND J GASTROENTERO, V39, P283, DOI 10.1080/00365520310008467; White P F, 1991, J Clin Anesth, V3, P32, DOI 10.1016/0952-8180(91)90203-Y; Willey J, 2002, GASTROINTEST ENDOSC, V56, P810, DOI 10.1067/mge.2002.129609; Wurz Susan M, 2004, Gastroenterol Nurs, V27, P69, DOI 10.1097/00001610-200403000-00007; Yong E, 2006, GASTROINTEST ENDOSC, V64, P760, DOI 10.1016/j.gie.2006.02.047; Zamir S, 2002, AM J GASTROENTEROL, V97, P1968	33	17	18	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0016-5107			GASTROINTEST ENDOSC	Gastrointest. Endosc.	JUN	2008	67	7					1067	1075		10.1016/j.gie.2007.11.038			9	Gastroenterology & Hepatology	Gastroenterology & Hepatology	310GE	WOS:000256516100012	18367187				2020-06-30	J	Newman, LC; Newman, EB				Newman, Lawrence C.; Newman, Eric B.			Rebound abdominal pain: Noncephalic pain in abdominal migraine is exacerbated by medication overuse	HEADACHE			English	Article						abdominal migraine; medication overuse; medication overuse; childhood; periodic syndromes	CHRONIC DAILY HEADACHE	Abdominal migraine usually has its onset during childhood or adolescence and resolves in adulthood, often being replaced by typical migraine headaches. Rarely, migraine headache and recurrent abdominal pain coexist in some patients during adulthood. We report a patient who developed abdominal migraine without headaches beginning for the first time at the age of 22 years. The abdominal symptoms increased in frequency coincident with medication overuse and resolved after the overuse was treated. Analgesic overuse may cause a worsening of noncephalic pain in patients with extra-cephalic variants of migraine.	[Newman, Lawrence C.] Roosevelt Hosp Ctr, Headache Inst, New York, NY USA; [Newman, Eric B.] John Jay Sch Sci Res, Cross River, NY USA	Newman, LC (reprint author), Roosevelt Hosp Ctr, Headache Inst, 1000 10th Ave, New York, NY USA.			Newman, Lawrence/0000-0002-2431-1570			ABUARAFEH I, 1995, ARCH DIS CHILD, V72, P413, DOI 10.1136/adc.72.5.413; Bahra A, 2003, HEADACHE, V43, P179, DOI 10.1046/j.1526-4610.2003.03041.x; d'Onofrio F, 2006, EUR J NEUROL, V13, P85, DOI 10.1111/j.1468-1331.2006.01129.x; DIGAN F, 2002, ARCH DIS CHILD, V84, P415; Headache Classification Subcommittee of the International Headache Society, 2004, CEPHALALGIA, V24, P30; MATHEW NT, 1982, HEADACHE, V22, P66, DOI 10.1111/j.1526-4610.1982.hed2202066.x; Moran JA, 1998, IRISH MED J, V91, P215; Pryszmont M, 1998, Neurol Neurochir Pol, V32, P395; Santoro G, 1990, Funct Neurol, V5, P61; Silberstein SD, 2005, CEPHALALGIA, V25, P460, DOI 10.1111/j.1468-2982.2005.00878.x; SYMON DNK, 1986, CEPHALALGIA, V6, P223, DOI 10.1046/j.1468-2982.1986.0604223.x; Wilkinson SM, 2001, HEADACHE, V41, P303, DOI 10.1046/j.1526-4610.2001.111006303.x	12	10	10	1	3	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0017-8748			HEADACHE	Headache	JUN	2008	48	6					959	961		10.1111/j.1526-4610.2008.01126.x			3	Clinical Neurology	Neurosciences & Neurology	308SM	WOS:000256410300032	18479426				2020-06-30	J	Minville, V; Lubrano, V; Bounes, V; Pianezza, A; Gris, C; Fourcade, O; Rabinowitz, A; Samii, K				Minville, Vincent; Lubrano, Vincent; Bounes, Vincent; Pianezza, Antoine; Gris, Claude; Fourcade, Olivier; Rabinowitz, Anna; Samii, Kamran			Postoperative analgesia after total hip arthroplasty: patient-controlled analgesia versus transdermal fentanyl patch	JOURNAL OF CLINICAL ANESTHESIA			English	Article						analgesia; fentanyl; matrix transdermal delivery system; patient-controlled analgesia; postoperative care	PAIN MANAGEMENT; MORPHINE; PHARMACOKINETICS; SURGERY; BLOCK	Study Objective: To determine whether a new transdermal fentanyl patch (TFP) is a good choice for the postoperative pain management of patients undergoing primary total hip arthroplasty compared with patient-controlled analgesia (PCA). Design: Randomized, prospective study. Setting: University hospital. Patients: 30 patients undergoing primary total hip arthoplasty. Interventions: Patients received either a TFP (group T; Duragesic 50 mu g/h, matrix fentanyl patch, Janssen-Cilag) applied approximately 10 hours before induction of general anesthesia and PCA programmed in the postanesthesia care unit (PACU), or PCA programmed in the PACU (group P). Measurements: Intraoperative sufentanil and additional postoperative morphine administration were recorded, as well as visual analog scores and routine vital signs at predetermined intervals during the first 48 hours. Main Results: Morphine consumption on arrival in the PACU was 3.5 +/- 3 mg in group T versus 13 +/- 5 mg in group P (P < 0.0001). Visual analog scores on arrival in the PACU were 37 +/- 22 mm in group T versus 73 +/- 13 mm in group P (P < 0.0001). Cumulative morphine consumption at the 24th hour was 43 +/- 16 mg in group P and 4 +/- 3 mg in group T (P < 0.0001). Cumulative morphine consumption at the 48th hour was 54 +/- 26 mg in group P and 5 +/- 4 mg in group T (P < 0.0001). Intraciperative sufentanil consumption was 38 +/- 15 mu g in group T versus 30 +/- 5 mu g in group P (not significant). The sedation score was 0 in both groups during the first 48 postoperative hours. Conclusions: Preoperative TFP application decreases pain scores and morphine consumption in the PACU and appears to have prolonged effects spanning the first 48 postoperative hours, (C) 2008 Elsevier Inc. All rights reserved.	[Minville, Vincent; Bounes, Vincent; Pianezza, Antoine; Gris, Claude; Fourcade, Olivier; Samii, Kamran] Univ Toulouse 3, Univ Hosp Toulouse, Rangueil Hosp, Dept Anesthesiol & Intens Care,GRCB 48, F-31403 Toulouse, France; [Lubrano, Vincent] Toulouse Univ Hosp, Federat Neurosurg, INSERM, U455, F-31403 Toulouse, France; [Rabinowitz, Anna] Univ Penn, Sch Med, Philadelphia, PA 19104 USA; [Minville, Vincent] Toulouse Univ, Hosp Rangueil, INSERM, U858,Physiol Lab, F-31403 Toulouse, France	Minville, V (reprint author), Univ Toulouse 3, Univ Hosp Toulouse, Rangueil Hosp, Dept Anesthesiol & Intens Care,GRCB 48, F-31403 Toulouse, France.	vincentminville@yahoo.fr	lubrano, vincent/E-4595-2012	Minville, Vincent/0000-0003-0516-4939			Biboulet P, 2004, REGION ANESTH PAIN M, V29, P102, DOI 10.1016/j.rapm.2003.11.006; CAPLAN RA, 1989, JAMA-J AM MED ASSOC, V261, P1036, DOI 10.1001/jama.261.7.1036; Gourlay G K, 2001, Lancet Oncol, V2, P165, DOI 10.1016/S1470-2045(00)00258-8; GOURLAY GK, 1989, PAIN, V37, P193, DOI 10.1016/0304-3959(89)90130-9; Marier JF, 2006, J CLIN PHARMACOL, V46, P642, DOI 10.1177/0091270006286901; N'Guyen L, 2004, ANN FR ANESTH, V23, P1016, DOI 10.1016/j.annfar.2004.08.003; Pechevis M, 2000, LETT PHARM, V14, P10; Pico L, 2000, CAN J ANAESTH, V47, P309, DOI 10.1007/BF03020943; ROWBOTHAM DJ, 1989, BRIT J ANAESTH, V63, P56, DOI 10.1093/bja/63.1.56; Sevarino FB, 1997, J CLIN ANESTH, V9, P173, DOI 10.1016/S0952-8180(97)00043-3; SEVARINO FB, 1992, ANESTHESIOLOGY, V77, P463, DOI 10.1097/00000542-199209000-00010; Singelyn FJ, 1999, J CLIN ANESTH, V11, P550, DOI 10.1016/S0952-8180(99)00092-6; Thompson JP, 1998, BRIT J ANAESTH, V81, P152; VARVEL JR, 1989, ANESTHESIOLOGY, V70, P928, DOI 10.1097/00000542-198906000-00008	14	15	15	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180			J CLIN ANESTH	J. Clin. Anesth.	JUN	2008	20	4					280	283		10.1016/j.jclinane.2007.12.013			4	Anesthesiology	Anesthesiology	331LM	WOS:000258013700008	18617126				2020-06-30	J	Abdel-Wahab, M; Khattab, AA; Liska, B; Kassner, G; Geist, V; Toelg, R; Richardt, G				Abdel-Wahab, Mohamed; Khattab, Ahmed A.; Liska, Branislav; Kassner, Guido; Geist, Volker; Toelg, Ralph; Richardt, Gert			Diazepam versus Fentanyl for Premedication during Percutaneous Coronary Intervention: Results from the Myocardial Protection by Fentanyl during Coronary Intervention (PROFIT) Trial	JOURNAL OF INTERVENTIONAL CARDIOLOGY			English	Article							ANGIOPLASTY; CARDIOVERSION	Background: Sedation is a cornerstone in the premedication for percutaneous coronary intervention (PCI). Benzodiazepines and opioids are frequently used. previous results suggest that opioids mimic the adaptation to ischemia during repeated balloon inflations and may provide directly myocardial protection in addition to their sedative effect. However, no comparative data exist. Methods: We conducted a prospective, randomized, controlled, single-blind trial comparing diazepam and fentanyl in 276 patients undergoing elective PCI. Patients were randomized to either diazepam 5 mg sublingually or fentanyl 0.05 mg or 0.1 mg intravenously at least 5 minutes prior to the first balloon inflation. The primary end-point was the postprocedural elevation of myocardial markers of necrosis defined as all elevation of cardiac troponin T >= 0.01 ng/ml. Results: The three groups had similar baseline clinical, angiographic, and procedural characteristics, with no significant differences in lesion morphology, procedural complexity, or adjunctive medical treatment. No significant variation in the hemodynamic response to the study drugs was observed in the three groups. The rate of postprocedural troponin T elevation was 28% in the diazepam group, 20% in the fentanyl 0.05 mg group, and 30% in the fentanyl 0.1 mg group (P = 0.26). Rates of postprocedural myocardial infarction were 3%, 2%, and 2%, respectively (P = 0.84), with one case of in-hospital death in the diazepam group and no urgent TVR in the whole study population. Conclusion: Although providing a well-tolerated alternative to diazepam for sedation during PCI fentanyl did not provide additional cardioprotection assessed through the postinterventional elevation of cardiac troponin T during elective coronary intervention. (J Interven Cardiol 2008;21:232-238)	[Abdel-Wahab, Mohamed; Khattab, Ahmed A.; Liska, Branislav; Kassner, Guido; Geist, Volker; Toelg, Ralph; Richardt, Gert] Univ Kiel, Acad Teaching Hosp, Segeberger Kliniken GmbH, Herz Kreislauf Zentrum, D-23795 Bad Segeberg, Germany	Khattab, AA (reprint author), Univ Kiel, Acad Teaching Hosp, Segeberger Kliniken GmbH, Herz Kreislauf Zentrum, Kurpark 1, D-23795 Bad Segeberg, Germany.	ahmed.khattab@segebergerkliniken.de					Alpert JS, 2000, J AM COLL CARDIOL, V36, P959, DOI 10.1016/S0735-1097(00)00804-4; Benedict PE, 1999, CIRCULATION, V100, P357; COTE P, 1974, CIRCULATION, V50, P1210, DOI 10.1161/01.CIR.50.6.1210; HAGEMEIJER F, 1982, EUR HEART J, V3, P155, DOI 10.1093/oxfordjournals.eurheartj.a061278; Kato T, 2003, DRUGS, V63, P133, DOI 10.2165/00003495-200363020-00001; Laskey WK, 2003, J AM COLL CARDIOL, V42, P998, DOI 10.1016/S0735-1097(03)00909-4; Leesar MA, 1999, J AM COLL CARDIOL, V34, P639, DOI 10.1016/S0735-1097(99)00297-1; Leesar MA, 1997, CIRCULATION, V95, P2500, DOI 10.1161/01.CIR.95.11.2500; Leesar MA, 2001, CIRCULATION, V103, P2935, DOI 10.1161/01.CIR.103.24.2935; LUDLAM R, 1971, LANCET, V8, P1397; NUTTER DO, 1965, NEW ENGL J MED, V273, P650, DOI 10.1056/NEJM196509162731208; Okmen E, 2006, ANGIOLOGY, V57, P161, DOI 10.1177/000331970605700205; Ricciardi MJ, 2003, AM HEART J, V145, P522, DOI 10.1067/mhj.2003.2; Sakai K, 2002, JPN HEART J, V43, P443, DOI 10.1536/jhj.43.443; Smith SC, 2006, CIRCULATION, V113, P156, DOI 10.1161/CIRCULATIONAHA.105.170815; Tomai F, 1999, CIRCULATION, V100, P559, DOI 10.1161/01.CIR.100.5.559; TOMAI F, 1998, CIRCULATION, V17, P576; Xenopoulos NP, 1998, J AM COLL CARDIOL, V31, p65A, DOI 10.1016/S0735-1097(97)83991-5	18	12	12	0	3	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0896-4327			J INTERV CARDIOL	J. Interv. Cardiol.	JUN	2008	21	3					232	238		10.1111/j.1540-8183.2008.00355.x			7	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	314DY	WOS:000256790600004	18422519				2020-06-30	J	Schneider, R; Reebye, U; Choi, C; Kalman, D				Schneider, Ronald; Reebye, Uday; Choi, Christopher; Kalman, Doron			Seizure-like activity and prolonged central nervous system side effects after intravenous sedation	JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY			English	Article							REFRACTORY STATUS EPILEPTICUS; GRAND-MAL SEIZURE; PROPOFOL; EPILEPSY; LIDOCAINE; RISK		[Schneider, Ronald; Reebye, Uday; Choi, Christopher; Kalman, Doron] Long Isl Jewish Med Ctr, Dept Oral & Maxillofacial Surg, New Hyde Pk, NY 11042 USA; [Schneider, Ronald] Gundersen Lutheran Med Ctr, La Crosse, WI USA	Reebye, U (reprint author), 5318,NC 55,Suite 106, Durham, NC 27713 USA.	ureebye@gmail.com					AGGARWAL P, 1993, AM J EMERG MED, V11, P243, DOI 10.1016/0735-6757(93)90135-X; Alsaadi TM, 2005, AM FAM PHYSICIAN, V72, P849; Alsaadi TM, 2004, SEIZURE-EUR J EPILEP, V13, P32, DOI 10.1016/S1059-1311(03)00072-4; BERNHARD CG, 1955, ARCH NEURO PSYCHIATR, V74, P208, DOI 10.1001/archneurpsyc.1955.02330140092017; BORGEAT A, 1991, ANESTHESIOLOGY, V74, P24, DOI 10.1097/00000542-199101000-00005; Bowman ES, 1996, AM J PSYCHIAT, V153, P57; Bragonier R, 2000, BRIT J ANAESTH, V84, P828; de JONG R. H., 1963, FED PROC, V22, P187; DeToledo JC, 2000, THER DRUG MONIT, V22, P320, DOI 10.1097/00007691-200006000-00014; Fujimoto Takahiro, 2003, J Anesth, V17, P55, DOI 10.1007/s005400300009; Gordon E, 2001, EPILEPSIA, V42, P1266, DOI 10.1046/j.1528-1157.2001.19301.x; Hauser WA, 1998, NEW ENGL J MED, V338, P429, DOI 10.1056/NEJM199802123380704; Hemmer SA, 2001, PEDIATR NEUROL, V24, P99, DOI 10.1016/S0887-8994(00)00240-X; Hendren RL, 2000, J AM ACAD CHILD PSY, V39, P815, DOI 10.1097/00004583-200007000-00010; HOIEN AO, 1984, ANESTHESIOLOGY, V60, P387, DOI 10.1097/00000542-198404000-00027; HUGHES NJ, 1995, CAN J ANAESTH, V42, P744, DOI 10.1007/BF03012676; Jensen PS, 1997, J AM ACAD CHILD PSY, V36, P1065, DOI 10.1097/00004583-199708000-00014; KANTO J, 1989, CLIN PHARMACOKINET, V17, P308, DOI 10.2165/00003088-198917050-00002; KARLER R, 1981, J CLIN PHARMACOL, V21, pS437, DOI 10.1002/j.1552-4604.1981.tb02624.x; KARLER R, 1986, NEUROPHARMACOLOGY, V25, P441, DOI 10.1016/0028-3908(86)90240-6; Lancman M, 1999, NEUROLOGY, V53, pS33; LOWSON S, 1990, BRIT J ANAESTH, V64, P59, DOI 10.1093/bja/64.1.59; Marsh L, 2002, EPILEPSY RES, V49, P11, DOI 10.1016/S0920-1211(02)00008-6; PATEL S, 2004, BRIT J PHARMACOL, V139, P1005; ROSENBERG M, 1986, J ORAL MAXIL SURG, V44, P577, DOI 10.1016/S0278-2391(86)80102-1; SAFWAT AM, 1983, ANESTHESIOLOGY, V59, P78, DOI 10.1097/00000542-198307000-00018; Schramm BM, 2002, ANESTH ANALG, V94, P1237, DOI 10.1097/00000539-200205000-00034; Shulka G, 2004, EPILEPSY BEHAV, V5, P517; Stecker MM, 1998, EPILEPSIA, V39, P18, DOI 10.1111/j.1528-1157.1998.tb01269.x; SUGIYAMA N, 2004, NO HATTATSU, V3, P451; SUTHERLAND MJ, 1994, ANAESTH INTENS CARE, V22, P733, DOI 10.1177/0310057X9402200620; van den Berg AA, 2001, ACTA ANAESTH SCAND, V45, P1051, DOI 10.1034/j.1399-6576.2001.450823.x; Walder B, 2002, NEUROLOGY, V58, P1327, DOI 10.1212/WNL.58.9.1327; WALKER G, 1998, ABPI COMPENDIUM DATA, P1093; Webb M D, 1990, Anesth Prog, V37, P306; YATE PM, 1986, EUR J ANAESTH, V3, P159	36	0	0	0	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0278-2391	1531-5053		J ORAL MAXIL SURG	J. Oral Maxillofac. Surg.	JUN	2008	66	6					1277	1282		10.1016/j.joms.2007.04.034			6	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	306SJ	WOS:000256267800028	18486797				2020-06-30	J	Dean, RL; Todtenkopf, MS; Deaver, DR; Arastu, MF; Dong, N; Reitano, K; O'Driscoll, K; Kriksciukaite, K; Gastfriend, DR				Dean, Reginald L.; Todtenkopf, Mark S.; Deaver, Daniel R.; Arastu, Mahin F.; Dong, Nan; Reitano, Krystal; O'Driscoll, Kevin; Kriksciukaite, Kristina; Gastfriend, David R.			Overriding the blockade of antinociceptive actions of opioids in rats treated with extended-release naltrexone	PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR			English	Article						XR-NTX; analgesia; antinociception; morphine; fentanyl; hydrocodone; respiration rate; locomotor activity; Vivitrol (R); PLG microspheres	INDUCED RESPIRATORY DEPRESSION; ACTING INJECTABLE NALTREXONE; ALCOHOL DEPENDENCE; 6-BETA-NALTREXOL LEVELS; CLINICAL-PHARMACOLOGY; MEDICATION COMPLIANCE; CONTROLLED-TRIAL; MORPHINE; PAIN; ANALGESICS	A monthly extended-release formulation of the opioid antagonist naltrexone (XR-NTX) is approved for treatment of alcohol dependence. There is little research regarding overriding chronic (>21 days) competitive opioid receptor blockade with opioids for acute pain. Using the hot plate test after XR-NTX or placebo microsphere administration, rats were treated with an opioid analgesic to determine the dose required to produce the maximum response latency (MRL; 60 s). Rats were later treated with the same opioid to determine any potential effects on respiration rate or locomotor activity. In naive rats, 15 mg/kg morphine, 0.1 mg/kg fentanyl and 8 mg/kg hydrocodone produced MRL. In XR-NTX treated rats, morphine produced 36% and 46% MRL at 90 mg/kg on days 4 and 19 and 96% MRL at 45 mg/kg on day 39. Fentanyl produced 100% MRL at 2.0 mg/kg on days 4 and 19 and at 0.5 mg/kg on day 39. Hydrocodone (80 mg/kg) produced 69%, 80% and 100% MRL on days 4, 19 and 39. Compared to placebo, these doses did not further depress respiration or alter locomotor activity. Thus, opioid receptor blockade with XR-NTX can be overcome in rats with higher doses of opioids without further affecting respiration or locomotor activity. (C) 2008 Elsevier Inc. All rights reserved.	[Dean, Reginald L.; Todtenkopf, Mark S.; Deaver, Daniel R.; Arastu, Mahin F.; Dong, Nan; Reitano, Krystal; O'Driscoll, Kevin; Kriksciukaite, Kristina] Alkermes Inc, Dept Life Sci & Toxicol, Cambridge, MA 02139 USA; [Gastfriend, David R.] Alkermes Inc, Med Affairs Dept, Cambridge, MA 02139 USA	Dean, RL (reprint author), Alkermes Inc, Dept Life Sci & Toxicol, 88 Sidney St, Cambridge, MA 02139 USA.	reggie.dean@alkermes.com	Todtenkopf, Mark/G-7538-2012	Todtenkopf, Mark/0000-0003-4764-7816			BABBINI M, 1972, BRIT J PHARMACOL, V46, P213, DOI 10.1111/j.1476-5381.1972.tb06866.x; Baranczewski P, 2006, PHARMACOL REP, V58, P341; Baros AM, 2007, ALCOHOL CLIN EXP RES, V31, P596, DOI 10.1111/j.1530-0277.2007.00343.x; Bartus RT, 2003, NEUROPSYCHOPHARMACOL, V28, P1973, DOI 10.1038/sj.npp.1300274; Borgbjerg FM, 1996, PAIN, V64, P123; BORISON HL, 1977, PHARMACOL THER PT B, V3, P227, DOI 10.1016/0306-039X(77)90034-4; Brewer C, 2002, ADDICT BIOL, V7, P321, DOI 10.1080/13556210220139541; Cicero TJ, 1997, J PHARMACOL EXP THER, V282, P939; Comer SD, 2006, ARCH GEN PSYCHIAT, V63, P210, DOI 10.1001/archpsyc.63.2.210; Dean RL, 2005, FRONT BIOSCI-LANDMRK, V10, P643, DOI 10.2741/1559; Dunbar JL, 2006, ALCOHOL CLIN EXP RES, V30, P480, DOI 10.1111/j.1530-0277.2006.00052.x; ECKENHOFF JE, 1960, CLIN PHARMACOL THER, V1, P483; Garbutt JC, 2005, JAMA-J AM MED ASSOC, V293, P1617, DOI 10.1001/jama.293.13.1617; GREEN AF, 1959, BRIT J PHARM CHEMOTH, V14, P26, DOI 10.1111/j.1476-5381.1959.tb00924.x; Harris KM, 2004, PSYCHIAT SERV, V55, P221, DOI 10.1176/appi.ps.55.3.221; He GA, 2001, ACTA PHARMACOL SIN, V22, P530; Hulse GK, 2005, DRUG ALCOHOL DEPEN, V79, P351, DOI 10.1016/j.drugalcdep.2005.02.009; Hulse GK, 2004, ADDICT BIOL, V9, P59, DOI 10.1080/13556210410001674103; Inturrisi CE, 2002, CLIN J PAIN, V18, pS3, DOI 10.1097/00002508-200207001-00002; Johnson BA, 2004, ALCOHOL CLIN EXP RES, V28, P1356, DOI 10.1097/01.ALC.0000139823.30096.52; Lalley PM, 2003, AM J PHYSIOL-REG I, V285, pR1287, DOI 10.1152/ajpregu.00199.2003; LEE MC, 1988, J NUCL MED, V29, P1207; MCLAUGHLIN CR, 1994, PHARMACOL BIOCHEM BE, V49, P1017, DOI 10.1016/0091-3057(94)90258-5; Meert TF, 2005, PHARMACOL BIOCHEM BE, V80, P309, DOI 10.1016/j.pbb.2004.12.002; NAVARATNAM V, 1994, DRUG ALCOHOL DEPEN, V34, P231, DOI 10.1016/0376-8716(94)90161-9; O'Brien C, 2006, J VIRAL HEPATITIS, V13, P6, DOI 10.1111/j.1365-2893.2006.00757.x; O'Malley SS, 2005, ALCOHOL CLIN EXP RES, V29, p77A; Pettinati Helen M, 2006, Curr Psychiatry Rep, V8, P383, DOI 10.1007/s11920-006-0040-0; Pettinati HM, 2000, J ADDICT DIS, V19, P71, DOI 10.1300/J069v19n01_06; Raehal KM, 2005, J PHARMACOL EXP THER, V314, P1195, DOI 10.1124/jpet.105.087254; SCHUG SA, 1992, DRUG SAFETY, V7, P200, DOI 10.2165/00002018-199207030-00005; Schuh KJ, 1999, PSYCHOPHARMACOLOGY, V145, P162, DOI 10.1007/s002130051045; SHOOK JE, 1990, AM REV RESPIR DIS, V142, P895, DOI 10.1164/ajrccm/142.4.895; Tambour S, 2007, FUND CLIN PHARMACOL, V21, P9, DOI 10.1111/j.1472-8206.2006.00459.x; VEREBEY K, 1976, CLIN PHARMACOL THER, V20, P315; Vickers AP, 2006, BMJ-BRIT MED J, V332, P132, DOI 10.1136/bmj.332.7534.132; Walker JKL, 1998, CAN J PHYSIOL PHARM, V76, P707, DOI 10.1139/cjpp-76-7-8-707; YAKSH TL, 1999, TXB PAIN, P253; YOBURN BC, 1986, J PHARMACOL EXP THER, V237, P126	39	17	18	0	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0091-3057			PHARMACOL BIOCHEM BE	Pharmacol. Biochem. Behav.	JUN	2008	89	4					515	522		10.1016/j.pbb.2008.02.006			8	Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy	Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy	302ZH	WOS:000256008200004	18342360				2020-06-30	J	Pogatzki-Zahn, EM; Zahn, PK				Pogatzki-Zahn, E. M.; Zahn, P. K.			New substances and applications for postoperative pain therapy	SCHMERZ			German	Article						anticonvulsants; cyclooxygenase-2 inhibitors; balanced analgesia; glucocorticoids; Ketamine; Lidocaine; NSAID; opioida; postoperative pain	ANALGESIA; KETAMINE	The onset of postoperative pain is the result of various pathophysiological mechanisms and depends on the type of surgery performed. Therefore, any adequate postoperative pain treatment requires multimodal and procedure-specific analgesia. In addition to reducing perioperative complications and improving patient comfort, optimal postoperative pain management also represents an important quality characteristic which can influence the patient in their choice of hospital. In the past 1 - 2 years, known groups of substances have been rediscovered for postoperative pain therapy (e. g., Gabapentin and Pregabalin, i.v. Lidocaine, Ketamine or glucocorticoids), while new substances (coxibe, oral oxycodone+naloxone) and applications have been developed. The present overview article discusses the advantages and disadvantages of these substances and analgesic methods, as well as their specific areas of application.	[Pogatzki-Zahn, E. M.; Zahn, P. K.] Univ Klinikum Munster, Klin & Poliklin Anasthesiol & Operat Intensivmed, D-48149 Munster, Germany	Pogatzki-Zahn, EM (reprint author), Univ Klinikum Munster, Klin & Poliklin Anasthesiol & Operat Intensivmed, Albert Schweitzer Str 33, D-48149 Munster, Germany.	pogatzki@anit.uni-muenster.de					Afman CE, 2006, OTOLARYNG HEAD NECK, V134, P181, DOI 10.1016/j.otohns.2005.11.010; Angst MS, 2006, ANESTHESIOLOGY, V104, P570, DOI 10.1097/00000542-200603000-00025; Bisgaard T, 2003, ANN SURG, V238, P651, DOI 10.1097/01.sla.0000094390.82352.cb; Elia N, 2005, PAIN, V113, P61, DOI 10.1016/j.pain.2004.09.036; Grond S, 2007, BRIT J ANAESTH, V98, P806, DOI 10.1093/bja/aem102; Hennekens CH, 2008, J CARDIOVASC PHARM T, V13, P41, DOI 10.1177/1074248407312990; Kehlet H, 2006, LANCET, V367, P1618, DOI 10.1016/S0140-6736(06)68700-X; Lavand'homme P, 2005, ANESTHESIOLOGY, V103, P813, DOI 10.1097/00000542-200510000-00020; Tiippana EM, 2007, ANESTH ANALG, V104, P1545, DOI 10.1213/01.ane.0000261517.27532.80; Zingman BS, 2007, GASTROENTEROLOGY, V132, pA791	10	12	12	0	1	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0932-433X	1432-2129		SCHMERZ	Schmerz	JUN	2008	22	3					353	367		10.1007/s00482-008-0665-5			15	Anesthesiology; Clinical Neurology	Anesthesiology; Neurosciences & Neurology	307LD	WOS:000256319500016	18491149				2020-06-30	J	Yamamoto, K; Kojima, M; Iguchi, H; Ohta, T				Yamamoto, Kayo; Kojima, Masanori; Iguchi, Hirofumi; Ohta, Takafumi			Measurement of amount of fentanyl remaining in used patches: Investigation of clinical factors affecting the remaining amounts in 4 patients	YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN			Japanese	Article						transdermal fentanyl patch; remaining-amount analysis; variability factor; cancer pain	TRANSDERMAL SYSTEM; ABSORPTION	Although fentanyl patches (FP) designed to sustain plasma fentanyl concentrations for 3 days are used in many patients for continuous relief of moderate to severe cancer pain, there are some cases in which effective pain relief is sustained less than for 3 days, and in which plasma fentanyl concentrations rapidly decrease at the third day after the application. In this study, we measured the amount of fentanyl remaining in FP after continuous 3-days use to clarify some clinical factors that can influence the remaining amounts in 4 patients. Average estimated fentanyl-dermal transfer rates of the collected 41 patches calculated from their remaining amounts were less than nominal rates (21.2 +/- 3.4 cf. 25 mu g/h (2.5 mg FP); 44.9 +/- 5.1 cf. 50 mu g/h (5 mg FP)). Intra-individual variability was also observed (CV: 6.6-14.3% (2.5 mg FP), 3.9-13.3% (5 mg FP)). The present study suggests that the estimated fentanyl-dermal transfer rates are affected by fever, patients' body mass index and application sites. Although further study is necessary to elucidate factors that can influence the variability in transdermal fentanyl absorption, the approach in this study would contribute to improving appropriate usage of FP.	[Kojima, Masanori; Iguchi, Hirofumi] Yokohama Municipal Citizens Hosp, Hodogaya Ku, Yokohama, Kanagawa 2408555, Japan; Tokyo Univ Sci, Fac Pharmaceut Sci, Noda, Chiba 2788510, Japan	Yamamoto, K (reprint author), Chiba Emergency Med Ctr, Mihama Ku, 3-32-1 Isobe, Chiba 2610012, Japan.	k.ymmt70@mc.pref.chiba.lg.jp					BJORKMAN S, 1990, ANESTHESIOLOGY, V72, P865, DOI 10.1097/00000542-199005000-00017; GUPTA SK, 1992, J PAIN SYMPTOM MANAG, V7, pS17, DOI 10.1016/0885-3924(92)90049-N; HAMADA Y, 2004, TDM KENKYU, V21, P169; KUROIWA Y, 2005, PROG MED, V25, P2455; MARQUARDT KA, 1995, ANN PHARMACOTHER, V29, P969, DOI 10.1177/106002809502901001; NAKAYAMA H, 2004, TDM KENKYU, V21, P248; NUMATA T, 2005, JPN J PHARM HLTH CAR, V31, P599; Ohtsuka H, 2001, JPN PHARMACOL THER, V29, P855; ROY SD, 1990, PHARMACEUT RES, V7, P842, DOI 10.1023/A:1015912932416; Solassol I, 2005, ONCOL REP, V14, P1029; *US PHARM CONV INC, 2002, US PHARM, P2018; VARVEL JR, 1989, ANESTHESIOLOGY, V70, P928, DOI 10.1097/00000542-198906000-00008	12	3	3	0	2	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0031-6903			YAKUGAKU ZASSHI	Yakugaku Zasshi-J. Pharm. Soc. Jpn.	JUN	2008	128	6					959	964		10.1248/yakushi.128.959			6	Pharmacology & Pharmacy	Pharmacology & Pharmacy	340GC	WOS:000258633100014	18520142	Bronze			2020-06-30	J	Wallden, J; Lindberg, G; Sandin, M; Thorn, SE; Wattwil, M				Wallden, J.; Lindberg, G.; Sandin, M.; Thorn, S. -E.; Wattwil, M.			Effects of fentanyl on gastric myoelectrical activity: a possible association with polymorphisms of the mu-opioid receptor gene?	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						gastrointestinal motility; gastric myoelectrical activity; electrogastrography; analgesics; opioid; single nucleotide polymorphism; opioid receptors; *genetics; genotype	GASTRODUODENAL MOTILITY; MORPHINE; STOMACH; ELECTROGASTROGRAPHY	Background: Opioids have inhibitory effects on gastric motility, but the mechanism is far from clear. Electrical slow waves in the stomach determine the frequency and the peristaltic nature of gastric contractions. The primary aim of this study was to investigate the effects of the opioid fentanyl on gastric myoelectric activity. As there were large variations between the subjects, we investigated whether the variation was correlated to single nucleotide polymorphisms (SNP) of the mu-opioid receptor (MOR) gene. Methods: We used cutaneous multichannel electrogastrography (EGG) to study myoelectrical activity in 20 patients scheduled for elective surgery. Fasting EGG was recorded for 30 min, followed by intravenous administration of fentanyl 1 mu g/kg and subsequent EGG recording for 30 min. Spectral analysis of the two recording periods was performed and the variables assessed were dominant frequency (DF) of the EGG and its power (DP). Genetic analysis of the SNP A118G and G691C of the MOR gene was performed with the polymerase chain reaction technique. Results: There was a significant reduction in DF and DP after intravenous fentanyl. However, there was a large variation between the patients. In eight subjects EGG was unaffected, five subjects had a slower DF (bradygastria) and in six subjects the slow waves disappeared. We found no correlation between the EGG outcome and the presence of A118G or G691C in the MOR gene. Conclusion: Fentanyl inhibited gastric myoelectrical activity in about half of the subjects. The variation could not be explained by SNP in the MOR gene. Because of small sample size, the results must be regarded as preliminary observations.	[Wallden, J.] Sundsvall Hosp, Dept Anesthesia, S-85186 Sundsvall, Sweden; [Wallden, J.; Thorn, S. -E.; Wattwil, M.] Univ Orebro, Dept Clin Med, Orebro, Sweden; [Lindberg, G.] Karolinska Univ, Karolinska Inst, Dept Med, Huddinge Hosp, Stockholm, Sweden; [Sandin, M.; Thorn, S. -E.; Wattwil, M.] Univ Orebro, Dept Anesthesia & Intens Care, Orebro, Sweden	Wallden, J (reprint author), Sundsvall Hosp, Dept Anesthesia, S-85186 Sundsvall, Sweden.	jakob.wallden@gmail.com		Thorn, Sven-Egron/0000-0001-7010-6757			Aicher SA, 2002, NEUROSCIENCE, V115, P851, DOI 10.1016/S0306-4522(02)00459-1; Belfer I, 2004, ANESTHESIOLOGY, V100, P1562, DOI 10.1097/00000542-200406000-00032; BITAR KN, 1982, NATURE, V297, P72, DOI 10.1038/297072a0; Browning KN, 2002, J NEUROSCI, V22, P2998, DOI 10.1523/JNEUROSCI.22-08-02998.2002; Chang FY, 2005, J GASTROEN HEPATOL, V20, P502, DOI 10.1111/j.1440-1746.2004.03751.x; Chou WY, 2006, ACTA ANAESTH SCAND, V50, P787, DOI 10.1111/j.1399-6576.2006.01058.x; Coulbault L, 2006, CLIN PHARMACOL THER, V79, P316, DOI 10.1016/j.clpt.2006.01.007; De Schepper HU, 2004, NEUROGASTROENT MOTIL, V16, P383, DOI 10.1111/j.1365-2982.2004.00513.x; EDIN R, 1980, GASTROENTEROLOGY, V78, P492; Hammas B, 2001, ACTA ANAESTH SCAND, V45, P1023, DOI 10.1034/j.1399-6576.2001.450816.x; Hicks GA, 2004, NEUROGASTROENT MOTIL, V16, P67, DOI 10.1111/j.1743-3150.2004.00560.x; Ikeda K, 2005, TRENDS PHARMACOL SCI, V26, P311, DOI 10.1016/j.tips.2005.04.001; Klepstad P, 2005, ACTA ANAESTH SCAND, V49, P902, DOI 10.1111/j.1399-6576.2005.00772.x; Klepstad P, 2004, ACTA ANAESTH SCAND, V48, P1232, DOI 10.1111/j.1399-6576.2004.00517.x; Lewis TD, 1999, DIGEST DIS SCI, V44, P2178, DOI 10.1023/A:1026684132254; Mikus G, 1997, CLIN PHARMACOL THER, V61, P459, DOI 10.1016/S0009-9236(97)90196-X; NIMMO WS, 1975, BRIT J CLIN PHARMACO, V2, P509, DOI 10.1111/j.1365-2125.1975.tb00568.x; Penagini R, 2004, GUT, V53, P1227, DOI 10.1136/gut.2003.035246; Qian LW, 2003, DIGEST DIS SCI, V48, P508, DOI 10.1023/A:1022532515172; SANDERS KM, 2004, HDB ELECTROGASTROGRA, P13; SHAFER SL, 1990, ANESTHESIOLOGY, V73, P1091, DOI 10.1097/00000542-199012000-00005; Shibutani K, 2004, ANESTHESIOLOGY, V101, P603, DOI 10.1097/00000542-200409000-00008; Simonian HP, 2004, DIGEST DIS SCI, V49, P594, DOI 10.1023/B:DDAS.0000026304.83214.50; TELFORD GL, 1985, AM J PHYSIOL, V249, pG557; Thorn SE, 1996, ACTA ANAESTH SCAND, V40, P773; Thorn SE, 1996, ACTA ANAESTH SCAND, V40, P177, DOI 10.1111/j.1399-6576.1996.tb04417.x; Wallden J, 2004, ANESTH ANALG, V99, P429; Yuan CS, 1998, J CLIN PHARMACOL, V38, P1017, DOI 10.1177/009127009803801105	28	16	18	0	0	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0001-5172			ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	MAY	2008	52	5					708	715		10.1111/j.1399-6576.2008.01624.x			8	Anesthesiology	Anesthesiology	289FL	WOS:000255040300021	18419726				2020-06-30	J	Bonomo, JB; Butler, AS; Lindsell, CJ; Venkat, A				Bonomo, Jordan B.; Butler, Andrew S.; Lindsell, Christopher J.; Venkat, Arvind			Inadequate provision of postintubation anxiolysis and analgesia in the ED	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article; Proceedings Paper	Annual Meeting of the Society-for-Academic-Emergency-Medicine	MAY, 2006	San Francisco, CA	Soc Acad Emergency Med				Introduction: Patients intubated in the emergency department (ED) often have extended ED stays. We hypothesize that ED intubated patients receive inadequate postintubation anxiolysis and analgesia after rapid sequence induction (RSI). Methods: This was a retrospective cohort study of every adult intubated in a tertiary-care ED (July 2003-June 2004). Patients were included if they underwent RSI, remained in the ED for more than 30 minutes post intubation, and survived to admission. Presuming a mean patient weight of 70 kg, we defined adequacy of anxiolysis and analgesia on the provision postintubation of weight-based doses of lorazepam (0.77 mg/h) or midazolam (4.2 mg/h) and fentanyl (3 5 mu g/h), referenced from pharmaceutical texts. Demographic data, time in ED, and dosage of each medication given were abstracted. The proportion, with 95% confidence intervals (CIs), of patients receiving inadequate anxiolysis and analgesia were computed. Results: One hundred seventeen patients met the inclusion criteria. Mean time in the ED was 4.2 hours (SD +/- 3.1 hours). Thirty-nine patients received no anxiolytic (33%, CI 25%-43%), and 62 received no analgesic (53%, CI 44%-62%). Twenty-three patients received neither anxiolytic nor analgesic (20%, CI 13%-28%). Of 70 patients given postintubation vecuronium, 67 received either no or inadequate anxiolysis or analgesia (96%, CI 87%-99%). Overall, 87 of 117 patients received no or inadequate anxiolysis (74%, CI 65%-82%); and 88 of 117 received no or inadequate analgesia (75%, CI 66%-83%). Conclusion: Patients undergoing RSI in the ED frequently receive inadequate postintubation anxiolysis and analgesia. (c) 2008 Elsevier Inc. All rights reserved.	[Bonomo, Jordan B.; Butler, Andrew S.; Lindsell, Christopher J.; Venkat, Arvind] Univ Cincinnati, Coll Med, Dept Emergency Med, Cincinnati, OH 45267 USA	Venkat, A (reprint author), Univ Cincinnati, Coll Med, Dept Emergency Med, Cincinnati, OH 45267 USA.	arvind.venkat@uc.edu		Lindsell, Christopher/0000-0002-3297-2811			Bergman IJ, 2002, ANAESTHESIA, V57, P549, DOI 10.1046/j.1365-2044.2002.02565.x; Chamberlain DE, 2001, GLOBAL ECOL BIOGEOGR, V10, P399, DOI 10.1046/j.1466-822X.2001.00236.x; Chao A, 2006, J TRAUMA, V60, P579, DOI 10.1097/01.ta.0000195644.58761.93; Dibble C, 2006, EMERG MED J, V23, P62, DOI 10.1136/emj.2005.032607; GUTSTEIN HB, 2001, GOODMAN GILMANS PHAR, P569; HEBRON BS, 1983, BRIT J ANAESTH, V55, P281, DOI 10.1093/bja/55.4.281; *I MED NAT SYST BO, 2006, HOSP BAS EM CAR BREA; Kress JP, 2006, CRIT CARE MED, V34, P2541, DOI 10.1097/01.CCM.0000239117.39890.E3; Taylor P., 2001, GOODMAN GILMANS PHAR, P193; TOPULOS GP, 1993, J CLIN ANESTH, V5, P369, DOI 10.1016/0952-8180(93)90099-Z	10	22	22	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0735-6757			AM J EMERG MED	Am. J. Emerg. Med.	MAY	2008	26	4					469	472		10.1016/j.ajem.2007.05.024			4	Emergency Medicine	Emergency Medicine	292JJ	WOS:000255262000015	18410818				2020-06-30	J	Padmanabhan, U; Leslie, K				Padmanabhan, U.; Leslie, K.			Australian anaesthetists' practice of sedation for gastrointestinal endoscopy in adult patients	ANAESTHESIA AND INTENSIVE CARE			English	Article						gastroscopy; endoscopic retrograde cholangiopancreatography; colonoscopy; survey; anaesthesia; sedation; propofol; midazolam; fentanyl	MIDAZOLAM PREMEDICATION; INTRAVENOUS FLUID; PROPOFOL; COINDUCTION; INDUCTION; COMBINATION; ANESTHESIA; RECOVERY	A wide spectrum of practice in sedation for gastrointestinal endoscopy in adult patients is documented overseas, but a current profile of the practice of Australian anaesthetists is unavailable. We therefore surveyed 200 Fellows of the Australian and New Zealand College of Anaesthetists on the choice of drugs and monitoring, use of analgesic throat spray and prophylactic intravenous fluids and the depth of sedation for gastrointestinal endoscopy. Our response rate was 57% and endoscopy formed a significant part of most respondents' practices. Propofol was used for almost all procedures, in combination with midazolam alone (14%), fentanyl alone (6%), midazolam and fentanyl (61%), another drug (15%) or no adjuvant (4%). The majority of patients received prophylactic intravenous fluids for endoscopic retrograde cholangio-pancreatography (83%) and colonoscopy (64%), but not for gastroscopy (20%). All patients received supplemental oxygen and monitoring with pulse oximetry. However; over 20% of patients having gastroscopy or colonoscopy did not have non-invasive blood pressure monitoring. A maximum depth of sedation during which the patient was unresponsive to painful stimulation (commensurate with general anaesthesia) was targeted by 54% of respondents. Significant variations exist in the practice of sedation and monitoring for endoscopy in adult patients by anaesthetists in Australia.	[Padmanabhan, U.; Leslie, K.] Royal Melbourne Hosp, Dept Anaesthesia & Pain Management, Melbourne, Vic, Australia	Padmanabhan, U (reprint author), Royal Melbourne Hosp, Dept Anaesthesia & Pain Management, Melbourne, Vic, Australia.						Abraham NS, 2004, AM J GASTROENTEROL, V99, P1692, DOI 10.1111/j.1572-0241.2004.40157.x; Ackland GL, 2004, BRIT J ANAESTH, V92, P134, DOI 10.1093/bja/aeh015; Anderson L, 1998, ANAESTHESIA, V53, P1117, DOI 10.1046/j.1365-2044.1998.00560.x; *AUSTR NZ COLL AN, 2006, [No title captured]; *AUSTR NZ COLL AN, 2007, GUID SED AN DIAGN IN; Bevan JC, 1997, ANESTH ANALG, V85, P50, DOI 10.1097/00000539-199707000-00009; Bowering K, 2006, GASTROINTEST ENDOSC, V63, pAB191, DOI 10.1016/j.gie.2006.03.440; Cohen LB, 2006, AM J GASTROENTEROL, V101, P967, DOI 10.1111/j.1572-0241.2006.00500.x; Cressey DM, 2001, ANAESTHESIA, V56, P108, DOI 10.1046/j.1365-2044.2001.01789.x; Heuss LT, 2005, ENDOSCOPY, V37, P161, DOI 10.1055/s-2004-826143; Holte K, 2003, ANESTH ANALG, V96, P1504, DOI 10.1213/01.ANE.0000055820.56129.EE; Jones NA, 2002, ANAESTHESIA, V57, P649, DOI 10.1046/j.1365-2044.2002.02609.x; Leslie K, 2006, ANAESTH INTENS CARE, V34, P316, DOI 10.1177/0310057X0603400314; Millar K, 2007, ANAESTHESIA, V62, P923, DOI 10.1111/j.1365-2044.2007.05148.x; QUINE MA, 1995, GUT, V36, P462, DOI 10.1136/gut.36.3.462; SEBEL PS, 1989, ANESTHESIOLOGY, V71, P260, DOI 10.1097/00000542-198908000-00015; Seifert H, 2000, ALIMENT PHARM THERAP, V14, P1207; Tighe KE, 1997, ANAESTHESIA, V52, P1000, DOI 10.1111/j.1365-2044.1997.198-az0333.x; VanNatta ME, 2006, AM J GASTROENTEROL, V101, P2209, DOI 10.1111/j.1572-0241.2006.00760.x; WHITWAM JG, 1995, EUR J ANAESTH, V12, P25	20	16	19	0	0	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0310-057X	1448-0271		ANAESTH INTENS CARE	Anaesth. Intensive Care	MAY	2008	36	3					436	441		10.1177/0310057X0803600316			6	Anesthesiology; Critical Care Medicine	Anesthesiology; General & Internal Medicine	364MY	WOS:000260341000018	18564807	Bronze			2020-06-30	J	Choquette, D; McCarthy, TG; Rodrigues, JFN; Kelly, AJ; Camacho, F; Horbay, GLA; Husein-Bhabha, FA				Choquette, Denis; McCarthy, Timothy G.; Rodrigues, Jude F. N.; Kelly, Allan J.; Camacho, Fernando; Horbay, G. L. A.; Husein-Bhabha, Farah A.			Transdermal fentanyl improves pain control and functionality in patients with osteoarthritis: an open-label Canadian trial	CLINICAL RHEUMATOLOGY			English	Article						chronic pain; opioids; osteoarthritis; transdermal fentanyl	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CONTROLLED-RELEASE OXYCODONE; KNEE OSTEOARTHRITIS; ORAL MORPHINE; DOUBLE-BLIND; HIP; OUTCOMES; REHABILITATION; CLASSIFICATION; MULTICENTER	Current treatment guidelines advocate opioids for arthritis when standard analgesics produce inadequate relief. Efficacy, adverse effects (AEs), dosing regimens, physician expertise and patient preference influence treatment selection. This study assessed transdermal fentanyl (TDF) as a treatment option for osteoarthritis (OA) patients. This prospective, Canadian open-label, 8-week trial assessed the efficacy and safety of TDF in patients with OA of hip or knee with moderate-to-severe target joint pain inadequately controlled using weak opioids. TDF was initiated at 25 mcg/h and titrated to optimal pain control. Rescue acetaminophen 500 mg was allowed (maximum 4 g/day). The main endpoint was improvement in pain control assessment rating (five rating categories); pain intensity (0-10 numerical scale), functionality (WOMAC-OA Index), health-related quality of life (SF-36 Health Survey) and global impression were also evaluated. Eighty-one patients (61% female, mean age 60 years) were enrolled; 62 were evaluable. All had failed on previous weak opioid therapy, primarily codeine or codeine combinations. At treatment end, 65% rated pain control as improved (Pain Control Assessment rating change >= 1 category; p<0.0001); mean change in pain intensity was a reduction of greater than 2 (p<0.0001); almost 50% were maintained on TDF 25 mcg/h with less than 1.3 g/day of rescue acetaminophen. At 1 month and end of treatment, changes in the SF-36 physical global scale and individual sub-scores for the pain index and role-physical scales were highly significant (p<0.0001). Improvement in functionality was noted at 1 month and at end of treatment with significant reductions in total WOMAC score, individual pain, stiffness and physical function sub-scores (p<0.0001). AEs causing discontinuation (n=32) included nausea, dizziness and vomiting. Most treatment-related AEs were mild to moderate in intensity. TDF improved pain control, functionality and health-related quality of life in these patients. The findings support current recommendations for use of opioids such as TDF as a treatment option for a sub-population of patients with OA pain.	[Choquette, Denis] Rheumatol Inst Montreal, Montreal, PQ H2L 1S6, Canada; [Choquette, Denis] Univ Montreal, Notre Dame Hosp, Montreal, PQ H3C 3J7, Canada; [McCarthy, Timothy G.] Rheumatol Manitoba Clin, Winnipeg, MB, Canada; [Kelly, Allan J.] Hermitage Medictr, Edmonton, AB, Canada; [Camacho, Fernando] DAMOS, Toronto, ON, Canada; [Horbay, G. L. A.; Husein-Bhabha, Farah A.] Clin Affairs, Janssen Ortho, Toronto, ON, Canada	Choquette, D (reprint author), Rheumatol Inst Montreal, 1551 Ontario St E, Montreal, PQ H2L 1S6, Canada.	denis.choquette.irm@videotron.ca					Allan L, 2001, BRIT MED J, V322, P1154, DOI 10.1136/bmj.322.7295.1154; ALTMAN R, 1991, ARTHRITIS RHEUM, V34, P505, DOI 10.1002/art.1780340502; ALTMAN R, 1986, ARTHRITIS RHEUM, V29, P1039, DOI 10.1002/art.1780290816; Angst F, 2002, J RHEUMATOL, V29, P131; Ashburn MA, 2003, PRINCIPLES ANALGESIC; BELLAMY N, 1988, J RHEUMATOL, V15, P1833; Caldwell JR, 1999, J RHEUMATOL, V26, P862; Clark AJ, 2004, CURR MED RES OPIN, V20, P1419, DOI 10.1185/030079904X2114; Ferguson RJ, 2002, QUAL LIFE RES, V11, P509, DOI 10.1023/A:1016350431190; Hagg O, 2003, EUR SPINE J, V12, P12, DOI 10.1007/s00586-002-0464-0; HOLBROOK AM, 2000, [No title captured]; Jovey Roman D, 2003, Pain Res Manag, V8 Suppl A, p3A; Langford R, 2006, ARTHRITIS RHEUM-US, V54, P1829, DOI 10.1002/art.21884; Le Loet X, 2005, BMC MUSCULOSKEL DIS, V6, DOI 10.1186/1471-2474-6-31; Mamdani M, 2004, LANCET, V363, P1751, DOI 10.1016/S0140-6736(04)16299-5; Mesrian A, 2007, SCHMERZ, V21, P212, DOI 10.1007/s00482-007-0543-6; Milligan K, 2001, J PAIN, V2, P197, DOI 10.1054/jpai.2001.25352; Nussmeier NA, 2005, NEW ENGL J MED, V352, P1081, DOI 10.1056/NEJMoa050330; Ostelo RWJG, 2005, BEST PRACT RES CL RH, V19, P593, DOI 10.1016/j.berh.2005.03.003; Peat G, 2004, BMC MUSCULOSKEL DIS, V5, DOI 10.1186/1471-2474-5-4; Peloso PM, 2000, J RHEUMATOL, V27, P764; Roth SH, 2000, ARCH INTERN MED, V160, P853, DOI 10.1001/archinte.160.6.853; Schunemann HJ, 2005, HEALTH SERV RES, V40, P593, DOI 10.1111/j.1475-6773.2005.0k375.x; SIMON L, 2002, [No title captured]; Simpson RK, 1997, J PAIN SYMPTOM MANAG, V14, P218, DOI 10.1016/S0885-3924(97)00183-8; Theodoridis T, 2003, Z ORTHOP GRENZGEB, V141, P217, DOI 10.1055/s-2003-38651; Tubach F, 2005, ANN RHEUM DIS, V64, P29, DOI 10.1136/ard.2004.022905; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WARE JE, 1993, SF36 NEW ENGL MED CT; Weigl M, 2006, OSTEOARTHR CARTILAGE, V14, P641, DOI 10.1016/j.joca.2006.01.001; Wolfe MM, 1999, NEW ENGL J MED, V340, P1888, DOI 10.1056/NEJM199906173402407; WYRWICH KW, 1998, ABSTR BOOK ASS HLTH, V15, P330	32	10	10	0	4	SPRINGER LONDON LTD	LONDON	236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND	0770-3198	1434-9949		CLIN RHEUMATOL	Clin. Rheumatol.	MAY	2008	27	5					587	595		10.1007/s10067-007-0751-6			9	Rheumatology	Rheumatology	284XW	WOS:000254742400007	18038178				2020-06-30	J	Zelena, D; Domokos, A; Barna, I; Mergl, Z; Haller, J; Makara, GB				Zelena, Dora; Domokos, Agnes; Barna, Istvan; Mergl, Zsuzsa; Haller, Jozsef; Makara, Gabor B.			Control of the hypothalamo-pituitary-adrenal axis in the neonatal period: Adrenocorticotropin and corticosterone stress responses dissociate in vasopressin-deficient Brattleboro rats	ENDOCRINOLOGY			English	Article							CORTICOTROPIN-RELEASING HORMONE; INFANT RAT; ACTH; SECRETION; RESPONSIVENESS; STIMULATION; DEPRIVATION; INNERVATION; SENSITIVITY; PLASMA	In adulthood the hypothalamo-pituitary-adrenal axis is controlled by both CRH and arginine vasopressin (AVP). However, in neonates CRH secretion is very low, whereas AVP secretion is fully functional. This suggests that the role of AVP is more pronounced in young than in adult rats. We investigated the role of AVP by studying stress responses in 5, 10, and 20-d-old AVP-deficient Brattleboro rats. Two different stressors were applied: 24-h maternal separation and Hypnorm Grove Oxford UK injections. In heterozygous controls ( that do express AVP), both stressors increased plasma ACTH and corticosterone. The ACTH stress response disappeared in AVP-deficient rats, demonstrating that during the perinatal period, the secretion of this hormone is controlled by AVP. Surprisingly, corticosterone responses remained intact in AVP- deficient rats. Similar findings were obtained after 1-, 4-,12-, and 24- h long maternal separations. Thus, preserved corticosterone stress responses were not explained by changes in the timing of ACTH secretion. In vitro experiments suggested that the dissociation of ACTH and corticosterone stress responses can only be partly explained by higher ACTH responsiveness of the adrenal cortex in AVP-deficient rats. Together, our results show that in neonatal periods, AVP is crucial for the expression of ACTH stress responses, but neither AVP nor ACTH is necessary for the induction of corticosterone stress responses. Discrepant ACTH and corticosterone stress responses may reflect compensatory mechanisms activated by AVP deficiency, but disparate findings suggest that they rather depict a neonate-specific mechanism of hypothalamopituitary- adrenal- axis control.	[Zelena, Dora; Domokos, Agnes; Barna, Istvan; Mergl, Zsuzsa; Haller, Jozsef; Makara, Gabor B.] Hungarian Acad Sci, Inst Expt Med, H-1083 Budapest 43, Szigony, Hungary	Zelena, D (reprint author), Hungarian Acad Sci, Inst Expt Med, H-1083 Budapest 43, Szigony, Hungary.	zelena@koki.hu	Zelena, Dora/AAO-5418-2020; Makara, Gabor/H-8397-2013	Makara, Gabor/0000-0001-9220-0373; Haller, Jozsef/0000-0003-4315-3026; Haller, Jozsef/0000-0002-1953-3726			ANTONI FA, 1993, FRONT NEUROENDOCRIN, V14, P76, DOI 10.1006/frne.1993.1004; AVISHAIELINER S, 1995, NEUROSCI LETT, V192, P49, DOI 10.1016/0304-3940(95)11606-W; BARNA I, 1993, LIFE SCI, V52, P1417, DOI 10.1016/0024-3205(93)90065-B; Bohus B, 1998, PROG BRAIN RES, V119, P555; Bornstein SR, 1999, J CLIN ENDOCR METAB, V84, P1729; de Kloet E Ronald, 2003, Endocr Regul, V37, P51; Drolet G, 2001, PEPTIDES, V22, P761, DOI 10.1016/S0196-9781(01)00389-8; Evans DAP, 2000, J NEUROENDOCRINOL, V12, P685; GRINO M, 1989, ENDOCRINOLOGY, V124, P2686, DOI 10.1210/endo-124-6-2686; Gunnar MR, 2002, PSYCHONEUROENDOCRINO, V27, P199, DOI 10.1016/S0306-4530(01)00045-2; HENNING SJ, 1978, AM J PHYSIOL, V235, pE451; Levine S, 2001, PHYSIOL BEHAV, V73, P255, DOI 10.1016/S0031-9384(01)00496-6; Levine Seymour, 2002, Neurotox Res, V4, P557, DOI 10.1080/10298420290030569; MARTIN CE, 1977, ACTA ENDOCRINOL-COP, V84, P167, DOI 10.1530/acta.0.0840167; McDonald TJ, 1998, HORM METAB RES, V30, P297, DOI 10.1055/s-2007-978888; MURET L, 1992, ENDOCRINOLOGY, V130, P2725, DOI 10.1210/en.130.5.2725; PAYET N, 1982, J PHYSIOLOGY PARIS, V78, P317; SAPOLSKY RM, 1986, BRAIN RES REV, V11, P65, DOI 10.1016/0165-0173(86)90010-X; SCHAPIRO S, 1962, ENDOCRINOLOGY, V71, P986, DOI 10.1210/endo-71-6-986; Scott LV, 1998, LIFE SCI, V62, P1985, DOI 10.1016/S0024-3205(98)00027-7; SIMMONS DM, 1989, J HISTOTECHNOL, V12, P169; SUCHECKI D, 1993, NEUROENDOCRINOLOGY, V57, P204, DOI 10.1159/000126361; Ulrich-Lai YM, 2002, NEUROENDOCRINOLOGY, V76, P79, DOI 10.1159/000064426; WALKER CD, 1986, ENDOCRINOLOGY, V118, P1445, DOI 10.1210/endo-118-4-1445; WALKER CD, 1986, ENDOCRINOLOGY, V119, P1816, DOI 10.1210/endo-119-4-1816; WALKER CD, 1991, ENDOCRINOLOGY, V128, P1385, DOI 10.1210/endo-128-3-1385; Walker CD, 1997, J NEUROENDOCRINOL, V9, P25, DOI 10.1046/j.1365-2826.1997.00544.x; WALKER CD, 1993, ENDOCRINOLOGY, V132, P1101, DOI 10.1210/en.132.3.1101; WILEY MK, 1974, NEUROENDOCRINOLOGY, V14, P257; YI SJ, 1994, ENDOCRINOLOGY, V135, P2364, DOI 10.1210/en.135.6.2364; Zelena D, 2003, AM J PHYSIOL-ENDOC M, V285, pE1110, DOI 10.1152/ajpendo.00219.2003; Zelena D, 2006, AM J PHYSIOL-ENDOC M, V290, pE243, DOI 10.1152/ajpendo.00118.2005; Zelena D, 2004, ANN NY ACAD SCI, V1018, P477, DOI 10.1196/annals.1296.058; Zelena D, 1999, PSYCHONEUROENDOCRINO, V24, P333, DOI 10.1016/S0306-4530(98)00081-X	34	36	37	0	5	ENDOCRINE SOC	WASHINGTON	2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA	0013-7227	1945-7170		ENDOCRINOLOGY	Endocrinology	MAY	2008	149	5					2576	2583		10.1210/en.2007-1537			8	Endocrinology & Metabolism	Endocrinology & Metabolism	291LX	WOS:000255200000058	18276753	Bronze			2020-06-30	J	Elvan, EG; Oc, B; Uzun, S; Karabulut, E; Coskun, E; Aypar, U				Elvan, E. G.; Oc, B.; Uzun, S.; Karabulut, E.; Coskun, E.; Aypar, Ue.			Dexmedetomidine and postoperative shivering in patients undergoing elective abdominal hysterectomy	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article						anaesthesia general; shivering; surgery gynaecological; dexmedetomidine; postoperative period	MEPERIDINE; PREMEDICATION; HYPOTHERMIA; ISOFLURANE; PREVENTION; THRESHOLD; PETHIDINE	Background: Post-anaesthetic shivering is one of the most common complications, occurring in 5-65% of patients recovering from general anaesthesia and 33916 of patients receiving epidural anaesthesia. Our objective was to investigate the efficacy of intraoperative dexmedetomidine infusion on postoperative shivering. Methods: Ninety female patients, ASA I-II, 35-60 yr old, scheduled for elective total abdominal hysterectomy with or without bilateral salpingo-oophorectomy were randomized into two groups. After endotracheal intubation one group received normal saline infusion and the other received dexmedetomidine as a loading dose of 1 mu g kg(-1) for 10 min followed by a maintenance infusion of 0.4 mu g kg(-1) h(-1). In the recovery room, pain was assessed using a 100 mm visual analogue scale and those patients who had a pain score of more than 40 mm were administered 1 mg kg(-1) intramuscular diclofenac sodium. Patients with shivering grades more than 2 were administered 25 mg intravenous meperidine. Patients were protected with passive insulation covers. Results: Post-anaesthetic shivering was observed in 21 patients in the saline group and in seven patients in the dexmedetomidine group (P = 0.001). Shivering occurred more often in the saline group. The Ramsay Sedation Scores were higher in the dexmedetomidine group during the first postoperative hour. Pain scores were higher in the saline group for 30 min after the operation. The need for intraoperative atropine was higher in the dexmedetomidine group. Intraoperative fentanyl use was higher in the saline group. Perioperative tympanic temperatures were not different between the groups whereas postoperative measurements were lower in the dexmedetomidine group (P < 0.05). Conclusion: Intraoperative dexmedetomidine infusion may be effective in the prevention of post-anaesthetic shivering.	[Elvan, E. G.; Oc, B.; Uzun, S.; Coskun, E.; Aypar, Ue.] Hacettepe Univ, Fac Med, Dept Anesthesiol & Reanimat, TR-06100 Ankara, Turkey; [Karabulut, E.] Hacettepe Univ, Fac Med, Dept Biostat, TR-06100 Ankara, Turkey	Uzun, S (reprint author), Hacettepe Univ, Fac Med, Dept Anesthesiol & Reanimat, TR-06100 Ankara, Turkey.	sennuruzun@superonline.com	Karabulut, Erdem/E-9242-2013				BAXENDALE BR, 1994, BRIT J ANAESTH, V72, P291, DOI 10.1093/bja/72.3.291; Bhana N, 2000, DRUGS, V59, P263, DOI 10.2165/00003495-200059020-00012; Bicer C, 2006, EUR J ANAESTH, V23, P149, DOI 10.1017/S0265021505002061; Bilotta F, 2002, REGION ANESTH PAIN M, V27, P380, DOI 10.1053/rapm.2002.33563; Bilotta F, 2001, ANAESTHESIA, V56, P514, DOI 10.1046/j.1365-2044.2001.02057.x; Bock Matthias, 1999, Anesthesiology (Hagerstown), V91, pA1184; Buggy DJ, 2000, BRIT J ANAESTH, V84, P615, DOI 10.1093/bja/84.5.615; Chow T C, 1994, Acta Anaesthesiol Sin, V32, P165; CIOFOLO MJ, 1989, ANESTHESIOLOGY, V70, P737; Cortinez LI, 2004, ANESTHESIOLOGY, V101, P1077, DOI 10.1097/00000542-200411000-00006; CROSSLEY AWA, 1995, BRIT MED J, V311, P764, DOI 10.1136/bmj.311.7008.764; CROSSLEY AWA, 1992, ANAESTHESIA, V47, P193, DOI 10.1111/j.1365-2044.1992.tb02114.x; CROSSLEY AWA, 1992, ANAESTHESIA, V47, P845, DOI 10.1111/j.1365-2044.1992.tb03143.x; Dal D, 2005, BRIT J ANAESTH, V95, P189, DOI 10.1093/bja/aei148; Doufas AG, 2003, STROKE, V34, P1218, DOI 10.1161/01.STR.0000068787.76670.A4; Ebert TJ, 2000, ANESTHESIOLOGY, V93, P382, DOI 10.1097/00000542-200008000-00016; El-Tahir Kamal El-Din Hussein, 2002, Middle East Journal of Anesthesiology, V16, P577; ERKOLA O, 1994, ANESTH ANALG, V79, P646; Greif R, 2001, ANESTH ANALG, V93, P620, DOI 10.1097/00000539-200109000-00018; Guler G, 2005, ACTA ANAESTH SCAND, V49, P1088, DOI 10.1111/j.1399-6576.2005.00780.x; HOLDCROFT A, 1978, BRIT J ANAESTH, V50, P157, DOI 10.1093/bja/50.2.157; Horn E P, 1999, Curr Opin Anaesthesiol, V12, P449, DOI 10.1097/00001503-199908000-00010; Horn EP, 1998, ANESTHESIOLOGY, V88, P108, DOI 10.1097/00000542-199801000-00018; Horn EP, 1998, ANESTHESIOLOGY, V89, P878, DOI 10.1097/00000542-199810000-00012; HURFORD WE, 2000, CRITICAL CARE HDB MA, P100; Jalonen J, 1997, ANESTHESIOLOGY, V86, P331; Mack PF, 2004, J NEUROSURG ANESTH, V16, P20, DOI 10.1097/00008506-200401000-00005; Panzer O, 1999, ANESTHESIOLOGY, V90, P1609, DOI 10.1097/00000542-199906000-00017; PAUCA AL, 1984, ACTA ANAESTH SCAND, V28, P138, DOI 10.1111/j.1399-6576.1984.tb02029.x; Piper SN, 2001, CAN J ANAESTH, V48, P742, DOI 10.1007/BF03016688; Powell RM, 2000, ANESTH ANALG, V90, P1423, DOI 10.1097/00000539-200006000-00032; Sahin A, 2002, ACTA ANAESTH SCAND, V46, P64, DOI 10.1111/j.1399-6576.2002.aas_460111.x; Shelly MP, 2001, BRIT J ANAESTH, V87, P677, DOI 10.1093/bja/87.5.677; Talke P, 1997, ANESTHESIOLOGY, V87, P835, DOI 10.1097/00000542-199710000-00017; Wrench IJ, 1997, ANAESTHESIA, V52, P32, DOI 10.1111/j.1365-2044.1997.006-az006.x	35	63	75	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0265-0215	1365-2346		EUR J ANAESTH	Eur. J. Anaesth.	MAY	2008	25	5					357	364		10.1017/S0265021507003110			8	Anesthesiology	Anesthesiology	300IQ	WOS:000255817900003	18205960				2020-06-30	J	Moksnes, K; Fredheim, OM; Klepstad, P; Kaasa, S; Angelsen, A; Nilsen, T; Dale, O				Moksnes, Kristin; Fredheim, Olav M.; Klepstad, Pal; Kaasa, Stein; Angelsen, Anders; Nilsen, Turid; Dale, Ola			Early pharmacokinetics of nasal fentanyl: is there a significant arterio-venous difference?	EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY			English	Article						fentanyl; nasal; opioids; pain; pharmacokinetics; safety	INTRANASAL FENTANYL; HUMAN VOLUNTEERS; PAIN MANAGEMENT; PHARMACODYNAMICS; CITRATE; SPRAY	Objective We have investigated the arterio-venous difference in the pharmacokinetics of 50 mu g fentanyl during the first hour following nasal administration and documented its tolerability in opioid-naive middle-aged to elderly patients. Methods Twelve male patients (range in age 47-84 years) scheduled for transurethral resection of the prostate gland received a 100-mu l dose of 50 mu g fentanyl base as a fentanyl citrate formulation in one nostril. Simultaneous arterial and venous blood samples for analyses of fentanyl were drawn at baseline and at 1, 3, 5, 7, 9, 13, 15, 20, 25, 35, 45 and 60 min after drug administration. Vital signs, sedation and symptoms of local irritation were recorded. Results The arterial C-max (maximum serum concentration) of 0.83 ng/ml was nearly twofold higher than the venous C-max of 0.47 ng/ml, and the arterial T-max (time to maximum serum concentration) of 7.0 min was about 5 min shorter than the venous T-max of 11.6 min. The arterial AUC(0-60) (area under the curve from 0 to 60 min after administration) of 21 min*ng/ml was approximately 30% larger than the venous AUC(0-60) of 15 min*ng/ml (all p values <= 0.005). Venous T-max and C-max did not predict the corresponding arterial values. No significant adverse events were observed. Conclusion A significant arterio-venous difference was present after intranasal administration of fentanyl. The short arterial T-max complies with its rapid onset of action. The use of venous concentrations for the prediction of onset time of analgesia should be discouraged. A 50-mu g dose of nasal fentanyl was well tolerated by opioid-naive middle-aged to elderly male patients.	[Moksnes, Kristin; Fredheim, Olav M.; Klepstad, Pal; Nilsen, Turid; Dale, Ola] Norwegian Univ Sci & Technol, St Olav Univ Hosp, Dept Circulat & Med Imaging, Pain & Palliat Res Grp, N-7006 Trondheim, Norway; [Fredheim, Olav M.] Sandnessjoen Hosp, Dept Surg, Helgelandssykehuset, Norway; [Klepstad, Pal; Dale, Ola] St Olavs Univ Hosp, Dept Anaesthesiol & Emergency Med, Intens Care Unit, Trondheim, Norway; [Kaasa, Stein] St Olavs Univ Hosp, Palliat Med Unit, Dept Oncol, Trondheim, Norway; [Kaasa, Stein; Angelsen, Anders] Norwegian Univ Sci & Technol, Pain & Palliat Res Grp, Dept Canc Res & Mol Med, N-7006 Trondheim, Norway; [Angelsen, Anders] St Olavs Univ Hosp, Dept Urol, Trondheim, Norway	Moksnes, K (reprint author), Norwegian Univ Sci & Technol, St Olav Univ Hosp, Dept Circulat & Med Imaging, Pain & Palliat Res Grp, Kreftbygget 5th Floor,Olav Kyrres Gate 17, N-7006 Trondheim, Norway.	kristin.moksnes@ntnu.no		Fredheim, Olav/0000-0002-0931-0027			Borgbjerg FM, 1996, PAIN, V64, P123; CHIOU WL, 1989, CLIN PHARMACOKINET, V17, P275, DOI 10.2165/00003088-198917040-00005; Dale O, 2002, CLIN PHARMACOL THER, V72, P536, DOI 10.1067/mcp.2002.128386; Dale O, 2002, ACTA ANAESTH SCAND, V46, P759, DOI 10.1034/j.1399-6576.2002.460702.x; Dale O, 2006, J PHARM PHARMACOL, V58, P1311, DOI 10.1211/jpp.58.10.0003; Galinkin JL, 2000, ANESTHESIOLOGY, V93, P1378, DOI 10.1097/00000542-200012000-00006; Glare P, 2004, INTERN MED J, V34, P45, DOI 10.1111/j.1444-0903.2004.t01-9-.x; Guthrie SK, 1999, EUR J CLIN PHARMACOL, V55, P639, DOI 10.1007/s002280050686; Hermann DJ, 1999, CLIN PHARMACOL THER, V65, P511, DOI 10.1016/S0009-9236(99)70070-6; Lee M, 2003, J PAIN SYMPTOM MANAG, V26, P743, DOI 10.1016/S0885-3924(03)00241-0; Lennernas B, 2005, BRIT J CLIN PHARMACO, V59, P249, DOI 10.1111/j.1365-2125.2004.02264.x; Paech MJ, 2003, ANAESTHESIA, V58, P740, DOI 10.1046/j.1365-2044.2003.03286.x; Rentsch KM, 2001, CLIN PHARMACOL THER, V70, P237, DOI 10.1067/mcp.2001.117981; SCOTT JC, 1987, J PHARMACOL EXP THER, V240, P159; STREISAND JB, 1991, ANESTHESIOLOGY, V75, P223, DOI 10.1097/00000542-199108000-00009; Striebel H W, 1993, Schmerz, V7, P122, DOI 10.1007/BF02527870; STRIEBEL HW, 1992, ANESTHESIOLOGY, V77, P281, DOI 10.1097/00000542-199208000-00010; Zeppetella G, 2000, PALLIATIVE MED, V14, P57, DOI 10.1191/026921600668793500	18	42	44	0	3	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0031-6970	1432-1041		EUR J CLIN PHARMACOL	Eur. J. Clin. Pharmacol.	MAY	2008	64	5					497	502		10.1007/s00228-007-0444-8			6	Pharmacology & Pharmacy	Pharmacology & Pharmacy	276ZW	WOS:000254183200008	18180911				2020-06-30	J	Fodale, V; Mafrica, F; Santamaria, LB; Coleman, JJ				Fodale, Vincenzo; Mafrica, Federica; Santamaria, Letterio B.; Coleman, John J.			Killer fentanyl: is the fear justified?	EXPERT OPINION ON DRUG SAFETY			English	Editorial Material						abuse; anesthesia; counterfeit drugs; deaths; fentanyl; fentanyl-laced heroin; occupational exposure; operating rooms; opioids; overdose; pain therapy; pain treatment; pharmacogenomics; public health; transdermal		Background: Fentanyl-related deaths have created havoc with public health and safety, especially in the United States. With this increasingly apparent role as a drug of abuse in cases of overdose and death, the drug has acquired the reputation of 'killer fentanyl'. Is this fear justified? Objective/methods: Information to clarify some of the present concerns regarding fentanyl abuse based on the review of the scientific literature in major databases and public sourced material available on the internet, followed by a quality assessment of reports. Results/conclusion: The opioid drug, fentanyl, is involved in medical cases of complications, toxic effects, addiction, abuse, overdose and death in patients, as well as abuse among healthcare professionals. The increase of fentanyl abuse is a growing public health problem that may evolve into a global problem. However, abuse patterns of legally and illegally produced fentanyl have produced confusion because media reporters and public officials often ignore important differences in the origins of the drug itself and the people who abuse it. In the light of possible fatal and nonfatal side effects, the use of fentanyl should be reconsidered, especially in view of the new opioid drugs that are now available.	[Fodale, Vincenzo] Univ Messina, Dept Neurosci Psychiat & Anesthesiolog Sci, Messina, Italy	Fodale, V (reprint author), Policlin Univ, Dept Neurosci Psychiat & Anesthesiolog Sci, Via C Valeria, I-98125 Messina, Italy.	vfodale@unime.it	Fodale, Vincenzo/G-5554-2010	Fodale, Vincenzo/0000-0001-9540-5665			Boddiger D, 2006, LANCET, V368, P569, DOI 10.1016/S0140-6736(06)69181-2; Coleman JJ, 2005, J PSYCHOACTIVE DRUGS, V37, P343, DOI 10.1080/02791072.2005.10399808; *FDA, 2006, SAF WARN REG US FENT; Fodale Vincenzo, 2007, J Opioid Manag, V3, P123; Fodale V, 2006, LANCET, V368, P1237, DOI 10.1016/S0140-6736(06)69516-0; *INT NARC CONTR BO, 2006, ANN REP 2006 REG HIG; Jin M, 2005, J ANAL TOXICOL, V29, P590, DOI 10.1093/jat/29.7.590; McAuliffe PF, 2006, MED HYPOTHESES, V66, P874, DOI 10.1016/j.mehy.2005.10.030; MEADOWS M, 2006, PROPER USE FENTANYL; *TEDS, 2006, DASIS SERIES S, V33	10	8	8	0	13	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1474-0338	1744-764X		EXPERT OPIN DRUG SAF	Expert Opin. Drug Saf.	MAY	2008	7	3					213	217		10.1517/14740338.7.3.213			5	Pharmacology & Pharmacy	Pharmacology & Pharmacy	306FN	WOS:000256233800001	18462178				2020-06-30	J	Yilmaz, E; Batislam, E; Tuglu, D; Yuvanc, E				Yilmaz, Erdal; Batislam, Ertan; Tuglu, Devrim; Yuvanc, Ercan			Local Anesthesia with 20 mL prilocaine infiltration: The ultimate point for analgesia during shockwave lithotripsy?	JOURNAL OF ENDOUROLOGY			English	Article							WAVE LITHOTRIPSY; EUTECTIC MIXTURE; CREAM; GENERATION; FENTANYL; REQUIREMENTS; ALFENTANIL; ESWL	Purpose: The effectiveness of 10 mL and 20 mL local prilocaine infiltration for analgesic purposes during shockwave lithotripsy (SWL) was compared, and the differences in pain intensity and need for additional analgesics were defined. Patients and Methods: One hundred and twenty-one patients between the ages of 16 and 69 with kidney stones were randomly separated into two groups. The 60 patients in group 1 received 10 mL prilocaine subcutaneously and deep lumbar infiltration into the area 1 cm below the twelfth rib 2 minutes before SWL. The 61 patients in group 2 received 20 mL subcutaneously and deep lumbar infiltration of prilocaine to the same locale, again 2 minutes before the process. All the patients received one session of SWL. For measurement of pain intensity, the 0 to 100 mm visual analog scale ( VAS) was used at 1 minute and every 10 minutes during the process. Intravenous fentanyl was administered to patients who had steady or increasing intensity of pain during the process. Results: VAS values were statistically significantly higher in patients in group 1 compared with patients in group 2 during the process. While 40 patients received additional analgesia in group 1, only three patients in group 2 needed additional analgesia. Conclusion: Use of 20 mL subcutaneous and deep lumbar prilocaine infiltration during SWL for analgesic purposes is recommended as an efficient, cost-effective, anesthetist-independent, and reliable method.	[Yilmaz, Erdal; Batislam, Ertan; Tuglu, Devrim; Yuvanc, Ercan] Kirikkale Univ, Fac Med, Dept Urol, Uroloji AD, TR-71100 Kirikkale, Turkey	Yilmaz, E (reprint author), Kirikkale Univ, Fac Med, Dept Urol, Uroloji AD, TR-71100 Kirikkale, Turkey.	erdaly69@mynet.com	Tuglu, Devrim/E-4651-2015; Batislam, Ertan/E-2892-2016	Batislam, Ertan/0000-0002-7493-4573			Barcena M, 1996, EUR J ANAESTH, V13, P373, DOI 10.1046/j.1365-2346.1996.00961.x; BIERKENS AF, 1991, J UROLOGY, V146, P287, DOI 10.1016/S0022-5347(17)37772-8; CATTERALL W, 2001, [No title captured], P367; CHAUSSY C, 1984, UROLOGY, V23, P59, DOI 10.1016/0090-4295(84)90243-7; CLEMENTS PJ, 1993, TXB RHEUMATOLOGY, P700; COVINO BG, 1989, GEN ANESTHESIA, P1036; DAWSON C, 1994, BRIT J UROL, V74, P302, DOI 10.1111/j.1464-410X.1994.tb16615.x; DELICHTENBERG MH, 1992, J UROLOGY, V147, P96, DOI 10.1016/S0022-5347(17)37143-4; Gesztesi Z, 2000, ANESTH ANALG, V90, P567, DOI 10.1097/00000539-200003000-00013; MCDONALD PF, 1992, BRIT J ANAESTH, V69, P399, DOI 10.1093/bja/69.4.399; MONK TG, 1991, ANESTH ANALG, V72, P616; MONK TG, 1991, ANESTHESIOLOGY, V74, P1023, DOI 10.1097/00000542-199106000-00009; MONK TG, 1994, ANESTH ANALG, V79, P506; Ozturk H, 2002, UROL RES, V30, P223, DOI 10.1007/s00240-002-0266-1; RASMUSSEN YH, 1994, SCAND J UROL NEPHROL, V28, P225, DOI 10.3109/00365599409181270; Richard Michel G., 1998, Anesthesia and Analgesia, V86, P1214, DOI 10.1097/00000539-199806000-00015; Salinas AS, 1999, UROL INT, V63, P92, DOI 10.1159/000030425; SCHOCKENHOFF B, 1987, EUR UROL, V13, P293; TISELIUS HG, 1993, J UROLOGY, V149, P8, DOI 10.1016/S0022-5347(17)35983-9; WILBERT DM, 1987, J UROLOGY, V138, P563, DOI 10.1016/S0022-5347(17)43259-9; Wilbert DM, 2002, BJU INT, V90, P507, DOI 10.1046/j.1464-410X.2002.02961.x; Yilmaz E, 2005, J ENDOUROL, V19, P589, DOI 10.1089/end.2005.19.589; Yilmaz E, 2006, UROLOGY, V68, P24, DOI 10.1016/j.urology.2006.01.047; Zhou YF, 2004, J UROLOGY, V172, P1892, DOI 10.1097/01.ju.0000142827.41910.a2	24	5	5	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0892-7790	1557-900X		J ENDOUROL	J. Endourol.	MAY	2008	22	5					883	887		10.1089/end.2007.0307			5	Urology & Nephrology	Urology & Nephrology	315LO	WOS:000256881700005	18393643				2020-06-30	J	Gordon, D; Schroeder, M				Gordon, Debra; Schroeder, Mark			Oral transmucosal fentanyl citrate - OTFC (ACTIQ (TM)) #103	JOURNAL OF PALLIATIVE MEDICINE			English	Editorial Material										Gordon, D (reprint author), Univ Wisconsin Hosp & Clin, Dept Nursing, 600 Highland Ave, Madison, WI 53792 USA.	dgordon@whealth.org					Fine P G, 1998, J Palliat Med, V1, P55, DOI 10.1089/jpm.1998.1.55; MONTVALE NJ, 2003, PHYS DESK REFERENCE; Portenoy RK, 1999, PAIN, V79, P303, DOI 10.1016/S0304-3959(98)00179-1	3	4	4	0	2	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1096-6218			J PALLIAT MED	J. Palliat. Med.	MAY	2008	11	4					633	634		10.1089/jpm.2008.9922			2	Health Care Sciences & Services	Health Care Sciences & Services	306IK	WOS:000256241300017	18454617				2020-06-30	J	Gauna, AA; Kang, SK; Triano, ML; Swatko, ER; Vanston, VJ				Gauna, Alberto A.; Kang, Sheila K.; Triano, Mary Lawhon; Swatko, Erica Rachel; Vanston, Vincent Jay			Oral transmucosal fentanyl citrate for dyspnea in terminally ill patients: An observational case series	JOURNAL OF PALLIATIVE MEDICINE			English	Editorial Material							CANCER-PATIENTS; SUBCUTANEOUS MORPHINE; MANAGEMENT; OPIOIDS; TRIAL	Objective: To evaluate the efficacy and safety of oral transmucosal fentanyl citrate (OTFC) in terminally ill patients experiencing dyspnea. Methods: Nonblinded, noncontrolled observational study of patients admitted to the hospice/palliative care unit for dyspnea from May 2006 to March 2007. Eligible patients were older than 18 years of age with satisfactory baseline cognitive function diagnosed with end-stage congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), or cancer complaining of dyspnea. At the onset of dyspnea, enrolled patients were instructed to slowly dissolve the OTFC lozenge and rate their dyspnea on a 10 point visual analog scale at 15-minute intervals for 60 minutes. Respiratory rate (RR) and arterial oxygen saturation (SaO(2)) were recorded at similar intervals. Patients were observed for approximately 48 hours. Results: Four patients were found eligible. In all four cases, patients experienced rapid relief of dyspnea as soon as five minutes. No significant adverse events were reported. Conclusions: OTFC appears to be safe and effective for dyspnea in terminally ill patients. The study population is limited to four cases, however, the initial findings are promising and merit further research.	[Gauna, Alberto A.] Mercy Hosp, Scranton Temple Residency Program, Dept Palliat Med, Scranton, PA 18510 USA; [Triano, Mary Lawhon; Vanston, Vincent Jay] Scranton Temple Residency Program, Dept Internal Med, Scranton, PA USA; [Kang, Sheila K.; Swatko, Erica Rachel] Wilkes Univ, Nesbitt Coll Pharm & Nursing, Dept Pharm Practice, Wilkes Barre, PA 18766 USA	Vanston, VJ (reprint author), Mercy Hosp, Scranton Temple Residency Program, Dept Palliat Med, 746 Jefferson Ave, Scranton, PA 18510 USA.	vanstonvj@strpweb.org					Allard P, 1999, J PAIN SYMPTOM MANAG, V17, P256, DOI 10.1016/S0885-3924(98)00157-2; Benitez-Rosario MA, 2005, J PAIN SYMPTOM MANAG, V30, P395, DOI 10.1016/j.jpainsymman.2005.10.002; Boyd KJ, 1997, PALLIATIVE MED, V11, P277, DOI 10.1177/026921639701100403; Bruera E, 2005, J PAIN SYMPTOM MANAG, V29, P613, DOI 10.1016/j.jpainsymman.2004.08.016; Bruera E, 2000, J PAIN SYMPTOM MANAG, V19, P357, DOI 10.1016/S0885-3924(00)00126-3; Bruera E, 1990, J Pain Symptom Manage, V5, P341, DOI 10.1016/0885-3924(90)90027-H; BRUERA E, 1993, ANN INTERN MED, V119, P906, DOI 10.7326/0003-4819-119-9-199311010-00007; *CEPH INC, 2004, ACT; COHEN MH, 1991, SOUTHERN MED J, V84, P229, DOI 10.1097/00007611-199102000-00019; Dudgeon DJ, 2001, J PAIN SYMPTOM MANAG, V21, P95, DOI 10.1016/S0885-3924(00)00258-X; Fine P G, 1998, J Palliat Med, V1, P55, DOI 10.1089/jpm.1998.1.55; Jennings AL, 2002, THORAX, V57, P939, DOI 10.1136/thorax.57.11.939; Mazzocato C, 1999, ANN ONCOL, V10, P1511, DOI 10.1023/A:1008337624200; Meek PM, 1999, AM J RESP CRIT CARE, V159, P321; Noseda A, 1997, EUR RESPIR J, V10, P1079, DOI 10.1183/09031936.97.10051079; REUBEN DB, 1986, CHEST, V89, P234, DOI 10.1378/chest.89.2.234; Shulman KI, 2000, INT J GERIATR PSYCH, V15, P548, DOI 10.1002/1099-1166(200006)15:6<548::AID-GPS242>3.0.CO;2-U; Wilcock A, 2002, J PAIN SYMPTOM MANAG, V23, P182, DOI 10.1016/S0885-3924(01)00417-1	18	29	31	0	3	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1096-6218			J PALLIAT MED	J. Palliat. Med.	MAY	2008	11	4					643	648		10.1089/jpm.2007.0161			6	Health Care Sciences & Services	Health Care Sciences & Services	306IK	WOS:000256241300022	18454622				2020-06-30	J	Downs, JW; Young, PE; Durning, SJ				Downs, John W.; Young, Patrick E.; Durning, Steven J.			Psychogenic coma following upper endoscopy: A case report and review of the literature	MILITARY MEDICINE			English	Review							GENERAL-ANESTHESIA; UNCONSCIOUSNESS; FAILURE; STATES; SIGN	Background: Failure to regain consciousness after general anesthesia has a multitude of life-threatening causes, including neurological injury, metabolic derangements, or drug effects. Failure to promptly recognize the cause of unconsciousness after anesthesia can result in significant patient morbidity or mortality, costly laboratory and radiographic evaluation, and physician anxiety. Rarely, patients fail to awaken after anesthesia due to a psychiatric cause. The early recognition of psychogenic coma can result in reduced iatrogenic complications, hospital cost, and physician anxiety. Case: We present a case of a 28-year-old female who became unresponsive after general anesthesia for an upper endoscopy. Physical, laboratory, and radiographic examination after the procedure revealed no apparent organic cause for her failure to awaken. The patient spontaneously awoke after 16 hours without neurological deficit. Discussion: We reviewed the literature and identified 10 previously reported cases of postanesthesia psychogenic coma. We have compared and contrasted our case with the 10 previous reports and propose bedside clues to assist the physician with diagnosing this unusual condition.	[Downs, John W.; Young, Patrick E.; Durning, Steven J.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA	Downs, JW (reprint author), Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA.						ADAMS AP, 1991, ANAESTHESIA, V46, P932, DOI 10.1111/j.1365-2044.1991.tb09850.x; ALBRECHT RF, 1995, ANESTHESIOLOGY, V83, P201, DOI 10.1097/00000542-199507000-00024; CAIN DL, 1983, ANN ROY COLL SURG, V65, P265; CAMPBELL WW, 2005, NEUROLOGIC EXAMINATI, P609; Chang Yi, 2002, Acta Anaesthesiol Sin, V40, P101; Haller M, 2003, ANAESTHESIST, V52, P1031, DOI 10.1007/s00101-003-0577-9; HAUGEN FP, 1961, ANESTHESIOLOGY, V22, P657, DOI 10.1097/00000542-196109000-00001; HENRY JA, 1978, LANCET, V2, P920; Hwang JL, 2002, HUM REPROD, V17, P1124, DOI 10.1093/humrep/17.4.1124; Jackson AO, 2000, ANAESTHESIA, V55, P409, DOI 10.1046/j.1365-2044.2000.01378-37.x; Kavirajan H, 1999, HARVARD REV PSYCHIAT, V7, P153, DOI 10.1093/hrp/7.3.153; Maddock H, 1999, ANAESTHESIA, V54, P717, DOI 10.1046/j.1365-2044.1999.1013v.x; MECCA RS, 2002, CLIN ANESTHESIA PRAC, P111; Meyers TJ, 1999, ARCH OTOLARYNGOL, V125, P1267, DOI 10.1001/archotol.125.11.1267; ORR DL, 1985, J ORAL MAXIL SURG, V43, P817; PLUM F, 1982, DIAGNOSIS STUPOR COM, P305; Posner J B, 1975, Clin Neurosurg, V22, P281; ROSENBERG ML, 1982, J CLIN NEURO-OPHTHAL, V2, P259; SOLOMON D, 2002, CLIN ANESTHESIA PRAC, P186; Weber JG, 1996, MAYO CLIN PROC, V71, P797	20	8	8	0	0	ASSOC MILITARY SURG US	BETHESDA	9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA	0026-4075			MIL MED	Milit. Med.	MAY	2008	173	5					509	512		10.7205/MILMED.173.5.509			4	Medicine, General & Internal	General & Internal Medicine	300SY	WOS:000255846700020	18543575	Bronze			2020-06-30	J	Kocabas, S; Yedicocuklu, D; Askar, F; Atay, Y				Kocabas, Seden; Yedicocuklu, Demet; Askar, Fatma; Atay, Yuksel			Anesthetic management of a child with Duchenne muscular dystrophy undergoing correction of Fallot's Tetralogy	PEDIATRIC ANESTHESIA			English	Letter									[Kocabas, Seden; Yedicocuklu, Demet; Askar, Fatma] Ege Univ, Fac Med, Dept Anesthesiol & Reanimat, Izmir, Turkey; [Atay, Yuksel] Ege Univ, Fac Med, Dept Cardiovasc Surg, Izmir, Turkey	Kocabas, S (reprint author), Ege Univ, Fac Med, Dept Anesthesiol & Reanimat, Izmir, Turkey.	nskocabas@hotmail.com	Kocabas, Seden/AAB-5505-2020	Askar, Fatma Zekiye/0000-0001-7237-574X; Kocabas, Seden/0000-0003-1686-2169			BIERI D, 1990, PAIN, V41, P139, DOI 10.1016/0304-3959(90)90018-9; Blake DJ, 2000, TRENDS NEUROSCI, V23, P92, DOI 10.1016/S0166-2236(99)01510-6; HICKEY PR, 1993, CARDIAC ANESTHESIA, P681; Nathan A, 2005, ANESTH ANALG, V100, P672, DOI 10.1213/01.ANE.0000146533.21771.2F; Wick S, 2005, ANESTHESIOLOGY, V102, P915, DOI 10.1097/00000542-200505000-00009; Yemen TA, 2006, PEDIATR ANESTH, V16, P105, DOI 10.1111/j.1460-9592.2005.01801.x	6	0	1	0	2	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	1155-5645			PEDIATR ANESTH	Pediatr. Anesth.	MAY	2008	18	5					448	450		10.1111/j.1460-9592.2008.02456.x			4	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	282JO	WOS:000254564000017	18312525				2020-06-30	J	Darnell, CM; Thompson, J; Stromberg, D; Roy, L; Sheeran, P				Darnell, Cindy Maria; Thompson, Jennifer; Stromberg, Daniel; Roy, Lonnie; Sheeran, Paul			Effect of low-dose naloxone infusion on fentanyl requirements in critically ill children	PEDIATRICS			English	Article						critically ill children; opiate dependent neonate; pain management; sedation; randomized; controlled trial	DECREASE OPIOID REQUIREMENTS; ACTIVITY ASSESSMENT SCALE; ANTINOCICEPTIVE POTENCY; ADMINISTERED MORPHINE; RECEPTOR FUNCTIONS; SENSORY NEURONS; TOLERANCE; ANALGESIA; SEDATION; DEPENDENCE	OBJECTIVE. Sedating critically ill patients often involves prolonged opioid infusions causing opioid tolerance. Naloxone has been hypothesized to limit opioid tolerance by decreasing adenylate cyclase/cyclic adenosine monophosphate activation. The study purpose was to investigate the effect of low-dose naloxone on the maximum cumulative daily fentanyl dose in critically ill children. METHODS. We conducted a double-blinded, randomized, placebo-control trial from December 2002 through July 2004 in a university PICU. We enrolled 82 children age 1 day to 18 years requiring mechanical ventilation and fentanyl infusions anticipated to last for > 4 days were eligible for enrollment. Those receiving additional oral analgesia or sedation, having a history of drug dependence or withdrawal, or having significant neurologic, renal, or hepatic disease were excluded. In addition to fentanyl infusions, patients received low-dose naloxone or placebo infusions. Medications were adjusted using the Modified Motor Activity Assessment Scale. Withdrawal was monitored using the Modified Narcotic Withdrawal Scale. Intervention was a low-dose naloxone infusion (0.25 mu g/kg per hour) and the main outcome variable was the maximum cumulative daily fentanyl dose (micrograms per kilogram per day). RESULTS. There was no difference in the maximum cumulative daily fentanyl dose between patients treated with naloxone (N = 37) or those receiving placebo (N = 35). Adjustment for the starting fentanyl dose also failed to reveal group differences. Total fentanyl dose received throughout the study in the naloxone group (360 mu g/kg) versus placebo (223 mu g/kg) was not statistically different. Placebo patients trended toward fewer rescue midazolam boluses (10.7 vs 17.8), lower total midazolam dose (11.6 mg/kg vs 23.9 mg/kg), and fewer rescue fentanyl boluses (18.5 vs 23.9). CONCLUSIONS. We conclude that administration of low-dose naloxone (0.25 mu g/kg per hour) does not decrease fentanyl requirements in critically ill, mechanically ventilated children.	[Darnell, Cindy Maria; Stromberg, Daniel; Sheeran, Paul] Univ Texas SW, Dept Pediat, Dallas, TX USA; [Thompson, Jennifer] Naval Med Ctr, Portsmouth, VA USA; [Roy, Lonnie] Childrens Med Ctr, Dallas, TX 75235 USA	Darnell, CM (reprint author), Childrens Med Ctr, Crit Care Serv, 1935 Motor St, Dallas, TX 75235 USA.	cindy.darnell@childrens.com					ANAND KJS, 1994, CRIT CARE MED, V22, P334, DOI 10.1097/00003246-199402000-00027; ARNOLD JH, 1990, ANESTHESIOLOGY, V73, P1136, DOI 10.1097/00000542-199012000-00011; AvidorReiss T, 1996, J BIOL CHEM, V271, P21309, DOI 10.1074/jbc.271.35.21309; AVIDORREISS T, 1995, J BIOL CHEM, V270, P29732; Berde CB, 2002, NEW ENGL J MED, V347, P1094, DOI 10.1056/NEJMra012626; Cepeda MS, 2004, PAIN, V107, P41, DOI 10.1016/j.pain.2003.09.011; Cepeda MS, 2002, PAIN, V96, P73, DOI 10.1016/S0304-3959(01)00425-0; Cheung CLS, 2007, INTENS CARE MED, V33, P190, DOI 10.1007/s00134-006-0387-z; Clark MJ, 2006, J PHARMACOL EXP THER, V317, P858, DOI 10.1124/jpet.105.096818; Clemmer TP, 2000, CRIT CARE MED, V28, P3124, DOI 10.1097/00003246-200008000-00096; Crain S M, 1990, NIDA Res Monogr, V105, P34; CRAIN SM, 1988, BRAIN RES, V455, P99, DOI 10.1016/0006-8993(88)90118-7; Crain SM, 2000, PAIN, V84, P121, DOI 10.1016/S0304-3959(99)00223-7; Crain SM, 1998, TRENDS PHARMACOL SCI, V19, P358, DOI 10.1016/S0165-6147(98)01241-3; Crain SM, 1996, NEUROCHEM RES, V21, P1347, DOI 10.1007/BF02532375; CRAIN SM, 1995, P NATL ACAD SCI USA, V92, P10540, DOI 10.1073/pnas.92.23.10540; Curley MAQ, 2005, JAMA-J AM MED ASSOC, V294, P229, DOI 10.1001/jama.294.2.229; Curley MAQ, 2006, PEDIATR CRIT CARE ME, V7, P107, DOI 10.1097/01.PCC.0000200955.40962.38; Devlin JW, 1999, CRIT CARE MED, V27, P1271, DOI 10.1097/00003246-199907000-00008; *FACTS COMP, [No title captured]; FINNEGAN LP, 1975, ADDICT DIS, V2, P141; Gan TJ, 1997, ANESTHESIOLOGY, V87, P1075, DOI 10.1097/00000542-199711000-00011; Golianu B, 2000, PEDIATR CLIN N AM, V47, P559, DOI 10.1016/S0031-3955(05)70226-1; Haeseler G, 2006, PAIN, V126, P234, DOI 10.1016/j.pain.2006.07.003; Joshi GP, 1999, ANESTHESIOLOGY, V90, P1007, DOI 10.1097/00000542-199904000-00013; KATZ R, 1994, CRIT CARE MED, V22, P763, DOI 10.1097/00003246-199405000-00009; Kendrick WD, 1996, ANESTH ANALG, V82, P641, DOI 10.1097/00000539-199603000-00037; Kieffer BL, 2002, CELL, V108, P587, DOI 10.1016/S0092-8674(02)00666-9; Kress JP, 2006, CRIT CARE MED, V34, P2541, DOI 10.1097/01.CCM.0000239117.39890.E3; Leteurtre S, 2003, LANCET, V362, P192, DOI 10.1016/S0140-6736(03)13908-6; LEVINE JD, 1988, J CLIN INVEST, V82, P1574, DOI 10.1172/JCI113768; Manworren Renee C B, 2003, Pediatr Nurs, V29, P140; McArdle P, 1999, CRIT CARE CLIN, V15, P89, DOI 10.1016/S0749-0704(05)70041-5; Mehlisch DR, 2003, PAIN, V101, P209, DOI 10.1016/S0304-3959(02)00352-4; MURRAY L, 2005, [No title captured]; Narita M, 2002, LIFE SCI, V70, P2341, DOI 10.1016/S0024-3205(01)01550-8; NESTLER EJ, 1993, NEURON, V11, P995, DOI 10.1016/0896-6273(93)90213-B; Nevo I, 1998, MOL PHARMACOL, V54, P419; Playfor S, 2006, INTENS CARE MED, V32, P1125, DOI 10.1007/s00134-006-0190-x; Prins S, 2006, INTENS CARE MED, V32, P1103, DOI 10.1007/s00134-006-0191-9; Raith K, 2004, INT J CLIN PHARM TH, V42, P191; RAWAL N, 1986, ANESTHESIOLOGY, V64, P194, DOI 10.1097/00000542-198602000-00011; REISINE T, 1996, [No title captured], P521; ROLLY G, 1986, J INT MED RES, V14, P148; Saidak Z, 2006, BRIT J PHARMACOL, V147, P671, DOI 10.1038/sj.bjp.0706661; SHARMA SK, 1975, P NATL ACAD SCI USA, V72, P3092, DOI 10.1073/pnas.72.8.3092; SHEN KF, 1989, BRAIN RES, V491, P227, DOI 10.1016/0006-8993(89)90059-0; Shen KF, 1997, BRAIN RES, V757, P176, DOI 10.1016/S0006-8993(97)00197-2; Stoller KB, 2001, PSYCHOPHARMACOLOGY, V154, P230, DOI 10.1007/s002130000637; Suresh S, 2001, PAEDIATR ANAESTH, V11, P511, DOI 10.1046/j.1460-9592.2001.00764.x; Takahashi Masahiko, 2004, J Anesth, V18, P1, DOI 10.1007/s00540-003-0214-4; Tobias JD, 2000, CRIT CARE MED, V28, P2122, DOI 10.1097/00003246-200006000-00079; Tobias JD, 2005, PEDIATR ANN, V34, P636, DOI 10.3928/0090-4481-20050801-12; Ueda H, 2003, LIFE SCI, V74, P313, DOI 10.1016/j.lfs.2003.09.018; Ummenhofer WC, 2000, ANESTHESIOLOGY, V92, P739, DOI 10.1097/00000542-200003000-00018; Voepel-Lewis T, 2002, ANESTH ANALG, V95, P1224, DOI 10.1097/00000539-200211000-00020; Waldhoer M, 2004, ANNU REV BIOCHEM, V73, P953, DOI 10.1146/annurev.biochem.73.011303.073940; WOOLF CJ, 1980, BRAIN RES, V189, P593, DOI 10.1016/0006-8993(80)90375-3	58	12	14	0	3	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	MAY	2008	121	5					E1363	E1371		10.1542/peds.2007-1468			9	Pediatrics	Pediatrics	295VL	WOS:000255501900086	18411237				2020-06-30	J	Pascoe, JE; Williams, KL; Mukhopadhyay, P; Rice, KC; Woods, JH; Ko, MC				Pascoe, John E.; Williams, Keith L.; Mukhopadhyay, Partha; Rice, Kenner C.; Woods, James H.; Ko, Mei-Chuan			Effects of mu, kappa, and delta opioid receptor agonists on the function of hypothalamic-pituitary-adrenal axis in monkeys	PSYCHONEUROENDOCRINOLOGY			English	Article						HPA axis; opioid receptor agonists; opioid receptor antagonists; ACTH; cortisol; primates	INTRACISTERNAL NOR-BINALTORPHIMINE; ADRENOCORTICAL HPA AXIS; MALE RHESUS-MONKEYS; THERMAL ANTINOCICEPTION; DIFFERENT DURATIONS; OPIATE; CORTISOL; ANTAGONIST; SECRETION; MORPHINE	Opioids can modulate neuroendocrine function. Less is known about the involvement of opioid receptor subtypes in the stimulatory effects of opioids on the primate hypothalamic-pituitary-adrenal (HPA) axis. The aim of this study was to investigate the stimulatory effects of opioids selective for each receptor subtype on plasma adrenocorticotropic hormone (ACTH) and cortisol. levels in both mate and female monkeys. The blood collection procedure was conducted in home-caged and unanesthetized rhesus monkeys that showed low and stable basal ACTH and cortisol levels. Three opioid receptor agonists, fentanyl, U-50488H, and SNC80, were used in behaviorally active doses; they are highly selective for mu, kappa, and delta opioid receptors, respectively. Plasma samples were collected at multiple time points before and after IV administration of each compound and were quantified by radioimmunoassay. Neither fentanyl (0.0003-0.02 mg/kg) nor SNC80 (0.03-0.3 mg/kg) changed either ACTH or cortisol. basal levels. In contrast, U-50488H (0.01-1 mg/kg) dose-dependently stimulated ACTH and cortisol release in both mate and female monkeys. Importantly, the stimulatory effects of U-50488H on the secretion of ACTH were Mocked by a selective kappa opioid receptor antagonist, nor-Binaltorphimine. The antagonist effect of nor-binaltorphimine lasted up to 20 weeks. These results indicate that only synthetic kappa, but not mu or delta opioid receptor agonists stimulate HPA axis activity after acute administration in primates. (C) 2008 Elsevier Ltd. All rights reserved.	[Pascoe, John E.; Mukhopadhyay, Partha; Woods, James H.; Ko, Mei-Chuan] Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA; [Williams, Keith L.] Oakland Univ, Dept Psychol, Rochester, MI 48309 USA; [Rice, Kenner C.] NIDA, Chem Biol Res Branch, Bethesda, MD 20892 USA; [Rice, Kenner C.] NIAAA, NIH, Bethesda, MD 20892 USA; [Ko, Mei-Chuan] Natl Chengchi Univ, Dept Psychol, Taipei 116, Taiwan; [Ko, Mei-Chuan] Natl Chengchi Univ, Grad Inst Life Sci, Taipei 116, Taiwan	Ko, MC (reprint author), Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA.	mko@umich.edu	Ko, Mei-Chuan/C-9468-2009	Ko, Mei-Chuan/0000-0003-2436-4506; Williams, Keith/0000-0003-2581-0491	NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [P01 DA000254-320004, P50 DA000254, K21 DA000254, R01 DA013685, P01 DA000254, R01 DA013685-03, DA-013685]		Bowen CA, 2002, PSYCHONEUROENDOCRINO, V27, P319, DOI 10.1016/S0306-4530(01)00053-1; Brandt MR, 2001, J PHARMACOL EXP THER, V296, P939; Broadbear JH, 1999, J PHARMACOL EXP THER, V289, P1641; Broadbear JH, 2004, PSYCHOPHARMACOLOGY, V176, P398, DOI 10.1007/s00213-004-1891-x; BUCKINGHAM JC, 1986, NEUROENDOCRINOLOGY, V44, P36, DOI 10.1159/000124618; Butelman ER, 2007, J PHARMACOL EXP THER, V320, P300, DOI 10.1124/jpet.106.112417; Butelman ER, 1999, J PHARMACOL EXP THER, V290, P678; Butelman ER, 1998, J PHARMACOL EXP THER, V285, P595; Butelman ER, 2004, J PHARMACOL EXP THER, V311, P155, DOI 10.1124/jpet.104.068411; BUTELMAN ER, 1993, J PHARMACOL EXP THER, V267, P1269; COWAN A, 1977, BRIT J PHARMACOL, V60, P537, DOI 10.1111/j.1476-5381.1977.tb07532.x; DYKSTRA LA, 1987, J PHARMACOL EXP THER, V242, P413; ENDOH T, 1992, ARCH INT PHARMACOD T, V316, P30; GONZALVEZ ML, 1991, EUR J PHARMACOL, V200, P155, DOI 10.1016/0014-2999(91)90678-J; HOEHE M, 1988, PSYCHONEUROENDOCRINO, V13, P397, DOI 10.1016/0306-4530(88)90046-7; HORAN P, 1992, J PHARMACOL EXP THER, V260, P1237; IGNAR DM, 1990, J PHARMACOL EXP THER, V255, P1287; IYENGAR S, 1987, BRAIN RES, V435, P220, DOI 10.1016/0006-8993(87)91604-0; JACKSON RV, 1995, CLIN ENDOCRINOL, V43, P423, DOI 10.1111/j.1365-2265.1995.tb02612.x; Jewett DC, 1995, BEHAV PHARMACOL, V6, P815; Ko MC, 1998, J PHARMACOL EXP THER, V286, P150; Ko MC, 2002, J PHARMACOL EXP THER, V301, P698, DOI 10.1124/jpet.301.2.698; Ko MCH, 1999, J PHARMACOL EXP THER, V291, P1113; Ko MCH, 2003, BRAIN RES, V982, P38, DOI 10.1016/S0006-8993(03)02938-X; Lee H, 2007, ANESTHESIOLOGY, V107, P478, DOI 10.1097/01.anes.0000278876.20263.a7; Martin TJ, 2001, J PHARMACOL EXP THER, V299, P811; MCDONALD RK, 1959, J PHARMACOL EXP THER, V125, P241; Mellon RD, 1998, J NEUROIMMUNOL, V83, P19, DOI 10.1016/S0165-5728(97)00217-8; Miller DB, 2002, METABOLISM, V51, P5, DOI 10.1053/meta.2002.33184; MORLEY JE, 1983, PSYCHONEUROENDOCRINO, V8, P361, DOI 10.1016/0306-4530(83)90016-1; NABER D, 1981, PSYCHOPHARMACOLOGY, V74, P125, DOI 10.1007/BF00432677; Negus SS, 1998, J PHARMACOL EXP THER, V286, P362; NIKOLARAKIS K, 1987, BRAIN RES, V421, P373, DOI 10.1016/0006-8993(87)91311-4; PECHNICK RN, 1993, ANNU REV PHARMACOL, V33, P353, DOI 10.1146/annurev.pharmtox.33.1.353; Peckys D, 1999, NEUROSCIENCE, V88, P1093, DOI 10.1016/S0306-4522(98)00251-6; PENDE A, 1986, BIOMED PHARMACOTHER, V40, P178; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; Rosen MI, 1996, J PHARMACOL EXP THER, V276, P1128; Sim-Selley LJ, 1999, NEUROSCIENCE, V94, P651, DOI 10.1016/S0306-4522(99)00344-9; SIMANTOV R, 1977, BRAIN RES, V124, P178, DOI 10.1016/0006-8993(77)90877-0; UBERTI ECD, 1992, J CLIN ENDOCR METAB, V75, P370; Ur E, 1997, BRIT J PHARMACOL, V120, P781, DOI 10.1038/sj.bjp.0700971; VOLAVKA J, 1979, NEW ENGL J MED, V300, P1056; WALKER EA, 1995, J PHARMACOL EXP THER, V273, P1345; Wand GS, 1998, J CLIN ENDOCR METAB, V83, P2138, DOI 10.1210/jc.83.6.2138; Williams KL, 2003, PSYCHONEUROENDOCRINO, V28, P513, DOI 10.1016/S0306-4530(02)00037-9; WINGER G, 1975, J PHARMACOL EXP THER, V195, P505; ZIS AP, 1984, PSYCHONEUROENDOCRINO, V9, P423, DOI 10.1016/0306-4530(84)90050-7	48	40	41	0	6	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4530			PSYCHONEUROENDOCRINO	Psychoneuroendocrinology	MAY	2008	33	4					478	486		10.1016/j.psyneuen.2008.01.006			9	Endocrinology & Metabolism; Neurosciences; Psychiatry	Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry	300TH	WOS:000255847600009	18325678	Green Accepted			2020-06-30	J	Choi, SH; Koo, BN; Nam, SH; Lee, SJ; Min, KJ; Kil, HK; Lee, KY; Jeon, DH				Choi, Seung Ho; Koo, Bon-Nyeo; Nam, Soon Ho; Lee, Sung Jin; Min, Ki Jun; Kil, Hae Keum; Lee, Ki-Young; Jeon, Dong Hyuk			Comparison of remifentanil and fentanyl for postoperative pain control after abdominal hysterectomy	YONSEI MEDICAL JOURNAL			English	Article						postoperative nausea and vomiting; postoperative pain control; remifentanil; respiratory depression	PATIENT-CONTROLLED ANALGESIA; CARDIAC-SURGERY; DIMENHYDRINATE; MORPHINE; POTENCY; NAUSEA; BOLUS	Purpose: In this randomized, double-blind study, we investigated the analgesic efficacy and side effects of continuous constant-dose infusions of remifentanil after total abdominal hysterectomy and compared it to fentanyl. Materials and Methods: Fifty-six adult female patients scheduled for elective total abdominal hysterectomy were enrolled in this study. Patients were randomly assigned to two groups according to fentanyl (group F, n = 28) or remifentanil (group R, n = 28) for postoperative analgesia. Patients in group F were given fentanyl intravenously with an infusion rate of fentanyl 0.5 mu g/kg/hr; group R was given remifentanil with an infusion rate of remifentanil 0.05 mu g/kg/min for 2 days. Pain intensity at rest, occurrence of postoperative nausea and vomiting (PONV), dizziness, pruritus, and respiratory depression were assessed 1 hr after arrival at the post-anesthesia care unit, at 6; 12; 24; and 48 hr postoperation and 6 hr post-infusion of the study drug. Pain was evaluated by using visual analogue scale (VAS; 0 - 10). The time that patients first requested analgesics was recorded as well as additional analgesics and antiemetics. Results: There were no significant differences in VAS, time to first postoperative analgesics, and additional analgesics between the 2 groups. The incidences and severities of PONV and opioid related side effects were not different between the groups; however, there were 3 episodes (10.7%) of serious respiratory depression in group R. Conclusion: Continuous infusion technique of remifentanil did not reveal any benefits compared to fentanyl. Furthermore, it is not safe for postoperative analgesia in the general ward.	[Choi, Seung Ho; Koo, Bon-Nyeo; Nam, Soon Ho; Lee, Sung Jin; Min, Ki Jun; Kil, Hae Keum; Lee, Ki-Young; Jeon, Dong Hyuk] Yonsei Univ, Coll Med, Dept Anesthesiol & Pain Med, Anesthesia & Pain Res Inst, Seoul 120752, South Korea	Koo, BN (reprint author), Yonsei Univ, Coll Med, Dept Anesthesiol & Pain Med, Anesthesia & Pain Res Inst, 250 Seongsanno, Seoul 120752, South Korea.	koobn@yuhs.ac		Lee, Ki-Young/0000-0003-4893-3195; Koo, Bon-Nyeo/0000-0002-3189-1673; Choi, Seung Ho/0000-0001-8442-4406; Kim, Ki Jun/0000-0003-1950-7998			Bouillon T, 2003, ANESTHESIOLOGY, V99, P779, DOI 10.1097/00000542-200310000-00007; Bowdle TA, 1996, ANESTH ANALG, V83, P1292, DOI 10.1097/00000539-199612000-00028; Calderon E, 2001, ANESTH ANALG, V92, P715; Cok OY, 2005, PEDIATR ANESTH, V15, P162, DOI 10.1111/j.1460-9592.2004.01403.x; Eberhart LHJ, 2000, CAN J ANAESTH, V47, P780, DOI 10.1007/BF03019481; Eberhart LHJ, 1999, EUR J ANAESTH, V16, P284, DOI 10.1046/j.1365-2346.1999.00477.x; Egan TD, 2004, BRIT J ANAESTH, V92, P335, DOI 10.1093/bja/aeh075; FELDMAN PL, 1991, J MED CHEM, V34, P2202, DOI 10.1021/jm00111a041; GLASS PSA, 1993, ANESTH ANALG, V77, P1031; Gross JB, 2003, ANESTHESIOLOGY, V99, P767, DOI 10.1097/00000542-200310000-00002; Gurbet A, 2004, J CARDIOTHOR VASC AN, V18, P755, DOI 10.1053/j.jvca.2004.08.014; Gust R, 1999, CRIT CARE MED, V27, P2218, DOI 10.1097/00003246-199910000-00025; KORTTILA K, 1992, BRIT J ANAESTH, V69, pS20, DOI 10.1093/bja/69.supplement_1.20S; Krishnan K, 2005, ACTA ANAESTH SCAND, V49, P876, DOI 10.1111/j.1399-6576.2005.00729.x; Kucukemre F, 2005, EUR J ANAESTH, V22, P378, DOI 10.1017/S0265021505000657; Mallick A, 2004, BRIT J ANAESTH, V93, P305, DOI 10.1093/bja/aeh589; Michelsen LG, 1996, ANESTHESIOLOGY, V84, P865, DOI 10.1097/00000542-199604000-00014; Rama-Maceiras P, 2005, ACTA ANAESTH SCAND, V49, P305, DOI 10.1111/j.1399-6576.2005.00650.x; Schuttler J, 1997, ANAESTHESIA, V52, P307, DOI 10.1111/j.1365-2044.1997.24-az0051.x; SINATRA RS, 1998, NEURAL BLOCKADE CLIN, P793	20	16	17	0	2	YONSEI UNIV COLL MEDICINE	SEOUL	50-1 YONSEI-RO, SEODAEMUN-GU, SEOUL 120-752, SOUTH KOREA	0513-5796	1976-2437		YONSEI MED J	Yonsei Med. J.	APR 30	2008	49	2					204	210		10.3349/ymj.2008.49.2.204			7	Medicine, General & Internal	General & Internal Medicine	296CQ	WOS:000255521500004	18452255	DOAJ Gold, Green Published			2020-06-30	J	Aouad, MT; Moussa, AR; Dagher, CM; Muwakkit, SA; Jabbour-Khoury, SI; Zbeidy, RA; Abboud, MR; Kanazi, GE				Aouad, M. T.; Moussa, A. R.; Dagher, C. M.; Muwakkit, S. A.; Jabbour-Khoury, S. I.; Zbeidy, R. A.; Abboud, M. R.; Kanazi, G. E.			Addition of ketamine to propofol for initiation of procedural anesthesia in children reduces propofol consumption and preserves hemodynamic stability	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						procedural pain; propofol; ketamine; pediatric oncology	CARDIAC-CATHETERIZATION; SEVOFLURANE ANESTHESIA; EMERGENCE AGITATION; PEDIATRIC-PATIENTS; DOSE KETAMINE; SEDATION; ANALGESIA; RECOVERY; ONCOLOGY; BOYS	Background: There is no ideal anesthesia protocol to perform short invasive procedures in pediatric oncology. The combination of propofol and ketamine may offer advantages over propofol alone. Methods: In a prospective, randomized, double-blind study, we analyzed 63 consecutive procedures performed in 47 oncology children. All patients received 1 mu g/kg fentanyl, followed by propofol 1 mg/kg in group P (n=33) or propofol 0.5 mg/kg and ketamine 0.5 mg/kg in group PK (n=30) for the initiation of anesthesia. The need for supplementation with propofol and/or fentanyl to maintain an adequate level of anesthesia was recorded. The hemodynamic and respiratory profile, recovery time and the occurrence of side effects were compared. Results: Significantly more children required propofol (100% vs. 83.3%) and fentanyl (75.5% vs. 43.3%) rescue doses, and developed hypotension (63.6% vs. 23.4%) and bradycardia (48.5 vs. 23.4%) in group P compared with group PK, with a comparable incidence of respiratory adverse events and recovery times. However, 40% of children in group PK were agitated following recovery compared with 6% in group P. Conclusions: The combination of propofol and ketamine for invasive procedures in pediatric oncology resulted in reduced propofol and fentanyl consumption and preserved hemodynamic stability, but more children in the combination group recovered with agitation.	[Aouad, M. T.; Moussa, A. R.; Dagher, C. M.; Jabbour-Khoury, S. I.; Zbeidy, R. A.; Kanazi, G. E.] Amer Univ Beirut, Med Ctr, Dept Anesthesiol, Beirut, Lebanon; [Muwakkit, S. A.; Abboud, M. R.] St Jude, Childrens Canc Ctr Lebanon, Beirut, Lebanon	Kanazi, GE (reprint author), Amer Univ Beirut, Med Ctr, Dept Anesthesiol, POB 11 0236, Beirut, Lebanon.	gk05@aub.edu.lb		Zbeidy, Reine/0000-0002-6963-885X			Abu-Shahwan I, 2007, PEDIATR ANESTH, V17, P846, DOI 10.1111/j.1460-9592.2007.02298.x; Akin A, 2005, PEDIATR CARDIOL, V26, P553, DOI 10.1007/s00246-004-0707-4; Aono J, 1997, ANESTHESIOLOGY, V87, P1298, DOI 10.1097/00000542-199712000-00006; Aono J, 1999, ACTA ANAESTH SCAND, V43, P542, DOI 10.1034/j.1399-6576.1999.430509.x; Bowdle TA, 1998, ANESTHESIOLOGY, V88, P82, DOI 10.1097/00000542-199801000-00015; Dalens BJ, 2006, ANESTH ANALG, V102, P1056, DOI 10.1213/01.ane.0000200282.38041.1f; Gottschling S, 2005, J PEDIAT HEMATOL ONC, V27, P471, DOI 10.1097/01.mph.0000179238.37647.91; Hertzog JH, 2000, PEDIATRICS, V106, P742, DOI 10.1542/peds.106.4.742; Jayabose S, 2001, J PEDIAT HEMATOL ONC, V23, P290, DOI 10.1097/00043426-200106000-00011; LEBOVIC S, 1992, ANESTH ANALG, V74, P490; Meyer S, 2003, PEDIATR HEMAT ONCOL, V20, P291, DOI 10.1080/08880010390203053; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; STEWARD DJ, 1975, CAN ANAESTH SOC J, V22, P111, DOI 10.1007/BF03004827; Suzuki M, 1999, ANESTH ANALG, V89, P98, DOI 10.1097/00000539-199907000-00017; Tomatir E, 2004, PEDIATR ANESTH, V14, P845, DOI 10.1111/j.1460-9592.2004.01303.x; Twite MD, 2005, CURR OPIN ANESTHESIO, V18, P442, DOI 10.1097/01.aco.0000168331.11853.03; WHITE PF, 1982, ANESTHESIOLOGY, V56, P119, DOI 10.1097/00000542-198202000-00007; Willman EV, 2007, ANN EMERG MED, V49, P23, DOI 10.1016/j.annemergmed.2006.08.002	18	40	42	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	APR	2008	52	4					561	565		10.1111/j.1399-6576.2008.01584.x			5	Anesthesiology	Anesthesiology	274DV	WOS:000253982900016	18339162				2020-06-30	J	Eipe, N; Kay, J				Eipe, N.; Kay, J.			Spontaneously breathing technique for opioid tolerance	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Letter							MORPHINE; REQUIREMENTS; PAIN		[Eipe, N.; Kay, J.] Sunnybrook Hlth Sci Ctr, Dept Anaesthesia, Toronto, ON M4N 3M5, Canada	Eipe, N (reprint author), Sunnybrook Hlth Sci Ctr, Dept Anaesthesia, B7-16,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	neipe@yahoo.com	Eipe, Naveen/AAI-8888-2020	Eipe, Naveen/0000-0002-8857-9998			Ashton CH, 1999, BRIT J ANAESTH, V83, P637; Henneberg SW, 2005, ACTA ANAESTH SCAND, V49, P293, DOI 10.1111/j.1399-6576.2005.00598.x; Lichtman AH, 2001, J PHARMACOL EXP THER, V298, P1007; Manchikanti Laxmaiah, 2006, Pain Physician, V9, P123; Mansfield MD, 1996, BRIT J ANAESTH, V76, P358; Mitra S, 2004, ANESTHESIOLOGY, V101, P212, DOI 10.1097/00000542-200407000-00032; Pico L, 2000, CAN J ANAESTH, V47, P309, DOI 10.1007/BF03020943; Tanda G, 1997, SCIENCE, V276, P2048, DOI 10.1126/science.276.5321.2048	8	0	0	0	0	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0001-5172			ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	APR	2008	52	4					575	576		10.1111/j.1399-6576.2007.01556.x			3	Anesthesiology	Anesthesiology	274DV	WOS:000253982900025	18339171				2020-06-30	J	Yuksek, YN; Akat, AZ; Gozalan, U; Daglar, G; Pala, Y; Canturk, M; Tutuncu, T; Kama, NA				Yuksek, Yunus Nadi; Akat, Arif Zeki; Gozalan, Ugur; Daglar, Gul; Pala, Yasar; Canturk, Mehmet; Tutuncu, Tanju; Kama, Nuri Aydin			Laparoscopic cholecystectomy under spinal anesthesia	AMERICAN JOURNAL OF SURGERY			English	Article						laparoscopy; cholelitiasis; cholecystectomy; spinal; anesthesia	EPIDURAL-ANESTHESIA; DISEASE	Background: Advantages of laparoscopic cholecystectomy (LC) such as less pain and short hospital stay make it the treatment of choice for cholelithiasis. There are limited data about LC under spinal anesthesia. This study was designed to evaluate LC under spinal anesthesia. Methods: Twenty-nine patients underwent surgery for LC under spinal anesthesia at the 4th Department of Surgery of the Ankara Numune Education and Research Hospital between April 2005 and January 2006. All patients were informed about spinal anesthesia in detail. The patients also were informed about the risk of conversion to general anesthesia, and all patients provided informed consent. The election criteria for spinal anesthesia were as follows: American Society of Anesthesiologists (ASA) risk group I or 2; risk score for conversion from LC to open cholecystectomy (RSCO) less than negative 3; and presence of gallstone disease. Standard laparoscopic technique was applied to all patients. Simple questionnaire forms were developed for both patients and surgeons to provide comments about the operation. Results: The operation was completed laparoscopically on 26 patients, while 3 patients needed general anesthesia due to severe right shoulder pain. None of the patients had cardiopulmonary problems other than transient hypotension during surgery. Intravenous fentanyl (25 jig) was needed in 13 patients due to severe right shoulder pain. Five patients still had severe shoulder pain after fentanyl injection. Local washing of the right diaphragm with 2% lidocaine solution was successful in the remaining 5 patients in whom fentanyl injection failed to stop the pain. All of the patients' answers to the questions regarding the comfort of operation were "very well" at the 1-month postoperative evaluation. All surgeons stated that there was no difference from LC under general anesthesia. Conclusions: All of the patients and. surgeons were satisfied with LC under spinal anesthesia. Therefore, LC under spinal anesthesia may be an appropriate treatment choice to increase the number of patients eligible for outpatient surgery. (c) 2008 Elsevier Inc. All rights reserved.	[Yuksek, Yunus Nadi; Akat, Arif Zeki; Gozalan, Ugur; Daglar, Gul; Tutuncu, Tanju; Kama, Nuri Aydin] Ankara Numune Hosp, Dept Surg 4, Ankara, Turkey; [Pala, Yasar; Canturk, Mehmet] Ankara Numune Hosp, Dept Anesthesia 2, Ankara, Turkey	Yuksek, YN (reprint author), Ankara Numune Hosp, Dept Surg 4, Ankara, Turkey.	ynyuksek@yahoo.com	canturk, mehmet/H-8631-2018	canturk, mehmet/0000-0003-4753-3341; Tutuncu, Tanju/0000-0001-9058-465X			Azurin DJ, 1996, J LAPAROENDOSC SURG, V6, P369, DOI 10.1089/lps.1996.6.369; GADACZ TR, 1990, SURG CLIN N AM, V70, P1249; Gramatica L, 2002, SURG ENDOSC, V16, P472, DOI 10.1007/s00464-001-8148-0; Hamad MA, 2003, SURG ENDOSC, V17, P1426, DOI 10.1007/s00464-002-8620-5; Kama NA, 2001, AM J SURG, V181, P520, DOI 10.1016/S0002-9610(01)00633-X; Pamela HL, 2002, ANESTH ANALG, V94, P346; Pursnani KG, 1998, SURG ENDOSC, V12, P1082, DOI 10.1007/s004649900785; REDDICK E J, 1989, Surgical Endoscopy, V3, P131, DOI 10.1007/BF00591357; So JBY, 2002, SURG ENDOSC, V16, P286, DOI 10.1007/s00464-001-9036-3; Tzovaras G, 2006, SURG ENDOSC, V20, P580, DOI 10.1007/s00464-005-0405-1	10	26	26	0	4	EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC	BRIDGEWATER	685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA	0002-9610			AM J SURG	Am. J. Surg.	APR	2008	195	4					533	536		10.1016/j.amjsurg.2007.05.043			4	Surgery	Surgery	285WG	WOS:000254806300023	18304510				2020-06-30	J	Sommers, MG; Nguyen, NK; Veening, JG; Vissers, KC; Ritskes-Hoitinga, M; van Egmond, J				Sommers, Mathieu G.; Nguyen, Nha-Khanh; Veening, Jan G.; Vissers, Kris C.; Ritskes-Hoitinga, Merel; van Egmond, Jan			Suppression of noxious-induced c-fos expression in the rat lumbar spinal cord by isoflurane alone or combined with fentanyl	ANESTHESIA AND ANALGESIA			English	Article							HINDLIMB FLEXOR REFLEX; KROX-24 PROTEINS; STIMULATION; SEVOFLURANE; IMMOBILITY; JUN; HYPERALGESIA; PAIN	BACKGROUND: Although our understanding of nociceptive processing during anesthesia has increased greatly over the last decade, many patients still experience hyperalgesia and acute pain postoperatively. The noxious-induced withdrawal reflex (NTWR) model is specifically designed and validated to quantitatively study the reaction on painful, multimodal stimuli in animals under anesthetic conditions. Since the anesthetic mechanisms differ between inhaled anesthetics and opioids, we evaluated the differential effects of isoflurane and fentanyl on c-fos expression at the lumbar level as a measure of nociceptive information transfer during general anesthesia. METHODS: The experimental setup consisted of a randomized block design with four experimental groups: two light 3/4 minimum alveolar concentration (MAC) isoflurane anesthesia groups (unstimulated/NIWR-stimulated) and two NIWR-simulated surgical anesthesia groups (11/2 MAC isoflurane anesthesia and 3/4 MAC isoflurane anesthesia combined with fentanyl 400-600 mu g (.) kg(-1) (.) h(-1)). After 2 h of intermittent electrical stimulation of the hind paw of the rat, the number of Fos immunoreactive (Fos-IR) neurons in the dorsal horn was measured quantitatively. RESULTS: The main suppressive effects on lumbar c-fos expression of isoflurane were observed in the superficial lamina II (P = 0.02), whereas fentanyl showed the strongest effects in lamina V (P = 0.05). CONCLUSIONS: This study demonstrates that the NIWR model combined with spinal Fos-immunoreactivity is a suitable and useful model for evaluating the differential effects of inhaled anesthetics and opioids on nociceptive information transfer during general anesthesia.	[Sommers, Mathieu G.; Ritskes-Hoitinga, Merel] Radboud Univ Nijmegen, Med Ctr, Cent Anim Lab, Nijmegen, Netherlands; [Nguyen, Nha-Khanh; Veening, Jan G.] Radboud Univ Nijmegen, Med Ctr, Dept Anat, Nijmegen, Netherlands; [Veening, Jan G.] Univ Utrecht, UIPS, Dept Psychopharmacol, Utrecht, Netherlands; [Vissers, Kris C.; van Egmond, Jan] Radboud Univ Nijmegen, Dept Anesthesiol Pain & Palliat Med, Nijmegen, Netherlands	Sommers, MG (reprint author), DVM, POB 9101,231 CDL, NL-6500 HB Nijmegen, Netherlands.	M.Sommers@cdl.umcn.nl	Egmond, J./L-4290-2015; Vissers, Kris C.P./D-3569-2009; Vissers, Kris/H-8110-2014; Ritskes-Hoitinga, J./H-8083-2014	Vissers, Kris C.P./0000-0002-2919-6356; Vissers, Kris/0000-0002-2919-6356; 			Baars JH, 2005, BRIT J ANAESTH, V95, P789, DOI 10.1093/bja/aei252; Brennan TJ, 2005, ANESTHESIOLOGY, V103, P681, DOI 10.1097/00000542-200510000-00004; Chang C, 2001, BRAIN RES, V897, P71, DOI 10.1016/S0006-8993(01)02094-7; Coggeshall RE, 2005, PROG NEUROBIOL, V77, P299, DOI 10.1016/j.pneurobio.2005.11.002; Coolen LM, 1998, J COMP NEUROL, V397, P421, DOI 10.1002/(SICI)1096-9861(19980803)397:3<421::AID-CNE8>3.0.CO;2-4; DUYSENS J, 1989, BRAIN RES, V499, P131, DOI 10.1016/0006-8993(89)91142-6; DUYSENS J, 1988, J NEUROSCI METH, V24, P73, DOI 10.1016/0165-0270(88)90035-0; Edwards RR, 2005, NEUROLOGY, V65, P437, DOI 10.1212/01.wnl.0000171862.17301.84; Harris JA, 1998, BRAIN RES BULL, V45, P1, DOI 10.1016/S0361-9230(97)00277-3; HERDEGEN T, 1991, J COMP NEUROL, V313, P178, DOI 10.1002/cne.903130113; Herdegen T, 1998, BRAIN RES REV, V28, P370, DOI 10.1016/S0165-0173(98)00018-6; HUNT SP, 1987, NATURE, V328, P632, DOI 10.1038/328632a0; Inturrisi CE, 2002, CLIN J PAIN, V18, pS3, DOI 10.1097/00002508-200207001-00002; Jinks SL, 2002, ANESTH ANALG, V95, P1622, DOI 10.1097/00000539-200212000-00028; Le Bars D, 2001, PHARMACOL REV, V53, P597; Lin Feng-Sheng, 2003, Acta Anaesthesiol Sin, V41, P115; MOLANDER C, 1984, J COMP NEUROL, V230, P133, DOI 10.1002/cne.902300112; Nakamura T, 2001, CAN J ANAESTH, V48, P993, DOI 10.1007/BF03016590; Paxinos G, 2005, RAT BRAIN STEREOTAXI; Rehberg B, 2004, ANESTHESIOLOGY, V100, P44, DOI 10.1097/00000542-200401000-00011; Sonner JM, 2003, ANESTH ANALG, V97, P718, DOI 10.1213/01.ANE.0000081063.76651.33; TOLLE TR, 1994, NEUROSCIENCE, V58, P305, DOI 10.1016/0306-4522(94)90037-X; van den Broek PLC, 2006, EUR J ANAESTH, V23, P391, DOI 10.1017/S0265021505001857; Veening JG, 2004, PROG NEURO-PSYCHOPH, V28, P699, DOI 10.1016/j.pnpbp.2004.05.007; Wilder-Smith OHG, 2006, ANESTHESIOLOGY, V104, P601, DOI 10.1097/00000542-200603000-00028; Woolf CJ, 2000, SCIENCE, V288, P1765, DOI 10.1126/science.288.5472.1765	26	8	8	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	APR	2008	106	4					1303	1308		10.1213/ane.0b013e3181678831			6	Anesthesiology	Anesthesiology	278CD	WOS:000254260200042	18349210				2020-06-30	J	Agustin-Pavon, C; Martinez-Ricos, J; Martinez-Garcia, F; Lanuza, E				Agustin-Pavon, Carmen; Martinez-Ricos, Joana; Martinez-Garcia, Fernando; Lanuza, Enrique			Sex versus sweet: Opposite effects of opioid drugs on the reward of sucrose and sexual pheromones	BEHAVIORAL NEUROSCIENCE			English	Article						naloxone; fentanyl; chemical signals; place preference; intersexual attraction	VENTRAL TEGMENTAL AREA; FEMALE MICE; MALE-RAT; BETA-ENDORPHIN; NUCLEUS-ACCUMBENS; REINFORCING PROPERTIES; VENTROMEDIAL NUCLEUS; ENDOGENOUS OPIOIDS; LORDOSIS BEHAVIOR; MORPHINE	Endogenous opioids mediate some reward processes involving both natural (food, sweet taste) and artificial (morphine, heroin) rewards. In contrast, sexual behavior (which is also reinforcing) is generally inhibited by opioids. To establish the role of endogenous opioids for a newly described natural reinforcer, namely male sexual pheromones for female mice, we checked the effects of systemic injections of the general opioid antagonist naloxone (1-10 mg/kg) and the agonist fentanyl (0.1-0.5 mg/kg) in a number of behavioral tests. Naloxone affected neither the innate preference for male-soiled bedding (vs. female-soiled bedding) in 2-choice tests nor the induction of place conditioning using male pheromones as rewarding stimuli, although it effectively blocked the preference for consuming a sucrose solution. In contrast, fentanyl inhibited the preference for male chemosignals without altering sucrose preference. These results suggest that, in macrosmatic animals such as rodents, opioidergic inhibition of sexual behavior might be due, at least partially, to an impaired processing of pheromonal cues and that the hedonic value of sweet-tasting solutions and sexual pheromones are under different opioid modulation.	[Agustin-Pavon, Carmen; Lanuza, Enrique] Univ Valencia, Fac Ciencias Biol, Dept Cell Biol, E-46100 Burjassot, Spain; [Martinez-Ricos, Joana; Martinez-Garcia, Fernando] Univ Valencia, Fac Ciencias Biol, Dept Funct Biol & Phys Anthropol, Valencia, Spain	Lanuza, E (reprint author), Univ Valencia, Fac Ciencias Biol, Dept Cell Biol, Carrer Dr Moliner 50, E-46100 Burjassot, Spain.	enrique.lanuza@uv.es	Lanuza, Enrique/C-4068-2009; Martinez-Garcia, Fernando/K-7159-2013; Agustin-Pavon, Carmen/A-5638-2013	Lanuza, Enrique/0000-0001-9498-7966; Martinez-Garcia, Fernando/0000-0003-3181-4579; Agustin-Pavon, Carmen/0000-0002-6725-6954			Acosta-Martinez M, 2002, HORM BEHAV, V41, P88, DOI 10.1006/hbeh.2001.1741; AGMO A, 1995, PHARMACOL BIOCHEM BE, V52, P403, DOI 10.1016/0091-3057(95)00128-J; AGMO A, 1990, BEHAV NEUROSCI, V104, P177, DOI 10.1037/0735-7044.104.1.177; Agustin-Pavon C, 2007, BEHAV NEUROSCI, V121, P920, DOI 10.1037/0735-7044.121.5.920; Argiolas A, 1999, NEUROSCI BIOBEHAV R, V23, P1127, DOI 10.1016/S0149-7634(99)00068-8; Bespalov AY, 1999, PSYCHOPHARMACOLOGY, V141, P118, DOI 10.1007/s002130050815; Blaustein J.D., 2002, FEMININE SEXUAL BEHA; Bodnar RJ, 2006, PEPTIDES, V27, P3391, DOI 10.1016/j.peptides.2006.07.011; BROG JS, 1993, J COMP NEUROL, V338, P255, DOI 10.1002/cne.903380209; CROWDER WF, 1992, PHARMACOL BIOCHEM BE, V41, P817, DOI 10.1016/0091-3057(92)90233-6; CZIRR SA, 1986, BRAIN RES BULL, V17, P639, DOI 10.1016/0361-9230(86)90195-4; FABIAN I, 1995, BRAIN RES, V697, P205, DOI 10.1016/0006-8993(95)00845-H; Giacchino JL, 1998, PROG NEURO-PSYCHOPH, V22, P1157, DOI 10.1016/S0278-5846(98)00053-0; Hajnal A, 2001, BRAIN RES, V904, P76, DOI 10.1016/S0006-8993(01)02451-9; Halpern M, 2003, PROG NEUROBIOL, V70, P245, DOI 10.1016/S0301-0082(03)00103-5; Hayward MD, 2001, BRAIN RES BULL, V56, P537, DOI 10.1016/S0361-9230(01)00626-8; HERKENHAM M, 1980, P NATL ACAD SCI-BIOL, V77, P5532, DOI 10.1073/pnas.77.9.5532; Ikemoto S, 2005, J NEUROSCI, V25, P5061, DOI 10.1523/JNEUROSCI.0892-05.2005; JIANG ZG, 1992, J NEUROSCI, V12, P356; Kelley AE, 2002, PHYSIOL BEHAV, V76, P365, DOI 10.1016/S0031-9384(02)00751-5; KINSLEY CH, 1995, BRAIN RES BULL, V37, P103, DOI 10.1016/0361-9230(94)00263-0; LANDAUER MR, 1982, PHARMACOL BIOCHEM BE, V17, P1181, DOI 10.1016/0091-3057(82)90117-4; Martinez-Hernandez J, 2006, EUR J NEUROSCI, V24, P885, DOI 10.1111/j.1460-9568.2006.04944.x; Martinez-Ricos J, 2007, CHEM SENSES, V32, P139, DOI 10.1093/chemse/bjl039; MARTINEZRICOS J, 2007, 39 ANN M EUR BRAIN B; MCGREGOR A, 1992, NEUROSCIENCE, V46, P173, DOI 10.1016/0306-4522(92)90016-U; MCINTOSH TK, 1980, PHARMACOL BIOCHEM BE, V13, P435, DOI 10.1016/0091-3057(80)90251-8; MEYERSON BJ, 1981, EUR J PHARMACOL, V69, P453, DOI 10.1016/0014-2999(81)90449-0; MITCHELL JB, 1990, PHARMACOL BIOCHEM BE, V35, P643, DOI 10.1016/0091-3057(90)90302-X; MOLES A, 1995, PHYSIOL BEHAV, V58, P791, DOI 10.1016/0031-9384(95)00134-5; Moncho-Bogani J, 2005, EUR J NEUROSCI, V21, P2186, DOI 10.1111/j.1460-9568.2005.04036.x; Moncho-Bogani J, 2004, PHYSIOL BEHAV, V81, P427, DOI 10.1016/j.physbeh.2004.01.014; Moncho-Bogani J, 2002, PHYSIOL BEHAV, V77, P167, DOI 10.1016/S0031-9384(02)00842-9; MOSKOWITZ AS, 1984, J NEUROSCI, V4, P1331; Mossman CA, 1996, J COMP PSYCHOL, V110, P131, DOI 10.1037/0735-7036.110.2.131; NOVEJARQUE A, 2005, 35 ANN M SOC NEUR WA; OSTROWSKI NL, 1979, PHARMACOL BIOCHEM BE, V11, P673, DOI 10.1016/0091-3057(79)90261-2; Paredes Raul G., 1997, V8, P68; Paredes RG, 2001, BEHAV NEUROSCI, V115, P1363, DOI 10.1037//0735-7044.115.6.1363; Pecina S, 2005, J NEUROSCI, V25, P11777, DOI 10.1523/JNEUROSCI.2329-05.2005; PFAFF DW, 1979, J PHYSIOL-LONDON, V288, P203; PFAFF DW, 1979, J PHYSIOL-LONDON, V288, P189; PFAUS JG, 1987, NEUROSCI BIOBEHAV R, V11, P1, DOI 10.1016/S0149-7634(87)80002-7; PRADOALCALA R, 1984, BRAIN RES, V297, P265, DOI 10.1016/0006-8993(84)90567-5; ROMERO PR, 1990, PHYSIOL BEHAV, V47, P685, DOI 10.1016/0031-9384(90)90078-I; Smith KS, 2005, J NEUROSCI, V25, P8637, DOI 10.1523/JNEUROSCI.1902-05.2005; Smith KS, 2007, J NEUROSCI, V27, P1594, DOI 10.1523/JNEUROSCI.4205-06.2007; Van den Berg CL, 1999, EUR J NEUROSCI, V11, P3023, DOI 10.1046/j.1460-9568.1999.00717.x; Van Ree JM, 2000, EUR J PHARMACOL, V405, P89, DOI 10.1016/S0014-2999(00)00544-6; Van Ree JM, 1999, PHARMACOL REV, V51, P341; vanFurth WR, 1996, BRAIN RES, V729, P20, DOI 10.1016/S0006-8993(96)00225-9; VANFURTH WR, 1995, BEHAV NEUROSCI, V109, P123, DOI 10.1037/0735-7044.109.1.123; von Campenhausen H, 2000, EUR J NEUROSCI, V12, P33, DOI 10.1046/j.1460-9568.2000.00879.x; WIESNER JB, 1984, LIFE SCI, V34, P1455, DOI 10.1016/0024-3205(84)90060-2; Zhu W, 2005, NEUROSCIENCE, V133, P97, DOI 10.1016/j.neuroscience.2005.02.004	55	12	12	0	7	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0735-7044			BEHAV NEUROSCI	Behav. Neurosci.	APR	2008	122	2					416	425		10.1037/0735-7044.122.2.416			10	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	283ZN	WOS:000254675100017	18410180				2020-06-30	J	Jeleazcov, C; Ihmsen, H; Schmidt, J; Ammon, C; Schwilden, H; Schuttler, J; Fechner, J				Jeleazcov, C.; Ihmsen, H.; Schmidt, J.; Ammon, C.; Schwilden, H.; Schuettler, J.; Fechner, J.			Pharmacodynamic modelling of the bispectral index response to propofol-based anaesthesia during general surgery in children	BRITISH JOURNAL OF ANAESTHESIA			English	Article						anaesthesia, paediatric; model, pharmacodynamic; monitoring, EEG; monitoring, bispectral index	EFFECT SITE EQUILIBRATION; PEDIATRIC-PATIENTS; REMIFENTANIL; PHARMACOKINETICS; INDUCTION; FENTANYL; ESOPHAGOGASTRODUODENOSCOPY; PERFORMANCE; ALFENTANIL; MIDAZOLAM	Background. This study describes a pharmacodynamic model during general anaesthesia in children relating the bispectral index (BIS) response to the anaesthetic dosing of propofol, fentanyl, and remifentanil. Methods. BIS, heart rate, mean arterial pressure, sedation scores, and anaesthetic protocols from 59 children aged 1 - 16 yr undergoing general surgery were considered for the study. Anaesthesia was performed with propofol, fentanyl, and remifentanil. A sigmoid model assuming additive interaction of propofol, fentanyl, and remifentanil was fitted to individual BIS as effect variable. The pharmacodynamic parameters were estimated by non-linear regression analysis. The ability of BIS to predict anaesthetic drug effect was quantified by the prediction probability Pk. Results. BIS started at a baseline of 90 (9), decreased during induction to 30 (14) and remained at 57 (10) during anaesthesia. BIS predicted the anaesthetic drug effect with a Pk of 0.79 (0.08). The EC50 Propofol and the k(e0) Propofol were 5.2 (2.7) mu g ml(-1) and 0.60 (0.45) min(-1), respectively. The k(e0) Propofol decreased from approximately 0.91 min(-1) at 1 yr to 0.15 min(-1) at 16 yr. The EC50 (Remifentanil), k(e0) (Remifentanil), EC50 Fentanyl, and the k(e0) (Fentanyl) were 24.1 (13.0) ng ml(-1), 0.71 (0.32) min(-1), 8.6 (7.4) ng ml(-1), and 0.28 (0.46) min(-1), respectively. Conclusions. The effect equilibration half-time of propofol in children was age dependent. The pharmacodynamics of fentanyl and remifentanil in children were similar to those reported in adults. The BIS showed a close relationship to the modelled effect-site concentration, and therefore, it may serve as a measure of anaesthetic drug effect in children older than 1 yr.	[Jeleazcov, C.; Ihmsen, H.; Schmidt, J.; Ammon, C.; Schwilden, H.; Schuettler, J.; Fechner, J.] Univ Erlangen Nurnberg, Dept Anaesthesiol, D-91054 Erlangen, Germany	Jeleazcov, C (reprint author), Univ Erlangen Nurnberg, Dept Anaesthesiol, Krankenhausstr 12, D-91054 Erlangen, Germany.	christian.jeleazcov@kfa.imed.uni-erlangen.de					BENSHLOMO I, 1993, ANAESTHESIA, V48, P111; Billard V, 1997, CLIN PHARMACOL THER, V61, P45, DOI 10.1016/S0009-9236(97)90181-8; BOOKER PD, 2001, BEST PRACT RES CLIN, V15, P97; Bouillon TW, 2004, ANESTHESIOLOGY, V100, P1353, DOI 10.1097/00000542-200406000-00006; Coetzee Johan Francois, 2003, Curr Opin Anaesthesiol, V16, P285, DOI 10.1097/00001503-200306000-00008; Constant I, 2004, BRIT J ANAESTH, V92, P504, DOI 10.1093/bja/aeh093; Davidson AJ, 2005, BRIT J ANAESTH, V95, P674, DOI 10.1093/bja/aei247; Doufas AG, 2004, ANESTHESIOLOGY, V101, P1112, DOI 10.1097/00000542-200411000-00010; Drover DR, 2004, ANESTHESIOLOGY, V100, P1382, DOI 10.1097/00000542-200406000-00008; Egan TD, 1996, ANESTHESIOLOGY, V84, P821, DOI 10.1097/00000542-199604000-00009; Fechner J, 2003, EUR J ANAESTH, V20, P373, DOI 10.1097/00003643-200305000-00004; Ginsberg B, 1996, ANESTHESIOLOGY, V85, P1268, DOI 10.1097/00000542-199612000-00007; Hammer GB, 2001, PAEDIATR ANAESTH, V11, P549, DOI 10.1046/j.1460-9592.2001.00731.x; Jeleazcov C, 2007, BRIT J ANAESTH, V99, P845, DOI 10.1093/bja/aem275; KATARIA BK, 1994, ANESTHESIOLOGY, V80, P104, DOI 10.1097/00000542-199401000-00018; Manyam SC, 2007, ANESTHESIOLOGY, V106, P472, DOI 10.1097/00000542-200703000-00011; Minto CF, 1997, ANESTHESIOLOGY, V86, P10, DOI 10.1097/00000542-199701000-00004; Minto CF, 2000, ANESTHESIOLOGY, V92, P1603, DOI 10.1097/00000542-200006000-00017; Munoz HR, 2007, ANESTH ANALG, V104, P77, DOI 10.1213/01.ane.0000251201.81210.e7; Munoz HR, 2004, ANESTHESIOLOGY, V101, P1269; Niedermeyer E., 1999, ELECTROENCEPHALOGRAP, P189; Park HJ, 2007, ANESTH ANALG, V105, P57, DOI 10.1213/01.ane.0000266447.23037.e4; Peeters MYM, 2006, ANESTHESIOLOGY, V104, P466, DOI 10.1097/00000542-200603000-00013; Ross AK, 2001, ANESTH ANALG, V93, P1393, DOI 10.1097/00000539-200112000-00008; Schuttler J, 2000, ANESTHESIOLOGY, V92, P727, DOI 10.1097/00000542-200003000-00017; SCOTT JC, 1991, ANESTHESIOLOGY, V74, P34, DOI 10.1097/00000542-199101000-00007; Smith WD, 1996, ANESTHESIOLOGY, V84, P38, DOI 10.1097/00000542-199601000-00005; STANSKI DR, 1995, ANESTHESIOLOGY, V83, P1, DOI 10.1097/00000542-199507000-00001; Struys MMRF, 2007, ANESTHESIOLOGY, V107, P386, DOI 10.1097/01.anes.0000278902.15505.f8	29	54	61	1	8	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0007-0912			BRIT J ANAESTH	Br. J. Anaesth.	APR	2008	100	4					509	516		10.1093/bja/aem408			8	Anesthesiology	Anesthesiology	287ZB	WOS:000254954900014	18270231	Bronze			2020-06-30	J	Kucukguclu, S; Unlugenc, H; Gunenc, E; Kuvaki, B; Gokmen, N; Gunasti, S; Guclu, S; Yilmaz, F; Isik, G				Kucukguclu, S.; Unlugenc, H.; Gunenc, E.; Kuvaki, B.; Gokmen, N.; Gunasti, S.; Guclu, S.; Yilmaz, F.; Isik, G.			The influence of epidural volume extension on spinal block with hyperbaric or plain bupivacaine for caesarean delivery	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article						anaesthesia spinal; anaesthesia epidural; bupivacaine; epidural space; volume expansion; caesarean section	0.5-PERCENT BUPIVACAINE; SALINE INJECTION; TOP-UP; ANESTHESIA; SECTION; MECHANISM; BARICITY	Background and objective: Epidural volume extension via a combined spinal-epidural is the enhancement of a small-dose intrathecal block by an epidural injection of physiological saline solution. We evaluated the effect of epidural volume extension on the combined spinal-epidural technique of providing spinal anaesthesia for Caesarean section with hyperbaric or plain 0.5% bupivacaine. Methods: Patients (n = 240) with height > 163 cm received 9 mg and patients < 163 cm received 8 mg of bupivacaine. Each study drug was combined with 20 jig fentanyl. Using the combined spinal-epidural technique, Group A (n = 60) received hyperbaric bupivacaine, and Group B (n = 60) received hyperbaric bupivacaine and 10 mL saline epidurally 5 min after subarachnoid injection. Group C (n = 60) received plain bupivacaine and Group D (n = 60) received plain bupivacaine and 10 mL saline epidurally 5 min after subarachnoid injection. An anaesthetist blinded to the anaesthetic solution injected examined the level of analgesia by the pinprick method and motor block with the modified Bromage scale for 30 min after subarachnoid injection, during the intraoperative period and subsequently every 15 min for 135 min during the recovery period. Results: Time to reach a sensory block at T4 was significantly shorter in Groups C and D than in Groups A (P = 0.003 and 0.017) and B (P = 0.006 and 0.048), respectively. During the intraoperative period, sensory block levels were significantly higher in Group C than in Group A. Recovery was similar in all groups; only onset was faster in Groups C and D. Conclusion: There was no effect of epidural volume extension on the profile of spinal anaesthesia with the combined spinal-epidural technique for Caesarean section using hyperbaric or plain bupivacaine.	[Kucukguclu, S.; Gunenc, E.; Kuvaki, B.; Gokmen, N.; Yilmaz, F.] Dokuz Eylul Univ, Tip Fak, Sch Med, Dept Anesthesiol & Reanimat, Izmir, Turkey; [Unlugenc, H.; Gunasti, S.; Isik, G.] Cukurova Univ, Sch Med, Dept Anesthesiol & Reanimat, Adana, Turkey; [Guclu, S.] Dokuz Eylul Univ, Sch Med, Dept Obstet & Gynecol, Izmir, Turkey	Gokmen, N (reprint author), Dokuz Eylul Univ, Tip Fak, Sch Med, Dept Anesthesiol & Reanimat, Izmir, Turkey.	necati.gokmen@deu.edu.tr	Gokmen, Necati/J-9761-2019; Balkan, Bahar Kuvaki/AAE-4716-2019; Unlugenc, Hakki/W-9586-2018; Gokmen, Necati/B-1775-2008	Gokmen, Necati/0000-0002-3225-7666; Unlugenc, Hakki/0000-0003-0164-8258; Gokmen, Necati/0000-0002-3225-7666; Gokmen, Necati/0000-0003-1835-4133			Balki M, 2005, INT J OBSTET ANESTH, V14, P230, DOI 10.1016/j.ijoa.2004.12.004; Beale N, 2005, BRIT J ANAESTH, V95, P500, DOI 10.1093/bja/aei200; BLUMGART CH, 1992, BRIT J ANAESTH, V69, P457, DOI 10.1093/bja/69.5.457; Buttner J, 1991, Reg Anaesth, V14, P17; Camorcia M, 2006, EUR J ANAESTH, V23, P611, DOI 10.1017/S0265021506000421; CHAMBERS WA, 1981, BRIT J ANAESTH, V53, P279, DOI 10.1093/bja/53.3.279; Danelli G, 2001, Minerva Anestesiol, V67, P573; Harten JM, 2005, ANAESTHESIA, V60, P348, DOI 10.1111/j.1365-2044.2005.04113.x; Higuchi H, 2005, ANESTHESIOLOGY, V102, P285, DOI 10.1097/00000542-200502000-00008; Karaman S, 2005, EUR J OBSTET GYN R B, V121, P18, DOI 10.1016/j.ejogrb.2004.08.017; Khaw KS, 2002, ANESTH ANALG, V94, P680, DOI 10.1097/00000539-200203000-00037; Lew E, 2004, ANESTH ANALG, V98, P810; LOGAN MR, 1986, BRIT J ANAESTH, V58, P292, DOI 10.1093/bja/58.3.292; Malinovsky JM, 1999, ANESTHESIOLOGY, V91, P1260, DOI 10.1097/00000542-199911000-00016; Mardirosoff C, 1998, REGION ANESTH PAIN M, V23, P92, DOI 10.1016/S1098-7339(98)90117-1; MOLLER IW, 1984, BRIT J ANAESTH, V56, P1191, DOI 10.1093/bja/56.11.1191; RAWAL N, 1988, ACTA ANAESTH SCAND, V32, P61, DOI 10.1111/j.1399-6576.1988.tb02689.x; Rucklidge MWM, 2005, ANAESTHESIA, V60, P535, DOI 10.1111/j.1365-2044.2005.04178.x; RUSSELL IF, 1987, BRIT J ANAESTH, V59, P347, DOI 10.1093/bja/59.3.347; Sarvela PJ, 1999, ANESTH ANALG, V89, P1257, DOI 10.1213/00000539-199911000-00033; Stienstra R, 1999, ANESTH ANALG, V88, P810, DOI 10.1097/00000539-199904000-00024; Stienstra R, 1996, ANESTH ANALG, V83, P382, DOI 10.1097/00000539-199608000-00031; Takiguchi T, 1997, ANESTH ANALG, V85, P1097, DOI 10.1097/00000539-199711000-00024; Vercauteren MP, 1998, ANESTH ANALG, V86, P989, DOI 10.1097/00000539-199805000-00014; Yamazaki Y, 2000, J Anesth, V14, P73, DOI 10.1007/s005400050070	25	17	20	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0265-0215			EUR J ANAESTH	Eur. J. Anaesth.	APR	2008	25	4					307	313		10.1017/S0265021507002670			7	Anesthesiology	Anesthesiology	291VZ	WOS:000255226500008	17888192				2020-06-30	J	Winterhalter, M; Brandl, K; Rahe-Meyer, N; Osthaus, A; Hecker, H; Hagl, C; Adams, HA; Piepenbrock, S				Winterhalter, M.; Brandl, K.; Rahe-Meyer, N.; Osthaus, A.; Hecker, H.; Hagl, C.; Adams, H. A.; Piepenbrock, S.			Endocrine stress response and inflammatory activation during CABG surgery. A randomized trial comparing remifentanil infusion to intermittent flentanyl	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article; Proceedings Paper	Joint Annual Meeting of the European-Society-of-Anaesthesiology/Annual Meeting of the EAA	JUN 03-06, 2006	Madrid, SPAIN	European Soc Anaesthesiol, EAA		CARDIAC SURGERY; CARDIOPULMONARY BYPASS; ANALGESICS OPIOID; fentanyl; remifentanil; MONITORING PHYSIOLOGIC; ENDOCRINE SYSTEM; stress response	PEDIATRIC CARDIAC-SURGERY; CARDIOPULMONARY BYPASS; COMPLEMENT ACTIVATION; CYTOKINE RESPONSE; ANESTHESIA; CHILDREN; SYSTEM; TIME; AGE	Background and objective: Our aim was to compare a continuous infusion of remifentanil with intermittent boluses of fentanyl as regards the perioperative hormonal. stress response and inflammatory activation in coronary artery bypass graft patients under sevoflurane-based anaesthesia. Methods: In all, 42 patients undergoing coronary artery bypass grafting with cardiopulmonary bypass were prospectively randomized to a fentanyl group (n = 2 1, total fentanyl dose 2.6 +/- 0.3 mg), or a rernifentarill group (n = 2 1, infusion rate 0.25 mu g kg(-1) min(-1)). Haemodynamics, plasma levels of epinephrine, norepinephrine, antidiuretic hormone, adrenocorticotropic hormone, cortisol, complement activation (C3a, C5b-9), interleukin (IL)-6, IL-8 and turnout necrosis factor-alpha were measured at T1: baseline, T2: intubation, T3: sternotomy, T4: 30 min on cardiopulmonary bypass, T5: end of surgery and T6: 8 h postoperatively. Troponin T and creatine kinase-MB were measured postoperatively. Results: Patients in the remifentanil group were extubated significantly earlier than fentanyl patients (240 +/- 182 min vs. 418 +/- 212 min, P = 0.006). Stress hormones 30 min after start of cardiopulmonary bypass showed higher values in the fentanyl group compared to the remifentanil group (antidiuretic hormone (ADH): 39.94 +/- 30-98 vs. 11.7 +/- 22.8 pg mL(-1) P = 0.002; adrenocorticotropic hormone: 111.5 +/- 116.8 vs. 21.81 +/- 24.71 pg mL(-1) , P = 0.0 1; cortisol 185 +/- 86 vs. 131 +/- 82 ng mL(-1) 1, P = 0.04). The interleukins were significantly higher at some perioperative time points in the fentanyl group compared to the remifentanil group (turnout necrosis factor: T5: 3.57 vs. 2.37; IL-6: T5: 4.62 vs. 3.73; and IL-8: T5: 4.43 vs. 2.65 and T6: 2.61 vs. 1.13). However, cardiopulmonary bypass times and aortic cross-clamp times were longer in the fentanyl group, which may to some extent account for the differences. Conclusions: The perloperative endocrine stress response was attenuated in patients supplemented with continuous remifentanil infusion as compared to intermittent fentanyl.	[Winterhalter, M.; Brandl, K.; Rahe-Meyer, N.; Osthaus, A.; Adams, H. A.; Piepenbrock, S.] Hannover Med Sch, Dept Anesthesiol, D-30625 Hannover, Germany; [Hagl, C.] Hannover Med Sch, Div Thorac & Cardiovasc Surg, D-30625 Hannover, Germany; [Hecker, H.] Hannover Med Sch, Dept Biometry, D-30625 Hannover, Germany	Winterhalter, M (reprint author), Hannover Med Sch, Dept Anesthesiol, Carl NeubergStr 1, D-30625 Hannover, Germany.	Winterhatter.Michael@mh-hannover.de					Bell G, 2004, PEDIATR ANESTH, V14, P856, DOI 10.1111/j.1460-9592.2004.01326.x; Besedovsky HO, 1996, ENDOCR REV, V17, P64, DOI 10.1210/edrv-17-1-64; Brix-Christensen V, 2001, ACTA ANAESTH SCAND, V45, P671, DOI 10.1034/j.1399-6576.2001.045006671.x; ELETR AA, 1981, CLEVELAND CLIN Q, V48, P132, DOI 10.3949/ccjm.48.1.132; Fitch JCK, 1999, CIRCULATION, V100, P2499, DOI 10.1161/01.CIR.100.25.2499; Gold SM, 2005, TRENDS IMMUNOL, V26, P644, DOI 10.1016/j.it.2005.09.010; Guggenberger H, 2006, EUR J ANAESTH, V23, P832, DOI 10.1017/S0265021506000251; Ibrahim AE, 2001, ANESTHESIOLOGY, V95, P1151, DOI 10.1097/00000542-200111000-00019; Ito H, 1997, SURG TODAY, V27, P220, DOI 10.1007/BF00941649; KIRKLIN JK, 1983, J THORAC CARDIOV SUR, V86, P845; KUCHEL O, 1985, ENDOCR RES, V11, P17, DOI 10.3109/07435808509035421; Laffey JG, 2002, ANESTHESIOLOGY, V97, P215; Matsumoto ED, 2005, J ENDOUROL, V19, P1140, DOI 10.1089/end.2005.19.1140; Molina PE, 2005, SHOCK, V24, P3, DOI 10.1097/01.shk.0000167112.18871.5c; Rady MY, 1997, CRIT CARE MED, V25, P1831, DOI 10.1097/00003246-199711000-00021; REVES JG, 1982, CIRCULATION, V66, P49, DOI 10.1161/01.CIR.66.1.49; Rokutan K, 2005, J MED INVESTIG, V52, P137, DOI 10.2152/jmi.52.137; SAAR N, 1979, BRIT J CLIN PHARMACO, V8, P353, DOI 10.1111/j.1365-2125.1979.tb04718.x; SEGHAYE MC, 1993, J THORAC CARDIOV SUR, V106, P978, DOI 10.1016/S0022-5223(19)33968-6; SLOGOFF S, 1989, ANESTHESIOLOGY, V70, P179, DOI 10.1097/00000542-198902000-00002; Soulika AM, 2000, CLIN IMMUNOL, V96, P212, DOI 10.1006/clim.2000.4903; TAN CK, 1976, J THORAC CARDIOV SUR, V71, P928; VOSS EM, 1995, ARCH PATHOL LAB MED, V119, P799; Wallace AW, 2003, ANESTHESIOLOGY, V99, P774, DOI 10.1097/00000542-200310000-00004; Wan S, 1996, J THORAC CARDIOV SUR, V111, P469, DOI 10.1016/S0022-5223(96)70458-0; Wan S, 1997, CHEST, V112, P676, DOI 10.1378/chest.112.3.676; Weale NK, 2004, BRIT J ANAESTH, V92, P187, DOI 10.1093/bja/aeh038; Yokoyama M, 2005, ANESTH ANALG, V101, P1521, DOI 10.1213/01.ANE.0000184287.15086.1E; ZIEGLER MG, 1976, NATURE, V261, P333, DOI 10.1038/261333a0	29	58	64	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0265-0215			EUR J ANAESTH	Eur. J. Anaesth.	APR	2008	25	4					326	335		10.1017/S0265021507003043			10	Anesthesiology	Anesthesiology	291VZ	WOS:000255226500011	18005471				2020-06-30	J	Crescenzi, G; Covello, RD; Landoni, G; De Luca, M; Fracasso, G; Melone, M; Serini, SM; Bignami, E; Rosica, C; Zangrillo, A				Crescenzi, G.; Covello, R. D.; Landoni, G.; De Luca, M.; Fracasso, G.; Melone, M.; Serini, S. M.; Bignami, E.; Rosica, C.; Zangrillo, A.			Thoracic epidural anaesthesia in valvular cardiac surgery	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Letter							ANALGESIA; HEMATOMA; RISK		[Crescenzi, G.; Covello, R. D.; Landoni, G.; De Luca, M.; Fracasso, G.; Melone, M.; Serini, S. M.; Bignami, E.; Rosica, C.; Zangrillo, A.] Univ Vita Salute San Raffaele, San Raffaele Sci Inst, Dept Cardiothorac & Vasc Anesthesia, I-20132 Milan, Italy	Landoni, G (reprint author), Univ Vita Salute San Raffaele, San Raffaele Sci Inst, Dept Cardiothorac & Vasc Anesthesia, Via Olgettina 60, I-20132 Milan, Italy.	landoni.giovanni@hsr.it		LANDONI, Giovanni/0000-0002-8594-5980; ZANGRILLO, Alberto/0000-0002-7687-7648			Castellano JM, 2000, CHEST, V117, P305, DOI 10.1378/chest.117.2.305; Chakravarthy M, 2005, J CARDIOTHOR VASC AN, V19, P44, DOI 10.1053/j.jvca.2004.11.008; Chaney MA, 2006, ANESTH ANALG, V102, P45, DOI 10.1213/01.ane.0000183650.16038.f6; Ho AMH, 2000, CHEST, V117, P551, DOI 10.1378/chest.117.2.551; Liu SS, 2004, ANESTHESIOLOGY, V101, P153, DOI 10.1097/00000542-200407000-00024; Sharma S, 2004, J CARDIOTHOR VASC AN, V18, P759, DOI 10.1053/j.jvca.2004.08.015; Williams JP, 2002, CAN J ANAESTH, V49, pR1	7	4	4	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0265-0215			EUR J ANAESTH	Eur. J. Anaesth.	APR	2008	25	4					339	340		10.1017/S0265021507002840			2	Anesthesiology	Anesthesiology	291VZ	WOS:000255226500014	18334038				2020-06-30	J	del Pozo, JG; Carvajal, A; Viloria, JM; Velasco, A; del Pozo, VG				del Pozo, Javier Garcia; Carvajal, Alfonso; Viloria, Jose Maria; Velasco, Alfonso; del Pozo, Victorina Garcia			Trends in the consumption of opioid analgesics in Spain. Higher increases as fentanyl replaces morphine	EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY			English	Article						DDD; fentanyl; morphine; opioids; pain	LAW	Objective During the past few years there have been changes in the availability of opioids in Spain, and new policies on palliative care have been implemented. The aim of this study was to describe the new pattern of opioid consumption in Spain and the associated economic impact. Methods A search in the ECOM (Especialidades Consumo de Medicamentos) database of the Ministry of Health and Consumer Affairs for the 1992-2006 period was carried out. This database contains information on prescriptions of primary care medicines that are covered by the National Health System in Spain. Results Since 1992, overall opioid consumption has increased 14-fold, from 0.3 DDD/1000 inhabitants per day to 4.4 DDD/1000 inhabitants per day. For the six drugs that require a special prescription form - morphine, methadone, oxycodone pethidine, tilidine and fentanyl - consumption increased from 0.1 DDD/1000 inhabitants per day in 1992 to 1.2 in 2006. During this same period, the total costs of these prescriptions increased by 36.8-fold, and the cost per day and per patient doubled. Conclusion A huge increase in opioid consumption has occurred during the time period covered by this study, with fentanyl consumption accounting for most of that increase. Although oral morphine is the first-choice drug among strong opioids, fentanyl is currently the most consumed.	[del Pozo, Javier Garcia; Carvajal, Alfonso; Viloria, Jose Maria; Velasco, Alfonso; del Pozo, Victorina Garcia] Univ Valladolid, Inst Pharmacoepidemiol, Valladolid, Spain	del Pozo, JG (reprint author), Univ Valladolid, Inst Pharmacoepidemiol, Valladolid, Spain.	javiergp@ife.uva.es					BANDIERI E, BMJ LETT; Chinellato A, 2003, LANCET, V362, P78, DOI 10.1016/S0140-6736(03)13819-6; Chinellato A, 2006, BRIT J CLIN PHARMACO, V62, P130, DOI 10.1111/j.1365-2125.2006.02600.x; *DAN MED AG, 1999, CONS STRONG AN OP PR; del Pozo JG, 1999, EUR J CLIN PHARMACOL, V55, P681, DOI 10.1007/s002280050693; Escortell-Mayor E, 2006, Aten Primaria, V37, P88, DOI 10.1157/13084486; Fallon M, 2006, BRIT MED J, V332, P1022, DOI 10.1136/bmj.332.7548.1022; Garcia D, 2000, SUPPORT CARE CANCER, V8, P169, DOI 10.1007/s005200050280; Genf World Health Organization, 1986, CANC PAIN REL; Hudec R, 2004, EUR J CLIN PHARMACOL, V60, P445, DOI 10.1007/s00228-004-0793-5; LUNDE PKM, 1979, STUDIES DRUG UTILIZA, P17; Mercadante S, 2004, J PAIN SYMPTOM MANAG, V27, P391, DOI 10.1016/j.jpainsymman.2004.02.009; Mercadante S, 2002, LANCET, V360, P1254, DOI 10.1016/S0140-6736(02)11261-X; National Statistics Institute, POP SPAIN; *NORW I PUBL HLTH, 2007, DRUG CONS NORW 2002; *WHO, 2007, WHO COLL CTR DRUG ST; World Health Organization, 2007, ACC CONTR MED PROGR; World Health Organization, ACH BAL NAT OP CONTR	18	61	64	0	6	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0031-6970	1432-1041		EUR J CLIN PHARMACOL	Eur. J. Clin. Pharmacol.	APR	2008	64	4					411	415		10.1007/s00228-007-0419-9			5	Pharmacology & Pharmacy	Pharmacology & Pharmacy	268HN	WOS:000253571000012	18157671				2020-06-30	J	Atienzaar, MC; Palanca, JM; Torres, F; Borras, R; Gil, S; Esteve, I				Atienzaar, M. C.; Palanca, J. M.; Torres, F.; Borras, R.; Gil, S.; Esteve, I.			A randomized comparison of levobupivacaine, bupivacaine and ropivacaine with fentanyl, for labor analgesia	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Article						analgesia : obstetric, epidural; anesthetics, local : levobupivacaine, bupivacaine; ropivacaine; opioids : fentanyl	EPIDURAL ANALGESIA; RACEMIC BUPIVACAINE; PAIN RELIEF; POTENCIES; SHEEP	Background: To compare the analgesic efficacy of epidural infusions of levobupivacaine, bupivacaine and ropivacaine in labor. Methods: 102 nulliparous parturients in early labor were enrolled in this randomized, double-blind clinical trial. They were randomly assigned to receive one of three continuous epidural infusion regimens: levobupivacaine 0.125%, bupivacaine 0.125% or ropivacaine 0.2%, all with fentanyl 1 mu g/mL at 8 mL/h. Supplementary analgesia was provided with an 8-mL epidural bolus of the study solution if visual analogue scale (VAS) score for pain was >= 40 (0-100 mm). Pain and motor and sensory block were measured at 0, 15 and 30 min, 1, 2, 3 and 4 h and full cervical dilatation. Results: Analgesia was satisfactory in all three groups, with VAS score <40 mm at all measurements. VAS scores were greater in those receiving levobupivacaine (P <0.005). Motor block was greater with bupivacaine than levobupivacaine (P <0.01). There were no differences in motor block between levobupivacaine and ropivacaine. There were no other differences between groups. Conclusion: All three regimens were effective during first stage of labor although pain scores were higher in those receiving levobupivacaine. Motor block was greater with bupivacaine than with levobupivacaine. (c) 2007 Elsevier Ltd. All rights reserved.	[Atienzaar, M. C.] Hosp Gen Castellon, Dept Anesthesia, Castellon de La Plana 12004, Spain; [Palanca, J. M.] Univ Valencia, Sch Med, Dept Surg, Valencia, Spain; [Torres, F.] Univ Autonoma Barcelona, Serv Farmacol Clin, Lab Bioestadist & Epidemiol, Hosp Cllin, E-08193 Barcelona, Spain; [Borras, R.; Gil, S.; Esteve, I.] Inst Univ Dexeus, Dept Anesthesia, Barcelona, Spain	Atienzaar, MC (reprint author), Hosp Gen Castellon, Dept Anesthesia, Avda Benicassim S-N, Castellon de La Plana 12004, Spain.	carmen.atienzar@uv.es	Torres, Ferran/J-1758-2019; Torres, Ferran/D-1296-2011	Torres, Ferran/0000-0002-7355-7913; Torres, Ferran/0000-0002-7355-7913			Atienzar MC, 2004, EUR J ANAESTH, V21, P770; Benhamou D, 2003, ANESTHESIOLOGY, V99, P1383, DOI 10.1097/00000542-200312000-00022; Burke D, 1999, BRIT J ANAESTH, V83, P750; Camorcia M, 2003, EUR J ANAESTH, V20, P636, DOI 10.1097/00003643-200308000-00008; Capogna G, 1999, BRIT J ANAESTH, V82, P371, DOI 10.1093/bja/82.3.371; Huang YF, 1998, ANESTH ANALG, V86, P797, DOI 10.1097/00000539-199804000-00023; Lacassie HJ, 2003, ANESTH ANALG, V97, P1509, DOI 10.1213/01.ANE.0000083375.48151.FF; Lim Y, 2004, ANESTH ANALG, V98, P235, DOI 10.1213/01.ANE.0000094338.80430.C5; Lyons G, 1997, BRIT J ANAESTH, V78, P493; Lyons G, 1998, BRIT J ANAESTH, V81, P899; Moher D, 2001, LANCET, V357, P1191, DOI 10.1016/S0140-6736(00)04337-3; Morrison SG, 2000, ANESTH ANALG, V90, P1308, DOI 10.1097/00000539-200006000-00009; Polley LS, 2003, ANESTHESIOLOGY, V99, P1354, DOI 10.1097/00000542-200312000-00017; Purdie NL, 2004, ANAESTHESIA, V59, P133, DOI 10.1111/j.1365-2044.2004.03582.x; Robinson AP, 2001, ANESTH ANALG, V92, P410, DOI 10.1213/00000539-200102000-00025; RUTTEN AJ, 1989, ANESTH ANALG, V69, P291; Schug SA, 2001, REGION ANESTH PAIN M, V26, P91, DOI 10.1053/rapm.2001.19883; Supandji M, 2004, CAN J ANAESTH, V51, P918, DOI 10.1007/BF03018891	18	22	24	0	2	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0959-289X			INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	APR	2008	17	2					106	111		10.1016/j.ijoa.2007.10.003			6	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	291VR	WOS:000255225700003	18295469				2020-06-30	J	Sivasankar, R; Adekanye, O				Sivasankar, R.; Adekanye, O.			Is there a role for test dosing through the Tuohy needle?	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Letter									[Sivasankar, R.; Adekanye, O.] Univ Wales Hosp, Dept Anaesthet & Intens Care Med, Cardiff CF4 4XW, S Glam, Wales	Sivasankar, R (reprint author), Univ Wales Hosp, Dept Anaesthet & Intens Care Med, Cardiff CF4 4XW, S Glam, Wales.	sivasankar.raman@gmail.com					Balestrieri PJ, 2007, INT J OBSTET ANESTH, V16, P296, DOI 10.1016/j.ijoa.2007.01.009; Evron S, 2007, ANESTH ANALG, V105, P460, DOI 10.1213/01.ane.0000267543.39388.3e; Gardner IC, 2005, INT J OBSTET ANESTH, V14, P96, DOI 10.1016/j.ijoa.2004.07.013; VANZUNDERT AA, 1988, ANESTH ANALG, V67, P784	4	1	1	0	1	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0959-289X			INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	APR	2008	17	2					191	192		10.1016/j.ijoa.2007.09.009			2	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	291VR	WOS:000255225700022	18308538				2020-06-30	J	Waters, JH				Waters, Jonathan H.			Is there a role for test-dosing through the Tuohy needle?	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Letter									Univ Pittsburgh, Med Ctr, Magee Womens Hosp, Dept Anesthesiol, Pittsburgh, PA 15260 USA	Waters, JH (reprint author), Univ Pittsburgh, Med Ctr, Magee Womens Hosp, Dept Anesthesiol, Pittsburgh, PA 15260 USA.	watejh@upmc.edu					Balestrieri PJ, 2007, INT J OBSTET ANESTH, V16, P296, DOI 10.1016/j.ijoa.2007.01.009	1	1	1	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-289X	1532-3374		INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	APR	2008	17	2					192	193		10.1016/j.ijoa.2007.09.011			2	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	291VR	WOS:000255225700024	18308552				2020-06-30	J	Schneider, S; Ait-M-Bark, Z; Schummer, C; Lemmer, P; Yegles, M; Appenzeller, B; Wennig, R				Schneider, Serge; Ait-m-bark, Zahra; Schummer, Claude; Lemmer, Patrick; Yegles, Michel; Appenzeller, Brice; Wennig, Robert			Determination of fentanyl in sweat and hair of a patient using transdermal patches	JOURNAL OF ANALYTICAL TOXICOLOGY			English	Article							CANCER PAIN; PHARMACOLOGICAL-PROPERTIES; THERAPEUTIC-EFFICACY; OPIOIDS; SPECTROMETRY; GC/MS/MS; PLASMA; SYSTEM		[Schneider, Serge; Ait-m-bark, Zahra; Schummer, Claude; Lemmer, Patrick; Yegles, Michel; Wennig, Robert] Univ Luxembourg, Lab Natl Sante, Div Toxicol, L-1511 Luxembourg, Luxembourg; [Appenzeller, Brice] Lab Natl Sante, CRP Sante, L-1511 Luxembourg, Luxembourg	Schneider, S (reprint author), Univ Luxembourg, Lab Natl Sante, Div Toxicol, 162a Ave Faiencerie, L-1511 Luxembourg, Luxembourg.	serge.schneider@lns.etat.lu	Yegles, Michel/M-2107-2016	Yegles, Michel/0000-0003-1163-2487			Appenzeller BMR, 2007, J CHROMATOGR B, V852, P333, DOI 10.1016/j.jchromb.2007.01.037; Ben-David B, 2000, ANESTHESIOLOGY, V92, P6, DOI 10.1097/00000542-200001000-00007; Bracht Stefan, 2000, INNOVATIONS PHARM TE, P92; Follador MJD, 2004, J CHROMATOGR B, V811, P37, DOI 10.1016/j.jchromb.2004.03.071; GROBOSCH T, 2007, TOXICHEM KRIMTECH, V74, P59; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; HAYASHI S, 1991, BRIT J DERMATOL, V125, P123, DOI 10.1111/j.1365-2133.1991.tb06058.x; Herrero-Beaumont G, 2004, RHEUMATOL INT, V24, P325, DOI 10.1007/s00296-004-0520-7; Jeal W, 1997, DRUGS, V53, P109, DOI 10.2165/00003495-199753010-00011; Kintz P, 2005, FORENSIC SCI INT, V153, P81, DOI 10.1016/j.forsciint.2005.04.033; Kintz P, 1996, J ANAL TOXICOL, V20, P197, DOI 10.1093/jat/20.3.197; Kintz P, 1996, J FORENSIC SCI, V41, P851; Koo PJS, 2005, AM J HEALTH-SYST PH, V62, P1171, DOI 10.1093/ajhp/62.11.1171; Kornick CA, 2003, DRUG SAFETY, V26, P951, DOI 10.2165/00002018-200326130-00004; Kuhlman JJ, 2003, J ANAL TOXICOL, V27, P499, DOI 10.1093/jat/27.7.499; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; Lemmer P, 2005, THER DRUG MONIT, V27, P521, DOI 10.1097/01.ftd.0000164613.91555.2e; Martin TL, 2006, J ANAL TOXICOL, V30, P603, DOI 10.1093/jat/30.8.603; Martins LF, 2006, J CHROMATOGR B, V842, P98, DOI 10.1016/j.jchromb.2006.04.024; Michel Y., 2007, ANAL PRACTICAL ASPEC, P73; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; Musel AL, 2006, DERMATITIS, V17, P109, DOI 10.2310/6620.2006.05051; Mystakidou K, 2002, ONCOLOGY-BASEL, V62, P9, DOI 10.1159/000048241; Pragst F., 2004, TOXICHEM KRIMTECH, V71, P69; Sachs H, 1996, INT J LEGAL MED, V109, P213, DOI 10.1007/BF01225521; Saito T, 2004, CLIN CHEM, V50, P2083, DOI 10.1373/clinchem.2004.034868; Samyn N, 2002, FORENSIC SCI INT, V128, P90, DOI 10.1016/S0379-0738(02)00157-3; SELAVKA CM, 1995, J FORENSIC SCI, V40, P681; Sinatra R, 2005, CLIN PHARMACOKINET, V44, P1; Skaer TL, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-24; Taylor JR, 1998, ADDICTION, V93, P847, DOI 10.1046/j.1360-0443.1998.9368476.x; Uhl M, 1997, FORENSIC SCI INT, V84, P281, DOI 10.1016/S0379-0738(96)02072-5; VARVEL JR, 1989, ANESTHESIOLOGY, V70, P928, DOI 10.1097/00000542-198906000-00008; WANG WL, 1993, FORENSIC SCI INT, V61, P65, DOI 10.1016/0379-0738(93)90250-E	34	16	17	1	10	PRESTON PUBL INC	NILES	7800 MERRIMAC AVE PO BOX 48312, NILES, IL 60648 USA	0146-4760			J ANAL TOXICOL	J. Anal. Toxicol.	APR	2008	32	3					260	264		10.1093/jat/32.3.260			5	Chemistry, Analytical; Toxicology	Chemistry; Toxicology	297MN	WOS:000255620900009	18397579	Bronze			2020-06-30	J	Mitsogiannis, IC; Anagnostou, T; Tzortzis, V; Karatzas, A; Gravas, S; Poulakis, V; Melekos, MD				Mitsogiannis, Iraklis C.; Anagnostou, Theodore; Tzortzis, Vassilios; Karatzas, Anastasios; Gravas, Stavros; Poulakis, Vassilis; Melekos, Michael D.			Analgesia during extracorporeal shockwave lithotripsy: Fentanyl citrate versus parecoxib sodium	JOURNAL OF ENDOUROLOGY			English	Article							GYNECOLOGIC LAPAROTOMY SURGERY; WAVE LITHOTRIPSY; LOCAL-ANESTHETICS; EUTECTIC MIXTURE; DOUBLE-BLIND; CYCLOOXYGENASE-2-SPECIFIC INHIBITOR; GENERAL-ANESTHESIA; URETERAL CALCULI; PAIN RESPONSE; REQUIREMENT	Background and Purpose: Shockwave-induced pain may become an important issue during extracorporeal shockwave lithotripsy (SWL), although the new generation of lithotriptors generally produces less pain than previous models. The aim of the study was to compare the analgesic effect of a cyclooxygenase-2-specific inhibitor (parecoxib sodium) with that of our standard method of analgesia (fentanyl citrate) in patients who needed pain relief when undergoing SWL. Patients and Methods: Fifty-eight patients who were undergoing SWL for renal calculi were randomized to receive intravenously either fentanyl citrate (group A, n = 30) or parecoxib sodium (group B, n = 28) when they felt that their pain during the session became intolerable. Lithotripsy was recommenced 10 minutes after administration of analgesia. The severity of pain before and after administration of the analgesic regimens was evaluated using a five-level verbal scale. The effectiveness of each drug was evaluated with respect to degree of pain relief and ensuing tolerance of the procedure to completion, as well as the need for supplementary analgesia (half the standard dose of fentanyl citrate). Results: The patients in the two groups were comparable with regard to age, sex, body mass index, and stone size. There was no statistically significant difference in the maximum energy level achieved as well as in the total number of shock waves given in the two groups. Administration of fentanyl citrate resulted in alleviation of pain and completion of SWL in 27 patients (90%), whereas parecoxib sodium was effective in five patients (17.8%) (P < 0.01). The remaining 23 patients in group B received supplementary analgesia, and 22 completed the lithotripsy session. Conclusions: Parecoxib sodium was not as effective as fentanyl citrate in alleviating pain during SWL. Its use, however, may lower the dose of opioid-based analgesia in this group of patients.	[Mitsogiannis, Iraklis C.; Anagnostou, Theodore; Tzortzis, Vassilios; Karatzas, Anastasios; Gravas, Stavros; Poulakis, Vassilis; Melekos, Michael D.] Univ Thessaly, Sch Med, Dept Urol, Larisa, Greece	Mitsogiannis, IC (reprint author), 5 Proussis St, Athens 14232, Greece.	icm@med.uth.gr					Alhashemi JA, 2006, CAN J ANAESTH, V53, P449, DOI 10.1007/BF03022616; Aybek Z, 1998, EUR UROL, V34, P207, DOI 10.1159/000019714; Barton SF, 2002, ANESTHESIOLOGY, V97, P306, DOI 10.1097/00000542-200208000-00004; Becker AJ, 1999, J UROLOGY, V162, P18, DOI 10.1097/00005392-199907000-00005; Beloeil H, 2002, BRIT J ANAESTH, V89, P567, DOI 10.1093/bja/aef202; BIERKENS AF, 1991, J UROLOGY, V146, P287, DOI 10.1016/S0022-5347(17)37772-8; CASS AS, 1995, J UROLOGY, V153, P588, DOI 10.1016/S0022-5347(01)67654-7; CHAPMAN CR, 1985, PAIN, V22, P1, DOI 10.1016/0304-3959(85)90145-9; DAWSON C, 1994, BRIT J UROL, V74, P302, DOI 10.1111/j.1464-410X.1994.tb16615.x; FREDMAN B, 1993, J CLIN ANESTH, V5, P141, DOI 10.1016/0952-8180(93)90142-2; Ganapathy S, 1996, CAN J ANAESTH, V43, P1030, DOI 10.1007/BF03011905; Gesztesi Z, 2000, ANESTH ANALG, V90, P567, DOI 10.1097/00000539-200003000-00013; Harris SI, 2001, CLIN THER, V23, P1422, DOI 10.1016/S0149-2918(01)80117-X; Hubbard RC, 2003, BRIT J ANAESTH, V90, P166, DOI 10.1093/bja/aeg038; Lingeman JE, 1997, UROL CLIN N AM, V24, P185, DOI 10.1016/S0094-0143(05)70363-3; LOENING S, 1987, J UROLOGY, V137, P626, DOI 10.1016/S0022-5347(17)44158-9; Malan TP, 2005, ANESTH ANALG, V100, P454, DOI 10.1213/01.ANE.0000143355.52418.CF; MCDONALD PF, 1992, BRIT J ANAESTH, V69, P399, DOI 10.1093/bja/69.4.399; MOBLEY TB, 1993, J UROLOGY, V149, P1419, DOI 10.1016/S0022-5347(17)36404-2; MONK TG, 1991, ANESTHESIOLOGY, V74, P1023, DOI 10.1097/00000542-199106000-00009; MONK TG, 1994, ANESTH ANALG, V79, P506; Noveck RJ, 2001, CLIN DRUG INVEST, V21, P465, DOI 10.2165/00044011-200121070-00002; Ozcan S, 2002, SCAND J UROL NEPHROL, V36, P281, DOI 10.1080/003655902320248254; Parkin J, 2002, J UROLOGY, V167, P1613, DOI 10.1016/S0022-5347(05)65164-6; Rasmussen G Lynn, 2002, Am J Orthop (Belle Mead NJ), V31, P336; RASMUSSEN YH, 1994, SCAND J UROL NEPHROL, V28, P225, DOI 10.3109/00365599409181270; Reichelt O, 1999, UROLOGY, V54, P433, DOI 10.1016/S0090-4295(99)00155-7; Schelling G, 1996, J UROLOGY, V155, P43, DOI 10.1016/S0022-5347(01)66534-0; Tauzin-Fin P, 1998, EUR J ANAESTH, V15, P147, DOI 10.1046/j.1365-2346.1998.00250.x; Turker AK, 2000, EUR UROL, V37, P331, DOI 10.1159/000052365; Zommick J, 1996, J ENDOUROL, V10, P489, DOI 10.1089/end.1996.10.489	31	7	9	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0892-7790	1557-900X		J ENDOUROL	J. Endourol.	APR	2008	22	4					623	626		10.1089/end.2007.0344			4	Urology & Nephrology	Urology & Nephrology	292DU	WOS:000255247500013	18324902				2020-06-30	J	Tassinari, D; Sartori, S; Tamburin, E; Scarpi, E; Raffaeli, W; Tombesi, P; Maltoni, M				Tassinari, Davide; Sartori, Sergio; Tamburini, Emiliano; Scarpi, Emanuela; Raffaeli, William; Tombesi, Paola; Maltoni, Marco			Adverse effects of transdermal opiates treating moderate-severe cancer pain in comparison to long-acting morphine: A meta-analysis and systematic review of the literature	JOURNAL OF PALLIATIVE MEDICINE			English	Review							RELEASE ORAL MORPHINE; ANALGESIC LADDER; CARE RESEARCH; FENTANYL; QUALITY; OPIOIDS; EFFICACY; LIFE; RECOMMENDATIONS; CONSTIPATION	Background: To assess the adverse effects of transdermal opiates treating moderate - severe cancer pain in comparison with slow release oral morphine. Methods: A systematic review of the literature in the MEDLINE and EMBASE databases from 1966 to June 2007 was independently performed by two authors. All phase 3 randomized trials comparing transdermal opiates and slow-release oral morphine in the treatment of moderate-severe cancer pain were considered eligible and included in the analysis. The primary end point was the overall adverse effects odds ratio (OR); secondary end points were the overall gastrointestinal adverse effects, constipation, nausea, somnolence, patients' preference, and trial withdrawal. Heterogeneity was analyzed using the Mantel-Haenszel test, and outcome analysis was performed using a random effect model; an alpha error lower than 5% was assumed as statistically significant. Results: Four trials met the selection criteria. The safety of transdermal opiates (fentanyl and buprenorphine) and slow-release oral morphine was analyzed in 425 patients. A significant difference in favor of transdermal opiates was observed for constipation (OR = 0.38, p < 0.001), and patients' preference (OR = 0.43, p = 0.014, in the three trials investigating transdermal fentanyl). No significant differences were observed for overall adverse effects, overall gastrointestinal adverse effects, overall neurologic adverse effects, nausea, somnolence, hypoventilation, trial withdrawal, and changes in opiate treatments. Conclusion: Although no difference in the overall adverse effect profile exists between transdermal opiates and slow release oral morphine, the difference in some adverse effects (mainly constipation) seems to favor transdermal opiates in the preference of patients with moderate-severe cancer pain.	[Tassinari, Davide; Tamburini, Emiliano] City Hosp, Dept Oncol, Support & Palliat Care Unit, I-47900 Rimini, Italy; [Sartori, Sergio; Tombesi, Paola] Dept Internal Med, Ferrara, Italy; [Scarpi, Emanuela; Maltoni, Marco] Palliat Care Unit, Forli, Italy; [Raffaeli, William] Infermi Hosp, Dept Hospice, Rimini, Italy; [Raffaeli, William] Infermi Hosp, Palliat Care Serv, Rimini, Italy	Tassinari, D (reprint author), City Hosp, Dept Oncol, Support & Palliat Care Unit, Via Settembrini 2, I-47900 Rimini, Italy.	dtassinari@rimini.com	Scarpi, Emanuela/AAD-7036-2019	Scarpi, Emanuela/0000-0001-7230-9267			Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; Allan L, 2005, SPINE, V30, P2484, DOI 10.1097/01.brs.0000186860.23078.a8; Allan L, 2001, BRIT MED J, V322, P1154, DOI 10.1136/bmj.322.7295.1154; Brouwers Melissa C, 2005, BMC Med Res Methodol, V5, P8, DOI 10.1186/1471-2288-5-8; Cherny N, 2001, J CLIN ONCOL, V19, P2542, DOI 10.1200/JCO.2001.19.9.2542; Chinellato A, 2003, LANCET, V362, P78, DOI 10.1016/S0140-6736(03)13819-6; Clark AJ, 2004, CURR MED RES OPIN, V20, P1419, DOI 10.1185/030079904X2114; De Conno F, 2005, PALLIATIVE MED, V19, P179, DOI 10.1191/0269216305pm1002oa; FLYNN TN, 1999, [No title captured], V2, P15; FREI A, 2000, VALUE HEALTH, V3, P309; Gourlay G K, 2001, Lancet Oncol, V2, P165, DOI 10.1016/S1470-2045(00)00258-8; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; Hunt R, 1999, J PAIN SYMPTOM MANAG, V18, P111, DOI 10.1016/S0885-3924(99)00051-2; JADAD A, 1998, [No title captured], P45; JADAD AR, 1995, JAMA-J AM MED ASSOC, V274, P1870, DOI 10.1001/jama.274.23.1870; Kaasa S, 2002, LANCET ONCOL, V3, P175, DOI 10.1016/S1470-2045(02)00682-4; Kaasa S, 2001, EUR J CANCER, V37, pS153; Kaasa S, 2006, PALLIATIVE MED, V20, P727, DOI 10.1177/0269216306072620; Klepstad P, 2005, PALLIATIVE MED, V19, P477, DOI 10.1191/0269216305pm1054oa; Maltoni M, 2005, SUPPORT CARE CANCER, V13, P888, DOI 10.1007/s00520-005-0807-6; Marinangeli F, 2004, J PAIN SYMPTOM MANAG, V27, P409, DOI 10.1016/j.jpainsymman.2003.10.006; Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X; Pace MC, 2007, FRONT BIOSCI-LANDMRK, V12, P1291, DOI 10.2741/2147; Payne R, 1998, J CLIN ONCOL, V16, P1588, DOI 10.1200/JCO.1998.16.4.1588; Radbruch L, 2000, PALLIATIVE MED, V14, P111, DOI 10.1191/026921600671594561; Ripamonti C, 2006, SUPPORT CARE CANCER, V14, P400, DOI 10.1007/s00520-005-0918-0; Ripamonti C, 2001, SUPPORT CARE CANCER, V9, P223, DOI 10.1007/s005200000198; Staats PS, 2004, SOUTH MED J, V97, P129, DOI 10.1097/01.SMJ.0000109215.54052.D8; Tassinari D, 2002, ANN ONCOL, V13, P1322, DOI 10.1093/annonc/mdf298; Tassinari D, 2002, J CLIN ONCOL, V20, P1704, DOI 10.1200/JCO.2002.20.6.1704; van Seventer R, 2003, CURR MED RES OPIN, V19, P457, DOI 10.1185/030079903125002045; Wong J O, 1997, Acta Anaesthesiol Sin, V35, P25; World Health Organization, 1996, CANC PAIN REL GUID O	33	66	74	4	13	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1096-6218	1557-7740		J PALLIAT MED	J. Palliat. Med.	APR	2008	11	3					492	501		10.1089/jpm.2007.0200			10	Health Care Sciences & Services	Health Care Sciences & Services	283QO	WOS:000254651800018	18363493				2020-06-30	J	Virk, MS; Williams, JT				Virk, Michael S.; Williams, John T.			Agonist-specific regulation of mu-opioid receptor desensitization and recovery from desensitization	MOLECULAR PHARMACOLOGY			English	Article							LOCUS-COERULEUS NEURONS; IN-VIVO; OPIATE DRUGS; TOLERANCE; MORPHINE; INTERNALIZATION; RATS; ENDOCYTOSIS; MECHANISMS; DEPENDENCE	Agonist-selective actions of opioids on the desensitization of mu-opioid receptors ( MORs) have been well characterized, but few if any studies have examined agonist-dependent recovery from desensitization. The outward potassium current induced by several opioids was studied using whole-cell voltage-clamp recordings in locus ceruleus neurons. A brief application of the irreversible opioid antagonist beta-chlornaltrexamine (beta-CNA) was applied immediately after treatment of slices with saturating concentrations of opioid agonists. This approach permitted the measurement of desensitization and recovery from desensitization using multiple opioid agonists, including [ Met](5)enkephalin ( ME), [ D-Ala(2), N-Me-Phe(4), Gly(5)-ol]-enkephalin ( DAMGO), etorphine, fentanyl, methadone, morphine, morphine-6-glucuronide, oxycodone, and oxymorphone. The results indicate that desensitization protects receptors from irreversible antagonism with beta-CNA. The amount of desensitization was measured as the decrease in current during a 10-min application of a saturating agonist concentration and was a good predictor of the extent of receptor protection from irreversible inactivation with beta-CNA. After desensitization with ME or DAMGO and treatment with beta-CNA, there was an initial profound inhibition of MOR-induced current that recovered significantly after 45 min. There was, however, no recovery of MOR-mediated current with time after treatment with agonists that did not cause desensitization, such as oxycodone. These results demonstrate that desensitization prevents irreversible inactivation of receptors by mu-CNA.	[Virk, Michael S.; Williams, John T.] Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97239 USA	Williams, JT (reprint author), Oregon Hlth & Sci Univ, Vollum Inst, L474,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	williamj@ohsu.edu			NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA08163, 1F30-DA021466, F30 DA021466, R01 DA008163]		Alvarez VA, 2002, J NEUROSCI, V22, P5769; Arttamangkul S, 2006, J NEUROSCI, V26, P4118, DOI 10.1523/JNEUROSCI.0303-06.2006; AvidorReiss T, 1997, J BIOL CHEM, V272, P5040, DOI 10.1074/jbc.272.8.5040; Bailey CP, 2005, CURR OPIN PHARMACOL, V5, P60, DOI 10.1016/j.coph.2004.08.012; Bohn LM, 2000, NATURE, V408, P720, DOI 10.1038/35047086; Borgland SL, 2003, J BIOL CHEM, V278, P18776, DOI 10.1074/jbc.M300525200; Celver J, 2004, MOL PHARMACOL, V65, P528, DOI 10.1124/mol.65.3.528; Christie M J, 1986, NIDA Res Monogr, V75, P591; Connor M, 2004, BRIT J PHARMACOL, V143, P685, DOI 10.1038/sj.bjp.0705938; Dang VC, 2005, MOL PHARMACOL, V68, P1127, DOI 10.1124/mol.105.013185; Dang VC, 2004, J NEUROSCI, V24, P7699, DOI 10.1523/JNEUROSCI.2499-04.2004; Fiorillo CD, 1996, J NEUROSCI, V16, P1479; Grecksch G, 2006, PSYCHOPHARMACOLOGY, V186, P177, DOI 10.1007/s00213-006-0365-8; HARRIS GC, 1991, J NEUROSCI, V11, P2574; Johnson EA, 2006, MOL PHARMACOL, V70, P676, DOI 10.1124/mol.106.022376; Keith DE, 1998, MOL PHARMACOL, V53, P377; Koch T, 2005, MOL PHARMACOL, V67, P280, DOI 10.1124/mol.104.004994; Koch T, 2004, J NEUROCHEM, V88, P680, DOI 10.1046/j.1471-4159.2003.02189.x; Law PY, 2000, MOL PHARMACOL, V58, P388; Lemberg KK, 2006, ANESTHESIOLOGY, V105, P801, DOI 10.1097/00000542-200610000-00027; OSBORNE PB, 1995, BRIT J PHARMACOL, V115, P925, DOI 10.1111/j.1476-5381.1995.tb15899.x; Patel MB, 2002, MOL PHARMACOL, V62, P1464, DOI 10.1124/mol.62.6.1464; Pawar M, 2007, EUR J PHARMACOL, V563, P92, DOI 10.1016/j.ejphar.2007.01.059; Peckham EM, 2006, J PHARMACOL EXP THER, V316, P1195, DOI 10.1124/jpet.105.094276; Schulz S, 2004, EMBO J, V23, P3282, DOI 10.1038/sj.emboj.7600334; Stafford K, 2001, PHARMACOL BIOCHEM BE, V69, P233, DOI 10.1016/S0091-3057(01)00525-1; von Zastrow M, 2004, NEUROPHARMACOLOGY, V47, P286, DOI 10.1016/j.neuropharm.2004.05.007; Walker EA, 2001, PSYCHOPHARMACOLOGY, V154, P131, DOI 10.1007/s002130000620; Whistler JL, 1999, NEURON, V23, P737, DOI 10.1016/S0896-6273(01)80032-5; Whistler JL, 1998, P NATL ACAD SCI USA, V95, P9914, DOI 10.1073/pnas.95.17.9914; Williams JT, 2001, PHYSIOL REV, V81, P299; WILLIAMS JT, 1984, NEUROSCIENCE, V13, P137, DOI 10.1016/0306-4522(84)90265-3; Yu YK, 1997, J BIOL CHEM, V272, P28869, DOI 10.1074/jbc.272.46.28869; Zhang J, 1997, RECEPTOR CHANNEL, V5, P193	34	36	38	0	3	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA	0026-895X			MOL PHARMACOL	Mol. Pharmacol.	APR	2008	73	4					1301	1308		10.1124/mol.107.042952			8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	275IK	WOS:000254064900028	18198283	Green Accepted			2020-06-30	J	Iodice, F; Harban, F; Walker, I				Iodice, Francesca; Harban, Fraser; Walker, Isabeau			Anesthetic management of a patient with bilateral congenital lobar emphysema	PEDIATRIC ANESTHESIA			English	Letter									[Iodice, Francesca; Harban, Fraser; Walker, Isabeau] Great Ormond St Hosp Sick Children, Dept Anaesthet, London WC1N 3JH, England	Iodice, F (reprint author), Great Ormond St Hosp Sick Children, Dept Anaesthet, Great Ormond St, London WC1N 3JH, England.	francesca_odice@yahoo.it		Iodice, Francesca Giovanna/0000-0002-0478-619X			ALSALEM AH, 1990, CAN J ANAESTH, V37, P377, DOI 10.1007/BF03005595; Arora MK, 2006, PEDIATR ANESTH, V16, P998, DOI 10.1111/j.1460-9592.2006.01906.x; EKKELKAMP S, 1987, J PEDIATR SURG, V22, P1001, DOI 10.1016/S0022-3468(87)80495-5; GEORGE G, 2002, PEDIAT ANESTHESIA TX, P428; Maiya S, 2005, PEDIATR SURG INT, V21, P659, DOI 10.1007/s00383-005-1425-6	5	1	1	0	1	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	1155-5645			PEDIATR ANESTH	Pediatr. Anesth.	APR	2008	18	4					340	341		10.1111/j.1460-9592.2008.02473.x			2	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	269FU	WOS:000253635700019	18315649				2020-06-30	J	Ajala, AM; Goodwin, JA; Goodwin, SR; Josephson, GD				Ajala, Adebisi M.; Goodwin, Jane A.; Goodwin, Salvatore R.; Josephson, Gary D.			Undiagnosed Graves' Disease contributing to sleep disordered breathing in a child undergoing adenotonsillectomy	PEDIATRIC ANESTHESIA			English	Letter							APNEA		[Ajala, Adebisi M.; Goodwin, Jane A.; Goodwin, Salvatore R.] Nemours Childrens Clin, Dept Anesthesiol & Crit Care Med, Jacksonville, FL USA; [Josephson, Gary D.] Nemours Childrens Clin, Div Pediat Otolaryngol, Jacksonville, FL USA	Ajala, AM (reprint author), Nemours Childrens Clin, Dept Anesthesiol & Crit Care Med, Childrens Way, Jacksonville, FL USA.	aajala@nemours.org					Bossowski AT, 2007, J ENDOCRINOL INVEST, V30, P388, DOI 10.1007/BF03346315; Kraiem Z, 2001, J PEDIATR ENDOCR MET, V14, P229, DOI 10.1515/JPEM.2001.14.3.229; Sterni LM, 2003, PEDIATR CLIN N AM, V50, P427, DOI 10.1016/S0031-3955(03)00037-3; Winkelman JW, 1996, SLEEP, V19, P790, DOI 10.1093/sleep/19.10.790	4	0	0	0	0	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	1155-5645			PEDIATR ANESTH	Pediatr. Anesth.	APR	2008	18	4					358	359		10.1111/j.1460-9592.2008.02482.x			3	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	269FU	WOS:000253635700035	18315665				2020-06-30	J	Butelman, ER; Reed, B; Chait, BT; Mandau, M; Yuferov, V; Kreek, MJ				Butelman, Eduardo R.; Reed, Brian; Chait, Brian T.; Mandau, Marek; Yuferov, Vadim; Kreek, Mary Jeanne			Limited effects of beta-endorphin compared to loperamide or fentanyl in a neuroendocrine biomarker assay in non-human primates	PSYCHONEUROENDOCRINOLOGY			English	Article						beta-endorphin; prolactin; Macaca; loperamide; biomarker; opioid	MU-OPIOID RECEPTOR; SINGLE-NUCLEOTIDE POLYMORPHISM; MESSENGER-RNA EXPRESSION; SERUM PROLACTIN LEVELS; RHESUS-MONKEYS; PLASMA-CONCENTRATIONS; PITUITARY-HORMONES; APPARENT EFFICACY; BINDING; OPIATE	The in vivo pharmacodynamics of the opioid neuropeptide beta-endorphin (a major endogenous agonist at the V-opioid receptor) is difficult to determine in non-human primate models with translational value, or in humans. The present studies therefore employed a neuroendocrine biomarker assay, prolactin release, to systematically compare the in vivo profile of i.v. beta-endorphin (0.01-0.32mg/kg; i.v.) in gonadally intact male rhesus monkeys (n = 4) to that of the peripherally selective p-agonist loperamide (0.01-0.32mg/kg; i.v.) and the centrally penetrating p-agonist fentanyl (0.0056-0.018 mg/kg; i.v.). Studies utilized a standardized time course design (measuring prolactin levels 5-120 min after agonist administration). beta-Endorphin displayed only limited effectiveness in causing protactin release when tested over this 30-fold dose range, compared to loperamide or fentanyl. Furthermore, two of the four subjects were only minimally responsive to R-endorphin. This differential responsiveness was not due to the presence of a previously described single nucleotide polymorphism at the OPRM1 gene (C77G), known to affect beta-endorphin pharmacodynamics in vitro. In vivo biotransformation studies with MALDI-mass spectrometry determined that full-length beta-endorphin was detectable in all subjects up to at least 5 min after i.v. administration. Thus, the relative ineffectiveness of i.v. beta-endorphin in this assay does not appear to be principally due to rapid generation of non-opioid fragments of this neuropeptide. (C) 2007 Elsevier Ltd. All rights reserved.	[Butelman, Eduardo R.; Reed, Brian; Mandau, Marek; Yuferov, Vadim; Kreek, Mary Jeanne] Rockefeller Univ, Lab Biol Addict Dis, New York, NY 10065 USA; [Chait, Brian T.] Rockefeller Univ, Lab Mass Spectrometry & Gaseous Ion Chem, New York, NY 10065 USA	Butelman, ER (reprint author), Rockefeller Univ, Lab Biol Addict Dis, 1230 York Ave, New York, NY 10065 USA.	butelme@rockefeller.edu			NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [RR00862, P41 RR000862]; NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [R01 DA017369, DA05130, P60 DA005130-19, DA17369, P50 DA005130, R01 DA017369-03, DA00049, P60 DA005130, K05 DA000049]		Alt A, 1998, J PHARMACOL EXP THER, V286, P282; ARMSTRONG WE, 1980, BRAIN RES BULL, V5, P473, DOI 10.1016/S0361-9230(80)80018-9; BABU CV, 2006, J PHARM BIOMED ANAL, V23, P136; Barr CS, 2007, ARCH GEN PSYCHIAT, V64, P369, DOI 10.1001/archpsyc.64.3.369; Bart G, 2005, NEUROPSYCHOPHARMACOL, V30, P417, DOI 10.1038/sj.npp.1300598; BEAUVILLAIN JC, 1992, NEUROSCIENCE, V49, P925, DOI 10.1016/0306-4522(92)90368-C; Bero L A, 1987, Brain Res, V465, P189; Beyer A, 2004, J NEUROCHEM, V89, P553, DOI 10.1111/j.1471-4159.2004.02340.x; BLACKFORD SP, 1992, ENDOCRINOLOGY, V131, P2891, DOI 10.1210/en.131.6.2891; Bond C, 1998, P NATL ACAD SCI USA, V95, P9608, DOI 10.1073/pnas.95.16.9608; Bowen CA, 2002, PSYCHONEUROENDOCRINO, V27, P319, DOI 10.1016/S0306-4530(01)00053-1; BROWN NA, 1994, BIOL REPROD, V50, P543, DOI 10.1095/biolreprod50.3.543; Butelman ER, 2004, PSYCHONEUROENDOCRINO, V29, P307, DOI 10.1016/S0306-4530(03)00030-1; Butelman ER, 1999, PSYCHOPHARMACOLOGY, V147, P73, DOI 10.1007/s002130051144; Butelman ER, 1999, EUR J PHARMACOL, V383, P305, DOI 10.1016/S0014-2999(99)00640-8; Butelman ER, 2002, PSYCHOPHARMACOLOGY, V164, P115, DOI 10.1007/s00213-002-1195-y; CALDARA R, 1981, EUR J CLIN PHARMACOL, V21, P185, DOI 10.1007/BF00627918; CATLIN DH, 1980, J CLIN ENDOCR METAB, V50, P1021, DOI 10.1210/jcem-50-6-1021; Chong RY, 2006, NEUROPSYCHOPHARMACOL, V31, P204, DOI 10.1038/sj.npp.1300856; Crockett CM, 2007, PEPTIDES, V28, P1987, DOI 10.1016/j.peptides.2007.07.014; Dehaven-Hudkins DL, 1999, J PHARMACOL EXP THER, V289, P494; DENT RRM, 1981, J CLIN ENDOCR METAB, V52, P942, DOI 10.1210/jcem-52-5-942; DOMINO EF, 1985, NEUROPEPTIDES, V6, P343, DOI 10.1016/0143-4179(85)90007-1; FOLEY KM, 1979, P NATL ACAD SCI USA, V76, P5377, DOI 10.1073/pnas.76.10.5377; FORTMAN JD, 2002, LAB NONHUMAN PRIMATE; FRANCE CP, 1994, J PHARMACOL EXP THER, V270, P992; GERAK LR, 1994, J PHARMACOL EXP THER, V271, P993; GILBEAU PM, 1985, J CLIN ENDOCR METAB, V60, P299, DOI 10.1210/jcem-60-2-299; HEYKANTS J, 1974, ARZNEIMITTEL-FORSCH, V24, P1649; HOEHE M, 1988, PSYCHONEUROENDOCRINO, V13, P397, DOI 10.1016/0306-4530(88)90046-7; KALIN NH, 1980, SCIENCE, V209, P827, DOI 10.1126/science.6250217; KENAKIN TP, 1993, PHARM ANAL DRUG RECE; Ko MC, 2002, J PHARMACOL EXP THER, V301, P698, DOI 10.1124/jpet.301.2.698; KREEK MJ, 1983, LIFE SCI, V33, P409, DOI 10.1016/0024-3205(83)90529-5; LEHMANN H, 1979, AM J PSYCHIAT, V136, P762; Lotsch J, 2004, CLIN PHARMACOKINET, V43, P983; MANSOUR A, 1995, BRAIN RES, V700, P89, DOI 10.1016/0006-8993(95)00928-J; MANZANARES J, 1992, BRAIN RES, V587, P301, DOI 10.1016/0006-8993(92)91011-3; MERCHENTHALER I, 1991, NEUROSCIENCE, V44, P655, DOI 10.1016/0306-4522(91)90085-3; Miller GM, 2004, MOL PSYCHIATR, V9, P99, DOI 10.1038/sj.mp.4001378; Moore Kenneth E., 1995, P245; ODIO M, 1990, PHARMACOL BIOCHEM BE, V35, P963, DOI 10.1016/0091-3057(90)90386-V; PANERAI AE, 1981, ENDOCRINOLOGY, V108, P2400, DOI 10.1210/endo-108-6-2400; PECHNICK RN, 1987, PSYCHONEUROENDOCRINO, V12, P67, DOI 10.1016/0306-4530(87)90024-2; PecinsThompson M, 1996, J NEUROSCI, V16, P7021; Remmers AE, 1999, J PHARMACOL EXP THER, V288, P827; Rittner HL, 2001, ANESTHESIOLOGY, V95, P500, DOI 10.1097/00000542-200108000-00036; ROWLAND M, 1980, CLIN PHARMACOKINETIC; Sandin J, 1998, REGUL PEPTIDES, V73, P67, DOI 10.1016/S0167-0115(97)01065-3; SATO H, 1985, LIFE SCI, V37, P1309, DOI 10.1016/0024-3205(85)90246-2; SATO H, 1987, DRUG METAB DISPOS, V15, P540; SCHUTZ A, 2006, INT J SPORTS MED, V21, P513; Selley DE, 1997, MOL PHARMACOL, V51, P87; SIMPKINS JW, 1991, NEUROENDOCRINOLOGY, V54, P384, DOI 10.1159/000125918; SPIES HG, 1980, NEUROENDOCRINOLOGY, V30, P249, DOI 10.1159/000123009; THORNTON JR, 1997, GUT, V32, P306; WARDLAW SL, 1980, ENDOCRINOLOGY, V107, P1663, DOI 10.1210/endo-107-6-1663; WIEDEMANN E, 1979, J CLIN ENDOCR METAB, V49, P478, DOI 10.1210/jcem-49-3-478; Yanagita T, 1979, NIDA Res Monogr, V27, P106; Zheng SX, 2005, J COMP NEUROL, V487, P332, DOI 10.1002/cne.20557; Zhu JM, 1997, J PHARMACOL EXP THER, V282, P676	61	6	6	0	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4530			PSYCHONEUROENDOCRINO	Psychoneuroendocrinology	APR	2008	33	3					292	304		10.1016/j.psyneuen.2007.11.011			13	Endocrinology & Metabolism; Neurosciences; Psychiatry	Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry	282LD	WOS:000254568400004	18171605	Green Accepted			2020-06-30	J	Basson, MD				Basson, Marc D.			Choosing sedation for upper endoscopy	SOUTHERN MEDICAL JOURNAL			English	Editorial Material									John D Dingell VA Med Ctr, Dept Surg, Surg Serv, Detroit, MI 48301 USA; John D Dingell VA Med Ctr, Dept Anesthesiol, Detroit, MI 48301 USA; Wayne State Univ, Detroit, MI USA	Basson, MD (reprint author), John D Dingell VA Med Ctr, Dept Surg, Surg Serv, 4646 John R St, Detroit, MI 48301 USA.	marc.basson@va.gov					Barriga J, 2008, SOUTH MED J, V101, P362, DOI 10.1097/SMJ.0b013e318168521b	1	1	1	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0038-4348			SOUTH MED J	South.Med.J.	APR	2008	101	4					345	346		10.1097/SMJ.0b013e3181685378			2	Medicine, General & Internal	General & Internal Medicine	285WK	WOS:000254806700008	18360337				2020-06-30	J	Barriga, J; Sachdev, MS; Royall, L; Brown, G; Tombazzi, CR				Barriga, Jose; Sachdev, Mankanwal S.; Royall, Lee; Brown, Garrick; Tombazzi, Claudio R.			Sedation for upper endoscopy: Comparison of Midazolam versus fentanyl plus Midazolam	SOUTHERN MEDICAL JOURNAL			English	Article						upper endoscopy; sedation; midazolam; fentanyl	UPPER GASTROINTESTINAL ENDOSCOPY; CONSCIOUS SEDATION; INTRAVENOUS MIDAZOLAM; PATIENT; MEPERIDINE; PROPOFOL; RATES; RISK	Background: The benefit of using one or two drugs for conscious sedation in upper endoscopy remains unproven. This study evaluates the adequacy of conscious sedation during upper endoscopy using midazolam alone compared with midazolam plus fentanyl. Methods: Patients older than 18 years of age who underwent elective, outpatient upper endoscopy were included. They were randomized to receive either a combination of midazolam/fentanyl or midazolam alone. The adequacy of sedation obtained was assessed using a questionnaire answered by the physician at the end of the procedure, and by the patient 24 to 72 hours after endoscopy. Results: From the endoscopist's perspective, following an intention-to-treat analysis, patients had better tolerance in the combination group (78.3% excellent/good tolerance M/F group versus 55.8% M group) (P = 0.043) (Table 2). Per patient's assessment excellent/good tolerance was found in 93% of M group and 94% in F/M group (P = 1.0). No difference in duration of the procedure was found between the two groups. No complications during endoscopies were reported. Conclusions: In diagnostic upper endoscopy, an adequate level of sedation can be obtained safely either by midazolam or midazolam plus fentanyl. From an endoscopist's perspective, the combination is significantly better.	[Tombazzi, Claudio R.] Univ Tennessee, Div Gastroenterol, Dept Med, Memphis, TN 38163 USA	Tombazzi, CR (reprint author), Univ Tennessee, Div Gastroenterol, Dept Med, 920 Madison Suite 240, Memphis, TN 38163 USA.	ctombazzi@utmem.edu					ARROWSMITH JB, 1991, GASTROINTEST ENDOSC, V37, P421, DOI 10.1016/S0016-5107(91)70773-6; BELL GD, 1987, BRIT J CLIN PHARMACO, V23, P241, DOI 10.1111/j.1365-2125.1987.tb03037.x; BELL GD, 1990, ALIMENT PHARM THERAP, V4, P103; BRODY DS, 1980, ARCH INTERN MED, V140, P1286, DOI 10.1001/archinte.140.10.1286; Carey WD, 1987, GASTROENTEROLOGIC EN, P296; Ciriza C, 2001, REV ESP ENFERM DIG, V93, P593; Cohen J, 2000, GASTROINTEST ENDOSC, V51, P546, DOI 10.1016/S0016-5107(00)70287-2; FREEMAN ML, 2003, TXB GASTROENTEROLOGY, P2812; FROEHLICH F, 1995, GASTROENTEROLOGY, V108, P697, DOI 10.1016/0016-5085(95)90441-7; Holm C, 1996, ENDOSCOPY, V28, P703, DOI 10.1055/s-2007-1005581; Jones MP, 2004, J CLIN GASTROENTEROL, V38, P35, DOI 10.1097/00004836-200401000-00009; Kulling Daniel, 2004, Gastrointest Endosc Clin N Am, V14, P353, DOI 10.1016/j.giec.2004.01.002; LAINE L, 1994, GASTROINTEST ENDOSC, V40, P411, DOI 10.1016/S0016-5107(94)70202-0; LaLuna L, 2001, GASTROINTEST ENDOSC, V53, P289, DOI 10.1067/mge.2001.112192; LAUVEN PM, 1990, SCAND J GASTROENTERO, V25, P1, DOI 10.3109/00365529009093164; LIEBERMAN DA, 1985, GASTROENTEROLOGY, V88, P468, DOI 10.1016/0016-5085(85)90508-6; MAGUIRE GP, 1974, BRIT MED J, V1, P268, DOI 10.1136/bmj.1.5902.268; Martins NB, 2006, CURR OPIN GASTROEN, V22, P612; Montes RG, 2000, J PEDIATR GASTR NUTR, V31, P41, DOI 10.1097/00005176-200007000-00010; QUINE MA, 1995, BRIT J SURG, V82, P530, DOI 10.1002/bjs.1800820430; Rex DK, 2006, ALIMENT PHARM THER, V24, P163, DOI 10.1111/j.1365-2036.2006.02986.x; SMITH MR, 1993, BRIT J CLIN PHARMACO, V36, P573, DOI 10.1111/j.1365-2125.1993.tb00417.x; Vargo JJ, 2006, ALIMENT PHARM THER, V24, P955, DOI 10.1111/j.1365-2036.2006.03099.x; Vargo JJ, 2002, GASTROENTEROLOGY, V123, P8, DOI 10.1053/gast.2002.34232; Vicari Joseph J, 2002, Gastrointest Endosc Clin N Am, V12, P297, DOI 10.1016/S1052-5157(01)00011-3; Waring JP, 2003, GASTROINTEST ENDOSC, V58, P317, DOI 10.1067/S0016-5107(03)00001-4; WHITWAM JG, 1998, [No title captured]; Zuccaro G Jr, 2000, Gastrointest Endosc Clin N Am, V10, P1	28	9	10	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0038-4348	1541-8243		SOUTH MED J	South.Med.J.	APR	2008	101	4					362	366		10.1097/SMJ.0b013e318168521b			5	Medicine, General & Internal	General & Internal Medicine	285WK	WOS:000254806700015	18360335				2020-06-30	J	Moore, C; Marinetti, L; Coulter, C; Crompton, K				Moore, C.; Marinetti, L.; Coulter, C.; Crompton, K.			Analysis of pain management drugs, specifically fentanyl, in hair: Application to forensic specimens	FORENSIC SCIENCE INTERNATIONAL			English	Article; Proceedings Paper	International Meeting of the Society-of-Hair-Testing	MAY 14-15, 2007	Cardiff, WALES	Soc Hair Testing		hair; pain management drugs; two-dimensional gas chromatography	MASS-SPECTROMETRY; CHROMATOGRAPHY; HYDROCODONE; MS	This article discusses the immunoassay screening of pain management drugs, and the mass spectrometric confirmation of fentanyl in human hair. Hair specimens were screened for fentanyl, opiates (including oxycodone), tramadol, propoxyphene, carisoprodol, methadone, and benzodiazepines and any positive results were confirmed using gas chromatography or liquid chromatography with mass spectral detection. The specific focus of the work was the determination of fentanyl in hair, since autopsy specimens were also available for comparison with hair concentrations. Using two-dimensional gas chromatography with electron impact mass spectrometric detection, fentanyl was confirmed in four of nine hair specimens collected at autopsy. The accuracy of the assay at 10 pg/mg was 95.17% and the inter-day and intra-day precision was 5.04 and 13.24%, respectively (n = 5). The assay was linear over the range 5-200 pg/mg with a correlation of r(2) > 0.99. The equation of the calibration curve forced through the origin was y = 0.0053x and the limit of quantitation of the assay was 5 pg/mg. The fentanyl concentrations detected were 12, 17, 490, and 1930 pg/mg and the results were compared with toxicology from routine post-mortem analysis. The screening of pain management drugs in hair is useful in cases where other matrices may not be available, and in routine testing of hair for abused drugs. (C) 2007 Elsevier Ireland Ltd. All rights reserved.	[Moore, C.; Coulter, C.; Crompton, K.] Immunanalysis Corp, Pomona, CA 91767 USA; [Marinetti, L.] Montgomery Cty Med Examiners Off, Dayton, OH 45402 USA	Moore, C (reprint author), Immunanalysis Corp, 829 Towne Ctr Dr, Pomona, CA 91767 USA.	cmoore@immunalysis.com					Hadidi KA, 2003, FORENSIC SCI INT, V135, P129, DOI 10.1016/S0379-0738(03)00196-8; Jones J, 2002, J ANAL TOXICOL, V26, P171, DOI 10.1093/jat/26.3.171; Kelly T, 2005, J CHROMATOGR B, V814, P315, DOI 10.1016/j.jchromb.2004.10.053; Kintz P, 2005, FORENSIC SCI INT, V153, P81, DOI 10.1016/j.forsciint.2005.04.033; Miller EI, 2006, J ANAL TOXICOL, V30, P441, DOI 10.1093/jat/30.7.441; Moore C, 2006, J ANAL TOXICOL, V30, P171, DOI 10.1093/jat/30.3.171; Moore C, 2006, J ANAL TOXICOL, V30, P353, DOI 10.1093/jat/30.6.353; Sachs H, 1996, INT J LEGAL MED, V109, P213, DOI 10.1007/BF01225521; Stout PR, 1998, DRUG METAB DISPOS, V26, P689; WANG WL, 1993, FORENSIC SCI INT, V61, P65, DOI 10.1016/0379-0738(93)90250-E	10	29	30	1	4	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0379-0738			FORENSIC SCI INT	Forensic Sci.Int.	MAR 21	2008	176	1					47	50		10.1016/j.forsciint.2007.06.027			4	Medicine, Legal	Legal Medicine	285PV	WOS:000254789600010	18006260				2020-06-30	J	Puri, GD; Jayant, A; Dorje, M; Tashi, M				Puri, G. D.; Jayant, A.; Dorje, M.; Tashi, M.			Propofol-fentanyl anaesthesia at high altitude: anaesthetic requirements and haemodynamic variations when compared with anaesthesia at low altitude	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						high altitude; general anaesthesia; propofol; haemodynamic response	EXERCISE HEART-RATE; CARDIAC-OUTPUT; PHARMACODYNAMICS; HYPOXIA	Background: There are few published accounts of anaesthesia delivery at high altitude. Natives at high altitude are known to have altered cardiorespiratory reserve. This study seeks to demonstrate the safety of propofol-fentanyl anaesthesia at high altitude titrated to the bispectral index (BIS) (3505 metres above sea level) in native highlanders. It also shows the differential effects of anaesthesia and surgery on the haemodynamics of such individuals as compared with individuals living at low altitude. Methods: Fifteen consenting adults scheduled to undergo general surgical/orthopaedic procedures under general anaesthesia using fentanyl, and propofol infusions titrated to the BIS along with nitrous oxide in oxygen after intubation, were recruited in the high-altitude arm. Their anaesthesia record was compared with retrospective data from low altitude with respect to anaesthetic requirements, recovery after anaesthesia and the haemodynamic responses to surgical stress. Results: The high-altitude dwellers required significantly larger doses of propofol at anaesthetic induction (2.31 +/- 0.64 vs. 1.41 +/- 0.24 mg/kg, P < 0.0001) and thereafter to maintain designated BIS than their low-altitude counterparts (6.22 +/- 1.14 vs. 4.61 +/- 1.29 mg/kg/h, P < 0.01). They, however, had uneventful and short recovery times. The high-altitude population also had significantly lower baseline heart rates (72 +/- 9.83 vs. 88 +/- 12.1, P < 0.04) as also the heart rate responses to noxious stimulation such as direct laryngoscopy or skin incision (P < 0.04, P < 0.005, respectively). Conclusions: High-altitude dwellers require significantly larger amounts of intravenous anaesthetic propofol. Heart rate at rest as also the heart rate responses to surgical stress were significantly attenuated at high altitude.	[Puri, G. D.; Jayant, A.] Postgrad Inst Med Educ & Res, Dept Anesthesia & Intens Care, Chandigarh 160012, India; [Puri, G. D.; Jayant, A.] SNM Hosp, Leh, Ladakh, India	Puri, GD (reprint author), Postgrad Inst Med Educ & Res, Dept Anesthesia & Intens Care, Chandigarh 160012, India.	gdpuri007@hotmail.com	; Jayant, Aveek/B-6042-2014	Jayant, Arvind/0000-0002-6715-3023; Jayant, Aveek/0000-0002-3465-1229			ASTRAND PO, 1958, J APPL PHYSIOL, V13, P75; BANCHERO N, 1966, CIRCULATION, V33, P249, DOI 10.1161/01.CIR.33.2.249; Beall CM, 1998, AM J PHYS ANTHROPOL, V106, P385, DOI 10.1002/(SICI)1096-8644(199807)106:3<385::AID-AJPA10>3.0.CO;2-X; Bishop R A, 2000, High Alt Med Biol, V1, P111, DOI 10.1089/15270290050074251; Boushel R, 2001, CIRCULATION, V104, P1785, DOI 10.1161/hc4001.097040; Doloman L. B., 2002, Fiziolohichnyi Zhurnal (Kiev), V48, P33; HARTLEY LH, 1974, J APPL PHYSIOL, V36, P362; Hoymork SC, 2005, BRIT J ANAESTH, V95, P627, DOI 10.1093/bja/aei245; HUGHES MA, 1992, ANESTHESIOLOGY, V76, P334, DOI 10.1097/00000542-199203000-00003; JAMES MFM, 1984, ANESTH ANALG, V63, P1097; MACDOUGALL J D, 1976, Journal of Human Ergology, V5, P103; MANIER G, 1988, J APPL PHYSIOL, V65, P2107; MOON RE, 2005, MILLERS ANESTHESIA, P2665; Norcliffe LJ, 2005, J PHYSIOL-LONDON, V566, P287, DOI 10.1113/jphysiol.2005.086629; PEDERSON L, 1993, ANAESTHESIA, V48, P67; SAFAR P, 1964, ANESTHESIOLOGY, V25, P515, DOI 10.1097/00000542-196407000-00014; Schnider TW, 1999, ANESTHESIOLOGY, V90, P1502, DOI 10.1097/00000542-199906000-00003; Schoene RB, 2005, CLIN CHEST MED, V26, P405, DOI 10.1016/j.ccm.2005.06.015; SHAFER SL, 1993, J CLIN ANESTH, V5, pS14; Wagner PD, 2000, RESP PHYSIOL, V120, P1, DOI 10.1016/S0034-5687(99)00101-2; Wilson ES, 2004, ANAESTHESIA, V59, P122, DOI 10.1111/j.1365-2044.2004.03460.x; ZHUANG JG, 1993, J APPL PHYSIOL, V75, P1968	22	7	8	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	MAR	2008	52	3					427	431		10.1111/j.1399-6576.2007.01561.x			5	Anesthesiology	Anesthesiology	259TK	WOS:000252963600016	18269393				2020-06-30	J	Yamamoto, Y; Kawaguchi, M; Hayashi, H; Horiuchi, T; Inoue, S; Nakase, H; Sakaki, T; Furuya, H				Yamamoto, Yuri; Kawaguchi, Masahiko; Hayashi, Hironobu; Horiuchi, Toshinori; Inoue, Satoki; Nakase, Hiroyuki; Sakaki, Toshisuke; Furuya, Hitoshi			The effects of the neuromuscular blockade levels on amplitudes of posttetanic motor-evoked potentials and movement in response to transcranial stimulation in patients receiving propofol and fentanyl anesthesia	ANESTHESIA AND ANALGESIA			English	Article							ELECTRICAL-STIMULATION	BACKGROUND: Patient movement in response to transcranial stimulation during, monitoring of myogenic motor-evoked potentials (MEPs) may interfere with surgery. We recently reported a new technique to augment the amplitudes of myogenic MEPs, called "post-tetanic MEPs (p-MEPs)," in which tetanic stimulation of a peripheral nerve was applied prior to transcranial stimulation. We conducted the present study to determine an appropriate level of neuromuscular blockade during the monitoring of p-MEPs with a focus on patient movement. METHODS: In 15 patients under propofol/fentanyl anesthesia, conventional MEPs (c-MEPs) and p-MEPs in response to transcranial electrical stimulation were recorded from the abductor hallucis muscle. For p-MEP recording, tetanic stimulation to the posterior tibial nerve at an intensity of 50 mA for 5 s was started 6 s prior to transcranial stimulation. The level of neuromuscular blockade was assessed by recording the amplitude of compound muscle action potentials (T1) from the abductor hallucis brevis muscle in response to supramaximal electrical stimulation of the median nerve at the wrist. After the baseline recordings of c-MEP and p-MEP at a T1 of 50% of control, 0.1 mg/kg of vecuronium was injected and the amplitudes of c-MEPs and p-MEPs were recorded. Patient movement was also assessed with the movement score ranging from 1 to 4 (1 = no movement, 4 severe movement). RESULTS: T1, %T1, the amplitudes of c-MEPs and p-MEPs, and the movement score changed in parallel after the administration of vecuronium. The amplitudes of p-MEPs before and 15-45 min after the administration of vecuronium were significantly higher than those of c-MEPs. When T1 and %T1 were less than and equal to 1 mV and 10%, respectively, the movement score was 1 or 2 in all patients, indicating that microscopic surgery was possible without the interruption of surgical procedures. When T1 was around 1 mV (0.8-1.2 mV), the success rates of recording of c-MEPs and p-MEPs were 73% (11 of 15) and 100% (15 of 15), respectively. CONCLUSIONS: Under propofol/fentanyl anesthesia, p-MEP could be recorded at a T1 of 1 mV, in which patient movement in response to transcranial stimulation did not interfere with surgery. This technique may be used in patients without preoperative motor deficits, in which patient movement during surgical procedures is not preferable.	[Yamamoto, Yuri; Kawaguchi, Masahiko; Hayashi, Hironobu; Horiuchi, Toshinori; Inoue, Satoki; Furuya, Hitoshi] Nara Med Univ, Dept Anesthesiol, Nara 6348522, Japan; [Inoue, Satoki; Nakase, Hiroyuki; Sakaki, Toshisuke] Nara Med Univ, Dept Neurosurg, Nara 6348522, Japan	Kawaguchi, M (reprint author), Nara Med Univ, Dept Anesthesiol, 840 Shijo Cho, Nara 6348522, Japan.	drjkawa@naramed-u.ac.jp		Hayashi, Hironobu/0000-0002-4352-0423			Kakimoto M, 2005, ANESTHESIOLOGY, V102, P733, DOI 10.1097/00000542-200504000-00007; KALKMAN CJ, 1992, ANESTH ANALG, V75, P584; Kawaguchi Masahiko, 2004, J Anesth, V18, P18, DOI 10.1007/s00540-003-0201-9; Lotto ML, 2004, J NEUROSURG ANESTH, V16, P32, DOI 10.1097/00008506-200401000-00008; Reinacher PC, 2006, ANESTH ANALG, V102, P888, DOI 10.1213/01.ane.0000195235.02162.5d; Sekimoto K, 2006, J NEUROSURG ANESTH, V18, P106, DOI 10.1097/00008506-200604000-00003; Sloan TB, 2002, J CLIN NEUROPHYSIOL, V19, P430, DOI 10.1097/00004691-200210000-00006; van Dongen EP, 1999, ANESTH ANALG, V88, P22, DOI 10.1097/00000539-199901000-00005	8	18	24	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	MAR	2008	106	3					930	934		10.1213/ane.0b013e3181617508			5	Anesthesiology	Anesthesiology	265XA	WOS:000253393900037	18292442				2020-06-30	J	Hofmann-Kiefer, K; Eiser, T; Chappell, D; Leuschner, S; Conzen, P; Schwender, D				Hofmann-Kiefer, Klaus; Eiser, Tim; Chappell, Daniel; Leuschner, Stephan; Conzen, Peter; Schwender, Dirk			Does patient-controlled continuous interscalene block improve early functional rehabilitation after open shoulder surgery?	ANESTHESIA AND ANALGESIA			English	Article							BRACHIAL-PLEXUS BLOCK; ROTATOR CUFF TEARS; DOUBLE-BLIND; ANALGESIA; ANESTHESIA; PAIN; DIAGNOSIS; REPAIR; TRIAL	BACKGROUND: Early mobilization after shoulder surgery plays a vital role in successful functional rehabilitation. However, postoperative pain often reduces, or even prevents, effective physiotherapy. We investigated the effect of analgesia via patient-controlled interscalene technique on early functional rehabilitation after open shoulder surgery. METHODS: Eighty-seven patients were randomly assigned to one of two groups: patient-controlled continuous interscalene block (PCISB) and patient-controlled IV (opioid) analgesia (PCA). Interscalene block was performed preoperatively; otherwise analgesic protocols were started in the postanesthesia care unit and were continued for 72 h. Physiotherapy was performed for 60 min a day on day 2 and 3 after surgery according to a standardized protocol. Maximum mobility was defined as the range of motion that could be achieved with pain as the limiting factor. Efficiency of functional rehabilitation was evaluated I day before and 3 days after surgery with the help of a multimodal scoring system (Constant-Score) that evaluates pain, daily life activity, strength and range of motion. Maximum intensity of pain was also monitored via Visual Analog Scales for the first 72 h after surgery and during in-hospital physiotherapy. RESULTS: Constant-Score rates were significantly improved by the interscalene block. However, no significant differences in mobility and strength sub-scores were observed between the groups. Compared with PCA, PCISB proved to be beneficial concerning pain at rest at 6 h (P < 0.001), 24 h (P = 0.044), and 72 h (P = 0.013) and for pain during physiotherapy at 48 h after surgery (P = 0.016). CONCLUSION: Compared with opioid-based PCA, PCISB improved analgesia, but not function, during early rehabilitation of the shoulder joint.	[Hofmann-Kiefer, Klaus; Eiser, Tim; Chappell, Daniel; Conzen, Peter] Univ Munich, Anasthesiol Klin, Klinikum Innenstadt, Clin Anesthesiol Crit Care Med & Pain Therapy, D-80337 Munich, Germany; [Schwender, Dirk] Municipal Hosp Freidrichshafen, Dept Anesthesia, Freidrichshafen, Germany; [Leuschner, Stephan] Municipal Hosp Luebeck, Dept Anesthesia, Lubeck, Germany	Hofmann-Kiefer, K (reprint author), Univ Munich, Anasthesiol Klin, Klinikum Innenstadt, Clin Anesthesiol Crit Care Med & Pain Therapy, Maistr 11, D-80337 Munich, Germany.	klaus.hofmann-kiefer@med.uni-muenchen.de					BATEMAN JE, 1963, SURG CLIN N AM, V43, P1523; Borgeat A, 1997, ANESTHESIOLOGY, V87, P1343, DOI 10.1097/00000542-199712000-00013; Borgeat A, 1998, BRIT J ANAESTH, V81, P603, DOI 10.1093/bja/81.4.603; Brull R, 2007, ANESTH ANALG, V104, P965, DOI 10.1213/01.ane.0000258740.17193.ec; Capdevila X, 1999, ANESTHESIOLOGY, V91, P8, DOI 10.1097/00000542-199907000-00006; Capdevila X, 2006, ANESTHESIOLOGY, V105, P566, DOI 10.1097/00000542-200609000-00022; Conboy VB, 1996, J BONE JOINT SURG BR, V78B, P229; CONSTANT CR, 1991, ORTHOPADE, V20, P289; CONSTANT CR, 1987, CLIN ORTHOP RELAT R, P160; Constant CR, 1997, J BONE JOINT SURG BR, V79B, P695; ELLMAN H, 1990, CLIN ORTHOP RELAT R, P64; *EUR SOC SURG SHOU, 2007, INT COMM; Fokter SK, 2003, CLIN ORTHOP RELAT R, P121, DOI 10.1097/01.000093903.12372.3f; Gartsman GM, 1998, J BONE JOINT SURG AM, V80A, P832, DOI 10.2106/00004623-199806000-00007; Habermeyer P, 2000, ORTHOPADE, V29, P196; Hsu SL, 2007, J FORMOS MED ASSOC, V106, P452, DOI 10.1016/S0929-6646(09)60294-1; Ilfeld BM, 2002, ANESTHESIOLOGY, V96, P1297, DOI 10.1097/00000542-200206000-00006; Ilfeld BM, 2006, ANESTHESIOLOGY, V105, P999, DOI 10.1097/00000542-200611000-00022; Julien RE, 2005, INT ANESTHESIOL CLIN, V43, P167, DOI 10.1097/01.aia.0000166334.61627.c6; Kean J, 2006, J BONE JOINT SURG BR, V88B, P1173, DOI 10.1302/0301-620X.88B9.17412; MATTA BF, 1992, CAN J ANAESTH, V39, P1067, DOI 10.1007/BF03008377; Meier G, 1997, ANAESTHESIST, V46, P715, DOI 10.1007/s001010050458; Meier G, 2001, ANAESTHESIST, V50, P333, DOI 10.1007/s001010170018; Simon MAM, 1997, REGION ANESTH, V22, P29, DOI 10.1016/S1098-7339(06)80053-2; Vyas A, 1996, ANESTHESIOLOGY, V85, P675, DOI 10.1097/00000542-199609000-00027; WINNIE AP, 1970, ANESTH ANAL CURR RES, V49, P455	26	28	28	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	MAR	2008	106	3					991	996		10.1213/ane.0b013e31816151ab			6	Anesthesiology	Anesthesiology	265XA	WOS:000253393900047	18292451				2020-06-30	J	Van Elstraete, AC; Sitbon, P; Mazoit, JX; Benhamou, D				Van Elstraete, Alain C.; Sitbon, Philippe; Mazoit, Jean-Xavier; Benhamou, Dan			Gabapentin prevents delayed and long-lasting hyperalgesia induced by fentanyl in rats	ANESTHESIOLOGY			English	Article							POSTOPERATIVE PAIN; MORPHINE-TOLERANCE; INTRATHECAL GABAPENTIN; CALCIUM-CHANNEL; KETAMINE; SENSITIVITY; MECHANISMS; MODEL; NEUROTRANSMISSION; CATHETERIZATION	Background: Opioid-induced hyperalgesia can develop rapidly after opioid exposure. Neuropathic pain and opioid-induced hyperalgesia share common pathophysiologic mechanisms. Gabapentin is effective for the management of neuropathic pain and may therefore prevent opioid-induced hyperalgesia. This study tested the effectiveness of gabapentin for prevention of long-lasting hyperalgesia induced by acute systemic fentanyl in uninjured rats. Involvement of the alpha(2)delta auxiliary subunits of voltage-gated calcium channels in the prevention of opioid-induced hyperalgesia by gabapentin also was assessed. Methods: Hyperalgesia was induced in mate Sprague-Dawley rats with subcutaneous fentanyl (four injections, 20, 60, or 100 mu g/kg per injection at 15-min intervals). Intraperitoneal (30, 75, 150, or 300 mg/kg) or intrathecal (300 mu g) gabapentin was administered 30 min before or 300 min after (intraperitoneal 150 mg/kg) the first fentanyl injection. Sensitivity to nociceptive stimuli (paw-pressure test) was assessed on the day of the experiment and for several days after injections. The effects combining gabapentin with intrathecal ruthenium red (20 ng) also were assessed. Results: Fentanyl administration was followed by an early increase (analgesia) and by a later and sustained decrease (hyperalgesia) in nociceptive thresholds. Gabapentin did not significantly modify the early analgesic component but dose-dependently prevented the delayed decrease in nociceptive threshold. Ruthenium red partially, but significantly, opposed the prevention of opioid-induced hyperalgesia by gabapentin. Conclusions: Intraperitoneal and intrathecal gabapentin pre vents the development of hyperalgesia induced by acute systemic exposure to opioids. This prevention may result, at least in part, from binding of gabapentin to the a,S auxiliary subunits of voltage-gated calcium channels.	[Van Elstraete, Alain C.; Sitbon, Philippe; Mazoit, Jean-Xavier; Benhamou, Dan] Univ Paris 11, AP HP, Hop Bicetre, Dept Anesthesie Reanim,Serv Anesthesie Reanim, F-94275 Le Kremlin Bicetre, France	Sitbon, P (reprint author), Univ Paris 11, AP HP, Hop Bicetre, Dept Anesthesie Reanim,Serv Anesthesie Reanim, F-94275 Le Kremlin Bicetre, France.	philippe.sitbon@bct.aphp.fr		Sitbon, Philippe/0000-0003-0520-9180			Bryans JS, 1999, MED RES REV, V19, P149, DOI 10.1002/(SICI)1098-1128(199903)19:2<149::AID-MED3>3.0.CO;2-B; Cao YQ, 2006, PAIN, V126, P5, DOI 10.1016/j.pain.2006.10.019; Celerier E, 2000, ANESTHESIOLOGY, V92, P465, DOI 10.1097/00000542-200002000-00029; Cheng JK, 2006, J PHARMACOL SCI, V100, P471, DOI 10.1254/jphs.CR0050020; Cheng JK, 2003, ANESTHESIOLOGY, V98, P1472, DOI 10.1097/00000542-200306000-00026; Chia YT, 1999, CAN J ANAESTH, V46, P872, DOI 10.1007/BF03012978; Dirks J, 2002, ANESTHESIOLOGY, V97, P1591, DOI 10.1097/00000542-200212000-00035; Dirks J, 2002, ANESTHESIOLOGY, V97, P102, DOI 10.1097/00000542-200207000-00015; Dobos I, 2003, ANESTH ANALG, V96, P487, DOI 10.1097/00000539-200302000-00035; Feng Y, 2003, ANESTHESIOLOGY, V98, P729, DOI 10.1097/00000542-200303000-00023; Fletcher D, 1997, PAIN, V69, P303, DOI 10.1016/S0304-3959(96)03227-7; Gardell LR, 2006, NEUROSCI LETT, V396, P44, DOI 10.1016/j.neulet.2005.11.009; Gardell LR, 2002, J NEUROSCI, V22, P6747; Gee NS, 1996, J BIOL CHEM, V271, P5768, DOI 10.1074/jbc.271.10.5768; Gilron I, 2003, ANESTHESIOLOGY, V98, P1288, DOI 10.1097/00000542-200305000-00037; Gilron I, 2002, ANESTHESIOLOGY, V97, P537, DOI 10.1097/00000542-200209000-00004; Gilron I, 2006, CAN J ANAESTH, V53, P562, DOI 10.1007/BF03021846; Guignard B, 2000, ANESTHESIOLOGY, V93, P409, DOI 10.1097/00000542-200008000-00019; Hansen C, 2004, ANESTH ANALG, V99, P1180, DOI 10.1213/01.ANE.0000130383.87438.A9; Ho KY, 2006, PAIN, V126, P91, DOI 10.1016/j.pain.2006.06.018; Joshi I, 2006, EUR J PHARMACOL, V553, P82, DOI 10.1016/j.ejphar.2006.09.019; KAYSER V, 1987, PAIN, V28, P99, DOI 10.1016/0304-3959(87)91064-5; Kest B, 1997, J PHARMACOL EXP THER, V283, P1249; Kroin JS, 2002, REGION ANESTH PAIN M, V27, P451, DOI 10.1053/rapm.2002.35521; Laulin JP, 2002, ANESTH ANALG, V94, P1263, DOI 10.1097/00000539-200205000-00040; Laulin JP, 1998, EUR J NEUROSCI, V10, P782, DOI 10.1046/j.1460-9568.1998.00083.x; LONG JB, 1988, J PHARMACOL EXP THER, V246, P1158; Ma W, 2003, ANESTHESIOLOGY, V98, P203, DOI 10.1097/00000542-200301000-00031; MAO J, 1994, J NEUROSCI, V14, P2301; Mao JR, 2002, PAIN, V100, P213, DOI 10.1016/S0304-3959(02)00422-0; MAO JR, 1995, PAIN, V62, P259, DOI 10.1016/0304-3959(95)00073-2; Mao JR, 2000, ANESTH ANALG, V91, P680, DOI 10.1213/00000539-200009000-00034; Ossipov MH, 2004, J NEUROBIOL, V61, P126, DOI 10.1002/neu.20091; RANDALL LO, 1957, ARCH INT PHARMACOD T, V111, P409; Richebe P, 2005, ANESTHESIOLOGY, V102, P421, DOI 10.1097/00000542-200502000-00028; Rivat C, 2002, ANESTHESIOLOGY, V96, P381, DOI 10.1097/00000542-200202000-00025; SERPELL MG, 1993, LIFE SCI, V53, P1887, DOI 10.1016/0024-3205(93)90028-2; Shimoyama M, 2000, PAIN, V85, P405, DOI 10.1016/S0304-3959(99)00283-3; Van Elstracte AC, 2006, CAN J ANAESTH, V53, P1180, DOI 10.1007/BF03021578; Van Elstraete AC, 2005, ANESTH ANALG, V101, P1750, DOI 10.1213/01.ANE.0000184136.08194.9B; Verleye M, 2004, BRAIN RES, V1013, P249, DOI 10.1016/j.brainres.2004.04.035; Vinik HR, 1998, ANESTH ANALG, V86, P1307, DOI 10.1097/00000539-199806000-00033; YAKSH TL, 1976, PHYSIOL BEHAV, V17, P1031, DOI 10.1016/0031-9384(76)90029-9; Yoshikawa M, 2000, BRAIN RES, V859, P217, DOI 10.1016/S0006-8993(00)01961-2; ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4	45	35	37	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	MAR	2008	108	3					484	494		10.1097/ALN.0b013e318164cf85			11	Anesthesiology	Anesthesiology	265XS	WOS:000253395800020	18292686	Bronze			2020-06-30	J	Chawla, G; Drummond, GB				Chawla, G.; Drummond, G. B.			Fentanyl decreases end-expiratory lung volume in patients anaesthetized with sevoflurane	BRITISH JOURNAL OF ANAESTHESIA			English	Article						anaesthetics volatile, sevoflurane; analgesics opioid, fentanyl; lung, volume; ventilation, analgesics, effects; ventilation, muscle, respiratory	ABDOMINAL-MUSCLES; RIB CAGE; ANESTHESIA; INDUCTION; PRESSURE; THIOPENTONE; PROPOFOL; SURGERY; RABBITS	Background. In patients breathing spontaneously during anaesthesia, expiratory muscle activity can be a prominent feature. This activity is triggered or exaggerated by opioid administration, which causes a prompt increase in intra-abdominal pressure. The effect of this increased expiratory activity on end-expiratory lung volume is not described. Methods. Nine patients having minor gynaecological procedures were studied during stable anaesthetic conditions, breathing sevoflurane (end tidal 2.6%) through a laryngeal mask airway, in a circle system. The spill valve was closed and the fresh gas flow was temporarily reduced to approximate the oxygen uptake. The volume of the reservoir bag was then measured by placing it in a hinged, wedge-shaped container. Fentanyl (0.5 mu g kg(-1) ideal body weight) was given after 1 min of stable recording, and the change in end-expiratory volume measured after 3 min. Results. End-expiratory lung volume decreased in all patients by 160 (111) ml (mean, SD) (P < 0.01). The decrease did not relate to obesity. Conclusions. During sevoflurane anaesthesia, fentanyl causes a rapid reduction in functional residual capacity. This is caused by increased activity of expiratory muscles and an increase in intra-abdominal pressure.	[Chawla, G.; Drummond, G. B.] Univ Dept Anaesthesia, Edinburgh EH16 4SA, Midlothian, Scotland	Drummond, GB (reprint author), Univ Dept Anaesthesia, 51 Little France Crescent, Edinburgh EH16 4SA, Midlothian, Scotland.	g.b.drummond@ed.ac.uk					ALEXANDER JI, 1973, BRIT J ANAESTH, V45, P34, DOI 10.1093/bja/45.1.34; BERGMAN NA, 1982, ANESTHESIOLOGY, V57, P14, DOI 10.1097/00000542-198207000-00004; D'Angelo E, 2003, RESP PHYSIOL NEUROBI, V135, P17, DOI 10.1016/S1569-9048(03)00017-X; DAngelo E, 1996, RESP PHYSIOL, V104, P147, DOI 10.1016/0034-5687(96)00005-9; DETROYER A, 1983, J APPL PHYSIOL, V54, P465; DIEM K, 1970, DOCUMENTA GEIGY SCI, V7, P711; DiMarco AF, 1999, J APPL PHYSIOL, V86, P1881; DOUGLAS FG, 1972, J APPL PHYSIOL, V33, P559; Drummond GB, 2003, BRIT J ANAESTH, V91, P73, DOI 10.1093/bja/aeg145; Drummond GB, 2002, BRIT J ANAESTH, V88, P384, DOI 10.1093/bja/88.3.384; DUECK R, 1988, ANESTHESIOLOGY, V69, P854, DOI 10.1097/00000542-198812000-00009; DUGGAN JE, 1989, ANESTH ANALG, V69, P598; FREUND F, 1964, J APPL PHYSIOL, V19, P693; FREUND FG, 1973, ANESTHESIOLOGY, V38, P358; GILROY RL, 1986, J APPL PHYSIOL, V58, P1997; Iscoe S, 1998, PROG NEUROBIOL, V56, P433, DOI 10.1016/S0301-0082(98)00046-X; KALLOS T, 1973, ANESTHESIOLOGY, V39, P558, DOI 10.1097/00000542-197311000-00025; Prasad CV, 2004, ANAESTHESIA, V59, P715, DOI 10.1111/j.1365-2044.2004.03683.x; RUTHERFORD JS, 1994, BRIT J ANAESTH, V73, P579, DOI 10.1093/bja/73.5.579; Spens HJ, 1996, BRIT J ANAESTH, V76, P369; WERCHOWSKI JL, 1990, J APPL PHYSIOL, V68, P1732	21	19	19	0	1	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0007-0912			BRIT J ANAESTH	Br. J. Anaesth.	MAR	2008	100	3					411	414		10.1093/bja/aem376			4	Anesthesiology	Anesthesiology	263WK	WOS:000253247000019	18216033	Bronze			2020-06-30	J	Bruyere, M; Benhamou, D				Bruyere, Marie; Benhamou, Dan			Optimizing bupivacaine dosing for Cesarean delivery - II	CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Letter							FENTANYL; ANALGESIA; EFFICACY; SECTION		[Bruyere, Marie; Benhamou, Dan] Hop Antoine Beclere, Clamart, France	Bruyere, M (reprint author), Hop Antoine Beclere, Clamart, France.	dan.benhamou@bct.aphp.fr					BELZARENA SD, 1992, ANESTH ANALG, V74, P653; Bryson GL, 2007, CAN J ANAESTH, V54, P531, DOI 10.1007/BF03022316; Dahl JB, 1999, ANESTHESIOLOGY, V91, P1919, DOI 10.1097/00000542-199912000-00045; HUNT CO, 1989, ANESTHESIOLOGY, V71, P535, DOI 10.1097/00000542-198910000-00009; Wong CA, 2004, INT J OBSTET ANESTH, V13, P19, DOI 10.1016/S0959-289X(03)00106-7	5	0	0	0	0	CANADIAN ANESTHESIOLOGISTS SOC	TORONTO	1 EGLINTON AVE EAST, SUITE 208, TORONTO, ONTARIO M4P 3A1, CANADA	0832-610X			CAN J ANAESTH	Can. J. Anaesth.-J. Can. Anesth.	MAR	2008	55	3					187	187		10.1007/BF03016095			1	Anesthesiology	Anesthesiology	275ZG	WOS:000254110300010	18310631	Bronze			2020-06-30	J	Christrup, LL; Foster, D; Popper, LD; Troen, T; Upton, R				Christrup, Lona L.; Foster, David; Popper, Lars D.; Troen, Tine; Upton, Richard			Pharmacokinetics, efficacy, and tolerability of fentanyl following intranasal versus intravenous administration in adults undergoing third-molar extraction: A randomized, double-blind, double-dummy, two-way, crossover study	CLINICAL THERAPEUTICS			English	Article						intranasal fentanyl; pharmacokinetics; efficacy; tolerability	POSTOPERATIVE PAIN MANAGEMENT; BREAKTHROUGH PAIN; ORAL MORPHINE; ANALGESIA; CITRATE; TITRATION; BURNS	Objective: The aim of this study was to compare the pharmacokinetic profile, as well as the efficacy and tolerability, of IN and IV administration of fentanyl in acute, episodic pain in patients undergoing third-molar extraction. Methods: In this randomized, double-blind, doubledummy, 2-way, crossover study, patients were randomized to receive 1 of 4 doses (75, 100, 150, or 200 mu g) by both the IN and IV routes in random order, after each of 2 separate molar extractions (interval, >= 1 week). Venous blood samples were obtained for quantification of plasma fentanyl concentrations before and at 1, 3, 5, 7, 9, 12, 15, 25, 40, 60, 90, 120, and 180 minutes after administration. Pain scores (on an 11-point numeric rating scale) were recorded before and at 15, 30, 45, 60, 75, 90, 105, 120, 150, 180, 210, and 240 minutes. Patients indicated the times at which they perceived meaningful pain relief (onset of action) and at which analgesia ended (duration of effect), after which they were able to use rescue medication (time to rescue medication use). Results: A total of 24 patients were enrolled (in all, 47 extractions) (46% male; mean age, 24.1 years; 94% white, 6% Asian). Mean T-max values were 12.8 and 6.0 minutes (P < 0.001), times to onset of analgesia were 7 and 2 minutes (P < 0.001), and durations of effect were 56 and 59 minutes after IN and IV administration (P = NS), respectively. Differences in the onsets and durations of analgesia after IN and IV administration of single doses were not significantly different, and neither was the difference in overall analgesia, with pain scores returning to near-predose values at statistically similar times after dosing. Duration of effect was directly related to IN fentanyl dose, with significantly less use of rescue medication after IN than after IV administration (P < 0.005). The IN and IV formulations were both well tolerated, with similar numbers of nasally related adverse events recorded for both routes of administration. Conclusions: Onsets and durations of analgesia were not significantly different between single doses of IN and IV fentanyl in these adults undergoing third-molar extraction. Both IN and IV administration were generally well tolerated.	[Christrup, Lona L.] Univ Copenhagen, Dept Pharmacol & Pharmacotherapy, Fac Pharmaceut Sci, Copenhagen, Denmark; [Foster, David] Univ S Australia, Sansom Inst, Sch Pharm & Med Sci, Adelaide, SA 5001, Australia; [Popper, Lars D.] Nycomed Pharma, Dept Med Sci Strategy & Med Mkt, Roskilde, Denmark; [Troen, Tine] Nycomed Pharma, Dept Biostat, Roskilde, Denmark; [Upton, Richard] Univ Adelaide, Discipline Anaesthesia & Intens Care, Royal Adelaide Hosp, Adelaide, SA, Australia	Christrup, LL (reprint author), Univ Copenhagen, Dept Pharmacol & Pharmacotherapy, Fac Pharmaceut Sci, Copenhagen, Denmark.	llc@farma.ku.dk	Upton, Richard N/G-4727-2011; Foster, David J R/D-1172-2011	Upton, Richard N/0000-0001-9996-4886; Foster, David/0000-0002-7345-4084; Christrup, Lona/0000-0002-4128-7373			Barden J, 2004, BRIT DENT J, V197, P407, DOI 10.1038/sj.bdj.4811721; Borland Meredith L, 2002, Emerg Med (Fremantle), V14, P275, DOI 10.1046/j.1442-2026.2002.00344.x; Borland ML, 2005, BURNS, V31, P831, DOI 10.1016/j.burns.2005.05.001; COOPER SA, 1976, CLIN PHARMACOL THER, V20, P241; Dale O, 2002, ACTA ANAESTH SCAND, V46, P759, DOI 10.1034/j.1399-6576.2002.460702.x; Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9; Finn J, 2004, BURNS, V30, P262, DOI 10.1016/j.burns.2003.10.017; Galinkin JL, 2000, ANESTHESIOLOGY, V93, P1378, DOI 10.1097/00000542-200012000-00006; Hersh EV, 2000, CLIN THER, V22, P1306, DOI 10.1016/S0149-2918(00)83027-1; KIERSCH TA, 1994, CLIN THER, V16, P394; Lim Stephen C. B., 2003, Journal of Pharmacy Practice and Research, V33, P59; Manjushree R, 2002, CAN J ANAESTH, V49, P190; MEIER J, 1974, EUR J CLIN PHARMACOL, V7, P429, DOI 10.1007/BF00560355; Paech MJ, 2003, ANAESTHESIA, V58, P740, DOI 10.1046/j.1365-2044.2003.03286.x; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; Streisand JB, 1998, ANESTHESIOLOGY, V88, P305, DOI 10.1097/00000542-199802000-00006; STREISAND JB, 1991, ANESTHESIOLOGY, V75, P223, DOI 10.1097/00000542-199108000-00009; Striebel H W, 1993, Schmerz, V7, P122, DOI 10.1007/BF02527870; STRIEBEL HW, 1993, ANAESTHESIA, V48, P753, DOI 10.1111/j.1365-2044.1993.tb07583.x; Striebel HW, 1996, ANESTH ANALG, V83, P548, DOI 10.1097/00000539-199609000-00019; STRIEBEL HW, 1992, ANESTHESIOLOGY, V77, P281, DOI 10.1097/00000542-199208000-00010; Striebel HW, 1996, J CLIN ANESTH, V8, P4, DOI 10.1016/0952-8180(95)00167-0; TABURET AM, 1986, THERAPIE, V41, P1; Toussaint S, 2000, CAN J ANAESTH, V47, P299, DOI 10.1007/BF03020941; Wong P, 2003, ANAESTHESIA, V58, P818, DOI 10.1046/j.1365-2044.2003.03295_24.x; *WORLD MED ASS DEC, 1964, ETH PRINC MED RES IN; YAMAOKA K, 1978, J PHARMACOKINET BIOP, V6, P547, DOI 10.1007/BF01062109; Zeppetella G, 2000, PALLIATIVE MED, V14, P57, DOI 10.1191/026921600668793500; Zeppetella G, 2000, J PAIN SYMPTOM MANAG, V20, P253, DOI 10.1016/S0885-3924(00)00180-9	29	79	80	0	7	ELSEVIER	BRIDGEWATER	685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA	0149-2918	1879-114X		CLIN THER	Clin. Ther.	MAR	2008	30	3					469	481		10.1016/j.clinthera.2008.03.001			13	Pharmacology & Pharmacy	Pharmacology & Pharmacy	288BY	WOS:000254962400004	18405786				2020-06-30	J	Ozkardesler, S; Gurpinar, T; Akan, M; Koca, U; Sankaya, H; Olmez, T; Elar, Z				Ozkardesler, Sevda; Gurpinar, Tugba; Akan, Mert; Koca, Ugur; Sankaya, Huriye; Olmez, Tulay; Elar, Zahide			A possible perianesthetic Serotonin syndrome related to intrathecal fentanyl	JOURNAL OF CLINICAL ANESTHESIA			English	Editorial Material						ergot alkaloids; intrathecal fentanyl; marijuana; methylenedioxy-N-methy-lamphetamine (MDMA); selective serotonin; reuptake inhibitors; Serotonin syndrome	5-HT1A RECEPTORS; MIGRAINE	Serotonin syndrome occurs with selective serotonin reuptake inhibitors, opioids, and other serotonergic agents. We describe a possible serotonin syndrome related to intrathecal fentanyl in a patient taking multiple drugs and substances such as ergot alkaloids, marijuana, methylenedioxy-N-methylamphetamine, and ephedrine. (c) 2008 Elsevier Inc. All rights reserved.	[Ozkardesler, Sevda; Akan, Mert; Koca, Ugur; Sankaya, Huriye; Olmez, Tulay; Elar, Zahide] Dokuz Eylul Univ, Dept Anesthesiol & Reanim, Sch Med, TR-35340 Izmir, Turkey; [Gurpinar, Tugba] Celal Bayar Univ, Dept Pharmacol, Sch Med, Manisa, Turkey	Akan, M (reprint author), Dokuz Eylul Univ, Dept Anesthesiol & Reanim, Sch Med, TR-35340 Izmir, Turkey.	mert.akan@deu.edu.tr	Akan, Mert/A-1157-2018; koca, ugur/F-1265-2016; Akan, Mert/O-8856-2019	Akan, Mert/0000-0003-0195-7149; koca, ugur/0000-0002-2949-4265; Akan, Mert/0000-0003-0195-7149			Bijl D, 2004, NETH J MED, V62, P309; Birmes P, 2003, CAN MED ASSOC J, V168, P1439; Brown TM, 1996, ANN PHARMACOTHER, V30, P527, DOI 10.1177/106002809603000517; Clarke RW, 2000, PAIN, V85, P239, DOI 10.1016/S0304-3959(99)00272-9; Ener RA, 2003, PAIN MED, V4, P63, DOI 10.1046/j.1526-4637.2003.03005.x; Giese SY, 2001, PLAST RECONSTR SURG, V107, P293, DOI 10.1097/00006534-200101000-00069; Hernandez M, 2005, CURR OPIN ANESTHESIO, V18, P315, DOI 10.1097/01.aco.0000169241.21680.0b; Jones D, 2005, ANAESTH INTENS CARE, V33, P181, DOI 10.1177/0310057X0503300205; Kaufman Kenneth R, 2006, Ann Clin Psychiatry, V18, P201, DOI 10.1080/10401230600801259; MAGUIRE P, 1992, EUR J PHARMACOL, V213, P219, DOI 10.1016/0014-2999(92)90685-W; MARTIN DC, 1991, NEUROPHARMACOLOGY, V30, P323, DOI 10.1016/0028-3908(91)90056-H; Mathew NT, 1996, CEPHALALGIA, V16, P323, DOI 10.1046/j.1468-2982.1996.1605323.x; MCKENZIE AJ, 1992, ANAESTH INTENS CARE, V20, P165, DOI 10.1177/0310057X9202000208; SILBERSTEIN SD, 1995, NEUROLOGY, V45, P577, DOI 10.1212/WNL.45.3.577; Symons IE, 2002, ANAESTHESIA, V57, P1142, DOI 10.1046/j.1365-2044.2002.288312.x; Tao R, 2003, BRIT J PHARMACOL, V139, P1498, DOI 10.1038/sj.bjp.0705378; Turkel SB, 2001, PSYCHOSOMATICS, V42, P258, DOI 10.1176/appi.psy.42.3.258	17	7	8	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180			J CLIN ANESTH	J. Clin. Anesth.	MAR	2008	20	2					143	145		10.1016/j.jclinane.2007.06.024			3	Anesthesiology	Anesthesiology	292FN	WOS:000255252000014	18410872				2020-06-30	J	Zollner, C; Mousa, SA; Fischer, O; Rittner, HL; Shaqura, M; Brack, A; Shakibaei, M; Binder, W; Urban, F; Stein, C; Schafer, M				Zoellner, Christian; Mousa, Shaaban A.; Fischer, Oliver; Rittner, Heike L.; Shaqura, Mohammed; Brack, Alexander; Shakibaei, Mehdi; Binder, Waltraud; Urban, Florian; Stein, Christoph; Schaefer, Michael			Chronic morphine use does not induce peripheral tolerance in a rat model of inflammatory pain	JOURNAL OF CLINICAL INVESTIGATION			English	Article							MU-OPIOID RECEPTOR; PRIMARY AFFERENT NEURONS; CHRONIC NONCANCER PAIN; ELECTRON-MICROSCOPY; CANCER PAIN; DESENSITIZATION; ENDOCYTOSIS; INTERNALIZATION; ANALGESIA; PHOSPHORYLATION	Although opioids are highly effective analgesics, they are also known to induce cellular adaptations resulting in tolerance. Experimental studies are often performed in the absence of painful tissue injury, which precludes extrapolation to the clinical situation. Here we show that rats with chronic morphine treatment do not develop signs of tolerance at peripheral R-opioid receptors (mu-receptors) in the presence of painful CFA-induced paw inflammation. In sensory neurons of these animals, internalization of mu-receptors was significantly increased and G protein coupling of mu-receptors as well as inhibition of cAMP accumulation were preserved. Opioid receptor trafficking and signaling were reduced, and tolerance was restored when endogenous opioid peptides in inflamed tissue were removed by antibodies or by depleting opioid-producing granulocytes, monocytes, and lymphocytes with cyclophosphamide (CTX). Our data indicate that the continuous availability of endogenous opioids in inflamed tissue increases recycling and preserves signaling of R-receptors in sensory neurons, thereby counteracting the development of peripheral opioid tolerance. These findings infer that the use of peripherally acting opioids for the prolonged treatment of inflammatory pain associated with diseases such as chronic arthritis, inflammatory neuropathy, or cancer, is not necessarily accompanied by opioid tolerance.	[Zoellner, Christian; Mousa, Shaaban A.; Fischer, Oliver; Rittner, Heike L.; Shaqura, Mohammed; Brack, Alexander; Binder, Waltraud; Urban, Florian; Stein, Christoph; Schaefer, Michael] Charite Univ Med Berlin, Klin Anaesthesiol & Operat Intens Med, D-12200 Berlin, Germany; [Shakibaei, Mehdi] Univ Munich, Inst Anat, Munich, Germany	Zollner, C (reprint author), Charite Univ Med Berlin, Klin Anaesthesiol & Operat Intens Med, Campus Benjamin Franklin,Hindenburgdamm 30, D-12200 Berlin, Germany.	christian.zoellner@charite.de	RIttner, Heike/AAC-6523-2019; Schafer, Michael/AAB-1395-2020; Shakibaei, Mehdi/AAA-7004-2020	RIttner, Heike/0000-0003-4867-0188; Stein, Christoph/0000-0001-5240-6836			ABE K, 1981, J ELECTRON MICROSC, V30, P141; Adriaensen H, 2003, Acta Anaesthesiol Belg, V54, P37; Aley KO, 1995, J NEUROSCI, V15, P8031; ANTONIJEVIC I, 1995, J NEUROSCI, V15, P165; Bailey CP, 2003, J NEUROSCI, V23, P10515; Bohn LM, 2000, NATURE, V408, P720, DOI 10.1038/35047086; Bolyard LA, 2000, PAIN, V88, P277, DOI 10.1016/S0304-3959(00)00341-9; Carroll IR, 2004, REGION ANESTH PAIN M, V29, P576, DOI 10.1016/j.rapm.2004.06.009; DRAME MT, 2006, CIRC RES, V99, P570; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Fernandez-Duenas V, 2007, J PHARMACOL EXP THER, V322, P360, DOI 10.1124/jpet.106.118901; Finn AK, 2001, NEURON, V32, P829, DOI 10.1016/S0896-6273(01)00517-7; Furlan AD, 2006, CAN MED ASSOC J, V174, P1589, DOI 10.1503/cmaj.051528; Gendron L, 2006, J NEUROSCI, V26, P953, DOI 10.1523/JNEUROSCI.3598-05.2006; Gutstein HB, 1996, PHARMACOL REV, V48, P403; Hashimoto T, 2006, ANESTHESIOLOGY, V105, P574, DOI 10.1097/00000542-200609000-00023; He L, 2005, CURR BIOL, V15, P1028, DOI 10.1016/j.cub.2005.04.052; He L, 2002, CELL, V108, P271, DOI 10.1016/S0092-8674(02)00613-X; Kalso E, 2004, PAIN, V112, P372, DOI 10.1016/j.pain.2004.09.019; KAYSER V, 1991, BRAIN RES, V560, P237, DOI 10.1016/0006-8993(91)91238-V; Keith DE, 1998, MOL PHARMACOL, V53, P377; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; Kim KS, 2006, P NATL ACAD SCI USA, V103, P3908, DOI 10.1073/pnas.0508812103; Kissin I, 2005, ANESTH ANALG, V101, P1727, DOI 10.1213/01.ANE.0000184531.28307.DC; Koch T, 2005, MOL PHARMACOL, V67, P280, DOI 10.1124/mol.104.004994; Kolesnikov Y, 1999, J PHARMACOL EXP THER, V290, P247; Machelska H, 2003, J NEUROIMMUNOL, V141, P30, DOI 10.1016/S0165-5728(03)00213-3; Mousa SA, 2001, J NEUROIMMUNOL, V115, P71, DOI 10.1016/S0165-5728(01)00271-5; Mousa SA, 2004, ENDOCRINOLOGY, V145, P1331, DOI 10.1210/en.2003-1287; Muranski P, 2006, NAT CLIN PRACT ONCOL, V3, P668, DOI 10.1038/ncponc0666; Nestler EJ, 1997, SCIENCE, V278, P58, DOI 10.1126/science.278.5335.58; POOLE JCF, 1969, BRIT J DERMATOL, VS 81, P11, DOI 10.1111/j.1365-2133.1969.tb12849.x; Portenoy RK, 2004, LANCET, V364, P739, DOI 10.1016/S0140-6736(04)16951-1; PORTENOY RK, 1986, CANCER TREAT REP, V70, P575; Qiu Y, 2003, J BIOL CHEM, V278, P36733, DOI 10.1074/jbc.M305857200; Rittner HL, 2006, FASEB J, V20, P2627, DOI 10.1096/fj.06-6077fje; Schulz S, 2004, EMBO J, V23, P3282, DOI 10.1038/sj.emboj.7600334; Shaqura MA, 2004, J PHARMACOL EXP THER, V308, P712, DOI 10.1124/jpet.103.057257; Sim-Selley LJ, 2000, J NEUROSCI, V20, P4555, DOI 10.1523/JNEUROSCI.20-12-04555.2000; Song BB, 2003, J NEUROSCI, V23, P1847; Stein C, 2003, NAT MED, V9, P1003, DOI 10.1038/nm908; Sternini C, 1996, P NATL ACAD SCI USA, V93, P9241, DOI 10.1073/pnas.93.17.9241; Tegeder I, 2003, BRAIN, V126, P1092, DOI 10.1093/brain/awg115; VACCARINO AL, 1993, BRAIN RES, V627, P287, DOI 10.1016/0006-8993(93)90332-H; Whistler JL, 1999, NEURON, V23, P737, DOI 10.1016/S0896-6273(01)80032-5; Williams DF, 2001, IEEE MICROW WIREL CO, V11, P299, DOI 10.1109/7260.933777; Yu YK, 1997, J BIOL CHEM, V272, P28869, DOI 10.1074/jbc.272.46.28869; Zaki PA, 2000, J PHARMACOL EXP THER, V292, P1127; ZECH DFJ, 1995, PAIN, V63, P65, DOI 10.1016/0304-3959(95)00017-M; Zollner C, 2003, MOL PHARMACOL, V64, P202, DOI 10.1124/mol.64.2.202	50	87	91	1	8	AMER SOC CLINICAL INVESTIGATION INC	ANN ARBOR	35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA	0021-9738			J CLIN INVEST	J. Clin. Invest.	MAR	2008	118	3					1065	1073		10.1172/JCI25911			9	Medicine, Research & Experimental	Research & Experimental Medicine	269JX	WOS:000253646400031	18246198	Green Published, Bronze			2020-06-30	J	Denton, JS; Donoghue, ER; McReynolds, J; Kalelkar, MB				Denton, J. Scott; Donoghue, Edmund R.; McReynolds, Jennifer; Kalelkar, Mitra B.			An epidemic of illicit fentanyl deaths in Cook County, Illinois: September 2005 through April 2007	JOURNAL OF FORENSIC SCIENCES			English	Article						forensic science; fentanyl intoxication; drug abuse; Cook County; IL	TRANSDERMAL FENTANYL; MISUSE; ABUSE	Between September 2005 and April 2007, 350 fentanyl intoxication deaths were investigated and certified by the Cook County Medical Examiners Office. Investigations revealed that the majority of these fatalities were by intravenous injection of a white powder followed by a rapid collapse. The fentanyl was clandestinely produced in a lab in Toluca, Mexico and sold by the Mickey Cobra street gang. The term "Drop Dead" was coined for this "tainted heroin." Postmortem samples were screened by ELISA and confirmed by standard GC-MS methods. Fentanyl fatalities peaked at 47 per month in May and June 2006. Fifty-two percent were single fentanyl intoxications, with the remainder accompanied by either cocaine, morphine from heroin, or alcohol. This epidemic stressed the limited resources of the toxicology laboratory and autopsy service of the Medical Examiners Office. The clandestine lab was terminated, distributing gang members and leaders arrested, and the epidemic ceased in April 2007.	[Denton, J. Scott] McLean & Peoria Cty Coroners Off, Bloomington, IL 61702 USA; [Denton, J. Scott] Rush Univ, Med Ctr, Dept Pathol, Chicago, IL 60612 USA; [Donoghue, Edmund R.] Georgia Bur Invest, Savannah, GA 31419 USA; [McReynolds, Jennifer; Kalelkar, Mitra B.] Cook Cty Med Examiners Off, Chicago, IL 60612 USA; [Kalelkar, Mitra B.] Univ Illinois, Dept Pathol, Chicago, IL 60612 USA	Denton, JS (reprint author), 2211 Ridge Creek, Bloomington, IL 61704 USA.	sdenton@gmail.com					Anderson DT, 2000, J ANAL TOXICOL, V24, P627, DOI 10.1093/jat/24.7.627; Baselt R.C., 2002, DISPOSITION TOXIC DR, P430; ESCOBEDO LG, 1991, ARCH PATHOL LAB MED, V115, P900; Hamilton RJ, 2000, J TOXICOL-CLIN TOXIC, V38, P597, DOI 10.1081/CLT-100102008; HEMDERSON GL, 1991, J FORENSIC SCI, V36, P422; HIBBS J, 1991, JAMA-J AM MED ASSOC, V265, P1011, DOI 10.1001/jama.265.8.1011; Kornick CA, 2003, DRUG SAFETY, V26, P951, DOI 10.2165/00002018-200326130-00004; Kramer Christopher, 1998, Journal of the American Osteopathic Association, V98, P385; Kronstrand R, 1997, FORENSIC SCI INT, V88, P185, DOI 10.1016/S0379-0738(97)00068-6; Kuhlman JJ, 2003, J ANAL TOXICOL, V27, P499, DOI 10.1093/jat/27.7.499; Lilleng PK, 2004, J FORENSIC SCI, V49, P1364; MARTIN M, 1991, ANN EMERG MED, V20, P158, DOI 10.1016/S0196-0644(05)81216-8; SMIALEK JE, 1994, J FORENSIC SCI, V39, P159; Tharp AM, 2004, AM J FOREN MED PATH, V25, P178, DOI 10.1097/01.paf.0000127398.67081.11	14	37	38	1	16	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0022-1198			J FORENSIC SCI	J. Forensic Sci.	MAR	2008	53	2					452	454		10.1111/j.1556-4029.2008.00669.x			3	Medicine, Legal	Legal Medicine	278SF	WOS:000254305900030	18366578				2020-06-30	J	Wong, SC; Curtis, JA; Wingert, WE				Wong, Stella C.; Curtis, John A.; Wingert, William E.			Concurrent detection of heroin, fentanyl, and xylazine in seven drug-related deaths reported from the Philadelphia Medical Examiner's Office	JOURNAL OF FORENSIC SCIENCES			English	Article; Proceedings Paper	Annual Meeting of the North-American-Congress-of-Clinical-Toxicology	OCT 19-24, 2007	New Orleans, LA	N Amer Congress Clin Toxicol		forensic science; xylazine; fentanyl; heroin adulterants	SEVERE INTOXICATION	Recreational drugs, such as cocaine and heroin, are often adulterated with other pharmacological agents to either enhance or diminish the drug effects. Between April 21, 2006 and August 8, 2006, the Philadelphia Medical Examiner's Office detected xylazine (a veterinary sedative) and fentanyl (a synthetic opioid) in specimens taken from seven cases. Initial immunoassay screening was performed on urine and blood for fentanyl, opiate, cocaine, phencyclidine (PCP), and benzodiazepines. All tests reported positive were confirmed by gas chromatography-mass spectrometry. All seven xylazine positive cases tested positive for fentanyl and six cases tested positive for 6-acetylmorphine (a metabolite and definitive marker for heroin). The seventh case was positive for morphine and had a history of heroin abuse. Xylazine was present in urine in all seven cases and blood levels were detected in three cases. The blood concentrations ranged from trace to 130 ng/mL. Fentanyl was present in the blood and urine in each case and blood concentrations ranged from 4.7 to 47 ng/mL. Adulteration of illicit drugs has become an epidemic health concern for drug users. Healthcare professionals need to be aware of this issue, so the patients can be treated in an effective, timely manner.	[Wong, Stella C.; Curtis, John A.] Nazareth Hosp, Dept Emergency Med, Philadelphia, PA USA; [Wingert, William E.] Philadelphia Med Examiner Off, Philadelphia, PA USA	Wong, SC (reprint author), Nazareth Hosp, Dept Emergency Med, 2601 Holme Ave, Philadelphia, PA USA.	scw101@gmail.com					Capraro AJ, 2001, PEDIATR EMERG CARE, V17, P447, DOI 10.1097/00006565-200112000-00012; Elejalde JI, 2003, EUR J EMERG MED, V10, P252, DOI 10.1097/00063110-200309000-00022; GALLANOSA AG, 1981, CLIN TOXICOL, V18, P663, DOI 10.3109/15563658108990293; Hamilton RJ, 2000, J TOXICOL-CLIN TOXIC, V38, P597, DOI 10.1081/CLT-100102008; Hoffmann U, 2001, J ANAL TOXICOL, V25, P245, DOI 10.1093/jat/25.4.245; KITZMAN JV, 1982, AM J VET RES, V43, P2165; MASON T, 2006, PHILADELPHIA INQUI B; Moore KA, 2003, J ANAL TOXICOL, V27, P110, DOI 10.1093/jat/27.2.110; *ORASURE TECHN INC, 2004, MIC PLAT EIA APPL ME; SHANNON M, 1988, ANN EMERG MED, V17, P1243, DOI 10.1016/S0196-0644(88)80078-7; SHESSER R, 1991, AM J EMERG MED, V9, P336, DOI 10.1016/0735-6757(91)90053-M; Stillwell ME, 2003, FORENSIC SCI INT, V134, P25, DOI 10.1016/S0379-0738(03)00083-5; *SUP, 1977, B SUP, V909; Tharp AM, 2004, AM J FOREN MED PATH, V25, P178, DOI 10.1097/01.paf.0000127398.67081.11; *UN CHEM TECHN INC, 2005, [No title captured]; *US DEP JUST, SR000001 US DEP JUST; US Drug Enforcement Administration, HER	17	27	29	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-1198	1556-4029		J FORENSIC SCI	J. Forensic Sci.	MAR	2008	53	2					495	498		10.1111/j.1556-4029.2007.00648.x			4	Medicine, Legal	Legal Medicine	278SF	WOS:000254305900040	18284526				2020-06-30	J	Okon, TR; George, ML				Okon, Tomasz R.; George, Mathews Lal			Fentanyl-induced neurotoxicity and paradoxic pain	JOURNAL OF PAIN AND SYMPTOM MANAGEMENT			English	Article						cancer; fentanyl; neurotoxicity; opioid-induced hyperalgesia	OPIOID-INDUCED HYPERALGESIA; NEUROPATHIC PAIN; INTRATHECAL MORPHINE; ANALGESIA; RECEPTOR; MORPHINE-3-GLUCURONIDE; TOLERANCE; CANCER; RATS; REMIFENTANIL	A patient with pain associated with metastatic leiomyosarcoma received escalating doses of opioids. Upon discontinuation of intravenous morphine, transdermal fentanyl was initiated, and after several days, the dose was increased to 200 mu g/hour for persistent, severe pain. The patient became somnolent, and further dose adjustments and route change were carried out. She then exhibited severe allodynia, myoclonus, and delirium thereafter fentanyl was stopped. All symptoms resolved with discontinuation of fentanyl and subsequent introduction of a weak opioid. Pain was well controlled. Gradually increasing standard doses of fentanyl may lead to severe neurotoxicity, which may respond to opioid discontinuation and/or rotation. Vigilant scrutiny of all possible causes of apparent analgesic failure followed by consideration of opioid reduction and rotation is warranted in cases of neurotoxicity accompanying opioid treatment.	[Okon, Tomasz R.] Marshfield Clin Fdn Med Res & Educ, Dept Palliat Med, Marshfield, WI 54449 USA; [George, Mathews Lal] Med Coll Wisconsin, Dept Internal Med, Milwaukee, WI 53226 USA	Okon, TR (reprint author), Marshfield Clin Fdn Med Res & Educ, Dept Palliat Med, 1000 N Oak Ave, Marshfield, WI 54449 USA.	okon.tomasz@marshfieldclinic.org					Adair JC, 1996, ANN EMERG MED, V27, P791; ADAMS AP, 1978, BRIT MED J, V1, P278, DOI 10.1136/bmj.1.6108.278; Ammer H, 1997, J PHARMACOL EXP THER, V280, P512; Angst MS, 2006, ANESTHESIOLOGY, V104, P570, DOI 10.1097/00000542-200603000-00025; Angst MS, 2003, PAIN, V106, P49, DOI 10.1016/S0304-3959(03)00276-8; BARTLETT SE, 1994, PHARMACOL TOXICOL, V75, P73, DOI 10.1111/j.1600-0773.1994.tb00327.x; Bruera E, 1997, PAIN, V69, P199, DOI 10.1016/S0304-3959(96)03238-1; Celerier E, 2000, ANESTHESIOLOGY, V92, P465, DOI 10.1097/00000542-200002000-00029; Celerier E, 2001, J NEUROSCI, V21, P4074, DOI 10.1523/JNEUROSCI.21-11-04074.2001; Cherny N, 2001, J CLIN ONCOL, V19, P2542, DOI 10.1200/JCO.2001.19.9.2542; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; Crain SM, 2004, BRAIN RES, V995, P260, DOI 10.1016/j.brainres.2003.09.068; DECONNO F, 1991, PAIN, V47, P337, DOI 10.1016/0304-3959(91)90225-M; Devulder J, 1997, J NEUROSURG ANESTH, V9, P146, DOI 10.1097/00008506-199704000-00007; Diatchenko L, 2006, AM J MED GENET B, V141B, P449, DOI 10.1002/ajmg.b.30324; Gardell LR, 2002, J NEUROSCI, V22, P6747; Gilron I, 2005, NEW ENGL J MED, V352, P1324, DOI 10.1056/NEJMoa042580; Guignard B, 2000, ANESTHESIOLOGY, V93, P409, DOI 10.1097/00000542-200008000-00019; Hagen N, 1997, J PAIN SYMPTOM MANAG, V14, P51, DOI 10.1016/S0885-3924(97)00001-8; Koppert W, 2005, PAIN, V118, P15, DOI 10.1016/j.pain.2005.06.030; Kronenberg MF, 1998, PAIN, V75, P383, DOI 10.1016/S0304-3959(97)00173-5; Li XQ, 2001, MOL BRAIN RES, V86, P56, DOI 10.1016/S0169-328X(00)00260-6; Liang DY, 2006, ANESTHESIOLOGY, V104, P1054, DOI 10.1097/00000542-200605000-00023; Liu HT, 1997, NATURE, V386, P721, DOI 10.1038/386721a0; Lufty K, 1994, EUR J PHARMACOL, V252, P261; MAO JR, 1995, PAIN, V62, P259, DOI 10.1016/0304-3959(95)00073-2; McNeill JA, 2004, J PAIN SYMPTOM MANAG, V28, P47, DOI 10.1016/j.jpainsymman.2003.11.005; Mercadante Sebastiano, 2005, Am J Hosp Palliat Care, V22, P291, DOI 10.1177/104990910502200411; Moran TD, 2002, J PHARMACOL EXP THER, V302, P568, DOI 10.1124/jpet.102.035626; National Comprehensive Cancer Network (NCCN), NCCN CLIN PRACT GUID; Quigley C, 2003, PALLIATIVE MED, V17, P185, DOI 10.1191/0269216303pm658oa; Rowbotham MC, 2003, NEW ENGL J MED, V348, P1223, DOI 10.1056/NEJMoa021420; ROZAN JP, 1995, ANESTHESIOLOGY, V83, P860, DOI 10.1097/00000542-199510000-00027; SJOGREN P, 1994, PAIN, V59, P313, DOI 10.1016/0304-3959(94)90084-1; SMITH MT, 1990, LIFE SCI, V47, P579, DOI 10.1016/0024-3205(90)90619-3; Stillman M J, 2000, J Palliat Med, V3, P449, DOI 10.1089/jpm.2000.3.4.449; Vanderah TW, 1996, PAIN, V68, P275, DOI 10.1016/S0304-3959(96)03225-3; WILLENS JS, 1993, HEART LUNG, V22, P239; YAKSH TL, 1988, J PHARMACOL EXP THER, V244, P501	39	16	17	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0885-3924	1873-6513		J PAIN SYMPTOM MANAG	J. Pain Symptom Manage.	MAR	2008	35	3					327	333		10.1016/j.jpainsymman.2007.04.023			7	Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology	Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology	273GS	WOS:000253919000017	18222628	Bronze			2020-06-30	J	O'Connor, AB				O'Connor, Alec B.			Is actiq use in noncancer-related pain really "A Recipe for Success"?	PAIN MEDICINE			English	Letter							FENTANYL CITRATE OTFC(R); CANCER PAIN; MORPHINE; OPIOIDS; ADDICTION		Univ Rochester, Sch Med & Dent, Dept Med, Rochester, NY 14642 USA	O'Connor, AB (reprint author), Univ Rochester, Sch Med & Dent, Dept Med, Rochester, NY 14642 USA.			O'Connor, Alec/0000-0001-8181-5567			Bamezai A, 2006, MED CARE, V44, P835, DOI 10.1097/01.mlr.0000218854.55306.a8; Breivik H, 2001, ACTA ANAESTH SCAND, V45, P1059, DOI 10.1034/j.1399-6576.2001.450902.x; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Fleming T., 2006, RED BOOK PHARM FUNDA; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; Hojsted J, 2007, EUR J PAIN, V11, P490, DOI 10.1016/j.ejpain.2006.08.004; Katz NP, 2007, CLIN J PAIN, V23, P103, DOI 10.1097/01.ajp.0000210953.86255.8f; Lichtor JL, 1999, ANESTH ANALG, V89, P732, DOI 10.1097/00000539-199909000-00038; Marsch LA, 2001, J PHARMACOL EXP THER, V299, P1056; Martell BA, 2007, ANN INTERN MED, V146, P116, DOI 10.7326/0003-4819-146-2-200701160-00006; Passik SD, 2007, PAIN MED, V8, P130, DOI 10.1111/j.1526-4637.2006.00295.x; Porter ME, 2007, JAMA-J AM MED ASSOC, V297, P1103, DOI 10.1001/jama.297.10.1103; Steinman MA, 2006, ANN INTERN MED, V145, P284, DOI 10.7326/0003-4819-145-4-200608150-00008; Taylor DR, 2007, PAIN MED, V8, P281, DOI 10.1111/j.1526-4637.2007.00298.x; U.S. Department of Labor, 2016, CONS PRIC IND MED CA; Zacny J, 2003, DRUG ALCOHOL DEPEN, V69, P215, DOI 10.1016/S0376-8716(03)00003-6	16	4	4	0	2	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	1526-2375			PAIN MED	Pain Med.	MAR	2008	9	2					258	260		10.1111/j.1526-4637.2008.00413.x			3	Anesthesiology; Medicine, General & Internal	Anesthesiology; General & Internal Medicine	267BK	WOS:000253483100016	18298711	Bronze			2020-06-30	J	Pohl-Schickinger, A; Lemmer, J; Hubler, M; Alexi-Meskishvili, V; Redlin, M; Berger, F; Stiller, B				Pohl-Schickinger, Anja; Lemmer, Julia; Huebler, Michael; Alexi-Meskishvili, Vladimir; Redlin, Matthias; Berger, Felix; Stiller, Brigitte			Intravenous clonidine infusion in infants after cardiovascular surgery	PEDIATRIC ANESTHESIA			English	Article						cardiovascular surgery; clonidine; infants; withdrawal	PEDIATRIC INTENSIVE-CARE; CRITICALLY-ILL CHILDREN; PRETERM-INFANT; CAUDAL ANESTHESIA; ANALGESIA; SEDATION; APNEA; BUPIVACAINE; AGITATION; EFFICACY	Background: The aim of this study was to investigate the hemodynamic profile and heart rhythm in infants who were given intravenous clonidine infusion after prolonged analgesia/sedation following cardiac surgery. Methods: This is a single center retrospective review. A total of 542 cardiovascular surgical procedures in infants aged 0-24 months with congenital heart disease were performed between 01/2003 and 12/2005 at the Deutsches Herzzentrum in Berlin. The majority received no long-term analgesia/sedation, but 50 (9%) of these infants received clonidine (dosed at 0.18-3.6 mu g.kg(-1).h(-1)) for sedation and to reduce withdrawal symptoms such as CNS hyperactivation, hypertension, tachycardia, and fever. The hospital records of these infants were studied. Results: Fifty infants (median age 5.0 months, median body weight 5.3 kg, 32 males/18 females) received prolonged analgesia/sedation to ensure hemodynamic stability. Clonidine infusion started on day 5 (median) after surgery. During clonidine treatment we found an age-related normalized profile of hemodynamic parameters with a reduction of heart rate and mean arterial pressure from the upper norm to the mean within 24 h (p < 0.001). In no case did clonidine cause low blood pressure resulting in additional therapy to reach the target blood pressure. There were no adverse effects on cardiac rhythm, especially no onset of atrioventricular block. Midazolam, fentanyl, and other opioids could be ended on day 4 of clonidine treatment. Conclusions: Although off-label, it is feasible to use clonidine infusions in infants in the PICU setting after cardiac surgery without hemodynamic problems arising.	[Pohl-Schickinger, Anja] Univ Hosp Charite, Campus Virchow Klinikum, Dept Neonatol, D-13353 Berlin, Germany; [Lemmer, Julia] Deutsch Herzzentrum Berlin, Dept Congenital Heart Dis, Berlin, Germany; [Huebler, Michael; Alexi-Meskishvili, Vladimir] Deutsch Herzzentrum Berlin, Dept Cardiothorac & Vasc Surg, Berlin, Germany; [Redlin, Matthias] Deutsch Herzzentrum Berlin, Dept Anesthesia, Berlin, Germany; [Berger, Felix] Univ Childrens Hosp, Deutsches Herzzentrum Berlin & Charite, Dept Congenital Heart Dis, Berlin, Germany; [Stiller, Brigitte] Deutsch Herzzentrum Berlin, Dept Congenital Heart Dis, Freiburg, Germany; [Stiller, Brigitte] Childrens Univ Hosp, Freiburg, Germany	Pohl-Schickinger, A (reprint author), Univ Hosp Charite, Campus Virchow Klinikum, Dept Neonatol, Augustenburger Pl 1, D-13353 Berlin, Germany.	anja.pohl@charite.de	Rose, Rebecca J/B-7812-2011	Alexi-Meskishvili, Vladimir V./0000-0002-3945-1242; Berger, Felix/0000-0001-7881-1557			Ambrose C, 2000, BRIT J ANAESTH, V84, P794; ANDERSON RJ, 1981, ANN EMERG MED, V10, P107, DOI 10.1016/S0196-0644(81)80350-2; Arenas-Lopez S, 2004, INTENS CARE MED, V30, P1625, DOI 10.1007/s00134-004-2319-0; BAILEY PL, 1991, ANESTHESIOLOGY, V74, P43, DOI 10.1097/00000542-199101000-00008; Bergendahl H, 2006, ACTA ANAESTH SCAND, V50, P135, DOI 10.1111/j.1399-6576.2006.00940.x; Bouchut JC, 2001, REGION ANESTH PAIN M, V26, P83; Breschan C, 1999, PAEDIATR ANAESTH, V9, P81, DOI 10.1046/j.1460-9592.1999.t01-1-9120277.x; Dupeyrat A, 1998, PAEDIATR ANAESTH, V8, P145, DOI 10.1046/j.1460-9592.1998.00716.x; Fellmann C, 2002, PAEDIATR ANAESTH, V12, P637, DOI 10.1046/j.1460-9592.2002.00924.x; Galante D, 2005, PEDIATR ANESTH, V15, P708, DOI 10.1111/j.1460-9592.2005.01683.x; Hall JE, 2001, BRIT J ANAESTH, V86, P5, DOI 10.1093/bja/86.1.5; Ivani G, 1996, PAEDIATR ANAESTH, V6, P111, DOI 10.1111/j.1460-9592.1996.tb00371.x; JAMALI S, 1994, ANESTH ANALG, V78, P663; Jenkins IA, 2007, PEDIATR ANESTH, V17, P675, DOI 10.1111/j.1460-9592.2006.02180.x; LEE JJ, 1994, BRIT J ANAESTH, V72, P258, DOI 10.1093/bja/72.3.258; LITOVITZ TL, 1986, AM J EMERG MED, V4, P427, DOI 10.1016/0735-6757(86)90220-2; Malviya S, 2006, PEDIATR ANESTH, V16, P554, DOI 10.1111/j.1460-9592.2006.01818.x; Nichols MH, 1997, ANN EMERG MED, V29, P511, DOI 10.1016/S0196-0644(97)70225-7; NISHINA K, 1994, ANESTH ANALG, V79, P766; Nishina K, 1996, ACTA ANAESTH SCAND, V40, P746, DOI 10.1111/j.1399-6576.1996.tb04522.x; Nishina K, 1999, PAEDIATR ANAESTH, V9, P187; OLSSON JM, 1983, J PEDIATR-US, V103, P646, DOI 10.1016/S0022-3476(83)80607-6; Playfor S, 2006, INTENS CARE MED, V32, P1125, DOI 10.1007/s00134-006-0190-x; Tesoro S, 2005, ANESTH ANALG, V101, P1619, DOI 10.1213/01.ANE.0000184204.81877.53; Tobias JD, 2000, CRIT CARE MED, V28, P2122, DOI 10.1097/00003246-200006000-00079; Tobias JD, 2007, PEDIATR CRIT CARE ME, V8, P115, DOI 10.1097/01.PCC.0000257100.31779.41	26	19	19	0	0	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	1155-5645			PEDIATR ANESTH	Pediatr. Anesth.	MAR	2008	18	3					217	222		10.1111/j.1460-9592.2008.02413.x			6	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	264TL	WOS:000253313200004	18230064				2020-06-30	J	Viscusi, ER				Viscusi, Eugene R.			Patient-controlled drug delivery for acute postoperative pain management: A review of current and emerging technologies	REGIONAL ANESTHESIA AND PAIN MEDICINE			English	Review						patient-controlled analgesia; PCA; postoperative pain; epidural analgesia; regional analgesia; iontophoresis	CONTROLLED EPIDURAL ANALGESIA; IONTOPHORETIC TRANSDERMAL SYSTEM; CONTROLLED INTRANASAL ANALGESIA; CONTROLLED INTRAVENOUS ANALGESIA; CONTROLLED REGIONAL ANALGESIA; TOTAL HIP-ARTHROPLASTY; SCIATIC-NERVE BLOCK; INTRAMUSCULAR INJECTION; CONTINUOUS-INFUSION; ORTHOPEDIC-SURGERY	Postoperative pain management has dramatically improved with the advent of patient-controlled analgesia (PCA) delivery. The optimal PCA system would encompass several key characteristics, including consistent efficacy across a number of surgeries; safety of both the analgesic drug delivered and the delivery system; ease of setup, maintenance, and administration; patient comfort during analgesic delivery; avoidance of analgesic gaps; minimal invasiveness; and it would be associated with high patient satisfaction. Existing PCA modalities (using intravenous or epidural routes) encompass some of these characteristics (e.g., they have demonstrated efficacy across a number of surgeries); however, they are limited by the need for an indwelling catheter and the time and resources required for system setup and use. Device programming-related medication errors by hospital staff are an unfortunate risk, and could lead to significant harm. New PCA technologies are on the horizon that address some of the limitations to existing modalities; however, the added complexity of these newer systems are a concern, and their benefits and drawbacks remain to be assessed. These technologies include "smart" intravenous PCA infusion pumps to improve the safety of analgesic administration; needle-free options, such as the fentanyl HCl iontophoretic transdermal system for transdermal delivery; and a number of PCA devices for intranasal delivery, as well as several new options for patient-controlled regional analgesia. This review will discuss the benefits and drawbacks of both existing and emerging PCA modalities in the context of the ideal PCA system, and provide a critical evaluation of their use in postoperative settings.	Thomas Jefferson Univ, Jefferson Med Coll, Dept Anesthesiol, Philadelphia, PA 19107 USA	Viscusi, ER (reprint author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Anesthesiol, 111 S 11th St,Suite G 8940, Philadelphia, PA 19107 USA.	eugene.viscusi@jefferson.edu					Alexander-Williams JM, 1998, BRIT J ANAESTH, V81, P3; *AM PAIN SOC, 2003, [No title captured]; Apfelbaum JL, 2003, ANESTH ANALG, V97, P534, DOI 10.1213/01.ANE.0000068822.10113.9E; Ashburn MA, 2004, ANESTHESIOLOGY, V100, P1573; Axelsson K, 2003, ACTA ANAESTH SCAND, V47, P993, DOI 10.1034/j.1399-6576.2003.00146.x; BALLANTYNE JC, 1993, J CLIN ANESTH, V5, P182, DOI 10.1016/0952-8180(93)90013-5; Bartha E, 2006, BRIT J ANAESTH, V96, P111, DOI 10.1093/bja/aei270; Block BM, 2003, JAMA-J AM MED ASSOC, V290, P2455, DOI 10.1001/jama.290.18.2455; Breivik H, 1998, EUR J ANAESTH, V15, P748, DOI 10.1097/00003643-199811000-00022; Brown S L, 1997, J Intraven Nurs, V20, P311; Capdevila X, 2006, ANESTHESIOLOGY, V105, P566, DOI 10.1097/00000542-200609000-00022; Carr DB, 1999, LANCET, V353, P2051, DOI 10.1016/S0140-6736(99)03313-9; Carr DB, 2004, PAIN, V108, P17, DOI 10.1016/j.pain.2003.07.001; Carr DB, 1998, J CLIN ANESTH, V10, P77, DOI 10.1016/S0952-8180(97)00227-4; Cashman JN, 2004, BRIT J ANAESTH, V93, P212, DOI 10.1093/bja/aeh180; CHAN V, 2004, [No title captured], V10, pA77; Chang AM, 2004, J ADV NURS, V46, P531, DOI 10.1111/j.1365-2648.2004.03027.x; Chelly JE, 2004, ANESTH ANALG, V98, P427, DOI 10.1213/01.ANE.0000093314.13848.7E; Chen PP, 2001, ANAESTHESIA, V56, P1106; Cherny NI, 1996, DRUGS, V51, P713, DOI 10.2165/00003495-199651050-00002; Choiniere M, 1998, ANESTHESIOLOGY, V89, P1377, DOI 10.1097/00000542-199812000-00015; COLWELL CW, 1995, J BONE JOINT SURG AM, V77A, P726, DOI 10.2106/00004623-199505000-00009; Dale O, 2002, ACTA ANAESTH SCAND, V46, P759, DOI 10.1034/j.1399-6576.2002.460702.x; DELEONCASASOLA OA, 1994, ANESTHESIOLOGY, V81, P368, DOI 10.1097/00000542-199408000-00015; DeWeese FT, 2001, CLIN ORTHOP RELAT R, P226; di Benedetto P, 2002, REGION ANESTH PAIN M, V27, P168, DOI 10.1053/rapm.2002.29741; Dolin SJ, 2002, BRIT J ANAESTH, V89, P409, DOI 10.1093/bja/aef207; EGAN KJ, 1994, CAN J ANAESTH, V41, P6, DOI 10.1007/BF03009653; Eledjam JJ, 2002, REGION ANESTH PAIN M, V27, P604, DOI 10.1053/rapm.2002.36454; Etches RC, 1999, SURG CLIN N AM, V79, P297, DOI 10.1016/S0039-6109(05)70384-4; Fredman B, 2000, ANESTH ANALG, V91, P1436, DOI 10.1097/00000539-200012000-00025; Ganapathy S, 2000, CAN J ANAESTH, V47, P897, DOI 10.1007/BF03019672; GANAPATHY S, 2006, ANESTHESIOLOGY, V105, pA1191; Grass JA, 2005, ANESTH ANALG, V101, pS44, DOI 10.1213/01.ANE.0000177102.11682.20; Greengrass RA, 1998, CAN J ANAESTH, V45, P1094, DOI 10.1007/BF03012398; Grond S, 2007, BRIT J ANAESTH, V98, P806, DOI 10.1093/bja/aem102; Hallett A, 2000, ANAESTHESIA, V55, P532, DOI 10.1046/j.1365-2044.2000.01373.x; Hankin CS, 2007, AM J HEALTH-SYST PH, V64, P1492, DOI 10.2146/ajhp060220; Hartrick CT, 2006, REGION ANESTH PAIN M, V31, P546, DOI 10.1016/j.rapm.2006.08.011; HIGGINS MJ, 1991, ANAESTHESIA, V46, P973, DOI 10.1111/j.1365-2044.1991.tb09862.x; Horlocker Terese T., 2004, Regional Anesthesia and Pain Medicine, V29, P1, DOI 10.1016/j.rapm.2003.12.006; HORLOCKER TT, 2001, THROMB RES, V41, P154; Hudcova J, 2006, COCHRANE DB SYST REV, DOI 10.1002/146518583.CD003348.pub2; HUTCHISON R, 2008, IN PRESS HOSP PHARM; Ilfeld BM, 2003, ANESTH ANALG, V96, P1089, DOI 10.1213/01.ANE.0000049824.51036.EF; Keohane CA, 2005, J INFUS MURS, V28, P321, DOI 10.1097/00129804-200509000-00005; Lebovits AH, 2001, PAIN MED, V2, P280, DOI 10.1046/j.1526-4637.2001.01051.x; Lehmann KA, 2005, J PAIN SYMPTOM MANAG, V29, pS72, DOI 10.1016/j.jpainsymman.2005.01.005; Liu SS, 1998, ANESTHESIOLOGY, V88, P688, DOI 10.1097/00000542-199803000-00020; Miaskowski Christine, 2005, J Perianesth Nurs, V20, P255, DOI 10.1016/j.jopan.2005.05.005; Minkowitz HS, 2007, PAIN MED, V8, P657, DOI 10.1111/j.1526-4637.2006.00257.x; Momeni M, 2006, DRUGS, V66, P2321, DOI 10.2165/00003495-200666180-00005; Mystakidou Kyriaki, 2005, Am J Hosp Palliat Care, V22, P228, DOI 10.1177/104990910502200313; Nielsen KC, 2003, CAN J ANAESTH, V50, P57, DOI 10.1007/BF03020188; Paech MJ, 2003, ANAESTHESIA, V58, P740, DOI 10.1046/j.1365-2044.2003.03286.x; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; Rawal N, 2007, EUR J ANAESTH, V24, P299, DOI 10.1017/S026502150600189X; Rawal N, 2002, ANESTHESIOLOGY, V96, P1290, DOI 10.1097/00000542-200206000-00005; Ready LB, 1999, REGION ANESTH PAIN M, V24, P499, DOI 10.1016/S1098-7339(99)90038-X; Reeves MD, 2002, MED J AUSTRALIA, V177, P552, DOI 10.5694/j.1326-5377.2002.tb04951.x; Richman JM, 2006, ANESTH ANALG, V102, P248, DOI 10.1213/01.ANE.0000181289.09675.7D; Rothschild JM, 2005, CRIT CARE MED, V33, P533, DOI 10.1097/01.ccm.0000155912.73313.cd; Saito Miwako, 2005, J Anesth, V19, P208, DOI 10.1007/s00540-005-0316-2; Schafheutle EI, 2001, J ADV NURS, V33, P728, DOI 10.1046/j.1365-2648.2001.01714.x; Schuster M, 2004, ANESTH ANALG, V98, P708; Silvasti M, 2001, ACTA ANAESTH SCAND, V45, P471, DOI 10.1034/j.1399-6576.2001.045004471.x; SINATRA RS, 2002, J AM ACAD ORTHOP SUR, V10, P117; Singelyn FJ, 1999, ANESTH ANALG, V89, P1216, DOI 10.1213/00000539-199911000-00024; Singelyn FJ, 2001, ANESTH ANALG, V92, P455, DOI 10.1213/00000539-200102000-00033; Singelyn FJ, 2000, ANESTH ANALG, V91, P176; Singelyn FJ, 1999, J CLIN ANESTH, V11, P550, DOI 10.1016/S0952-8180(99)00092-6; SMYTHE M, 1994, AM J HOSP PHARM, V51, P1433, DOI 10.1093/ajhp/51.11.1433; Standl T, 2003, CAN J ANAESTH, V50, P258, DOI 10.1007/BF03017795; Striebel HW, 1996, ANESTH ANALG, V83, P548, DOI 10.1097/00000539-199609000-00019; Striebel HW, 1996, J CLIN ANESTH, V8, P4, DOI 10.1016/0952-8180(95)00167-0; STRIEBEL HW, 1999, ACUTE PAIN, V2, P36; Taylor S, 2003, AM J SURG, V186, P472, DOI 10.1016/j.amjsurg.2003.07.021; Tetzlaff JE, 2000, REGION ANESTH PAIN M, V25, P611, DOI 10.1053/rapm.2000.8573; Tharp AM, 2004, AM J FOREN MED PATH, V25, P178, DOI 10.1097/01.paf.0000127398.67081.11; Thipphawong JB, 2003, ANESTHESIOLOGY, V99, P693, DOI 10.1097/00000542-200309000-00026; THOMPSON S, 2007, [No title captured]; Toussaint S, 2000, CAN J ANAESTH, V47, P299, DOI 10.1007/BF03020941; van der Vyver M, 2002, BRIT J ANAESTH, V89, P459, DOI 10.1093/bja/aef217; Vicente KJ, 2003, CAN J ANAESTH, V50, P328, DOI 10.1007/BF03021027; Vintar N, 2005, ANESTH ANALG, V101, P573, DOI 10.1213/01.ANE.0000158608.27411.A9; Vintar N, 2002, CAN J ANAESTH, V49, P481, DOI 10.1007/BF03017925; Viscusi ER, 2006, ANESTH ANALG, V102, P188, DOI 10.1213/01.ane.0000183649.58483.77; Viscusi ER, 2004, JAMA-J AM MED ASSOC, V291, P1333, DOI 10.1001/jama.291.11.1333; Viscusi ER, 2007, ANESTH ANALG, V105, P1428, DOI 10.1213/01.ane.0000281913.28623.fd; Walder B, 2001, ACTA ANAESTH SCAND, V45, P795, DOI 10.1034/j.1399-6576.2001.045007795.x; Ward M, 2002, ANAESTHESIA, V57, P48; WASYLAK TJ, 1990, CAN J ANAESTH, V37, P726, DOI 10.1007/BF03006529; Webster LR, 2006, EXPERT OPIN INV DRUG, V15, P1469, DOI 10.1517/13543784.15.11.1469; WERMELING DP, 2002, [No title captured], V2, P56; WORSLEY MH, 1990, ANAESTHESIA, V45, P449, DOI 10.1111/j.1365-2044.1990.tb14331.x; Wu CL, 2005, ANESTHESIOLOGY, V103, P1079, DOI 10.1097/00000542-200511000-00023; YU PYH, 1993, CAN J ANAESTH, V40, P416, DOI 10.1007/BF03009509; Zafar S. U., 2004, JPMA Journal of the Pakistan Medical Association, V54, P353; Zohar E, 2001, ANESTH ANALG, V93, P482, DOI 10.1097/00000539-200108000-00048	99	50	57	0	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1098-7339	1532-8651		REGION ANESTH PAIN M	Region. Anesth. Pain Med.	MAR-APR	2008	33	2					146	158		10.1016/j.rapm.2007.11.005			13	Anesthesiology	Anesthesiology	271II	WOS:000253781700010	18299096				2020-06-30	J	Kokubun, H; Matoba, M; Okazaki, M; Hoka, S; Yago, K				Kokubun, Hideya; Matoba, Motohiro; Okazaki, Miyoko; Hoka, Sumio; Yago, Kazuo			Evaluation of the 2.5 mg fentanyl patch, applied using the half-side application procedure in patients with cancer pain	YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN			Japanese	Article						transdermal fentanyl; tegaderm; mini-dose titration; cancer pain	ABSORPTION; TITRATION	Occasionally, pain control with the fentanyl patch may lead to overdose at an initial dose of 2.5 mg, as well as during dose increase from 2.5 to 5.0 mg. Respiratory depression and other adverse drug reactions associated with fentanyl overdose have been observed in several of our patients. We developed a procedure for applying one-half of the fentanyl patch formulations and evaluated the new mode of application by examining the fentanyl concentration in 32 patients with cancer-related pain who had been using the fentanyl patch for pain control. While some patients were treated with the full-sized 2.5-, 5.0-, or 7.5-mg formulations, others were treated with the half-sized 2.5-mg formulation. The fentanyl patch was equally divided by drawing a line on the side on which the product name and dose were written. Tegaderm was applied to the patient's skin, and after detaching from the protective liner, half of the patch was applied to overlap Tegaderm along the line and the other half applied directly to the skin. Blood samples were collected 48-72 h after patch application. The mean serum concentration of fentanyl given in the half-sized 2.5-mg formulation was 0.286 ng/ml, which was approximately one-half of the concentration of the full-sized 2.5-mg formulation, 0.544 ng/ml. Therefore the 2.5-mg fentanyl patch, applied using the one-half procedure we developed, is clinically useful.	[Kokubun, Hideya; Okazaki, Miyoko; Yago, Kazuo] Kitasato Univ Hosp, Dept Pharm, Sagamihara, Kanagawa 2288555, Japan; [Matoba, Motohiro] Natl Canc Ctr, Ctr Canc Control & Informat Serv, Canc Informat Serv & Surveillance Div, Canc Informat Serv Sect,Chuo Ku, Tokyo 1040045, Japan; [Hoka, Sumio] Kitasato Univ, Sch Med, Dept Anesthesiol, Sagamihara, Kanagawa 2288555, Japan	Kokubun, H (reprint author), Kitasato Univ Hosp, Dept Pharm, 1-15-1 Kitasato, Sagamihara, Kanagawa 2288555, Japan.	kokubun@kitasato-u.ac.jp					Mercadante S, 2001, J PAIN SYMPTOM MANAG, V21, P448, DOI 10.1016/S0885-3924(01)00289-5; Mercadante S, 1999, PALLIATIVE MED, V13, P95, DOI 10.1191/026921699678158579; Numata C., 2005, JPN J PHARM HLTH CAR, V31, P599; Otis J, 2006, CURR MED RES OPIN, V22, P1493, DOI 10.1185/030079906X115540; PAIX A, 1995, PAIN, V63, P263, DOI 10.1016/0304-3959(95)00084-6; Peng YR, 2005, J PAIN SYMPTOM MANAG, V30, P7, DOI 10.1016/j.jpainsymman.2005.05.002; SCHNEIDER E, 1986, N-S ARCH PHARMACOL, V334, P267, DOI 10.1007/BF00508781; VARVEL JR, 1989, ANESTHESIOLOGY, V70, P928, DOI 10.1097/00000542-198906000-00008	8	3	3	0	1	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0031-6903			YAKUGAKU ZASSHI	Yakugaku Zasshi-J. Pharm. Soc. Jpn.	MAR	2008	128	3					447	450		10.1248/yakushi.128.447			4	Pharmacology & Pharmacy	Pharmacology & Pharmacy	281LM	WOS:000254499100019	18311065	Bronze			2020-06-30	J	Volmanen, P; Sarvela, J; Akural, EI; Raudaskoski, T; Korttila, K; Alahuhta, S				Volmanen, P.; Sarvela, J.; Akural, E. I.; Raudaskoski, T.; Korttila, K.; Alahuhta, S.			Intravenous remifentanil vs. epidural levobupivacaine with fentanyl for pain relief in early labour: a randomised, controlled, double-blinded study	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						analgesia; obstetrical; opioids; remifentanil; epidural; side effects	PATIENT-CONTROLLED ANALGESIA; CONTROLLED-TRIAL; PETHIDINE	Background: We hypothesised that intravenous patient-controlled analgesia (IV PCA) with remifentanil could provide as satisfactory pain relief for labour as epidural analgesia. Methods: Fifty-two parturients with singleton uncomplicated pregnancies were randomised to receive either IV PCA with remifentanil or epidural analgesia with 20 ml levobupivacaine 0.625 mg/ml and fentanyl 2 mu g/ml in saline. The PCA dose of remifentanil was given over 1 min with a lockout time of 1 min. The dose was increased starting from the bolus of 0.1 mu g/kg and following a dose escalation scheme up until the individual-effective dose was reached. The parturients assessed contraction pain (0-10), pain relief (0-4), sedation and nausea during 60 min. Results: Forty-five parturients were included in the analysis. The median cervical opening was 4 cm before the study and 7 cm after the study. The median pain scores were 7.3 and 5.2 during remifentanil and epidural analgesia, respectively (P=0.009). The median pain relief scores were 2.5 and 2.8 (P=0.17). There was no difference between the groups in the proportion of parturients who discontinued due to ineffective analgesia, nor in the proportion of parturients who would have liked to continue the given medication at the end of the study. Sedation and low haemoglobin oxygen saturation were observed more often during remifentanil analgesia. Foetal heart rate tracing abnormalities were as common in both groups. Conclusions: In terms of pain scores, epidural analgesia is superior to that provided by IV remifentanil. However, there was no difference in the pain relief scores between the treatments.	[Volmanen, P.] Lapland Cent Hosp, Rovaniemi 96200, Finland; [Sarvela, J.; Korttila, K.] Univ Helsinki, Cent Hosp, Dept Anaesthesia & Intens Care, Helsinki, Finland; [Akural, E. I.; Alahuhta, S.] Univ Oulu, Dept Anaesthesiol, Oulu, Finland; [Raudaskoski, T.] Univ Oulu, Dept Obstet & Gynaecol, Oulu, Finland	Volmanen, P (reprint author), Lapland Cent Hosp, POB 8041, Rovaniemi 96200, Finland.	petri.volmanen@lshp.fi					Blair JM, 2005, ANAESTHESIA, V60, P22, DOI 10.1111/j.1365-2044.2004.03975.x; Blair JM, 2001, BRIT J ANAESTH, V87, P415, DOI 10.1093/bja/87.3.415; Capogna G, 1998, BRIT J ANAESTH, V80, P11; Evron S, 2005, ANESTH ANALG, V100, P233, DOI 10.1213/01.ANE.0000143351.64538.BC; Halpern SH, 2004, ANESTH ANALG, V99, P1532, DOI 10.1213/01.ANE.0000136850.08972.07; Kan RE, 1998, ANESTHESIOLOGY, V88, P1467, DOI 10.1097/00000542-199806000-00008; KAPILA A, 1995, ANESTHESIOLOGY, V83, P968, DOI 10.1097/00000542-199511000-00009; Kee WDN, 2006, ANESTHESIOLOGY, V104, P14, DOI 10.1097/00000542-200601000-00004; Landow L, 1999, ANESTHESIOLOGY, V90, P882, DOI 10.1097/00000542-199903000-00032; Leppa M, 2006, NEUROIMAGE, V31, P661, DOI 10.1016/j.neuroimage.2005.12.019; Robinson AP, 2001, ANESTH ANALG, V92, P410, DOI 10.1213/00000539-200102000-00025; Ross AK, 2001, ANESTH ANALG, V93, P1393, DOI 10.1097/00000539-200112000-00008; Smith C V, 1996, J Matern Fetal Med, V5, P89; Thurlow JA, 2002, BRIT J ANAESTH, V88, P374, DOI 10.1093/bja/88.3.374; Volikas I, 2005, BRIT J ANAESTH, V95, P504, DOI 10.1093/bja/aei219; Volikas I, 2001, INT J OBSTET ANESTH, V10, P86, DOI 10.1054/ijoa.2000.0831; Volmanen P, 2005, ACTA ANAESTH SCAND, V49, P453, DOI 10.1111/j.1399-6576.2005.00639.x; Volmanen P, 2002, ANESTH ANALG, V94, P913, DOI 10.1097/00000539-200204000-00026	18	70	76	0	8	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0001-5172			ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	FEB	2008	52	2					249	255		10.1111/j.1399-6576.2007.01509.x			7	Anesthesiology	Anesthesiology	251RP	WOS:000252391900012	18005381				2020-06-30	J	Wang, TF; Liu, YH; Chu, CC; Shieh, JP; Tzeng, JI; Wang, JJ				Wang, T. F.; Liu, Y. H.; Chu, C. C.; Shieh, J. P.; Tzeng, J. I.; Wang, J. J.			Low-dose haloperidol prevents post-operative nausea and vomiting after ambulatory laparoscopic surgery	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						antiemetics; droperidol; haloperidol; laparoscopic surgery; post-operative nausea and vomiting	MENSTRUAL-CYCLE; DROPERIDOL; ANESTHESIA; ONDANSETRON; DEXAMETHASONE; MANAGEMENT; PATIENT; WOMEN	Background: We evaluated the prophylactic effect of low-dose haloperidol (1 mg) on post-operative nausea and vomiting (PONV) in women undergoing ambulatory laparoscopic surgery. Droperidol (0.625 mg) and saline were controls. Methods: One hundred and fifty women undergoing ambulatory laparoscopic surgery under general anaesthesia were enrolled in this randomized, double-blind, and placebo-controlled study. After tracheal intubation, the haloperidol group (n=50) received intravenous haloperidol (1 mg), the droperidol group (n=50) received intravenous droperidol (0.625 mg), and the saline group (n=50) received intravenous saline. Results: Haloperidol- and droperidol-group patients reported a lower incidence of PONV [24% and 23% vs. 49% (saline group); P < 0.05] and requested fewer doses of rescue antiemetics [13% and 16% vs. 38% (saline group); P < 0.05] during the first four post-operative hours. During the 24-h post-operative period, haloperidol- and droperidol-group patients also reported a lower incidence of PONV [31% and 32% vs. 62% (saline group); P < 0.01]. No differences were found between the haloperidol and droperidol groups. Conclusion: Like droperidol (0.625 mg), prophylactic intravenous haloperidol (1 mg) significantly reduced the incidence of PONV in women undergoing ambulatory laparoscopic surgery.	[Wang, T. F.; Chu, C. C.; Shieh, J. P.; Tzeng, J. I.; Wang, J. J.] Chi Mei Med Ctr, Dept Anaesthesiol, Tainan, Hsien, Taiwan; [Wang, T. F.] Song Shan Armed Forces Gen Hosp, Dept Gastroenterol, Taipei, Taiwan; [Liu, Y. H.] Cathay Med Ctr, Dept Anaesthesiol, Taipei, Taiwan	Wang, JJ (reprint author), Chi Mei Med Ctr, Dept Anaesthesiol, No 901,Chung-Hwa RD, Tainan, Hsien, Taiwan.	400002@mail.chimei.org.tw		Chu, Chin-Chen/0000-0001-8745-239X			Aouad MT, 2007, EUR J ANAESTH, V24, P171, DOI 10.1017/S0265021506001323; Apfel CC, 2002, ACTA ANAESTH SCAND, V46, P921, DOI 10.1034/j.1399-6576.2002.460801.x; AYD FJ, 1978, J CLIN PSYCHIAT, V39, P807; BEATTIE WS, 1991, CAN J ANAESTH, V38, P298, DOI 10.1007/BF03007618; Buttner M, 2004, ANESTHESIOLOGY, V101, P1454; Critchley P, 2001, J PAIN SYMPTOM MANAG, V22, P631, DOI 10.1016/S0885-3924(01)00323-2; DYRBERG V, 1962, ACTA ANAESTH SCAND, V6, P37, DOI 10.1111/j.1399-6576.1962.tb00102.x; FORREST JB, 1990, ANESTHESIOLOGY, V72, P262, DOI 10.1097/00000542-199002000-00009; Gan TJ, 2002, ANESTHESIOLOGY, V97, P287, DOI 10.1097/00000542-200207000-00059; Gan TJ, 2006, ANESTH ANALG, V102, P1884, DOI 10.1213/01.ANE.0000219597.16143.4D; HONKAVAARA P, 1991, CAN J ANAESTH, V38, P876, DOI 10.1007/BF03036963; Huang JC, 2001, CAN J ANAESTH, V48, P973, DOI 10.1007/BF03016586; McKeage K, 2006, DRUGS, V66, P2123, DOI 10.2165/00003495-200666160-00009; Myles PS, 2000, BRIT J ANAESTH, V84, P6; PALAZZO MGA, 1984, CAN ANAESTH SOC J, V31, P407, DOI 10.1007/BF03015417; Parlow JL, 2004, ANESTH ANALG, V98, P1072, DOI 10.1213/01.ANE.0000105880.59649.5C; Raeder J, 2005, ACTA ANAESTH SCAND, V49, P1403, DOI 10.1111/j.1399-6576.2005.00903.x; RITA L, 1981, CAN ANAESTH SOC J, V28, P259, DOI 10.1007/BF03005511; Rusch D, 2005, CAN J ANAESTH, V52, P478; Shende D, 2001, ACTA ANAESTH SCAND, V45, P756, DOI 10.1034/j.1399-6576.2001.045006756.x; Sniadach MS, 1997, ANESTH ANALG, V85, P797, DOI 10.1097/00000539-199710000-00015; Wang JJ, 2000, BRIT J ANAESTH, V84, P459; Wisely NA, 2002, EUR J ANAESTH, V19, P853, DOI 10.1017/S0265021502001370	23	11	13	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	FEB	2008	52	2					280	284		10.1111/j.1399-6576.2007.01525.x			5	Anesthesiology	Anesthesiology	251RP	WOS:000252391900017	17999708				2020-06-30	J	Mandel, JE; Tanner, JW; Lichtenstein, GR; Metz, DC; Katzka, DA; Ginsberg, GG; Kochman, ML				Mandel, Jeff E.; Tanner, Jonathan W.; Lichtenstein, Gary R.; Metz, David C.; Katzka, David A.; Ginsberg, Gregory G.; Kochman, Michael L.			A randomized, controlled, double-blind trial of patient-controlled sedation with propofol/remifentanil versus midazolam/fentanyl for colonoscopy	ANESTHESIA AND ANALGESIA			English	Article							PROPOFOL; ENDOSCOPY; COMPLICATIONS; ANESTHESIA	BACKGROUND: Patient-controlled sedation (PCS) with propofol has been advocated as a method for dealing with the narrow therapeutic window for moderate sedation, but previous studies have methodologic limitations. We hypothesized that, by using remifentanil in conjunction with propofol and using PCS in both arms of the study, we could demonstrate marked improvements in facility use compared with fentanyl plus midazolam. METHODS: Fifty patients undergoing elective colonoscopy were randomized (with concealed allocation) to midazolam/fentanyl (group MF) or propofol/remifentanil (group PR) administered via PCS. Time intervals for sedation and recovery, perceptions by patient, nurse, and gastroenterologist, and need for anesthesiologist intervention were assessed. RESULTS: Group PR patients were sedated and recovered significantly more rapidly than did group MF (P < 0.0001). In the group PR, recovery room time was actually shorter than procedure room time. Patient, nurse, and gastroenterologist perceptions were equivalent between the groups. Two patients in group PR required anesthesiologist intervention for arterial desaturation exceeding the primary safety end point. CONCLUSIONS: PCS with propofol/remifentanil yields superior facility throughput compared with midazolam/fentanyl when used in an appropriate care setting.	[Mandel, Jeff E.; Tanner, Jonathan W.] Univ Penn, Sch Med, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA; [Lichtenstein, Gary R.; Metz, David C.; Katzka, David A.; Ginsberg, Gregory G.; Kochman, Michael L.] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA	Mandel, JE (reprint author), Hosp Univ Penn, Dept Anesthesiol & Crit Care, 780 B Dulles Bldg,3400 Spruce St, Philadelphia, PA 19104 USA.	mandelj@uphs.upenn.edu	Mandel, Jeff/D-1128-2009	Mandel, Jeff/0000-0002-8846-4154			Bright E, 2003, ENDOSCOPY, V35, P683; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Hannenberg Alexander A, 2004, Curr Opin Anaesthesiol, V17, P171, DOI 10.1097/00001503-200404000-00014; Heuss LT, 2004, AM J GASTROENTEROL, V99, P511, DOI 10.1111/j.1572-0241.2004.04088.x; JOHNSON LR, 1989, PAIN, V39, P17, DOI 10.1016/0304-3959(89)90170-X; Lalwani K, 2006, CURR OPIN ANESTHESIO, V19, P430, DOI 10.1097/01.aco.0000236145.38722.2f; Lee DWH, 2002, GASTROINTEST ENDOSC, V56, P629, DOI 10.1067/mge.2002.128919; Marcus SN, 2006, GASTROINTEST ENDOSC, V64, P765, DOI 10.1016/j.gie.2006.07.028; MOLLER JT, 1991, BRIT J ANAESTH, V66, P437, DOI 10.1093/bja/66.4.437; Nelson DB, 2002, GASTROINTEST ENDOSC, V55, P307, DOI 10.1067/mge.2002.121883; Nieuwenhuijs DJF, 2003, ANESTHESIOLOGY, V98, P312, DOI 10.1097/00000542-200302000-00008; PASOO CK, 1996, BRIT J ANAESTH, V77, P370; Rex DK, 2006, ALIMENT PHARM THER, V24, P163, DOI 10.1111/j.1365-2036.2006.02986.x; Rex DK, 2005, AM J GASTROENTEROL, V100, P510, DOI 10.1111/j.1572-0241.2005.41885.x; RUDKIN GE, 1992, ANAESTHESIA, V47, P376, DOI 10.1111/j.1365-2044.1992.tb02216.x; Seeff LC, 2004, GASTROENTEROLOGY, V127, P1670, DOI 10.1053/j.gastro.2004.09.051; SEVERINGHAUS JW, 1989, J CLIN MONITOR, V5, P72, DOI 10.1007/BF01617877; Sieg A, 2001, GASTROINTEST ENDOSC, V53, P620, DOI 10.1067/mge.2001.114422; Sipe BW, 2002, GASTROINTEST ENDOSC, V55, P815, DOI 10.1067/mge.2002.124636; Vargo JJ, 2006, ALIMENT PHARM THER, V24, P955, DOI 10.1111/j.1365-2036.2006.03099.x; Vuyk J, 1997, ANESTHESIOLOGY, V87, P1549, DOI 10.1097/00000542-199712000-00033	21	53	71	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	FEB	2008	106	2					434	439		10.1213/01.ane.0000297300.33441.32			6	Anesthesiology	Anesthesiology	254ZE	WOS:000252625700013	18227297				2020-06-30	J	Stanley, TH; Egan, TD; Van Aken, H				Stanley, Theodore H.; Egan, Talmage D.; Van Aken, Hugo			A tribute to Dr. Paul A. J. Janssen: Entrepreneur extraordinaire, innovative scientist, and significant contributor to anesthesiology	ANESTHESIA AND ANALGESIA			English	Article							INTRAVENOUS MORPHINE; RATS; ANALGESICS; FENTANYL; POTENT	Dr. Paul Janssen was the founder of Janssen Pharmaceutica and the developer of over 80 pharmaceutical compounds that proved useful in human, botanical, and veterinary medicine. He and his coworkers synthesized the fentanyl family of drugs, many other potent analgesics, droperidol, etomidate, and numerous other important medicines that were extremely useful in psychiatry, parasitology, gastroenterology, cardiology, virology, and immunology. Anesthesiology and medicine as a whole have benefited a great deal from his resourcefulness, creativity, and entrepreneurial spirit.	[Stanley, Theodore H.; Egan, Talmage D.] Univ Utah, Sch Med, Dept Anesthesiol, Salt Lake City, UT 84132 USA; [Van Aken, Hugo] Univ Klinikum Munster, Dept Anesthesiol & Crit Care, Munster, Germany	Stanley, TH (reprint author), Univ Utah, Sch Med, Dept Anesthesiol, 30 N 1900 E,3C444 SOM, Salt Lake City, UT 84132 USA.	theodore.stanley@hsc.utah.edu					Black J, 2005, J MED CHEM, V48, P1687, DOI 10.1021/jm040195b; Broers H., 2006, INVENTOR LIFE STORY; COLLIER D, 1996, CORPORATE COMMUNICAT; COLLIER D, 1992, CORPORATE COMMUNICAT; de Castro J, 1979, Acta Anaesthesiol Belg, V30, P5; DECASTRO J, 1959, ANESTH ANALG, V16, P1022; JANSSEN PAJ, 1960, J MED PHARMACEUT CH, V2, P31; JANSSEN PAJ, 1963, ARZNEIMITTEL-FORSCH, V13, P502; JANSSEN PAJ, 1962, BRIT J ANAESTH, V34, P260, DOI 10.1093/bja/34.4.260; LOWENSTEIN E, 1969, NEW ENGL J MED, V281, P1389, DOI 10.1056/NEJM196912182812503; LOWENSTEIN E, 1971, ANESTHESIOLOGY, V35, P563, DOI 10.1097/00000542-197112000-00001; NIEMEGEERS CJE, 1981, DRUG DEVELOP RES, V1, P83, DOI 10.1002/ddr.430010111; NIEMEGEERS CJE, 1976, ARZNEIMITTEL-FORSCH, V26, P1551; NILSSON E, 1961, ACTA ANAESTH SCAND, V5, P73, DOI 10.1111/j.1399-6576.1961.tb00085.x; SCHWARTZ H, 1990, BREAKTHROUGH DISCOV; STANLEY TH, 1978, ANESTH ANALG, V57, P411; VANBEVER WFM, 1976, ARZNEIMITTELFORSCH, V26, P1548	17	33	35	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	FEB	2008	106	2					451	462		10.1213/ane.0b013e3181605add			12	Anesthesiology	Anesthesiology	254ZE	WOS:000252625700016	18227300				2020-06-30	J	Scott, DJ; Stohler, CS; Egnatuk, CM; Wang, H; Koeppe, RA; Zubieta, JK				Scott, David J.; Stohler, Christian S.; Egnatuk, Christine M.; Wang, Heng; Koeppe, Robert A.; Zubieta, Jon-Kar			Placebo and nocebo effects are defined by opposite opioid and dopaminergic responses	ARCHIVES OF GENERAL PSYCHIATRY			English	Article							MESSENGER-RNA EXPRESSION; HUMAN BRAIN; AFFECTIVE DIMENSIONS; SUBTHALAMIC NUCLEUS; PARKINSONS-DISEASE; HEALTHY-VOLUNTEERS; PAIN; REWARD; MU; ANALGESIA	Context: Placebo and nocebo effects, the therapeutic and adverse effects, respectively, of inert substances or sham procedures, represent serious confounds in the evaluation of therapeutic interventions. They are also an example of cognitive processes, particularly expectations, capable of influencing physiology. Objective: To examine the contribution of 2 different neurotransmitters, the endogenous opioid and the dopaminergic (DA) systems, to the development of placebo and nocebo effects. Design and Setting: Using a within-subject design, subjects twice underwent a 20-minute standardized pain challenge, in the absence and presence of a placebo with expected analgesic properties. Studies were conducted in a university hospital setting. Participants: Twenty healthy men and women aged 20 to 30 years recruited by advertisement. Main Outcome Measures: Activation of DA and opioid neurotransmission by a pain stressor with and without placebo (changes in the binding potential of carbon 11 [C-11]-labeled raclopride and [C-11] carfentanil with positron emission tomography) and ratings of pain, affective state, and anticipation and perception of analgesia. Results: Placebo-induced activation of opioid neurotransmission was detected in the anterior cingulate, orbitofrontal and insular cortices, nucleus accumbens, amygdala, and periaqueductal gray matter. Dopaminergic activation was observed in the ventral basal ganglia, including the nucleus accumbens. Regional DA and opioid activity were associated with the anticipated and subjectively perceived effectiveness of the placebo and reductions in continuous pain ratings. High placebo responses were associated with greater DA and opioid activity in the nucleus accumbens. Nocebo responses were associated with a deactivation of DA and opioid release. Nucleus accumbens DA release accounted for 25% of the variance in placebo analgesic effects. Conclusions: Placebo and nocebo effects are associated with opposite responses of DA and endogenous opioid neurotransmission in a distributed network of regions. The brain areas involved in these phenomena form part of the circuit typically implicated in reward responses and motivated behavior.	[Scott, David J.; Egnatuk, Christine M.; Wang, Heng; Zubieta, Jon-Kar] Univ Michigan, Mol & Behav Neurosci Inst, Ann Arbor, MI 48109 USA; [Koeppe, Robert A.; Zubieta, Jon-Kar] Univ Michigan, Dept Radiol, Ann Arbor, MI 48109 USA; [Stohler, Christian S.] Univ Maryland, Sch Dent, Baltimore, MD 21201 USA	Zubieta, JK (reprint author), Univ Michigan, Mol & Behav Neurosci Inst, 205 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.	zubieta@umich.edu	STOHLER, CHRISTIAN/AAQ-7539-2020		NCCIH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine [R01 AT 001415]; NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [R01 DA 016423]; NIDCR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR) [R01 DE 15396]		Amanzio M, 1999, J NEUROSCI, V19, P484; Arthurs OJ, 2002, TRENDS NEUROSCI, V25, P27, DOI 10.1016/S0166-2236(00)01995-0; Badiani A, 1999, BEHAV BRAIN RES, V103, P203, DOI 10.1016/S0166-4328(99)00041-8; Benedetti F, 2004, NAT NEUROSCI, V7, P587, DOI 10.1038/nn1250; Benedetti F, 2005, J NEUROSCI, V25, P10390, DOI 10.1523/JNEUROSCI.3458-05.2005; Berridge KC, 1998, BRAIN RES REV, V28, P309, DOI 10.1016/S0165-0173(98)00019-8; Bingel U, 2006, PAIN, V120, P8, DOI 10.1016/j.pain.2005.08.027; Borras MC, 2004, J NEUROPHYSIOL, V91, P2723, DOI 10.1152/jn.00249.2003; Breiter HC, 2001, NEURON, V30, P619, DOI 10.1016/S0896-6273(01)00303-8; Casey KL, 2000, J NEUROPHYSIOL, V84, P525; CHEN JF, 1993, NEUROSCIENCE, V54, P669, DOI 10.1016/0306-4522(93)90238-B; de la Fuente-Fernandez R, 2004, BIOL PSYCHIAT, V56, P67, DOI 10.1016/j.biopsych.2003.11.019; de la Fuente-Fernandez R, 2002, BEHAV BRAIN RES, V136, P359, DOI 10.1016/S0166-4328(02)00130-4; de la Fuente-Fernandez R, 2001, SCIENCE, V293, P1164, DOI 10.1126/science.1060937; DRICI MD, 1995, BRIT J CLIN PHARMACO, V39, P204, DOI 10.1111/j.1365-2125.1995.tb04434.x; Fields H, 2004, NAT REV NEUROSCI, V5, P565, DOI 10.1038/nrn1431; Friston K J, 1994, Hum Brain Mapp, V1, P210, DOI 10.1002/hbm.460010306; FRISTON KJ, 1991, J CEREBR BLOOD F MET, V11, P690, DOI 10.1038/jcbfm.1991.122; GEAR RW, 1995, J NEUROSCI, V15, P3154; Gear RW, 1999, J NEUROSCI, V19, P7175, DOI 10.1523/JNEUROSCI.19-16-07175.1999; GRACELY RH, 1983, NATURE, V306, P264, DOI 10.1038/306264a0; Hommer DW, 2003, ANN NY ACAD SCI, V985, P476; Horvitz JC, 2000, NEUROSCIENCE, V96, P651, DOI 10.1016/S0306-4522(00)00019-1; Hrobjartsson A, 2001, NEW ENGL J MED, V344, P1594, DOI 10.1056/NEJM200105243442106; Irizarry KJ, 2005, SCIENCE, V307, P1411, DOI 10.1126/science.307.5714.1411; Jewett DM, 2001, NUCL MED BIOL, V28, P733, DOI 10.1016/S0969-8051(01)00226-8; KAHNEMAN D, 1979, ECONOMETRICA, V47, P263, DOI 10.2307/1914185; Kalivas PW, 1999, ANN NY ACAD SCI, V877, P64, DOI 10.1111/j.1749-6632.1999.tb09261.x; Knutson B, 2005, J NEUROSCI, V25, P4806, DOI 10.1523/JNEUROSCI.0642-05.2005; LEVINE JD, 1978, LANCET, V2, P654, DOI 10.1016/S0140-6736(78)92762-9; Logan J, 1996, J CEREBR BLOOD F MET, V16, P834, DOI 10.1097/00004647-199609000-00008; Logothetis NK, 2001, NATURE, V412, P150, DOI 10.1038/35084005; LONG DM, 1989, STEREOT FUNCT NEUROS, V53, P149, DOI 10.1159/000099531; Manning BH, 1998, J NEUROSCI, V18, P9453; MANSOUR A, 1995, TRENDS NEUROSCI, V18, P22, DOI 10.1016/0166-2236(95)93946-U; Mayberg HS, 2002, AM J PSYCHIAT, V159, P728, DOI 10.1176/appi.ajp.159.5.728; Mellers B, 1999, J EXP PSYCHOL GEN, V128, P332, DOI 10.1037/0096-3445.128.3.332; Mellers BA, 1997, PSYCHOL SCI, V8, P423, DOI 10.1111/j.1467-9280.1997.tb00455.x; MELZACK R, 1971, ANESTHESIOLOGY, V34, P50; MELZACK R, 1965, SCIENCE, V150, P971, DOI 10.1126/science.150.3699.971; Meyer C R, 1997, Med Image Anal, V1, P195, DOI 10.1016/S1361-8415(97)85010-4; MINOSHIMA S, 1993, J NUCL MED, V34, P322; MINTUN MA, 1984, ANN NEUROL, V15, P217, DOI 10.1002/ana.410150302; MOGENSON GJ, 1991, ADV EXP MED BIOL, V295, P267; MORGAN MM, 1991, BRAIN RES, V545, P17, DOI 10.1016/0006-8993(91)91264-2; Petrovic P, 2002, SCIENCE, V295, P1737, DOI 10.1126/science.1067176; Petrovic P, 2005, NEURON, V46, P957, DOI 10.1016/j.neuron.2005.05.023; Rainville P, 2006, PAIN, V121, P177, DOI 10.1016/j.pain.2006.01.011; Schlaepfer TE, 1998, AM J PSYCHIAT, V155, P470, DOI 10.1176/ajp.155.4.470; Schultz W, 2006, ANNU REV PSYCHOL, V57, P87, DOI 10.1146/annurev.psych.56.091103.070229; Scott DJ, 2006, J NEUROSCI, V26, P10789, DOI 10.1523/JNEUROSCI.2577-06.2006; Smith YR, 2006, J NEUROSCI, V26, P5777, DOI 10.1523/JNEUROSCI.5223-05.2006; Stohler CS, 1999, PAIN, V79, P165, DOI 10.1016/S0304-3959(98)00171-7; Tobler PN, 2005, SCIENCE, V307, P1642, DOI 10.1126/science.1105370; Tom SM, 2007, SCIENCE, V315, P515, DOI 10.1126/science.1134239; Unterwald EM, 2001, ANN NY ACAD SCI, V937, P74; Uslaner J, 2001, EUR J NEUROSCI, V13, P1977, DOI 10.1046/j.0953-816x.2001.01574.x; Volkow ND, 2003, J NEUROSCI, V23, P11461; Volkow ND, 2006, NEUROIMAGE, V32, P1782, DOI 10.1016/j.neuroimage.2006.04.192; Wager TD, 2004, SCIENCE, V303, P1162, DOI 10.1126/science.1093065; Wager TD, 2007, P NATL ACAD SCI USA, V104, P11056, DOI 10.1073/pnas.0702413104; Wall P., 1993, PAIN PLACEBO RESPONS; WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063; Yacubian J, 2006, J NEUROSCI, V26, P9530, DOI 10.1523/JNEUROSCI.2915-06.2006; ZHANG X, 1993, IEEE T BIO-MED ENG, V40, P344, DOI 10.1109/10.222327; Zubieta JK, 2006, BRAIN BEHAV IMMUN, V20, P15, DOI 10.1016/j.bbi.2005.08.006; Zubieta JK, 2005, J NEUROSCI, V25, P7754, DOI 10.1523/JNEUROSCI.0439-05.2005; Zubieta JK, 2003, ARCH GEN PSYCHIAT, V60, P1145, DOI 10.1001/archpsyc.60.11.1145; Zubieta JK, 2002, J NEUROSCI, V22, P5100, DOI 10.1523/JNEUROSCI.22-12-05100.2002; Zubieta JK, 2001, SCIENCE, V293, P311, DOI 10.1126/science.1060952	70	369	383	0	59	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0003-990X			ARCH GEN PSYCHIAT	Arch. Gen. Psychiatry	FEB	2008	65	2					220	231		10.1001/archgenpsychiatry.2007.34			12	Psychiatry	Psychiatry	258HV	WOS:000252859900013	18250260	Bronze			2020-06-30	J	Capici, F; Ingelmo, PM; Davidson, A; Sacchi, CA; Milan, B; Sperti, LR; Lorini, L; Fumagalli, R				Capici, F.; Ingelmo, P. M.; Davidson, A.; Sacchi, C. A.; Milan, B.; Sperti, L. Rota; Lorini, L.; Fumagalli, R.			Randomized controlled trial of duration of analgesia following intravenous or rectal acetaminophen after adenotonsillectomy in children	BRITISH JOURNAL OF ANAESTHESIA			English	Article						analgesia, paediatric; analgesic techniques, i.v.; analgesics non-opioid, acetaminophen; drug delivery, rectal; surgery, otolaryngological	PARACETAMOL PROPACETAMOL PHARMACOKINETICS; EFFICACY; TONSILLECTOMY; PAIN; SURGERY	Background. Doses of acetaminophen 40 mg kg(-1) rectally and 15 mg kg(-1) i.v. produce similar effect-site concentrations. However, the clinical effectiveness of these routes has not been compared. The aim of this study was to compare duration and efficacy of analgesia in children following adenotonsillectomy after acetaminophen either 40 mg kg(-1) rectally or 15 mg kg(-1) i.v. Methods. Fifty children aged between 2 and 5 yr were recruited. They received a standardized anaesthetic, including 2 mu g kg(-1) of fentanyl. Children were randomized to receive either rectal or i.v. acetaminophen. Postoperative pain was assessed regularly with the Children and Infants Postoperative Pain Scale score and rescue analgesia provided if scores were 4 or greater. The primary outcome measure was time to first analgesia. Results were plotted with a Kaplan-Meier analysis and median time to rescue analgesia compared between the groups. Results. The protocol was successfully completed in 46 children. Forty-five children required rescue medication. The time to first rescue analgesia was longer in children receiving rectal acetaminophen (median 10 h, inter-quartile range 9-11 h) compared with those receiving i.v. acetaminophen (7, 6-10 h) with a P-value of 0.01 by log-rank test for equality in survivor function. Few children in either group required rescue analgesia within the first 6 h with differences between the groups being most prominent in the period from 6 to 10 h. Conclusions. Rectal acetaminophen 40 mg kg(-1) provides longer analgesia for moderately painful procedures when compared with 15 mg kg(-1) acetaminophen i.v.	[Davidson, A.] Royal Childrens Hosp, Dept Anaesthesia & Pain Management, Melbourne, Vic 3052, Australia; [Capici, F.; Sacchi, C. A.; Milan, B.; Sperti, L. Rota; Lorini, L.] Osped Riuniti Bergamo, Dept Anaesthesia & Intens Care, I-24100 Bergamo, Italy; [Ingelmo, P. M.; Fumagalli, R.] AO San Gerardo, Dept Perioperat Med & Intens Care, Monza, Italy; [Ingelmo, P. M.] Univ Milan, Dipartimento Med Sperimentale Ambientale & Biotec, Milan, Italy; [Davidson, A.] Univ Melbourne, Dept Pharmacol, Melbourne, Vic, Australia; [Davidson, A.] Murdoch Childrens Res Inst, Melbourne, Vic, Australia	Davidson, A (reprint author), Royal Childrens Hosp, Dept Anaesthesia & Pain Management, Flemington Rd, Melbourne, Vic 3052, Australia.	andrew.davidson@rch.org.au	Fumagalli, Roberto/AAB-9746-2019	Fumagalli, Roberto/0000-0003-0398-1329; lorini, luca ferdinando/0000-0002-2711-3377			Alhashemi JA, 2007, EUR J ANAESTH, V24, P128, DOI 10.1017/S0265021506001232; Allegaert K, 2004, EUR J CLIN PHARMACOL, V60, P191, DOI 10.1007/s00228-004-0756-x; Allegaert K, 2007, PEDIATR ANESTH, V17, P811, DOI 10.1111/j.1460-9592.2007.02227.x; Anderson B, 1996, ANAESTH INTENS CARE, V24, P669, DOI 10.1177/0310057X9602400606; Anderson BJ, 2005, PEDIATR ANESTH, V15, P282, DOI 10.1111/j.1460-9592.2005.01455.x; Anderson BJ, 2004, PEDIATR ANESTH, V14, P201, DOI 10.1046/j.1460-9592.2003.01138.x; ANDERSON BJ, 1995, PAEDIATR ANAESTH, V5, P237; Anderson BJ, 1999, ANESTHESIOLOGY, V90, P411, DOI 10.1097/00000542-199902000-00014; Birmingham PK, 2001, ANESTHESIOLOGY, V94, P385; Buttner W, 2000, PAEDIATR ANAESTH, V10, P303, DOI 10.1046/j.1460-9592.2000.00530.x; Cormack CRH, 2006, PEDIATR ANESTH, V16, P417, DOI 10.1111/j.1460-9592.2005.01789.x; Cravero J, 2000, PAEDIATR ANAESTH, V10, P419, DOI 10.1046/j.1460-9592.2000.00560.x; Duhamel JF, 2007, INT J CLIN PHARM TH, V45, P221; GAUDREAULT P, 1988, CAN J ANAESTH, V35, P149, DOI 10.1007/BF03010655; Howell TK, 2003, ANAESTHESIA, V58, P69, DOI 10.1046/j.1365-2044.2003.02788_5.x; Madadaki C, 2002, ANN FR ANESTH, V21, P767, DOI 10.1016/S0750-7658(02)00808-0; MONTGOMERY CJ, 1995, CAN J ANAESTH, V42, P982, DOI 10.1007/BF03011069; Murat I, 2005, PEDIATR ANESTH, V15, P663, DOI 10.1111/j.1460-9592.2004.01518.x; Murat I, 2004, PAEDIATR ANAESTH, V14, P158, DOI 10.1111/j.1460-9592.2004.01167.x; Pettersson PH, 2004, ACTA ANAESTH SCAND, V48, P867, DOI 10.1111/j.1399-6576.2004.00452.x; Ravi R, 2007, BJA EDUC, V7, P33, DOI 10.1093/bjaceaccp/mkm004; Remy C, 2006, CURR OPIN ANESTHESIO, V19, P562, DOI 10.1097/01.aco.0000245285.30282.70; Viitanen H, 2003, BRIT J ANAESTH, V91, P363, DOI 10.1093/bja/aeg196; White MC, 2005, PEDIATR ANESTH, V15, P683, DOI 10.1111/j.1460-9592.2004.01516.x	24	32	33	0	3	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0007-0912			BRIT J ANAESTH	Br. J. Anaesth.	FEB	2008	100	2					251	255		10.1093/bja/aem377			5	Anesthesiology	Anesthesiology	256GQ	WOS:000252716400016	18211998	Bronze			2020-06-30	J	Giovannelli, M; Bedforth, N; Aitkenhead, A				Giovannelli, M.; Bedforth, N.; Aitkenhead, A.			Survey of intrathecal opioid usage in the UK	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article						anaesthesia; spinal; analgesics opioid; morphine; fentanyl; diamorphine; anaesthesia recovery period; guidelines	RESPIRATORY DEPRESSION; EPIDURAL MORPHINE; POSTOPERATIVE PAIN; ANALGESIA; SWEDEN	Background and objective: Intrathecal opioids are now used routinely in the UK for intra- and postoperative analgesia. The opioids of choice have altered over recent years and the dosage regimens used can vary between institutions. Concerns over safety have been reduced probably because much lower doses of opioids are now being used. This survey explored the practice of intrathecal opioid usage in the UK. Methods: We sent a questionnaire survey to 270 anaesthetic departments and received 199 replies, a response rate of 73.7%. Results: Intrathecal opioids were used in 175 (88.4%) departments. Of these departments, 107 (61.1%) had local guidelines or protocols in place. Opioids such as diamorphine (used in 136 (78.2%) of departments) and fentanyl (129 (74.1%)) with a shorter duration of action are now more commonly used than morphine (37 (21-3%)) for intrathecal analgesia. In 96 (54.5%) departments, patients were nursed on regular surgical wards following administration of spinal opioids. Conclusions: The use of low-dose lipophilic intrathecal opioids for postoperative analgesia is widespread in the UK. Patients are commonly nursed in low-dependency postanaesthetic care areas. The low incidence of adverse events reported by the respondents along with the popularity of the technique suggests that low-dose spinal opioid administration is safe.	[Giovannelli, M.] Derby Hosp NHS Trust, Dept Crit Care, Derby DE22 3NE, England; [Bedforth, N.; Aitkenhead, A.] Queens Med Ctr, Dept Anaesthesia, Nottingham NG7 2UH, England	Giovannelli, M (reprint author), Derby Hosp NHS Trust, Dept Crit Care, Uttoxeter Rd, Derby DE22 3NE, England.	marco.giovannelli@derbyhospitals.nhs.uk		Bedforth, Nigel/0000-0003-3323-1131			AGUILAR JL, 1997, INT MONIT REG ANESTH, V9, P3; BAILEY PL, 1993, ANESTHESIOLOGY, V79, P49, DOI 10.1097/00000542-199307000-00010; BROMAGE PR, 1982, ANESTH ANALG, V61, P490; CHANEY MA, 1994, JAMA-J AM MED ASSOC, V271, P429, DOI 10.1001/jama.1994.03510300029026; COLEMAN J, 2004, BRIT J ANAESTH, V93, P212; COUSINS MJ, 1984, ANESTHESIOLOGY, V61, P276; DICHIRO G, 1966, ACTA RADIOL DIAGN, V5, P988, DOI 10.1177/02841851660050P242; DUPEN SL, 1987, ANESTHESIOLOGY, V67, P987, DOI 10.1097/00000542-198712000-00020; ETCHES RC, 1989, CAN J ANAESTH, V36, P165, DOI 10.1007/BF03011441; GREGORY MA, 1985, ANESTH ANALG, V64, P929; GUSTAFSSON LL, 1982, BRIT J ANAESTH, V54, P479, DOI 10.1093/bja/54.5.479; Gwirtz KH, 1999, ANESTH ANALG, V88, P599, DOI 10.1097/00000539-199903000-00026; HAYS RL, 1994, ANESTHESIOLOGY, V81, P511, DOI 10.1097/00000542-199408000-00032; JORDAN C, 1982, BRIT J ANAESTH, V54, P763, DOI 10.1093/bja/54.7.763; Ko S, 2003, CAN J ANAESTH, V50, P679, DOI 10.1007/BF03018710; MATHEWS E, 1979, LANCET, V1, P673; MILLER RR, 1976, EXPERIENCES BOSTON C; MORGAN M, 1989, BRIT J ANAESTH, V63, P165, DOI 10.1093/bja/63.2.165; MORGAN M, 1982, ANAESTHESIA, V37, P1365; MUELLER RA, 1982, PHARMACOL REV, V34, P255; NORDBERG G, 1984, ANESTHESIOLOGY, V60, P448, DOI 10.1097/00000542-198405000-00010; PALMER CM, 1991, ANESTHESIOLOGY, V74, P1153, DOI 10.1097/00000542-199106000-00029; RACOVICEANUPITE.N, 1900, REV CHIRURGIE, V4, P11; RAWAL N, 1987, BRIT J ANAESTH, V59, P791, DOI 10.1093/bja/59.6.791; Rawal N, 1998, EUR J ANAESTH, V15, P354, DOI 10.1097/00003643-199805000-00019; READY LB, 1988, ANESTHESIOLOGY, V68, P100, DOI 10.1097/00000542-198801000-00016; SHOOK JE, 1990, AM REV RESPIR DIS, V142, P895, DOI 10.1164/ajrccm/142.4.895; SJOSTROM S, 1987, ANESTHESIOLOGY, V67, P889	28	20	21	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0265-0215			EUR J ANAESTH	Eur. J. Anaesth.	FEB	2008	25	2					118	122		10.1017/S0265021507001305			5	Anesthesiology	Anesthesiology	262HT	WOS:000253140300005	17672923				2020-06-30	J	Stamenkovic, DM; Geric, V; Slavkovic, Z; Raskovic, J; Djordjevic, M				Stamenkovic, D. M.; Geric, V.; Slavkovic, Z.; Raskovic, J.; Djordjevic, M.			Combined spinal-epidural analgesia vs. intermittent bolus epidural analgesia for pain relief after major abdominal surgery. A prospective, randomised, double-blind clinical trial	INTERNATIONAL JOURNAL OF CLINICAL PRACTICE			English	Article							POSTOPERATIVE PAIN; GENERAL-ANESTHESIA; EFFICACY; INFUSION	Background: The primary aim of this study was to compare the efficacy of combined spinal-epidural (CSE) analgesia vs. intermittent bolus epidural analgesia (EA) for pain relief after major abdominal surgery. The secondary aim was to assess the effects of fentanyl addition to subarachnoid morphine and bupivacaine. Methods: This was a prospective, randomised, double-blind trial; 160 patients scheduled for major abdominal surgery enrolled. All patients had a thoracic epidural catheter for administration of intra-operative and postoperative analgesia. Patients were assigned to one of four groups: (i) subarachnoid morphine, bupivacaine and fentanyl (MBF group); (ii) morphine and bupivacaine (MB group); (iii) morphine (M group) and (iv) normal saline (EA group). Use of additional intravenous (i.v.) fentanyl and epidural bupivacaine was recorded to measure the need for supplemental intra-operative analgesia. Pain at rest, with movement, and with cough (measured with a visual analogue scale), additional analgesia requests, and side effects were recorded over 72 h postoperatively. Results: Compared with the EA group, the MBF group had significantly reduced pain with cough and lower analgesia requirements during the first 24 h (p < 0.001) and after EA discontinuation (p = 0.041). The MBF group required less intra-operative epidural bupivacaine compared with all other groups (p < 0.001), and less intra-operative i.v. fentanyl compared with group M (p < 0.001). Conclusions: Combined spinal-epidural improved intra-operative analgesia and reduced pain with cough in the immediate postoperative period. The addition of fentanyl to subarachnoid morphine and bupivacaine decreased the need for additional i.v. fentanyl and epidural bupivacaine analgesia.	[Stamenkovic, D. M.; Geric, V.; Slavkovic, Z.] Med Ctr Bezanijska Kosa, Dept Anaesthesia, Belgrade, Serbia; [Raskovic, J.; Djordjevic, M.] Univ Belgrade, Dept Stat, Sch Econ, Belgrade, Serbia	Stamenkovic, DM (reprint author), Med Ctr Bezanijska Kosa, Dept Anaesthesia, Belgrade, Serbia.	dusicastamenkovic@hotmail.com	Stamenkovic, Dusica M/A-3319-2008	Stamenkovic, Dusica/0000-0003-4121-1966			Benzon HT, 2007, SPINAL EPIDURAL ANES, P325; BROMAGE PR, 1998, TXB PAIN, P744; DAHL JB, 1990, BRIT J ANAESTH, V64, P518, DOI 10.1093/bja/64.4.518; DAHL JB, 1992, ANESTH ANALG, V74, P362; ELDOR J, 1995, MED HYPOTHESES, V45, P86, DOI 10.1016/0306-9877(95)90209-0; GOULD TH, 1992, BRIT MED J, V305, P1187, DOI 10.1136/bmj.305.6863.1187; Gwirtz KH, 1999, ANESTH ANALG, V88, P599, DOI 10.1097/00000539-199903000-00026; HANSENFLASCHEN J, 1994, CRIT CARE MED, V22, P732; Hogan Q, 2002, REGION ANESTH PAIN M, V27, P150, DOI 10.1053/rapm.2002.29748; Kaynar AM, 1999, ANESTH ANALG, V89, P534, DOI 10.1097/00000539-199908000-00063; Kehlet H, 2001, BRIT J ANAESTH, V87, P62, DOI 10.1093/bja/87.1.62; Lim Y, 2005, INT J OBSTET ANESTH, V14, P305, DOI 10.1016/j.ijoa.2005.05.004; Rathmell JP, 2005, ANESTH ANALG, V101, pS30, DOI 10.1213/01.ANE.0000177101.99398.22; Rawal N, 1997, REGION ANESTH, V22, P406, DOI 10.1016/S1098-7339(97)80026-0; Rawal N, 2000, Anesthesiol Clin North Am, V18, P267, DOI 10.1016/S0889-8537(05)70164-4; Sakura S, 2001, ANESTH ANALG, V93, P77; Scott NB, 1996, ACTA ANAESTH SCAND, V40, P691, DOI 10.1111/j.1399-6576.1996.tb04512.x; Stienstra R, 1999, ANESTH ANALG, V88, P810, DOI 10.1097/00000539-199904000-00024; STOELING RK, 2006, HDB PHARM PHYSL ANES, V81; Wang JJ, 1996, REGION ANESTH, V21, P281; Williams RK, 1997, CAN J ANAESTH, V44, P511, DOI 10.1007/BF03011940; Zoric Sava, 2003, Med Arh, V57, P21	22	4	4	0	1	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	1368-5031			INT J CLIN PRACT	Int. J. Clin. Pract.	FEB	2008	62	2					255	262		10.1111/j.1742-1241.2007.01642.x			8	Medicine, General & Internal; Pharmacology & Pharmacy	General & Internal Medicine; Pharmacology & Pharmacy	250SZ	WOS:000252322200018	18028385				2020-06-30	J	Tsou, CH; Fan, KT; Wang, JH; Luk, HN; Koenig, HM				Tsou, Chih-Hsiang; Fan, Kuo-Tung; Wang, Jia-Horng; Luk, Hsiang-Ning; Koenig, Heidi M.			Clinical assessment of propofol-induced yawning with heart rate variability: a pilot study	JOURNAL OF CLINICAL ANESTHESIA			English	Article						heart rate variability; propofol; yawning	SPECTRAL-ANALYSIS; PARAVENTRICULAR NUCLEUS; PENILE ERECTION; NITRIC-OXIDE; ANESTHESIA; REFLEX; INVOLVEMENT; INDUCTION; SCLEROSIS; BEHAVIOR	Study Objectives: To investigate the proportion of propofol-induced yawning and sympathovagal balance during propofol-induced yawning. Design: Prospective, observational, clinical study. Setting: University hospital and 2400-bed tertiary medical center. Patients: 546 ASA physical status I and II patients undergoing elective surgery with general anesthesia. Interventions: Standard induction of anesthesia was performed with intravenous (IV) propofol two to four mg/kg (group P), or pretreatment with atropine 0.1 mg/kg (group AP) or with fentanyl 1 to 3 mu g/kg (group FP) before propofol. Continuous standard electrocardiogram for heart rate variability (HRV) was performed in another 20 patients to investigate sympathovagal balance during propofol-induced yawning. Measurements and Main Results: The proportions of yawning were 53.5% (207/386), 61.1% (55/90), and 0% (0150) in the P, AP, and FP groups, respectively. Propofol-induced yawning could be dramatically decreased by pretreatment with IV fentanyl (P < 0.001, chi(2) test). Significant increased ratio of low-frequency/high-frequency power was detected during HRV monitoring in 9 patients with yawning in comparison with 11 patients without yawning (P < 0.05, Wilcoxon signed-rank test). Conclusions: Pretreatment with fentanyl may inhibit propofol-induced yawning. Fluctuations in autonomic function have been noted during propofol-induced yawning. (C) 2008 Elsevier Inc. All rights reserved.	[Fan, Kuo-Tung; Luk, Hsiang-Ning] Taichung Vet Gen Hosp, Dept Anesthesiol & Appl Math, Taichung 407, Taiwan; [Fan, Kuo-Tung; Luk, Hsiang-Ning] Providence Univ, Taichung 407, Taiwan; [Tsou, Chih-Hsiang] Taipei City Hosp, Ren Ai Branch, Dept Pulm, Taipei 483, Taiwan; [Tsou, Chih-Hsiang; Fan, Kuo-Tung] Natl Yang Ming Univ, Inst Biomed Engn, Taipei 407, Taiwan; [Wang, Jia-Horng] Taipei Vet Gen Hosp, Dept Resp Therapy, Taipei 112, Taiwan; [Koenig, Heidi M.] Univ Louisville, Dept Anesthesiol & Perioperat Med, Louisville, KY 40202 USA	Luk, HN (reprint author), Taichung Vet Gen Hosp, Dept Anesthesiol & Appl Math, Taichung 407, Taiwan.	luk1015@vghtc.gov.tw	Koenig, Heidi/L-6169-2019				AKSELROD S, 1981, SCIENCE, V213, P220, DOI 10.1126/science.6166045; Argiolas A, 1998, EUR J PHARMACOL, V343, P1, DOI 10.1016/S0014-2999(97)01538-0; Askenasy JJM, 1996, CLIN AUTON RES, V6, P237, DOI 10.1007/BF02291140; ASKENASY JJM, 1989, J PSYCHOL, V123, P609, DOI 10.1080/00223980.1989.10543014; Baenninger R, 1996, PHYSIOL BEHAV, V59, P421, DOI 10.1016/0031-9384(95)02014-4; Blasi A, 2003, J APPL PHYSIOL, V95, P1394, DOI 10.1152/japplphysiol.01095.2002; Camm AJ, 1996, CIRCULATION, V93, P1043, DOI 10.1016/0044-8486(94)90048-5; CRONIN TG, 1988, AM J ROENTGENOL, V150, P209, DOI 10.2214/ajr.150.1.209; DOGER E, 1989, PHARMACOL BIOCHEM BE, V34, P237, DOI 10.1016/0091-3057(89)90305-5; GALLETLY DC, 1994, BRIT J ANAESTH, V72, P219, DOI 10.1093/bja/72.2.219; GOWER AJ, 1986, EUR J PHARMACOL, V122, P239, DOI 10.1016/0014-2999(86)90108-1; HOWELL SJ, 1995, BRIT J ANAESTH, V74, P168, DOI 10.1093/bja/74.2.168; Huang HH, 1997, BRIT J ANAESTH, V79, P754; Kanaya N, 2003, ANESTHESIOLOGY, V98, P34, DOI 10.1097/00000542-200301000-00009; Kasuya Y, 2005, ANESTH ANALG, V101, P382, DOI 10.1213/01.ANE.0000150943.87520.6D; Kim DW, 2002, J CLIN ANESTH, V14, P241, DOI 10.1016/S0952-8180(02)00348-3; LOBO LL, 1995, PHARMACOL BIOCHEM BE, V52, P485, DOI 10.1016/0091-3057(95)00035-U; Melis MR, 2002, EUR J NEUROSCI, V15, P852, DOI 10.1046/j.1460-9568.2002.01922.x; Melis MR, 1997, N-S ARCH PHARMACOL, V355, P595, DOI 10.1007/PL00004989; NOVAK P, 1993, MED BIOL ENG COMPUT, V31, P103, DOI 10.1007/BF02446667; Ogura H, 2001, EUR J PHARMACOL, V415, P157, DOI 10.1016/S0014-2999(01)00824-X; Postert T, 1996, J NEUROL, V243, P300, DOI 10.1007/BF00868532; Sato-Suzuki I, 1998, J NEUROPHYSIOL, V80, P2765; SKORZEWSKA A, 1993, NEUROPSYCHOBIOLOGY, V27, P17, DOI 10.1159/000118948; URBAHOLMGREN R, 1977, NATURE, V267, P261, DOI 10.1038/267261a0; Williams DR, 2000, NEUROLOGY, V55, P1592, DOI 10.1212/WNL.55.10.1592	26	7	7	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	FEB	2008	20	1					25	29		10.1016/j.jclinane.2007.07.008			5	Anesthesiology	Anesthesiology	280ST	WOS:000254447200005	18346605				2020-06-30	J	Anschel, DJ; Aherne, A; Soto, RG; Carrion, W; Hoegerl, C; Nori, P; Seidman, PA				Anschel, David J.; Aherne, Andrew; Soto, Roy G.; Carrion, Wesley; Hoegerl, Carl; Nori, Palgun; Seidman, Peggy A.			Successful intraoperative spinal cord monitoring during scoliosis surgery using a total intravenous anesthetic regimen including dexmedetomidine	JOURNAL OF CLINICAL NEUROPHYSIOLOGY			English	Article						dexmedetomidine; intraoperative neurophysiological monitoring; motor-evoked potentials; somatosensory-evoked potentials; idiopathic scoliosis; total intravenous anesthesia	EVOKED-POTENTIALS; PROPOFOL; HUMANS; MOTOR; INFUSION	Intraoperative neurophysiological monitoring (IONM) during corrective spinal surgery is widely used. Because of the possible interference with the recording of evoked potentials by inhalational anesthetics, total intravenous anesthetic (TIVA) regimens have been advocated. TIVA regimens may be difficult to use in pediatric populations due to metabolic factors. We report on the results of multimodality IONM during 18 cases in which a TIVA regimen incorporating dexmedetomidine (Precedex, Hespira, Lake Forest, IL) was used. Monitoring techniques included sensory (SSEP) and motor evoked potentials (MEP), as well as pedicle screw stimulation. SSEPs were maintained within an acceptable range of baseline amplitude (50%) and latency (10%), and MEPs remained elicitable throughout each case. We therefore found that the anesthetic regimen did not significantly interfere with any of the monitoring modalities used and conclude that IONM in the presence of dexmedetomidine is feasible under appropriate conditions.	[Anschel, David J.; Aherne, Andrew; Hoegerl, Carl; Nori, Palgun] SUNY Stony Brook, Med Ctr, Dept Neurol, Stony Brook, NY 11794 USA; [Soto, Roy G.; Seidman, Peggy A.] SUNY Stony Brook, Med Ctr, Dept Anesthesiol, Stony Brook, NY 11794 USA; [Carrion, Wesley] SUNY Stony Brook, Med Ctr, Dept Orthopaed, Stony Brook, NY 11794 USA	Anschel, DJ (reprint author), St Charles Hosp, Dept Clin Neurophysiol, 200 Belle Terre Rd, Port Jefferson, NY 11777 USA.	danschel@yahoo.com					Bachand R, 1999, INTENSIVE CARE ME S1, V25, pS160; Bhana N, 2000, DRUGS, V59, P263, DOI 10.2165/00003495-200059020-00012; Bloom M, 2001, J NEUROSURG ANESTH, V13, P320, DOI 10.1097/00008506-200110000-00007; BLOOR BC, 1992, ANESTHESIOLOGY, V77, P1134, DOI 10.1097/00000542-199212000-00014; Chen Zhengyong, 2004, J Clin Monit Comput, V18, P303, DOI 10.1007/s10877-005-5097-5; Clapcich AJ, 2004, ANESTH ANALG, V99, P1334, DOI 10.1213/01.ANE.0000134807.73615.5C; Ebert TJ, 2000, ANESTHESIOLOGY, V93, P382, DOI 10.1097/00000542-200008000-00016; Hall JE, 2000, ANESTH ANALG, V90, P699, DOI 10.1097/00000539-200003000-00035; HOUSMANS PR, 1990, ANESTHESIOLOGY, V73, P919, DOI 10.1097/00000542-199011000-00020; KALKMAN CJ, 1992, ANESTHESIOLOGY, V76, P502, DOI 10.1097/00000542-199204000-00003; Li BH, 2003, ANESTH ANALG, V96, P1155, DOI 10.1213/01.ANE.0000053239.62623.32; Mahmoud M, 2007, ANESTHESIOLOGY, V106, P393, DOI 10.1097/00000542-200702000-00027; Mantz J, 1999, DRUGS TODAY, V35, P151, DOI 10.1358/dot.1999.35.3.533844; Martin Eike, 2003, J Intensive Care Med, V18, P29, DOI 10.1177/0885066602239122; MIRSKI MAZ, 1994, ANESTHESIOLOGY, V81, P1422, DOI 10.1097/00000542-199412000-00017; NUWER MR, 1995, EVOKED POTENTIAL, V96, P6, DOI 10.1016/0013-4694(94)00235-D; Pelosi L, 2002, CLIN NEUROPHYSIOL, V113, P1082, DOI 10.1016/S1388-2457(02)00027-5; SCHMELING WT, 1991, ANESTHESIOLOGY, V75, P499, DOI 10.1097/00000542-199109000-00018; SLOAN T, 1995, J NEUROSURG ANESTH, V7, P314; Venn RM, 2001, BRIT J ANAESTH, V87, P684, DOI 10.1093/bja/87.5.684	20	24	28	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0736-0258			J CLIN NEUROPHYSIOL	J. Clin. Neurophysiol.	FEB	2008	25	1					56	61		10.1097/WNP.0b013e318163cca6			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	261SP	WOS:000253100600008	18303561				2020-06-30	J	Choi, SH; Lee, WK; Lee, SJ; Bai, SJ; Lee, SH; Park, BY; Min, KT				Choi, Seung Ho; Lee, Woo Kyung; Lee, Sung Jin; Bai, Sun Jun; Lee, Su Hyun; Park, Beyoung Yun; Min, Kyeong Tae			Parent-controlled analgesia in children undergoing cleft palate repair	JOURNAL OF KOREAN MEDICAL SCIENCE			English	Article						analgesia; parent-controlled; cleft palate; fentanyl; pain; postoperative	PATIENT-CONTROLLED ANALGESIA; POSTOPERATIVE PAIN MANAGEMENT; EFFICACY; INFUSION; SURGERY; INFANTS; SAFETY	The aims of this study were to find an optimal basal infusion dose of fentanyl for parent-controlled analgesia (PrCA) in children undergoing cleft palate repair and the degree of parents' satisfaction with PrCA. Thirty consecutive children between 6 months and 2 yr of age were enrolled. At the end of surgery, a PrCA device with a basal infusion rate of 2 mL/hr and bolus of 0.5 mL with lockout time of 15 min was applied. Parents were educated in patient-controlled analgesia (PCA) devices, the Wong Baker face pain scoring system, and monitoring of adverse effects of fentanyl. Fentanyl was infused 0.3 mu g/kg/hr at first, and we obtained a predetermined fentanyl regimen by the response of the previous patient to a larger or smaller dose of fentanyl (0.1 mu g/kg/hr as the step size), using an up-and-down method. ED50 and ED95 by probit analysis were 0.63 mu g/kg/hr (95% confidence limits, 0.55-0.73 mu g/kg/hr) and 0.83 mu g/kg/hr (95% confidence limits, 0.73-1.47 mu g/kg/hr), respectively. Eighty seven percent of the parents were satisfied with participating in the PrCA modality. PrCA using fentanyl with a basal infusion rate of 0.63 mu g/kg/hr can be applied effectively for postoperative pain management in children undergoing cleft palate repair with a high level of parents' satisfaction.	[Choi, Seung Ho; Lee, Sung Jin; Bai, Sun Jun; Lee, Su Hyun; Min, Kyeong Tae] Yonsei Univ, Coll Med, Dept Anesthesiol & Pain Med, Seoul, South Korea; [Choi, Seung Ho; Lee, Sung Jin; Bai, Sun Jun; Lee, Su Hyun; Min, Kyeong Tae] Yonsei Univ, Coll Med, Anesthesia & Pain Res Inst, Seoul, South Korea; [Park, Beyoung Yun] Yonsei Univ, Coll Med, Inst Human Tissue Restorat, Dept Plast & Reconstruct Surg, Seoul, South Korea; [Lee, Woo Kyung] Kwandong Univ, Coll Med, Dept Anesthesiol & Pain Med, Goyang, South Korea	Min, KT (reprint author), Yonsei Univ, Coll Med, Dept Anesthesiol & Pain Med, CPO Box 8044, Seoul, South Korea.	ktmin501@yumc.yonsei.ac.kr		Choi, Seung Ho/0000-0001-8442-4406; Bai, Sun Joon/0000-0001-5027-3232			Buttner W, 2000, PAEDIATR ANAESTH, V10, P303, DOI 10.1046/j.1460-9592.2000.00530.x; Dell'Oste C, 2004, ACTA ANAESTH SCAND, V48, P787, DOI 10.1111/j.0001-5172.2004.00407.x; DIXON WJ, 1991, NEUROSCI BIOBEHAV R, V15, P47, DOI 10.1016/S0149-7634(05)80090-9; Kanagasundaram SA, 1997, J PAEDIATR CHILD H, V33, P352, DOI 10.1111/j.1440-1754.1997.tb01616.x; KATZ R, 1993, CRIT CARE MED, V21, P995, DOI 10.1097/00003246-199307000-00012; Kehlet Henrik, 2005, Anesthesiol Clin North Am, V23, P203, DOI 10.1016/j.atc.2004.11.001; Kelly AM, 2002, PEDIATR EMERG CARE, V18, P159, DOI 10.1097/00006565-200206000-00002; Klimscha W, 1998, ANESTH ANALG, V86, P54; Monitto CL, 2000, ANESTH ANALG, V91, P573, DOI 10.1213/00000539-200009000-00014; Munro HM, 1999, J CLIN ANESTH, V11, P187, DOI 10.1016/S0952-8180(99)00022-7; Peters JWB, 1999, PAEDIATR ANAESTH, V9, P235, DOI 10.1046/j.1460-9592.1999.00358.x; Roulleau P, 2003, PAEDIATR ANAESTH, V13, P701, DOI 10.1046/j.1460-9592.2003.01102.x; Verghese Susan T, 2005, Anesthesiol Clin North Am, V23, P163, DOI 10.1016/j.atc.2004.11.008; Wong D L, 1988, Pediatr Nurs, V14, P9; Yildiz K, 2003, PAEDIATR ANAESTH, V13, P427, DOI 10.1046/j.1460-9592.2003.01061.x	15	9	9	0	2	KOREAN ACAD MEDICAL SCIENCES	SEOUL	302 75 DONG DU ICHON, DONG YONGSAN KU, SEOUL 140 031, SOUTH KOREA	1011-8934			J KOREAN MED SCI	J. Korean Med. Sci.	FEB	2008	23	1					122	125		10.3346/jkms.2008.23.1.122			4	Medicine, General & Internal	General & Internal Medicine	271XZ	WOS:000253823300021	18303211	Other Gold, Green Published			2020-06-30	J	Ray, NP				Ray, Neil P.			Pediatric "Sedation" protocols: Exchanging old problems for new ones	JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY			English	Editorial Material							PAINFUL PROCEDURES; ANESTHESIA; CHILDREN; MIDAZOLAM; FENTANYL; CANCER		Columbia Univ, Childrens Hosp, Med Ctr, New York, NY 10027 USA	Ray, NP (reprint author), Columbia Univ, Childrens Hosp, Med Ctr, New York, NY 10027 USA.	nr2243@columbia.edu					BAILEY PL, 1990, ANESTHESIOLOGY, V73, P826, DOI 10.1097/00000542-199011000-00005; Bhananker SM, 2006, ANESTHESIOLOGY, V104, P228, DOI 10.1097/00000542-200602000-00005; Casamassimo P, 2006, PEDIATRICS, V118, P2587, DOI 10.1542/peds.2006-2780; Crock C, 2003, ARCH DIS CHILD, V88, P253, DOI 10.1136/adc.88.3.253; Friesen RH, 2004, ANESTH ANALG, V98, P277; Joint Commission on Accreditation of Healthcare Organisations, 1999, COMPR ACCR MAN HOSP; Kissin I, 2000, ANESTH ANALG, V90, P1114, DOI 10.1097/00000539-200005000-00021; McDermott NB, 2003, ANESTH ANALG, V97, P39, DOI 10.1213/01.ANE.0000067402.02136.A2; Reeves ST, 2004, PEDIATRICS, V114, pE74, DOI 10.1542/peds.114.1.e74; SANDLER ES, 1992, PEDIATRICS, V89, P631; SECTISH T, 1997, AM FAM PHYSICIAN, P55	11	1	1	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1077-4114	1536-3678		J PEDIAT HEMATOL ONC	J. Pediatr. Hematol. Oncol.	FEB	2008	30	2					117	118		10.1097/MPH.0b013e31815d892a			2	Oncology; Hematology; Pediatrics	Oncology; Hematology; Pediatrics	266TW	WOS:000253460900001	18376261				2020-06-30	J	Cechvala, MM; Christenson, D; Eickhoff, JC; Hollman, GA				Cechvala, Meredith M.; Christenson, Devon; Eickhoff, Jens C.; Hollman, Gregory A.			Sedative preference of families for lumbar punctures in children with acute leukemia: Propofol alone or propofol and fentanyl	JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY			English	Article						procedure sedation; propofol; fentanyl; lumbar puncture	PEDIATRIC ONCOLOGY; PAINFUL PROCEDURES; GENERAL-ANESTHESIA; CANCER; DISTRESS; PREMEDICATION; ADOLESCENTS; MIDAZOLAM	Propofol is a common sedative/anesthetic used for invasive procedures in children with cancer. The purpose of this study was to determine whether families of children with acute leukemia prefer propofol alone or propofol plus fentanyl for lumbar puncture (LP) sedation. We conducted a randomized, placebo controlled, double blind, crossover study. Each patient was studied twice, once with propofol/placebo and once with propofol/fentanyl. Data collected included the modified Yale Preoperative Anxiety Score (M-YPAS) at baseline and after placebo or fentanyl, Induction Compliance Checklist, recovery excitement, recovery time, and adverse events. After the study, families were asked which sedative regimen they preferred for future LPs. Twenty-two patients received 44 LP sedations: propofol 22, propofol/fentanyl 22. The average age was 6.4 +/- 4.2 years (mean +/- SD). There were no significant differences between groups in M-YPAS, Induction Compliance Checklist or recovery excitement. Adverse events occurred in 11/22 patients (50%) propofol and 4/22 (18.2%) propofol/fentanyl (P = 0.0196). Average recovery time (mean SD) was 36.86 +/- 17.1 minutes propofol versus 26.36 +/- 16.4 minutes propofol/fentanyl (P = 0.047), Sixteen families (72.7%) chose propofol with fentanyl for future LP sedations (P = 0.05). In conclusion, most families prefer propofol and fentanyl for LP's. Propofol with fentanyl was also associated with fewer adverse events and faster recovery.	[Cechvala, Meredith M.; Christenson, Devon; Eickhoff, Jens C.; Hollman, Gregory A.] Univ Wisconsin, Childrens Hosp, Dept Pediat, Madison, WI USA	Hollman, GA (reprint author), 600 Highland Ave,CSC H4-470, Madison, WI 53792 USA.	ghollman@wisc.edu			NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR03186]		Barbi E, 2005, J PEDIAT HEMATOL ONC, V27, P639, DOI 10.1097/01.mph.0000193474.06870.9c; Barnes C, 2002, J PAEDIATR CHILD H, V38, P170, DOI 10.1046/j.1440-1754.2002.00761.x; Crock C, 2003, ARCH DIS CHILD, V88, P253, DOI 10.1136/adc.88.3.253; Disma N, 2005, EUR J ANAESTH, V22, P848, DOI 10.1017/S0265021505001432; Eastwood PR, 2005, ANESTHESIOLOGY, V103, P470, DOI 10.1097/00000542-200509000-00007; ELLIS JA, 1994, J PAIN SYMPTOM MANAG, V9, P96, DOI 10.1016/0885-3924(94)90162-7; FRADET C, 1990, PAIN, V40, P53, DOI 10.1016/0304-3959(90)91050-S; Gottschling S, 2005, J PEDIAT HEMATOL ONC, V27, P471, DOI 10.1097/01.mph.0000179238.37647.91; Hain RDW, 2001, ARCH DIS CHILD, V85, P12, DOI 10.1136/adc.85.1.12; Hertzog JH, 2000, PEDIATRICS, V106, P742, DOI 10.1542/peds.106.4.742; Jayabose S, 2001, J PEDIAT HEMATOL ONC, V23, P290, DOI 10.1097/00043426-200106000-00011; Kain ZN, 1997, ANESTH ANALG, V85, P783, DOI 10.1097/00000539-199710000-00012; Kain ZN, 1998, ANESTHESIOLOGY, V89, P1147, DOI 10.1097/00000542-199811000-00015; KATZ ER, 1980, J CONSULT CLIN PSYCH, V48, P356, DOI 10.1037/0022-006X.48.3.356; KAUFFMAN RE, 1992, PEDIATRICS, V89, P1110; Kazak AE, 1996, J PEDIATR PSYCHOL, V21, P195, DOI 10.1093/jpepsy/21.2.195; KEEGAN NJ, 1995, ANAESTHESIA, V50, P200, DOI 10.1111/j.1365-2044.1995.tb04555.x; KRAUSS B, 1988, PEDIATRIC PROCEDURAL; Ljungman G, 1999, ACTA PAEDIATR, V88, P623, DOI 10.1080/08035259950169279; MCGRATH P J, 1990, Journal of Psychosocial Oncology, V8, P109, DOI 10.1300/J077v08n02_06; SANDLER ES, 1992, PEDIATRICS, V89, P631; SCOTT JC, 1985, ANESTHESIOLOGY, V62, P234, DOI 10.1097/00000542-198503000-00005; VanNatta ME, 2006, AM J GASTROENTEROL, V101, P2209, DOI 10.1111/j.1572-0241.2006.00760.x; Weisman SJ, 1998, ARCH PEDIAT ADOL MED, V152, P147; ZELTZER L K, 1990, Pediatrics, V86, P826	25	14	15	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1077-4114			J PEDIAT HEMATOL ONC	J. Pediatr. Hematol. Oncol.	FEB	2008	30	2					142	147		10.1097/MPH.0b013e31815d8953			6	Oncology; Hematology; Pediatrics	Oncology; Hematology; Pediatrics	266TW	WOS:000253460900007	18376267				2020-06-30	J	Weerts, EM; Kim, YK; Wand, GS; Dannals, RF; Lee, JS; Frost, JJ; McCaul, ME				Weerts, Elise M.; Kim, Yu Kyeong; Wand, Gary S.; Dannals, Robert F.; Lee, Jae Sung; Frost, J. James; McCaul, Mary E.			Differences in delta- and mu-opioid receptor blockade measured by positron emission tomography in naltrexone-treated recently abstinent alcohol-dependent subjects	NEUROPSYCHOPHARMACOLOGY			English	Article						mu-opioid receptors; delta-opioid receptors; naltrexone; alcoholism; dependence; PET imaging	BETA-ENDORPHIN SYSTEM; AVOIDING ANA RATS; PREFERRING AA; ETHANOL-CONSUMPTION; RHESUS-MONKEYS; ENDOGENOUS OPIOIDS; HUMAN BRAIN; 6-BETA-NALTREXOL LEVELS; OPIATE RECEPTORS; FAMILY-HISTORY	Blockade of brain mu-opioid receptor (mu-OR) and delta-opioid receptor (delta-OR) was investigated in recently abstinent alcohol-dependent subjects (N=21) maintained on naltrexone. Subjects completed a 19-day inpatient protocol, which included alcohol abstinence followed by naltrexone treatment (50 mg)on days 15-19. Blood samples were collected after the first administration of naltrexone to evaluate serum levels of naltrexone and 6-beta-naltrexol. Regional brain mu-OR binding potential (BP) and delta-OR K-i was measured using [C-11] carfentanil (CAR) positron emission tomography (PET) and [C-11] methyl naltrindole ([C-11]MeNTI) PET, respectively, before (day 5) and during naltrexone treatment (day 18). Naltrexone inhibition of [C-11] CAR BP was near maximal across all brain regions of interest with little variability across subjects (mean + SD% inhibition 94.9 + 4.9%). Naltrexone only partially inhibited the [C-11] MeNTI Ki and there was more variability across subjects (mean + SD% inhibition 21.1 + 14.49%). Peak serum levels of naltrexone were positively correlated with % inhibition of delta-OR K-i in neocortex and basal ganglia. Peak serum levels of naltrexone were not correlated with % inhibition of mu-OR BP. Peak levels of 6-beta-naltrexol were not significantly correlated with % inhibition of mu-OR BP or delta-OR K-i. Thus, the FDA recommended therapeutic dose of naltrexone was sufficient to produce near complete inhibition of the mu-OR in recently abstinent alcohol dependent subjects. The lower percent inhibition of delta-OR and greater variability in delta-OR blockade by naltrexone across subjects may contribute to individual differences in treatment outcomes to naltrexone. Further investigations on the relationship between individual differences in delta-OR blockade by naltrexone and clinical outcomes should be explored.	[Weerts, Elise M.; Wand, Gary S.; Dannals, Robert F.; Frost, J. James; McCaul, Mary E.] Johns Hopkins Univ, Sch Med, Dept Radiol, Baltimore, MD 21205 USA; [Weerts, Elise M.; Wand, Gary S.; Dannals, Robert F.; Frost, J. James; McCaul, Mary E.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; [Weerts, Elise M.; Wand, Gary S.; Dannals, Robert F.; Frost, J. James; McCaul, Mary E.] Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD 21205 USA; [Weerts, Elise M.; Wand, Gary S.; Dannals, Robert F.; Frost, J. James; McCaul, Mary E.] Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; [Kim, Yu Kyeong; Lee, Jae Sung] Seoul Natl Univ, Coll Med, Dept Nucl Med, Seoul, South Korea	Weerts, EM (reprint author), Johns Hopkins Bayview, BBRC, 5510 Nathan Shock Dr,Suite 3000, Baltimore, MD 21224 USA.	eweerts@jhmi.edu	Lee, Jae Sung/J-2781-2012	Weerts, Elise/0000-0002-8234-0919	NIAAA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R01 AA011855, AA12303, R01 AA011855-05, AA11855, R01 AA011872, AA11872, R01 AA011872-04]		ALTSHULER HL, 1980, LIFE SCI, V26, P679, DOI 10.1016/0024-3205(80)90257-X; Anton RF, 2003, AM J ADDICTION, V12, pS53, DOI 10.1111/j.1521-0391.2003.tb00496.x; Becker A, 2002, N-S ARCH PHARMACOL, V365, P296, DOI 10.1007/s00210-002-0533-2; Bencherif B, 2004, BIOL PSYCHIAT, V55, P255, DOI 10.1016/j.biopsych.2003.07.007; BLUM K, 1987, EXPERIENTIA, V43, P408, DOI 10.1007/BF01940430; Boyle AEL, 1998, ALCOHOL CLIN EXP RES, V22, P359, DOI 10.1111/j.1530-0277.1998.tb03661.x; Brauer LH, 1999, PSYCHOPHARMACOLOGY, V143, P339, DOI 10.1007/s002130050957; BUCHOLZ KK, 1994, J STUD ALCOHOL, V55, P149, DOI 10.15288/jsa.1994.55.149; Cowen MS, 1999, ALCOHOL CLIN EXP RES, V23, P1008, DOI 10.1111/j.1530-0277.1999.tb04218.x; Cowen MS, 1998, BRAIN RES, V796, P323, DOI 10.1016/S0006-8993(98)00432-6; Cox RF, 2001, ANESTH ANALG, V93, P354, DOI 10.1097/00000539-200108000-00024; CZIRR SA, 1987, ALCOHOL, V4, P157, DOI 10.1016/0741-8329(87)90037-1; DAVENPORT KE, 1990, NEUROSCI LETT, V113, P40, DOI 10.1016/0304-3940(90)90491-Q; Davidson AF, 1996, J PHARMACEUT BIOMED, V14, P1717, DOI 10.1016/0731-7085(96)01794-3; DEWAELE JP, 1995, J PHARMACOL EXP THER, V275, P518; DEWAELE JP, 1992, J PHARMACOL EXP THER, V261, P788; DEWAELE JP, 1994, EUR J PHARMACOL, V258, P119, DOI 10.1016/0014-2999(94)90064-7; DHATT RK, 1995, J NEUROCHEM, V64, P1878; Djouma E, 2002, J PHARMACOL EXP THER, V302, P551, DOI 10.1124/jpet.102.035915; Endres CJ, 2003, NUCL MED BIOL, V30, P177, DOI 10.1016/S0969-8051(02)00411-0; Ferrari A, 1998, DRUG ALCOHOL DEPEN, V52, P211, DOI 10.1016/S0376-8716(98)00098-2; Franck J, 1998, ALCOHOL CLIN EXP RES, V22, P1185, DOI 10.1111/j.1530-0277.1998.tb03897.x; FROEHLICH JC, 1990, PHARMACOL BIOCHEM BE, V35, P385, DOI 10.1016/0091-3057(90)90174-G; FROEHLICH JC, 1991, PSYCHOPHARMACOLOGY, V103, P467, DOI 10.1007/BF02244246; FROST JJ, 1985, J COMPUT ASSIST TOMO, V9, P231, DOI 10.1097/00004728-198503000-00001; FROST JJ, 1989, J CEREBR BLOOD F MET, V9, P398, DOI 10.1038/jcbfm.1989.59; Garbutt JC, 1999, JAMA-J AM MED ASSOC, V281, P1318, DOI 10.1001/jama.281.14.1318; GIANOULAKIS C, 1992, ALCOHOL CLIN EXP RES, V16, P453, DOI 10.1111/j.1530-0277.1992.tb01399.x; Gianoulakis C, 2004, CURR TOP MED CHEM, V4, P39, DOI 10.2174/1568026043451573; Hall FS, 2001, PSYCHOPHARMACOLOGY, V154, P43, DOI 10.1007/s002130000622; Heinz A, 2005, ARCH GEN PSYCHIAT, V62, P57, DOI 10.1001/archpsyc.62.1.57; Herz A, 1997, PSYCHOPHARMACOLOGY, V129, P99, DOI 10.1007/s002130050169; Honkanen A, 1996, EUR J PHARMACOL, V304, P7, DOI 10.1016/0014-2999(96)00118-5; HOUDI AA, 1991, PEPTIDES, V12, P161, DOI 10.1016/0196-9781(91)90183-P; HUBBELL CL, 1986, ALCOHOL, V3, P39, DOI 10.1016/0741-8329(86)90070-4; HYYTIA P, 1993, PHARMACOL BIOCHEM BE, V45, P697, DOI 10.1016/0091-3057(93)90527-Z; June HL, 1999, PSYCHOPHARMACOLOGY, V147, P81, DOI 10.1007/s002130051145; King AC, 2000, PHARMACOL BIOCHEM BE, V66, P563, DOI 10.1016/S0091-3057(00)00258-6; KORNET M, 1991, PSYCHOPHARMACOLOGY, V104, P367, DOI 10.1007/BF02246038; Krishnan-Sarin S, 1998, PHARMACOL BIOCHEM BE, V59, P627, DOI 10.1016/S0091-3057(97)00474-7; KRISHNANSARIN S, 1995, PHARMACOL BIOCHEM BE, V52, P153, DOI 10.1016/0091-3057(95)00080-G; KRISHNANSARIN S, 1995, PSYCHOPHARMACOLOGY, V120, P177, DOI 10.1007/BF02246191; LEVER JR, 1992, EUR J PHARMACOL, V216, P459, DOI 10.1016/0014-2999(92)90448-D; LINSEMAN MA, 1990, PHARMACOL BIOCHEM BE, V36, P405, DOI 10.1016/0091-3057(90)90423-F; Logan J, 1996, J CEREBR BLOOD F MET, V16, P834, DOI 10.1097/00004647-199609000-00008; Madar I, 1996, SYNAPSE, V24, P19, DOI 10.1002/(SICI)1098-2396(199609)24:1<19::AID-SYN3>3.0.CO;2-J; Mann K, 2004, CNS DRUGS, V18, P485, DOI 10.2165/00023210-200418080-00002; Marinelli PW, 2000, LIFE SCI, V66, P1915, DOI 10.1016/S0024-3205(00)00517-8; McBride WJ, 1998, ALCOHOL, V16, P317, DOI 10.1016/S0741-8329(98)00021-4; McCaul ME, 2000, NEUROPSYCHOPHARMACOL, V22, P480, DOI 10.1016/S0893-133X(99)00147-5; McCaul ME, 2000, ALCOHOL CLIN EXP RES, V24, P1385, DOI 10.1111/j.1530-0277.2000.tb02107.x; McGehee DS, 2006, MOL INTERV, V6, P311, DOI 10.1124/mi.6.6.4; MELTZER CC, 1990, J COMPUT ASSIST TOMO, V14, P418, DOI 10.1097/00004728-199005000-00019; Middaugh LD, 2000, PHARMACOL BIOCHEM BE, V65, P145, DOI 10.1016/S0091-3057(99)00184-7; MYERS RD, 1986, ALCOHOL, V3, P383, DOI 10.1016/0741-8329(86)90058-3; NICHOLS ML, 1991, ALCOHOL, V8, P237, DOI 10.1016/0741-8329(91)90273-Y; NYLANDER I, 1994, ALCOHOL CLIN EXP RES, V18, P1272, DOI 10.1111/j.1530-0277.1994.tb00118.x; OMALLEY SS, 1992, ARCH GEN PSYCHIAT, V49, P881; Oswald LM, 2004, PHYSIOL BEHAV, V81, P339, DOI 10.1016/j.physbeh.2004.02.008; PATLAK CS, 1985, J CEREBR BLOOD F MET, V5, P584, DOI 10.1038/jcbfm.1985.87; POMERLEAU OF, 1983, PSYCHOPHARMACOLOGY, V81, P61, DOI 10.1007/BF00439275; Pomerleau OF, 1998, PSYCHONEUROENDOCRINO, V23, P115, DOI 10.1016/S0306-4530(97)00074-7; PRICE JC, 1993, J CEREBR BLOOD F MET, V13, P656, DOI 10.1038/jcbfm.1993.84; Reid L D, 1986, NIDA Res Monogr, V75, P359; Roberts AJ, 2000, J PHARMACOL EXP THER, V293, P1002; Rohsenow DJ, 2004, CNS DRUGS, V18, P547, DOI 10.2165/00023210-200418090-00001; SADZOT B, 1991, J CEREBR BLOOD F MET, V11, P204, DOI 10.1038/jcbfm.1991.52; SAMSON HH, 1985, PHARMACOL BIOCHEM BE, V22, P91, DOI 10.1016/0091-3057(85)90491-5; Schnoll Robert A, 2006, Expert Opin Emerg Drugs, V11, P429, DOI 10.1517/14728214.11.3.429; SKINNER HA, 1982, J ABNORM PSYCHOL, V91, P199, DOI 10.1037/0021-843X.91.3.199; Smith JS, 1999, J CEREBR BLOOD F MET, V19, P956, DOI 10.1097/00004647-199909000-00003; SOBELL LC, 1992, MEASURING ALCOHOL CONSUMPTION, P41; Soini SL, 1998, ALCOHOL, V15, P227, DOI 10.1016/S0741-8329(97)00125-0; Stromberg MF, 1998, ALCOHOL, V15, P281, DOI 10.1016/S0741-8329(97)00131-6; SULLIVAN JT, 1989, BRIT J ADDICT, V84, P1353; TITELER M, 1989, EUR J PHARMACOL, V167, P221, DOI 10.1016/0014-2999(89)90582-7; VEREBEY K, 1976, CLIN PHARMACOL THER, V20, P315; Volpicelli JR, 1997, ARCH GEN PSYCHIAT, V54, P737; VOLPICELLI JR, 1992, ARCH GEN PSYCHIAT, V49, P876; Wall M E, 1981, NIDA Res Monogr, V28, P105; Walters CL, 2005, NEURON, V46, P933, DOI 10.1016/j.neuron.2005.05.005; Wand G, 2001, ALCOHOL CLIN EXP RES, V25, P1134, DOI 10.1097/00000374-200108000-00007; Wand GS, 1999, ALCOHOL CLIN EXP RES, V23, P1185, DOI 10.1097/00000374-199907000-00007; Wang DX, 2001, J NEUROCHEM, V77, P1590, DOI 10.1046/j.1471-4159.2001.00362.x; WEISS F, 1990, PSYCHOPHARMACOLOGY, V101, P178, DOI 10.1007/BF02244123; Wewers ME, 1999, BRAIN RES, V822, P107, DOI 10.1016/S0006-8993(99)01095-1; Williams KL, 1998, ALCOHOL CLIN EXP RES, V22, P1634, DOI 10.1097/00000374-199811000-00004; Williams KL, 1998, PSYCHOPHARMACOLOGY, V139, P53, DOI 10.1007/s002130050689; Zubieta JK, 1999, AM J PSYCHIAT, V156, P842, DOI 10.1176/ajp.156.6.842	89	81	82	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0893-133X			NEUROPSYCHOPHARMACOL	Neuropsychopharmacology	FEB	2008	33	3					653	665		10.1038/sj.npp.1301440			13	Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	250LE	WOS:000252300700020	17487229	Bronze			2020-06-30	J	Papoff, P; Mancuso, M; Caresta, E; Moretti, C				Papoff, Paola; Mancuso, Michele; Caresta, Elena; Moretti, Corrado			Effectiveness and safety of propofol in newborn infants	PEDIATRICS			English	Letter									[Papoff, Paola; Mancuso, Michele; Caresta, Elena; Moretti, Corrado] Univ Roma La Sapienza, Dept Pediat, I-00161 Rome, Italy	Papoff, P (reprint author), Univ Roma La Sapienza, Dept Pediat, I-00161 Rome, Italy.						GHANTA S, 2007, PEDIATRICS, V119; HELBOHANSEN S, 1988, ACTA ANAESTH SCAND, V32, P41; Williams GD, 1999, ANESTH ANALG, V89, P1411, DOI 10.1097/00000539-199912000-00016	3	21	21	0	1	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	FEB	2008	121	2					448	448		10.1542/peds.2007-3132			1	Pediatrics	Pediatrics	258OQ	WOS:000252877600031	18245439				2020-06-30	J	Larenza, MP; Zanolari, P; Jaggin-Schmucker, N				Larenza, M. P.; Zanolari, P.; Jaeggin-Schmucker, N.			Balanced anesthesia and ventilation strategies for an alpaca (Lama pacos) with an increased anesthetic-risk	SCHWEIZER ARCHIV FUR TIERHEILKUNDE			English	Article						South American camelids; Alpaca; anesthetic risk; positive end expiratory pressure (PEEP) ventilation	HORSES; PARAMETERS; KETAMINE	We report the use of a balanced anesthetic technique in a three-year-old, female Huacaya alpaca with an increased anesthetic risk that underwent an extensive dental surgery. Anesthesia was provided with an infusion of midazolam, fentanyl, S-ketamine and low concentrations of isoflurane in oxygen. The mandibular alveolar nerve was desensitized with a lidocaine-bupivacaine combination. The alpaca showed signs of hypoxemia fifteen minutes after anesthesia induction and arterial blood gases confirmed severe venous admixture. Application of positive end expiratory pressure (PEEP) of 6-9 cm H2O improved the arterial oxygenation. Other cardiopulmonary variables remained within the normal range. At the end of surgery, sarmazenil was administered to antagonize the effects of midazolam and emergence from anesthesia was smooth and uneventful. Flunixine meglumine and a transdermal delivery system for fentanyl were administered for post-operative analgesia. This method of balanced anesthesia allowed for an adequate anesthetic plane and a safe recovery, however, special ventilation strategies (PEEP) had to be applied.	[Larenza, M. P.; Jaeggin-Schmucker, N.] Univ Bern, Div Anesthesiol, CH-3012 Bern, Switzerland; [Zanolari, P.] Univ Bern, Clin Ruminants, CH-3012 Bern, Switzerland	Larenza, MP (reprint author), Univ Zurich, Vetsuisse Fac, Clin Horses, Winterthurerstr 260, CH-8057 Zurich, Switzerland.	plarenza@vetclinics.unizh.ch	Zanolari, Patrik/K-9665-2019	Zanolari, Patrik/0000-0002-9549-2487			BETTSCHARTWOLFE.R, 2007, IN PRESS CLIN TECH E; Burri IH, 2005, SCHWEIZ ARCH TIERH, V147, P335, DOI [10.1024/0036-7281.147.08.335, 10.1024/0036-7281.147.8.335]; KEATS AS, 1978, ANESTHESIOLOGY, V49, P233, DOI 10.1097/00000542-197810000-00001; Kohrs R, 1998, ANESTH ANALG, V87, P1186, DOI 10.1097/00000539-199811000-00039; Larenza MP, 2005, AM J VET RES, V66, P2135, DOI 10.2460/ajvr.2005.66.2135; Lukasik VM, 1997, EQUINE VET J, V29, P236, DOI 10.1111/j.2042-3306.1997.tb01676.x; Magnusson L, 2003, BRIT J ANAESTH, V91, P61, DOI 10.1093/bja/aeg085; Mama KR, 1999, VET SURG, V28, P121, DOI 10.1053/jvet.1999.0121; Marntell S, 2005, VET ANAESTH ANALG, V32, P338, DOI 10.1111/j.1467-2995.2005.00199.x; NASH G, 1971, ARCH PATHOL, V91, P234; Neiger-Aeschbacher G, 1999, SCHWEIZ ARCH TIERH, V141, P307; Robertson SA, 2002, VET ANAESTH ANALG, V29, P212, DOI [10.1046/j.1467-2995.2002.00100.x, 10.1046/j.1467-2995.2002.00709.x]; Thomasy SM, 2004, J VET INTERN MED, V18, P550, DOI 10.1892/0891-6640(2004)18&lt;550:TFCWNA&gt;2.0.CO;2; Wettstein D, 2006, AM J VET RES, V67, P152, DOI 10.2460/ajvr.67.1.152	14	3	3	1	6	VERLAG HANS HUBER	BERN 9	LANGGASS-STRASSE 76, CH-3000 BERN 9, SWITZERLAND	0036-7281			SCHWEIZ ARCH TIERH	Schweiz. Arch. Tierheilkd.	FEB	2008	150	2					77	81		10.1024/0036-7281.150.2.77			5	Veterinary Sciences	Veterinary Sciences	264RP	WOS:000253307200005	18369052				2020-06-30	J	Novello, L; Corletto, F; Rabozzi, R; Platt, SR				Novello, Lorenzo; Corletto, Federico; Rabozzi, Roberto; Platt, Simon R.			Sparing effect of a low dose of intrathecal morphine on fentanyl requirements during spinal surgery: A preliminary clinical investigation in dogs	VETERINARY SURGERY			English	Article							CONTROLLED INTRAVENOUS MORPHINE; EPIDURAL MORPHINE; POSTOPERATIVE ANALGESIA; POSTTHORACOTOMY PAIN; LAMINECTOMY SURGERY; LUMBAR-DISK; ANESTHESIA; REMIFENTANIL; SEVOFLURANE; BUPIVACAINE	Objective-To evaluate the effect of preoperative intrathecal administration of a low dose of morphine on intraoperative fentanyl requirements in dogs undergoing cervical and thoracolumbar spinal surgery. Study Design-Prospective randomized clinical study. Animals-Dogs (n=18) matched by surgical procedure administered intrathecal morphine (MG) or no-treatment (control group, CG). Methods-After premedication with romifidine (4 mu g/kg, intravenously) and induction with propofol, anesthesia was maintained with sevoflurane in oxygen. Intrathecal morphine 0.03 (0.023-0.034) mg/kg was administered at lumbar level 41 (25-65) minutes before surgery in MG. Ketamine (0.5 mg/kg) was administered hourly, starting before incision. Fentanyl infusion (1.2 and 4.2 mu g/kg/h in MG and CG, respectively) was administered after a loading dose (5 and 10 mu g/kg in MG and CG, respectively), and boluses were given if an increase > 20% in heart rate and arterial blood pressure was observed. Total amount of fentanyl administered was recorded, to calculate hourly requirements and predict plasma concentration using a computer simulation. Results-Hourly fentanyl consumption and predicted plasma concentrations at the time of response to surgery were significantly lower in MG compared with CG. Conclusions-Preoperative administration of a low dose of intrathecal morphine has a sparing effect on intraoperative fentanyl requirements. Clinical Relevance-Preoperative intrathecal administration of a low dose of morphine at the lumbar level represented a safe and effective mean of providing intraoperative analgesia in dogs undergoing cervical and thoracolumbar spinal surgery. (c) Copyright 2008 by The American College of Veterinary Surgeons.	[Novello, Lorenzo] Italian Soc Vet Reg Anaesthesia & Pain Med, I-30016 Venice, Italy; [Novello, Lorenzo; Corletto, Federico; Rabozzi, Roberto; Platt, Simon R.] Queens Vet Sch Hosp, Dept Anaesthet, Cambridge, England; [Novello, Lorenzo; Corletto, Federico; Rabozzi, Roberto; Platt, Simon R.] Dick White Referrals, Mile Bottom 6, Newmarket, Suffolk, England; [Novello, Lorenzo; Corletto, Federico; Rabozzi, Roberto; Platt, Simon R.] Addenbrookes Hosp, Dept Anaesthet, Cambridge, England; [Novello, Lorenzo; Corletto, Federico; Rabozzi, Roberto; Platt, Simon R.] Ambulatorio Vet Adriat, Chieti, Italy; [Novello, Lorenzo; Corletto, Federico; Rabozzi, Roberto; Platt, Simon R.] Univ Georgia, Coll Vet Med, Dept Small Anim Med & Surg, Athens, Greece	Novello, L (reprint author), Italian Soc Vet Reg Anaesthesia & Pain Med, Via Meucci 13, I-30016 Venice, Italy.	novello@isvra.org		Platt, Simon/0000-0002-7818-1011			Albertin A, 2006, EUR J ANAESTH, V23, P510, DOI 10.1017/S0265021506000305; Albertin A, 2004, ANESTHESIOLOGY, V100, P255, DOI 10.1097/00000542-200402000-00012; BARRON DW, 1981, ANAESTHESIA, V36, P937, DOI 10.1111/j.1365-2044.1981.tb08651.x; BOURKE DL, 1992, J CLIN ANESTH, V4, P277, DOI 10.1016/0952-8180(92)90128-N; Brown DR, 2004, ANESTHESIOLOGY, V100, P926, DOI 10.1097/00000542-200404000-00024; CHADWICK HS, 1988, ANESTHESIOLOGY, V68, P925, DOI 10.1097/00000542-198806000-00015; FRINK EJ, 1992, ANESTHESIOLOGY, V76, P85, DOI 10.1097/00000542-199201000-00013; Goyagi T, 1996, ANESTH ANALG, V82, P1192, DOI 10.1097/00000539-199606000-00016; GRAY JR, 1986, ANESTH ANALG, V65, P873; HEATH RB, 1989, COMP CONT EDUC PRACT, V11, P50; Howie MB, 2001, ANESTH ANALG, V92, P1084; Jellish WS, 1996, ANESTH ANALG, V83, P559, DOI 10.1097/00000539-199609000-00021; JOSHI GP, 1995, ANESTH ANALG, V80, P511, DOI 10.1097/00000539-199503000-00013; Kona-Boun JJ, 2003, VET ANAESTH ANALG, V30, P257, DOI 10.1046/j.1467-2995.2003.00076.x; Liu SS, 2001, ANESTHESIOLOGY, V94, P888, DOI 10.1097/00000542-200105000-00030; Lotsch J, 2006, CLIN PHARMACOKINET, V45, P1051; LOPER KA, 1989, ANESTH ANALG, V69, P826; MANDEL RJ, 1981, CLIN ORTHOP RELAT R, P27; MATHESON D, 1960, Can Anaesth Soc J, V7, P149; Milner AR, 1996, ANAESTHESIA, V51, P871, DOI 10.1111/j.1365-2044.1996.tb12622.x; MURPHY MR, 1979, ANESTHESIOLOGY, V50, P13, DOI 10.1097/00000542-197901000-00004; Mutoh T, 1997, AM J VET RES, V58, P885; NOVELLO L, 2006, VET REGIONAL ANAESTH, V4, P9; NOVELLO L, 2007, ECVS M DUBL IR JUN; PASCOE PJ, 1993, VET SURG, V22, P141, DOI 10.1111/j.1532-950X.1993.tb01689.x; Popilskis S., 1993, Journal of Veterinary Anaesthesia, V20, P21; Pypendop BH, 2001, AM J VET RES, V62, P490, DOI 10.2460/ajvr.2001.62.490; RAISIS AL, 2004, BSAVA MANUAL CANINE, P337; RAWAL N, 1997, CURR OPIN ANAESTH, V10, P350; Sano T, 2006, VET ANAESTH ANALG, V33, P266, DOI 10.1111/j.1467-2995.2005.00266.x; SCOVILLE WB, 1977, SURG NEUROL, V7, P163; Sharp NJH, 2005, SMALL ANIMAL SPINAL, P339, DOI DOI 10.1016/B978-0-7234-3209-8.50019-4; SHULMAN M, 1984, ANESTHESIOLOGY, V61, P569, DOI 10.1097/00000542-198411000-00017; Skarda RT, 1996, LUMB JONES VET ANEST, P426; Torske KE, 2000, VET CLIN N AM-SMALL, V30, P859, DOI 10.1016/S0195-5616(08)70011-1; Troncy E, 2002, J AM VET MED ASSOC, V221, P666, DOI 10.2460/javma.2002.221.666; Ummenhofer WC, 2000, ANESTHESIOLOGY, V92, P739, DOI 10.1097/00000542-200003000-00018; VALVERDE A, 1989, CAN J ANAESTH, V36, P629, DOI 10.1007/BF03005412; YAMAGUCHI H, 1990, ANESTH ANALG, V70, P168; YEAGER MP, 1987, ANESTHESIOLOGY, V66, P729, DOI 10.1097/00000542-198706000-00004	40	7	9	0	2	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0161-3499			VET SURG	Vet. Surg.	FEB	2008	37	2					153	160		10.1111/j.1532-950X.2007.00358.x			8	Veterinary Sciences	Veterinary Sciences	257CM	WOS:000252776800006	18251809				2020-06-30	J	Wang, X; Zhang, XF				Wang, Xuan; Zhang, Xue-Feng			Enflurane requirement for blocking adrenergic responses to incision in infants and children	WORLD JOURNAL OF PEDIATRICS			English	Article						anesthesia; children; enflurane; infants	CARDIOVASCULAR-RESPONSES; SKIN INCISION; ANESTHESIA; MAC; STRESS; REMIFENTANIL; DESFLURANE; AUGMENTS; FENTANYL; SURGERY	Background. Enflurane is one of the most commonly used inhaled anesthetics in China, but its requirement to block adrenergic responses after skin incision in pediatric patients is still unknown. This study was to determine the minimum alveolar anesthetic concentration (MAC) of potent inhaled anesthetics required to blunt the adrenergic response to skin incision of enflurane (MAC(BAR) in infants and children. Methods: Twenty-eight patients, 10 infants (6-12 months) and 18 young children (1-6 years), were studied. The 18 children were randomly assigned into two groups, with or without fentanyl. Anesthesia was induced with 3 mg/kg propofol and 0.15 mg/kg vecuronium, and maintained with enflurane in 100% oxygen. Fentanyl (3 mu g/kg) was given intravenously 5 minutes before incision for the patients of fentanyl group. The '' up and down '' method (with 0.3 MAC as a step size and 1 MAC as the start dose) was applied to determine MAC(BAR),. The response was considered positive if the mean arterial pressure (MAP) or heart rate (HR) increased >= 15% after incision. The MAC(BAR). was calculated as the mean of four independent cross-over responses in each group. Results: MAC(BAR) of enflurane in children of 1-6 years old was 3.2% (95% Cl, 2.8%-3.6%) and was reduced to 2.2% (95% CI, 1.8%-2.5%) by 3 mu g/kg fentanyl. In infants of 6-12 months old, the MAC(BAR) of enflurane was 3.4% (95% CI, 3.0%-3.8%). Conclusions: MAC(BAR) of enflurane in infants older than 6 months is similar to that in young children. The MAC(BAR) of enflurane decreases with co-administration of fentanyl in the pediatric population.	[Wang, Xuan; Zhang, Xue-Feng] Fudan Univ, Childrens Hosp, Dept Anesthesiol, Shanghai 200032, Peoples R China	Wang, X (reprint author), Fudan Univ, Childrens Hosp, Dept Anesthesiol, 183 Fenglin Rd, Shanghai 200032, Peoples R China.	Davidxwang@citiz.net					Albertin A, 2004, ANESTHESIOLOGY, V100, P255, DOI 10.1097/00000542-200402000-00012; BADGWELL JM, 1987, ANESTH ANALG, V66, P959; Billard V, 2004, ACTA ANAESTH SCAND, V48, P355, DOI 10.1111/j.0001-5172.2004.0324.x; Bonnet F, 2005, BRIT J ANAESTH, V95, P52, DOI 10.1093/bja/aei038; Daniel M, 1998, ANESTHESIOLOGY, V88, P43, DOI 10.1097/00000542-199801000-00009; Desborough JP, 2000, BRIT J ANAESTH, V85, P109, DOI 10.1093/bja/85.1.109; EGER EI, 1965, ANESTHESIOLOGY, V26, P756, DOI 10.1097/00000542-196511000-00010; Hahnenkamp Klaus, 2004, Best Pract Res Clin Anaesthesiol, V18, P509, DOI 10.1016/j.bpa.2004.01.004; Herroeder S, 2002, HOSP MED, V63, P99, DOI 10.12968/hosp.2002.63.2.2088; Herroeder S, 2007, ANN SURG, V246, P192, DOI 10.1097/SLA.0b013e31805dac11; Huiku M, 2007, BRIT J ANAESTH, V98, P447, DOI 10.1093/bja/aem004; ISHIZAWA Y, 1993, CAN J ANAESTH, V40, P18, DOI 10.1007/BF03009312; Katoh T, 2000, BRIT J ANAESTH, V84, P63; Koblin D.D., 2005, MILLERS ANESTHESIA, P105; Mapleson WW, 1996, BRIT J ANAESTH, V76, P179; Moraca RJ, 2003, ANN SURG, V238, P663, DOI 10.1097/01.sla.0000094300.36689.ad; ROIZEN MF, 1981, ANESTHESIOLOGY, V54, P390, DOI 10.1097/00000542-198105000-00008; Seitsonen ERJ, 2005, ACTA ANAESTH SCAND, V49, P284, DOI 10.1111/j.1399-6576.2005.00654.x; Tziavrangos E, 2006, CURR OPIN ANESTHESIO, V19, P521, DOI 10.1097/01.aco.0000245278.22658.1e; ZBINDEN AM, 1994, ANESTHESIOLOGY, V80, P261, DOI 10.1097/00000542-199402000-00005	20	3	3	0	0	ZHEJIANG UNIV SCH MEDICINE	HANGZHOU	CHILDRENS HOSPITAL, 57 ZHUGAN XIANG, HANGZHOU, 310003, PEOPLES R CHINA	1708-8569	1867-0687		WORLD J PEDIATR	World Journal of Pediatrics	FEB	2008	4	1					49	52		10.1007/s12519-008-0010-1			4	Pediatrics	Pediatrics	283QY	WOS:000254652800010	18402253				2020-06-30	J	Greenwald, MK				Greenwald, Mark K.			Behavioral economic analysis of drug preference using multiple choice procedure data	DRUG AND ALCOHOL DEPENDENCE			English	Article						behavioral economic analysis; drug choice; multiple choice procedure; unit price; demand curve	ABUSE LIABILITY; DEPENDENT VOLUNTEERS; UNIT PRICE; HUMANS; REINFORCEMENT; COCAINE; ALPRAZOLAM; WITHDRAWAL; CAFFEINE; IMPACT	The multiple choice procedure has been used to evaluate preference for psychoactive drugs, relative to money amounts (price), in human subjects. The present re-analysis shows that MCP data are compatible with behavioral economic analysis of drug choices. Demand curves were constructed from studies with intravenous fentanyl, intramuscular hydromorphone and oral methadone in opioid-dependent individuals; oral d-amphetamine, oral MDMA alone and during fluoxetine treatment, and smoked marijuana alone or following naltrexone pretreatment in recreational drug users. For each participant and dose, the MCP crossover point was converted into unit price (UP) by dividing the money value ($) by the drug dose (mg/70 kg). At the crossover value, the dose ceases to function as a reinforcer, so "0" was entered for this and higher UPs to reflect lack of drug choice. At lower UPs, the dose functions as a reinforcer and "1" was entered to reflect drug choice. Data for UP vs. average percent choice were plotted in log-log space to generate demand functions. Rank of order of opioid inelasticity (slope of non-linear regression) was: fentanyl > hydromorphone (continuing heroin users) > methadone > hydromorphone (heroin abstainers). Rank order of psychostimulant inelasticity was d-amphetamine > MDMA > MDMA + fluoxetine. Smoked marijuana was more inelastic with high-dose naltrexone. These findings show this method translates individuals' drug preferences into estimates of population demand, which has the potential to yield insights into pharmacotherapy efficacy, abuse liability assessment, and individual differences in susceptibility to drug abuse. (c) 2007 Elsevier Ireland Ltd. All rights reserved.	Wayne State Univ, Sch Med, Dept Psychiat & Behav Neurosci, Subst Abuse Res Div, Detroit, MI 48202 USA	Greenwald, MK (reprint author), Wayne State Univ, Sch Med, Dept Psychiat & Behav Neurosci, Subst Abuse Res Div, Detroit, MI 48202 USA.	mgreen@med.wayne.edu			NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [R01 DA15462, R29 DA011079-05, R01 DA015462, R01 DA015462-05]		Abreu ME, 2001, PSYCHOPHARMACOLOGY, V154, P76, DOI 10.1007/s002130000624; Alessi SM, 2003, BEHAV PHARMACOL, V14, P19, DOI 10.1097/00008877-200302000-00002; Bickel WK, 2000, PSYCHOPHARMACOLOGY, V153, P44, DOI 10.1007/s002130000589; BICKEL WK, 1993, DRUG ALCOHOL DEPEN, V33, P173, DOI 10.1016/0376-8716(93)90059-Y; BICKEL WK, 1990, LIFE SCI, V47, P1501, DOI 10.1016/0024-3205(90)90178-T; Bickel WK, 1998, BEHAV THER, V29, P545, DOI 10.1016/S0005-7894(98)80050-6; DEGRANDPRE RJ, 1993, J EXP ANAL BEHAV, V60, P641, DOI 10.1901/jeab.1993.60-641; Garrett BE, 1998, PSYCHOPHARMACOLOGY, V139, P195, DOI 10.1007/s002130050704; Greenwald MK, 2006, DRUG ALCOHOL DEPEN, V85, P35, DOI 10.1016/j.drugalcdep.2006.03.007; Greenwald MK, 2006, EXP CLIN PSYCHOPHARM, V14, P52, DOI 10.1037/1064-1297.14.1.52; Greenwald MK, 2005, EXP CLIN PSYCHOPHARM, V13, P3, DOI 10.1037/1064-1297.13.1.3; Greenwald MK, 2000, DRUG ALCOHOL DEPEN, V59, P261, DOI 10.1016/S0376-8716(99)00128-3; Greenwald MK, 1999, DRUG ALCOHOL DEPEN, V56, P191, DOI 10.1016/S0376-8716(99)00032-0; Griffin T, 2003, ARTFORUM, V41, P54; GRIFFITHS RR, 1993, BEHAV PHARMACOL, V4, P3; HURSH SR, 1993, DRUG ALCOHOL DEPEN, V33, P165, DOI 10.1016/0376-8716(93)90058-X; HURSH SR, 1995, J EXP ANAL BEHAV, V64, P373, DOI 10.1901/jeab.1995.64-373; Jones HE, 1999, J PHARMACOL EXP THER, V288, P188; KIDORF M, 1995, DRUG ALCOHOL DEPEN, V39, P167, DOI 10.1016/0376-8716(95)01136-7; Lile JA, 2004, PSYCHOPHARMACOLOGY, V171, P441, DOI 10.1007/s00213-003-1598-4; Mansbach RS, 2006, DRUG ALCOHOL DEPEN, V83, pS15, DOI 10.1016/j.drugalcdep.2005.10.018; McColl S, 2006, DRUG ALCOHOL DEPEN, V83, pS52, DOI 10.1016/j.drugalcdep.2006.01.015; Mintzer MZ, 1998, DRUG ALCOHOL DEPEN, V53, P49, DOI 10.1016/S0376-8716(98)00110-0; MUMFORD GK, 1995, CLIN PHARMACOL THER, V57, P356, DOI 10.1016/0009-9236(95)90162-0; MUMFORD GK, 1995, J PHARMACOL EXP THER, V272, P570; REISINE T, 1996, [No title captured]; Schuh KJ, 1997, PSYCHOPHARMACOLOGY, V130, P320, DOI 10.1007/s002130050246; Schuh LM, 2000, PSYCHOPHARMACOLOGY, V147, P339, DOI 10.1007/s002130050001; Stoops WW, 2003, DRUG ALCOHOL DEPEN, V71, P179, DOI 10.1016/S0376-8716(03)00131-5; Tancer M, 2007, PSYCHOPHARMACOLOGY, V189, P565, DOI 10.1007/s00213-006-0576-z; Winger G, 2002, J PHARMACOL EXP THER, V301, P690, DOI 10.1124/jpet.301.2.690	31	16	16	0	2	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0376-8716	1879-0046		DRUG ALCOHOL DEPEN	Drug Alcohol Depend.	JAN 11	2008	93	1-2					103	110		10.1016/j.drugalcdep.2007.09.002			8	Substance Abuse; Psychiatry	Substance Abuse; Psychiatry	260SW	WOS:000253031700012	17949924	Green Accepted			2020-06-30	J	Lindholm, ML; Brudin, L; Sandin, RH				Lindholm, M. -L.; Brudin, L.; Sandin, R. H.			Bispectral index monitoring: appreciated but does not affect drug dosing and hypnotic levels	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article; Proceedings Paper	28th Congress of the Scandinavian-Society-of-Anaesthesiology-and-Intensive-Care-Medicine	JUN 29-JUL 03, 2005	Reykjavik, ICELAND	Scandinavian Soc Anaesthesiol & Intens Care Med		BIS; anesthesia management; general anesthesia; drug consumption	AMBULATORY ANESTHESIA; RECOVERY; PROPOFOL; TITRATION; AWARENESS; CONSUMPTION; DESFLURANE; REDUCTION; MORTALITY	Background: Bispectral index (BIS) has been associated with benefits from less-deep anesthesia as well as preventing awareness, albeit not at the same time. We investigated how increasing experience from BIS in clinical practice affect the hypnotic level, drug consumption, as well as subjective opinions on this monitoring. Methods: Eight certified registered nurse anesthetists (CRNAs) with previous experience from 88 (46-121) BIS monitored cases anesthetized 80 cases with concealed BIS, followed by 80 cases with available BIS. Additional education and training was followed by yet another 160 patients randomized to open or blindly recorded BIS. BIS levels, anesthetic gas consumption, fentanyl use, and subjective opinions on utility and reliability were investigated. Results: After gaining initial experience from BIS monitoring, the fraction of time with BIS levels of 40-60 did not deteriorate in cases with concealed monitoring and no further improvement was found in subsequent cases with available data from the BIS monitoring, not even after additional training and encouragement to adhere to the 40-60 interval. Compared with the first experience from BIS monitoring the subjective opinions on utility had increased from 33 to 78 mm (100 mm visual analog scales) (P < 0.0001). Conclusion: Although BIS became considerably appreciated, growing experience and repeated education had no impact on drug dosing and BIS levels.	[Lindholm, M. -L.; Sandin, R. H.] Karolinska Inst, Dept Pharmacol, Sect Anesthesia & Intens Care, S-10401 Stockholm, Sweden; [Brudin, L.] Kalmar Cty Hosp, Dept Clin Physiol, Kalmar, Sweden	Lindholm, ML (reprint author), Dept Anesthesia & Intens Care, S-39185 Kalmar, Sweden.	majlisl@ltkalmar.se		Brudin, Lars/0000-0002-6278-1362			BRICE DD, 1970, BRIT J ANAESTH, V42, P535, DOI 10.1093/bja/42.6.535; Drummond JC, 2005, ANESTH ANALG, V101, P1238, DOI 10.1213/01.ANE.0000173755.25143.50; Eger EI, 2001, ANESTH ANALG, V93, P947, DOI 10.1097/00000539-200110000-00029; Ekman A, 2004, ACTA ANAESTH SCAND, V48, P20, DOI 10.1111/j.1399-6576.2004.00260.x; Ellerkmann RK, 2006, ACTA ANAESTH SCAND, V50, P1244, DOI 10.1111/j.1399-6576.2006.01146.x; Farag E, 2006, ANESTH ANALG, V103, P633, DOI 10.1213/01.ane.0000228870.48028.b5; Gan TJ, 1997, ANESTHESIOLOGY, V87, P808, DOI 10.1097/00000542-199710000-00014; Guignard B, 2001, ACTA ANAESTH SCAND, V45, P308, DOI 10.1034/j.1399-6576.2001.045003308.x; Johansen JW, 2000, J CLIN ANESTH, V12, P433, DOI 10.1016/S0952-8180(00)00187-2; Liu SS, 2004, ANESTHESIOLOGY, V101, P311, DOI 10.1097/00000542-200408000-00010; Luginbuhl M, 2003, ACTA ANAESTH SCAND, V47, P165, DOI 10.1034/j.1399-6576.2003.00041.x; Monk TG, 2005, ANESTH ANALG, V100, P4, DOI 10.1213/01.ANE.0000147519.82841.5E; Myles PS, 2004, LANCET, V363, P1757, DOI 10.1016/S0140-6736(04)16300-9; Nelskyla KA, 2001, ANESTH ANALG, V93, P1165, DOI 10.1097/00000539-200111000-00021; Pavlin DJ, 2001, ANESTH ANALG, V93, P613, DOI 10.1097/00000539-200109000-00017; Pavlin JD, 2005, ANESTHESIOLOGY, V102, P566, DOI 10.1097/00000542-200503000-00015; Recart A, 2003, ANESTH ANALG, V97, P1667, DOI 10.1213/01.ANE.0000087041.63034.8C; Sebel PS, 2004, ACTA ANAESTH SCAND, V48, P1, DOI 10.1111/j.1399-6576.2004.00303.x; Song DJ, 1997, ANESTHESIOLOGY, V87, P842, DOI 10.1097/00000542-199710000-00018; Song DJ, 1998, ANESTH ANALG, V87, P1245, DOI 10.1097/00000539-199812000-00006; White PF, 2004, ANESTHESIOLOGY, V100, P811, DOI 10.1097/00000542-200404000-00010; Wong J, 2002, CAN J ANAESTH, V49, P13, DOI 10.1007/BF03020413; Yli-Hankala A, 1999, ACTA ANAESTH SCAND, V43, P545, DOI 10.1034/j.1399-6576.1999.430510.x	23	11	11	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	JAN	2008	52	1					88	94		10.1111/j.1399-6576.2007.01466.x			7	Anesthesiology	Anesthesiology	242ZD	WOS:000251763800013	17976226				2020-06-30	J	Lenz, H; Raeder, J; Hoymork, SC				Lenz, H.; Raeder, J.; Hoymork, S. C.			Administration of fentanyl before remifentanil-based anaesthesia has no influence on post-operative pain or analgesic consumption	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						remifentanil; fentanyl; post-operative pain	ACUTE OPIOID TOLERANCE; SMALL-DOSE KETAMINE; MORPHINE-SULFATE; HYPERALGESIA; INFUSION; HUMANS; VOLUNTEERS; CAPSAICIN; NALOXONE; MODULATION	Background: Remifentanil's short-acting analgesic effect and the potential of producing hyperalgesia is a challenge to post-operative pain control. This study investigated whether pre-treating the patients with fentanyl before remifentanil-based anaesthesia could reduce post-operative pain or analgesic consumption. Methods: One-hundred patients admitted for anterior cruciate ligament repair were included in a double-blind study. Propofol and remifentanil were used for general anaesthesia. Group Pre received fentanyl 1.5 mu g/kg intravenously (IV) and Group Post placebo before the remifentanil infusion. At the end of surgery, Group Pre received 1.5 mu g/kg and Group Post received 3.0 mu g/kg. Patient-controlled analgesia with fentanyl was used as analgesic rescue medication during the first 4 h post-operatively. Oxycodone 5 mg orally was taken as needed during the subsequent 4-24-h period. Results: A mean dose of remifentanil 0.43 mu g/kg/min was used for 90 min during surgery in both groups. There were no differences in the verbal rate scale (VRS) score or need of rescue analgesic medication between the groups during the first 4 h. Group Post had significantly less pain in the 4-24-h period after surgery, with a median VRS score of 'slight pain' vs. 'moderate pain' in Group Pre (P < 0.05). The oxycodone consumption was similar in both groups. Conclusion: Pre-treatment with fentanyl 1.5 mu g/kg IV yielded no reduction in post-operative pain or analgesic consumption after 90 min of remifentanil-based anaesthesia with 0.43 mu g/kg/min of remifentanil.	[Lenz, H.; Raeder, J.] Univ Oslo, Ullevaal Univ Hosp, Dept Anaesthesia, Fac Div Ullevaal Univ Hosp, N-0407 Oslo, Norway; [Hoymork, S. C.] Asker & Baerum Hosp, Dept Anaesthesia & Intens Care, Oslo, Norway	Lenz, H (reprint author), Univ Oslo, Ullevaal Univ Hosp, Dept Anaesthesia, Fac Div Ullevaal Univ Hosp, N-0407 Oslo, Norway.	harald.lenz@medisin.uio.no					Aasbo V, 2002, ACTA ANAESTH SCAND, V46, P674, DOI 10.1034/j.1399-6576.2002.460607.x; Anderson WS, 2002, PAIN, V99, P207, DOI 10.1016/S0304-3959(02)00103-3; Angst MS, 2003, PAIN, V106, P49, DOI 10.1016/S0304-3959(03)00276-8; Chindalore VL, 2005, J PAIN, V6, P392, DOI 10.1016/j.jpain.2005.01.356; Crawford MW, 2006, ANESTH ANALG, V102, P1662, DOI 10.1213/01.ane.0000216036.95705.c2; Dahl V, 1997, ACTA ANAESTH SCAND, V41, P1341, DOI 10.1111/j.1399-6576.1997.tb04655.x; Fletcher D, 2000, ANESTH ANALG, V90, P666, DOI 10.1097/00000539-200003000-00029; Gan TJ, 1997, ANESTHESIOLOGY, V87, P1075, DOI 10.1097/00000542-199711000-00011; Gelb AW, 2003, CAN J ANAESTH, V50, P946, DOI 10.1007/BF03018745; Guignard B, 2000, ANESTHESIOLOGY, V93, P409, DOI 10.1097/00000542-200008000-00019; Hood DD, 2003, ANESTH ANALG, V97, P810, DOI 10.1213/01.ANE.0000078811.80093.88; Joly V, 2005, ANESTHESIOLOGY, V103, P147, DOI 10.1097/00000542-200507000-00022; Koppert W, 2003, ANESTHESIOLOGY, V99, P152, DOI 10.1097/00000542-200307000-00025; Koppert W, 2007, ACUTE PAIN, V9, P21; Lee SC, 1997, ANESTH ANALG, V84, P810, DOI 10.1097/00000539-199704000-00021; Luginbuhl M, 2003, ANESTH ANALG, V96, P726, DOI 10.1213/01.ANE.0000048086.58161.18; Petersen KL, 2001, ANESTHESIOLOGY, V94, P15, DOI 10.1097/00000542-200101000-00008; Servin Frederique S, 2003, Curr Opin Anaesthesiol, V16, P367, DOI 10.1097/00001503-200308000-00001; SHAFER SL, 1990, ANESTHESIOLOGY, V73, P1091, DOI 10.1097/00000542-199012000-00005; Suarez-Roca H, 2006, BEHAV BRAIN RES, V167, P205, DOI 10.1016/j.bbr.2005.09.006; van der Zwan T, 2005, EUR J ANAESTH, V22, P438, DOI 10.1017/S0265021505000748; Vinik HR, 1998, ANESTH ANALG, V86, P1307, DOI 10.1097/00000539-199806000-00033; Wang HY, 2005, NEUROSCIENCE, V135, P247, DOI 10.1016/j.neuroscience.2005.06.003; Yarmush J, 1997, ANESTHESIOLOGY, V87, P235, DOI 10.1097/00000542-199708000-00009	24	12	17	0	2	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0001-5172			ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	JAN	2008	52	1					149	154		10.1111/j.1399-6576.2007.01471.x			6	Anesthesiology	Anesthesiology	242ZD	WOS:000251763800023	17996006	Green Published			2020-06-30	J	Shafer, SL; Nekhendzy, V				Shafer, Steven L.; Nekhendzy, Vladimir			Anesthesia matters: Statistical anomaly or new paradigm?	ANESTHESIA AND ANALGESIA			English	Editorial Material							TOTAL INTRAVENOUS ANESTHESIA; ISOFLURANE-NITROUS-OXIDE; SPINAL-ANESTHESIA; PROPOFOL		[Shafer, Steven L.] Columbia Univ, Med Ctr, Dept Anesthesiol, New York, NY 10032 USA; [Nekhendzy, Vladimir] Stanford Univ, Dept Anesthesia, Stanford, CA 94305 USA	Shafer, SL (reprint author), Columbia Univ, Med Ctr, Dept Anesthesiol, 622 W 168th St,PH 5-505, New York, NY 10032 USA.	sshafer@columbia.edu		Shafer, Steven/0000-0002-0289-7793			Boccara G, 1998, CAN J ANAESTH, V45, P839, DOI 10.1007/BF03012216; Cheng SS, 2008, ANESTH ANALG, V106, P264, DOI 10.1213/01.ane.0000287653.77372.d9; Drasner K, 1997, ANESTHESIOLOGY, V87, P469, DOI 10.1097/00000542-199709000-00002; Flood P, 2002, ANESTHESIOLOGY, V97, P192, DOI 10.1097/00000542-200207000-00027; HENDOLIN H, 1994, ACTA ANAESTH SCAND, V38, P694, DOI 10.1111/j.1399-6576.1994.tb03979.x; Kevin LG, 2005, ANESTH ANALG, V101, P1275, DOI 10.1213/01.ANE.0000180999.81013.D0; RIGLER ML, 1991, ANESTH ANALG, V72, P275; Rohm KD, 2005, EUR J ANAESTH, V22, P209, DOI 10.1017/S0265021505000360; Shafer SL, 2007, ANESTH ANALG, V104, P247, DOI 10.1213/01.ane.0000253033.96992.f5; Visser K, 2001, ANESTHESIOLOGY, V95, P616, DOI 10.1097/00000542-200109000-00012; Zhang SH, 2004, ACTA PHARMACOL SIN, V25, P334	11	9	9	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	JAN	2008	106	1					3	4		10.1213/01.ane.0000299045.22629.86			2	Anesthesiology	Anesthesiology	243VB	WOS:000251824300002	18165544				2020-06-30	J	Mathews, DM; Gaba, V; Zaku, B; Neuman, GG				Mathews, Donald M.; Gaba, Vijay; Zaku, Bledi; Neuman, George G.			Can remifentanil replace nitrous oxide during anesthesia for ambulatory orthopedic surgery with desflurane and fentanyl?	ANESTHESIA AND ANALGESIA			English	Article							MINIMUM ALVEOLAR CONCENTRATION; FISCHER RATS; GABAERGIC NEURONS; BISPECTRAL INDEX; SPINAL-CORD; MAC-BAR; SEVOFLURANE; PROPOFOL; ISOFLURANE; INCISION	BACKGROUND: The administration of nitrous oxide (N2O) may be associated with side effects and toxicities. Remifentanil shares characteristics with N2O, including MAC-reducing and antinociceptive effects and a rapid decrease in clinical effect when discontinued. We compared the outcome after ambulatory orthopedic surgery with desflurane and fentanyl supplemented with clinically equivalent doses of either N2O or remifentanil. METHODS: Seventy patients undergoing ambulatory orthopedic surgery were studied. Thirty-five received 66% N,O and 35 received remifentanil 0.085 ug - kg - nun addition to desflurane, titrated to a bispectral index (BIS) value of 50, and a fentanyl infusion. The principle outcome measure was time to awakening to verbal stimulation. Secondary outcome measures included neuropsychological testing, time to orientation, hemodynamic values, pain and nausea visual analog scores, discharge times, and satisfaction scores. The average end-tidal desflurane concentration and fentanyl effect-site concentration were determined. RESULTS: The median time (interquartile range) to awakening to verbal stimulation, 3.0 min (3.0-5.0 min) in the remifentanil group and 4.6 min (3.0-8.1 min) in the N2O group was not significantly different. Median time to orientation was significantly faster in the remifentanil group: 6.0 min (5.0-8.5 min) compared with 8.0 min (5.0-12.8 min) for the N2O group. There was no difference between groups in desflurane or fentanyl administration, neuropsychological testing, or any other outcome measure. CONCLUSIONS: This study demonstrates that a remifentanil infusion of 0.085 Ag center dot kg(-1) center dot min(-1) may be substituted for 66% N2O during desflurane/fentanyl anesthesia without any clinically significant change in outcome.	St Vincents Manhattan, St Vincent Catholic Med Ctr, Dept Anesthesiol, New York, NY 10011 USA; New York Med Coll, Valhalla, NY 10595 USA	Mathews, DM (reprint author), St Vincents Hosp & Med Ctr, Dept Anesthesiol, 170 W 12th St,NR 408, New York, NY 10011 USA.	dmathews@svcmcny.org					Albertin A, 2006, EUR J ANAESTH, V23, P510, DOI 10.1017/S0265021506000305; Arellano RJ, 2000, ANESTHESIOLOGY, V93, P332, DOI 10.1097/00000542-200008000-00009; Badner NH, 2000, ANESTH ANALG, V91, P1073, DOI 10.1097/00000539-200011000-00006; Barr G, 1999, BRIT J ANAESTH, V82, P827; Daniel M, 1998, ANESTHESIOLOGY, V88, P43, DOI 10.1097/00000542-199801000-00009; Eger EI, 2005, ANESTH ANALG, V101, P688, DOI 10.1213/01.ANE.0000158611.15820.3D; Eger EI, 2001, ANESTH ANALG, V93, P947, DOI 10.1097/00000539-200110000-00029; Felmet K, 2000, J PEDIATR-US, V137, P427, DOI 10.1067/mpd.2000.107387; Glass PS, 1997, ANESTHESIOLOGY, V86, P836, DOI 10.1097/00000542-199704000-00014; HADZIC A, 1995, ANESTHESIOLOGY, V83, P863, DOI 10.1097/00000542-199510000-00028; Hashimoto T, 2001, ANESTHESIOLOGY, V95, P463, DOI 10.1097/00000542-200108000-00031; Hopkins PM, 2005, BEST PRACT RES-CLIN, V19, P381, DOI 10.1016/j.bpa.2005.03.002; HORNBEIN TF, 1982, ANESTH ANALG, V61, P553; Karalapillai D, 2006, ANESTH ANALG, V102, P1088, DOI 10.1213/01.ane.0000198672.05639.0a; Katoh T, 1999, ANESTHESIOLOGY, V90, P398, DOI 10.1097/00000542-199902000-00012; Kihara S, 2003, ANESTHESIOLOGY, V99, P1055, DOI 10.1097/00000542-200311000-00008; KOBLIN DD, 1982, ANESTH ANALG, V61, P75; Lang E, 1996, ANESTHESIOLOGY, V85, P721, DOI 10.1097/00000542-199610000-00006; Lee LHY, 2005, ANESTHESIOLOGY, V102, P398, DOI 10.1097/00000542-200502000-00024; Lee P, 1999, LANCET, V353, P554, DOI 10.1016/S0140-6736(98)10090-9; Lysakowski C, 2001, BRIT J ANAESTH, V86, P523, DOI 10.1093/bja/86.4.523; Manyam SC, 2006, ANESTHESIOLOGY, V105, P267, DOI 10.1097/00000542-200608000-00009; Mckay RE, 2005, ANESTH ANALG, V100, P697, DOI 10.1213/01.ANE.0000146514.65070.AE; Ohashi Y, 2003, ANESTHESIOLOGY, V99, P947, DOI 10.1097/00000542-200310000-00030; Orii R, 2002, ANESTHESIOLOGY, V97, P1458, DOI 10.1097/00000542-200212000-00018; Richebe P, 2005, ANESTHESIOLOGY, V103, P845, DOI 10.1097/00000542-200510000-00024; ROIZEN MF, 1981, ANESTHESIOLOGY, V54, P390, DOI 10.1097/00000542-198105000-00008; ROWLAND AS, 1995, AM J EPIDEMIOL, V141, P531, DOI 10.1093/oxfordjournals.aje.a117468; SEBEL PS, 1992, ANESTHESIOLOGY, V76, P52, DOI 10.1097/00000542-199201000-00008; Selzer RR, 2003, NEW ENGL J MED, V349, P45, DOI 10.1056/NEJMoa021867; Shaw ADS, 1998, ANAESTHESIA, V53, P213, DOI 10.1046/j.1365-2044.1998.00412.x; Smith I, 2006, CURR OPIN ANESTHESIO, V19, P592, DOI 10.1097/01.aco.0000247339.84685.d7; Stenqvist O, 2001, ACTA ANAESTH SCAND, V45, P135, DOI 10.1034/j.1399-6576.2001.450201.x; Swan HD, 1999, ANESTHESIOLOGY, V91, P667, DOI 10.1097/00000542-199909000-00017; Tramer M, 1996, BRIT J ANAESTH, V76, P186	35	17	18	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	JAN	2008	106	1					101	108		10.1213/01.ane.0000289526.20117.26			8	Anesthesiology	Anesthesiology	243VB	WOS:000251824300020	18165562				2020-06-30	J	Kaygusuz, K; Gokce, G; Gursoy, S; Ayan, S; Mimaroglu, C; Gultekin, Y				Kaygusuz, Kenan; Gokce, Gokhan; Gursoy, Sinan; Ayan, Semih; Mimaroglu, Caner; Gultekin, Yener			A comparison of sedation with dexmedetomidine or propofol during shockwave lithotripsy: A Randomized controlled trial	ANESTHESIA AND ANALGESIA			English	Article							INTENSIVE-CARE-UNIT; HEALTHY-VOLUNTEERS; CONSCIOUS SEDATION; WAVE LITHOTRIPSY; HUMANS; ANALGESIA; FENTANYL; EFFICACY; MORPHINE; PATTERN	BACKGROUND: Dexmedetomidine, because it has both sedative and analgesic properties, may be suitable for conscious sedation during painful procedures. Extracor-Poreal shockwave lithotripsy (ESWL) is a minimal to mildly painful procedure that requires conscious sedation. We thus evaluated the utility of dexmedetomidine compared with propofol during an ESWL procedure. METHODS: Forty-six patients were randomly allocated into two groups to receive either dexmedetomidine or propofol for elective ESWL. Dexmedetomidine was infused at 6 mu g center dot kg(-1) center dot h(-1) for 10 min followed by an infusion rate of 0.2 mu g center dot kg(-1) center dot h(-1). Propofol was infused at 6 mg center dot kg(-1) center dot h(-1) for 10 min followed by an infusion of 2.4 mg center dot kg(-1) center dot h(-1). Fentanyl 1 mu g/kg IV was given to all patients 10 min before ESWL. Pain intensity was evaluated with a visual analog scale at 5-min intervals during ESWL (10-35 min). Sedation was determined using the Observer's Assessment of Alertness/Sedation. The Observer's Assessment of Alertness/ Sedation scores and hemodynamic and respiratory variables were recorded regularly during ESWL (35 min) and up to 85 min after. RESULTS: Forty patients were evaluated. Visual analog scale values with dexmedetomidine were significantly lower than those with propofol only at the 25-35 min assessments (P < 0.05). During sedation, the respiratory rate with dexmedetomidine was significantly slower but Spo(2) was significantly higher than with propofol (P < 0.05). Other clinical variables were similar (P > 0.05). CONCLUSION: A combination of dexmedetomidine with fentanyl can be used safely and effectively for sedation and analgesia during ESWL.	[Kaygusuz, Kenan; Gursoy, Sinan; Mimaroglu, Caner] Cumhuriyet Univ, Sch Med, Dept Anesthesiol, TR-58140 Sivas, Turkey; [Gokce, Gokhan; Ayan, Semih; Gultekin, Yener] Cumhuriyet Univ, Sch Med, Dept Urol, TR-58140 Sivas, Turkey	Kaygusuz, K (reprint author), Cumhuriyet Univ, Sch Med, Dept Anesthesiol, TR-58140 Sivas, Turkey.	kaygusuz@cumhuriyet.edu.tr					Alhashemi JA, 2004, CAN J ANAESTH, V51, P342, DOI 10.1007/BF03018237; Arain SR, 2002, ANESTH ANALG, V95, P461, DOI 10.1097/00000539-200208000-00042; Aybek Z, 1998, EUR UROL, V34, P207, DOI 10.1159/000019714; BELLEVILLE JP, 1992, ANESTHESIOLOGY, V77, P1125, DOI 10.1097/00000542-199212000-00013; BLOUIN RT, 1993, ANESTHESIOLOGY, V79, P1177, DOI 10.1097/00000542-199312000-00007; Candela Toha AM, 1991, REV ESP ANESTESIOL R, V38, P218; CLAEYS MA, 1988, BRIT J ANAESTH, V60, P3, DOI 10.1093/bja/60.1.3; Ebert TJ, 2000, ANESTHESIOLOGY, V93, P382, DOI 10.1097/00000542-200008000-00016; Gesztesi Z, 2000, ANESTH ANALG, V90, P567, DOI 10.1097/00000539-200003000-00013; Glass PS, 1997, ANESTHESIOLOGY, V86, P836, DOI 10.1097/00000542-199704000-00014; Hall JE, 2000, ANESTH ANALG, V90, P699, DOI 10.1097/00000539-200003000-00035; Hosking MP, 1997, J ENDOUROL, V11, P309, DOI 10.1089/end.1997.11.309; Hsu YW, 2004, ANESTHESIOLOGY, V101, P1066, DOI 10.1097/00000542-200411000-00005; JAAKOLA ML, 1991, PAIN, V46, P281, DOI 10.1016/0304-3959(91)90111-A; Jalowiecki P, 2005, ANESTHESIOLOGY, V103, P269, DOI 10.1097/00000542-200508000-00009; KAYSER V, 1995, PAIN, V60, P275, DOI 10.1016/0304-3959(94)00125-X; Leino K, 1999, ANAESTHESIA, V54, P835; MCMURRAY TJ, 1990, ANAESTHESIA, V45, P322, DOI 10.1111/j.1365-2044.1990.tb14743.x; ROSA G, 1992, ACTA ANAESTH SCAND, V36, P128, DOI 10.1111/j.1399-6576.1992.tb03438.x; SAREGO MM, 1999, ANESTH ANALG, V88, P518; SCHEININ B, 1992, BRIT J ANAESTH, V68, P126, DOI 10.1093/bja/68.2.126; Talke P, 2003, ANESTHESIOLOGY, V99, P65, DOI 10.1097/00000542-200307000-00014; Torigoe K, 2000, Masui, V49, P740; Venn RM, 2001, BRIT J ANAESTH, V87, P684, DOI 10.1093/bja/87.5.684; Venn RM, 1999, ANAESTHESIA, V54, P1136, DOI 10.1046/j.1365-2044.1999.01114.x; Venn RM, 2000, CRIT CARE, V4, P302, DOI 10.1186/cc712	26	55	61	0	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	JAN	2008	106	1					114	119		10.1213/01.ane.0000296453.75494.64			6	Anesthesiology	Anesthesiology	243VB	WOS:000251824300022	18165564				2020-06-30	J	Cheng, SS; Yeh, J; Flood, P				Cheng, Sean S.; Yeh, Janet; Flood, Pamela			Anesthesia matters: Patients anesthetized with propofol have less postoperative pain than those anesthetized with isoflurane	ANESTHESIA AND ANALGESIA			English	Article							NICOTINE NASAL SPRAY; TOTAL INTRAVENOUS ANESTHESIA; EARLY RECOVERY; SOMATIC PAIN; INHALATION; SURGERY; PHARMACOKINETICS; EXPERIENCES; INHIBITION; DESFLURANE	BACKGROUND: Preclinical studies have suggested that some volatile anesthetics induce a hyperalgesic state that may be secondary to nicotinic inhibition. A previous trial of treatment with nicotine nasal spray demonstrated postoperative analgesia in women anesthetized with isoflurane. To determine whether the effect of nicotine was reversing hyperalgesia induced by isoflurane, or simply acting as an analgesic, we studied the effect of nicotine on postoperative pain in women anesthetized with isoflurane or propofol, with fentanyl. METHODS: In a randomized, prospective, double-blind trial, we assigned 80 women having open uterine surgery to be anesthetized with isoflurane or propofol. Within each anesthetic group, the subjects were further randomly assigned to receive nicotine 3 mg or placebo. Pain reported with a numerical analog scale was the primary outcome variable. RESULTS: The patient demographics were similar. Women who were anesthetized with propofol reported less pain and used less morphine during the first day after surgery than women who were anesthetized with isoflurane (P < 0.01, P < 0.01). Nicotine treatment did not change pain report or morphine use in either anesthetic group (P > 0.05). CONCLUSIONS: General anesthesia with propofol and is associated with less postoperative pain and morphine use than general anesthesia with isoflurane. Nicotine was not analgesic in this trial. If these results are repeated in other populations, reduced postoperative pain can be added to the previously described improvement in nausea and vomiting as a potential benefit of anesthesia with propofol.	[Cheng, Sean S.; Yeh, Janet; Flood, Pamela] Columbia Univ, Dept Anesthesiol, New York, NY 10032 USA	Flood, P (reprint author), Columbia Univ, Dept Anesthesiol, 630 W 168th St, New York, NY 10032 USA.	Pdf3@columbia.edu		Yeh, Janet/0000-0003-1205-1262			Benowitz NL, 1997, BRIT J CLIN PHARMACO, V43, P259, DOI 10.1111/j.1365-2125.1997.00566.x; BRIGGS LP, 1982, BRIT J ANAESTH, V54, P307, DOI 10.1093/bja/54.3.307; DUNDEE JW, 1960, BRIT J ANAESTH, V32, P453, DOI 10.1093/bja/32.10.453; Eriksson H, 1996, ANESTH ANALG, V82, P533, DOI 10.1097/00000539-199603000-00019; Fishbein L, 2000, J INVEST MED, V48, P435; Flood P, 2004, ANESTHESIOLOGY, V101, P1417; Flood P, 1997, ANESTHESIOLOGY, V86, P859, DOI 10.1097/00000542-199704000-00016; Flood P, 2002, ANESTHESIOLOGY, V97, P192, DOI 10.1097/00000542-200207000-00027; Goldstein Frederick J., 2002, Journal of the American Osteopathic Association, V102, pS15; Guthrie SK, 1999, EUR J CLIN PHARMACOL, V55, P639, DOI 10.1007/s002280050686; Habib AS, 2004, ANESTH ANALG, V99, P77, DOI 10.1213/01.ANE.0000120161.30788.04; Hand R Jr, 2001, AANA J, V69, P466; Hofer CK, 2003, BRIT J ANAESTH, V91, P631, DOI 10.1093/bja/aeg243; Holtman JR, 2003, EUR J PHARMACOL, V470, P149, DOI 10.1016/S0014-2999(03)01782-5; JEWETT BA, 1992, ANESTHESIOLOGY, V77, P1148, DOI 10.1097/00000542-199212000-00016; Mukherjee K, 2003, ANAESTHESIA, V58, P176, DOI 10.1046/j.1365-2044.2003.02964_4.x; Nemmani KVS, 2003, NEUROPHARMACOLOGY, V44, P304, DOI 10.1016/S0028-3908(02)00374-X; OWEN H, 1990, PAIN, V41, P303, DOI 10.1016/0304-3959(90)90007-Z; Ozkose Z, 2001, J NEUROSURG ANESTH, V13, P296, DOI 10.1097/00008506-200110000-00003; Rohm KD, 2006, ACTA ANAESTH SCAND, V50, P14, DOI 10.1111/j.1399-6576.2006.00905.x; Rowley TJ, 2005, ANESTH ANALG, V100, P991, DOI 10.1213/01.ANE.0000147708.73945.B3; Schneider NG, 1996, CLIN PHARMACOKINET, V31, P65, DOI 10.2165/00003088-199631010-00005; Stephens J, 2003, RHEUMATOLOGY, V42, P40, DOI 10.1093/rheumatology/keg497; Sun YY, 2005, BRAIN RES, V1043, P231, DOI 10.1016/j.brainres.2005.02.048; Svensson I, 2000, J PAIN SYMPTOM MANAG, V20, P193, DOI 10.1016/S0885-3924(00)00174-3; Thomas T, 1998, PAIN, V75, P177, DOI 10.1016/S0304-3959(97)00218-2; Udesky JO, 2005, ANESTH ANALG, V101, P407, DOI 10.1213/01.ANE.0000155291.81338.90; Wong J, 2002, CAN J ANAESTH, V49, P13, DOI 10.1007/BF03020413; Zhang Y, 2000, ANESTH ANALG, V91, P462, DOI 10.1097/00000539-200008000-00044	29	80	83	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	JAN	2008	106	1					264	269		10.1213/01.ane.0000287653.77372.d9			6	Anesthesiology	Anesthesiology	243VB	WOS:000251824300047	18165589				2020-06-30	J	Forster, JG; Lumme, HM; Palkama, VJ; Rosenberg, PH; Pitkanen, MT				Forster, Johannes G.; Lumme, Hilkka M.; Palkama, Vilja J.; Rosenberg, Per H.; Pitkanen, Mikko T.			Epinephrine 4 mu g/ml added to a low-dose mixture of ropivacaine and fentanyl for lumbar epidural analgesia after total knee arthroplasty	ANESTHESIA AND ANALGESIA			English	Article; Proceedings Paper	26th Annual Congress of the European-Society-of-Regional-Anesthesia-and-Pain-Therapy	SEP 12-15, 2007	Valencia, SPAIN	European Soc Reg Anesthesia & Pain Therapy			CORD BLOOD-FLOW; SPINAL-CORD; ABDOMINAL-SURGERY; BUPIVACAINE; ADRENALINE; INFUSION; CLONIDINE	BACKGROUND: Epinephrine 2 mu g/mL added to a local anesthetic-opioid mixture has been found to improve postoperative continuous epidural analgesia at the thoracic (TEA) but not at lumbar (LEA) level. Therefore, we studied whether a higher dose of epinephrine could improve LEA. METHODS: Patients received LEA comprising of ropivacaine 1.8 mg/mL and fentanyl 3 mu g/mL either without (group RF, n = 32) or with epinephrine 4 mu g/mL (group RFE, n = 31) for 2 days after total knee arthroplasty. Rescue pain medication consisted of epidural top-ups (study mixture) and parenteral oxycodone. RESULTS: Total amounts of epidurally administered drugs were significantly higher in group RFE. Otherwise, the groups did not differ significantly regarding pain relief and side effects. CONCLUSIONS: As part of the multimodal pain treatment used, the epidural adjuvant epinephrine 4 mu g/mL (12-32 mu g/h) did not improve LEA after total knee arthroplasty.	[Forster, Johannes G.; Rosenberg, Per H.] Helsinki Univ Hosp, Dept Anaesthesiol & Intens Care Med, Helsinki 00029, Finland; [Lumme, Hilkka M.; Palkama, Vilja J.; Pitkanen, Mikko T.] Invalid Fdn, Orton Orthoped Hosp, Dept Anesthesia, Helsinki, Finland	Forster, JG (reprint author), Helsinki Univ Hosp, Dept Anaesthesiol & Intens Care Med, Haartmaninkatu 4,POB 340, Helsinki 00029, Finland.	johannes.forster@hus.fi		Forster, Johannes Georg/0000-0001-5344-9926			Baron CM, 1996, ANESTH ANALG, V82, P760, DOI 10.1097/00000539-199604000-00015; Bernards CM, 2003, ANESTHESIOLOGY, V99, P466, DOI 10.1097/00000542-200308000-00030; CEDERHOLM I, 1994, ACTA ANAESTH SCAND, V38, P322, DOI 10.1111/j.1399-6576.1994.tb03901.x; COLLINS JG, 1984, ANESTHESIOLOGY, V60, P269, DOI 10.1097/00000542-198404000-00001; COVINO BG, 1998, UEURAL BLOCKADE CLIN, P97; Curatolo M, 2002, ANESTH ANALG, V94, P1381, DOI 10.1097/00000539-200206000-00001; Curatolo M, 1997, ANESTHESIOLOGY, V87, P785, DOI 10.1097/00000542-199710000-00011; Forster JG, 2004, BRIT J ANAESTH, V93, P670, DOI 10.1093/bja/aeh259; Forster JG, 2003, ACTA ANAESTH SCAND, V47, P1106, DOI 10.1034/j.1399-6576.2003.00211.x; Gogarten W, 2003, ANASTH INTENSIVMED, V44, P218; KOZODY R, 1984, CAN ANAESTH SOC J, V31, P503, DOI 10.1007/BF03009534; Kristensen JD, 1998, ACTA ANAESTH SCAND, V42, P685, DOI 10.1111/j.1399-6576.1998.tb05302.x; Millet L, 1998, J APPL PHYSIOL, V85, P181; Niemi G, 1998, ACTA ANAESTH SCAND, V42, P897, DOI 10.1111/j.1399-6576.1998.tb05348.x; Niemi G, 2002, ANESTH ANALG, V94, P1598, DOI 10.1097/00000539-200206000-00044; REDDY SVR, 1980, J PHARMACOL EXP THER, V213, P525; Sakaguchi Y, 2000, ANAESTH INTENS CARE, V28, P522, DOI 10.1177/0310057X0002800506; Silvasti M, 2001, ACTA ANAESTH SCAND, V45, P471, DOI 10.1034/j.1399-6576.2001.045004471.x	18	9	10	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	JAN	2008	106	1					301	304		10.1213/01.ane.0000287673.27439.19			4	Anesthesiology	Anesthesiology	243VB	WOS:000251824300052	18165594				2020-06-30	J	Chang, LC; Kuczkowski, KM				Chang, Leon C.; Kuczkowski, Krzysztof M.			The ex utero intrapartum treatment procedure: anesthetic considerations	ARCHIVES OF GYNECOLOGY AND OBSTETRICS			English	Article; Proceedings Paper	39th Annual Meeting of the Society-for-Obstetric-Anesthesia-and-Perinatology	MAY 16-19, 2007	Banff, CANADA	Soc Obstet Anesthesia & Perinatol		ex utero intrapartum treatment (EXIT); procedure; fetal malformation; cesarean delivery; obstetric anesthesia; general anesthesia; pregnancy; fetal perinatal surgery	AIRWAY MANAGEMENT	The ex-utero intrapartum treatment ( EXIT) procedure is an uncommon operation indicated for fetal lesions with the potential to cause life-threatening airway obstruction immediately after delivery. By maintaining utero-placental circulation, the fetal airway can be evaluated and secured prior to delivery. The anesthetic goals for the EXIT procedure differ significantly from a cesarean delivery and include profound uterine relaxation, fetal anesthesia and maintenance of the maternal-fetal circulation. We present a case of an uneventful EXIT procedure and include a discussion of the anesthetic goals for this operation.	[Chang, Leon C.; Kuczkowski, Krzysztof M.] Univ Calif San Diego, Med Ctr, Dept Anesthesiol, San Diego, CA 92103 USA; [Chang, Leon C.; Kuczkowski, Krzysztof M.] Univ Calif San Diego, Dept Reprod Med, San Diego, CA 92103 USA	Kuczkowski, KM (reprint author), Univ Calif San Diego, Med Ctr, Dept Anesthesiol, 200 W Arbor Dr, San Diego, CA 92103 USA.	kkuczkowski@ucsd.edu					BALSER JR, 2003, PRACTICAL APPROACH C, P50; Chan DFY, 2006, ACTA PAEDIATR, V95, P1303, DOI 10.1080/08035250600580545; Dahlgren G, 2004, INT J OBSTET ANESTH, V13, P178, DOI 10.1016/j.ijoa.2004.01.007; Ducloy-Bouthors AS, 2006, ANN FR ANESTH, V25, P638, DOI 10.1016/j.annfar.2006.02.023; Hullett BJ, 2006, PEDIATR ANESTH, V16, P794, DOI 10.1111/j.1460-9592.2006.01859.x; Kuczkowski KM, 2006, CAN J ANAESTH, V53, P1117, DOI 10.1007/BF03022880; MacKenzie TC, 2002, CURR OPIN PEDIATR, V14, P453, DOI 10.1097/00008480-200208000-00018; Manrique S, 2007, Rev Esp Anestesiol Reanim, V54, P45; Stevens GH, 2002, EUR J OBSTET GYN R B, V100, P246, DOI 10.1016/S0301-2115(01)00467-5; Zadra Nicola, 2004, Best Pract Res Clin Anaesthesiol, V18, P259, DOI 10.1016/j.bpa.2003.11.001	10	11	15	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0932-0067			ARCH GYNECOL OBSTET	Arch. Gynecol. Obstet.	JAN	2008	277	1					83	85		10.1007/s00404-007-0402-9			3	Obstetrics & Gynecology	Obstetrics & Gynecology	255MN	WOS:000252662200015	17619892				2020-06-30	J	Chiaretti, A; Genovese, O; Antonelli, A; Tortorolo, L; Ruggiero, A; Focarelli, B; Di Rocco, C				Chiaretti, Antonio; Genovese, Orazio; Antonelli, Alessia; Tortorolo, Luca; Ruggiero, Antonio; Focarelli, Benedetta; Di Rocco, Concezio			Patient-controlled analgesia with fentanil and midazolam in children with postoperative neurosurgical pain	CHILDS NERVOUS SYSTEM			English	Article						children; fentanil; midazolam; pain; patient-controlled analgesia	MUCOSITIS PAIN; ADOLESCENTS; MORPHINE; CANCER; CARE	Backgorund Pain is the most common discomfort experienced by children undergoing major operations. It is most often not adequately treated because of inexperience and unfounded fears related to the use of opioid drugs. In adults, patient-controlled analgesia (PCA) is widely administered, while in children, its use with opioid drugs is still under evaluation for safety and efficacy. Objectives The objective of the study is to evaluate the safety and efficacy of an opioid drug (fentanil) administered by PCA associated with a sedative-adjuvant drug (midazolam) administered by continuous infusion in children having undergone major neurosurgical procedures. Materials and methods Sixteen children with moderate to severe postoperative pain were treated with fentanil by PCA (booster doses of 1 mu g/kg) plus continuous infusion of midazolam (2 mu g/kg per min) by an intravenous route. To evaluate safety and efficacy of this analgesic protocol, different subjective and objective parameters were monitored at 4-h intervals. In addition, patients' satisfaction was assessed by a questionnaire at the end of the treatment. Main results All children experienced a good degree of analgesia and did not require any other analgesic drug during the treatment. Both subjective and objective parameters improved after starting pain-relieving treatment, and no major side effects occurred. The analysis of the answers of the questionnaire administered to the children showed a high grade of satisfaction. Conclusions PCA with fentanil plus continuous infusion of midazolam is a safe and efficacious method for analgesia in children with moderate to severe postoperative neurosurgical pain. The association of midazolam to fentanil also contributes to control anxiety and stress in this subset of patients and does not show any important side effects.	Univ Cattolica Sacro Cuore, A Gemelli Hosp, Pediat Intens Care Unit, I-00168 Rome, Italy	Chiaretti, A (reprint author), Univ Cattolica Sacro Cuore, A Gemelli Hosp, Pediat Intens Care Unit, Largo A Gemelli 8, I-00168 Rome, Italy.	achiaretti@yahoo.it	Ruggiero, Antonio/M-7849-2018	Ruggiero, Antonio/0000-0002-6052-3511; GENOVESE, Orazio/0000-0002-1989-1363			BERDE CB, 1991, J PEDIATR-US, V118, P460, DOI 10.1016/S0022-3476(05)82169-9; Bray RJ, 1996, PAEDIATR ANAESTH, V6, P121, DOI 10.1111/j.1460-9592.1996.tb00374.x; Coda BA, 1997, PAIN, V72, P333, DOI 10.1016/S0304-3959(97)00059-6; DICKENSON AH, 1991, BRIT MED BULL, V47, P690, DOI 10.1093/oxfordjournals.bmb.a072501; Dunbar PJ, 1995, J PAIN SYMPTOM MANAG, V10, P604, DOI 10.1016/0885-3924(95)00122-0; GAUKROGER PB, 1991, BURNS, V17, P396, DOI 10.1016/S0305-4179(05)80073-7; Griffin MJ, 1997, ANESTH ANALG, V85, P1317, DOI 10.1097/00000539-199712000-00025; Lehmann KA, 2005, J PAIN SYMPTOM MANAG, V29, pS72, DOI 10.1016/j.jpainsymman.2005.01.005; MACKIE AM, 1991, PAIN, V46, P265, DOI 10.1016/0304-3959(91)90109-B; OWEN H, 1989, ANAESTHESIA, V44, P7, DOI 10.1111/j.1365-2044.1989.tb11087.x; OWEN H, 1987, BRIT J ANAESTH, V159, P1328; Peters JWB, 1999, PAEDIATR ANAESTH, V9, P235, DOI 10.1046/j.1460-9592.1999.00358.x; Plummer JL, 1997, ANESTH ANALG, V84, P794, DOI 10.1097/00000539-199704000-00018; RODGERS BM, 1988, J PEDIATR SURG, V23, P259, DOI 10.1016/S0022-3468(88)80735-8; SHAPIRO BS, 1993, J PAIN SYMPTOM MANAG, V8, P22, DOI 10.1016/0885-3924(93)90116-D; Sidebotham D, 1997, J PAIN SYMPTOM MANAG, V14, P202, DOI 10.1016/S0885-3924(97)00182-6; Sirkia K, 1998, J PAIN SYMPTOM MANAG, V15, P220, DOI 10.1016/S0885-3924(98)00366-2; TOBIAS JD, 1994, PEDIATR CLIN N AM, V41, P1269; TOBIAS JD, 1991, CLIN PEDIATR, V31, P177; Trentadue N O, 1998, J Pediatr Nurs, V13, P15, DOI 10.1016/S0882-5963(98)80064-X; Tyler DC, 1996, PAEDIATR ANAESTH, V6, P33, DOI 10.1111/j.1460-9592.1996.tb00350.x; WALCO GA, 1994, NEW ENGL J MED, V331, P541, DOI 10.1056/NEJM199408253310812; Wong D L, 1988, Pediatr Nurs, V14, P9; Yeh CH, 1999, J ADV NURS, V30, P193, DOI 10.1046/j.1365-2648.1999.01064.x	24	12	13	0	2	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013 USA	0256-7040			CHILD NERV SYST	Childs Nerv. Syst.	JAN	2008	24	1					119	124		10.1007/s00381-007-0429-z			6	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	234JC	WOS:000251156400026	17639417				2020-06-30	J	Darwish, M; Kirby, M; Jiang, JG; Tracewell, W; Robertson, P				Darwish, Mona; Kirby, Mary; Jiang, John G.; Tracewell, William; Robertson, Philmore, Jr.			Bioequivalence following buccal and sublingual placement of fentanyl buccal tablet 400 mu g in healthy subjects	CLINICAL DRUG INVESTIGATION			English	Article							DOSE PROPORTIONALITY; BREAKTHROUGH PAIN; ADULT VOLUNTEERS; OPEN-LABEL; PHARMACOKINETICS; CANCER	Background and objective: The fentanyl buccal tablet (FBT) is formulated to enhance the rate and extent of fentanyl absorption across the buccal mucosa. FBT is indicated for the management of breakthrough pain (a transient flare of pain on a background of chronic pain otherwise controlled by treatment with opioids) in patients with cancer who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. This study assessed the bioequivalence of a single 400-mu g dose of FBT following buccal (i.e. above a molar tooth between the upper gum and cheek) and sublingual (i.e. placed under the tongue) placement in order to provide an alternative option to patients. Methods: Healthy subjects were randomized to receive one FBT 400 mu g buccally and sublingually (with naltrexone to minimize opioid effects) in an open-label, crossover design. Bioequivalence, as determined from the maximum plasma drug concentration (C-max) and the area under the plasma drug concentration-time curve from time 0 to infinity (AUC(infinity)), was established if the 90% confidence interval (CI) for the ratio of the means of sublingual/buccal values fell within the range of 0.80 to 1.25. Results: Ninety subjects were enrolled (67 men, 23 women; median age 24 years), and 78 completed the study. The criteria for bioequivalence were met for both C-max and AUC(infinity) for the two sites of tablet placement: sublingual/buccal ratio for C-max = 0.868 (90% CI 0.815, 0.924); sublingual/buccal ratio for AUC(infinity) = 0.947 (90% CI 0.901, 0.995). Buccal and sublingual placement resulted in similar values for both AUC from time 0 to tmax ' (AUC(tmax ')), where tmax ' is the median time to C-max of a single 400-mu g dose of FBT administered buccally (mean [SD]: 0.35 [0.16] ng center dot h/mL buccal; 0.35 [0.16] ng center dot h/mL sublingual) and for time to C-max (median [range]: 0.75 [0.33-3.13] hours buccal; 0.78 [0.17-3.00] hours sublingual). FBT was generally well tolerated following placement at both sites in healthy volunteers administered naltrexone. Conclusion: The results of this study support sublingual FBT placement as a viable alternative to buccal placement in patients who may require an alternate administration site.	[Darwish, Mona; Kirby, Mary] Cephalon Inc, Clin Pharmacol, Frazer, PA 19355 USA; [Jiang, John G.] Cephalon Inc, Biostat, Frazer, PA 19355 USA; [Tracewell, William; Robertson, Philmore, Jr.] Cephalon Inc, Drug Disposit, W Chester, PA USA	Darwish, M (reprint author), Cephalon Inc, Clin Pharmacol, 41 Moores Rd, Frazer, PA 19355 USA.	mdarwish@cephalon.com					Darwish M, 2007, EXPERT OPIN PHARMACO, V8, P2011, DOI 10.1517/14656566.8.13.2011; Darwish M, 2006, CLIN THER, V28, P707, DOI 10.1016/j.clinthera.2006.05.015; Darwish M, 2006, CLIN THER, V28, P715, DOI 10.1016/j.clinthera.2006.05.016; Darwish M, 2005, CLIN PHARMACOKINET, V44, P1279, DOI 10.2165/00003088-200544120-00006; Darwish M, 2007, J CLIN PHARMACOL, V47, P56, DOI 10.1177/0091270006294129; Darwish M, 2006, CLIN PHARMACOKINET, V45, P843, DOI 10.2165/00003088-200645080-00006; Durfee S, 2006, AM J DRUG DELIV, V4, P1, DOI DOI 10.2165/00137696-200604010-00001; GIBALDI M, 1982, [No title captured], P409; GUTSTEIN HB, 2001, GOODMAN GILMANS PHAR, P569; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Shojaei A H, 1998, J Pharm Pharm Sci, V1, P15; Slatkin Neal E, 2007, J Support Oncol, V5, P327; Stanley TH, 2005, J PAIN SYMPTOM MANAG, V29, pS67, DOI 10.1016/j.jpainsymman.2005.01.009	14	21	23	0	2	ADIS INT LTD	AUCKLAND	41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW ZEALAND	1173-2563			CLIN DRUG INVEST	Clin. Drug Invest.		2008	28	1					1	7		10.2165/00044011-200828010-00001			7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	248SB	WOS:000252174300001	18081355				2020-06-30	J	Miyazaki, T; Hanaoka, K; Namiki, A; Ogawa, S; Kitajima, T; Hosokawa, T; Ishida, T; Nogami, S; Mashimo, S				Miyazaki, Toyo; Hanaoka, Kazuo; Namiki, Akiyoshi; Ogawa, Setsuro; Kitajima, Toshimitsu; Hosokawa, Toyoshi; Ishida, Tomozo; Nogami, Shoji; Mashimo, Shigeto			Efficacy, safety and pharmacokinetic study of a novel fentanyl-containing matrix transdermal patch system in Japanese patients with cancer pain	CLINICAL DRUG INVESTIGATION			English	Article							AVAILABLE RESERVOIR FORMULATION; DELIVERY-SYSTEM; BIOEQUIVALENCE; MANAGEMENT; MISUSE	Background and objectives: A novel transdermal matrix patch delivery system for fentanyl has been developed to deliver improved management of cancer pain compared with that obtained using current fentanyl reservoir patches. This study was carried out to assess the efficacy, safety and pharmacokinetic profiles of a 12.5 mu g/h transdermal matrix fentanyl patch administered with the objective of replacing morphine, oral oxycodone or fentanyl injection formulations. The study also evaluated how the pharmacokinetic profiles of higher dose fentanyl patches (25, 37.5 and 50 mu g/h) changed following dose adjustments to optimize management of cancer pain. Methods: This open-label, multicentre study involved 87 patients of both sexes (>= 20 years) with a confirmed diagnosis of cancer. Patients were receiving any one of the following at the time of enrolment for the management of their cancer pain: (a) morphine < 45 mg/day orally, < 30 mg/day as suppositories, or < 15 mg/day by injection; (b) oral oxycodone < 30 mg/day; or (c) fentanyl injectable preparations < 03 mg/day. The patients were administered a 3-day course of fentanyl transdermal matrix patch application three times. The initial dose was 12.5 mu g/h, which could be increased when a new patch was applied if the physician deemed this to be appropriate based on pain intensity ratings and use of rescue medications. Efficacy outcomes included patients' global assessment scores (primary efficacy endpoint) measured on a five-step scale and dichotomous scores for physicians' global assessment. The occurrence of adverse events and changes in laboratory tests were evaluated as safety variables. Serum fentanyl levels were measured immediately after removal of the old patch on days 4, 7 and 10 to obtain data on trough serum concentrations. Results: The percentage of patients in category 3 or higher (very satisfied, satisfied, or neither satisfied nor dissatisfied) for the patient's global assessment score was 89.4% (76/85), indicating high patient satisfaction and attainment of sufficient pain control after patients switched from their previously used opioid analgesics. Similar findings were obtained on physicians' global assessment scores. A total of 316 adverse events occurred in 78 (90.7%) of 86 patients who were administered at least one patch. These included nausea (31 [36.0%]), somnolence (26 [30.2%]), vomiting (22 [25.6%]), diarrhoea (17 [19.8%]), constipation (14 [16.3%]), pyrexia (11[12.8%]) and insomnia (9 [10.5%]). The mean (SD) serum fentanyl concentration determined on day 4 was 169.9 +/- 103.4 pg/mL (n = 83). Serum fentanyl measurement results indicated that the same fentanyl patch dose resulted in similar serum fentanyl levels, while increased doses produced higher serum fentanyl concentrations. Conclusion: The fentanyl matrix transdermal patch formulation employed in this study demonstrated sufficient cancer pain control for patients switching from morphine or oral oxycodone preparations. The patch tested was well tolerated and its use did not result in any increased incidence of adverse drug reactions over those commonly found with opioid analgesics.	[Hanaoka, Kazuo] JR Tokyo Gen Hosp, Tokyo, Japan; [Miyazaki, Toyo] Tokyo Clin, Tokyo, Japan; [Namiki, Akiyoshi] Sapporo Med Univ, Dept Anesthesiol, Sapporo, Hokkaido, Japan; [Ogawa, Setsuro] Nihon Univ, Sch Med, Dept Anesthesiol, Tokyo, Japan; [Kitajima, Toshimitsu] Dokkyo Univ, Sch Med, Dept Anesthesiol, Dokkyo, Tochigi, Japan; [Hosokawa, Toyoshi] Kyoto Prefectural Univ Med, Dept Anesthesiol, Kyoto 602, Japan; [Ishida, Tomozo; Nogami, Shoji; Mashimo, Shigeto] Janssen Pharmaceut KK, Tokyo, Japan	Miyazaki, T (reprint author), Shin Otemachi Bldg,2-2-1 Otemachi,Chiyoda Ku, Tokyo, Japan.	h.miyazaki@mt.strins.or.jp					Aubrun F, 2004, CAN J ANAESTH, V51, P969, DOI 10.1007/BF03018481; CALIS KA, 1992, CLIN PHARMACY, V11, P22; Collins SL, 1997, PAIN, V72, P95, DOI 10.1016/S0304-3959(97)00005-5; Freynhagen R, 2005, J PAIN SYMPTOM MANAG, V30, P289, DOI 10.1016/j.jpainsymman.2005.03.015; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; Jeal W, 1997, DRUGS, V53, P109, DOI 10.2165/00003495-199753010-00011; Kuhlman JJ, 2003, J ANAL TOXICOL, V27, P499, DOI 10.1093/jat/27.7.499; Marier JF, 2007, BRIT J CLIN PHARMACO, V63, P121, DOI 10.1111/j.1365-2125.2006.02758.x; Marier JF, 2006, J CLIN PHARMACOL, V46, P642, DOI 10.1177/0091270006286901; MARQUARDT KA, 1995, ANN PHARMACOTHER, V29, P969, DOI 10.1177/106002809502901001; Mizuguchi T., 2001, MED DRUG J, V37, P2403; MIZUGUCHI T, 2001, MED DRUG J, V37, P2389; Radbruch L, 2001, PALLIATIVE MED, V15, P309, DOI 10.1191/026921601678320296; Reeves MD, 2002, MED J AUSTRALIA, V177, P552, DOI 10.5694/j.1326-5377.2002.tb04951.x; Sathyan G, 2005, CURR MED RES OPIN, V21, P1961, DOI 10.1185/030079905X65259; Tateishi T, 1996, ANESTH ANALG, V82, P167; *US FDA, 2005, PUBL HLTH ADV SAF WA; World Health Organization, 1996, CANC PAIN REL; *WORLD MED ASS DEC, 1996, REC GUID PHYS BIOM R	19	10	11	1	4	ADIS INT LTD	AUCKLAND	41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW ZEALAND	1173-2563			CLIN DRUG INVEST	Clin. Drug Invest.		2008	28	5					313	325		10.2165/00044011-200828050-00005			13	Pharmacology & Pharmacy	Pharmacology & Pharmacy	298VZ	WOS:000255716500005	18407717				2020-06-30	J	Schumann, H; Erickson, T; Thompson, TM; Zautcke, JL; Denton, JS				Schumann, Heather; Erickson, Tim; Thompson, Trevonne M.; Zautcke, John L.; Denton, J. Scott			Fentanyl epidemic in Chicago, Illinois and surrounding Cook County	CLINICAL TOXICOLOGY			English	Article						fentanyl; epidemic; Chicago	TRANSDERMAL FENTANYL; OVERDOSE; ABUSE; NALOXONE; DEATHS; MISUSE; USERS	Introduction. Epidemics related to illicit fentanyl abuse have been reported and the potential exists for a national epidemic associated with high mortality. This report describes emergency department visits for opioid toxicity and a recent outbreak of illicit fentanyl fatalities in Chicago, Illinois and surrounding Cook County. Methods. Retrospective chart review of opioid-related overdoses seen in our emergency department and a retrospective review of data from the Cook County Medical Examiner's Office Fentanyl Fatality Database from April 2005 through December 2006. Results. Our emergency department treated 43 patients with a total of 55 emergency department visits during this time. Paramedic transport was utilized for 83.6% of the emergency department visits and naloxone was administered during 80.4% of transports. Naloxone was administered during 47.3% of emergency department visits witwh total doses ranging from 0.4 mg to 12 mg. Eighty percent of cases were treated and discharged from the emergency department. During this same time frame, the Medical Examiner's office identified 342 fentanyl-related fatalities. In 2006, illicit fentanyl fatalities represented 6.9% of all Medical Examiner cases for that year. Approximately 80% of deaths occurred in Chicago. A peak in fentanyl-related deaths occurred in the spring of 2006 and again in the fall of 2006 while the number of emergency department visits peaked during May of 2006. Conclusion. Chicago and surrounding Cook County experienced an outbreak of 342 fentanyl-related deaths between April 2005 and December 2006. The experience demonstrated a clear need for an interdisciplinary approach to identifying, communicating, and managing an outbreak.	[Schumann, Heather] Univ Illinois, Coll Pharm, Dept Pharm Practice, Chicago, IL 60612 USA; [Erickson, Tim; Thompson, Trevonne M.; Zautcke, John L.] Univ Illinois, Dept Emergency Med, Chicago, IL 60612 USA; [Denton, J. Scott] Cook Cty Med Examiners Off, Chicago, IL USA	Schumann, H (reprint author), Univ Illinois, Coll Pharm, Dept Pharm Practice, 833 S Wood St, Chicago, IL 60612 USA.	heather.eyrich@gmail.com					Arvanitis ML, 2002, AM J EMERG MED, V20, P58, DOI 10.1053/ajem.2002.29562; Boddiger D, 2006, LANCET, V368, P569, DOI 10.1016/S0140-6736(06)69181-2; COEN J, 2007, CHICAGO TRIBUNE 0302; COEN J, 2006, CHICAGO TRIBUNE 0621; *COOK COUNT MED EX, 2007, DAT FIL; DALY C, 2006, COMMUNICATION   0515; GARRIOTT JC, 1984, J ANAL TOXICOL, V8, P288, DOI 10.1093/jat/8.6.288; GOODMAN DM, 2007, CHICAGO TRIBUNE 0125; HEINZMAN D, 2006, CHICAGO TRIBUNE 0207; HEINZMAN D, 2006, CHICAGO TRIBUNE 0608; HIBBS J, 1991, JAMA-J AM MED ASSOC, V265, P1011, DOI 10.1001/jama.265.8.1011; KRAM TC, 1981, ANAL CHEM, V3, pA1379; LABARBERA M, 1983, J PSYCHOACTIVE DRUGS, V15, P293, DOI 10.1080/02791072.1983.10471966; MARQUARDT KA, 1994, J TOXICOL-CLIN TOXIC, V32, P75, DOI 10.3109/15563659409000433; MARTIN M, 1991, ANN EMERG MED, V20, P158, DOI 10.1016/S0196-0644(05)81216-8; MATEJCZYK RJ, 1988, J ANAL TOXICOL, V12, P236, DOI 10.1093/jat/12.4.236; Maxwell S, 2006, J ADDICT DIS, V25, P89, DOI 10.1300/J069v25n03_11; NELSON LS, 2002, GOLDFRANKS TOXICOLOG, P901; PARE EM, 1987, J ANAL TOXICOL, V11, P272, DOI 10.1093/jat/11.6.272; POKLIS A, 1995, J TOXICOL-CLIN TOXIC, V33, P439, DOI 10.3109/15563659509013752; Reeves MD, 2002, MED J AUSTRALIA, V177, P552, DOI 10.5694/j.1326-5377.2002.tb04951.x; SILSBY HD, 1984, MIL MED, V149, P227; SMIALEK JE, 1994, J FORENSIC SCI, V39, P159; Sporer KA, 2007, ANN EMERG MED, V49, P172, DOI 10.1016/j.annemergmed.2006.05.025; SWEENEY A, 2005, CHICAGO SUN TIM 0817; Tharp AM, 2004, AM J FOREN MED PATH, V25, P178, DOI 10.1097/01.paf.0000127398.67081.11; 2001, 2002S0382IL001 NAT D; 2005, STATE CRIME LAB REPO	28	73	73	0	9	INFORMA HEALTHCARE	NEW YORK	52 VANDERBILT AVE, NEW YORK, NY 10017 USA	1556-3650			CLIN TOXICOL	Clin. Toxicol.		2008	46	6					501	506		10.1080/15563650701877374			6	Toxicology	Toxicology	319CR	WOS:000257142200003	18584361				2020-06-30	J	Hoy, SM; Keating, GM				Hoy, Sheridan M.; Keating, Gillian M.			Fentanyl transdermal matrix patch (Durotep (R) MT Patch; Durogesic (R) DTrans (R); Duragesic (R) SMAT) - In adults with cancer-related pain	DRUGS			English	Article							MU-OPIOID RECEPTOR; PHARMACOLOGICAL-PROPERTIES; THERAPEUTIC-EFFICACY; MORPHINE; INVOLVEMENT; MANAGEMENT; PREFERENCE; SYSTEMS	The fentanyl transdermal matrix patch is approved in Japan for the management of moderate to severe cancer-related pain in adults. Bioequivalence, in terms of exposure and the maximum and minimum serum concentrations, has been established between the fentanyl transdermal matrix patch 16.8 mg (100 mu g/h) and the fentanyl transdermal reservoir patch 10 mg (100 mu g/h) after single and multiple applications. The fentanyl transdermal matrix patch 2.1-8.4 mg (12.5-50 mu g/h) effectively managed chronic cancer-related pain in adults in a noncomparative, multicentre, phase II study; 89.4% of recipients rated their global assessment of pain as 'very satisfied', 'satisfied' or 'neither satisfied not-dissatisfied'. Adults with cancer- or non-cancer-related chronic pain were switched from fentanyl transdemal reservoir patch to fentanyl transdermal matrix patch therapy without compromising efficacy; no differences in pain intensity or sleep interference scores were seen between the two formulations in an nonblind, multicentre, switching pilot study. Given the nature of the therapy, the tolerability profile of the fentanyl transdermal matrix patch was generally acceptable. Topical adverse events included erythema, application-site irritation and pruritus. In general, patients and physicians preferred the fentanyl transdermal matrix patch over the fentanyl transdermal reservoir patch in the pilot study.	[Hoy, Sheridan M.; Keating, Gillian M.] Wolters Kluwer Hlth I Adis, Auckland 0754, New Zealand	Hoy, SM (reprint author), Wolters Kluwer Hlth I Adis, 41 Centorian Dr,Private Bag 65901, Auckland 0754, New Zealand.	demail@adis.co.nz					Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; Chen SW, 1996, EUR J PHARMACOL, V312, P241, DOI 10.1016/0014-2999(96)00571-7; CHEN Y, 1993, MOL PHARMACOL, V44, P8; Collett BJ, 1998, BRIT J ANAESTH, V81, P58; Davis M.P., 2006, AM J CANC, V5, P171; Davis MP, 2007, ONCOLOGY-NY, V21, P1229; DONNER B, 1995, ANTI-CANCER DRUG, V6, P39, DOI 10.1097/00001813-199504003-00007; Freynhagen R, 2005, J PAIN SYMPTOM MANAG, V30, P289, DOI 10.1016/j.jpainsymman.2005.03.015; GUTSTEIN HB, 2006, GOODMAN GILMANS PHAR, P547; HERZ A, 1970, NEUROPHARMACOLOGY, V9, P539, DOI 10.1016/0028-3908(70)90004-3; IMAI S, 2000, 31 M INT NARC RES C; *JANSS PHARM KK, 2008, DUR MT PATCH TRANSD; JANSSEN LP, IMPORTANT DRUG WARNI; JANSSENCILAG, DUROGESIC DTRANS 12; Jeal W, 1997, DRUGS, V53, P109, DOI 10.2165/00003495-199753010-00011; MAGUIRE P, 1992, EUR J PHARMACOL, V213, P219, DOI 10.1016/0014-2999(92)90685-W; MARTIN WR, 1976, J PHARMACOL EXP THER, V197, P517; Miyazaki T, 2008, CLIN DRUG INVEST, V28, P313, DOI 10.2165/00044011-200828050-00005; MOSKOWITZ AS, 1985, BRAIN RES, V360, P108; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; Narita M, 2002, LIFE SCI, V70, P2341, DOI 10.1016/S0024-3205(01)01550-8; Nicholson B, 2003, DRUGS, V63, P17, DOI 10.2165/00003495-200363010-00002; Portenoy RK, 1999, LANCET, V353, P1695, DOI 10.1016/S0140-6736(99)01310-0; Sathyan G, 2005, CURR MED RES OPIN, V21, P1961, DOI 10.1185/030079905X65259; Schindler AE, 2006, GYNECOL ENDOCRINOL, V22, P9, DOI 10.1080/09513590500431482; SUZUKI T, 1993, BRAIN RES, V602, P45, DOI 10.1016/0006-8993(93)90239-J; Sweetman S. C., 2007, MARTINDALE COMPLETE; von Cube B, 1970, Naunyn Schmiedebergs Arch Pharmakol, V265, P455	28	9	9	2	5	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	0012-6667	1179-1950		DRUGS	Drugs		2008	68	12					1711	1721		10.2165/00003495-200868120-00008			11	Pharmacology & Pharmacy; Toxicology	Pharmacology & Pharmacy; Toxicology	342BC	WOS:000258758600008	18681493				2020-06-30	J	Hair, PI; Keating, GM; McKeage, K				Hair, Philip I.; Keating, Gillian M.; McKeage, Kate			Transdermal Matrix Fentanyl Membrane Patch (Matrifen (R)) In Severe Cancer-Related Chronic Pain	DRUGS			English	Article							AVAILABLE RESERVOIR FORMULATION; QUALITY-OF-LIFE; PHARMACOLOGICAL-PROPERTIES; THERAPEUTIC-EFFICACY; DELIVERY-SYSTEM; ORAL MORPHINE; PHARMACOKINETICS; OPIOIDS	The matrix fentanyl membrane patch is a new transdermal patch designed with a reduced drug load compared with established reservoir and matrix fentanyl patches. The drug is contained within a silicone matrix with a rate-control ling membrane designed to maintain constant serum fentanyl concentrations over the 72-hour application period. The matrix fentanyl membrane patch was equivalent to the reservoir fentanyl patch in terms of transdermal delivery of fentanyl, as demonstrated after both single (100 mu g/h) and multiple (50 mu g/h) applications by the peak serum fentanyl concentration and the area under the serum concentration-time curve over 72 hours. In a randomized, nonblind, multicentre trial, the transdermal matrix fentanyl membrane patch was noninferior to standard opioid therapy (transdermal reservoir or matrix fentanyl patch or an oral opioid) in terms of analgesic efficacy over 30 days in patients with cancer-related chronic pain requiring long-term opioid use. The transdermal matrix fentanyl membrane patch was as well tolerated as standard opioid therapy; patient-rated tolerability scores for constipation, nausea, daytime drowsiness and sleep disturbance were similar between treatments.	[Hair, Philip I.; Keating, Gillian M.; McKeage, Kate] Wolters Kluwer Hlth Adis, Auckland 0754, New Zealand	McKeage, K (reprint author), Wolters Kluwer Hlth Adis, 41 Centorian Dr,Private Bag 65901, Auckland 0754, New Zealand.	demail@adis.co.nz					Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; Boddiger D, 2006, LANCET, V368, P569, DOI 10.1016/S0140-6736(06)69181-2; Davis M.P., 2006, AM J CANC, V5, P171; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; Hase I, 1997, BRIT J ANAESTH, V79, P740; Hoy SM, 2008, DRUGS, V68, P1711, DOI 10.2165/00003495-200868120-00008; JANSSEN LP, IMPORTANT DRUG WARNI; Jeal W, 1997, DRUGS, V53, P109, DOI 10.2165/00003495-199753010-00011; Kornick CA, 2003, DRUG SAFETY, V26, P951, DOI 10.2165/00002018-200326130-00004; KRESS HG, J PAIN SYMPTOM MANAG; Marier JF, 2007, BRIT J CLIN PHARMACO, V63, P121, DOI 10.1111/j.1365-2125.2006.02758.x; Marier JF, 2006, J CLIN PHARMACOL, V46, P642, DOI 10.1177/0091270006286901; Mercadante S, 2005, ANN ONCOL, V16, P132, DOI 10.1093/annonc/mdi922; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; *NYC AB, MATR SUMM PROD CHAR; *NYC MATR, 2006, COMP IN VITR REL STU; *NYC MATR, 2007, ADV TECHN; Payne R, 1998, J CLIN ONCOL, V16, P1588, DOI 10.1200/JCO.1998.16.4.1588; Portenoy RK, 1999, LANCET, V353, P1695, DOI 10.1016/S0140-6736(99)01310-0; Takane H, 2005, ANN PHARMACOTHER, V39, P2139, DOI 10.1345/aph.1G370; VARVEL JR, 1989, ANESTHESIOLOGY, V70, P928, DOI 10.1097/00000542-198906000-00008; Wong J O, 1997, Acta Anaesthesiol Sin, V35, P25; World Healh Organization, 2007, WHOS PAIN LADD	24	15	15	1	5	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	0012-6667	1179-1950		DRUGS	Drugs		2008	68	14					2001	2009		10.2165/00003495-200868140-00005			9	Pharmacology & Pharmacy; Toxicology	Pharmacology & Pharmacy; Toxicology	368LF	WOS:000260621900006	18778121				2020-06-30	J	Messina, J; Darwish, M; Fine, PG				Messina, John; Darwish, Mona; Fine, Perry G.			Fentanyl buccal tablet	DRUGS OF TODAY			English	Article							HEALTHY ADULT VOLUNTEERS; OPIOID-TREATED PATIENTS; EXPERT WORKING GROUP; BREAKTHROUGH PAIN; DOSE PROPORTIONALITY; EUROPEAN-ASSOCIATION; OUTCOME MEASURES; PALLIATIVE-CARE; OPEN-LABEL; MU-G	Studies of populations with chronic cancer pain have shown a high prevalence of breakthrough pain (BTP), defined as transitory, severe flares of pain that occur on a background of otherwise controlled, persistent pain. High BTP prevalence rates have also been reported in patients with chronic noncancer pain, although data in these patient populations are more limited. The incidence of BTP appears to be associated with progression of chronic disease, with more than 80% of patients reporting BTP with far-advanced, end-stage cancer and noncancer terminal conditions (1). The most widely accepted therapeutic approach for the management of BTP involves use of short-acting opioids taken as needed in addition to the around-the-clock opioid regimen being used for the continuous component of the persistent pain syndrome. For some patients, an optimal treatment outcome for BTP may be unattainable because of a mismatch between the time course of the BTP episode and the onset of analgesia of short-acting opioids. Breakthrough pain typically reaches peak intensity within a few minutes, whereas the onset of analgesia with traditional, orally administered short-acting opioids is between 30 and 60 minutes (2-7). Consequently, treatment outcomes for BTP are likely to be improved with agents that have a more rapid onset of analgesia. Fentanyl buccal tablet (FBT) is a new formulation of fentanyl indicated for the management of BTP in patients with cancer who are already receiving, and who are tolerant to, opioid therapy for their underlying persistent cancer pain. The FBT formulation uses OraVescent (R) (Cephalon, Inc., Frazer, PA, USA) drug delivery technology to provide rapid absorption of fentanyl through the buccal mucosa. In pharmacokinetic studies in healthy volunteers, FBT demonstrated high, early systemic absorption. In addition, FBT delivered a larger proportion of the fentanyl dose transmucosally and produced a greater early systemic exposure than oral transmucosal fentanyl citrate (OTFC), which is also indicated for the management of BTP in opioid-tolerant cancer patients. A number of short-term studies have evaluated the efficacy, safety and tolerability of FBT in the management of BTP in opioid-tolerant patients with chronic pain. All these studies included an open-label close-titration phase prior to randomized, placebo-controlled, double-blind treatment. Pain Intensity of a BTP episode was measured using an 11 -point scale (0 = no pain, 10 = worst pain), and the primary outcome measure was the Summed Pain Intensity Difference (SPID) at a specified time point. Secondary efficacy measures included Pain Relief, Pain Intensity Differences, and the proportion of BTP episodes demonstrating >= 33% and >= 50% improvement in Pain Intensity scores at each time point postdose, and the proportion of BTP episodes requiring supplemental medication. In a pivotal study of opioid-tolerant patients with cancer-related chronic pain and BTP, the primary outcome measure, SPID at 30 minutes (SPID 30)1 significantly favored FBT compared with placebo (mean +/- SE: 3.0 +/- 0.12 vs. 1.8 +/- 0.18, p <0.0001). Better efficacy was also observed with FBT compared with placebo for pain relief, Pain Intensity Differences, and the proportion of episodes showing >= 33% and >= 50% improvement in Pain Intensity Scores. Treatment with FBT was generally well tolerated. Most adverse events were mild to moderate in severity and typical of those associated with opioid use (e.g., nausea, dizziness) (8). Similar results have been observed in studies of opioid-tolerant patients with BTP in association with noncancer-related chronic pain. In a study of patients with chronic low back pain, the primary outcome measure, SPID60, significantly favored FBT over placebo (mean +/- SE: 8.3 +/- 0.66 vs. 3.6 +/- 0.57, p <0.0001). All secondary efficacy measures were similarly improved, with Pain Intensity Differences and Pain Relief scores showing significant differences versus placebo as early as 10 and 15 minutes, respectively. As in the study of cancer patients, treatment with FBT was well tolerated (9). Across all studies, there was no simple linear relationship between the effective dose of FBT and the dose of the around-the-clock opioid regimen or the previous supplemental opioid, indicating that doses of FBT should be individually titrated to effectiveness rather than calculated as a percentage of existing opioid regimens. This monograph summarizes current data on the clinical pharmacology, efficacy, safety and tolerability of FBT relating to the management of opioid-tolerant patients with BTP in association with chronic pain. (c) 2008 Prous Science, S.A.U. or its licensors. All rights reserved.	[Messina, John; Darwish, Mona] Cephalon Inc, Clin Res, Frazer, PA 19355 USA; [Fine, Perry G.] Univ Utah, Sch Med, Pain Res Ctr, Salt Lake City, UT USA	Messina, J (reprint author), Cephalon Inc, Clin Res, 41 Moores Rd, Frazer, PA 19355 USA.	jmessina@cephalon.com					BENNETT D, 2005, [No title captured], V30, P354; Caraceni A, 2002, J PAIN SYMPTOM MANAG, V23, P239, DOI 10.1016/S0885-3924(01)00409-2; *CEPH INC, 2006, FENT PRESCR INF; Darwish M, 2006, CLIN THER, V28, P707, DOI 10.1016/j.clinthera.2006.05.015; Darwish M, 2006, CLIN THER, V28, P715, DOI 10.1016/j.clinthera.2006.05.016; Darwish M, 2005, CLIN PHARMACOKINET, V44, P1279, DOI 10.2165/00003088-200544120-00006; DARWISH M, 2006, AM SOC HLTH SYST PHA; Darwish M, 2007, J CLIN PHARMACOL, V47, P56, DOI 10.1177/0091270006294129; Darwish M, 2006, CLIN PHARMACOKINET, V45, P843, DOI 10.2165/00003088-200645080-00006; Durfee S, 2006, AM J DRUG DELIV, V4, P1, DOI DOI 10.2165/00137696-200604010-00001; Dworkin RH, 2005, PAIN, V113, P9, DOI 10.1016/j.pain.2004.09.012; Farrar JT, 2000, PAIN, V88, P287, DOI 10.1016/S0304-3959(00)00339-0; Fine PG, 1998, J PAIN SYMPTOM MANAG, V16, P179, DOI 10.1016/S0885-3924(98)00045-1; Fortner BV, 2002, J PAIN, V3, P38, DOI 10.1054/jpai.2002.27136; Hwang SS, 2003, PAIN, V101, P55, DOI 10.1016/S0304-3959(02)00293-2; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; Mercadante S, 2002, CANCER, V94, P832, DOI 10.1002/cncr.10249; PORTENOY R, 2006, AM PAIN SOC ANN M; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Portenoy RK, 2007, CURR MED RES OPIN, V23, P222, DOI 10.1185/030079906X162818; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Portenoy RK, 2006, J PAIN, V7, P583, DOI 10.1016/j.jpain.2006.02.003; Simpson DM, 2007, CLIN THER, V29, P588, DOI 10.1016/j.clinthera.2007.04.007; Slatkin Neal E, 2007, J Support Oncol, V5, P327; Stanley TH, 2005, J PAIN SYMPTOM MANAG, V29, pS67, DOI 10.1016/j.jpainsymman.2005.01.009; Svendsen KB, 2005, EUR J PAIN, V9, P195, DOI 10.1016/j.ejpain.2004.06.001; TAYLOR DR, 2007, AM PAIN SOC ANN M; WEBSTER L, 2006, AM PAIN SOC ANN M; Zeppetela G, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004311.pub2; Zeppetella G, 2001, PALLIATIVE MED, V15, P243, DOI 10.1191/026921601678576220	31	27	30	0	4	PROUS SCIENCE, SAU-THOMSON REUTERS	BARCELONA	398 PROVENCA, 08025 BARCELONA, SPAIN	1699-3993	1699-4019		DRUG TODAY	Drugs Today	JAN	2008	44	1					41	54		10.1358/dot.2008.44.1.1178469			14	Pharmacology & Pharmacy	Pharmacology & Pharmacy	272VQ	WOS:000253889500005	18301803				2020-06-30	J	Saari, TI; Laine, K; Neuvonen, M; Neuvonen, PJ; Olkkola, KT				Saari, Teijo I.; Laine, Kari; Neuvonen, Mikko; Neuvonen, Pertti J.; Olkkola, Klaus T.			Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl	EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY			English	Article						fentanyl; voriconazole; fluconazole; cytochrome P450; CYP3A; pharmacokinetics	HUMAN LIVER-MICROSOMES; TRANSDERMAL FENTANYL; DRUG-INTERACTIONS; ORAL MIDAZOLAM; HALF-LIFE; ALFENTANIL; PHARMACODYNAMICS; METABOLISM; IDENTIFICATION; DISPOSITION	Objective Fentanyl is a widely used opioid analgesic, which is extensively metabolized by hepatic cytochrome P450 (CYP) 3A. Recent reports suggest that concomitant administration of CYP3A inhibitors with fentanyl may lead to dangerous drug interactions. Methods The potential interactions of fentanyl with triazole antifungal agents voriconazole and fluconazole were studied in a randomized crossover study in three phases. Twelve healthy volunteers were given 5 mu g/ kg of intravenous fentanyl without pretreatment ( control), after oral voriconazole ( 400 mg twice on the first day and 200 mg twice on the second day), or after oral fluconazole ( 400 mg once on the first day and 200 mg once on the second day). Plasma concentrations of fentanyl, norfentanyl, voriconazole, and fluconazole were determined up to 24 h. Pharmacokinetic parameters were calculated using compartmental methods. Results The mean plasma clearance of intravenous fentanyl was decreased by 23% ( range-22 to 48%; p<0.05) and 16% (-34 to 53%; p<0.05) after voriconazole and fluconazole administration, respectively. Voriconazole increased the area under the fentanyl plasma concentration-time curve by 1.4fold ( p<0.05). The initial plasma concentrations and volume of distribution of fentanyl did not differ significantly between phases. Conclusion Both voriconazole and fluconazole delay the elimination of fentanyl significantly. Caution should be exercised, especially in patients who are given voriconazole or fluconazole during long-lasting fentanyl treatment, because insidiously elevated fentanyl concentration may lead to respiratory depression.	[Saari, Teijo I.; Olkkola, Klaus T.] Univ Turku, Dept Anaesthesiol Intens Care Emergency Care & Pa, FI-20520 Turku, Finland; [Laine, Kari] Univ Turku, Dept Pharmacol Drug Dev & Therapeut, Turku, Finland; [Neuvonen, Mikko; Neuvonen, Pertti J.] Univ Helsinki, Dept Clin Pharmacol, SF-00250 Helsinki, Finland	Saari, TI (reprint author), Univ Turku, Dept Anaesthesiol Intens Care Emergency Care & Pa, POB 52,Kiinamyllynkatu 4-8, FI-20520 Turku, Finland.	teijo.saari@tyks.fi	Neuvonen, Pertti/Z-4818-2019; Neuvonen, Pertti J/G-4675-2011	Neuvonen, Pertti/0000-0003-3631-9411; Neuvonen, Mikko/0000-0002-7627-1638; Olkkola, Klaus/0000-0001-7872-8665			Akaike H, 1976, MATH SCI, V14, P5; BOWER S, 1982, BRIT J ANAESTH, V54, P871, DOI 10.1093/bja/54.8.871; Gage R, 1998, J PHARMACEUT BIOMED, V17, P1449, DOI 10.1016/S0731-7085(98)00004-1; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; Guitton J, 1997, BIOCHEM PHARMACOL, V53, P1613, DOI 10.1016/S0006-2952(96)00893-3; Hallberg P, 2006, EUR J CLIN PHARMACOL, V62, P491, DOI 10.1007/s00228-006-0120-4; HANDAL KA, 1983, ANN EMERG MED, V12, P438, DOI 10.1016/S0196-0644(83)80343-6; Hyland R, 2003, DRUG METAB DISPOS, V31, P540, DOI 10.1124/dmd.31.5.540; Hynninen VV, 2006, ANTIMICROB AGENTS CH, V50, P1967, DOI 10.1128/AAC.01483-05; Ibrahim AE, 2003, ANESTHESIOLOGY, V98, P853, DOI 10.1097/00000542-200304000-00011; INAGAKI K, 1992, THER DRUG MONIT, V14, P306, DOI 10.1097/00007691-199208000-00008; Jung BF, 2005, CLIN PHARMACOL THER, V77, P324, DOI 10.1016/j.clpt.2004.10.013; Kharasch ED, 2004, ANESTHESIOLOGY, V101, P729, DOI 10.1097/00000542-200409000-00022; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; MCCLINTOCK FA, 1980, J MECH PHYS SOLIDS, V28, P1, DOI 10.1016/0022-5096(80)90008-3; MORITA K, 1992, CHEM PHARM BULL, V40, P1247; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; Mystakidou K, 2006, DRUG DELIV, V13, P269, DOI 10.1080/10717540500394661; Niwa T, 2005, BIOL PHARM BULL, V28, P1805, DOI 10.1248/bpb.28.1805; Olkkola KT, 1996, ANESTH ANALG, V82, P511, DOI 10.1097/00000539-199603000-00015; Olkkola KT, 1999, ANESTHESIOLOGY, V91, P681, DOI 10.1097/00000542-199909000-00020; Palkama VJ, 1998, ANESTH ANALG, V87, P190, DOI 10.1097/00000539-199807000-00039; Pennick GJ, 2003, ANTIMICROB AGENTS CH, V47, P2348, DOI 10.1128/AAC.47.7.2348-2350.2003; Portenoy RK, 2007, CURR MED RES OPIN, V23, P222, DOI 10.1185/030079906X162818; Romero AJ, 2002, CLIN PHARMACOL THER, V71, P226, DOI 10.1067/mcp.2002.121911; ROWLAND M, 1995, CLIN PHARMACOKINET, P156; Saari TI, 2006, CLIN PHARMACOL THER, V80, P502, DOI 10.1016/j.clpt.2006.07.008; Saari TI, 2006, CLIN PHARMACOL THER, V79, P362, DOI 10.1016/j.clpt.2005.12.305; Tateishi T, 1996, ANESTH ANALG, V82, P167; Theuretzbacher U, 2006, CLIN PHARMACOKINET, V45, P649, DOI 10.2165/00003088-200645070-00002; Varhe A, 1996, BRIT J CLIN PHARMACO, V41, P319, DOI 10.1046/j.1365-2125.1996.03189.x; WAGNER JG, 1976, J PHARMACOKINET BIOP, V4, P443, DOI 10.1007/BF01062831; Wienkers LC, 1996, DRUG METAB DISPOS, V24, P610	33	55	61	0	7	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0031-6970	1432-1041		EUR J CLIN PHARMACOL	Eur. J. Clin. Pharmacol.	JAN	2008	64	1					25	30		10.1007/s00228-007-0398-x			6	Pharmacology & Pharmacy	Pharmacology & Pharmacy	248XW	WOS:000252191500004	17987285				2020-06-30	J	Alpay, NR; Satar, S; Sebe, A; Demir, M; Topal, M				Alpay, N. Ranu; Satar, S.; Sebe, A.; Demir, M.; Topal, M.			Unusual presentations of scorpion envenomation	HUMAN & EXPERIMENTAL TOXICOLOGY			English	Article						envenomation; hypopotassemia; myocardial infarction; scorpion	EDEMA	Scorpions are nocturnal arthropods that inject their venom through the victims' skin by stingers. By the envenomation, clinical manifestations in a wide spectrum may occur, including pain at one side and death because of severe cardiopulmonary or neurological abnormalities. Sometimes the victim cannot describe the insect or does not remember even being stung after the event. We present two cases of scorpion envenomation with different and rare clinical situations with a short review of the literature.	[Alpay, N. Ranu; Satar, S.; Sebe, A.; Demir, M.] Cukurova Univ, Sch Med, Dept Emergency Med, TR-01330 Balcali, Turkey; [Topal, M.] Cukurova Univ, Sch Med, Dept Cardiol, TR-01330 Balcali, Turkey	Alpay, NR (reprint author), Cukurova Univ, Sch Med, Dept Emergency Med, TR-01330 Balcali, Turkey.	ranalpay@cu.edu.tr	Disel, Nezihat Rana/V-1265-2018	Disel, Nezihat Rana/0000-0003-2381-3066			Bahloul M, 2005, PRESSE MED, V34, P115, DOI 10.1016/S0755-4982(05)88241-7; Bawaskar H. S., 2005, J. Venom. Anim. Toxins incl. Trop. Dis, V11, P3, DOI 10.1590/S1678-91992005000100002; Bonilha L, 2004, ARCH NEUROL-CHICAGO, V61, P1294, DOI 10.1001/archneur.61.8.1294; BUCARETCHI F, 1995, TOXICON, V33, P292; DITTRICH K, 1995, ANN SAUDI MED, V15, P148, DOI 10.5144/0256-4947.1995.148; Everson GW, 2005, ENCY TOXICOLOGY, V3, P771; Farghly WMA, 1999, ACTA PAEDIATR, V88, P290, DOI 10.1080/08035259950170042; GUERON M, 1980, AM J CARDIOL, V45, P979, DOI 10.1016/0002-9149(80)90166-6; Gueron M, 1996, TOXICON, V34, P393, DOI 10.1016/0041-0101(95)00147-6; KLASCO RK, 2005, POISINDEX SYSTEM THO, V125; Kochar D K, 2002, J Assoc Physicians India, V50, P606; Kovarik Frantisek, 1999, Serket, V6, P38; Mahaba H. M. A., 1997, Eastern Mediterranean Health Journal, V3, P82; Mocan H, 1998, NEPHROL DIAL TRANSPL, V13, P2639, DOI 10.1093/ndt/13.10.2639; Naqvi R, 1998, BRIT J UROL, V82, P295; Raichur Devaraj V., 2001, Indian Journal of Pediatrics, V68, P669, DOI 10.1007/BF02752282; Romero N. O., 2005, J. Venom. Anim. Toxins incl. Trop. Dis, V11, P594, DOI 10.1590/S1678-91992005000400015; Udayakumar N, 2006, Indian J Med Sci, V60, P241; Wheatley GH, 2005, ANN THORAC SURG, V80, P1489, DOI 10.1016/j.athoracsur.2004.04.004	19	3	4	0	4	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0960-3271			HUM EXP TOXICOL	Hum. Exp. Toxicol.	JAN	2008	27	1					81	85		10.1177/0960327108088974			5	Toxicology	Toxicology	304YE	WOS:000256144200009	18480153				2020-06-30	J	Mhyre, JM				Mhyre, J. M.			Strategies to induce labor analgesia with epidural hydrolmorphone	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Letter							BUPIVACAINE; FENTANYL; HYDROMORPHONE		Univ Michigan Hlth Syst, Dept Anesthesiol, Ann Arbor, MI USA	Mhyre, JM (reprint author), Univ Michigan Hlth Syst, Dept Anesthesiol, Ann Arbor, MI USA.	jmmhyre@med.umich.edu					Eige S., 1998, Anesthesiology (Hagerstown), V89, pA1032, DOI 10.1097/00000542-199809180-00015; Lyons G, 1997, BRIT J ANAESTH, V78, P493; Parker RK, 2002, CAN J ANAESTH, V49, P600, DOI 10.1007/BF03017388; Polley LS, 2000, ANESTHESIOLOGY, V93, P122, DOI 10.1097/00000542-200007000-00022; Sevarino F. B., 1998, Anesthesiology (Hagerstown), V89, pA1031, DOI 10.1097/00000542-199809180-00014; Sevarino FB, 1996, ANESTHESIOLOGY, V85, pA912; Sinatra Raymond, 1999, Anesthesiology (Hagerstown), V91, pA1085; Sinatra RS, 2002, ANESTH ANALG, V94, P1310, DOI 10.1097/00000539-200205000-00047; SINATRA RS, 1998, ANESTH ANALG, V86, pS388; Sinatra RS, 2000, SEMIN ANESTH PERIO M, V19, P108; TIOURIRINE M, 2006, ANESTHESIOLOGY, V105, pA915	11	0	1	0	1	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0959-289X			INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	JAN	2008	17	1					81	82		10.1016/j.ijoa.2007.03.005			2	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	262SI	WOS:000253167900019	17643287				2020-06-30	J	Merlo, LJ; Goldberger, BA; Kolodner, D; Fitzgerald, K; Gold, MS				Merlo, Lisa J.; Goldberger, Bruce A.; Kolodner, Dara; Fitzgerald, Kimberly; Gold, Mark S.			Fentanyl and propofol exposure in the operating room: Sensitization hypotheses and further data	JOURNAL OF ADDICTIVE DISEASES			English	Article						physician impairment; addiction; neurobiological sensitization	SUBSTANCE USE; DRUG-USE; NICOTINE REPLACEMENT; 2ND-HAND EXPOSURE; PHYSICIANS; ABUSE; ADDICTION; SMOKING; PAIN; SENSITIVITY	Inflated rates of opioid addiction among anesthesiologists may be caused by chronic exposure to low doses of aerosolized anesthetic/analgesic agents in the operating room. Such secondhand exposure produces neurobiological sensitization to the reinforcing effects of these substances, making later addiction more likely. This article extends findings that fentanyl and propofol are detectable in the air of the operating room and demonstrates that fentanyl is also detectable on surfaces in the operating room. Secondhand exposure could, therefore, occur by inhalation and skin absorption. Additionally, data show that many physicians with opiate addiction have a family history of addiction, suggesting genetic vulnerability to the effects of secondhand exposure. Other new data demonstrate that the rates of marijuana and tobacco smoking are much higher among opioid-addicted physicians, suggesting that prior exposure to THC (the psychoactive component of cannabis) or nicotine might increase vulnerability to secondhand effects. Suggestions for reducing secondhand exposure in the operating room are discussed.	[Gold, Mark S.] Univ Florida, Coll Med, Dept Psychiat, McKnight Brain Inst, Gainesville, FL 32610 USA; [Gold, Mark S.] Univ Florida, Coll Med, Dept Neurosci, McKnight Brain Inst, Gainesville, FL 32610 USA; [Gold, Mark S.] Univ Florida, Coll Med, Dept Anesthesiol, McKnight Brain Inst, Gainesville, FL 32610 USA; [Gold, Mark S.] Univ Florida, Coll Med, Dept Community Hlth & Family Med, McKnight Brain Inst, Gainesville, FL 32610 USA; [Goldberger, Bruce A.] Univ Florida, Coll Med, Dept Pathol Immunol & Lab Med, Gainesville, FL 32610 USA	Gold, MS (reprint author), Univ Florida, Coll Med, Dept Psychiat, McKnight Brain Inst, POB 100183, Gainesville, FL 32610 USA.	msgold@ufl.edu					Agrawal A, 2004, PSYCHOL MED, V34, P1227, DOI 10.1017/S0033291704002545; Baird WLM, 2000, ANAESTHESIA, V55, P943, DOI 10.1046/j.1365-2044.2000.01765.x; Bennett J, 2001, CURR OPIN PSYCHIATR, V14, P195, DOI 10.1097/00001504-200105000-00006; Bodnar RJ, 2003, PEPTIDES, V24, P1241, DOI 10.1016/j.peptides.2003.08.002; Christie JD, 1998, JAMA-J AM MED ASSOC, V280, P1253, DOI 10.1001/jama.280.14.1253; Cossu G, 2001, BEHAV BRAIN RES, V118, P61, DOI 10.1016/S0166-4328(00)00311-9; Ellgren M, 2007, NEUROPSYCHOPHARMACOL, V32, P607, DOI 10.1038/sj.npp.1301127; Everitt BJ, 2002, J NEUROSCI, V22, P3312; FISCHMAN MW, 1992, CIBA F SYMP, V166, P165; FOLLETTE JW, 1992, ANESTHESIOLOGY, V77, P817, DOI 10.1097/00000542-199210000-00028; Gallegos K V, 1988, QRB Qual Rev Bull, V14, P116; GLASS PSA, 2000, ANESTHESIA; Gold MS, 2006, J ADDICT DIS, V25, P141, DOI 10.1300/J069v25n04_17; Gold MS, 2006, J ADDICT DIS, V25, P15, DOI 10.1300/J069v25n01_04; Gold MS, 2004, PSYCHIAT CLIN N AM, V27, P745, DOI 10.1016/j.psc.2004.07.006; Han WH, 2004, ANN NY ACAD SCI, V1025, P370, DOI 10.1196/annals.1307.045; HUGHES PH, 1992, JAMA-J AM MED ASSOC, V267, P2333, DOI 10.1001/jama.267.17.2333; Hutchison KE, 1999, PSYCHOPHARMACOLOGY, V142, P139, DOI 10.1007/s002130050872; Hyman SE, 2001, NAT REV NEUROSCI, V2, P695, DOI 10.1038/35094560; Ikeda K, 2005, TRENDS PHARMACOL SCI, V26, P311, DOI 10.1016/j.tips.2005.04.001; Iwersen-Bergmann S, 2001, INT J LEGAL MED, V114, P248, DOI 10.1007/s004149900129; Kim HS, 2004, PAIN, V109, P488, DOI 10.1016/j.pain.2004.02.027; KLEBER H D, 1984, Journal of Substance Abuse Treatment, V1, P137, DOI 10.1016/0740-5472(84)90039-4; Koide T, 2000, MAMM GENOME, V11, P664, DOI 10.1007/s003350010129; Luck Stephanie, 2004, J Perianesth Nurs, V19, P308, DOI 10.1016/j.jopan.2004.06.002; LUTSKY I, 1993, CAN J ANAESTH, V40, P915, DOI 10.1007/BF03010092; Lynskey MT, 2003, JAMA-J AM MED ASSOC, V289, P427, DOI 10.1001/jama.289.4.427; Mansky PA, 1999, PSYCHIAT QUART, V70, P107, DOI 10.1023/A:1022197218945; McAuliffe PF, 2006, MED HYPOTHESES, V66, P874, DOI 10.1016/j.mehy.2005.10.030; MENSCH BS, 1988, J HEALTH SOC BEHAV, V29, P169, DOI 10.2307/2137056; Mogil JS, 1999, P NATL ACAD SCI USA, V96, P7744, DOI 10.1073/pnas.96.14.7744; Mogil JS, 2000, ANNU REV NEUROSCI, V23, P777, DOI 10.1146/annurev.neuro.23.1.777; NELSON DE, 1994, JAMA-J AM MED ASSOC, V271, P1273, DOI 10.1001/jama.271.16.1273; O'Malley SS, 2006, ARCH INTERN MED, V166, P667, DOI 10.1001/archinte.166.6.667; OConnor PG, 1997, MED CLIN N AM, V81, P1037, DOI 10.1016/S0025-7125(05)70562-9; Patel S, 2003, BRIT J PHARMACOL, V139, P1005, DOI 10.1038/sj.bjp.0705334; Patkar AA, 2003, CHEST, V124, P1415, DOI 10.1378/chest.124.4.1415; POLOMANO RC, 2001, SEMIN PERIOP NURS, V10; Reimer C, 2001, PSYCHOTHERAPEUT, V46, P376, DOI 10.1007/s00278-001-0185-6; RICHMAN JA, 1992, ALCOHOL CLIN EXP RES, V16, P166, DOI 10.1111/j.1530-0277.1992.tb01360.x; *SAMHSA, 2004, OFF APPL STUD NSDU H, V25; *SAMHSA, 2006, OFF APPL STUD NSDU H, V30; Storr CL, 2000, SUBST USE MISUSE, V35, P1443, DOI 10.3109/10826080009148225; Tarter RE, 2006, AM J PSYCHIAT, V163, P2134, DOI 10.1176/appi.ajp.163.12.2134; Timberlake DS, 2007, DRUG ALCOHOL DEPEN, V88, P272, DOI 10.1016/j.drugalcdep.2006.11.005; Uhl GR, 1999, P NATL ACAD SCI USA, V96, P7752, DOI 10.1073/pnas.96.14.7752; Verghese A, 2002, NEW ENGL J MED, V346, P1510, DOI 10.1056/NEJM200205163462002; WALTERS J, 2006, COMMUNICATION   0726; ZACNY JP, 1993, ANESTH ANALG, V77, P544; Zacny JP, 1999, ANESTHESIOLOGY, V90, P269, DOI 10.1097/00000542-199901000-00033	50	19	21	0	6	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	1055-0887	1545-0848		J ADDICT DIS	J. Addict. Dis.		2008	27	3					67	76		10.1080/10550880802122661			10	Substance Abuse	Substance Abuse	331JJ	WOS:000258008200009	18956530				2020-06-30	J	Beilin, B; Hoofien, D; Poran, R; Gral, I; Grinevich, G; Butin, B; Mayburd, E; Shavit, Y				Beilin, Benzion; Hoofien, Dan; Poran, Ravit; Gral, Inbal; Grinevich, Galina; Butin, Berta; Mayburd, Eduard; Shavit, Yehuda			Comparison of two patient-controlled analgesia techniques on neuropsychological functioning in the immediate postoperative period	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						cognitive function; local anaesthetics; opiates; PCA-IV; PCEA; postoperative pain	COGNITIVE DYSFUNCTION; EPIDURAL ANALGESIA; CARDIAC-SURGERY; PAIN; METAANALYSIS; MANAGEMENT; ACTIVATION; CYTOKINES; ATTENTION; EFFICACY	Pain may contribute to cognitive decline, which is a common complication in the early postoperative period. We compared the effects of two common pain management techniques, intravenous patient-controlled analgesia (PCA-IV) and patient-controlled epidural analgesia (PCEA), on cognitive functioning in the immediate postoperative period. Patients hospitalized for elective surgery were randomly assigned to one of the treatment groups (30 patients per group). A battery of objective, standardized neuropsychological tests was administered preoperatively and 24 hours after surgery. Pain intensity was also evaluated. Nonoperated volunteers served as controls. Patients of the PCA-IV group exhibited significantly higher pain scores than did patients of the PCEA group. PCA-IV patients exhibited significant deterioration in the postoperative period in all the neuropsychological measures, while the PCEA patients exhibited significant deterioration only in one cognitive index, compared to controls.	[Hoofien, Dan; Poran, Ravit; Gral, Inbal; Shavit, Yehuda] Hebrew Univ Jerusalem, Dept Psychol, IL-91905 Jerusalem, Israel; [Beilin, Benzion; Grinevich, Galina; Butin, Berta; Mayburd, Eduard] Hasharon Hosp, Rabin Med Ctr, Dept Anesthesiol, IL-49372 Petah Tiqwa, Israel	Shavit, Y (reprint author), Hebrew Univ Jerusalem, Dept Psychol, Mt Scopus, IL-91905 Jerusalem, Israel.	udi.shavit@huji.ac.il	Shavit, Yehuda/A-1219-2010				Abildstrom H, 2000, ACTA ANAESTH SCAND, V44, P1246, DOI 10.1034/j.1399-6576.2000.441010.x; Arrowsmith JE, 2000, BRIT J ANAESTH, V84, P378; Beaumont J.Graham, 1999, BLACKWELL DICT NEURO; Beilin B, 2003, ANESTH ANALG, V97, P822, DOI 10.1213/01.ANE.0000078586.82810.3B; Ben-Yishay Y, 1987, NEUROPSYCHOL REHABIL, P165; BLACKBURN H L, 1955, Confin Neurol, V15, P327; Block BM, 2003, JAMA-J AM MED ASSOC, V290, P2455, DOI 10.1001/jama.290.18.2455; DUGGLEBY W, 1994, J PAIN SYMPTOM MANAG, V9, P19, DOI 10.1016/0885-3924(94)90142-2; DYER CB, 1995, ARCH INTERN MED, V155, P461, DOI 10.1001/archinte.155.5.461; Eccleston C, 1999, PSYCHOL BULL, V125, P356, DOI 10.1037/0033-2909.125.3.356; ECCLESTON C, 1995, PAIN, V63, P3, DOI 10.1016/0304-3959(95)00093-8; Ersek Mary, 2004, Pain Manag Nurs, V5, P75, DOI 10.1016/j.pmn.2003.11.002; FERRANTE FM, 1993, POSTOPERATIVE PAIN M; Goshen I, 2003, ENDOCRINOLOGY, V144, P4453, DOI 10.1210/en.2003-0338; Hollmann MW, 2000, ANESTHESIOLOGY, V93, P858, DOI 10.1097/00000542-200009000-00038; Kiraly SJ, 1997, CAN J PSYCHIAT, V42, P415, DOI 10.1177/070674379704200409; Lewis MS, 2006, ACTA ANAESTH SCAND, V50, P50, DOI 10.1111/j.1399-6576.2006.00893.x; LEZAK M, 2004, NEUROPSYCHOLOGICAL A; Loong J., 1988, CONTINUOUS PERFORMAN; Maier SF, 2003, BRAIN BEHAV IMMUN, V17, P69, DOI 10.1016/S0889-1591(03)00032-1; Mann C, 2000, ANESTHESIOLOGY, V92, P433, DOI 10.1097/00000542-200002000-00025; Moller JT, 1998, LANCET, V351, P857, DOI 10.1016/S0140-6736(97)07382-0; Rasmussen LS, 2001, ACTA ANAESTH SCAND, V45, P275, DOI 10.1034/j.1399-6576.2001.045003275.x; Riccio CA, 2002, ARCH CLIN NEUROPSYCH, V17, P235, DOI 10.1016/S0887-6177(01)00111-1; Rohan D, 2005, CAN J ANAESTH, V52, P137, DOI 10.1007/BF03027718; ROSVOLD HE, 1956, J CONSULT PSYCHOL, V20, P343, DOI 10.1037/h0043220; Silbert BS, 2001, J CARDIOTHOR VASC AN, V15, P20, DOI 10.1053/jcan.2001.20212; Spreen O., 1998, COMPENDIUM NEUROPSYC; Wang DX, 2002, ANESTH ANALG, V95, P1134, DOI 10.1097/00000539-200211000-00002; Wang Y, 2007, AM J GERIAT PSYCHIAT, V15, P50, DOI 10.1097/01.JGP.0000229792.31009.da; Watkins LR, 1999, ADV EXP MED BIOL, V461, P153; Watkins LR, 1995, PAIN, V63, P289, DOI 10.1016/0304-3959(95)00186-7; Wechsler D., 1997, WECHSLER ADULT INTEL; Wu CL, 2005, ANESTHESIOLOGY, V103, P1079, DOI 10.1097/00000542-200511000-00023; Wu CL, 2004, REGION ANESTH PAIN M, V29, P257, DOI 10.1016/j.rapm.2003.11.007; Yardeni Israel Z, 2007, Int J Surg, V5, P239, DOI 10.1016/j.ijsu.2006.09.008	36	11	13	0	3	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2008	30	6					674	682		10.1080/13803390701667310			9	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	323SS	WOS:000257469300007	18612876				2020-06-30	J	Woodall, KL; Martin, TL; McLellan, BA				Woodall, Karen L.; Martin, Teri L.; McLellan, Barry A.			Oral abuse of fentanyl patches (Duragesic (R)): Seven case reports	JOURNAL OF FORENSIC SCIENCES			English	Article						forensic science; forensic toxicology; fentanyl; death; blood concentration; postmortem; oral; Duragesic((R)); transmucosal	TRANSDERMAL FENTANYL; CITRATE; DEATHS; MISUSE	In order to increase the understanding regarding the oral abuse and potential toxicity of fentanyl patches seven cases were identified over a 3-year period where fentanyl, either alone or in combination with other factors, contributed to death following the oral abuse of Duragesic((R)) patches. The decedents comprised three females and four males with ages ranging from 20 to 51 years. Postmortem blood fentanyl concentrations were determined in all cases and ranged from 7 to 97 ng/mL. Two deaths were classified as a fentanyl overdose, three deaths were classified as a fentanyl and ethanol overdose, one death was considered a mixed drug intoxication and the remaining death was determined to be a combination of fentanyl and medical causes. These cases represent the largest reported series of deaths following the oral administration of transdermal fentanyl patches and provide detailed information on the potential for the abuse of transdermal Duragesic((R)) patches via this route. The postmortem blood fentanyl concentrations detected for each of the decedents demonstrate the potentially fatal blood concentrations that can arise after this relatively rare route of administration.	[Woodall, Karen L.; Martin, Teri L.] Ctr Forens Sci, Toxicol Sect, Toronto, ON M7A 2G8, Canada; [McLellan, Barry A.] Off Chief Coroner, Toronto, ON M7A 2G9, Canada	Woodall, KL (reprint author), Ctr Forens Sci, Toxicol Sect, 25 Grosvenor St, Toronto, ON M7A 2G8, Canada.	karen.woodall@ontario.ca					Anderson DT, 2000, J ANAL TOXICOL, V24, P627, DOI 10.1093/jat/24.7.627; Coon TP, 2005, ANN EMERG MED, V46, P473, DOI 10.1016/j.annemergmed.2005.06.450; GUALTIERI JF, 2000, P 20 INT C EUR ASS P; Hanks GW, 2004, PALLIATIVE MED, V18, P698, DOI 10.1191/0269216304pm966oa; JENTZEN JM, 2003, CLIN FORENSIC TO DEC, P1; Kharasch ED, 2004, ANESTHESIOLOGY, V101, P729, DOI 10.1097/00000542-200409000-00022; Kramer Christopher, 1998, Journal of the American Osteopathic Association, V98, P385; Kuhlman JJ, 2003, J ANAL TOXICOL, V27, P499, DOI 10.1093/jat/27.7.499; Liappas IA, 2004, J PSYCHOPHARMACOL, V18, P277, DOI 10.1177/0269881104042634; Lilleng PK, 2004, J FORENSIC SCI, V49, P1364; MARQUARDT KA, 1994, J TOXICOL-CLIN TOXIC, V32, P75, DOI 10.3109/15563659409000433; Martin TL, 2006, J ANAL TOXICOL, V30, P603, DOI 10.1093/jat/30.8.603; STREISAND JB, 1991, ANESTHESIOLOGY, V75, P223, DOI 10.1097/00000542-199108000-00009; Tharp AM, 2004, AM J FOREN MED PATH, V25, P178, DOI 10.1097/01.paf.0000127398.67081.11	14	52	53	2	28	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0022-1198			J FORENSIC SCI	J. Forensic Sci.	JAN	2008	53	1					222	225		10.1111/j.1556-4029.2007.00597.x			4	Medicine, Legal	Legal Medicine	262AM	WOS:000253121400039	18279262				2020-06-30	J	Hewitt, M; Goldman, A; Collins, GS; Childs, M; Hain, R				Hewitt, Martin; Goldman, Ann; Collins, Gary S.; Childs, Margaret; Hain, Richard			Opioid use in palliative care of children and young people with cancer	JOURNAL OF PEDIATRICS			English	Article							TRANSDERMAL FENTANYL; PAINFUL PROCEDURES; ORAL MORPHINE; PHARMACOKINETICS; SYMPTOMS; PATIENT; ONCOLOGY; LIFE; END	Objective Identify opioids prescribed, preferred routes, and doses among children with incurable cancer. Studydesign Prospective survey with monthly questionnaires regarding patientss 0 to 19 years old from oncology centers. Data were collected by professionals on each patient for 6 months or until death, and analyzed from patients who died. Impact of tumor was analyzed with Kruskal-Wallis and Mann-Whitney tests. Major opioid dosages are expressed as oral morphine equivalents. Results Of 185 children recruited, 164 (88 boys, 76 girls) died. Mean palliative care duration was 67 days. One hundred forty-seven (89.6%) received major opioids. Morphine, diamorphine, and fentanyl were prescribed in 75%, 57.9%, and 11.6%, respectively. Seventy-three (44.5%) received > 1 major opioid. Median monthly maximum doses prescribed rose from 2.1 mg/kg/24 h (study entry) to 4.4 mg/kg/24 h (death) (P <.001); overall variable (0.09-1500 mg/kg/24 h, median 3.7 mg/kg/24 h). Opioids were given by the oral (117/164, 71.3%), intravenous (68/164, 41.5%), subcutaneous (40, 28%), rectal (20, 12.2%), and transdermal(18, 11%) routes. There was a shift to intravenous use as death approached. Numbers within each tumor group were too small to show significance. Children with solid tumors outside the central nervous system were likely to receive more opioids, be given multiple different opioids, and receive opioids in the last month. Conclusions The study shows the United Kingdom practice of opioid use and provides comparator data for practice in children's palliative medicine.	[Hain, Richard] Cardiff Univ, Cardiff, Wales; [Hewitt, Martin] Univ Hosp, Queens Med Ctr, Nottingham, England; [Goldman, Ann] Great Ormond St Hosp Sick Children, Symptom Ctr, London, England; [Collins, Gary S.; Childs, Margaret] UK Childrens Kingdom Canc Stud Grp, Leicester, Leics, England	Hain, R (reprint author), Cardiff Univ, Sch Med, Dept Child Hlth, Heath Pk, Cardiff CF14 4XN, Wales.		Collins, Gary S/A-2258-2014	Collins, Gary S/0000-0002-2772-2316			Ablett S, 2003, BRIT J CANCER, V88, P1661, DOI 10.1038/sj.bjc.6600990; BAUMANN TJ, 1986, DRUG INTEL CLIN PHAR, V20, P297, DOI 10.1177/106002808602000419; Collins JJ, 1999, J PEDIATR-US, V134, P319, DOI 10.1016/S0022-3476(99)70457-9; COLLINS JJ, 1995, J PEDIATR-US, V126, P653, DOI 10.1016/S0022-3476(95)70370-5; DiCiccio TJ, 1996, STAT SCI, V11, P189; Drake R, 2003, J PAIN SYMPTOM MANAG, V26, P594, DOI 10.1016/S0885-3924(03)00202-1; Faura CC, 1998, PAIN, V74, P43, DOI 10.1016/S0304-3959(97)00142-5; Goldman A, 2006, PEDIATRICS, V117, pE1179, DOI 10.1542/peds.2005-0683; GRAVES DA, 1984, DRUG INTEL CLIN PHAR, V18, P598, DOI 10.1177/106002808401800708; Hain R., 2006, OXFORD TXB PALLIATIV, P304; Hain RDW, 1999, BRIT J CLIN PHARMACO, V48, P37, DOI 10.1046/j.1365-2125.1999.00948.x; Hain Richard D W, 2005, Paediatr Drugs, V7, P1, DOI 10.2165/00148581-200507010-00001; HANKS GW, 1987, LANCET, V2, P723; Heger S, 1999, BRIT MED J, V319, P627, DOI 10.1136/bmj.319.7210.627; Hongo T, 2003, PEDIATR INT, V45, P60, DOI 10.1046/j.1442-200X.2003.01668.x; Hoskin P J, 1989, Clin J Pain, V5, P199; HOSKIN PJ, 1989, BRIT J CLIN PHARMACO, V27, P499, DOI 10.1111/j.1365-2125.1989.tb05399.x; Hunt A, 1999, J PEDIATR-US, V135, P47, DOI 10.1016/S0022-3476(99)70326-4; King T, 2005, PAIN, V116, P276, DOI 10.1016/j.pain.2005.04.014; Klepstad P, 2003, ACTA ANAESTH SCAND, V47, P725, DOI 10.1034/j.1399-6576.2003.00138.x; Kokki H, 2004, CLIN PHARMACOKINET, V43, P613, DOI 10.2165/00003088-200443090-00004; Kornick CA, 2001, CANCER, V92, P3056, DOI 10.1002/1097-0142(20011215)92:12<3056::AID-CNCR10166>3.0.CO;2-H; LO SL, 1986, CLIN PHARMACY, V5, P828; McDonald AJ, 2001, PEDIATR DRUGS, V3, P273, DOI 10.2165/00128072-200103040-00004; MCQUAY HJ, 1990, CLIN PHARMACOL THER, V48, P236, DOI 10.1038/clpt.1990.145; Mercadante S, 2004, PALLIATIVE MED, V18, P654, DOI 10.1191/0269216304pm945rr; Mystakidou Kyriaki, 2004, Int J Palliat Nurs, V10, P476; *NAT I HLTH CLIN E, 2005, GUID CANC SERV IMPR, P81; Noyes M, 2001, Am J Hosp Palliat Care, V18, P411, DOI 10.1177/104990910101800612; Ossipov MH, 2005, BIOPOLYMERS, V80, P319, DOI 10.1002/bip.20254; Pasero C, 2005, AM J NURS, V105, P30, DOI 10.1097/00000446-200507000-00024; SCHECHTER NL, 1995, PEDIATRICS, V95, P335; TWYCROSS R, 1993, BRIT MED J, V306, P793, DOI 10.1136/bmj.306.6880.793-a; Wheeler M, 2002, PAEDIATR ANAESTH, V12, P594, DOI 10.1046/j.1460-9592.2002.00949.x; Wolfe J, 2000, NEW ENGL J MED, V342, P326, DOI 10.1056/NEJM200002033420506; World Health Organization (WHO), 1998, CANC PAIN REL PALL C, P24; Zernikow B, 2001, MED PEDIATR ONCOL, V36, P451, DOI 10.1002/mpo.1109	37	22	23	2	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0022-3476			J PEDIATR	J. Pediatr.	JAN	2008	152	1					39	44		10.1016/j.jpeds.2007.07.005			6	Pediatrics	Pediatrics	247LG	WOS:000252080100012	18154896				2020-06-30	J	Reynolds, RM; Bass, KD; Thureen, PJ				Reynolds, Regina M.; Bass, Kathryn D.; Thureen, Patti J.			Achieving positive protein balance in the immediate postoperative period in neonates undergoing abdominal surgery	JOURNAL OF PEDIATRICS			English	Article							BIRTH-WEIGHT INFANTS; AMINO-ACIDS; FENTANYL ANESTHESIA; NITROGEN-BALANCE; PRETERM INFANTS; METABOLISM; TRIAL; INDEX	Objectives To determine whether neonates undergoing major abdominal surgical procedures in the first day of life could achieve a positive protein balance without protein toxicity in the immediate perioperative period by using parenteral amino acids and fentanyl analgesia. Study design Newborns undergoing major surgery for gastroschisis in the first 24 hours of life (n = 13) were alternately allocated to immediate postoperative parenteral administration of 1.5 g/kg(-1)/day(-1) versus 2.5 g/kg(-1)/day(-1) amino acids. Protein balance was determined at 1.6 to 2.6 days postoperatively with both nitrogen balance and lencine stable isotope methodology. Statistical analyses were conducted with the unpaired t test and linear regression. Results Protein balance was significantly different in the 2 groups with both nitrogen balance and leucine stable isotope methodology. There was no evidence of protein toxicity as determined with blood urea nitrogen, creatinine, and ammonia concentrations. Conclusions Neonates undergoing the metabolic stress of abdominal surgery shortly after birth are able to achieve a net positive protein balance with parenteral amino acid administration without evidence of protein intolerance.	[Reynolds, Regina M.; Thureen, Patti J.] Univ Colorado, Hlth Sci Ctr, Dept Pediat, Sect Neonatol, Denver, CO 80262 USA; [Bass, Kathryn D.] Rush Univ, Med Ctr, Dept Paediat Surg, Chicago, IL 60612 USA	Reynolds, RM (reprint author), Univ Colorado, Hlth Sci Ctr, Sect Neonatol, B-195,4200 E 9th Ave, Denver, CO 80262 USA.	regina.reynolds@uchsc.edu			NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [RR00069, K24 RR018358]; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD046752]		ANAND KJS, 1987, LANCET, V1, P62; ANDERSON TL, 1979, J PEDIATR-US, V94, P947, DOI 10.1016/S0022-3476(79)80230-9; CATZEFLIS C, 1985, PEDIATR RES, V19, P679, DOI 10.1203/00006450-198507000-00009; GIESECKE K, 1994, BRIT J ANAESTH, V72, P697, DOI 10.1093/bja/72.6.697; GRAY JE, 1992, PEDIATRICS, V90, P561; HUGHES EA, 1965, BRIT J SURG, V52, P402; LOPEZ AM, 1986, JPEN-PARENTER ENTER, V10, P517, DOI 10.1177/0148607186010005517; LOY GL, 1990, ANAL BIOCHEM, V185, P1, DOI 10.1016/0003-2697(90)90246-6; PINEAULT M, 1990, JPEN-PARENTER ENTER, V14, P53, DOI 10.1177/014860719001400153; RICHARDSON DK, 1993, PEDIATRICS, V91, P617; RIVERA A, 1993, PEDIATR RES, V33, P106, DOI 10.1203/00006450-199302000-00003; SAINI J, 1989, ARCH DIS CHILD, V64, P1362, DOI 10.1136/adc.64.10_Spec_No.1362; Shew SB, 2000, J PEDIATR SURG, V35, P1277, DOI 10.1053/jpsu.2000.0350001; Thureen PJ, 2003, PEDIATR RES, V53, P24, DOI 10.1203/00006450-200301000-00008; Thureen PJ, 1997, CRIT CARE MED, V25, P171, DOI 10.1097/00003246-199701000-00031; ZLOTKIN SH, 1981, J PEDIATR-US, V99, P115, DOI 10.1016/S0022-3476(81)80975-4	16	13	15	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0022-3476			J PEDIATR	J. Pediatr.	JAN	2008	152	1					63	67		10.1016/j.jpeds.2007.05.042			5	Pediatrics	Pediatrics	247LG	WOS:000252080100018	18154902				2020-06-30	J	Kato, A; Minami, K; Ito, H; Tomii, T; Matsumoto, M; Orita, S; Kihara, T; Narita, M; Suzuki, T				Kato, Akira; Minami, Kazuhisa; Ito, Hisanori; Tomii, Takako; Matsumoto, Mitsunobu; Orita, Satoshi; Kihara, Tsuyoshi; Narita, Minoru; Suzuki, Tsutomu			Oxycodone-induced analgesic effects in a bone cancer pain model in mice	ONCOLOGY			English	Article; Proceedings Paper	4th Asia Pacific Symposium on Pain Control	NOV 02-04, 2007	Kuala Lumpur, MALAYSIA			bone cancer pain; femur bone cancer; oxycodone; morphine; fentanyl	MURINE MODEL; BREAKTHROUGH PAIN; NEUROPATHIC PAIN; NERVE-FIBERS; SPINAL-CORD; MORPHINE; DESTRUCTION; REORGANIZATION; SENSITIVITY; NOCICEPTION	The femur bone cancer pain model was developed by implanting mouse osteolytic tumor cells (NCTC 2472) into the intramedulla of the femur in C3H/HeN mice. In vivo imaging analysis revealed that the implanted tumor cells grew progressively over 14 days. Associated with the tumor growth, guarding behavior, which was an indication of ongoing pain, time-dependently increased. Limb use abnormality and allodynia, which were indications of ambulatory and neuropathic pain, respectively, also appeared. The analgesic effects of oxycodone and other opioids, such as morphine and fentanyl, were evaluated at 14 days when all pain-related behaviors clearly appeared. Oxycodone (2-20 mg/kg, s.c.), morphine (10-50 mg/kg, s.c.) and fentanyl (0.05-0.2 mg/kg, s.c.) significantly reduced guarding behavior. Oxycodone (5 20 mg/kg, s.c.) and fentanyl (0.1 and 0.2 mg/kg, s.c.) significantly reversed limb use abnormality, but morphine (5-50 mg/kg, s.c.) did not. Moreover, oxycodone (5-20 mg/kg, s.c.) dose-dependently reversed allodynia without affecting the sham-treated mice. Morphine (50 mg/kg, s.c.) and fentanyl (0.075-0.2 mg/kg, s.c.) also reversed allodynia, but morphine (50 mg/kg, s.c.) tended to affect and fentanyl (0.1 and 0.2 mg/kg, s.c.) affected the withdrawal threshold in sham-treated mice. These results suggested that oxycodone relieved not only ongoing pain, but also ambulatory and neuropathic pain, and that the analgesic profile of oxycodone could be different from that of either morphine or fentanyl. Copyright (c) 2008 S. Karger AG, Basel.	[Kato, Akira; Minami, Kazuhisa; Ito, Hisanori; Tomii, Takako; Kihara, Tsuyoshi] Shionogi & Co Ltd, Discovery Res Labs, Pain & Neurol, Koka 5203423, Japan; [Matsumoto, Mitsunobu; Orita, Satoshi] Shionogi & Co Ltd, Frontier Drug Discovery, Discovery Res Labs, Osaka, Japan; [Narita, Minoru; Suzuki, Tsutomu] Hoshi Univ, Sch Pharm & Pharmaceut Sci, Dept Toxicol, Tokyo 142, Japan	Kato, A (reprint author), Shionogi & Co Ltd, Discovery Res Labs, Pain & Neurol, 1405 Gotanda,Koka Cho, Koka 5203423, Japan.	akira_kato@shionogi.co.jp					ARNER S, 1988, PAIN, V33, P11, DOI 10.1016/0304-3959(88)90198-4; Becker R, 2000, STEREOT FUNCT NEUROS, V75, P16, DOI 10.1159/000048379; Bercovitch Michaela, 2006, J Pain Palliat Care Pharmacother, V20, P33, DOI 10.1300/J354v20n04_06; Bridges D, 2001, BRIT J ANAESTH, V87, P12, DOI 10.1093/bja/87.1.12; El Mouedden M, 2005, PHARMACOL BIOCHEM BE, V82, P109, DOI 10.1016/j.pbb.2005.07.016; El Mouedden M, 2007, PHARMACOL BIOCHEM BE, V87, P30, DOI 10.1016/j.pbb.2007.03.017; Gilchrist LS, 2005, BRAIN RES, V1044, P197, DOI 10.1016/j.brainres.2005.02.081; Honore P, 2000, NAT MED, V6, P521, DOI 10.1038/74999; Lemberg K, 2006, ANESTH ANALG, V102, P1768, DOI 10.1213/01.ane.0000205751.88422.41; Lemberg KK, 2006, ANESTHESIOLOGY, V105, P801, DOI 10.1097/00000542-200610000-00027; Luger NM, 2002, PAIN, V99, P397, DOI 10.1016/S0304-3959(02)00102-1; Mercadante S, 1998, CANCER TREAT REV, V24, P425, DOI 10.1016/S0305-7372(98)90005-6; Monory K, 1999, LIFE SCI, V64, P2011, DOI 10.1016/S0024-3205(99)00148-4; Narita M, 2008, NEUROPSYCHOPHARMACOL, V33, P1097, DOI 10.1038/sj.npp.1301471; Nozaki C, 2006, EUR J PHARMACOL, V535, P145, DOI 10.1016/j.ejphar.2006.02.002; Pan YX, 2005, MOL PHARMACOL, V68, P866, DOI 10.1124/mol.105.011858; Peckham EM, 2006, J PHARMACOL EXP THER, V316, P1195, DOI 10.1124/jpet.105.094276; Peters CM, 2005, EXP NEUROL, V193, P85, DOI 10.1016/j.expneurol.2004.11.028; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Schwei MJ, 1999, J NEUROSCI, V19, P10886; Sevcik MA, 2005, PAIN, V115, P128, DOI 10.1016/j.pain.2005.02.022; STANFA L, 1995, INFLAMM RES, V44, P231, DOI 10.1007/BF01782974; Vermeirsch H, 2004, PHARMACOL BIOCHEM BE, V79, P243, DOI 10.1016/j.pbb.2004.07.011	23	16	16	0	1	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0030-2414			ONCOLOGY-BASEL	Oncology		2008	74						55	60		10.1159/000143220			6	Oncology	Oncology	345GK	WOS:000258984100011	18758199				2020-06-30	J	Parker, R; Gordon, FH				Parker, Richard; Gordon, Fiona H.			A different cause of erythema ab igne in chronic pancreatitis	PANCREATOLOGY			English	Editorial Material									[Parker, Richard; Gordon, Fiona H.] Univ Hosp Bristol NHS Fdn Trust, Bristol, Avon, England	Parker, R (reprint author), Bristol Royal Infirm & Gen Hosp, Dept Liver Med, Marlborough St, Bristol BS2 8HW, Avon, England.	richardparker@nhs.net					Ashburn MA, 2003, J PAIN, V4, P291, DOI 10.1016/S1526-5900(03)00618-7; BUTLER ML, 1977, AM J GASTROENTEROL, V67, P77	2	1	1	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1424-3903			PANCREATOLOGY	Pancreatology		2008	8	4-5					532	532		10.1159/000152002			1	Gastroenterology & Hepatology	Gastroenterology & Hepatology	345GL	WOS:000258984200016	18765958				2020-06-30	J	Tosun, Z; Esmaoglu, A; Coruh, A				Tosun, Zeynep; Esmaoglu, Aliye; Coruh, Atilla			Propofol-ketamine vs propofol-fentanyl combinations for deep sedation and analgesia in pediatric patients undergoing burn dressing changes	PEDIATRIC ANESTHESIA			English	Article; Proceedings Paper	4th Meeting of the Middle-East-Burn-and-Fire-Disaster-Society	JUN 15-17, 2006	Ankara, TURKEY	Middle E Burn & Fire Disaster Soc		sedation; analgesia; ketamine; propofol; fentanyl; burn dressing change; children	ORAL MORPHINE; PAIN; MANAGEMENT; INJURIES; EFFICACY; CHILDREN	background: The aim of this study was to compare propofol-ketamine (PK) and propofol-fentanyl (PF) combinations for deep sedation and analgesia in pediatric burn wound dressing changes. Methods: Thirty-two ASA physical status II and III inpatients with a second degree total burn surface area ranging from 5% to 25% were studied in a randomized, double blind fashion. Heart rate, systolic arterial pressure, peripheral oxygen saturation, respiratory rate and Ramsey sedation scores of all patients were recorded perioperatively. Patients were randomly assigned to receive either PK or PF: PK group (n = 17) received 1 mg.kg(-1) ketamine + 1.2 mg.kg(-1) propofol, and PF group (n = 15) received 1 mu g.kg(-1) fentanyl + 1.2 mg.kg(-1) propofol for induction. Additional propofol (0.5-1 mg.kg(-1)) was administered when the patients showed discomfort in both groups. If the patient showed discomfort and/or increase in heart rate or systolic arterial pressure, despite additional propofol dose, additional bolus of 0.5-1 mg.kg(-1) ketamine or 0.5-1 mu g.kg(-1) fentanyl was administered. Results: There were no significant differences in heart rate, systolic arterial pressure, peripheral oxygen saturation, respiratory rate and sedation scores during the procedure between the groups. Restlessness during the procedure was seen in seven (47%) patients in Group PF and one (5.9%) patient in Group PK (P = 0.013). Conclusion: Both propofol-ketamine and propofol-fentanyl combinations provided effective sedation and analgesia during dressing changes in pediatric burn patients. But propofol-ketamine combination was superior to propofol-fentanyl combination because of more restlessness in patients given propofol-fentanyl.	[Tosun, Zeynep; Esmaoglu, Aliye] Erciyes Univ, Fac Med, Dept Anesthesiol & Reanimat, TR-38039 Kayseri, Turkey; [Coruh, Atilla] Erciyes Univ, Fac Med, Dept Plast & Reconstruct Surg, TR-38039 Kayseri, Turkey	Tosun, Z (reprint author), Erciyes Univ, Fac Med, Dept Anesthesiol & Reanimat, TR-38039 Kayseri, Turkey.	zeynept@erciyes.edu.tr	Coruh, Atilla/AAJ-4560-2020	Coruh, Atilla/0000-0002-3592-3433			Borland ML, 2005, BURNS, V31, P831, DOI 10.1016/j.burns.2005.05.001; Escarment J, 1995, Cah Anesthesiol, V43, P31; FAUCHER LD, 2003, MODERN PAIN MANAGEME, V20; Frenay MC, 2001, BURNS, V27, P793, DOI 10.1016/S0305-4179(01)00035-3; Green SM, 2000, ANN EMERG MED, V35, P35, DOI 10.1016/S0196-0644(00)70102-8; GUIT JBM, 1991, ANAESTHESIA, V46, P24, DOI 10.1111/j.1365-2044.1991.tb09308.x; Heinrich M, 2004, EUR J PEDIATR SURG, V14, P235, DOI 10.1055/s-2004-817960; Humphries Yvonne, 1997, Journal of Burn Care and Rehabilitation, V18, P34; Linneman PK, 2000, J BURN CARE REHABIL, V21, P519, DOI 10.1097/00004630-200021060-00008; Murat I, 1996, ANESTHESIOLOGY, V84, P526, DOI 10.1097/00000542-199603000-00006; Owens VF, 2006, J BURN CARE RES, V27, P211, DOI 10.1097/01.BCR.0000204310.67594.A1; Pal SK, 1997, BURNS, V23, P404, DOI 10.1016/S0305-4179(97)00029-6; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; Petrack EM, 2000, CLIN PED EMERG MED, V1, P281; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; Robert R, 2003, J BURN CARE REHABIL, V24, P351, DOI 10.1097/01.BCR.0000095504.69283.F2; Sharar S. R., 2002, Journal of Burn Care & Rehabilitation, V23, P27, DOI 10.1097/00004630-200201000-00006; STEWARD DJ, 1975, CAN ANAESTH SOC J, V22, P111, DOI 10.1007/BF03004827	18	63	67	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645	1460-9592		PEDIATR ANESTH	Pediatr. Anesth.	JAN	2008	18	1					43	47		10.1111/j.1460-9592.2007.02380.x			5	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	239YR	WOS:000251554700010	18095965				2020-06-30	J	Yassen, A; Olofsen, E; Kan, J; Dahan, A; Danhof, M				Yassen, Ashraf; Olofsen, Erik; Kan, Jingmin; Dahan, Albert; Danhof, Meindert			Pharmacokinetic-pharmacodynamic modeling of the effectiveness and safety of buprenorphine and fentanyl in rats	PHARMACEUTICAL RESEARCH			English	Article						effectiveness; PK-PD; respiratory depression; safety; utility function	PATIENT-CONTROLLED ANALGESIA; POSTOPERATIVE ANALGESIA; RESPIRATORY DEPRESSION; HEALTHY-VOLUNTEERS; INTRATHECAL MORPHINE; VENTILATORY RESPONSE; EFFICACY; RECEPTOR; OPIOIDS; SUFENTANIL	Objective. Respiratory depression is a serious and potentially life-threatening side-effect of opioid therapy. The objective of this investigation was to characterize the relationship between buprenorphine or fentanyl exposure and the effectiveness and safety outcome in rats. Methods. Data on the time course of the antinociceptive and respiratory depressant effect were analyzed on the basis of population logistic regression PK-PD models using non-linear mixed effects modeling software (NONMEM). The pharmacokinetics of buprenorphine and fentanyl were described by a three- and two-compartment model, respectively. A logistic regression model (linear logit model) was used to characterize the relationship between drug exposure and the binary effectiveness and safety outcome. Results. For buprenorphine, the odds ratios (OR) were 28.5 (95% CI, 6.9-50.1) and 2.10 (95% CI, 0.71-3.49) for the antinociceptive and respiratory depressant effect, respectively. For fentanyl these odds ratios were 3.03 (95% CI, 1.87-4.21) and 2.54 (95% CI, 1.26-3.82), respectively. Conclusion.The calculated safety index (ORantinociception/ORrespiratory depression) for fentanyl of 1.20 suggests that fentanyl has a low safety margin, implicating that fentanyl needs to be titrated with caution. For buprenorphine the safety index is 13.54 suggesting that buprenorphine is a relatively safe opioid.	[Yassen, Ashraf; Kan, Jingmin; Danhof, Meindert] Gorlaeus Labs, Leiden Amsterdam Ctr Drug Res, Div Pharmacol, NL-2300 RA Leiden, Netherlands; [Olofsen, Erik; Dahan, Albert] Leiden Univ, Med Ctr, Pain & Anesthesia Res Unit, Dept Anesthesiol, Leiden, Netherlands; [Danhof, Meindert] LAP&P Consultants BV, Leiden, Netherlands	Danhof, M (reprint author), Gorlaeus Labs, Leiden Amsterdam Ctr Drug Res, Div Pharmacol, POB 9502, NL-2300 RA Leiden, Netherlands.	m.danhof@lacdr.leidenuniv.nl	Dahan, Albert/B-8845-2008	Dahan, Albert/0000-0003-3161-3945			Bailey PL, 2000, NEW ENGL J MED, V343, P1228, DOI 10.1056/NEJM200010263431705; BAXTER AD, 1994, CAN J ANAESTH, V41, P87, DOI 10.1007/BF03009796; BEAL SL, 1999, [No title captured]; Bowdle TA, 1998, DRUG SAFETY, V19, P173, DOI 10.2165/00002018-199819030-00002; BRADY LS, 1982, J PHARMACOL EXP THER, V222, P190; Budd K, 2003, BRIT J ANAESTH, V90, P722, DOI 10.1093/bja/aeg133; CLARK AJ, 1937, HEFFNERS HDB EXPT PH, V4, P38; Cox EH, 1998, J PHARMACOL EXP THER, V284, P1095; Cullberg M, 2005, CLIN PHARMACOL THER, V77, P279, DOI 10.1016/j.clpt.2004.11.001; DAHAN A, 1990, J PHYSIOL-LONDON, V428, P485, DOI 10.1113/jphysiol.1990.sp018223; Dahan A, 2005, BRIT J ANAESTH, V94, P825, DOI 10.1093/bja/aei145; DAHAN A, 2006, BR J ANAESTH; Gan TJ, 2006, ANESTH ANALG, V102, P1884, DOI 10.1213/01.ANE.0000219597.16143.4D; GRACE D, 1995, ANESTH ANALG, V80, P86, DOI 10.1097/00000539-199501000-00015; Graham G, 2002, J PHARMACOKINET PHAR, V29, P67, DOI 10.1023/A:1015720718875; GUSTAFSSON LL, 1982, BRIT J ANAESTH, V54, P479, DOI 10.1093/bja/54.5.479; Huang P, 2001, J PHARMACOL EXP THER, V297, P688; JACOBSON L, 1989, ANESTHESIOLOGY, V70, P742, DOI 10.1097/00000542-198905000-00005; Jonsson S, 2005, EUR J PHARM SCI, V25, P123, DOI 10.1016/j.ejps.2005.02.004; KENAKI T, 1997, PHARM ANAL DRUG RECE; Ko S, 2003, CAN J ANAESTH, V50, P679, DOI 10.1007/BF03018710; Lejus C, 1996, EUR J ANAESTH, V13, P57, DOI 10.1097/00003643-199601000-00011; Modesti C, 2006, MINERVA ANESTESIOL, V72, P627; Mould DR, 2006, BRIT J CLIN PHARMACO, V62, P56, DOI 10.1111/j.1365-2125.2006.02718.x; Regnard C, 2003, PALLIATIVE MED, V17, P714, DOI 10.1191/0269216303pm838cr; Romberg R, 2003, ANESTHESIOLOGY, V99, P788, DOI 10.1097/00000542-200310000-00008; SCHAICKVAN EA, 1998, BRIT J PHARMACOL, V124, P607; SCOTT JC, 1991, ANESTHESIOLOGY, V74, P34, DOI 10.1097/00000542-199101000-00007; Sheiner L B, 1978, Ann N Y Acad Sci, V304, P112, DOI 10.1111/j.1749-6632.1978.tb25582.x; SHEINER LB, 1979, CLIN PHARMACOL THER, V25, P358; Skaer TL, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-24; Sporer KA, 2004, ANN EMERG MED, V43, P580, DOI 10.1016/j.annemergmed.2003.11.006; Van der Graaf PH, 1999, J PHARMACOL EXP THER, V290, P702; Waara-Wolleat KL, 2006, PAIN MED, V7, P251, DOI 10.1111/j.1526-4637.2006.00155.x; WALSH SL, 1994, CLIN PHARMACOL THER, V55, P569, DOI 10.1038/clpt.1994.71; Woodhouse A, 2000, REGION ANESTH PAIN M, V25, P259, DOI 10.1016/S1098-7339(00)90008-7; Yassen A, 2005, J PHARMACOL EXP THER, V313, P1136, DOI 10.1124/jpet.104.082560; Yassen A, 2007, CLIN PHARMACOL THER, V81, P50, DOI 10.1038/sj.clpt.6100025; Yassen A, 2006, J PHARMACOL EXP THER, V319, P682, DOI 10.1124/jpet.106.107953; Yassen A, 2006, ANESTHESIOLOGY, V104, P1232, DOI 10.1097/00000542-200606000-00019; Yassen A, 2007, CLIN PHARMACOKINET, V46, P433, DOI 10.2165/00003088-200746050-00005; Zanderigo E, 2006, ANESTHESIOLOGY, V104, P742, DOI 10.1097/00000542-200604000-00019	42	34	34	0	5	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0724-8741			PHARM RES	Pharm. Res.	JAN	2008	25	1					183	193		10.1007/s11095-007-9440-z			11	Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Chemistry; Pharmacology & Pharmacy	249TW	WOS:000252253700019	17914664	Green Published, Bronze			2020-06-30	J	Bujalska, M; Malinowska, E; Makulska-Nowak, H; Gumulka, SW				Bujalska, Magdalena; Malinowska, Ewelina; Makulska-Nowak, Helena; Gumulka, Stanislaw Witold			Magnesium ions and opioid agonist activity in streptozotocin-induced hyperalgesia	PHARMACOLOGY			English	Article						diabetes; hyperalgesia; streptozotocin; magnesium ions; morphine; fentanyl; buprenorphine; rats	PAIN-RELATED BEHAVIOR; NEUROPATHIC PAIN; MECHANICAL HYPERALGESIA; RECEPTOR ANTAGONIST; RAT MODEL; MORPHINE; SULFATE; ANALGESIA; EFFICACY; HYPERGLYCEMIA	Streptozotocin-induced hyperglycemia accompanied by a chronic decrease in the nociceptive threshold is considered a useful model of experimental hyperalgesia. We examined (1) the effect of the opioid receptor agonists and (2) the effect of the magnesium ions (Mg(2+)) on the antinociceptive action of opioid agonists in a diabetic neuropathic pain model. When administered alone, opioid agonists like morphine (5 mg/kg i.p.) and fentanyl (0.0625 mg/kg i.p.), as well as the partial agonist buprenorphine (0.075 mg/kg) had only little effect on streptozotocin-induced hyperalgesia. However, pretreatment with Mg(2+) at a dose of 40 mg magnesium sulfate/kg i.p. markedly enhanced the analgesic activity of all three investigated opioids. Practical aspects of co-administration of magnesium and opioids in diabetic neuropathy are discussed. Copyright (C) 2008 S. Karger AG, Basel.	[Bujalska, Magdalena; Malinowska, Ewelina; Makulska-Nowak, Helena; Gumulka, Stanislaw Witold] Med Univ Warsaw, Dept Pharmacodynam, PL-00927 Warsaw 64, Poland	Bujalska, M (reprint author), Med Univ Warsaw, Dept Pharmacodynam, Krakowskie Przedmiescie Str 26-28,POB 3, PL-00927 Warsaw 64, Poland.	mbujalska@gmail.com		Bujalska-Zadrozny, Magdalena/0000-0002-4270-6373			Aley KO, 2002, NEUROSCIENCE, V111, P389, DOI 10.1016/S0306-4522(02)00009-X; Begon S, 2002, ANESTHESIOLOGY, V96, P627, DOI 10.1097/00000542-200203000-00019; Bolcal C, 2005, J CARDIOTHOR VASC AN, V19, P714, DOI 10.1053/j.jvca.2005.08.010; Bordi F, 2000, PAIN, V84, P213, DOI 10.1016/S0304-3959(99)00205-5; Buvanendran A, 2002, ANESTH ANALG, V95, P661, DOI 10.1097/00000539-200209000-00031; Christensen D, 1999, PAIN, V83, P433, DOI 10.1016/S0304-3959(99)00126-8; CLARK CM, 1995, NEW ENGL J MED, V332, P1210, DOI 10.1056/NEJM199505043321807; COURTEIX C, 1994, PAIN, V57, P153, DOI 10.1016/0304-3959(94)90218-6; Crosby V, 2000, J PAIN SYMPTOM MANAG, V19, P35, DOI 10.1016/S0885-3924(99)00135-9; Dellemijn P, 1999, PAIN, V80, P453, DOI 10.1016/S0304-3959(98)00256-5; Dickenson AH, 1997, ACTA ANAESTH SCAND, V41, P112, DOI 10.1111/j.1399-6576.1997.tb04624.x; Dobretsov M, 2003, BRAIN RES, V960, P174, DOI 10.1016/S0006-8993(02)03828-3; Dyck PJ, 2000, DIABETES CARE, V23, P510, DOI 10.2337/diacare.23.4.510; Ebert B, 1998, BIOCHEM PHARMACOL, V56, P553, DOI 10.1016/S0006-2952(98)00088-4; Gabra BH, 2005, J NEUROPATH EXP NEUR, V64, P782, DOI 10.1097/01.jnen.0000178448.79713.5f; KAMEI J, 1992, BRAIN RES, V571, P199, DOI 10.1016/0006-8993(92)90655-S; Malyshkin AA, 2005, EUR J PHARMACOL, V519, P80, DOI 10.1016/j.ejphar.2005.07.003; MAO JR, 1995, PAIN, V61, P353, DOI 10.1016/0304-3959(95)00022-K; McCarthy RJ, 1998, ANESTH ANALG, V86, P830, DOI 10.1097/00000539-199804000-00028; NAKHODA A, 1979, EXPERIENTIA, V35, P1679, DOI 10.1007/BF01953269; Nichols ML, 1997, PAIN, V69, P317, DOI 10.1016/S0304-3959(96)03282-4; Ozalevli M, 2005, ACTA ANAESTH SCAND, V49, P1514, DOI 10.1111/j.1399-6576.2005.00793.x; Parsons CG, 2001, EUR J PHARMACOL, V429, P71, DOI 10.1016/S0014-2999(01)01307-3; RANDALL LO, 1957, ARCH INT PHARMACOD T, V111, P409; RAZ I, 1988, DIABETES, V37, P1253, DOI 10.2337/diabetes.37.9.1253; Romanovsky D, 2004, J PERIPHER NERV SYST, V9, P62, DOI 10.1111/j.1085-9489.2004.009204.x; TALLARIDA RJ, 1986, [No title captured], P113; Tramer MR, 1996, ANESTHESIOLOGY, V84, P340, DOI 10.1097/00000542-199602000-00011; Ulugol A, 2002, BRAIN RES, V943, P101, DOI 10.1016/S0006-8993(02)02618-5; Yamakura T, 1999, ANESTHESIOLOGY, V91, P1053, DOI 10.1097/00000542-199910000-00026; YAMAMOTO T, 1992, NEUROSCI LETT, V135, P67, DOI 10.1016/0304-3940(92)90137-V; Zurek JR, 2001, PAIN, V90, P57, DOI 10.1016/S0304-3959(00)00386-9	32	17	17	0	2	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0031-7012			PHARMACOLOGY	Pharmacology		2008	82	3					180	186		10.1159/000151346			7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	356OB	WOS:000259786400002	18701828				2020-06-30	J	Kalso, E; Simpson, KH; Slappendel, R; Dejonckheere, J; Richarz, U				Kalso, Eija; Simpson, Karen H.; Slappendel, Robert; Dejonckheere, Joachim; Richarz, Ute			Predicting long-term response to strong opioids in patients with low back pain: findings from a randomized, controlled trial of transdermal fentanyl and morphine	BMC MEDICINE			English	Article							RELEASE ORAL MORPHINE; SUBPOPULATION PROGRAM; EFFICACY; POPULATION; DISABILITY; CANCER; SAFETY	Background: Some patients with long-standing low back pain will benefit from treatment with strong opioids. However, it would be helpful to predict which patients will have a good response. A fixed-term opioid trial has been recommended, but there is little evidence to suggest how long this trial should be. We assessed data from a large-scale randomized comparison of transdermal fentanyl (TDF) and sustained-release oral morphine (slow-release morphine; SRM) to determine characteristics of treatment responders. Methods: This was a secondary analysis of a previously published 13-month randomized trial involving 680 patients with long-standing low back pain (median age 52 years, 61% women, median duration of back pain 87 months). Pain relief was recorded using visual analogue scales (VAS). Treatment response was defined as pain relief of at least 30% from baseline to any point during the trial. We used a step-wise logistic regression to identify variables that might predict response to treatment. Covariates included treatment group, sex, age, duration of pain, presence of neuropathic pain, baseline pain scores, educational/employment status, use of high doses of opioids, and social functioning (SF)-36 scores. Results: Over half the patients in both groups (n = 370; 54% TDF, 55% SRM) were treatment responders. There were no differences between the TDF and SRM responders in terms of age, sex, type or duration of pain between responders and non-responders. The difference in response to treatment between responders and non-responders could be detected at 3 weeks. Lack of response after 1 month had a stronger negative predictive value (i.e., ability to detect non-responders) than the presence of response after 1 month. The most influential factors for predicting a response were employment status (chi(2) = 11.06, p = 0.0259) and use of high doses of opioids (chi(2) = 3.04, p = 0.0811). Conclusion: No clear pattern of baseline pain (type or severity) or patient characteristics emerged that could be used to predict responders before the start of opioid treatment. However, a 1-month trial period appears sufficient to determine response and tolerability in most cases.	[Kalso, Eija] Univ Helsinki, Cent Hosp, Pain Clin, Helsinki, Finland; [Simpson, Karen H.] Leeds Teaching Hosp, Leeds, W Yorkshire, England; [Slappendel, Robert] Sint Maartensklin, Nijmegen, Netherlands; [Dejonckheere, Joachim] SGS Thomson Microelect, Mechelen, Belgium; [Richarz, Ute] Janssen Cilag, Baar, Switzerland	Richarz, U (reprint author), Univ Helsinki, Cent Hosp, Pain Clin, Helsinki, Finland.	eija.kalso@hus.fi; karen.simpson@dsl.pipex.com; robslappendel@hotmail.com; joachim.dejonckheere@sgs.com; urichar1@jacc.jnj.com		Kalso, Eija/0000-0002-4899-605X			Allan L, 2005, SPINE, V30, P2484, DOI 10.1097/01.brs.0000186860.23078.a8; Axen I, 2005, J MANIP PHYSIOL THER, V28, P381, DOI 10.1016/j.jmpt.2005.06.008; Clark AJ, 2004, CURR MED RES OPIN, V20, P1419, DOI 10.1185/030079904X2114; Dellemijn PLI, 1998, J PAIN SYMPTOM MANAG, V16, P220, DOI 10.1016/S0885-3924(98)00070-0; Dionne CE, 2001, J EPIDEMIOL COMMUN H, V55, P455, DOI 10.1136/jech.55.7.455; Eisenberg E, 2005, JAMA-J AM MED ASSOC, V293, P3043, DOI 10.1001/jama.293.24.3043; Enthoven P, 2006, PAIN, V122, P137, DOI 10.1016/j.pain.2006.01.022; Farrar JT, 2000, PAIN, V88, P287, DOI 10.1016/S0304-3959(00)00339-0; Hagen KB, 2000, SPINE, V25, P2480, DOI 10.1097/00007632-200010010-00010; Heiskanen T, 1997, PAIN, V73, P37, DOI 10.1016/S0304-3959(97)00072-9; Jellema P, 2006, SPINE, V31, P1699, DOI 10.1097/01.brs.0000224179.04964.aa; Kalso E, 2004, PAIN, V112, P372, DOI 10.1016/j.pain.2004.09.019; Karjalainen K, 2003, SPINE, V28, P2634, DOI 10.1097/01.BRS.0000099097.61495.2E; Leboeuf-Yde C, 2004, J MANIP PHYSIOL THER, V27, P493, DOI 10.1016/j.jmpt.2004.08.001; Wasan AD, 2005, PAIN, V117, P450, DOI 10.1016/j.pain.2005.08.006	15	30	31	0	5	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1741-7015			BMC MED	BMC Med.	DEC 21	2007	5								39	10.1186/1741-7015-5-39			8	Medicine, General & Internal	General & Internal Medicine	278UC	WOS:000254310800001	18154644	DOAJ Gold, Green Published			2020-06-30	J	Ammon-Treiber, S; Stolze, D; Hollt, V				Ammon-Treiber, Susanne; Stolze, Daniela; Hoellt, Volker			Differential effects of mu-opioid receptor agonists in a hippocampal hypoxia/hypoglycemia model	BRAIN RESEARCH			English	Article						opioid; rat hippocampus; hypoxia/hypoglycemia	IN-VITRO; CEREBRAL-ISCHEMIA; CELL-DEATH; CA1 REGION; MORPHINE; ENDOCYTOSIS; MECHANISMS; FENTANYL	Background: In rat hippocampal slices, a short hypoxia/hypoglycemia causes immediate loss of evoked potentials (population spike amplitude) in the CA1 region and the extent of electrophysiological restoration during reperfusion can serve as a parameter for cell function. Previous experiments using this model revealed that exposure to morphine aggravates the neurotoxic effects of a subsequent hypoxia/hypoglycemia in a concentration-dependent manner. Therefore, the aim of the present study was to evaluate the effects of additional mu-opioid receptor (MOPr) agonists on the electrophysiological restoration after hypoxia/hypoglycemia. Methods: Rat hippocampal slices were exposed to either morphine (10 mu M), pethidine (10 mu M), fentanyl (100 nM/1 mu M) or to the synthetic peptide [D-Ala(2), N-Me-Phe(4), Glycinol(5)]-enkephalin (DAMGO, 10 mu M) for 60 min; thereafter, slices underwent a brief hypoxic/hypoglycemic episode followed by reperfusion (drug-free) for 2.5 h. Electrophysiological recording consisted of determination of population spike amplitude in CA1 in response to constant stimulation of Schaffer's collaterals. Results: Exposure to morphine prior to hypoxia/hypoglycermia resulted in a significantly impaired electrophysiological recovery during reperfusion when compared to controls. Following exposure to pethidine, the electrophysiological recovery was slightly reduced, whereas fentanyl or DAMGO did not affect restoration of population spike amplitude during reperfusion. Conclusions: The results of the present study demonstrate that different MOPr agonists differentially influence the electrophysiological recovery of hippocampal slices following a brief hypoxia/hypoglycemia. It is speculated that known receptor-internalizing opioids such as fentanyl or DAMGO may have less neurotoxic effect in hypoxia/hypoglycemia than the non-internalizing drug morphine. (c) 2007 Elsevier B.V. All rights reserved.	[Ammon-Treiber, Susanne; Stolze, Daniela; Hoellt, Volker] Otto von Guericke Univ, Inst Pharmacol & Toxicol, D-39120 Magdeburg, Germany	Ammon-Treiber, S (reprint author), Saarland Univ Hosp, Dept Internal Med 2, Kirrberger Str, D-66421 Homburg, Germany.	susanne.ammon-treiber@uniklinikum-saarland.de					Ammon-Treiber S, 2005, NEUROPHARMACOLOGY, V49, P1160, DOI 10.1016/j.neuropharm.2005.06.016; Charchaflieh J, 1998, ANESTH ANALG, V87, P68, DOI 10.1097/00000539-199807000-00015; GRUDT TJ, 1995, REV NEUROSCIENCE, V6, P279; Inturrisi CE, 2002, CLIN J PAIN, V18, pS3, DOI 10.1097/00002508-200207001-00002; Kehl F, 2004, BRAIN RES, V1021, P76, DOI 10.1016/j.brainres.2004.06.038; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; Koch T, 2005, MOL PHARMACOL, V67, P280, DOI 10.1124/mol.104.004994; Kofke WA, 1999, BRAIN RES, V818, P326, DOI 10.1016/S0006-8993(98)01228-1; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Lim YJ, 2004, ANESTHESIOLOGY, V100, P562, DOI 10.1097/00000542-200403000-00015; MILLER KK, 1994, J PHARMACOL EXP THER, V268, P753; Murphy E, 2004, CIRC RES, V94, P7, DOI 10.1161/01.RES.0000108082.76667.F4; Nagy K, 2004, J NEUROSCI RES, V76, P697, DOI 10.1002/jnr.20120; Pugliese AM, 2003, BRIT J PHARMACOL, V140, P305, DOI 10.1038/sj.bjp.0705442; Ruthrich HL, 1999, RESTOR NEUROL NEUROS, V15, P327; Ruthrich HL, 2001, BRAIN RES, V922, P153, DOI 10.1016/S0006-8993(01)03163-8; Schulz S, 2004, EMBO J, V23, P3282, DOI 10.1038/sj.emboj.7600334; von Zastrow M, 2003, CURR OPIN NEUROBIOL, V13, P348, DOI 10.1016/S0959-4388(03)00069-2; Williams JT, 2001, PHYSIOL REV, V81, P299; Zhao P, 2006, J NEUROPATH EXP NEUR, V65, P945, DOI 10.1097/01.jnen.0000235123.05677.4b	20	8	8	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	DEC 5	2007	1183						60	65		10.1016/j.brainres.2007.09.002			6	Neurosciences	Neurosciences & Neurology	244NC	WOS:000251871600007	17936735				2020-06-30	J	Agarwal, A; Gautam, S; Nath, SS; Gupta, D; Singh, U				Agarwal, A.; Gautam, S.; Nath, S. S.; Gupta, D.; Singh, U.			Comparison of the incidence and severity of cough induced by sufentanil and fentanyl: a prospective, randomised, double-blind study	ANAESTHESIA			English	Article							CITRIC-ACID; GUINEA-PIGS; BOLUS	We compared the incidence and severity of cough following a bolus of sufentanil with that following fentanyl in 510 patients, randomly allocated to receive sufentanil 0.3 mu g.kg(-1), fentanyl 3 mu g.kg(-1) or 5 ml sterile water intravenously over 5 s. Coughing was graded depending on the number of coughs as mild (1-2), moderate (3-5) and severe (> 5). The incidence of coughing was higher after sufentanil (26/165; 15%) and fentanyl (54/169; 32%) than in the control group (0/168; p < 0.001). Sufentanil was also associated with a lesser severity (p = 0.039) of coughing compared with fentanyl. We conclude that equipotent boluses of sufentanil and fentanyl increase the incidence of cough, although the incidence and severity of coughing with sufentanil are less than those with fentanyl.	Sanjay Gandhi Postgrad Inst Med Sci, Dept Anaesthesiol, Lucknow 226014, Uttar Pradesh, India; Sanjay Gandhi Postgrad Inst Med Sci, Dept Biostat, Lucknow 226014, Uttar Pradesh, India	Agarwal, A (reprint author), Sanjay Gandhi Postgrad Inst Med Sci, Dept Anaesthesiol, Lucknow 226014, Uttar Pradesh, India.	aagarwal@sgpgi.ac.in					Agarwal A, 2003, CAN J ANAESTH, V50, P297, DOI 10.1007/BF03017801; Bennett JA, 1997, ANESTHESIOLOGY, V87, P1070, DOI 10.1097/00000542-199711000-00010; BOHRER H, 1990, ANAESTHESIA, V45, P18, DOI 10.1111/j.1365-2044.1990.tb14496.x; CODA BA, 2006, CLIN ANESTH, P329; Gal TJ, 2005, MILLERS ANESTHESIA, P1617; HORROW JC, 1991, ANESTHESIOLOGY, V75, P969, DOI 10.1097/00000542-199112000-00007; Lui PW, 1996, CAN J ANAESTH, V43, P1216; NORDEGREN T, 2002, ENCY ALCOHOL DRUG AB, P291; Paice J, 1995, CANC PAIN MANAGEMENT, P131; Pandey CK, 2005, CAN J ANAESTH, V52, P172, DOI 10.1007/BF03027724; PHUA WT, 1991, CAN J ANAESTH, V38, P330, DOI 10.1007/BF03007623; SIFERI SA, 2003, MED TOXICOL, P756; Tanaka M, 2005, J PHARMACOL SCI, V99, P77, DOI 10.1254/jphs.FPJ05014X; Tanaka M, 2003, J PHARMACOL SCI, V93, P465, DOI 10.1254/jphs.93.465; YASUDA I, 1978, ANESTHESIOLOGY, V49, P117, DOI 10.1097/00000542-197808000-00012; Yemen TA, 1998, ANESTHESIOLOGY, V89, P271, DOI 10.1097/00000542-199807000-00043	16	21	30	0	2	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0003-2409			ANAESTHESIA	Anaesthesia	DEC	2007	62	12					1230	1232		10.1111/j.1365-2044.2007.05249.x			3	Anesthesiology	Anesthesiology	228JT	WOS:000250726900006	17991258				2020-06-30	J	Ishiyama, T; Iijima, T; Sugawara, T; Shibuya, K; Sato, H; Terada, Y; Ichikawa, M; Sessler, DI; Matsukawa, T				Ishiyama, T.; Iijima, T.; Sugawara, T.; Shibuya, K.; Sato, H.; Terada, Y.; Ichikawa, M.; Sessler, D. I.; Matsukawa, T.			The use of patient-controlled epidural fentanyl in elderly patients	ANAESTHESIA			English	Article; Proceedings Paper	Annual Meeting of the American-Society-of-Anesthesiologists	OCT 22-26, 2005	Atlanta, GA	Amer Soc Anesthesiologists			CONTROLLED ANALGESIA; SURGICAL-PATIENTS; PAIN PERCEPTION; AGE; ROPIVACAINE; REQUIREMENTS; BUPIVACAINE	We studied whether delivering postoperative analgesia, using a patient-controlled epidural analgesia (PCEA) device was effective and safe in elderly patients. We enrolled 40 patients aged > 65 years (elderly group) and 40 patients aged 20-64 years (young group) scheduled for elective major abdominal surgery. PCEA infusion was started following completion of surgery. Mean (SD) fentanyl consumption (10.7 (3.7) compared with 10.5 (2.7) mu g.kg(-1), p = 0.76) and number of times patients pressed the bolus switch (32 (36) compared with 44 (38), p = 0.16) during the first 24 h postoperatively were similar in the two groups. Pain scores, which were similar in both groups at rest, were significantly lower in the elderly on coughing (at 24 h, p < 0.05). In addition, average pain scores were similar at the time of PCEA bolus demands in the two groups. Elderly and young adult patients therefore required similar amounts of patient-controlled epidural fentanyl to produce satisfactory pain relief.	Yamanashi Univ Hosp, Chuo Ku, Yamanashi 4093898, Japan; Univ Yamanashi, Dept Anaesthesiol, Fac Med, Yamanashi, Japan; Fujiyoshida Municipal Hosp, Dept Anaesthesia, Yamanashi, Japan; Cleveland Clin, Dept Outcomes Res, Cleveland, OH 44106 USA	Ishiyama, T (reprint author), Yamanashi Univ Hosp, Chuo Ku, 1110 Shimokato, Yamanashi 4093898, Japan.	ishiyama@yamanashi.ac.jp	Sessler, Daniel/D-3504-2011	Sessler, Daniel/0000-0001-9932-3077	NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [GM 061655]		Cooper DW, 1999, BRIT J ANAESTH, V82, P366, DOI 10.1093/bja/82.3.366; Evron S, 2004, ANESTH ANALG, V99, P245, DOI 10.1213/01.ane.0000120084.56136.15; Gagliese L, 2000, ANESTHESIOLOGY, V93, P601, DOI 10.1097/00000542-200009000-00007; Gibson SJ, 2001, CLIN GERIATR MED, V17, P433, DOI 10.1016/S0749-0690(05)70079-3; Gloth FM, 2000, GERIATRICS, V55, P46; Hodgson PS, 2001, ANESTH ANALG, V92, P1024; Iijima T, 2007, ANESTH ANALG, V105, P507, DOI 10.1213/01.ane.0000269491.04233.3b; Iwata K, 2002, J NEUROPHYSIOL, V87, P1086, DOI 10.1152/jn.00243.2001; Karci A, 2003, EUR SURG RES, V35, P363, DOI 10.1159/000070608; Kostamovaara PA, 2001, ACTA ANAESTH SCAND, V45, P489, DOI 10.1034/j.1399-6576.2001.045004489.x; Liu SS, 1998, ANESTHESIOLOGY, V88, P688, DOI 10.1097/00000542-199803000-00020; Macintyre PE, 1996, PAIN, V64, P357, DOI 10.1016/0304-3959(95)00128-X; Macintyre PE, 2001, BRIT J ANAESTH, V87, P36, DOI 10.1093/bja/87.1.36; Mann C, 2003, DRUG AGING, V20, P337, DOI 10.2165/00002512-200320050-00003; OWEN JA, 1983, CLIN PHARMACOL THER, V34, P364, DOI 10.1038/clpt.1983.180; Pasero C L, 1996, Am J Nurs, V96, P38, DOI 10.2307/3465055; Pickering G, 2002, GERONTOLOGY, V48, P112, DOI 10.1159/000048937; SCOTT JC, 1987, J PHARMACOL EXP THER, V240, P159; Silvasti M, 2001, ACTA ANAESTH SCAND, V45, P471, DOI 10.1034/j.1399-6576.2001.045004471.x; SINGLETON MA, 1988, BRIT J ANAESTH, V60, P619, DOI 10.1093/bja/60.6.619; Woodhouse A, 1997, ANAESTHESIA, V52, P949, DOI 10.1111/j.1365-2044.1997.216-az0350.x	21	1	1	0	1	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0003-2409			ANAESTHESIA	Anaesthesia	DEC	2007	62	12					1246	1250		10.1111/j.1365-2044.2007.05256.x			5	Anesthesiology	Anesthesiology	228JT	WOS:000250726900009	17991261				2020-06-30	J	Benhamou, D				Benhamou, D.			Local anaesthetic-opioid mixture for emergency Caesarean section	ANAESTHESIA			English	Letter							EPIDURAL ANALGESIA		Hop Bicetre, F-94275 Le Kremlin Bicetre, France	Benhamou, D (reprint author), Hop Bicetre, F-94275 Le Kremlin Bicetre, France.	dan.benhamou@bct.aphp.fr					Malhotra S, 2007, ANAESTHESIA, V62, P667, DOI 10.1111/j.1365-2044.2007.05096.x; Tortosa JC, 2003, BRIT J ANAESTH, V91, P532, DOI 10.1093/bja/aeg214	2	0	0	0	0	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0003-2409			ANAESTHESIA	Anaesthesia	DEC	2007	62	12					1298	1298		10.1111/j.1365-2044.2007.05362_1.x			1	Anesthesiology	Anesthesiology	228JT	WOS:000250726900027	17991279				2020-06-30	J	Hasenberg, T; Niedergethmann, M; Rittler, P; Post, S; Jauch, KW; Senkal, M; Spies, C; Schwenk, W; Shang, E				Hasenberg, T.; Niedergethmann, M.; Rittler, P.; Post, S.; Jauch, K. W.; Senkal, M.; Spies, C.; Schwenk, W.; Shang, E.			Elective colon resection in Germany - A survey of the perioperative anaesthesiological management	ANAESTHESIST			German	Article						colon resection; fast-track program; early recovery after surgery; survey; Germany; anesthesiology	NORTHERN-EUROPEAN COUNTRIES; FLUID MANAGEMENT; HEAT-BALANCE; SURGERY; TRIAL; CARE; REHABILITATION; INTERVENTIONS; NORMOTHERMIA; DESFLURANE	Background. Fast-track rehabilitation after elective colon resection is an interdisciplinary multimodal procedure, which combines surgical and anesthesiological aspects. This leads to an improved and accelerated recovery and avoids perioperative complications. This survey focuses on the extent and use of such concepts in Germany. Methods. In January 2006, a questionnaire was sent to 1270 anesthesiology departments in Germany in which they were asked to describe the standard anesthesia procedures based on a conventional sigmoid resection. Results. The response rate was 385 out of 1270 (30.3%). Preoperative fasting of solid food 12 h before the operation was practiced in 52% and for 6 h in 44% of the clinics. For fluid intake the fasting time was 6 h in 47% and 2 h in 41%. Prophylactic measures for postoperative nausea and vomiting (PONV) were administered in 33% of clinics. Propofol (68%) was the leading narcotic, fentanyl (56%) and sufentanil (48%) were the most commonly used intraoperative analgesics and 75% of clinics used epidural analgesia. Conclusion. In Germany the anesthesiological treatment after elective colon surgery adheres broadly to the evidence-based recommendations for fast-track concepts.	[Hasenberg, T.; Niedergethmann, M.; Post, S.; Shang, E.] Klinikum Mannheim gGmbH, Chirurg Univ Klin, D-68167 Mannheim, Germany; Klinikum Univ Munchen, Chirurg Klin & Poliklin Grosshadern, Munich, Germany; Univ Med Berlin Charite, Univ Klin Anasthesiol & Operat Intensivmed, Berlin, Germany; Univ Med Berlin Charite, Univ Klin Allgemien Visceral Gefass & Thoraxchiru, Berlin, Germany	Hasenberg, T (reprint author), Klinikum Mannheim gGmbH, Chirurg Univ Klin, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.	till.hasenberg@chir.ma.uni-heidelberg.de		Hasenberg, Till/0000-0003-2681-8006			Apfel C. C., 2004, Anaesthesist, V53, P377, DOI 10.1007/s00101-004-0662-8; Apfel CC, 2004, NEW ENGL J MED, V350, P2441, DOI 10.1056/NEJMoa032196; Basse L, 2004, DIS COLON RECTUM, V47, P271, DOI 10.1007/s10350-003-0055-0; Beaussier M, 2000, J CLIN ANESTH, V12, P586, DOI 10.1016/S0952-8180(00)00227-0; Beers R, 2004, CNS DRUGS, V18, P1085, DOI 10.2165/00023210-200418150-00004; Block BM, 2003, JAMA-J AM MED ASSOC, V290, P2455, DOI 10.1001/jama.290.18.2455; Brady M, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD004423; Brandstrup B, 2003, ANN SURG, V238, P641, DOI 10.1097/01.sla.0000094387.50865.23; Grebe D, 2005, CHIR GASTROENTEROL, V21, P318, DOI 10.1159/000089187; Gupta A, 2004, ANESTH ANALG, V98, P632, DOI 10.1213/01.ANE.0000103187.70627.57; Hannemann P, 2006, ACTA ANAESTH SCAND, V50, P1152, DOI 10.1111/j.1399-6576.2006.01121.x; HASENBERG T, 2007, SURVEY PERIOPERATIVE; Hensel M, 2006, ANAESTHESIST, V55, P80, DOI 10.1007/s00101-005-0923-1; Hobbhahn J, 1997, ANASTH INTENSIVMED, V38, P607; Holte K, 2004, ANN SURG, V240, P892, DOI 10.1097/01.sla.0000143269.96649.3b; Jones SB, 2004, J CLIN ANESTH, V16, P11, DOI 10.1016/j.jclinane.2003.03.003; JORGENSEN H, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001893; Kaudasch G, 1996, ANAESTHESIST, V45, P1075, DOI 10.1007/s001010050342; Kehlet H, 2006, J AM COLL SURGEONS, V202, P45, DOI 10.1016/j.jamcollsurg.2005.08.006; Kehlet H, 2002, AM J SURG, V183, P630, DOI 10.1016/S0002-9610(02)00866-8; Kurz A, 1996, NEW ENGL J MED, V334, P1209, DOI 10.1056/NEJM199605093341901; Lassen K, 2005, BRIT MED J, V330, P1420, DOI 10.1136/bmj.38478.568067.AE; Ng SF, 2003, ANESTH ANALG, V96, P171, DOI 10.1097/00000539-200301000-00036; Nisanevich V, 2005, ANESTHESIOLOGY, V103, P25, DOI 10.1097/00000542-200507000-00008; Nygren J, 2005, CLIN NUTR, V24, P455, DOI 10.1016/j.clnu.2005.02.003; Osmer C, 1996, EUR J ANAESTH, V13, P389, DOI 10.1046/j.1365-2346.1996.00993.x; ROBERTS I, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000567.PUB3; Sessler DI, 2000, ANESTHESIOLOGY, V92, P578, DOI 10.1097/00000542-200002000-00042; Spies CD, 2003, ANAESTHESIST, V52, P1039, DOI 10.1007/s00101-003-0573-0; von Heymann C, 2006, Anasthesiol Intensivmed Notfallmed Schmerzther, V41, pE1; Wakeling HG, 2005, BRIT J ANAESTH, V95, P634, DOI 10.1093/bja/aei223; Zutshi M, 2005, AM J SURG, V189, P268, DOI 10.1016/j.amjsurg.2004.11.012	32	4	4	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0003-2417	1432-055X		ANAESTHESIST	Anaesthesist	DEC	2007	56	12					1223	+		10.1007/s00101-007-1259-9			7	Anesthesiology	Anesthesiology	241FE	WOS:000251641500004	17882388				2020-06-30	J	Amor, MB; Ouezini, R; Lamine, K; Barakette, M; Labbne, I; Ferjani, M				Amor, M. Belhadj; Ouezini, R. .; Lamine, K.; Barakette, M.; Labbne, I.; Ferjani, M.			Daily interruption of sedation in intensive care unit patients with renal impairment: remifentanil-midazolam compared to fentanyl-midazolam	ANNALES FRANCAISES D ANESTHESIE ET DE REANIMATION			French	Article						sedation; remifentanil; renal failure	CRITICALLY-ILL PATIENTS; MECHANICAL VENTILATION; SUFENTANIL	Objective.-We compared extubation time following daily interruption of sedation in intensive care unit patients with renal impairment with two sedation regimes remifentanil-midazolam and fentanyl-midazolam. Study design. Prospective, randomized double-blind trial. Patients and methods.-Patients with renal impairment needing mechanical ventilation for more than 48 hours. Two groups: remifentanil (R) and, fentanyl (F), Infusion rates were titrated to achieve the desired Ramsay score. The two groups received midazolam (2.5 mg then 0.1 mg/kg/h). Results.-Nineteen patients were included. Patient's characteristics, mean sedation time and sedation quality were comparable. Extubation time was significantly shorter in R group (1480 +/- 980 versus 2880 +/- 1280 min, P = 0.04). Weaning time was also shorter in R group (220 +/- 164 versus 720 +/- 480 min)., Agitation on weaning was comparable in the two groups. Group R received significantly more morphine than group F after interruption of sedation. Conclusion.-Daily interruption of sedation with remifentanil is associated with shorter weaning and extubation time in patients with renal impairment. However further studies are necessary to determine if this issue is associated with lower rate of ventilation induced complications. (C) 2007 Elsevier Masson SAS. Tons droits reserves.	[Amor, M. Belhadj; Ouezini, R. .; Lamine, K.; Barakette, M.; Labbne, I.; Ferjani, M.] Hop Mil Principal Instruct Tunis, Serv Anethesie Reanimat, Tunis 1008, Tunisia	Amor, MB (reprint author), Hop Mil Principal Instruct Tunis, Serv Anethesie Reanimat, Tunis 1008, Tunisia.	mondherbenhaj@yahoo.fr					Baillard CB, 2005, ANN FR ANESTH, V24, P480, DOI 10.1016/j.annfar.2005.02.027; Breen D, 2004, CRIT CARE, V8, pR21, DOI 10.1186/cc2399; Kollef MH, 1998, CHEST, V114, P541, DOI 10.1378/chest.114.2.541; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; Kress JP, 1996, AM J RESP CRIT CARE, V153, P1012, DOI 10.1164/ajrccm.153.3.8630539; Pitsiu M, 2004, BRIT J ANAESTH, V92, P493, DOI 10.1093/bja/aeh086; Soltesz S, 2001, BRIT J ANAESTH, V86, P763, DOI 10.1093/bja/86.6.763; TOBIN MJ, 1994, NEW ENGL J MED, V330, P1056, DOI 10.1056/NEJM199404143301507; Wilhelm W, 1999, ANAESTHESIST, V48, P625, DOI 10.1007/s001010050762; 2000, ANN FR ANESTH REANIM, V19, pF98	10	10	10	1	1	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0750-7658	1769-6623		ANN FR ANESTH	Ann. Fr. Anest. Reanim.	DEC	2007	26	12					1041	1044		10.1016/j.annfar.2007.10.005			4	Anesthesiology	Anesthesiology	247HB	WOS:000252067900004	17988824				2020-06-30	J	Cicero, TJ; Inciardi, JA; Surratt, H				Cicero, Theodore J.; Inciardi, James A.; Surratt, Hilary			Trends in the use and abuse of branded and generic extended release oxycodone and fentanyl products in the United States	DRUG AND ALCOHOL DEPENDENCE			English	Article						opioids; oxycodone; fentanyl; generics; prescription drug abuse; pharmacoeconomics	PRESCRIPTION DRUGS; TRAMADOL; SUBSTITUTION; COCAINE; PRICES; ULTRAM(R); DIVERSION; EMERGENCY; COVERAGE; ALCOHOL	Background: A great deal of previous work on the pharmacoeconomics of alcohol, tobacco and illicit drug abuse indicates that as cost decreases, abuse increases and vice versa. The application of these cost principles to the abuse of prescribed medications is largely unknown. In this paper we assessed whether the introduction of generic products in the U.S. increased the therapeutic use and illicit abuse of extended release oxycodone products and the fentanyl patch. Methods: As an index of therapeutic use, we purchased prescription data for each of the ZIP codes in which we had corresponding abuse data. To gather information about prescription drug abuse, we elicited cases with quarterly questionnaires completed by a key informant network. Results: The introduction of generic extended release (ER) oxycodone and fentanyl patch did not significantly change the total prescriptions written for these products, but markedly altered the composition of sales: branded sales dropped precipitously over a very short time and this was compensated for by a corresponding increase in sales of generics. Surprisingly, the introduction of generic products did not increase the abuse of ER oxycodone or fentanyl products; the branded version was the drug of choice for at least 2 years. Conclusions: Our data suggest that drug costs alone do not increase the overall likelihood that a prescription opioid analgesic will be used therapeutically or abused. However, while generics are rapidly endorsed by insurance companies as a prescribed entity, abuse of the branded versions of ER oxycodone and fentanyl remains predominant for some time. (c) 2007 Published by Elsevier Ireland Ltd.	Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA; Univ Delaware, Ctr Drug & Alcohol Studies, Coral Gables, FL USA	Cicero, TJ (reprint author), Washington Univ, Sch Med, Dept Psychiat, 660 S Euclid Ave,Campus Box 8134, St Louis, MO 63110 USA.	Cicerot@wustl.edu		Surratt, Hilary/0000-0003-4027-7840			Adams EH, 2006, J PAIN SYMPTOM MANAG, V31, P465, DOI 10.1016/j.jpainsymman.2005.10.006; [Anonymous], 1994, DIAGN STAT MAN MENT; Bailey JE, 2006, DRUG ALCOHOL DEPEN, V84, P182, DOI 10.1016/j.drugalcdep.2006.01.011; Campo Katia, 2005, Health Mark Q, V22, P73; Caulkins JP, 2001, AM J PUBLIC HEALTH, V91, P1446, DOI 10.2105/AJPH.91.9.1446; Cicero TJ, 2005, PHARMACOEPIDEM DR S, V14, P851, DOI 10.1002/pds.1113; Cicero TJ, 2005, JAMA-J AM MED ASSOC, V293, P297, DOI 10.1001/jama.293.3.297; Cicero TJ, 2005, J PAIN, V6, P662, DOI 10.1016/j.jpain.2005.05.004; Cicero TJ, 1999, DRUG ALCOHOL DEPEN, V57, P7, DOI 10.1016/S0376-8716(99)00041-1; CICERO TJ, 2007, IN PRESS PHARMACOEPI; DeWitt EM, 2006, ARCH INTERN MED, V166, P57, DOI 10.1001/archinte.166.1.57; Federman AD, 2001, JAMA-J AM MED ASSOC, V286, P1732, DOI 10.1001/jama.286.14.1732; Goldman DP, 2004, JAMA-J AM MED ASSOC, V291, P2344, DOI 10.1001/jama.291.19.2344; Huskamp HA, 2005, ARCH GEN PSYCHIAT, V62, P435, DOI 10.1001/archpsyc.62.4.435; HYATT RR, 1995, STAT MED, V14, P655, DOI 10.1002/sim.4780140522; Hyland A, 2005, TOB CONTROL, V14, P86, DOI 10.1136/tc.2004.008730; Inciardi JA, 2006, J ADDICT DIS, V25, P53, DOI 10.1300/J069v25n02_08; Monnet DL, 2005, CLIN INFECT DIS, V41, P114, DOI 10.1086/430822; PALMER E, 2006, BUNDESGESUNDHEITSBLA, V49, P660; Paterson JM, 2006, JAMA-J AM MED ASSOC, V296, P1969, DOI 10.1001/jama.296.16.1969-b; Petry NM, 2001, DRUG ALCOHOL DEPEN, V62, P31, DOI 10.1016/S0376-8716(00)00157-5; SLOAN FA, 1994, J STUD ALCOHOL, V55, P454, DOI 10.15288/jsa.1994.55.454; SMITH DG, 1993, INQUIRY-J HEALTH CAR, V30, P189; Taira DA, 2003, AM J MANAG CARE, V9, P305; Wadland WC, 2005, FAM MED, V37, P259; Walker Scot, 2004, J Manag Care Pharm, V10, P345; Zhang B, 2006, AM J PREV MED, V30, P474, DOI 10.1016/j.amepre.2006.02.001	27	27	27	0	5	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0376-8716			DRUG ALCOHOL DEPEN	Drug Alcohol Depend.	DEC 1	2007	91	2-3					115	120		10.1016/j.drugalcdep.2007.05.008			6	Substance Abuse; Psychiatry	Substance Abuse; Psychiatry	228RN	WOS:000250747500002	17590285				2020-06-30	J	Paisansathan, C; Hoffman, WE; Gatto, RG; Baughman, VL; Mueller, M; Charbel, FT				Paisansathan, C.; Hoffman, W. E.; Gatto, R. G.; Baughman, V. L.; Mueller, M.; Charbel, F. T.			Increased brain oxygenation during intubation-related stress	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article						spectroscopy near infrared; hypoxia; brain; blood flow; regional; anaesthesia general; electroencephalogram; entropy	LARYNGEAL MASK AIRWAY; SPECTROSCOPY; HUMANS; DESFLURANE; ACTIVATION; ANESTHESIA; INDUCTION; RESPONSES; BOLD; ISOFLURANE	Background and objectives: The purpose of this study was to determine whether brain oxyhaemoglobin-deoxyhaemoglobin coupling was altered by anaesthesia or intubation-induced stress. Methods: This was a prospective observational study in the operating room. Thirteen patients (ASA I and II) undergoing spinal or peripheral nerve procedures were recruited. They were stabilized before surgery with mask ventilation of 100% oxygen. Anaesthesia was induced with 2 mu g kg(-1) fentanyl and 3 mg kg(-1) thiopental. Laryngoscopy and intubation were performed 4 min later. After intubation, desflurane anaesthesia (F(i)O(2)=1.0) was adjusted to maintain response entropy of the electroencephalogram at 40-45 for 20 min. Prefrontal cortex oxyhaemoglobin and deoxyhaemoglobin were determined every 2 s using frequency domain near-infrared spectroscopy. Blood pressure, heart rate and response entropy were collected every 10 s. Results: Awake oxyhaemoglobin and deoxyhaemoglobin were 18.9 +/- 2.3 mu mol (mean +/- SD) and 12.7 +/- 0.8 mu mol, respectively, and neither changed significantly during induction. Intubation increased oxyhaemoglobin by 37% (P < 0.05) and decreased deoxyhaemoglobin by 16% (P < 0.05), and both measures returned to baseline within 20 min of desflurane anaesthesia. Blood pressure, heart rate and electroencephalogram response entropy increased during intubation, and the increase in heart rate correlated with the increase in brain oxygen saturation (r = 0.48, P < 0.05). Conclusions: Intubation-related stress increased oxyhaemoglobin related to electroencephalogram and autonomic activation. Stress-induced brain stimulation may be monitored during anaesthesia using frequency domain near-infrared spectroscopy.	[Hoffman, W. E.] Univ Illinois, Dept Anaesthesiol, Chicago, IL 60612 USA; [Paisansathan, C.; Hoffman, W. E.; Baughman, V. L.; Mueller, M.] Univ Illinois, Dept Anesthesia, Chicago, IL USA; [Gatto, R. G.; Charbel, F. T.] Univ Illinois, Dept Neurosurg, Chicago, IL USA	Hoffman, WE (reprint author), Univ Illinois, Dept Anaesthesiol, 1740 W Taylor,Suite 3200, Chicago, IL 60612 USA.	whoffman@uic.edu	Gatto, Rodolfo Gabriel/R-7155-2018	Gatto, Rodolfo Gabriel/0000-0003-2170-6662			Akbar AN, 1996, J CLIN ANESTH, V8, P194, DOI 10.1016/0952-8180(95)00228-6; BUNTING HE, 1995, BRIT J ANAESTH, V75, P631, DOI 10.1093/bja/75.5.631; Buxton RB, 2004, NEUROIMAGE, V23, pS220, DOI 10.1016/j.neuroimage.2004.07.013; Choi J, 2004, J BIOMED OPT, V9, P221, DOI 10.1117/1.1628242; Dahaba AA, 2006, ANAESTHESIA, V61, P330, DOI 10.1111/j.1365-2044.2006.04548.x; Fantini S, 1999, PHYS MED BIOL, V44, P1543, DOI 10.1088/0031-9155/44/6/308; Gatto R, 2006, J NEUROSCI METH, V157, P274, DOI 10.1016/j.jneumeth.2006.04.013; Huppert TJ, 2006, NEUROIMAGE, V29, P368, DOI 10.1016/j.neuroimage.2005.08.065; Li CSR, 2006, J PSYCHIATR NEUROSCI, V31, P115; Li CSR, 2005, BIOL PSYCHIAT, V57, P487, DOI 10.1016/j.biopsych.2004.11.048; LICKER M, 1995, J CLIN ANESTH, V7, P281, DOI 10.1016/0952-8180(95)00025-D; Lovell AT, 1999, ANESTH ANALG, V88, P554, DOI 10.1097/00000539-199903000-00017; MATTA BF, 1995, ANESTHESIOLOGY, V83, P980, DOI 10.1097/00000542-199511000-00011; Peeters RR, 2001, MAGN RESON IMAGING, V19, P821, DOI 10.1016/S0730-725X(01)00391-5; Schwarz G, 1996, J NEUROSURG ANESTH, V8, P189, DOI 10.1097/00008506-199607000-00001; Tanner K, 2005, J BIOMED OPT, V10, DOI 10.1117/1.2137291; Toronov V, 2003, NEUROIMAGE, V19, P1521, DOI 10.1016/S1053-8119(03)00152-6; WEISKOPF RB, 1994, ANESTHESIOLOGY, V80, P1035	18	4	6	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0265-0215			EUR J ANAESTH	Eur. J. Anaesth.	DEC	2007	24	12					1016	1020		10.1017/S0265021507000567			5	Anesthesiology	Anesthesiology	244VQ	WOS:000251893800004	17568474				2020-06-30	J	Taylor, DR				Taylor, Donald R.			Fentanyl buccal tablet: rapid relief from breakthrough pain	EXPERT OPINION ON PHARMACOTHERAPY			English	Review						analgesia; breakthrough pain; effervescent; fentanyl buccal tablet; opioid agonist	OPIOID-TREATED PATIENTS; CANCER-PATIENTS; CITRATE; PHARMACOKINETICS; PREVALENCE; ABSORPTION	Breakthrough pain - a transient increase in pain occurring over a baseline of controlled persistent pain - represents an important clinical challenge in the management of cancer and other chronic pain conditions. The fentanyl buccal tablet is a new sugar-free, easily-administered formulation that uses an effervescent drug delivery system to enhance the rate and extent of fentanyl absorption across the buccal mucosa. Clinical trials indicate that the rapid systemic exposure provided by fentanyl buccal tablets translates into clinically significant improvements in pain intensity. Pain relief is observed within 10 - 15 min of administration. Fentanyl buccal tablets are generally well tolerated, with the most commonly observed adverse events being typical opioid side effects. Fentanyl buccal tablets represent a convenient and effective treatment for the control of breakthrough pain.	So Coll Technol, Comprehens Pain Care PC, Marietta, GA 30060 USA	Taylor, DR (reprint author), So Coll Technol, Comprehens Pain Care PC, 840 Church St,Suite B, Marietta, GA 30060 USA.	dtaylor@cpcnopain.com					BENNETT D, 2005, [No title captured], V30, P296; BENNETT D, 2005, [No title captured], V30, P354; Caraceni A, 2004, PALLIATIVE MED, V18, P177, DOI 10.1191/0269216304pm890oa; Darwish M, 2007, EXPERT OPIN PHARMACO, V8, P2011, DOI 10.1517/14656566.8.13.2011; Darwish M, 2007, CLIN DRUG INVEST, V27, P605, DOI 10.2165/00044011-200727090-00002; Darwish M, 2007, J CLIN PHARMACOL, V47, P343, DOI 10.1177/0091270006297749; Darwish M, 2007, J CLIN PHARMACOL, V47, P56, DOI 10.1177/0091270006294129; Durfee S, 2006, AM J DRUG DELIV, V4, P1, DOI DOI 10.2165/00137696-200604010-00001; Farrar JT, 1998, JNCI-J NATL CANCER I, V90, P611, DOI 10.1093/jnci/90.8.611; FINE PG, 1991, PAIN, V45, P149, DOI 10.1016/0304-3959(91)90181-V; Fortner BV, 2002, J PAIN, V3, P38, DOI 10.1054/jpai.2002.27136; Fortner BV, 2003, J PAIN SYMPTOM MANAG, V25, P9, DOI 10.1016/S0885-3924(02)00597-3; GHEE S, 2007, 23 ANN M AM AC PAIN; HILL HF, 1990, PAIN, V43, P69, DOI 10.1016/0304-3959(90)90051-E; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; MERCADANTE S, 1992, PAIN, V50, P151, DOI 10.1016/0304-3959(92)90155-5; MERCADANTE S, 1994, PAIN, V59, P141, DOI 10.1016/0304-3959(94)90058-2; Mystakidou Kyriaki, 2005, Am J Hosp Palliat Care, V22, P228, DOI 10.1177/104990910502200313; NALAMACHU S, 2007, J PAIN, V8, pS43; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Portenoy RK, 2007, CURR MED RES OPIN, V23, P222, DOI 10.1185/030079906X162818; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Portenoy RK, 2006, J PAIN, V7, P583, DOI 10.1016/j.jpain.2006.02.003; Simpson DM, 2007, CLIN THER, V29, P588, DOI 10.1016/j.clinthera.2007.04.007; Slatkin Neal E, 2007, J Support Oncol, V5, P327; Stanley TH, 2005, J PAIN SYMPTOM MANAG, V29, pS67, DOI 10.1016/j.jpainsymman.2005.01.009; STREISAND JB, 1995, ANESTHESIOLOGY, V82, P759, DOI 10.1097/00000542-199503000-00018; TAYLOR DR, 2007, 26 ANN SCI M AM PAIN; Webster LR, 2006, EXPERT OPIN INV DRUG, V15, P1469, DOI 10.1517/13543784.15.11.1469	30	7	8	0	2	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1465-6566	1744-7666		EXPERT OPIN PHARMACO	Expert Opin. Pharmacother.	DEC	2007	8	17					3043	3051		10.1517/14656566.8.17.3043			9	Pharmacology & Pharmacy	Pharmacology & Pharmacy	238XT	WOS:000251482400013	18001263				2020-06-30	J	Atim, A; Ergin, A; Kurt, E; Ozdemiroglu, Y; Guzeldemir, E				Atim, Abdulkadir; Ergin, Atilla; Kurt, Ercan; Ozdemiroglu, Yusuf; Guzeldemir, Erdal			Comparison of sciatic psoas compartment block and sciatic femoral 3-in-1 block for knee arthroscopy	JOURNAL OF CLINICAL ANESTHESIA			English	Article						arthroscopy; sciatic psoas compartment block; sciatic femoral 3-in-1 block; tourniquet pain	LUMBAR PLEXUS BLOCK; NERVE BLOCK; POSTOPERATIVE ANALGESIA; GENERAL-ANESTHESIA; POPLITEAL FOSSA; POSTERIOR; TOURNIQUET; SURGERY	Study Objectives: To compare the clinical effectiveness of two peripheral nerve block techniques combined with sciatic nerve block: sciatic psoas compartment (SPC) and sciatic femoral 3-in-1 (SF 3-in-1) block. Design: Prospective, randomized study. Setting: Military medical academy hospital. Patients: Thirty-six ASA physical status I patients, aged 20 to 33 years, undergoing elective knee arthroscopy. Interventions: Patients having SPC block (n = 19) or SF 3-in-1 block (n = 17) received 40 mL of a mixture of solution containing 15 mL of 0.5% bupivacaine, 15 mL of 2.0% prilocaine, and 10 mL of 0.9% sodium chloride. In both groups, the sciatic nerve was blocked with 20 mL of the same solution. An intravenous bolus injection of fentanyl 0.1 mg was used if patients complained of pain. Measurements and Main Results: None of the patients in the SPC group experienced pain owing to the applied tourniquet during the operation, whereas 7 patients from the SF 3-in-1 group (41.2 %) reported tourniquet pain. All SF 3-in-1 group patients but only 5 patients (26.3 %) in the SPC group required fentanyl during the operation. In addition, 7 patients in the SF 3-in-I group required second doses of fentanyl. Patient satisfaction was significantly higher in the SPC group than in the SF 3-in-1 block group (P < 0.0001). Conclusions: Both SPC and SF 3-in-1 provided sufficient anesthetic efficacy for knee arthroscopy. However, SPC may be preferable to SF 3-in-1 block owing to better patient satisfaction and less requirement for opioid analgesics. (c) 2007 Elsevier Inc. All rights reserved.	[Atim, Abdulkadir; Ozdemiroglu, Yusuf] Beytepe Mil Hosp, Dept Anesthesiol, TR-06835 Ankara, Turkey; [Ergin, Atilla; Kurt, Ercan; Guzeldemir, Erdal] Gulhane Mil Med Acad, Dept Anesthesiol, Ankara, Turkey	Atim, A (reprint author), Beytepe Mil Hosp, Dept Anesthesiol, TR-06835 Ankara, Turkey.	drkadiratim@yahoo.com					Al-Nasser B, 2004, REGION ANESTH PAIN M, V29, P361, DOI 10.1016/j.rapm.2004.01.016; Auroy Y, 2002, ANESTHESIOLOGY, V97, P1274, DOI 10.1097/00000542-200211000-00034; Bouaziz H, 2002, ANESTH ANALG, V94, P445, DOI 10.1097/00000539-200202000-00041; Brown DL, 1990, ANESTHESIA, P1377; Cappelleri G, 2000, Minerva Anestesiol, V66, P131; Casati A, 2000, ANESTH ANALG, V91, P388, DOI 10.1097/00000539-200008000-00029; Cuvillon P, 2003, ANESTHESIOLOGY, V98, P1436, DOI 10.1097/00000542-200306000-00021; DALENS B, 1989, ANESTH ANALG, V69, P852; de Benedetto P, 2001, ANESTH ANALG, V93, P1040, DOI 10.1097/00000539-200110000-00049; De Biasi P, 2003, REGION ANESTH PAIN M, V28, P135, DOI 10.1053/rapm.2003.50039; Dilger J A, 2000, Anesthesiol Clin North Am, V18, P319, DOI 10.1016/S0889-8537(05)70166-8; Dupont WD, 1997, CONTROL CLIN TRIALS, V18, P274, DOI 10.1016/S0197-2456(97)00074-3; ELMAS C, 1992, ANAESTHESIST, V41, P639; Enneking FK, 2005, REGION ANESTH PAIN M, V30, P4, DOI 10.1016/j.rapm.2004.10.002; Fanelli G, 1998, ACTA ANAESTH SCAND, V42, P80, DOI 10.1111/j.1399-6576.1998.tb05084.x; Ganidagli S, 2005, INT J CLIN PRACT, V59, P771, DOI 10.1111/j.1368-5031.2005.00414.x; GIELEN MJM, 1991, REGION ANESTH, V16, P191; Hadzic A, 1998, ANESTHESIOLOGY, V88, P1480, DOI 10.1097/00000542-199806000-00010; Hall M J, 1998, Adv Data, P1; Jankowski CJ, 2003, ANESTH ANALG, V97, P1003, DOI 10.1213/01.ANE.0000081798.89853.E7; Jochum D, 2005, ANAESTHESIA, V60, P974, DOI 10.1111/j.1365-2044.2005.04329.x; Kaloul I, 2004, CAN J ANAESTH, V51, P45, DOI 10.1007/BF03018546; Kam PCA, 2001, ANAESTHESIA, V56, P534, DOI 10.1046/j.1365-2044.2001.01982.x; Labat G, 1923, REGIONAL ANESTHESIA; Mannion S, 2005, ANESTH ANALG, V101, P259, DOI 10.1213/01.ANE.0000153866.38440.43; PARKINSON SK, 1989, ANESTH ANALG, V68, P243; PATEL NJ, 1986, ANESTH ANALG, V65, P185; Stevens RD, 2000, ANESTHESIOLOGY, V93, P115, DOI 10.1097/00000542-200007000-00021; Tokat O, 2002, J INT MED RES, V30, P161, DOI 10.1177/147323000203000208; WINNIE AP, 1973, ANESTH ANALG, V52, P989; WINNIE AP, 1974, [No title captured], V1, P11; Zetlaoui PJ, 1998, ANESTH ANALG, V87, P79, DOI 10.1097/00000539-199807000-00017	32	8	8	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	DEC	2007	19	8					591	595		10.1016/j.jclinane.2007.06.014			5	Anesthesiology	Anesthesiology	249LV	WOS:000252230800005	18083472				2020-06-30	J	Vallejo, MC; Ramesh, V; Phelps, AL; Sah, N				Vallejo, Manuel C.; Ramesh, Vimala; Phelps, Amy L.; Sah, Neera			Epidural labor analgesia: Continuous infusion versus patient-controlled epidural analgesia with background infusion versus without a background infusion	JOURNAL OF PAIN			English	Article						labor analgesia; continuous epidural; patient-controlled epidural analgesia; maternal outcome	INTERMITTENT; ROPIVACAINE; SATISFACTION; SUFENTANIL; DELIVERY; BOLUS; PCEA	The purpose of this study was to compare the total epidural dose of 3 commonly used labor epidural modalities. After local institutional review board approval, 195 laboring parturients received an epidural catheter for labor analgesia. All patients received an initial bolus of 0.1% ropivacaine (10 mL) and fentanyl (100 mu g). Maintenance of labor analgesia consisted of ropivacaine 0.1% with fentanyl 2 mu g/mL. Patients were then randomly assigned into 3 groups: Group 1 (continuous epidural infusion [CEI]), continuous infusion at 10 mL/h; group 2 (CEI + patient-controlled epidural analgesia [PCEA]), CEI at 5 mL/h with a demand dose of 5 mL allowed every 20 minutes with a 20 mL/h maximum dose; group 3 (PCEA), demand doses only of 5 mL every 15 minutes with a 20 mL/h maximum dose. Measured variables included total epidural dose, total bolus requests and boluses delivered, number of staff interventions, pain Visual Analog Scale (VAS; 0-100), modified Bromage scores, stage I and II labor duration, delivery outcome, and maternal satisfaction after delivery. No differences were noted with respect to pain VAS, modified Bromage scores, stage I and II labor duration, number of staff interventions, delivery outcome, and maternal satisfaction score. Total infusion dose was lower in demand dose only PCEA compared with CEI and CEI + PCEA groups (P = < .01). Demand dose-only PCEA results in less total epidural dose compared with CEI and CEI + PCEA without affecting labor duration, motor block, pain VAS, maternal and neonatal outcomes, and maternal satisfaction. Perspective: This article compares 3 commonly used labor epidural delivery modalities (traditional continuous epidural infusion, patient-controlled epidural analgesia with a background infusion, and demand dose-only patient-controlled epidural analgesia). Benefits in epidural dose reduction with demand dose only PCEA does not translate into improved maternal and neonatal outcome. (c) 2007 by the American Pain Society.	[Vallejo, Manuel C.; Ramesh, Vimala; Sah, Neera] Univ Pittsburgh, Magee Womens Hosp, Dept Anesthesiol, Pittsburgh, PA 15213 USA; [Phelps, Amy L.] Duquesne Univ, AJ Palumbo Sch Business Adm, Pittsburgh, PA 15219 USA	Vallejo, MC (reprint author), Univ Pittsburgh, Magee Womens Hosp, Dept Anesthesiol, 300 Halket St, Pittsburgh, PA 15213 USA.	vallejomc@aanes.upmc.edu	Vallejo, Manuel C/X-5544-2019	Vallejo, Manuel C/0000-0002-1240-3670			Boselli E, 2004, ANESTHESIOLOGY, V100, P968, DOI 10.1097/00000542-200404000-00030; Boutros A, 1999, INT J OBSTET ANESTH, V8, P236, DOI 10.1016/S0959-289X(99)80103-4; Bremerich DH, 2005, INT J OBSTET ANESTH, V14, P114, DOI 10.1016/j.ijoa.2004.12.005; Carvalho B, 2006, INT J OBSTET ANESTH, V15, P217, DOI 10.1016/j.ijoa.2006.03.006; Carvalho B, 2005, INT J OBSTET ANESTH, V14, P223, DOI 10.1016/j.ijoa.2005.02.003; FERRANTE FM, 1994, ANESTH ANALG, V79, P80; Fettes PDW, 2006, BRIT J ANAESTH, V97, P359, DOI 10.1093/bja/ael157; GAMBLING DR, 1988, CAN J ANAESTH, V35, P249, DOI 10.1007/BF03010618; GLANTZ SA, 1997, PRIMER BIOSTAT; Halpern S, 2005, CURR OPIN ANESTHESIO, V18, P247, DOI 10.1097/01.aco.0000169229.75938.c8; Hogan Q, 2002, REGION ANESTH PAIN M, V27, P150, DOI 10.1053/rapm.2002.29748; Nikkola E, 2006, ACTA OBSTET GYN SCAN, V85, P188, DOI 10.1080/00016340500409935; Saito Miwako, 2005, J Anesth, V19, P208, DOI 10.1007/s00540-005-0316-2; SLADE P, 1993, BRIT J CLIN PSYCHOL, V32, P469, DOI 10.1111/j.2044-8260.1993.tb01083.x; TAYLOR HJC, 1983, CAN ANAESTH SOC J, V30, P277, DOI 10.1007/BF03013808; van der Vyver M, 2002, BRIT J ANAESTH, V89, P459, DOI 10.1093/bja/aef217; Wong CA, 2006, ANESTH ANALG, V102, P904, DOI 10.1213/01.ane.0000197778.57615.1a; 2007, [No title captured], V106, P843	18	35	39	0	1	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	1526-5900			J PAIN	J. Pain	DEC	2007	8	12					970	975		10.1016/j.jpain.2007.07.002			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	243MS	WOS:000251802600010	17686658				2020-06-30	J	Minkowitz, HS; Rathmell, JP; Vallow, S; Gargiulo, K; Damaraju, CV; Hewitt, DJ				Minkowitz, Harold S.; Rathmell, James P.; Vallow, Sue; Gargiulo, Kathryn; Damaraju, C. V.; Hewitt, David J.			Efficacy and safety of the fentanyl iontophoretic transdermal system (ITS) and intravenous patient-controlled analgesia (IV PCA) with morphine for pain management following abdominal or pelvic surgery	PAIN MEDICINE			English	Article						pain management; fentanyl ITS; postoperative; acute Pain	PLACEBO-CONTROLLED TRIAL; ACUTE POSTOPERATIVE PAIN; MULTICENTER; DELIVERY; ERRORS	Objective. The fentanyl HCl iontophoretic transdermal system (ITS) has effectively managed pain following several types of surgery. This study evaluated the efficacy, safety, and ease of care associated with fentanyl ITS and morphine intravenous patient-controlled analgesia (IV PCA) for pain management following abdominal or pelvic surgery. Design. This open-label, multicenter, randomized, active-controlled, parallel-group, phase IIIb study enrolled 506 postoperative patients at 39 U. S. sites. Patients received fentanyl ITS (40 mu g fentanyl/dose) or morphine IV PCA (1 mg morphine/dose). The primary efficacy measure was demonstrating equivalence on the patient global assessment (PGA) of the method of pain control in the first 24 hours of treatment between the groups. Results. Percentages of patients in the fentanyl ITS and morphine IV PCA groups reporting PGA ratings of "good" or "excellent" in the first 24 hours were statistically equivalent (84.9% vs 84.3%, respectively; difference = 0.7%, 95% CI: -5.6% to 7.0%). Equivalence was also demonstrated based on mean last pain intensity scores in the first 24 hours (3.0 vs 2.9, respectively; difference = 0.1, 95% CI: -0.28 to 0.43). Overall discontinuation rates were not significantly different between groups (16.7% vs 11.8%, respectively; P = 0.128). Patients and nurses reported better ease-of- care ratings for fentanyl ITS than for morphine IV PCA. Commonly occurring adverse events were similar between groups. Conclusions. Fentanyl ITS and morphine IV PCA were comparable methods of pain control following abdominal or pelvic surgery; however, fentanyl ITS was rated better than morphine IV PCA for ease of care by patients and nurses.	Mem Hermann Mem City Hosp, Dept Anesthesiol, Houston, TX 77024 USA; Massachusetts Gen Hosp, Harvard Med Sch, Dept Anesthesia & Crit Care, Boston, MA 02114 USA; Ortho McNeil Janssen Sci Afairs, LLC, Titusville, NJ USA; Ortho McNeil Inc, Raritan, NJ USA; Ortho McNeil Janssen Sci Affairs, LLC, Raritan, NJ USA	Minkowitz, HS (reprint author), Mem Hermann Mem City Hosp, Dept Anesthesiol, 921 Gessner Rd, Houston, TX 77024 USA.	research@houston.rr.com					*AG HLTH CAR POL R, 1992, [No title captured], V11, P391; Agency for Health Care Policy and Research, 1992, CLIN PHARM, V11, P309; *AM PAIN SOC, 2003, [No title captured]; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; [Anonymous], 2002, Health Devices, V31, P342; Apfelbaum JL, 2003, ANESTH ANALG, V97, P534, DOI 10.1213/01.ANE.0000068822.10113.9E; Ashburn MA, 2004, ANESTHESIOLOGY, V100, P1573; BALLANTYNE JC, 1993, J CLIN ANESTH, V5, P182, DOI 10.1016/0952-8180(93)90013-5; BARKE KE, 1993, J PHARMACOL EXP THER, V266, P934; Bertolini G, 2002, EUR J CLIN PHARMACOL, V58, P73, DOI 10.1007/s00228-002-0432-y; Chelly JE, 2005, EXPERT OPIN PHARMACO, V6, P1205, DOI 10.1517/14656566.6.7.1205; Chelly JE, 2004, ANESTH ANALG, V98, P427, DOI 10.1213/01.ANE.0000093314.13848.7E; Etches RC, 1999, SURG CLIN N AM, V79, P297, DOI 10.1016/S0039-6109(05)70384-4; HARDING G, 2004, ISPOR 7 ANN EUR C HA; Kalia YN, 2004, ADV DRUG DELIVER REV, V56, P619, DOI 10.1016/j.addr.2003.10.026; Puig MM, 2001, ACTA ANAESTH SCAND, V45, P465, DOI 10.1034/j.1399-6576.2001.045004465.x; RAMSAY MA, 1974, BMJ; Rawal N, 2002, REGION ANESTH PAIN M, V27, P117, DOI 10.1053/rapm.2002.29110; READY LB, 1988, ANESTHESIOLOGY, V68, P100, DOI 10.1097/00000542-198801000-00016; Sathyan G, 2005, CLIN PHARMACOKINET, V44, P7, DOI 10.2165/00003088-200544001-00003; Taxis K, 2004, EUR J CLIN PHARMACOL, V59, P815, DOI 10.1007/s00228-003-0689-9; Vicente KJ, 2003, CAN J ANAESTH, V50, P328, DOI 10.1007/BF03021027; Viscusi ER, 2006, ANESTH ANALG, V102, P188, DOI 10.1213/01.ane.0000183649.58483.77; Viscusi ER, 2004, JAMA-J AM MED ASSOC, V291, P1333, DOI 10.1001/jama.291.11.1333; Walder B, 2001, ACTA ANAESTH SCAND, V45, P795, DOI 10.1034/j.1399-6576.2001.045007795.x; Wilburn Susan Q, 2004, Online J Issues Nurs, V9, P5	26	58	60	1	4	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1526-2375	1526-4637		PAIN MED	Pain Med.	DEC	2007	8	8					657	668		10.1111/j.1526-4637.2006.00257.x			12	Anesthesiology; Medicine, General & Internal	Anesthesiology; General & Internal Medicine	232OJ	WOS:000251028700008	18028044	Bronze			2020-06-30	J	Kabon, B; Kugener, A; Gruenberger, T; Niedermayr, M; Fleischmann, E; Freissmuth, M; Kurz, A				Kabon, B.; Kugener, A.; Gruenberger, T.; Niedermayr, M.; Fleischmann, E.; Freissmuth, M.; Kurz, A.			Effects of continuous remifentanil administration on intra-operative subcutaneous tissue oxygen tension	ANAESTHESIA			English	Article							DOSE FENTANYL ANESTHESIA; SURGICAL-WOUND INFECTION; SUPPLEMENTAL PERIOPERATIVE OXYGEN; CORONARY-ARTERY SURGERY; METABOLIC RESPONSES; LAPAROSCOPIC CHOLECYSTECTOMY; POSTOPERATIVE-PATIENTS; PLASMA-CATECHOLAMINE; STRESS; INCREASES	Surgical stress response markedly increases sympathetic nerve activity and catecholamine concentrations. This may contribute to peripheral vasoconstriction, reduced wound perfusion and subsequent tissue hypoxia. Opioids are known to depress the hypothalamic-adrenal response to surgery in a dose-dependent manner. We tested the hypothesis that continuous remifentanil administration produces improved subcutaneous tissue oxygen tension compared to fentanyl bolus administration. Forty-six patients undergoing major abdominal surgery were randomly assigned to receive either fentanyl bolus administration or continuous remifentanil infusion. Mean subcutaneous tissue oxygen values over the entire intra-operative period were significantly higher in the remifentanil group, when compared to the fentanyl group: 8 (2) kPa vs 6.7 (1.5) kPa, % CI difference: - 2.3 kPa to - 0.3 kPa, p = 0.013. Continuous intra-operative opioid administration may blunt vasoconstriction caused by surgical stress and adrenergic responses more than an equi-effective anaesthetic regimen based on smaller-dose bolus opioid administration.	Med Univ Vienna, Dept Anaesthesia & Intens Care Med, A-1090 Vienna, Austria; Med Univ Vienna, Dept Gen Surg, A-1090 Vienna, Austria; Med Univ Vienna, Ctr Biomol Med & Pharmacol, Inst Pharmacol, A-1090 Vienna, Austria; Univ Bern, Dept Anaesthesiol, Bern, Switzerland; Univ Louisville, Outcomes Res Inst, Louisville, KY 40292 USA	Kabon, B (reprint author), Med Univ Vienna, Dept Anaesthesia & Intens Care Med, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	barbara.kabon@meduniwien.ac.at		Freissmuth, Michael/0000-0001-9398-1765; Kabon, Barbara/0000-0002-9269-4657; Gruenberger, Thomas/0000-0002-2671-0540			Akca O, 2003, ANAESTHESIA, V58, P536, DOI 10.1046/j.1365-2044.2003.03193.x; Akca O, 1999, LANCET, V354, P41, DOI 10.1016/S0140-6736(99)00874-0; Aono H, 1998, J CLIN ANESTH, V10, P546, DOI 10.1016/S0952-8180(98)00079-8; Arkilic CF, 2003, SURGERY, V133, P49, DOI 10.1067/msy.2003.80; BABIOR BM, 1978, NEW ENGL J MED, V298, P659, DOI 10.1056/NEJM197803232981205; Belda FJ, 2005, JAMA-J AM MED ASSOC, V294, P2035, DOI 10.1001/jama.294.16.2035; Buggy DJ, 2002, ANESTHESIOLOGY, V97, P952, DOI 10.1097/00000542-200210000-00030; Burkle H, 1996, ANESTH ANALG, V83, P646, DOI 10.1097/00000539-199609000-00038; CALLINGHAM BA, 1975, HDB PHYSL, P427; CHANG N, 1983, ANN SURG, V197, P470, DOI 10.1097/00000658-198304000-00017; COOPER GM, 1981, ANAESTHESIA, V36, P667, DOI 10.1111/j.1365-2044.1981.tb08777.x; DERBYSHIRE DR, 1984, BRIT J ANAESTH, V56, P725, DOI 10.1093/bja/56.7.725; Fleischmann E, 2007, BRIT J SURG, V94, P362, DOI 10.1002/bjs.5569; GIESECKE K, 1988, BRIT J ANAESTH, V61, P575, DOI 10.1093/bja/61.5.575; GILLIGAN DM, 1994, CIRCULATION, V90, P786, DOI 10.1161/01.CIR.90.2.786; GLASER F, 1995, ANN SURG, V221, P372; GLASS PSA, 1993, ANESTH ANALG, V77, P1031; GOTTRUP F, 1994, ANN CHIR GYNAECOL FE, V83, P183; Greif R, 2000, NEW ENGL J MED, V342, P161, DOI 10.1056/NEJM200001203420303; Hager H, 2006, ANESTH ANALG, V103, P677, DOI 10.1213/01.ane.0000229715.71464.90; HAKANSON E, 1984, CLIN PHYSIOL, V4, P461, DOI 10.1111/j.1475-097X.1984.tb00132.x; HALTER JB, 1977, J CLIN ENDOCR METAB, V45, P936, DOI 10.1210/jcem-45-5-936; Hopf HW, 1997, ARCH SURG-CHICAGO, V132, P997; Izumi K, 2000, ANESTHESIOLOGY, V92, P1426, DOI 10.1097/00000542-200005000-00034; Jensen J A, 1985, Curr Surg, V42, P472; JONSSON K, 1987, BRIT J SURG, V74, P263, DOI 10.1002/bjs.1800740413; Kabon B, 2003, ANESTH ANALG, V97, P1812, DOI 10.1213/01.ANE.0000087040.48267.54; Kabon B, 2004, ANESTHESIOLOGY, V100, P274, DOI 10.1097/00000542-200402000-00015; KEHLET H, 1989, ACTA CHIR SCAND, P22; Kehlet H, 1997, BRIT J ANAESTH, V78, P606; KEHLET H, 1998, NEURAL BLOCKADE CLIN, P129; Kurz A, 1996, NEW ENGL J MED, V334, P1209, DOI 10.1056/NEJM199605093341901; Lotsch JR, 2005, J PAIN SYMPTOM MANAG, V29, pS90, DOI 10.1016/j.jpainsymman.2005.01.012; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; MILES AA, 1957, BRIT J EXP PATHOL, V38, P79; Myre K, 2003, ACTA ANAESTH SCAND, V47, P267, DOI 10.1034/j.1399-6576.2003.00073.x; Nickalls RWD, 2003, BRIT J ANAESTH, V91, P170, DOI 10.1093/bja/aeg132; Reis FM, 1998, EXP PHYSIOL, V83, P1, DOI 10.1113/expphysiol.1998.sp004086; ROIZEN MF, 1983, SURGERY, V94, P941; SEBEL PS, 1981, BRIT J ANAESTH, V53, P941, DOI 10.1093/bja/53.9.941; SHEFFIELD CW, 1997, WOUND REPAIR REGEN, V4, P339; STANLEY TH, 1979, CAN ANAESTH SOC J, V26, P168, DOI 10.1007/BF03006976; STANLEY TH, 1980, ANESTHESIOLOGY, V53, P250, DOI 10.1097/00000542-198009000-00016; STHAXHOLDT O, 1981, ACTA ANAESTH SCAND, V25, P434, DOI 10.1111/j.1399-6576.1981.tb01681.x; VANESBROECK G, 1992, BRIT J SURG, V79, P584, DOI 10.1002/bjs.1800790640; WATTERS JM, 1990, ANN SURG, V212, P213, DOI 10.1097/00000658-199008000-00017; WILLIAMS JK, 1994, J PHARMACOL EXP THER, V271, P671; ZURICK AM, 1982, ANESTH ANALG, V61, P521	48	5	5	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0003-2409	1365-2044		ANAESTHESIA	Anaesthesia	NOV	2007	62	11					1101	1109		10.1111/j.1365-2044.2007.05228.x			9	Anesthesiology	Anesthesiology	218JT	WOS:000250012500004	17924889				2020-06-30	J	Tank, S; Stork, K; Skibba, W; Zittel, S; Andresen, H; Goetz, AE; Beck, H				Tank, S.; Stork, K.; Skibba, W.; Zittel, S.; Andresen, H.; Goetz, A. E.; Beck, H.			Accidental intoxication with unlabeled, generic transdermal fentanyl patches caused by insufficient instruction	ANAESTHESIST			German	Article						transdermal fentanyl; opioid intoxication; depression of ventilation; non-cancer pain; pain management	OPIOID INTOXICATION; PAIN	A somnolent 78-year-old male patient was brought to our emergency room by an ambulance with the presumptive diagnosis of stroke. Cranial computed tomography provided no evidence. On the intensive care unit of the neurosurgical department the patient was completely undressed. Covered by a sock and underwear the ICU staff found five unlabeled, transparent patches. Under the presumptive diagnosis of an opioid intoxication by a transdermal therapeutic system naiox-one was infused over 3 days. The patient reported after rapidly awaking that fentanyl patches had been prescribed by his family practitioner the day before. The patient recovered without any sequelae.	Univ Klinikum Hamburg Eppendorf, Anasthesiol Klin, D-20246 Hamburg, Germany; Univ Klinikum Hamburg Eppendorf, Klin & Poliklin Neurochirurg, Hamburg, Germany; Univ Klinikum Hamburg Eppendorf, Klin & Poliklin Neurol, Hamburg, Germany; Univ Klinikum Hamburg Eppendorf, Inst Rechtsmed, Hamburg, Germany	Tank, S (reprint author), Univ Klinikum Hamburg Eppendorf, Anasthesiol Klin, Martinistr 52, D-20246 Hamburg, Germany.	sascha.tank@gmx.de					Ballantyne JC, 2006, PAIN, V125, P3, DOI 10.1016/j.pain.2006.07.005; DONNER B, 1997, DTSCH ARZTEBL, V94, pA598; Edinboro LE, 1997, J FORENSIC SCI, V42, P741; Eriksen J, 2006, PAIN, V125, P172, DOI 10.1016/j.pain.2006.06.009; Flannagan LM, 1996, J FORENSIC SCI, V41, P320; Frolich M, 2001, ANESTH ANALG, V93, P647; GOURLAY GK, 1988, ANESTH ANALG, V67, P326; HENDERSON GL, 1991, J FORENSIC SCI, V36, P422; Jage J, 2006, SCHMERZ, V20, P79, DOI 10.1007/s00482-006-0467-6; Jost U, 2004, DEUT MED WOCHENSCHR, V129, P313, DOI 10.1055/s-2004-818627; Klockgether-Radke AP, 2002, ANAESTHESIST, V51, P269, DOI 10.1007/s00101-002-0299-4; KlockgetherRadke A, 1997, ANAESTHESIST, V46, P428, DOI 10.1007/s001010050420; Kramer Christopher, 1998, Journal of the American Osteopathic Association, V98, P385; MARQUARDT KA, 1994, J TOXICOL-CLIN TOXIC, V32, P75, DOI 10.3109/15563659409000433; Sorgatz H, 2002, DTSCH ARZTEBL, V99, P2180; VARVEL JR, 1989, ANESTHESIOLOGY, V70, P928, DOI 10.1097/00000542-198906000-00008; Zimmermann M, 2006, ANAESTHESIST, V55, P706, DOI 10.1007/s00101-006-1022-7	17	4	4	0	2	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013 USA	0003-2417			ANAESTHESIST	Anaesthesist	NOV	2007	56	11					1137	1141		10.1007/s00101-007-1240-7			5	Anesthesiology	Anesthesiology	230MK	WOS:000250880400008	17846727				2020-06-30	J	Collard, V; Mistraletti, G; Taqi, A; Asenjo, JF; Feldman, LS; Fried, GM; Carli, F				Collard, Vincent; Mistraletti, Giovanni; Taqi, Ali; Asenjo, Juan Francisco; Feldman, Liane S.; Fried, Gerald M.; Carli, Franco			Intraloperative esmolol infusion in the absence of Opioids spares postoperative fentanyl in patients undergoing ambulatory Laparoscopic cholecystectomy	ANESTHESIA AND ANALGESIA			English	Article							FACILITATES EARLY RECOVERY; REMIFENTANIL INFUSION; DESFLURANE ANESTHESIA; SURGERY; PAIN; HIPPOCAMPAL; TOLERANCE; ANALGESIA; BLOCKADE; OUTCOMES	The use of opioids during ambulatory surgery can delay hospital discharge or cause unexpected hospital admission. Preliminary studies using an intraoperative continuous infusion of esmolol in place of an opioid have inconsistently reported a postoperative opioid-sparing effect. In this study, we compared esmolol versus either intermittent fentanyl or continuous remifentanil on postoperative opioid-sparing, side effects, and time of discharge. METHODS: Ninety patients (consisting of three groups) were enrolled in this pro, spective, randomized, and observer-blinded study. The control group (n = 30) received intermittent doses of fentanyl, the esmolol group (n = 30) received a continuous infusion of esmolol (5-15 mu g center dot kg(-1) center dot min(-1)) and no supplemental opioids during surgery, and the remifentanil group (n = 30) received a continuous infusion of rernifentanil (0.1-0.5 mu g center dot kg(-1) center dot min(-1)). General anesthesia was standardized, and adjuvant medications included acetaminophen, ketorolac, local anesthetics in the skin incisions, dexamethasone, and droperidol. Postoperative analgesia included fentanyl. RESULTS: The amount of fentanyl in the postanesthesia care unit was significantly less in the esmolol group, 91.5 +/- 42.7 mu g, compared with the other two groups, rernifentanil, 237.8 +/- 54.7 mu g, control, 168.1. +/- 96.8 mu g (P < 0.0001). The incidence of nausea was more frequent in the control (66.7%) and remifentanil (67.9%) groups compared with the esmolol group (30%) (P < 0.01.). The esmolol group reached the White-Song score of 12 of 14 faster than the remifentanil group (P < 0.01), and left the hospital 45-60 min earlier (P < 0.004). CONCLUSIONS: Intraoperative IV infusion of esmolol contributes to a significant decrease in postoperative administration of fentanyl and ondansetron and facilitates earlier discharge. (Anesth Analg 2007;105:1255-62)	McGill Univ, Dept Anesthesia, Ctr Hlth, Steinberg Bernstein Ctr Minimally Invas Surg, Montreal, PQ, Canada; McGill Univ, Dept Surg, Ctr Hlth, Steinberg Bernstein Ctr Minimally Invas Surg, Montreal, PQ, Canada	Carli, F (reprint author), McGill Univ, Dept Anesthesia, Ctr Hlth, Steinberg Bernstein Ctr Minimally Invas Surg, Room D10-144, Montreal, PQ, Canada.	franco.carli@mcgill.ca	Mistraletti, Giovanni/O-5859-2017	Mistraletti, Giovanni/0000-0001-8322-1623			Avram MJ, 2004, J PHARMACOL EXP THER, V311, P617, DOI 10.1124/jpet.104.070094; Avramov MN, 1997, ANESTH ANALG, V85, P566, DOI 10.1097/00000539-199709000-00015; Bisgaard T, 2006, ANESTHESIOLOGY, V104, P835, DOI 10.1097/00000542-200604000-00030; BOOZE RM, 1993, SYNAPSE, V13, P206, DOI 10.1002/syn.890130303; Chia YY, 2004, BRIT J ANAESTH, V93, P799, DOI 10.1093/bja/aeh268; Coloma M, 2001, ANESTH ANALG, V92, P352, DOI 10.1213/00000539-200102000-00014; Cortinez LI, 2001, BRIT J ANAESTH, V87, P866, DOI 10.1093/bja/87.6.866; Davidson EM, 2001, CAN J ANAESTH, V48, P59, DOI 10.1007/BF03019816; GORCZYNSKI RJ, 1983, J CARDIOVASC PHARM, V5, P668, DOI 10.1097/00005344-198307000-00023; Guignard B, 2000, ANESTHESIOLOGY, V93, P409, DOI 10.1097/00000542-200008000-00019; Kalkman CJ, 2002, ANESTHESIOLOGY, V96, P784, DOI 10.1097/00000542-200204000-00003; Koivusalo AM, 1998, ACTA ANAESTH SCAND, V42, P510, DOI 10.1111/j.1399-6576.1998.tb05159.x; Lau H, 2002, WORLD J SURG, V26, P1117, DOI 10.1007/s00268-002-6264-1; Logan DE, 2004, PAIN, V109, P481, DOI 10.1016/j.pain.2004.02.026; Ploghaus A, 2001, J NEUROSCI, V21, P9896, DOI 10.1523/JNEUROSCI.21-24-09896.2001; Richardson WS, 2001, SURG ENDOSC, V15, P193, DOI 10.1007/s004640000301; SARVEY JM, 1989, J NEUROSCI METH, V28, P109, DOI 10.1016/0165-0270(89)90016-2; Sinha R, 2004, ANN NY ACAD SCI, V1032, P254, DOI 10.1196/annals.1314.032; Song D, 1999, J CLIN ANESTH, V11, P364, DOI 10.1016/S0952-8180(99)00061-6; Song DJ, 2000, ANESTH ANALG, V90, P1111, DOI 10.1097/00000539-200005000-00020; Surguladze SA, 2003, NEUROIMAGE, V19, P1317, DOI 10.1016/S1053-8119(03)00085-5; Taenzer AH, 2000, ANESTHESIOLOGY, V93, P670, DOI 10.1097/00000542-200009000-00015; Vinik HR, 1998, ANESTH ANALG, V86, P1307, DOI 10.1097/00000539-199806000-00033; White PF, 1999, ANESTH ANALG, V88, P1069, DOI 10.1097/00000539-199905000-00018; White PF, 2003, ANESTH ANALG, V97, P1633, DOI 10.1213/01.ANE.0000085296.07006.BA; WOOD AJJ, 1983, CLIN PHARMACOKINET, V8, P253, DOI 10.2165/00003088-198308030-00004; Yang H, 2003, CAN J ANAESTH, V50, P627, DOI 10.1007/BF03018700; Zhao SZ, 2004, J PAIN SYMPTOM MANAG, V28, P35, DOI 10.1016/j.jpainsymman.2003.11.001	28	77	80	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	NOV	2007	105	5					1255	1262		10.1213/01.ane.0000282822.07437.02			8	Anesthesiology	Anesthesiology	222SN	WOS:000250317500016	17959952				2020-06-30	J	Viscusi, ER; Siccardi, M; Damaraju, CV; Hewitt, DJ; Kershaw, P				Viscusi, Eucene R.; Siccardi, Matthew; Damaraju, C. V.; Hewitt, David J.; Kershaw, Paul			The safety and efficacy of fentanyl iontophoretic transdermal system compared with morphine intravenous patient-controlled analgesia for postoperative pain management: An analysis of pooled data from three randomized, active-controlled clinical studies	ANESTHESIA AND ANALGESIA			English	Article							PLACEBO-CONTROLLED TRIAL; HISTAMINE-RELEASE; MULTICENTER	Postoperative pain is often managed using IV patient-controlled analgesia (PCA). In this analysis of pooled data, we compared the safety and efficacy of tile fentanyl iontophoretic transclermal system (ITS) with morphine IV PCA. METHODS: Data were obtained from three multicenter, randomized, activecontrolled trials (N = 1941). The primary efficacy measure was success ("good"/ "excellent" ratings) on the 24-h patient global assessment of the method of pain control. Pain intensity, relative dosing ratios, discontinuation rates, and adverse eventswere assessed. Efficacy was evaluated across age, surgery type, and body mass index (BMT). RESULTS: Comparable percentages of patients reported success on the 24-h patient ulobal assessment of the method of pain control (fentanyl ITS, 80.5%; morphine IV PCA, 81.0%; difference = -0.5%; 95%, confidence interval, -4.0%, to 3.0%). Mean last pairi intensity scores in the first 24 h were comparable (feiituivl ITS, 3.1; morphine IV PCA, 3.0; difference - 0.07; 95%, confidence interval, -0.14 to 0.29). Relative dosing ratios of fentanyl to morphine overall and in subpopulations (age, 13MI) were comparable over 6, 12, and 24 h. Fentanyl ITS was equally effective when compared with morphine IV PCA for patient subpopulations (age, surgery type, and BMI). Discontinuation rates and the incidence of adverse events were similar between groups. CONCLUSIONS: These pooled data represent one of the largest head-to-head comparisons of fentanyl versus morphine in a Postoperative acute pain setting. Results suggest that fentanyl ITS is effective across subpopulations defined by age and BMI, and support a consistent safety and efficacy profile of fentanyl delivered by fentanyl ITS for postoperative pain management. (Anesth Analg 2007;105:1428-36)	Thomas Jefferson Univ, Dept Anesthesiol, Philadelphia, PA 19107 USA; Johnson & Johnson Pharmaceut Serv, Raritan, NJ USA; LLC, Ortho McNeil Janssen Sci Affairs, Raritan, NJ USA	Viscusi, ER (reprint author), Thomas Jefferson Univ, Dept Anesthesiol, 111 S 11th St,Suite G-8490, Philadelphia, PA 19107 USA.	eugene.viscusi@jefferson.edu					Apfelbaum JL, 2003, ANESTH ANALG, V97, P534, DOI 10.1213/01.ANE.0000068822.10113.9E; Austrup ML, 1999, SURG CLIN N AM, V79, P253, DOI 10.1016/S0039-6109(05)70382-0; BARKE KE, 1993, J PHARMACOL EXP THER, V266, P934; Bertolini G, 2002, EUR J CLIN PHARMACOL, V58, P73, DOI 10.1007/s00228-002-0432-y; Breivik EK, 2000, CLIN J PAIN, V16, P22, DOI 10.1097/00002508-200003000-00005; Cabrera MC, 2004, ACTA ANAESTH SCAND, V48, P1190, DOI 10.1111/j.1399-6576.2004.00496.x; Chelly JE, 2004, ANESTH ANALG, V98, P427, DOI 10.1213/01.ANE.0000093314.13848.7E; Etches RC, 1999, SURG CLIN N AM, V79, P297, DOI 10.1016/S0039-6109(05)70384-4; Gilron I, 2005, PAIN, V113, P191, DOI 10.1016/j.pain.2004.10.008; Hartrick CT, 2006, REGION ANESTH PAIN M, V31, P546, DOI 10.1016/j.rapm.2006.08.011; MINKOWITZ HS, 2007, [No title captured]; Murphy EJ, 2005, ANAESTH INTENS CARE, V33, P311, DOI 10.1177/0310057X0503300306; PAYNE R, 1992, J PAIN SYMPTOM MA S3, V7, P40; Puig MM, 2001, ACTA ANAESTH SCAND, V45, P465, DOI 10.1034/j.1399-6576.2001.045004465.x; ROSOW CE, 1982, ANESTHESIOLOGY, V56, P93, DOI 10.1097/00000542-198202000-00003; Sathyan G, 2005, CLIN PHARMACOKINET, V44, P7, DOI 10.2165/00003088-200544001-00003; Skinner Harry B, 2004, Am J Orthop (Belle Mead NJ), V33, P5; Viscusi ER, 2006, ANESTH ANALG, V102, P188, DOI 10.1213/01.ane.0000183649.58483.77; Viscusi ER, 2004, JAMA-J AM MED ASSOC, V291, P1333, DOI 10.1001/jama.291.11.1333	19	28	31	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	NOV	2007	105	5					1428	1436		10.1213/01.ane.0000281913.28623.fd			9	Anesthesiology	Anesthesiology	222SN	WOS:000250317500042	17959978				2020-06-30	J	Panchal, SJ; Damaraju, CV; Nelson, WW; Hewitt, DJ; Schein, JR				Panchal, Sunil J.; Damaraju, C. V.; Nelson, Winnie W.; Hewitt, David J.; Schein, Jeff R.			System-related events and analgesic gaps during postoperative pain management with the fentanyl lontophoretic transdermal system and morphine intravenous patient-controlled analgesia	ANESTHESIA AND ANALGESIA			English	Article								Analgesic gaps (interruptions in analgesic delivery) contribute to ineffective postoperative pain management. In this analysis, we evaluated the incidence of analgesic gaps resulting from system-related events (SREs) for patients using the fentanyl iontophoretic transdermal system (ITS), a noninvasive patientcontrolled analgesia (PCA) system, or morphine IV PCA for postoperative pain management. METHODS: Data were pooled from two open-label, randomized, active-controlled System-Related Events and Analgesic Gaps During Postoperative Pain Management with the Fentanyl lontophoretic Transdermal System and Morphine Intravenous Patient-Controlled Analgesiatrials that evaluated the efficacy and safety of fentanyl ITS a nd morphine IV PCA after total hip replacement, abdominal, or pelvic surgery. The incidence and duration of analgesic gaps resulting frorn SREs were assessed, along with SRE resolution times. RESULTS: A total of 1305 patients received fentanyl ITS (n = 647) or morphine TV PCA (n = 658). Fentanyl ITS was associated with a significantly lower incidence of analgesic gaps per 100 patients compared with morphine IV PCA (5.87 vs 12.01, respectively; P < 0.001). Compared with patients receiving morphine IV PCA, patients receiving fentanyl ITS had both a numerically lower median total analgesic gap time (15.0 min vs 20.0 min) and a numerically lower median total SRE resolution time (11.0 min vs 20.0 min). Most fentanyl ITS SREs were resolved by applying a new system, whereas many different SRE resolution methods were used for morphine IV PCA. CONCLUSIONS: Fentanyl ITS was associated with a significantly lower incidence of analgesic gaps relative to morphine IV PCA. Fentanyl ITS may provide patients with fewer interruptions and more continuous analgesic delivery. (Anesth Analg 2007;105:1437-41)	Coalit Pain Educ Fdn, Tampa, FL USA; Ortho McNeil Janssen Sci Affairs LLC, Raritan, NJ USA; Xcenda, Palm Harbor, FL USA	Panchal, SJ (reprint author), 4911 Van Dyke Rd, Lutz, FL 33558 USA.	sunilpanchal2000@yahoo.com					[AHCPR Panel on the Prediction and Prevention of Pressure Ulcers in Adults], 1992, AHCPR PUBL; Apfelbaum JL, 2003, ANESTH ANALG, V97, P534, DOI 10.1213/01.ANE.0000068822.10113.9E; Ashburn MA, 2004, ANESTHESIOLOGY, V100, P1573; *BAXT HEALTHC CORP, [No title captured]; Campbell L, 1998, Br J Nurs, V7, P1364; Campbell L., 1998, BR J NURS, V7, P1372; Campbell L., 1998, BR J NURS, V7, P1368; Carr DB, 2005, REGION ANESTH PAIN M, V30, P286, DOI 10.1016/j.rapm.2004.10.009; Chelly JE, 2004, ANESTH ANALG, V98, P427, DOI 10.1213/01.ANE.0000093314.13848.7E; Dolin SJ, 2002, BRIT J ANAESTH, V89, P409, DOI 10.1093/bja/aef207; Grond S, 2007, BRIT J ANAESTH, V98, P806, DOI 10.1093/bja/aem102; Hartrick CT, 2006, REGION ANESTH PAIN M, V31, P546, DOI 10.1016/j.rapm.2006.08.011; MINKOWITZ HS, 2007, [No title captured]; Ng A, 2000, ACUTE PAIN, V3, P194; READY LB, 1988, ANESTHESIOLOGY, V68, P100, DOI 10.1097/00000542-198801000-00016; Smith G, 1998, ANAESTHESIA, V53, P521; Viscusi ER, 2006, ANESTH ANALG, V102, P188, DOI 10.1213/01.ane.0000183649.58483.77; Viscusi ER, 2004, JAMA-J AM MED ASSOC, V291, P1333, DOI 10.1001/jama.291.11.1333; WOOLF B, 1955, ANN HUM GENET, V19, P251, DOI 10.1111/j.1469-1809.1955.tb01348.x	19	32	34	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	NOV	2007	105	5					1437	1441		10.1213/01.ane.0000281442.36582.81			5	Anesthesiology	Anesthesiology	222SN	WOS:000250317500043	17959979				2020-06-30	J	Theiler, R; Alon, E; Brugger, S; Ljutow, A; Mietzsch, T; Muller, D; Ott, A; Rimle, M; Zemp, A; Urwyler, A				Theiler, Robert; Alon, Eli; Brugger, Stephan; Ljutow, Andre; Mietzsch, Thomas; Mueller, Daniel; Ott, Alexander; Rimle, Markus; Zemp, Andre; Urwyler, Albert			Evaluation of a standardized internet-based and telephone-based patient monitoring system for pain therapy with transdermal fentanyl	CLINICAL JOURNAL OF PAIN			English	Article						electronic pain diary; disability monitoring; Internet-based and telephone-based pain monitoring	LOW-BACK-PAIN; RELEASE ORAL MORPHINE; OPIOID-NAIVE PATIENTS; TOUCH-SCREEN VERSION; CHRONIC CANCER PAIN; QUALITY-OF-LIFE; INTERNATIONAL CLASSIFICATION; RANDOMIZED CROSSOVER; ELECTRONIC DIARY; HEALTH ICF	The aim of the present observational 4-week study was to document the feasibility and utility of telephone-based or Internet-based pain monitoring in patients with chronic cancer or noncancer pain, such as nociceptive or neuropathic pain, using transdermal fentanyl. Pain intensity, treatment tolerability, activities of daily living, quality of life, and patient and physician satisfaction were evaluated in 60 (60% women, 42% opioid-naive) chronic pain patients who were switched from oral pain therapy to transdermal fentanyl therapy because of persisting severe pain. When the total dataset of all patient entries was analyzed, treatment with transdermal fentanyl led to decreases in maximal and mean pain scores as reported by the patients ( - 14% and - 19%, respectively, last observation carried forward vs. baseline). Pain reduction was more pronounced in opioid-naive than in opioid-experienced patients (- 35% and - 25% vs. baseline, respectively; P = 0.03). Overall, impairment of daily activities was reduced by 23% with transdermal fentanyl. No effect was observed with regard to quality of life and use of rescue pain medication. Transdermal fentanyl was generally well tolerated. Most patients (60%) preferred the telephone-based to the Internet-based or Internet combined with telephone questionnaires. Patient preference was driven by age, whereby younger patients tended to prefer the Internet and older patients the telephone (mean age, 45 and 54 y, respectively; difference n.s.). Internet-based and telephone-based monitoring of the efficacy and tolerability of opioid treatment for chronic pain was feasible in daily practice and generally well accepted by patients and physicians. Future research will determine the relative contribution of these 2 new options for patient-physician interaction and delineate their role in improving chronic pain control.	Triemli City Hosp, Dept Rheumatol, CH-8063 Zurich, Switzerland; Univ Zurich Hosp, CH-8091 Zurich, Switzerland; Univ Basel Hosp, CH-4031 Basel, Switzerland; Swiss Parapleg Ctr, CH-6207 Nottwil, Switzerland; Medcontrol AG, CH-4415 Lausen, Switzerland; Cantonal Hosp, CH-9007 St Gallen, Switzerland; Janssen Cilag AG, CH-6341 Baar, Switzerland	Theiler, R (reprint author), Triemli City Hosp, Dept Rheumatol, CH-8063 Zurich, Switzerland.	robert.theiler@triemli.stzh.ch					Aaron LA, 2004, PAIN, V109, P389, DOI 10.1016/j.pain.2004.02.014; Abdullah M, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-18; Allan L, 2005, SPINE, V30, P2484, DOI 10.1097/01.brs.0000186860.23078.a8; Allan L, 2001, BRIT MED J, V322, P1154, DOI 10.1136/bmj.322.7295.1154; Bischoff-Ferrari HA, 2005, ANN RHEUM DIS, V64, P80, DOI 10.1136/ard.2003.019307; FRIED BJ, 1993, J RHEUMATOL, V20, P548; Gaertner J, 2004, J PAIN SYMPTOM MANAG, V28, P259, DOI 10.1016/j.jpainsymman.2003.12.017; Kongsgaard UE, 1998, EUR J PAIN-LONDON, V2, P53, DOI 10.1016/S1090-3801(98)90046-5; Liszka-Hackzell JJ, 2004, ANESTH ANALG, V99, P477, DOI 10.1213/01.ANE.0000132696.15310.DD; Litcher-Kelly L, 2004, J PAIN, V5, P433, DOI 10.1016/j.jpain.2004.07.005; Mayo NE, 2004, J AM MED INFORM ASSN, V11, P514, DOI 10.1197/jamia.M1462; MISER AW, 1989, PAIN, V37, P15, DOI 10.1016/0304-3959(89)90148-6; Mystakidou K, 2004, J PAIN, V5, P119, DOI 10.1016/j.jpain.2003.12.003; Palermo TA, 2004, PAIN, V107, P213, DOI 10.1016/j.pain.2003.10.005; Pistevou-Gompaki K, 2004, CURR MED RES OPIN, V20, P159, DOI 10.1185/030079903125002829; Roelofs J, 2006, BRIT J HEALTH PSYCH, V11, P595, DOI 10.1348/135910705X74819; Schaeren S, 2005, J BONE JOINT SURG BR, V87B, P201, DOI 10.1302/0301-620X.87B2.15548; Steiner WA, 2002, PHYS THER, V82, P1098, DOI 10.1093/ptj/82.11.1098; Stone AA, 2003, PAIN, V104, P343, DOI 10.1016/S0304-3959(03)00040-X; Stone AA, 2003, CONTROL CLIN TRIALS, V24, P182, DOI 10.1016/S0197-2456(02)00320-3; Theiler R, 2002, SWISS MED WKLY, V132, P566; Vielvoye-Kerkmeer APE, 2000, J PAIN SYMPTOM MANAG, V19, P185, DOI 10.1016/S0885-3924(99)00152-9; Weigl M, 2003, OSTEOARTHR CARTILAGE, V11, P519, DOI 10.1016/S1063-4584(03)00086-4; Williams DA, 2004, CLIN J PAIN, V20, P348, DOI 10.1097/00002508-200409000-00010	24	2	2	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0749-8047			CLIN J PAIN	Clin. J. Pain	NOV-DEC	2007	23	9					804	811		10.1097/AJP.0b013e3181565d04			8	Anesthesiology; Clinical Neurology	Anesthesiology; Neurosciences & Neurology	224CW	WOS:000250424400012	18075409				2020-06-30	J	Agostoni, M; Fanti, L; Arcidiacono, PG; Gemma, M; Strini, G; Torri, G; Testoni, PA				Agostoni, M.; Fanti, L.; Arcidiacono, P. G.; Gemma, M.; Strini, G.; Torri, G.; Testoni, P. A.			Midazolam and pethidine versus propofol and fentanyl patient controlled sedation/analgesia for upper gastrointestinal tract ultrasound endoscopy: A prospective randomized controlled trial	DIGESTIVE AND LIVER DISEASE			English	Article						endoscopic ultrasonography; fentanyl; midazolam; patient controlled sedation analgesia; pethidine; propofol	ADMINISTERED PROPOFOL; CONTROLLED SEDATION; CONSCIOUS SEDATION; AMERICAN-SOCIETY; MEPERIDINE; ALFENTANIL; INFUSION; EUS; COMPLICATIONS; MULTICENTER	Background and objectives. The aim of this prospective, randomized study was to compare the standard regimen of midazolam and pethidine administered by the gastroenterologist versus patient controlled sedation with a propofol-fentanyl mixture during upper gastrointestinal tract endoscopic ultrasonography. Our primary end-points were patient satisfaction and patient cooperation assessed by endoscopist. Methods. Fifty-four consecutive patients, undergoing endoscopic ultrasonography, received sedation with midazolam and pethidine (Group M: n = 27) or propofol and fentanyl (Group P: n = 27). Group M: pethidine 0.7 mg/kg midazolam 0.04 mg/kg before examination; boluses of same drugs if the sedation was insufficient plus a sham patient controlled sedation analgesia; Group P: propofol 17 mg plus fentanyl 15 mu g before examination and a patient controlled sedation analgesia pump containing 170 mg propofol plus 150 mu g fentanyl injecting 0.5 ml every time the patient pressed the button (no "lock out"). Boluses of I ml of the same mixture if the sedation was insufficient. Results. Group M: mean dosage of pethidine and midazolam 88.6 and 5 mg, respectively. Group P: mean dosage of propofol and fentanyl 119.7 mg and 106 mu g, respectively. Both groups were similar for duration and difficulty of the procedure, the grade of sedation (Observer's Assessment of Alertness/Sedation Score) and judgement by endoscopist and patient about cooperation and satisfaction. The only difference between groups was about the extra boluses administered during the procedure. Conclusion. This study demonstrated that a patient controlled sedation analgesia with propofol and fentanyl is an effective and safe technique for upper gastrointestinal tract endoscopic ultrasonography procedures and results in a high level of satisfaction both for patients and operator. (c) 2007 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.	[Agostoni, M.; Gemma, M.; Torri, G.] Vita Salute Univ Milan, IRCCS San Raffaele Hosp, Dept Anesthesiol, I-20132 Milan, Italy; [Fanti, L.; Arcidiacono, P. G.; Strini, G.; Testoni, P. A.] Vita Salute Univ Milan, IRCCS San Raffaele Hosp, Dept Gastroenterol, Milan, Italy	Agostoni, M (reprint author), Vita Salute Univ Milan, IRCCS San Raffaele Hosp, Dept Anesthesiol, Via Olgettina 60, I-20132 Milan, Italy.	agostoni.massimo@hsr.it	Arcidiacono, Paolo Giorgio/K-2122-2018	Arcidiacono, Paolo Giorgio/0000-0001-6692-7720; Gemma, Marco/0000-0002-9543-3831			Allescher HD, 1999, GASTROINTEST ENDOSC, V50, P737, DOI 10.1016/S0016-5107(99)70152-5; ARROWSMITH JB, 1991, GASTROINTEST ENDOSC, V37, P421, DOI 10.1016/S0016-5107(91)70773-6; *ASA, 2006, ASA GUID APPR ASA HO; Bright E, 2003, ENDOSCOPY, V35, P683; Buscarini E, 2006, DIGEST LIVER DIS, V38, P762, DOI 10.1016/j.dld.2006.06.005; CHEMIK DA, 1990, J CLIN PSYCHOPHARM, V10, P244; Fanti L, 2004, GASTROINTEST ENDOSC, V60, P361, DOI 10.1016/S0016-5107(04)01713-4; Gross JB, 2002, ANESTHESIOLOGY, V96, P1004; IBER FL, 1993, GASTROINTEST ENDOSC, V39, P620, DOI 10.1016/S0016-5107(93)70211-4; KEATS AS, 1978, ANESTHESIOLOGY, V49, P233, DOI 10.1097/00000542-197810000-00001; Koshy G, 2000, AM J GASTROENTEROL, V95, P1476; Kulling D, 2001, GASTROINTEST ENDOSC, V54, P1, DOI 10.1067/mge.2001.116174; Marshall SI, 1997, CURR OPIN ANAESTH, V10, P445, DOI [DOI 10.1097/00001503-1997112000-00011, 10.1097/00001503-1997112000-00011]; OSBORNE GA, 1994, ANAESTHESIA, V49, P287, DOI 10.1111/j.1365-2044.1994.tb14175.x; Patel S, 2005, AM J GASTROENTEROL, V100, P2689, DOI 10.1111/j.1572-0241.2005.00320.x; PUNTO E, 2003, FARMA ANNUARIO 2003; Qadeer MA, 2005, CLIN GASTROENTEROL H, V3, P1049, DOI 10.1016/S1542-3565(05)00742-1; Riphaus A, 2005, AM J GASTROENTEROL, V100, P1957, DOI 10.1111/j.1572-0241.2005.41672.x; Rizzo J, 1999, GASTROINTEST ENDOSC, V50, P178, DOI 10.1016/S0016-5107(99)70221-X; Scholz J, 1996, CLIN PHARMACOKINET, V31, P275, DOI 10.2165/00003088-199631040-00004; Servin FS, 1998, ANAESTHESIA, V53, P82, DOI 10.1111/j.1365-2044.1998.53s107.x; *SIED, 1998, LIN GUID SEDAZIONE E; Vargo JJ, 2002, GASTROENTEROLOGY, V123, P8, DOI 10.1053/gast.2002.34232; Yusoff IF, 2004, GASTROINTEST ENDOSC, V60, P356, DOI 10.1016/S0016-5107(04)01711-0	24	22	25	0	1	PACINI EDITORE	PISA	VIA DELLA GHERARDESCA-ZONA INDUSTRIALE OSPEDALETTO, 56121 PISA, ITALY	1590-8658			DIGEST LIVER DIS	Dig. Liver Dis.	NOV	2007	39	11					1024	1029		10.1016/j.dld.2007.08.004			6	Gastroenterology & Hepatology	Gastroenterology & Hepatology	244QG	WOS:000251879800006	17913605				2020-06-30	J	Rehberg, B; Ryll, C; Hadzidiakos, D; Baars, J				Rehberg, B.; Ryll, C.; Hadzidiakos, D.; Baars, J.			Use of a target-controlled infusion system for propofol does not improve subjective assessment of anaesthetic depth by inexperienced anaesthesiologists	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article; Proceedings Paper	Congress for Anaesthesia and Intensive Medicine	APR 06-08, 2006	Berlin, GERMANY			anaesthesia intravenous; propofol; electroencephalography; bispectral index; depth of anaesthesia	MANUALLY-CONTROLLED INFUSION; SURGERY; PHARMACOKINETICS; ISOFLURANE; VOLUNTEERS; MORTALITY; MEMORY	Background and objectives: Target-controlled infusion, via the calculated effect compartment concentrations, may help anaesthesiologists to titrate anaesthetic depth and to shorten recovery from anaesthesia. Methods: In this prospective, randomized clinical study, we compared the performance of six inexperienced anaesthesiologists with <1 yr of training when using target- or manually controlled infusion of propofol, combined with manual dosing of fentanyl. Ninety-two premedicated ASA I-III patients undergoing minor elective urological or gynaecological surgery were assigned to the manual- or target-controlled infusion group. Bispectral index was recorded in a blinded manner. Subjective assessment of anaesthetic depth on a 10 point numerical scale (1 = very deep anaesthesia, 10 = awake) was asked at regular intervals and the correlation with the blinded bispectral index was analysed using the prediction probability, P(K). The propofol concentration profile was calculated post hoc. Results: Propofol administration was similar in both groups with no significant difference for the administered amount and concentrations of propofol. Recovery times were also not different. In both groups, a large percentage of the bispectral index data points recorded during surgery showed bispectral index values below the recommended value of 40, but in the target-controlled infusion group there were significantly less bispectral index values above the recommended upper limit of 60 (2.5% vs. 5.1%). Conclusions: A target-controlled infusion system does not help inexperienced anaesthesiologists to assess anaesthetic depth or to shorten recovery times, but may reduce episodes of overly light anaesthesia and thus help to prevent awareness.	Univ Med Berlin, Charite, Klin Anasthesiol & Operat Intens Med, D-10117 Berlin, Germany	Rehberg, B (reprint author), Univ Med Berlin, Charite, Klin Anasthesiol & Operat Intens Med, Campus Mitte,Schumannstr 20-21, D-10117 Berlin, Germany.	benno.rehberg@charite.de	Rehberg, Benno/AAF-3897-2019	Rehberg, Benno/0000-0002-3145-1555			Breslin DS, 2004, ANAESTHESIA, V59, P1059, DOI 10.1111/j.1365-2044.2004.03870.x; Drummond JC, 2005, ANESTH ANALG, V101, P1238, DOI 10.1213/01.ANE.0000173755.25143.50; Ecoffey C, 2001, ANN FR ANESTH, V20, P228; Glass PS, 1997, ANESTHESIOLOGY, V86, P836, DOI 10.1097/00000542-199704000-00014; HADZIDIAKOS D, 2006, EUR J ANAESTH, P1; Hu CP, 2005, ANESTHESIOLOGY, V102, P639, DOI 10.1097/00000542-200503000-00024; Iselin-Chaves IA, 2005, ANESTHESIOLOGY, V103, P925, DOI 10.1097/00000542-200511000-00005; Monk TG, 2005, ANESTH ANALG, V100, P4, DOI 10.1213/01.ANE.0000147519.82841.5E; Passot S, 2005, ANESTH ANALG, V100, P1338, DOI 10.1213/01.ANE.0000149542.04833.55; Passot S, 2002, ANESTH ANALG, V94, P1212, DOI 10.1097/00000539-200205000-00030; RUSSELL D, 1995, BRIT J ANAESTH, V75, P562, DOI 10.1093/bja/75.5.562; Schnider TW, 1998, ANESTHESIOLOGY, V88, P1170, DOI 10.1097/00000542-199805000-00006; Schnider TW, 1999, ANESTHESIOLOGY, V90, P1502, DOI 10.1097/00000542-199906000-00003; Servin FS, 1998, ANAESTHESIA, V53, P82, DOI 10.1111/j.1365-2044.1998.53s107.x; SHAFER SL, 1990, ANESTHESIOLOGY, V73, P1091, DOI 10.1097/00000542-199012000-00005; Smith WD, 1996, ANESTHESIOLOGY, V84, P38, DOI 10.1097/00000542-199601000-00005; Struys M, 1997, Acta Anaesthesiol Belg, V48, P207	17	6	7	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0265-0215			EUR J ANAESTH	Eur. J. Anaesth.	NOV	2007	24	11					920	926		10.1017/S0265021507000907			7	Anesthesiology	Anesthesiology	234WZ	WOS:000251196400003	17588273				2020-06-30	J	Singh, M; Chauhan, H; Rath, GP; Prabhakar, H; Bithal, PK; Dash, HH				Singh, Mukta; Chauhan, Himanshu; Rath, Girija P.; Prabhakar, Hemanshu; Bithal, Parmod K.; Dash, Hari H.			Effect of narcotic pretreatment on pain after rocuronium injection: a randomized, double-blind controlled comparison with lidocaine	JOURNAL OF ANESTHESIA			English	Article						Rocuronium; Pain; Narcotics; Neurosurgical patients	PREVENTION	Various strategies have been studied to reduce the discomfort of rocuronium pain. These studies have shown fentanyl and lidocaine to be effective in reducing the incidence of pain on rocuronium injection. This prospective, randomized, and double-blind study was carried out on 80 neurosurgical patients for whom pain on rocuronium injection was assessed after pretreatment with lidocaine, fentanyl, sufentanil, or normal saline. The 80 neurosurgical patients were randomly allocated to anyone of the groups to receive lidocaine, fentanyl, sufentanil, or normal saline prior to being given rocuronium. The patients were asked about any discomfort in the hand, and also to rank that discomfort on a 5-point scale. In the normal saline group, the incidence of pain was 95%, of which 90% had very severe pain. In the lidocaine group, only 10% of patients reported pain, which was mild in nature. In the fentanyl group, 95% of patients had pain, of whom 25% had severe to very severe pain. In the sufentanil group, 85% of patients reported pain, of whom 25% fell into the severe to very severe group. We found that lidocaine was best at decreasing the incidence of pain on intravenous (i.v.) injection of rocuronium. Although the incidence of pain on injection of rocuronium with both fentanyl and sufentanil was high, the intensity was definitely reduced, with most patients falling in the mild pain group.	[Singh, Mukta; Chauhan, Himanshu; Rath, Girija P.; Prabhakar, Hemanshu; Bithal, Parmod K.; Dash, Hari H.] All India Inst Med Sci, Dept Neuroanaesthesiol, Ctr Neurosci, New Delhi 110029, India	Prabhakar, H (reprint author), All India Inst Med Sci, Dept Neuroanaesthesiol, Ctr Neurosci, New Delhi 110029, India.		Rath, Girija Prasad/J-4046-2019	Rath, Girija Prasad/0000-0002-3985-8202			Borgeat A, 1997, BRIT J ANAESTH, V79, P382, DOI 10.1093/bja/79.3.382; Borgeat A, 1997, J CLIN ANESTH, V9, P650, DOI 10.1016/S0952-8180(97)00192-X; Cheong KF, 2000, BRIT J ANAESTH, V84, P106; Chiarella AB, 2003, BRIT J ANAESTH, V90, DOI 10.1093/bja/aeg054; Dalgleish DJ, 2000, ANAESTHESIA, V55, P828, DOI 10.1046/j.1365-2044.2000.01629-34.x; Joshi GP, 1997, ANESTH ANALG, V84, P228, DOI 10.1097/00000539-199701000-00044; KLEMENT W, 1991, BRIT J ANAESTH, V66, P189, DOI 10.1093/bja/66.2.189; LOCKEY D, 1995, ANAESTHESIA, V50, P474, DOI 10.1111/j.1365-2044.1995.tb06019.x; Martin R, 1998, CAN J ANAESTH, V45, P521, DOI 10.1007/BF03012701; Memis D, 2002, ANESTH ANALG, V94, P1517, DOI 10.1097/00000539-200206000-00026; MOORTHY SS, 1995, ANESTH ANALG, V80, P1067, DOI 10.1097/00000539-199505000-00057; Reddy MS, 2001, ANAESTHESIA, V56, P902, DOI 10.1046/j.1365-2044.2001.02059-6.x; Shevchenko Y, 1999, ANESTH ANALG, V88, P746, DOI 10.1097/00000539-199904000-00011; Steegers MAH, 1996, ANESTH ANALG, V83, P203, DOI 10.1097/00000539-199607000-00065; Tuncali B, 2004, ANESTH ANALG, V99, P740, DOI 10.1213/01.ANE.0000130005.94395.B2; Turan A, 2003, ANAESTH INTENS CARE, V31, P277, DOI 10.1177/0310057X0303100306	16	11	15	0	0	SPRINGER JAPAN KK	TOKYO	SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	NOV	2007	21	4					510	512		10.1007/s00540-007-0560-8			3	Anesthesiology	Anesthesiology	V03YI	WOS:000207025700012	18008122				2020-06-30	J	Mizuno, J; Akune, T; Tsuda, T; Fukui, Y; Otsuji, M; Kin, N; Saito, Y; Orii, R; Hayashida, M; Arita, H; Hanaoka, K				Mizuno, Ju; Akune, Tohru; Tsuda, Takeshi; Fukui, Yasuyuki; Otsuji, Mikiya; Kin, Nobuhide; Saito, Yuichiro; Orii, Ryo; Hayashida, Masakazu; Arita, Hideko; Hanaoka, Kazuo			Time course of systolic and diastolic blood pressure decreases during the preintubation period of anesthesia induction: modeling with a logistic function	JOURNAL OF CLINICAL ANESTHESIA			English	Article						arterial blood pressure; cubic function; curve fitting; logistic model; propofol	TRACHEAL INTUBATION; HEMODYNAMIC-RESPONSE; PROPOFOL; AGE; FENTANYL; CURVE; PHARMACODYNAMICS; PHARMACOKINETICS; REQUIREMENTS; REMIFENTANIL	Study Objective: To investigate whether systolic (SBP) and diastolic blood pressure (DBP) decreases during the preintubation period could be expressed as 4-parameter logistic and cubic functions giving S-shaped curves. Design: Prospective, clinical study. Setting: Operating room of a metropolitan general hospital. Patients: Seven ASA physical status I and II patients scheduled for elective spinal surgery during general anesthesia. Interventions: Anesthesia was induced with fentanyl, propofol, and vecuronium injection followed by inhalation of sevoflurane. Measurements: The SBP and DBP data were recorded at all beats from fentanyl injection to direct laryngoscopy. The respective changes were analyzed using a logistic function: P(t) = P-L + (q(L) - P-L)/(1 + exp {[4 m(L)/(q(L) - P-L)][k(L) - t]}) and a cubic function: P(t) = at(3) + bt(2) + ct + d, where parameter P-L is the upper asymptote, q(L) is the lower asymptote, m(L) is the slope at the inflection point, and k(L), is the time to the inflection point and where a, b, and c are coefficients, and d are constants. Goodness of fit of the two functions was compared using a correlation coefficient and residual mean squares. Each parameter was compared with the corresponding observed data. Main Results: Logistic correlation coefficient values for SBP and DBP decreases were larger than the cubic correlation coefficient values (0.990 [Z transformation: 2.64 +/- 0.32] vs 0.981 [Z: 2.32 +/- 0.37] and 0.977 [Z: 2.22 +/- 0.33] vs 0.967 [Z: 2.05 +/- 0.34], respectively, P < 0.05). Logistic residual mean squares values for SBP and DBP decreases were smaller than cubic residual mean squares values (20.6 vs 41.0 and 9.2 vs 13.7 mmHg(2), respectively; P < 0.05). There were significant correlations between P-L and SBP or DBP after anesthesia induction, between q(L) and SBP or DBP before endotracheal intubation, and between k(L) and time to maximal rate of the SBP or DBP decrease (dP/dt(min)), but no significant correlation between m(L) and dP/dt(min) for SBP or DBP. Conclusions: Time courses of SBP and DBP decreases during the preintubation period of anesthesia induction are modeled effectively by a logistic function. (c) 2007 Elsevier Inc. All rights reserved.	[Mizuno, Ju; Akune, Tohru; Otsuji, Mikiya; Kin, Nobuhide; Saito, Yuichiro; Orii, Ryo; Hayashida, Masakazu; Arita, Hideko; Hanaoka, Kazuo] Univ Tokyo, Fac Med, Dept Anesthesiol, Tokyo 1138655, Japan; [Mizuno, Ju; Tsuda, Takeshi] Alfred I Dupont Hosp Children, Mol Cardiol Lab, Wilmington, DE 19803 USA; [Fukui, Yasuyuki] Int Univ Hlth & Welfare, Mita Hosp, Tokyo 1088329, Japan	Mizuno, J (reprint author), Univ Tokyo, Fac Med, Dept Anesthesiol, Tokyo 1138655, Japan.	mizuno_ju4@yahoo.co.jp					BAUD M, 1991, SCAND J CLIN LAB INV, V51, P120, DOI 10.3109/00365519109104610; BILLARD V, 1994, ANESTHESIOLOGY, V81, P1384, DOI 10.1097/00000542-199412000-00013; Christenfeld N, 2000, PSYCHOPHYSIOLOGY, V37, P543, DOI 10.1111/1469-8986.3740543; Fujikawa H, 2005, APPL ENVIRON MICROB, V71, P7920, DOI 10.1128/AEM.71.12.7920-7926.2005; Habib AS, 2002, BRIT J ANAESTH, V88, P430, DOI 10.1093/bja/88.3.430; Harris C E, 1988, Anaesthesia, V43 Suppl, P32, DOI 10.1111/j.1365-2044.1988.tb09065.x; Iijima Takehiko, 2005, J Anesth, V19, P193, DOI 10.1007/s00540-005-0320-6; Julius S, 1992, Curr Opin Nephrol Hypertens, V1, P299, DOI 10.1097/00041552-199212000-00016; Katoh T, 1999, BRIT J ANAESTH, V82, P561; Knibbe CAJ, 1999, BRIT J CLIN PHARMACO, V47, P653, DOI 10.1046/j.1365-2125.1999.00942.x; Lyoo IK, 2003, PSYCHIAT CLIN NEUROS, V57, P417, DOI 10.1046/j.1440-1819.2003.01141.x; Minto CF, 1997, ANESTHESIOLOGY, V86, P10, DOI 10.1097/00000542-199701000-00004; Mizuno Ju, 2005, Masui, V54, P1030; Mizuno J, 2007, EUR J CLIN PHARMACOL, V63, P243, DOI 10.1007/s00228-006-0249-1; Munoz HR, 1999, J CLIN ANESTH, V11, P567, DOI 10.1016/S0952-8180(99)00098-7; REID J, 1993, J VET PHARMACOL THER, V16, P488, DOI 10.1111/j.1365-2885.1993.tb00215.x; Schnider TW, 1999, ANESTHESIOLOGY, V90, P1502, DOI 10.1097/00000542-199906000-00003; SCOTT JC, 1987, J PHARMACOL EXP THER, V240, P159; SEBEL PS, 1989, ANESTHESIOLOGY, V71, P260, DOI 10.1097/00000542-198908000-00015; Sheehy JE, 2004, ANN BOT-LONDON, V94, P811, DOI 10.1093/aob/mch208; Snedecor G.W., 1971, STAT METHODS, P185; Sprung J, 2001, ANESTH ANALG, V93, P550, DOI 10.1097/00000539-200109000-00006; STADNICKA A, 1993, ANESTHESIOLOGY, V78, P326, DOI 10.1097/00000542-199302000-00017; Sugimoto SI, 1998, ACTA PHYSIOL SCAND, V163, P17, DOI 10.1046/j.1365-201x.1998.00340.x; THOMPSON DS, 1983, BRIT HEART J, V49, P250; TOMORI Z, 1969, J PHYSIOL-LONDON, V200, P25, DOI 10.1113/jphysiol.1969.sp008680; VANAKEN H, 1988, ANESTHESIOLOGY, V68, P157; WILSON DL, 1994, MECH AGEING DEV, V74, P15, DOI 10.1016/0047-6374(94)90095-7	28	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	NOV	2007	19	7					497	505		10.1016/j.jclinane.2007.04.002			9	Anesthesiology	Anesthesiology	246MT	WOS:000252011800003	18063203				2020-06-30	J	Lenkovsky, F; Robertson, BD; Yer, C; Ross, L; Ahmed, SA; Herazo, L; Markin, V; Joshi, GP				Lenkovsky, Fima; Robertson, Brian D.; Yer, ChandramouLi; Ross, Larry; Ahmed, Syed A.; Herazo, Luis; Markin, Vadistav; Joshi, Girish P.			Metoclopramide does not influence the frequency of propofol-induced spontaneous movements	JOURNAL OF CLINICAL ANESTHESIA			English	Article						anesthesiageneral; metoclopramide; propofol; involuntary movements	CLINICAL USE; INJECTION; ETOMIDATE; INDUCTION	Study Objective: To evaluate the effects of metoclopramide on the frequency and severity of propofol-induced movements. Design: Randomized, double blind, placebo-controlled trial. Setting: Veterans Administration Medical Center. Patients: One hundred thirty-seven consenting adults scheduled to receive general anesthesia with propofol induction. Interventions: Patients were randomized to receive either metoclopramide 10 mg intravenously (IV) or placebo (saline) 3 min before induction of general anesthesia. All patients received midazolam 1 to 2 mg IV, fentanyl 50 to 150 mu g IV, and lidocaine 50 to 80 mg IV before induction of anesthesia. Measurements: Occurrence of spontaneous movements and severity during the observation period were recorded after propofol induction by observing movement in the hands/arms and feet/legs, as well as presence of a hiccup. The dosage of anesthetic medications administered was also recorded for each patient. Main Results: No differences were noted in the frequency and severity of spontaneous movement in the patients who had received metoclopramide and placebo. However, compared with the patients who did not move, patients who experienced movements received a significantly higher dose of propofol (P = 0.025) and a lower dose of fentanyl (P = 0.049). Conclusions: Metoclopramide does not affect the frequency of propofol-induced movements, but propofol and fentanyl doses influence the frequency of movements during propofol induction. (c) 2007 Elsevier Inc. All rights reserved.	[Lenkovsky, Fima; Robertson, Brian D.; Yer, ChandramouLi; Ross, Larry; Ahmed, Syed A.; Herazo, Luis] Dallas Vet Affairs Med Ctr, Dept Anesthesiol, Dallas, TX 75216 USA; [Lenkovsky, Fima; Robertson, Brian D.; Yer, ChandramouLi; Ross, Larry; Ahmed, Syed A.; Herazo, Luis] Dallas Vet Affairs Med Ctr, Pain Management Serv, Dallas, TX 75216 USA; [Markin, Vadistav; Joshi, Girish P.] Univ Texas SW Med Ctr Dallas, Dept Anesthesiol & Pain Management, Dallas, TX 75390 USA	Lenkovsky, F (reprint author), Dallas Vet Affairs Med Ctr, Dept Anesthesiol, Dallas, TX 75216 USA.	fima.lenkovsky@va.gov		Robertson, Brian/0000-0002-2744-5873			ALBIBI R, 1983, ANN INTERN MED, V98, P86, DOI 10.7326/0003-4819-98-1-86; APPADU BL, 1994, ANESTH ANALG, V79, P1191; Bevan JC, 1997, ANESTH ANALG, V85, P50, DOI 10.1097/00000539-199707000-00009; BORGEAT A, 1991, ANESTHESIOLOGY, V74, P24, DOI 10.1097/00000542-199101000-00005; BORGEAT A, 1993, J CLIN ANESTH, V5, P12, DOI 10.1016/0952-8180(93)90081-O; Chan A, 1996, ANAESTHESIA, V51, P663; Ghabash Maroun, 1996, Middle East Journal of Anesthesiology, V13, P419; GILLIES GWA, 1989, ANAESTHESIA, V44, P386, DOI 10.1111/j.1365-2044.1989.tb11333.x; HARRINGTON RA, 1983, DRUGS, V25, P451, DOI 10.2165/00003495-198325050-00002; JOSHI GP, 2004, EVIDENCE BASED PRACT, P236; MILLER LG, 1989, ARCH INTERN MED, V149, P2486, DOI 10.1001/archinte.149.11.2486; REDDY RV, 1993, ANESTH ANALG, V77, P1008; Schramm BM, 2002, ANESTH ANALG, V94, P1237, DOI 10.1097/00000539-200205000-00034; SMITH I, 1994, ANESTHESIOLOGY, V81, P1005	14	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180			J CLIN ANESTH	J. Clin. Anesth.	NOV	2007	19	7					530	533		10.1016/j.jclinane.2007.05.004			4	Anesthesiology	Anesthesiology	246MT	WOS:000252011800008	18063208				2020-06-30	J	Hull, MJ; Juhascik, M; Mazur, F; Flomenbaum, MA; Behonick, GS				Hull, Mindy J.; Juhascik, Matthew; Mazur, Frank; Flomenbaum, Mark A.; Behonick, George S.			Fatalities associated with fentanyl and co-administered cocaine or opiates	JOURNAL OF FORENSIC SCIENCES			English	Article						forensic science; forensic toxicology; fentanyl; opiates; cocaine; drug abuse; overdose; fatality; autopsy	TRANSDERMAL FENTANYL; UNITED-STATES; DEATHS; ABUSE; CIRCUMSTANCES; MISUSE	Fatalities associated with fentanyl hydrochloride are increasingly seen in Massachusetts. Between September 2005 and November 2006, 5009 medicolegal investigations associated 107 deaths with licit or illicit fentanyl use, along with a co-detection of an opiate/opioid or cocaine/benzoylecognine, or both. Deaths associated with illicit fentanyl use occur in younger people (39.4 vs. 61.5 years) with higher fentanyl (17.1 ng/mL vs. 4.4 ng/mL) and lower morphine (76.9 ng/mL vs. 284.2 ng/mL) postmortem blood concentrations, and more frequent cocaine co-intoxication (65% vs. 3%), than deaths associated with licit fentanyl use. A wide range of postmortem blood concentrations of fentanyl was detected (trace-280 ng/mL), with a minimum concentration of 7 ng/mL of fentanyl strongly associated with illicit use of fentanyl in poly-drug cases. The most commonly detected opiates/opioids in illicit fentanyl users were: morphine (29%), oxycodone (14.5%), and methadone (14.5%). Ethanol, cannabinoids, diazepam, citalopram, and diphenhydramine were each detected in greater than 10% of the illicit fentanyl cases. Most fentanyl abusers died at their own home and their deaths were most often classified as accidental. Mapping of primary residences of decedents revealed conspicuous clustering of the illicit fentanyl use cases, as opposed to the random pattern in licit use cases. Fentanyl misuse is a public health problem in Massachusetts.	[Hull, Mindy J.; Flomenbaum, Mark A.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Juhascik, Matthew; Mazur, Frank; Behonick, George S.] UMass Mem Med Ctr, Dept Hosp Labs, Worcester, MA 01605 USA; [Flomenbaum, Mark A.] Off Chief Med Examiner, Boston, MA 02118 USA	Behonick, GS (reprint author), DABFT, UMass Forens Toxicol Lab, 1 Innovat Dr,3rd Floor,Suite 360, Worcester, MA 01605 USA.	behonicg@ummhc.org					Barreto GP, 2001, REV BRAS ZOOTECN, V30, P1; Baselt R, 2004, DISPOSITION TOXICOL, P451; Boddiger D, 2006, LANCET, V368, P569, DOI 10.1016/S0140-6736(06)69181-2; Compton WM, 2006, DRUG ALCOHOL DEPEN, V81, P103, DOI 10.1016/j.drugalcdep.2005.05.009; HENDERSON GL, 1991, J FORENSIC SCI, V36, P422; HIBBS J, 1991, JAMA-J AM MED ASSOC, V265, P1011, DOI 10.1001/jama.265.8.1011; ISENSCHMID DS, 2006, SOC FOR TOX ANN M, pS7; Kuhlman JJ, 2003, J ANAL TOXICOL, V27, P499, DOI 10.1093/jat/27.7.499; Leri F, 2003, ADDICTION, V98, P7, DOI 10.1046/j.1360-0443.2003.00236.x; Liappas IA, 2004, J PSYCHOPHARMACOL, V18, P277, DOI 10.1177/0269881104042634; Lilleng PK, 2004, J FORENSIC SCI, V49, P1364; Martin TL, 2006, J ANAL TOXICOL, V30, P603, DOI 10.1093/jat/30.8.603; Paulozzi LJ, 2006, PHARMACOEPIDEM DR S, V15, P618, DOI 10.1002/pds.1276; SMALLEY S, 2006, OPIATE FENTAYL GAINI; SMIALEK JE, 1994, J FORENSIC SCI, V39, P159; Tharp AM, 2004, AM J FOREN MED PATH, V25, P178, DOI 10.1097/01.paf.0000127398.67081.11; WODALL KL, 2006, P 58 ANN M AM AC FOR, P361; 2006, MICROGRAM B, V39, P68; 2006, MICROGRAM B, V39, P45	19	39	43	0	21	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0022-1198			J FORENSIC SCI	J. Forensic Sci.	NOV	2007	52	6					1383	1388		10.1111/j.1556-4029.2007.00564.x			6	Medicine, Legal	Legal Medicine	239YH	WOS:000251553700024	17944902				2020-06-30	J	Mercadante, S; Porzio, G; Fulfaro, F; Aielli, F; Verna, L; Ficorella, C; Casuccio, A; Riina, S; Intravaia, G; Mangione, S				Mercadante, Sebastiano; Porzio, Giampiero; Fulfaro, Fabio; Aielli, Federica; Verna, Lucilla; Ficorella, Corrado; Casuccio, Alessandra; Riina, Salvatore; Intravaia, Giuseppe; Mangione, Salvatore			Switching from transdermal drugs: An observational "N of 1" study of fentanyl and buprenorphine	JOURNAL OF PAIN AND SYMPTOM MANAGEMENT			English	Article						cancer pain; opioid switching; transdermal fenlanyl; transdermal buprenorphine	ORAL MORPHINE; CHRONIC PAIN; CANCER PAIN; MULTICENTER; EFFICACY	The aim of this study was to confirm that the concomitant Presence of transdermal fentanyl (TTS FE) and buprenorphine (TTS BU) may be feasible without important consequences, using doses presumed to be equianalgesic. A prospective "N of 1" study was carried out in a sample of volunteers with cancer pain receiving stable doses of TTS FE or TTS BU, with adequate pain and symptom control. In the study design, each patient provided data before and after a switch from one opioid to the other and then back to the previous one. Sixteen patients receiving daily stable doses of 0.6 or 1.2 mg of TTS FE were switched to TTS BU using an FE-BU ratio of 0.6-0.8. After three days, the TTS BU patch was removed and TTS IT patch was placed for another three days. Six patients receiving TTS B U were switched to TTS FE and then rotated back to TTS BU with the same dosing considerations. No statistical differences in changes in pain and symptom intensity during switching and between the two different sequences were observed. No significant changes in rescue doses of oral morphine were reported at the same intervals. Cancer patients receiving stable doses of TTS FE or TTS BU can be safely switched to the alternative transdermal opioid. Further studies should be performed to gather data about the use of TTS BU with other opioids, at different doses, and in different clinical conditions.	La Maddalena Canc Ctr, Pain Relief & Pallat Care Unit, I-90146 Palermo, Italy; Univ Palermo, Dept Oncol & Neurosci, Intens Care & Emergency & Pallat Med Teaching, I-90133 Palermo, Italy; Univ Aquila, Dept Oncol, I-67100 Laquila, Italy	Mercadante, S (reprint author), La Maddalena Canc Ctr, Pain Relief & Pallat Care Unit, Via San Lorenzo 312, I-90146 Palermo, Italy.	terapiadeldolore@lamaddalena.it	casuccio, alessandra/B-1730-2013; VERNA, Lucilla/M-3998-2017	casuccio, alessandra/0000-0002-5676-9535; AIELLI, Federica/0000-0003-2785-0702; VERNA, Lucilla/0000-0002-2046-3980; Porzio, Giampiero/0000-0002-9875-9220			Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; ATKINSON RE, 1990, ROY SOC MED INT CONG, V146, P81; Christoph T, 2005, EUR J PHARMACOL, V507, P87, DOI 10.1016/j.ejphar.2004.11.052; Donner B, 1996, PAIN, V64, P527, DOI 10.1016/0304-3959(95)00180-8; Genf World Health Organization, 1986, CANC PAIN REL; Kogel B, 2005, EUR J PAIN, V9, P599, DOI 10.1016/j.ejpain.2005.02.002; Likar R, 2005, ANESTH ANALG, V100, P781, DOI 10.1213/01.ANE.0000145066.06538.20; MERCADANTE S, 2006, CANC CARE, V2, P117; Mercadante S, 2007, SUPPORT CARE CANCER, V15, P441, DOI 10.1007/s00520-006-0169-8; Mercadante S, 2006, J PAIN SYMPTOM MANAG, V32, P175, DOI 10.1016/j.jpainsymman.2006.01.013; Schriek P, 2004, SUPPORT CARE CANCER, V12, P882, DOI 10.1007/s00520-004-0695-1; Sittl R, 2005, CLIN THER, V27, P225, DOI 10.1016/j.clinthera.2005.02.012; Sittl R, 2003, CLIN THER, V25, P150, DOI 10.1016/S0149-2918(03)90019-1	13	22	22	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0885-3924	1873-6513		J PAIN SYMPTOM MANAG	J. Pain Symptom Manage.	NOV	2007	34	5					532	538		10.1016/j.jpainsymman.2007.01.006			7	Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology	Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology	232SZ	WOS:000251041100014	17629666	Bronze			2020-06-30	J	Bessiere, B; Richebe, P; LaboureyraS, E; Laulin, JP; Contarino, A; Simonnet, G				Bessiere, Baptiste; Richebe, Philippe; Laboureyras, Emilie; Laulin, Jean-Paul; Contarino, Angelo; Simonnet, Guy			Nitrous oxide (N2O) prevents latent pain sensitization and long-term anxiety-like behavior in pain and opioid-experienced rats	NEUROPHARMACOLOGY			English	Article						nitrous oxide; opioid; pain sensitization; anxiety; stress; rehabilitation	D-ASPARTATE RECEPTOR; ELEVATED PLUS-MAZE; LASTING HYPERALGESIA; MORPHINE; FENTANYL; ANTAGONISTS; INCREASES; KETAMINE; MODEL	Improving rehabilitation after a severe tissue injury does not only require a reduction in pain, but also requires alleviation of negative affects, particularly anxiety. Although opioids remain unsurpassed analgesics to relieve moderate to severe pain, it has been shown that they also induce latent pain sensitization leading to long-lasting hyperalgesia via N-methyl-D-aspartate-(NMDA)-dependent pronociceptive systems. The present study evaluated the ability of nitrous oxide (N2O), a gas with NMDA antagonist properties, to prevent latent pain sensitization and long-term anxiety-like behavior (ALB) in rats with pain and opioid experiences. On Do, the pro-inflammatory drug carrageenan was injected in one hind paw of rats treated with fentanyl (4 x 100 mu g/kg subcutaneously). Nociceptive threshold was evaluated with the paw pressure vocalization test. Rats were re-exposed to carrageenan or exposed to repeated non-nociceptive environmental stress (NNES) 2-3 weeks later. Rats were also challenged in the elevated plus-maze 2 weeks after fentanyl administration for evaluating ALB. The preventive effects of a single 4 h 50/50% N2O-O-2 exposure performed on D-0 was evaluated. Fifty percent N2O strongly reduced hyperalgesia induced by a first inflammation and its enhancement by fentanyl, and prevented exaggerated hyperalgesia induced by second inflammatory pain or NNES. Moreover, we provide first evidence that a high fentanyl dose induces long-term ALB 2 weeks after its administration. When associated with fentanyl, 50% N2O prevented such long-term ALB. These results suggest that a single exposure to N2O could improve post-injury pain management and facilitate rehabilitation especially when potent analgesics as opioids have to be used. (C) 2007 Elsevier Ltd. All rights reserved.	Univ Bordeaux 2, Univ Bordeaux 1, CNRS,UMR 5227, Team Homeostasie Allostasie Pathol Rehabil, F-33076 Bordeaux, France; Ctr Hosp Univ Bordeaux, Dept Anesthesie & Reanimat 2, Bordeaux, France; Univ Bordeaux 2, Univ Bordeaux 1, Unite Nutr & Neurosci, F-33076 Bordeaux, France; Ctr Rech Claude Delorme, Jouy En Josas, France	Simonnet, G (reprint author), Univ Bordeaux 2, Univ Bordeaux 1, CNRS,UMR 5227, Team Homeostasie Allostasie Pathol Rehabil, 146 Rue Leo Saignat, F-33076 Bordeaux, France.	gsimonnet@yahoo.com	Contarino, Angelo/C-9429-2014	Contarino, Angelo/0000-0002-7286-6941			Adamec RE, 1999, PHYSIOL BEHAV, V65, P723; Angst MS, 2006, ANESTHESIOLOGY, V104, P570, DOI 10.1097/00000542-200603000-00025; Bergink V, 2004, EUR NEUROPSYCHOPHARM, V14, P175, DOI 10.1016/S0924-977X(03)00100-7; Celerier E, 2000, ANESTHESIOLOGY, V92, P465, DOI 10.1097/00000542-200002000-00029; Chia YT, 1999, CAN J ANAESTH, V46, P872, DOI 10.1007/BF03012978; CODERRE TJ, 1987, BRAIN RES, V404, P95, DOI 10.1016/0006-8993(87)91359-X; DWORKIN RH, 1991, CLIN J PAIN, V7, P79, DOI 10.1097/00002508-199106000-00004; Eriksen J, 2006, PAIN, V125, P172, DOI 10.1016/j.pain.2006.06.009; Fujinaga M, 2002, MOL NEUROBIOL, V25, P167, DOI 10.1385/MN:25:2:167; Georgiev SK, 2008, PAIN, V134, P24, DOI 10.1016/j.pain.2007.03.026; Guignard B, 2000, ANESTHESIOLOGY, V93, P409, DOI 10.1097/00000542-200008000-00019; Guignard B, 2002, ANESTH ANALG, V95, P103, DOI 10.1097/00000539-200207000-00018; IIKJAER S, 2000, PAIN, V86, P19; Jevtovic-Todorovic V, 1998, NAT MED, V4, P460, DOI 10.1038/nm0498-460; Joly V, 2005, ANESTHESIOLOGY, V103, P147, DOI 10.1097/00000542-200507000-00022; KAYSER V, 1987, BRAIN RES, V414, P155, DOI 10.1016/0006-8993(87)91338-2; Kehlet H, 2006, LANCET, V367, P1618, DOI 10.1016/S0140-6736(06)68700-X; Koks S, 1999, NEUROPEPTIDES, V33, P63, DOI 10.1054/npep.1999.0015; Koppert W, 2003, ANESTHESIOLOGY, V99, P152, DOI 10.1097/00000542-200307000-00025; McCartney CJL, 2004, ANESTH ANALG, V98, P1385, DOI 10.1213/01.ANE.0000108501.57073.38; Mennerick S, 1998, J NEUROSCI, V18, P9716; MOTTA V, 1993, PHARMACOL BIOCHEM BE, V44, P119, DOI 10.1016/0091-3057(93)90288-5; Nagele P, 2004, P NATL ACAD SCI USA, V101, P8791, DOI 10.1073/pnas.0402825101; PELLOW S, 1985, J NEUROSCI METH, V14, P149, DOI 10.1016/0165-0270(85)90031-7; Richebe P, 2005, ANESTHESIOLOGY, V103, P845, DOI 10.1097/00000542-200510000-00024; Rivat C, 2002, ANESTHESIOLOGY, V96, P381, DOI 10.1097/00000542-200202000-00025; Simonnet G, 2003, NEUROREPORT, V14, P1, DOI 10.1097/00001756-200301200-00001; Sullivan MD, 2005, PAIN, V119, P95, DOI 10.1016/j.pain.2005.09.020; Wiley JL, 1995, EUR J PHARMACOL, V294, P101, DOI 10.1016/0014-2999(95)00506-4; Woolf CJ, 2000, SCIENCE, V288, P1765, DOI 10.1126/science.288.5472.1765	30	21	21	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	NOV	2007	53	6					733	740		10.1016/j.neuropharm.2007.08.003			8	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	229IO	WOS:000250796700003	17884109				2020-06-30	J	Weiss, M				Weiss, Michael			Residence time dispersion as a general measure of drug distribution kinetics: Estimation and physiological interpretation	PHARMACEUTICAL RESEARCH			English	Article						diffusion; distribution; pharmacokinetics; residence time; tissue binding	PHARMACOKINETIC PARAMETERS; BLOOD-VOLUME; DISPOSITION; ALFENTANIL; VARIANCE; FENTANYL; DIGOXIN; MODEL	To evaluate distribution kinetics of drugs by the relative dispersion of disposition residence time and demonstrate its uses, interpretation and limitations. The relative dispersion was estimated from drug disposition data of inulin and digoxin fitted by three-exponential functions, and calculated from compartmental parameters published for fentanyl and alfentanil. An interpretation is given in terms of a lumped organs model and the distributional equilibration process in a noneliminating system. As a measure of the deviation from mono-exponential disposition (one-compartment behavior), the relative dispersion provides information on the distribution kinetics of drugs, i.e., diffusion-limited distribution or slow tissue binding, without assuming a specific structural model. It also defines the total distribution clearance which has a clear physical meaning. The residence time dispersion is a model-independent measure that can be used to characterize the distribution kinetics of drugs and to reveal the influence of disease states. It can be estimated with high precision from drug disposition data.	Univ Halle Wittenberg, Dept Pharmacol, Sect Pharmacokinet, D-06097 Halle, Germany	Weiss, M (reprint author), Univ Halle Wittenberg, Dept Pharmacol, Sect Pharmacokinet, D-06097 Halle, Germany.	michael.weiss@medizin.uni-halle.de	Weiss, Michael/D-2132-2012				BAILEY JM, 1994, J PHARMACOKINET BIOP, V22, P157, DOI 10.1007/BF02353541; BJORKMAN S, 1994, J PHARMACOKINET BIOP, V22, P381, DOI 10.1007/BF02353862; Clausen T, 2003, PHYSIOL REV, V83, P1269, DOI 10.1152/physrev.00011.2003; DARGENIO DZ, 1997, ADAPT 2 USERS GUIDE; Egan TD, 1999, ANESTHESIOLOGY, V91, P156, DOI 10.1097/00000542-199907000-00024; HENTHORN TK, 1992, CLIN PHARMACOL THER, V52, P190, DOI 10.1038/clpt.1992.129; KRAMER WG, 1974, J PHARMACOKINET BIOP, V2, P299, DOI 10.1007/BF01061404; Krejcie TC, 1999, J PHARMACOL EXP THER, V291, P1308; LEMMENS HJM, 1994, CLIN PHARMACOL THER, V56, P261, DOI 10.1038/clpt.1994.136; Looby M, 1995, J PHARMACOKINET BIOP, V23, P635, DOI 10.1007/BF02353465; Niemann CU, 2000, CLIN PHARMACOL THER, V67, P342, DOI 10.1067/mcp.2000.104945; PRESCOTT LF, 1991, EUR J CLIN PHARMACOL, V40, P619; PURVES RD, 1994, J PHARM SCI, V83, P202, DOI 10.1002/jps.2600830217; Sato H, 1996, COMPUT METH PROG BIO, V50, P43, DOI 10.1016/0169-2607(96)01730-0; Weiss M, 1996, BRIT J CLIN PHARMACO, V41, P261, DOI 10.1046/j.1365-2125.1996.03121.x; Weiss M, 1997, J PHARM SCI, V86, P1491, DOI 10.1021/js9702271; WEISS M, 1986, J PHARMACOKINET BIOP, V14, P635, DOI 10.1007/BF01067968; Weiss M, 1999, J PHARMACOKINET BIOP, V27, P233, DOI 10.1023/A:1020990912291; Weiss M, 1996, J PHARMACOKINET BIOP, V24, P173, DOI 10.1007/BF02353488; WEISS M, 1982, J MATH BIOL, V15, P305, DOI 10.1007/BF00275690; WEISS M, 1983, J PHARMACOKINET BIOP, V11, P63, DOI 10.1007/BF01061768; WEISS M, 1992, J PHARMACOKINET BIOP, V20, P253, DOI 10.1007/BF01062527; WEISS M, 1992, EUR J CLIN PHARMACOL, V43, P571, DOI 10.1007/BF02284953; Weiss M, 2007, EUR J PHARM SCI, V30, P256, DOI 10.1016/j.ejps.2006.11.012; Weiss M, 2006, AM J PHYSIOL-HEART C, V291, pH861, DOI 10.1152/ajpheart.01052.2005; WEISSM, 2007, J PHARM SCI, V96, P913	26	5	5	0	3	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0724-8741	1573-904X		PHARM RES-DORDR	Pharm. Res.	NOV	2007	24	11					2025	2030		10.1007/s11095-007-9332-2			6	Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Chemistry; Pharmacology & Pharmacy	215IS	WOS:000249802500006	17510754				2020-06-30	J	Price, D				Price, Darcy			High thoracic epidural plus suprascapular nerve block analgesia for thoracoscapular fusion	REGIONAL ANESTHESIA AND PAIN MEDICINE			English	Letter									N Shore Univ Hosp, Dept Anaesthesia & Perioperat Med, Auckland, New Zealand	Price, D (reprint author), N Shore Univ Hosp, Dept Anaesthesia & Perioperat Med, Auckland, New Zealand.						Glenn RE, 2005, TECH SHOULDER ELBOW, V6, P178; HO AMH, 2007, TXB REGIONAL ANESTHE, P599; Meier G, 2002, ANAESTHESIST, V51, P747, DOI 10.1007/s00101-002-0380-z; URMEY WF, 1993, REGION ANESTH, V18, P244	4	2	2	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1098-7339	1532-8651		REGION ANESTH PAIN M	Region. Anesth. Pain Med.	NOV-DEC	2007	32	6					541	542		10.1016/j.rapm.2007.07.007			2	Anesthesiology	Anesthesiology	238DZ	WOS:000251428800021	18035308				2020-06-30	J	Zarth, R; Ehmer, M; Sittig, HB				Zarth, R.; Ehmer, M.; Sittig, H. -B.			Oral transmucosal fentanyl citrate for the treatment of breakthrough pain	SCHMERZ			German	Article						cancer-related pain; breakthrough pain; oral transmucosal fentanyl citrate; observational study	CANCER PAIN; DOSE-TITRATION; EAPC RECOMMENDATIONS; ALTERNATIVE OPIOIDS; PREVALENCE; MORPHINE; OTFC(R); MULTICENTER; IMPACT; TRIAL	In a non-interventional study the efficacy and tolerability of oral transmucosal fentanyl citrate (OTFC) was studied in patients with opioid-treated cancer pain suffering from breakthrough pain. The prospective multicenter observational trial included 406 patients. For 3-4 months, efficacy of OTFC treatment for breakthrough pain was documented using a numerical analog pain intensity scale (NAS). Further, OTFC therapy was rated and adverse events were recorded. With application of oral transmucosal fentanyl citrate median pain intensity fell from NAS 8 points at the beginning to NAS 2 points at the end of the study. The median effective dosage was 400 g. Tolerability was rated as good or very good by 87.5% of the patients. Oral transmucosal fentanyl citrate is a safe and effective treatment for breakthrough pain in chronic cancer-related pain.	Univ Tubingen, Akad Lehrkrankenhaus, Zollernalb Klinikum, Anaesthesiol & Intens Med Abt, D-72336 Balingen, Germany; Praxis Schemerztherapie & Palliativ Med, Freiburg, Germany; Spezielle Schmerztherapie Palliativ Med, MVZ Buntenskamp, Geesthacht, Germany	Zarth, R (reprint author), Univ Tubingen, Akad Lehrkrankenhaus, Zollernalb Klinikum, Anaesthesiol & Intens Med Abt, Tubinger Str 23-3, D-72336 Balingen, Germany.	ralf.zarth@zollernalb-klinikum.de					Aronoff GM, 2005, PAIN MED, V6, P305, DOI 10.1111/j.1526-4637.2005.00045.x; Arzneimittelkommission der Deutschen Arzteschaft, 2007, ARZNEIVERORDNUNG PRA, V34, P1; Christie JM, 1998, J CLIN ONCOL, V16, P3238, DOI 10.1200/JCO.1998.16.10.3238; Coluzzi P H, 1998, Am J Hosp Palliat Care, V15, P13, DOI 10.1177/104990919801500105; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Farrar JT, 1998, JNCI-J NATL CANCER I, V90, P611, DOI 10.1093/jnci/90.8.611; HANKS G, 1998, OXFORD TXB PALLIATIV, P545; Hanks GW, 2004, PALLIATIVE MED, V18, P698, DOI 10.1191/0269216304pm966oa; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; Lichtor JL, 1999, ANESTH ANALG, V89, P732, DOI 10.1097/00000539-199909000-00038; McMenamin Erin, 2002, Expert Rev Neurother, V2, P625, DOI 10.1586/14737175.2.5.625; Mercadante S, 2002, CANCER, V94, P832, DOI 10.1002/cncr.10249; Payne R, 2001, J PAIN SYMPTOM MANAG, V22, P575, DOI 10.1016/S0885-3924(01)00306-2; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, PAIN, V79, P303, DOI 10.1016/S0304-3959(98)00179-1; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; PORTENOY RK, 1991, PRIM CARE CANC, P27; Radbruch L, 2002, SCHMERZ, V16, P186, DOI 10.1007/s004820100104; Rees Elizabeth, 2002, Int J Palliat Nurs, V8, P304; Streisand JB, 1998, ANESTHESIOLOGY, V88, P305, DOI 10.1097/00000542-199802000-00006; STREISAND JB, 1991, ANESTHESIOLOGY, V75, P223, DOI 10.1097/00000542-199108000-00009; Svendsen KB, 2005, EUR J PAIN, V9, P195, DOI 10.1016/j.ejpain.2004.06.001; Taylor DR, 2007, PAIN MED, V8, P281, DOI 10.1111/j.1526-4637.2007.00298.x; Vainio A, 1996, J PAIN SYMPTOM MANAG, V12, P3, DOI 10.1016/0885-3924(96)00042-5; Zeppetella G, 2000, J PAIN SYMPTOM MANAG, V20, P87, DOI 10.1016/S0885-3924(00)00161-5	25	5	5	0	0	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013 USA	0932-433X			SCHMERZ	Schmerz	NOV	2007	21	6					545	552		10.1007/s00482-007-0590-z			8	Anesthesiology; Clinical Neurology	Anesthesiology; Neurosciences & Neurology	232HT	WOS:000251010100007	17899213				2020-06-30	J	Miner, JR; Kletti, C; Herold, M; Hubbard, D; Biros, MH				Miner, James R.; Kletti, Christine; Herold, Matthew; Hubbard, Daniel; Biros, Michelle H.			Randomized clinical trial of nebulized fentanyl citrate versus IV fentanyl citrate in children presenting to the emergency department with acute pain	ACADEMIC EMERGENCY MEDICINE			English	Article						emergency medicine; pediatrics; pain treatment; fentanyl administration	INTRANASAL FENTANYL; MORPHINE	Objectives: To compare the pain relief achieved with nebulized fentanyl citrate with intravenous (IV) tentanyl citrate in children presenting to the emergency department (ED) with painful conditions to determine if nebulized fentanyl is a feasible alternative to IV fentanyl for the treatment of acute pain in children. Methods: This was a randomized controlled trial in an urban county medical center ED with an annual census of 99,000 visits. ED patients, aged 6 months to 17 years, presenting with acute pain who were going to be treated with IV pain medications, were eligible for enrollment. After the parents had provided informed consent, and children older than 6 years had provided assent, patients were randomized (1:2) to receive either fentanyl citrate IV (1.5 mu g/kg) or fentanyl citrate by breath-actuated nebulizer (3.0 mu g/kg). Patients aged 6 years and older completed a 100-mm visual analog scale (VAS) describing their pain, and patients younger than 6 years had their pain assessed by the treating physician using the Children's Hospital of Eastern Ontario Pain Scale. Additionally, treating physicians used a 100-mm VAS to describe their perception of the patients' pain. These pain measurements were taken before treatment and every 10 minutes thereafter for 30 minutes. Baseline blood pressure, heart rate, and oxygen saturation were also measured before treatment and every 10 minutes for 30 minutes. After 30 minutes, physicians were asked whether or not they believed the medication provided adequate pain relief for the patient. Parents were asked to rate their satisfaction with the treatment using a five-point scale. Patients who received additional pain medications by any method before the 30-minute measurement period was completed were considered treatment failures. Data were compared using descriptive statistics and 95% confidence intervals; the rates of adequate pain relief between the groups were compared using Fisher exact tests. Results: Forty-one patients were enrolled in the study; 14 were randomized to IV fentanyl (ten actually received it), and 27 patients were randomized to nebulized fentanyl (31 actually received it). In the four patients who were randomized to IV fentanyl but received nebulized fentanyl, the parents requested the nebulized medication after being told their child had been randomized to IV fentanyl. Baseline pain VAS scores were 82.8 mm (SD +/- 14.3, 69-100) in the IV group and 76.2 mm (SD +/- 20.5, 34-100) in the nebulized group. There were five treatment failures: one who received IV fentanyl and four who received nebulized fentanyl. The four patients who were considered treatment failures in the nebulized fentanyl group were all younger than 3 years and had difficulty triggering the breath-actuated nebulizer. The mean decrease in pain for patients remaining in the study was 55.1 mm (95% Cl = 40.3 to 70.0) for the IV group and 77.8 mm (95% Cl = 67.4 to 88.4) for the nebulized group. The pain treatment was described as adequate by the treating physician in eight of 14 patients in the IV group and 20 of 27 patients in the nebulized group (p = 0.42). No adverse events were detected. Conclusions: Nebulized fentanyl citrate 3 mu g/kg through a breath-actuated nebulizer appears to be a feasible alternative to IV fentanyl citrate for a variety of painful conditions in patients older than 3 years.	Hennepin Cty Med Ctr, Dept Emergency Med, Minneapolis, MN 55415 USA; Ridgeview Med Ctr, Dept Emergency Med, Waconia, MN USA	Miner, JR (reprint author), Hennepin Cty Med Ctr, Dept Emergency Med, Minneapolis, MN 55415 USA.	miner015@umn.edu	Miner, James/AAI-4801-2020				Bartfield JM, 2003, ACAD EMERG MED, V10, P215, DOI 10.1197/aemj.10.3.215; Borland M, 2007, ANN EMERG MED, V49, P335, DOI 10.1016/j.annemergmed.2006.06.016; Borland Meredith L, 2002, Emerg Med (Fremantle), V14, P275, DOI 10.1046/j.1442-2026.2002.00344.x; Borland ML, 2005, BURNS, V31, P831, DOI 10.1016/j.burns.2005.05.001; CHUDNOFSKY CR, 1989, ANN EMERG MED, V18, P635, DOI 10.1016/S0196-0644(89)80517-7; EMSC Grant Panel Pharmacologic Ag, 2004, J PEDIATR SURG, V39, P1472, DOI 10.1016/j.jpedsurg.2004.07.002; Friedland LR, 1997, PEDIATR EMERG CARE, V13, P103, DOI 10.1097/00006565-199704000-00005; Mather LE, 1998, BRIT J CLIN PHARMACO, V46, P37, DOI 10.1046/j.1365-2125.1998.00035.x; TYLER DC, 1993, PAIN, V52, P301, DOI 10.1016/0304-3959(93)90163-J	9	28	28	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1069-6563	1553-2712		ACAD EMERG MED	Acad. Emerg. Med.	OCT	2007	14	10					895	898		10.1197/j.aem.2007.06.036			4	Emergency Medicine	Emergency Medicine	218MX	WOS:000250020700010	17898251				2020-06-30	J	Oh, AY; Seo, KS; Goo, EK; Park, YO; Kim, SJ; Kim, JH				Oh, A. Y.; Seo, K. S.; Goo, E. K.; Park, Y. O.; Kim, S. J.; Kim, J. H.			Prevention of withdrawal movement associated with injection of rocuronium in children: comparison of remifentanil, alfentanil and fentanyl	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						alfentanil; children; fentanyl; remifentanil; rocuronium; movement	PAIN; PRETREATMENT; LIDOCAINE; ONDANSETRON; PROPOFOL	Background: We compared the efficacy of remifentanil, alfentanil and fentanyl in reducing withdrawal movement associated with the injection of rocuronium in children. Methods: In total, 164 ASA physical status I or II pediatric patients, aged 1-14 years, were randomly assigned to four treatment groups: group C received saline; group R, remifentanil 1 mu g/kg; group A, alfentanil 10 mu g/kg; and group F, fentanyl 2 mu g/kg. Treatments were injected over 30 s, followed by thiopental 5 mg/kg. At 90 s after the start of the study drug injection, rocuronium 0.6 mg/kg was injected over 10 s. The patient's response to the injection of rocuronium was graded on a four-point scale in a double-blinded manner. Results: The incidence of withdrawal movement was 89.5% in group C, 70.3% in group F, 36.3% in group A and 7.2% in group R. The incidence of generalized movement (grade 4) was 86.9% in group C, 58.5% in group F, 15.9% in group A and 2.4% in group R. Conclusions: Remifentanil, alfentanil and fentanyl all reduced the incidence of withdrawal movement when administered 90 s before the injection of rocuronium compared with saline. Remifentanil was the most effective, followed by alfentanil. Fentanyl was less effective but significantly different from the saline in reducing withdrawal movement in children.	Seoul Natl Univ, Bundang Hosp, Dept Anesthesiol & Pain Med, Seoul 463707, South Korea; Seoul Natl Univ, Dent Hosp, Dept Dent Anesthesiol, Seoul, South Korea; Seoul Natl Univ, Coll Med, Dept Anesthesiol, Seoul, South Korea	Kim, JH (reprint author), Seoul Natl Univ, Bundang Hosp, Dept Anesthesiol & Pain Med, 300 Gumi-dong Bundang-gu, Seoul 463707, South Korea.	anesing1@snu.ac.kr	Oh, Ah-Young/J-5541-2012	Seo, Kwang-Suk/0000-0001-5906-0639			Borgeat A, 1997, BRIT J ANAESTH, V79, P382, DOI 10.1093/bja/79.3.382; Chiarella AB, 2003, BRIT J ANAESTH, V90, DOI 10.1093/bja/aeg054; Kim JY, 2007, BRIT J ANAESTH, V98, P120, DOI 10.1093/bja/ael285; Kim KS, 2006, J CLIN ANESTH, V18, P334, DOI 10.1016/j.jclinane.2005.12.001; Liou JT, 2003, ANESTH ANALG, V97, P1294, DOI 10.1213/01.ANE.0000082247.39704.79; Lui Jiin-Tarng, 2002, Chang Gung Med J, V25, P617; Memis D, 2002, ANESTH ANALG, V94, P1517, DOI 10.1097/00000539-200206000-00026; Mencke T, 2004, ACTA ANAESTH SCAND, V48, P1245, DOI 10.1111/j.1399-6576.2004.00506.x; Nathanson MH, 1996, ANESTH ANALG, V82, P469, DOI 10.1097/00000539-199603000-00006; Reddy MS, 2001, ANAESTHESIA, V56, P902, DOI 10.1046/j.1365-2044.2001.02059-6.x; Scott LJ, 2005, DRUGS, V65, P1793, DOI 10.2165/00003495-200565130-00007; Shevchenko Y, 1999, ANESTH ANALG, V88, P746, DOI 10.1097/00000539-199904000-00011; Steegers MAH, 1996, ANESTH ANALG, V83, P203, DOI 10.1097/00000539-199607000-00065; STOELTING RK, 1999, PHARM PHYSL ANESTHET, P77	14	18	20	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	OCT	2007	51	9					1190	1193		10.1111/j.1399-6576.2007.01371.x			4	Anesthesiology	Anesthesiology	209GE	WOS:000249376200011	17711566				2020-06-30	J	Lessa, S; Passarelli, CA				Lessa, Sergio; Passarelli, Carlos Alberto			Peribulbar anesthesia for blepharoplasty	AESTHETIC PLASTIC SURGERY			English	Article						blepharoplasty; ophthalmologic procedures; peribulbar anesthesia	RETROBULBAR ANESTHESIA; STRABISMUS SURGERY; CATARACT-SURGERY; GLOBE; COMPLICATIONS; PERFORATION	Background: Peribulbar anesthesia for inferior blepharoplasty was used successfully in 788 selected cases over the past 9 years. This technique is largely accepted for ophthalmologic procedures, but is not yet specifically used for blepharoplasty. Methods: In the past 9 years, 788 patients ages 36 to 77 years were submitted to inferior peribulbar anesthesia for blepharoplasty procedures. Of these patients, 623 (79%) were women and 165 (21%) were men. The anesthetic procedure is performed using a needle introduced at the junction of the medial two-thirds and the lateral third of the inferior orbital rim (point A). With the patient staring forward, the needle is introduced through the lid at point A. It enters the orbital cavity just above the orbital floor periosteum until the globe equator is minimally trespassed (depth, similar to 31 mm). There, 3 ml of the local anesthetic solution (2% lidocaine + 0.5% bupivacaine) is slowly injected. Results: None of our treated patients reported pain or discomfort during or after the surgical procedure. Immediately after inferior peribulbar anesthesia, chemosis was observed in 17 cases (2.2%) and orbital hematoma in 3 cases (0.4%). Diplopia, or a slight imaging distortion lasting a few hours may occur after inferior peribulbar anesthesia. Conclusions: Inferior peribulbar anesthesia for blepharoplasty offers surprising results. The surgical procedures are performed pain free, leaving the patients completely relaxed and allowing an easier surgical procedure. This technique should be performed only by highly skilled anesthesiologists or surgeons with a perfect knowledge of the complex orbital anatomy.	Univ Fed Rio de Janeiro, Oculo Plast Surg Dept, Infirm Santa Casa Misericordia Rio de Janeiro 1, Infirm Santa Casa Misericordia Rio de Janeiro 38, BR-22440030 Rio De Janeiro, Brazil; Brazilian Soc Anesthesiol, Dept Anesthesiol, Rio De Janeiro, Brazil	Lessa, S (reprint author), Univ Fed Rio de Janeiro, Oculo Plast Surg Dept, Infirm Santa Casa Misericordia Rio de Janeiro 1, Infirm Santa Casa Misericordia Rio de Janeiro 38, Rua Ataulfo Paiva 135-1101, BR-22440030 Rio De Janeiro, Brazil.	s.lessa@alternex.com.br					ALEXANDER JP, 1975, BRIT J OPHTHALMOL, V59, P518, DOI 10.1136/bjo.59.9.518; Atkins CJ, 2004, B GEOL SOC DENMARK, V51, P1; BOSOMWORTH PP, 1958, ANESTHESIOLOGY, V91, P7; DAVIS DV, 1986, J CATARACT REFR SURG, V12, P182, DOI 10.1016/S0886-3350(86)80040-2; DAVIS PL, 1989, CAN J OPHTHALMOL, V24, P155; FREITAS ACH, 1997, REV BRAS ANESTESIOLO, V47, P134; HAY A, 1991, OPHTHALMOLOGY, V98, P1017; JOSEPH JP, 1991, BRIT J OPHTHALMOL, V75, P504, DOI 10.1136/bjo.75.8.504; KATSEV DA, 1989, OPHTHALMOLOGY, V96, P1221; KEZIRIAN GM, 1991, OPHTHALMIC SURG LAS, V22, P601; KIMBLE JA, 1987, ARCH OPHTHALMOL-CHIC, V105, P749; KIRCH RE, 1957, ARCH OPHTHALMOL-CHIC, V58, P348; LEMKE BN, 1987, OPHTHAL PLAST RECONS, P57; MOUNT AM, 1993, EYE, V7, P766, DOI 10.1038/eye.1993.179; NICOLL JMV, 1987, ANESTH ANALG, V66, P1298; SANDERS RJ, 1990, AM J OPHTHALMOL, V109, P705, DOI 10.1016/S0002-9394(14)72440-7; SZMYD SM, 1985, ARCH OPHTHALMOL-CHIC, V103, P809, DOI 10.1001/archopht.1985.01050060069028; UNSOLD R, 1981, A GRAEF ARCH KLIN EX, V217, P125, DOI 10.1007/BF00418987; WANG HS, 1988, J CATARACT REFR SURG, V14, P441, DOI 10.1016/S0886-3350(88)80156-1; WEISS JL, 1989, ARCH OPHTHALMOL-CHIC, V107, P96, DOI 10.1001/archopht.1989.01070010098035; WITTPENN JR, 1986, OPHTHALMOLOGY, V93, P867	21	2	2	0	0	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013 USA	0364-216X			AESTHET PLAST SURG	Aesthet. Plast. Surg.	OCT	2007	31	5					463	466		10.1007/s00266-006-0240-3			4	Surgery	Surgery	212EA	WOS:000249575200009	17674093				2020-06-30	J	Rickard, C; O'Meara, P; McGrail, M; Garner, D; McLean, A; Le Lievre, P				Rickard, Claire; O'Meara, Peter; McGrail, Matthew; Garner, David; McLean, Alan; Le Lievre, Peter			A randomized controlled trial of intranasal fentanyl vs intravenous morphine for analgesia in the prehospital setting	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article							POSTOPERATIVE PAIN MANAGEMENT; ORAL MORPHINE; TITRATION; CROSSOVER; MEDICINE; BURNS; CARE	Study Objective: The objective of the study was to compare intranasal fentanyl (INF) with intravenous morphine (IVM) for prehospital analgesia. Methods: This was a randomized, controlled, open-label trial. Consecutive adult patients (n = 258) requiring analgesia (Verbal Rating Score [VRS] >2/10 noncardiac or >5/10 cardiac) were recruited. Patients received INF 180 mu g +/- 2 doses of 60 mu g at >= 5-minute intervals or IVM 2.5 to 5 mg +/- 2 doses of 2.5 to 5 mg at >= 5-minute intervals. The end point was the difference in baseline/destination VRS. Results: Groups were equivalent (P = not significant) for baseline VRS [mean (SD): INF 8.3 (1.7), IVM 8.1 (1.6)] and minutes to destination [mean (SD): INF 27.2 (15.5), IVM 30.6 (19. 1)]. Patients had a mean (95% confidence interval) VRS reduction as follows: INF 4.22 (3.74-4.71), IVM 3.57 (3.104.03); P =.08. Higher baseline VRS (P <.001), no methoxyflurane use (P <.01), and back pain (P.02) predicted VRS reduction. Safety and acceptability were comparable. Conclusions: There was no significant difference in the effectiveness of TNF and IVM for prehospital analgesia. (C) 2007 Elsevier Inc. All rights reserved.	Griffith Univ, Res Ctr Practice Innovat, Nathan, Qld 4111, Australia; Charles Sturt Univ, Sch Publ Hlth, Bathurst, NSW 2795, Australia; Monash Univ, Sch Rural Hlth, Clayton, Vic 3800, Australia; Rural Ambulance Victoria, Clin & Educ Serv, Ballarat, Vic 3354, Australia; S Australia Ambulance Serv, Clin & Operat Serv, Eastwood, SA 5063, Australia; Workforce Regulat Sect, Dept Hlth & Aging, Canberra, ACT 2600, Australia	Rickard, C (reprint author), Griffith Univ, Res Ctr Practice Innovat, Nathan, Qld 4111, Australia.	rickard_claire@yahoo.com.au	Rickard, Claire M./C-3440-2008; McGrail, Matthew R/I-1738-2013	Rickard, Claire M./0000-0002-6341-7415; McGrail, Matthew R/0000-0002-6901-8845; O'Meara, Peter/0000-0001-8657-5646			Bijur PE, 2005, ANN EMERG MED, V46, P362, DOI 10.1016/j.annemergmed.2005.03.010; Bijur PE, 2003, ACAD EMERG MED, V10, P390, DOI 10.1111/j.1553-2712.2003.tb01355.x; BIMBAUM A, 2006, ANN EMERG MED   0913; Borland Meredith L, 2002, Emerg Med (Fremantle), V14, P77, DOI 10.1046/j.1442-2026.2002.00288.x; Borland Meredith L, 2002, Emerg Med (Fremantle), V14, P275, DOI 10.1046/j.1442-2026.2002.00344.x; Borland ML, 2005, BURNS, V31, P831, DOI 10.1016/j.burns.2005.05.001; Braude Darren, 2004, Prehosp Emerg Care, V8, P441, DOI 10.1016/j.prehos.2004.07.001; CHAMBERS JA, 1993, ARCH EMERG MED, V10, P187; DeVellis P, 1998, Prehosp Emerg Care, V2, P293, DOI 10.1080/10903129808958883; Devellis P, 1998, PEDIATR EMERG CARE, V14, P321; Finn J, 2004, BURNS, V30, P262, DOI 10.1016/j.burns.2003.10.017; Galinkin JL, 2000, ANESTHESIOLOGY, V93, P1378, DOI 10.1097/00000542-200012000-00006; Galinski M, 2005, AM J EMERG MED, V23, P114, DOI 10.1016/j.ajem.2004.03.010; Kanowitz A, 2006, PREHOSP EMERG CARE, V10, P1, DOI 10.1080/10903120500373264; Paech MJ, 2003, ANAESTHESIA, V58, P740, DOI 10.1046/j.1365-2044.2003.03286.x; Ricard-Hibon A, 1997, ANN FR ANESTH, V16, P945, DOI 10.1016/S0750-7658(97)82142-9; Ricard-Hibon A, 1999, ANN EMERG MED, V34, P738, DOI 10.1016/S0196-0644(99)70099-5; STRIEBEL HW, 1993, ANAESTHESIA, V48, P753, DOI 10.1111/j.1365-2044.1993.tb07583.x; Striebel HW, 1996, ANESTH ANALG, V83, P548, DOI 10.1097/00000539-199609000-00019; STRIEBEL HW, 1992, ANESTHESIOLOGY, V77, P281, DOI 10.1097/00000542-199208000-00010; Striebel HW, 1996, J CLIN ANESTH, V8, P4, DOI 10.1016/0952-8180(95)00167-0; Thomas SH, 2005, J EMERG MED, V29, P179, DOI 10.1016/j.jemermed.2005.02.007; Yealy DM, 1996, ANN EMERG MED, V27, P471, DOI 10.1016/S0196-0644(96)70235-4	23	67	67	0	7	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0735-6757			AM J EMERG MED	Am. J. Emerg. Med.	OCT	2007	25	8					911	917		10.1016/j.ajem.2007.02.027			7	Emergency Medicine	Emergency Medicine	222UL	WOS:000250322800008	17920976	Green Published			2020-06-30	J	Wieczorek, PM; Schricker, T; Vinet, B; Backman, SB				Wieczorek, P. M.; Schricker, T.; Vinet, B.; Backman, S. B.			Airway topicalisation in morbidly obese patients using atomised lidocaine: 2% compared with 4%	ANAESTHESIA			English	Article; Proceedings Paper	59th Annual Meeting of the Canadian-Anaesthesiologists-Society	JUN   23, 2003	Ottawa, CANADA	Canadian Anaesthesiol Soc			ENDOTRACHEAL INTUBATION; TRACHEAL INTUBATION; ANESTHESIA	We evaluated the technique of airway anaesthesia using atomised lidocaine for awake oral fibreoptic intubation in morbidly obese patients using two doses of local anaesthetic. Morbidly obese patients were allocated to receive either 2% or 4% lidocaine (40 ml) for oral airway anaesthesia using an atomiser with high oxygen flow. Patients were carefully sedated using midazolam and fentanyl. Outcomes included patient tolerance to airway manipulation, haemodynamic parameters, and serial plasma lidocaine concentrations. In all, 27 patients were enrolled in the study (2% cohort n = 14, 4% cohort n = 13). Patient characteristics and time for topicalisation and airway management were similar. Haemodynamic parameters did not change significantly. Tolerance to insertion of the Ovassapian airway, bronchoscopy, and tracheal tube positioning was excellent (12 vs 12 patients, 12 vs 12 patients, and 8 vs 12 patients had no response, respectively, 2% vs 4%). Differences did not reach statistical significance. Peak plasma lidocaine concentration was significantly lower in the 2% group (2.8 (0.8) mu g.ml(-1) compared with 6.5 (1.0) mu g.ml(-1), p < 0.05). Airway anaesthesia using atomised lidocaine for awake fibreoptic intubation in the morbidly obese is efficacious, rapid, and safe. Compared with 4% lidocaine, the 2% dose provides acceptable intubating conditions in most cases and produces lower plasma lidocaine levels.	McGill Univ, Ctr Hlth, Royal Victoria Hosp Site, Dept Anaesthesia, Montreal, PQ H3A 1A1, Canada; CHUM Notre Dame Hosp, Dept Biochem, Montreal, PQ H2L 4M1, Canada; Univ Montreal, Montreal, PQ H2L 4M1, Canada	Wieczorek, PM (reprint author), McGill Univ, Ctr Hlth, Royal Victoria Hosp Site, Dept Anaesthesia, 687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	paul.wieczorek@mail.mcgill.ca					BERTHOUD MC, 1991, BRIT J ANAESTH, V67, P464, DOI 10.1093/bja/67.4.464; Blouin RA, 1999, J PHARM SCI, V88, P1, DOI 10.1021/js980173a; BOURKE DL, 1985, ANESTHESIOLOGY, V63, P690, DOI 10.1097/00000542-198512000-00023; Brodsky JB, 2002, ANESTH ANALG, V94, P732, DOI 10.1097/00000539-200203000-00047; Ezri T, 2003, CAN J ANAESTH, V50, P179, DOI 10.1007/BF03017853; Juvin P, 2003, ANESTH ANALG, V97, P595, DOI 10.1213/01.ANE.0000072547.75928.B0; Kundra P, 2000, ACTA ANAESTH SCAND, V44, P511, DOI 10.1034/j.1399-6576.2000.00503.x; Kushner RF, 2003, ENDOCRIN METAB CLIN, V32, P915, DOI 10.1016/S0889-8529(03)00068-9; Loukides S, 2000, RESPIRATION, V67, P13, DOI 10.1159/000029456; Ogunnaike BO, 2002, ANESTH ANALG, V95, P1793, DOI 10.1097/00000539-200212000-00061; REASONER DK, 1995, J NEUROSURG ANESTH, V7, P94, DOI 10.1097/00008506-199504000-00004; SANCHEZ A, 1996, AIRWAY MANAGEMENT PR, P159; Simmons ST, 2002, REGION ANESTH PAIN M, V27, P180, DOI 10.1053/rapm.2002.30659; Siyam MA, 2002, ANESTH ANALG, V95, P1098, DOI 10.1097/00000539-200210000-00058; STOELTING RK, 1999, PHARM PHYSL ANESTHET, P158	15	27	29	1	6	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0003-2409			ANAESTHESIA	Anaesthesia	OCT	2007	62	10					984	988		10.1111/j.1365-2044.2007.05179.x			5	Anesthesiology	Anesthesiology	208LK	WOS:000249320600003	17845648				2020-06-30	J	Phadke, A; Broadman, LM; Brandom, BW; Ozolek, J; Davis, PJ				Phadke, Aparna; Broadman, Lynn M.; Brandom, Barbara W.; Ozolek, John; Davis, Peter J.			Postoperative hyperthermia, rhabdomyolysis, critical temperature, and death in a former premature infant after his ninth general anesthetic	ANESTHESIA AND ANALGESIA			English	Article							DUCHENNE MUSCULAR-DYSTROPHY; HYPERKALEMIC CARDIAC-ARREST; CHILDREN	An 8-mo-old infant born at 24-wk of gestation died unexpectedly 12 h after his ninth uneventful general anesthetic. Preoperatively, he required low-flow nasal oxygen due to bronchopulmonary dysplasia, chronic diuretic therapy, and IV alimentation. As planned preoperatively, the infant remained tracheally intubated after his elective surgery and went to the Neonatal Intensive Care Unit in stable condition. However, over the next 6 h, he developed fever. The diagnosis of postoperative sepsis was considered. One hour before his death his temperature reached 43 degrees C. Autopsy documented Duchenne's muscular dystrophy and renal tubules containing myoglobin.	Childrens Hosp Pittsburgh, Dept Anesthesiol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Childrens Hosp Pittsburgh, Dept Anesthesiol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Childrens Hosp Pittsburgh, Dept Pathol, Pittsburgh, PA 15213 USA	Broadman, LM (reprint author), Childrens Hosp Pittsburgh, Dept Anesthesiol, 3705 5th Ave, Pittsburgh, PA 15213 USA.	lbroadman@aol.com					Bouchama A, 2002, NEW ENGL J MED, V346, P1978, DOI 10.1056/NEJMra011089; GABOW PA, 1982, MEDICINE, V61, P141, DOI 10.1097/00005792-198205000-00002; Girshin M, 2006, PEDIATR ANESTH, V16, P170, DOI 10.1111/j.1460-9592.2005.01698.x; Larach MG, 1997, CLIN PEDIATR, V36, P9; Morris P, 1997, PAEDIATR ANAESTH, V7, P1, DOI 10.1046/j.1460-9592.1997.d01-41.x; Nathan A, 2005, ANESTH ANALG, V100, P672, DOI 10.1213/01.ANE.0000146533.21771.2F; PERLOFF JK, 1992, J CARDIOVASC ELECTR, V3, P394, DOI 10.1111/j.1540-8167.1992.tb00982.x; SAKAGUCHI Y, 1995, CANCER RES, V55, P5459; SETHNA NF, 1988, ANESTHESIOLOGY, V68, P462, DOI 10.1097/00000542-198803000-00028; Shukry M, 2006, PEDIATR ANESTH, V16, P462, DOI 10.1111/j.1460-9592.2005.01742.x; SINGHAL PC, 1990, NEW ENGL J MED, V323, P1488; Slater MS, 1998, J AM COLL SURGEONS, V186, P693, DOI 10.1016/S1072-7515(98)00089-1; TONIN P, 1990, ANN NEUROL, V27, P181, DOI 10.1002/ana.410270214; Warren JD, 2002, MUSCLE NERVE, V25, P332, DOI 10.1002/mus.10053; WILLIAMS SGJ, 1995, EUR J GASTROEN HEPAT, V7, P183; Yemen TA, 2006, PEDIATR ANESTH, V16, P105, DOI 10.1111/j.1460-9592.2005.01801.x	16	13	13	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	OCT	2007	105	4					977	980		10.1213/01.ane.0000280935.90260.d0			4	Anesthesiology	Anesthesiology	213PB	WOS:000249678500014	17898376				2020-06-30	J	Cheung, MY; Viney, M				Cheung, Man-Yiu; Viney, Melissa			A unique case of recurrent asystole secondary to paroxysmal pain of acute herpetic ophthalmicus	ANESTHESIA AND ANALGESIA			English	Article							POSTOPERATIVE ANALGESIA; MANAGEMENT	Postherpetic neuralgia is considered to be the most common and debilitating complication of acute herpes zoster and its incidence and duration of symptoms increase with age. We describe an unusual, but life-threatening complication of postherpetic neuralgia. The following case report is the first to describe a patient who developed unexpected asystolic episodes as a result of complicating pain secondary to acute herpetic ophthalmicus. The underlying pathogenesis of her cardiovascular disturbance coinciding with her painful paroxysms is unclear. This uncommon phenomenon may be explained by an exaggerated vasovagal response or even by the oculocardiac reflex rarely observed outside ocular or maxillofacial surgery. Her severe paroxysmal pain and asystole were eventually managed with oxycontin, amitriptyline, gabapentin, and intranasal fentanyl spray.	Geelong Hosp, Balwyn, Vic, Australia	Cheung, MY (reprint author), 7 Ian St, Balwyn, Vic 3103, Australia.	manyiucheung@yahoo.com					Dubinsky RM, 2004, NEUROLOGY, V63, P959, DOI 10.1212/01.WNL.0000140708.62856.72; Gnann JW, 2002, NEW ENGL J MED, V347, P340, DOI 10.1056/NEJMcp1302674; Grubb BP, 2005, NEW ENGL J MED, V352, P1004, DOI 10.1056/NEJMcp042601; LANG S, 1991, CAN J ANAESTH, V38, P757, DOI 10.1007/BF03008454; LOESER JD, 2001, BONICAS MANAGEMENT P, P1683; MANCHANDA L, 2005, AUST ANESTH, P135; Manjushree R, 2002, CAN J ANAESTH, V49, P190; Paech MJ, 2003, ANAESTHESIA, V58, P740, DOI 10.1046/j.1365-2044.2003.03286.x; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; Striebel H W, 1993, Schmerz, V7, P122, DOI 10.1007/BF02527870; STRIEBEL HW, 1993, ANAESTHESIA, V48, P753, DOI 10.1111/j.1365-2044.1993.tb07583.x; Toussaint S, 2000, CAN J ANAESTH, V47, P299, DOI 10.1007/BF03020941; Wood M, 2002, J INFECT DIS, V186, pS78, DOI 10.1086/342958	13	3	3	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	OCT	2007	105	4					1127	1129		10.1213/01.ane.0000280536.96489.95			3	Anesthesiology	Anesthesiology	213PB	WOS:000249678500036	17898398				2020-06-30	J	Hohlrieder, M; Tiefenthaler, W; Klaus, H; Gabl, M; Kavakebi, P; Keller, C; Benzer, A				Hohlrieder, M.; Tiefenthaler, W.; Klaus, H.; Gabl, M.; Kavakebi, P.; Keller, C.; Benzer, A.			Effect of total intravenous anaesthesia and balanced anaesthesia on the frequency of coughing during emergence from the anaesthesia	BRITISH JOURNAL OF ANAESTHESIA			English	Article						airway; complications; anaesthetic techniques; inhalation; anaesthetic techniques; i.v. infusion; cough	CLINICAL-PRACTICE GUIDELINES; TRACHEAL EXTUBATION; GENERAL-ANESTHESIA; ENDOTRACHEAL-TUBE; ISOFLURANE ANESTHESIA; INTRACUFF LIDOCAINE; LARYNGEAL MASK; AIRWAY; PROPOFOL; PRESSURE	Background. The effects of total intravenous anaesthesia (TIVA) and balanced anaesthesia (BAL) on coughing during emergence from the general anaesthesia have not yet been compared. Methods. Fifty patients, aged 18-60 yr, undergoing elective lumbar disk surgery were randomly allocated to undergo TIVA (propofol-remifentanil) or BAL (fentanyl- nitrous oxide-sevoflurane). Extubation was performed in the knee-elbow position, documented on video, and subsequently evaluated by blinded examiners. Results. There was no difference between TIVA and BAL patients with respect to patient characteristics, proportion of smokers, surgical time, or time of emergence. The median number of coughs was significantly lower in the TIVA group (1, range 0-9) than in the BAL group (4, range 0-20, P=0.007). Mean maximal heart rate and mean maximal arterial pressure measured during emergence were also significantly lower in the TIVA group (P=0.009 and P=0.006, respectively). Conclusions. During emergence from anaesthesia in the knee-elbow position, TIVA is associated with significantly less coughing and reduced haemodynamic response when compared with BAL.	Innsbruck Med Univ, Dept Anaesthesiol & Crit Care Med, A-6020 Innsbruck, Austria; Innsbruck Med Univ, Dept Neurosurg, A-6020 Innsbruck, Austria	Benzer, A (reprint author), Innsbruck Med Univ, Dept Anaesthesiol & Crit Care Med, Anichstr 35, A-6020 Innsbruck, Austria.	arnulf.benzer@uki.at					Andrzejowski J, 2002, ANAESTHESIA, V57, P399; Batra YK, 2005, PEDIATR ANESTH, V15, P1094, DOI 10.1111/j.1460-9592.2005.01633.x; BIDWAI AV, 1979, ANESTHESIOLOGY, V51, P171, DOI 10.1097/00000542-197908000-00020; Canning BJ, 2006, CHEST, V129, p33S, DOI 10.1378/chest.129.1_suppl.33S; Diachun CAB, 2001, J CLIN ANESTH, V13, P447, DOI 10.1016/S0952-8180(01)00299-9; DOI M, 1993, CAN J ANAESTH, V40, P122, DOI 10.1007/BF03011308; Estebe JP, 2002, ANESTH ANALG, V94, P227, DOI 10.1097/00000539-200201000-00044; Fagan C, 2000, ANESTH ANALG, V91, P201; GEFKE K, 1983, ACTA ANAESTH SCAND, V27, P111, DOI 10.1111/j.1399-6576.1983.tb01917.x; Guglielminotti J, 2005, BRIT J ANAESTH, V95, P406, DOI 10.1093/bja/aei175; Guler G, 2005, ACTA ANAESTH SCAND, V49, P1088, DOI 10.1111/j.1399-6576.2005.00780.x; Heck M, 2000, J CARDIOTHOR VASC AN, V14, P693, DOI 10.1053/jcan.2000.18447; HOLDEN R, 1991, ANAESTHESIA, V46, P922, DOI 10.1111/j.1365-2044.1991.tb09847.x; Irwin RS, 2006, CHEST, V129, p54S, DOI 10.1378/chest.129.1_suppl.54S; Kim FS, 1998, ANESTH ANALG, V87, P1170; Koga K, 1998, ANAESTHESIA, V53, P540, DOI 10.1046/j.1365-2044.1998.00397.x; LEECH P, 1974, BRIT J ANAESTH, V46, P315, DOI 10.1093/bja/46.4.315-a; MCKEATING K, 1988, ANAESTHESIA, V43, P638, DOI 10.1111/j.1365-2044.1988.tb04146.x; MENDEL P, 1995, J CLIN ANESTH, V7, P114, DOI 10.1016/0952-8180(94)00024-X; Minogue SC, 2004, ANESTH ANALG, V99, P1253, DOI 10.1213/01.ANE.0000132779.27085.52; NEELAKANTA G, 1994, ANESTHESIOLOGY, V80, P811, DOI 10.1097/00000542-199404000-00013; Olympio MA, 2000, ANESTHESIOLOGY, V93, P959, DOI 10.1097/00000542-200010000-00014; PHILBIN DM, 1990, ANESTHESIOLOGY, V73, P5, DOI 10.1097/00000542-199007000-00002; Saghaei Mahmood, 2005, Acta Anaesthesiol Taiwan, V43, P205; SANTAMBROGIO G, 1987, EUR PHYSIOPATHOL S10, V23, pS19; Shajar MA, 1999, BRIT J ANAESTH, V83, P654; Siedlecki J, 1974, Anaesth Resusc Intensive Ther, V2, P247; Sundman E, 2001, ANESTHESIOLOGY, V95, P1125, DOI 10.1097/00000542-200111000-00016; Tagaito Y, 1998, ANESTHESIOLOGY, V88, P1459, DOI 10.1097/00000542-199806000-00007; Widdicombe JG, 1998, RESP PHYSIOL, V114, P5, DOI 10.1016/S0034-5687(98)00076-0	30	46	49	0	6	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0007-0912	1471-6771		BRIT J ANAESTH	Br. J. Anaesth.	OCT	2007	99	4					587	591		10.1093/bja/aem203			5	Anesthesiology	Anesthesiology	221AL	WOS:000250198700023	17660457	Bronze			2020-06-30	J	Pena, LR; Mardini, H; Nickl, N				Pena, Luis R.; Mardini, Houssam; Nickl, Nicholas			An instrument to predict endoscopy tolerance: A prospective randomized study	DIGESTIVE DISEASES AND SCIENCES			English	Article						endoscopy; outcome; sedation; satisfaction	PATIENT SATISFACTION; SEDATION; PAIN	Our purpose in this study was to determine if the use of an instrument developed by our group to direct sedation choice improves patient satisfaction with endoscopy sedation compared to standard sedation practice. After 200 enrollments, data were available for 194 patients who completed the study. There were nine cases of dissatisfaction: five (5%) in the control group and four (4%) in the intervention group (P = 0.78). The 95% confidence intervals (1%-10%) were almost identical, indicating no difference between groups. The study was stopped after an interim analysis showed no significant difference in satisfaction between the groups. This could have been because the assumption that patients with increased risk of dissatisfaction do better with deeper sedation is incorrect. Another explanation could be the increased awareness of the value of benzodiazepines in endoscopy. Consistent with our findings, nervousness rather than pain predicted dissatisfaction, and the optimal use of anxiolytics with amnesic properties may be comparable to that of propofol.	Univ Kentucky, Albert B Chandler Med Ctr, Div Digest Dis & Nutr, Lexington, KY 40536 USA	Pena, LR (reprint author), Univ Kentucky, Albert B Chandler Med Ctr, Div Digest Dis & Nutr, 800 Rose St,Room MN-649, Lexington, KY 40536 USA.	Luis.pena@uky.edu					Ciriza C, 2001, REV ESP ENFERM DIG, V93, P593; EVERHART JE, 1994, NIH PUBLICATION, P3; Froehlich F, 1997, GASTROINTEST ENDOSC, V45, P1, DOI 10.1016/S0016-5107(97)70295-5; GREENLEY JR, 1982, MED CARE, V20, P373, DOI 10.1097/00005650-198204000-00003; LINDERPELZ S, 1982, SOC SCI MED, V16, P583, DOI 10.1016/0277-9536(82)90312-4; LINN LS, 1982, MED CARE, V20, P425, DOI 10.1097/00005650-198204000-00007; Morgan J, 1998, GASTROINTEST ENDOSC, V48, P119, DOI 10.1016/S0016-5107(98)70152-X; Pena LR, 2005, DIGEST DIS SCI, V50, P1860, DOI 10.1007/s10620-005-2952-7; Raymond JM, 1996, GASTROEN CLIN BIOL, V20, P570; SCHUTZ SM, 1994, AM J GASTROENTEROL, V89, P1476; WARE JE, 1998, [No title captured], V1; Waye JD, 1999, GASTROINTEST ENDOSC, V50, P889, DOI 10.1016/S0016-5107(99)70189-6; Yacavone RF, 2001, GASTROINTEST ENDOSC, V53, P703, DOI 10.1067/mge.2001.115337	13	3	3	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0163-2116	1573-2568		DIGEST DIS SCI	Dig. Dis. Sci.	OCT	2007	52	10					2888	2891		10.1007/s10620-007-9797-1			4	Gastroenterology & Hepatology	Gastroenterology & Hepatology	208DN	WOS:000249300100065	17394063				2020-06-30	J	Whitty, R; Goldsmidt, E; Parkes, RK; Carvalho, JCA				Whitty, R.; Goldsmidt, E.; Parkes, R. K.; Carvalho, J. C. A.			Determination of the ED95 for intrathecal plain bupivacaine combined with fentanyl in active labor	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Article; Proceedings Paper	Annual Meeting of the American-Society-of-Anesthesiologists	OCT 14-18, 2006	Chicago, IL	Amer Soc Anesthesiologists		labor; analgesia; combined spinal-epidural; bupivacaine; fentanyl; ED95; dose-finding study; fetal bradycardia	SPINAL-EPIDURAL ANALGESIA; SUFENTANIL; LEVOBUPIVACAINE; ROPIVACAINE; EFFICACY	Background: Combined spinal-epidural (CSE) analgesia is an effective technique for pain control in labor and is particularly useful in the active phase. Excessive doses of intrathecal bupivacaine may be associated with adverse effects. This study is designed to estimate the ED95 for intrathecal plain bupivacaine with fentanyl 15 mu g in labor. Methods: Forty healthy women in active labor (cervical dilatation >= 5 cm and verbal numeric pain score >= 6/10) were given CSE for labor analgesia with intrathecal plain bupivacaine and fentanyl 15 mu g. The initial dose of bupivacame was 1.75 mg. Doses were varied in a 0.25-mg testing interval according to a method of sequential allocation designed to cluster the dose around the ED95. Effectiveness was defined as a verbal numeric pain score <= 1 within 40 min of intrathecal injection. Results: There was a 100% response rate to the 1.75-mg dose (95% CI 84.6-100.0%) and an 85.0% response rate to 1.50 mg (95% CI 64.0-95.8%). The ED95 for intrathecal plain bupivacaine with fentanyl 15 mu g in active labor was 1.66 mg (95% CI 1.50-482.5 mg). The incidence of fetal bradycardia was 7.5%. The incidence of pruritus was 55%. No patient experienced motor block. Conclusions: This is the first dose-finding study specifically designed to estimate the ED95 of intrathecal bupivacaine combined with a fixed amount of fentanyl for analgesia in active labor. The combination of bupivacaine 1.75 mg with fentanyl 15 mu g rapidly and reliably alleviated pain in the active phase of labor. (c) 2007 Elsevier Ltd. All rights reserved.	Mt Sinai Hosp, Dept Anesthesia & Pain Management, Toronto, ON M5G 1X5, Canada	Goldsmidt, E (reprint author), Mt Sinai Hosp, Dept Anesthesia & Pain Management, 600 Univ Ave,Suite 1514, Toronto, ON M5G 1X5, Canada.	e.goldszmidt@utoronto.ca					Camorcia M, 2005, ANESTHESIOLOGY, V102, P646, DOI 10.1097/00000542-200503000-00025; CAMPBELL DC, 1995, ANESTH ANALG, V81, P305, DOI 10.1097/00000539-199508000-00017; Capogna G, 2003, ANESTH ANALG, V96, P1178, DOI 10.1213/01.ANE.0000054003.03645.CF; Chan GW, 2004, BIOL BLOOD MARROW TR, V10, P11, DOI 10.1016/j.bbmt.2003.12.034; COLLIS RE, 1995, LANCET, V345, P1413, DOI 10.1016/S0140-6736(95)92602-X; DIXON WJ, INTRO STAT ANAL, P428; Dresner M, 1999, BRIT J ANAESTH, V83, P756; FIRTH D, 1993, BIOMETRIKA, V80, P27, DOI 10.1093/biomet/80.1.27; Ivanova A, 2003, STAT MED, V22, P69, DOI 10.1002/sim.1336; Lee BB, 1999, BRIT J ANAESTH, V83, P868, DOI 10.1093/bja/83.6.868; Nielsen PE, 1996, ANESTH ANALG, V83, P742, DOI 10.1097/00000539-199610000-00014; Rawal N, 2000, Anesthesiol Clin North Am, V18, P267, DOI 10.1016/S0889-8537(05)70164-4; Rofaeel A, 2007, CAN J ANAESTH, V54, P15, DOI 10.1007/BF03021894; Stocks GM, 2001, ANESTHESIOLOGY, V94, P593, DOI 10.1097/00000542-200104000-00011; van de Velde M, 2007, ANESTHESIOLOGY, V106, P149, DOI 10.1097/00000542-200701000-00024; Van de Velde M, 2005, CURR OPIN ANESTHESIO, V18, P253, DOI 10.1097/01.aco.0000169230.53067.49; Vaughan DJA, 2001, BRIT J ANAESTH, V86, P567, DOI 10.1093/bja/86.4.567; Wong CA, 2004, INT J OBSTET ANESTH, V13, P19, DOI 10.1016/S0959-289X(03)00106-7	18	12	12	0	1	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0959-289X			INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	OCT	2007	16	4					341	345		10.1016/j.ijoa.2007.06.004			5	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	222GR	WOS:000250284800009	17697771				2020-06-30	J	Evans, L; Adekanye, O				Evans, L.; Adekanye, O.			Ultra-low dose combined spinal-epidural anaesthesia	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Letter							BUPIVACAINE		Univ Wales Hosp, Dept Anaesthesia, Cardiff, Wales	Adekanye, O (reprint author), Univ Wales Hosp, Dept Anaesthesia, Cardiff, Wales.	adekanyeo@Cardiff.ac.uk					Liu SS, 1996, ANESTHESIOLOGY, V85, P729, DOI 10.1097/00000542-199610000-00007; Russell IF, 2001, INT J OBSTET ANESTH, V10, P83, DOI 10.1054/ijoa.2000.0770; Teoh WHL, 2006, INT J OBSTET ANESTH, V15, P273, DOI 10.1016/j.ijoa.2006.03.004	3	2	2	0	0	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0959-289X			INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	OCT	2007	16	4					387	388		10.1016/j.ijoa.2007.05.005			2	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	222GR	WOS:000250284800024	17693075				2020-06-30	J	Peer, CJ; Shakleya, DM; Younis, IR; Kraner, JC; Callery, PS				Peer, Cody J.; Shakleya, Diaa M.; Younis, Islam R.; Kraner, James C.; Callery, Patrick S.			Direct-injection mass spectrometric method for the rapid identification of fentanyl and norfentanyl in postmortem urine of six drug-overdose cases	JOURNAL OF ANALYTICAL TOXICOLOGY			English	Article							HUMAN PLASMA; ELECTROSPRAY-IONIZATION; QUANTITATIVE-DETERMINATION; TRANSDERMAL DELIVERY; LIVER-TISSUE; LC-MS/MS; METABOLITES; SUPPRESSION; SUFENTANIL; EXTRACTION		W Virginia Univ, Dept Basic Pharmaceut Sci, Morgantown, WV 26506 USA; Natl Inst Drug Abuse, Intramural Res Program, Baltimore, MD 21224 USA; Off Chief Med Examiner, Charleston, WV 25302 USA	Callery, PS (reprint author), W Virginia Univ, Dept Basic Pharmaceut Sci, PO Box 9530, Morgantown, WV 26506 USA.	pcallery@hsc.wvu.edu					Coopman V, 2007, FORENSIC SCI INT, V169, P223, DOI 10.1016/j.forsciint.2006.03.018; Day J, 2003, J ANAL TOXICOL, V27, P513, DOI 10.1093/jat/27.7.513; GOROMARU T, 1984, ANESTHESIOLOGY, V61, P73, DOI 10.1097/00000542-198461010-00013; Gunnar T, 2005, J MASS SPECTROM, V40, P739, DOI 10.1002/jms.846; Hunter RP, 2003, J CHROMATOGR B, V793, P351, DOI 10.1016/S1570-0232(03)00351-9; Huynh NH, 2005, J PHARMACEUT BIOMED, V37, P1095, DOI 10.1016/j.jpba.2004.09.024; Kebarle P, 2000, J MASS SPECTROM, V35, P804, DOI 10.1002/1096-9888(200007)35:7<804::AID-JMS22>3.0.CO;2-Q; King R, 2000, J AM SOC MASS SPECTR, V11, P942, DOI 10.1016/S1044-0305(00)00163-X; Koch DE, 2004, J PHARMACEUT BIOMED, V34, P577, DOI 10.1016/S0731-7085(03)00652-6; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; Liang HR, 2003, RAPID COMMUN MASS SP, V17, P2815, DOI 10.1002/rcm.1268; Lilleng PK, 2004, J FORENSIC SCI, V49, P1364; LIN SN, 1981, J PHARM SCI, V70, P1276, DOI 10.1002/jps.2600701124; Marier JF, 2006, J CLIN PHARMACOL, V46, P642, DOI 10.1177/0091270006286901; Martens-Lobenhoffer J, 2002, J CHROMATOGR B, V769, P227, DOI 10.1016/S1570-0232(01)00569-4; Musshoff F, 2006, J MASS SPECTROM, V41, P633, DOI 10.1002/jms.1021; Palleschi L, 2003, J PHARMACEUT BIOMED, V32, P329, DOI 10.1016/S0731-7085(03)00110-9; Pihlainen K, 2005, J MASS SPECTROM, V40, P539, DOI 10.1002/jms.831; Poklis A, 2004, J ANAL TOXICOL, V28, P422, DOI 10.1093/jat/28.6.422; Roy SD, 1996, J PHARM SCI, V85, P491, DOI 10.1021/js950415w; Shakleya DM, 2006, FORENSIC SCI INT, V157, P87, DOI 10.1016/j.forsciint.2005.04.012; Shakleya DM, 2005, J ANAL TOXICOL, V29, P715, DOI 10.1093/jat/29.7.715; Shou WZ, 2001, RAPID COMMUN MASS SP, V15, P466, DOI 10.1002/rcm.255; SILVERSTEIN JH, 1993, ANESTH ANALG, V76, P618; *SOC FOR TOX DRUG, 2005, REC MAX DET LIM COMM; Sojo LE, 2003, ANALYST, V128, P51, DOI 10.1039/b209521c; Solassol I, 2005, THER DRUG MONIT, V27, P491, DOI 10.1097/01.ftd.0000160717.50704.42; Thevis M, 2005, EUR J MASS SPECTROM, V11, P419, DOI 10.1255/ejms.761; Van Nimmen NFJ, 2004, J CHROMATOGR B, V804, P375, DOI 10.1016/j.jchromb.2004.01.044; WATTS VW, 1990, J ANAL TOXICOL, V14, P266, DOI 10.1093/jat/14.5.266; Weng ND, 2002, J PHARMACEUT BIOMED, V28, P1115, DOI 10.1016/S0731-7085(02)00002-X	31	12	13	1	9	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-4760	1945-2403		J ANAL TOXICOL	J. Anal. Toxicol.	OCT	2007	31	8					515	521		10.1093/jat/31.8.515			7	Chemistry, Analytical; Toxicology	Chemistry; Toxicology	222SX	WOS:000250318600012	17988466	Bronze			2020-06-30	J	Chang, YW; Yao, HT; Chao, YS; Yeh, TK				Chang, Yi-Wei; Yao, Hsien-Tsung; Chao, Yu-Sheng; Yeh, Teng-Kuang			Rapid and sensitive determination of fentanyl in dog plasma by on-line solid-phase extraction integrated with a hydrophilic column coupled to tandem mass spectrometry	JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES			English	Article						fentanyl; on-line SPE; HILIC; LC/MS/MS; bioanalysis; pharmacokinetics	PERFORMANCE LIQUID-CHROMATOGRAPHY; ULTRAVIOLET DETECTION; RADIORECEPTOR ASSAY; GAS-CHROMATOGRAPHY; RECEPTOR ASSAY; CANCER PAIN; PHARMACOKINETICS; ALFENTANIL; URINE; TOLERABILITY	We have developed and validated a method for the quantification of fentanyl, a synthetic opioid, in dog plasma by on-line SPE with a hydrophilic column coupled to tandem mass spectrometry in positive electrospray mode. A column-switching instrument with 10-port valve and two HPLC pumping systems were employed. Deuterated fentanyl served as the internal standard. A Waters Oasis HLB extraction column and a Waters Atlantis HILIC Silica analytical column in a column-switching set-up with gradient elution were utilized. Both fentanyl (analyte) and the internal standard (fentanyl-d5) were determined via multiple reaction monitoring (MRM) and the MS/MS ion transitions monitored were m/z 337.0/188.0 and 342.0/188.0, respectively. Each plasma sample was chromatographed within 5 min. The calibration curves were linear over a widely range of 0.01-50 ng/mL using weighted linear regression analysis (1/x). The low limit of quantitation was 0.01 ng/mL. The intra- and inter-day accuracy ranged from 102 to 112% and the overall precision was less than 3%. The recoveries ranged from 90 to 105% in plasma at the concentrations of 0.04, 0.4, 4 and 40 ng/mL. No influence of freeze/thaw and long-term stability were observed. This validated method has been successfully applied to analyze the dog plasma samples of a pharmacokinetics study. (c) 2007 Elsevier B.V. All rights reserved.	Natl Hlth Res Inst, Div Biotechnol & Pharmaceut Res, Zhunan Town, Miaoli County, Taiwan	Yeh, TK (reprint author), Natl Hlth Res Inst, Div Biotechnol & Pharmaceut Res, 35 Keyan Rd, Zhunan Town, Miaoli County, Taiwan.	tkyeh@nhri.org.tw	Chao, Yu-Sheng/D-2074-2010				ALBURGES ME, 1991, J ANAL TOXICOL, V15, P311, DOI 10.1093/jat/15.6.311; ALBURGES ME, 1992, J ANAL TOXICOL, V16, P36, DOI 10.1093/jat/16.1.36; BJORKMAN S, 1993, J PHARMACOKINET BIOP, V21, P255, DOI 10.1007/BF01059779; Day J, 2003, J ANAL TOXICOL, V27, P513, DOI 10.1093/jat/27.7.513; Deng YZ, 2005, RAPID COMMUN MASS SP, V19, P2929, DOI 10.1002/rcm.2144; HENDERSON GL, 1990, J ANAL TOXICOL, V14, P172, DOI 10.1093/jat/14.3.172; Kagan M, 2004, J CHROMATOGR A, V1033, P321, DOI 10.1016/j.chroma.2004.01.042; Kharasch ED, 2004, ANESTHESIOLOGY, V101, P729, DOI 10.1097/00000542-200409000-00022; KUMAR K, 1987, J CHROMATOGR-BIOMED, V419, P464, DOI 10.1016/0378-4347(87)80317-1; Lennernas B, 2005, BRIT J CLIN PHARMACO, V59, P249, DOI 10.1111/j.1365-2125.2004.02264.x; Lin ZL, 1998, INT J CONTROL, V70, P1, DOI 10.1080/002071798222433; Marier JF, 2006, J CLIN PHARMACOL, V46, P642, DOI 10.1177/0091270006286901; Ohta H, 1999, J ANAL TOXICOL, V23, P280, DOI 10.1093/jat/23.4.280; Paradis C, 2002, THER DRUG MONIT, V24, P768, DOI 10.1097/00007691-200212000-00014; PORTENOY RK, 1993, ANESTHESIOLOGY, V78, P36, DOI 10.1097/00000542-199301000-00007; Portier EJG, 1999, J CHROMATOGR B, V723, P313, DOI 10.1016/S0378-4347(98)00518-0; Shou WZ, 2001, RAPID COMMUN MASS SP, V15, P466, DOI 10.1002/rcm.255; Solassol I, 2005, THER DRUG MONIT, V27, P491, DOI 10.1097/01.ftd.0000160717.50704.42; Thevis M, 2005, EUR J MASS SPECTROM, V11, P419, DOI 10.1255/ejms.761; WATTS V, 1988, J ANAL TOXICOL, V12, P246, DOI 10.1093/jat/12.5.246; Weng ND, 2004, BIOMED CHROMATOGR, V18, P28, DOI 10.1002/bmc.288; Weng ND, 2002, J PHARMACEUT BIOMED, V28, P1115, DOI 10.1016/S0731-7085(02)00002-X; Yan KX, 2004, J CHROMATOGR B, V813, P95, DOI 10.1016/j.jchromb.2004.09.016	23	23	24	0	7	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1570-0232	1873-376X		J CHROMATOGR B	J. Chromatogr. B	OCT 1	2007	857	2					195	201		10.1016/j.jchromb.2007.07.014			7	Biochemical Research Methods; Chemistry, Analytical	Biochemistry & Molecular Biology; Chemistry	221EZ	WOS:000250211500003	17656164				2020-06-30	J	Davis, MP; Shaiova, LA; Angst, MS				Davis, Mellar P.; Shaiova, Lauren A.; Angst, Martin S.			When Opioids cause pain	JOURNAL OF CLINICAL ONCOLOGY			English	Editorial Material							ANTINOCICEPTIVE TOLERANCE; INDUCED HYPERALGESIA; MORPHINE; REMIFENTANIL; WITHDRAWAL; RESPONSES; EXPOSURE; HUMANS		Cleveland Clin Hlth Syst, Harry R Horvitz Ctr Palliat Med, Cleveland, OH USA; Mem Sloan Kettering Canc Ctr, Dept Neurol, New York, NY 10021 USA; Stanford Univ, Sch Med, Dept Anesthesia, Stanford, CA USA	Davis, MP (reprint author), Cleveland Clin Fdn, 9500 Euclid Ave,R35, Cleveland, OH 44195 USA.	davism6@ccf.org					Angst MS, 2006, ANESTHESIOLOGY, V104, P570, DOI 10.1097/00000542-200603000-00025; Angst MS, 2003, PAIN, V106, P49, DOI 10.1016/S0304-3959(03)00276-8; Chu LF, 2006, J PAIN, V7, P43, DOI 10.1016/j.jpain.2005.08.001; Compton P, 2003, J PAIN, V4, P511, DOI 10.1016/j.jpain.2003.08.003; Compton P, 2000, J PAIN SYMPTOM MANAG, V20, P237, DOI 10.1016/S0885-3924(00)00191-3; Gardell LR, 2002, J NEUROSCI, V22, P6747; Guignard B, 2000, ANESTHESIOLOGY, V93, P409, DOI 10.1097/00000542-200008000-00019; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; Hara N, 1997, BRIT J PHARMACOL, V121, P401, DOI 10.1038/sj.bjp.0701146; King T, 2005, NEUROSIGNALS, V14, P194, DOI 10.1159/000087658; MAO J, 1994, C J NEUROSCI, V14, P2301; Mayer DJ, 1999, P NATL ACAD SCI USA, V96, P7731, DOI 10.1073/pnas.96.14.7731; WERZ MA, 1982, BRAIN RES, V236, P107, DOI 10.1016/0006-8993(82)90038-5; Xie JY, 2005, J NEUROSCI, V25, P409, DOI 10.1523/JNEUROSCI.4054-04.2005	14	25	28	0	1	AMER SOC CLINICAL ONCOLOGY	ALEXANDRIA	330 JOHN CARLYLE ST, STE 300, ALEXANDRIA, VA 22314 USA	0732-183X			J CLIN ONCOL	J. Clin. Oncol.	OCT 1	2007	25	28					4497	4498		10.1200/JCO.2006.09.1462			2	Oncology	Oncology	233EN	WOS:000251073300028	17906213				2020-06-30	J	Magni, G; La Rosa, I; Gimignani, S; Melillo, G; Imperiale, C; Rosa, G				Magni, Giuseppina; La Rosa, Italia; Gimignani, Simona; Melillo, Guido; Imperiale, Carmela; Rosa, Giovanni			Early postoperative complications after intracranial surgery - Comparison between total intravenous and balanced anesthesia	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						remifentanil; propofol; neuroanesthesia; neurosurgery; sevolurane	POSTANESTHESIA CARE UNIT; NEUROSURGICAL PROCEDURES; COGNITIVE FUNCTION; PAIN RELIEF; CRANIOTOMY; PROPOFOL; RECOVERY; REMIFENTANIL; FENTANYL; AUDIT	This prospective study was performed to compare the incidence of complications occurring after neurosurgical procedures in patients anesthetized with either sevoflurane-fentanyl or propofol-remifentanil anesthesia. We enrolled 162 American Society of Anesthesiologists (ASA) I to III patients (82 females and 80 males, Glasgow 15) undergoing elective neurosurgical procedures. Anesthesia was conducted using either propofol-remifentanil (T group; n = 80 patients) or sevoflurane-fentanyl (S group; n = 82 patients). All patients were monitored in the postanesthesia care unit for 6 hours after extubation. We analyzed and compared in both groups the incidence of high severity complications such as respiratory events (PaO2 < 90 mm Hg; PaCO2 > 45 mm Hg) and neurologic events (seizures, new motor or sensory deficit, unexpected delay of awakening) and the incidence of low severity complications such as hypertension (mean arterial pressure increase above 30% of baseline), hypotension (mean arterial pressure decrease below 30% of baseline), pain, shivering, nausea, and vomiting. A total of 162 complications occurred in 92 patients (57%) with 50 patients (31%) having had 1, 26 patients (16%) having had 2, and 16 patients (10%) having had 3 or more events. The most frequent complication was respiratory impairment (28%) which was frequently reported only in the first postoperative hour. Out of the total number of complicating events, 77 (48%) were found in group S, and 85 (52%) in group T (P = ns). Severe complications were rarely reported and evenly distributed in the 2 anesthetic groups. Similarly, no difference could be demonstrated in the composite incidence of less serious complications between the 2 anesthetic regimens tested in this study. This study confirms that the recovery period after neurosurgical procedures remains a time of great potential danger to patients given the high incidence of postoperative complicating events independently from the anesthetic strategy.	Univ Roma La Sapienza, Policlin Umberto I, Dept Anaesthesia & Intens Care, I-00100 Rome, Italy; IRCCS, Ist Dermopat Immacolata, Rome, Italy	Magni, G (reprint author), Univ Roma La Sapienza, Policlin Umberto I, Dept Anaesthesia & Intens Care, Viale Policlin 155, I-00100 Rome, Italy.	gmagni@yahoo.com	Melillo, Guido/K-6341-2016	Melillo, Guido/0000-0002-2379-9471			Basali A, 2000, ANESTHESIOLOGY, V93, P48, DOI 10.1097/00000542-200007000-00012; Bloomfield EL, 1998, ANESTH ANALG, V87, P579, DOI 10.1097/00000539-199809000-00015; Brian JE, 1998, ANESTHESIOLOGY, V88, P1365, DOI 10.1097/00000542-199805000-00029; Bruder N, 2002, ANESTH ANALG, V94, P650, DOI 10.1097/00000539-200203000-00031; Bruder N, 1999, ANESTH ANALG, V89, P674, DOI 10.1097/00000539-199909000-00027; Cashman JN, 2004, BRIT J ANAESTH, V93, P212, DOI 10.1093/bja/aeh180; CHENG C, 1995, ANESTHESIOLOGY, V82, P1160, DOI 10.1097/00000542-199505000-00011; DeBenedittis G, 1996, NEUROSURGERY, V38, P466, DOI 10.1227/00006123-199603000-00008; Dunbar PJ, 1999, ANESTH ANALG, V88, P335, DOI 10.1097/00000539-199902000-00021; Feld JM, 2003, CAN J ANAESTH, V50, P336, DOI 10.1007/BF03021029; Forrest JB, 2002, BRIT J ANAESTH, V88, P227, DOI 10.1093/bja/88.2.227; Himmelseher S, 2001, Curr Opin Anaesthesiol, V14, P483, DOI 10.1097/00001503-200110000-00004; Kathirvel S, 2001, J NEUROSURG ANESTH, V13, P207, DOI 10.1097/00008506-200107000-00005; KEHLET H, 1995, EUR J ANAESTH, V12, P31; Larsen B, 2000, ANESTH ANALG, V90, P168, DOI 10.1097/00000539-200001000-00035; Magni G, 2005, J NEUROSURG ANESTH, V17, P134, DOI 10.1097/01.ana.0000167447.33969.16; Manninen PH, 1999, CAN J ANAESTH, V46, P7, DOI 10.1007/BF03012507; Ozkose Z, 2001, J NEUROSURG ANESTH, V13, P296, DOI 10.1097/00008506-200110000-00003; Quiney N, 1996, BRIT J NEUROSURG, V10, P295, DOI 10.1080/02688699650040179; Roberts F L, 1988, Anaesthesia, V43 Suppl, P14, DOI 10.1111/j.1365-2044.1988.tb09061.x; ROSA G, 1995, ACTA ANAESTH SCAND, V39, P90, DOI 10.1111/j.1399-6576.1995.tb05598.x; ROSE DK, 1994, ANESTHESIOLOGY, V81, P410, DOI 10.1097/00000542-199408000-00020; Rosenberg J, 1999, ANAESTHESIA, V54, P323, DOI 10.1046/j.1365-2044.1999.00744.x; RUSSELL GB, 1993, CHEST, V104, P899, DOI 10.1378/chest.104.3.899; Sneyd JR, 2005, BRIT J ANAESTH, V94, P778, DOI 10.1093/bja/aei141; Talke P, 2002, ANESTH ANALG, V95, P430, DOI 10.1097/00000539-200208000-00036; THOMEE R, 1995, SCAND J REHABIL MED, V27, P145; TODD MM, 1993, ANESTHESIOLOGY, V78, P1005, DOI 10.1097/00000542-199306000-00002; Tsui SL, 1997, ANAESTHESIA, V52, P1042, DOI 10.1111/j.1365-2044.1997.232-az0371.x; Wolters U, 1996, BRIT J ANAESTH, V77, P217, DOI 10.1093/bja/77.2.217; Wong AYC, 2006, EUR J ANAESTH, V23, P586, DOI 10.1017/S0265021506000214	31	25	33	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0898-4921	1537-1921		J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	OCT	2007	19	4					229	234		10.1097/ANA.0b013e31806e5f5a			6	Anesthesiology; Clinical Neurology; Surgery	Anesthesiology; Neurosciences & Neurology; Surgery	213ZL	WOS:000249705700003	17893573				2020-06-30	J	Schmittner, MD; Vajkoczy, SL; Horn, P; Bertsch, T; Ouintel, M; Vajkoczy, P; Muench, E				Schmittner, Marc D.; Vajkoczy, Susanne L.; Horn, Peter; Bertsch, Thomas; Ouintel, Michael; Vajkoczy, Peter; Muench, Elke			Effects of fentanyl and S(+)-ketamine on cerebral hemodynamics, gastrointestinal motility, and need of vasopressors in patients with intracranial pathologies - A pilot study	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						intracranial pressure; ketamine; fentanyl; bispectral index; gastrointestinal motility	BISPECTRAL INDEX; BLOOD-FLOW; KETAMINE ANESTHESIA; DRUG ABSORPTION; PRESSURE; SEDATION; PHARMACOLOGY; INHIBITION; SUFENTANIL; ALFENTANIL	In neurosurgical patients, opioids are administered to prevent secondary cerebral damage. Complications often related to the administration of opioids are a decrease in blood pressure affording the use of vasopressors and intestinal atonia. One alternative approach to opioids is the application of S(+)ketamine. However, owing to a suspected elevation of intracranial pressure (ICP), the administration of S(+)-ketamine has questioned for a long time. The aim of the present study was to evaluate ICP, gastrointestinal motility, and catecholamine consumption in neurosurgical patients undergoing 2 different protocols of anesthesia using fentanyl or S(+)-ketamine. Twenty-four patients sustaining traumatic brain injury or aneurysmal subarachnoid hemorrhage received methohexitone plus either fentanyl or S(+)-ketamine to establish a comparable level of sedation. To reach an adequate cerebral perfusion pressure (CPP), the norepinephrine dosage was adapted successively. Enteral nutrition and gastrointestinal stimulation were started directly after admission on the critical care unit. ICP, CPP, and norepinephrine dosage were recorded over 5 days and also the time intervals to full enteral nutrition and first defecation. There was no difference regarding ICP, CPP, and the time period until full enteral nutrition or first defecation between both groups. Patients who underwent analgesia with S(+)ketamine showed a trend to a lower demand of norepinephrine compared with the fentanyl group. Our results indicate that S(+)-ketamine does not increase ICP and that its use in neurosurgical patients should not be discouraged on the basis of ICP-related concerns.	Heidelberg Univ, Univ Hosp Mannheim, Dept Anesthesiol & Crit Care Med, D-6900 Heidelberg, Germany; Heidelberg Univ, Univ Hosp Mannheim, Dept Neurosurg, D-6900 Heidelberg, Germany; Univ Gottingen, Dept Anesthesiol & Crit Care Med, D-3400 Gottingen, Germany	Muench, E (reprint author), Heidelberg Univ, Fac Med Mannheim, Dept Anesthesiol & Crit Care Med, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.	elke.muench@t-online.de					Adams HA, 1997, ANAESTHESIST, V46, P1081, DOI 10.1007/s001010050510; Adams HA, 2001, ANASTH INTENSIV NOTF, V36, P417, DOI 10.1055/s-2001-15435; Albanese J, 1999, CRIT CARE MED, V27, P407, DOI 10.1097/00003246-199902000-00050; Banki N, 2006, J NEUROSURG, V105, P15, DOI 10.3171/jns.2006.105.1.15; BENNETT MWR, 1994, ANAESTHESIA, V49, P155, DOI 10.1111/j.1365-2044.1994.tb03376.x; Botero CA, 2000, J CARDIOTHOR VASC AN, V14, P409, DOI 10.1053/jcan.2000.7933; Bourgoin A, 2005, CRIT CARE MED, V33, P1109, DOI 10.1097/01.CCM.0000162491.26292.98; Bourgoin A, 2003, CRIT CARE MED, V31, P711, DOI 10.1097/01.CCM.0000044505.24727.16; *BRAIN TRAUM FDN, 2003, UPD NOT GUID MAN SEV; CHI OZ, 1994, ANESTH ANALG, V79, P860; Christ G, 1997, ANAESTH INTENS CARE, V25, P255, DOI 10.1177/0310057X9702500308; Citerio G, 2001, CRIT CARE MED, V29, P1466, DOI 10.1097/00003246-200107000-00027; De Schepper HU, 2004, NEUROGASTROENT MOTIL, V16, P383, DOI 10.1111/j.1365-2982.2004.00513.x; Deeren DH, 2005, INTENS CARE MED, V31, P1577, DOI 10.1007/s00134-005-2802-2; DeLuca A, 1996, PHARMACOL THERAPEUT, V69, P103, DOI 10.1016/0163-7258(95)02053-5; DOMINO EF, 1965, CLIN PHARMACOL THER, V6, P279; FREYE E, 1994, ANAESTHESIST, V43, P87, DOI 10.1007/s001010050036; FRIESEN R, 1987, ANESTH ANALG, V66, P431, DOI 10.1213/00000539-198705000-00011; GARDNER AE, 1972, ANESTH ANAL CURR RES, V51, P741; GOODING JM, 1977, ANESTH ANALG, V56, P813; Hans P, 2005, BRIT J ANAESTH, V94, P336, DOI 10.1093/bja/aei047; JENNETT B, 1975, LANCET, V1, P480; Kolbel CB, 2000, INTENS CARE MED, V26, P1421, DOI 10.1007/s001340000630; Kolenda H, 1996, ACTA NEUROCHIR, V138, P1193, DOI 10.1007/BF01809750; Langsjo JW, 2003, ANESTHESIOLOGY, V99, P614, DOI 10.1097/00000542-200309000-00016; MAYBERG TS, 1993, ANESTHESIOLOGY, V79, pA204; Mayer SA, 1999, STROKE, V30, P780, DOI 10.1161/01.STR.30.4.780; MCARTHUR CJ, 1995, INTENS CARE MED, V21, P573, DOI 10.1007/BF01700162; McDermott NB, 2003, ANESTH ANALG, V97, P39, DOI 10.1213/01.ANE.0000067402.02136.A2; NIMMO WS, 1975, BRIT J CLIN PHARMACO, V2, P509, DOI 10.1111/j.1365-2125.1975.tb00568.x; NIMMO WS, 1984, BRIT J ANAESTH, V56, P29, DOI 10.1093/bja/56.1.29; PAPAZIAN L, 1993, BRIT J ANAESTH, V71, P267, DOI 10.1093/bja/71.2.267; PFENNINGER E, 1985, ACTA NEUROCHIR, V78, P113, DOI 10.1007/BF01808689; Proescholdt M, 2001, BRAIN RES, V904, P245, DOI 10.1016/S0006-8993(01)02465-9; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; Reeker W, 2000, CAN J ANAESTH, V47, P572, DOI 10.1007/BF03018950; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; SCHWEDLER M, 1982, CAN ANAESTH SOC J, V29, P222, DOI 10.1007/BF03007120; SHAPIRA Y, 1994, STROKE, V25, P1637, DOI 10.1161/01.STR.25.8.1637; SHAPIRO HM, 1972, BRIT J ANAESTH, V44, P1200, DOI 10.1093/bja/44.11.1200; TAKESHITA H, 1972, ANESTHESIOLOGY, V36, P69, DOI 10.1097/00000542-197201000-00013; The Brain Trauma Foundation The American Association of Neurological Surgeons The Joint Section on Neurotrauma and Critical Care, 2000, J NEUROTRAUM, V17, P537; TODD JG, 1983, BRIT J ANAESTH, V55, P1189, DOI 10.1093/bja/55.12.1189; Vereecke HEM, 2003, ANAESTHESIA, V58, P957, DOI 10.1046/j.1365-2044.2003.03403.x; Vincent JL, 2005, CRIT CARE MED, V33, P1392, DOI 10.1097/01.CCM.0000166890.93559.2D; WHITE PF, 1982, ANESTHESIOLOGY, V56, P119, DOI 10.1097/00000542-198202000-00007	46	41	45	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0898-4921	1537-1921		J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	OCT	2007	19	4					257	262		10.1097/ANA.0b013e31811f3feb			6	Anesthesiology; Clinical Neurology; Surgery	Anesthesiology; Neurosciences & Neurology; Surgery	213ZL	WOS:000249705700008	17893578				2020-06-30	J	Curtis, KM; Henriques, HF; Fanciullo, G; Reynolds, CM; Suber, F				Curtis, Kevin M.; Henriques, Horace F.; Fanciullo, Gilbert; Reynolds, Cecily M.; Suber, Freeman			A fentanyl-based pain management protocol provides early analgesia for adult trauma patients	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						trauma; analgesia protocol; fentanyl; pain management	EMERGENCY-MEDICINE	Background: In the past two decades, a number of reports have identified inadequate treatment of pain among emergency department patients. No study has evaluated the frequency or effectiveness of early analgesia in the trauma patient. The objective of this study was to determine the effect of a protocol-driven pain management scheme on time to initiation of analgesia among trauma patients. Methods: A fentanyl-based protocol was developed with patients being assigned to one of three treatment arms based on hemodynamics and Glasgow Coma Scale (GCS) score. Using an institutional review board-approved before and after study design, patients over the age of 14 and meeting trauma system activation criteria at the Dartmouth-Hitchcock Medical Center were eligible. Results were compared with a retrospective chart review of eligible patients treated during a matched preprotocol time period in 2002. The primary outcome measure was time to initiation of analgesia. Secondary outcome measures included (1) the proportion of patients receiving their first analgesia dose within 30 minutes, (2) the number of patients receiving multiple doses of analgesia in the trauma bay, and (3) adverse events. Pain level was assessed using either a Numeric Pain Scale (for patients with a GCS score of 15) or a Behavioral Pain Assessment Scale (GCS score < 15). Results: Implementation of the protocol resulted in a decrease in the mean time to initiation of analgesia from 53.61 minutes +/- 6.88 minutes to 27.94 minutes +/- 3.34 minutes (p = 0.001). The protocol also increased the percentage of patients receiving analgesia within the first 30 minutes of arrival from 44.4% to 74.6% (p < 0.001). There were no differences between the two groups in terms of baseline characteristics or adverse events. Conclusions: The implementation of a fentanyl-based pain management protocol resulted in a marked reduction in time to initial analgesia among trauma patients. There was no evidence of an increase in adverse events. This tool has the potential to be easily extrapolated and applied to other trauma systems.	Dartmouth Coll, Hitchcock Med Ctr, Dept Emergency Med, Lebanon, NH 03756 USA; Dartmouth Coll, Hitchcock Med Ctr, Dept Surg, Lebanon, NH 03756 USA; Dartmouth Coll, Hitchcock Med Ctr, Dept Anesthesia, Lebanon, NH 03756 USA; Highland Gen Hosp, Highland Hosp, Dept Emergency Med, Oakland, CA USA	Curtis, KM (reprint author), Dartmouth Coll, Hitchcock Med Ctr, Dept Emergency Med, 1 Med Ctr Dr, Lebanon, NH 03756 USA.	Kevin.m.curtis@hitchcock.org					Alpen M A, 2001, Crit Care Nurs Clin North Am, V13, P243; Ballantyne JC, 1998, ANESTH ANALG, V86, P598, DOI 10.1097/00000539-199803000-00032; Carr DB, 1999, LANCET, V353, P2051, DOI 10.1016/S0140-6736(99)03313-9; Desai PM, 1999, CRIT CARE CLIN, V15, P151, DOI 10.1016/S0749-0704(05)70045-2; Ducharme J, 2000, ANN EMERG MED, V35, P592, DOI 10.1016/S0196-0644(00)70033-3; HODGKINS M, 1985, PAIN, V23, P273, DOI 10.1016/0304-3959(85)90105-8; Jadad AR, 2000, ANN EMERG MED, V36, P247, DOI 10.1067/mem.2000.108095; Joint Commission on Accreditation of Healthcare Organizations, 2003, IMPR QUAL PAIN MAN M; Jones JB, 1999, J EMERG MED, V17, P349, DOI 10.1016/S0736-4679(98)00180-2; KAISER K S, 1992, Critical Care Nursing Quarterly, V15, P14; Loeser JD, 1999, LANCET, V353, P1607, DOI 10.1016/S0140-6736(99)01311-2; Payen JF, 2001, CRIT CARE MED, V29, P2258, DOI 10.1097/00003246-200112000-00004; Rupp T, 2004, ANN EMERG MED, V43, P494, DOI 10.1016/j.annemergmed.2003.11.019; Turk DC, 1999, LANCET, V353, P1784, DOI 10.1016/S0140-6736(99)01309-4; WILSON JE, 1989, AM J EMERG MED, V7, P620, DOI 10.1016/0735-6757(89)90286-6	15	20	21	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	OCT	2007	63	4					819	826		10.1097/01.ta.0000240979.31046.98			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	219XL	WOS:000250121400016	18090011				2020-06-30	J	Rivat, C; Laboureyras, E; Laulin, JP; Le Roy, C; Richebe, P; Simonnet, G				Rivat, Cyril; Laboureyras, Emilie; Laulin, Jean-Paul; Le Roy, Chloe; Richebe, Philippe; Simonnet, Guy			Non-nociceptive environmental stress induces hyperalgesia, not analgesia, in pain and opioid-experienced rats	NEUROPSYCHOPHARMACOLOGY			English	Article						stress; analgesia; hyperalgesia; opioid; pain sensitization	PROTEIN-KINASE-C; RECEPTOR ANTAGONIST KETAMINE; LONG-LASTING HYPERALGESIA; ANTINOCICEPTIVE TOLERANCE; THERMAL HYPERALGESIA; MORPHINE-TOLERANCE; ABNORMAL PAIN; DELAYED HYPERALGESIA; POSTOPERATIVE PAIN; RESTRAINT STRESS	It is well admitted that stress induces analgesia (SIA) via endogenous opioid release. However, there is evidence that stressful events play a role in the pathogenesis of pain, but little is known about mechanisms underlying such pain vulnerability. Previous studies reported that a single opioid exposure activates NMDA-dependent pronociceptive systems leading to long-term pain vulnerability after analgesia. Here, we studied whether prior inflammatory pain or/and opioid experiences may favour the development of pain vulnerability after non-nociceptive environmental stress (NNES). Nociceptive threshold (NT) changes were evaluated by paw pressure vocalization test. By contrast to discrete SIA observed in naive rats, 1 h stress induced hyperalgesia (SIH) for several hours (15-65% NT decrease) in pain and opioid experienced rats. Repetition of NNES induced an 18-to 22-fold SIH enhancement (3-4 days), whereas SIA decreased. SIH was still observed 4 months after pain and opioid experiences. This phenomenon is referred to as latent pain sensitization. Furthermore, a fentanyl ultra-low dose (ULD, 50 ng/kg) administration, mimicking SIA in naive rats, induced hyperalgesia (65% NT decrease, 4 h), not analgesia, in pain and opioid-experienced rats. This indicates that low levels of opioids induce opposite effects, that is analgesia vs hyperalgesia dependent on prior life events. In pain and opioid-experienced rats, NMDA receptor antagonists, ketamine or BN2572, completely prevented hyperalgesia when injected just before NNES or fentanyl ULD. This latent pain sensitization model may be important for studying the transition from acute to chronic pain and individual differences in pain vulnerability associated with prior life events.	Univ Bordeaux 2, Lab Homeostasie Allostasie Pathol, F-33076 Bordeaux, France; Univ Bordeaux 1, Dept Cellular Biol & Physiol, F-33405 Talence, France; CHU Bordeaux, Dept Anesthesia & Intens Care 2, Bordeaux, France	Simonnet, G (reprint author), Univ Bordeaux 2, Lab Homeostasie Allostasie Pathol, EA3666,146 Rue Leo Saignat, F-33076 Bordeaux, France.	gsimonnet@yahoo.com	Rivat, Cyril/F-8482-2019; RIVAT, Cyril/B-5697-2008	Rivat, Cyril/0000-0002-7491-6113; 			AKIL H, 1976, [No title captured], P63; Angst MS, 2006, ANESTHESIOLOGY, V104, P570, DOI 10.1097/00000542-200603000-00025; Angst MS, 2003, PAIN, V106, P49, DOI 10.1016/S0304-3959(03)00276-8; Bespalov AY, 2001, NEUROSCI BIOBEHAV R, V25, P343, DOI 10.1016/S0149-7634(01)00018-5; Bradesi S, 2005, AM J PHYSIOL-GASTR L, V289, pG42, DOI 10.1152/ajpgi.00500.2004; Celerier E, 2000, ANESTHESIOLOGY, V92, P465, DOI 10.1097/00000542-200002000-00029; Celerier E, 2001, J NEUROSCI, V21, P4074, DOI 10.1523/JNEUROSCI.21-11-04074.2001; CHEN L, 1992, NATURE, V356, P521, DOI 10.1038/356521a0; CHEN L, 1991, NEURON, V7, P319, DOI 10.1016/0896-6273(91)90270-A; Chia YT, 1999, CAN J ANAESTH, V46, P872, DOI 10.1007/BF03012978; CRAIN SM, 1990, TRENDS PHARMACOL SCI, V11, P77, DOI 10.1016/0165-6147(90)90322-Y; Crain SM, 1998, TRENDS PHARMACOL SCI, V19, P358, DOI 10.1016/S0165-6147(98)01241-3; De Kock M, 2001, PAIN, V92, P373, DOI 10.1016/S0304-3959(01)00278-0; Galeotti N, 2006, PAIN, V123, P294, DOI 10.1016/j.pain.2006.03.008; Gameiro GH, 2006, PHYSIOL BEHAV, V87, P643, DOI 10.1016/j.physbeh.2005.12.007; Guignard B, 2000, ANESTHESIOLOGY, V93, P409, DOI 10.1097/00000542-200008000-00019; Guignard B, 2002, ANESTH ANALG, V95, P103, DOI 10.1097/00000539-200207000-00018; Hirbec H, 2000, BRAIN RES, V859, P177, DOI 10.1016/S0006-8993(99)02420-8; Hirota K, 1996, BRIT J ANAESTH, V77, P441, DOI 10.1093/bja/77.4.441; Hoizey G, 2001, INT J PHARM, V229, P147, DOI 10.1016/S0378-5173(01)00842-0; KAYSER V, 1990, PAIN, V41, P353, DOI 10.1016/0304-3959(90)90012-3; Khasar SG, 2005, PAIN, V116, P79, DOI 10.1016/j.pain.2005.03.040; KIM DH, 1990, BRAIN RES, V516, P37, DOI 10.1016/0006-8993(90)90894-H; Laulin JP, 2002, ANESTH ANALG, V94, P1263, DOI 10.1097/00000539-200205000-00040; Laulin JP, 1998, EUR J NEUROSCI, V10, P782, DOI 10.1046/j.1460-9568.1998.00083.x; LEWIS JW, 1980, SCIENCE, V208, P623, DOI 10.1126/science.7367889; MAO J, 1994, J NEUROSCI, V14, P2301; Mao JR, 2002, PAIN, V100, P213, DOI 10.1016/S0304-3959(02)00422-0; Mao JR, 2002, J NEUROSCI, V22, P8312; MARTIN WR, 1987, J PHARMACOL EXP THER, V240, P565; NORTH R A, 1976, Nature (London), V264, P460, DOI 10.1038/264460a0; Ossipov MH, 2003, LIFE SCI, V73, P783, DOI 10.1016/S0024-3205(03)00410-7; Perkins FM, 2000, ANESTHESIOLOGY, V93, P1123, DOI 10.1097/00000542-200010000-00038; Richebe P, 2005, ANESTHESIOLOGY, V102, P421, DOI 10.1097/00000542-200502000-00028; Rivat C, 2002, ANESTHESIOLOGY, V96, P381, DOI 10.1097/00000542-200202000-00025; SATOH M, 1992, PAIN, V49, P273, DOI 10.1016/0304-3959(92)90151-Z; Simonin F, 2006, P NATL ACAD SCI USA, V103, P466, DOI 10.1073/pnas.0502090103; Simonnet G, 2003, NEUROREPORT, V14, P1, DOI 10.1097/00001756-200301200-00001; Stubhaug A, 1997, ACTA ANAESTH SCAND, V41, P329, DOI 10.1111/j.1399-6576.1997.tb04693.x; Suarez-Roca H, 2006, BEHAV BRAIN RES, V167, P205, DOI 10.1016/j.bbr.2005.09.006; Torres ILD, 2003, NEUROSCI RES, V45, P277, DOI 10.1016/S0168-0102(02)00232-8; Vanderah TW, 2000, J NEUROSCI, V20, P7074, DOI 10.1523/JNEUROSCI.20-18-07074.2000; VIDAL C, 1982, NEUROSCI LETT, V32, P75, DOI 10.1016/0304-3940(82)90232-4; Wilder-Smith OHG, 2006, ANESTHESIOLOGY, V104, P601, DOI 10.1097/00000542-200603000-00028; Woolf CJ, 2000, SCIENCE, V288, P1765, DOI 10.1126/science.288.5472.1765; Xie JY, 2005, J NEUROSCI, V25, P409, DOI 10.1523/JNEUROSCI.4054-04.2005; Zarate E, 1999, ANESTHESIOLOGY, V90, P956, DOI 10.1097/00000542-199904000-00005	47	78	79	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0893-133X			NEUROPSYCHOPHARMACOL	Neuropsychopharmacology	OCT	2007	32	10					2217	2228		10.1038/sj.npp.1301340			12	Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	211EB	WOS:000249506000018	17299508	Bronze			2020-06-30	J	Kanai, A; Osawa, S; Suzuki, A; Ozawa, A; Okamoto, H; Hoka, S				Kanai, Akifumi; Osawa, Satoru; Suzuki, Asaha; Ozawa, Akiko; Okamoto, Hirotsugu; Hoka, Sumio			Regression of sensory and motor blockade, and analgesia during continuous epidural infusion of ropivacaine and fentanyl in comparison with other local anesthetics	PAIN MEDICINE			English	Article						ropivacaine; fentanyl; epidural block	MORPHINE BUPIVACAINE; POSTOPERATIVE PAIN; ABDOMINAL-SURGERY; TACHYPHYLAXIS; POTENCIES; SPREAD; RELIEF; AGENTS; LABOR	Background: To compare the regression of sensory and motor blockade, and the analgesia during continuous epidural infusion between ropivacaine and other local anesthetics. Design. Two studies were conducted. Study 1: Eighty patients were scheduled for orthopedic procedures of the lower extremity under lumbar epidural anesthesia. Following the operation, continuous infusion of a randomized solution (0.2% ropivacaine, 0.125% bupivacaine, 0.5% lidocaine, or 0.2% ropivacaine with 2.5 mu g/mL fentanyl) was commenced at a rate of 6 mL/h. The regression of sensory and motor blockade were compared among the groups. Study 2: After gynecologic abdominal surgery, 39 patients were randomized to one of the three epidural infusion groups: 0.2% ropivacaine, 0.125% bupivacaine, or 0.2% ropivacaine with 2.5 mu g/mL fentanyl at a rate of 6 mL/h with an additional bolus injection of 3 mL, which can be used when patients have pain. Visual analog scale (VAS) was compared among the groups. Results. Study 1: The level of sensory blockade in all the groups appeared to decrease progressively. However, the regression of sensory blockade was significantly prolonged in patients treated with ropivacaine. The addition of fentanyl to ropivacaine augmented this prolonged analgesic effect. Study 2: VAS after the bolus in the ropivacaine and the ropivacaine + fentanyl groups were significantly lower than that in the bupivacaine group. Patients in the ropivacaine + fentanyl group required significantly fewer supplemental bolus injections. Conclusions. Continuous epidural infusion of ropivacaine may induce a slower regression of sensory blockade compared with bupivacaine and lidocaine. The addition of fentanyl to ropivacaine can enhance this prolonged analgesic effect with little effect on motor blockade. Epidural infusion of ropivacaine with fentanyl provides effective pain relief, possibly because of the maintenance of sensory blockade by ropivacaine and fentanyl.	Kitasato Univ, Sch Med, Dept Anesthesiol, Sagamihara, Kanagawa 228, Japan	Kanai, A (reprint author), Kitasato Univ, Sch Med, Dept Anesthesiol, 1-15-1 Kitasato, Sagamihara, Kanagawa 228, Japan.	Kanaiakifumi@aol.com					BIGLER D, 1986, ACTA ANAESTH SCAND, V30, P289, DOI 10.1111/j.1399-6576.1986.tb02415.x; BIGLER D, 1987, ACTA ANAESTH SCAND, V31, P664, DOI 10.1111/j.1399-6576.1987.tb02642.x; BROMAGE PR, 1969, J CLIN PHARMACOL N D, V9, P30; Capogna G, 1999, BRIT J ANAESTH, V82, P371, DOI 10.1093/bja/82.3.371; COHEN EN, 1968, ANESTHESIOLOGY, V29, P994, DOI 10.1097/00000542-196809000-00027; FERRANTE FM, 1993, ANESTH ANALG, V77, P1179; FISCHER RL, 1988, ANESTH ANALG, V67, P559; HJORTSO NC, 1986, ANESTH ANALG, V65, P1033; LUND C, 1985, LANCET, V2, P1156; MATHER LE, 1986, ANAESTHESIOL INTENS, V176, P3; MULDOON T, 1998, ACUTE PAIN, V1, P13; NAKAMURA K, 1993, ACTA ANAESTH SCAND, V37, P269, DOI 10.1111/j.1399-6576.1993.tb03714.x; Oda A, 2000, ANESTH ANALG, V91, P1213, DOI 10.1097/00000539-200011000-00031; Polley LS, 1999, ANESTHESIOLOGY, V90, P944, DOI 10.1097/00000542-199904000-00003; RENCK H, 1980, ANASTH INTENSIVMED, V124, P188; ROSENBERG PH, 1986, BRIT J ANAESTH, V58, P310, DOI 10.1093/bja/58.3.310; SAITO Y, 1994, ACTA ANAESTH SCAND, V38, P398, DOI 10.1111/j.1399-6576.1994.tb03915.x; SCOTT DA, 1995, ANESTH ANALG, V81, P982, DOI 10.1097/00000539-199511000-00015; TUCKER GT, 1975, BRIT J ANAESTH, V47, P213; Vallejo MC, 2000, CAN J ANAESTH, V47, P406, DOI 10.1007/BF03018968; WHITE MJ, 1992, CAN J ANAESTH, V39, P576, DOI 10.1007/BF03008321; WOLFF CJ, 1983, NATURE, V306, P686	22	10	12	0	0	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	1526-2375			PAIN MED	Pain Med.	OCT	2007	8	7					546	553		10.1111/j.1526-4637.2006.00174.x			8	Anesthesiology; Medicine, General & Internal	Anesthesiology; General & Internal Medicine	215RN	WOS:000249826800003	17883739	Bronze			2020-06-30	J	Agarwal, S; Polydefkis, M; Block, B; Haythornthwaite, J; Raja, SN				Agarwal, Shefali; Polydefkis, Michael; Block, Brian; Haythornthwaite, Jennifer; Raja, Srinivasa N.			Transdermal fentanyl reduces pain and improves functional activity in neuropathic pain states	PAIN MEDICINE			English	Article						transdermal; neuropathic pain; actiwatch; activity	PLACEBO-CONTROLLED TRIAL; CHRONIC NONCANCER PAIN; RELEASE ORAL MORPHINE; QUALITY-OF-LIFE; CANCER PAIN; OPIOID THERAPY; DIABETIC-NEUROPATHY; DOUBLE-BLIND; EFFICACY; SAFETY	Objective. The efficacy of transdermal fentanyl in chronic neuropathic pain has not been well studied. We examined the effects of transdermal fentanyl on pain and function in patients with chronic neuropathic pain states. Design. A 16- week open- label study evaluated pre- and postdrug therapy effects. An actigraph was used to record pain scores ( 0 - 10) three times a day and activity level ( 8 am - 8 pm) continuously. Pain scores were also entered in pain diary logs. Setting. The study was conducted on subjects visiting the Johns Hopkins Hospital as outpatients. Patients. Patients with peripheral neuropathic pain ( N = 25), complex regional pain syndrome- 1 ( N = 19), and postamputation pain ( N = 9) were enrolled in the study. Interventions. After a 2- week baseline, transdermal fentanyl was titrated over 6 weeks with a dose of 25 - 150 mu g/ h based on individual response and then followed for an 8- week maintenance period. Outcome Measures. Average pain score and activity level were compared during the last week of the baseline and maintenance periods. Subgroup effects were also examined. Other outcome measures included pain relief ( 0 - 100%), cognition, affect, and impairment of function. Results. Forty patients completed the study, and 13 withdrew at varying time points. The average dose for transdermal fentanyl was 105.6 mu g/ h. Significant reductions in pain ( - 2.94 +/- 0.27) and percent pain relief ( 33.7 +/- 14%) were observed. These reductions in pain were accompanied by a 37.4% average increase in daytime activity. Sedation and nausea/ vomiting were the common side effects. No signifi.cant changes were observed in tests of cognition or affect. Conclusions. Overall, there was a significant reduction in pain intensity and increase in activity in neuropathic pain patients treated with transdermal fentanyl.	Johns Hopkins Univ Hosp, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21287 USA; Johns Hopkins Univ Hosp, Dept Neurol, Baltimore, MD 21205 USA; Johns Hopkins Univ Hosp, Dept Psychiat, Baltimore, MD 21205 USA	Raja, SN (reprint author), Johns Hopkins Univ Hosp, Dept Anesthesiol & Crit Care Med, 600 N Wolfe Str Osler 292, Baltimore, MD 21287 USA.	sraja@jhmi.edu	Stevens, David/F-4683-2015	Stevens, David/0000-0002-8412-2202; Yang, Shuman/0000-0002-9638-0890	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS26363]		Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; Ballantyne JC, 2003, NEW ENGL J MED, V349, P1943, DOI 10.1056/NEJMra025411; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Bruera E, 2004, J CLIN ONCOL, V22, P185, DOI 10.1200/JCO.2004.03.172; CHERNY NJ, 1995, CANCER-AM CANCER SOC, V76, P1283, DOI 10.1002/1097-0142(19951001)76:7<1283::AID-CNCR2820760728>3.0.CO;2-0; Clark AJ, 2004, CURR MED RES OPIN, V20, P1419, DOI 10.1185/030079904X2114; Dworkin RH, 2005, PAIN, V113, P9, DOI 10.1016/j.pain.2004.09.012; FISHBAIN DA, 1992, CLIN J PAIN, V8, P77, DOI 10.1097/00002508-199206000-00003; Foley KM, 2003, NEW ENGL J MED, V348, P1279, DOI 10.1056/NEJMe030014; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Freynhagen R, 2005, PAIN, V115, P254, DOI 10.1016/j.pain.2005.02.032; Goldstein DJ, 2005, PAIN, V116, P109, DOI 10.1016/j.pain.2005.03.029; HAYTHORNTHWAITE JA, 1991, PAIN, V46, P177, DOI 10.1016/0304-3959(91)90073-7; Jean-Louis G, 1999, PHYSIOL BEHAV, V65, P659; Kahneman D, 2004, SCIENCE, V306, P1776, DOI 10.1126/science.1103572; Kalso E, 2004, PAIN, V112, P372, DOI 10.1016/j.pain.2004.09.019; KERNS RD, 1985, PAIN, V23, P345, DOI 10.1016/0304-3959(85)90004-1; Liszka-Hackzell JJ, 2004, ANESTH ANALG, V99, P477, DOI 10.1213/01.ANE.0000132696.15310.DD; MERSKEY H, 1995, [No title captured]; Mystakidou K, 2002, ONCOLOGY-BASEL, V62, P9, DOI 10.1159/000048241; Payne R, 1998, J CLIN ONCOL, V16, P1588, DOI 10.1200/JCO.1998.16.4.1588; Puyau MR, 2002, OBES RES, V10, P150, DOI 10.1038/oby.2002.24; Raja SN, 2002, NEUROLOGY, V59, P1015, DOI 10.1212/WNL.59.7.1015; Rowbotham MC, 2003, NEW ENGL J MED, V348, P1223, DOI 10.1056/NEJMoa021420; Shirota AI, 2000, PSYCHIAT CLIN NEUROS, V54, P309, DOI 10.1046/j.1440-1819.2000.00691.x; Sindrup SH, 1999, PAIN, V83, P389, DOI 10.1016/S0304-3959(99)00154-2; Stone AA, 2003, PAIN, V104, P343, DOI 10.1016/S0304-3959(03)00040-X; Tryon WW, 2004, SLEEP, V27, P158, DOI 10.1093/sleep/27.1.158; Watson CPN, 2003, PAIN, V105, P71, DOI 10.1016/S0304-3959(03)00160-X; Wechsler D., 1981, WECHSLER ADULT INTEL; ZENZ M, 1992, J PAIN SYMPTOM MANAG, V7, P69, DOI 10.1016/0885-3924(92)90116-Y; Zieglgansberger W, 2005, CNS SPECTRUMS, V10, P298, DOI 10.1017/S1092852900022628	32	29	30	0	4	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	1526-2375			PAIN MED	Pain Med.	OCT	2007	8	7					554	562		10.1111/j.1526-4637.2006.00246.x			9	Anesthesiology; Medicine, General & Internal	Anesthesiology; General & Internal Medicine	215RN	WOS:000249826800004	17883740	Bronze			2020-06-30	J	Tosun, Z; Aksu, R; Guler, G; Esmaoglu, A; Akin, A; Aslan, D; Boyaci, A				Tosun, Zeynep; Aksu, Recep; Guler, Gulen; Esmaoglu, Aliye; Akin, Aynur; Aslan, Duran; Boyaci, Adem			Propofol-ketamine vs propofol-fentanyl for sedation during pediatric upper gastrointestinal endoscopy	PEDIATRIC ANESTHESIA			English	Article						sedation; children; ketamine; propofol; fentanyl; gastroscopy	INTRAMUSCULAR KETAMINE; GENERAL-ANESTHESIA; GI ENDOSCOPY; CHILDREN; MIDAZOLAM; ESOPHAGOGASTRODUODENOSCOPY; COMBINATION; MEPERIDINE; ANALGESIA	Background: The aim of this study was to compare the clinical efficacy and safety of propofol-ketamine with propofol-fentanyl in pediatric patients undergoing diagnostic upper gastrointestinal endoscopy (UGIE). Methods: This was a prospective, randomized, double blinded comparison of propofol-ketamine with propofol-fentanyl for sedation in patients undergoing elective UGIE. Ninety ASA I-II, aged 1 to 16-year-old patients were included in the study. Heart rate (HR), systolic arterial pressure, peripheral oxygen saturation, respiratory rate (RR) and Ramsey sedation scores of all patients were recorded perioperatively. Patients were randomly assigned to receive either propofol-ketamine (PK; n = 46) or propofol-fentanyl (PF; n = 44). PK group received 1 mg.kg(-1) ketamine + 1.2 mg.kg(-1) propofol, and PF group received 1 mu g.kg(-1) fentanyl + 1.2 mg.kg(-1) propofol for sedation induction. Additional propofol (0.5-1 mg.kg(-1)) was administered when a patient showed discomfort in either group. Results: The number of patients who needed additional propofol in the first minute after sedation induction was eight in Group PK (17%), and 22 in Group PF (50%) (P < 0.01) and those who did not need additional propofol throughout the endoscopy were 14 in Group PK (30%) and three in Group PF (7%) (P < 0.01). HR and RR values after induction in Group PF were significantly lower than Group PK (P < 0.01). Conclusions: Both PK and PF combinations provided effective sedation in pediatric patients undergoing UGIE, but the PK combination resulted in stable hemodynamics and deeper sedation though more side effects.	Erciyes Univ, Sch Med, Dept Anesthesiol & Reanimatol, TR-38039 Kayseri, Turkey; Erciyes Univ, Sch Med, Dept Anesthesiol, Kayseri, Turkey; Erciyes Univ, Sch Med, Dept Pediat Gastroenterol, Kayseri, Turkey	Tosun, Z (reprint author), Erciyes Univ, Sch Med, Dept Anesthesiol & Reanimatol, TR-38039 Kayseri, Turkey.	zeynept@erciyes.edu.tr					Akin A, 2005, INT J PEDIATR OTORHI, V69, P1541, DOI 10.1016/j.ijporl.2005.04.011; Akin A, 2005, PEDIATR CARDIOL, V26, P553, DOI 10.1007/s00246-004-0707-4; Ali S, 2004, DIGEST DIS SCI, V49, P888, DOI 10.1023/B:DDAS.0000030106.01928.b4; Bauman LA, 1999, AM J EMERG MED, V17, P1, DOI 10.1016/S0735-6757(99)90001-3; CHUANG E, 1995, GASTROINTEST ENDOSC, V42, P156, DOI 10.1016/S0016-5107(95)70073-0; Disma N, 2005, EUR J ANAESTH, V22, P848, DOI 10.1017/S0265021505001432; Elitsur Y, 2000, ENDOSCOPY, V32, P788, DOI 10.1055/s-2000-7713; Gilger MA, 2004, GASTROINTEST ENDOSC, V59, P659, DOI 10.1016/S0016-5107(04)00180-4; Godambe SA, 2003, PEDIATRICS, V112, P116, DOI 10.1542/peds.112.1.116; Green SM, 2000, ANN EMERG MED, V35, P35, DOI 10.1016/S0196-0644(00)70102-8; GUIT JBM, 1991, ANAESTHESIA, V46, P24, DOI 10.1111/j.1365-2044.1991.tb09308.x; Hwang J, 2005, ACTA ANAESTH SCAND, V49, P1334, DOI 10.1111/j.1399-6576.2005.00842.x; Kaddu R, 2002, GASTROINTEST ENDOSC, V55, P27, DOI 10.1067/mge.2002.120386; Khoshoo V, 2003, J PEDIATR GASTR NUTR, V37, P146, DOI 10.1097/00005176-200308000-00012; Kirberg A, 2005, GASTROINTEST ENDOSC, V61, P501, DOI 10.1016/S0016-5107(04)02724-5; Law AK, 2003, PEDIATR INT, V45, P180, DOI 10.1046/j.1442-200X.2003.01680.x; Leffler Therese M, 2004, Gastroenterol Nurs, V27, P176, DOI 10.1097/00001610-200407000-00006; Martlew RA, 1996, BRIT J ANAESTH, V76, P308; Michaud L, 2005, ENDOSCOPY, V37, P167, DOI 10.1055/s-2004-826144; Petrack EM, 2000, CLIN PED EMERG MED, V1, P281; RAMSAY MA, 1974, [No title captured], V22, P656; STEWARD DJ, 1975, CAN ANAESTH SOC J, V22, P111, DOI 10.1007/BF03004827; Tolia V, 2000, J PEDIATR GASTR NUTR, V30, P477, DOI 10.1097/00005176-200005000-00003; Tomatir E, 2004, PEDIATR ANESTH, V14, P845, DOI 10.1111/j.1460-9592.2004.01303.x; Wengrower D, 2004, SCAND J GASTROENTERO, V39, P283, DOI 10.1080/00365520310008467	25	48	50	0	6	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	1155-5645			PEDIATR ANESTH	Pediatr. Anesth.	OCT	2007	17	10					983	988		10.1111/j.1460-9592.2007.02206.x			6	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	210BI	WOS:000249431300012	17767636				2020-06-30	J	Friedrichsdorf, SJ; Kang, TI				Friedrichsdorf, Stefan J.; Kang, Tammy I.			The management of pain in children with life-limiting illnesses	PEDIATRIC CLINICS OF NORTH AMERICA			English	Article							LIDOCAINE PATCH 5-PERCENT; PEDIATRIC PALLIATIVE CARE; SEVERE CANCER PAIN; HEALTH-ORGANIZATION GUIDELINES; NEUROPATHIC PAIN; DOUBLE-BLIND; POSTHERPETIC NEURALGIA; HOSPITALIZED CHILDREN; TRANSDERMAL FENTANYL; POSTOPERATIVE PAIN	The management of pain in children with life-limiting illnesses is complex and unfortunately not often done effectively. Pain is a multidimensional symptom that can overshadow all other experiences of both the child and family This article focuses on topics common to practitioners caring for children with lifelimiting illnesses, including a review of myths and obstacles to achieving adequate pain control, a review of the pathophysiology of pain, an overview of the use of opioids in children, an approach to the management of neuropathic pain, and a brief discussion of nonpharmacologic pain management strategies.	[Kang, Tammy I.] Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA; [Friedrichsdorf, Stefan J.] Childrens Hosp & Clin Minnesota, Minneapolis, MN 55404 USA; [Kang, Tammy I.] Childrens Hosp Philadelphia, Pediat Adv Care Team, Philadelphia, PA 19104 USA	Kang, TI (reprint author), Childrens Hosp Philadelphia, Div Oncol, 34th & Civ Ctr Blvd,4314 Wood Bldg, Philadelphia, PA 19104 USA.	kang@email.chop.edu		Friedrichsdorf, Stefan/0000-0001-6144-3620			Albano Edythe A., 1993, Current Opinion in Pediatrics, V5, P131; Argoff CE, 2004, CURR MED RES OPIN, V20, pS21, DOI 10.1185/030079904X12960; Armstrong SC, 2003, PSYCHOSOMATICS, V44, P515, DOI 10.1176/appi.psy.44.6.515; Arvio M, 2001, Duodecim, V117, P1447; Aspinall RL, 2001, PAEDIATR ANAESTH, V11, P333, DOI 10.1046/j.1460-9592.2001.00676.x; Babul N, 1993, J Palliat Care, V9, P19; BABUL N, 1995, J PAIN SYMPTOM MANAG, V10, P335, DOI 10.1016/0885-3924(95)90012-8; BABUL N, 1995, J PAIN SYMPTOM MANAG, V10, P184, DOI 10.1016/0885-3924(94)00121-Z; Behm MO, 2001, PEDIATRICS, V108, P482, DOI 10.1542/peds.108.2.482; Beider S, 2007, EVID-BASED COMPL ALT, V4, P23, DOI 10.1093/ecam/nel068; BELL R, 2003, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD003351; BERDE CB, 1991, J PEDIATR-US, V119, P136, DOI 10.1016/S0022-3476(05)81054-6; BERDE CB, 2003, PAIN INFANTS CHILDRE, P620; Brown R, 2004, POSTGRAD MED J, V80, P654, DOI 10.1136/pgmj.2004.022988; Brown R E Jr, 1993, J Ark Med Soc, V90, P112; Butkovic D, 2006, PEDIATR ANESTH, V16, P325, DOI 10.1111/j.1460-9592.2005.01687.x; Caraceni A, 2002, J PAIN SYMPTOM MANAG, V23, P239, DOI 10.1016/S0885-3924(01)00409-2; Carter BS, 2004, PEDIATRICS, V114, pE361, DOI 10.1542/peds.2003-0654-F; CHANG SF, 1988, PHARMACEUT RES, V5, P718, DOI 10.1023/A:1015959912021; Chen E, 2000, PEDIATR CLIN N AM, V47, P513, DOI 10.1016/S0031-3955(05)70223-6; Cherny N, 2001, J CLIN ONCOL, V19, P2542, DOI 10.1200/JCO.2001.19.9.2542; Chiu YK, 1999, PEDIATR DERMATOL, V16, P465, DOI 10.1046/j.1525-1470.1999.00120.x; Choi YS, 2002, J PAIN SYMPTOM MANAG, V24, P71, DOI 10.1016/S0885-3924(02)00424-4; CLARK JL, 1995, J PAIN SYMPTOM MANAG, V10, P310, DOI 10.1016/0885-3924(95)00010-V; COHEN S, 2004, PRINCIPLES PRACTICES; COLLINS C, 1985, ANESTH ANALG, V64, P1078; COLLINS JJ, 1995, PAIN, V63, P271, DOI 10.1016/0304-3959(95)00094-9; Collins JJ, 1999, J PEDIATR-US, V134, P319, DOI 10.1016/S0022-3476(99)70457-9; COLLINS JJ, 1995, J PEDIATR-US, V126, P653, DOI 10.1016/S0022-3476(95)70370-5; COLLINS JJ, 1995, J PAIN SYMPTOM MANAG, V10, P471, DOI 10.1016/0885-3924(95)00062-4; Contro N, 2002, ARCH PEDIAT ADOL MED, V156, P14, DOI 10.1001/archpedi.156.1.14; DAMPIER CD, 1995, J PEDIATR-US, V126, P461, DOI 10.1016/S0022-3476(95)70472-8; Davies PS, 2004, DRUGS, V64, P937, DOI 10.2165/00003495-200464090-00002; Dean M, 2004, J PAIN SYMPTOM MANAG, V28, P497, DOI 10.1016/j.jpainsymman.2004.02.021; Dix P, 2003, PAEDIATR ANAESTH, V13, P422, DOI 10.1046/j.1460-9592.2003.01090.x; Doyle L, 2006, PEDIATR CLIN N AM, V53, P279, DOI 10.1016/j.pcl.2005.09.008; Drake R, 2003, J PAIN SYMPTOM MANAG, V26, P594, DOI 10.1016/S0885-3924(03)00202-1; DRAKE R, 2006, PAIN PHARM MANAGEMEN; Drake Ross, 2004, J Palliat Med, V7, P419, DOI 10.1089/1096621041349590; Ducharme J, 2000, ANN EMERG MED, V35, P592, DOI 10.1016/S0196-0644(00)70033-3; Ellis Jacqueline A, 2003, J Pediatr Oncol Nurs, V20, P26; FAULKNER KW, 2006, OXFORD TXB PALLIATIV, P409; FAUSETT H, 2004, PRINCIPLES PRACTICE, P28; Finkel JC, 2007, J PAIN, V8, P515, DOI 10.1016/j.jpain.2007.02.429; Franck LS, 2000, PEDIATR CLIN N AM, V47, P487, DOI 10.1016/S0031-3955(05)70222-4; Galer BS, 2002, CLIN J PAIN, V18, P297, DOI 10.1097/00002508-200209000-00004; Gammaitoni AR, 2004, CURR MED RES OPIN, V20, pS13, DOI 10.1185/030079904X12951; Gay C T, 1999, Semin Pediatr Neurol, V6, P182, DOI 10.1016/S1071-9091(99)80011-4; Goldman A, 2006, PEDIATRICS, V117, pE1179, DOI 10.1542/peds.2005-0683; Greco C, 2005, PEDIATR CLIN N AM, V52, P995, DOI 10.1016/j.pcl.2005.04.005; Guler Nurhan, 2005, N Y State Dent J, V71, P38; Herrmann DN, 2005, PAIN MED, V6, P379, DOI 10.1111/j.1526-4637.2005.00058.x; Hilden JM, 2001, J CLIN ONCOL, V19, P205, DOI 10.1200/JCO.2001.19.1.205; Hocking G., 2007, PAIN CLIN UPDATES, V15, P1; Hooke MC, 2007, J PEDIATR ONCOL NURS, V24, P29, DOI 10.1177/1043454206296026; Hunt A, 1999, J PEDIATR-US, V135, P47, DOI 10.1016/S0022-3476(99)70326-4; Hunt R, 1999, J PAIN SYMPTOM MANAG, V18, P111, DOI 10.1016/S0885-3924(99)00051-2; Inturrisi CE, 2002, CLIN J PAIN, V18, pS3, DOI 10.1097/00002508-200207001-00002; Jalmsell L, 2006, PEDIATRICS, V117, P1314, DOI 10.1542/peds.2005-1479; Keskinbora K, 2004, ACTA ANAESTH SCAND, V48, P663, DOI 10.1111/j.0001-5172.2004.0376c.x; Klepstad P, 2001, J PEDIAT HEMATOL ONC, V23, P616, DOI 10.1097/00043426-200112000-00013; Kokki H, 2004, CLIN PHARMACOKINET, V43, P613, DOI 10.2165/00003088-200443090-00004; KOREN G, 1989, PEDIATR CLIN N AM, V36, P1141; KORNENBERG RH, 2002, J PAIN PALLIAT CARE, V16, P27; Lauder GR, 2005, PEDIATR ANESTH, V15, P412, DOI 10.1111/j.1460-9592.2005.01431.x; Laufer M, 2005, SCHMERZ, V19, P220, DOI 10.1007/s00482-004-0323-5; Lugo Ralph A, 2004, J Pain Palliat Care Pharmacother, V18, P17; Lugo Ralph A, 2002, J Pain Palliat Care Pharmacother, V16, P5; Mack JW, 2005, J CLIN ONCOL, V23, P9155, DOI 10.1200/JCO.2005.04.010; Marcus RJ, 2000, BRIT J ANAESTH, V84, P739; McGrath PA, 1996, J PAIN SYMPTOM MANAG, V12, P87, DOI 10.1016/0885-3924(96)00099-1; McGraw T, 1998, CLIN J PAIN, V14, P354, DOI 10.1097/00002508-199812000-00014; McGraw T, 1997, ANESTHESIOLOGY, V86, P988, DOI 10.1097/00000542-199704000-00029; McQuay HJ, 1996, PAIN, V68, P217, DOI 10.1016/S0304-3959(96)03140-5; Meier T, 2004, SCHMERZ, V18, P172, DOI 10.1007/s00482-003-0272-4; Meier T, 2003, PAIN, V106, P151, DOI 10.1016/S0304-3959(03)00317-8; Noyes M, 2001, Am J Hosp Palliat Care, V18, P411, DOI 10.1177/104990910101800612; Poltorak DY, 2006, CHILD ADOL PSYCH CL, V15, P683, DOI 10.1016/j.chc.2006.02.009; Rowbotham MC, 1996, PAIN, V65, P39, DOI 10.1016/0304-3959(95)00146-8; Rusy LM, 2001, J PAIN SYMPTOM MANAG, V21, P78, DOI 10.1016/S0885-3924(00)00243-8; Rusy LM, 2000, PEDIATR CLIN N AM, V47, P589, DOI 10.1016/S0031-3955(05)70227-3; SCHECHTER NL, 1989, PEDIATR CLIN N AM, V36, P781; Sharar S. R., 2002, Journal of Burn Care & Rehabilitation, V23, P27, DOI 10.1097/00004630-200201000-00006; SHIR Y, 1990, BRIT J ANAESTH, V65, P204, DOI 10.1093/bja/65.2.204; Shir Y, 2001, CAN J ANAESTH, V48, P1109, DOI 10.1007/BF03020377; Shir Y, 1998, CLIN J PAIN, V14, P350, DOI 10.1097/00002508-199812000-00013; Siden H, 2003, J PAIN SYMPTOM MANAG, V25, P397, DOI 10.1016/S0885-3924(03)00071-X; Smith MT, 2000, CLIN EXP PHARMACOL P, V27, P524, DOI 10.1046/j.1440-1681.2000.03290.x; Subramaniam K, 2004, ANESTH ANALG, V99, P482, DOI 10.1213/01.ANE.0000118109.12855.07; Taketomo CK, 2006, PEDIAT DOSAGE HDB; Theunissen JMJ, 2007, PEDIATR BLOOD CANCER, V49, P160, DOI 10.1002/pbc.21042; Tobias JD, 2000, PEDIATR CLIN N AM, V47, P527, DOI 10.1016/S0031-3955(05)70224-8; Tsao JCI, 2005, EVID-BASED COMPL ALT, V2, P521, DOI 10.1093/ecam/neh132; Tsui BCH, 2004, J PEDIAT HEMATOL ONC, V26, P678, DOI 10.1097/01.mph.0000140656.96085.2c; VENTAFRIDDA V, 1985, INT J TISSUE REACT, V7, P93; Wolfe J, 2000, NEW ENGL J MED, V342, P326, DOI 10.1056/NEJM200002033420506; ZECH DFJ, 1995, PAIN, V63, P65, DOI 10.1016/0304-3959(95)00017-M; Zeltzer LK, 2002, J PAIN SYMPTOM MANAG, V24, P437, DOI 10.1016/S0885-3924(02)00506-7; Zernikow B, 2007, J PAIN, V8, P187, DOI 10.1016/j.jpain.2006.11.008; ZICHTERMAN A, 2007, PHAR U	100	35	38	0	7	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0031-3955	1557-8240		PEDIATR CLIN N AM	Pediatr. Clin. N. Am.	OCT	2007	54	5					645	+		10.1016/j.pcl.2007.07.007			29	Pediatrics	Pediatrics	249ET	WOS:000252210800005	17933616				2020-06-30	J	del Consuelo, ID; Falson, F; Guy, RH; Jacques, Y				del Consuelo, Isabel Diaz; Falson, Francoise; Guy, Richard H.; Jacques, Yves			Ex vivo evaluation of bioadhesive films for buccal delivery of fentanyl	JOURNAL OF CONTROLLED RELEASE			English	Article						bioadhesion; esophagus; buccal drug delivery; permeability barrier; fentanyl	PERMEABILITY BARRIER; EPITHELIUM; MORPHINE; CITRATE; PAIN	The goals of this work were (i) to develop bioadhesive films for the buccal delivery of fentanyl, and (ii) to evaluate their performance in vitro using the pig esophageal model. Films were made with polyvinylpyrrolidone (PVP) of two different molecular weights: PVP K30 and PVP K90. Delivery of fentanyl was determined across full-thickness mucosa and across heat-separated epithelium (where the permeability barrier was shown to be located). The influence of film pH was investigated, and it was found that fentanyl permeation increased with increasing pH (i.e., when a higher percentage of the unionized fraction of drug was present). However, at the pH values studied, fentanyl was predominantly ionized suggesting that transport pathways offering a hydrophilic, or polar, environment across the mucosa were available. The transport rates achieved from the PVP films providing the highest delivery suggest that a buccal system of only 1-2 cm(2) in surface area could achieve a therapeutic effect equivalent to a 10 cm(2) transdermal patch, with a much shorter lag-time. (C) 2007 Published by Elsevier B.V.	Univ Geneva, Sch Pharmaceut Sci, CH-1211 Geneva 4, Switzerland; Univ Lyon 1, ISPB, Lab Rech & Dev Pharm Galen Ind, F-69373 Lyon, France; Ctr Interuniv Rech Enseignement Pharmapeptides, F-74160 Archamps, France; Univ Bath, Dept Pharm & Pharmacol, Bath BA2 7AY, Avon, England; OM Pharma, CH-1217 Geneva, Switzerland	Jacques, Y (reprint author), Univ Geneva, Sch Pharmaceut Sci, Quai Ernest Ansermet 30, CH-1211 Geneva 4, Switzerland.	yvesjacques@mac.com	Guy, Richard H/H-3471-2012	Guy, Richard/0000-0003-3227-9862			ANDERS R, 1989, INT J PHARM, V49, P231, DOI 10.1016/0378-5173(89)90347-5; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; DANIEL JC, 1984, STRUCTURE FUNCTION O, P159; Del Consuelo ID, 2005, J PHARM SCI-US, V94, P2777, DOI 10.1002/jps.20409; Diaz Del Consuelo I., 2005, ARCH ORAL BIOL, V50, P981, DOI DOI 10.1016/J.ARCHORALBIO.2005.04.008; Gourlay G K, 2001, Lancet Oncol, V2, P165, DOI 10.1016/S1470-2045(00)00258-8; HILL MW, 1982, HISTOCHEM J, V14, P641, DOI 10.1007/BF01011896; JACQUES Y, 2004, EUR C DRUG DEL PHARM, V48; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; MAK VHW, 1991, PHARMACEUT RES, V8, P1064, DOI 10.1023/A:1015873511692; MORTAZAVI SA, 1993, J CONTROL RELEASE, V25, P197, DOI 10.1016/0168-3659(93)90078-J; ORLANDO RC, 1992, GASTROENTEROLOGY, V102, P910, DOI 10.1016/0016-5085(92)90177-Z; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; ROY SD, 1989, PHARMACEUT RES, V6, P147, DOI 10.1023/A:1015932610010; STABLEIN MJ, STURCTURE FUNCTION O, P237; STREISAND JB, 1991, ANESTHESIOLOGY, V75, P223, DOI 10.1097/00000542-199108000-00009; THASSU D, 1993, DRUG DEV IND PHARM, V19, P1343, DOI 10.3109/03639049309074405; WERTZ PW, 1991, CRIT REV THER DRUG, V8, P237	18	64	66	0	17	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0168-3659			J CONTROL RELEASE	J. Control. Release	SEP 26	2007	122	2					135	140		10.1016/j.jconrel.2007.05.017			6	Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Chemistry; Pharmacology & Pharmacy	219EY	WOS:000250068700002	17688966				2020-06-30	J	Thomas, SH				Thomas, Stephen H.			Fentanyl in the prehospital setting	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article							ANALGESIA; TRAUMA; SEDATION; CITRATE; SAFETY; PAIN		Massachusetts Gen Hosp, Harvard Med Sch, Dept Emergency Serv, Boston MedFlight, Boston, MA USA	Thomas, SH (reprint author), Massachusetts Gen Hosp, Dept Emergency Serv, Boston, MA 02114 USA.	thomas.stephen@mgh.harvard.edu					Borland Meredith L, 2002, Emerg Med (Fremantle), V14, P275, DOI 10.1046/j.1442-2026.2002.00344.x; Braude Darren, 2004, Prehosp Emerg Care, V8, P441, DOI 10.1016/j.prehos.2004.07.001; CHRUBASIK J, 1988, BRIT J ANAESTH, V61, P228, DOI 10.1093/bja/61.2.228; CHUDNOFSKY CR, 1989, ANN EMERG MED, V18, P635, DOI 10.1016/S0196-0644(89)80517-7; DeVellis P, 1998, Prehosp Emerg Care, V2, P293, DOI 10.1080/10903129808958883; Devellis P, 1998, PEDIATR EMERG CARE, V14, P321; Ducharme J, 2000, ANN EMERG MED, V35, P592, DOI 10.1016/S0196-0644(00)70033-3; Fairbanks R, 2007, PREHOSP EMERG CARE, V11, P134; Frakes MA, 2006, AM J EMERG MED, V24, P286, DOI 10.1016/j.ajem.2005.11.021; Fulda Gerard J, 2005, J Trauma, V59, P383, DOI 10.1097/01.ta.0000179452.70520.1b; Garyfallou G, 1997, ACAD EMERG MED, V4, P405; HIGGINS MJ, 1991, ANAESTHESIA, V46, P973, DOI 10.1111/j.1365-2044.1991.tb09862.x; Kanowitz A, 2006, PREHOSP EMERG CARE, V10, P1, DOI 10.1080/10903120500373264; Mystakidou K, 2006, DRUG DELIV, V13, P269, DOI 10.1080/10717540500394661; POHLGEERS AP, 1995, ACAD EMERG MED, V2, P879, DOI 10.1111/j.1553-2712.1995.tb03101.x; SCHUTZMAN SA, 1994, ANN EMERG MED, V24, P1059, DOI 10.1016/S0196-0644(94)70234-9; SHAH S, 2007, PREHOSP EMERG CARE, V11, P133; THOMAS SH, 1996, AIR MED J, V15, P57; WALSH M, 1991, ANN EMERG MED, V20, P913, DOI 10.1016/S0196-0644(05)81439-8; Webster LR, 2006, EXPERT OPIN INV DRUG, V15, P1469, DOI 10.1517/13543784.15.11.1469; WORSLEY MH, 1990, ANAESTHESIA, V45, P449, DOI 10.1111/j.1365-2044.1990.tb14331.x	21	10	10	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0735-6757	1532-8171		AM J EMERG MED	Am. J. Emerg. Med.	SEP	2007	25	7					842	843		10.1016/j.ajem.2007.02.010			2	Emergency Medicine	Emergency Medicine	216SF	WOS:000249898600021	17870493				2020-06-30	J	Yu, H; Yang, XY; Zhang, X; Li, Q; Zhu, T; Wang, Y; Liu, B				Yu, H.; Yang, X.-Y.; Zhang, X.; Li, Q.; Zhu, T.; Wang, Y.; Liu, B.			The effect of dilution and prolonged injection time on fentanyl-induced coughing	ANAESTHESIA			English	Article							INTRAVENOUS LIDOCAINE; BOLUS	This study was designed to evaluate the effect of diluting fentanyl 50 mu g.ml(-1) to 25 or 10 mu g.ml(-1) with 0.9% saline and prolonged injection time on fentanyl-induced cough. Two hundred patients requiring general anaesthesia were randomly allocated into four groups: 50 mu g.ml(-1) (Group I), 25 mu g.ml(-1) (Group II), 10 mu g.ml(-1) (Group III) or 10 mu g.ml(-1) combined with prolonged injection (Group IV). Fentanyl 3 mu g.kg(-1) was administered within 5 s in Groups I, II, and III, or over 30 s in Group IV. Occurrence of cough was significantly reduced in Group IV (2% vs 32%, 16% and 12% in Groups I, II and III, respectively, p < 0.05). There were no statistically significant differences in the severity of coughing between the four groups (p > 0.05). We conclude that dilution of fentanyl to 10 mu g.ml(-1) with 0.9% saline combined with a prolonged injection time eliminates fentanyl-induced cough.	Sichuan Univ, W China Hosp, Dept Anaesthesiol, Chengdu 610041, Sichuan, Peoples R China; Sichuan Univ, W China Hosp 2, Dept Obstet & Gynecol, Chengdu 610041, Sichuan, Peoples R China	Liu, B (reprint author), Sichuan Univ, W China Hosp, Dept Anaesthesiol, Chengdu 610041, Sichuan, Peoples R China.	benbinliu@hotmail.com					Agarwal A, 2003, CAN J ANAESTH, V50, P297, DOI 10.1007/BF03017801; Bailey PL, 1999, ANESTHESIOLOGY, V90, P335, DOI 10.1097/00000542-199901000-00067; BOHRER H, 1990, ANAESTHESIA, V45, P18, DOI 10.1111/j.1365-2044.1990.tb14496.x; Lin CS, 2004, CAN J ANAESTH, V51, P654, DOI 10.1007/BF03018421; Lin JA, 2005, ANESTH ANALG, V101, P670, DOI 10.1213/01.ANE.0000159161.31276.DB; Lui PW, 1996, CAN J ANAESTH, V43, P1216; Pandey CK, 2005, CAN J ANAESTH, V52, P172, DOI 10.1007/BF03027724; PHUA WT, 1991, CAN J ANAESTH, V38, P330, DOI 10.1007/BF03007623; REITAN JA, 1978, ANESTH ANALG, V57, P31; Ricciardolo FLM, 2001, AM J MED, V111, P18, DOI 10.1016/S0002-9343(01)00816-6; Schlimp CJ, 2005, CAN J ANAESTH, V52, P207, DOI 10.1007/BF03027731; STELLATO C, 1992, ANESTHESIOLOGY, V77, P932, DOI 10.1097/00000542-199211000-00016; Tweed WA, 2001, ANESTH ANALG, V92, P1442; YASUDA I, 1978, ANESTHESIOLOGY, V49, P117, DOI 10.1097/00000542-197808000-00012	14	30	44	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0003-2409			ANAESTHESIA	Anaesthesia	SEP	2007	62	9					919	922		10.1111/j.1365-2044.2007.05147.x			4	Anesthesiology	Anesthesiology	198ZM	WOS:000248666000010	17697219				2020-06-30	J	Beilin, Y; Guinn, NR; Bernstein, HH; Zahn, J; Hossain, S; Bodian, CA				Beilin, Yaakov; Guinn, Nicole R.; Bernstein, Howard H.; Zahn, Jeff; Hossain, Sabera; Bodian, Carol A.			Local anesthetics and mode of delivery: Bupivacaine versus ropivacaine versus levobupivacaine	ANESTHESIA AND ANALGESIA			English	Article; Proceedings Paper	37th Annual Meeting of the Society-for-Obstetric-Anesthesia-and-Perinatology	MAY 04-07, 2005	Palm Desert, CA	Soc Obstet Anesthesia & Perinatol			CONTROLLED EPIDURAL ANALGESIA; MOTOR BLOCKING POTENCIES; LABOR ANALGESIA; 0.125-PERCENT BUPIVACAINE; CONTROLLED-TRIAL; SUFENTANIL; FENTANYL; METAANALYSIS; MULTICENTER; WOMEN	BACKGROUND: The influence of the labor epidural local anesthetic (LA) on mode of delivery has not been adequately studied. In this study, we sought to determine if there is a difference in mode of delivery among parturients who receive epidural bupivacaine, ropivacaine, or levobupivacaine. METHODS: Nulliparous women at term requesting labor analgesia with a cervical dilation <5 cm were randomized to receive epidural bupivacaine, ropivacaine, or levobupivacaine. Analgesia was initiated with a bolus of 15 mL of 0.0625% of the assigned LA with fentanyl 2 mu g/mL. Analgesia was maintained with an infusion of the same solution at 10 mL/h. The primary endpoint was the operative delivery rate (instrumental assisted vaginal delivery plus cesarean delivery). RESULTS: Ninety-eight women received bupivacaine, 90 ropivacaine, and 34 levobupivacaine (before it was removed from the US market). There was no significant difference in the operative delivery rate (bupivacaine = 46%, ropivacaine = 39%, and levobupivacaine = 32%, P = 0.35) among groups. There was less motor block in the levobupivacaine group when compared with the ropivacaine and bupivacaine groups, P < 0.05. There was no significant difference in the duration of the first or second stage of labor, the total dose of LA received per hour of labor, or neonatal outcome among groups. CONCLUSIONS: Bupivacaine, ropivacaine, and levobupivacaine all confer adequate labor epidural analgesia, with no significant influence on mode of delivery, duration of labor, or neonatal outcome.	NYU, Mt Sinai Sch Med, Dept Anesthesiol, New York, NY USA; NYU, Mt Sinai Sch Med, Dept Obstet, New York, NY USA; NYU, Mt Sinai Sch Med, Dept Gynecol, New York, NY USA; NYU, Mt Sinai Sch Med, Dept Reprod Sci, New York, NY USA; NYU, Mt Sinai Sch Med, Div Biostat, New York, NY USA	Beilin, Y (reprint author), Mt Sinai Med Ctr, Dept Anesthesiol, Box 1010,Gustave L Levy Pl 1, New York, NY 10029 USA.	yaakov.beilin@mountsinai.org					Beilin Y, 1998, ANESTHESIOLOGY, V88, P1502, DOI 10.1097/00000542-199806000-00013; Bolukbasi D, 2005, INT J OBSTET ANESTH, V14, P288, DOI 10.1016/j.ijoa.2005.04.007; BROCKWAY MS, 1991, BRIT J ANAESTH, V66, P31, DOI 10.1093/bja/66.1.31; Burke D, 1999, BRIT J ANAESTH, V83, P750; Camorcia M, 2003, EUR J ANAESTH, V20, P636, DOI 10.1097/00003643-200308000-00008; Campbell DC, 2000, ANESTH ANALG, V90, P1384, DOI 10.1097/00000539-200006000-00023; Capogna G, 1999, BRIT J ANAESTH, V82, P371, DOI 10.1093/bja/82.3.371; D'Angelo R, 1999, ANESTHESIOLOGY, V90, P941, DOI 10.1097/00000542-199904000-00002; ELDOR J, 1988, RESUSCITATION, V16, P155, DOI 10.1016/0300-9572(88)90042-1; Evron S, 2004, INT J OBSTET ANESTH, V13, P5, DOI 10.1016/S0959-289X(03)00092-X; Gautier P, 1999, ANESTHESIOLOGY, V90, P772, DOI 10.1097/00000542-199903000-00020; Gogarten W, 2004, EUR J ANAESTH, V21, P38, DOI 10.1017/S0265021504001073; Halpern SH, 2003, ANESTHESIOLOGY, V98, P1431, DOI 10.1097/00000542-200306000-00020; Halpern SH, 2003, ANESTH ANALG, V96, P1473, DOI 10.1213/01.ANE.0000052383.01056.8F; Lacassie HJ, 2002, ANESTH ANALG, V95, P204, DOI 10.1097/00000539-200207000-00036; Lacassie HJ, 2003, ANESTH ANALG, V97, P1509, DOI 10.1213/01.ANE.0000083375.48151.FF; Lee BB, 2004, ANESTH ANALG, V98, P1145, DOI 10.1213/01.ANE.0000103264.71747.0F; Lieberman E, 2005, OBSTET GYNECOL, V105, P974, DOI 10.1097/01.AOG.0000158861.43593.49; Lyons G, 1998, BRIT J ANAESTH, V81, P899; MacArthur C, 2001, LANCET, V358, P19; Meister GC, 2000, ANESTH ANALG, V90, P632, DOI 10.1097/00000539-200003000-00024; Nageotte MP, 1997, NEW ENGL J MED, V337, P1715, DOI 10.1056/NEJM199712113372402; Polley LS, 1999, ANESTHESIOLOGY, V90, P944, DOI 10.1097/00000542-199904000-00003; Purdie NL, 2004, ANAESTHESIA, V59, P133, DOI 10.1111/j.1365-2044.2004.03582.x; Reynolds F, 1997, INT J OBSTET ANESTH, V6, P257, DOI 10.1016/S0959-289X(97)80034-9; Russell R, 1996, ANAESTHESIA, V51, P266, DOI 10.1111/j.1365-2044.1996.tb13645.x; Vercauteren MP, 2001, ANESTH ANALG, V93, P996, DOI 10.1097/00000539-200110000-00040; VERTOMMEN JD, 1991, ANESTHESIOLOGY, V74, P809, DOI 10.1097/00000542-199105000-00002; Writer WDR, 1998, BRIT J ANAESTH, V81, P713, DOI 10.1093/bja/81.5.713	29	31	38	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	SEP	2007	105	3					756	763		10.1213/01.ane.0000278131.73472.f4			8	Anesthesiology	Anesthesiology	202SS	WOS:000248924400032	17717236				2020-06-30	J	Kardash, K; Hickey, D; Tessler, MJ; Payne, S; Zukor, D; Velly, AM				Kardash, Ken; Hickey, Don; Tessler, Michael J.; Payne, Stacey; Zukor, David; Velly, Ana Miriam			Obturator versus femoral nerve block for analgesia after total knee arthroplasty	ANESTHESIA AND ANALGESIA			English	Article							SINGLE-INJECTION; POSTOPERATIVE ANALGESIA; 3-IN-ONE BLOCK; REPLACEMENT; REHABILITATION; ANESTHESIA; RECOVERY; SURGERY; LENGTH; STAY	BACKGROUND: Both femoral and obturator nerve blocks have been suggested to be useful in relieving pain after total knee arthroplasty (TKA). We sought to compare their efficacy. METHODS: Sixty patients undergoing elective unilateral TKA under spinal anesthesia received in a randomized, double-blind manner a femoral, obturator, or sham nerve block at the end of surgery. Blocks were performed using nerve stimulation and 20 mL, bupivacaine 0.5% containing epinephrine 5 mu g/mL. Patient-controlled, IV analgesia with fentanyl, celecoxib 100 mg PO bid, and acetaminophen 650 mg PO every 6 h were started on arrival in the recovery room. Pain (0-10 numeric rating scale, NRS) at rest and with movement, analgesic use, and side effects were recorded for 48 h. Maximum knee flexion and total days in hospital were recorded as functional outcomes. RESULTS: There were no significant differences in the obturator block group and the control group in any outcome variable. With baseline pain scores subtracted, femoral block resulted in less pain at rest compared with control (NRS difference from baseline 2.1 +/- 0.4 SEM vs 3.4 +/- 0.4, respectively; P = 0.02) and less pain with movement (NRS difference 2.6 +/- 0.6, 4.3 +/- 0.6, P = 0.05) at recovery room discharge. Neither block had a significant effect on opioid use, functional outcome, or side effects. Only one (5%) patient with femoral block developed obturator motor block. CONCLUSION: Femoral nerve blocks rarely block the obturator nerve. Single-injection femoral nerve block improved multimodal analgesia after spinal anesthesia for TKA, but this effect did not persist beyond the day of surgery. Obturator nerve block alone was of no benefit.	McGill Univ, Jewish Gen Hosp, Dept Anesthesia, Montreal, PQ H3T 1E2, Canada; McGill Univ, Jewish Gen Hosp, Dept Nursing, Montreal, PQ H3T 1E2, Canada; McGill Univ, Jewish Gen Hosp, Dept Orthoped Surg, Montreal, PQ H3T 1E2, Canada; Univ Minnesota, Dept Diagnost & Behav Sci, Minneapolis, MN USA	Kardash, K (reprint author), SMBD Jewish Gen Hosp, Dept Anesthesia, 3755 Cote Ste Catherine, Montreal, PQ H3T 1E2, Canada.	kenneth.kardash@mcgill.ca					Allen HW, 1998, ANESTH ANALG, V87, P93, DOI 10.1097/00000539-199807000-00020; ATANASSOFF PG, 1995, ANESTH ANALG, V81, P529, DOI 10.1097/00000539-199509000-00018; Ben-David B, 2004, ANESTH ANALG, V98, P747; Bouaziz H, 2002, ANESTH ANALG, V94, P445, DOI 10.1097/00000539-200202000-00041; Capdevila X, 1999, ANESTHESIOLOGY, V91, P8, DOI 10.1097/00000542-199907000-00006; Chelly JE, 2001, J ARTHROPLASTY, V16, P436, DOI 10.1054/arth.2001.23622; Choyce A, 2001, REGION ANESTH PAIN M, V26, P100, DOI 10.1053/rapm.2001.21740; Enneking FK, 2005, REGION ANESTH PAIN M, V30, P4, DOI 10.1016/j.rapm.2004.10.002; Hirst GC, 1996, REGION ANESTH, V21, P292; Jochum D, 2005, ANAESTHESIA, V60, P974, DOI 10.1111/j.1365-2044.2005.04329.x; LANG SA, 1993, J CLIN ANESTH, V5, P292, DOI 10.1016/0952-8180(93)90121-T; Levesque S, 2005, REGION ANESTH PAIN M, V30, P410, DOI 10.1016/j.rapm.2005.03.007; Macalou D, 2004, ANESTH ANALG, V99, P251, DOI 10.1213/01.ANE.0000121350.09915.84; McNamee DA, 2002, ACTA ANAESTH SCAND, V46, P95, DOI 10.1034/j.1399-6576.2002.460117.x; Ng HP, 2001, CAN J ANAESTH, V48, P1102; Salinas FV, 2006, ANESTH ANALG, V102, P1234, DOI 10.1213/01.ane.0000198675.20279.81; Singelyn FJ, 1998, ANESTH ANALG, V87, P88, DOI 10.1097/00000539-199807000-00019; Wang H, 2002, REGION ANESTH PAIN M, V27, P139, DOI 10.1053/rapm.2002.29253; WilliamsRusso P, 1996, CLIN ORTHOP RELAT R, P199, DOI 10.1097/00003086-199610000-00028; WINNIE AP, 1973, ANESTH ANALG, V52, P989	20	37	43	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	SEP	2007	105	3					853	858		10.1213/01.ane.0000278158.36843.f7			6	Anesthesiology	Anesthesiology	202SS	WOS:000248924400046	17717250				2020-06-30	J	Spence, AG				Spence, Andrew G.			Lipid reversal of central nervous system symptoms of bupivacaine toxicity	ANESTHESIOLOGY			English	Letter							INDUCED ASYSTOLE; INFUSION; RESUSCITATION; EMULSION; PATIENT		King Edward VII Mem Hosp, Hamilton, Bermuda	Spence, AG (reprint author), King Edward VII Mem Hosp, Hamilton, Bermuda.	aspence@transact.bm					Litz RJ, 2006, ANAESTHESIA, V61, P800, DOI 10.1111/j.1365-2044.2006.04740.x; Rosenblatt MA, 2006, ANESTHESIOLOGY, V105, P217, DOI 10.1097/00000542-200607000-00033; Weinberg G, 2006, ANESTHESIOLOGY, V105, P7, DOI 10.1097/00000542-200607000-00005; Weinberg G, 2003, REGION ANESTH PAIN M, V28, P198, DOI 10.1053/rapm.2003.50041; Weinberg GL, 1998, ANESTHESIOLOGY, V88, P1071, DOI 10.1097/00000542-199804000-00028; Weinberg GL, 2006, REGION ANESTH PAIN M, V31, P296, DOI 10.1016/j.rapm.2005.02.011	6	78	87	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-3022			ANESTHESIOLOGY	Anesthesiology	SEP	2007	107	3					516	517		10.1097/01.anes.0000278864.75082.72			2	Anesthesiology	Anesthesiology	208CK	WOS:000249297200029	17721262	Bronze			2020-06-30	J	Atangana, R; Esiene, A; Medou, A; Binam, F; Moyo, JS; Sosso, MA				Atangana, R.; Esiene, A.; Medou, A.; Binam, F.; Moyo, J. Simo; Sosso, M. A.			Comparison between fentanyl and ketamine as adjuvants of bupivacaine in spinal anaesthesia	ANNALES FRANCAISES D ANESTHESIE ET DE REANIMATION			French	Letter						adjuvants; bupivacaine; spinal anaesthesia; fentanyl; ketamine			Hop Gen Yaounde, Fac Med & Sci Biomed, Dept Chirurg & Specialites, Yaounde, Cameroon	Atangana, R (reprint author), Hop Gen Yaounde, Fac Med & Sci Biomed, Dept Chirurg & Specialites, BP 5408, Yaounde, Cameroon.	reneatangana@yahoo.fr					Kathirvel S, 2000, ANAESTHESIA, V55, P899, DOI 10.1046/j.1365-2044.2000.01472.x; Malinovsky JM, 1996, ANN FR ANESTH, V15, P647, DOI 10.1016/0750-7658(96)82129-0; Unlugenc H, 2006, EUR J ANAESTH, V23, P1018, DOI 10.1017/S0265021506000950; Vranken JH, 2006, ANESTHESIOLOGY, V105, P813, DOI 10.1097/00000542-200610000-00028; Vranken JH, 2006, PAIN, V121, P284, DOI 10.1016/j.pain.2006.01.008	5	0	0	0	0	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0750-7658	1769-6623		ANN FR ANESTH	Ann. Fr. Anest. Reanim.	SEP	2007	26	9					815	816		10.1016/j.annfar.2007.05.013			2	Anesthesiology	Anesthesiology	212IK	WOS:000249589700013	17629662				2020-06-30	J	Muller, AA; Osterhoudt, KC; Wingert, W				Muller, Allison A.; Osterhoudt, Kevin C.; Wingert, William			Heroin: What's in the mix?	ANNALS OF EMERGENCY MEDICINE			English	Letter									Childrens Hosp Philadelphia, Poison control Ctr, Philadelphia, PA 19104 USA; Med Examiners Off, Philadelphia, PA USA	Muller, AA (reprint author), Childrens Hosp Philadelphia, Poison control Ctr, Philadelphia, PA 19104 USA.						HOFFMAN RS, 2005, MMWR-MORBID MORTAL W, V54, P793; LEINWARD D, 2006, USA TODAY       0426; PERRONE J, 1996, MMWR-MORBID MORTAL W, V45, P457; Werder Gabriel, 2006, Conn Med, V70, P5	4	8	9	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644			ANN EMERG MED	Ann. Emerg. Med.	SEP	2007	50	3					352	353		10.1016/j.annemergmed.2007.03.041			2	Emergency Medicine	Emergency Medicine	206YN	WOS:000249218900024	17709054				2020-06-30	J	Bollen, PJA; Nielsen, BJ; Toft, P				Bollen, Peter J. A.; Nielsen, Bjorn J.; Toft, Palle			Influence of endotoxin-induced sepsis on the requirements of propofol-fentanyl infusion rate in pigs	BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY			English	Article							HEMORRHAGIC-SHOCK; PHARMACODYNAMIC ANALYSIS; CEREBRAL STATE; PORCINE MODEL; INDEX; ENCEPHALOPATHY; GRANULOCYTES	Endotoxin-induced sepsis in pigs is a recognized experimental model for the study of human septic shock. Generally, pigs are brought into general anaesthesia before sepsis is induced. It is our experience that drug dosages of propofol and fentanyl need to be reduced during endotoxin-induced sepsis, in order to prevent respiratory and cardiovascular depression, but the scientific evidence for this observation is lacking. Therefore, we measured the consumption of propofol and fentanyl at equal level of anaesthesia in pigs with (n = 5) and without (n = 5) endotoxin-induced sepsis, using the cerebral state index (CSI) as measure of anaesthetic depth. Infusion rates of propofol (P < 0.01) and fentanyl (P < 0.05) were significantly lower in septic pigs. Pigs with endotoxin-induced sepsis had an infusion rate of 2.2 mg/kg/hr (S.D. 0.5) for propofol and 12 mu g/kg/hr (S.D. 2) for fentanyl, whereas healthy pigs had infusion rates of 3.5 ing/kg/hr (S.D. 0.6) and 17 mu g/kg/hr (S.D. 4), respectively. CSI was equal in both groups throughout the experiment, and had a lowest average value of 47 (S.D. 10) at t = 30 in healthy pigs and reached a highest average value of 67 (S.D. 19) at t = 240 in pigs with endotoxin-induced sepsis. Anaesthetic depth was sufficient, assessed clinically, throughout the experiment in both groups. We concluded that the consumption of propofol and fentanyl was significantly reduced in pigs with endotoxin-induced sepsis. In the present study, we adjusted the level of anaesthesia according to clinical signs, and found good agreement with CSI.	Univ So Denmark, Biomed Lab, DK-5000 Odense, Denmark; Odense Univ Hosp, Dept Anesthesiol, DK-5000 Odense, Denmark	Bollen, PJA (reprint author), Univ So Denmark, Biomed Lab, Winslowparken 23, DK-5000 Odense, Denmark.	pbollen@health.sdu.dk		Bollen, Peter/0000-0003-3796-1609			Aghajani E, 2004, SHOCK, V21, P103, DOI 10.1097/01.shk.0000105503.75189.17; Allaouchiche B, 2001, BRIT J ANAESTH, V86, P832, DOI 10.1093/bja/86.6.832; *ASP MED SYST, 2004, A 2000 BISP IND MON; Bleck TP, 2002, CRIT CARE MED, V30, P1176, DOI 10.1097/00003246-200205000-00047; Chan MTV, 2000, EUR J ANAESTH, V17, P146, DOI 10.1046/j.1365-2346.2000.00613.x; Cortinez LI, 2007, ANESTH ANALG, V104, P605, DOI 10.1213/01.ane.0000255152.96354.17; DANMETER AS, 2004, CEREBAL STATE MONITO; Egan TD, 1999, ANESTHESIOLOGY, V91, P156, DOI 10.1097/00000542-199907000-00024; Eidelman LA, 1996, JAMA-J AM MED ASSOC, V275, P470, DOI 10.1001/jama.275.6.470; Johnson KB, 2003, ANESTHESIOLOGY, V99, P409, DOI 10.1097/00000542-200308000-00023; Johnson KB, 2003, ANESTH ANALG, V96, P1360, DOI 10.1213/01.ANE.0000055804.30509.69; Johnson KB, 2001, ANESTHESIOLOGY, V94, P322, DOI 10.1097/00000542-200102000-00023; Pilge S, 2006, ANESTHESIOLOGY, V104, P488, DOI 10.1097/00000542-200603000-00016; Tiren C, 2005, ANAESTHESIA, V60, P189, DOI 10.1111/j.1365-2044.2004.04063.x; Toft P, 2002, ACTA ANAESTH SCAND, V46, P138, DOI 10.1034/j.1399-6576.2002.460203.x; Toft P, 2000, INTENS CARE MED, V26, P770, DOI 10.1007/s001340051245; Walsh TS, 2004, INTENS CARE MED, V30, P1511, DOI 10.1007/s00134-004-2271-z; Zauner C, 2000, CRIT CARE MED, V28, P1310, DOI 10.1097/00003246-200005000-00009; Ziser A, 2003, CRIT CARE MED, V31, P2029, DOI 10.1097/01.CCM.0000070445.76287.6E	19	8	8	0	7	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	1742-7835			BASIC CLIN PHARMACOL	Basic Clin. Pharmacol. Toxicol.	SEP	2007	101	3					192	196		10.1111/j.1742-7843.2007.00099.x			5	Pharmacology & Pharmacy; Toxicology	Pharmacology & Pharmacy; Toxicology	206SR	WOS:000249203700009	17697040				2020-06-30	J	Dewachter, P; Mouton-Faivre, C				Dewachter, Pascale; Mouton-Faivre, Claudic			Patients who experience a perioperative anaphylactic reaction should not be skin-tested too early	CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Letter									Ctr Hosp Univ, Hop Cent, Nancy, France	Dewachter, P (reprint author), Ctr Hosp Univ, Hop Cent, Nancy, France.	pascale.dewachter@yahoo.fr					*ASS AN GREAT BRIT, 2003, SUSP AN REACT ASS AN; Cummings KC, 2007, CAN J ANAESTH, V54, P301, DOI 10.1007/BF03022776; *FRENCH SOC AN INT, 2002, ANN FR ANESTH S, V21, P7; Johansson SGO, 2001, ALLERGY, V56, P813, DOI 10.1034/j.1398-9995.2001.t01-1-00001.x; Joint Task Force on Practice Parameters American Academy of Allergy Asthma and Immunology American College of Allergy Asthma and Immunology Joint Council of Allergy Asthma and Immunology, 2005, J ALLERGY CLIN IM S2, V115, pS483; RING J, 1977, LANCET, V1, P466; 1992, [No title captured], V90, P263	7	3	4	0	0	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0832-610X			CAN J ANAESTH	Can. J. Anaesth.-J. Can. Anesth.	SEP	2007	54	9					768	769		10.1007/BF03026875			2	Anesthesiology	Anesthesiology	213CH	WOS:000249643000012	17766746	Bronze			2020-06-30	J	Darwish, M; Kirby, M; Jiang, JG				Darwish, M.; Kirby, M.; Jiang, J. G.			Effect of buccal dwell time on the pharmacokinetic profile of fentanyl buccal tablet	EXPERT OPINION ON PHARMACOTHERAPY			English	Review						breakthrough pain; dwell time; fentanyl buccal tablet; pharmacokinetics	HEALTHY ADULT VOLUNTEERS; DOSE PROPORTIONALITY; BREAKTHROUGH PAIN; OPEN-LABEL; MU-G; CITRATE; CANCER	Background: The time fentanyl buccal tablet (FBT) takes to completely dissolve after placement on the buccal mucosa (i.e.,'dwell time') could exceed the time to onset of analgesia. Objective: To examine the relationship between FBT dwell time and fentanyl pharmacokinetic parameters. Research design and methods: This was a post hoc exploratory analysis of data from two randomized, openlabel, crossover, pharmacokinetic studies that were designed to assess dose proportionality within the anticipated therapeutic dose range. Healthy adults received single FBT doses of 200 - 1080 mu g in Study 1 (n = 28) and 270 - 1300 mu g in Study 2 (n = 42). Main outcome measures: Assessments included buccal dwell time, defined as the duration of FBT presence in the oral cavity, and the following pharmacokinetic measures: maximum serum concentration (Cm,)), time to C-max (T-max) and area under the concentration-time curve (AUC; exposure) from 0 minutes to median T-max adjusted for the dose (T-max) (AUCO-T-max)- Spontaneously reported adverse events were recorded. Results: Mean buccal dwell time for FBT across the dose range varied from 14 to 25 minutes (range 3 - 62 minutes). There was no evidence of an association between FBT dwell time and values for T-max (medians 45 - 60 minutes), dose-normalized Cmax (means 0.42 - 0.66 pg/ml/200 mu g) or dose-normalized AILIC(0) - T-max, (means 0.24 - 0.38 pg.h/ml/200 mu g) over the range of FBT doses delivered. All adverse events reported were mild to moderate; none were unexpected or serious. Conclusion: The pharmacokinetic parameters of FBT did not appear to be related to its buccal dwell time.	Cephalon Inc, Clin Pharmacol, Frazer, PA 19355 USA	Darwish, M (reprint author), Cephalon Inc, Clin Pharmacol, 41 Moores Rd, Frazer, PA 19355 USA.	mdarwish@cephalon.com					Darwish M, 2006, CLIN THER, V28, P707, DOI 10.1016/j.clinthera.2006.05.015; Darwish M, 2006, CLIN THER, V28, P715, DOI 10.1016/j.clinthera.2006.05.016; Darwish M, 2005, CLIN PHARMACOKINET, V44, P1279, DOI 10.2165/00003088-200544120-00006; Darwish M, 2007, J CLIN PHARMACOL, V47, P56, DOI 10.1177/0091270006294129; Darwish M, 2006, CLIN PHARMACOKINET, V45, P843, DOI 10.2165/00003088-200645080-00006; Durfee S, 2006, AM J DRUG DELIV, V4, P1, DOI DOI 10.2165/00137696-200604010-00001; PAYNE R, 1992, J PAIN SYMPTOM MANAG, V7, pS40, DOI 10.1016/0885-3924(92)90052-J; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Rees Elizabeth, 2002, Int J Palliat Nurs, V8, P304; Slatkin Neal E, 2007, J Support Oncol, V5, P327; Stanley TH, 2005, J PAIN SYMPTOM MANAG, V29, pS67, DOI 10.1016/j.jpainsymman.2005.01.009; WEINBERG DS, 1988, CLIN PHARMACOL THER, V44, P335, DOI 10.1038/clpt.1988.159; Zeppetella G, 2001, PALLIATIVE MED, V15, P323, DOI 10.1191/026921601678320304; 1983, [No title captured], V64, P3; 2006, FENTORA	15	12	12	0	1	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	1465-6566			EXPERT OPIN PHARMACO	Expert Opin. Pharmacother.	SEP	2007	8	13					2011	2016		10.1517/14656566.8.13.2011			6	Pharmacology & Pharmacy	Pharmacology & Pharmacy	211FL	WOS:000249509600002	17714055				2020-06-30	J	Vargo, JJ				Vargo, John J.			Big NAPS, little NAPS, mixed NAPS, computerized NAPS: what is your flavor of propofol?	GASTROINTESTINAL ENDOSCOPY			English	Editorial Material							NURSE-ADMINISTERED PROPOFOL; GASTROINTESTINAL-ENDOSCOPY; AMERICAN-SOCIETY; CONTROLLED-TRIAL; MODERATE SEDATION; COLONOSCOPY; MIDAZOLAM; MEPERIDINE; ADJUNCT; ERCP		Cleveland Clin Fdn, Dept Gastroenterol & Hepatol, Sect Therapeut & Hepatobiliary Endoscopy, Cleveland, OH 44195 USA	Vargo, JJ (reprint author), Cleveland Clin Fdn, Dept Gastroenterol & Hepatol, Sect Therapeut & Hepatobiliary Endoscopy, 9500 Euclid Ave, Cleveland, OH 44195 USA.			Vargo, John/0000-0001-7638-5283			ARROWSMITH JB, 1991, GASTROINTEST ENDOSC, V37, P421, DOI 10.1016/S0016-5107(91)70773-6; Chen SC, 2004, AM J GASTROENTEROL, V99, P1081, DOI 10.1111/j.1572-0241.2004.03279.x; Cohen LB, 2004, GASTROINTEST ENDOSC, V59, P795, DOI 10.1016/S0016-5107(04)00349-9; Drake LM, 2006, AM J GASTROENTEROL, V101, P2003, DOI 10.1111/j.1572-0241.2006.00806.x; Fechner J, 2005, ANESTH ANALG, V100, P701, DOI 10.1213/01.ANE.0000144772.13372.F4; Gross JB, 2002, ANESTHESIOLOGY, V96, P1004; Kulling D, 2007, GASTROINTEST ENDOSC, V66, P443, DOI 10.1016/j.gie.2007.01.037; Lightdale JR, 2006, PEDIATRICS, V117, pE1170, DOI 10.1542/peds.2005-1709; Nelson DB, 2000, GASTROINTEST ENDOSC, V51, P288, DOI 10.1016/S0016-5107(00)70357-9; Pambianco D, 2006, AM J GASTROENTEROL, V101, pS509, DOI 10.14309/00000434-200609001-01325; Rex DK, 2005, GASTROENTEROLOGY, V129, P1384, DOI 10.1053/j.gastro.2005.08.014; Sharma VK, 2002, GASTROINTEST ENDOSC, V55, pAB99; SILVIS SE, 1976, JAMA-J AM MED ASSOC, V235, P928, DOI 10.1001/jama.235.9.928; Sipe BW, 2002, GASTROINTEST ENDOSC, V55, P815, DOI 10.1067/mge.2002.124636; VanNatta ME, 2006, AM J GASTROENTEROL, V101, P2209, DOI 10.1111/j.1572-0241.2006.00760.x; Vargo JJ, 2002, GASTROENTEROLOGY, V123, P8, DOI 10.1053/gast.2002.34232; Wehrmann T, 2002, GASTROINTEST ENDOSC, V56, P817, DOI 10.1067/mge.2002.129603; Weitz G, 2007, GASTROINTEST ENDOSC, V66, P450, DOI 10.1016/j.gie.2007.01.036; Weston BR, 2003, AM J GASTROENTEROL, V98, P2440, DOI 10.1016/S0002-9270(03)01701-5	19	8	8	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0016-5107			GASTROINTEST ENDOSC	Gastrointest. Endosc.	SEP	2007	66	3					457	459		10.1016/j.gie.2007.03.1035			3	Gastroenterology & Hepatology	Gastroenterology & Hepatology	211DE	WOS:000249503700005	17725935				2020-06-30	J	Vedtofte, JI; Rasmussen, LS				Vedtofte, Jakob I.; Rasmussen, Lars S.			The use of bispectral index monitoring in education - a tool to improve nurse-anaesthetists practice	JOURNAL OF ADVANCED NURSING			English	Article						bispectral monitoring; empirical research report; experimental design; depth of anaesthesia; nurse-anaesthetists; nurse education	AUDITORY-EVOKED-RESPONSE; PROPOFOL ANESTHESIA; RECOVERY; AWARENESS; SEVOFLURANE; CONSUMPTION; TITRATION	Title. The use of bispectral index monitoring in education - a tool to improve nurse-anaesthetists practice Aim. This paper is a report of a study to investigate whether monitoring depth of anaesthesia by bispectral index would reduce recovery time and consumption of anaesthetic drugs in anaesthetics performed by student nurse-anaesthetists. Background. It is difficult to assess the depth of anaesthesia clinically. Studies have shown that experienced anaesthetists can titrate anaesthetics more accurately when using bispectral index monitors. It is not known if student nurse-anaesthetists can benefit from their use in a similar way. Method. A multicentre study involving four hospitals was carried out during a 13-month period in 2003 and 2004. In total 25 nurses participated, each contributing with two procedures: one with monitoring and one without. The nurses had at least 10 months of experience in conducting anaesthesia and all had a theoretical introduction and a test session to become familiar with the equipment. The sequence was randomized and the observer was blinded to whether a monitor was used. Fifty patients were anaesthetized with propofol and fentanyl. Recovery time, consumption of anaesthetic drugs, and patient satisfaction were measured in both groups. Results. Recovery time was 11 minutes in the monitor group (range: 2-53 minutes) and 15 minutes in the control group, (range: 3-60 minutes). P = 0.26. There were no statistically significant differences in consumption of anaesthetic drugs or patient satisfaction in the two groups. Conclusion. It was not possible to demonstrate a statistically significant reduction in recovery time or consumption of anaesthetic drugs when using bispectral index monitoring during training of student nurse-anaesthetists.	Univ Copenhagen Hosp, Ctr Head & Orthopaed, Dept Anaesthesia, DK-2100 Copenhagen, Denmark	Vedtofte, JI (reprint author), Univ Copenhagen Hosp, Ctr Head & Orthopaed, Dept Anaesthesia, DK-2100 Copenhagen, Denmark.	jakob.vedtofte@rh.regionh.dk		Rasmussen, Lars/0000-0002-7480-3004			Basar H, 2003, EUR J ANAESTH, V20, P396; Chan MTV, 2000, EUR J ANAESTH, V17, P146, DOI 10.1046/j.1365-2346.2000.00613.x; Guignard B, 2001, ACTA ANAESTH SCAND, V45, P308, DOI 10.1034/j.1399-6576.2001.045003308.x; Leslie K, 2003, ANAESTH INTENS CARE, V31, P63, DOI 10.1177/0310057X0303100113; Loveman E, 2001, BRIT J ANAESTH, V86, P513, DOI 10.1093/bja/86.4.513; Luginbuhl M, 2003, ACTA ANAESTH SCAND, V47, P165, DOI 10.1034/j.1399-6576.2003.00041.x; MAHLA ME, 2001, ANESTHESIOLOGY, V95, pA1151; Pavlin DJ, 2001, ANESTH ANALG, V93, P613, DOI 10.1097/00000539-200109000-00017; Song DJ, 1997, ANESTHESIOLOGY, V87, P842, DOI 10.1097/00000542-199710000-00018; STROMBERG W, 2001, J CLIN NURS, V10, P429; THORNTON C, 1989, BRIT J ANAESTH, V63, P113, DOI 10.1093/bja/63.1.113; Wong J, 2002, CAN J ANAESTH, V49, P13, DOI 10.1007/BF03020413; Yli-Hankala A, 1999, ACTA ANAESTH SCAND, V43, P545, DOI 10.1034/j.1399-6576.1999.430510.x	13	1	1	0	1	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0309-2402			J ADV NURS	J. Adv. Nurs.	SEP	2007	59	6					577	582		10.1111/j.1365-2648.2007.04349.x			6	Nursing	Nursing	205CP	WOS:000249091100003	17727401				2020-06-30	J	Temiz, OM; Lang, GK				Temiz, O. M.; Lang, G. K.			A case of protracted, bilateral angle closure glaukoma, masked by fentanyl	KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE			German	Article							TRANSDERMAL FENTANYL; GLAUCOMA		Univ Ulm, Augenklin, D-89075 Ulm, Germany	Temiz, OM (reprint author), Univ Ulm, Augenklin, Prittwitzstr 43, D-89075 Ulm, Germany.						Ahmedzai S, 1997, Ann Oncol, V8 Suppl 3, pS21; Congdon Nathan G, 2003, Curr Opin Ophthalmol, V14, P70, DOI 10.1097/00055735-200304000-00002; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; Jeal W, 1997, DRUGS, V53, P109, DOI 10.2165/00003495-199753010-00011; Johnson GJ, 2005, EYE, V19, P1119, DOI 10.1038/sj.eye.6701970; LANG GK, 2004, LEHRBUCH AUGENHEILKU, P285; PATEL KH, 1995, AM J OPHTHALMOL, V120, P709, DOI 10.1016/S0002-9394(14)72724-2	7	0	0	0	0	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0023-2165	1439-3999		KLIN MONATSBL AUGENH	Klinische Monatsblat. Augenheilkunde	SEP	2007	224	9					738	739		10.1055/s-2007-963374			2	Ophthalmology	Ophthalmology	216JD	WOS:000249873400009	17846966				2020-06-30	J	Von Ungern-Sternberg, BS; Regli, A; Frei, FJ; Hammer, J; Ritz, EMJ; Erb, TO				Von Ungern-Sternberg, Britta S.; Regli, Adrian; Frei, Franz J.; Hammer, Juerg; Ritz, Eva-Maria Jordi; Erb, Thomas O.			Decrease in functional residual capacity and ventilation homogeneity after neuromuscular blockade in anesthetized preschool children in the lateral position	PEDIATRIC ANESTHESIA			English	Article						pediatric anesthesia; respiratory function; functional; residual capacity; ventilation distribution; lateral position; neuromuscular; blockade	LUNG	Background: While functional residual capacity (FRC) is reduced in children undergoing general anesthesia, the lateral position leads to an increase in FRC compared with the supine position. The impact of neuromuscular blockade remains unknown. We tested the hypothesis that neuromuscular blockade leads to a decrease in FRC and increase in lung clearance index (LCI) while the application of positive endexpiratory pressure (PEEP) of 6 cmH(2)O leads to a restoration in both parameters. Methods: After approval of the local Ethics Committee, we studied 18 preschool children (2-6 years) without cardiopulmonary disease, who were scheduled for elective surgery. Anesthesia was standardized using propofol and fentanyl. FRC and LCI were calculated by a blinded observer using a SF6 multibreath washout technique with an ultrasonic transit-time airflow meter (Exhalyzer D). Measurements were taken in the left lateral position (PEEP 3 cmH(2)O) after 1. intubation with a cuffed tracheal tube, 2. neuromuscular blockade with rocuronium, and 3. the additional application of PEEP (6 cmH(2)O). Results: Functional residual capacity mean (SD) decreased from 31.6 (4.4) ml.kg(-1) to 27.6 (4.2) ml.kg(-1) (P < 0.001) following neuromuscular blockade while the LCI increased from 6.54 (0.6) to 7.0 (0.6) (P <= 0.001). After the application of PEEP (6 cmH(2)O), FRC increased to 32.4 (5.0) ml.kg(-1) whereas the LCI decreased to 6.58 (0.5) showing no significant changes from baseline measurements. Conclusions: In the lateral position, neuromuscular blockade led to a significant decrease in FRC associated with a small increase in ventilation inhomogeneity. FRC and LCI were restored to baseline levels with the application of PEEP 3 cmH(2)O that is in addition to a background of PEEP 3 cmH(2)O giving a total of 6 cmH(2)O PEEP.	Univ Childrens Hosp, Div Anesthesia, CH-4005 Basel, Switzerland; Univ Childrens Hosp, Dept Anesthesia, CH-4005 Basel, Switzerland; Univ Childrens Hosp, Div Pneumol & Intens Care, CH-4005 Basel, Switzerland	Von Ungern-Sternberg, BS (reprint author), Univ Childrens Hosp, Div Anesthesia, Roemergasse 8, CH-4005 Basel, Switzerland.	bvonungern@uhbs.ch		Regli, Adrian/0000-0002-3960-6013; von Ungern-Sternberg, Britta/0000-0002-8043-8541			BHUYAN U, 1989, THORAX, V44, P480, DOI 10.1136/thx.44.6.480; DOBBINSON TL, 1973, CAN ANAESTH SOC J, V20, P322, DOI 10.1007/BF03027170; FROESE AB, 1974, ANESTHESIOLOGY, V41, P242, DOI 10.1097/00000542-197409000-00006; Gustafsson PM, 2003, EUR RESPIR J, V22, P972, DOI 10.1183/09031936.03.00049502; LARSSON A, 1989, BRIT J ANAESTH, V62, P378, DOI 10.1093/bja/62.4.378; MACKLEM PT, 1974, AM J MED, V57, P371, DOI 10.1016/0002-9343(74)90132-6; MANSELL A, 1972, J APPL PHYSIOL, V33, P711; NUNN JF, 1987, APPLIED RESPIRATORY, P23; Steur RJ, 2004, PEDIATR ANESTH, V14, P462, DOI 10.1111/j.1460-9592.2004.01238.x; Thome U, 1998, EUR J PEDIATR, V157, P831, DOI 10.1007/s004310050946; Tusman G, 2003, ANESTHESIOLOGY, V98, P14, DOI 10.1097/00000542-200301000-00006; von Ungern-Sternberg BS, 2006, ANAESTHESIA, V61, P758, DOI 10.1111/j.1365-2044.2006.04720.x; von Ungern-Sternberg BS, 2006, ANESTHESIOLOGY, V105, P670, DOI 10.1097/00000542-200610000-00010; VONUNGERNSTERNB.BS, 2005, PAEDIATR ANAESTH, V15, P800	14	11	11	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645	1460-9592		PEDIATR ANESTH	Pediatr. Anesth.	SEP	2007	17	9					841	845		10.1111/j.1460-9592.2007.02226.x			5	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	203ZD	WOS:000249011700004	17683401				2020-06-30	J	Ponde, V; Athani, B; Thruppal, S				Ponde, Vrushali; Athani, B.; Thruppal, Shreedhar			Infraclavicular coracoid approach brachial plexus block for radial club hand repair	PEDIATRIC ANESTHESIA			English	Article						infraclavicular coracoid approach brachial plexus block in children; radial club hand			All India Inst Phys Med & Rehabilitat, Dept Anesthesiol, Bombay, Maharashtra, India	Ponde, V (reprint author), Amit Apartments,401 Veronica Rd, Bombay 400050, Maharashtra, India.	vrushaliponok@yahoo.co.in					Borgeat A, 2001, ANESTH ANALG, V93, P436, DOI 10.1097/00000539-200108000-00040; Desroches T, 2003, CAN J ANAESTH, V50, P253, DOI 10.1007/BF03017794; Fisher WJ, 1999, PAEDIATR ANAESTH, V9, P435, DOI 10.1046/j.1460-9592.1999.00405.x; Kapral S, 1999, ACTA ANAESTH SCAND, V43, P1047, DOI 10.1034/j.1399-6576.1999.431013.x; KILKA HG, 1995, ANAESTHESIST, V44, P339, DOI 10.1007/s001010050162; Ponde V, 2006, PEDIATR ANESTH, V16, P601, DOI 10.1111/j.1460-9592.2006.01894.x; Salazar CH, 1999, REGION ANESTH PAIN M, V24, P411, DOI 10.1016/S1098-7339(99)90006-8; Waltl B, 2001, ANESTHESIOLOGY, V95, pA1235; WHIFFLER K, 1981, BRIT J ANAESTH, V53, P845; Wilson JL, 1998, ANESTH ANALG, V87, P870; WINNIE AP, 1973, ANESTH ANALG, V52, P989	11	5	6	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645	1460-9592		PEDIATR ANESTH	Pediatr. Anesth.	SEP	2007	17	9					863	866		10.1111/j.1460-9592.2007.02219.x			4	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	203ZD	WOS:000249011700008	17683405				2020-06-30	J	Jooste, EH; Chalifoux, T; Broadman, LM				Jooste, Edmund H.; Chalifoux, Thomas; Broadman, Lynn M.			A perioperative strategy for the placement of a thoracic epidural catheter in a pediatric patient on high-dose enoxaprin	PEDIATRIC ANESTHESIA			English	Letter							ANESTHESIA		Univ Pittsburgh, Childrens Hosp Pittsburgh, Dept Anesthesia & Pediat Anesthesiol, Pittsburgh, PA 15260 USA	Jooste, EH (reprint author), Univ Pittsburgh, Childrens Hosp Pittsburgh, Dept Anesthesia & Pediat Anesthesiol, Pittsburgh, PA 15260 USA.	joosteeh@upmc.edu					Heit JA, 1998, REGION ANESTH PAIN M, V23, P135, DOI 10.1016/S1098-7339(98)90138-9; Horlocker TT, 2003, REGION ANESTH PAIN M, V28, P172, DOI 10.1053/rapm.2003.50046; Moen V, 2004, ANESTHESIOLOGY, V101, P950, DOI 10.1097/00000542-200410000-00021; Tryba M, 1993, Anasthesiol Intensivmed Notfallmed Schmerzther, V28, P179, DOI 10.1055/s-2007-998902; VANDERMEULEN EP, 1994, ANESTH ANALG, V79, P1165	5	1	1	0	0	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	1155-5645			PEDIATR ANESTH	Pediatr. Anesth.	SEP	2007	17	9					907	909		10.1111/j.1460-9592.2007.02290.x			3	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	203ZD	WOS:000249011700022	17683419				2020-06-30	J	Pershad, J; Wan, J; Anghelescu, DL				Pershad, Jay; Wan, Jim; Anghelescu, Doralina L.			Comparison of propofol with Pentobarbital/Midazolam/Fentanyl sedation for magnetic resonance Imaging of the brain in children	PEDIATRICS			English	Article						propofol; pentobarbital/midazolam/fentanyl; MRI	PEDIATRIC EMERGENCY-DEPARTMENT; PROCEDURAL SEDATION; CHLORAL HYDRATE; DEEP SEDATION; MRI; CT; ANESTHESIA; EXPERIENCE; PHYSICIANS; MIDAZOLAM	OBJECTIVE. Propofol and pentobarbital, alone or combined with other agents, are frequently used to induce deep sedation in children for MRI. However, we are unaware of a previous comparison of these 2 agents as part of a randomized, controlled trial. We compared the recovery time of children after deep sedation with single-agent propofol with a pentobarbital-based regimen for MRI and considered additional variables of safety and efficacy. METHODS. This prospective, randomized trial at a tertiary children's hospital enrolled 60 patients 1 to 17 years old who required intravenous sedation for elective cranial MRI. Patients were assigned randomly to receive a loading dose of propofol followed by continuous intravenous infusion of propofol or to receive sequential doses of midazolam, pentobarbital, and fentanyl until a modified Ramsay score of > 4 was attained. A nurse who was blind to group assignment assessed discharge readiness ( Aldrete score > 8) and administered a follow-up questionnaire. We compared recovery time, time to induction of sedation, total sedation time, quality of imaging, number of repeat-image sequences, adverse events, caregiver satisfaction, and time to return to presedation functional status. RESULTS. The groups were similar in age, gender, race, American Society of Anesthesiology physical status class, and frequency of cognitive impairment. No sedation failure or significant adverse events were observed. Propofol offered significantly shorter sedation induction time, recovery time, total sedation time, and time to return to baseline functional status. Caregiver satisfaction scores were also significantly higher in the patients in the propofol group. CONCLUSIONS. Propofol permits faster onset and recovery than, and comparable efficacy to, a pentobarbital/ midazolam/ fentanyl regimen for sedation of children for MRI.	Univ Tennessee, Ctr Hlth Sci, Dept Pediat, Le Bonheur Childrens Med Ctr,Div Emergency Med, Memphis, TN 38103 USA; Univ Tennessee, Ctr Hlth Sci, Dept Prevent Med, Memphis, TN 38163 USA; St Jude Childrens Res Hosp, Div Anesthesiol, Memphis, TN 38105 USA	Pershad, J (reprint author), Univ Tennessee, Ctr Hlth Sci, Dept Pediat, Le Bonheur Childrens Med Ctr,Div Emergency Med, Memphis, TN 38103 USA.	pers2260@bellsouth.net	Anghelescu, Doralina L./N-8082-2018	Anghelescu, Doralina L./0000-0002-8521-2744	NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [CA21765]		ALDRETE JA, 1970, ANESTH ANAL CURR RES, V49, P924; Barbi E, 2003, ARCH PEDIAT ADOL MED, V157, P1097, DOI 10.1001/archpedi.157.11.1097; Bassett KE, 2003, ANN EMERG MED, V42, P773, DOI 10.1016/S0196-0644(03)00619-X; BLOOMFIELD EL, 1993, RADIOLOGY, V186, P93, DOI 10.1148/radiology.186.1.8416594; BRYSON HM, 1995, DRUGS, V50, P513, DOI 10.2165/00003495-199550030-00008; BURKE A, 1994, ANAESTHESIA, V49, P647; Connor L, 2003, AM J ROENTGENOL, V181, P1691, DOI 10.2214/ajr.181.6.1811691; Elitsur Y, 2000, ENDOSCOPY, V32, P788, DOI 10.1055/s-2000-7713; EMSC Grant Panel Pharmacologic Ag, 2004, J PEDIATR SURG, V39, P1472, DOI 10.1016/j.jpedsurg.2004.07.002; FRANKVILLE DD, 1993, ANESTHESIOLOGY, V79, P953, DOI 10.1097/00000542-199311000-00013; FULTON B, 1995, DRUGS, V50, P636, DOI 10.2165/00003495-199550040-00006; Godambe SA, 2003, PEDIATRICS, V112, P116, DOI 10.1542/peds.112.1.116; Greenberg SB, 2000, PEDIATR RADIOL, V30, P689, DOI 10.1007/s002470000304; Guenther E, 2003, ANN EMERG MED, V42, P783, DOI 10.1016/S0196-0644(03)00634-6; HANNALLAH RS, 1991, ANESTHESIOLOGY, V74, P217, DOI 10.1097/00000542-199102000-00004; Hasan Rashed A, 2003, Pediatr Crit Care Med, V4, P454, DOI 10.1097/01.PCC.0000090013.66899.33; Havel CJ, 1999, ACAD EMERG MED, V6, P989, DOI 10.1111/j.1553-2712.1999.tb01180.x; Herman M, 2004, PEDIATR EMERG CARE, V20, P648, DOI 10.1097/01.pec.0000139752.71248.0f; Hertzog JH, 2000, PEDIATRICS, V106, P742, DOI 10.1542/peds.106.4.742; Karian VE, 1999, PEDIATR RADIOL, V29, P869, DOI 10.1007/s002470050715; Keengwe IN, 1999, ANAESTHESIA, V54, P1069, DOI 10.1046/j.1365-2044.1999.01106.x; Kienstra AJ, 2004, PEDIATR EMERG CARE, V20, P499, DOI 10.1097/01.pec.0000136065.22328.df; Malviya S, 2000, BRIT J ANAESTH, V84, P743; Malviya S, 2004, PEDIATR ANESTH, V14, P589, DOI 10.1111/j.1460-9592.2004.01243.x; Mason KP, 2004, RADIOLOGY, V233, P723, DOI 10.1148/radiol.2333031872; Mason KP, 2004, RADIOLOGY, V230, P537, DOI 10.1148/radiol.2302030107; Mason KP, 2001, AM J ROENTGENOL, V177, P427, DOI 10.2214/ajr.177.2.1770427; Pershad J, 2004, J EMERG MED, V27, P11, DOI 10.1016/j.jemermed.2004.02.004; PERSHAD J, 2006, PEDIATRICS, P117; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; REEVES ST, 2004, PEDIATRICS       JUL, P114; Reves J. G., 2000, ANESTHESIA, P251; Rubin JT, 2004, PEDIATR RADIOL, V34, P980, DOI 10.1007/s00247-004-1303-8; Skokan EG, 2001, CLIN PEDIATR, V40, P663, DOI 10.1177/000992280104001204; SMITH I, 1994, ANESTHESIOLOGY, V81, P1005; STRAIN JD, 1988, AM J ROENTGENOL, V151, P975, DOI 10.2214/ajr.151.5.975; Taylor DM, 2005, ACAD EMERG MED, V12, P13, DOI 10.1197/j.aem.2004.08.039; ZELEN M, 1974, J CHRON DIS, V27, P365, DOI 10.1016/0021-9681(74)90015-0	38	50	52	0	4	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	SEP	2007	120	3					E629	E636		10.1542/peds.2006-3108			8	Pediatrics	Pediatrics	207DO	WOS:000249232000069	17698968				2020-06-30	J	Lazaraki, G; Kountouras, J; Metallidis, S; Dokas, S; Bakaloudis, T; Chatzopoulos, D; Gavalas, E; Zavos, C				Lazaraki, G.; Kountouras, J.; Metallidis, S.; Dokas, S.; Bakaloudis, T.; Chatzopoulos, D.; Gavalas, E.; Zavos, C.			Single use of fentanyl in colonoscopy is safe and effective and significantly shortens recovery time	SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES			English	Article; Proceedings Paper	13th United European Gastroenterology Week	2005	Copenhagen, DENMARK			colonoscopy; sedation; fentanyl; endoscopy	PATIENT-CONTROLLED SEDATION; CONSCIOUS SEDATION; GASTROINTESTINAL ENDOSCOPY; OUTPATIENT COLONOSCOPY; AMERICAN-SOCIETY; DEEP SEDATION; PROPOFOL; MIDAZOLAM; PREMEDICATION; ANALGESIA	Background: Colonoscopy remains an uncomfortable examination and many patients prefer to be sedated. The aim of this study was to evaluate the efficacy and safety of intravenous administration of fentanyl in titrated doses compared with intravenous administration of the well- known midazolam in titrated doses. Methods: One hundred twenty- six patients scheduled for ambulatory colonoscopy were randomly assigned to receive either 25 mcg fentanyl ( Fentanyl group, n = 66, 35 females, mean age = 61.5 years) and titrated up to 50 mcg or 2 mg midazolam ( Midazolam group, n = 60, 33 females, mean age = 63.2 years) and titrated up to 5 mg. Patients graded discomfort on a scale from 0 to 4 and pain on a scale from 0 to 10. Success of the procedure, time to cecum, complications, and recovery time for each patient were independently recorded. Results: Mean discomfort scores were 0.4 in the Fentanyl group and 1.0 in the Midazolam group ( p = 0.002). Similarly, mean scores for pain and anus to cecum time were lower in the Fentanyl group than in the Midazolam group [ 2.59 vs. 4.43 ( p = 0.002) and 8.7 vs. 12.9 min ( p = 0.012), respectively]. No adverse events were reported in the Fentanyl group, while in the Midazolam group a decrease in oxygen saturation was noted in 23/ 60 ( 35%) patients. Mean recovery time was 5.6 min in the Fentanyl group and 16 min in the Midazolam group ( p = 0.014). Mean dosage was36 mcg for fentanyl and 4.6 mg for midazolam. Conclusion: Administration of fentanyl in low incremental doses is sufficient to achieve a satisfactory level of comfort during colonoscopy.	Aristotle Univ Thessaloniki, Ippokrat Hosp, Med Clin 2, Dept Med, Thessaloniki, Greece; Aristotle Univ Thessaloniki, AHEPA Gen Hosp, Dept Internal Med 1, Thessaloniki, Greece	Lazaraki, G (reprint author), Aristotle Univ Thessaloniki, Ippokrat Hosp, Med Clin 2, Dept Med, Thessaloniki, Greece.		Zavos, Christos/N-8618-2015; Lazaraki, Georgia/AAJ-1449-2020; Dokas, Stefanos/AAI-3396-2020; Zavos, Christos/F-4877-2011	Zavos, Christos/0000-0002-3443-7791; 			Abraham N, 2002, GASTROINTEST ENDOSC, V56, P180, DOI 10.1067/mge.2002.125825; Ali S, 2004, DIGEST DIS SCI, V49, P888, DOI 10.1023/B:DDAS.0000030106.01928.b4; ARROWSMITH JB, 1991, GASTROINTEST ENDOSC, V37, P421, DOI 10.1016/S0016-5107(91)70773-6; Bell GD, 2004, ENDOSCOPY, V36, P23; Bhardwaj G, 2002, AM J GASTROENTEROL, V97, P495; Bright E, 2003, ENDOSCOPY, V35, P683; Cohen LB, 2004, GASTROINTEST ENDOSC, V59, P795, DOI 10.1016/S0016-5107(04)00349-9; Cohen LB, 2003, GASTROINTEST ENDOSC, V58, P725, DOI 10.1016/S0016-5107(03)02010-8; Crepeau T, 2005, GASTROEN CLIN BIOL, V29, P1090, DOI 10.1016/S0399-8320(05)82172-4; Dahan A, 2006, PALLIATIVE MED, V20, pS3, DOI 10.1191/0269216306pm1126oa; DANESHMEND TK, 1991, GUT, V32, P12, DOI 10.1136/gut.32.1.12; Faigel DO, 2002, GASTROINTEST ENDOSC, V56, P613; Gross JB, 2002, ANESTHESIOLOGY, V96, P1004; Harikumar R, 2006, Indian J Gastroenterol, V25, P3; Jalowiecki P, 2005, ANESTHESIOLOGY, V103, P269, DOI 10.1097/00000542-200508000-00009; Kim WH, 2000, GASTROINTEST ENDOSC, V52, P600, DOI 10.1067/mge.2000.109802; Kulling D, 2001, GASTROINTEST ENDOSC, V54, P1, DOI 10.1067/mge.2001.116174; Lazzaroni M, 2003, ENDOSCOPY, V35, P103, DOI 10.1055/s-2003-37012; Mui WLM, 2005, AM J GASTROENTEROL, V100, P2669, DOI 10.1111/j.1572-0241.2005.00261.x; PASERO C, 1999, PAIN CLIN MANUAL, P362; Pasero Chris, 2005, J Perianesth Nurs, V20, P279, DOI 10.1016/j.jopan.2005.03.007; Patel S, 2005, AM J GASTROENTEROL, V100, P2689, DOI 10.1111/j.1572-0241.2005.00320.x; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; Radaelli F, 2003, GASTROINTEST ENDOSC, V57, P329, DOI 10.1067/mge.2003.104; Radbruch L, 1999, J PAIN SYMPTOM MANAG, V18, P180, DOI 10.1016/S0885-3924(99)00064-0; Ristikankare M, 2000, GASTROINTEST ENDOSC, V52, P48, DOI 10.1067/mge.2000.105982; SCHUTZ SM, 1994, AM J GASTROENTEROL, V89, P1476; Shah SG, 2002, ENDOSCOPY, V34, P435, DOI 10.1055/s-2002-31995; Sipe BW, 2002, GASTROINTEST ENDOSC, V55, P815, DOI 10.1067/mge.2002.124636; Thiis-Evensen E, 2000, GASTROINTEST ENDOSC, V52, P606, DOI 10.1067/mge.2000.109804; Vargo JJ, 2000, GASTROINTEST ENDOSC, V52, P250, DOI 10.1067/mge.2000.106684; Wehrmann T, 2005, EUR J GASTROEN HEPAT, V17, P1395, DOI 10.1097/00042737-200512000-00020; Wood JD, 1999, GUT, V45, P6; Yoshikawa I, 2006, DIS COLON RECTUM, V49, P1393, DOI 10.1007/s10350-006-0560-z	34	11	13	0	1	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013 USA	0930-2794			SURG ENDOSC	Surg. Endosc.	SEP	2007	21	9					1631	1636		10.1007/s00464-007-9215-y			6	Surgery	Surgery	211XA	WOS:000249555400031	17762959				2020-06-30	J	Scott, DJ; Stohler, CS; Koeppe, RA; Zubieta, JK				Scott, David J.; Stohler, Christian S.; Koeppe, Robert A.; Zubieta, Jon-Kar			Time-course of change in [C-11]carfentanil and [C-11]raclopride binding potential after a nonpharmacological challenge	SYNAPSE			English	Article						positron emission tomography; neurotransmitter release; dopamine; opioid; D2 receptor; mu-opioid receptor; pain; stress; human	POSITRON-EMISSION-TOMOGRAPHY; INDUCED DOPAMINE RELEASE; AMPHETAMINE-INDUCED DISPLACEMENT; NUCLEUS-ACCUMBENS; C-11 RACLOPRIDE; HUMAN BRAIN; ENDOGENOUS DOPAMINE; EXTRASTRIATAL REGIONS; F-18 FALLYPRIDE; PET	Positron Emission Tomography (PET) with appropriate radiotracers and quantification methods allows the detection of changes in endogenous neurotransmission by determine the reduction in the binding potential (BP) of receptors before and after experimental challenges. These have typically employed psychostimulants and PET with dopamine (DA) receptor radiotracers. However, reductions in BP persist far beyond the increases in the release of the endogenous neurotransmitter, an effect ascribed to receptor internalization and recycling, a possible confound in repeated studies. Here we examined the time-course of changes in BP during a nonpharmacological challenge, moderate levels of sustained pain, shown to induce robust reductions in mu-opioid and DA D2 BP, as measured with [C-11]carfentanil and [C-11]raclopride. It was hypothesized that, contrary to pharmacological probes, the use of a more "physiological" stimulus would not be associated with persistent changes in the BP measures. The pain challenge was associated with reductions in mu-opioid receptor BP in several cortical and subcortical regions. These did not persist in a subsequent scan. Similar results were obtained for DA D2 receptor BP, where the pain challenge induced significant reductions in the caudate nucleus. These data demonstrate that changes in receptor BP induced by a nonpharmacological challenge did not persist into subsequent scans. They further suggest differences in the effect of pharmacological and nonpharmacological probes on PET BP measures. These may reflect varying levels of change in receptor affinity, receptor internalization, and recycling depending on the type of challenge employed.	Univ Michigan, Mol & Behav Neurosci Inst, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA; Univ Maryland, Sch Dent, Baltimore, MD 21201 USA; Univ Michigan, Dept Radiol, Div Nucl Med, Ann Arbor, MI 48109 USA	Zubieta, JK (reprint author), Univ Michigan, Mol & Behav Neurosci Inst, 205 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.	zubieta@umich.edu	STOHLER, CHRISTIAN/AAQ-7539-2020		NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [R01 DA 016423]		Abi-Dargham A, 1998, AM J PSYCHIAT, V155, P761; Bencherif B, 2002, PAIN, V99, P589, DOI 10.1016/S0304-3959(02)00266-X; Breier A, 1997, P NATL ACAD SCI USA, V94, P2569, DOI 10.1073/pnas.94.6.2569; Carson RE, 1997, J CEREBR BLOOD F MET, V17, P437, DOI 10.1097/00004647-199704000-00009; CHUGANI DC, 1988, J CEREBR BLOOD F MET, V8, P291, DOI 10.1038/jcbfm.1988.64; de la Fuente-Fernandez R, 2001, SCIENCE, V293, P1164, DOI 10.1126/science.1060937; DEWEY SL, 1991, SYNAPSE, V7, P324, DOI 10.1002/syn.890070409; DEWEY SL, 1993, SYNAPSE, V13, P350, DOI 10.1002/syn.890130407; Endres CJ, 1997, J CEREBR BLOOD F MET, V17, P932, DOI 10.1097/00004647-199709000-00002; FRISTON KJ, 1991, J CEREBR BLOOD F MET, V11, P690, DOI 10.1038/jcbfm.1991.122; Friston KJ, 1994, HUMAN BRAIN MAPPING, V2, P189, DOI DOI 10.1002/HBM.460020402; Gear RW, 1999, J NEUROSCI, V19, P7175, DOI 10.1523/JNEUROSCI.19-16-07175.1999; Heidbreder C, 1998, SYNAPSE, V29, P310, DOI 10.1002/(SICI)1098-2396(199808)29:4<310::AID-SYN3>3.0.CO;2-8; HERNANDEZ L, 1987, BRAIN RES BULL, V19, P623, DOI 10.1016/0361-9230(87)90047-5; HOOKS MS, 1992, PHARMACOL BIOCHEM BE, V42, P765, DOI 10.1016/0091-3057(92)90027-D; INNIS RB, 1992, SYNAPSE, V10, P177, DOI 10.1002/syn.890100302; Jewett DM, 2001, NUCL MED BIOL, V28, P733, DOI 10.1016/S0969-8051(01)00226-8; Kenakin T, 1997, TRENDS PHARMACOL SCI, V18, P456, DOI 10.1016/S0165-6147(97)90683-0; Lapeyre S, 2001, N-S ARCH PHARMACOL, V363, P399; Laruelle M, 2000, J CEREBR BLOOD F MET, V20, P423, DOI 10.1097/00004647-200003000-00001; LARUELLE M, 1995, J NUCL MED, V36, P1182; Laruelle M, 1996, P NATL ACAD SCI USA, V93, P9235, DOI 10.1073/pnas.93.17.9235; Logan J, 1996, J CEREBR BLOOD F MET, V16, P834, DOI 10.1097/00004647-199609000-00008; Marinelli S, 2005, NEUROPSYCHOPHARMACOL, V30, P864, DOI 10.1038/sj.npp.1300615; Martinez D, 2005, BIOL PSYCHIAT, V58, P779, DOI 10.1016/j.biopsych.2005.04.044; Mawlawi O, 2001, J CEREBR BLOOD F MET, V21, P1034, DOI 10.1097/00004647-200109000-00002; MELZACK R, 1971, ANESTHESIOLOGY, V34, P50; MINOSHIMA S, 1993, J NUCL MED, V34, P322; MINTUN MA, 1984, ANN NEUROL, V15, P217, DOI 10.1002/ana.410150302; Narendran R, 2004, SYNAPSE, V52, P188, DOI 10.1002/syn.20013; Pruessner JC, 2004, J NEUROSCI, V24, P2825, DOI 10.1523/JNEUROSCI.3422-03.2004; Riccardi P, 2006, NEUROPSYCHOPHARMACOL, V31, P1016, DOI 10.1038/sj.npp.1300916; Riccardi P, 2006, AM J PSYCHIAT, V163, P1639, DOI 10.1176/appi.ajp.163.9.1639; Rouge-Pont F, 1998, EUR J NEUROSCI, V10, P3903, DOI 10.1046/j.1460-9568.1998.00438.x; SASTRE M, 1994, J PHARMACOL EXP THER, V269, P1062; Schmidt BL, 2002, J NEUROSCI, V22, P6773; Scott DJ, 2006, J NEUROSCI, V26, P10789, DOI 10.1523/JNEUROSCI.2577-06.2006; VOLKOW ND, 1993, J NUCL MED, V34, P609; VOLKOW ND, 1994, SYNAPSE, V16, P255, DOI 10.1002/syn.890160402; WORSLEY KJ, 1992, J CEREBR BLOOD F MET, V12, P900, DOI 10.1038/jcbfm.1992.127; YOUNG LT, 1991, SYNAPSE, V9, P188; Zald DH, 2004, J NEUROSCI, V24, P4105, DOI 10.1523/JNEUROSCI.4643-03.2004; Zubieta JK, 2003, ARCH GEN PSYCHIAT, V60, P1145, DOI 10.1001/archpsyc.60.11.1145; Zubieta JK, 2001, SCIENCE, V293, P311, DOI 10.1126/science.1060952	44	37	37	2	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0887-4476	1098-2396		SYNAPSE	Synapse	SEP	2007	61	9					707	714		10.1002/syn.20404			8	Neurosciences	Neurosciences & Neurology	193PY	WOS:000248287700003	17559096				2020-06-30	J	Horng, HC; Wong, CS; Hsiao, KN; Huh, BK; Kuo, CP; Cherng, CH; Wu, CT				Horng, H.-C.; Wong, C.-S.; Hsiao, K.-N.; Huh, B. K.; Kuo, C.-P.; Cherng, C.-H.; Wu, C.-T.			Pre-medication with intravenous clonidine suppresses fentanyl-induced cough	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						clonidine; fentanyl-induced cough	ANESTHESIA; SURGERY; LIDOCAINE; BOLUS	Background: A reflex cough is often observed after an intravenous bolus of fentanyl. This study was conducted to determine whether pre-treatment with intravenous clonidine could effectively attenuate fentanyl-induced cough. Methods: Three hundred ASA I-II patients, aged between 18 and 80 years, undergoing various elective surgeries, were enrolled in this study. All patients were randomly assigned to one of two groups treated with intravenous clonidine 2 mu g/kg (clonidine group) or the same volume of normal saline (control group). Intravenous fentanyl (2 mu g/kg in 2 s) was injected 2 min after the clonidine or normal saline injection. Changes in the hemodynamics, auditory evoked potentials (AEPs) and Observer Assessment of Alertness/Sedation (OAA/S) rating scale were recorded before and 2 min after the clonidine or normal saline injection and 1 min after the fentanyl injection. The number of coughs 1 min after the fentanyl injection was also recorded. Results: Patients in the clonidine group showed a significantly lower incidence of cough than those in the control group (17.3% vs. 38.7%, respectively; P < 0.01). The blood pressure was lower in the clonidine group than in the control group. There were no significant differences in AEP or OAA/S rating scale. Conclusions: Pre-treatment with intravenous clonidine (2 mu g/kg) suppressed the reflex cough induced by fentanyl, with mild hemodynamic changes. Therefore, intravenous clonidine may be a clinically useful method of suppressing fentanyl-induced cough.	Tri Serv Gen Hosp, Dept Anesthesiol, Taipei 114, Taiwan; Natl Def Med Ctr, Taipei 114, Taiwan; Taichung Armed Forces Gen Hosp, Div Anesthesiol, Taichung, Taiwan; Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27706 USA	Wu, CT (reprint author), Tri Serv Gen Hosp, Dept Anesthesiol, 325 Sect 2,Chenggung Rd, Taipei 114, Taiwan.	wuchingtang@msn.com					Agarwal A, 2003, CAN J ANAESTH, V50, P297, DOI 10.1007/BF03017801; BOHRER H, 1990, ANAESTHESIA, V45, P18, DOI 10.1111/j.1365-2044.1990.tb14496.x; Cheng EY, 1996, ANESTH ANALG, V83, P162, DOI 10.1097/00000539-199607000-00028; CHERNIK DA, 1990, J CLIN PSYCHOPHARM, V10, P244; FLACKE JW, 1987, ANESTHESIOLOGY, V67, P11, DOI 10.1097/00000542-198707000-00003; GHIGNONE M, 1987, ANESTHESIOLOGY, V67, P3, DOI 10.1097/00000542-198707000-00002; Lin CS, 2004, CAN J ANAESTH, V51, P654, DOI 10.1007/BF03018421; Lin JA, 2005, ANESTH ANALG, V101, P670, DOI 10.1213/01.ANE.0000159161.31276.DB; Lui PW, 1996, CAN J ANAESTH, V43, P1216; Mantzaridis H, 1997, ANAESTHESIA, V52, P1030, DOI 10.1111/j.1365-2044.1997.185-az0327.x; MAZE M, 1991, ANESTHESIOLOGY, V74, P581, DOI 10.1097/00000542-199103000-00029; OCONNELL F, 1994, J APPL PHYSIOL, V76, P1082; Oddby-Muhrbeck E, 2002, ANESTHESIOLOGY, V96, P1109, DOI 10.1097/00000542-200205000-00013; Oshima T, 2006, CAN J ANAESTH, V53, P753, DOI 10.1007/BF03022790; Pandey CK, 2004, ANESTH ANALG, V99, P1696, DOI 10.1213/01.ANE.0000136967.82197.82; PHUA WT, 1991, CAN J ANAESTH, V38, P330, DOI 10.1007/BF03007623; QUINTIN L, 1991, ANESTHESIOLOGY, V74, P236, DOI 10.1097/00000542-199102000-00008	17	34	45	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	AUG	2007	51	7					862	865		10.1111/j.1399-6576.2007.01335.x			4	Anesthesiology	Anesthesiology	190FG	WOS:000248042800010	17578464				2020-06-30	J	Curry, EA; Palla, S; Hung, F; Arbuckle, R; Bruera, E				Curry, Eardie A., III; Palla, Shana; Hung, Frank; Arbuckle, Rebecca; Bruera, Eduardo			Prescribing patterns and purchasing costs of long-acting opioids over nine years at an academic oncology hospital	AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY			English	Article						costs; drug use; fentanyl; hospitals; methadone; morphine; opiates; oxycodone; palliative care; patches transdermal; prescribing; sustained action medications	CANCER PAIN; METHADONE; ROTATION	Purpose. The prescribing patterns and purchasing costs of long-acting opioids over nine years at an academic oncology hospital were studied. Methods. Data were collected for doses of transdermal fentanyl, methadone (all routes of administration), and oral sustained-release morphine and oxycodone dispensed for individual inpatient use for the month of October for each year between 1996 and 2004. The dates included in the retrieval were selected to document long-acting opioid use before and after the establishment of the palliative care and rehabilitation medicine department. For each opioid the number of milligrams dispensed daily per patient was determined and converted into a morphine-equivalent daily dose (MEDD). The average wholesale price per dosing unit of each drug during each period studied was obtained from internal databases. Costs were calculated by multiplying the number of units dispensed by the average wholesale price per unit and then normalized to 1996 U.S. dollars. The mean aggregate cost for a single MEDD in a month was determined by multiplying the mean cost per MEDD for each agent by that agent's percent contribution to the total MEDDs dispensed in that month. Results. Long-acting opioid and methadone usage increased from 1996 to 2004. Between 1996 and 2004, the mean cost of a single MEDD dropped from $0.0738 to $0.0330. During the study period, the median daily cost to treat one patient dropped from $5.96 to $2.80. Conclusion. Long-acting opioid use increased and cost per MEDD decreased at an academic oncology hospital between 1996 and 2004. The decreased cost of purchasing opioids was attributed to the increased proportional use of methadone.	Univ Texas, MD Anderson Canc Ctr, Dept Drug Use Policy & Pharmacoecon, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Div Quantitat Sci, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Palliat Care & Rehabil Med, Houston, TX 77030 USA	Curry, EA (reprint author), Univ Texas, MD Anderson Canc Ctr, Dept Drug Use Policy & Pharmacoecon, 1515 Holcombe Blvd,Unit 706, Houston, TX 77030 USA.	eacurry@mdanderson.org					Bruera E, 2004, J CLIN ONCOL, V22, P185, DOI 10.1200/JCO.2004.03.172; Butler LD, 2003, PSYCHOSOM MED, V65, P416, DOI 10.1097/01.PSY.0000041472.77692.C6; CUZICK J, 1985, STAT MED, V4, P87, DOI 10.1002/sim.4780040112; DAGOSTINO RB, 1990, AM STAT, V44, P316, DOI 10.2307/2684359; Higginson IJ, 1997, J PAIN SYMPTOM MANAG, V14, P29, DOI 10.1016/S0885-3924(97)00006-7; Indelicato RA, 2003, J CLIN ONCOL, V21, P3005, DOI 10.1200/JCO.2003.99.094; Mancini I, 2000, CURR OPIN ONCOL, V12, P308, DOI 10.1097/00001622-200007000-00006; Mercadante S, 1999, CANCER, V86, P1856, DOI 10.1002/(SICI)1097-0142(19991101)86:9<1856::AID-CNCR30>3.0.CO;2-G; Moryl N, 2002, PAIN, V96, P325, DOI 10.1016/S0304-3959(01)00465-1; Pasternak GW, 2004, NEUROPHARMACOLOGY, V47, P312, DOI 10.1016/j.neuropharm.2004.07.004; QUIGLEY C, 2004, DATABASE SYST REV, V3, P169; *U ALB, [No title captured]; *US BUR LAB STAT, 2006, PHARM PREP MAN PROD	13	7	7	1	3	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	1079-2082	1535-2900		AM J HEALTH-SYST PH	Am. J. Health-Syst. Pharm.	AUG 1	2007	64	15					1619	1625		10.2146/ajhp060608			7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	196PQ	WOS:000248494900014	17646565				2020-06-30	J	Iijima, T; Ishiyama, T; Kashimoto, S; Yamaguchi, T; Andoh, T; Hanawa, K; Tanzawa, I; Kawata, K; Hanawa, T; Hiejima, Y				Iijima, Tetsuya; Ishiyama, Tadahiko; Kashimoto, Satoshi; Yamaguchi, Toshiaki; Andoh, Tomio; Hanawa, Kazumi; Tanzawa, Izumi; Kawata, Keisi; Hanawa, Takehisa; Hiejima, Yoshimitsu			A comparison of three different concentrations of ropivacaine with fentanyl for patient-controlled epidural analgesia	ANESTHESIA AND ANALGESIA			English	Article							POSTOPERATIVE NAUSEA; DROPERIDOL; SURGERY; BUPIVACAINE; PAIN; PREVENTION; MANAGEMENT; ANESTHESIA; EFFICACY; INFUSION	BACKGROUND: The optimal concentration of ropivacaine in combination with fentanyl for patient-controlled epidural analgesia focusing on preservation of bowel function, analgesia, and motor function remains unclear. METHODS: Three hundred-twelve women scheduled to undergo gynecologic lower abdominal surgery, were randomly allocated to receive ropivacaine 0.05, 0.075, or 0.1% in combination with fentanyl 4 mu g/mL and droperidol 25 mu g/mL. The settings of patient-controlled epidural analgesia were as follows: initial loading volume 5 mL, background infusion 2 mL/h during night-time, no background infusion during daytime, bolus volume 2 mL, and lockout interval 10 min. Bowel function was evaluated by the first passage of flatus and feces. Pain was assessed with a visual analog scale, and motor function was examined by modified Bromage scale. Data were collected in the evening on the day of surgery, in the morning and in the evening on the first postoperative day, and in the morning on the second postoperative day. RESULTS: Gastrointestinal motility was not different among the three groups. All three solutions produced equivalent analgesia and no motor blockade. CONCLUSION: We conclude that ropivacaine 0.05% is sufficient to preserve gastrointestinal motility, and provides excellent postoperative pain relief without motor, blockade.	Univ Yamanashi, Fac Med, Dept Anesthesiol, Yamanashi 4093898, Japan; Univ Yamanashi Hosp, Dept Pharm, Yamanashi, Japan; Tokyo Healthcare Univ, Fac Healthcare, Sch Nursing, Tokyo, Japan	Ishiyama, T (reprint author), Univ Yamanashi, Fac Med, Dept Anesthesiol, 1110 Shimokato, Yamanashi 4093898, Japan.	ishiyama@yamanashi.ac.jp					ATHANASSIADIS C, 1992, PAIN, V50, P203, DOI 10.1016/0304-3959(92)90162-5; Badner NH, 1996, CAN J ANAESTH, V43, P17, DOI 10.1007/BF03015952; Block BM, 2003, JAMA-J AM MED ASSOC, V290, P2455, DOI 10.1001/jama.290.18.2455; Gan TJ, 2002, ANESTHESIOLOGY, V97, P287, DOI 10.1097/00000542-200207000-00059; Gan TJ, 2003, ANESTH ANALG, V97, P62, DOI 10.1213/01.ANE.0000068580.00245.95; Habib AS, 2004, CAN J ANAESTH, V51, P326, DOI 10.1007/BF03018236; Heinberg EM, 2003, GYNECOL ONCOL, V90, P158, DOI 10.1016/S0090-8258(03)00247-6; Henzi I, 2000, CAN J ANAESTH, V47, P537, DOI 10.1007/BF03018945; Hodgson PS, 2001, ANESTH ANALG, V92, P1024; Kurz A, 2003, DRUGS, V63, P649, DOI 10.2165/00003495-200363070-00003; Liu SS, 1999, ANESTHESIOLOGY, V90, P727, DOI 10.1097/00000542-199903000-00014; LIU SS, 1995, ANESTHESIOLOGY, V83, P757, DOI 10.1097/00000542-199510000-00015; Liu SS, 1998, ANESTHESIOLOGY, V88, P688, DOI 10.1097/00000542-199803000-00020; Macmillan SLM, 2000, OBSTET GYNECOL, V96, P604, DOI 10.1016/S0029-7844(00)00957-1; Nakata K, 2002, J CLIN ANESTH, V14, P121, DOI 10.1016/S0952-8180(01)00366-X; SCOTT DA, 1995, ANESTH ANALG, V81, P982, DOI 10.1097/00000539-199511000-00015; Steinbrook RA, 1998, ANESTH ANALG, V86, P837, DOI 10.1097/00000539-199804000-00029; Stuth EAE, 2004, PEDIATR ANESTH, V14, P831, DOI 10.1111/j.1460-9592.2004.01472.x; THOREN T, 1989, ACTA ANAESTH SCAND, V33, P181, DOI 10.1111/j.1399-6576.1989.tb02886.x; Zink W, 2004, DRUG SAFETY, V27, P1093, DOI 10.2165/00002018-200427140-00003; ZONTINE WJ, 1973, J AM VET MED ASSOC, V162, P878	21	3	4	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	AUG	2007	105	2					507	511		10.1213/01.ane.0000269491.04233.3b			5	Anesthesiology	Anesthesiology	194KN	WOS:000248343400037	17646513				2020-06-30	J	Franchi, S; Panerai, AE; Sacerdote, P				Franchi, Silvia; Panerai, Alberto E.; Sacerdote, Paola			Buprenorphine ameliorates the effect of surgery on hypothalamus-pituitary-adrenal axis, natural killer cell activity and metastatic colonization in rats in comparison with morphine or fentanyl treatment	BRAIN BEHAVIOR AND IMMUNITY			English	Article						buprenorphine; experimental metastasis; natural killer cells; opioids; surgery-induced immunosuppression; corticosterone	IMMUNE-RESPONSES; TUMOR-METASTASIS; OPIOID RECEPTOR; POSTOPERATIVE PAIN; SURGICAL STRESS; NERVOUS-SYSTEM; NK CELLS; CANCER; CYTOTOXICITY; RESISTANCE	Not all opioids employed in clinical practice share the same immunosuppressive properties. The potent partial lt-agonist buprenorphine appears to exhibit a neutral effect on the immune responses. Surgery stress is associated with decreased natural killer cell activity (NK) and enhancement of tumor metastasis in rats. We analyzed the ability of buprenorphine to prevent the effects of experimental surgery on HPA activation (plasma corticosterone levels), NK activity and lung diffusion of the NK sensitive tumor MADB106. Buprenorphine (0.1 mg/kg) was compared with equianalgesic doses of fentanyl (0.1 mg/kg) and morphine (10 mg/kg) in this animal model. In normal animals morphine and fentanyl stimulate the HPA axis, decrease NK activity and augment tumor metastasis, while buprenorphine is devoid of these effects. Surgery significantly raised corticosterone levels, suppressed NK activity and increased MADB106 metastasis. Only buprenorphine was able to prevent the neuroendocrine and immune system alterations and ameliorate the increase of tumor metastasis induced by surgical stress. These preclinical findings suggest that an adequate treatment of surgically induced stress immunosuppression with an opioid drug devoid of immuno suppressive effects may also play a protective role against the metastatic diffusion following cancer surgery. (C) 2007 Elsevier Inc. All rights reserved.	Univ Milan, Dept Pharmacol, I-20129 Milan, Italy	Sacerdote, P (reprint author), Univ Milan, Dept Pharmacol, Via Vanvitelli 32, I-20129 Milan, Italy.	paola.sacerdote@unimi.it	, Franchi/AAK-5400-2020				Alicea C, 1996, J NEUROIMMUNOL, V64, P83, DOI 10.1016/0165-5728(95)00159-X; Beilin B, 1996, ANESTH ANALG, V82, P492, DOI 10.1097/00000539-199603000-00011; Beilin B, 2003, ANESTH ANALG, V97, P822, DOI 10.1213/01.ANE.0000078586.82810.3B; Ben-Eliyahu S, 1999, INT J CANCER, V80, P880; Ben-Eliyahu S, 2002, LANCET ONCOL, V3, P578; COLACCHIO TA, 1994, AM J SURG, V167, P174, DOI 10.1016/0002-9610(94)90070-1; D'Elia M, 2003, CLIN IMMUNOL, V109, P179, DOI 10.1016/S1521-6616(03)00177-3; Eisenstein TK, 1998, J NEUROIMMUNOL, V83, P36, DOI 10.1016/S0165-5728(97)00219-1; Evans HC, 2003, DRUGS, V63, P1999, DOI 10.2165/00003495-200363190-00003; Fecho K, 1996, J PHARMACOL EXP THER, V276, P626; FREIER DD, 1994, J PHARMACOL EXP THER, V277, P633; Fujisawa T, 1997, CANCER, V79, P474, DOI 10.1002/(SICI)1097-0142(19970201)79:3<474::AID-CNCR8>3.3.CO;2-I; Gaspani L, 2002, J NEUROIMMUNOL, V129, P18, DOI 10.1016/S0165-5728(02)00165-0; Gaveriaux-Ruff C, 2003, J NEUROIMMUNOL, V134, P72, DOI 10.1016/S0165-5728(02)00419-8; Gomez-Flores R, 2000, IMMUNOPHARMACOLOGY, V48, P145, DOI 10.1016/S0162-3109(00)00198-3; GORELIK E, 1982, INT J CANCER, V30, P107, DOI 10.1002/ijc.2910300118; Hall DM, 1998, J NEUROIMMUNOL, V83, P29, DOI 10.1016/S0165-5728(97)00218-X; HANNA N, 1984, BIOCHIM BIOPHYS ACTA, V780, P213, DOI 10.1016/0304-419X(85)90004-6; HANSBROUGH JF, 1984, AM J SURG, V148, P303, DOI 10.1016/0002-9610(84)90459-8; HAYES AG, 1985, EUR J PHARMACOL, V116, P75, DOI 10.1016/0014-2999(85)90186-4; HERBERMAN RB, 1981, SCIENCE, V214, P24, DOI 10.1126/science.7025208; Koda K, 1997, INT SURG, V82, P190; LENNARD TWJ, 1985, BRIT J SURG, V72, P771, DOI 10.1002/bjs.1800721002; LEVY SM, 1985, HEALTH PSYCHOL, V150, P199; Lotsch JR, 2005, J PAIN SYMPTOM MANAG, V29, pS90, DOI 10.1016/j.jpainsymman.2005.01.012; Martucci C, 2004, PAIN, V110, P385, DOI 10.1016/j.pain.2004.04.020; Melamed R, 2005, BRAIN BEHAV IMMUN, V19, P114, DOI 10.1016/j.bbi.2004.07.004; Neri S, 2005, PSYCHOPHARMACOLOGY, V179, P700, DOI 10.1007/s00213-005-2239-x; OHTANI M, 1994, DRUG METAB DISPOS, V22, P2; PAGE GG, 1994, BRAIN BEHAV IMMUN, V8, P241, DOI 10.1006/brbi.1994.1022; Page GG, 1995, J NEUROIMMUNOL, V63, P69; Page GG, 1998, BRIT J ANAESTH, V81, P216; Page GG, 2001, PAIN, V90, P191, DOI 10.1016/S0304-3959(00)00403-6; PAYNE JH, 1994, ARCH SURG-CHICAGO, V129, P973; PETERSON PK, 1993, BIOCHEM PHARMACOL, V46, P343, DOI 10.1016/0006-2952(93)90508-T; POLLOCK RE, 1991, ARCH SURG-CHICAGO, V126, P338; Roughan JV, 2004, BEHAV PHARMACOL, V15, P461, DOI 10.1097/00008877-200411000-00002; Sacerdote P, 1997, PAIN, V72, P325, DOI 10.1016/S0304-3959(97)00055-9; Sacerdote P, 2000, ANESTH ANALG, V90, P1411, DOI 10.1097/00000539-200006000-00028; Sacerdote P, 1997, BRIT J PHARMACOL, V121, P834, DOI 10.1038/sj.bjp.0701138; SAITO T, 1992, J INFECT DIS, V166, P1459, DOI 10.1093/infdis/166.6.1459; SCHANTZ SP, 1987, CANCER IMMUNOL IMMUN, V25, P141; Shavit Y, 2004, NEUROIMMUNOMODULAT, V11, P255, DOI 10.1159/000078444; TARTTER PI, 1987, ARCH SURG-CHICAGO, V122, P1264; UDELSMAN R, 1991, SURGERY, V110, P1125; Vallejo Ricardo, 2004, Am J Ther, V11, P354, DOI 10.1097/01.mjt.0000132250.95650.85; Wang JH, 2002, J LEUKOCYTE BIOL, V71, P782; WILTROUT RH, 1985, J IMMUNOL, V134, P4267; Yassen A, 2005, J PHARMACOL EXP THER, V313, P1136, DOI 10.1124/jpet.104.082560; YEAGER MP, 1995, ANESTHESIOLOGY, V83, P500, DOI 10.1097/00000542-199509000-00008; YEAGER MP, 1991, ARCH SURG-CHICAGO, V126, P454; Yokota T, 2000, CAN J ANAESTH, V47, P303, DOI 10.1007/BF03020942	52	83	91	0	5	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0889-1591	1090-2139		BRAIN BEHAV IMMUN	Brain Behav. Immun.	AUG	2007	21	6					767	774		10.1016/j.bbi.2007.01.001			8	Immunology; Neurosciences; Psychiatry	Immunology; Neurosciences & Neurology; Psychiatry	196SG	WOS:000248501700007	17291715				2020-06-30	J	Bytzer, P; Lindeberg, B				Bytzer, P.; Lindeberg, B.			Impact of an information video before colonoscopy on patient satisfaction and anxiety - a randomized trial	ENDOSCOPY			English	Article							PAIN; SEDATION	Background and study aims: Anxiety before colonoscopy may have adverse consequences and increase requirements for sedation and analgesics. We aimed to examine the effects of adding an information video to our usual preprocedural information. Patients and methods: 162 colonoscopy patients were randomly assigned to video (72) or no video (90) groups. Patients in the video group watched a video on colonoscopy procedures and cleansing. The patients' situational anxiety was measured using the State-Trait Anxiety Inventory (STAI) questionnaire. Patients rated pain and overall satisfaction related to the procedure. The colonoscopist and the endoscopy nurse, who were blinded to the patient's allocation, completed questionnaires on use of medication, procedure outcome, and their assessments of patient pain and toleration of the procedure. Results: There were no differences between the two groups concerning situational anxiety (mean STAI-State score 45.0 +/- 13.3 vs. 45.9 +/- 12.9, P= 0.7), rating of pain, tolerability of the procedure, or the willingness to undergo a future colonoscopy. The staff rated the outcomes equally in the two groups. There was no difference in use of midazolam, but patients, who had seen the video used higher doses of fentanyl (P < 0.02). Situational anxiety ratings were significantly higher in women, and they found the procedure significantly more painful (P = 0.001) and were less satisfied (P < 0.05). Conclusions: An information video shown to patients preparing for colonoscopy had no impact on tolerability or anxiety. Colonoscopy is less tolerable and more painful for women and this is probably related to a higher degree of anxiety. Endoscopy personnel should be aware of these gender differences and adjust information and medication accordingly.	Glostrup Univ Hosp, Dept Gastroenterol, Copenhagen, Denmark	Bytzer, P (reprint author), Univ Copenhagen, Koge Hosp, Dept Gastroenterol, DK-4600 Copenhagen, Denmark.	peter.bytzer@dadlnet.dk					AGRE P, 1994, GASTROINTEST ENDOSC, V40, P271, DOI 10.1016/S0016-5107(94)70054-0; Andrada JMLC, 2004, EUR J GASTROEN HEPAT, V16, P1381, DOI 10.1097/00042737-200412000-00024; Brandt LJ, 2001, AM J GASTROENTEROL, V96, P280, DOI 10.1111/j.1572-0241.2001.03508.x; Eckardt VF, 1996, GASTROINTEST ENDOSC, V44, P177, DOI 10.1016/S0016-5107(96)70136-0; Froehlich F, 1997, GASTROINTEST ENDOSC, V45, P1, DOI 10.1016/S0016-5107(97)70295-5; Hayee BH, 2006, GUT, V55, pA69; Jones MP, 2004, J CLIN GASTROENTEROL, V38, P35, DOI 10.1097/00004836-200401000-00009; Kim WH, 2000, GASTROINTEST ENDOSC, V52, P600, DOI 10.1067/mge.2000.109802; Ladas SD, 2000, ENDOSCOPY, V32, P688; LANIUS M, 1990, Z GASTROENTEROL, V28, P651; Lim CH, 2006, GUT, V55, pA68; Luck A, 1999, LANCET, V354, P2032, DOI 10.1016/S0140-6736(98)10495-6; Morgan J, 1998, GASTROINTEST ENDOSC, V48, P119, DOI 10.1016/S0016-5107(98)70152-X; Ness RM, 2001, AM J GASTROENTEROL, V96, P1797, DOI 10.1016/S0002-9270(01)02437-6; Pearson S, 2005, DIS COLON RECTUM, V48, P2047, DOI 10.1007/s10350-005-0172-z; Ramakrishnan S, 2004, GUT, V53, pA46; Ristikankare M, 2001, J CLIN GASTROENTEROL, V32, P69, DOI 10.1097/00004836-200101000-00016; Spielberger CD, 1970, MANUAL STATE TRAIT A; Takahashi Y, 2005, DIS COLON RECTUM, V48, P1295, DOI 10.1007/s10350-004-0940-1; Tawil A, 2006, GUT, V55, pA53; Tohda G, 2006, ENDOSCOPY, V38, P360, DOI 10.1055/s-2005-921192	21	42	46	0	3	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0013-726X	1438-8812		ENDOSCOPY	Endoscopy	AUG	2007	39	8					710	714		10.1055/s-2007-966718			5	Gastroenterology & Hepatology; Surgery	Gastroenterology & Hepatology; Surgery	201CJ	WOS:000248808800007	17661246				2020-06-30	J	Jin, HS; Yum, MS; Kim, SL; Shin, HY; Lee, EH; Ha, EJ; Hong, SJ; Park, SJ				Jin, Hyun-Seung; Yum, Mi-Sun; Kim, Seoung-Lan; Shin, Hye Young; Lee, Eun-Hee; Ha, Eun-Ju; Hong, Soo Jong; Park, Seong Jong			The efficacy of the COMFORT scale in assessing optimal sedation in critically ill children requiring mechanical ventilation	JOURNAL OF KOREAN MEDICAL SCIENCE			English	Article						sedation; children; mechanical ventilation; withdrawal; critical care	INTENSIVE-CARE-UNIT; ICU SEDATION; ANALGESIA; DURATION; PROPOFOL; PROTOCOL; TRIAL; GUIDELINES; MANAGEMENT; INFUSIONS	Sedation is often necessary to optimize care for critically ill children requiring mechanical ventilation. If too light or too deep, however, sedation can cause significant adverse reactions, making it important to assess the degree of sedation and maintain its optimal level. We evaluated the efficacy of the COMFORT scale in assessing optimal sedation in critically ill children requiring mechanical ventilation. We compared 12 month data in 21 patients (intervention group), for whom we used the pediatric intensive care unit (PICU) sedation protocol of Asan Medical Center (Seoul, Korea) and the COMFORT scale to maintain optimal sedation, with the data in 20 patients (control group) assessed before using the sedation protocol and the COMPORT scale. Compared with the control group, the intervention group showed significant decreases in the total usage of sedatives and analgesics, the duration of mechanical ventilation (11.0 days vs. 12.5 days) and PICU stay (115.0 days vs. 19.5 days), and the development of withdrawal symptoms (1 case vs. 7 cases). The total duration of sedation (8.0 days vs. 11.5 days) also tended to decrease. These findings suggest that application of protocol-based sedation with the COMPORT scale may benefit children requiring mechanical ventilation.	Univ Ulsan, Asan Med Ctr, Dept Pediat, Seoul 138736, South Korea; Univ Ulsan, Asan Med Ctr, Dept Pharmacol, Seoul, South Korea	Park, SJ (reprint author), Univ Ulsan, Asan Med Ctr, Dept Pediat, 388-1 Pungnap-dong, Seoul 138736, South Korea.	drpsj@amc.seoul.kr		Park, Seong Jong/0000-0003-0250-2381			AMBUEL B, 1992, J PEDIATR PSYCHOL, V17, P95, DOI 10.1093/jpepsy/17.1.95; Bavdekar S B, 1999, J Postgrad Med, V45, P95; Brook AD, 1999, CRIT CARE MED, V27, P2609, DOI 10.1097/00003246-199912000-00001; COHEN IL, 1991, CRIT CARE MED, V19, P1278, DOI 10.1097/00003246-199110000-00010; Cooke SE, 2002, AM J HEALTH-SYST PH, V59, P150; Crain Noreen, 2002, Pediatr Crit Care Med, V3, P11, DOI 10.1097/00130478-200201000-00003; De Jonghe B, 2000, INTENS CARE MED, V26, P275, DOI 10.1007/s001340051150; Detriche O, 1999, BRIT J ANAESTH, V83, P698; Devlin JW, 1997, ANN PHARMACOTHER, V31, P689, DOI 10.1177/106002809703100604; Ely EW, 1996, NEW ENGL J MED, V335, P1864, DOI 10.1056/NEJM199612193352502; Hall RI, 2001, CHEST, V119, P1151, DOI 10.1378/chest.119.4.1151; Ista Erwin, 2005, Pediatr Crit Care Med, V6, P58, DOI 10.1097/01.PCC.0000149318.40279.1A; KEENAN SP, 2000, CRITICAL CARE ROUNDS, V1, P13; Kelly DF, 1999, J NEUROSURG, V90, P1042, DOI 10.3171/jns.1999.90.6.1042; Kollef MH, 1997, CRIT CARE MED, V25, P567, DOI 10.1097/00003246-199704000-00004; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; MacLaren R, 2000, PHARMACOTHERAPY, V20, P662, DOI 10.1592/phco.20.7.662.35172; MARX CM, 1994, CRIT CARE MED, V22, P163, DOI 10.1097/00003246-199401000-00029; McCollam JS, 1999, CRIT CARE MED, V27, P2454, DOI 10.1097/00003246-199911000-00022; Polaner DM, 2001, PEDIATR CLIN N AM, V48, P695, DOI 10.1016/S0031-3955(05)70335-7; Tobias JD, 2000, CRIT CARE MED, V28, P2122, DOI 10.1097/00003246-200006000-00079; van Dijk M, 2000, PAIN, V84, P367, DOI 10.1016/S0304-3959(99)00239-0; VENDER JS, 2004, CRIT CARE MED, V32, P554; Wood G, 1995, Respir Care, V40, P219; Yaster M, 1996, PEDIATRICS, V98, P135	25	33	34	0	6	KOREAN ACAD MEDICAL SCIENCES	SEOUL	302 75 DONG DU ICHON, DONG YONGSAN KU, SEOUL 140 031, SOUTH KOREA	1011-8934	1598-6357		J KOREAN MED SCI	J. Korean Med. Sci.	AUG	2007	22	4					693	697		10.3346/jkms.2007.22.4.693			5	Medicine, General & Internal	General & Internal Medicine	206IY	WOS:000249178300019	17728512	Other Gold, Green Published			2020-06-30	J	Meyer, M; Wagner, K; Benvenuto, A; Plante, D; Howard, D				Meyer, Marjorie; Wagner, Katherine; Benvenuto, Anna; Plante, Dawn; Howard, Diantha			Intrapartum and postpartum analgesia for women maintained on methadone during pregnancy	OBSTETRICS AND GYNECOLOGY			English	Article							ACUTE PAIN MANAGEMENT	OBJECTIVE: To determine whether methadone maintenance alters intrapartum or postpartum pain or medication requirements. METHODS: Sixty-eight patients treated with methadone for opiate dependence during pregnancy (vaginal n=35; cesarean n=33) were matched retrospectively to control women. Analgesic medication and pain scores (0-10) were extracted from the medical record. The primary endpoint was opiate use postpartum (oxycodone equivalents). The secondary endpoints were pain scores and intrapartum analgesia. RESULTS: There were no differences in intrapartum pain or analgesia. After vaginal birth, methadone-maintained women experienced increased pain (methadone, 2.7 [1.9-5.0]; control, 1.4 [0.5-3.0], P=.001) but no increase in opiate use ([mean +/- standard deviation] methadone 12.7 +/- 32.1; control 6.8 +/- 12.7 mg/24 h, P=.33); after cesarean delivery both pain (methadone, 5.3 [4.1-6.0]; control, 3.0 [2.2-3.9], P=.001) and opiate use (methadone, 91.6 +/- 51.8; control, 54.0 +/- 18.6 mg/24 h, P=.001) increased. CONCLUSION: Methadone-maintained women have similar analgesic needs and response during labor, but require 70% more opiate analgesic after cesarean delivery.	Fletcher Allen Hlth Care, Dept Obstet & Gynecol, Burlington, VT 05401 USA; Univ Vermont, Coll Med, Div Maternal Fetal Med, Dept Obstet & Gynecol, Burlington, VT USA; Univ Vermont, Coll Med, Dept Stat, Burlington, VT USA	Meyer, M (reprint author), Fletcher Allen Hlth Care, Dept Obstet & Gynecol, Smith 419, Burlington, VT 05401 USA.	marjorie.meyer@uvm.edu			NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01 RR 00109]; NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA 14028]		Alford DP, 2006, ANN INTERN MED, V144, P127, DOI 10.7326/0003-4819-144-2-200601170-00010; *AM PAIN SOC, 2003, [No title captured]; Devulder J, 1997, J NEUROSURG ANESTH, V9, P146, DOI 10.1097/00008506-199704000-00007; Fischer G, 2000, ADDICTION, V95, P1141, DOI 10.1046/j.1360-0443.2000.95811411.x; Gordon DB, 2005, ARCH INTERN MED, V165, P1574, DOI 10.1001/archinte.165.14.1574; Mehta V, 2006, ANAESTHESIA, V61, P269, DOI 10.1111/j.1365-2044.2005.04503.x; Rayburn WF, 2004, AM J OBSTET GYNECOL, V191, P1885, DOI 10.1016/j.ajog.2004.06.082; Williamson A, 2005, J CLIN NURS, V14, P798, DOI 10.1111/j.1365-2702.2005.01121.x	8	52	52	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0029-7844			OBSTET GYNECOL	Obstet. Gynecol.	AUG	2007	110	2	1				261	266		10.1097/01.AOG.0000275288.47258.e0			6	Obstetrics & Gynecology	Obstetrics & Gynecology	193QY	WOS:000248290500007	17666599				2020-06-30	J	Mahar, PJ; Rana, JA; Kennedy, CS; Christopher, NC				Mahar, Patrick J.; Rana, Jamal A.; Kennedy, Christopher S.; Christopher, Norman C.			A Randomized clinical trial of oral transmucosal fentanyl citrate versus intravenous morphine sulfate for initial control of pain in children with extremity injuries	PEDIATRIC EMERGENCY CARE			English	Article						oral transmucosat fentanyl citrate; pain control for pediatric extremity fractures	LACERATION REPAIR; EMERGENCY; SEVERITY; SEDATION; PLACEBO	Background: Extremity injury is a common condition that requires pain management in an emergency department. In pediatric patients, the most frequently used method of pain control is intravenous (IV) morphine sulfate. Oral transmucosal fentanyl citrate (OTFC) is a potential alternative to morphine, which may obviate the need to place an IV before addressing pain. Objective: To compare OTFC with IV morphine for sedation and analgesia during initial evaluation of children with deformity of an extremity and suspected fracture. Design/Methods: A randomized controlled trial of OTFC versus IV morphine in which 8- to 18-year-olds presenting to pediatric tertiary care emergency department with extremity deformity and suspected fracture were eligible. Only those with visual analog scale (VAS) (0 = no pain, 100 = worst pain imaginable) score equal to or greater than 50/100, and American Society of Anesthesia I or 11 qualified. Patients were excluded if history of loss of/altered level of consciousness, multiple traumatic injuries, or if patient had received prior medication for pain control. All patients enrolled were randomly assigned to receive either IV morphine (0.1 mg/kg) or OTFC (10-15 mu g/kg). Patients rated pain intensity using VAS; scores were recorded before medicating and at 15-minute intervals after the medication was given. Adverse events such as emesis, pruritus, and respiratory depression were recorded. Results: A total of 87 patients were enrolled in study (OTFC, 47; morphine, 40). There are no significant differences between the 2 groups when comparing sex, age, weight, and pretreatment VAS score (P > 0.05). Although the VAS scores were not significantly different before medicating the patient, an analysis of variance shows that there was a significant difference (P > 0.05) in VAS scores at 30 minutes. The differences persisted for every 15 minutes through the 75 minutes of monitoring. There was no statistically significant difference between the 2 groups when comparing the number of adverse events (P = 0.23). Conclusions: The use of OTFC can provide improved pain control when compared with IV morphine. The pain reduction starts 30 minutes after initiation of medication, and the effect is seen as far as 75 minutes after the initiation of analgesic medication. The study size was too small to make any statements concerning adverse effects; thus, further studies with larger sample sizes are needed to determine the use of OTFC.	Childrens Hosp, Dept Pediat, Div Emergency Med, Denver, CO 80218 USA; Univ Colorado, Sch Med, Denver, CO USA; Akron Childrens Hosp, Akron, OH USA; Loudon Hosp Ctr, Leesburg, VA USA; Childrens Mercy Hosp, Div Emergency Med, Kansas City, MO 64108 USA; Univ Coll Med, Rootstown, OH USA	Mahar, PJ (reprint author), 1056 E,19th Ave,Box B251, Denver, CO 80218 USA.	mahar.patrick@tchden.org					Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Farrar JT, 1998, JNCI-J NATL CANCER I, V90, P611, DOI 10.1093/jnci/90.8.611; Fosnocht DE, 2001, AM J EMERG MED, V19, P399, DOI 10.1053/ajem.2001.24462; Gallagher EJ, 2001, ANN EMERG MED, V38, P633, DOI 10.1067/mem.2001.118863; Klein EJ, 2002, PEDIATRICS, V109, P894, DOI 10.1542/peds.109.5.894; Lichtor JL, 1999, ANESTH ANALG, V89, P732, DOI 10.1097/00000539-199909000-00038; Menegazzi J, 1996, ANN EMERG MED, V27, P433, DOI 10.1016/S0196-0644(96)70224-X; Petrack EM, 1997, PEDIATRICS, V99, P711, DOI 10.1542/peds.99.5.711; Robert R, 2003, J BURN CARE REHABIL, V24, P351, DOI 10.1097/01.BCR.0000095504.69283.F2; Rockwood CA, 1996, FRACTURES CHILDREN S; SCHECHTER NL, 1995, PEDIATRICS, V95, P335; Schutzman SA, 1996, ANN EMERG MED, V28, P385, DOI 10.1016/S0196-0644(96)70001-X; SELBST SM, 1990, ANN EMERG MED, V19, P1010, DOI 10.1016/S0196-0644(05)82565-X; Sharer SR, 1998, J BURN CARE REHABIL, V19, P516, DOI 10.1097/00004630-199811000-00010; STREISAND JB, 1989, ANESTH ANALG, V69, P28; STREISAND JB, 1991, ANESTHESIOLOGY, V75, P223, DOI 10.1097/00000542-199108000-00009; Todd KH, 1996, ANN EMERG MED, V27, P485, DOI 10.1016/S0196-0644(96)70238-X	17	26	28	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0749-5161			PEDIATR EMERG CARE	Pediatr. Emerg. Care	AUG	2007	23	8					544	548		10.1097/PEC.0b013e318128f80b			5	Emergency Medicine; Pediatrics	Emergency Medicine; Pediatrics	200QE	WOS:000248777100005	17726413				2020-06-30	J	Bufalari, A; Di Meo, A; Nannarone, S; Padua, S; Adami, C				Bufalari, A.; Di Meo, A.; Nannarone, S.; Padua, S.; Adami, C.			Fentanyl or sufentanil continuous infusion during isoflurane anaesthesia in dogs: Clinical experiences	VETERINARY RESEARCH COMMUNICATIONS			English	Article; Proceedings Paper	60th Annual Meeting of the Italian-Society-of-Veterinary-Sciences	2006	Terrasini, ITALY	Italian Soc Vet Sci		analgesia; dog; fentanyl; opioids; perioperative analgesia; sufentanil	TOTAL INTRAVENOUS ANESTHESIA; ALFENTANIL; PROPOFOL; SURGERY		Univ Perugia, FAcolta Med Vet, Dipartimento Patol Diagnost & Clin Vet, Sez Clin Chirurgica & Radiodiagnost Vet, I-06100 Perugia, Italy	Bufalari, A (reprint author), Univ Perugia, FAcolta Med Vet, Dipartimento Patol Diagnost & Clin Vet, Sez Clin Chirurgica & Radiodiagnost Vet, Via S Costanzo 4, I-06100 Perugia, Italy.	antonello.bufalari@unipg.it		Nannarone, Sara/0000-0002-7774-9920; Adami, Chiara/0000-0002-8219-6881; BUFALARI, Antonello/0000-0001-5073-6540			Ahonen J, 2000, BRIT J ANAESTH, V85, P533, DOI 10.1093/bja/85.4.533; BOVILL JG, 1984, ANESTH ANALG, V63, P1081; BUFALARI A, 2004, ATTI SICV, V11, P45; Mendes GM, 2003, J AM VET MED ASSOC, V223, P1608, DOI 10.2460/javma.2003.223.1608; MONK JP, 1988, DRUGS, V36, P286, DOI 10.2165/00003495-198836030-00003	5	10	10	0	8	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0165-7380			VET RES COMMUN	Vet. Res. Commun.	AUG	2007	31			1			277	280		10.1007/s11259-007-0046-z			4	Veterinary Sciences	Veterinary Sciences	209OK	WOS:000249397700056	17682894				2020-06-30	J	Coopman, V; Cordonnier, J; Pien, K; Van Varenbergh, D				Coopman, Vera; Cordonnier, Jan; Pien, Karen; Van Varenbergh, Dirk			LC-MS/MS analysis of fentanyl and norfentanyl in a fatality due to application of multiple Durogesic (R) transdermal therapeutic systems	FORENSIC SCIENCE INTERNATIONAL			English	Article						fentanyl; transdermal; lethal intoxication; LC-MS/MS	PHARMACOKINETICS; TOXICOLOGY; PATCHES; MISUSE; ABUSE	Fentanyl is a potent synthetic narcotic analgesic administered in the form of a transdermal patch for the management of chronic pain. A 78-year-old woman with a history of cancer was found dead in bed. She was lying on her back. The external examination revealed 10 Durogesic (R) transdermal therapeutic systems (100 mu g/h fentanyl) on the body. Liquid-liquid extraction and liquid chromatography tandem mass spectrometry with electrospray source in positive ionization mode was applied for the quantitation of fentanyl and its major metabolite norfentanyl in the post-mortem samples. Fentanyl-d5 and norfentanyl-d5 were used as internal standards. Multiple reaction monitoring was used for specific detection. Calibration was performed by addition of standard solutions to drug-free matrix (blood, urine and liver) prior to extraction. The method showed good linearity for fentanyl and norfentanyl over a concentration range of 5-150 mu g/L in reconstituted extracts with coefficients of determination equal or greater than 0.998. Percent mean within-day precision and accuracy of 0.9-1.0% and 99.4-101.1% for fentanyl and 2.0-4.5% and 93.1-101.0% for norfentanyl were obtained. Mean extraction recoveries varied between 95.5% and 100.3% for fentanyl and 39.2-57.4% for norfentanyl. The following fentanyl (norfentanyl) concentration in the post-mortem samples were measured; 28.6 mu g/L (3.0 mu g/L) in right and 28.2 mu g/L (3.5 mu g/L) in left subelavian blood, 21.3 mu g/L (< 2 mu g/L) in right and 20.9 mu g/L (< 2 mu g/L) in left femoral blood, 37.6 mu g/L (4.2 mu g/L) in right and 33.9 mu g/L (4.4 mu g/L) in left ventricular blood, 282.9 mu g/L (121.2 mu g/L) in urine, 688.2 mu g/L in stomach contents, 122.5 mu g/L (25.4 mu g/L) in bile, 19.5 mu g/L (< 2 mu g/L) in vitreous humour, 203.0 mu g/kg (26.6 mu g/kg) in liver and 78.6 mu g/kg (46.3 mu g/kg) in kidney. We concluded that the woman's death was caused by acute intoxication with fentanyl. The manner of death was presumed to be suicide due to excessive administered Durogesic (R) transdermal therapeutic systems. (c) 2006 Elsevier Ireland Ltd. All rights reserved.	Chemiphar NV, Dept Analyt Toxicol, B-8200 Brugge, Belgium; Free Univ Brussels, Dept Forens Med, B-1090 Brussels, Belgium	Cordonnier, J (reprint author), Chemiphar NV, Dept Analyt Toxicol, Lieven Bauwensstr 4, B-8200 Brugge, Belgium.	jan.cordonnier@chemiphar.com					Anderson DT, 2000, J ANAL TOXICOL, V24, P627, DOI 10.1093/jat/24.7.627; Baselt R.C., 2002, DISPOSITION TOXIC DR, P430; Day J, 2003, J ANAL TOXICOL, V27, P513, DOI 10.1093/jat/27.7.513; DRUMMER OH, 2000, ENCY FORENSIC SCI, P1404; DVORCHIK BH, 1976, CLIN CHEM, V22, P868; Edinboro LE, 1997, J FORENSIC SCI, V42, P741; HENDERSON GL, 1991, J FORENSIC SCI, V36, P422; HESS R, 1972, EUR J CLIN PHARMACOL, V4, P137, DOI 10.1007/BF00561135; *JANSS PHARM, 1998, DUR FENT TRANSD SYST; KARCH SB, 2002, KARCHS PATHOLOGY DRU, P364; Kramer Christopher, 1998, Journal of the American Osteopathic Association, V98, P385; Kuhlman JJ, 2003, J ANAL TOXICOL, V27, P499, DOI 10.1093/jat/27.7.499; Poklis A, 2004, J ANAL TOXICOL, V28, P422, DOI 10.1093/jat/28.6.422; POUNDER DJ, 1990, FORENSIC SCI INT, V45, P253, DOI 10.1016/0379-0738(90)90182-X; Radovanovic D, 2002, ARCH ONCOL, V10, P263; Reeves MD, 2002, MED J AUSTRALIA, V177, P552, DOI 10.5694/j.1326-5377.2002.tb04951.x; Richardson T, 2000, ANN CLIN BIOCHEM, V37, P20, DOI 10.1258/0004563001901498; STOECKEL H, 1979, BRIT J ANAESTH, V51, P741, DOI 10.1093/bja/51.8.741; Tharp AM, 2004, AM J FOREN MED PATH, V25, P178, DOI 10.1097/01.paf.0000127398.67081.11	19	51	54	1	21	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0379-0738			FORENSIC SCI INT	Forensic Sci.Int.	JUL 4	2007	169	2-3					223	227		10.1016/j.forsciint.2006.03.018			5	Medicine, Legal	Legal Medicine	185FN	WOS:000247696900018	16650707				2020-06-30	J	Wong, CM; Critchley, LA; Lee, A; Khaw, KS; Kee, WDN				Wong, C. M.; Critchley, L. A.; Lee, A.; Khaw, K. S.; Kee, W. D. Ngan			Fentanyl dose-response curves when inserting the LMA Classic((TM)) laryngeal mask airway	ANAESTHESIA			English	Article; Proceedings Paper	Combined Scientific Meeting in Anaesthesiology	AUG 27-28, 2005	Hong Kong, PEOPLES R CHINA				PROPOFOL REQUIREMENT; ALFENTANIL; THIOPENTONE; INDUCTION	Probit analysis was used to predict an optimal dose of fentanyl, co-administered with propofol 2.5 mg.kg(-1), when inserting the laryngeal mask airway. In all, 21 male and 54 female healthy Chinese patients, aged 18-63 years, requiring anaesthesia for minor surgery were recruited. They were assigned to one of five groups: placebo, 0.5, 1.0, 1.5 and 2.0 mu g.kg(-1). Insertion was performed 90 s after administration and insertion conditions assessed using a six-category score. Dose-response curves could only be drawn for swallowing and movement categories, and only the ED50 could be predicted with certainty. To provide optimal conditions in over 95% of patients, fentanyl doses well above the clinical range were required. A standard fentanyl dose of 1 mu g.kg(-1), co-administered with propofol 2.5 mg.kg(-1), provided optimal conditions in 65% of cases. Ninety seconds may have been insufficient time for fentanyl to reach its peak effect.	Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anaesthesia & Intens Care, Shatin, Hong Kong, Peoples R China	Critchley, LA (reprint author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anaesthesia & Intens Care, Shatin, Hong Kong, Peoples R China.	hcritchley@cuhk.edu.hk	Ngan Kee, Warwick/J-8817-2013; Khaw, K/J-9469-2013; Lee, Anna/B-2773-2009; Critchley, Lester A H/J-9420-2013	Ngan Kee, Warwick/0000-0003-1000-7735; Khaw, K/0000-0002-5950-0275; Lee, Anna/0000-0003-2864-0045; 			BRAIN AIJ, 1985, ANAESTHESIA, V40, P356; Brimacombe J, 1996, ACTA ANAESTH SCAND, V40, P201, DOI 10.1111/j.1399-6576.1996.tb04420.x; BROWN GW, 1991, ANAESTHESIA, V46, P771, DOI 10.1111/j.1365-2044.1991.tb09776.x; CHU MC, 2004, HK COLL ANAETHESIOL, V13, P27; CHUI PT, 1998, ANAESTHESIA, V53, P486; Goyagi T, 2003, ACTA ANAESTH SCAND, V47, P771, DOI 10.1034/j.1399-6576.2003.00123.x; Hui JKL, 2002, CAN J ANAESTH, V49, P508, DOI 10.1007/BF03017932; Ko SH, 1998, ANESTH ANALG, V86, P658, DOI 10.1097/00000539-199803000-00041; Kodaka M, 2004, BRIT J ANAESTH, V92, P238, DOI 10.1093/bja/aeh033; MOTULSKY H, 2003, PRACTICAL GUIDE CURV, P264; OMEARA ME, 1993, BMJ-BRIT MED J, V306, P224, DOI 10.1136/bmj.306.6872.224; SCANLON P, 1993, CAN J ANAESTH, V40, P816, DOI 10.1007/BF03009250; Sivalingam P, 1999, ANAESTHESIA, V54, P271, DOI 10.1046/j.1365-2044.1999.00663.x; STONEHAM MD, 1995, ANAESTHESIA, V50, P464, DOI 10.1111/j.1365-2044.1995.tb06007.x; TALLARIDA RJ, 2000, LINEAR REGRESSION FU, P41; Tanaka M, 2003, BRIT J ANAESTH, V90, P14, DOI 10.1093/bja/aeg018; Yu ALY, 2006, ANESTHESIOLOGY, V105, P684, DOI 10.1097/00000542-200610000-00012	17	13	18	0	4	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0003-2409			ANAESTHESIA	Anaesthesia	JUL	2007	62	7					654	660		10.1111/j.1365-2044.2007.05057.x			7	Anesthesiology	Anesthesiology	178MM	WOS:000247224800003	17567339				2020-06-30	J	Malhotra, S; Yentis, SM				Malhotra, S.; Yentis, S. M.			Extending low-dose epidural analgesia in labour for emergency Caesarean section - a comparison of levobupivacaine with or without fentanyl	ANAESTHESIA			English	Article; Proceedings Paper	Annual Meeting of the Obstetric-Anaesthetists-Association	MAY, 2006	Glasgow, SCOTLAND	Obstet Anaesthetists Assoc			0.5-PERCENT BUPIVACAINE; TOP-UP; ANESTHESIA	Women in labour receiving epidural analgesia with 15 ml bupivacaine 0.1% and 2 mu g.ml(-1) fentanyl followed by 10-15-ml top-ups as required, who needed Caesarean section, were randomly allocated to receive 20 ml levobupivacaine 0.5% over 3 min with either 75 mu g fentanyl (1.5 ml) or 1.5 ml saline. Further top-ups or inhaled or intravenous supplementation were given for breakthrough pain. Time to onset (loss of cold sensation to T4 and touch sensation to T5 bilaterally), quality of analgesia and side-effects were recorded. The study was stopped after 112 patients had been randomly assigned, due to a unit protocol change, from midwife-administered top-ups to patient-controlled epidural analgesia. Data from 51 patients given fentanyl and 54 given saline were available for analysis. There were no significant differences in onset times or supplementation between the groups, but there was more intra-operative nausea/vomiting with fentanyl (53%) than with saline (18%; p = 0.004). We found no advantage of adding fentanyl to epidural levobupivacaine when extending epidural analgesia in women already receiving epidural fentanyl during labour and there was an increased incidence of intra-operative nausea and vomiting. Power analysis suggested the same conclusion even had the study proceeded to completion.	Chelsea & Westminster Hosp, Magill Dept Anaesthesia, London SW10 9NH, England	Malhotra, S (reprint author), St Marys Hosp, Dept Anaesthesia, Praed St, London W2 1NY, England.	surbhi27@googlemail.com					Goring-Morris J, 2006, INT J OBSTET ANESTH, V15, P109, DOI 10.1016/j.ijoa.2005.11.005; HALONEN PM, 1993, ACTA ANAESTH SCAND, V37, P774, DOI 10.1111/j.1399-6576.1993.tb03808.x; Helbo-Hansen H S, 1993, Int J Obstet Anesth, V2, P21, DOI 10.1016/0959-289X(93)90025-D; HOWELL P, 1990, BRIT J ANAESTH, V65, P648, DOI 10.1093/bja/65.5.648; KING MJ, 1990, ANAESTHESIA, V45, P285, DOI 10.1111/j.1365-2044.1990.tb14733.x; Lam DTC, 2001, ANAESTHESIA, V56, P790; Lucas DN, 2000, BRIT J ANAESTH, V84, P494; Lucas DN, 1999, ANAESTHESIA, V54, P1173, DOI 10.1046/j.1365-2044.1999.01108.x; McLeod GA, 2001, ANAESTHESIA, V56, P331, DOI 10.1046/j.1365-2044.2001.01964.x; PAECH MJ, 1990, ANAESTH INTENS CARE, V18, P22, DOI 10.1177/0310057X9001800105; Price M L, 1991, Int J Obstet Anesth, V1, P13, DOI 10.1016/0959-289X(91)90024-K; Robinson AP, 2001, ANESTH ANALG, V92, P410, DOI 10.1213/00000539-200102000-00025; Sanders RD, 2004, ANAESTHESIA, V59, P988, DOI 10.1111/j.1365-2044.2004.03753.x; YEE I, 1993, CAN J ANAESTH, V40, P722, DOI 10.1007/BF03009768; Yentis SM, 2006, INT J OBSTET ANESTH, V15, P2, DOI 10.1016/j.ijoa.2005.06.010; Yentis SM, 2003, INT J OBSTET ANESTH, V12, P246, DOI 10.1016/S0959-289X(03)00009-8	16	14	15	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0003-2409	1365-2044		ANAESTHESIA	Anaesthesia	JUL	2007	62	7					667	671		10.1111/j.1365-2044.2007.05096.x			5	Anesthesiology	Anesthesiology	178MM	WOS:000247224800005	17567341				2020-06-30	J	Miloudi, Y; El Harrar, N; Bensaid, A; Hussein, MA				Miloudi, Y.; El Harrar, N.; Bensaid, A.; Hussein, M. A.			Cutaneous reactions secondary with anaesthetic induction with mivacurium	ANNALES FRANCAISES D ANESTHESIE ET DE REANIMATION			French	Letter									CHU Ibn Rochd, Serv Anesthesie Reanimat, Hop Aout 20, Casablanca, Morocco	Miloudi, Y (reprint author), 11 Rue Varsovie,Mers Sultan-angle Rue Rome, Casablanca 20000, Morocco.	myoussef2@menara.ma					Laxenaire MC, 1999, ANN FR ANESTH, V18, P796, DOI 10.1016/S0750-7658(00)88460-9; SAVARESE JJ, 1989, ANESTHESIOLOGY, V70, P386, DOI 10.1097/00000542-198903000-00003	2	0	0	0	1	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0750-7658	1769-6623		ANN FR ANESTH	Ann. Fr. Anest. Reanim.	JUL-AUG	2007	26	7-8					717	717		10.1016/j.annfar.2007.04.002			1	Anesthesiology	Anesthesiology	197VY	WOS:000248585800021	17572045				2020-06-30	J	Heurich, M; Mousa, SA; Lenzner, M; Morciniec, P; Kopf, A; Welte, M; Stein, C				Heurich, Martin; Mousa, Shaaban A.; Lenzner, Moritz; Morciniec, Pawel; Kopf, Andreas; Welte, Martin; Stein, Christoph			Influence of pain treatment by epidural fentanyl and bupivacaine on homing of opioid-containing leukocytes to surgical wounds	BRAIN BEHAVIOR AND IMMUNITY			English	Article						inflammation; beta-endorphin; local anesthetic; bupivacaine; fentanyl; peripheral opioid analgesia; epidural analgesia; pain	ROOT GANGLION NEURONS; INFLAMMATORY PAIN; BETA-ENDORPHIN; POSTOPERATIVE PAIN; LOCAL-ANESTHETICS; IMMUNE-RESPONSES; CELLS; INHIBITION; ANALGESIA; RAT	Endogenous opioids released from leukocytes extravasating into injured tissue can interact with peripheral opioid receptors to inhibit nociception. Animal studies have shown that the homing of opioid-producing leukocytes to the injured site is modulated by spinal blockade of noxious input. This study investigated whether epidural analgesia (EDA) influences the migration of beta-endorphin (END) and/or met-enkephalin (ENK)-containing leukocytes into the subcutaneous wound tissue of patients undergoing abdominal surgery. In part I patients received general anesthesia combined either with intra- and postoperative EDA (with bupivacaine and fentanyl) or with postoperative patient controlled intravenous analgesia (PCIA; with the opioid piritramide). In part 11 patients received general anesthesia combined with either epidural fentanyl or bupivacaine which was continued postoperatively. Samples of cutanous and subcutanous tissue were taken from the wound site at the beginning, at the end and at various times after surgery, and were examined by immunohistochemistry for the presence of END and ENK. We found that (i) epidural bupivacaine, fentanyl and PCIA provided similar and clinically acceptable postoperative pain relief, (ii) compared to PCIA, epidural bupivacame or fentanyl did not change the gross inflammatory reaction within the surgical wound; (iii) opioid-containing leukocytes were almost absent in normal subcutaneous tissue but migrated to the inflamed wound tissue in ascending numbers within a few hours, reaching a peak at about 24 h after surgery; (iv) compared to PCIA, EDA resulted in significantly decreased homing of END-containing leukocytes to the injured site at 24 It after surgery; and (v) the magnitude of this decrease was similar regardless of the epidural medication. These findings suggest that nociceptive but not sympathetic neurons are primarily involved in the attraction of opioid-containing leukocytes during early stages of inflammation. (c) 2006 Elsevier Inc. All rights reserved.	Univ Med Berlin, Charite, Klin Anaesthesiol & Operat Intens Med, D-12200 Berlin, Germany; Klinikum Darmstadt, Inst Anasthesiol Operat Intens Med & Schmerzthera, D-64283 Darmstadt, Germany	Heurich, M (reprint author), Univ Med Berlin, Charite, Klin Anaesthesiol & Operat Intens Med, Campus Benjamin Franklin,Hindenburgdamm 30, D-12200 Berlin, Germany.	martin.heurich@charite.de		Stein, Christoph/0000-0001-5240-6836			ACKERMAN NR, 1979, ARTHRITIS RHEUM, V22, P1365, DOI 10.1002/art.1780221208; Baum CL, 2005, DERMATOL SURG, V31, P674; Bernards Christopher M, 2002, Best Pract Res Clin Anaesthesiol, V16, P489, DOI 10.1053/bean.2002.0255; Bischoff U, 2003, BRIT J PHARMACOL, V139, P1273, DOI 10.1038/sj.bjp.0705363; Blalock JE, 1998, IMMUNOL TODAY, V19, P191, DOI 10.1016/S0167-5699(97)01245-0; Block BM, 2003, JAMA-J AM MED ASSOC, V290, P2455, DOI 10.1001/jama.290.18.2455; Bong GW, 1996, J CLIN INVEST, V98, P2779, DOI 10.1172/JCI119104; Brack A, 2003, EXP NEUROL, V184, P44, DOI 10.1016/j.expneurol.2003.08.021; Brack A, 2004, ANESTHESIOLOGY, V101, P204, DOI 10.1097/00000542-200407000-00031; Brack A, 2004, PAIN, V112, P229, DOI 10.1016/j.pain.2004.08.029; Eisenstein TK, 1998, J NEUROIMMUNOL, V83, P36, DOI 10.1016/S0165-5728(97)00219-1; FERREIRA SH, 1979, PROSTAGLANDINS, V18, P191, DOI 10.1016/0090-6980(79)90104-7; Freise H, 2005, ANESTH ANALG, V100, P255, DOI 10.1213/01.ANE.0000140253.65577.1C; George MJ, 2006, ANAESTHESIA, V61, P659, DOI 10.1111/j.1365-2044.2006.04713.x; Ginosar Y, 2003, ANESTH ANALG, V97, P1439, DOI 10.1213/01.ANE.0000081792.84877.A2; GLASS PSA, 1992, ANESTH ANALG, V74, P345; Khasabova IA, 2004, J NEUROSCI, V24, P1744, DOI 10.1523/JNEUROSCI.4298-03.2004; Kietzmann D, 1997, ACTA ANAESTH SCAND, V41, P888, DOI 10.1111/j.1399-6576.1997.tb04805.x; Machelska H, 1998, NAT MED, V4, P1425, DOI 10.1038/4017; Machelska H, 2003, J NEUROIMMUNOL, V141, P30, DOI 10.1016/S0165-5728(03)00213-3; Machelska H, 2004, BRIT J PHARMACOL, V142, P772, DOI 10.1038/sj.bjp.0705837; Mather LE, 2003, ANESTH ANALG, V97, P1211, DOI 10.1213/01.ANE.0000092951.32643.A6; Mazoit JX, 2004, CLIN PHARMACOKINET, V43, P17, DOI 10.2165/00003088-200443010-00002; Mousa SA, 2001, J NEUROIMMUNOL, V115, P71, DOI 10.1016/S0165-5728(01)00271-5; Mousa SA, 2004, ENDOCRINOLOGY, V145, P1331, DOI 10.1210/en.2003-1287; Panerai AE, 1997, IMMUNOL TODAY, V18, P317, DOI 10.1016/S0167-5699(97)01045-1; Richman Jeffrey M, 2005, Anesthesiol Clin North Am, V23, P125, DOI 10.1016/j.atc.2004.11.004; Rittner HL, 2001, ANESTHESIOLOGY, V95, P500, DOI 10.1097/00000542-200108000-00036; RITTNER HL, 2006, FASEB J; Saravia F, 1998, NEUROPEPTIDES, V32, P351, DOI 10.1016/S0143-4179(98)90058-0; Schmitt TK, 2003, ANESTHESIOLOGY, V98, P195, DOI 10.1097/00000542-200301000-00030; SIBINGA NES, 1988, ANNU REV IMMUNOL, V6, P219; Sorkin LS, 2003, EXP NEUROL, V184, P162, DOI 10.1016/S0014-4886(03)00102-X; Stein C, 2003, NAT MED, V9, P1003, DOI 10.1038/nm908; STEIN C, 1988, PAIN, V32, P251, DOI 10.1016/0304-3959(88)90074-7; STEIN C, 1988, [No title captured], V31, P451; Taylor BK, 2000, PAIN, V84, P263, DOI 10.1016/S0304-3959(99)00212-2; Vallejo Ricardo, 2004, Am J Ther, V11, P354, DOI 10.1097/01.mjt.0000132250.95650.85; Vuori A, 2004, ACTA ANAESTH SCAND, V48, P738, DOI 10.1111/j.1399-6576.2004.00404.x; YAKSH TL, 1988, BRAIN RES, V458, P319, DOI 10.1016/0006-8993(88)90474-X	40	19	19	0	2	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0889-1591			BRAIN BEHAV IMMUN	Brain Behav. Immun.	JUL	2007	21	5					544	552		10.1016/j.bbi.2006.10.014			9	Immunology; Neurosciences; Psychiatry	Immunology; Neurosciences & Neurology; Psychiatry	184OU	WOS:000247652200005	17174527				2020-06-30	J	Bryson, GL; MacNeil, R; Jevaraj, LM; Rosaeg, OP				Bryson, Gregory L.; MacNeil, Robert; Jevaraj, Leo M.; Rosaeg, Ola P.			Small dose spinal bupivacaine for Cesarean delivery does not reduce hypotension but accelerates motor recovery	CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Article; Proceedings Paper	61st Annual Meeting of the Canadian-Anesthesiology-Society	JUN 17-21, 2005	Toronto, CANADA	Canadian Anesthesol Soc			ISOBARIC BUPIVACAINE; ANESTHESIA; INJECTION; FENTANYL; SECTION; OPIOIDS; HUMANS; VOLUME; PLAIN	Background: Maternal hypotension occurs in 60-94% of Cesarean deliveries with 10-15 mg spinal bupivacaine. Reduced doses of bupivacaine may decrease the incidence of hypotension, nausea, and vasopressor use. The primary objective of this study was to compare 4.5 mg and 12 mg doses of intrathecal bupivacaine on maternal hemodynamics. The secondary objective was to determine if anticipated reductions in side effects were reflected in increased patient satisfaction. Methods: Following Research Ethics Board approval and informed consent 52 term parturients undergoing elective Cesarean delivery were randomly assigned to isobaric bupivacaine 4.5 mg or hyperbaric bupivacaine 12 mg for spinal anesthesia. All patients received fentanyl 50 mu g and morphine 200 mu g intrathecally. Intravenous fluid and vasopressor administration were standardized. Maternal hemodynamics, and sensorimotor levels were recorded at regular intervals. Side effects and patient satisfaction were documented. Results: Median cepahalad sensory block was C8 in both groups (NS) but the intensity of motor block was significantly less (P < 0.001) and of shorter duration (P < 0.001) with bupivacaine 4.5 mg. The proportion of patients requiring ephedrine (> 70%) and the quantities cf ephedrine used were similar in both groups (NS). Use of supplemental analgesia, side effects, and measures of patient satisfaction were comparable in both groups. Discussion: Intrathecal bupivacaine 4.5 and 12 mg yielded similar sensory block and side effects during Cesarean delivery. Patients receiving 4.5 mg did, however, experience significantly less motor blockade of shorter duration.	Ottawa Hosp, Dept Anesthesiol, Ottawa, ON K1Y 4E9, Canada; James Cook Univ Hosp, Dept Anaesthesia, Middlesbrough, Cleveland, England; Natl Matern Hosp, Dept Anaesthet, Dublin 2, Ireland	Bryson, GL (reprint author), Ottawa Hosp, Dept Anesthesiol, Box 249C,Civic Campus,1053 Carling Ave, Ottawa, ON K1Y 4E9, Canada.	glbryson@ohri.ca					Anderson L, 2001, BRIT J ANAESTH, V86, P245, DOI 10.1093/bja/86.2.245; Ben-David B, 2000, REGION ANESTH PAIN M, V25, P235, DOI 10.1016/S1098-7339(00)90004-X; BRIDENBAUGH PO, 1999, NEURAL BLOCKADE CLIN; Carvalho B, 2005, ANESTHESIOLOGY, V103, P606, DOI 10.1097/00000542-200509000-00025; Dahl JB, 1999, ANESTHESIOLOGY, V91, P1919, DOI 10.1097/00000542-199912000-00045; HORLOCKER TT, 1994, ANESTH ANALG, V79, P773; JACKSON R, 1995, BRIT J ANAESTH, V75, P262, DOI 10.1093/bja/75.3.262; Kuczkowski KM, 2004, OBSTET ANESTHESIA PR, P421; Lee A, 2002, CAN J ANAESTH, V49, P588, DOI 10.1007/BF03017387; Malinovsky JM, 1999, ANESTHESIOLOGY, V91, P1260, DOI 10.1097/00000542-199911000-00016; Myles PS, 1999, ANESTH ANALG, V88, P83, DOI 10.1097/00000539-199901000-00016; Richardson MG, 1997, ANESTH ANALG, V84, P95, DOI 10.1097/00000539-199701000-00018; Richardson MG, 1996, ANESTHESIOLOGY, V85, P326, DOI 10.1097/00000542-199608000-00014; ROSAEG OP, 1993, CAN J ANAESTH, V40, P346, DOI 10.1007/BF03009634; Santos AC, 2006, CLIN ANESTH, P1152; Sarvela PJ, 1999, ANESTH ANALG, V89, P1257, DOI 10.1213/00000539-199911000-00033; Siddik-Sayyid SM, 2002, ANESTH ANALG, V95, P209, DOI 10.1097/00000539-200207000-00037; VANGESSEL EF, 1993, ANESTH ANALG, V77, P483; Vercauteren MP, 1998, ANESTH ANALG, V86, P989, DOI 10.1097/00000539-199805000-00014	19	25	28	0	4	CANADIAN ANESTHESIOLOGISTS SOC	TORONTO	1 EGLINTON AVE EAST, SUITE 208, TORONTO, ONTARIO M4P 3A1, CANADA	0832-610X			CAN J ANAESTH	Can. J. Anaesth.-J. Can. Anesth.	JUL	2007	54	7					531	537		10.1007/BF03022316			7	Anesthesiology	Anesthesiology	187JW	WOS:000247844800005	17602038	Bronze			2020-06-30	J	Dhir, S; Fuller, J				Dhir, Shalini; Fuller, John			Case report: Pregnancy in hemodialysis-dependent end-stage renal disease: anesthetic considerations	CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Article							BRACHIAL-PLEXUS BLOCK; DIALYSIS; FAILURE; BUPIVACAINE; ANTICOAGULANT; ROPIVACAINE; MANAGEMENT; OUTCOMES; PATIENT; VOLUME	Purpose: To describe the obstetrical and anesthetic management of a parturient with end-stage renal disease. Clinical features: A 38-yr-old woman had severe renal impairment due to Wegener's granulomatosis. She was on hemodialysis for 12 years following two failed kidney transplants. She had two unsuccessful pregnancies, two and 12 years previously. The antenatal care of the present pregnancy incorporated a multidisciplinary approach involving obstetrics, nephrology and anesthesiology. Labour was induced at 36 weeks gestation. Bupivacaine 0.0625% with fentanyl 2 mu g(.)mL(-1) was injected through an epidural catheter inserted for labour analgesia. Lidocaine 2% with epinephrine 2.5 mu g-mL(-1) was given later for Cesarean delivery. There was no associated maternal or neonatal morbidity. The management focused on minimizing hemodynamic disturbances while providing maximum pain relief. Conclusions: For a successful outcome in the parturient with end-stage renal disease, a multidisciplinary approach is essential.	Univ Western Ontario, Dept Anesthesia & Perioperat Med, London, ON N6A 4V2, Canada	Dhir, S (reprint author), St Josephs Hlth Care, Dept Anesthesia & Perioperat Med, 268 Grosvenor St, London, ON N6A 4V2, Canada.	shalini.dhir@sjhc.london.on.ca	Dhir, Shalini/B-3323-2017				Altintas F, 2005, ANESTH ANALG, V100, P1166, DOI 10.1213/01.ANE.0000154443.68396.70; Brost BC, 1996, ULTRASOUND OBST GYN, V8, P34, DOI 10.1046/j.1469-0705.1996.08010034.x; Chao AS, 2002, AM J OBSTET GYNECOL, V187, P152, DOI 10.1067/mob.2002.123200; Escolar G, 1999, HAEMATOLOGICA, V84, P614; Faura CC, 1998, PAIN, V74, P43, DOI 10.1016/S0304-3959(97)00142-5; Giatras I, 1998, NEPHROL DIAL TRANSPL, V13, P3266, DOI 10.1093/ndt/13.12.3266; GOULD DB, 1983, ACTA ANAESTH SCAND, V27, P18, DOI 10.1111/j.1399-6576.1983.tb01898.x; Holley JL, 2003, SEMIN DIALYSIS, V16, P384, DOI 10.1046/j.1525-139X.2003.16085.x; Horlocker TT, 2003, REGION ANESTH PAIN M, V28, P172, DOI 10.1053/rapm.2003.50046; Hou S, 2002, INT J ARTIF ORGANS, V25, P823; JACKSON R, 1995, BRIT J ANAESTH, V75, P262, DOI 10.1093/bja/75.3.262; Liu Fu-Chao, 2005, Chang Gung Med J, V28, P180; Llau J V, 2001, Rev Esp Anestesiol Reanim, V48, P270; London GM, 1999, SEMIN DIALYSIS, V12, P77, DOI 10.1046/j.1525-139X.1999.00007.x; Misiolek HD, 2005, EUR J ANAESTH, V22, P473, DOI 10.1017/S0265021505220811; RICE ASC, 1991, ANAESTHESIA, V46, P354, DOI 10.1111/j.1365-2044.1991.tb09542.x; Romao JE, 1997, NEPHROL DIAL TRANSPL, V12, P106, DOI 10.1093/ndt/12.1.106; Tan LK, 2006, INT J GYNECOL OBSTET, V94, P17, DOI 10.1016/j.ijgo.2006.03.033; Wald-Oboussier G, 1988, Reg Anaesth, V11, P65; WYLD PJ, 1988, CLIN LAB HAEMATOL, V10, P235	20	9	9	1	2	CANADIAN ANESTHESIOLOGISTS SOC	TORONTO	1 EGLINTON AVE EAST, SUITE 208, TORONTO, ONTARIO M4P 3A1, CANADA	0832-610X			CAN J ANAESTH	Can. J. Anaesth.-J. Can. Anesth.	JUL	2007	54	7					556	560		10.1007/BF03022320			5	Anesthesiology	Anesthesiology	187JW	WOS:000247844800009	17602042	Bronze			2020-06-30	J	Batra, YK; Rajeev, S; Lokesh, VC; Rao, KLN				Batra, Yatindra Kumar; Rajeev, Subramanyam; Lokesh, Vanajakshi C.; Rao, Katragadda L. N.			Spinal myoclonus associated with intrathecal bupivacaine and fentanyl in an infant	CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Letter							ANESTHESIA		Postgrad Inst Med Educ & Res, Chandigarh, India	Batra, YK (reprint author), Postgrad Inst Med Educ & Res, Chandigarh, India.	ykbatra@glide.net.in					Agarwal P, 2003, CURR OPIN NEUROL, V16, P515, DOI 10.1097/01.wco.0000084231.82329.9c; BOWDLE TA, 1994, ANESTH ANALG, V78, P783; FOX EJ, 1979, NEUROLOGY, V29, P379, DOI 10.1212/WNL.29.3.379; HOEHN MM, 1977, NEUROLOGY, V27, P942, DOI 10.1212/WNL.27.10.942; Menezes FV, 2006, ANAESTHESIA, V61, P597, DOI 10.1111/j.1365-2044.2006.04655.x	5	6	6	0	1	CANADIAN ANESTHESIOLOGISTS SOC	TORONTO	1 EGLINTON AVE EAST, SUITE 208, TORONTO, ONTARIO M4P 3A1, CANADA	0832-610X			CAN J ANAESTH	Can. J. Anaesth.-J. Can. Anesth.	JUL	2007	54	7					587	588		10.1007/BF03022328			2	Anesthesiology	Anesthesiology	187JW	WOS:000247844800017	17602048	Bronze			2020-06-30	J	Shaladi, A; Saltari, MR; Piva, B; Crestani, F; Tartari, S; Pinato, P; Micheletto, G; Dall'Ara, R				Shaladi, Ali; Saltari, Maria Rita; Piva, Bruno; Crestani, Francesco; Tartari, Stefano; Pinato, Paolo; Micheletto, Giuseppe; Dall'Ara, Roberto			Continuous intrathecal morphine infusion in patients with vertebral fractures due to osteoporosis	CLINICAL JOURNAL OF PAIN			English	Article						osteoporosis; vertebral fracture; continuous intrathecal morphine infusion	CHRONIC NONMALIGNANT PAIN; QUALITY-OF-LIFE; PERCUTANEOUS VERTEBROPLASTY; BACK-PAIN; WOMEN; COMPLICATIONS; EPIDEMIOLOGY; KYPHOPLASTY; ETIOLOGY; EFFICACY	Objectives: Vertebral fractures are the most common consequences of severe osteoporosis. The chronic pain from collapse of osteoporotic vertebrae affects quality of life (QOL) and autonomy of patients. The management of pain with oral or transdermal opiates can cause severe side effects. Continuous intrathecal administration of morphine via an implantable pump might represent an alternative therapy to conventional oral or transdermal administration of opioids and has some advantages and disadvantages for pain relief and improvement in QOL when compared with conventional opioid delivery. It is our objective to report our experience using intrathecal delivery of analgesics in a population of patients with refractory pain due to vertebral fractures. Materials and Methods: In 24 patients, refractory to conventional delivery of opioids, we used intrathecal analgesic therapy. To test for efficacy and improvement in QOL, we administered the visual analog scale for pain and the Questionnaire of the European Foundation of Osteoporosis (QUALEFFO). Before patients were selected for pump implantation, an intraspinal drug delivery trial was performed to monitor side effects and responses to intrathecal therapy. Results: Significant pain relief was obtained in all implanted patients. Using the QUALEFFO, we observed significant improvement of all variables such as quality of daily life, domestic work, ambulation, and perception of health status, before and after 1 year after pump implantation. With intrathecal morphine infusion, none of the 24 patients required additional systemic analgesic medication. The mean morphine dose during the spinal trial was 11.28 mg/d, 7.92 mg/d at pump implantation, and 16.32mg/d at I-year follow-up. Conclusions: Our result!; show that intrathecal administration of morphine efficiently relieves the symptoms of pain and improves QOL. Continuous intrathecal administration of morphine appears to be an alternative therapy to conventional analgesic drug delivery and has advantages in those patients who have severe side effects with systemic administration of analgesics.	Osped S Maria Misericordia, Pain Unit & Palliat Care, I-45030 Trecenta, Rovigo, Italy; Delta Hosp, Dept Radiol & Intervent Radiol, Ferrara, Italy; Umberto Hosp 1, Pain Unit, Venice, Italy; Hosp Dolo, Pain Unit & Palliat Care, Venice, Italy; Hosp Mater Salutes, Pain Unit, Legnago, Italy	Crestani, F (reprint author), Osped S Maria Misericordia, Pain Unit & Palliat Care, Via Grisetti, I-45030 Trecenta, Rovigo, Italy.	crestanifrancesco@libero.it					ADAMI S, 1992, BONE, V13, P33; ADAMS PF, 1987, HLTH STAT OLDER PERS; Anderson VC, 1999, NEUROSURGERY, V44, P289, DOI 10.1097/00006123-199902000-00026; [Anonymous], 1994, 843 WHO; Barr JD, 2000, SPINE, V25, P923, DOI 10.1097/00007632-200004150-00005; BRAZENOR GA, 1987, NEUROSURGERY, V21, P484, DOI 10.1227/00006123-198710000-00008; COOPER C, 1994, SPINE STATE ART REV, V8, P1; Cotten A, 1998, RADIOGRAPHICS, V18, P311, DOI 10.1148/radiographics.18.2.9536480; Crandall Dennis, 2004, Spine J, V4, P418, DOI 10.1016/j.spinee.2004.01.003; CUMMINGS SR, 1995, VERTEBRAL FRACTURE O, P3; FOLLETT KA, 1992, PAIN, V49, P21, DOI 10.1016/0304-3959(92)90183-C; Gagliese L, 1997, PAIN, V70, P3, DOI 10.1016/S0304-3959(96)03266-6; Gaitanis IN, 2005, EUR SPINE J, V14, P250, DOI 10.1007/s00586-004-0767-4; Grados F, 2000, RHEUMATOLOGY, V39, P1410, DOI 10.1093/rheumatology/39.12.1410; HARRINGTON KD, 2002, J BONE JOINT SURG AM, V27, P419; Kaufmann TJ, 2001, AM J NEURORADIOL, V22, P1860; KLOZBECHER CM, 2000, J BONE MINER RES, V15, P721; Krames Elliot, 2002, Best Pract Res Clin Anaesthesiol, V16, P619, DOI 10.1053/bean.2002.0263; Krames ES, 1996, J PAIN SYMPTOM MANAG, V11, P333, DOI 10.1016/0885-3924(96)00010-3; KRAMES ES, 1993, J PAIN SYMPTOM MANAG, V8, P539, DOI 10.1016/0885-3924(93)90083-8; KRANE SM, 1998, HARRISONS PRINCIPLES, P2247; Kumar K, 2001, SURG NEUROL, V55, P79, DOI 10.1016/S0090-3019(01)00353-6; LEIDIG G, 1990, BONE MINER, V8, P217, DOI 10.1016/0169-6009(90)90107-Q; LeidigBruckner G, 1997, J BONE MINER RES, V12, P663, DOI 10.1359/jbmr.1997.12.4.663; Lips P, 1999, OSTEOPOROSIS INT, V10, P150, DOI 10.1007/s001980050210; Lips Paul, 1997, American Journal of Medicine, V103, p3S, DOI 10.1016/S0002-9343(97)90021-8; LUKERT BP, 1994, GERIATRICS, V49, P22; Majd Mohammad E, 2005, Spine J, V5, P244, DOI 10.1016/j.spinee.2004.09.013; MARTIN JB, 1999, [No title captured], V25, P11; MELTON LJ, 1989, AM J EPIDEMIOL, V129, P1000, DOI 10.1093/oxfordjournals.aje.a115204; Moulin DE, 1996, LANCET, V347, P143, DOI 10.1016/S0140-6736(96)90339-6; *NAT OST SOC, 1997, MEN OST THER MAN; Nussbaum DA, 2004, J VASC INTERV RADIOL, V15, P1185, DOI 10.1097/01.RVI.0000144757.14780.E0; ORWOLL ES, 1995, ENDOCR REV, V16, P87, DOI 10.1210/er.16.1.87; Paice JA, 1996, J PAIN SYMPTOM MANAG, V11, P71, DOI 10.1016/0885-3924(95)00099-2; PECK WA, 1993, AM J MED, V94, P646; RIGGS BL, 1995, BONE, V17, pS505, DOI 10.1016/8756-3282(95)00258-4; Ringe J D, 2003, MMW Fortschr Med, V145, P43; Ringe JD, 2002, RHEUMATOL INT, V22, P199, DOI 10.1007/s00296-002-0217-8; ROSS PD, 1991, ANN INTERN MED, V114, P919, DOI 10.7326/0003-4819-114-11-919; Ross Philip D., 1997, American Journal of Medicine, V103, p30S, DOI 10.1016/S0002-9343(97)90025-5; Saltuari L, 1992, Acta Neurol (Napoli), V14, P187; SARTORI L, 2000, EPIDEMIOLOGIA OSTEOP, P9; SCOTT J, 1976, PAIN, V2, P175, DOI 10.1016/0304-3959(76)90113-5; Silverman SL, 2002, OSTEOPOROSIS INT, V13, P858, DOI 10.1007/s001980200118; TERRENCE H, 2003, AM J MED, V114, P257; *WHO, 1989, WHO CANC PAIN REL; Winkelmuller M, 1996, J NEUROSURG, V85, P458, DOI 10.3171/jns.1996.85.3.0458; Wolfe MM, 1999, NEW ENGL J MED, V340, P1888, DOI 10.1056/NEJM199906173402407; YAKSH TL, 1987, PAIN, V31, P211, DOI 10.1016/0304-3959(87)90037-6; Young M H, 1973, J Bone Joint Surg Br, V55, P295	51	22	24	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0749-8047	1536-5409		CLIN J PAIN	Clin. J. Pain	JUL-AUG	2007	23	6					511	517		10.1097/AJP.0b013e31806a23d4			7	Anesthesiology; Clinical Neurology	Anesthesiology; Neurosciences & Neurology	183PC	WOS:000247583700007	17575491				2020-06-30	J	Berliner, MN; Giesecke, T; Bornhovd, KD				Berliner, Michael N.; Giesecke, Thorsten; Bornhoevd, Karin D.			Impact of transdermal fentanyl on quality of life in rheumatoid arthritis	CLINICAL JOURNAL OF PAIN			English	Article						noncancer pain; quality of life; transdermal fentanyl; rheumatoid arthritis	NONSTEROIDAL ANTIINFLAMMATORY AGENTS; CHRONIC NONCANCER PAIN; BACK-PAIN; OSTEOARTHRITIS; EFFICACY; MANAGEMENT; OPIOIDS; SAFETY	Objectives: The purpose of the study was to investigate the effectiveness and tolerability of transdermal fentanyl in a treatment regimen in patients with rheumatoid arthritis (RA). Methods: Two hundred twenty-six patients (mean age 66 y) with severe pain caused by RA who had not previously been treated with transdermal fentanyl were included in this prospective, open-label study. Pain intensity, functional impairment, and well-being were documented prospectively for 30 days after treatment with transdermal fentanyl had been initiated. Patients evaluated pain on an 11-point numerical rating scale. Quality of sleep, daily and social functioning, and treatment satisfaction were rated using 5-point categorical rating scales. General wellbeing was assessed by the Marburg questionnaire. Results: Adding transdermal fentanyl to the ongoing RA therapy reduced pain intensity significantly from 8.0 (7.82 to 8.18) to 4.0 (3.75 to 4.25). Mean functional impairment due to pain also decreased significantly from "severe" at the beginning to "mild to moderate." Treatment with transdermal fentanyl also led to a significant improvement by approximately 1.5 units for all items in the Marburg questionnaire on general well-being. At the end of the study, nearly all patients were satisfied with the pain treatment. Transdermal fentanyl was generally well tolerated. The most frequent side effects were nausea (9.7%) and vomiting (7.1%). Discussion: Patients with pain caused by RA improved in terms of pain intensity, sleep, function, and general well-being when transdermal fentanyl was added to the treatment regimen. Treatment satisfaction was high. Transdermal fentanyl also demonstrated good tolerability over a period of 30 days.	Humboldt Univ, Teaching Hosp, HELIOS Klinikum Berlin Buch, Dept Phys Med & Rehabil, D-13125 Berlin, Germany; Janssen Cilag GmbH, D-41470 Neuss, Germany	Berliner, MN (reprint author), HELIOS Klinikum Berlin Buch, Dept Phys Med & Rehabil, Hobrechtsfelder Chaussee 100, D-13125 Berlin, Germany.	Mberliner@berlin.helios-kliniken.de					Allan L, 2001, BRIT MED J, V322, P1154, DOI 10.1136/bmj.322.7295.1154; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; BADLEY EM, 1993, ANN RHEUM DIS, V52, P6, DOI 10.1136/ard.52.1.6; Basler HD, 1999, SCHMERZ, V13, P385, DOI 10.1007/s004820050216; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; Kalso E, 2004, PAIN, V112, P372, DOI 10.1016/j.pain.2004.09.019; Lee C, 2004, ARTHRIT RHEUM-ARTHR, V51, P746, DOI 10.1002/art.20698; LICHTENSTEIN DR, 1995, ARTHRITIS RHEUM, V38, P5, DOI 10.1002/art.1780380103; Moran C., 1991, BR J CLIN RES, V2, P1; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; Palmer BF, 1995, J INVEST MED, V43, P516; Pavelka K, 2004, CURR MED RES OPIN, V20, P1967, DOI 10.1185/030079904X14120; Ringe JD, 2002, RHEUMATOL INT, V22, P199, DOI 10.1007/s00296-002-0217-8; Scott DL, 1998, BRIT J RHEUMATOL, V37, P546; Simpson RK, 1997, J PAIN SYMPTOM MANAG, V14, P218, DOI 10.1016/S0885-3924(97)00183-8; Singh G, 1998, J RHEUMATOL, V25, P8; STEINBROCKER O, 1949, JAMA-J AM MED ASSOC, V140, P659, DOI 10.1001/jama.1949.02900430001001; Theodoridis T, 2003, Z ORTHOP GRENZGEB, V141, P217, DOI 10.1055/s-2003-38651; VLAK T, 1996, REUMATIZAM, V43, P1; Wiech K, 2000, SCAND J RHEUMATOL, V29, P13, DOI 10.1080/030097400446571; Ytterberg SR, 1998, ARTHRITIS RHEUM, V41, P1603, DOI 10.1002/1529-0131(199809)41:9<1603::AID-ART10>3.0.CO;2-U; Zimmermann M, 2001, SCHMERZ, V15, P85, DOI 10.1007/s004820170030	22	12	13	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0749-8047	1536-5409		CLIN J PAIN	Clin. J. Pain	JUL-AUG	2007	23	6					530	534		10.1097/AJP.0b013e318074c9b1			5	Anesthesiology; Clinical Neurology	Anesthesiology; Neurosciences & Neurology	183PC	WOS:000247583700010	17575494				2020-06-30	J	Camann, W				Camann, William			Labor analgesia and breast feeding: avoid parenteral narcotics and provide lactation support	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Editorial Material							EPIDURAL ANALGESIA		Brigham & Womens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Camann, W (reprint author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.	WCAMANN@PARTNERS.ORG					Beilin Y, 2005, ANESTHESIOLOGY, V103, P1211, DOI 10.1097/00000542-200512010-00016; Chang ZM, 2005, J HUM LACT, V21, P305, DOI 10.1177/0890334405277604; Fernando R, 2007, INT J OBSTET ANESTH, V16, P236, DOI 10.1016/j.ijoa.2007.01.004; Halpern SH, 2005, ANESTHESIOLOGY, V103, P1111, DOI 10.1097/00000542-200512000-00002; Halpern SH, 1999, BIRTH-ISS PERINAT C, V26, P83, DOI 10.1046/j.1523-536x.1999.00083.x; Jordan S, 2005, BJOG-INT J OBSTET GY, V112, P927, DOI 10.1111/j.1471-0528.2005.00548.x; Ransjo-Arvidson AB, 2001, BIRTH-ISS PERINAT C, V28, P5, DOI 10.1046/j.1523-536x.2001.00005.x; Riordan J, 2000, J Hum Lact, V16, P7, DOI 10.1177/089033440001600103; TORVALDSEN S, 2007, COMMUNICATION    JAN; Torvaldsen S, 2006, INT BREASTFEED J, V1, DOI 10.1186/1746-4358-1-24; Wittels B, 1997, ANESTH ANALG, V85, P600, DOI 10.1097/00000539-199709000-00021	11	9	9	0	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-289X	1532-3374		INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	JUL	2007	16	3					199	201		10.1016/j.ijoa.2007.03.008			3	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	191VQ	WOS:000248160500001	17521903				2020-06-30	J	Soundararajan, N; Russell, I				Soundararajan, N.; Russell, I.			A randomised comparison of a hand-held Neurotip and the Neuropen for assessing loss of touch sensation during spinal anaesthesia for caesarean section	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Article						spinal anaesthesia; assessing sensory block; caesarean section	DIFFERENTIAL EPIDURAL BLOCK; AGREEMENT; PINPRICK; ZONES; COLD	Background: With spinal anaesthesia various methods may be used to assess the block to touch. We wished to compare the levels of block assessed using a non-standardised, assessor-dependent touch stimulus with those assessed when the same stimulus was applied in a standardised manner independent of the assessor. Methods: In a double-blind, randomised study the levels of block to touch were assessed by two investigators, one using a hand-held Neurotip tester pin and the other using the same tester pin mounted in a spring loaded system (Neuropen). Both the testing device and the order of testing were randomised between the two observers. The dermatomes were marked on patients' torsos before surgery. Results: Whole group data analysis in a Bland Altman plot demonstrated a median difference of 0 dermatomes between the two methods: the 5(th), 25(th), 75(th), and 95(th) centiles of agreement being -2, -1, +1, and +2 dermatomes respectively. There were occasional wide differences in levels of block to touch with the Neuropen varying between seven dermatomes rostral to and four dermatomes caudal to the Neurotip. These differences were short-lived and did not affect clinical management. Conclusion: When comparing two very similar touch stimuli, one standardised and user-independent and one non-standardised, we observed occasional wide but short lived differences in the assessed levels of block to touch. Although these differences did not affect clinical management, whether more dissimilar touch testing methods might affect clinical management remains to be seen. (C) 2006 Elsevier Ltd. All rights reserved.	Hull Royal Infirm, Dept Anaesthesia, Kingston Upon Hull HU3 2JZ, N Humberside, England	Russell, I (reprint author), Hull Royal Infirm, Dept Anaesthesia, Kingston Upon Hull HU3 2JZ, N Humberside, England.	i.f.russell@hull.ac.uk					Bland JM, 1999, STAT METHODS MED RES, V8, P135, DOI 10.1177/096228029900800204; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Bourne TM, 1997, ANAESTHESIA, V52, P901, DOI 10.1111/j.1365-2044.1997.180-az0314.x; BRULL SJ, 1989, ANESTH ANALG, V69, P342; BRULL SJ, 1991, BRIT J ANAESTH, V66, P651, DOI 10.1093/bja/66.6.651; CONGREVE K, 2005, INT J OBSTET ANESTH, V14, pS12; HOLDCROFT A, 2000, PRINCIPLES PRACTICE, P268; Hollmen A., 1966, ACTA ANAESTHESIOL S, V21, P53; KOCAREV M, 2006, INT J OBSTET ANEST S, V15, pS9; LEWIS E, 2006, INT J OBSTET ANEST S, V15, pS9; MORRISON LMM, 1996, PAIN RELIEF ANAESTHE, P450; MUKHERJEE J, 2003, INT J OBSTET ANEST S, V12, pS18; Paisley AN, 2002, DIABETIC MED, V19, P400; ROCCO AG, 1985, ANESTH ANALG, V64, P917; Russell IF, 2004, INT J OBSTET ANESTH, V13, P146, DOI 10.1016/j.ijoa.2003.12.007; Russell IF, 2001, INT J OBSTET ANESTH, V10, P83, DOI 10.1054/ijoa.2000.0770; STEVENS RA, 1992, REGION ANESTH, V17, P22; WHITE JL, 1994, REGION ANESTH, V19, P335; YENTIS SM, 2001, ANALGESIA ANAESTHESI, P360	19	4	4	0	0	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0959-289X			INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	JUL	2007	16	3					202	207		10.1016/j.ijoa.2006.11.008			6	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	191VQ	WOS:000248160500002	17337179				2020-06-30	J	Co, A; Connelly, NR				Co, Anthony; Connelly, Neil Roy			Epidural volume	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Letter							DILUENT VOLUME; ANALGESIA; LABOR		Baystate Med Ctr, Springfield, MA USA; Tufts Univ, Sch Med, Springfield, MA 01199 USA	Co, A (reprint author), Baystate Med Ctr, Springfield, MA USA.	anthony.Co@bhs.org					Chan L, 2006, INT J OBSTET ANESTH, V15, P201, DOI 10.1016/j.ijoa.2005.11.001; Connelly NR, 2003, ANESTH ANALG, V96, P1799, DOI 10.1213/01.ANE.0000061583.77068.0B	2	0	0	0	0	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0959-289X			INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	JUL	2007	16	3					291	292		10.1016/j.ijoa.2006.10.018			2	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	191VQ	WOS:000248160500021	17399978				2020-06-30	J	Turker, G; Gurbet, A; Aksu, HA				Turker, Gurkan; Gurbet, Alp; Aksu, Hale Ayca			Continuous spinal analgesia in parturients with severe heart disease	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Letter							ANESTHESIA; DELIVERY; LABOR		Uludag Univ, Fac Med, Dept Anesthesiol & Reanimat, Bursa, Turkey	Turker, G (reprint author), Uludag Univ, Fac Med, Dept Anesthesiol & Reanimat, Bursa, Turkey.	agurbet@uludag.edu.tr	Erdost, Hale Aksu/S-2847-2016	TURKER, YUNUS GURKAN/0000-0002-3019-581X; GURBET, ALP/0000-0002-6503-8232			Ben-David B, 2000, REGION ANESTH PAIN M, V25, P235, DOI 10.1016/S1098-7339(00)90004-X; Gurbet A, 2005, INT J OBSTET ANESTH, V14, P121, DOI 10.1016/j.ijoa.2004.12.002; Imbelloni LE, 2006, INT J OBSTET ANESTH, V15, P171, DOI 10.1016/j.ijoa.2005.09.009; Muralidhar V, 1999, REGION ANESTH PAIN M, V24, P417; Okutomi T, 2002, ACTA ANAESTH SCAND, V46, P329, DOI 10.1034/j.1399-6576.2002.t01-1-460317.x; RANSOM DM, 1995, ANESTH ANALG, V80, P418, DOI 10.1097/00000539-199502000-00038; Shah D M, 1985, Obstet Gynecol Surv, V40, P444, DOI 10.1097/00006254-198507000-00005	7	6	6	1	3	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0959-289X			INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	JUL	2007	16	3					297	299		10.1016/j.ijoa.2007.02.003			3	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	191VQ	WOS:000248160500028	17509871				2020-06-30	J	Thompson, JG; Baker, AM; Bracey, AH; Seningen, J; Kloss, JS; Strobl, AQ; Apple, FS				Thompson, Jonathan G.; Baker, Andrew M.; Bracey, Anne H.; Seningen, Justin; Kloss, Julie S.; Strobl, A. Quinn; Apple, Fred S.			Fentanyl concentrations in 23 postmortem cases from the Hennepin County Medical Examiner's Office	JOURNAL OF FORENSIC SCIENCES			English	Article; Proceedings Paper	58th Annual Meeting of the American-Academy-of-Forensic-Sciences	FEB, 2006	Seattle, WA	Amer Acad Forens Sci		forensic science; fentanyl; postmortem; cause of death	OPIOID ANALGESICS; DEATHS; CIRCUMSTANCES; MISUSE; ABUSE	The purpose of this study was to compare blood fentanyl concentrations in fentanyl-related deaths with fentanyl concentrations found incidentally at autopsy, as well as with fentanyl concentrations found in hospitalized patients receiving fentanyl. Between the years 1997 to 2005, 23 fentanyl-positive postmortem cases were identified. Nineteen of 23 (82.6%) cases were deemed to be drug overdoses. Fentanyl alone was responsible for 8 of the 19 (42.1%) overdose deaths. Mean and median fentanyl concentrations were 36 (SD 38) mu g/L and 22 mu g/L, respectively, range 5-120 mu g/L. Seven of the cases were accidental, one undetermined. The remaining 11 of the 19 (57.9%) cases were mixed drug overdoses. Fentanyl concentrations in these cases were 31 (SD 46) mu g/L, range 5-152 mu g/L. All of the mixed drug overdoses were determined to be accidental. Four cases where fentanyl was considered an incidental postmortem finding were determined to be natural deaths. In hospitalized inpatients (n = 11) receiving fentanyl 2 of the patients receiving fentanyl for chronic pain for more than 3 months had concentrations of 8.5 mu g/L and 9.9 mu g/L. The other nine inpatient concentrations were less than 4 mu g/L. In conclusion, blood fentanyl concentrations found in cases where fentanyl alone was determined to be the cause of death were similar to cases where fentanyl was part of a mixed drug overdose. There was also considerable overlap between fentanyl concentrations in fentanyl-related overdose deaths compared to hospitalized patients being treated for chronic pain. Fentanyl concentrations in postmortem cases must be interpreted in the context of the deceased's past medical history and autopsy findings.	Hennepin Cty Med Examiners Off, Minneapolis, MN 55415 USA; Hennepin Cty Med Ctr, Minneapolis, MN 55305 USA; Univ Minnesota, Sch Med, Clin Labs P4, Minneapolis, MN 55305 USA	Apple, FS (reprint author), Hennepin Cty Med Ctr, Clin Labs P4, 701 Pk Ave, Minneapolis, MN 55415 USA.	apple004@umn.edu					Anderson DT, 2000, J ANAL TOXICOL, V24, P627, DOI 10.1093/jat/24.7.627; HENDERSON GL, 1991, J FORENSIC SCI, V36, P422; Joranson DE, 2000, JAMA-J AM MED ASSOC, V283, P1710, DOI 10.1001/jama.283.13.1710; Kuhlman JJ, 2003, J ANAL TOXICOL, V27, P499, DOI 10.1093/jat/27.7.499; Lilleng PK, 2004, J FORENSIC SCI, V49, P1364; Martin TL, 2006, J ANAL TOXICOL, V30, P603, DOI 10.1093/jat/30.8.603; OLKKOLA KT, 1995, CLIN PHARMACOKINET, V28, P385, DOI 10.2165/00003088-199528050-00004; PARONIS CA, 1992, J PHARMACOL EXP THER, V262, P1; POKLIS A, 1995, J TOXICOL-CLIN TOXIC, V33, P439, DOI 10.3109/15563659509013752; THOMSON PDR, 1999, MED EC CORP, P1418	10	41	44	0	8	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0022-1198			J FORENSIC SCI	J. Forensic Sci.	JUL	2007	52	4					978	981		10.1111/j.1556-4029.2007.00481.x			4	Medicine, Legal	Legal Medicine	178NO	WOS:000247227600038	17553084				2020-06-30	J	Colpaert, F; Koek, W; Kleven, M; Besnard, J				Colpaert, Francis; Koek, Wouter; Kleven, Mark; Besnard, Joel			Induction by antipsychotics of "win-shift" in the drug discrimination paradigm	JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS			English	Article							DOPAMINE-D-2 RECEPTOR ANTAGONIST; PARTIAL AGONIST PROPERTIES; D-2/D-3 ANTAGONIST; CUE SENSITIVITY; 5-HT1A AGONIST; HALOPERIDOL; FENTANYL; REWARD; SALINE; CLASSIFICATION	In a two- lever, food- rewarded drug discrimination paradigm, behavior seems to be governed by a win- stay/ lose- shift rule; rats continue to press the lever that yields food, and, when not rewarded, they shift responding to the alternative lever. Here, we report on the effects that antipsychotics and further neuropharmacological agents exert in those conditions. At higher doses, antipsychotics disrupt most or all behavioral parameters in this paradigm. However, at lower doses, rats may select the appropriate lever with normal latency and accuracy, obtain a first food pellet ( i. e., " win"), and then, remarkably, shift responding to the alternative lever (" win- shift"). This suggests that antipsychotics can block the effects of reward selectively, i. e., at doses where the initial, secondarily reinforced behavior including the initiation of lever pressing, remains intact. Indeed, saline- treated rats that are given no reward ( i. e., " lose") after having selected a lever, also press the alternative lever (" loseshift"). The induction of selective win- shift is specific to antipsychotics, but it varies greatly among them. Perhaps relating to its alleged " incisive" action on delirium and hallucinations, and, surprisingly, in view of its extrapyramidal actions, acutely administered haloperidol ( 0.04 - 0.08 mg/ kg) demonstrates win- shift to an exceptional extent, shared only with the newly proposed agent ( 3- cyclopent- 1- enyl- benzyl)-[ 2-( 2,2- dimethyl- 2,3- dihydro- benzofuran7- yloxy)- ethyl]- amine fumarate ( F 15063; 0.31 - 0.63 mg/ kg); the more sedative antipsychotic chlorpromazine demonstrated little selectivity. The paradigm offers a novel tool to characterize antipsychotics with regard to presumably pathogenic motivational processes; mixed D-2- antagonist/ 5hydroxytryptamine(1A)- agonist agents such as F 15063 may conceivably share the powerful antipsychotic action of haloperidol while avoiding the sensitization that develops to extrapyramidal effects of haloperidol and consequent negative symptoms.	Ctr Rech Pierre Fabre, F-81106 Castres, France; Univ Texas, Hlth Sci Ctr San Antonio, Dept Psychiat, Alcohol & Drug Addict Div, San Antonio, TX 78285 USA; Yaupon Therapeut Inc, Radnor, PA USA	Colpaert, F (reprint author), Ctr Rech Pierre Fabre, 17 Ave Jean Moulin, F-81106 Castres, France.	francis.colpaert@pierre-fabre.com					Andrezina R, 2006, PSYCHOPHARMACOLOGY, V188, P281, DOI 10.1007/s00213-006-0541-x; Berridge KC, 2007, PSYCHOPHARMACOLOGY, V191, P391, DOI 10.1007/s00213-006-0578-x; Blin O, 1999, CAN J PSYCHIAT, V44, P235, DOI 10.1177/070674379904400303; BOBON J, 1972, COMPR PSYCHIAT, V13, P123, DOI 10.1016/0010-440X(72)90017-X; BROEKKAMP CLE, 1988, N-S ARCH PHARMACOL, V338, P191, DOI 10.1007/BF00174869; Charney DS, 2004, AM J PSYCHIAT, V161, P1, DOI 10.1176/appi.ajp.161.1.1; Claustre Y, 2003, NEUROPSYCHOPHARMACOL, V28, P2064, DOI 10.1038/sj.npp.1300262; COLONNA L, 1989, DICT NEUROLEPTIQUES; COLPAERT FC, 1980, NEUROPHARMACOLOGY, V19, P705, DOI 10.1016/0028-3908(80)90061-1; COLPAERT FC, 1977, PSYCHOPHARMACOLOGY, V53, P169, DOI 10.1007/BF00426488; Colpaert FC, 2001, BEHAV PHARMACOL, V12, P575, DOI 10.1097/00008877-200112000-00002; COLPAERT FC, 1980, J PHARMACOL EXP THER, V212, P474; COLPAERT FC, 1984, J PHARMACOL EXP THER, V230, P193; COLPAERT FC, 1978, STIMULUS PROPERTIES, P217; COLPAERT FC, 1987, METHODS ASSESSING RE, P341; Depoortere R, 2007, BRIT J PHARMACOL, V151, P253, DOI 10.1038/sj.bjp.0707159; Dietrich A, 2003, CONSCIOUS COGN, V12, P231, DOI 10.1016/S1053-8100(02)00046-6; Dietrich A, 2001, BRAIN RES, V919, P41, DOI 10.1016/S0006-8993(01)02992-4; ETTENBERG A, 1986, PHARMACOL BIOCHEM BE, V25, P813, DOI 10.1016/0091-3057(86)90392-8; Ferguson HJ, 2001, ANIM BEHAV, V61, P527, DOI 10.1006/anbe.2000.1635; FLACH J, 1975, NEUROLEPTIQUES 20 AP, P277; GERARD A, 1984, SEM PSYCH BIOL FHARM, P158; GOUDIE AJ, 1986, NEUROPHARMACOLOGY, V25, P85, DOI 10.1016/0028-3908(86)90063-8; Hamann J, 2003, INT CLIN PSYCHOPHARM, V18, P237, DOI 10.1097/00004850-200307000-00006; HARLOW HF, 1949, PSYCHOL REV, V56, P51, DOI 10.1037/h0062474; Kapur S, 2005, SCHIZOPHR RES, V79, P59, DOI 10.1016/j.schres.2005.01.003; KOEK W, 1995, BEHAV PHARMACOL, V6, P590; LEYSEN JE, 1993, PSYCHOPHARMACOLOGY, V112, pS40, DOI 10.1007/BF02245006; Matsen FA, 2004, P NATL ACAD SCI USA, V101, P18053, DOI 10.1073/pnas.0406608102; McCreary AC, 2007, NEUROPSYCHOPHARMACOL, V32, P78, DOI 10.1038/sj.npp.1301098; Newman-Tancredi A, 2007, BRIT J PHARMACOL, V151, P237, DOI 10.1038/sj.bjp.0707158; NIEMEGEERS CJE, 1979, LIFE SCI, V24, P2201, DOI 10.1016/0024-3205(79)90096-1; RESTLE F, 1958, PSYCHOL REV, V65, P77, DOI 10.1037/h0045864; Salamone JD, 2003, J PHARMACOL EXP THER, V305, P1, DOI 10.1124/jpet.102.035063; Schmidt WJ, 2006, NEUROTOX RES, V10, P161, DOI 10.1007/BF03033244; Schmidt WJ, 1999, EUR J NEUROSCI, V11, P3365, DOI 10.1046/j.1460-9568.1999.00794.x; SIMON P, 1984, REV PRATICIEN, V34, P589; Tremblay L, 1998, J NEUROPHYSIOL, V80, P964; Wadenberg MLG, 1999, NEUROSCI BIOBEHAV R, V23, P851, DOI 10.1016/S0149-7634(99)00037-8; WISE RA, 1978, CAN J PSYCHOL, V32, P77, DOI 10.1037/h0081678; Wise RA, 2004, NAT REV NEUROSCI, V5, P483, DOI 10.1038/nrn1406	41	7	7	0	2	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA	0022-3565	1521-0103		J PHARMACOL EXP THER	J. Pharmacol. Exp. Ther.	JUL	2007	322	1					288	298		10.1124/jpet.107.119446			11	Pharmacology & Pharmacy	Pharmacology & Pharmacy	180FO	WOS:000247348100035	17431135				2020-06-30	J	Alves, HC; Valentim, AM; Olsson, IAS; Antunes, LM				Alves, H. C.; Valentim, A. M.; Olsson, I. A. S.; Antunes, L. M.			Intraperitoneal propofol and propofol fentanyl, sufentanil and remifentanil combinations for mouse anaesthesia	LABORATORY ANIMALS			English	Article						propofol; opioids; intraperitoneal; anaesthesia; mice	MICE; PHARMACODYNAMICS; PHARMACOKINETICS; RATS; ATIPAMEZOLE; VOLUNTEERS; MIDAZOLAM; RECOVERY; XYLAZINE; REVERSAL	The combination of propofol and a rapid-acting opioid, such as fentanyl, sufentanil or remifentanil, is a relatively safe, total intravenous anaesthesia technique, commonly used in humans and which has been investigated in laboratory animals. The objective of this study was to evaluate these combinations for anaesthesia of mice by the intraperitoneal (i.p.) route. Sixty-seven mice, divided into groups of four, were used to test 28 combinations of propofol alone and propofol with fentanyl, sufentanil or remifentanil administered i.p. The dose ranges of drugs studied were propofol 50-200 mg/kg, fentanyl 0.2-0.4 mg/kg, sufentanil 0.05-0.1 mg/kg and remifentanil 0.2-1.0mg/kg. The loss of righting reflex (RR) and the loss of pedal withdrawal reflex (PWR) were recorded along with the duration and quality of recovery. The results obtained in these studies were unpredictable. The same dose combinations of propofol and opioids were associated with different responses in different individuals. Higher doses did not induce loss of RR and PWR in all animals and were associated with high mortality rates. An adequate hypnotic level was only observed with higher doses of propofol. The synergistic effect of propofol and the opioids was not sufficient to allow surgical procedures. Animals that reached PWR loss showed tail rigidity, shaking limbs and scratched their heads with their forefeet. Higher opioid doses induced respiratory depression and higher death rates. The inconsistency between and within groups may be associated with the i.p. route. The results reported here show that the i.p. route is not appropriate for mouse anaesthesia using propofol alone or in combination with fentanyl, sufentanil or remifentanil.	Univ Porto, Inst Biol Mol & Celular, Lab Anim Sci, P-4150180 Oporto, Portugal; Univ Tras os Montes & Alto Douro, CECAV, Vila Real, Portugal	Alves, HC (reprint author), Univ Porto, Inst Biol Mol & Celular, Lab Anim Sci, Rua Campo Alegre 823, P-4150180 Oporto, Portugal.	heber.alves@sapo.pt	Valentim, Ana/C-3389-2013; Olsson, Anna/C-1792-2008	Valentim, Ana/0000-0003-1428-0691; Olsson, Anna/0000-0002-4369-8723; Antunes, Luis/0000-0002-9757-6879			ANTUNES LM, 2003, 8 WORLD C VET AN; Anwar MM, 1998, COMP BIOCHEM PHYS A, V120, P249, DOI 10.1016/S1095-6433(98)00025-7; Arras M, 2001, COMPARATIVE MED, V51, P443; CLAASSEN V, 1994, NEGLECTED FACTORS PH, P46; Cruz JI, 1998, LAB ANIM-UK, V32, P18, DOI 10.1258/002367798780559383; Dershwitz M, 1996, J CLIN ANESTH, V8, pS88, DOI 10.1016/S0952-8180(96)90020-3; EGAN TD, 1995, CLIN PHARMACOKINET, V29, P80, DOI 10.2165/00003088-199529020-00003; ERHARDT W, 1984, RES EXP MED, V184, P159, DOI 10.1007/BF01852390; FLECKNELL PA, 1984, LAB ANIM, V18, P143, DOI 10.1258/002367784780891406; Flecknell PA, 1996, LAB ANIMAL ANAESTHES, P159; FLECKNELL PA, 1997, LAB ANIM, V26, P143; GARDNER DJ, 1995, LAB ANIM SCI, V45, P199; GREEN CJ, 1979, LAB ANIMALS HDB; GURTU S, 1990, LIFE SCI, V46, P1539, DOI 10.1016/0024-3205(90)90427-S; Hacker SO, 2005, CONTEMP TOP LAB ANIM, V44, P7; Hedenqvist P, 2000, LAB ANIM-UK, V34, P244, DOI 10.1258/002367700780384762; Hoke JF, 1997, ANESTHESIOLOGY, V87, P533, DOI 10.1097/00000542-199709000-00012; KANTO JH, 1988, INT J CLIN PHARM TH, V26, P41; LEWIS RE, 1966, LAB ANIM CARE, V16, P505; NIEMEGEERS CJE, 1976, ARZNEIMITTEL-FORSCH, V26, P1551; Nunes CS, 2005, J NEUROSURG ANESTH, V17, P110, DOI 10.1097/01.ana.0000163198.02742.9d; SMITH W, 1993, LAB ANIM, V27, P30, DOI 10.1258/002367793781082377; WHELAN G, 1994, LAB ANIM, V28, P70, DOI 10.1258/002367794781065735	23	21	24	0	5	ROYAL SOC MEDICINE PRESS LTD	LONDON	1 WIMPOLE STREET, LONDON W1G 0AE, ENGLAND	0023-6772			LAB ANIM-UK	Lab. Anim.	JUL	2007	41	3					329	336		10.1258/002367707781282767			8	Veterinary Sciences; Zoology	Veterinary Sciences; Zoology	195IR	WOS:000248406400004	17640460	Bronze			2020-06-30	J	Yildiz, TS; Solak, M; Iseri, M; Karaca, B; Toker, K				Yildiz, Tulay Sahin; Solak, Mine; Iseri, Mete; Karaca, Burhan; Toker, Kamil			Hearing loss after spinal anesthesia: The effect of different infusion solutions	OTOLARYNGOLOGY-HEAD AND NECK SURGERY			English	Article							HYPOTENSION	OBJECTIVE: We speculate that the preoperative volume replacement with a convenient solution may protect the inner ear function after spinal anesthesia. METHODS: The patients were randomized in a single-blind fashion into two groups: group LR (n = 40) received lactated Ringer's and group GF (n = 40) received gelatin polysuccinate 4% (Gelofusine). Spinal anesthesia was performed with a 25 G Quincke needle and was given bupivacaine 0.5% 10 mg and fentanyl 25 pg. Audiograms were performed preoperatively and 2 days postoperatively. RESULTS: The overall incidence of hearing loss was 7.5%. The hearing loss was unilateral in two and bilateral in four patients. Hearing loss occurred within the low-frequency range and the hearing thresholds returned to normal by the fifth postoperative day. CONCLUSIONS: Although the incidence of hearing loss for the lactated Ringer's group was higher than the Gelofusine group, there was no statistically significant difference between the groups. For medicolegal and ethical reasons, patients should be informed about the possibility of hearing loss after spinal anesthesia. (C) 2007 American Academy of Otolaryngology-Head and Neck Surgery Foundation. All rights reserved.	Univ Kocaeli, Sch Med, Dept Anesthesiol & Otorhinolaryngol, Kocaeli, Turkey	Iseri, M (reprint author), Kocaeli Univ, Fac Med, Dept Otolaryngol, TR-41380 Umuttepe, Kocaeli, Turkey.						BARAKA AS, 1994, ANESTH ANALG, V78, P301, DOI 10.1213/00000539-199402000-00017; CHONG ML, 1986, ANESTH ANALG, V65, P312; FOG J, 1990, ANESTH ANALG, V70, P517; Fujino M, 1999, EUR ARCH OTO-RHINO-L, V256, pS18, DOI 10.1007/PL00014146; Gultekin S, 2002, ANESTH ANALG, V94, P1318; HAHN RG, 1993, ACTA ANAESTH SCAND, V37, P357, DOI 10.1111/j.1399-6576.1993.tb03728.x; KAYE AD, 2005, MILLERS ANESTHESIA, P1786; Kilickan L, 2002, ACTA ANAESTH SCAND, V46, P1155, DOI 10.1034/j.1399-6576.2002.460916.x; Lamberg T, 1997, REGION ANESTH, V22, P539; Malhotra SK, 2002, EUR J ANAESTH, V19, P69; MICHEL O, 1992, ANN OTO RHINOL LARYN, V101, P390, DOI 10.1177/000348949210100503; MOSS GS, 1969, SURG GYNECOL OBSTETR, V129, P1247; MUDGE GH, 1975, PHARMACOL BASIS THER, P767; Panning B, 1983, LANCET, V2, P582; Schaffartzik W, 2000, ANESTH ANALG, V91, P1466, DOI 10.1097/00000539-200012000-00032; Stoeckli SJ, 1999, J NEUROSURG, V90, P773, DOI 10.3171/jns.1999.90.4.0773; WALSTED A, 1991, SCAND AUDIOL, V20, P211, DOI 10.3109/01050399109045965; WANG LP, 1987, ANAESTHESIA, V42, P1258, DOI 10.1111/j.1365-2044.1987.tb05270.x; Wemama JP, 1996, ANESTH ANALG, V82, P406, DOI 10.1097/00000539-199602000-00033; WLODYKA J, 1978, ANN OTO RHINOL LARYN, V87, P22	20	9	9	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0194-5998			OTOLARYNG HEAD NECK	Otolaryngol. Head Neck Surg.	JUL	2007	137	1					79	82		10.1016/j.otohns.2007.02.018			4	Otorhinolaryngology; Surgery	Otorhinolaryngology; Surgery	185VY	WOS:000247739700014	17599570				2020-06-30	J	Woloszczuk-Gebicka, B; Wyska, E; Grabowski, T				Woloszczuk-Gebicka, Bogumila; Wyska, Elzbieta; Grabowski, Tomasz			Sevoflurane increases fade of neuromuscular response to TOF stimulation following rocuronium administration in children. A PK/PD analysis	PEDIATRIC ANESTHESIA			English	Article						pediatric : pharmacokinetic-pharmacodynamic modeling; pharmacodynamics : synergism; inhalational : sevoflurane; anesthetics	PHARMACOKINETIC-PHARMACODYNAMIC RELATIONSHIP; NICOTINIC ACETYLCHOLINE-RECEPTORS; TIME-COURSE; ISOFLURANE ANESTHESIA; TRAIN-OF-4 FADE; TETANIC FADE; HALOTHANE; VECURONIUM; DESFLURANE; PROPOFOL	Background: Sevoflurane enhances neuromuscular block produced by rocuronium, affecting not only single twitch response but also the response to high-frequency stimulation, increasing tetanic [or train-of-four (TOF)] fade. Methods: We compared the degree of fade during spontaneous recovery from rocuronium-induced neuromuscular block in 24 children (3-11 years old, ASA groups I and II), anesthetized with nitrous oxide-sevoflurane (one MAC, endtidal concentration) or nitrous oxide-fentanyl. Neuromuscular transmission was monitored electromyographically (EMG), stimulating the ulnar nerve at the wrist with TOF, 2 Hz for 2 s, repeated at 20-s intervals and recording EMG potential from adductor pollicis brevis. Depression of the fourth twitch, T4, was used as a measure of fade. Following an intubating dose of rocuronium, 0.6 mg.kg(-1), continuous infusion of rocuronium was given to maintain stable 90-99% T1 depression. Plasma concentration of rocuronium was determined with high performance liquid chromatography with electrochemical detection (HPLC-EC) method at the moment of discontinuation of rocuronium infusion and 10, 20, 30, 40, 50, 60, and 75 min afterwards. A two compartment model was used for pharmacokinetic (PK) calculations. PK parameters were fixed and pharmacodynamic data were fitted to effect compartment model proposed by Sheiner. Results: Sevoflurane reduced rocuronium concentration in effect compartment producing 50% inhibition of both T1 and T4 response and significantly delayed not only T1, but also T4 recovery. Conclusions: Potentiating effect of sevoflurane on rocuronium-induced neuromuscular block influences not only postsynaptic, but also the presynaptic part of the neuromuscular junction, enhancing fade of neuromuscular response to high-frequency stimulation. The intensity of this latter effect is clinically relevant.	Warsaw Med Univ, Dept Paediat Anaesthesiol & Intens Therapy, PL-00576 Warsaw, Poland; Jagiellonian Univ, Dept Pharmacokinet & Phys Pharm, Collegium Medicum, Krakow, Poland; Ctr Pharmacokinet Res Filab, Lajski, Poland	Woloszczuk-Gebicka, B (reprint author), Warsaw Med Univ, Dept Paediat Anaesthesiol & Intens Therapy, Marszalkowska 24, PL-00576 Warsaw, Poland.	Bogumila.Gebicka@acn.waw.pl	Grabowski, Tomasz/AAE-6300-2020	Grabowski, Tomasz/0000-0002-3077-9698; Wyska, Elzbieta/0000-0002-4798-0574			BAURAIN MJ, 1991, ANESTHESIOLOGY, V74, P474, DOI 10.1097/00000542-199103000-00014; Bock M, 2000, BRIT J ANAESTH, V84, P43; BOWMAN WC, 1976, CLIN EXP PHARMACOL P, V3, P545, DOI 10.1111/j.1440-1681.1976.tb00636.x; BOWMAN WC, 1988, TRENDS PHARMACOL SCI, V9, P16, DOI 10.1016/0165-6147(88)90236-2; Chiodini F, 2001, ANESTHESIOLOGY, V94, P643, DOI 10.1097/00000542-200104000-00019; DARGENIO DZ, 1997, ADAPT 2 USERS GUIDE; Dragne A, 2002, CAN J ANAESTH, V49, P353, DOI 10.1007/BF03017322; Faria M, 2003, SYNAPSE, V49, P77, DOI 10.1002/syn.10211; GABRIELSSON J, 2001, PHARMACOKINETIC PHAR, P770; Izawa H, 1997, Masui, V46, P177; KATOH T, 1992, BRIT J ANAESTH, V68, P139, DOI 10.1093/bja/68.2.139; Kopman AF, 1997, ANESTHESIOLOGY, V86, P765, DOI 10.1097/00000542-199704000-00005; Kumar N, 1996, BRIT J ANAESTH, V77, P488, DOI 10.1093/bja/77.4.488; Lowry DW, 1998, ANESTH ANALG, V87, P936, DOI 10.1097/00000539-199810000-00036; McCoy EP, 1996, BRIT J ANAESTH, V76, P29; Meretoja OA, 1996, BRIT J ANAESTH, V76, P235; Mori T, 2001, MOL PHARMACOL, V59, P732; MORITA A, 1996, CAN J ANAESTH, V43, P799; Morita T, 1997, ANAESTHESIA, V52, P538, DOI 10.1111/j.1365-2222.1997.119-az0123.x; O'Kelly B, 1994, Eur J Anaesthesiol Suppl, V9, P57; Paul M, 2002, ANESTH ANALG, V95, P362, DOI 10.1213/01.ANE.0000022408.02985.33; Reid JE, 2001, CAN J ANAESTH, V48, P351, DOI 10.1007/BF03014962; SHEINER LB, 1979, CLIN PHARMACOL THER, V25, P358; TSUNEKI H, 1995, NEUROSCI LETT, V196, P13, DOI 10.1016/0304-3940(95)11824-G; Vermeyen KM, 2003, BRIT J ANAESTH, V90, P183, DOI 10.1093/bja/aeg043; VibyMogensen J, 1996, ACTA ANAESTH SCAND, V40, P59, DOI 10.1111/j.1399-6576.1996.tb04389.x; Warwick NR, 1998, ANESTHESIOLOGY, V88, P874, DOI 10.1097/00000542-199804000-00005; Woloszczuk-Gebicka B, 2001, ACTA ANAESTH SCAND, V45, P73, DOI 10.1034/j.1399-6576.2001.450112.x; Woloszczuk-Gebicka B, 2006, PEDIATR ANESTH, V16, P761, DOI 10.1111/j.1460-9592.2005.01840.x; WOLOSZCZUKGEBICKA B, 1990, BRIT J ANAESTH, V65, P540, DOI 10.1093/bja/65.4.540; Wulf H, 1998, CAN J ANAESTH, V45, P526, DOI 10.1007/BF03012702; Xue FS, 1998, ANAESTHESIA, V53, P25, DOI 10.1046/j.1365-2044.1998.00278.x	32	8	15	0	4	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	1155-5645			PEDIATR ANESTH	Pediatr. Anesth.	JUL	2007	17	7					637	646		10.1111/j.1460-9592.2006.02181.x			10	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	185AM	WOS:000247683700005	17564645				2020-06-30	J	Wager, TD; Scott, DJ; Zubieta, JK				Wager, Tor D.; Scott, David J.; Zubieta, Jon-Kar			Placebo effects on human mu-opioid activity during pain	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						neuroimaging; periaqueductal gray; expectancy; affective neuroscience	VENTROLATERAL ORBITAL CORTEX; PERIAQUEDUCTAL GRAY-MATTER; ELECTRICAL-STIMULATION; ANALGESIA; EXPECTATION; MECHANISMS; ANTINOCICEPTION; RECEPTORS; SYSTEMS; RAT	Placebo-induced expectancies have been shown to decrease pain in a manner reversible by opioid antagonists, but little is known about the central brain mechanisms of opioid release during placebo treatment. This study examined placebo effects in pain by using positron-emission tomography with [C-11]carfentanil, which measures regional mu-opioid receptor availability in vivo. Noxious thermal stimulation was applied at the same temperature for placebo and control conditions. Placebo treatment affected endogenous opioid activity in a number of predicted mu-opioid receptor-rich regions that play central roles in pain and affect, including periaqueductal gray and nearby dorsal raphe and nucleus cuneiformis, amygdala, orbitofrontal cortex, insula, rostral anterior cingulate, and lateral prefrontal cortex. These regions appeared to be subdivided into two sets, one showing placebo-induced opioid activation specific to noxious heat and the other showing placebo-induced opioid reduction during warm stimulation in anticipation of pain. These findings suggest that a mechanism of placebo analgesia is the potentiation of endogenous opioid responses to noxious stimuli. Opioid activity in many of these regions was correlated with placebo effects in reported pain. Connectivity analyses on individual differences in endogenous opioid system activity revealed that placebo treatment increased functional connectivity between the periaqueductal gray and rostra[ anterior cingulate, as hypothesized a priori, and also increased connectivity among a number of limbic and prefrontal regions, suggesting increased functional integration of opioid responses. Overall, the results suggest that endogenous opioid release in core affective brain regions is an integral part of the mechanism whereby expectancies regulate affective and nociceptive circuits.	Columbia Univ, Dept Psychol, New York, NY 10027 USA; Univ Michigan, Dept Radiol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA; Univ Michigan, Mol & Behav Neurosci Inst, Ann Arbor, MI 48109 USA	Wager, TD (reprint author), Columbia Univ, Dept Psychol, 1190 Amsterdam Ave, New York, NY 10027 USA.	tor@psych.columbia.edu			NCCIH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine [R01 AT001415, R01 AT 001415]		Amanzio M, 1999, J NEUROSCI, V19, P484; Apkarian AV, 2005, EUR J PAIN, V9, P463, DOI 10.1016/j.ejpain.2004.11.001; BARBARO NM, 1988, PROG BRAIN RES, V77, P165; BCHBEHANI MM, 1995, PROG NEUROBIOL, V46, P575; Benedetti F, 2005, J NEUROSCI, V25, P10390, DOI 10.1523/JNEUROSCI.3458-05.2005; Benedetti F, 1999, EUR J NEUROSCI, V11, P625, DOI 10.1046/j.1460-9568.1999.00465.x; Benedetti F, 1999, J NEUROSCI, V19, P3639; Bingel U, 2006, PAIN, V120, P8, DOI 10.1016/j.pain.2005.08.027; CLARK WC, 1969, J ABNORM PSYCHOL, V74, P363, DOI 10.1037/h0027509; De Pascalis V, 2002, PAIN, V96, P393, DOI 10.1016/S0304-3959(01)00485-7; DEVINE DP, 1993, J PHARMACOL EXP THER, V266, P1236; DUVERNOY HM, 1999, HUMAN BRAIN SURFACE; EVANS FJ, 1985, PLACEBO THEORY RES M, P215; Faymonville ME, 2003, COGNITIVE BRAIN RES, V17, P255, DOI 10.1016/S0926-6410(03)00113-7; Fields H, 2004, NAT REV NEUROSCI, V5, P565, DOI 10.1038/nrn1431; FIELDS HL, 1981, AM J MED, V70, P745, DOI 10.1016/0002-9343(81)90525-8; Genovese CR, 2002, NEUROIMAGE, V15, P870, DOI 10.1006/nimg.2001.1037; GRACELY RH, 1983, NATURE, V306, P264, DOI 10.1038/306264a0; HOSOBUCHI Y, 1983, APPL NEUROPHYSIOL, V46, P112; Keltner JR, 2006, J NEUROSCI, V26, P4437, DOI 10.1523/JNEUROSCI.4463-05.2006; LEVINE JD, 1978, LANCET, V2, P654, DOI 10.1016/S0140-6736(78)92762-9; LEVINE JD, 1979, P NATL ACAD SCI USA, V76, P3528, DOI 10.1073/pnas.76.7.3528; Logan J, 1996, J CEREBR BLOOD F MET, V16, P834, DOI 10.1097/00004647-199609000-00008; Lorenz J, 2003, BRAIN, V126, P1079, DOI 10.1093/brain/awg102; Marchand S, 2003, PAIN, V105, P481, DOI 10.1016/S0304-3959(03)00265-3; Matre D, 2006, J NEUROSCI, V26, P559, DOI 10.1523/JNEUROSCI.4218-05.2006; MCGLASHA.TH, 1969, PSYCHOSOM MED, V31, P227, DOI 10.1097/00006842-196905000-00003; MORGAN MM, 1991, BRAIN RES, V545, P17, DOI 10.1016/0006-8993(91)91264-2; NICHOLS DS, 1990, PAIN, V41, P347, DOI 10.1016/0304-3959(90)90011-2; Pollo A, 2003, PAIN, V102, P125, DOI 10.1016/S0304-3959(02)00345-7; Prado WA, 2003, BRAIN RES, V972, P207, DOI 10.1016/S0006-8993(03)02541-1; Price DD, 1999, PAIN, V83, P147, DOI 10.1016/S0304-3959(99)00081-0; Rosen A, 2004, BRAIN RES, V1001, P87, DOI 10.1016/j.brainres.2003.11.060; ROSSIER J, 1979, SCIENCE, V203, P279, DOI 10.1126/science.83674; Seymour B, 2004, NATURE, V429, P664, DOI 10.1038/nature02581; SPANAGEL R, 1992, P NATL ACAD SCI USA, V89, P2046, DOI 10.1073/pnas.89.6.2046; STEIGER JH, 1980, PSYCHOL BULL, V87, P245, DOI 10.1037/0033-2909.87.2.245; Valet M, 2004, PAIN, V109, P399, DOI 10.1016/j.pain.2004.02.033; Vase L, 2005, PAIN, V115, P338, DOI 10.1016/j.pain.2005.03.014; Vase L, 2003, PAIN, V105, P17, DOI 10.1016/S0304-3959(03)00073-3; VOUDOURIS NJ, 1989, PAIN, V38, P109, DOI 10.1016/0304-3959(89)90080-8; Wager TD, 2004, SCIENCE, V303, P1162, DOI 10.1126/science.1093065; Wager TD, 2006, BRAIN BEHAV IMMUN, V20, P219, DOI 10.1016/j.bbi.2006.01.007; Wager TD, 2005, NEUROIMAGE, V26, P99, DOI 10.1016/j.neuroimage.2005.01.011; Willis WD, 1997, J CLIN NEUROPHYSIOL, V14, P2, DOI 10.1097/00004691-199701000-00002; YOUNG RF, 1987, J NEUROSURG, V66, P364, DOI 10.3171/jns.1987.66.3.0364; Zambreanu L, 2005, PAIN, V114, P397, DOI 10.1016/j.pain.2005.01.005; Zhang S, 1998, BRAIN RES, V813, P359, DOI 10.1016/S0006-8993(98)01050-6; Zhang S, 1997, NEUROSCI LETT, V224, P142, DOI 10.1016/S0304-3940(97)13478-4; Zhang YQ, 1997, PAIN, V72, P127, DOI 10.1016/S0304-3959(97)00025-0; Zubieta JK, 2005, J NEUROSCI, V25, P7754, DOI 10.1523/JNEUROSCI.0439-05.2005; Zubieta JK, 2003, SCIENCE, V299, P1240, DOI 10.1126/science.1078546; Zubieta JK, 2001, SCIENCE, V293, P311, DOI 10.1126/science.1060952	53	348	353	2	30	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	JUN 26	2007	104	26					11056	11061		10.1073/pnas.0702413104			6	Multidisciplinary Sciences	Science & Technology - Other Topics	184LC	WOS:000247641900056	17578917	Bronze, Green Published			2020-06-30	J	Mercadante, S; Villari, P; Ferrera, P; Casuccio, A; Mangione, S; Intravaia, G				Mercadante, S.; Villari, P.; Ferrera, P.; Casuccio, A.; Mangione, S.; Intravaia, G.			Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain	BRITISH JOURNAL OF CANCER			English	Article						intravenous morphine; OTFC; breakthrough pain; cancer pain; opioids	CANCER PAIN; PALLIATIVE CARE; CITRATE; TITRATION; MULTICENTER; SAFETY; TRIAL	The use of supplemental doses of opioids is commonly suggested to manage breakthrough pain. A comparative study of intravenous morphine (IV-MO) and oral transmucosal fentanyl citrate (OTFC) given in doses proportional to the basal opioid regimen was performed in 25 cancer patients receiving stable opioid doses. For each episode, when it occurred and 15 and 30 min after the treatment, pain intensity and opioid-related symptoms were recorded. Fifty-three couples of breakthrough events, each treated with IV-MO and OTFC, were recorded. In episodes treated with IV-MO, pain intensity decreased from a mean of 6.9 to 3.3 and to 1.7 at T1 and T2, respectively. In episodes treated with OTFC, pain intensity decreased from a mean of 6.9 to 4.1 and to 2.4 at T1 and T2, respectively. Statistical differences between the two treatments were found at T1 (P = 0.013), but not at T2 (P = 0.059). Adverse effects were comparable and were not significantly related with the IV-MO and OTFC doses. Intravenous morphine and OTFC in doses proportional to the scheduled daily dose of opioids were both safe and effective, IV-MO having a shorter onset than OTFC. Future comparative studies with appropriate design should compare titration methods and proportional methods of OTFC dosing.	La Maddalena Canc Ctr, Anesthesia & Intens Care Unit, I-90145 Palermo, Italy; La Maddalena Canc Ctr, Pain Relief & Palliat Care Unit, I-90145 Palermo, Italy; Univ Palermo, Dept Anesthesia & Intens Care, Palermo, Italy; Univ Palermo, Dept Clin Neurosci, Palermo, Italy	Mercadante, S (reprint author), La Maddalena Canc Ctr, Anesthesia & Intens Care Unit, Via S Lorenzo 312, I-90145 Palermo, Italy.	terapiadeldolore@lamaddalenanet.it	casuccio, alessandra/B-1730-2013	casuccio, alessandra/0000-0002-5676-9535			Bailey PL, 2003, ANESTHESIOLOGY, V99, pA967; Christie JM, 1998, J CLIN ONCOL, V16, P3238, DOI 10.1200/JCO.1998.16.10.3238; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Farrar JT, 1998, JNCI-J NATL CANCER I, V90, P611, DOI 10.1093/jnci/90.8.611; Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9; Fine PG, 2005, ANESTH ANALG, V100, P183, DOI 10.1213/01.ANE.0000141061.74294.DE; Hagen NA, 2007, J PALLIAT MED, V10, P47, DOI 10.1089/jpm.2006.0151; Hanks GW, 2004, PALLIATIVE MED, V18, P698, DOI 10.1191/0269216304pm966oa; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; Lichtor JL, 1999, ANESTH ANALG, V89, P732, DOI 10.1097/00000539-199909000-00038; Mercadante S, 2005, J PAIN SYMPTOM MANAG, V30, P485, DOI 10.1016/j.jpainsymman.2005.04.014; Mercadante S, 2004, J PAIN SYMPTOM MANAG, V27, P352, DOI 10.1016/j.jpainsymman.2003.09.006; Mercadante S, 2003, SUPPORT CARE CANCER, V11, P114, DOI 10.1007/s00520-002-0403-y; Mercadante S, 2006, J PAIN SYMPTOM MANAG, V32, P175, DOI 10.1016/j.jpainsymman.2006.01.013; Portenoy RK, 1999, PAIN, V79, P303, DOI 10.1016/S0304-3959(98)00179-1; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8	16	76	78	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0007-0920	1532-1827		BRIT J CANCER	Br. J. Cancer	JUN 18	2007	96	12					1828	1833		10.1038/sj.bjc.6603811			6	Oncology	Oncology	178JX	WOS:000247218100009	17519902	Green Published, Other Gold			2020-06-30	J	Cordova, MS; Braun, CB				Cordova, Micah S.; Braun, Christopher B.			The use of anesthesia during evoked potential audiometry in goldfish (Carassius auratus)	BRAIN RESEARCH			English	Article						auditory-evoked potential; auditory brainstem response; anesthesia; sound detection threshold; ABR; AEP	BRAIN-STEM RESPONSE; LATERAL-LINE; AUDITORY-SENSITIVITY; HEARING SENSITIVITY; FISHES; MS-222; TRICAINE; MORPHINE; NERVE; NOISE	Auditory-evoked potentials (AEPs) have become a widely utilized measure of hearing sensitivity. Most investigators use pharmacological paralysis to reduce myogenic noise and immobilize the animal for stable electrical recordings, but additional anesthesia is generally not used because the most commonly available fish anesthetic, the cholinergic antagonist tricaine methanosulfate (MS222), is known to disrupt hair cell and primary afferent physiology. Anesthetic agents that do not interfere with auditory function would be a useful adjunct to paralytic immobilization and would reduce any possible distress incurred by prolonged immobilization. In this report we tested the opiate anesthetic fentanyl and compared hearing thresholds in immobilized versus immobilized and anesthetized animals. Short-term effects of mild MS222 anesthesia were also measured via evoked potential audiometry. Animals were tested before and after fentanyl injection (100, 500 and 2500 mu g g(-1) fish body-weight) using standard evoked potential audiometry. Tone pips, 0.2-3 kHz, from an aerial loudspeaker served as stimuli. Fentanyl altered evoked potential waveforms slightly but did not altei estimated threshold sensitivity. These results suggest fentanyl be considered as a possible addition to AEP techniques in goldfish (Carassius auratus) and poikilothermic vertebrates generally. (c) 2007 Elsevier B.V. All rights reserved.	CUNY Hunter Coll, Dept Psychol, New York, NY 10021 USA; CUNY, Grad Sch, Biopsychol Program, New York, NY 10016 USA; CUNY, Univ Ctr, New York, NY 10016 USA	Braun, CB (reprint author), CUNY Hunter Coll, Dept Psychol, 695 Pk Ave, New York, NY 10021 USA.	cbraun@hunter.cuny.edu			NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [G12 RR003037-227710, G12 RR003037, RR-03037]; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [GM 60665, 1 S06 GM60654, T34 GM007823, 5T34GM07823-24, S06 GM060654, R25 GM060665, S06 GM060654-060024, GM60665]; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R03 MH067808, 1 R03 MH067808, R03 MH067808-01A1]		Amoser S, 2003, J ACOUST SOC AM, V113, P2170, DOI 10.1121/1.1557212; Arnolds DEW, 2002, BIOL BULL, V203, P188, DOI 10.2307/1543388; Bodnar DA, 1997, J NEUROSCI, V17, P7553; BURKARD R, 1984, ELECTROEN CLIN NEURO, V57, P83, DOI 10.1016/0013-4694(84)90010-5; Casper BM, 2003, ENVIRON BIOL FISH, V68, P371, DOI 10.1023/B:EBFI.0000005750.93268.e4; CORDOVA MS, 2004, SOC NEUROSCI; CORWIN JT, 1982, ELECTROEN CLIN NEURO, V54, P629, DOI 10.1016/0013-4694(82)90117-1; FLECKNELL PA, 2000, PAIN MANAGEMENT ANIM; Fletcher LB, 2001, J EXP BIOL, V204, P175; FOUTZ AS, 1983, BRAIN RES, V263, P119, DOI 10.1016/0006-8993(83)91207-6; HENSEL H, 1975, EXPERIENTIA, V31, P958, DOI 10.1007/BF02358876; JANSSEN PAJ, 1962, BRIT J ANAESTH, V34, P260, DOI 10.1093/bja/34.4.260; JEWETT DL, 1970, ELECTROEN CLIN NEURO, V28, P609, DOI 10.1016/0013-4694(70)90203-8; Kenyon TN, 1998, J COMP PHYSIOL A, V182, P307, DOI 10.1007/s003590050181; Ladich F, 2003, HEARING RES, V182, P119, DOI 10.1016/S0378-5955(03)00188-6; LOWENSTEIN E, 1969, NEW ENGL J MED, V281, P1389, DOI 10.1056/NEJM196912182812503; Lu Z, 2002, J COMP PHYSIOL A, V188, P807, DOI 10.1007/s00359-002-0369-8; Nolan A. M., 2001, PAIN MANAGEMENT ANIM, P21; Palmer LM, 2004, J NEUROPHYSIOL, V92, P1034, DOI 10.1152/jn.01151.2003; Scholik AR, 2002, ENVIRON BIOL FISH, V63, P203, DOI 10.1023/A:1014266531390; SMITH KJ, 1981, J PHARMACOL EXP THER, V217, P719; Smith ME, 2004, J EXP BIOL, V207, P3591, DOI 10.1242/jeb.01188; SPATH M, 1977, N-S ARCH PHARMACOL, V297, P9, DOI 10.1007/BF00508804; STANLEY TH, 1992, J PAIN SYMPTOM MANAG, V7, pS3, DOI 10.1016/0885-3924(92)90047-L; Wysocki LE, 2002, HEARING RES, V169, P36, DOI 10.1016/S0378-5955(02)00336-2; Yan Hong Y., 2001, Proceedings of the Institute of Acoustics, V23, P15; Yan HY, 2000, J COMP PHYSIOL A, V186, P595, DOI 10.1007/s003590000114; Yan HY, 1998, J COMP PHYSIOL A, V183, P325, DOI 10.1007/s003590050259	28	16	18	0	11	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	JUN 11	2007	1153						78	83		10.1016/j.brainres.2007.03.055			6	Neurosciences	Neurosciences & Neurology	181FZ	WOS:000247423800009	17448451	Green Accepted			2020-06-30	J	Gupta, PK; Manral, L; Ganesan, K; Dubey, DK				Gupta, Pradeep Kumar; Manral, Laxmi; Ganesan, Kumaran; Dubey, Devendra Kumar			Use of single-drop microextraction for determination of fentanyl in water samples	ANALYTICAL AND BIOANALYTICAL CHEMISTRY			English	Article						fentanyl; narcotic analgesic; water; sample preparation; SDME; GC-MS	GAS-CHROMATOGRAPHY; MASS-SPECTROMETRY; CLINICAL PHARMACOKINETICS; SOLVENT MICROEXTRACTION; PHASE MICROEXTRACTION; TRANSDERMAL FENTANYL; SCREENING METHOD; METABOLITES; EXTRACTION; IDENTIFICATION	Fentanyl is a very potent synthetic narcotic analgesic. Because of its strong sedative properties, it has become an analogue of illicit drugs such as heroin. Its unambiguous detection and identification in environmental samples can be regarded as strong evidence of its illicit preparation. In this paper we report application of single-drop microextraction (SDME) for analysis of water samples spiked with fentanyl. Experimental conditions which affect the performance of SDME, for example the nature of the extracting solvent, sample stirring speed, extraction time, ionic strength, and solution pH, were optimized. The method was found to be linear in the concentration range 0.10-10 ng mL(-1). The limits of quantitation and detection of the method were 100 pg mL(-1) and < 75 pg mL(-1), respectively. This technique is superior to other sample-preparation techniques because of the simple experimental set-up, short analysis time, high sensitivity, and minimum use of organic solvent.	Def Res & Dev Estab, Gwalior 474002, MP, India	Gupta, PK (reprint author), Def Res & Dev Estab, Gwalior 474002, MP, India.	pr_14@rediffmail.com					Ahmadi F, 2006, J CHROMATOGR A, V1101, P307, DOI 10.1016/j.chroma.2005.11.017; BUSZEWSKI B, 2002, 26 LC GC; Day J, 2003, J ANAL TOXICOL, V27, P513, DOI 10.1093/jat/27.7.513; de Jager LS, 2001, J CHROMATOGR A, V911, P97, DOI 10.1016/S0021-9673(00)01256-5; DOWNES JJ, 1967, J PHARMACOL EXP THER, V158, P416; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; Guitton J, 1997, J CHROMATOGR B, V693, P59, DOI 10.1016/S0378-4347(97)00050-9; Janssen PAJ, 1965, US patent, Patent No. 3164600; Jeal W, 1997, DRUGS, V53, P109, DOI 10.2165/00003495-199753010-00011; Koch DE, 2004, J PHARMACEUT BIOMED, V34, P577, DOI 10.1016/S0731-7085(03)00652-6; Liu HH, 1996, ANAL CHEM, V68, P1817, DOI 10.1021/ac960145h; Lopez-Blanco MC, 2003, J CHROMATOGR A, V984, P245, DOI 10.1016/S0021-9673(02)01873-3; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; MIOVIC IV, 2000, BIOORG MED CHEM LETT, V10, P2011; NIMMEN NFJ, 2004, J CHROMATOGR B, V804, P375; NIMMEN NFJ, 2004, J CHROMATOGR A, V1035, P249; Psillakis E, 2001, J CHROMATOGR A, V907, P211, DOI 10.1016/S0021-9673(00)01017-7; Saraji M, 2005, J CHROMATOGR A, V1098, P30, DOI 10.1016/j.chroma.2005.08.063; Tankeviciute A, 2001, ANALYST, V126, P1674, DOI 10.1039/b103493f; Thevis M, 2005, EUR J MASS SPECTROM, V11, P419, DOI 10.1255/ejms.761; Valaer AK, 1997, J CHROMATOGR SCI, V35, P461, DOI 10.1093/chromsci/35.10.461; Verga R, 1966, Boll Chim Farm, V105, P332; Wang Y, 1998, ANAL CHEM, V70, P4610, DOI 10.1021/ac9804339	23	18	20	0	14	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1618-2642	1618-2650		ANAL BIOANAL CHEM	Anal. Bioanal. Chem.	JUN	2007	388	3					579	583		10.1007/s00216-007-1279-y			5	Biochemical Research Methods; Chemistry, Analytical	Biochemistry & Molecular Biology; Chemistry	164GE	WOS:000246220800013	17440712				2020-06-30	J	Murphy, GS; Szokol, JW; Marymont, JH; Avram, MJ; Vender, JS				Murphy, Glenn S.; Szokol, Joseph W.; Marymont, Jesse H.; Avram, Michael J.; Vender, Jeffery S.			The effects of morphine and fentanyl on the inflammatory response to cardiopulmonary bypass in patients undergoing elective coronary artery bypass graft surgery	ANESTHESIA AND ANALGESIA			English	Article							TUMOR-NECROSIS-FACTOR; NEUTROPHIL ADHESION MOLECULES; INTERLEUKIN-6; LEUKOCYTES; PLASMA; PHAGOCYTOSIS; HYPERTHERMIA; DYSFUNCTION; ALFENTANIL; ANESTHESIA	BACKGROUND: Experimental data suggest that morphine has unique antiinflammatory properties. We hypothesized that morphine, when compared with fentanyl, would attenuate the perioperative inflammatory response to cardiopulmonary bypass (CPB) when administered as part of a balanced anesthetic technique. METHODS: Thirty patients undergoing elective coronary artery bypass graft surgery were randomized to receive, in a double-blind manner, either morphine (40 mg) or fentanyl (1000 mu g) as part of a standardized opioid-isoflurane anesthetic. Serum concentrations of interleukin (IL)-6 and IL-8 and expression of neutrophil surface adhesion molecules (CD 11a, CD 11b, CD 11c, and CD 18) were measured perioperatively as indicators of the inflammatory response to surgery. Core temperatures were monitored in the intensive care unit to determine the incidence of postoperative hyperthermia (temperature > 38.0 degrees C). RESULTS: IL-6 and IL-8 concentrations increased in all patients after CPB. The increase in serum IL-6 levels was significantly attenuated in the morphine group compared to the fentanyl group at 3 and 24 h post-CPB (P < 0.05). Reductions in expression of neutrophil adhesion molecules were observed in both groups 15 min and 3 h post-CPB; however, a significantly larger reduction in CD 11b and CD 18 expression was noted in patients receiving morphine (P < 0.05). The incidence of postoperative hyperthermia was more frequent in the fentanyl group (73%) compared to the morphine group (0%, P < 0.05). CONCLUSIONS: Compared with fentanyl, the administration of morphine as part of balanced anesthetic technique suppressed several components the inflammatory response (IL-6, CD 11b, CID 18, postoperative hyperthermia) to cardiac surgery and CPB.	Northwestern Univ, Feinberg Sch Med, Evanston NW Healthcare, Dept Anesthesiol, Evanston, IL 60201 USA	Murphy, GS (reprint author), Northwestern Univ, Feinberg Sch Med, Evanston NW Healthcare, Dept Anesthesiol, 2650 Ridge Ave, Evanston, IL 60201 USA.	dgmurphy2@yahoo.com	Avram, Michael/M-7681-2019				ANAND KJS, 1992, NEW ENGL J MED, V326, P1, DOI 10.1056/NEJM199201023260101; ANAND KJS, 1990, ANESTHESIOLOGY, V73, P661, DOI 10.1097/00000542-199010000-00012; Bencsics A, 1997, J NEUROIMMUNOL, V73, P1, DOI 10.1016/S0165-5728(96)00163-4; Bilfinger TV, 1996, INT J CARDIOL, V53, pS39, DOI 10.1016/0167-5273(96)02574-0; BILFINGER TV, 1993, J CARDIOVASC SURG, V34, P129; Bilfinger TV, 1998, INT J CARDIOL, V64, pS61, DOI 10.1016/S0167-5273(98)00037-0; Brix-Christensen V, 1998, ACTA ANAESTH SCAND, V42, P63, DOI 10.1111/j.1399-6576.1998.tb05082.x; Brull DJ, 2001, ARTERIOSCL THROM VAS, V21, P1458, DOI 10.1161/hq0901.094280; CHAO CC, 1993, INT J IMMUNOPHARMACO, V15, P447, DOI 10.1016/0192-0561(93)90057-6; Clark JA, 2005, J CARDIOTHOR VASC AN, V19, P426, DOI 10.1053/j.jvca.2005.01.042; Coda BA, 2006, CLIN ANESTH, P353; FINCH JS, 1967, J CLIN PHARMACOL N D, V7, P46, DOI 10.1002/j.1552-4604.1967.tb00029.x; Frank SM, 2000, ANESTHESIOLOGY, V93, P1426, DOI 10.1097/00000542-200012000-00014; Fransen E, 1998, CHEST, V113, P1290, DOI 10.1378/chest.113.5.1290; Galinanes M, 1996, CIRCULATION, V94, P364; Grocott HP, 2002, STROKE, V33, P537, DOI 10.1161/hs0202.102600; Hall RI, 1997, ANESTH ANALG, V85, P766, DOI 10.1097/00000539-199710000-00011; HENNEIN HA, 1994, J THORAC CARDIOV SUR, V108, P626; Ilton MK, 1999, J THORAC CARDIOV SUR, V118, P930, DOI 10.1016/S0022-5223(99)70064-4; KRUMHOLZ W, 1995, ACTA ANAESTH SCAND, V39, P624, DOI 10.1111/j.1399-6576.1995.tb04138.x; KRUMHOLZ W, 1993, ACTA ANAESTH SCAND, V37, P386, DOI 10.1111/j.1399-6576.1993.tb03734.x; Murphy GS, 2006, J CARDIOTHOR VASC AN, V20, P493, DOI 10.1053/j.jvca.2005.07.036; Partrick DA, 1996, AM J SURG, V172, P425, DOI 10.1016/S0002-9610(96)00252-8; Rot A, 1996, J LEUKOCYTE BIOL, V59, P39; Roy S, 1998, MOL BRAIN RES, V61, P190, DOI 10.1016/S0169-328X(98)00212-5; Scott BH, 1998, INT J CARDIOL, V64, pS35, DOI 10.1016/S0167-5273(98)00034-5; STEFANO GB, 1995, J CARDIOVASC SURG, V36, P25; Stefano GB, 1996, CRIT REV IMMUNOL, V16, P109, DOI 10.1615/CritRevImmunol.v16.i2.10; STEFANO GB, 1994, INT J IMMUNOPHARMACO, V16, P329, DOI 10.1016/0192-0561(94)90008-6; Taylor NM, 1997, ANAESTHESIA, V52, P112, DOI 10.1111/j.1365-2044.1997.65-az0063.x; Thong WY, 2002, ANESTH ANALG, V95, P1489, DOI 10.1097/00000539-200212000-00006; Wan S, 1997, CHEST, V112, P676, DOI 10.1378/chest.112.3.676; Welters ID, 2000, J NEUROIMMUNOL, V111, P139, DOI 10.1016/S0165-5728(00)00401-X; WORTEL CH, 1993, SURGERY, V114, P564; YEAGER MP, 1995, ANESTHESIOLOGY, V83, P500, DOI 10.1097/00000542-199509000-00008	35	34	38	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	JUN	2007	104	6					1334	1342		10.1213/01.ane.0000264108.47280.f5			9	Anesthesiology	Anesthesiology	172GB	WOS:000246791000004	17513621				2020-06-30	J	Smiley, RM; Moore, RP				Smiley, Richard M.; Moore, Robert P.			Loss of gag reflex and swallowing ability after administration of intrathecal fentanyl	ANESTHESIOLOGY			English	Letter							LABOR ANALGESIA		Columbia Univ, New York, NY 10027 USA	Smiley, RM (reprint author), Columbia Univ, New York, NY 10027 USA.	rms7@columbia.edu					Albright GA, 1999, REGION ANESTH PAIN M, V24, P117, DOI 10.1016/S1098-7339(99)90071-8; COHEN SE, 1993, ANESTH ANALG, V77, P1155; Gadalla F, 2003, CAN J ANAESTH, V50, P382, DOI 10.1007/BF03021036	3	6	6	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	JUN	2007	106	6					1253	1253		10.1097/01.anes.0000265423.95135.78			1	Anesthesiology	Anesthesiology	172IM	WOS:000246797500041	17525617	Bronze			2020-06-30	J	Grond, S; Hall, J; Spacek, A; Hoppenbrouwers, M; Richarz, U; Bonnet, F				Grond, S.; Hall, J.; Spacek, A.; Hoppenbrouwers, M.; Richarz, U.; Bonnet, F.			Iontophoretic transdermal system using fentanyl compared with patient-controlled intravenous analgesia using morphine for postoperative pain management	BRITISH JOURNAL OF ANAESTHESIA			English	Article						analgesia, patient-controlled; analgesia, postoperative; analgesics opioid, fentanyl; analgesics opioid, morphine; analgesic techniques, transdermal iontophoresis	PLACEBO-CONTROLLED TRIAL; EFFICACY; THERAPY; DELIVERY; SAFETY	Background. The fentanyl iontophoretic transdermal system (fentanyl ITS) enables needle-free, patient-controlled analgesia for postoperative pain management. This study compared the efficacy, safety, and ease of care of fentanyl ITS with patient-controlled, i.v. analgesia (PCIA) with morphine for postoperative pain management. Methods. A prospective, randomized, multicentre trial enrolled patients in Europe after abdominal or orthopaedic surgery. Patients received fentanyl ITS (n=325; 40.0 mu g fentanyl over 10 min) or morphine PCIA [n=335; bolus doses (standard at each hospital)] for <= 72 h. Supplemental i.v. morphine was available during the first 3 h. The primary efficacy measure was the patient global assessment (PGA) of the pain control method during the first 24 h. Results. PGA ratings of 'good' or 'excellent' were reported by 86.2 and 87.5% of patients using fentanyl ITS or morphine PCIA, respectively (95% CI, -6.5 to 3.9%). Mean (SD) last pain intensity scores (numerical rating scale, 0-10) were 1.8 (1.77) and 1.9 (1.86) in the fentanyl ITS and morphine PCIA groups, respectively (95% CI, -0.38 to 0.18). More patients reported a system-related problem for fentanyl ITS than morphine PCIA (51.1 vs 17.9%, respectively). However, fewer of these problems interrupted pain control (4.4 vs 41.3%, respectively). Patients, nurses, and physiotherapists reported more favourable overall ease-of-care ratings for fentanyl ITS than morphine PCIA. Study termination rates and opioid-related side-effects were similar between groups. Conclusion. Fentanyl ITS and morphine PCIA were comparably effective and safe.	Univ Halle Wittenberg, Anasthesiol Klin, D-06097 Halle, Germany; Anaesthet & Intens Care Med, Cardiff, Wales; Med Univ Wien, Klin Anasthesie & Allgemeine Intens Med, Vienna, Austria; SGS Med Int, Mechelen, Belgium; Janssen Cilag EMEA, Baarn, Switzerland; Univ Paris 06, Assistance Publ Hop Paris, Hop Tenon, Dept Anesthesie Reanimat, Paris, France	Grond, S (reprint author), Univ Halle Wittenberg, Anasthesiol Klin, Ernst Grube Str 40, D-06097 Halle, Germany.	stefan.grond@Medizin.Uni-Halle.de					Badner NH, 1996, J CLIN ANESTH, V8, P382, DOI 10.1016/0952-8180(96)00077-3; BALLANTYNE JC, 1993, J CLIN ANESTH, V5, P182, DOI 10.1016/0952-8180(93)90013-5; Campbell L, 1998, Br J Nurs, V7, P1364; Chelly JE, 2004, ANESTH ANALG, V98, P427, DOI 10.1213/01.ANE.0000093314.13848.7E; Choiniere M, 1998, ANESTHESIOLOGY, V89, P1377, DOI 10.1097/00000542-199812000-00015; COLWELL CW, 1995, J BONE JOINT SURG AM, V77A, P726, DOI 10.2106/00004623-199505000-00009; *DHHS, 1995, COSTART COD SYMB THE; HARDING G, IN PRESS J ADV NURS; Hartrick CT, 2006, REGION ANESTH PAIN M, V31, P546, DOI 10.1016/j.rapm.2006.08.011; Kalia YN, 2004, ADV DRUG DELIVER REV, V56, P619, DOI 10.1016/j.addr.2003.10.026; Lebovits AH, 2001, PAIN MED, V2, P280, DOI 10.1046/j.1526-4637.2001.01051.x; Lehmann KA, 1999, EUR SURG RES, V31, P112, DOI 10.1159/000008629; MAKUCH R, 1978, CANCER TREAT REP, V62, P1037; MANTEL N, 1959, J NATL CANCER I, V22, P719; MINKOWITZ HS, IN PRESS PAIN MED; Power I, 2007, BRIT J ANAESTH, V98, P4, DOI 10.1093/bja/ael314; Rawal N, 1998, EUR J ANAESTH, V15, P354, DOI 10.1097/00003643-199805000-00019; SMYTHE M, 1993, ANN PHARMACOTHER, V27, P691, DOI 10.1177/106002809302700601; SMYTHE M, 1994, AM J HOSP PHARM, V51, P1433, DOI 10.1093/ajhp/51.11.1433; Vicente KJ, 2003, CAN J ANAESTH, V50, P328, DOI 10.1007/BF03021027; Viscusi ER, 2006, ANESTH ANALG, V102, P188, DOI 10.1213/01.ane.0000183649.58483.77; Viscusi ER, 2004, JAMA-J AM MED ASSOC, V291, P1333, DOI 10.1001/jama.291.11.1333; Walder B, 2001, ACTA ANAESTH SCAND, V45, P795, DOI 10.1034/j.1399-6576.2001.045007795.x; Williamson A, 2005, J CLIN NURS, V14, P798, DOI 10.1111/j.1365-2702.2005.01121.x	24	64	68	0	2	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0007-0912			BRIT J ANAESTH	Br. J. Anaesth.	JUN	2007	98	6					806	815		10.1093/bja/aem102			10	Anesthesiology	Anesthesiology	178GD	WOS:000247208300017	17519263	Bronze			2020-06-30	J	Rofaeel, A; Balki, M; Carvalho, JCA				Rofaeel, Ayman; Balki, Mrinalini; Carvalho, Jose C. A.			Case report: Successful labour epidural analgesia in a patient with spinocerebellar ataxia	CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Article							ANESTHESIA	Purpose: To report the favourable outcome associated with epidural analgesia in a parturient with spinocerebellar ataxia (SCA). Clinical Features: A 34-yr-old patient, G2 PO, presented at term with a history of SCA since the age of 22 characterized by slurred speech, balance and gait disturbances, diplopia and nystagmus. A magnetic resonance imaging of the brain at the age of 27 showed cerebellar degeneration. Neurological examination revealed an unsteady, wide-based gait, nystagmus, mild dysarthria, moderate finger to nose ataxia, absent reflexes in all upper and lower limbs, sensory loss to vibration and temperature discrimination up to the level of both knees, and normal motor strength. The patient presented for induction of labour at 40 weeks and requested epidural analgesia, which was performed in the usual manner. Following a negative test dose of 3 mL of 2% liclocaine, a loading dose of 10 mL of 0.125% bupivacaine was administered, and maintenance of analgesia was achieved with a mixture of bupivacaine 0.0625% and fentanyl 2 mu gmL(-1). The patient required standard doses of the epidural mixture, and experienced effective analgesia for labour and delivery. Her recovery was uneventful and no subsequent neurological deficit was detected up to two years after delivery. Conclusions: Neurological disorders may contraindicate regional anesthesia, and the decision to proceed with a regional technique should be based on the pathophysiology and severity of each particular case. Uneventful epidural analgesia was provided to a parturient with SCA, with no long term effects detected up to two years after delivery.	Univ Toronto, Mt Sinai Hosp, Dept Anesthesia & Pain Management, Toronto, ON M5G 1X5, Canada	Carvalho, JCA (reprint author), Univ Toronto, Mt Sinai Hosp, Dept Anesthesia & Pain Management, 600 Univ Ave,Room 781, Toronto, ON M5G 1X5, Canada.	jose.carvalho@uhn.on.ca	Balki, Mrinalini/A-2669-2015				Abele M, 1997, BRAIN, V120, P2141, DOI 10.1093/brain/120.12.2141; ALON E, 1988, ANAESTHESIST, V37, P58; Bader A M, 1988, J Clin Anesth, V1, P21, DOI 10.1016/0952-8180(88)90006-2; Beach T P, 1971, Anesth Analg, V50, P431; BERCIANO J, 1982, J NEUROL SCI, V53, P253, DOI 10.1016/0022-510X(82)90011-9; BLANLOEIL Y, 1982, ANAESTHESIA, V37, P695, DOI 10.1111/j.1365-2044.1982.tb01287.x; BREEN TW, 1993, ANESTH ANALG, V77, P919; Briggs Edward D, 2003, J Anesth, V17, P177; CRAWFORD JS, 1983, ANESTH ANALG, V62, P620, DOI 10.1213/00000539-198306000-00022; Criscuolo C, 2006, NEUROLOGY, V66, P1207, DOI 10.1212/01.wnl.0000208402.10512.4a; Dalmas AF, 2003, ANN FR ANESTH, V22, P861, DOI 10.1016/j.annfar.2003.08.005; Iwasaki Y, 2004, ARCH NEUROL-CHICAGO, V61, P1625, DOI 10.1001/archneur.61.10.1625-c; KUBAL K, 1991, ANESTH ANALG, V72, P257, DOI 10.1213/00000539-199102000-00022; Kubis N, 1999, MUSCLE NERVE, V22, P712; KUME M, 1976, JPN J ANESTH, V25, P877; Schelhaas HJ, 2004, ANN NEUROL, V55, P451, DOI 10.1002/ana.20015; Timmann D, 2000, J NEUROL, V247, P812, DOI 10.1007/s004150070102; Tsen LC, 1997, ANESTH ANALG, V85, P1071, DOI 10.1097/00000539-199711000-00020; van de Warrenburg BPC, 2004, ARCH NEUROL-CHICAGO, V61, P257, DOI 10.1001/archneur.61.2.257; van de Warrenburg BPC, 2002, NEUROLOGY, V58, P702, DOI 10.1212/WNL.58.5.702	20	4	4	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0832-610X			CAN J ANAESTH	Can. J. Anaesth.-J. Can. Anesth.	JUN	2007	54	6					467	470		10.1007/BF03022033			4	Anesthesiology	Anesthesiology	175DP	WOS:000246993100009	17541076	Bronze			2020-06-30	J	Evron, S; Ezri, T				Evron, Shmuel; Ezri, Tiberiu			Options for systemic labor analgesia	CURRENT OPINION IN ANESTHESIOLOGY			English	Article						labor analgesia; remifentanil; systemic opioids	PATIENT-CONTROLLED ANALGESIA; PAIN RELIEF; INTRAVENOUS REMIFENTANIL; CESAREAN-SECTION; MEPERIDINE; PHARMACOKINETICS; PETHIDINE; FENTANYL; TRAMADOL; INFUSION	Purpose of review This article reviews the challenging practice of systemic analgesia as an alternative to epidural analgesia for labor pain, and places remifentanil within the context of opioid analgesics suitable for managing for labor pain. Recent findings Although systemic opioids have long been used for labor analgesia, they have become less popular because of frequent maternal and neonatal side effects. Recently, their efficacy has been questioned. Patient-controlled intravenous analgesia with fentanyl or sufentanil is currently the method of choice for achieving analgesia during early labor, when epidural analgesia is not feasible. Remifentanil has been suggested as the opioid of choice for labor analgesia, having the advantage of easy administration, predictable pharmacokinetics, and improved neonatal outcomes. The position of remifentanil in obstetric analgesia is now better understood, as reflected by the increasing number of reported studies describing its use. Summary Remifentanil is now gaining popularity. Remifentanil may be more suitable than other traditional opioids for inducing labor analgesia. Careful monitoring of the parturient and the newborn is recommended, however, to mitigate the potential for maternal and neonatal hypoxemia.	Tel Aviv Univ, Sackler Sch Med, Edith Wolfson Med Ctr, Dept Anesthesia, IL-69978 Tel Aviv, Israel; Univ Louisville, Outcomes Res Inst, Louisville, KY 40292 USA	Ezri, T (reprint author), Wolfson Med Ctr, Dept Anesthesia, IL-58100 Holon, Israel.	tezri@netvision.net.il					Allen JS, 2003, TERATOGEN CARCIN MUT, P137, DOI 10.1002/tcm.10069; Babenco HD, 2000, ANESTHESIOLOGY, V92, P393, DOI 10.1097/00000542-200002000-00020; Bedard JM, 1999, CAN J ANAESTH, V46, P576, DOI 10.1007/BF03013550; BELSEY EM, 1981, BRIT J OBSTET GYNAEC, V88, P398, DOI 10.1111/j.1471-0528.1981.tb01004.x; Blair JM, 2005, ANAESTHESIA, V60, P22, DOI 10.1111/j.1365-2044.2004.03975.x; Blair JM, 2001, BRIT J ANAESTH, V87, P415, DOI 10.1093/bja/87.3.415; CAMANN WR, 1992, ANESTHESIOLOGY, V77, P884, DOI 10.1097/00000542-199211000-00008; Caprogna G, 1998, BRIT J ANAESTH, V80, P11; Carroll CP, 2001, BRIT J ANAESTH, V80, P135; Carvalho B, 2004, INT J OBSTET ANESTH, V13, P53, DOI 10.1016/j.ijoa.2003.09.001; Claahsen-van der Grinten HL, 2005, EUR J CLIN PHARMACOL, V61, P523, DOI 10.1007/s00228-005-0955-0; CRAFT JB, 1983, ANESTH ANALG, V62, P894; Crankshaw DP, 2002, ANAESTH INTENS CARE, V30, P578, DOI 10.1177/0310057X0203000505; Davis PJ, 2002, ANESTH ANALG, V95, P1305, DOI 10.1097/00000539-200211000-00038; Elbourne T, 2000, COCHRANE DB SYST REV, V2; Evron S, 2005, ANESTH ANALG, V100, P233, DOI 10.1213/01.ANE.0000143351.64538.BC; GLASS PSA, 1993, ANESTH ANALG, V77, P1031; Johannsen EK, 1999, ANAESTH INTENS CARE, V27, P527, DOI 10.1177/0310057X9902700517; Jones R, 1999, ANAESTHESIA, V54, P461, DOI 10.1046/j.1365-2044.1999.00857.x; Jordan S, 2005, BJOG-INT J OBSTET GY, V112, P927, DOI 10.1111/j.1471-0528.2005.00548.x; Kan RE, 1998, ANESTHESIOLOGY, V88, P1467, DOI 10.1097/00000542-199806000-00008; Keskin HL, 2003, INT J GYNECOL OBSTET, V82, P11, DOI 10.1016/S0020-7292(03)00047-X; KUHNERT BR, 1985, ANESTH ANALG, V64, P335; KUHNERT BR, 1979, AM J OBSTET GYNECOL, V133, P904, DOI 10.1016/0002-9378(79)90310-7; Lotsch JR, 2005, J PAIN SYMPTOM MANAG, V29, pS90, DOI 10.1016/j.jpainsymman.2005.01.012; Lyons G, 2001, INT J OBSTET ANESTH, V10, P259, DOI 10.1054/ijoa.2001.0859; Mattingly Jay E, 2003, Paediatr Drugs, V5, P615, DOI 10.2165/00148581-200305090-00004; Morley-Forster PK, 2000, CAN J ANAESTH, V47, P113, DOI 10.1007/BF03018845; Nelson KE, 2005, ANESTHESIOLOGY, V102, P1008, DOI 10.1097/00000542-200505000-00021; Nikkola EM, 1997, CAN J ANAESTH, V44, P1248, DOI 10.1007/BF03012771; Olofsson C, 1996, BRIT J OBSTET GYNAEC, V103, P968, DOI 10.1111/j.1471-0528.1996.tb09545.x; Olufolabi AJ, 2000, ANESTH ANALG, V91, P606, DOI 10.1213/00000539-200009000-00020; Owen MD, 2002, ANESTH ANALG, V94, P918, DOI 10.1097/00000539-200204000-00027; Rayburn W F, 1991, Anesthesiol Rev, V18, P31; RAYBURN WF, 1989, OBSTET GYNECOL, V74, P604; Reynolds F, 2002, BJOG-INT J OBSTET GY, V109, P1344, DOI 10.1016/S1470-0328(02)01961-4; Roelants F, 2001, CAN J ANAESTH, V48, P175, DOI 10.1007/BF03019731; Ross AK, 2001, ANESTH ANALG, V93, P1393, DOI 10.1097/00000539-200112000-00008; SHAFER SL, 1991, ANESTHESIOLOGY, V74, P53, DOI 10.1097/00000542-199101000-00010; Shannon KT, 1995, OBSTET PAIN MANAGE, V2, P1; Soontrapa Sukree, 2002, Journal of the Medical Association of Thailand, V85, P1169; Thurlow JA, 2000, BRIT J ANAESTH, V84, P411; Thurlow JA, 2002, BRIT J ANAESTH, V88, P374, DOI 10.1093/bja/88.3.374; Tsui MHY, 2004, BJOG-INT J OBSTET GY, V111, P648, DOI 10.1111/j.1471-0528.2004.00160.x; Volikas I, 2005, BRIT J ANAESTH, V95, P504, DOI 10.1093/bja/aei219; Volikas I, 2001, INT J OBSTET ANESTH, V10, P86, DOI 10.1054/ijoa.2000.0831; Volmanen P, 2005, ACTA ANAESTH SCAND, V49, P453, DOI 10.1111/j.1399-6576.2005.00639.x; Volmanen P, 2002, ANESTH ANALG, V94, P913, DOI 10.1097/00000539-200204000-00026	48	35	37	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0952-7907	1473-6500		CURR OPIN ANESTHESIO	Curr. Opin. Anesthesiol.	JUN	2007	20	3					181	185		10.1097/ACO.0b013e328136c1d1			5	Anesthesiology	Anesthesiology	V42SD	WOS:000209632600004	17479017				2020-06-30	J	Takada, M; Dohi, S; Akamatsu, S; Suzuki, A				Takada, Motoshi; Dohi, Shuji; Akamatsu, Shigeru; Suzuki, Akira			Effects of pericardial lidocaine on hemodynamic parameters and responses in dogs anesthetized with midazolam and fentanyl	JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA			English	Article; Proceedings Paper	Annual Meeting of the American-Society-of-Anesthesiologists	OCT 22-26, 2005	Atlanta, GA	Amer Soc Anesthesiologists		local anesthetics; lidocaine; dogs; hemodynamic phenomena; heart rate; stroke volume; infusions; pericardium	THORACIC EPIDURAL-ANESTHESIA; HEART-RATE-VARIABILITY; VENTRICULAR-FIBRILLATION; MYOCARDIAL-ISCHEMIA; REVERSIBLE BLOCKADE; CARDIAC AFFERENTS; CANINE MODEL; PROCAINE; SURGERY; INNERVATION	Objective: Tachycardia during anesthesia should be avoided, especially during off-pump coronary artery bypass graft surgery. Decreasing heart rate without reducing cardiac contractility is an ideal goal. To achieve this, the authors attempted to block the cardiac nerves by pericardial administration of local anesthetic. Design: A prospective study. Setting: A laboratory. Participants: Anesthetized, mechanically ventilated dogs (n = 69). Interventions: The pericardial space was infused with 2.5 or 5 mL of 1% liclocaine, 5 mL of 2% lidocaine, or normal saline solution. The hemodynamic changes and the cardiac responses to atropine or isoproterenol were measured during cardiac nerve blockade. To examine the inhibitory action of pericardial lidocaine on arrhythmias, an electrical fibrillator was installed. Furthermore, the blood level of lidocaine was measured. Measurements and Main Results: Pericardial injection of liclocaine significantly decreased heart rate without a change in stroke volume. Under pericardial lidocaine, the tachycardia response to isoproterenol was similar to that observed without pericardial liclocaine, but response to atropine was significantly reduced. Pericardial liclocaine increased the voltage thresholds for inducing arrhythmias and ventricular fibrillation. Intravenous injection of liclocaine elevated the plasma concentration of liclocaine immediately, whereas the plasma concentration peaked at 10 minutes after pericardial administration. Conclusions: Pericardial liclocaine (1) decreased heart rate without affecting stroke volume, (2) preserved the tachycardiac response to isoproterenol but completely blocked the response to atropine, and (3) increased the voltage thresholds for arrhythmias and ventricular fibrillation induced by an electrical fibrillator. These results suggest that pericardial lidocaine may be useful for controlling heart rate during off-pump coronary artery bypass graft surgery. (c) 2007 Elsevier Inc. All rights reserved.	Gifu Univ, Grad Sch Med, Dept Anesthesiol & Pain Med, Gifu, Japan; Matsunami Gen Hosp, Dept Intens Care Med, Gifu, Japan; Daiyukai Gen Hosp, Dept Anesthesia & Intens Care Med, Aichi, Japan	Takada, M (reprint author), Gifu Univ, Sch Med, Dept Anesthesiol & Pain Med, 1-1 Yanagido, Gifu 5011194, Japan.	mtakada_md@ybb.ne.jp					ARNDT JO, 1981, CARDIOVASC RES, V15, P61, DOI 10.1093/cvr/15.2.61; Asano Mitsuru, 2003, Jpn J Thorac Cardiovasc Surg, V51, P1, DOI 10.1007/s11748-003-0057-9; BARAKA A, 1993, ANN THORAC SURG, V55, P1529, DOI 10.1016/0003-4975(93)91104-U; BARBER MJ, 1984, CIRC RES, V55, P532, DOI 10.1161/01.RES.55.4.532; Booth JV, 2002, ANESTHESIOLOGY, V97, P162, DOI 10.1097/00000542-200207000-00023; Chakravarthy M, 2003, J CARDIOTHOR VASC AN, V17, P160, DOI 10.1053/jcan.2003.40; Chiou CW, 1998, CIRCULATION, V98, P360, DOI 10.1161/01.CIR.98.4.360; Dobson GP, 2004, J THORAC CARDIOV SUR, V127, P794, DOI 10.1016/S0022-5223(03)01192-9; DOHI S, 1982, ANESTHESIOLOGY, V57, P359, DOI 10.1097/00000542-198211000-00002; DORWARD PK, 1983, AUST J EXP BIOL MED, V61, P219, DOI 10.1038/icb.1983.20; EVANS RG, 1993, AM J PHYSIOL, V264, pH1861; Feeley TW, 1997, J CARDIOTHOR VASC AN, V11, P10, DOI 10.1016/S1053-0770(97)80004-3; Hanouz JL, 2003, ANESTH ANALG, V97, P1230, DOI 10.1213/01.ANE.0000086731.87098.99; HILL RJ, 1989, MOL PHARMACOL, V36, P150; Hinokiyama Kazuhiro, 2003, Ann Thorac Cardiovasc Surg, V9, P36; HUNT GB, 1988, CIRCULATION, V78, P221, DOI 10.1161/01.CIR.78.1.221; ITO M, 1994, CIRCULATION, V90, P1459, DOI 10.1161/01.CIR.90.3.1459; Jansen EWL, 1998, ANN THORAC SURG, V66, P576, DOI 10.1016/S0003-4975(98)00477-9; JIA HJ, 1993, J PHARMACOL EXP THER, V264, P1275; Kessler P, 2002, ANESTH ANALG, V95, P791, DOI 10.1097/00000539-200210000-00002; LOWN B, 1976, NEW ENGL J MED, V294, P1165; Minisi AJ, 1998, CIRCULATION, V98, P2615, DOI 10.1161/01.CIR.98.23.2615; Myles PS, 1999, ANAESTH INTENS CARE, V27, P137, DOI 10.1177/0310057X9902700202; ODONNELL CP, 1991, AM J PHYSIOL, V260, pR1176; PERLMUTTER NS, 1990, PHARMACOLOGY, V41, P280, DOI 10.1159/000138734; Rivenes SM, 2001, ANESTHESIOLOGY, V94, P223, DOI 10.1097/00000542-200102000-00010; SAMODELOV LF, 1982, CARDIOVASC RES, V16, P187, DOI 10.1093/cvr/16.4.187; SCHWARTZ PJ, 1976, AM J CARDIOL, V37, P1034, DOI 10.1016/0002-9149(76)90420-3; Scott TM, 2004, J POSIT BEHAV INTERV, V6, P21, DOI 10.1177/10983007040060010401; Stuhmeier KD, 1996, ANESTHESIOLOGY, V85, P706, DOI 10.1097/00000542-199610000-00004; Zickmann B, 1996, J CARDIOTHOR VASC AN, V10, P609, DOI 10.1016/S1053-0770(96)80138-8	31	3	3	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1053-0770			J CARDIOTHOR VASC AN	J. Cardiothorac. Vasc. Anesth.	JUN	2007	21	3					393	399		10.1053/j.jvca.2006.02.004			7	Anesthesiology; Cardiac & Cardiovascular Systems; Respiratory System; Peripheral Vascular Disease	Anesthesiology; Cardiovascular System & Cardiology; Respiratory System	185BK	WOS:000247686100014	17544893				2020-06-30	J	Kulkarni, V				Kulkarni, Venugopal			Opioids and cardioprotection: The impact of morphine and fentanyl on recovery of ventricular function after cardiopulmonary bypass	JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA			English	Letter							TEI INDEX		Royal Brompton Hosp, London SW3 6LY, England	Kulkarni, V (reprint author), Royal Brompton Hosp, London SW3 6LY, England.						Croal BL, 2006, CIRCULATION, V114, P1468, DOI 10.1161/CIRCULATIONAHA.105.602370; Duncan AM, 2004, INT J CARDIOL, V95, P211, DOI 10.1016/j.ijcard.2003.07.007; JIN XY, 1995, CIRCULATION, V92, P155, DOI 10.1161/01.CIR.92.9.155; Murphy GS, 2006, J CARDIOTHOR VASC AN, V20, P493, DOI 10.1053/j.jvca.2005.07.036; Pellett AA, 2004, ECHOCARDIOGR-J CARD, V21, P669, DOI 10.1111/j.0742-2822.2004.04052.x; Zhou L, 2005, TRANSFUSION, V45, P1056, DOI 10.1111/j.1537-2995.2005.04326.x	6	1	2	1	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1053-0770			J CARDIOTHOR VASC AN	J. Cardiothorac. Vasc. Anesth.	JUN	2007	21	3					474	475		10.1053/j.jvca.2006.11.010			2	Anesthesiology; Cardiac & Cardiovascular Systems; Respiratory System; Peripheral Vascular Disease	Anesthesiology; Cardiovascular System & Cardiology; Respiratory System	185BK	WOS:000247686100035	17544914				2020-06-30	J	Han, TH; Harmatz, JS; Greenblatt, DJ; Martyn, JAJ				Han, Taehyung; Harmatz, Jerold S.; Greenblatt, David J.; Martyn, J. A. Jeevendra			Fentanyl clearance and volume of distribution are increased in patients with major burns	JOURNAL OF CLINICAL PHARMACOLOGY			English	Article						pharmacokinetics; cardiac index; hepatic blood flow; opiates	THERMAL-INJURY; CONTROLLED ANALGESIA; METABOLIC-RESPONSE; CARDIAC-OUTPUT; PHARMACOKINETICS; ALFENTANIL; PAIN; ITRACONAZOLE; DISPOSITION; DYSFUNCTION	This study examined the pharmacokinetics of fentanyl in burned patients during the hyperdynamic phase. Twenty adults, aged 37 +/- 2 years (mean SE), with 49 +/- 3% total body surface area burn, were studied at 17 +/- 2 days after the injury and compared to demographically matched controls. After a 200-mu g IV bolus of fentanyl, blood samples (n = 20) were collected for 4.5 hours. Concentration-time curves were fitted to a 2-compartment model. Burned patients had a higher cardiac index. Median fentanyl clearance (CL, 21.0 vs 29.4 mL/kg/min), central comportment volume (V-1, 0.37 vs 0.61 L/kg), and total volume of distribution (V-area, 3.6 vs 5.8 L/kg) were higher in burned patients. Cardiac index was unrelated to CL. The increased V-1 and V-area are likely due to large intravenous fluid replacement and tissue edema. Higher CL and larger V-1 and V-area leading to a lower fentanyl plasma concentration may partially explain the increased opiate requirement previously observed after burn injury.	Univ Iowa Hosp & Clin, Dept Anesthesia, Carver Coll Med, Iowa City, IA 52242 USA; Tufts Univ, Sch Med, Dept Pharmacol & Expt Therapeut, Boston, MA 02111 USA; Tufts Univ, New England Med Ctr, Boston, MA 02111 USA; Harvard Univ, Sch Med, Dept Anesthesia & Crit Care, Massachusetts Gen Hosp, Boston, MA USA; Shriners Hosp Children, Boston, MA USA	Han, TH (reprint author), Univ Iowa Hosp & Clin, Dept Anesthesia, Carver Coll Med, 5936 JPP,200 Hawkins Dr, Iowa City, IA 52242 USA.	anthony-han@uiowa.edu			NCCIH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine [AT-01381]; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [RR-00054]; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG-17780]; NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA-05258]; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [GM 55082, GM 31569, R01 GM055082]		Arturson G, 2000, BURNS, V26, P599, DOI 10.1016/S0305-4179(00)00069-3; Bjorkman S, 2000, J PHARM PHARMACOL, V52, P1065, DOI 10.1211/0022357001774985; BLOEDOW DC, 1986, RES COMMUN CHEM PATH, V54, P87; BOWER S, 1982, BRIT J ANAESTH, V54, P871, DOI 10.1093/bja/54.8.871; Day J, 2003, J ANAL TOXICOL, V27, P513, DOI 10.1093/jat/27.7.513; DENSON DD, 1990, J CLIN PHARMACOL, V30, P70, DOI 10.1002/j.1552-4604.1990.tb03441.x; Egan TD, 1999, ANESTHESIOLOGY, V91, P156, DOI 10.1097/00000542-199907000-00024; FURMAN W R, 1990, Journal of Burn Care and Rehabilitation, V11, P391, DOI 10.1097/00004630-199009000-00003; Furukori H, 1999, PSYCHOPHARMACOLOGY, V145, P189, DOI 10.1007/s002130051048; GAUKROGER PB, 1991, BURNS, V17, P396, DOI 10.1016/S0305-4179(05)80073-7; HARMATZ JS, 1987, COMPUT BIOL MED, V17, P199, DOI 10.1016/0010-4825(87)90044-8; HENTHORN TK, 1992, CLIN PHARMACOL THER, V52, P190, DOI 10.1038/clpt.1992.129; Herman R. A., 1994, Journal of Burn Care and Rehabilitation, V15, P95, DOI 10.1097/00004630-199403000-00002; Herndon DN, 2004, LANCET, V363, P1895, DOI 10.1016/S0140-6736(04)16360-5; Kerbusch T, 2001, CLIN PHARMACOL THER, V70, P132, DOI 10.1067/mcp.2001.117283; Kim KM, 2004, J TRAUMA, V57, P1013, DOI 10.1097/01.TA.0000105925.51950.08; Kuipers JA, 1999, ANESTHESIOLOGY, V90, P1146, DOI 10.1097/00000542-199904000-00030; Linneman PK, 2000, J BURN CARE REHABIL, V21, P519, DOI 10.1097/00004630-200021060-00008; MACFIE AG, 1992, BRIT J ANAESTH, V69, P447, DOI 10.1093/bja/69.5.447; MacLennan N, 1998, ANESTHESIOLOGY, V89, P749, DOI 10.1097/00000542-199809000-00027; MARTYN J, 1988, CLIN PHARMACOL THER, V43, P250, DOI 10.1038/clpt.1988.29; MARTYN J, 1986, ANESTHESIOLOGY, V65, P67, DOI 10.1097/00000542-198607000-00011; MARTYN JAJ, 1980, ANN SURG, V191, P330; MARTYN JAJ, 1985, JAMA-J AM MED ASSOC, V253, P1288, DOI 10.1001/jama.253.9.1288; Nugent N, 2004, BURNS, V30, P610, DOI 10.1016/j.burns.2004.03.003; Palkama VJ, 1998, BRIT J ANAESTH, V81, P598, DOI 10.1093/bja/81.4.598; Perreault S, 2001, ANN PHARMACOTHER, V35, P1588; Pham TN, 2004, J TRAUMA, V57, P867, DOI 10.1097/01.TA.0000096641.32787.3F; Prakash S, 2004, ANESTH ANALG, V99, P552, DOI 10.1213/01.ANE.0000125110.56886.90; Ring A, 2000, SEMIN THROMB HEMOST, V26, P589, DOI 10.1055/s-2000-13215; SHIMAZAKI S, 1991, J TRAUMA, V31, P623, DOI 10.1097/00005373-199105000-00005; Sparkes BG, 1997, BURNS, V23, P106, DOI 10.1016/S0305-4179(96)00089-7; Stoddard FJ, 2002, J BURN CARE REHABIL, V23, P135, DOI 10.1097/00004630-200203000-00012; Varela JE, 2000, J ANTIMICROB CHEMOTH, V45, P337, DOI 10.1093/jac/45.3.337; Wang SX, 2005, PAIN, V116, P87, DOI 10.1016/j.pain.2005.03.044; Weng ND, 2002, J PHARMACEUT BIOMED, V28, P1115, DOI 10.1016/S0731-7085(02)00002-X; WILMORE DW, 1980, ANN SURG, V192, P491, DOI 10.1097/00000658-198010000-00008; Wilmore DW, 2000, WORLD J SURG, V24, P705, DOI 10.1007/s002689910113; Wojkcikowski J, 2003, BRIT J PHARMACOL, V138, P1465, DOI 10.1038/sj.bjp.0705195	39	23	23	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0091-2700	1552-4604		J CLIN PHARMACOL	J. Clin. Pharmacol.	JUN	2007	47	6					674	680		10.1177/0091270007299756			7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	173RD	WOS:000246889300001	17428913				2020-06-30	J	Behrman, A; Goertemoeller, S				Behrman, Alysha; Goertemoeller, Sheila			A sticky situation: Toxicity of clonidine and fentanyl transdermal patches in pediatrics	JOURNAL OF EMERGENCY NURSING			English	Article									Cincinnati Drug & Poison Informat Ctr, Cincinnati, OH 45219 USA	Behrman, A (reprint author), Cincinnati Drug & Poison Informat Ctr, 2900 Vernon Pl,3rd Floor, Cincinnati, OH 45219 USA.	Alysha.Behrman@cchmc.org					BENOWITZ NL, 2004, POISONING DRUG OVERD, P168; *BOEHR ING PHARM I, 2006, CAT TTS PACK INS; *JANS PHARM PROD L, 2003, DUR PACK INS; *THOM MICR, 2005, US PHARM DRUG INF, V1, P888	4	8	9	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0099-1767			J EMERG NURS	J. Emerg. Nurs.	JUN	2007	33	3					290	293		10.1016/j.jen.2007.02.004			4	Emergency Medicine; Nursing	Emergency Medicine; Nursing	176BP	WOS:000247058000036	17517283				2020-06-30	J	Robertson, LJ; Drummond, PD; Hammond, GR				Robertson, Lucy J.; Drummond, Peter D.; Hammond, Geoffrey R.			Naloxone antagonizes the local antihyperalgesic effect of fentanyl in burnt skin of healthy humans	JOURNAL OF PAIN			English	Article						peripheral opioid analgesia; thermal hyperalgesia; mechanical hyperalgesia; naloxone; human volunteers	INTRAARTICULAR MORPHINE; PAIN; HYPERALGESIA; ANALGESIA; INFLAMMATION; OPIOIDS	The aim of this study was to investigate local opioid effects in the inflamed skin of healthy human volunteers. To induce inflammation, the circular tip of a 10-mm-diameter probe was heated to 48 degrees C and applied for 120 seconds to a site on each forearm of 24 healthy participants. Thirty minutes later, 0.2 mL of normal saline was injected subcutaneously into 1 inflamed site, and the opioid antagonist naloxone hydrochloride (80 mu g in 0.2 mL) was injected subcutaneously into the other inflamed site. Participants completed tests of pain sensitivity (heat pain thresholds, heat pain ratings, and mechanical pain ratings) before and after the injections. Fentanyl citrate (10 mu g in 0.2 mL) was then injected into the pretreated sites, and pain sensitivity was measured again. The thermal injuries produced thermal and mechanical hyperalgesia that did not differ between the saline and naloxone sites. After the fentanyl injections, decreases in thermal and mechanical hyperalgesia were greater at the saline site than the naloxone site. These findings demonstrate that pretreatment with naloxone blocks local opioid effects produced by the subcutaneous injection of a low dose of fentanyl in the inflamed skin of healthy humans. Thus, peripheral opioid receptors could be a therapeutic target for painful cutaneous disorders. Perspective: This article demonstrates that activation of opioid receptors in the skin inhibits sensitivity to painful mechanical and thermal stimuli. Thus, local application of low-dose opioid medications could relieve painful skin disorders. (c) 2007 by the American Pain Society.	Murdoch Univ, Sch Psychol, Perth, WA 6150, Australia; Univ Western Australia, Sch Psychol, Perth, WA 6009, Australia	Drummond, PD (reprint author), Murdoch Univ, Sch Psychol, South St, Perth, WA 6150, Australia.	p.drummond@murdoch.edu.au					ANTONIJEVIC I, 1995, J NEUROSCI, V15, P165; DAVIS KD, 1995, PAIN, V62, P373, DOI 10.1016/0304-3959(95)00007-F; HERMENS JM, 1985, ANESTHESIOLOGY, V62, P124, DOI 10.1097/00000542-198502000-00005; Kalso E, 2002, PAIN, V98, P269, DOI 10.1016/S0304-3959(02)00019-2; KILO S, 1995, PAIN, V62, P187, DOI 10.1016/0304-3959(94)00265-G; KILO S, 1994, BRAIN, V117, P385, DOI 10.1093/brain/117.2.385; Kinnman E, 1997, ANESTH ANALG, V84, P595, DOI 10.1097/00000539-199703000-00024; Ko MC, 1998, J PHARMACOL EXP THER, V286, P150; Koppert W, 1999, ANESTH ANALG, V88, P117, DOI 10.1097/00000539-199901000-00022; LEVINE JD, 1979, NATURE, V278, P740, DOI 10.1038/278740a0; LEVY JH, 1989, ANESTHESIOLOGY, V70, P756, DOI 10.1097/00000542-198905000-00008; Likar R, 1997, ANESTH ANALG, V84, P1313, DOI 10.1097/00000539-199706000-00025; List T, 2001, PAIN, V94, P275, DOI 10.1016/S0304-3959(01)00361-X; MOINICHE S, 1993, ACTA ANAESTH SCAND, V37, P710, DOI 10.1111/j.1399-6576.1993.tb03795.x; Nozaki-Taguchi N, 1999, ANESTHESIOLOGY, V90, P225, DOI 10.1097/00000542-199901000-00029; Pedersen JL, 1998, PAIN, V74, P139, DOI 10.1016/S0304-3959(97)00160-7; ROBERTSON LJ, 2003, THESIS U W AUSTR; Stander S, 2002, REGUL PEPTIDES, V110, P75, DOI 10.1016/S0167-0115(02)00159-3; STEIN C, 1993, LANCET, V342, P321, DOI 10.1016/0140-6736(93)91471-W; STEIN C, 1995, NEW ENGL J MED, V332, P1685, DOI 10.1056/NEJM199506223322506; Wiesenfeld-Hallin Zsuzsanna, 2005, Gend Med, V2, P137, DOI 10.1016/S1550-8579(05)80042-7	21	5	5	0	1	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	1526-5900			J PAIN	J. Pain	JUN	2007	8	6					489	493		10.1016/j.jpain.2007.01.007			5	Clinical Neurology; Neurosciences	Neurosciences & Neurology	180TL	WOS:000247388800006	17368995				2020-06-30	J	Evans, C; Schein, J; Nelson, W; Crespi, S; Gargiulo, K; Horowicz-Mehler, N; Panchal, S				Evans, Christopher; Schein, Jeff; Nelson, Winnie; Crespi, Simone; Gargiulo, Kathryn; Horowicz-Mehler, Nathalie; Panchal, Sunil			Improving patient and nurse outcomes: A comparison of nurse tasks and time associated with two patient-controlled analgesia modalities using delphi panels	PAIN MANAGEMENT NURSING			English	Article							POSTOPERATIVE PAIN; CONTROLLED-TRIAL; DELIVERY-SYSTEM; FENTANYL; METAANALYSES; MANAGEMENT; CARE	increased demand on nursing time may adversely affect nurse satisfaction and patient outcomes. Technologies to reduce nursing time and burden may improve patient care. Two Delphi panels assessed the perceived nursing time of fentanyl iontophoretic transdermal system (ITS) and intravenous patient-controlled analgesia (IV PCA) for postoperative pain management. The panels were asked to estimate the time spent on individual nursing tasks from a list. The Clinical Trial panel (n = 14) was composed of nurses who participated in two clinical trials, and data for both PCA modalities were collected from this panel. The routine practice panel (n = 13) was composed of nurses from various hospital units, and only data for IV PCA were collected from this panel. From the Clinical Trial panel, the estimated total average task time was 251 minutes for YV PCA and 210 minutes for fentanyl ITS. From the Routine Practice panel, the estimated total average task time was 163 minutes for IV PCA. Thirteen extra tasks were identified by the Clinical Trial panel to be associated only with IV PCA, and these eliminated steps primarily explained the estimated total nursing time difference between IV PCA and fentanyl ITS. According to the two Delphi panels, the perceived nursing time consumed was less and the number of tasks was lower for fentanyl ITS than for IV PCA. This benefit associated with fentanyl ITS may lead to other positive outcomes, such as improved nurse satisfaction and improved patient outcomes. (c) 2007 by the American Society for Pain Management Nursing.	Columbia Univ, New York, NY 10027 USA	Evans, C (reprint author), 15 Court Sq,Suite 620, Boston, MA 02108 USA.	Chris.evans@mapivalues.com					Aiken LH, 2001, HEALTH AFFAIR, V20, P43, DOI 10.1377/hlthaff.20.3.43; Aiken LH, 2002, JAMA-J AM MED ASSOC, V288, P1987, DOI 10.1001/jama.288.16.1987; Ballantyne JC, 1998, ANESTH ANALG, V86, P598, DOI 10.1097/00000539-199803000-00032; BALLANTYNE JC, 1993, J CLIN ANESTH, V5, P182, DOI 10.1016/0952-8180(93)90013-5; Blendon RJ, 2002, NEW ENGL J MED, V347, P1933, DOI 10.1056/NEJMsa022151; CHAN VWS, 1995, REGION ANESTH, V20, P506; CHELLY JE, 2004, COMMONWEALTH FUND Q, V6, P1; COUSINES DD, 2004, ADV PATIENT SAFETY U, P60; Evans C, 2000, PHARMACOECONOMICS, V17, P545, DOI 10.2165/00019053-200017060-00002; Evans C, 1997, PHARMACOECONOMICS, V12, P121, DOI 10.2165/00019053-199712020-00003; HANKIN CS, 2005, 10 ANN INT M INT SOC; Hartrick CT, 2006, REGION ANESTH PAIN M, V31, P546, DOI 10.1016/j.rapm.2006.08.011; HECKER D, 2004, MON LABOR REV, V2, P80; Kalia YN, 2004, ADV DRUG DELIVER REV, V56, P619, DOI 10.1016/j.addr.2003.10.026; Koo PJS, 2005, AM J HEALTH-SYST PH, V62, P1171, DOI 10.1093/ajhp/62.11.1171; Ludwick Ruth, 2003, Online J Issues Nurs, V8, P9; MINKOWITZ HS, 2007, [No title captured]; ShindulRothschild J, 1996, AM J NURS, V96, P25, DOI 10.1097/00000446-199611000-00034; Sudman Seymour, 1996, THINKING ANSWERS APP; Viscusi ER, 2006, ANESTH ANALG, V102, P188, DOI 10.1213/01.ane.0000183649.58483.77; Viscusi ER, 2004, JAMA-J AM MED ASSOC, V291, P1333, DOI 10.1001/jama.291.11.1333; WADE RL, 2006, ANN SPRING PRACT RES	22	11	11	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1524-9042			PAIN MANAG NURS	Pain Manag. Nurs.	JUN	2007	8	2					86	95		10.1016/j.pmn.2007.03.004			10	Nursing	Nursing	180LI	WOS:000247364400007	17544128				2020-06-30	J	Xue, FS; Liu, KP; Liu, Y; Xu, YC; Liao, X; Zhang, GH; Li, CW; Yang, QY; Sun, HT				Xue, Fu Shan; Liu, Kun Peng; Liu, Yi; Xu, Ya Chao; Liao, Xu; Zhang, Guo-Hua; Li, Cheng-Wen; Yang, Quan Yong; Sun, Hai-Tao			Assessment of small-dose fentanyl and sufentanil blunting the cardiovascular responses to laryngoscopy and intubation in children	PEDIATRIC ANESTHESIA			English	Article						sufentanil; fentanyl; orotracheal intubation; cardiovascular responses; children	TRACHEAL INTUBATION; CIRCULATORY RESPONSES; HEMODYNAMIC-RESPONSE; ANESTHESIA; PROPOFOL; REMIFENTANIL; ISOFLURANE; ALFENTANIL; INDUCTION	Background: The authors found no study assessing the efficacy of small-dose narcotics on the cardiovascular response from intubation in children, so they observed the effects of fentanyl 2 mu g.kg(-1) and sufentanil 0.2 mu g.kg(-1) on the cardiovascular changes during laryngoscopy and intubation in children. Methods: Ninety-three children aged 3-9 years were randomized to one of three groups to receive the following treatments in a double-blind manner: normal saline (group C), fentanyl 2 mu g.kg(-1) (group F) and sufentanil 0.2 mu g.kg(-1) (group S) 2 min before induction. Noninvasive blood pressure (BP) and heart rate (HR) were recorded before anesthesia induction (baseline value), immediately before intubation (postinduction values), at intubation and 5 min after intubation at 1-min interval. Results: Tracheal intubation caused significant increases in BP and HR in the three groups compared with baseline values. BP and HR at intubation and after intubation and their maximum values during observation were significantly lower in groups F and S than in group C (P < 0.05). The mean percent increases of systolic blood pressure (SBP) and HR at intubation were significantly lower in group S, 7% and 10%, than in group F, 17% and 25% (P < 0.05). The increases in SBP and HR of more than 30% of baseline values during the observation period were significantly higher in group F, 27% and 43%, than in group S, 0% and 3% (P < 0.05). Conclusions: When used as part of anesthesia induction with propofol in children, sufentanil 0.2 mu g.kg(-1) 2 min before induction is more effective in attenuating the cardiovascular intubation response than fentanyl 2 mu g.kg(-1).	Chinese Acad Med Sci, Plast Surg Hosp, Dept Anesthesiol, Beijing 100037, Peoples R China; Peking Union Med Coll, Beijing, Peoples R China; Xinxiang Med Coll, Xinxiang, Henan, Peoples R China	Xue, FS (reprint author), Chinese Acad Med Sci, Plast Surg Hosp, Dept Anesthesiol, Ba Da Chu Rd,Shi Jing Shan Dist, Beijing 100037, Peoples R China.	fruitxue@yahoo.com.cn					Adachi YU, 2002, ANESTH ANALG, V95, P233, DOI 10.1097/00000539-200207000-00043; Bennett JA, 1997, ANESTHESIOLOGY, V87, P1070, DOI 10.1097/00000542-199711000-00010; Bowman WC, 2006, BRIT J PHARMACOL, V147, pS277, DOI 10.1038/sj.bjp.0706404; Braga ADD, 2001, EUR J ANAESTH, V18, P384, DOI 10.1046/j.0265-0215.2001.00861.x; BRUNNER MD, 1994, BRIT J ANAESTH, V72, P42, DOI 10.1093/bja/72.1.42; BUTTERWORTH JF, 1989, BRIT J ANAESTH, V63, P351, DOI 10.1093/bja/63.3.351; Casati A, 2001, EUR J ANAESTH, V18, P108, DOI 10.1046/j.1365-2346.2001.0790e.x; CHUNG F, 1985, CAN ANAESTH SOC J, V32, P622, DOI 10.1007/BF03011409; CLOTZ MA, 1991, CLIN PHARMACY, V10, P581; Egan TD, 1997, ANESTH ANALG       S, P8; GUAY J, 1992, CAN J ANAESTH, V39, P14, DOI 10.1007/BF03008666; Gupta A, 2006, PEDIATR ANESTH, V16, P399, DOI 10.1111/j.1460-9592.2005.01783.x; HOWIE MB, 1985, ANESTH ANALG, V64, P877; Ikeda K, 1989, Masui, V38, P1469; KAY B, 1987, ANAESTHESIA, V42, P382, DOI 10.1111/j.1365-2044.1987.tb03979.x; Ko SH, 1998, ANESTH ANALG, V86, P658, DOI 10.1097/00000539-199803000-00041; Lentschener C, 2003, ACTA ANAESTH SCAND, V47, P84, DOI 10.1034/j.1399-6576.2003.470115.x; MATHEWS HML, 1988, BRIT J ANAESTH, V60, P530, DOI 10.1093/bja/60.5.530; ROSOW CE, 1984, PHARMACOTHERAPY, V4, P11; SINGLETON MA, 1987, CAN J ANAESTH, V34, P152, DOI 10.1007/BF03015333; SUTCLIFFE N, 2000, STUDY PRACTICE INTRA, P130; WESTMORELAND CL, 1994, ANESTH ANALG, V78, P23; XUE FS, 2002, [No title captured], P270; XUE FS, 2007, ANESTH ANALG, V104	24	19	34	0	0	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	1155-5645			PEDIATR ANESTH	Pediatr. Anesth.	JUN	2007	17	6					568	574		10.1111/j.1460-9592.2006.02162.x			7	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	165PP	WOS:000246317900010	17498020				2020-06-30	J	Richardson, J; Holdcroft, A				Richardson, Jennifer; Holdcroft, Anita			Results of forty years Yellow Card reporting for commonly used perioperative analgesic drugs	PHARMACOEPIDEMIOLOGY AND DRUG SAFETY			English	Article						pharmacovigilance; analgesics; mortality	ODDS RATIO; ADVERSE; ANESTHESIA; PHARMACOVIGILANCE; SAFETY; SYSTEM	Background A variety of analgesics are used perioperatively and associated adverse drug reactions (ADRs) may complicate anaesthesia and recovery. Methods We aimed to measure the demographics of reported suspected ADRs to alfentanil, fentanyl, ketorolac, morphine, nalbuphine, papaveretum, pethidine and remifentanil. We report a retrospective analysis of Yellow Card reports of suspected ADRs from 1965-2004 as classified in the Adverse Drug Reaction On-line Tracking database (ADROIT) of the Medicines and Healthcare products Regulatory Agency (MHRA). Results In total, 1312 reactions were retrieved. A single drug was reported in 908, 39 were fatal and 219 categorised as 'allergic'. Allergic phenomenon varied from 2/33 (6%) for remifentanil to 11/53 (21%) for alfentanil. 'Cardiovascular' reactions were reported frequently with remifentanil (18/33, 55%) and alfentanil (19/53, 36%) and these generated a signal for possible hazards from proportional reporting ratios (PRRs). The opioid fentanyl was associated with similar hazard signals for muscular and psychiatric ADRs. Conclusions Perioperative vigilance may reduce morbidity and mortality from preventable ADRs to analgesic drugs. Denominator and diagnostic data are essential for prospective studies. Copyright (C) 2007 John Wiley & Sons, Ltd.	Univ London Imperial Coll Sci Technol & Med, Magill Dept Anaesthesia Pain Med & Intens Care, London SW7 2AZ, England	Holdcroft, A (reprint author), Imperial Coll Sch Med, Chelsea & Westminster Hosp, Dept Anaesthesia Pain Med & Intens Care, London SW10 9NH, England.	a.holdcroft@imperial.ac.uk					Almenoff JS, 2006, DRUG SAFETY, V29, P875, DOI 10.2165/00002018-200629100-00005; Alvarez-Requejo A, 1998, EUR J CLIN PHARMACOL, V54, P483, DOI 10.1007/s002280050498; Beers R, 2004, CNS DRUGS, V18, P1085, DOI 10.2165/00023210-200418150-00004; Bradley BA, 2002, TRANSPL IMMUNOL, V10, P125, DOI 10.1016/S0966-3274(02)00058-8; Camu F, 1996, Acta Anaesthesiol Belg, V47, P143; Chen A H, 1994, Anesth Prog, V41, P102; CLARKE RSJ, 1993, ANN FR ANESTH, V12, P105, DOI 10.1016/S0750-7658(05)81017-2; Evans SJW, 2001, PHARMACOEPIDEM DR S, V10, P483, DOI 10.1002/pds.677; FARROW R, 1984, IEEE SOFTWARE, V1, P77, DOI 10.1109/MS.1984.229467; FISHER M, 1995, BRIT MED J, V311, P731, DOI 10.1136/bmj.311.7007.731; FISHER MM, 1993, ANN FR ANESTH, V12, P97, DOI 10.1016/S0750-7658(05)81016-0; Freye E, 2004, ANASTH INTENSIV NOTF, V39, P527, DOI 10.1055/s-2004-825883; Fujimoto Takahiro, 2003, J Anesth, V17, P55, DOI 10.1007/s005400300009; Herdeiro MT, 2005, DRUG SAFETY, V28, P825, DOI 10.2165/00002018-200528090-00007; Knight B, 2000, AUST NZ J MED, V30, P513, DOI 10.1111/j.1445-5994.2000.tb02064.x; Lau L., 2002, Hong Kong Medical Journal, V8, P99; LAXENAIRE MC, 1993, ANN FR ANESTH, V12, P91, DOI 10.1016/S0750-7658(05)81015-9; Light KP, 2006, PHARMACOEPIDEM DR S, V15, P151, DOI 10.1002/pds.1196; MEHTA D, 2005, BRIT NATL FORMULARY, V49; Mertes PM, 2002, EUR J ANAESTH, V19, P240, DOI 10.1017/S0265021502000418; Moore N, 2005, PHARMACOEPIDEM DR S, V14, P285, DOI 10.1002/pds.1058; Pirmohamed M, 2004, BMJ-BRIT MED J, V329, P15, DOI 10.1136/bmj.329.7456.15; Rothman KJ, 2004, PHARMACOEPIDEM DR S, V13, P519, DOI 10.1002/pds.1001; Sitenga GL, 1996, OPHTHALMOLOGY, V103, P890, DOI 10.1016/S0161-6420(96)30591-5; Thiessard F, 2005, DRUG SAFETY, V28, P731, DOI 10.2165/00002018-200528080-00007; van der Heijden PGM, 2002, STAT MED, V21, P2027, DOI 10.1002/sim.1157; Waller P, 2003, PHARMACOEPIDEM DR S, V12, P283, DOI 10.1002/pds.849; ZUCKERPINCHOFF B, 1989, ANESTHESIOLOGY, V71, P599, DOI 10.1097/00000542-198910000-00020	28	3	5	0	4	JOHN WILEY & SONS LTD	CHICHESTER	THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND	1053-8569			PHARMACOEPIDEM DR S	Pharmacoepidemiol. Drug Saf.	JUN	2007	16	6					687	694		10.1002/pds.1403			8	Public, Environmental & Occupational Health; Pharmacology & Pharmacy	Public, Environmental & Occupational Health; Pharmacology & Pharmacy	185WC	WOS:000247740100012	17436358				2020-06-30	J	Cinnella, G; Meola, S; Portincasa, A; Parisi, D; Morgese, F; Pavone, G; Dambrosio, M				Cinnella, Gilda; Meola, Salvatore; Portincasa, Aurelio; Parisi, Domenico; Morgese, Francesco; Pavone, Giovanna; Dambrosio, Michele			Sedation analgesia during office-based plastic surgery procedures: Comparison of two opioid regimens	PLASTIC AND RECONSTRUCTIVE SURGERY			English	Article; Proceedings Paper	Annual Congress of the Sociata-Italiana-di-Anestesia-Analgesia-Rianimazione-e-Terapia-Intensiva	OCT 22-25, 2003	Rome, ITALY	Soc Italiana Anestesia, Analgesia, Rianimazione & Terapia Intens			MONITORED ANESTHESIA CARE; DOSE PROPOFOL INFUSION; REGIONAL ANESTHESIA; CONSCIOUS SEDATION; LOCAL-ANESTHESIA; MIDAZOLAM; REMIFENTANIL; FENTANYL; KETOROLAC; SCALE	Background: The combination of sedative and analgesic drugs is increasingly being used during minimally invasive surgery. The authors compared the clinical efficacy of two different fentanyl regimens, in combination with midazolam, for sedation analgesia in patients undergoing office-based plastic surgery procedures under local anesthesia. Methods: One-hundred patients were randomized into two groups of 50 subjects each. Group F-1 received a fentanyl bolus of 0.7 mu g/kg before infiltration with local anaesthetics; group F-2 received the same bolus plus 0.6 gg/kg fentanyl every 45 minutes. All patients received a midazolam bolus of 0.05 mu g/kg plus continuous infusion 0.08 mu g/kg per hour. Results: High-quality analgesia was obtained in every group, without significant differences between the two fentanyl regimens. Group F-1 was associated with lower intraoperative mean blood pressure and SpO(2) values compared with group F-1. No differences were detected between the two groups in perioperative side effects or postoperative pain. Conclusion: Higher doses of opioid did not improve the quality of perioperative patient comfort but acted synergistically with the sedative drugs, amplifying the hemodynamic and respiratory side effects.	Univ Foggia, Dept Anesthesiol & Intens Care, Foggia, Italy; Univ Foggia, Dept Plast Surg, Foggia, Italy	Cinnella, G (reprint author), Univ Foggia, UO Anestesia Rianimaz & Terapia Intens, Osped Matern, Via L Pinto 1, I-71100 Foggia, Italy.	g.cinnella@unifg.it	Cinnella, Gilda/O-2987-2016	Cinnella, Gilda/0000-0001-9864-2893; PARISI, DOMENICO/0000-0002-7755-9115			ALDRETE JA, 1970, ANESTH ANAL CURR RES, V49, P924; Avramov MN, 1996, ANESTHESIOLOGY, V85, P1283, DOI 10.1097/00000542-199612000-00009; Bitar G, 2003, PLAST RECONSTR SURG, V111, P150, DOI 10.1097/01.PRS.0000037756.88297.BC; BORGEAT A, 1992, ANESTH ANALG, V74, P539; BOSEK V, 1992, J CLIN ANESTH, V38, P218; BUCHARDI H, 2004, MINERVA ANESTESIOL, V4, P137; Burmeister MA, 2002, ANAESTHESIA, V57, P877, DOI 10.1046/j.1365-2044.2002.02820.x; CHERNIK DA, 1990, J CLIN PSYCHOPHARM, V10, P244; DECAPRARIS A, 2004, MINERVA ANESTESIOL, V70, P307; Deng XM, 2001, ANESTH ANALG, V93, P1174, DOI 10.1097/00000539-200111000-00023; GUTSTEIN HB, 2001, GOODMAN GILMANS PHAR, P569; Hasen KV, 2003, PLAST RECONSTR SURG, V112, P1683, DOI 10.1097/01.PRS.0000086363.34535.A4; Howell TK, 2002, ANAESTHESIA, V57, P798; Iverson RE, 1999, PLAST RECONSTR SURG, V104, P1559, DOI 10.1097/00006534-199910000-00055; Kryger ZB, 2004, PLAST RECONSTR SURG, V113, P1807, DOI 10.1097/01.PRS.0000117303.63028.7D; LYSAK SZ, 1994, OBSTET GYNECOL, V83, P270; MINOCHA A, 1998, DIGEST DIS SCI, V8, P1935; Nemethy M, 2002, ANESTH ANALG, V94, P723, DOI 10.1097/00000539-200203000-00045; NIV D, 1997, CURR PAIN HEADACHE R, V1, P79; Sanjay OP, 2004, ANESTH ANALG, V99, P339; SaRego MM, 1997, ANESTH ANALG, V85, P1020, DOI 10.1097/00000539-199711000-00012; Servin FS, 2002, ACTA ANAESTH SCAND, V46, P309, DOI 10.1034/j.1399-6576.2002.t01-1-460314.x; Sharma S, 2001, PLAST RECONSTR SURG, V107, P352, DOI 10.1097/00006534-200102000-00009; SMITH I, 1994, ANESTH ANALG, V79, P313; Solca M, 2004, Minerva Anestesiol, V70, P5; Wang CY, 2000, ANAESTHESIA, V55, P654, DOI 10.1046/j.1365-2044.2000.01520.x; White P F, 1991, J Clin Anesth, V3, P32, DOI 10.1016/0952-8180(91)90203-Y; WILSON E, 1990, BRIT J ANAESTH, V64, P48, DOI 10.1093/bja/64.1.48; Yoon HD, 2002, PLAST RECONSTR SURG, V109, P956, DOI 10.1097/00006534-200203000-00023; 2002, ANESTHESIOLOGY, V4, P1004	30	9	9	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0032-1052			PLAST RECONSTR SURG	Plast. Reconstr. Surg.	JUN	2007	119	7					2263	2270		10.1097/01.prs.0000260754.59310.38			8	Surgery	Surgery	170NB	WOS:000246669000042	17519730				2020-06-30	J	Nishioka, K; Shibata, O; Yamaguchi, M; Makita, T; Sumikawa, K				Nishioka, Kenji; Shibata, Osamu; Yamaguchi, Masakazu; Makita, Tetsuji; Sumikawa, Koji			The effects of fentanyl on the contractile response of ovalbumin-sensitized rat trachea	ANESTHESIA AND ANALGESIA			English	Article							GUINEA-PIG; CHOLINERGIC NEUROTRANSMISSION; PARASYMPATHETIC NERVES; INHIBITION; AIRWAY; OPIOIDS; ACETYLCHOLINE; CONSTRICTION; MODULATION; ANESTHESIA	BACKGROUND: It is not clear whether fentanyl affects a hyperresponsive airway. We examined the effects of fentanyl on the contractile response of ovalbumin (OA)-sensitized rat tracheas. METHODS: Rats were sensitized with a single intraperitoneal injection of 10 mu g of OA mixed with adjuvant. Fourteen days later, the trachea was cut into 3-mm-wide rings. The OA-induced tension was measured, and the effects of fentanyl were studied in the presence of naloxone. Second the role of cholinergic nerves and h serotonin in the contraction an the effects of fentanyl were examined using tetrodotoxin and ketanserin. Third, lungs of sensitized rats were ventilated, and respiratory system resistance was calculated before and after the administration of OA in the presence of fentanyl. RESULTS: Fentanyl dose-dependently attenuated the OA-induced contraction, and naloxone partly reversed it. Both tetrodotoxin and ketanserin attenuated the contraction. Fentanyl had no further effect on the contraction in the presence of tetrodotoxin, whereas the contraction was nearly abolished by fentanyl in the presence of ketanserin. OA increased respiratory system resistance in sensitized rats, and this effect was attenuated by fentanyl. CONCLUSIONS: Fentanyl attenuates the airway hyperresponsiveness of sensitized rat trachea through the inhibition of cholinergic nerves on the smooth muscle.	Nagasaki Univ, Sch Med, Dept Anesthesiol, Nagasaki 8528501, Japan	Shibata, O (reprint author), Nagasaki Univ, Sch Med, Dept Anesthesiol, 1-7-1 Sakamoto, Nagasaki 8528501, Japan.	opshiba@net.nagasaki-u.ac.jp					BELVISI MG, 1990, BRIT J PHARMACOL, V100, P131, DOI 10.1111/j.1476-5381.1990.tb12064.x; BELVISI MG, 1992, J APPL PHYSIOL, V72, P1096; CIGARINI I, 1990, ACTA ANAESTH SCAND, V34, P253, DOI 10.1111/j.1399-6576.1990.tb03080.x; COHENDY R, 1992, BRIT J ANAESTH, V69, P595, DOI 10.1093/bja/69.6.595; COLEMAN JW, 1983, EUR J IMMUNOL, V13, P994, DOI 10.1002/eji.1830131208; Damazo AS, 2001, EUR J PHARMACOL, V426, P123, DOI 10.1016/S0014-2999(01)01093-7; Eum SY, 1999, BRIT J PHARMACOL, V126, P312, DOI 10.1038/sj.bjp.0702304; Fischer A, 1999, BRIT J PHARMACOL, V127, P605, DOI 10.1038/sj.bjp.0702630; FRYER AD, 1991, J APPL PHYSIOL, V71, P2255; GENTIL B, 1989, EUR J PHARMACOL, V159, P181, DOI 10.1016/0014-2999(89)90703-6; KASHIMOTO S, 1997, EUR J ANAESTH, V80, P1841; LIMA WT, 1998, GEN PHARMACOL, V30, P689; MAYR SI, ROLE IMMUNOGLOBULIN, V36, P821; NAGASE T, 1995, AM J RESP CRIT CARE, V152, P81, DOI 10.1164/ajrccm.152.1.7599867; Patel HJ, 1997, BRIT J PHARMACOL, V120, P735, DOI 10.1038/sj.bjp.0701013; Shinagawa K, 2003, AM J RESP CRIT CARE, V168, P959, DOI 10.1164/rccm.200210-1188OC; TODA N, 1980, ANESTHESIOLOGY, V53, P93, DOI 10.1097/00000542-198008000-00001; Tsujita T, 1997, RES COMMUN MOL PATH, V95, P287; VOS JG, 1970, [No title captured], V12, P289; Yamaguchi M, 2006, ANESTH ANALG, V103, P594, DOI 10.1213/01.ane.0000229853.01875.60; YASUDA I, 1978, ANESTHESIOLOGY, V49, P117, DOI 10.1097/00000542-197808000-00012; Zappi L, 1997, ANESTHESIOLOGY, V86, P1334, DOI 10.1097/00000542-199706000-00015	22	4	4	1	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	MAY	2007	104	5					1103	1108		10.1213/01.ane.0000260266.34430.e1			6	Anesthesiology	Anesthesiology	161FB	WOS:000245998800018	17456659				2020-06-30	J	Wolfe, T				Wolfe, Tim			Intranasal fentanyl for acute pain: Techniques to enhance efficacy	ANNALS OF EMERGENCY MEDICINE			English	Letter									Univ Utah, Sch Med, Div Emergency Med, Salt Lake City, UT 84112 USA	Wolfe, T (reprint author), Univ Utah, Sch Med, Div Emergency Med, Salt Lake City, UT 84112 USA.						Borland M, 2007, ANN EMERG MED, V49, P335, DOI 10.1016/j.annemergmed.2006.06.016; CHIEN YW, 1989, NASAL SYSTEMIC DRUG, P1; Dale O, 2002, ACTA ANAESTH SCAND, V46, P759, DOI 10.1034/j.1399-6576.2002.460702.x; Kendall JM, 2001, BMJ-BRIT MED J, V322, P261, DOI 10.1136/bmj.322.7281.261; Wolfe Timothy R, 2004, J Emerg Nurs, V30, P141, DOI 10.1016/j.jen.2004.01.006	5	3	3	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644	1097-6760		ANN EMERG MED	Ann. Emerg. Med.	MAY	2007	49	5					721	722		10.1016/j.annemergmed.2006.11.031			2	Emergency Medicine	Emergency Medicine	163ED	WOS:000246140700029	17452275				2020-06-30	J	Mayr, HO; Entholzner, E; Hube, R; Hein, W; Weig, TG				Mayr, Hermann O.; Entholzner, Elmar; Hube, Robert; Hein, Werner; Weig, Thomas G.			Pre- versus postoperative intraarticular application of local anesthetics and opioids versus femoral nerve block in anterior cruciate ligament repair	ARCHIVES OF ORTHOPAEDIC AND TRAUMA SURGERY			English	Article						postoperative analgesia; intraarticular analgesics; knee arthroscopy; preoperative intraarticular analgesia; anterior cruciate ligament repair	ARTHROSCOPIC KNEE SURGERY; PAIN-CONTROL; REGIONAL ANESTHESIA; MORPHINE; BUPIVACAINE; ANALGESIA; RECONSTRUCTION; CATHETER; FENTANYL; RELIEF	Background: Often anterior cruciate ligament (ACL) reconstruction is performed as outpatient surgery. This requires a patient friendly postoperative pain management. Three common procedures were compared in this trial. Methods: In a prospective, randomized study the effect of postoperative pain management using preoperative intraarticular anesthesia (0.1 mg Fentanyl + 8 ml Bupivacain 0.5%) was compared with postoperative intraarticular anesthesia (0.1 mg Fentanyl + 8 ml Bupivacain 0.5%) and the femoralis 3-in-1 nerve block (20 ml Prilocain 1% + 20 ml Bupivacain 0.5%) in 157 patients who underwent arthroscopic ACL-plasty. Results: Preoperative intraarticular anesthesia and the femoralis 3-in-1 nerve block showed the same postoperative analgesia and satisfactory pain scores in most cases. Postoperative intraarticular anesthesia was less effective. Conclusion: Our data show that in anterior cruciate ligament reconstruction preoperative intraarticular analgesia with Bupivacain/Fentanyl is satisfactory and equal to the femoralis 3-in-1 nerve block with Bupivacain.	OCM Clin, Dept Orthoped Surg, D-81369 Munich, Germany; Univ Munich, Anesthesiol Clin, D-81377 Munich, Germany; Univ Halle Wittenberg, Clin Orthoped Surg, D-06097 Halle, Germany	Mayr, HO (reprint author), OCM Clin, Dept Orthoped Surg, Steiner Str 6, D-81369 Munich, Germany.	hermann.mayr@ocm-muenchen.de					Atchabahian A, 2001, ANESTHESIOLOGY, V94, P534, DOI 10.1097/00000542-200103000-00029; BUTTERFIELD N, 2000, COMBINED PRE POSTSUR; Cappellino A, 1996, ARTHROSCOPY, V12, P120, DOI 10.1016/S0749-8063(96)90233-9; Cepeda MS, 1997, REGION ANESTH, V22, P233, DOI 10.1016/S1098-7339(06)80007-6; Cuvillon P, 2001, ANESTH ANALG, V93, P1045, DOI 10.1097/00000539-200110000-00050; Dauri M, 2003, ACTA ANAESTH SCAND, V47, P20, DOI 10.1034/j.1399-6576.2003.470104.x; Denti M, 1997, Knee Surg Sports Traumatol Arthrosc, V5, P206, DOI 10.1007/s001670050051; Goranson BD, 1997, CAN J ANAESTH, V44, P371, DOI 10.1007/BF03014456; Iskandar H, 2003, REGION ANESTH PAIN M, V28, P29, DOI 10.1053/rapm.2003.50019; JOSHI GP, 1993, REGION ANESTH, V18, P254; KHOURY GF, 1992, ANESTHESIOLOGY, V77, P263, DOI 10.1097/00000542-199208000-00007; LAWRENCE AJ, 1992, EUR J CLIN PHARMACOL, V43, P351, DOI 10.1007/BF02220608; Lundin O, 1998, ARTHROSCOPY, V14, P192, DOI 10.1016/S0749-8063(98)70040-4; Lynch J, 1991, Acta Anaesthesiol Belg, V42, P207; Mehdi SA, 2004, KNEE SURG SPORT TR A, V12, P180, DOI 10.1007/s00167-003-0464-6; Rosseland LA, 2005, REGION ANESTH PAIN M, V30, P83, DOI 10.1016/j.rapm.2004.08.022; Shaw A, 1997, EUR J ANAESTH, V14, P635, DOI 10.1046/j.1365-2346.1994.00203.x; STEIN C, 1991, NEW ENGL J MED, V325, P1123, DOI 10.1056/NEJM199110173251602; Stein C, 2003, NAT MED, V9, P1003, DOI 10.1038/nm908; Tetzlaff JE, 1997, J CLIN ANESTH, V9, P542, DOI 10.1016/S0952-8180(97)00141-4; Tetzlaff JE, 1999, REGION ANESTH PAIN M, V24, P220, DOI 10.1016/S1098-7339(99)90131-1; Uysalel A, 1995, ARTHROSCOPY, V11, P660, DOI 10.1016/0749-8063(95)90105-1; Varkel V, 1999, CAN J ANAESTH, V46, P867, DOI 10.1007/BF03012977	23	34	35	0	2	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013 USA	0936-8051			ARCH ORTHOP TRAUM SU	Arch. Orthop. Trauma Surg.	MAY	2007	127	4					241	244		10.1007/s00402-006-0147-0			4	Orthopedics; Surgery	Orthopedics; Surgery	162NJ	WOS:000246094300003	16721618				2020-06-30	J	Liberzon, I; Taylor, SF; Phan, KL; Britton, JC; Fig, LM; Bueller, JA; Koeppe, RA; Zubieta, JK				Liberzon, Israel; Taylor, Stephan F.; Phan, K. Luan; Britton, Jennifer C.; Fig, Lorraine M.; Bueller, Joshua A.; Koeppe, Robert A.; Zubieta, Jon-Kar			Altered central mu-opioid receptor binding after psychological trauma	BIOLOGICAL PSYCHIATRY			English	Article; Proceedings Paper	41st Annual Meeting of the American-College-of-Neuropsychopharmacology	DEC 08-12, 2002	SAN JUAN, PR	Amer Coll Neuropsychopharmacol		amygdala; cortex; neuroimaging; PET; PTSD; veteran	POSTTRAUMATIC-STRESS-DISORDER; SCRIPT-DRIVEN IMAGERY; PLASMA BETA-ENDORPHIN; CEREBRAL-BLOOD-FLOW; INDUCED ANALGESIA; COMBAT VETERANS; LEARNED HELPLESSNESS; PERIAQUEDUCTAL GRAY; SYMPTOM PROVOCATION; ANTERIOR CINGULATE	Background: Functional neuroimaging studies have detected abnormal limbic and paralimbic activation to emotional probes in posttraumatic stress disorder (PTSD), but few studies have examined neurochemical mechanisms that underlie functional alterations in regional cerebral blood flow. The mu-opioid neurotransmitter system, implicated in responses to stress and suppression of pain, is distributed in and is thought to regulate the function of brain regions that are implicated in affective processing. Methods: Here we examined the mu-opioid system with positron emission tomography and the mu-opioid receptor-selective radiotracer [C-11] carfentanil in 16 male patients with PTSD and two non-PTSD male control groups, with (n=14) and without combat exposure (n=15). Differences in R-opioid receptor binding potential (BP2) were detected within discrete limbic and paralimbic regions. Results: Relative to healthy controls, both trauma-exposed groups had lower R-opioid receptor BP2 in extended amygdala, nucleus accumbens, and dorsal frontal and insular cortex but had higher BP2 in the orbitofrontal cortex. PTSD patients exhibited reduced BP2 in anterior cingulate cortex compared with both control groups. mu-Opioid receptor BP2 in combat-exposed subjects without PTSD was lower in the amygdala but higher in the orbitofrontal cortex compared with both PTSD patients and healthy controls. Conclusions: These findings differentiate the general response of the mu-opioid system to trauma from more specific changes associated with PTSD.	Univ Michigan, Dept Psychiat, Sch Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Radiol, Sch Med, Ann Arbor, MI 48109 USA; Univ Michigan, Neurosci Program, Ann Arbor, MI 48109 USA; Vet Adm Med Ctr, Psychiat Serv, Ann Arbor, MI 48105 USA; Vet Adm Med Ctr, Nucl Med Serv, Ann Arbor, MI 48105 USA; Univ Chicago, Dept Psychiat, Chicago, IL 60637 USA	Liberzon, I (reprint author), Univ Michigan, Dept Psychiat, Sch Med, UH-9D Box 0118,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	liberzon@umich.edu	Britton, Jennifer/J-4501-2013; Taylor, Stephan F/A-1211-2007	Taylor, Stephan/0000-0001-8777-4292; Liberzon, Israel/0000-0002-4990-556X			Baker DG, 1997, PSYCHONEUROENDOCRINO, V22, P517, DOI 10.1016/S0306-4530(97)00053-X; BILLS LJ, 1993, AM J PSYCHIAT, V150, P1430; Bohus MJ, 1999, J CLIN PSYCHIAT, V60, P598, DOI 10.4088/JCP.v60n0906; Bremner J Douglas, 2002, Curr Psychiatry Rep, V4, P254, DOI 10.1007/s11920-996-0044-9; Bremner JD, 1997, AM J PSYCHIAT, V154, P624; Bremner JD, 1999, BIOL PSYCHIAT, V45, P806, DOI 10.1016/S0006-3223(98)00297-2; DANNALS RF, 1985, INT J APPL RADIAT IS, V36, P303, DOI 10.1016/0020-708X(85)90089-4; Davidson RJ, 2000, MENT RETARD DEV D R, V6, P166, DOI 10.1002/1098-2779(2000)6:3<166::AID-MRDD3>3.3.CO;2-F; DAVIS M, 1992, ANNU REV NEUROSCI, V15, P353, DOI 10.1146/annurev.ne.15.030192.002033; Drake CT, 1999, BRAIN RES, V849, P203, DOI 10.1016/S0006-8993(99)01910-1; Filliol D, 2000, NAT GENET, V25, P195, DOI 10.1038/76061; First MB, 1997, STRUCTURED CLIN INTE; GABILONDO AM, 1995, BRAIN RES, V682, P245, DOI 10.1016/0006-8993(95)00333-L; GLOVER H, 1993, ISRAEL J PSYCHIAT, V30, P255; GOOD AJ, 1995, BEHAV NEUROSCI, V109, P631, DOI 10.1037/0735-7044.109.4.631; GRAEFF FG, 1994, BRAZ J MED BIOL RES, V27, P811; GROSSISSEROFF R, 1990, BRAIN RES, V530, P312, DOI 10.1016/0006-8993(90)91301-V; HAMNER MB, 1992, J NEUROPSYCH CLIN N, V4, P59; HOFFMAN L, 1989, AUST NZ J PSYCHIAT, V23, P269, DOI 10.3109/00048678909062145; HYSON RL, 1982, PHARMACOL BIOCHEM BE, V17, P1019, DOI 10.1016/0091-3057(82)90488-9; JACKSON RL, 1979, SCIENCE, V206, P91, DOI 10.1126/science.573496; KALIN NH, 1988, BRAIN RES, V440, P285, DOI 10.1016/0006-8993(88)90997-3; Kang W, 2000, NEUROPSYCHOPHARMACOL, V22, P77, DOI 10.1016/S0893-133X(99)00090-1; KOSTEN TR, 1987, PSYCHONEUROENDOCRINO, V12, P13, DOI 10.1016/0306-4530(87)90017-5; Lanius RA, 2002, BIOL PSYCHIAT, V52, P305, DOI 10.1016/S0006-3223(02)01367-7; Lanius RA, 2003, BIOL PSYCHIAT, V53, P204, DOI 10.1016/S0006-3223(02)01466-X; Lanius RA, 2001, AM J PSYCHIAT, V158, P1920, DOI 10.1176/appi.ajp.158.11.1920; LeDoux JE, 2000, ANNU REV NEUROSCI, V23, P155, DOI 10.1146/annurev.neuro.23.1.155; Liberzon I, 1999, BIOL PSYCHIAT, V45, P817, DOI 10.1016/S0006-3223(98)00246-7; Liberzon I, 2002, P NATL ACAD SCI USA, V99, P7084, DOI 10.1073/pnas.102174799; Logan J, 1996, J CEREBR BLOOD F MET, V16, P834, DOI 10.1097/00004647-199609000-00008; Lubin G, 2002, HUM PSYCHOPHARM CLIN, V17, P181, DOI 10.1002/hup.395; Manning BH, 2001, J NEUROSCI, V21, P8238; Mayberg HS, 1997, J NEUROPSYCH CLIN N, V9, P471; Meyer C R, 1997, Med Image Anal, V1, P195, DOI 10.1016/S1361-8415(97)85010-4; MINOSHIMA S, 1993, INT CONGR SER, V1030, P409; Napier TC, 1999, ANN NY ACAD SCI, V877, P176, DOI 10.1111/j.1749-6632.1999.tb09268.x; O'Doherty J, 2001, NAT NEUROSCI, V4, P95; Ochsner KN, 2002, J COGNITIVE NEUROSCI, V14, P1215, DOI 10.1162/089892902760807212; Osuch EA, 2001, BIOL PSYCHIAT, V50, P246, DOI 10.1016/S0006-3223(01)01107-6; Phan KL, 2002, NEUROIMAGE, V16, P331, DOI 10.1006/nimg.2002.1087; Pissiota A, 2002, EUR ARCH PSY CLIN N, V252, P68, DOI 10.1007/s004060200014; PITMAN RK, 1990, ARCH GEN PSYCHIAT, V47, P541; Quirarte GL, 1998, BRAIN RES, V808, P134, DOI 10.1016/S0006-8993(98)00795-1; Quirk GJ, 2000, J NEUROSCI, V20, P6225, DOI 10.1523/JNEUROSCI.20-16-06225.2000; Rauch SL, 1996, ARCH GEN PSYCHIAT, V53, P380; Saxe G, 2001, J AM ACAD CHILD PSY, V40, P915, DOI 10.1097/00004583-200108000-00013; SHAIKH MB, 1991, BRAIN RES, V559, P109, DOI 10.1016/0006-8993(91)90293-5; Sharot T, 2004, NAT NEUROSCI, V7, P1376, DOI 10.1038/nn1353; Shin LM, 2005, ARCH GEN PSYCHIAT, V62, P273, DOI 10.1001/archpsyc.62.3.273; Shin LM, 1999, AM J PSYCHIAT, V156, P575; Shin LM, 2001, BIOL PSYCHIAT, V50, P932, DOI 10.1016/S0006-3223(01)01215-X; Southwick SM, 1997, ARCH GEN PSYCHIAT, V54, P749; TEJEDORREAL P, 1995, PHARMACOL BIOCHEM BE, V52, P145, DOI 10.1016/0091-3057(95)00067-7; TITELER M, 1989, EUR J PHARMACOL, V167, P221, DOI 10.1016/0014-2999(89)90582-7; Vaccarino AL, 1999, PEPTIDES, V20, P1527, DOI 10.1016/S0196-9781(99)00166-7; VANDERKOLK BA, 1989, PSYCHOPHARMACOL BULL, V25, P417; Vermetten E, 2002, DEPRESS ANXIETY, V15, P126, DOI 10.1002/da.10016; Volpicelli J, 1999, ALCOHOL RES HEALTH, V23, P256; Wiedenmayer CP, 2000, BEHAV NEUROSCI, V114, P125, DOI 10.1037/0735-7044.114.1.125; WORSLEY KJ, 1992, J CEREBR BLOOD F MET, V12, P900, DOI 10.1038/jcbfm.1992.127; YEHUDA R, 1992, J NERV MENT DIS, V180, P321, DOI 10.1097/00005053-199205000-00006; Zubieta JK, 1999, AM J PSYCHIAT, V156, P842, DOI 10.1176/ajp.156.6.842; Zubieta JK, 2003, ARCH GEN PSYCHIAT, V60, P1145, DOI 10.1001/archpsyc.60.11.1145; Zubieta JK, 2002, J NEUROSCI, V22, P5100, DOI 10.1523/JNEUROSCI.22-12-05100.2002; Zubieta JK, 2003, SCIENCE, V299, P1240, DOI 10.1126/science.1078546; Zubieta JK, 2001, SCIENCE, V293, P311, DOI 10.1126/science.1060952	67	74	76	1	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0006-3223	1873-2402		BIOL PSYCHIAT	Biol. Psychiatry	MAY 1	2007	61	9					1030	1038		10.1016/j.biopsych.2006.06.021			9	Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	160VK	WOS:000245970200004	16945349				2020-06-30	J	Butkovic, D; Kralik, S; Matolic, M; Kralik, M; Toljan, S; Radesic, L				Butkovic, D.; Kralik, S.; Matolic, M.; Kralik, M.; Toljan, S.; Radesic, L.			Postoperative analgesia with intravenous fentanyl PCA vs epidural block after thoracoscopic pectus excavatum repair in children	BRITISH JOURNAL OF ANAESTHESIA			English	Article						analgesia, patient controlled; analgesic techniques, epidural; analgesics opioid, fentanyl; children; procedure, Nuss	PATIENT-CONTROLLED ANALGESIA; THORACIC-SURGERY; NUSS PROCEDURE; INFUSION; ADOLESCENTS; ANESTHESIA; MORPHINE; SITE	Background. The aim of this prospective, randomized trial was to compare analgesia, sedation, and cardiorespiratory function in children after thoracoscopic surgery for pectus excavatum repair, using two types of analgesia-epidural block with bupivacaine plus fentanyl vs patient-controlled analgesia (PCA) with fentanyl. Methods. Twenty-eight patients scheduled for thoracoscopic pectus excavatum surgery were randomly assigned to receive either thoracic epidural block or i.v. PCA for postoperative analgesia. Pain was assessed using a visual-analogue scale (VAS). The Ramsay sedation score, arterial pressure, ventilatory frequency, and heart rate were also measured, and blood gas analysis was performed regularly during the first 48 h after surgery. Results. A significant decrease in the VAS pain score, Ramsay sedation score, heart rate ventilatory frequency, systolic and diastolic blood pressure, and Pa-CO2, and a significant increase in Pa-O2 and oxygen saturation were found over time. Patients in the PCA group had significantly higher Pa-CO2 values. In addition, a significantly slower decline of systolic blood pressure and heart rate, and faster recovery of Pa-CO2 were found in PCA patients than in patients with epidural block. Conclusions. I.V. fentanyl PCA is as effective as thoracic epidural for postoperative analgesia in children after thoracoscopic pectus excavatum repair. Bearing in mind the possible complications of epidural catheterization in children, the use of fentanyl PCA is recommended.	Univ Zagreb, Childrens Hosp, Dept Anaesthesiol Reanimatol & Intens Care, Zagreb 10000, Croatia; Univ Zagreb, Clin Hosp Rebro, Clin Inst Diagnost & Intervent Radiol, Zagreb, Croatia	Butkovic, D (reprint author), Univ Zagreb, Childrens Hosp, Dept Anaesthesiol Reanimatol & Intens Care, Klaiceva 16, Zagreb 10000, Croatia.	diana.butkovic1@zg.htnet.hr					AGUILAR JL, 1997, INT MONIT REG ANESTH, V9, P3; Bloch MB, 2002, ANESTH ANALG, V94, P523, DOI 10.1097/00000539-200203000-00009; Bozkurt P, 2002, PAEDIATR ANAESTH, V12, P248, DOI 10.1046/j.1460-9592.2002.00791.x; Cassady Joseph F. Jr., 2000, Regional Anesthesia and Pain Medicine, V25, P246, DOI 10.1016/S1098-7339(00)90006-3; Engum S, 2000, J PEDIATR SURG, V35, P246, DOI 10.1016/S0022-3468(00)90018-6; Ginosar Y, 2003, ANESTH ANALG, V97, P1439, DOI 10.1213/01.ANE.0000081792.84877.A2; Ginosar Y, 2003, ANESTH ANALG, V97, P1428, DOI 10.1213/01.ANE.0000081793.60059.10; Hammer Gregory B, 2002, Anesthesiol Clin North Am, V20, P153, DOI 10.1016/S0889-8537(03)00059-2; Hergert M, 2002, Anaesthesiol Reanim, V27, P152; Inge TH, 2003, SURG ENDOSC, V17, P1609, DOI 10.1007/s00464-002-8767-0; Jacobs JP, 2002, EUR J CARDIO-THORAC, V21, P869, DOI 10.1016/S1010-7940(02)00069-6; Kasai T, 2003, ANESTH ANALG, V96, P65, DOI 10.1097/00000539-200301000-00014; KAVANAGH BP, 1994, ANESTHESIOLOGY, V81, P737, DOI 10.1097/00000542-199409000-00028; Lejus C, 2001, PAEDIATR ANAESTH, V11, P327, DOI 10.1046/j.1460-9592.2001.00659.x; Licker M, 2003, BRIT J ANAESTH, V91, P525, DOI 10.1093/bja/aeg212; MCBRIDGE WJ, 1996, J PEDIATR SURG, V3181, P105; McDonald AJ, 2001, PEDIATR DRUGS, V3, P273, DOI 10.2165/00128072-200103040-00004; Nuss D, 2002, EUR J PEDIATR SURG, V12, P230, DOI 10.1055/s-2002-34485; Ong CCP, 2005, ANZ J SURG, V75, P421, DOI 10.1111/j.1445-2197.2005.03402.x; Peters JWB, 1999, PAEDIATR ANAESTH, V9, P235, DOI 10.1046/j.1460-9592.1999.00358.x; Rawal N, 1999, SURG CLIN N AM, V79, P313, DOI 10.1016/S0039-6109(05)70385-6; STRAFFORD MA, 1995, ANESTH ANALG, V80, P234, DOI 10.1097/00000539-199502000-00006; Veering BT, 2000, ANAESTH INTENS CARE, V28, P620, DOI 10.1177/0310057X0002800603; Williams DG, 2003, PAEDIATR ANAESTH, V13, P769, DOI 10.1046/j.1460-9592.2003.01211.x; Yildiz K, 2003, PAEDIATR ANAESTH, V13, P427, DOI 10.1046/j.1460-9592.2003.01061.x	25	46	51	0	5	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0007-0912	1471-6771		BRIT J ANAESTH	Br. J. Anaesth.	MAY	2007	98	5					677	681		10.1093/bja/aem055			5	Anesthesiology	Anesthesiology	162WS	WOS:000246120800019	17363405	Bronze			2020-06-30	J	Somri, M; Tome, R; Teszler, CB; Vaida, SJ; Mogilner, J; Shneeifi, A; Nurit, L; Avital, G; Zinder, O; Gaitini, LA				Somri, M.; Tome, R.; Teszler, C. B.; Vaida, S. J.; Mogilner, J.; Shneeifi, A.; Nurit, L.; Avital, G.; Zinder, O.; Gaitini, L. A.			Does adding intravenous fentanyl to caudal block in children enhance the efficacy of multimodal analgesia as reflected in the plasma level of catecholamines?	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article						anaesthesia general, paediatric; stress response; combined modality therapy; catecholamines, epinephrine, norepinephrine; child; anaesthesia caudal; fentanyl	CARDIAC-SURGERY; METABOLIC STRESS; EPIDURAL BLOCK; ANESTHESIA; RESPONSES; RECOVERY	Background and objective: Several studies showed that single analgesic modality management can attenuate perioperative stress, but little is known about the effect of multimodal analgesia on catecholamine responses to surgical trauma in children. Methods: Fifty children (American Society of Anesthesiologists Grade I or II) were randomly allocated to one of two groups: one received general anaesthesia and a caudal block (control group), and one group was given general anaesthesia, caudal block and intravenous (i.v.) fentanyl 2 mu g kg(-1) (fentanyl group). Plasma epinephrine and norepinephrine concentrations were measured three times during the perioperative period: at induction time (T(0)), at the end of surgery (T(1)) and when the children were fully awake in the postanaesthesia care unit (TA Results: There was a significant reduction in the catecholamine levels in the two groups when (T(1)) and (T(2)) were compared with To. When plasma epinephrine levels (at T(0) T(1) and T(2)) between the two groups were compared, a statistically significant reduction at T2 was obtained in the fentanyl group, when compared with ihe control group. However, plasma norepinephrine levels showed no statistically significant difference between the two groups (at T(0) T(1) and T(2)) Conclusion: These findings suggest that the multimodal analgesic approach of adding i.v. low-dose fentanyl to a caudal block may decrease the plasma epinephrine release in children undergoing inguinal herniotomy.	Bnai Zion Med Ctr, Dept Anaesthesiol, Haifa, Israel; Bnai Zion Med Ctr, Dept Paediat Surg, Haifa, Israel; Technion Israel Inst Technol, Bruce Rappaport Fac Med, IL-31096 Haifa, Israel; Rambam Med Ctr, Dept Clin Biochem, Haifa, Israel	Somri, M (reprint author), Bnai Zion Med Ctr, Dept Anaesthesia, POB 4940, IL-31048 Haifa, Israel.	somri_m@yahoo.com					ALDRETE JA, 1995, J CLIN ANESTH, V7, P89, DOI 10.1016/0952-8180(94)00001-K; ANAND KJS, 1992, NEW ENGL J MED, V326, P1, DOI 10.1056/NEJM199201023260101; ANAND KJS, 1990, ANESTHESIOLOGY, V73, P661, DOI 10.1097/00000542-199010000-00012; Bailey P.L., 2000, ANESTHESIA, P273; Brodner G, 2001, ANESTH ANALG, V92, P1594, DOI 10.1097/00000539-200106000-00049; CANDITO M, 1993, J CHROMATOGR-BIOMED, V617, P304, DOI 10.1016/0378-4347(93)80503-V; CHUNG F, 1995, CAN J ANAESTH, V42, P1056, DOI 10.1007/BF03011083; DALENS B, 1989, ANESTH ANALG, V68, P83, DOI 10.1213/00000539-198902000-00002; Epstein J, 1999, CRIT CARE CLIN, V15, P17, DOI 10.1016/S0749-0704(05)70037-3; Gaitini LA, 1999, EUR J ANAESTH, V16, P92, DOI 10.1046/j.1365-2346.1999.00416.x; Gaitini LA, 2000, ANESTH ANALG, V90, P1029, DOI 10.1097/00000539-200005000-00006; HALTER JB, 1980, J CLIN ENDOCR METAB, V51, P1093, DOI 10.1210/jcem-51-5-1093; JEFFREY AG, 2000, ANESTHESIOL CLIN N A, V18, P407; Katz N, 1993, POSTOPERATIVE PAIN M, P17; Kehlet H, 2000, WORLD J SURG, V24, P690, DOI 10.1007/s002689910111; KEHLET H, 1988, ACTA CHIR SCAND    S, V550, P22; Kokinsky E, 2003, PAEDIATR ANAESTH, V13, P334, DOI 10.1046/j.1460-9592.2003.00999.x; Michaloliakou C, 1996, ANESTH ANALG, V82, P44, DOI 10.1097/00000539-199601000-00009; SALZMAN SK, 1985, J CHROMATOGR, V343, P285, DOI 10.1016/S0378-4347(00)84598-3; Somri M, 2002, PAEDIATR ANAESTH, V12, P791, DOI 10.1046/j.1460-9592.2002.00916.x; Splinter WM, 1997, ANESTHESIOLOGY, V87, P542, DOI 10.1097/00000542-199709000-00013; Taylor NM, 1997, ANAESTHESIA, V52, P112, DOI 10.1111/j.1365-2044.1997.65-az0063.x; WALSH ES, 1981, BRIT J ANAESTH, V53, P1155, DOI 10.1093/bja/53.11.1155; WILLIAM M, 1997, ANESTHESIOLOGY, V87, P542; Wolf AR, 1998, PAEDIATR ANAESTH, V8, P305, DOI 10.1046/j.1460-9592.1998.00239.x	25	4	4	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0265-0215			EUR J ANAESTH	Eur. J. Anaesth.	MAY	2007	24	5					408	413		10.1017/S0265021506001414			6	Anesthesiology	Anesthesiology	167WJ	WOS:000246482900004	17087839				2020-06-30	J	Subramaniam, R; Joshi, C; Sharma, A; Prasad, CN				Subramaniam, R.; Joshi, C.; Sharma, A.; Prasad, C. N.			Analgesic efficacy of single-dose parecoxib for corneal suturing in children	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Letter							PAIN		All India Inst Med Sci, Dept Anaesthesiol & Crit Care, New Delhi, India	Subramaniam, R (reprint author), All India Inst Med Sci, Dept Anaesthesiol & Crit Care, New Delhi, India.	rajeshwarisubramaniam@hotmail.com					Boni JP, 1999, CLIN THER, V21, P1715, DOI 10.1016/S0149-2918(99)80050-2; Dalpiaz Anthony S, 2004, Expert Rev Neurother, V4, P165, DOI 10.1586/14737175.4.2.165; Joshi W, 2003, ANESTH ANALG, V97, P35, DOI 10.1213/01.ANE.0000069507.93582.6E; Malan TP, 2005, ANESTH ANALG, V100, P454, DOI 10.1213/01.ANE.0000143355.52418.CF; TOPLISS D, 2004, AUST ADV DRUG REACT, V23, P10; TURNER S, 2004, [No title captured], V89, pEP46; VALLEE E, 2004, PAIN, V5, pS84	7	3	3	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0265-0215			EUR J ANAESTH	Eur. J. Anaesth.	MAY	2007	24	5					464	465		10.1017/S0265021506001426			2	Anesthesiology	Anesthesiology	167WJ	WOS:000246482900012	17087840				2020-06-30	J	Davis, RL; Buck, DJ; Saffarian, N; Stevens, CW				Davis, Randall L.; Buck, Daniel J.; Saffarian, Neda; Stevens, Craig W.			The opioid antagonist, beta-funaltrexamine, inhibits chemokine expression in human astroglial cells	JOURNAL OF NEUROIMMUNOLOGY			English	Article						astrocyte; brain injury; Mu-opioid receptor; neuroinflammation; tumor necrosis factor alpha	INTERFERON-INDUCIBLE PROTEIN-10; NITRIC-OXIDE SYNTHASE; SPINAL-CORD-INJURY; FACTOR-KAPPA-B; CENTRAL-NERVOUS-SYSTEM; RECEPTOR EXPRESSION; MU-RECEPTOR; HIV-1 TAT; NEURODEGENERATIVE DISEASES; CEREBROSPINAL-FLUID	Emerging evidence indicates that neuroinflammatory responses in astroglia, including chemokine expression, are altered by opioids. Astroglial chemokines, such as CXCL10, are instrumental in response to many neuropathological insults. Opioid mediated disruption of astroglial CXCL10 expression may be detrimental in opioid abusers or patients receiving acute opioid therapy. We have characterized the in vitro effects of opioids on CXCL10 protein expression in human astroglial (A172) cells. The proinflammatory cytokine, tumor necrosis factor (TNF)alpha induced CXCL10 expression in A172 cells. Using MG-132, helenalin and SN50 [inhibitors of the transcription factor, nuclear factor (NF)-kappa B], we determined that NF-kappa B activation is instrumental in TNF alpha-induced CXCL10 expression in A172 astroglia. Morphine exposure during the 24 h TNF alpha stimulation period did not alter CXCL10 expression. However, fentanyl, a more potent mu-opioid receptor (MOR) agonist, inhibited TNF alpha-induced CXCL10 expression. Interestingly, neither the non-selective opioid receptor antagonist, naltrexone nor beta-funaltrexamine (beta-FNA), a highly selective MOR antagonist, blocked fentanyl mediated inhibition of TNF alpha-induced CXCL10 expression. Rather, beta-FNA dose-dependently inhibited TNF alpha-induced CXCL10 expression with a greater potency than that observed for fentanyl. Immunoblot analysis indicated that morphine, fentanyl and beta-FNA each reduced TNF alpha-induced nuclear translocation of NF-kappa B p65. These data show that beta-FNA and fentanyl inhibit TNF alpha-induced CXCL10 expression via a MOR-independent mechanism. Data also suggest that inhibition of TNF alpha-induced CXCL10 expression by fentanyl and beta-FNA is not directly related to a reduction in NF-kappa B p65 nuclear translocation. Further investigation is necessary in order to fully elucidate the mechanism through which these two opioid compounds inhibit CXCL10 expression. Understanding the mechanism by which chemokine expression is suppressed, particularly by the opioid antagonist, beta-FNA, may provide insights into the development of safe and effective treatments for neuroinflammation. (c) 200 Elsevier B.V. All rights reserved.	Oklahoma State Univ, Hlth Sci Ctr, Dept Pharmacol Physiol, Tulsa, OK 74107 USA	Davis, RL (reprint author), Oklahoma State Univ, Hlth Sci Ctr, Dept Pharmacol Physiol, 1111 W 17th St, Tulsa, OK 74107 USA.	randall.davis@okstate.edu			NIAAA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [AA 014955, R21 AA014955-01A2, R21 AA014955]; NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [R15 DA012448, DA 012448]		Bajetto A, 2002, J NEUROCHEM, V82, P1311, DOI 10.1046/j.1471-4159.2002.01091.x; BAUMHAKER Y, 1993, MOL PHARMACOL, V44, P461; Beech JS, 2001, J CEREBR BLOOD F MET, V21, P683, DOI 10.1097/00004647-200106000-00006; Belperio JA, 2000, J LEUKOCYTE BIOL, V68, P1; Borner C, 2004, MOL PHARMACOL, V66, P1719, DOI 10.1124/mol.104.003806; Brambilla R, 2005, J EXP MED, V202, P145, DOI 10.1084/jem.20041918; CARMICHAEL J, 1987, CANCER RES, V47, P936; Cinque P, 2005, J NEUROIMMUNOL, V168, P154, DOI 10.1016/j.jneuroim.2005.07.002; Davis RL, 2004, NEUROSCI LETT, V371, P128, DOI 10.1016/j.neulet.2004.08.051; Davis RL, 2004, ALCOHOL, V32, P195, DOI 10.1016/j.alcohol.2004.01.006; Davis RL, 2004, NEUROSCI LETT, V362, P220, DOI 10.1016/j.neulet.2004.03.015; Davis RL, 2002, ALCOHOL CLIN EXP RES, V26, P1404, DOI 10.1097/01.ALC.0000030841.92766.80; El-Hage N, 2006, GLIA, V53, P132, DOI 10.1002/glia.20262; El-Hage N, 2005, GLIA, V50, P91, DOI 10.1002/glia.20148; Flynn G, 2003, J NEUROIMMUNOL, V136, P84, DOI 10.1016/S0165-5728(03)00009-2; Glaser J, 2004, J NEUROSCI RES, V77, P701, DOI 10.1002/jnr.20204; Gonzalez R, 2003, EXP NEUROL, V184, P456, DOI 10.1016/S0014-4886(03)00257-7; Guthikonda P, 1998, J NEUROIMMUNOL, V82, P133, DOI 10.1016/S0165-5728(97)00172-0; Holtzman SG, 1997, PHARMACOL BIOCHEM BE, V57, P771, DOI 10.1016/S0091-3057(96)00395-4; Kadiu I, 2005, NEUROTOX RES, V8, P25, DOI 10.1007/BF03033818; Khurdayan VK, 2004, EUR J NEUROSCI, V19, P3171, DOI 10.1111/j.0953-816X.2004.03461.x; Kolb SA, 1999, J NEUROIMMUNOL, V93, P172, DOI 10.1016/S0165-5728(98)00223-9; Kraus J, 2003, MOL PHARMACOL, V64, P876, DOI 10.1124/mol.64.4.876; Kubota N, 2001, EUR J PHARMACOL, V417, P69, DOI 10.1016/S0014-2999(01)00906-2; Lee DH, 1996, J BIOL CHEM, V271, P27280, DOI 10.1074/jbc.271.44.27280; Lee J, 2004, IMMUNOPHARM IMMUNOT, V26, P17, DOI 10.1081/IPH-120029941; Liao SL, 2003, NEUROSCI LETT, V345, P169, DOI 10.1016/S0304-3940(03)00540-8; Liu B, 2000, J PHARMACOL EXP THER, V293, P607; Liu B, 2003, J PHARMACOL EXP THER, V304, P1, DOI 10.1124/jpet.102.035048; Liu YX, 2002, J PHARMACOL EXP THER, V302, P1212, DOI 10.1124/jpet.102.035956; LUSTER AD, 1985, NATURE, V315, P672, DOI 10.1038/315672a0; Lyss G, 1998, J BIOL CHEM, V273, P33508, DOI 10.1074/jbc.273.50.33508; Mahajan SD, 2005, CLIN IMMUNOL, V115, P323, DOI 10.1016/j.clim.2005.02.004; Mahajan SD, 2002, J IMMUNOL, V169, P3589, DOI 10.4049/jimmunol.169.7.3589; Myers RR, 2006, DRUG DISCOV TODAY, V11, P8, DOI 10.1016/S1359-6446(05)03637-8; Pahan K, 2001, J BIOL CHEM, V276, P7899, DOI 10.1074/jbc.M008262200; Peart JN, 2005, VASC PHARMACOL, V42, P211, DOI 10.1016/j.vph.2005.02.003; Poluektova L, 2005, GLIA, V52, P344, DOI 10.1002/glia.20253; Rambhia S, 2005, MED SCI MONITOR, V11, pBR386; Ruzicka BB, 1995, MOL BRAIN RES, V34, P209, DOI 10.1016/0169-328X(95)00165-O; Sanchez AC, 2003, J NEUROCHEM, V86, P1379, DOI 10.1046/j.1471-4159.2003.01943.x; SAYRE LM, 1984, J MED CHEM, V27, P1325, DOI 10.1021/jm00376a018; Sorensen TL, 2004, CURR NEUROVASC RES, V1, P183, DOI 10.2174/1567202043480143; Stefano GB, 1996, CRIT REV IMMUNOL, V16, P109, DOI 10.1615/CritRevImmunol.v16.i2.10; Stiene-Martin A, 1998, GLIA, V22, P249, DOI 10.1002/(SICI)1098-1136(199803)22:3<249::AID-GLIA4>3.0.CO;2-0; TAUB DD, 1993, J EXP MED, V177, P1809, DOI 10.1084/jem.177.6.1809; Toborek M, 2005, CELL MOL NEUROBIOL, V25, P181, DOI 10.1007/s10571-004-1383-x; Vlodavsky E, 2006, NEUROPATH APPL NEURO, V32, P40, DOI 10.1111/j.1365-2990.2005.00698.x; Wang XK, 2000, MOL PHARMACOL, V57, P1190; Wang XK, 2004, MOL PHARMACOL, V65, P890, DOI 10.1124/mol.65.4.890; Wang XK, 1998, J NEUROCHEM, V71, P1194; Xia MQ, 2000, J NEUROIMMUNOL, V108, P227, DOI 10.1016/S0165-5728(00)00285-X; Yang YT, 2005, J NEUROCHEM, V93, P513, DOI 10.1111/j.1471-4159.2005.03032.x; Zaheer A, 1995, NEUROCHEM RES, V20, P1457, DOI 10.1007/BF00970594	54	21	21	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-5728			J NEUROIMMUNOL	J. Neuroimmunol.	MAY	2007	186	1-2					141	149		10.1016/j.jneuroim.2007.03.021			9	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	181RB	WOS:000247452700015	17475341	Green Accepted			2020-06-30	J	Baad-Hansen, L; Juhl, GI; Jensen, TS; Brandsborg, B; Svensson, P				Baad-Hansen, Lene; Juhl, Gitte Irene; Jensen, Troels Staehefin; Brandsborg, Birgitte; Svensson, Peter			Differential effect of intravenous S-ketamine and fentanyl on atypical odontalgia and capsaicin-evoked pain	PAIN			English	Article						atypical odontalgia; opioids; NMDA-receptor antagonist; orofacial pain; pain mechanisms; trigeminal pain; quantitative sensory testing	RECEPTOR ANTAGONIST KETAMINE; NEUROPATHIC PAIN; DOUBLE-BLIND; INTRADERMAL CAPSAICIN; HYPERALGESIA; ALFENTANIL; MORPHINE; ALLODYNIA; LIDOCAINE; PLACEBO	Atypical odontalgia (AO) is an intraoral pain condition of currently unknown mechanisms. In 10 AO patients and 10 matched healthy controls, we examined the effect of intravenous infusion of an N-methyl-D-aspartate (NMDA) receptor antagonist S-ketamine and a mu-opioid agonist fentanyl on spontaneous AO pain and on an acute intraoral nociceptive input evoked by topical application of capsaicin. The drugs were administered in a randomized, placebo-controlled, cross-over manner. Furthermore, measures of intraoral sensitivity to mechanical and thermal quantitative sensory testing (QST) including temporal summation were compared between groups and sides. Both drugs failed to produce an analgesic effect on spontaneous AO pain, but fentanyl effectively reduced capsaicin-evoked pain. AO patients showed increased sensitivity to capsaicin and heat pain, but no significant differences in cold and mechanical sensitivity compared with healthy controls. No side-to-side differences in QST measures were found in AO patients. The present study demonstrates that AO is unlikely to be primarily due to a persistent afferent barrage from the peripheral region. Furthermore, in contrast to studies on various neuropathic pain conditions, fentanyl and S-ketamine in the present doses failed to attenuate AO pain. (c) 2006 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.	Univ Aarhus, Sch Dent, Dept Clin Oral Physiol, DK-8000 Aarhus C, Denmark; Aarhus Univ Hosp, Danish Pain Res Ctr, DK-8000 Aarhus C, Denmark; Aarhus Univ Hosp, Dept Maxillofacial Surg, DK-8000 Aarhus C, Denmark; Aalborg Univ, Ctr Sensory Motor Interact, DK-9220 Aalborg, Denmark	Baad-Hansen, L (reprint author), Univ Aarhus, Sch Dent, Dept Clin Oral Physiol, Vennelyst Blvd 9, DK-8000 Aarhus C, Denmark.	lbhansen@odont.au.dk	Jensen, Troels Staehelin/A-3418-2009; Svensson, Peter/H-6735-2012; Baad-Hansen, Lene/AAE-3252-2020	Jensen, Troels Staehelin/0000-0002-3487-6380; Baad-Hansen, Lene/0000-0002-2399-7910			Andersen OK, 1996, PAIN, V66, P51, DOI 10.1016/0304-3959(96)02995-8; ARENDTNIELSEN L, 1995, ANESTH ANALG, V81, P63, DOI 10.1097/00000539-199507000-00013; Baad-Hansen L, 2003, J OROFAC PAIN, V17, P333; Baad-Hansen L, 2006, J OROFAC PAIN, V20, P107; Baad-Hansen L, 2005, PAIN, V116, P359, DOI 10.1016/j.pain.2005.05.006; Baad-Hansen L, 2005, J OROFAC PAIN, V19, P239; Baad-Hansen L, 2006, EXP BRAIN RES, V172, P498, DOI 10.1007/s00221-006-0358-1; BACKONJA M, 1994, PAIN, V56, P51, DOI 10.1016/0304-3959(94)90149-X; Benedetti F, 1998, PAIN, V74, P205, DOI 10.1016/S0304-3959(97)00172-3; Cairns BE, 2003, J NEUROPHYSIOL, V90, P2098, DOI 10.1152/jn.00353.2003; DREWES AM, 1993, CLIN J PAIN, V9, P80, DOI 10.1097/00002508-199306000-00002; Dworkin Samuel F., 1992, Journal of Craniomandibular Disorders, V6, P301; EIDE PK, 1994, PAIN, V58, P347, DOI 10.1016/0304-3959(94)90129-5; Gottrup H, 2006, ANESTHESIOLOGY, V104, P527, DOI 10.1097/00000542-200603000-00021; Gottrup H, 2000, BRIT J ANAESTH, V84, P155; GREEN BG, 1989, NEUROSCI LETT, V107, P173, DOI 10.1016/0304-3940(89)90812-4; Jaaskelainen SK, 2005, PAIN, V117, P349, DOI 10.1016/j.pain.2005.06.028; Jensen TS, 2001, EUR J PHARMACOL, V429, P1, DOI 10.1016/S0014-2999(01)01302-4; Jorum E, 2003, PAIN, V101, P229, DOI 10.1016/S0304-3959(02)00122-7; KEEFE FJ, 1987, PAIN, V28, P309, DOI 10.1016/0304-3959(87)90066-2; KILO S, 1994, BRAIN, V117, P385, DOI 10.1093/brain/117.2.385; Lang E, 2005, PAIN, V118, P80, DOI 10.1016/j.pain.2005.07.014; Leung A, 2001, PAIN, V91, P177, DOI 10.1016/S0304-3959(00)00433-4; List T, 2006, PAIN, V122, P306, DOI 10.1016/j.pain.2006.02.005; Marbach J J, 1993, N Y State Dent J, V59, P28; MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5; Nikolajsen L, 1996, PAIN, V67, P69, DOI 10.1016/0304-3959(96)03080-1; PARK KM, 1995, PAIN, V63, P163, DOI 10.1016/0304-3959(95)00029-R; PRICE DD, 1986, PAIN, V24, P197, DOI 10.1016/0304-3959(86)90042-4; ROWBOTHAM MC, 1991, NEUROLOGY, V41, P1024, DOI 10.1212/WNL.41.7.1024; Schulte H, 2003, ACTA ANAESTH SCAND, V47, P1020, DOI 10.1034/j.1399-6576.2003.00204.x; Staud R, 2005, J PAIN, V6, P323, DOI 10.1016/j.jpain.2005.01.357; Suzuki R, 2005, PAIN, V117, P292, DOI 10.1016/j.pain.2005.06.015; Turp JC, 2001, SCHMERZ, V15, P59, DOI 10.1007/s004820170049; Wallace MS, 2002, CLIN J PAIN, V18, P373, DOI 10.1097/00002508-200211000-00005; Wallace MS, 2002, J CLIN PHARMACOL, V42, P70, DOI 10.1177/0091270002042001008; Warncke T, 1997, PAIN, V72, P99, DOI 10.1016/S0304-3959(97)00006-7; Watson CPN, 1998, NEUROLOGY, V50, P1837; Woda A, 2005, PAIN, V116, P396, DOI 10.1016/j.pain.2005.05.009; Woda A, 1999, J OROFAC PAIN, V13, P172	40	37	37	1	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0304-3959	1872-6623		PAIN	Pain	MAY	2007	129	1-2					46	54		10.1016/j.pain.2006.09.032			9	Anesthesiology; Clinical Neurology; Neurosciences	Anesthesiology; Neurosciences & Neurology	168HV	WOS:000246515300009	17088020				2020-06-30	J	El Mouedden, M; Meert, TF				El Mouedden, Mohammed; Meert, Theo Frans			The impact of the opioids fentanyl and morphine on nociception and bone destruction in a murine model of bone cancer pain	PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR			English	Article						fentanyl; morphine; bone cancer pain model; hyperalgesia; murine model; bone structure	26-L5 CARCINOMA-CELLS; TUMOR-GROWTH; BREAKTHROUGH PAIN; METASTASIS; APOPTOSIS; MICE; RECEPTOR; MANAGEMENT; STRESS; PATHOPHYSIOLOGY	Chronic pain resulting from metastasis into skeleton of certain neoplastic diseases remains poorly understood and relatively resistant to analgesic treatment. Opioids are the principal axis in drug therapy for this type of pain, especially at the end stage of cancer. Our aim was to examine whether, fentanyl as well as morphine, two potent analgesic opioids commonly used to treat cancer pain, would inhibit pain and bone lesion-related responses in a murine model of bone cancer pain. Repeated administration of equianalgesic doses of fentanyl (0.16 mg/kg s.c. once a day) and morphine (20 mg/kg s.c. once a day) initiated at day 1 (prophylactic treatment) or at day 7 (curative treatment) after tumor cell inoculation in the femoral cavity consistently decreased bone pain symptoms and tumor growth-induced bone destruction (micro-CT bone structure parameters). Both fentanyl and morphine treatments resulted in clear antinociceptive properties as well as reductions in cancer cell-induced bone lesions. The present results demonstrate that fentanyl, and to some lesser degree morphine, has potential benefits in the treatment and development of bone cancer pain. As such, chronic administration of high doses of certain opioids like fentanyl may have clinical utility in the management of bone cancer pain. (c) 2007 Published by Elsevier Inc.	Johnson & Johnson Pharmaceut Res & Dev, Dept Pain & Neurol, Div Janssen Pharmaceut NV, B-2340 Beerse, Belgium	Meert, TF (reprint author), Johnson & Johnson Pharmaceut Res & Dev, Dept Pain & Neurol, Div Janssen Pharmaceut NV, Turnhoutseweg 30, B-2340 Beerse, Belgium.	TMEERT@prdbe.jnj.com					Adriaensen H, 2003, Acta Anaesthesiol Belg, V54, P37; Coleman RE, 2002, AM J CLIN ONCOL-CANC, V25, pS25, DOI 10.1097/00000421-200212001-00005; Coleman Robert E., 1998, Current Opinion in Oncology, V10, pS7; El Mouedden M, 2005, PHARMACOL BIOCHEM BE, V82, P109, DOI 10.1016/j.pbb.2005.07.016; GAVERIAUX C, 1995, FEBS LETT, V369, P272, DOI 10.1016/0014-5793(95)00766-3; GIRALDI T, 1989, EUR J CANCER CLIN ON, V25, P1583, DOI 10.1016/0277-5379(89)90301-5; Gupta K, 2002, CANCER RES, V62, P4491; Harimaya Y, 2002, CANCER LETT, V187, P121, DOI 10.1016/S0304-3835(02)00360-9; Hatzoglou A, 1996, EUR J PHARMACOL, V296, P199, DOI 10.1016/0014-2999(95)00703-2; Hildebrand T, 1997, COMPUTER METH BIOMEC, V1, P15, DOI DOI 10.1080/01495739708936692; Hu SX, 2002, NEUROPHARMACOLOGY, V42, P829, DOI 10.1016/S0028-3908(02)00030-8; ISHIKAWA M, 1993, BIOL PHARM BULL, V16, P762; Kanno J, 1997, MECH AGEING DEV, V93, P107, DOI 10.1016/S0047-6374(96)01827-1; Kawase M, 2002, ANTICANCER RES, V22, P211; Kugawa F, 2000, BIOL PHARM BULL, V23, P930; Kugawa F, 1998, EUR J PHARMACOL, V347, P105, DOI 10.1016/S0014-2999(98)00080-6; Levy MH, 1996, NEW ENGL J MED, V335, P1124, DOI 10.1056/NEJM199610103351507; LEWIS J W, 1983, Natural Immunity and Cell Growth Regulation, V3, P43; MANECKJEE R, 1992, P NATL ACAD SCI USA, V89, P1169, DOI 10.1073/pnas.89.4.1169; Mao JR, 2002, J NEUROSCI, V22, P7650; Meert TF, 2005, PHARMACOL BIOCHEM BE, V80, P309, DOI 10.1016/j.pbb.2004.12.002; Meert TF, 1996, PHARM WORLD SCI, V18, P1, DOI 10.1007/BF00449683; Mercadante S, 1997, PAIN, V69, P1, DOI 10.1016/S0304-3959(96)03267-8; Mercadante S, 1998, CANCER TREAT REV, V24, P425, DOI 10.1016/S0305-7372(98)90005-6; Meuser T, 2001, PAIN, V93, P247, DOI 10.1016/S0304-3959(01)00324-4; Miguel R, 2000, Cancer Control, V7, P97; ODGAARD A, 1993, BONE, V14, P173, DOI 10.1016/8756-3282(93)90245-6; PAGE GG, 1993, PAIN, V54, P21, DOI 10.1016/0304-3959(93)90095-7; Page GG, 1998, BRIT J ANAESTH, V81, P216; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; Payne R, 1997, CANCER, V80, P1608, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1608::AID-CNCR11>3.0.CO;2-3; PEI G, 1995, MOL PHARMACOL, V48, P173; Portenoy RK, 1999, PAIN, V79, P303, DOI 10.1016/S0304-3959(98)00179-1; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Radbruch L, 1996, J CLIN ANESTH, V8, P144, DOI 10.1016/0952-8180(95)00201-4; Radbruch L, 2001, PALLIATIVE MED, V15, P309, DOI 10.1191/026921601678320296; Sasamura T, 2002, EUR J PHARMACOL, V441, P185, DOI 10.1016/S0014-2999(02)01450-4; Standifer KM, 1997, CELL SIGNAL, V9, P237, DOI 10.1016/S0898-6568(96)00174-X; Tegeder I, 2003, CANCER RES, V63, P1846; TONG D, 1982, CANCER, V50, P893, DOI 10.1002/1097-0142(19820901)50:5<893::AID-CNCR2820500515>3.0.CO;2-Y; Vermeirsch H, 2004, PHARMACOL BIOCHEM BE, V79, P243, DOI 10.1016/j.pbb.2004.07.011; Whistler JL, 1998, P NATL ACAD SCI USA, V95, P9914, DOI 10.1073/pnas.95.17.9914; Wu WJ, 2000, LIFE SCI, V66, P1827, DOI 10.1016/S0024-3205(00)00506-3; Zhang H. W., 2001, PAIN RES, V16, P43; ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4	45	20	20	0	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0091-3057			PHARMACOL BIOCHEM BE	Pharmacol. Biochem. Behav.	MAY	2007	87	1					30	40		10.1016/j.pbb.2007.03.017			11	Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy	Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy	185WE	WOS:000247740300004	17521715				2020-06-30	J	Herndon, CM				Herndon, Chris M.			Iontophoretic drug delivery system: Focus on fentanyl	PHARMACOTHERAPY			English	Review						fentanyl; iontophoresis; iontophoretic transdermal system; ITS; lonsys; acute postoperative pain; drug delivery; patient-controlled analgesia	CONTROLLED TRANSDERMAL SYSTEM; POSTOPERATIVE PAIN MANAGEMENT; PLACEBO-CONTROLLED TRIAL; DAY-SURGERY; PHARMACOKINETICS; LIDOCAINE; ANESTHESIA; PCTS; DEMOGRAPHICS; ANALGESIA	Fentanyl iontophoretic transdermal system (ITS) is a novel, patient-activated drug delivery device used for the management of acute postoperative pain in the hospital setting. This credit-card-sized device uses an imperceptible current of 170 milliampere to actively deliver a fentanyl hydrochloride 40-mu g dose into the vasculature over a 10-minute interval. The unit is programmed to lock out further doses after either 80 doses or 24 hours, whichever is reached first. When comparing fentanyl ITS with intravenously administered fentanyl, serum concentrations differ significantly at 10 minutes after the initial dose is administered: 0.1 ng/ml for fentanyl ITS versus 0.7 ng/ml for intravenous fentanyl. Fentanyl ITS absorption increases in a time-dependent fashion over the first 10 hours of dosing. Other pharmacokinetic parameters of fentanyl ITS are comparable to those of intravenous fentanyl after 24 hours (maximum concentration 1.37 and 1.82 mu g/ml, time to maximum concentration 0.65 and 0.58 hr, and area under the concentration-time curve at 23-24 hrs 1.23 and.1.34 pg center dot hr/ml for fentanyl ITS and intravenous fentanyl, respectively,). This new technology exhibited superior analgesia compared with placebo in two placebo-controlled studies that used time to exit as a primary end point. In addition, fentanyl ITS proved equivalent to patient-controlled analgesia with intravenous morphine. Although adverse effects were congruent with those expected from pure-agonist opioids, subjects assigned to the ITS group did experience a higher rate of mild, clinically nonsignificant erythema at the system placement site. judicious monitoring for opioid-induced respiratory depression is recommended for fentanyl ITS, although this adverse effect has not been observed in clinical trials. Fentanyl ITS may provide another useful alternative in the management of acute postoperative pain.	So Illinois Univ, Sch Pharm, Dept Pharm Practice, Edwardsville, IL 62026 USA; St Louis Univ, Sch Med, Dept Community & Family Med, St Louis, MO 63103 USA	Herndon, CM (reprint author), So Illinois Univ, Sch Pharm, Dept Pharm Practice, Campus Box 2000, Edwardsville, IL 62026 USA.	cherndo@siue.edu					ASHBURN MA, 1995, ANESTHESIOLOGY, V82, P1146, DOI 10.1097/00000542-199505000-00009; Ashburn MA, 2004, ANESTHESIOLOGY, V100, P1573; Beauregard L, 1998, CAN J ANAESTH, V45, P304, DOI 10.1007/BF03012019; Camu F, 1998, ANESTH ANALG, V87, P890, DOI 10.1097/00000539-199810000-00027; *CDCP, 2004, HLTH US; Chelly JE, 2004, ANESTH ANALG, V98, P427, DOI 10.1213/01.ANE.0000093314.13848.7E; Classen DC, 1997, JAMA-J AM MED ASSOC, V277, P301, DOI 10.1001/jama.277.4.301; Coley KC, 2002, J CLIN ANESTH, V14, P349, DOI 10.1016/S0952-8180(02)00371-9; Day RE, 2005, J BONE JOINT SURG BR, V87B, P1568, DOI 10.1302/0301-620X.87B11.16384; ECHOLS DF, 1975, ARCH OTOLARYNGOL, V101, P418; ERNST AA, 1995, AM J EMERG MED, V13, P17, DOI 10.1016/0735-6757(95)90233-3; Gokoglu F, 2005, AM J PHYS MED REHAB, V84, P92, DOI 10.1097/01.PHM.0000151942.49031.DD; Gupta SK, 2005, CLIN PHARMACOKINET, V44, P25, DOI 10.2165/00003088-200544001-00005; Gupta SK, 1999, J PHARM SCI, V88, P835, DOI 10.1021/js980258b; Herndon CM, 2005, PHARMACOTHERAPY, V25, P474; *ORTHOMCNEIL INC, 2006, IONS FENT IONT TRANS; Pasero Chris, 2006, J Perianesth Nurs, V21, P48, DOI 10.1016/j.jopan.2005.12.001; Perkins FM, 2000, ANESTHESIOLOGY, V93, P1123, DOI 10.1097/00000542-200010000-00038; Phahonthep Rosaya, 2004, Journal of the Medical Association of Thailand, V87, pS15; Pogatzki-Zahn EM, 2006, CURR OPIN ANESTHESIO, V19, P551, DOI 10.1097/01.aco.0000245283.45529.f9; Sastre MTM, 2006, EUR J PAIN, V10, P57, DOI 10.1016/j.ejpain.2005.01.009; Sathyan G, 2005, CLIN PHARMACOKINET, V44, P7, DOI 10.2165/00003088-200544001-00003; Strassels SA, 2005, AM J HEALTH-SYST PH, V62, P2019, DOI 10.2146/ajhp040490.p2; Strassels SA, 2005, AM J HEALTH-SYST PH, V62, P1904, DOI 10.2146/ajhp040490.p1; THYSMAN S, 1993, ANESTH ANALG, V77, P61; *US FDA, 2006, MAN US FAC DEV EXP D; Viscusi ER, 2006, ANESTH ANALG, V102, P188, DOI 10.1213/01.ane.0000183649.58483.77; Viscusi ER, 2004, JAMA-J AM MED ASSOC, V291, P1333, DOI 10.1001/jama.291.11.1333; Wallace MS, 2001, REGION ANESTH PAIN M, V26, P229, DOI 10.1053/rapm.2001.22633; Zempsky WT, 2004, CLIN THER, V26, P1110, DOI 10.1016/S0149-2918(04)90183-X	30	17	17	0	5	PHARMACOTHERAPY PUBLICATIONS INC	BOSTON	NEW ENGLAND MEDICAL CENTER, 806, 750 WASHINGTON ST, BOSTON, MA 02111 USA	0277-0008			PHARMACOTHERAPY	Pharmacotherapy	MAY	2007	27	5					745	754		10.1592/phco.27.5.745			10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	164ON	WOS:000246243500016	17461710				2020-06-30	J	Bruijnzeel, AW; Marcinkiewcz, C; Isaac, S; Booth, MM; Dennis, DM; Gold, MS				Bruijnzeel, Adrie W.; Marcinkiewcz, Catherine; Isaac, Shani; Booth, Matthew M.; Dennis, Donn M.; Gold, Mark S.			The effects of buprenorphine on fentanyl withdrawal in rats	PSYCHOPHARMACOLOGY			English	Article						fentanyl; buprenorphine; Mu-opioid receptor; dependence; withdrawal; reward; rats	INTRACRANIAL SELF-STIMULATION; BRAIN REWARD FUNCTION; BEHAVIORAL SENSITIZATION; TRANSDERMAL FENTANYL; OPIATE WITHDRAWAL; OPIOID WITHDRAWAL; CHRONIC PAIN; MEDICAL USE; MORPHINE; ABUSE	Rationale Fentanyl is a potent mu-opioid receptor agonist that is widely used for the treatment of severe chronic pain. Discontinuation of fentanyl administration has been shown to induce a negative emotional state. Objectives The aim of the present studies was to investigate the effects of the partial mu-opioid receptor agonist buprenorphine on the negative emotional state associated with precipitated and spontaneous fentanyl withdrawal in rats. Materials and methods Fentanyl and saline were chronically administered via osmotic minipumps. A discrete-trial intracranial self-stimulation procedure was used to provide a measure of brain reward function. Somatic signs were recorded from a checklist of opioid abstinence signs. Results Naloxone induced a deficit in brain reward function in rats chronically treated with fentanyl. Buprenorphine dose-dependently prevented the naloxone-induced deficit in brain reward function. Discontinuation of fentanyl administration was also associated with a deficit in brain reward function. After explantation of the minipumps, the administration of buprenorphine induced a potentiation of brain reward function in the fentanyl-withdrawing rats, but did not affect brain reward function of saline-treated control rats. Buprenorphine prevented the somatic withdrawal signs associated with spontaneous fentanyl withdrawal and attenuated the somatic signs associated with precipitated fentanyl withdrawal. Conclusions Buprenorphine prevents affective and somatic fentanyl withdrawal signs. Moreover, buprenorphine is rewarding in rats previously exposed to fentanyl, but not in opioid-naive rats. This pattern of results suggests that buprenorphine may be an effective treatment for the anhedonic-state associated with fentanyl withdrawal, but further study of buprenorphine's abuse potential is warranted.	Univ Florida, Coll Med, Dept Psychiat, McKnight Brain Inst, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Anesthesiol, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Pharmacol & Expt Therapeut, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Neurosci, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Community Hlth & Family Med, Gainesville, FL 32610 USA	Bruijnzeel, AW (reprint author), Univ Florida, Coll Med, Dept Psychiat, McKnight Brain Inst, 100 S Newell Dr, Gainesville, FL 32610 USA.	awbruijn@psychiatry.ufl.edu	Marcinkiewcz, Catherine/X-2339-2019	Marcinkiewcz, Catherine/0000-0001-7161-7815	NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [R03 DA020502-01]		ARNOLD JH, 1990, ANESTHESIOLOGY, V73, P1136, DOI 10.1097/00000542-199012000-00011; Barr AM, 2005, NEUROSCI BIOBEHAV R, V29, P675, DOI 10.1016/j.neubiorev.2005.03.012; Bedi N. S., 1998, Indian Journal of Physiology and Pharmacology, V42, P95; BODKIN JA, 1995, J CLIN PSYCHOPHARM, V15, P49, DOI 10.1097/00004714-199502000-00008; Bruijnzeel AW, 2006, BIOL PSYCHIAT, V59, P477, DOI 10.1016/j.biopsych.2005.07.020; Bruijnzeel AW, 2005, BRAIN RES REV, V49, P505, DOI 10.1016/j.brainresrev.2005.01.007; Bruijnzeel AW, 2004, NEUROPHARMACOLOGY, V47, P572, DOI 10.1016/j.neuropharm.2004.05.005; Carlezon WA, 1999, SYNAPSE, V31, P256, DOI 10.1002/(SICI)1098-2396(19990315)31:4<256::AID-SYN3>3.0.CO;2-E; Carlezon WA, 2003, METH MOLEC MED, V84, P243; Chabal C, 1997, CLIN J PAIN, V13, P150, DOI 10.1097/00002508-199706000-00009; Chen SA, 2006, NEUROPSYCHOPHARMACOL, V31, P2692, DOI 10.1038/sj.npp.1301008; Cowan DT, 2003, PAIN MED, V4, P340, DOI 10.1111/j.1526-4637.2003.03038.x; DAI S, 1989, PHARMACOL BIOCHEM BE, V32, P1009, DOI 10.1016/0091-3057(89)90074-9; DOLE VP, 1966, ARCH INTERN MED, V118, P304, DOI 10.1001/archinte.118.4.304; Dominguez KD, 2003, ANN PHARMACOTHER, V37, P473, DOI 10.1345/aph.1C324; Easterling KW, 2000, PSYCHOPHARMACOLOGY, V148, P263, DOI 10.1007/s002130050050; EDWARDS G, 1976, BRIT MED J, V1, P1058, DOI 10.1136/bmj.1.6017.1058; Franck L, 1995, Neonatal Netw, V14, P39; Franck L S, 1998, Am J Crit Care, V7, P364; FRANCK LS, 2004, [No title captured], V20, P344; FREDERICKSON RCA, 1975, J PHARMACOL EXP THER, V193, P44; GELLERT VF, 1978, J PHARMACOL EXP THER, V205, P536; Gilson AM, 2004, J PAIN SYMPTOM MANAG, V28, P176, DOI 10.1016/j.jpainsymman.2004.01.003; Gopal S, 2002, EUR J PHARM SCI, V15, P287, DOI 10.1016/S0928-0987(02)00009-X; Gowing L, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002025.pub4; HENDERSON GL, 1988, J FORENSIC SCI, V33, P569; Hyman SE, 2006, ANNU REV NEUROSCI, V29, P565, DOI 10.1146/annurev.neuro.29.051605.113009; Ide S, 2004, NEUROPSYCHOPHARMACOL, V29, P1656, DOI 10.1038/sj.npp.1300463; JEZIORSKI M, 1994, SYNAPSE, V16, P137, DOI 10.1002/syn.890160207; Joranson DE, 2000, JAMA-J AM MED ASSOC, V283, P1710, DOI 10.1001/jama.283.13.1710; KATON W, 1985, AM J PSYCHIAT, V142, P1156; Kayemba-Kay's S, 2003, ADDICTION, V98, P1599, DOI 10.1046/j.1360-0443.2003.00551.x; Kenny PJ, 2003, BEHAV NEUROSCI, V117, P1103, DOI 10.1037/0735-7044.117.5.1103; Koob GF, 1997, PHARMACOL BIOCHEM BE, V57, P513, DOI 10.1016/S0091-3057(96)00438-8; Koob GF, 1997, SCIENCE, V278, P52, DOI 10.1126/science.278.5335.52; KORNETSKY C, 1979, FED PROC, V38, P2473; Kreek MJ, 2002, NAT REV DRUG DISCOV, V1, P710, DOI 10.1038/nrd897; Kreek MJ, 2000, ANN NY ACAD SCI, V909, P186; Kronstrand R, 1997, FORENSIC SCI INT, V88, P185, DOI 10.1016/S0379-0738(97)00068-6; Kuhlman JJ, 2003, J ANAL TOXICOL, V27, P499, DOI 10.1093/jat/27.7.499; LEANDER JD, 1987, NEUROPHARMACOLOGY, V26, P1445, DOI 10.1016/0028-3908(87)90112-2; Levine AS, 2006, PHYSIOL BEHAV, V89, P92, DOI 10.1016/j.physbeh.2006.01.031; Lilleng PK, 2004, J FORENSIC SCI, V49, P1364; Lin D, 2002, NEUROSCIENCE, V114, P925, DOI 10.1016/S0306-4522(02)00366-4; Linneman PK, 2000, J BURN CARE REHABIL, V21, P519, DOI 10.1097/00004630-200021060-00008; Lintzeris N, 2003, DRUG ALCOHOL DEPEN, V70, P287, DOI 10.1016/S0376-8716(03)00015-2; Liu JA, 2004, PHARMACOL BIOCHEM BE, V79, P101, DOI 10.1016/j.pbb.2004.06.006; Lohmann AB, 2001, PEDIATR RES, V49, P50, DOI 10.1203/00006450-200101000-00013; Mague SD, 2003, J PHARMACOL EXP THER, V305, P323, DOI 10.1124/jpet.102.046433; Mattick RP, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002207.pub3; MELLO NK, 1980, SCIENCE, V207, P657, DOI 10.1126/science.7352279; MELLO NK, 1983, J PHARMACOL EXP THER, V225, P378; MILLAN MJ, 1988, BRAIN RES, V450, P247, DOI 10.1016/0006-8993(88)91564-8; Milligan K, 2001, J PAIN, V2, P197, DOI 10.1054/jpai.2001.25352; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; NGAI SH, 1976, ANESTHESIOLOGY, V44, P398, DOI 10.1097/00000542-197605000-00008; OBrien CP, 1997, SCIENCE, V278, P66, DOI 10.1126/science.278.5335.66; OHTANI M, 1994, DRUG METAB DISPOS, V22, P2; Parfitt T, 2006, LANCET, V368, P273, DOI 10.1016/S0140-6736(06)69056-9; PFEIFFER A, 1986, SCIENCE, V233, P774, DOI 10.1126/science.3016896; Saal D, 2003, NEURON, V37, P577, DOI 10.1016/S0896-6273(03)00021-7; SAN L, 1992, BRIT J ADDICT, V87, P55; SCHAEFER GJ, 1983, PHARMACOL BIOCHEM BE, V18, P571, DOI 10.1016/0091-3057(83)90283-6; Schieffer BM, 2005, J PAIN, V6, P620, DOI 10.1016/j.jpain.2005.04.004; SCHULTEIS G, 1994, J PHARMACOL EXP THER, V271, P1391; Shippenberg TS, 1996, EUR J PHARMACOL, V299, P33, DOI 10.1016/0014-2999(95)00852-7; SHOOK JE, 1990, AM REV RESPIR DIS, V142, P895, DOI 10.1164/ajrccm/142.4.895; Stinus L, 2005, NEUROPSYCHOPHARMACOL, V30, P90, DOI 10.1038/sj.npp.1300487; STOLERMAN IP, 1975, PSYCHOPHARMACOLOGIA, V45, P157, DOI 10.1007/BF00429054; Thornton SR, 1997, J PHARMACOL EXP THER, V281, P514; Todtenkopf MS, 2004, PSYCHOPHARMACOLOGY, V172, P463, DOI 10.1007/s00213-003-1680-y; Twite Mark D, 2004, Pediatr Crit Care Med, V5, P521, DOI 10.1097/01.PCC.0000144710.13710.2E; Tzschentke TM, 2004, PSYCHOPHARMACOLOGY, V172, P58, DOI 10.1007/s00213-003-1626-4; Van Ree JM, 1999, PHARMACOL REV, V51, P341; Vanderschuren LJMJ, 2000, PSYCHOPHARMACOLOGY, V151, P99, DOI 10.1007/s002130000493; WAUQUIER A, 1976, PSYCHOPHARMACOLOGIA, V46, P179, DOI 10.1007/BF00421389	76	14	14	1	6	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0033-3158	1432-2072		PSYCHOPHARMACOLOGY	Psychopharmacology	MAY	2007	191	4					931	941		10.1007/s00213-006-0670-2			11	Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	144VM	WOS:000244824400008	17211652				2020-06-30	J	Lattermann, R; Wykes, L; Eberhart, L; Carli, F; Meterissian, S; Schricker, T				Lattermann, Ralph; Wykes, Linda; Eberhart, Leopold; Carli, Franco; Meterissian, Sarkis; Schricker, Thomas			A randomized controlled trial of the anticatabolic effect of epidural analgesia and hypocaloric glucose	REGIONAL ANESTHESIA AND PAIN MEDICINE			English	Article						epidural analgesia; stable isotopes; protein metabolism; glucose	POSTOPERATIVE INSULIN-RESISTANCE; ABDOMINAL-SURGERY; METABOLISM; INFUSION; BLOCK	Background and Objectives: The goal of the present study was to investigate whether epidural analgesia exerts a protein-sparing effect after colorectal surgery in the presence of hypocaloric glucose supply initiated with surgical skin incision. Methods: We randomly allocated 10 patients to receive general anesthesia combined with epidural anesthesia with bupivacaine, followed by epidural analgesia using bupivacaine/fentanyl, and 10 patients to receive general anesthesia, followed by patient-controlled analgesia with intravenous morphine. All patients received a 48-hour infusion of glucose 10% from surgical skin incision until the second day after surgery. The glucose infusion rate provided 50% of the patient's resting energy expenditure. Kinetics of protein and glucose metabolism were assessed by a stable-isotope tracer technique (L-[1-C-13]Ieucine and [6,6-H-2(2)] glucose). Results: The rate of appearance of leucine increased in the intravenous-analgesia group (112 +/- 29 to 130 +/- 25 mu mol/kg/h) 2 days after surgery, and this increase was more pronounced than in the epidural analgesia group (preoperative 120 +/- 24, postoperative 123 +/- 22 mu mol/kg/h, P <.05). Leucine oxidation rate increased in the intravenous analgesia group from 17 +/- 8 to 23 +/- 8 mu mol/kg/h and in the epidural group from 17 +/- 6 to 19 +/- 7 mu mol/kg/h without the difference between the groups reaching statistical significance (P =.067). Nonoxidative leucine disposal remained unaltered in both groups. No differences in glucose metabolism were seen between the groups. Conclusions: Epidural analgesia inhibits the increase in whole-body protein breakdown in patients receiving perioperative hypocaloric glucose infusion initiated with surgical skin incision. However, oxidative protein loss, protein synthesis, and glucose metabolism are not affected by epidural analgesia.	McGill Univ, Royal Victoria Hosp, Dept Anesthesia, Montreal, PQ, Canada	Schricker, T (reprint author), McGill Univ, Royal Victoria Hosp, Dept Anesthesia, 687 Pine Ave,Room C5-20, Montreal, PQ, Canada.	thomas.schricker@mcgill.ca					Ang B, 2000, NUTRITION, V16, P221, DOI 10.1016/S0899-9007(99)00288-9; CARLI F, 1991, BRIT J ANAESTH, V67, P729, DOI 10.1093/bja/67.6.729; Carli F, 1997, ANESTHESIOLOGY, V86, P1033, DOI 10.1097/00000542-199705000-00005; Carli F, 1997, METABOLISM, V46, P796, DOI 10.1016/S0026-0495(97)90125-6; CROWE PJ, 1984, BRIT J SURG, V71, P635, DOI 10.1002/bjs.1800710828; Greisen J, 2001, ANESTHESIOLOGY, V95, P578, DOI 10.1097/00000542-200109000-00007; KEHLET H, 1998, NEURAL BLOCKADE CLIN, P129; Lattermann R, 2003, ANESTH ANALG, V96, P555, DOI 10.1097/00000539-200302000-00047; Lattermann R, 2001, ACTA ANAESTH SCAND, V45, P1140, DOI 10.1034/j.1399-6576.2001.450915.x; LJUNGQVIST O, 1994, J AM COLL SURGEONS, V178, P329; MATTHEWS DE, 1980, AM J PHYSIOL, V238, pE473; Schricker T, 2000, AM J PHYSIOL-ENDOC M, V279, pE646; Schricker T, 2005, BRIT J SURG, V92, P947, DOI 10.1002/bjs.5105; Schricker T, 2004, ANN SURG, V240, P916, DOI 10.1097/01.sla.0000143249.93856.66; Schricker T, 2002, ANESTHESIOLOGY, V97, P943, DOI 10.1097/00000542-200210000-00029; Schricker T, 1998, CLIN INTENSIVE CARE, V9, P118; UCHIDA I, 1988, BRIT J SURG, V75, P557, DOI 10.1002/bjs.1800750618; VEDRINNE C, 1989, ANESTH ANALG, V69, P354; WILMORE DW, 1991, NEW ENGL J MED, V325, P695, DOI 10.1056/NEJM199109053251005	19	7	7	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1098-7339			REGION ANESTH PAIN M	Region. Anesth. Pain Med.	MAY-JUN	2007	32	3					227	232		10.1016/j.rapm.2007.02.009			6	Anesthesiology	Anesthesiology	177CJ	WOS:000247130900009	17543818				2020-06-30	J	Ruggiero, A; Barone, G; Liotti, L; Chiaretti, A; Lazzareschi, I; Riccardi, R				Ruggiero, A.; Barone, G.; Liotti, L.; Chiaretti, A.; Lazzareschi, I.; Riccardi, R.			Safety and efficacy of fentanyl administered by patient controlled analgesia in children with cancer pain	SUPPORTIVE CARE IN CANCER			English	Article						pain; patient controlled analgesia; children; fentanyl	MUCOSITIS PAIN; ADOLESCENTS; MORPHINE	Background: Pain is the most common discomfort experienced by children with cancer and occurs in almost 89% of patients in an advanced stage of the disease. It is most often not adequately treated because of inexperience and unfounded fears of analgesic treatment. In adults, patient controlled analgesia (PCA) is widely administered, while in children with moderate to severe cancer pain its use is still under evaluation for safety and efficacy. Goals of work: To evaluate the efficacy and safety of fentanyl administered by PCA in children with cancer pain. Materials and methods: Eighteen children (range 6 to 15 years) with moderate to severe pain were enrolled and treated with fentanyl by PCA plus background infusion (BI) (BI of 1 mu g/kg/h with booster doses of 1 mu g/kg by intravenous route). To evaluate efficacy and safety of the analgesic treatment, different subjective and objective parameters were monitored at 4-h intervals. In addition, patients' satisfaction was assessed by a questionnaire at the end of the treatment. Main results: All children experienced a good degree of analgesia and did not require any other analgesic drug during the treatment. Both subjective and objective parameters improved after starting pain-relieving treatment and no major side effects occurred. The questionnaire administered to the children showed a high grade of satisfaction. Conclusions: PCA plus BI with fentanyl administered by intravenous route is a safe and efficacious method for analgesia in children with moderate to severe cancer pain. Our policy of fentanyl-treatment did not show any major side effects.	Univ Cattolica Sacro Cuore, A Gemelli Hosp, Dept Paediat Sci, Div Paediat Oncol, I-00168 Rome, Italy; Univ Cattolica Sacro Cuore, Pediat Intens Care Unit, I-00168 Rome, Italy	Ruggiero, A (reprint author), Univ Cattolica Sacro Cuore, A Gemelli Hosp, Dept Paediat Sci, Div Paediat Oncol, Largo A Gemelli 8, I-00168 Rome, Italy.	ruggiero@rm.unicatt.it	Ruggiero, Antonio/M-7849-2018	Ruggiero, Antonio/0000-0002-6052-3511; RICCARDI, RICCARDO/0000-0001-7515-6622			BERDE CB, 1991, J PEDIATR-US, V118, P460, DOI 10.1016/S0022-3476(05)82169-9; Bray RJ, 1996, PAEDIATR ANAESTH, V6, P121, DOI 10.1111/j.1460-9592.1996.tb00374.x; Coda BA, 1997, PAIN, V72, P333, DOI 10.1016/S0304-3959(97)00059-6; Dunbar PJ, 1995, J PAIN SYMPTOM MANAG, V10, P604, DOI 10.1016/0885-3924(95)00122-0; GAUKROGER PB, 1991, BURNS, V17, P396, DOI 10.1016/S0305-4179(05)80073-7; Lehmann KA, 2005, J PAIN SYMPTOM MANAG, V29, pS72, DOI 10.1016/j.jpainsymman.2005.01.005; MACKIE AM, 1991, PAIN, V46, P265, DOI 10.1016/0304-3959(91)90109-B; OWEN H, 1989, ANAESTHESIA, V44, P7, DOI 10.1111/j.1365-2044.1989.tb11087.x; OWEN H, 1987, BRIT J ANAESTH, V59, pP1328; Peters JWB, 1999, PAEDIATR ANAESTH, V9, P235, DOI 10.1046/j.1460-9592.1999.00358.x; Plummer JL, 1997, ANESTH ANALG, V84, P794, DOI 10.1097/00000539-199704000-00018; RODGERS BM, 1988, J PEDIATR SURG, V23, P259, DOI 10.1016/S0022-3468(88)80735-8; SHAPIRO BS, 1993, J PAIN SYMPTOM MANAG, V8, P22, DOI 10.1016/0885-3924(93)90116-D; Sidebotham D, 1997, J PAIN SYMPTOM MANAG, V14, P202, DOI 10.1016/S0885-3924(97)00182-6; Sirkia K, 1998, J PAIN SYMPTOM MANAG, V15, P220, DOI 10.1016/S0885-3924(98)00366-2; TOBIAS JD, 1991, CLIN PEDIATR, V31, P177; Trentadue N O, 1998, J Pediatr Nurs, V13, P15, DOI 10.1016/S0882-5963(98)80064-X; Tyler DC, 1996, PAEDIATR ANAESTH, V6, P33, DOI 10.1111/j.1460-9592.1996.tb00350.x; WALCO GA, 1994, NEW ENGL J MED, V331, P541, DOI 10.1056/NEJM199408253310812; Wong D L, 1988, Pediatr Nurs, V14, P9; Yeh CH, 1999, J ADV NURS, V30, P193, DOI 10.1046/j.1365-2648.1999.01064.x	21	30	30	0	1	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013 USA	0941-4355			SUPPORT CARE CANCER	Support. Care Cancer	MAY	2007	15	5					569	573		10.1007/s00520-006-0193-8			5	Oncology; Health Care Sciences & Services; Rehabilitation	Oncology; Health Care Sciences & Services; Rehabilitation	153RF	WOS:000245452000015	17146653				2020-06-30	J	Egger, CM; Glerum, L; Haag, KM; Rohrbach, BW				Egger, Christine M.; Glerum, Leigh; Haag, Katherine Michelle; Rohrbach, Barton W.			Efficacy and cost-effectiveness of transdermal fentanyl patches for the relief of post-operative pain in dogs after anterior cruciate ligament and pelvic limb repair	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article						analgesia; dog; economics; efficacy; orthopedic; transdermal fentanyl	ADMINISTERED FENTANYL; VENTILATORY DEPRESSION; SERUM CONCENTRATIONS; PLASMA; PHARMACOKINETICS; MORPHINE; OVARIOHYSTERECTOMY; PHARMACODYNAMICS; TEMPERATURE; DISPOSITION	Objectives To determine whether transdermal fentanyl patches provided cost-effective post-operative analgesia in dogs with pelvic limb injuries. Study design Prospective, randomized, blinded clinical trial. Animals Twenty-four dogs undergoing repair of ruptured cranial cruciate ligaments or pelvic limb fractures. Methods Dogs were randomly assigned to one of two groups: those receiving transdermal fentanyl patches (group F) and those receiving injectable morphine for control of post-operative pain (group M). Patients in both treatment groups were monitored for adequacy of analgesia and alterations in physiological variables. Plasma fentanyl concentrations were measured in Group F. Rescue morphine was given if a dog was deemed uncomfortable. The time of first rescue morphine, the total amount, and number of doses of morphine administered over 72 hours was quantified and compared for each group. Results There was no significant treatment effect on any of the parameters, except for serum cortisol concentration, which was significantly lower overall in group F (p = 0.01). Pain scores peaked at 6 hours post-extubation and were higher than baseline from 2 to 20 hours post-extubation. Cortisol concentrations were the highest at time 0 (extubation) and were significantly higher than baseline until 2 hours post-extubation. Pain scores correlated with fentanyl plasma concentrations (p = 0.0001 and p = 0.01, respectively), but the correlation was low (r = 0.26 and r = 0.16, respectively). No correlation was found between serum cortisol concentrations and pain scores in either group. Fentanyl cost and total cost for pain management were considerably higher for group F. Conclusions Fentanyl patches did not provide better analgesia or a reduced requirement for rescue opioid compared with intramuscular morphine. Clinical relevance When considering overall costs to the client for comparable analgesic intervention, fentanyl patches increased rather than decreased cost during the first 24 hours post-operatively.	Univ Tennessee, Coll Vet Med, Dept Comparat Med, Knoxville, TN 37996 USA; Univ Georgia, Dept Small Anim Med & Surg, Athens, GA 30602 USA	Egger, CM (reprint author), Univ Tennessee, Coll Vet Med, Dept Small Anim Med, POB 1071, Knoxville, TN 37996 USA.	cmegger@mail.ag.utk.edu					ARNDT JO, 1984, ANESTHESIOLOGY, V61, P355, DOI 10.1097/00000542-198410000-00001; Barnhart MD, 2000, AM J VET RES, V61, P24, DOI 10.2460/ajvr.2000.61.24; Broadbear JH, 2004, PSYCHOPHARMACOLOGY, V176, P398, DOI 10.1007/s00213-004-1891-x; CARTWRIGHT P, 1983, ANESTH ANALG, V62, P966; Conzemius MG, 1997, J AM VET MED ASSOC, V210, P1619; EGGER CM, 1998, VET SURG, V27, P156; Firth AM, 1999, J AM VET MED ASSOC, V214, P651; Frank LA, 1998, J AM VET MED ASSOC, V212, P1569; GOURLAY GK, 1989, PAIN, V37, P193, DOI 10.1016/0304-3959(89)90130-9; Hofmeister EH, 2004, J AM ANIM HOSP ASSOC, V40, P468, DOI 10.5326/0400468; HOLLEY FO, 1988, BRIT J ANAESTH, V60, P608, DOI 10.1093/bja/60.6.608; Holton LL, 1998, J SMALL ANIM PRACT, V39, P469, DOI 10.1111/j.1748-5827.1998.tb03681.x; HUG CC, 1979, ANESTHESIOLOGY, V50, P342, DOI 10.1097/00000542-197904000-00011; Kyles AE, 1998, RES VET SCI, V65, P245, DOI 10.1016/S0034-5288(98)90151-5; Kyles AE, 1996, AM J VET RES, V57, P715; Mastrocinque S, 2003, VET ANAESTH ANALG, V30, P220, DOI 10.1046/j.1467-2995.2003.00090.x; MICHIELS M, 1977, EUR J CLIN PHARMACOL, V12, P153, DOI 10.1007/BF00645137; MORTON DB, 1985, VET REC, V116, P431, DOI 10.1136/vr.116.16.431; Pettifer GR, 2004, VET ANAESTH ANALG, V31, P109, DOI 10.1111/j.1467-2987.2004.00158.x; Pettifer GR, 2003, AM J VET RES, V64, P1557, DOI 10.2460/ajvr.2003.64.1557; Riviere JE, 2001, ADV DRUG DELIVER REV, V50, P175, DOI 10.1016/S0169-409X(01)00157-0; Robinson TM, 1999, J AM ANIM HOSP ASSOC, V35, P95, DOI 10.5326/15473317-35-2-95; SANFORD J, 1986, Veterinary Record, V118, P334; Schultheiss P J, 1995, Contemp Top Lab Anim Sci, V34, P75; THURMON JC, 1996, LUMB JONES VET ANEST, P56	25	27	27	0	15	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	1467-2987			VET ANAESTH ANALG	Vet. Anaesth. Analg.	MAY	2007	34	3					200	208		10.1111/j.1467-2995.2006.00310.x			9	Veterinary Sciences	Veterinary Sciences	157UH	WOS:000245746000007	17444933				2020-06-30	J	Bagheri, H; Es-haghi, A; Khalilian, F; Rouini, MR				Bagheri, Habib; Es-haghi, Ali; Khalilian, Faezeh; Rouini, Mohammad-Reza			Determination of fentanyl in human plasma by head-space solid-phase microextraction and gas chromatography-mass spectrometry	JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS			English	Article						sol-gel technology; solid-phase microextraction; gas chromatography-mass spectrometry; fentanyl	PERFORMANCE LIQUID-CHROMATOGRAPHY; ULTRAVIOLET DETECTION; SELECTIVE DETECTION; SCREENING METHOD; URINE; METABOLITES; SUFENTANIL; ALFENTANIL; DEXTROMETHORPHAN; IMMUNOASSAY	A head-space solid-phase microextraction (HS-SPME) method coupled to GC-MS was developed to extract fentanyl from human plasma. The protein binding was reduced by acidification and, eventually, the sample was deproteinized with trichloroacetic acid. The parameters influencing adsorption (extraction time, temperature, pH and salt addition) and desorption (desorption time and temperature) of the analyte on the fibre were investigated and validated for method development. The developed method proved to be rapid, simple, easy and inexpensive and offers high sensitivity and reproducibility. Linear range was obtained from 0. 1 ng/ml to 2 mu g/ml. The limit of detection was 0.03 ng/ml while an inter-day precision of less than 5% (n = 15) could be achieved. The method has been applied for the determination of fentanyl in plasma samples after application of 50 mu g/h Duragesic fentanyl patch. (C) 2007 Elsevier B.V. All rights reserved.	Sharif Univ Technol, Dept Chem, Tehran, Iran; Univ Tehran Med Sci, Dept Pharmaceut, Fac Pharm, Biopharmaceut & Pharmacokinet Div, Tehran 141556451, Iran	Bagheri, H (reprint author), Sharif Univ Technol, Dept Chem, POB 11365-9516, Tehran, Iran.	bagheri@sharif.edu	Es-haghi, Ali/S-8663-2016	Es-haghi, Ali/0000-0001-6533-3656			Abdel-Rehim M, 2003, ANAL CHIM ACTA, V492, P253, DOI 10.1016/S0003-2670(03)00574-9; Afshar M, 2004, J CHROMATOGR B, V802, P317, DOI 10.1016/j.jchromb.2003.12.009; Bagheri H, 2005, J CHROMATOGR B, V818, P147, DOI 10.1016/j.jchromb.2004.12.031; Bagheri H, 2004, CHROMATOGRAPHIA, V59, P501, DOI 10.1365/s10337-004-0226-8; BERLARDI R, 1989, WATER POLLUTION RES, V24, P179; Bjorksten AR, 2002, J CHROMATOGR B, V775, P97, DOI 10.1016/S1570-0232(02)00178-2; BOWER S, 1982, J PHARM PHARMACOL, V34, P181, DOI 10.1111/j.2042-7158.1982.tb04217.x; Choi HS, 2001, J CHROMATOGR B, V765, P63, DOI 10.1016/S0378-4347(01)00405-4; Dotsikas Y, 2004, ANAL CHIM ACTA, V509, P103, DOI 10.1016/j.aca.2003.12.007; Dotsikas Y, 2002, ANAL CHIM ACTA, V459, P177, DOI 10.1016/S0003-2670(02)00133-2; Fryirsa B, 1997, J CHROMATOGR B, V688, P79, DOI 10.1016/S0378-4347(97)88058-9; Huynh NH, 2005, J PHARMACEUT BIOMED, V37, P1095, DOI 10.1016/j.jpba.2004.09.024; Koch DE, 2004, J PHARMACEUT BIOMED, V34, P577, DOI 10.1016/S0731-7085(03)00652-6; Koster EHM, 2000, J CHROMATOGR B, V739, P175, DOI 10.1016/S0378-4347(99)00344-8; KUMAR K, 1987, J CHROMATOGR-BIOMED, V419, P464, DOI 10.1016/0378-4347(87)80317-1; KWONG TC, 1985, CLIN CHIM ACTA, V151, P193, DOI 10.1016/0009-8981(85)90082-8; Lord HL, 1997, ANAL CHEM, V69, P3899, DOI 10.1021/ac970375b; MCCLAIN DA, 1980, CLIN PHARMACOL THER, V28, P106, DOI 10.1038/clpt.1980.138; MCDONALD J, 1987, RES COMMUN CHEM PATH, V57, P389; MIKKELSEN SR, 2004, [No title captured]; Mills GA, 2000, J CHROMATOGR A, V902, P267, DOI 10.1016/S0021-9673(00)00767-6; Palleschi L, 2003, J PHARMACEUT BIOMED, V32, P329, DOI 10.1016/S0731-7085(03)00110-9; Pawliszyn J., 1999, APPL SOLID PHASE MIC; Pawliszyn J., 1997, SOLID PHASE MICROEXT; Poerschmann J, 1997, ANAL CHEM, V69, P597, DOI 10.1021/ac9609788; Portier EJG, 1999, J CHROMATOGR B, V723, P313, DOI 10.1016/S0378-4347(98)00518-0; RUNAGYUTTIKARN W, 1990, J ANAL TOXICOL, V14, P160, DOI 10.1093/jat/14.3.160; SEYDEL JK, 1981, PHARMACOL THERAPEUT, V15, P131, DOI 10.1016/0163-7258(81)90040-1; Ulrich S, 1997, J CHROMATOGR B, V696, P217, DOI 10.1016/S0378-4347(97)00249-1; Ulrich S, 2000, J CHROMATOGR A, V902, P167, DOI 10.1016/S0021-9673(00)00934-1; Van Nimmen NFJ, 2004, J CHROMATOGR B, V804, P375, DOI 10.1016/j.jchromb.2004.01.044; Van Nimmen NFJ, 2004, J CHROMATOGR A, V1035, P249, DOI 10.1016/j.chroma.2004.02.074; Weng ND, 2002, J PHARMACEUT BIOMED, V28, P1115, DOI 10.1016/S0731-7085(02)00002-X; Yuansheng L., 1996, MICROCHEM J, V53, P130	34	36	37	1	24	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0731-7085	1873-264X		J PHARMACEUT BIOMED	J. Pharm. Biomed. Anal.	APR 11	2007	43	5					1763	1768		10.1016/j.jpba.2006.12.016			6	Chemistry, Analytical; Pharmacology & Pharmacy	Chemistry; Pharmacology & Pharmacy	161IO	WOS:000246008300024	17250988				2020-06-30	J	Ang, CK; Leung, DYC; Lo, S; French, JK; Juergens, CP				Ang, Choon Kiat; Leung, Dominic Y. C.; Lo, Sidney; French, John K.; Juergens, Craig P.			Effect of local anesthesia and intravenous sedation on pain perception and vasovagal reactions during femoral arterial sheath removal after percutaneous coronary intervention	INTERNATIONAL JOURNAL OF CARDIOLOGY			English	Article						percutaneous coronary intervention; sheath; pain; sedation; analgesia	PERIPHERAL VASCULAR COMPLICATIONS; RANDOMIZED-TRIAL; ANGIOPLASTY; DEVICE; HEMOSTASIS; CLOSURE; GENDER; ACCESS	Background: There is no consensus with respect to the use of analgesia during femoral arterial sheath removal after percutaneous coronary intervention (PCI). We performed a randomized controlled trial to assess the impact of intravenous sedation and local anesthesia during femoral sheath removal after PCI on patient comfort and the incidence of vasovagal reactions. Methods: All patients undergoing PCI whose femoral sheaths were to be removed with assisted manual compression were eligible. Patients were randomized to receive either intravenous sedation (Fentanyl and Midazolam) or local anesthesia (1% lignocaine) infiltrated around the sheath site or both or neither. The primary endpoint of the study was the patients reported worst pain according to a Visual Analogue scale (VAS) after sheath removal. The incidence and predictors of vasovagal reactions during sheath removal and occurrence of vascular complications was also determined. Results: A total of 611 patients were randomized into this study. The mean pain score was highest in the local anesthesia only arm as compared to the sedation only arm, the combined local and sedation arm and the neither sedation or local arm (p = 0.001). vasovagal reactions were experienced by 35 patients (5.1%) with the highest percentage in the local anesthesia only group (9.8%). Multivariate logistic regression analysis identified a higher pain score (OR 1.18, 95% CI 1.12-1.24, p = 0.001), use of glyceryl trinitrate during sheath removal (OR 9.05, 95% CI 5.06-16. 1, p < 0.001), a lower body mass index (OR 1.12, 95% CI 1.08-1.18, p = 0.009) and the left anterior descending artery as the treated vessel (OR 5.2, 95% CI 3.41-7.87, p < 0.001) as independent predictors of the occurrence of a vasovagal reaction. There was no significant difference in vascular complications between the 4 study groups. Conclusions: The routine use of fentanyl and midazolam prior to sheath removal leads to a reduction in pain perception and vasovagal incidence, whilst the routine use of local infiltration during sheath removal should be discouraged as it leads to more pain and a trend to more vasovagal reactions. (c) 2006 Elsevier Ireland Ltd. All rights reserved.	Liverpool Hosp, Dept Cardiol, Liverpool, NSW 1871, Australia; Sarawak Gen Hosp, Dept Cardiol, Kuching, Malaysia	Juergens, CP (reprint author), Liverpool Hosp, Dept Cardiol, Locked Bag 7103, Liverpool, NSW 1871, Australia.	C.Juergens@unsw.edu.au	Juergens, Craig/R-2919-2019	Leung, Dominic/0000-0002-5626-7236			Amin FR, 2000, INT J CARDIOL, V76, P235, DOI 10.1016/S0167-5273(00)00386-7; Applegate RJ, 2002, J AM COLL CARDIOL, V40, P78, DOI 10.1016/S0735-1097(02)01924-1; Barbiere C C, 1994, Crit Care Nurse, V14, P90; Boss B J, 1988, J Neurosci Nurs, V20, P245; Bowden S M, 1995, Am J Crit Care, V4, P368; Chowdhary S, 1999, CLIN SCI, V97, P5, DOI 10.1042/CS19980399; Fulton T R, 2000, Am J Crit Care, V9, P125; Jackson T, 2005, J PAIN, V6, P228, DOI 10.1016/j.jpain.2004.12.004; JOHNSON LW, 1994, CATHETER CARDIO DIAG, V31, P165, DOI 10.1002/ccd.1810310302; Juergens CP, 2004, CATHETER CARDIO INTE, V63, P166, DOI 10.1002/ccd.20161; Juergens CR, 2005, CATHETER CARDIO INTE, V66, P528, DOI 10.1002/ccd.20534; Juran N B, 1996, Am J Crit Care, V5, P442; Keogh E, 2002, PAIN, V97, P195, DOI 10.1016/S0304-3959(01)00427-4; Kiemeneij F, 1997, J AM COLL CARDIOL, V29, P1269, DOI 10.1016/S0735-1097(97)00064-8; KUSSMAUL WG, 1995, J AM COLL CARDIOL, V25, P1685, DOI 10.1016/0735-1097(95)00101-9; Logan HL, 2004, J PAIN, V5, P406, DOI 10.1016/j.jpain.2004.06.007; MAGER A, 1994, AM J CARDIOL, V74, P1085, DOI 10.1016/0002-9149(94)90456-1; MULLER DWM, 1992, AM J CARDIOL, V69, P63, DOI 10.1016/0002-9149(92)90677-Q; Peet G I, 1995, Can J Cardiovasc Nurs, V6, P13; SLAUGHTER PMP, 1995, CATHETER CARDIO DIAG, V34, P210, DOI 10.1002/ccd.1810340106; Wadas TM, 1998, HEART LUNG, V27, P31, DOI 10.1016/S0147-9563(98)90066-8; Wilentz JR, 1999, J INVASIVE CARDIOL, V11, P709	22	14	16	0	1	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0167-5273			INT J CARDIOL	Int. J. Cardiol.	APR 4	2007	116	3					321	326		10.1016/j.ijcard.2006.04.045			6	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	149ST	WOS:000245167600005	16904773				2020-06-30	J	Kirov, MY; Lenkin, AI; Kuzkov, VV; Suborov, EV; Slastilin, VY; Borodin, VV; Chernov, II; Shonbin, AN; Bjertnaes, LJ				Kirov, M. Y.; Lenkin, A. I.; Kuzkov, V. V.; Suborov, E. V.; Slastilin, V. Y.; Borodin, V. V.; Chernov, I. I.; Shonbin, A. N.; Bjertnaes, L. J.			Single transpulmonary thermodilution in off-pump coronary artery bypass grafting: haemodynamic changes and effects of different anaesthetic techniques	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						haemodynamics; transpulmonary thermodilution; pulse-contour analysis; isoflurane; midazolam; propofol; off-pump coronary artery bypass grafting	INTRATHORACIC BLOOD-VOLUME; CARDIAC-OUTPUT; INTENSIVE-CARE; BEATING-HEART; SURGERY; PRELOAD; ISOFLURANE; PRESSURE; SEVOFLURANE; PROTECTION	Background Off-pump coronary artery bypass grafting (OPCAB) can be associated with severe cardiovascular changes, thus requiring advanced haemodynamic monitoring. Our aim was to investigate the feasibility of transpulmonary single thermodilution (STD) combined with pulse-contour analysis, a newly introduced method for cardiovascular monitoring, for assessment of changes in haemodynamics during different anaesthetic techniques in OPCAB. Methods Thirty-six patients scheduled for elective OPCAB were randomized to receive anaesthesia either with midazolam, propofol or isoflurane, in addition to fentanyl and pipecuronium. After catheterization of the femoral artery, haemodynamic parameters were assessed using STD and pulse-contour analysis. The measurements were performed after induction of anaesthesia, during surgery and at 2, 4 and 6 h post-operatively. Results At the end of surgery, the global ejection fraction decreased by 29% and 19% in the midazolam and the propofol groups, respectively, (P < 0.05) but remained unchanged in the isoflurane group. Moreover, in the isoflurane group, the left ventricular contractility index was higher and the mean arterial pressure (MAP) and the systemic vascular resistance index (SVRI) decreased in comparison with pre-operative values. Post-operatively, the cardiac index (CI) and the cardiac function index (CFI) increased in all groups (P < 0.05). The peri-operative requirement for ephedrine and nitroglycerin increased in the propofol and the midazolam groups, respectively (P < 0.05). Conclusions During OPCAB, STD and pulse-contour analysis displayed changes in preload, myocardial function and afterload that gave valuable guidance for the conduct of anaesthesia, fluid management, and the administration of vasoactive agents. As assessed using STD, isoflurane within the present dose range appears to maintain myocardial performance and vascular tone better than midazolam or propofol.	No State Med Univ, Dept Anaesthesiol & Intens Care Med, Arkhangelsk 163000, Russia; Univ Tromso, Fac Med, Inst Clin Med, Dept Anaesthesiol, N-9001 Tromso, Norway; City Hosp, Dept Anaesthesiol & Intens Care, Arkhangelsk 163000, Russia; City Hosp, Dept Cardiac Surg, Arkhangelsk 163000, Russia	Kirov, MY (reprint author), No State Med Univ, Dept Anaesthesiol & Intens Care Med, Troitsky Ave 51, Arkhangelsk 163000, Russia.	kirm@arh.ru	Kuzkov, Vsevolod V./R-6331-2016; Kirov, Mikhail/R-2320-2016	Kirov, Mikhail/0000-0002-4375-3374; Kuzkov, Vsevolod/0000-0002-8191-1185			Al-Ruzzeh S, 2001, EUR J CARDIO-THORAC, V20, P1152, DOI 10.1016/S1010-7940(01)00978-2; Angelini GD, 2002, LANCET, V359, P1194, DOI 10.1016/S0140-6736(02)08216-8; Ascione R, 2000, ANN THORAC SURG, V69, P1198, DOI 10.1016/S0003-4975(00)01152-8; Ascione R, 1999, ANN THORAC SURG, V68, P2237, DOI 10.1016/S0003-4975(99)01123-6; Ascione R, 2001, J THORAC CARDIOV SUR, V121, P689, DOI 10.1067/mtc.2001.112823; Belhomme D, 1999, CIRCULATION, V100, P340; Berkenstadt H, 2005, BRIT J ANAESTH, V94, P721, DOI 10.1093/bja/aei116; Boldt J, 2002, CRIT CARE, V6, P52; Breukers RBGE, 2004, ACTA ANAESTH SCAND, V48, P658, DOI 10.1111/j.1399-6576.2004.00375.x; Cason BA, 1997, ANESTHESIOLOGY, V87, P1182, DOI 10.1097/00000542-199711000-00023; Chassot PG, 2004, BRIT J ANAESTH, V92, P400, DOI 10.1093/bja/aeh064; Cleveland JC, 2001, ANN THORAC SURG, V72, P1282, DOI 10.1016/S0003-4975(01)03006-5; Conzen PF, 2003, ANESTHESIOLOGY, V99, P826, DOI 10.1097/00000542-200310000-00013; De Hert SG, 2002, ANESTHESIOLOGY, V97, P42, DOI 10.1097/00000542-200207000-00007; Godje O, 1998, THORAC CARDIOV SURG, V46, P242, DOI 10.1055/s-2007-1010233; Godje O, 1999, ANN THORAC SURG, V68, P1532, DOI 10.1016/S0003-4975(99)00956-X; Kirov MY, 2005, INTENSIVE CARE MEDICINE: ANNUAL UPDATE 2005, P449; Lee MC, 2006, EUR J ANAESTH, V23, P841, DOI 10.1017/S0265021506000354; Neumann P, 2005, ACTA ANAESTH SCAND, V49, P1443, DOI 10.1111/j.1399-6576.2005.00868.x; NEUMANN P, 2005, INTENS CARE MED, V325, P216; Ngaage DL, 2004, MED SCI MONITOR, V10, pRA47; Ngaage DL, 2003, EUR J CARDIO-THORAC, V24, P557, DOI 10.1016/S1010-7940(03)00381-6; Ostergaard M, 2006, ACTA ANAESTH SCAND, V50, P1044, DOI 10.1111/j.1399-6576.2006.01080.x; Perner A, 2006, ACTA ANAESTH SCAND, V50, P1068, DOI 10.1111/j.1399-6576.2006.01120.x; Reuter DA, 2002, J CARDIOTHOR VASC AN, V16, P191, DOI 10.1053/jcan.2002.31064; Sakka SG, 2000, INTENS CARE MED, V26, P180, DOI 10.1007/s001340050043; Schmidt C, 1999, ANESTHESIOLOGY, V91, P58, DOI 10.1097/00000542-199907000-00012; van der Hoeven JG, 2000, NETH J MED, V57, P71, DOI 10.1016/S0300-2977(00)00061-9; VEGAS A, 2006, PERIOPERATIVE CARE C, P347; Wiesenack C, 2001, J CARDIOTHOR VASC AN, V15, P584, DOI 10.1053/jcan.2001.26536; Wouters PF, 2005, J CARDIOTHOR VASC AN, V19, P160, DOI 10.1053/j.jvca.2004.10.001	31	11	15	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	APR	2007	51	4					426	433		10.1111/j.1399-6576.2006.01247.x			8	Anesthesiology	Anesthesiology	145PR	WOS:000244877500007	17378780				2020-06-30	J	Kuczkowski, KM				Kuczkowski, K. M.			Anesthetic implications of botulinum toxin type A (Botox) injections for the treatment of 'the aging face' in the parturient	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Letter							EDGE		Univ Calif San Diego, Med Ctr, Dept Anesthesiol, San Diego, CA 92103 USA	Kuczkowski, KM (reprint author), Univ Calif San Diego, Med Ctr, Dept Anesthesiol, 200 W Arbor Dr, San Diego, CA 92103 USA.	kkuczkowski@ucsd.edu					Binder WJ, 2006, ARCH FACIAL PLAST S, V8, P426, DOI 10.1001/archfaci.8.6.426; Blickstein I, 2003, INT J FERTIL WOMEN M, V48, P17; Chapman JM, 2006, ANESTH ANALG, V103, P1335, DOI 10.1213/01.ane.0000242661.39489.ac; Flynn TC, 2006, SEMIN CUTAN MED SURG, V25, P115, DOI 10.1016/j.sder.2006.06.003; Kuczkowski KM, 2004, ANESTH ANALG, V99, P1873, DOI 10.1213/01.ANE.0000137806.09323.36; MONTEIRO ED, 2006, [No title captured], V5, P308; Naguib M, 2005, MILLERS ANESTHESIA, P481; Souayah N, 2006, NEUROLOGY, V67, P1855, DOI 10.1212/01.wnl.0000244417.34846.b6; Viby-Mogensen J, 2001, Curr Opin Anaesthesiol, V14, P655, DOI 10.1097/00001503-200112000-00010	9	4	5	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	APR	2007	51	4					515	U5		10.1111/j.1399-6576.2007.01279.x			2	Anesthesiology	Anesthesiology	145PR	WOS:000244877500023	17378795				2020-06-30	J	Weinstock, LB; Cohen, AM; Volotsky, GR				Weinstock, Leonard B.; Cohen, Albert M.; Volotsky, Gershon R.			How deep should "deep sedation" be ?	AMERICAN JOURNAL OF GASTROENTEROLOGY			English	Letter							PROPOFOL; COLONOSCOPY		Washington Univ, Sch Med, St Louis, MO 63130 USA	Weinstock, LB (reprint author), Washington Univ, Sch Med, St Louis, MO 63130 USA.						Heuss LT, 2003, GASTROINTEST ENDOSC, V57, P664, DOI 10.1067/mge.2003.191; Koshy G, 2000, AM J GASTROENTEROL, V95, P1476; Sipe BW, 2002, GASTROINTEST ENDOSC, V55, P815, DOI 10.1067/mge.2002.124636; VanNatta ME, 2006, AM J GASTROENTEROL, V101, P2209, DOI 10.1111/j.1572-0241.2006.00760.x	4	0	2	0	0	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0002-9270			AM J GASTROENTEROL	Am. J. Gastroenterol.	APR	2007	102	4					906	907		10.1111/j.1572-0241.2007.01090_3.x			2	Gastroenterology & Hepatology	Gastroenterology & Hepatology	150NS	WOS:000245224100032	17397415				2020-06-30	J	Fujiwara, Y; Ito, H; Asakura, Y; Sato, Y; Nishiwaki, K; Komatsu, T				Fujiwara, Yoshihiro; Ito, Hiroshi; Asakura, Yusuke; Sato, Yuko; Nishiwaki, Kimitoshi; Komatsu, Toru			Preoperative ultra short-term entropy predicts arterial blood pressure fluctuation during the induction of anesthesia	ANESTHESIA AND ANALGESIA			English	Article							HEART-RATE-VARIABILITY; CONTROLLED CLINICAL-TRIAL; INTRAVENOUS LIDOCAINE; HEMODYNAMIC-RESPONSES; AUTONOMIC NEUROPATHY; SPINAL-ANESTHESIA; DOUBLE-BLIND; HYPERTENSION; INTUBATION; LARYNGOSCOPY	BACKGROUND: In this study, we sought to determine whether the preoperative nonlinear index of heart rate variability, ultra short-term entropy (UsEn), could predict cardiovascular responses to the induction of general anesthesia. METHODS: UsEn was estimated by a linearized version of the nonlinear least squares method combined with the maximum entropy spectral analysis method (MemCalc method). Preoperative UsEn of 46 patients (ASA PS 1 or 2, aged 40 - 60 yr) without a history of hypertension was evaluated using the MemCalc method. Patients were assigned to two groups according to preoperative UsEn (Group LOW; UsEn < 45, Group HIGH; UsEn >= 45). Anesthesia was induced with propofol, fentanyl and vecuronium bromide and endotracheal intubation was performed. Hemodynamic fluctuations during the induction of anesthesia were recorded and compared between the two groups. RESULTS: It was found that arterial blood pressure fluctuations during the induction of anesthesia were significantly greater in patients with a low UsEn. CONCLUSION: UsEn could predict arterial blood pressure fluctuations during the induction of anesthesia.	Aichi Med Univ, Sch Med, Dept Anesthesiol, Nagakute, Aichi 4801195, Japan; Nagoya Univ, Grad Sch Med, Dept Anesthesiol, Nagoya, Aichi, Japan	Fujiwara, Y (reprint author), Aichi Med Univ, Sch Med, Dept Anesthesiol, 21 Karimata Yazako, Nagakute, Aichi 4801195, Japan.	yyoshiff@aichi-med-u.ac.jp	Komatsu, Toru/AAH-8504-2019				BURGOS LG, 1989, ANESTHESIOLOGY, V70, P591, DOI 10.1097/00000542-198904000-00006; Chamchad D, 2004, ANESTH ANALG, V99, P1818, DOI 10.1213/01.ANE.0000140953.40059.E6; CHRAEMMERJORGENSEN B, 1986, ANESTH ANALG, V65, P1037; Dishman RK, 2000, INT J PSYCHOPHYSIOL, V37, P121, DOI 10.1016/S0167-8760(00)00085-4; Hanss R, 2005, ANESTHESIOLOGY, V102, P1086, DOI 10.1097/00000542-200506000-00005; HELFMAN SM, 1991, ANESTH ANLG, V73, P502; Huikuri HV, 1996, AM J CARDIOL, V77, P1073, DOI 10.1016/S0002-9149(96)00135-X; INOUE K, 1988, BRIT J ANAESTH, V60, P10, DOI 10.1093/bja/60.1.10; Kanaya N, 2003, ANESTHESIOLOGY, V98, P34, DOI 10.1097/00000542-200301000-00009; KAUTTO UM, 1982, ACTA ANAESTH SCAND, V26, P599, DOI 10.1111/j.1399-6576.1982.tb01823.x; Kindler CH, 1996, J CLIN ANESTH, V8, P491, DOI 10.1016/0952-8180(96)00109-2; Knuttgen D, 2005, ANAESTHESIST, V54, P442, DOI 10.1007/s00101-005-0837-y; LATSON TW, 1994, ANESTHESIOLOGY, V80, P326, DOI 10.1097/00000542-199402000-00013; LISHNER M, 1987, J AUTONOM NERV SYST, V19, P119, DOI 10.1016/0165-1838(87)90005-1; LONGNECKER DE, 1987, ANESTHESIOLOGY, V9, P209; MILLER RD, 2005, MILLERS ANESTHESIA, P317; Neumann SA, 2005, PSYCHOSOM MED, V67, P168, DOI 10.1097/01.psy.0000155671.90861.c2; PINCUS SM, 1993, AM J PHYSIOL, V264, pR638; PINCUS SM, 1994, AM J PHYSIOL, V266, pH1463; PRYSROBERTS C, 1971, BRIT J ANAESTH, V43, P531, DOI 10.1093/bja/43.6.531; Sawada Y, 1997, MED BIOL ENG COMPUT, V35, P318, DOI 10.1007/BF02534083; SHANNON DC, 1987, AM J PHYSIOL, V253, P874; SINGH PP, 1992, CAN J ANAESTH, V39, P559, DOI 10.1007/BF03008318; Win NN, 2005, ANESTH ANALG, V101, P97, DOI 10.1213/01.ANE.0000156204.89879.5C	24	15	16	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	APR	2007	104	4					853	856		10.1213/01.ane.0000258756.41649.2d			4	Anesthesiology	Anesthesiology	152OS	WOS:000245371900021	17377094				2020-06-30	J	Bilir, A; Gulec, S; Erkan, A; Ozcelik, A				Bilir, A.; Gulec, S.; Erkan, A.; Ozcelik, A.			Epidural magnesium reduces postoperative analgesic requirement	BRITISH JOURNAL OF ANAESTHESIA			English	Article						analgesic techniques, extradural; pain, postoperative; pharmacology, fentanyl; pharmacology, magnesium sulphate	SPINAL-CORD; SULFATE; PAIN; KETAMINE; ANESTHESIA; INJURY	Background. Magnesium has antinociceptive effects in animal and human models of pain. Our hypothesis was that the addition of magnesium to postoperative epidural infusion of fentanyl may decrease the need for fentanyl. Methods. Fifty patients undergoing hip surgery were enrolled to receive either fentanyl (Group F) or fentanyl plus magnesium sulphate (Group FM) for 24 h for epidural analgesia. All patients were equipped with a patient-controlled epidural analgesia device and the initial settings of a demand bolus dose of fentanyl 25 mu g. In Group FM, patients received 50 mg magnesium sulphate epidurally as an initial bolus dose followed by a continuous infusion of 100 mg day(-1). Ventilatory frequency, heart rate, blood pressure, pain assessment using a visual analogue scale (VAS), sedation scores and fentanyl consumption were recorded in the postoperative period. Results. There was no significant difference between groups in the time to first analgesic requirement. Compared with Group F, patients in Group FM received smaller doses of epidural fentanyl (P<0.05). The cumulative fentanyl consumption in 24 h was 437 (SD110) mu g in Group F and 328 (121) mu g in Group FM (P<0.05). Patients in Group F showed a higher VAS score in the first hour of the postoperative period (P<0.05). The groups were similar with respect to haemodynamic and respiratory variables, sedation, pruritis, and nausea. Conclusion. Co-administration of magnesium for postoperative epidural analgesia results in a reduction in fentanyl consumption without any side-effects.	Osmangazi Univ, Fac Med, Dept Anaesthesiol & Reanimat, TR-26100 Eskisehir, Turkey; Osmangazi Univ, Fac Med, Dept Orthopaed & Traumatol, TR-26100 Eskisehir, Turkey	Bilir, A (reprint author), Osmangazi Univ, Fac Med, Dept Anaesthesiol & Reanimat, TR-26100 Eskisehir, Turkey.	aytbilir@yahoo.com					Begon S, 2002, ANESTHESIOLOGY, V96, P627, DOI 10.1097/00000542-200203000-00019; BENZON HT, 2002, TXB REGIONAL ANAESTH, P505; Bromage PR, 1965, ACTA ANEAESTHESIOL S, V75, P193; Buvanendran A, 2002, ANESTH ANALG, V95, P661, DOI 10.1097/00000539-200209000-00031; Chanimov M, 1997, ANAESTHESIA, V52, P223, DOI 10.1111/j.1365-2044.1997.034-az0057.x; Chi YY, 1998, ANAESTH ANALG, V86, P1245; Chia YY, 1998, ANESTH ANALG, V86, P1245, DOI 10.1097/00000539-199806000-00021; CODERRE TJ, 1993, PAIN, V52, P259, DOI 10.1016/0304-3959(93)90161-H; Fawcett WJ, 1999, BRIT J ANAESTH, V83, P302, DOI 10.1093/bja/83.2.302; Goodman EJ, 2006, INT J OBSTET ANESTH, V15, P63, DOI 10.1016/j.ijoa.2005.06.009; Ko SH, 2001, ANESTHESIOLOGY, V95, P640, DOI 10.1097/00000542-200109000-00016; Koinig H, 1998, ANESTH ANALG, V87, P206, DOI 10.1097/00000539-199807000-00042; Kroin JS, 2000, ANESTH ANALG, V90, P913, DOI 10.1213/00000539-200004000-00025; LANG E, 2002, TXB REGIONAL ANAESTH, P125; LEJUSTE MJ, 1985, S AFR MED J, V64, P715; Murphy K., 2004, STAT POWER ANAL SIMP; Ozalevli M, 2005, ACTA ANAESTH SCAND, V49, P1514, DOI 10.1111/j.1399-6576.2005.00793.x; POCKETT S, 1995, ANESTH ANALG, V80, P173, DOI 10.1097/00000539-199501000-00026; Saeki H, 2004, ANESTH ANALG, V99, P1805, DOI 10.1213/01.ANE.0000138039.04548.3D; SALOMAKI TE, 1991, ANESTHESIOLOGY, V75, P790, DOI 10.1097/00000542-199111000-00010; SIMPSON JI, 1994, ANESTHESIOLOGY, V81, P1493, DOI 10.1097/00000542-199412000-00025; Sirvinskas E., 2002, MEDICINE, V38, P147; Taura P, 2003, ANESTH ANALG, V96, P475, DOI 10.1097/00000539-200302000-00033; Tramer MR, 1996, ANESTHESIOLOGY, V84, P340, DOI 10.1097/00000542-199602000-00011; VARRASSI G, 2002, TXB REGIONAL ANAESTH, P35; WIDERSMITH O, 1998, ANESTH ANALG, V86, P95; WOLFF CJ, 1991, [No title captured], V44, P293; Yang CY, 1996, CAN J ANAESTH, V43, P379, DOI 10.1007/BF03011718	28	61	68	0	2	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0007-0912			BRIT J ANAESTH	Br. J. Anaesth.	APR	2007	98	4					519	523		10.1093/bja/aem029			5	Anesthesiology	Anesthesiology	158JX	WOS:000245788900017	17324976	Bronze			2020-06-30	J	Cummings, KC; Arnaut, K				Cummings, Kenneth C., III; Arnaut, Katherina			Case report: Fentanyl-associated intraoperative anaphylaxis with pulmonary edema	CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Article							ANESTHESIA; SENSITIVITY; ROCURONIUM	Purpose: To describe an atypical presentation of intraoperative anaphylaxis due to fentanyl. Clinical features: A 40-yr-old otherwise healthy woman was admitted for abdominal hysterectomy. She denied any drug allergies or past adverse anesthetic reactions. Physical examination, vital signs, and laboratory findings were all within normal limits. Twenty minutes after induction of general anesthesia with propofol, lidocaine, fentanyl, and rocuronium, she developed sudden onset of hypotension and bronchospasm. She was treated with fluids and epinephrine, but nonetheless required mechanical ventilation for 48 hr. Chest x-ray revealed pulmonary edema which resolved over two days. She recovered completely and was discharged home. Subsequent skin testing showed reactions to fentanyl and succinylcholine. Because the patient had not received succinylcholine, the cause of her anaphylaxis was attributed to fentanyl. The patient later returned for her hysterectomy and tolerated spinal anesthesia with bupivacaine and morphine. Conclusion: Anaphylaxis is a fulminant, unexpected, IgE-mediated allergic reaction which can be triggered by multiple agents. Common causative agents include neuromuscular blocking drugs, latex, antibiotics, colloids, hypnotics, and opioids. Fentanyl, however, is an extremely unusual cause of anaphylaxis. Pulmonary edema, although uncommon in anaphylaxis, can be a prominent feature, as was the case with this patient.	Cleveland Clin, Dept Reg Practice Anesthesiol, Cleveland, OH 44106 USA; Cleveland Clin, Dept Outcomes Res, Cleveland, OH 44106 USA	Cummings, KC (reprint author), Hillcrest Hosp, Dept Anesthesiol, 6780 Mayfield Rd, Mayfield Heights, OH 44124 USA.	cummink2@ccf.org					BENNETT MJ, 1986, CAN J ANAESTH, V33, P75, DOI 10.1007/BF03010913; Dhonneur G, 2004, ANESTH ANALG, V98, P986, DOI 10.1213/01.ANE.0000111206; Fisher MM, 1998, BRIT J ANAESTH, V80, P26; FUKUDA T, 1986, CAN J ANAESTH, V33, P826, DOI 10.1007/BF03027143; Gallerani M, 2002, AM J EMERG MED, V20, P371, DOI 10.1053/ajem.2002.33774; Hepner DL, 2003, ANESTH ANALG, V97, P1381, DOI 10.1213/01.ANE.0000082993.84883.7D; Kroigaard M, 2005, BRIT J ANAESTH, V95, P468, DOI 10.1093/bja/aei198; Laxenaire MC, 2001, BRIT J ANAESTH, V87, P549, DOI 10.1093/bja/87.4.549; Low I, 2006, PATHOLOGY, V38, P328, DOI 10.1080/00313020600820831; Matthey P, 2000, CAN J ANAESTH, V47, P890, DOI 10.1007/BF03019670; Mertes PM, 2005, J INVEST ALLERG CLIN, V15, P91; Mertes PM, 2003, ANESTHESIOLOGY, V99, P536, DOI 10.1097/00000542-200309000-00007; Nasser SMS, 2001, CLIN EXP ALLERGY, V31, P1014, DOI 10.1046/j.1365-2222.2001.01090.x; Porri F, 1999, CLIN EXP ALLERGY, V29, P72, DOI 10.1046/j.1365-2222.1999.00453.x; Roizen MF, 2005, ANESTHETIC IMPLICATI, P1092; ZUCKERPINCHOFF B, 1989, ANESTHESIOLOGY, V71, P599, DOI 10.1097/00000542-198910000-00020; ZUCKERPINCHOFF B, 1993, ANESTHESIOLOGY, V79, P1152	17	18	18	0	1	CANADIAN ANESTHESIOLOGISTS SOC	TORONTO	1 EGLINTON AVE EAST, SUITE 208, TORONTO, ONTARIO M4P 3A1, CANADA	0832-610X			CAN J ANAESTH	Can. J. Anaesth.-J. Can. Anesth.	APR	2007	54	4					301	306		10.1007/BF03022776			6	Anesthesiology	Anesthesiology	161ED	WOS:000245996300009	17400983	Bronze			2020-06-30	J	Park, HJ; Shinn, HK; Ryu, SH; Lee, HS; Park, CS; Kang, JH				Park, H-J; Shinn, H. K.; Ryu, S. H.; Lee, H-S; Park, C-S; Kang, J-H			Genetic Polymorphisms in the ABCB1 gene and the effects of fentanyl in Koreans	CLINICAL PHARMACOLOGY & THERAPEUTICS			English	Article							BLOOD-BRAIN-BARRIER; INTESTINAL P-GLYCOPROTEIN; MULTIDRUG-RESISTANCE GENE; BISPECTRAL INDEX; MDR1 GENE; SEQUENCE VARIATIONS; HAPLOTYPE PROFILES; IN-VIVO; MICE; PHARMACOKINETICS	P-glycoprotein (PGP) is a polymorphic transporter encoded by the ABCB1 gene that contributes to the access of xenobiotics into the brain. There is no report on associations between genetic polymorphisms in ABCB1 and the clinical effects of fentanyl, although fentanyl may be a substrate of PGP. One hundred and twenty-six ( 126) unrelated Korean patients under spinal anesthesia with intravenous fentanyl (2.5 mu g/kg) were recruited. Clinical effects (bispectral index, respiration rate, and need for oxygen supplementation) were monitored and these were compared between genotypes for three single nucleotide polymorphisms in ABCB1 (1236C > T, 2677G > T/A, and 3435C > T). The allele and genotype frequencies were similar to previous data from Asians; the three major haplotypes, TTT (30%), TGC (24%), and CGC ( 24%) were expected among nine known haplotypes. During the initial 10min, there were differences in suppression of respiration rate by fentanyl among the three genotypes (P = 0.0933 for 1236C > T; P = 0.0941 for 2677G4A/T; P = 0.0013 for 3435C > T, repeated-measures analysis of variance), but the differences in bispectral index among genotypes were not observed. Furthermore, patients carrying the linked 3435T and 2677T alleles showed a significant difference in the level of respiratory suppression (P = 0.0056); those with genotypes susceptible to fentanyl (1236TT, 2677TT, and 3435TT) showed early (2-3 min) and profound suppression of respiration (65-73% of initial respiration rate) compared with other resistant genotypes (83-85% of initial respiration rate in 1236CC, 2677GG, and 3435CC). Although the need to supply oxygen was not significantly different between genotypes, there was a trend for increased demand by patients carrying both 1236T and 3435T alleles (P = 0.0847). In conclusion, our results confirm ABCB1 genotype data for Koreans and suggest that analysis of ABCB1 polymorphisms may have clinical relevance to prevent respiratory suppression by intravenous fentanyl or to anticipate its clinical effects.	Inha Univ, Dept Pharmacol, Med Toxicol Res Ctr, Coll Med,Inha Res Inst Med Sci, Inchon, South Korea; Inha Univ Hosp, Dept Anesthesiol, Inchon, South Korea; Inha Univ, Coll Med, Ctr Adv Med Educ, Project BK21, Inchon, South Korea	Kang, JH (reprint author), Inha Univ, Dept Pharmacol, Med Toxicol Res Ctr, Coll Med,Inha Res Inst Med Sci, Inchon, South Korea.	johykang@inha.ac.kr					Bell JK, 2004, CLIN RADIOL, V59, P1106, DOI 10.1016/j.crad.2004.04.008; Cascorbi I, 2001, CLIN PHARMACOL THER, V69, P169, DOI 10.1067/mcp.2001.114164; CIRELLA VN, 1987, ANESTH ANALG, V66, P703; Coulbault L, 2006, CLIN PHARMACOL THER, V79, P316, DOI 10.1016/j.clpt.2006.01.007; Cutler L, 2006, J PHARM SCI-US, V95, P1944, DOI 10.1002/jps.20658; Dagenais C, 2004, BIOCHEM PHARMACOL, V67, P269, DOI 10.1016/j.bcp.2003.08.027; Eichelbaum M, 2004, THER DRUG MONIT, V26, P180, DOI 10.1097/00007691-200404000-00017; Glass PS, 1997, ANESTHESIOLOGY, V86, P836, DOI 10.1097/00000542-199704000-00014; GREENWALD S, 1994, ANESTHESIOLOGY, V81, pA477; Greiner B, 1999, J CLIN INVEST, V104, P147, DOI 10.1172/JCI6663; Henthorn TK, 1999, J PHARMACOL EXP THER, V289, P1084; Hoffmeyer S, 2000, P NATL ACAD SCI USA, V97, P3473, DOI 10.1073/pnas.050585397; Hsiao P, 2006, J PHARMACOL EXP THER, V317, P704, DOI 10.1124/jpet.105.097931; Kharasch ED, 2004, J CLIN PHARMACOL, V44, P224, DOI 10.1177/0091270003262075; Lee SS, 2005, THER DRUG MONIT, V27, P531, DOI 10.1097/01.ftd.0000164293.75854.11; Lown KS, 1997, CLIN PHARMACOL THER, V62, P248, DOI 10.1016/S0009-9236(97)90027-8; LUI J, 1996, [No title captured], V84, P64; Lysakowski C, 2001, BRIT J ANAESTH, V86, P523, DOI 10.1093/bja/86.4.523; Marzolini C, 2004, CLIN PHARMACOL THER, V75, P13, DOI 10.1016/j.clpt.2003.09.012; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; Mayer U, 1997, J CLIN INVEST, V100, P2430, DOI 10.1172/JCI119784; MCCLAIN DA, 1980, CLIN PHARMACOL THER, V28, P106, DOI 10.1038/clpt.1980.138; Pauli-Magnus C, 2003, CLIN PHARMACOL THER, V74, P487, DOI 10.1016/S0009-9236(03)00234-0; Sadeque AJM, 2000, CLIN PHARMACOL THER, V68, P231, DOI 10.1067/mcp.2000.109156; Saito K, 2003, CLIN BIOCHEM, V36, P511, DOI 10.1016/S0009-9120(03)00092-4; Sakaeda T, 2003, PHARMACOGENOMICS, V4, P397, DOI 10.1517/phgs.4.4.397.22747; Sandlin D, 2001, J Perianesth Nurs, V16, P420, DOI 10.1053/jpan.2001.28748; Schinkel AH, 1996, J CLIN INVEST, V97, P2517, DOI 10.1172/JCI118699; SCHINKEL AH, 1994, CELL, V77, P491, DOI 10.1016/0092-8674(94)90212-7; SCHINKEL AH, 1995, J CLIN INVEST, V96, P1698, DOI 10.1172/JCI118214; SCHLEIMER R, 1978, CLIN PHARMACOL THER, V23, P188; Takeuchi T, 2006, PHARM RES, V23, P1460, DOI 10.1007/s11095-006-0285-7; Tanabe M, 2001, J PHARMACOL EXP THER, V297, P1137; Tang K, 2002, PHARMACOGENETICS, V12, P437, DOI 10.1097/00008571-200208000-00004; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; Thompson SJ, 2000, ANESTHESIOLOGY, V92, P1392, DOI 10.1097/00000542-200005000-00030; vanAsperen J, 1996, J NATL CANCER I, V88, P994, DOI 10.1093/jnci/88.14.994; Yamazaki M, 2001, J PHARMACOL EXP THER, V296, P723; Yi SY, 2004, CLIN PHARMACOL THER, V76, P418, DOI 10.1016/j.clpt.2004.08.002	39	77	81	1	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	0009-9236			CLIN PHARMACOL THER	Clin. Pharmacol. Ther.	APR	2007	81	4					539	546		10.1038/sj.clpt.6100046			8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	153LJ	WOS:000245435900012	17192767				2020-06-30	J	Simpson, DM; Messina, J; Xie, F; Hale, M				Simpson, David M.; Messina, John; Xie, Fang; Hale, Martin			Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: A multicenter, randomized, double-blind, placebo-controlled study	CLINICAL THERAPEUTICS			English	Article						breakthrough pain; neuropathic pain; fentanyl buccal tablet; opioid tolerant; diabetic peripheral neuropathy; complex regional pain syndrome	CONTROLLED-RELEASE OXYCODONE; CONTROLLED-TRIAL; CANCER PAIN; DOSE PROPORTIONALITY; DIABETIC-NEUROPATHY; TREATED PATIENTS; OPEN-LABEL; MU-G; PREVALENCE; CITRATE	Background: Patients with chronic noncancer pain, including neuropathic pain, may have transitory exacerbations of pain (median duration, 60 minutes), termed breakthrough pain (BTP), that may reach peak intensity within minutes. Typical short-acting oral opioids may not provide sufficiently rapid relief (30- to 60-minute onset of analgesia). The fentanyl buccal tablet (FBT) provides a rapid onset of analgesia (10-15 minutes) by enhancing fentanyl absorption across the buccal mucosa. Objective: This study evaluated the efficacy and tolerability of FBT in oploid-tolerant patients with BTP associated with chronic noncancer neuropathic pain. Methods: This was a multicenter, randomized, doubleblind, placebo-controlled study in men and women aged 18 to 80 years who were oploid tolerant; had a 3-month history of chronic persistent neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, traumatic injury, or complex regional pain syndrome; and reported having episodes of BTP. After an open-label titration period to identify an effective FBT dose (the dose at which the patient reported receiving adequate pain relief within 30 minutes after administration of a single tablet of that dose during at least 2 of 3 BTP episodes), patients were randomly assigned to treat 9 consecutive episodes of BTP over the next 21 days with I of 3 double-blind dose sequences of FBT and placebo tablets. Pain intensity (PI) (rated on an 11-point pain scale, from 0 = no pain to 10 = worst pain) and other outcomes were assessed before dosing and for 2 hours after dosing. The primary efficacy measure was the sum of PI differences (PIDs) for the first 60 minutes (SPID60). Secondary efficacy measures included the proportion of BTP episodes with >= 33% and >= 50% improvement in PI from baseline; PID at other time points (5, 10, 15, 30, 45, 60, 90, and 120 minutes after dosing); pain relief (PR) at the same time points (rated on a 5-point Likert scale from 0 = none to 4 = complete); proportion of BTP episodes with meaningful PR; time to meaningful PR; and proportion of BTP episodes in which supplemental medication was required after administration of study drug. Adverse events (AEs) spontaneously reported by the patient or elicited by the investigator were recorded throughout the study. Results: Of 102 patients in the open-label titration period, 80 identified an effective dose of FBT and 79 entered the double-blind phase. Of these 79 patients, 77 (97%) completed the study and 75 (95%) were evaluable for efficacy. Of the 79 patients who entered the double-blind phase, 63% were women and 92% were white; their mean (SD) age was 48.3 (10.42) years, and their mean weight was 96.8 (33.42) kg. Baseline demographic and pain characteristics were similar between the overall population and the double-blind population. SPID60 was significantly greater for BTP episodes treated with FBT compared with those in which placebo was administered (mean [SE], 9.63 [0.75] vs 5.73 [0.72], respectively; P < 0.001). Significant differences between FBT and placebo were seen beginning at 10 minutes for PID (mean, 0.740 [0.149] vs 0.427 [0.081]; P < 0.047) and PR (mean, 0.561 [0.087] vs 0.324 [0.056]; P < 0.001). A >= 33% improvement in PI from baseline was seen in a greater proportion of BTP episodes treated with FBT compared with placebo from 10 minutes (9% vs 3%; P = 0.008) through 2 hours (66% vs 37%; P > 0.001). Patients were almost 4 times less likely to require supplemental opiolds when BTP episodes were treated with FBT compared with placebo (odds ratio = 0.28; 95% CI, 0.18-0.42). AEs were reported by 64 (63%) of 102 patients. The most commonly reported AEs were those typical of oploids (nausea [13%], dizziness [13%], somnolence [10%], and vomiting [5%]) and occurred more often during the dose-titration phase (55/102 [54%]) than during the double-blind phase (22/79 [28%]). Conclusion: In these oploid-tolerant patients with chronic neuropathic pain who identified an effective FBT dose, FBT had a rapid onset of action and was effective and well tolerated in the treatment of BTP.	CUNY Mt Sinai Sch Med, Clin Neurophysiol Labs, New York, NY 10029 USA; Cephalon Inc, Frazer, PA USA; Gold Coast Res LLC, Weston, FL USA	Simpson, DM (reprint author), CUNY Mt Sinai Sch Med, Clin Neurophysiol Labs, 1 Gustave Levy Pl,Box 1052, New York, NY 10029 USA.	david.simpson@mssm.edu	Hale, Martin/AAQ-6273-2020				*AM PAIN SOC, 2007, PRINC AN US TREATM A; Backonja MM, 2004, PAIN MED, V5, pS28, DOI 10.1111/j.1526-4637.2004.04020.x; Backonja MM, 2004, PAIN MED, V5, pS48, DOI 10.1111/j.1526-4637.2004.04021.x; Beniczky S, 2005, J NEURAL TRANSM, V112, P735, DOI 10.1007/s00702-005-0300-x; BENNETT D, 2005, [No title captured], V30, P354; Bennett GJ, 1998, HOSP PRACT, V33, P95, DOI 10.3810/hp.1998.10.114; Bennett GJ, 1997, PROG PAIN RES MANAG, V9, P109; Caraceni A, 2004, PALLIATIVE MED, V18, P177, DOI 10.1191/0269216304pm890oa; Cruccu G, 2004, EUR J NEUROL, V11, P153, DOI 10.1111/j.1468-1331.2004.00791.x; Darwish M, 2006, CLIN THER, V28, P707, DOI 10.1016/j.clinthera.2006.05.015; Darwish M, 2006, CLIN THER, V28, P715, DOI 10.1016/j.clinthera.2006.05.016; Darwish M, 2005, CLIN PHARMACOKINET, V44, P1279, DOI 10.2165/00003088-200544120-00006; DARWISH M, 2006, 25 ANN M AM PAIN SOC; Durfee S, 2006, AM J DRUG DELIV, V4, P1, DOI DOI 10.2165/00137696-200604010-00001; Dworkin RH, 2002, CLIN J PAIN, V18, P343, DOI 10.1097/00002508-200211000-00001; Eisenberg E, 2005, JAMA-J AM MED ASSOC, V293, P3043, DOI 10.1001/jama.293.24.3043; European Medicines Agency, GUID GOOD CLIN PRACT; Farrar JT, 1998, JNCI-J NATL CANCER I, V90, P611, DOI 10.1093/jnci/90.8.611; Fine PG, 1998, J PAIN SYMPTOM MANAG, V16, P179, DOI 10.1016/S0885-3924(98)00045-1; Foley KM, 2003, NEW ENGL J MED, V348, P1279, DOI 10.1056/NEJMe030014; Gimbel JS, 2003, NEUROLOGY, V60, P927, DOI 10.1212/01.WNL.0000057720.36503.2C; Hanks GW, 2004, PALLIATIVE MED, V18, P698, DOI 10.1191/0269216304pm966oa; Hwang SS, 2003, PAIN, V101, P55, DOI 10.1016/S0304-3959(02)00293-2; McCullagh P, 1989, GEN LINEAR MODELS; Mercadante S, 2002, CANCER, V94, P832, DOI 10.1002/cncr.10249; Merskey H, 1994, CLASSIFICATION CHRON, P209; MIASKOWSKI C, 2005, [No title captured], V3; MORLEYFORSTER P, 2006, [No title captured], V11, pA5; Payne R, 2001, J PAIN SYMPTOM MANAG, V22, P575, DOI 10.1016/S0885-3924(01)00306-2; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Portenoy RK, 2007, CURR MED RES OPIN, V23, P222, DOI 10.1185/030079906X162818; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Portenoy RK, 2006, J PAIN, V7, P583, DOI 10.1016/j.jpain.2006.02.003; Raja SN, 2005, NEW ENGL J MED, V352, P1373, DOI 10.1056/NEJMe058039; Rowbotham MC, 2003, NEW ENGL J MED, V348, P1223, DOI 10.1056/NEJMoa021420; Searle S. R, 1987, LINEAR MODELS UNBALA; Simon Steve, 2006, J Opioid Manag, V2, P347; Svendsen KB, 2005, EUR J PAIN, V9, P195, DOI 10.1016/j.ejpain.2004.06.001; Watson CPN, 2003, PAIN, V105, P71, DOI 10.1016/S0304-3959(03)00160-X; Zeppetella G, 2001, PALLIATIVE MED, V15, P243, DOI 10.1191/026921601678576220; Zeppetella G., 2006, COCHRANE DB SYST REV, V1, pCD004311	42	70	75	0	8	ELSEVIER	BRIDGEWATER	685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA	0149-2918	1879-114X		CLIN THER	Clin. Ther.	APR	2007	29	4					588	601		10.1016/j.clinthera.2007.04.007			14	Pharmacology & Pharmacy	Pharmacology & Pharmacy	170RQ	WOS:000246682100004	17617282				2020-06-30	J	Rawal, N; Langford, RM				Rawal, N.; Langford, R. M.			Current practices for postoperative pain management in Europe and the potential role of the fentanyl HCl iontophoretic transdermal system	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Review						PAIN, postoperative; ANAESTHETIC TECHNIQUES, patient-controlled analgesia; iontophoresis; ANALGESIC, fentanyl; HEALTH SERVICE, acute pain service	PATIENT-CONTROLLED ANALGESIA; EPIDURAL ANALGESIA; EFFICACY; SURGERY; SERVICES; ANESTHESIA; IMPROVE; PROVISION; SAFETY; METAANALYSES	Survey results continue to reveal that postoperative pain is insufficiently managed throughout Europe and the rest of the world. However, the efficient use of existing resources, as well as the introduction of novel technologies, may aid in its improvement. Use of an acute pain service has the potential to improve pain management through specialized patient care and utilization of effective analgesic techniques. Multimodal analgesic techniques, which include adjuvant non-opioids and/or regional analgesic techniques, can provide effective analgesia and reduce the amount of systemic opioids (or obviate the need) for postoperative pain management. Patient-controlled analgesia modalities may also offer improvements to pain management, as in practice they provide pain relief superior to the intermittent administration of bolus doses of opioids. A novel patient-controlled analgesia modality that has been approved by the European Medicines Evaluation Agency (EMEA) for the treatment of acute, moderate-to-severe pain is the needle-free, pre-programmed fentanyl HCl iontophoretic transdermal system. This system was shown in a recent US clinical trial to be comparable in efficacy to a standard regimen of morphine intravenous patient-controlled analgesia. Adverse events associated with the use of the fentanyl iontophoretic transdermal system are generally similar to those experienced by patients using intravenous morphine patient-controlled analgesia. Considerations regarding the selection of patients for treatment with the fentanyl iontophoretic transdermal system are similar to those with other patient-controlled analgesia modalities; sufficient upper limb mobility and alertness are required to operate the system. Utilization of the fentanyl iontophoretic transdermal system, together with the guidance of an effective acute pain service, may lead to improvements in postoperative pain management.	Orebro Univ Hosp, Dept Anaesthesiol & Intens Care, SE-70185 Orebro, Sweden; St Bartholomews Hosp, Anaesthet Lab, London, England	Rawal, N (reprint author), Orebro Univ Hosp, Dept Anaesthesiol & Intens Care, SE-70185 Orebro, Sweden.	n.rawal@orebroll.se					Andersen G, 2000, ACTA ANAESTH SCAND, V44, P296, DOI 10.1034/j.1399-6576.2000.440313.x; Apfelbaum JL, 2003, ANESTH ANALG, V97, P534, DOI 10.1213/01.ANE.0000068822.10113.9E; Ashburn MA, 2004, ANESTHESIOLOGY, V100, P1573; Aubrun E, 2003, EUR J ANAESTH, V20, P745, DOI 10.1097/00003643-200309000-00012; Austin J, 2002, ANAESTHESIA, V57, P778, DOI 10.1046/j.1365-2044.2002.02698_1.x; *AUSTR NZ COLL AN, 2005, AC PAIN MAN SCI EV; Austrup ML, 1999, SURG CLIN N AM, V79, P253, DOI 10.1016/S0039-6109(05)70382-0; Ballantyne JC, 1998, ANESTH ANALG, V86, P598, DOI 10.1097/00000539-199803000-00032; BALLANTYNE JC, 1993, J CLIN ANESTH, V5, P182, DOI 10.1016/0952-8180(93)90013-5; Basse L, 2004, DIS COLON RECTUM, V47, P271, DOI 10.1007/s10350-003-0055-0; Beattie WS, 2001, ANESTH ANALG, V93, P853, DOI 10.1097/00000539-200110000-00010; Ben-David Bruce, 2002, Anesthesiol Clin North Am, V20, P665; Bertolini G, 2002, EUR J CLIN PHARMACOL, V58, P73, DOI 10.1007/s00228-002-0432-y; Block BM, 2003, JAMA-J AM MED ASSOC, V290, P2455, DOI 10.1001/jama.290.18.2455; Breivik H, 1998, EUR J ANAESTH, V15, P748, DOI 10.1097/00003643-199811000-00022; Brodner G, 2000, EUR J ANAESTH, V17, P566, DOI 10.1046/j.1365-2346.2000.00738.x; BROWN CR, 1998, 17 ANN SCI M AM PAIN, P192; Carr DB, 1999, LANCET, V353, P2051, DOI 10.1016/S0140-6736(99)03313-9; Carr DB, 1998, J CLIN ANESTH, V10, P77, DOI 10.1016/S0952-8180(97)00227-4; Chelly JE, 2005, EXPERT OPIN PHARMACO, V6, P1205, DOI 10.1517/14656566.6.7.1205; Chelly JE, 2004, ANESTH ANALG, V98, P427, DOI 10.1213/01.ANE.0000093314.13848.7E; Choiniere M, 1998, ANESTHESIOLOGY, V89, P1377, DOI 10.1097/00000542-199812000-00015; Chumbley GM, 1999, ANAESTHESIA, V54, P386, DOI 10.1046/j.1365-2044.1999.00836.x; Cupitt JM, 2004, ANAESTHESIA, V59, P93, DOI 10.1111/j.1365-2044.2004.03589.x; Dawson SJ, 2001, J HOSP INFECT, V47, P3, DOI 10.1053/jhin.2000.0872; Dolin SJ, 2002, BRIT J ANAESTH, V89, P409, DOI 10.1093/bja/aef207; Filos KS, 1999, EUR SURG RES, V31, P97, DOI 10.1159/000008627; Francesca F, 2003, EUR UROL, V44, P383, DOI 10.1016/S0302-2838(03)00321-X; Gan TJ, 2004, ACTA ANAESTH SCAND, V48, P1194, DOI 10.1111/j.1399-6576.2004.00495.x; Good K, 2006, AORN J, V83, P1055; *INT ASS STUD PAIN, 1992, MAN AC PAIN PRACT GU; *JOINT COMM ACCR H, 2000, PAIN ASS MAN ORG APP; Kampe S, 2002, ANESTH ANALG, V95, P1767, DOI 10.1097/00000539-200212000-00055; Kehlet H, 2003, LANCET, V362, P1921, DOI 10.1016/S0140-6736(03)14966-5; Kehlet H, 2002, AM J SURG, V183, P630, DOI 10.1016/S0002-9610(02)00866-8; Macintyre PE, 2001, BRIT J ANAESTH, V87, P36, DOI 10.1093/bja/87.1.36; Mann E, 2000, Br J Nurs, V9, P2067; McDonnell A, 2003, J CLIN NURS, V12, P387, DOI 10.1046/j.1365-2702.2003.00748.x; Miaskowski C, 1999, PAIN, V80, P23, DOI 10.1016/S0304-3959(98)00192-4; Moen V, 2004, ANESTHESIOLOGY, V101, P950, DOI 10.1097/00000542-200410000-00021; Neugebauer E, 2003, CHIRURG, V74, P235, DOI 10.1007/s00104-003-0615-9; O'Higgins F, 2000, ACTA ANAESTH SCAND, V44, P1087, DOI 10.1034/j.1399-6576.2000.440909.x; PARKER RK, 1991, JAMA-J AM MED ASSOC, V266, P1947, DOI 10.1001/jama.266.14.1947; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; Persson K, 2004, SCAND J CARING SCI, V18, P304, DOI 10.1111/j.1471-6712.2004.00286.x; *PICK I EUR, 2002, IMPR QUAL HLTH CAR E; Powell AE, 2004, BRIT J ANAESTH, V92, P689, DOI 10.1093/bja/aeh130; Puig MM, 2001, ACTA ANAESTH SCAND, V45, P465, DOI 10.1034/j.1399-6576.2001.045004465.x; Rawal N, 1998, EUR J ANAESTH, V15, P354, DOI 10.1097/00003643-199805000-00019; Rawal Narinder, 2005, Anesthesiol Clin North Am, V23, P211, DOI 10.1016/j.atc.2004.11.012; Ready LB, 1999, REGION ANESTH PAIN M, V24, P499, DOI 10.1016/S1098-7339(99)90038-X; Rodgers A, 2000, BMJ-BRIT MED J, V321, P1493, DOI 10.1136/bmj.321.7275.1493; Sathyan G, 2005, CLIN PHARMACOKINET, V44, P7, DOI 10.2165/00003088-200544001-00003; SATHYAN G, 2000, CLIN PHARM S1, V44, P17; Schafheutle EI, 2001, J ADV NURS, V33, P728, DOI 10.1046/j.1365-2648.2001.01714.x; Seib RK, 2006, CAN J ANAESTH, V53, P461, DOI 10.1007/BF03022618; SINATRA RS, 2002, J AM ACAD ORTHOP SUR, V10, P117; Stamer UM, 2002, REGION ANESTH PAIN M, V27, P125, DOI 10.1053/rapm.2002.29258; Stomberg Margareta Warren, 2003, Pain Manag Nurs, V4, P11, DOI 10.1053/jpmn.2003.3; STRIEBEL HW, 1999, ACUTE PAIN, V2, P36; Stubhaug A, 1997, ACTA ANAESTH SCAND, V41, P1124, DOI 10.1111/j.1399-6576.1997.tb04854.x; Thompson JS, 2003, CAN J ANAESTH, V50, P143, DOI 10.1007/BF03017846; Trevisan P, 2004, Minerva Anestesiol, V70, P631; Vicente KJ, 2003, CAN J ANAESTH, V50, P328, DOI 10.1007/BF03021027; Viscusi ER, 2006, ANESTH ANALG, V102, P188, DOI 10.1213/01.ane.0000183649.58483.77; Viscusi ER, 2004, JAMA-J AM MED ASSOC, V291, P1333, DOI 10.1001/jama.291.11.1333; Walder B, 2001, ACTA ANAESTH SCAND, V45, P795, DOI 10.1034/j.1399-6576.2001.045007795.x; Werner MU, 2002, ANESTH ANALG, V95, P1361, DOI 10.1097/00000539-200211000-00049; Wilder-Smith OHG, 2002, EUR J PAIN-LONDON, V6, P189, DOI 10.1053/eujp.2001.0328; Windsor AM, 1996, ANAESTHESIA, V51, P228, DOI 10.1111/j.1365-2044.1996.tb13638.x; Wu CL, 2003, REGION ANESTH PAIN M, V28, P271, DOI 10.1016/S1098-7339(03)00095-6	71	8	9	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0265-0215	1365-2346		EUR J ANAESTH	Eur. J. Anaesth.	APR	2007	24	4					299	308		10.1017/S026502150600189X			10	Anesthesiology	Anesthesiology	155SC	WOS:000245597300001	17156510				2020-06-30	J	Porter, M; Mendonca, C				Porter, M.; Mendonca, C.			Anaesthesia for caesarean section in a patient with diastrophic dwarfism	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Article						dwarfism; diastrophic; anaesthesia; epidural; caesarean section; kyphoscoliosis	ACHONDROPLASTIC DWARF; PREGNANCY; SCOLIOSIS	Diastrophic dwarfism is a rare disease in which pregnancy is uncommon. In this report we present a woman with diastrophic dwarfism who underwent caesarean section under epidural anaesthesia. Her care was successfully managed with multidisciplinary team planning. The total dose of local anaesthetic needed for epidural block was greater than the doses reported for achondroplastic dwarfism. (c) 2006 Elsevier Ltd. All rights reserved.	Univ Hosp Coventry & Warwickshire, Dept Anaesthesia, Univ Hosp, Coventry CV2 2DX, W Midlands, England	Porter, M (reprint author), Univ Hosp Coventry & Warwickshire, Dept Anaesthesia, Univ Hosp, Clifford Bridge Rd, Coventry CV2 2DX, W Midlands, England.	mark.porter@uhcw.nhs.uk					Ayoubi JM, 2001, LANCET, V358, P1778, DOI 10.1016/S0140-6736(01)06806-4; BERKOWITZ ID, 1990, ANESTHESIOLOGY, V73, P739, DOI 10.1097/00000542-199010000-00021; BETHEM D, 1980, J BONE JOINT SURG AM, V62, P529, DOI 10.2106/00004623-198062040-00006; BETZ RR, 1987, J BONE JOINT SURG AM, V69A, P90, DOI 10.2106/00004623-198769010-00015; BRIMACOMBE JR, 1990, ANAESTHESIA, V45, P132, DOI 10.1111/j.1365-2044.1990.tb14278.x; COHEN SE, 1980, ANESTHESIOLOGY, V52, P264, DOI 10.1097/00000542-198003000-00014; Collier C B, 1996, Int J Obstet Anesth, V5, P19, DOI 10.1016/S0959-289X(96)80070-7; CRAWFORD M, 1992, ANAESTHESIA, V47, P1007, DOI 10.1111/j.1365-2044.1992.tb03223.x; DRESNER MR, 1995, ANAESTHESIA, V50, P807, DOI 10.1111/j.1365-2044.1995.tb06146.x; HASTBACKA J, 1994, CELL, V78, P1073, DOI 10.1016/0092-8674(94)90281-X; KRECAK J, 1987, PEDIATR RADIOL, V17, P321, DOI 10.1007/BF02388248; Morrow MJ, 1998, BRIT J ANAESTH, V81, P619, DOI 10.1093/bja/81.4.619; Smith PS, 2003, INT J OBSTET ANESTH, V12, P17, DOI 10.1016/S0959-289X(02)00136-x; STOELTING RK, 2002, SKIN MUSCULOSKELETAL, P505; STOVER CN, 1963, AMER J ROENTGENOL RA, V89, P914; WARDALL GJ, 1990, BRIT J ANAESTH, V64, P367, DOI 10.1093/bja/64.3.367	16	5	5	0	1	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0959-289X			INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	APR	2007	16	2					145	148		10.1016/j.ijoa.2006.08.012			4	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	159AW	WOS:000245838800009	17270421				2020-06-30	J	Hart, EM; Maharaj, R; Mushambi, MC; May, AE				Hart, E. M.; Maharaj, R.; Mushambi, M. C.; May, A. E.			Uncorrected total anomalous pulmonary venous drainage in pregnancy	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Article						total anomalous pulmonary venous drainage; congenital heart disease; cyanosis; pregnancy	MANAGEMENT; DISEASE; ADULTS	Total anomalous pulmonary venous drainage is a rare form of congenital heart disease. It usually presents in the neonatal period, although later presentation, including in adulthood, is known to occur. We could not find any accounts of adult survivors with the undiagnosed disease becoming pregnant. We describe the case of a 19-year-old Bengali primiparous woman who arrived in the UK at 27 weeks' gestation and needed an urgent caesarean section for intrauterine growth restriction at 34 weeks' gestation. Uncorrected congenital heart disease was diagnosed at this time although the exact nature of the pathology was not clear. She underwent an uncomplicated caesarean section using a combined spinal-epidural technique with invasive monitoring. Intrathecal 0.5% hyperbaric bupivacaine 0.7 mL and fentanyl 25 mu g were sufficient for surgery. She remained cardiovascularly stable throughout the procedure and a female infant was successfully delivered. She underwent corrective cardiac surgery 14 months after delivery. To our knowledge, this is the first report of caesarean section in a patient with uncorrected total anomalous pulmonary venous drainage. In this case, regional anaesthesia was successfully used. (c) 2006 Elsevier Ltd. All rights reserved.	Leicester Gen Hosp, Leicester LE5 4PW, Leics, England	Hart, EM (reprint author), Leicester Gen Hosp, Gwendolen Rd, Leicester LE5 4PW, Leics, England.	elaine_hart@hotmail.com					ARIKAWA K, 1990, J CARDIOVASC SURG, V31, P231; Choudhary S K, 2001, Indian Heart J, V53, P754; Cole PJ, 2001, BRIT J ANAESTH, V86, P723, DOI 10.1093/bja/86.5.723; Dob DP, 2006, INT J OBSTET ANESTH, V15, P137, DOI 10.1016/j.ijoa.2005.07.005; Goel M, 2000, Indian Heart J, V52, P559; JOHNSON MD, 1991, [No title captured], P210; KENNEDY I, 2001, [No title captured], pCH3; LANGLEY SM, 2004, KEY TOPICS CARDIAC S, P131; PRESBITERO P, 1994, CIRCULATION, V89, P2673, DOI 10.1161/01.CIR.89.6.2673; Ray P, 2004, BRIT J ANAESTH, V93, P428, DOI 10.1093/bja/aeh194; RODRIGUEZCOLLADO J, 1992, J THORAC CARDIOV SUR, V103, P877; Siu SC, 2001, CIRCULATION, V104, P515, DOI 10.1161/hc3001.093437; SUI SC, 1997, CIRCULATION, V96, P2789; WARNES A, 1997, HEART DIS PREGNANCY, P83	14	1	3	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-289X	1532-3374		INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	APR	2007	16	2					160	164		10.1016/j.ijoa.2006.10.010			5	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	159AW	WOS:000245838800012	17368175				2020-06-30	J	Adekanye, O; Srinivas, K; Collis, RE				Adekanye, O.; Srinivas, K.; Collis, R. E.			Bradyarrhythmias in pregnancy: a case report and review of management	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Article						pregnancy; bradyarrhythmia; bradycardia; pacemaker insertion; complete heart block; congenital	COMPLETE HEART-BLOCK; PACEMAKER; DELIVERY; PATIENT; MAGNET	We present a case of unpaced pre-existing congenital heart block in pregnancy, diagnosed for the first time in labour. Our patient was asymptomatic and was managed conservatively with temporary pacing equipment on standby. She had a post-partum cardiology follow-up and was paced in the puerperium. We discuss the aetiopathogenesis and the variable presentation patterns of bradyarrhythmia in pregnancy and the multidisciplinary approach to their management. Our recommendations combine the Advanced Life Support algorithm for treatment of bradycardia and the successful management strategies of several documented case reports in the literature. (c) 2006 Elsevier Ltd. All rights reserved.	Cardiff Univ, Wales Coll Med, Dept Anaesthet & Intens Care Med, Cardiff, S Glam, Wales; Univ Wales Hosp, Cardiff CF4 4XW, S Glam, Wales	Adekanye, O (reprint author), Cardiff Univ, Wales Coll Med, Dept Anaesthet & Intens Care Med, Heath Pk, Cardiff, S Glam, Wales.	adekanyeo@cf.ac.uk					ANDERSEN C, 1989, PACE, V12, P386, DOI 10.1111/j.1540-8159.1989.tb02672.x; Avasthi Kumkum, 2003, Indian Heart J, V55, P641; Bahhady IJ, 2004, CHEST, V126, P1974, DOI 10.1378/chest.126.6.1974; BIERMAN PQ, 1993, HEART LUNG, V22, P148; CAMANN WR, 2006, OBSTETRIC ANAESTHESI, P707; Clark RB, 1995, PRINCIPLES PRACTICE, P324; DALVI BV, 1992, OBSTET GYNECOL, V79, P802; DOMINO KB, 1983, ANESTH ANALG, V62, P609; FINFER SR, 1991, BRIT J ANAESTH, V66, P509, DOI 10.1093/bja/66.4.509; GRAY RP, 1997, TXB INTENSIVE CARE, P255; GULDAL M, 1987, PACE, V10, P543, DOI 10.1111/j.1540-8159.1987.tb04518.x; HANTLER CB, 1994, ANESTH ANALG, V79, P455; HUNTER S, 1992, BRIT HEART J, V68, P540; Jaffe R, 1987, Obstet Gynecol Surv, V42, P137; JORDAENS J, 1990, PACE, V13, P955, DOI 10.1111/j.1540-8159.1990.tb02138.x; KARPAWICH PP, 1981, AM J CARDIOL, V48, P1098, DOI 10.1016/0002-9149(81)90326-X; Kenmure AC, 1976, BRIT HEART J, V29, P911; Kinsella SM, 2001, BRIT J ANAESTH, V86, P859, DOI 10.1093/bja/86.6.859; Kowey PR, 2000, AM HEART J, V140, P12, DOI 10.1067/mhj.2000.106640; LAU CP, 1990, PACE, V13, P158, DOI 10.1111/j.1540-8159.1990.tb05065.x; Lee M S, 1994, J Am Soc Echocardiogr, V7, P182; Mehta S, 2003, J Postgrad Med, V49, P98; Michaelsson M, 1972, CLIN CARDIOL, V4, P86; Oakley C., 1997, HEART DIS PREGNANCY, P248; ODEMUYIWA O, 1992, PACE, V15, P1526, DOI 10.1111/j.1540-8159.1992.tb02926.x; Olufolabi AJ, 2002, BRIT J ANAESTH, V89, P652, DOI 10.1093/bja/aef230; REID JM, 1982, BRIT HEART J, V48, P236; Robins K, 2004, BRIT J ANAESTH, V92, P140, DOI 10.1093/bja/aeh004; SHOUSE EE, 1964, OBSTET GYNECOL, V24, P817; 1996, REPORT CONFIDENTIAL, P119; 1989, REPORT CONFIDENTIAL, P71	31	13	13	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-289X	1532-3374		INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	APR	2007	16	2					165	170		10.1016/j.ijoa.2006.10.003			6	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	159AW	WOS:000245838800013	17270418				2020-06-30	J	De la Gala, F; Reyes, A; Avellanal, M; Baticon, P; Gonzalez-Zarco, LM				De la Gala, F.; Reyes, A.; Avellanal, M.; Baticon, P.; Gonzalez-Zarco, L. M.			Trigeminal nerve palsy and Horner's syndrome following epidural analgesia for labor: a subdural block?	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Article						epidural analgesia; subdural block; Horner's syndrome; trigeminal nerve palsy	ANESTHESIA; COMPLICATIONS; INJECTION	Horner's syndrome is a rare complication of epidural analgesia for labor. Much more uncommon is trigeminal nerve palsy. Both complications may be attributed to a subdural localization of the catheter, as we demonstrated clinically by a repeat injection and patchy sympathetic block and with the typical image on epidurography. (c) 2006 Elsevier Ltd. All rights reserved.	Hosp Gen Univ Gregorio Maranon, Dept Anesthesiol, Madrid, Spain	Avellanal, M (reprint author), Sagasta 16, E-28004 Madrid, Spain.	mavellanai@telefonica.net		de la Gala Garcia, Francisco Andres/0000-0001-5765-1312			Ajar AH, 2002, REGION ANESTH PAIN M, V27, P72, DOI 10.1053/rapm.2002.29242; BRIDENBAUGH PO, 1998, NEURAL BLOCKADE CLIN, P206; CLAYTON KC, 1983, ANAESTHESIA, V38, P583, DOI 10.1111/j.1365-2044.1983.tb14074.x; Collier CB, 2004, REGION ANESTH PAIN M, V29, P45, DOI 10.1016/j.rapm.2003.10.012; Day CJE, 1996, REGION ANESTH, V21, P197; Garutti I, 2003, ANESTHESIOLOGY, V98, P1005, DOI 10.1097/00000542-200304000-00029; GAZMURI RR, 1992, REGION ANESTH, V17, P50; Hogagard JT, 2000, ACTA ANAESTH SCAND, V44, P1021, DOI 10.1034/j.1399-6576.2000.440822.x; LEE A, 1986, ANESTHESIA, V41, P794; Loo CC, 2000, INT J OBSTET ANESTH, V9, P99, DOI 10.1054/ijoa.1999.0347; LUBENOW T, 1988, ANESTH ANALG, V67, P175; MOHAN J, 1975, ANAESTHESIA, V30, P769, DOI 10.1111/j.1365-2044.1975.tb00953.x; Narouze SN, 2002, J CLIN ANESTH, V14, P532, DOI 10.1016/S0952-8180(02)00406-3; Palmer C, 2004, REGION ANESTH PAIN M, V29, P7, DOI 10.1016/j.rapm.2003.11.003; Rathmell JP, 2000, REGION ANESTH PAIN M, V25, P540; SHIGEMATSU T, 1985, ANESTH ANALG, V64, P653, DOI 10.1213/00000539-198506000-00023; SPRUNG J, 1991, CAN J ANAESTH, V38, P767, DOI 10.1007/BF03008457	17	15	16	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-289X	1532-3374		INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	APR	2007	16	2					180	182		10.1016/j.ijoa.2006.07.007			3	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	159AW	WOS:000245838800016	17270429				2020-06-30	J	Rees, SGO; Collis, RE				Rees, S. G. O.; Collis, R. E.			Spinal cord injury after accidental dural puncture for labour analgesia	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Letter							ANESTHESIA; ADULTS		Cheltenham Gen Hosp, Cheltenham, Glos, England; Univ Wales Hosp, Cardiff, Wales	Rees, SGO (reprint author), Cheltenham Gen Hosp, Cheltenham, Glos, England.	ted.rees@glos.nhs.uk					Akay KM, 2000, ACTA NEUROCHIR, V142, P1111, DOI 10.1007/s007010070038; CHAUDHARI LS, 1978, ANAESTHESIA, V33, P722; Hamandi K, 2002, NEUROLOGY, V59, P624, DOI 10.1212/WNL.59.4.624; Huttmann S, 2001, J NEUROSURG, V95, P173, DOI 10.3171/spi.2001.95.2.0173; YUEN EC, 1995, NEUROLOGY, V45, P1795, DOI 10.1212/WNL.45.10.1795	5	1	1	0	0	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0959-289X			INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	APR	2007	16	2					193	195		10.1016/j.ijoa.2006.12.002			3	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	159AW	WOS:000245838800032	17306973				2020-06-30	J	Clemens, KE; Klaschik, E				Clemens, Katri Elina; Klaschik, Eberhard			Clinical experience with transdermal and orally administered opioids in palliative care patients - A retrospective study	JAPANESE JOURNAL OF CLINICAL ONCOLOGY			English	Article						opioid switching; opioid-related side effects; cancer pain; palliative care; equianalgesic dose	CHRONIC CANCER PAIN; PHARMACOLOGICAL-PROPERTIES; THERAPEUTIC-EFFICACY; FENTANYL; HYDROMORPHONE; METHADONE; PHARMACOKINETICS; MANAGEMENT; MORPHINE	Background: Transdermal fentanyl is a widely used opioid for the treatment of cancer pain. Simplicity of use and high patient compliance are the main advantages of this opioid. However, based on our clinical experience, transdermal fentanyl is often not efficacious in terminally ill palliative care patients. We thus retrospectively examined the pain management and need for opioid switching in cancer patients admitted to our palliative care unit. Methods: Of 354 patients admitted to our palliative care unit from 2004 through 2005, 81 patients were pre-treated with transdermal fentanyl. Demographic and cancer-related data (diagnosis, symptoms, pain score on a numeric rating scale (NRS)), analgesic dose at admission and discharge were compared. Statistics: mean +/- SD, ANOVA, Wilcoxon's test was used for inter-group comparisons, significance P < 0.05, adjusted for multiple testing. Pain scores are given in median (range). Results: Mean transdermal fentanyl dose at admission was 81.0 +/- 55.8 mu g/h. In 79 patients transdermal fentanyl treatment was discontinued. In two patients, analgesic treatment according to WHO I provided sufficient pain relief. The other 77 patients were switched to other opioids: 33 patients to oral morphine and 44 to oral hydromorphone. In patients switched to morphine the dose at discharge (104.7 +/- 89.0 mg) was lower than at admission (165.5 mg morphine equivalence). In patients switched to hydromorphone the dose of 277.8 +/- 255.0 mg morphine equivalent was higher at discharge than at admission (218.2 +/- 131.4 mg morphine equivalence - considering an equianalgesic conversion ratio morphine: hydromorphone = 7.5: 1). Pain scores decreased significantly after opioid rotation (NRS at rest/on exertion: 4 (0-10)/7 (2-10) versus 1 (0-3)/2 (0-5); P < 0.001). Conclusions: In the patient group switched to morphine, sufficient pain relief was achieved by lower equianalgesic morphine doses, compared with the doses at admission. In the patient group switched to hydromorphone, higher equianalgesic morphine doses were needed at discharge, considering an equianalgesic conversion ratio of morphine: hydromorphone = 7.5: 1. Patients with far advanced cancer often suffer from sweating and cachexia, which may have negative effects on the absorption of transdermal fentanyl. Opioid switching to oral morphine or hydromorphone was well tolerated and proved to be an efficacious option for cancer pain treatment.	Malteser Hosp Bonn Rhein Sieg, Dept Anaesthesiol Intens Care PM&PT, D-53123 Bonn, Germany; Univ Bonn, Ctr Palliat Med, Dept Sci & Res, D-5300 Bonn, Germany	Clemens, KE (reprint author), Malteser Hosp Bonn Rhein Sieg, Dept Anaesthesiol Intens Care PM&PT, Von Hompesch Str 1, D-53123 Bonn, Germany.	Katri-Elina.Clemens@malteser.de					Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; ALLAN L, 2001, BMJ-BRIT MED J, V12, P1154; Anderson R, 2001, J PAIN SYMPTOM MANAG, V21, P397, DOI 10.1016/S0885-3924(01)00271-8; BABUL N, 1995, J PAIN SYMPTOM MANAG, V10, P335, DOI 10.1016/0885-3924(95)90012-8; BABUL N, 1992, PAIN, V51, P260, DOI 10.1016/0304-3959(92)90270-L; Benitez-Rosario MA, 2004, CANCER-AM CANCER SOC, V101, P2866, DOI 10.1002/cncr.20712; Berger Ariel, 2004, Manag Care Interface, V17, P28; BRUERA E, 1995, J PAIN SYMPTOM MANAG, V10, P287, DOI 10.1016/0885-3924(95)00005-J; Cherny N, 2000, J Oncol Manag, V9, P8; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; DESTOUTZ ND, 1995, J PAIN SYMPTOM MANAG, V10, P378, DOI 10.1016/0885-3924(95)90924-C; Eisenberg E, 2005, JAMA-J AM MED ASSOC, V293, P3043, DOI 10.1001/jama.293.24.3043; Ellershaw JE, 2002, J PAIN SYMPTOM MANAG, V24, P398, DOI 10.1016/S0885-3924(02)00507-9; Enting RH, 2002, CANCER-AM CANCER SOC, V94, P3049, DOI 10.1002/cncr.10518; Foley KM, 1998, J CLIN ONCOL, V16, P3213, DOI 10.1200/JCO.1998.16.10.3213; FOLEY KM, 1985, NEW ENGL J MED, V313, P84, DOI 10.1056/NEJM198507113130205; Genf World Health Organization, 1986, CANC PAIN REL; Gourlay G K, 2001, Lancet Oncol, V2, P165, DOI 10.1016/S1470-2045(00)00258-8; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; HAGEN N, 1995, J CLIN PHARMACOL, V35, P37, DOI 10.1002/j.1552-4604.1995.tb04743.x; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; Jeal W, 1997, DRUGS, V53, P109, DOI 10.2165/00003495-199753010-00011; Lawlor P, 1997, PAIN, V72, P79, DOI 10.1016/S0304-3959(97)00018-3; Lawlor PG, 2000, ARCH INTERN MED, V160, P786, DOI 10.1001/archinte.160.6.786; Lindena G, 1998, SCHMERZ, V12, P195, DOI 10.1007/s004820050142; MACDONALD N, 1993, PAIN, V53, P353, DOI 10.1016/0304-3959(93)90232-E; Mercadante S, 2005, J CLIN ONCOL, V23, P5229, DOI 10.1200/JCO.2005.13.128; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; Pasero C, 2001, AM J NURS, V101, P22; Payne R, 1998, J CLIN ONCOL, V16, P1588, DOI 10.1200/JCO.1998.16.4.1588; Pereira J, 2001, J PAIN SYMPTOM MANAG, V22, P672, DOI 10.1016/S0885-3924(01)00294-9; Przewlocki R, 2005, CURR PHARM DESIGN, V11, P3013, DOI 10.2174/1381612054865055; QUIGLEY C, 2004, [No title captured], DOI DOI 10.1002/14651858.CD004847; Radbruch Lukas, 2004, Keio J Med, V53, P23, DOI 10.2302/kjm.53.23; Santiago-Palma J, 2001, CANCER, V92, P1919, DOI 10.1002/1097-0142(20011001)92:7<1919::AID-CNCR1710>3.0.CO;2-G; SCHAG CC, 1984, J CLIN ONCOL, V2, P187, DOI 10.1200/JCO.1984.2.3.187; Stamer UM, 2005, EUR J PAIN, V9, P101, DOI 10.1016/j.ejpain.2004.05.008; Welsh J, 2005, PALLIATIVE MED, V19, P9, DOI 10.1191/0269216305pm971oa; *WHO EXP COMM, 1990, WHO TECHN REP SER, V804, P24; World Health Organization, 1996, CANC PAIN REL; Yeo W, 1997, PALLIATIVE MED, V11, P233, DOI 10.1177/026921639701100308; ZORN M, 2002, SYMPTOM MANAGEMENT C, P1	42	13	13	0	3	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0368-2811	1465-3621		JPN J CLIN ONCOL	Jpn. J. Clin. Oncol.	APR	2007	37	4					302	309		10.1093/jjco/hym017			8	Oncology	Oncology	190HV	WOS:000248050800009	17519302	Bronze			2020-06-30	J	Sinha, PK; Misra, S; Unnikrishnan, M; Bhuyan, RR				Sinha, Prabhat Kumar; Misra, Satyajeet; Unnikrishnan, Madathipat; Bhuyan, Ritwick Raj			Horseshoe lung secondary to hypoplastic left lung for pneumonectomy	JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA			English	Article						anesthesia; horseshoe lung; pneumonectomy; double-lumen tube; central venous cannulation	DOUBLE-LUMEN TUBE; ENDOBRONCHIAL TUBE; TRACHEAL DIAMETER; SIZE; AID			Sinha, PK (reprint author), KPIX-561,Podujanam Lane, Trivandrum 695011, Kerala, India.	pksinha@sctimst.ac.in					Bahk JH, 1998, ANESTH ANALG, V86, P1271, DOI 10.1097/00000539-199806000-00026; Bahk JH, 2000, J TRAUMA, V49, P899, DOI 10.1097/00005373-200011000-00018; Benumof J L, 1993, J Cardiothorac Vasc Anesth, V7, P513, DOI 10.1016/1053-0770(93)90303-3; BENUMOF JL, 1987, ANESTHESIOLOGY, V67, P729, DOI 10.1097/00000542-198711000-00018; BENUMOF JL, 1995, ANESTHESIA THORACIC, P330, DOI DOI 10.1213/ANE.0B013E318245DD38; Brodsky Jay B, 2004, Curr Opin Anaesthesiol, V17, P7, DOI 10.1097/00001503-200402000-00003; Brodsky JB, 1996, ANESTH ANALG, V82, P861, DOI 10.1097/00000539-199604000-00032; BURTON NA, 1983, ANN THORAC SURG, V36, P78, DOI 10.1016/S0003-4975(10)60655-8; Chow MYH, 1998, ANESTH ANALG, V87, P158, DOI 10.1097/00000539-199807000-00033; COMET R, 1998, ARCH BRONCONEUMOL, V34, P8; DIETERVOEGELE L, 1978, AM SURGEON, V44, P448; Hannallah M, 1997, J CARDIOTHOR VASC AN, V11, P168, DOI 10.1016/S1053-0770(97)90208-1; HASSBERG D, 1992, KLIN PADIATR, V204, P434, DOI 10.1055/s-2007-1025385; Lutterman J, 2004, ANN THORAC SURG, V77, P1085, DOI 10.1016/S0003-4975(03)01213-X; Mas A, 1997, RESPIRATION, V64, P240; READ RC, 1977, ANN THORAC SURG, V24, P156, DOI 10.1016/S0003-4975(10)63725-3; Takahashi M, 1997, BRIT J RADIOL, V70, P964, DOI 10.1259/bjr.70.837.9486078	17	2	2	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1053-0770	1532-8422		J CARDIOTHOR VASC AN	J. Cardiothorac. Vasc. Anesth.	APR	2007	21	2					250	252		10.1053/j.jvca.2006.07.008			3	Anesthesiology; Cardiac & Cardiovascular Systems; Respiratory System; Peripheral Vascular Disease	Anesthesiology; Cardiovascular System & Cardiology; Respiratory System	159NM	WOS:000245872800016	17418741				2020-06-30	J	Ailawadhi, S; Sung, KW; Carlson, LA; Baer, MR				Ailawadhi, S.; Sung, K. -W.; Carlson, L. A.; Baer, M. R.			Serotonin syndrome caused by interaction between citalopram and fentanyl	JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS			English	Article						citalopram; fentanyl; selective serotonin reuptake inhibitor; serotonin syndrome	REUPTAKE INHIBITORS; SERTRALINE; TOXICITY; OVERDOSE; UPDATE; CHILD	Objective To report a case of serotonin syndrome associated with interaction between fentanyl and citalopram, as evidenced by medication history, clinical features and reversal following discontinuation of fentanyl. Case Summary A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl. Based on the Naranjo probability scale, serotonin syndrome was a probable adverse reaction associated with co-administration of citalopram and fentanyl. Discussion Serotonin syndrome is a potentially lethal pharmacodynamic interaction between medications that increase serotonergic transmission at the synaptic junction. The development of new pharmacological agents with varied properties and actions has increased the risk of serotonin syndrome as a clinical diagnosis. SSRIs and fentanyl are commonly co-administered, especially in the setting of chronic or malignant pain, as underlying depression may contribute to the pathogenesis of pain. Conclusions Healthcare professionals should be aware of the possible development of serotonin syndrome as a complication of initiation of fentanyl and other phenylpiperidine opioids in patients treated with SSRIs.	Roswell Pk Canc Inst, Dept Pharm, Buffalo, NY 14263 USA; Roswell Pk Canc Inst, Dept Med, Buffalo, NY 14263 USA; SUNY Buffalo, Dept Med, Buffalo, NY 14260 USA	Baer, MR (reprint author), Roswell Pk Canc Inst I, Dept Med, Elm & Carlton St, Buffalo, NY 14263 USA.	maria.baer@roswellpark.org					Bezchlibnyk-Butler K, 2000, J PSYCHIATR NEUROSCI, V25, P241; Boyer EW, 2005, NEW ENGL J MED, V352, P1112, DOI 10.1056/NEJMra041867; FISCHER P, 1995, J CLIN PSYCHOPHARM, V15, P440, DOI 10.1097/00004714-199512000-00009; Gillman PK, 1999, J PSYCHOPHARMACOL, V13, P100, DOI 10.1177/026988119901300111; Goeringer KE, 2000, J FORENSIC SCI, V45, P633; Goldberg RJ, 1998, ARCH FAM MED, V7, P78, DOI 10.1001/archfami.7.1.78; HENRY JA, 1994, LANCET, V343, P607, DOI 10.1016/S0140-6736(94)91563-6; JAFFE ES, 2001, WHO CLASSIFICATION T; Jaunay E, 2001, PRESSE MED, V30, P1695; KAMINSKI CA, 1994, ANN EMERG MED, V23, P1371, DOI 10.1016/S0196-0644(94)70364-7; Kaneda Y, 2002, INT J NEUROPSYCHOPH, V5, P105, DOI 10.1017/S1461145701002723; Kolecki Paul, 1997, Journal of Emergency Medicine, V15, P491, DOI 10.1016/S0736-4679(97)00078-4; Lee DO, 1999, PHARMACOTHERAPY, V19, P894, DOI 10.1592/phco.19.10.894.31561; LENZI A, 1993, PHARMACOPSYCHIATRY, V26, P100, DOI 10.1055/s-2007-1014351; Mason PJ, 2000, MEDICINE, V79, P201, DOI 10.1097/00005792-200007000-00001; MEYER D, 1981, J CLIN PSYCHOPHARM, V1, P319, DOI 10.1097/00004714-198109000-00009; Mills KC, 1997, CRIT CARE CLIN, V13, P763, DOI 10.1016/S0749-0704(05)70368-7; Mitchell PB, 1997, DRUG SAFETY, V17, P390, DOI 10.2165/00002018-199717060-00005; NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154; Pao M, 1997, ARCH PEDIAT ADOL MED, V151, P1064, DOI 10.1001/archpedi.1997.02170470098028; Radomski JW, 2000, MED HYPOTHESES, V55, P218, DOI 10.1054/mehy.2000.1047; Sarko J, 2000, EMERG MED CLIN N AM, V18, P637, DOI 10.1016/S0733-8627(05)70151-6; STAHL SM, 2000, NEUROSCIENTIFIC BASI, P99; STERNBACH H, 1991, AM J PSYCHIAT, V148, P705; Tao R, 2003, BRIT J PHARMACOL, V139, P1498, DOI 10.1038/sj.bjp.0705378; Tao R, 1998, J PHARMACOL EXP THER, V286, P481; Tateishi T, 1996, ANESTH ANALG, V82, P167	27	40	41	0	4	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0269-4727			J CLIN PHARM THER	J. Clin. Pharm. Ther.	APR	2007	32	2					199	202		10.1111/j.1365-2710.2007.00813.x			4	Pharmacology & Pharmacy	Pharmacology & Pharmacy	148IH	WOS:000245067500012	17381671				2020-06-30	J	Senel, FC; Buchanan, JM; Senel, AC; Obeid, G				Senel, Figen Cizmeci; Buchanan, James M., Jr.; Senel, Ahmet Can; Obeid, George			Evaluation of sedation failure in the outpatient oral and maxillofacial surgery clinic	JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY			English	Article							AMBULATORY ANESTHESIA; PROCEDURAL SEDATION; ADVERSE EVENTS; MIDAZOLAM; OUTCOMES; CHILDREN; AMNESIA	Purpose: Our goal was to report on the incidence of sedation failures in our outpatient oral surgery clinic. Sedation failure is the inability to complete a procedure under intravenous sedation. There is very little in the oral surgery literature on this subject. Materials and Methods: Proper Institutional Review Board approval was obtained from the appropriate governing body for this project. The medical records of 539 intravenous sedation patients treated at the Oral and Maxillofacial Surgery Clinic at our institution were retrospectively evaluated to determine the incidence of failed sedation. Patients sedated with midazolam and fentanyl were placed in group A. There were 323 patients in group A. We placed patients sedated with midazolam, fentanyl and methohexital into group B. There were 216 patients in group B. The gender, medical history, type of procedure being performed, amount of drug given, and the patient's vital signs throughout the procedure were recorded. Results: There were 9 failed sedations with a rate of 1.6% (9/539); 3 in group B (1%) and 6 in group A (2%). Five of our failures were undergoing multiple tooth extractions. Two of the failures were undergoing surgical removal of impacted third molars. Two patients underwent mandibular fracture reduction. Failure was attributed to increased agitation and combativeness, uncontrolled hypertension, tachychardia and desaturation. Conclusion: The mandible fracture population and multiple teeth extraction patients had higher rates of failure than other groups. This may be the result of procedure length, type of procedure, or a preoperative anxiety and attitude toward treatment expressed by the patient making sedation unpredictable. Level of training and experience of the practitioner may contribute to sedation failure. These results allow us to develop a prospective study protocol of outpatient sedation and to quantify more detailed information about preoperative anxiety, medical status, and social history than we had available during our chart review. More specific conclusions may help us determine if certain patient populations are at a higher risk for failed sedations. (C) 2007 American Association of Oral and Maxillofacial Surgeons.	Washington Hosp Ctr, Dept Oral & Maxillofacial Surg, Washington, DC 20010 USA; Karadeniz Tech Univ, Fac Med, Dept Anesthesiol & Reanimatol, Trabzon, Turkey	Senel, FC (reprint author), Karadeniz Tech Univ, Fac Dent, Dept Oral & Maxillofacial Surg, TR-61080 Trabzon, Turkey.	fcsenel@hotmail.com	Senel, Ahmet/G-5687-2012				Bell GW, 2000, BRIT J ORAL MAX SURG, V38, P596, DOI 10.1054/bjom.2000.0473; Cheng C, 2002, J PAIN SYMPTOM MANAG, V23, P256, DOI 10.1016/S0885-3924(01)00412-2; Coyle TT, 2005, J ORAL MAXIL SURG, V63, P163, DOI 10.1016/j.joms.2004.10.003; Egelhoff JC, 1997, AM J ROENTGENOL, V168, P1259, DOI 10.2214/ajr.168.5.9129423; Hardman J, 1996, GOODMAN GILMANS PHAR; Hoffman GM, 2002, PEDIATRICS, V109, P236, DOI 10.1542/peds.109.2.236; Malviya S, 2000, BRIT J ANAESTH, V84, P743; Mason KP, 2001, AM J ROENTGENOL, V177, P427, DOI 10.2214/ajr.177.2.1770427; MASON KP, 1999, ANESTHESIOL CLIN N A, V2, P17; Moore PA, 1997, ORAL SURG ORAL MED O, V84, P5, DOI 10.1016/S1079-2104(97)90285-7; OCHS MW, 1990, J ORAL MAXIL SURG, V48, P240, DOI 10.1016/0278-2391(90)90387-H; Parworth LP, 1998, J ORAL MAXIL SURG, V56, P447, DOI 10.1016/S0278-2391(98)90710-8; Pena BMG, 1999, ANN EMERG MED, V34, P483, DOI 10.1016/S0196-0644(99)80050-X; Perrott DH, 2003, J ORAL MAXIL SURG, V61, P983, DOI 10.1016/S0278-2391(03)00668-2; REVES JG, 2004, MILLERS ANESTHESIA, P317; SLOVIS TL, 1993, PEDIATR RADIOL, V23, P345, DOI 10.1007/BF02011953	16	9	10	1	6	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0278-2391			J ORAL MAXIL SURG	J. Oral Maxillofac. Surg.	APR	2007	65	4					645	650		10.1016/j.joms.2006.06.252			6	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	152TT	WOS:000245385500009	17368358				2020-06-30	J	Mercadante, S; Villari, P; Ferrera, P; Casuccio, A; Gambaro, V				Mercadante, Sebastiano; Villari, Patrizia; Ferrera, Patrizia; Casuccio, Alessandra; Gambaro, Veniero			Opioid plasma concentrations during a switch from transdermal fentanyl to methadone	JOURNAL OF PALLIATIVE MEDICINE			English	Article							CANCER PAIN; ORAL METHADONE; MORPHINE; ROTATION	Opioid switching is often used to improve the opioid response in patients with cancer experiencing poor analgesia or adverse effects. When switching between drugs with delayed effect because of pharmacokinetics or type of delivery, concerns exist about the correct timing of introducing the second drug after stopping the previous one. The aim of this study was to assess plasmatic changes of fentanyl and methadone underlying the clinical events occurring during opioid switching. Eighteen patients with cancer receiving transdermal fentanyl with uncontrolled pain and/or moderate to severe opioid adverse effects, were switched to oral methadone using an initial fixed ratio of 1:20. Fentanyl patches were removed and the first of three daily doses of methadone was started concurrently. Blood samples were obtained at intervals after removing the fentanyl patch, and at 5-hour intervals for the first 25 hours. The intensity of pain and the adverse effects were assessed before switching, the day after, and then daily up to dose stabilization. A successful switch was considered when the intensity of pain and distress score decreased at least of 33% of the basal value recorded before the switch, within a reasonable period of time. Complete blood samples were obtained in 16 patients. Methadone plasma concentration increased from 2 to 245 ng/mL, and fentanyl plasma concentration decreased from 15 to 8 ng/mL, 25 hours after. A successful switch was determined the day after in 7 patients, while 4 patients did not respond favorably (effective switching, 63%). Five patients were considered too terminal for an appropriate evaluation. No differences in plasma concentration pattern of the two opioids were found between patients considered responders and nonresponders. Conversion ratios between opioids at time of stabilization did not significantly change in comparison with the initial conversion ratio chosen. Starting methadone soon after removing fentanyl patches results in a rapid increase of methadone concentration, while the half-life of transdermal fentanyl is reached after 25 hours. As a result, the rapid achievement of a clinical effect is obtained avoiding distressing therapeutic holes in patients with a clinical condition, mainly characterized by poor pain control and severe adverse effects, requiring an immediate intervention.	La Maddalena Canc Ctr, Anesthesia & Intens Care Unit, Pain Relief & Palliat Care Unit, I-90146 Palermo, Italy; Univ Palermo, Dept Anesthesiol Intens Care & Emergency, Palermo, Italy; Univ Palermo, Sect Ophthalmol, Palermo, Italy; Univ Milan, Inst Pharmacol & Toxicol Chem, I-20122 Milan, Italy	Mercadante, S (reprint author), La Maddalena Canc Ctr, Anesthesia & Intens Care Unit, Pain Relief & Palliat Care Unit, Via S Lorenzo 312, I-90146 Palermo, Italy.	terapiadeldolore@la-maddalena.it	casuccio, alessandra/B-1730-2013	casuccio, alessandra/0000-0002-5676-9535			Benitez-Rosario MA, 2004, CANCER-AM CANCER SOC, V101, P2866, DOI 10.1002/cncr.20712; Bruera E, 1996, CANCER, V78, P852, DOI 10.1002/(SICI)1097-0142(19960815)78:4<852::AID-CNCR23>3.0.CO;2-T; Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; Mercadante S, 1999, CANCER, V86, P1856, DOI 10.1002/(SICI)1097-0142(19991101)86:9<1856::AID-CNCR30>3.0.CO;2-G; Mercadante S, 2005, J CLIN ONCOL, V23, P5229, DOI 10.1200/JCO.2005.13.128; Mercadante S, 2003, SUPPORT CARE CANCER, V11, P326, DOI 10.1007/s00520-003-0440-1; Mercadante S, 2006, CANCER TREAT REV, V32, P304, DOI 10.1016/j.ctrv.2006.03.001; Ripamonti C, 1998, J CLIN ONCOL, V16, P3216, DOI 10.1200/JCO.1998.16.10.3216	9	13	13	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1096-6218	1557-7740		J PALLIAT MED	J. Palliat. Med.	APR	2007	10	2					338	344		10.1089/jpm.2006.0140			7	Health Care Sciences & Services	Health Care Sciences & Services	165AJ	WOS:000246275900016	17472504				2020-06-30	J	Angst, MS; Clark, JD				Angst, Martin S.; Clark, J. David			Comment on Koltzenburg et al.: Differential sensitivity of three experimental pain models in detecting the analgesic effects of transdermal fentanyl and buprenorphine. Pain 2006;126 : 165-74	PAIN			English	Letter							OPIOID AGONIST REMIFENTANIL; HUMANS; ALFENTANIL; HYPERALGESIA; INFUSION		Stanford Univ, Sch Med, Dept Anesthesia, Stanford, CA 94305 USA	Angst, MS (reprint author), Stanford Univ, Sch Med, Dept Anesthesia, 300 Pasteur Dr, Stanford, CA 94305 USA.	ang@stanford.edu					Angst MS, 2004, ANESTHESIOLOGY, V101, P744, DOI 10.1097/00000542-200409000-00024; Angst MS, 2001, ANESTHESIOLOGY, V94, P63, DOI 10.1097/00000542-200101000-00014; Angst MS, 2003, PAIN, V106, P49, DOI 10.1016/S0304-3959(03)00276-8; Angst MS, 2000, ANESTHESIOLOGY, V92, P312, DOI 10.1097/00000542-200002000-00011; Enggaard TP, 2001, PAIN, V92, P277, DOI 10.1016/S0304-3959(01)00267-6; Ginosar Y, 2003, ANESTH ANALG, V97, P1428, DOI 10.1213/01.ANE.0000081793.60059.10; KOLTZENBURG M, 2006, PAIN; Lotsch J, 2003, PAIN, V102, P151, DOI 10.1016/S0304-3959(02)00349-4; Luginbuhl M, 2001, ANESTHESIOLOGY, V95, P22, DOI 10.1097/00000542-200107000-00009; PETERSENFELIX S, 1994, BRIT J ANAESTH, V73, P326, DOI 10.1093/bja/73.3.326	10	4	4	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0304-3959			PAIN	Pain	APR	2007	128	3					292	294		10.1016/j.pain.2006.12.024			3	Anesthesiology; Clinical Neurology; Neurosciences	Anesthesiology; Neurosciences & Neurology	160AH	WOS:000245908700023	17276008				2020-06-30	J	Taylor, DR; Webster, LR; Chun, SY; Reinking, J; Stegman, M; Shoemaker, S; Fortner, B				Taylor, Donald R.; Webster, Lynn R.; Chun, Steven Y.; Reinking, Jeffrey; Stegman, Mary; Shoemaker, Steven; Fortner, Barry			Impact of breakthrough pain on quality of life in patients with chronic, noncancer pain: Patient perceptions and effect of treatment with oral transmucosal fentanyl citrate (OTFC (R), ACTIQ((R)))	PAIN MEDICINE			English	Article						chronic pain; breakthrough pain; quality of life; OTFC; opioids; analgesia	CANCER-PATIENTS; DOSE-TITRATION; PREVALENCE; MORPHINE; HOSPICE; COSTS	Objective. To characterize breakthrough pain (BTP), its qualitative impact on quality of life (QoL), and the effects of BTP treatment on QoL. Design. Multicenter patient-reported survey. Setting. Five pain treatment centers. Patients. Fifty-six adults with chronic noncancer pain using oral transmucosal fentanyl citrate (OTFC(R), ACTIQ(R)). Results. Forty-three patients qualified for in-depth analysis. BTP had a mean intensity of 9.0 (range 5-10) on an 11-point numerical scale (0 = no pain to 10 = worst possible pain), had a mean duration of 83 minutes, and had an adverse effect on multiple QoL domains. The largest negative QoL impacts were on "general activity level" and "ability to work." OTFC had a positive impact on both controlling BTP and improving QoL. Conclusions. BTP appears to be a clinically important condition in this population and is associated with an adverse impact on QoL. Understanding those QoL domains most affected by BTP and those potentially improved with treatment should help in developing quantitative QoL assessment tools and other outcome measures for BTP management studies.	Comprehans Pain Care PC, Marietta, GA 30060 USA; Lifetree Pain & Clin Res, Salt Lake City, UT USA; Sarasota Pain Associates, Sarasota, FL USA; Auburn Pain Clin, Auburn, CA USA; Cypress Pain Management, Ft Myers, FL USA; Sagemed Inc, Boulder, CO USA; W Clin, Memphis, TN USA	Taylor, DR (reprint author), Comprehans Pain Care PC, 840 Church St,Suite B, Marietta, GA 30060 USA.	dtaylor@cpcnopain.com					ASHBY MA, 1992, PAIN, V51, P153, DOI 10.1016/0304-3959(92)90256-B; BRUERA E, 1989, PAIN, V37, P203, DOI 10.1016/0304-3959(89)90131-0; CELLA DF, 1993, J CLIN ONCOL, V11, P570, DOI 10.1200/JCO.1993.11.3.570; Christie JM, 1998, J CLIN ONCOL, V16, P3238, DOI 10.1200/JCO.1998.16.10.3238; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; DAUT RL, 1983, PAIN, V17, P197, DOI 10.1016/0304-3959(83)90143-4; Fortner BV, 2002, J PAIN, V3, P38, DOI 10.1054/jpai.2002.27136; Fortner BV, 2003, J PAIN SYMPTOM MANAG, V25, P334, DOI 10.1016/S0885-3924(02)00679-6; Fortner BV, 2003, J PAIN SYMPTOM MANAG, V25, P9, DOI 10.1016/S0885-3924(02)00597-3; Lichtor JL, 1999, ANESTH ANALG, V89, P732, DOI 10.1097/00000539-199909000-00038; MERCADANTE S, 1992, PAIN, V50, P151, DOI 10.1016/0304-3959(92)90155-5; MERCADANTE S, 1994, PAIN, V59, P141, DOI 10.1016/0304-3959(94)90058-2; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, PAIN, V79, P303, DOI 10.1016/S0304-3959(98)00179-1; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Portenoy RK, 2006, J PAIN, V7, P583, DOI 10.1016/j.jpain.2006.02.003; SCOTT JC, 1985, ANESTHESIOLOGY, V62, P234, DOI 10.1097/00000542-198503000-00005; STREISAND JB, 1991, ANESTHESIOLOGY, V75, P223, DOI 10.1097/00000542-199108000-00009; Zeppetella G, 2001, PALLIATIVE MED, V15, P243, DOI 10.1191/026921601678576220; Zeppetella G, 2000, J PAIN SYMPTOM MANAG, V20, P87, DOI 10.1016/S0885-3924(00)00161-5	21	33	36	0	0	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	1526-2375			PAIN MED	Pain Med.	APR	2007	8	3					281	288		10.1111/j.1526-4637.2007.00298.x			8	Anesthesiology; Medicine, General & Internal	Anesthesiology; General & Internal Medicine	146OP	WOS:000244944200011	17371416	Bronze			2020-06-30	J	Easley, RB; Brady, KM; Tobias, JD				Easley, R. Blaine; Brady, Kenneth M.; Tobias, Joseph D.			Dexmedetomidine for the treatment of postanesthesia shivering in children	PEDIATRIC ANESTHESIA			English	Article						pediatric; dexmedetomidine; shivering; treatment	RANDOMIZED CONTROLLED-TRIALS; CEREBRAL BLOOD-FLOW; SEDATION; EXPERIENCE; DECREASES; VOLUNTEERS; THRESHOLD; CORONARY	Background: Shivering is a common postanesthesia adverse event with multiple etiologies and multiple suggested prophylactic and abortive treatment regimens. Dexmedetomidine, a centrally acting alpha(2)-adrenergic agonist, has been used as a sedative agent and is known to reduce the shivering threshold. We hypothesized that children with postanesthesia shivering would reduce shivering behavior following a single bolus dose of dexmedetomidine. Methods: Dexmedetomidine was administered in a prospective, open-label fashion. The anesthesia management was uniform consisting of maintenance inhaled anesthesia (sevoflurane) and the intraoperative administration of fentanyl (1-2 mu g.kg(-1)) plus a regional anesthetic technique (either a neuraxial or peripheral block) for postoperative analgesia. Criteria for treatment included: (i) shivering, (ii) successful extubation, and (iii) no other complaint/indication of pain. All children who met the criteria were treated with a single intravenous bolus dose of dexmedetomidine (0.5 mu g.kg(-1)) over 3-5 min. Following the completion of drug administration, shivering activity was recorded every minute (up to 10 min) with any adverse effects or complaints. The efficacy of shivering reduction at 5 min in this cohort is compared with previous reports from the literature of the efficacy of clonidine and meperidine. Results: Twenty-four children ranging in age from 7 to 16 years (11.5 +/- 2.5 years) were treated. All children had a cessation of shivering behavior within 5 min following the completion of dexmedetomidine administration. The onset of effect was 3.5 +/- 0.9 min. No adverse effects were observed. No shivering behavior recurred. Conclusions: This study demonstrates the efficacy of dexmedetomidine in the treatment of postanesthesia shivering.	Johns Hopkins Med Inst, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21287 USA; Univ Missouri, Dept Anesthesiol & Pediat, Columbia, MO USA	Easley, RB (reprint author), Johns Hopkins Med Inst, Dept Anesthesiol & Crit Care Med, 600 N Wolfe St, Baltimore, MD 21287 USA.	beasley@jhmi.edu					Akin A, 2005, PEDIATR ANESTH, V15, P1089, DOI 10.1111/j.1460-9592.2005.01646.x; Berkenbosch John W, 2005, Pediatr Crit Care Med, V6, P435, DOI 10.1097/01.PCC.0000163680.50087.93; Bicer C, 2006, EUR J ANAESTH, V23, P149, DOI 10.1017/S0265021505002061; Cortinez LI, 2004, ANESTHESIOLOGY, V101, P1077, DOI 10.1097/00000542-200411000-00006; COUGHLAN MG, 1992, ANESTHESIOLOGY, V77, P998, DOI 10.1097/00000542-199211000-00024; De Witte J, 2002, ANESTHESIOLOGY, V96, P467, DOI 10.1097/00000542-200202000-00036; Doufas AG, 2003, STROKE, V34, P1218, DOI 10.1161/01.STR.0000068787.76670.A4; Doufas Anthony G, 2003, Best Pract Res Clin Anaesthesiol, V17, P535, DOI 10.1016/S1521-6896(03)00052-1; DUKE P, 1998, INT C S SERIES, V221, P11; Eberhart LHJ, 2005, ANESTH ANALG, V101, P1849, DOI 10.1213/O1.ANE.0000184128.41795.FE; Fahy CJ, 2004, ANAESTH INTENS CARE, V32, P809, DOI 10.1177/0310057X0403200613; Finkel JC, 2005, CRIT CARE MED, V33, P2110, DOI 10.1097/01.CCM.0000178183.21883.23; Finkel JC, 2004, ANESTH ANALG, V98, P1658; Jalonen J, 1997, ANESTHESIOLOGY, V86, P331; Kranke P, 2004, ANESTH ANALG, V99, P718, DOI 10.1213/01.ANE.0000130589.00098.CD; Kranke P, 2002, ANESTH ANALG, V94, P453, DOI 10.1097/00000539-200202000-00043; Kranke Peter, 2003, Paediatr Drugs, V5, P373, DOI 10.2165/00128072-200305060-00003; LYONS B, 1995, ACTA ANAESTH SCAND, V39, P979, DOI 10.1111/j.1399-6576.1995.tb04209.x; Lyons B, 1996, ANAESTHESIA, V51, P442, DOI 10.1111/j.1365-2044.1996.tb07788.x; McPherson RW, 1997, ANESTH ANALG, V84, P139, DOI 10.1097/00000539-199701000-00026; PEROUTKA SJ, 1980, SCIENCE, V208, P610, DOI 10.1126/science.6102801; Prielipp RC, 2002, ANESTH ANALG, V95, P1052, DOI 10.1097/00000539-200210000-00048; SKARBY T, 1984, J AUTON PHARMACOL, V4, P219, DOI 10.1111/j.1474-8673.1984.tb00099.x; Talke P, 1997, ANESTHESIOLOGY, V87, P835, DOI 10.1097/00000542-199710000-00017; Talke P, 1997, ANESTH ANALG, V85, P1136, DOI 10.1097/00000539-199711000-00033; Tobias JD, 2005, PEDIATR ANN, V34, P636, DOI 10.3928/0090-4481-20050801-12; Tobias JD, 2003, SOUTH MED J, V96, P871, DOI 10.1097/01.SMJ.0000053557.75799.09; Tobias JD, 2004, SOUTH MED J, V97, P451, DOI 10.1097/00007611-200405000-00007; Tobias JD, 2002, PAEDIATR ANAESTH, V12, P171, DOI 10.1046/j.1460-9592.2002.00805.x; Vogelsang J, 1994, J Post Anesth Nurs, V9, P214	30	48	50	0	3	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	1155-5645			PEDIATR ANESTH	Pediatr. Anesth.	APR	2007	17	4					341	346		10.1111/j.1460-9592.2006.02100.x			6	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	143RV	WOS:000244742900006	17359402				2020-06-30	J	da Silva, PSL; Iglesias, SBO; Aguiar, VE; de Carvalho, WB				Lucas da Silva, Paulo Sergio; Oliveira Iglesias, Simone Brasil; Aguiar, Vania Euzebio; de Carvalho, Werther Brunow			Procedural sedation for insertion of central venous catheters in children: comparison of midazolam/fentanyl with midazolam/ketamine	PEDIATRIC ANESTHESIA			English	Article						central venous catheter; procedural sedation; midazolam; fentanyl; ketamine	CARDIAC-CATHETERIZATION; EMERGENCY-DEPARTMENT; PEDIATRIC-PATIENTS; KETAMINE SEDATION; ADVERSE EVENTS; ANESTHESIA; ANALGESIA; CARE; CAPNOGRAPHY; PROPOFOL	Background: There is a lack of studies evaluating procedural sedation for insertion of central venous catheters (CVC) in pediatric patients in emergency departments or pediatric intensive care units (PICU). This study was designed to evaluate whether there is a difference in the total sedation time for CVC insertion in nonintubated children receiving two sedation regimens. Methods: Patients were prospectively randomized to receive either midazolam/fentanyl (M/F) or midazolam/ketamine (M/K) i.v. The Children's Hospital of Wiscosin Sedation Scale was used to score the sedation level. Results: Fifty seven patients were studied (28 M/F and 29 M/K). Group M/F received midazolam (0.24 +/- 0.11 mg.kg(-1)) and fentanyl (1.68 +/- 0.83 mu g.kg(-1)) and group M/K received midazolam (0.26 +/- 0.09 mg.kg(-1)) and ketamine (1.40 +/- 0.72 mg.kg(-1)). The groups were similar in age, weight, risk classification time and sedation level. Median total sedation times for M/F and M/K were 97 vs 105 min, respectively (P = 0.67). Minor complications occurred in 3.5% (M/F) vs 20.7% (M/K) (P = 0.03). M/F promoted a greater reduction in respiratory rate (P = 0.005). Conclusions: In this study of nonventilated children in PICU undergoing central line placement, M/F and M/K provided a clinically comparable total sedation time. However, the M/K sedation regimen was associated with a higher rate of minor complications. A longer period of study is required to assess the efficacy and safety of these sedative agents for PICU procedures in nonintubated children.	Hosp Serv Publ Municipal Sao Paulo, Dept Pediat, Pediat Intens Care Unit, Sao Paulo, Brazil	da Silva, PSL (reprint author), Rua Aroeiras 30,Ap 22, Santo Andre, SP, Brazil.	psls.nat@terra.com.br	Silva, Paulo Sergio L/P-5182-2018				[Anonymous], 2004, ANN EMERG MED, V44, P342, DOI 10.1016/j.annemergmed.2004.04.012; Brown TB, 2005, AM FAM PHYSICIAN, V71, P85; de Jonge Rogier C J, 2005, Pediatr Crit Care Med, V6, P329, DOI 10.1097/01.PCC.0000161074.94315.0A; DRIPPS RD, 1961, JAMA-J AM MED ASSOC, V178, P261, DOI 10.1001/jama.1961.03040420001001; Gorman R, 2002, PEDIATRICS, V110, P836; Gozal D, 2004, J PEDIATR-US, V145, P47, DOI 10.1016/j.jpeds.2004.01.044; Green SM, 2004, ANN EMERG MED, V44, P460, DOI 10.1016/j.annemergmed.2004.06.006; Green SM, 2001, PEDIATR EMERG CARE, V17, P244, DOI 10.1097/00006565-200108000-00004; GREENE CA, 1991, AM J CARDIOL, V68, P1116, DOI 10.1016/0002-9149(91)90512-J; Gross JB, 2002, ANESTHESIOLOGY, V96, P1004; Hasan Rashed A, 2003, Pediatr Crit Care Med, V4, P454, DOI 10.1097/01.PCC.0000090013.66899.33; Hoffman GM, 2002, PEDIATRICS, V109, P236, DOI 10.1542/peds.109.2.236; Holger JS, 2005, AM J EMERG MED, V23, P248, DOI 10.1016/j.ajem.2005.01.001; Hunt GS, 2005, AM J EMERG MED, V23, P299, DOI 10.1016/j.ajem.2005.02.042; Jobeir A, 2003, PEDIATR CARDIOL, V24, P236, DOI 10.1007/s00246-002-0339-5; Kennedy RM, 1998, PEDIATRICS, V102, P956, DOI 10.1542/peds.102.4.956; Kogan A, 2003, J CARDIOTHOR VASC AN, V17, P691, DOI 10.1053/j.jvca.2003.09.008; LEBOVIC S, 1992, ANESTH ANALG, V74, P490; Mason KP, 2000, J CLIN MONITOR COMP, V16, P259, DOI 10.1023/A:1011436329848; McQuillen KK, 2000, PEDIATR EMERG CARE, V16, P401, DOI 10.1097/00006565-200012000-00005; Miner JR, 2005, ACAD EMERG MED, V12, P124, DOI 10.1197/j.aem.2004.08.054; Miner JR, 2002, ACAD EMERG MED, V9, P275, DOI 10.1197/aemj.9.4.275; Pees C, 2003, PEDIATR CARDIOL, V24, P424, DOI 10.1007/s00246-002-0356-4; Pena BMG, 1999, ANN EMERG MED, V34, P483, DOI 10.1016/S0196-0644(99)80050-X; Pitetti RD, 2003, ARCH PEDIAT ADOL MED, V157, P1090, DOI 10.1001/archpedi.157.11.1090; Roback MG, 2005, ACAD EMERG MED, V12, P508, DOI 10.1197/j.aem.2004.12.009; Yildizdas D, 2004, PEDIATR EMERG CARE, V20, P162, DOI 10.1097/01.pec.0000117922.65522.26	27	9	10	1	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645	1460-9592		PEDIATR ANESTH	Pediatr. Anesth.	APR	2007	17	4					358	363		10.1111/j.1460-9592.2006.02099.x			6	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	143RV	WOS:000244742900009	17359405				2020-06-30	J	Bagshaw, O				Bagshaw, Oliver			A combination of total intravenous anesthesia and thoracic epidural for thymectomy in juvenile myasthenia gravis	PEDIATRIC ANESTHESIA			English	Article							THORACOSCOPIC THYMECTOMY; CHILDREN; REMIFENTANIL; PROPOFOL; ALFENTANIL; SURGERY	Juvenile myasthenia gravis is the acquired form of the disease in children and presents with ocular signs, fatigability, weakness and bulbar problems. The majority of patients demonstrate thymic hyperplasia and have been shown to benefit from thymectomy. The main considerations for the anesthesiologist are the degree of muscle weakness, the muscle groups involved and sensitivity to neuromuscular blocking drugs and volatile agents. Total intravenous anesthesia (TIVA) with epidural analgesia is probably the anesthetic technique of choice, although the latter is often avoided, because of the risk of a very high block. Two cases of thymectomy are presented where anesthesia was provided using a combination of TIVA and thoracic epidural analgesia. Both patients tolerated the technique well and had an uncomplicated perioperative course.	Birmingham Childrens Hosp, Dept Anaesthesia, Birmingham B4 6NH, W Midlands, England	Bagshaw, O (reprint author), Birmingham Childrens Hosp, Dept Anaesthesia, Steelhouse Lane, Birmingham B4 6NH, W Midlands, England.	oliver.bagshaw@bch.nhs.uk					Abe Shuji, 2001, Japanese Journal of Anesthesiology, V50, P1217; Anlar B, 1999, NEUROPEDIATRICS, V30, P49, DOI 10.1055/s-2007-973458; Batra YK, 2004, PEDIATR ANESTH, V14, P452, DOI 10.1111/j.1460-9592.2004.01208.x; Bouaggad A, 2005, EUR J ANAESTH, V22, P393, DOI 10.1017/S0265021505220677; BROWNE BL, 1992, BRIT J ANAESTH, V69, P570, DOI 10.1093/bja/69.6.570; Ganidagli S, 2003, PAEDIATR ANAESTH, V13, P695, DOI 10.1046/j.1460-9592.2003.01124.x; GUNTER JB, 1992, ANESTHESIOLOGY, V76, P935, DOI 10.1097/00000542-199206000-00010; Hammer GB, 2000, ANESTH ANALG, V90, P1020, DOI 10.1097/00000539-200005000-00004; Hepaguslar H, 2003, PAEDIATR ANAESTH, V13, P842, DOI 10.1046/j.1460-9592.2003.01157.x; Itoh H, 2002, ANESTH ANALG, V95, P109, DOI 10.1097/00000539-200207000-00019; Kiran U, 2000, ACTA ANAESTH SCAND, V44, P351, DOI 10.1034/j.1399-6576.2000.440324.x; Kogut KA, 2000, J PEDIATR SURG, V35, P1576, DOI 10.1053/jpsu.2000.18315; Lindner A, 1997, J NEUROL, V244, P515, DOI 10.1007/s004150050135; Liu W, 2003, CHINESE MED J-PEKING, V116, P1578; Lorimer M, 1998, ANAESTH INTENS CARE, V26, P210, DOI 10.1177/0310057X9802600216; Masaoka A, 1996, ANN THORAC SURG, V62, P853, DOI 10.1016/S0003-4975(96)00376-1; Moriarty A, 1999, PAEDIATR ANAESTH, V9, P423, DOI 10.1046/j.1460-9592.1999.00395.x; Peterson KL, 2000, ANESTH ANALG, V90, P1014, DOI 10.1097/00000539-200005000-00002; Robinson DN, 1998, PAEDIATR ANAESTH, V8, P467; Schmidt J, 2001, ANAESTHESIST, V50, P757, DOI 10.1007/s001010100207; Skelly CL, 2003, AM SURGEON, V69, P1087; TOBIAS JD, 1993, CAN J ANAESTH, V40, P810; Venuta F, 1999, EUR J CARDIO-THORAC, V15, P621, DOI 10.1016/S1010-7940(99)00052-4; White MC, 2004, PEDIATR ANESTH, V14, P625, DOI 10.1111/j.1460-9592.2004.01292.x	24	11	14	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645	1460-9592		PEDIATR ANESTH	Pediatr. Anesth.	APR	2007	17	4					370	374		10.1111/j.1460-9592.2006.02122.x			5	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	143RV	WOS:000244742900011	17359407				2020-06-30	J	Quraishi, SA; Girdharry, TD; Xu, SG; Orkin, FK				Quraishi, Sadeq A.; Girdharry, Tyrone D.; Xu, Shu-Guang; Orkin, Fredrick K.			Prolonged retrograde amnesia following sedation with propofol in a 12-year-old boy	PEDIATRIC ANESTHESIA			English	Article						propofol; amnesia; sedation; complication	LONG-TERM POTENTIATION; SEIZURE-LIKE PHENOMENA; HIPPOCAMPAL SLICES; BRAIN; EVENTS; MEMORY; ANESTHESIA; REGIONS	Propofol is commonly used for sedation in a variety of clinical settings, as well as for induction and maintenance of anesthesia. The ease with which propofol can be administered and titrated to clinical effect, in addition to its accepted safety profile, has made it the drug of choice for sedation in outpatient procedures, such as gastrointestinal endoscopy. While short-term amnesia is a well-known side-effect of propofol, we present the first documented case of prolonged retrograde amnesia following propofol administration in a pediatric patient. Possible mechanisms and clinical management strategies related to this unique event are discussed.	Penn State Univ, Coll Med, Dept Anesthesiol, Div Pediat Neurol, Hershey, PA 17033 USA; Penn State Univ, Coll Med, Dept Pediat, Div Pediat Neurol, Hershey, PA 17033 USA; Penn State Univ World Campus, Program Homeland Secur Publ Hlth Preparedness, University Pk, PA USA; Yale Univ, Sch Med, Dept Anesthesiol, New Haven, CT 06510 USA	Quraishi, SA (reprint author), Penn State Univ, Coll Med, Dept Anesthesiol, Div Pediat Neurol, 500 Univ Dr,H187, Hershey, PA 17033 USA.	squraishi@psu.edu					Barber PA, 1999, STROKE, V30, P2059, DOI 10.1161/01.STR.30.10.2059; Buhr A, 2002, HUM GENET, V111, P154, DOI 10.1007/s00439-002-0766-7; FINLEY GA, 1993, CAN J ANAESTH, V40, P863, DOI 10.1007/BF03009258; Grant PE, 2001, RADIOLOGY, V221, P43, DOI 10.1148/radiol.2211001523; Hickey KS, 2005, J EMERG MED, V29, P447, DOI 10.1016/j.jemermed.2005.05.009; Ishitobi S, 2003, BEHAV BRAIN RES, V141, P223, DOI 10.1016/S0166-4328(02)00375-3; KAPUR N, 1993, CORTEX, V29, P217, DOI 10.1016/S0010-9452(13)80177-3; Kapur N, 1999, HIPPOCAMPUS, V9, P247, DOI 10.1002/(SICI)1098-1063(1999)9:3<247::AID-HIPO5>3.0.CO;2-W; Lopez U, 2006, PEDIATR ANESTH, V16, P85, DOI 10.1111/j.1460-9592.2005.01607.x; Marik PE, 2004, CURR PHARM DESIGN, V10, P3639, DOI 10.2174/1381612043382846; MCHUGH TJ, 1996, CELL, V87, P1147; Millar K, 2006, ANAESTHESIA, V61, P541, DOI 10.1111/j.1365-2044.2006.04662.x; Miner JR, 2005, ACAD EMERG MED, V12, P491, DOI 10.1197/j.aem.2005.01.011; Nagashima K, 2005, ANESTHESIOLOGY, V103, P318, DOI 10.1097/00000542-200508000-00015; Nyberg L, 1996, P NATL ACAD SCI USA, V93, P11280, DOI 10.1073/pnas.93.20.11280; Reed JM, 1998, J NEUROSCI, V18, P3943; Rees PM, 2003, ARCH PHYS MED REHAB, V84, P1885, DOI 10.1016/j.apmr.2003.03.001; Riker RR, 2005, PHARMACOTHERAPY, V25, p8S, DOI 10.1592/phco.2005.25.5_Part_2.8S; Sancar F, 2004, J BIOL CHEM, V279, P47034, DOI 10.1074/jbc.M403388200; SQUIRE LR, 1995, CURR OPIN NEUROBIOL, V5, P169, DOI 10.1016/0959-4388(95)80023-9; Squire LR, 2001, HIPPOCAMPUS, V11, P50, DOI 10.1002/1098-1063(2001)11:1<50::AID-HIPO1019>3.0.CO;2-G; Stracciari A, 2005, MEMORY, V13, P690, DOI 10.1080/09658210444000331; Sutherland RJ, 2001, HIPPOCAMPUS, V11, P27, DOI 10.1002/1098-1063(2001)11:1<27::AID-HIPO1017>3.0.CO;2-4; Takamatsu I, 2005, NEUROSCI LETT, V389, P129, DOI 10.1016/j.neulet.2005.07.043; Veselis RA, 2005, ANESTHESIOLOGY, V102, P26, DOI 10.1097/00000542-200501000-00008; Veselis RA, 2004, ANESTHESIOLOGY, V101, P831, DOI 10.1097/00000542-200410000-00006; Veselis RA, 2004, ANESTH ANALG, V99, P399; Veselis RA, 2002, ANESTHESIOLOGY, V97, P329, DOI 10.1097/00000542-200208000-00008; Walder B, 2002, NEUROLOGY, V58, P1327, DOI 10.1212/WNL.58.9.1327; Warrington EK, 1996, P NATL ACAD SCI USA, V93, P13523, DOI 10.1073/pnas.93.24.13523	30	7	9	0	1	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	1155-5645			PEDIATR ANESTH	Pediatr. Anesth.	APR	2007	17	4					375	379		10.1111/j.1460-9592.2006.02123.x			5	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	143RV	WOS:000244742900012	17359408				2020-06-30	J	Das Adhikary, S; Korula, PJ				Das Adhikary, Sanjib; Korula, Pritish John			The role of monitoring the depth of anesthesia in a case of hereditary sensory and autonomic neuropathy (Riley Day syndrome)	PEDIATRIC ANESTHESIA			English	Letter							FAMILIAL DYSAUTONOMIA		Christian Med Coll & Hosp, Dept Anaesthesia, Vellore 632004, Tamil Nadu, India	Das Adhikary, S (reprint author), Christian Med Coll & Hosp, Dept Anaesthesia, Vellore 632004, Tamil Nadu, India.	sanjibadhikary@gmail.com		Adhikary, Sanjib/0000-0001-7167-1184			Benini F, 2005, ANESTH ANALG, V101, P641, DOI 10.1213/01.ANE.0000157566.41739.2C; INKSTER JS, 1971, BRIT J ANAESTH, V43, P509, DOI 10.1093/bja/43.5.509; Ngai J, 2006, PEDIATR ANESTH, V16, P611, DOI 10.1111/j.1460-9592.2006.01947.x	3	0	0	0	0	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	1155-5645			PEDIATR ANESTH	Pediatr. Anesth.	APR	2007	17	4					402	403		10.1111/j.1460-9592.2006.02116.x			3	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	143RV	WOS:000244742900024	17359420				2020-06-30	J	Mills, PC; Cross, SE				Mills, P. C.; Cross, S. E.			Regional differences in transdermal penetration of fentanyl through equine skin	RESEARCH IN VETERINARY SCIENCE			English	Article						fentanyl; horse; transdermal; TTS fentanyl	CLINICAL PHARMACOKINETICS; PERCUTANEOUS-ABSORPTION; TRANSFOLLICULAR ROUTES; IN-VITRO; HYDROCORTISONE; DELIVERY; PATCHES; SITES	The rate and regional differences for the penetration of fentanyl through equine skin was investigated in vitro using a commercial transdermal therapeutic system (TTS) or 'patch'. Skin collected from the thorax, groin and leg (dorsal metacarpal) regions of five horses was placed in diffusion cells and a fentanyl TTS applied to each skin sample. Drug penetration through each skin sample over 48 h measured using high performance liquid chromatography (HPLC). Cumulative penetration (mu g/cm(2)) was plotted against time (h) and used to regress the steady state flux ( mu g/cm(2)/h) of fentanyl through each skin site. Results showed similar fluxes for both the thorax (2.32 +/- 0.17 mu g/cm(2)/h and groin (2.21 +/- 0.11 (mu g/cm(2) /h) regions, but significantly lower flux (P = < 0.05) for the leg region (1.56 +/- 0.120 mu g/cm(2)/h. Interestingly, there was a significantly longer lag time for the penetration of fentanyl through the groin region (7.87 +/- 0.51 h) compared to the other two sites (5.66 +/- 0.97 h and 5.75 +/- 0.43 h for the thorax and leg regions respectively). The results suggest that a fentanyl TTS applied to the leg region may have a small but significantly lower amount of fentanyl available systemically, compared to patches applied to the thorax or groin regions, which may affect the level of analgesia subsequently achieved in the horse. (c) 2006 Elsevier Ltd. All rights reserved.	Univ Queensland, Sch Vet Sci, Brisbane, Qld 4072, Australia; Univ Queensland, Princess Alexandra Hosp, So Clin Div, Therapeut Res Unit, Brisbane, Qld 4102, Australia	Mills, PC (reprint author), Univ Queensland, Sch Vet Sci, Brisbane, Qld 4072, Australia.	p.mills@uq.edu.au					Egger CM, 1998, VET SURG, V27, P159, DOI 10.1111/j.1532-950X.1998.tb00114.x; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; HUEBER F, 1992, SKIN PHARMACOL, V5, P99; HUEBER F, 1994, SKIN PHARMACOL, V7, P237, DOI 10.1159/000211300; KAMERLING SG, 1985, GEN PHARMACOL, V16, P253, DOI 10.1016/0306-3623(85)90078-3; Kyles AE, 1996, AM J VET RES, V57, P715; Magnusson BM, 2001, ADV DRUG DELIVER REV, V50, P205, DOI 10.1016/S0169-409X(01)00158-2; MANNING TO, 1991, AM J VET RES, V52, P1960; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; Maxwell LK, 2003, EQUINE VET J, V35, P484, DOI 10.2746/042516403775600415; Mills PC, 2005, AM J VET RES, V66, P43, DOI 10.2460/ajvr.2005.66.43; Mills PC, 2004, AM J VET RES, V65, P1697, DOI 10.2460/ajvr.2004.65.1697; MONTEIRORIVIERE NA, 1990, J INVEST DERMATOL, V95, P582, DOI 10.1111/1523-1747.ep12505567; MONTEIRORIVIERE NA, 1993, PHARMACEUT RES, V10, P1326, DOI 10.1023/A:1018973814456; PLEZIA PM, 1989, PHARMACOTHERAPY, V9, P2; QIAO GL, 1995, J PHARM SCI, V84, P425, DOI 10.1002/jps.2600840408; Riviere JE, 2001, ADV DRUG DELIVER REV, V50, P175, DOI 10.1016/S0169-409X(01)00157-0; Roberts MS, 2002, DRUGS PHARM SCI, V119, P89; ROY SD, 1990, PHARMACEUT RES, V7, P842, DOI 10.1023/A:1015912932416; Schaefer H, 2001, SKIN PHARMACOL APPL, V14, P23, DOI 10.1159/000056386; Schultheiss P J, 1995, Contemp Top Lab Anim Sci, V34, P75; Thomasy SM, 2004, J VET INTERN MED, V18, P550, DOI 10.1892/0891-6640(2004)18&lt;550:TFCWNA&gt;2.0.CO;2; TUR E, 1991, SKIN PHARMACOL, V4, P230; VARVEL JR, 1989, ANESTHESIOLOGY, V70, P928, DOI 10.1097/00000542-198906000-00008; WECKMAN TJ, 1989, AM J VET RES, V50, P502; WEGNER TJ, 2002, P AM ASS EQUINE PRAC, V48, P291	26	15	15	0	20	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0034-5288	1532-2661		RES VET SCI	Res. Vet. Sci.	APR	2007	82	2					252	256		10.1016/j.rvsc.2006.07.015			5	Veterinary Sciences	Veterinary Sciences	146FX	WOS:000244921000019	17011603				2020-06-30	J	Viscusi, ER				Viscusi, Eugene R.			Emerging treatment modalities: Balancing efficacy and safety	AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY			English	Article; Proceedings Paper	41st Midyear Clinical Meeting of the American-Society-of-Health-System-Pharmacists	DEC 03-07, 2006	Anaheim, CA	Amer Soc Hlth Syst Pharmacists		analgesics and antipyretics; drug administration routes; drug comparisons; duration of action; errors, medication; fentanyl; iontophoresis; morphine; opiate antagonists; opiates; pain; patient-controlled analgesia; surgery; sustained-action medications; technology; toxicity	IONTOPHORETIC TRANSDERMAL SYSTEM; PATIENT-CONTROLLED ANALGESIA; RELEASE EPIDURAL MORPHINE; ACUTE-PAIN MANAGEMENT; POSTOPERATIVE PAIN; DELIVERY; SURGERY	Purpose. The advantages and disadvantages of intravenous patient-controlled analgesia (i.v. PCA) and epidural analgesia are discussed. New approaches to the management of patients with acute postoperative pain are described. The results of controlled clinical trials with these modalities are presented. Summary. Intravenous patient-controlled analgesia, while effective, is a burdensome technology requiring approximately 125 steps and at least 6 staff members. Furthermore, medication and pump programming errors may lead to patient injury. Epidural analgesia via catheter has a high reported failure rate, causing analgesic gaps and requiring a high level of staff intervention. In a clinical trial involving hip arthroplasty, extended-release epidural morphine demonstrated a 48-hour duration of action with a marked reduction in need for supplemental analgesia. The fentanyl lontophoretic Transdermal System has demonstrated therapeutic equivalence with morphine intravenous patient-controlled analgesia and similar safety. Selective opioid antagonists are under development that may selectively block gastrointestinal opioid receptors while preserving analgesia. Conclusion. Recently approved agents and those in development may address a variety of unmet needs in the management of patients with post-operative pain.	Thomas Jefferson Univ Hosp, Dept Anesthesiol, Philadelphia, PA 19107 USA	Viscusi, ER (reprint author), Thomas Jefferson Univ Hosp, Dept Anesthesiol, 111 S 11th St,Suite G8490, Philadelphia, PA 19107 USA.	eugene.viscusi@jefferson.edu					*AM SOC REG AN PAI, CONS STAT; Apfelbaum JL, 2003, ANESTH ANALG, V97, P534, DOI 10.1213/01.ANE.0000068822.10113.9E; Block BM, 2003, JAMA-J AM MED ASSOC, V290, P2455, DOI 10.1001/jama.290.18.2455; Carr DB, 2005, REGION ANESTH PAIN M, V30, P286, DOI 10.1016/j.rapm.2004.10.009; Carvalho B, 2005, ANESTH ANALG, V100, P1150, DOI 10.1213/01.ANE.0000149544.58230.FF; *END PHARM INC, 2006, DEPODUR MORPH SULF E; Hartrick CT, 2006, REGION ANESTH PAIN M, V31, P546, DOI 10.1016/j.rapm.2006.08.011; Mayes S, 2006, ANN PHARMACOTHER, V40, P2178, DOI 10.1345/aph.1H135; *ORTH MCNEIL INC, 2006, IONSYS PACK INS; Ready LB, 1999, REGION ANESTH PAIN M, V24, P499, DOI 10.1016/S1098-7339(99)90038-X; Taguchi A, 2001, NEW ENGL J MED, V345, P935, DOI 10.1056/NEJMoa010564; *USP CTR ADV PAT S, PAT CONTR AN PUMPS; Viscusi ER, 2006, AM J HEALTH-SYST PH, V63, pS3, DOI 10.2146/ajhp060011; Viscusi ER, 2004, AM J HEALTH-SYST PH, V61, pS11, DOI 10.1093/ajhp/61.suppl_1.S11; Viscusi ER, 2004, JAMA-J AM MED ASSOC, V291, P1333, DOI 10.1001/jama.291.11.1333; Viscusi ER, 2006, SURG ENDOSC, V20, P64, DOI 10.1007/s00464-005-0104-y; Viscusi ER, 2005, REGION ANESTH PAIN M, V30, P491, DOI 10.1016/j.rapm.2005.05.001; Viscusi ER, 2005, ANESTHESIOLOGY, V102, P1014, DOI 10.1097/00000542-200505000-00022	18	4	4	0	6	AMER SOC HEALTH-SYSTEM PHARMACISTS	BETHESDA	7272 WISCONSIN AVE, BETHESDA, MD 20814 USA	1079-2082	1535-2900		AM J HEALTH-SYST PH	Am. J. Health-Syst. Pharm.	MAR 15	2007	64			S			S6	S11		10.2146/ajhp060680			6	Pharmacology & Pharmacy	Pharmacology & Pharmacy	153YB	WOS:000245472900002	17353558				2020-06-30	J	Hemingway, CJ; Malhotra, S; Almeida, M; Azadian, B; Yentis, SM				Hemingway, C. J.; Malhotra, S.; Almeida, M.; Azadian, B.; Yentis, S. M.			The effect of alcohol swabs and filter straws on reducing contamination of glass ampoules used for neuroaxial injections	ANAESTHESIA			English	Article; Proceedings Paper	Annual Meeting of the Obstetric-Anaesthetists-Association	MAY, 2006	Glasgow, SCOTLAND	Obstet Anaesthetists Assoc			SURGICAL FACE MASKS; REGIONAL ANESTHESIA; PARTICLE CONTAMINATION; NEURAXIAL BLOCKADE; DISPERSAL; OPIOIDS; COMPLICATION; MENINGITIS; INFECTION; BACTERIA	We have investigated the incidence of contamination of the contents of glass ampoules used for neuraxial injections, and whether this was reduced by wiping the outsides of the ampoules with isopropyl alcohol or using a filter straw. One hundred fentanyl and diamorphine ampoules used for routine regional anaesthesia were either wiped or not wiped with alcohol before their contents were aspirated, and the residual contents were swabbed and incubated. None of the swabs from the wiped ampoules grew organisms compared with nine (18%) from non-wiped ampoules (p = 0.004). In a second, laboratory study, 100 glass ampoules of saline were coated with Staphylococcus aureus and divided into four groups: wiped/not wiped with alcohol and with/without a filter straw. The contents of the ampoules were aspirated; the remnants and the aspirate were swabbed and incubated as before. Most contamination occurred in the unwiped groups and although numbers were small, filtering appeared to reduce contamination further. As filter straws also reduce the risk of injecting glass particles (even if not contaminated), our results suggest that wiping glass ampoules with isopropyl alcohol and using a filter straw should be part of routine practice when performing regional anaesthesia.	Chelsea & Westminster Hosp, London, England	Malhotra, S (reprint author), Chelsea & Westminster Hosp, 369 Fulham Rd, London, England.	surbhi27@googlemail.com					Baer ET, 2006, ANESTHESIOLOGY, V105, P381, DOI 10.1097/00000542-200608000-00022; Birnbach DJ, 2003, ANESTHESIOLOGY, V98, P164, DOI 10.1097/00000542-200301000-00026; Grewal S, 2006, BRIT J ANAESTH, V96, P292, DOI 10.1093/bja/ael006; HARDING SA, 1994, BRIT J ANAESTH, V73, P545, DOI 10.1093/bja/73.4.545; Hepner DL, 2006, ANESTHESIOLOGY, V105, P241, DOI 10.1097/00000542-200608000-00005; Lye ST, 2003, ANAESTHESIA, V58, P93, DOI 10.1046/j.1365-2044.2003.296812.x; McConaghy P, 1996, ANAESTHESIA, V51, P1079; McLure HA, 1998, ANAESTHESIA, V53, P624, DOI 10.1046/j.1365-2044.1998.435-az0528.x; McLure HA, 2000, ANAESTHESIA, V55, P173, DOI 10.1046/j.1365-2044.2000.055002173.x; Mulvein JT, 1997, ANAESTHESIA, V52, P183; PHILIPS BJ, 1992, BRIT J ANAESTH, V69, P407, DOI 10.1093/bja/69.4.407; Reynolds F, 2005, INT J OBSTET ANESTH, V14, P183, DOI 10.1016/j.ijoa.2005.04.001; SABON RL, 1989, ANESTHESIOLOGY, V70, P859, DOI 10.1097/00000542-198905000-00024; Tunstall ME, 1997, ANAESTHESIA, V52, P290; Yentis SM, 2006, INT J OBSTET ANESTH, V15, P85, DOI 10.1016/j.ijoa.2005.08.005; ZACHER AN, 1991, ANESTHESIOLOGY, V75, P893, DOI 10.1097/00000542-199111000-00022	16	16	20	2	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0003-2409	1365-2044		ANAESTHESIA	Anaesthesia	MAR	2007	62	3					286	288		10.1111/j.1365-2044.2007.04977.x			3	Anesthesiology	Anesthesiology	134RE	WOS:000244100700014	17300308				2020-06-30	J	Zohar, E; Noga, Y; Rislick, U; Leibovitch, I; Fredman, B				Zohar, Edna; Noga, Yossi; Rislick, Uri; Leibovitch, Ilan; Fredman, Brian			Intrathecal anesthesia for elderly patients undergoing short transurethral procedures: A dose-finding study	ANESTHESIA AND ANALGESIA			English	Article							FENTANYL SPINAL-ANESTHESIA; BUPIVACAINE; RECOVERY; SURGERY	One hundred elderly men (>= 65 yr) undergoing transurethral procedures (< 45 min) received bupivacaine 7.5 mg, or bupivacaine 5 mg + fentanyl 20 mu g, or bupivacaine 4 mg + fentanyl 20 mu g, or bupivacame 3 mg + fentanyl 20 mu g, intrathecally. Intracoperative "rescue" fentanyl requirements were higher (P < 0.03) in group bupivacaine 3 mg + fentanyl. Times (min) to ambulation eligibility were decreased in a dose-dependant manner (157 +/- 50 vs 147 +/- 37 vs 128 +/- 40 vs 116 +/- 29, respectively). Of the techniques studied, intrathecal bupivacaine 4 mg + fentanyl 20 mu g provided adequate analgesia and was associated with hemodynamic stability and a favorable recovery profile.	Meir Med Ctr, Dept Anesthesiol & Intens Care, Dept Anesthesiol Crit Care & Pain Management, IL-44281 Kefar Sava, Israel; Meir Med Ctr, Dept Urol, IL-44281 Kefar Sava, Israel; Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel	Fredman, B (reprint author), Meir Med Ctr, Dept Anesthesiol & Intens Care, Dept Anesthesiol Crit Care & Pain Management, IL-44281 Kefar Sava, Israel.	fredman.brian@clalit.org.il					Ben-David B, 2000, ANESTHESIOLOGY, V92, P6, DOI 10.1097/00000542-200001000-00007; BenDavid B, 1997, ANESTH ANALG, V85, P560, DOI 10.1097/00000539-199709000-00014; FRAGEN RJ, 1997, GERIATRIC ANESTHESIO, P275; Fredman B, 1999, ANESTH ANALG, V89, P1161, DOI 10.1213/00000539-199911000-00014; Goel S, 2003, EUR J ANAESTH, V20, P294, DOI 10.1097/00003643-200304000-00004; Kararmaz A, 2003, ANAESTHESIA, V58, P526, DOI 10.1046/j.1365-2044.2003.03153.x; Kuusniemi KS, 2000, ANESTH ANALG, V91, P1452, DOI 10.1097/00000539-200012000-00029; SINGH H, 1995, CAN J ANAESTH, V42, P987, DOI 10.1007/BF03011070; White PF, 1999, ANESTH ANALG, V88, P1069, DOI 10.1097/00000539-199905000-00018	9	12	14	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	MAR	2007	104	3					552	554		10.1213/01.ane.0000255329.55037.cd			3	Anesthesiology	Anesthesiology	139KU	WOS:000244431500021	17312207				2020-06-30	J	Sia, AT; Lim, Y; Ocampo, C				Sia, Alex T.; Lim, Yvonne; Ocampo, Cecilia			A comparison of a basal infusion with automated mandatory boluses in parturient-controlled epidural analgesia during labor	ANESTHESIA AND ANALGESIA			English	Article							BACKGROUND INFUSION; BUPIVACAINE; SUFENTANIL; DELIVERY	BACKGROUND: The use of parturient-controlled epidural analgesia (PCEA) with a basal infusion is commonly used in laboring women. We compared a novel approach of providing basal intermittent boluses concurrently with PCEA: PCEA plus automated mandatory boluses (PCEA+AMB) versus PCEA plus basal continuous infusion (PCEA+BCI). We hypothesized that epidural local anesthetic consumption would be lower if basal intermittent boluses were used instead of a basal infusion. METHODS: We randomized 42 healthy parturients in early labor to receive 0.1% ropivacaine + fentanyl 2 mu g/mL either via PCEA+BCI (n = 21,bolus 5 mL, lockout 10 min, basal infusion 5 mL/h) or via PCEA+AMB (n = 21, patient-activated bolus of 5 mL, lockout 10 min, basal automated boluses of 5 mL/h [omitted if a patient-activated bolus was successfully administered in the last 1 h]) after successful induction of combined spinal epidural analgesia. RESULTS:We found a reduction in the hourly consumption of ropivacaine with PCEA+AMB, i.e., the primary outcome measure (mean = 6.5 mL, SD = 3.4 in the PCEA+AMB group vs 7.5 mL, SD = 2.0 PCEA+BCI group, P = 0.011). A larger proportion of parturients in the PCEA+AMB group did not self-bolus (6/21 vs 1/21 in PCEA+BCI, P = 0.03). The time to the first self-bolus after combined spinal epidural was longer in the PCEA+AMB group (mean survival time 315 min vs 190 min in PCEA+BCI group, P = 0.04 by log rank test). There was no difference in pain scores or side effects. CONCLUSION: Our study showed that PCEA+AMB reduced analgesic consumption and could be useful as the mode of maintenance for epidural analgesia.	KK Womens & Childrens Hosp, Dept Womens Anaesthesia, Singapore 229899, Singapore	Sia, AT (reprint author), KK Womens & Childrens Hosp, Dept Womens Anaesthesia, 100 Bukit Timah Rd, Singapore 229899, Singapore.	athsia@kkh.com.sg					Boselli E, 2004, ANESTHESIOLOGY, V100, P968, DOI 10.1097/00000542-200404000-00030; Bremerich DH, 2005, INT J OBSTET ANESTH, V14, P114, DOI 10.1016/j.ijoa.2004.12.005; Capogna G, 1998, BRIT J ANAESTH, V80, P11; Christiaens F, 1998, REGION ANESTH PAIN M, V23, P134, DOI 10.1097/00115550-199823020-00004; Chua SMH, 2004, CAN J ANAESTH, V51, P581, DOI 10.1007/BF03018402; FERRANTE FM, 1994, ANESTH ANALG, V79, P80; Hogan Q, 2002, REGION ANESTH PAIN M, V27, P150, DOI 10.1053/rapm.2002.29748; Kaynar AM, 1999, ANESTH ANALG, V89, P534, DOI 10.1097/00000539-199908000-00063; Lim Y, 2005, INT J OBSTET ANESTH, V14, P305, DOI 10.1016/j.ijoa.2005.05.004; Missant C, 2005, ANAESTH INTENS CARE, V33, P452, DOI 10.1177/0310057X0503300405; PAECH MJ, 1992, ANAESTH INTENS CARE, V20, P15, DOI 10.1177/0310057X9202000103; POWER I, 1988, ANAESTHESIA, V43, P876; van der Vyver M, 2002, BRIT J ANAESTH, V89, P459, DOI 10.1093/bja/aef217; Wong CA, 2006, ANESTH ANALG, V102, P904, DOI 10.1213/01.ane.0000197778.57615.1a	14	57	61	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	MAR	2007	104	3					673	678		10.1213/01.ane.0000253236.89376.60			6	Anesthesiology	Anesthesiology	139KU	WOS:000244431500045	17312228				2020-06-30	J	Wan, YJ; Xu, J; Ma, DQ; Zeng, YM; Cibelli, M; Maze, M				Wan, Yanjie; Xu, Jing; Ma, Daqing; Zeng, Yinming; Cibelli, Mario; Maze, Mervyn			Postoperative impairment of cognitive function in rats - A possible role for cytokine-mediated inflammation in the hippocampus	ANESTHESIOLOGY			English	Article; Proceedings Paper	Annual Meeting of the American-Society-of-Anesthesiologists	OCT 14-18, 2006	Chicago, IL	Amer Soc Anesthesiologists			LONG-TERM POTENTIATION; NECROSIS-FACTOR-ALPHA; LAPAROSCOPIC CHOLECYSTECTOMY; SERUM INTERLEUKIN-6; GENERAL-ANESTHESIA; NEUROCOGNITIVE FUNCTION; REGIONAL ANESTHESIA; ELECTIVE SURGERY; BYPASS-SURGERY; MAJOR SURGERY	Background: Postoperative cognitive dysfunction is being increasingly reported as a complication. The authors investigated the role of cytokine-mediated inflammation within the central nervous system in the development of cognitive dysfunction in a rat model. Methods: Adult rats were subjected to neuroleptic anesthesia (20 mu g/kg fentanyl plus 500 mu g/kg droperidol, intraperitoneal) for splenectomy or no surgery. On postanesthetic days 1, 3, and 7, cognitive function was assessed in a Y maze. To evaluate the immune response in the hippocampus, the authors measured glial activation, as well as transcription and expression of key proinflammatory cytokines interleukin 10 and tumor necrosis factor a. To determine propensity for apoptosis, they measured expression of Bax and Bcl-2. Results: Cognitive function in splenectomized animals was impaired at days 1 and 3 after surgery compared with cognitive function in nonanesthetized rats. At all times, anesthetized rats that were not subjected to surgery were no different from control rats. Glial activation was observed in the hippocampus only in splenectomized rats at postsurgery days 1 and 3. Interleukin-1 beta messenger RNA (mRNA) was significantly increased at postsurgery days 1 and 3, with an increase in protein expression detected on day 1. There was a significant increase in tumor necrosis factor-a mRNA on day 1 after surgery, although this was not associated with an increase in protein expression. The ratio of Bcl-2:Bax was significantly decreased in the splenectomized animals. Conclusion: These results suggest that splenectomy performed during neuroleptic anesthesia triggers a cognitive decline that is associated with a hippocampal inflammatory response that seems to be due to proinflammatory cytokine-dependent activation of glial cells.	Univ London Imperial Coll Sci Technol & Med, Chelsea & Westminster Hosp, Dept Anaesthet Pain Med & Intens Care, Fac Med, London SW10 9NH, England; Gongli Hosp, Dept Anesthesiol, Shanghai, Peoples R China	Maze, M (reprint author), Univ London Imperial Coll Sci Technol & Med, Chelsea & Westminster Hosp, Dept Anaesthet Pain Med & Intens Care, Fac Med, 369 Fulham Rd, London SW10 9NH, England.	m.maze@imperial.ac.uk		Ma, Daqing/0000-0002-0688-2097			Bachman SL, 2005, SURG ENDOSC, V19, P1035, DOI 10.1007/s00464-004-8820-2; BAIGRIE RJ, 1992, BRIT J SURG, V79, P757, DOI 10.1002/bjs.1800790813; Bekker Alex Y, 2003, Best Pract Res Clin Anaesthesiol, V17, P259, DOI 10.1016/S1521-6896(03)00005-3; Bernardino L, 2005, J NEUROSCI, V25, P6734, DOI 10.1523/JNEUROSCI.1510-05.2005; Buvanendran A, 2006, ANESTHESIOLOGY, V104, P403, DOI 10.1097/00000542-200603000-00005; CAMPBELL DNC, 1993, ANAESTHESIA, V48, P422, DOI 10.1111/j.1365-2044.1993.tb07019.x; CROZIER TA, 1994, BRIT J ANAESTH, V72, P280, DOI 10.1093/bja/72.3.280; CRUICKSHANK AM, 1990, CLIN SCI, V79, P161, DOI 10.1042/cs0790161; Dantzer R, 2001, BRAIN BEHAV IMMUN, V15, P7, DOI 10.1006/brbi.2000.0613; Dodds C, 1998, BRIT J ANAESTH, V81, P449, DOI 10.1093/bja/81.3.449; DUNN AJ, 1992, J PHARMACOL EXP THER, V261, P964; EDWARDS H, 1981, JAMA-J AM MED ASSOC, V245, P1342, DOI 10.1001/jama.245.13.1342; FRANCIS J, 1992, J AM GERIATR SOC, V40, P601, DOI 10.1111/j.1532-5415.1992.tb02111.x; Gaykema RPA, 1998, NEUROIMMUNOMODULAT, V5, P234, DOI 10.1159/000026343; GHONEIM MM, 1988, ANESTHESIOLOGY, V69, P507, DOI 10.1097/00000542-198810000-00010; GIULIAN D, 1988, J NEUROSCI, V8, P2485; GLASER F, 1995, ANN SURG, V221, P372; GUTIERREZ EG, 1993, J NEUROIMMUNOL, V47, P169, DOI 10.1016/0165-5728(93)90027-V; Hansen MK, 1998, AM J PHYSIOL-REG I, V274, pR1734; Hanson MR, 2004, NEUROL CLIN, V22, P413, DOI 10.1016/j.ncl.2004.01.001; HEBERT JC, 1994, J TRAUMA, V37, P909, DOI 10.1097/00005373-199412000-00006; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Jarrard LE, 1995, BEHAV BRAIN RES, V71, P1, DOI 10.1016/0166-4328(95)00034-8; Johnson JD, 2002, BRAIN BEHAV IMMUN, V16, P461, DOI 10.1006/brbi.2001.0638; Jones MJ, 1998, ACTA CHIR SCAND, V550, P169; JORIS J, 1992, BRIT J ANAESTH, V69, P341, DOI 10.1093/bja/69.4.341; KARHUNEN U, 1982, ACTA ANAESTH SCAND, V26, P291, DOI 10.1111/j.1399-6576.1982.tb01769.x; KATSUKI H, 1990, EUR J PHARMACOL, V181, P323, DOI 10.1016/0014-2999(90)90099-R; Kelly A, 2003, J BIOL CHEM, V278, P19453, DOI 10.1074/jbc.M301938200; KLOOSTERMAN T, 1994, SURGERY, V115, P424; LAYE S, 1995, AM J PHYSIOL-REG I, V268, pR1327; Mahdy AM, 2002, BRIT J ANAESTH, V88, P797, DOI 10.1093/bja/88.6.797; Matsumoto ED, 2005, J ENDOUROL, V19, P1140, DOI 10.1089/end.2005.19.1140; McGeer PL, 1995, BRAIN RES REV, V21, P195, DOI 10.1016/0165-0173(95)00011-9; Moller JT, 1998, LANCET, V351, P857, DOI 10.1016/S0140-6736(97)07382-0; MOORE CM, 1994, BRIT J ANAESTH, V72, P272, DOI 10.1093/bja/72.3.272; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Newman MF, 2001, STROKE, V32, P2874, DOI 10.1161/hs1201.099803; Newman MF, 2001, NEW ENGL J MED, V344, P395, DOI 10.1056/NEJM200102083440601; Nguyen KT, 1998, J NEUROSCI, V18, P2239; O'Connor KA, 2003, BRAIN RES, V991, P123, DOI 10.1016/j.brainres.2003.08.006; Packard MG, 1996, NEUROBIOL LEARN MEM, V65, P65, DOI 10.1006/nlme.1996.0007; Rasmussen LS, 2004, ACTA ANAESTH SCAND, V48, P1137, DOI 10.1111/j.1399-6576.2004.00502.x; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; RIIS J, 1983, ACTA ANAESTH SCAND, V27, P44, DOI 10.1111/j.1399-6576.1983.tb01903.x; Roach GW, 1996, NEW ENGL J MED, V335, P1857, DOI 10.1056/NEJM199612193352501; SHENKIN A, 1989, LYMPHOKINE RES, V8, P123; Tanaka S, 2006, J NEUROSCI RES, V83, P557, DOI 10.1002/jnr.20752; UEO H, 1994, AM J SURG, V168, P358, DOI 10.1016/S0002-9610(05)80166-7; VanDam AM, 1996, FASEB J, V10, P351; WILLIAMSRUSSO P, 1995, JAMA-J AM MED ASSOC, V274, P44, DOI 10.1001/jama.274.1.44; Wilson CJ, 2002, J AM GERIATR SOC, V50, P2041, DOI 10.1046/j.1532-5415.2002.50619.x; Wu CL, 2004, REGION ANESTH PAIN M, V29, P257, DOI 10.1016/j.rapm.2003.11.007	53	247	315	4	27	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	MAR	2007	106	3					436	443		10.1097/00000542-200703000-00007			8	Anesthesiology	Anesthesiology	141ZI	WOS:000244617400006	17325501				2020-06-30	J	Borland, M; Jacobs, I; King, B; O'Brien, D				Borland, Meredith; Jacobs, Ian; King, Barbara; O'Brien, Debra			A randomized controlled trial comparing intranasal fentanyl to intravenous morphine for managing acute pain in children in the emergency department	ANNALS OF EMERGENCY MEDICINE			English	Article; Proceedings Paper	Annual Meeting of the Australasian College for Emergency Medicine	NOV, 2005	Melbourne, AUSTRALIA				POSTOPERATIVE ANALGESIA; ORAL MORPHINE; MANAGEMENT	Study objective: We compare the efficacy of intranasal fentanyl versus intravenous morphine in a pediatric population presenting to an emergency department (ED) with acute long-bone fractures. Methods: We conducted a prospective, randomized, double-blind, placebo-controlled, clinical trial in a tertiary pediatric ED between September 2001 and January 2005. A convenience sample of children aged 7 to 15 years with clinically deformed closed long-bone fractures was included to receive either active intravenous morphine (10 mg/mL) and intranasal placebo or active intranasal concentrated fentanyl (150 mu g/mL) and intravenous placebo. Exclusion criteria were narcotic analgesia within 4 hours of arrival, significant head injury, allergy to opiates, nasal blockage, or inability to per-form pain scoring. Pain scores were rated by using a 100-mm visual analog scale at 0, 5, 10, 20, and 30 minutes. Routine clinical observations and adverse events were recorded. Results: Sixty-seven children were enrolled (mean age 10.9 years [SD 2.4]). Fractures were radius or ulna 53 (79.1%), humerus 9 (13.4%), tibia or fibula 4 (6.0%), and femur 1 (1.5%). Thirty-four children received intravenous (IV) morphine and 33 received intranasal fentanyl. Statistically significant differences in visual analog scale scores were not observed between the 2 treatment arms either preanalgesia or at 5, 10, 20, or 30 minutes postanalgesia (P=.333). At 10 minutes, the difference in mean visual analog scale between the morphine and fentanyl groups was -5 mm (95% confidence interval -16 to 7 mm). Reductions in combined pain scores occurred at 5 minutes (20 mm; P=.000), 10 minutes (4 mm; P=.012), and 20 minutes (8 mm; P=.000) postanalgesia. The mean total INF dose was 1.7 mu g/kg, and the mean total IV morphine dose was 0.11 mg/kg. There were no serious adverse events. Conclusion: Intranasal fentanyl delivered as 150 mu g/mL at a dose of 1.7 mu g/kg was shown to be an effective analgesic in children aged 7 to 15 years presenting to an ED with an acute fracture when compared to intravenous morphine at 0.1 mg/kg.	Princess Margaret Hosp Children, Subiaco, WA, Australia; Univ Western Australia, Sch Paediat & Child Hlth, Perth, WA 6009, Australia; Univ Western Australia, Discipline Emergency Med, Perth, WA 6009, Australia; Sir Charles Gairdner Hosp, Emergency Dept, Nedlands, WA, Australia	Borland, M (reprint author), GPO Box D184, Perth, WA 6840, Australia.	Meredith.Borland@health.wa.gov.au					Borland Meredith L, 2002, Emerg Med (Fremantle), V14, P275, DOI 10.1046/j.1442-2026.2002.00344.x; Borland ML, 2005, BURNS, V31, P831, DOI 10.1016/j.burns.2005.05.001; Brent ASG, 2000, PEDIATR CLIN N AM, V47, P651; *COMM AUSTR CANB, 1999, [No title captured]; Finn J, 2004, BURNS, V30, P262, DOI 10.1016/j.burns.2003.10.017; Friedland LR, 1997, PEDIATR EMERG CARE, V13, P103, DOI 10.1097/00006565-199704000-00005; Galinkin JL, 2000, ANESTHESIOLOGY, V93, P1378, DOI 10.1097/00000542-200012000-00006; Ho K, 1996, ANN EMERG MED, V27, P427, DOI 10.1016/S0196-0644(96)70223-8; Holdgate Anna, 2003, Emerg Med (Fremantle), V15, P441, DOI 10.1046/j.1442-2026.2003.00499.x; Kendall JM, 2001, BMJ-BRIT MED J, V322, P261, DOI 10.1136/bmj.322.7281.261; Kennedy RM, 1999, PEDIATR CLIN N AM, V46, P1215, DOI 10.1016/S0031-3955(05)70184-X; Lim Stephen C. B., 2003, Journal of Pharmacy Practice and Research, V33, P59; Manjushree R, 2002, CAN J ANAESTH, V49, P190; ONeil G, 1997, ANAESTH INTENS CARE, V25, P408, DOI 10.1177/0310057X9702500414; Paech MJ, 2003, ANAESTHESIA, V58, P740, DOI 10.1046/j.1365-2044.2003.03286.x; Powell CV, 2001, ANN EMERG MED, V37, P28; Simpson N, 1998, BRIT MED J, V316, P396; Spagrud LJ, 2003, AM J NURS, V103, P62, DOI 10.1097/00000446-200312000-00020; STRIEBEL HW, 1993, ANAESTHESIA, V48, P753, DOI 10.1111/j.1365-2044.1993.tb07583.x; Todd KH, 1996, ANN EMERG MED, V27, P485, DOI 10.1016/S0196-0644(96)70238-X; Wong P, 2003, ANAESTHESIA, V58, P818, DOI 10.1046/j.1365-2044.2003.03295_24.x; Younge P, 1999, EMERGEN MED, V11, P90	22	172	173	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644	1097-6760		ANN EMERG MED	Ann. Emerg. Med.	MAR	2007	49	3					335	340		10.1016/j.annemergmed.2006.06.016			6	Emergency Medicine	Emergency Medicine	142GI	WOS:000244637000016	17067720				2020-06-30	J	Nightingale, JJ; Knight, MV; Higgins, B; Dean, T				Nightingale, J. J.; Knight, M. V.; Higgins, B.; Dean, T.			Randomized, double-blind comparison of patient-controlled epidural infusion vs nurse-administered epidural infusion for postoperative analgesia in patients undergoing colonic resection	BRITISH JOURNAL OF ANAESTHESIA			English	Article						anaesthetics local; bupivacaine; analgesia; postoperative; analgesia; patient-controlled; analgesic techniques; epidural; analgesics opioid; fentanyl	GYNECOLOGICAL SURGERY	Background. There is little published evidence of the analgesic efficacy of patient-controlled epidural analgesia (PCEA) for postoperative pain relief. The aim of this study was to compare the analgesic efficacy of epidural infusion of bupivacaine 0.125% and fentanyl 4 mu g ml(-1) administered by either PCEA with a background infusion or nurse-administered continuous epidural infusion (CEI) after major intra-abdominal surgery. Methods. In a double-blind, randomized clinical trial, 205 adult patients undergoing colonic resection by laparotomy received either PCEA or CEI. Pain scores were recorded via a four-point verbal rating scale at 1, 2, 3, 4, 8, 12, 24, 48, and 72 h after surgery. The administration of epidural top-ups and systemic analgesia over the same period was also recorded, and patient satisfaction questionnaires completed. Results. The median area under the curve of pain against time was significantly lower in the PCEA group (2 vs 24, P < 0.001) as were median summary pain scores on movement (0.67 vs 1.33, P < 0.001). Significantly fewer patients in the PCEA group received one or more epidural top-ups (13 vs 36%, P = 0.0002) or any systemic analgesics (41 vs 63%, P = 0.0021). Patients in the PCEA group were significantly more likely to be very satisfied than in the CEI group (76 vs 43%, P < 0.0001). Conclusions. PCEA provides greater analgesic efficacy than CEI for postoperative analgesia after major intra-abdominal surgery, and a decreased requirement for physician or nurse intervention.	Queen Alexandra Hosp, Dept Anesthesia, Portsmouth PO6 3LY, Hants, England; Queen Alexandra Hosp, Acad Res & Dev Unit, Portsmouth PO6 3LY, Hants, England; Univ Portsmouth, Inst Med Hlth & Social Care, Portsmouth PO1 2HY, Hants, England	Nightingale, JJ (reprint author), Queen Alexandra Hosp, Dept Anesthesia, Portsmouth PO6 3LY, Hants, England.	jeremy.nightingale@porthosp.nhs.uk		Dean, Taraneh/0000-0002-0123-7646			Block BM, 2003, JAMA-J AM MED ASSOC, V290, P2455, DOI 10.1001/jama.290.18.2455; Dolin SJ, 2002, BRIT J ANAESTH, V89, P409, DOI 10.1093/bja/aef207; Farrar JT, 2000, PAIN, V88, P287, DOI 10.1016/S0304-3959(00)00339-0; Komatsu H, 2001, BRIT J ANAESTH, V87, P633, DOI 10.1093/bja/87.4.633; Mann C, 2000, ANESTHESIOLOGY, V92, P433, DOI 10.1097/00000542-200002000-00025; Rigg JRA, 2002, LANCET, V359, P1276, DOI 10.1016/S0140-6736(02)08266-1; Rowbotham MC, 2001, PAIN, V94, P131, DOI 10.1016/S0304-3959(01)00371-2; Silvasti M, 2001, ACTA ANAESTH SCAND, V45, P471, DOI 10.1034/j.1399-6576.2001.045004471.x; Standl T, 2003, CAN J ANAESTH, V50, P258, DOI 10.1007/BF03017795; van der Vyver M, 2002, BRIT J ANAESTH, V89, P459, DOI 10.1093/bja/aef217; Whiteside R, 2000, BRIT J ANAESTH, V84, P720; Wiebalck A, 1997, ANESTH ANALG, V85, P124, DOI 10.1097/00000539-199707000-00022; Wong K, 2000, ANAESTHESIA, V55, P212, DOI 10.1046/j.1365-2044.2000.01204.x	13	11	12	0	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0007-0912	1471-6771		BRIT J ANAESTH	Br. J. Anaesth.	MAR	2007	98	3					380	384		10.1093/bja/ael367			5	Anesthesiology	Anesthesiology	149WF	WOS:000245176900013	17283006	Bronze			2020-06-30	J	George, RB; Melnick, AH; Rose, EC; Habib, AS				George, Ronald B.; Melnick, Abigail H.; Rose, Erin C.; Habib, Ashraf S.			Case series: Combined spinal epidural anesthesia for Cesarean delivery and ex utero intrapartum treatment procedure	CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Article							AIRWAY-OBSTRUCTION; MANAGEMENT; FETUS; NITROGLYCERIN; SURGERY	Purpose: To report the use of regional anesthesia and iv nitroglycerin to provide anesthesia and uterine relaxation for three Cesarean deliveries (CD) involving ex utero intrapartum treatment (EXIT) of potentially life-threatening airway obstruction in the newborn. Clinical features: Case 1 - a 36-yr-old woman at 38 weeks' gestation was scheduled for an elective CID for fetal skeletal dysplasia and micrognathia. Case 2 - a 34-yr-old woman at 35 weeks gestation had a fetal ultrasound revealing fixed neck flexion and micrognathia consistent with fetal arthrogryposis. Case 3 - a 27-yr-old woman presented at 38 weeks gestation for CID for severe fetal micrognathia, with mandibular growth below the fifth percentile. For each case, a combined spinal epidural anesthetic was performed with 0.75% bupivacaine, fentanyl and morphine intrathecally followed by placement of a multiorifice epidural catheter. Prior to uterine incision patients received a loading dose followed by an iv infusion of nitroglycerin. Uterine relaxation was sufficient in all cases for delivery of the fetus, and allowed for evaluation by direct laryngoscopy and intubation while maintaining fetal-placental circulation. The surgical procedures were completed without incident. Conclusions: Anesthesia and uterine relaxation for CID and EXIT procedures can be safely provided with regional anesthesia and iv nitroglycerin.	Duke Univ, Med Ctr, Dept Anesthesiol Womens Aesthesia & Crit Care, Durham, NC 27710 USA	George, RB (reprint author), Duke Univ, Med Ctr, Dept Anesthesiol Womens Aesthesia & Crit Care, Box 3094, Durham, NC 27710 USA.	ronald.george@duke.edu	Habib, Ashraf/K-4889-2019; George, Ronald B/S-9312-2019	George, Ronald B/0000-0002-1848-036X; Habib, Ashraf/0000-0002-6980-1856			Baker PA, 2004, PEDIATR ANESTH, V14, P781, DOI 10.1111/j.1460-9592.2004.01284.x; Benonis JG, 2006, ANESTHESIOLOGY, V104, pB55; Bui TH, 2000, EUR J PEDIATR SURG, V10, P328, DOI 10.1055/s-2008-1072385; Clark KD, 2004, OBSTET GYNECOL, V103, P1113, DOI 10.1097/01.AOG.0000125158.61232.b3; Dahlgren G, 2004, INT J OBSTET ANESTH, V13, P178, DOI 10.1016/j.ijoa.2004.01.007; Dayan SS, 1996, ANESTH ANALG, V82, P1091, DOI 10.1097/00000539-199605000-00041; Eschertzhuber S, 2005, ANESTH ANALG, V101, P658, DOI 10.1213/01.ANE.0000175206.91231.77; Faria A, 2005, EUR J ANAESTH, V22, P642, DOI 10.1017/S0265021505251062; Gaiser RR, 1997, ANESTH ANALG, V84, P1150, DOI 10.1097/00000539-199705000-00039; Hawkins JL, 1997, ANESTHESIOLOGY, V87, P135, DOI 10.1097/00000542-199707000-00018; Hawkins JL, 1997, ANESTHESIOLOGY, V86, P277, DOI 10.1097/00000542-199702000-00002; Mychaliska GB, 1997, J PEDIATR SURG, V32, P227, DOI 10.1016/S0022-3468(97)90184-6; Rosen MA, 2003, ANESTH ANALG, V96, P698, DOI 10.1213/01.ANE.0000049686.20464.3B; Rosen MA, 2001, YONSEI MED J, V42, P669, DOI 10.3349/ymj.2001.42.6.669; Schwartz DA, 2001, J CLIN ANESTH, V13, P387, DOI 10.1016/S0952-8180(01)00287-2; Silva V, 2006, ANESTHESIOLOGY, V104, pB12; Stevens GH, 2002, EUR J OBSTET GYN R B, V100, P246, DOI 10.1016/S0301-2115(01)00467-5; TANAKA M, 1994, CAN J ANAESTH, V41, P236, DOI 10.1007/BF03009837; Tsen LC, 1998, INT J OBSTET ANESTH, V7, P147, DOI 10.1016/S0959-289X(98)80001-0	19	31	34	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0832-610X			CAN J ANAESTH	Can. J. Anaesth.-J. Can. Anesth.	MAR	2007	54	3					218	222		10.1007/BF03022643			5	Anesthesiology	Anesthesiology	148YP	WOS:000245113600009	17331934	Bronze			2020-06-30	J	Power, I; McCormack, J				Power, Ian; McCormack, Jon			Postoperative pain management: new, convenient analgesic therapies	EXPERT OPINION ON PHARMACOTHERAPY			English	Review							CONTROLLED-RELEASE OXYCODONE; CONTROLLED TRANSDERMAL SYSTEM; DOUBLE-BLIND; POSTHERPETIC NEURALGIA; NEUROPATHIC PAIN; PHARMACOLOGICAL-TREATMENT; ANTINOCICEPTIVE ACTION; MORPHINE; PREGABALIN; PLACEBO	Despite the potential benefits to patient health that can result from effective pain management, survey results continue to indicate that acute postoperative pain remains inadequately managed worldwide. The development of novel analgesics and advanced analgesic delivery techniques has the potential to improve current strategies for postoperative pain management. This article outlines the pharmacological principles and clinical utility of recently developed agents and a novel drug delivery device indicated for the management of moderate-to-severe acute postoperative pain.	Univ Edinburgh, Royal Infirm, Edinburgh EH16 4SA, Midlothian, Scotland	McCormack, J (reprint author), Univ Edinburgh, Royal Infirm, Edinburgh EH16 4SA, Midlothian, Scotland.	jon.mccormack@ed.ac.uk					Anderson BJ, 2005, PEDIATR ANESTH, V15, P282, DOI 10.1111/j.1460-9592.2005.01455.x; ASHBURN MA, 1995, ANESTHESIOLOGY, V82, P1146, DOI 10.1097/00000542-199505000-00009; ASHBURN MA, 1992, J PAIN SYMPTOM MANAG, V7, P27, DOI 10.1016/0885-3924(92)90104-P; Attal N, 2006, EUR J NEUROL, V13, P1153, DOI 10.1111/j.1468-1331.2006.01511.x; BANNWARTH B, 1992, BRIT J CLIN PHARMACO, V34, P79, DOI 10.1111/j.1365-2125.1992.tb04112.x; Barry BW, 2001, EUR J PHARM SCI, V14, P101, DOI 10.1016/S0928-0987(01)00167-1; Bertolucci L E, 1982, J Orthop Sports Phys Ther, V4, P103; BJORKMAN R, 1994, PAIN, V57, P259, DOI 10.1016/0304-3959(94)90001-9; BJORKMAN R, 1995, ACTA ANAESTH SCAND, V39, P3; Bone M, 2002, REGION ANESTH PAIN M, V27, P481, DOI 10.1053/rapm.2002.35169; BROWN CR, 1998, 17 ANN SCI M AM PAIN; Caldwell JR, 1999, J RHEUMATOL, V26, P862; Chelly JE, 2004, ANESTH ANALG, V98, P427, DOI 10.1213/01.ANE.0000093314.13848.7E; Cheng JK, 2006, J PHARMACOL SCI, V100, P471, DOI 10.1254/jphs.CR0050020; Cobby TF, 1999, BRIT J ANAESTH, V83, P253, DOI 10.1093/bja/83.2.253; Coluzzi F, 2005, Minerva Anestesiol, V71, P451; Curtis GB, 1999, EUR J CLIN PHARMACOL, V55, P425, DOI 10.1007/s002280050651; Davis MP, 2003, SUPPORT CARE CANCER, V11, P84, DOI 10.1007/s00520-002-0385-9; Doggrell SA, 2005, EXPERT OPIN PHARMACO, V6, P2535, DOI 10.1517/14656566.6.14.2535; Dubinsky RM, 2004, NEUROLOGY, V63, P959, DOI 10.1212/01.WNL.0000140708.62856.72; Dworkin RH, 2003, NEUROLOGY, V60, P1274, DOI 10.1212/01.WNL.0000055433.55136.55; Edwards JE, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002763; EJBJMH MA, 2000, BANDOLIERS LITTLE BO; Faught Edward, 2005, Epilepsy Curr, V5, P217, DOI 10.1111/j.1535-7511.2005.00068.x; Field MJ, 1997, J PHARMACOL EXP THER, V282, P1242; Finnerup NB, 2005, PAIN, V118, P289, DOI 10.1016/j.pain.2005.08.013; Flouvat B, 2004, INT J CLIN PHARM TH, V42, P50; Freynhagen R, 2006, SCHMERZ, V20, P285, DOI 10.1007/s00482-005-0449-0; Graham Garry G, 2005, Am J Ther, V12, P46, DOI 10.1097/00045391-200501000-00008; Hernandez-Palazon J, 2001, ANESTH ANALG, V92, P1473, DOI 10.1097/00000539-200106000-00024; Hurley RW, 2002, ANESTHESIOLOGY, V97, P1263, DOI 10.1097/00000542-200211000-00033; Hwang JH, 1997, REGION ANESTH, V22, P249, DOI 10.1016/S1098-7339(06)80010-6; IRSFELD S, 1993, BRIT J ANAESTH, V71, P375, DOI 10.1093/bja/71.3.375; KALSO E, 1991, ACTA ANAESTH SCAND, V35, P642, DOI 10.1111/j.1399-6576.1991.tb03364.x; Kavoussi R, 2006, EUR NEUROPSYCHOPHARM, V16, pS128, DOI 10.1016/j.euroneuro.2006.04.005; KEHLET H, 1993, ANESTH ANALG, V77, P1048; Korpela R, 1999, ANESTHESIOLOGY, V91, P442, DOI 10.1097/00000542-199908000-00019; Lesser H, 2004, NEUROLOGY, V63, P2104, DOI 10.1212/01.WNL.0000145767.36287.A1; Levy MH, 2001, EUR J PAIN-LONDON, V5, P113, DOI 10.1053/eujp.2001.0292; Lugo Ralph A, 2004, J Pain Palliat Care Pharmacother, V18, P17; Luo ZD, 2002, J PHARMACOL EXP THER, V303, P1199, DOI 10.1124/jpet.102.041574; Maizels M, 2005, AM FAM PHYSICIAN, V71, P483; McCleane GJ, 2000, CLIN J PAIN, V16, P321, DOI 10.1097/00002508-200012000-00008; MCLEAN MJ, 1994, NEUROLOGY, V44, P17; MELLICK LB, 1995, AM J EMERG MED, V13, P96, DOI 10.1016/0735-6757(95)90263-5; Mimoz O, 2001, ANAESTHESIA, V56, P520, DOI 10.1046/j.1365-2044.2001.01980.x; Murphy EJ, 2005, ANAESTH INTENS CARE, V33, P311, DOI 10.1177/0310057X0503300306; NJRARRA HK, 2005, PLOS MED, V2, pE164; Oldfield V, 2005, DRUGS, V65, P2337, DOI 10.2165/00003495-200565160-00011; Peduto VA, 1998, ACTA ANAESTH SCAND, V42, P293, DOI 10.1111/j.1399-6576.1998.tb04919.x; Pini LA, 1996, EUR J PHARMACOL, V308, P31, DOI 10.1016/0014-2999(96)00261-0; Romsing J, 2002, BRIT J ANAESTH, V88, P215, DOI 10.1093/bja/88.2.215; Rosenstock J, 2004, PAIN, V110, P628, DOI 10.1016/j.pain.2004.05.001; Sathyan G, 2005, CLIN PHARMACOKINET, V44, P7, DOI 10.2165/00003088-200544001-00003; Serpell MG, 2002, PAIN, V99, P557, DOI 10.1016/S0304-3959(02)00255-5; Sindrup SH, 2000, NEUROLOGY, V55, P915, DOI 10.1212/WNL.55.7.915; SKJELBRED P, 1979, EUR J CLIN PHARMACOL, V15, P27, DOI 10.1007/BF00563555; TIEN JH, 1991, J PHARM SCI, V80, P741, DOI 10.1002/jps.2600800806; Van Aken H, 2004, ANESTH ANALG, V98, P159, DOI 10.1213/01.ANE.0000093312.72011.59; van Seventer R, 2006, CURR MED RES OPIN, V22, P375, DOI 10.1185/030079906X80404; Viscusi ER, 2006, ANESTH ANALG, V102, P188, DOI 10.1213/01.ane.0000183649.58483.77; Watson CPN, 1998, NEUROLOGY, V51, P1166, DOI 10.1212/WNL.51.4.1166; WATSON CPN, 1992, PAIN, V48, P29, DOI 10.1016/0304-3959(92)90128-X; Zhou TJ, 2001, ANESTH ANALG, V92, P1569	64	4	4	0	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1465-6566	1744-7666		EXPERT OPIN PHARMACO	Expert Opin. Pharmacother.	MAR	2007	8	4					391	399		10.1517/14656566.8.4.391			9	Pharmacology & Pharmacy	Pharmacology & Pharmacy	139UU	WOS:000244458900001	17309334				2020-06-30	J	Teske, J; Weller, JP; Larsch, K; Troger, HD; Karst, M				Teske, Joerg; Weller, Jens-Peter; Larsch, Klaus; Troeger, Hans Dieter; Karst, Matthias			Fatal outcome in a child after ingestion of a transdermal fentanyl patch	INTERNATIONAL JOURNAL OF LEGAL MEDICINE			English	Article						fatal intoxication; transdermal fentanyl patch; fentanyl; norfentanyl; LC-MS-MS	LIQUID-CHROMATOGRAPHY; OPIOID INTOXICATION; GAS-CHROMATOGRAPHY; HUMAN PLASMA; NORFENTANYL; ABSORPTION; ANALOGS; ABUSE	The case history and toxicological findings of a fatal fentanyl intoxication due to ingestion of a transdermal patch are presented. A 1-year-old otherwise healthy girl was put to bed and 2 h later she was found dead. The autopsy revealed a 25-mu g/h (4.2 mg) transdermal fentanyl patch in the stomach. Toxicological analysis by liquid chromatography-tandem mass spectrometry with positive electrospray ionization yielded fentanyl and norfentanyl concentrations in the peripheral blood of 5.6 and 5.9 ng/ml, heart blood 19.0 and 8.9 ng/ml, and liver 235 and 26 ng/g, respectively. The cause of death was determined to be a fentanyl overdose. The investigation established that the child has unintentionally swallowed the patch, which had been lying on the floor.	Hannover Med Sch, Inst Legal Med, D-30625 Hannover, Germany; Hannover Med Sch, Pain Clin, Dept Anesthesiol, D-30625 Hannover, Germany	Teske, J (reprint author), Hannover Med Sch, Inst Legal Med, Carl Neuberg Str 1, D-30625 Hannover, Germany.	teske.joerg@mh-hannover.de					Anderson DT, 2000, J ANAL TOXICOL, V24, P627, DOI 10.1093/jat/24.7.627; [Anonymous], 2005, Health News, V11, P6; Arvanitis ML, 2002, AM J EMERG MED, V20, P58, DOI 10.1053/ajem.2002.29562; Barrueto F, 2004, VET HUM TOXICOL, V46, P30; Baselt R.C., 2002, DISPOSITION TOXIC DR, P430; Carter KA, 2003, AM J HEALTH-SYST PH, V60, P191, DOI 10.1093/ajhp/60.2.191; Day J, 2003, J ANAL TOXICOL, V27, P513, DOI 10.1093/jat/27.7.513; Dussy FE, 2006, INT J LEGAL MED, V120, P323, DOI 10.1007/s00414-005-0042-1; Edinboro LE, 1997, J FORENSIC SCI, V42, P741; Favretto D, 2007, INT J LEGAL MED, V121, P259, DOI 10.1007/s00414-006-0078-x; Frolich M, 2001, ANESTH ANALG, V93, P647; Fryirsa B, 1997, J CHROMATOGR B, V688, P79, DOI 10.1016/S0378-4347(97)88058-9; Gardner-Nix J, 2001, J PAIN SYMPTOM MANAG, V21, P447, DOI 10.1016/S0885-3924(01)00285-8; GILLESPIE TJ, 1981, J ANAL TOXICOL, V5, P133, DOI 10.1093/jat/5.3.133; Hardwick WE, 1997, SOUTH MED J, V90, P962, DOI 10.1097/00007611-199709000-00023; Huynh NH, 2005, J PHARMACEUT BIOMED, V37, P1095, DOI 10.1016/j.jpba.2004.09.024; Jost U, 2004, DEUT MED WOCHENSCHR, V129, P313, DOI 10.1055/s-2004-818627; Kaferstein H, 2000, FORENSIC SCI INT, V113, P353, DOI 10.1016/S0379-0738(00)00224-3; Karst M, 2001, PAIN MED, V2, P225, DOI 10.1046/j.1526-4637.2001.01028.x; KINTZ P, 1989, J CHROMATOGR-BIOMED, V489, P459, DOI 10.1016/S0378-4347(00)82930-8; Klockgether-Radke AP, 2002, ANAESTHESIST, V51, P269, DOI 10.1007/s00101-002-0299-4; KlockgetherRadke A, 1997, ANAESTHESIST, V46, P428, DOI 10.1007/s001010050420; Koch DE, 2004, J PHARMACEUT BIOMED, V34, P577, DOI 10.1016/S0731-7085(03)00652-6; KOEHNTOP DE, 1986, ANESTH ANALG, V65, P227; Kramer Christopher, 1998, Journal of the American Osteopathic Association, V98, P385; KUMAR K, 1987, J CHROMATOGR-BIOMED, V419, P464, DOI 10.1016/0378-4347(87)80317-1; MARQUARDT KA, 1994, J TOXICOL-CLIN TOXIC, V32, P75, DOI 10.3109/15563659409000433; MARQUARDT KA, 1995, ANN PHARMACOTHER, V29, P969, DOI 10.1177/106002809502901001; Meyer D, 2005, CLIN PEDIATR, V44, P499, DOI 10.1177/000992280504400605; MICHIELS M, 1977, EUR J CLIN PHARMACOL, V12, P153, DOI 10.1007/BF00645137; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; Newshan G, 1998, J PAIN SYMPTOM MANAG, V16, P277; Pavlic M, 2005, INT J LEGAL MED, V119, P378, DOI 10.1007/s00414-005-0544-x; Sachs H, 1996, INT J LEGAL MED, V109, P213, DOI 10.1007/BF01225521; STREISAND JB, 1991, ANESTHESIOLOGY, V75, P223, DOI 10.1097/00000542-199108000-00009; WATTS VW, 1990, J ANAL TOXICOL, V14, P266, DOI 10.1093/jat/14.5.266; Yerasi AB, 1997, AM J HEALTH-SYST PH, V54, P85, DOI 10.1093/ajhp/54.1.85; 1996, ARZNEI TELEGRAMM, V9, P88	38	43	44	0	6	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0937-9827	1437-1596		INT J LEGAL MED	Int. J. Legal Med.	MAR	2007	121	2					147	151		10.1007/s00414-006-0137-3			5	Medicine, Legal	Legal Medicine	134OJ	WOS:000244092400010	17115172				2020-06-30	J	Darwish, M; Kirby, M; Robertson, P; Tracewell, W; Jiang, JG				Darwish, Mona; Kirby, Mary; Robertson, Philmore, Jr.; Tracewell, William; Jiang, John G.			Absolute and relative bioavailability of fentanyl buccal tablet and oral transmucosal fentanyl citrate	JOURNAL OF CLINICAL PHARMACOLOGY			English	Article						fentanyl buccal tablet; oral transmucosal fentanyl citrate; bioavailability	HEALTHY ADULT VOLUNTEERS; DOSE PROPORTIONALITY; BREAKTHROUGH PAIN; OPEN-LABEL; MU-G; PHARMACOKINETICS; PERMEABILITY; DISPOSITION	This study assessed the absolute and relative bioavailabilities and transmucosal and gastrointestinal absorbency of fentanyl buccal tablet (FBT) and oral transmucosal fentanyl citrate (OTFC). In a randomized crossover design, 26 healthy subjects received FBT 400 mu g (transmucosal), FBT 800 mu g (oral), OTFC 800 mu g (transmucosul), and fentanyl 400 mu g (intravenous). The transmucosal FBT had the highest absolute bioavailability (0.65) compared with the oral FBT (0.31) or transmucosal OTFC (0.47). More fentanyl was absorbed transmucosally from FBT than OTFC (48% vs 22%). Median t(max) values were shorter following the transmucosal FBT (47 minutes) than the oral FBT (90 minutes) or the transmucosul OTFC (91 minutes). Transmucosal administration of FBT compared with dose-normalized OTFC resulted in higher total systemic fentanyl exposure, higher early systemic exposure, and higher C-max. The rate and extent of fentanyl absorption were greater following administration of FBT compared to OTFC. An approximately 30% smaller dose of FBT achieved systemic exposures comparable to OTFC.	Cephalon Inc, Frazer, PA 19355 USA	Darwish, M (reprint author), Cephalon Inc, 41 Moores Rd, Frazer, PA 19355 USA.	mdarwish@cephalon.com					Darwish M, 2006, CLIN THER, V28, P707, DOI 10.1016/j.clinthera.2006.05.015; Darwish M, 2006, CLIN THER, V28, P715, DOI 10.1016/j.clinthera.2006.05.016; Darwish M, 2005, CLIN PHARMACOKINET, V44, P1279, DOI 10.2165/00003088-200544120-00006; Durfee S, 2006, AM J DRUG DELIV, V4, P1, DOI DOI 10.2165/00137696-200604010-00001; Eichman JD, 1998, PHARM RES-DORDR, V15, P925, DOI 10.1023/A:1011936901638; Eichman JD, 1997, EUR J PHARM BIOPHARM, V44, P33, DOI 10.1016/S0939-6411(97)00099-4; *FOOD DRUG ADM ADV, 2005, DISC TOP RISK EV LAB, P1; FRAZER P, 2006, FENTORA PRESCRIBING; GIBALDI M, 1982, [No title captured], P409; HUDSON RJ, 1986, ANESTHESIOLOGY, V64, P334, DOI 10.1097/00000542-198603000-00006; HUG CC, 1981, ANESTHESIOLOGY, V55, P369, DOI 10.1097/00000542-198110000-00006; Kharasch ED, 2004, ANESTHESIOLOGY, V101, P729, DOI 10.1097/00000542-200409000-00022; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; Mather L. E., 1991, TRANSDERMAL FENTANYL, P73; Mercadante S, 1998, CANCER TREAT REV, V24, P425, DOI 10.1016/S0305-7372(98)90005-6; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; SHARGEL L, 2005, APPL BIOPHARMACEUTIC, V371, P411; Stanley TH, 2005, J PAIN SYMPTOM MANAG, V29, pS67, DOI 10.1016/j.jpainsymman.2005.01.009; Streisand JB, 1998, ANESTHESIOLOGY, V88, P305, DOI 10.1097/00000542-199802000-00006; STREISAND JB, 1991, ANESTHESIOLOGY, V75, P223, DOI 10.1097/00000542-199108000-00009; Svendsen KB, 2005, EUR J PAIN, V9, P195, DOI 10.1016/j.ejpain.2004.06.001	21	65	69	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0091-2700			J CLIN PHARMACOL	J. Clin. Pharmacol.	MAR	2007	47	3					343	350		10.1177/0091270006297749			8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	142JD	WOS:000244644700007	17322146				2020-06-30	J	Zernikow, B; Michel, E; Anderson, B				Zernikow, Boris; Michel, Erik; Anderson, Brian			Transdermal fentanyl in childhood and adolescence: A comprehensive literature review	JOURNAL OF PAIN			English	Review						pain; children; transdermal; fentanyl	PEDIATRIC ONCOLOGY; CANCER PAIN; CHILDREN; PHARMACOKINETICS; TOLERABILITY; MANAGEMENT; ANALGESIA; RESERVOIR; EFFICACY; DELIVERY	The recently introduced fentanyl transdermal therapeutic system (TTS) with a drug release rate of 12.5 mu g/h matches the lower dosing requirements of cancer pain control in children. It is likely that fentanyl TTS will be used in pediatrics with increasing frequency. We compiled the published evidence on pediatric applications of this drug formulation to help physicians get the most benefit from its use. Within this systematic review, a total of 11 observational clinical or pharmacokinetic studies were identified. There are no pediatric randomized or controlled cohort studies. Pharmacokinetic studies poorly described time-concentration profiles after application. The time to reach steady-state serum drug concentrations seems to be longer, clearance (expressed as liters per kilogram per hour) higher, and elimination half-life shorter in children than in adults. There are no fundamental differences in effect or profile of adverse effects compared with adults. Fentanyl TTS may be associated with less constipation, compared with morphine use. Frequently, pediatric patients need supplemental mechanical fixation of the fentanyl TTS by means of medical tape. Younger patients tend to have a higher fentanyl requirement when referenced to body weight. Both parents and medical professionals are satisfied with fentanyl TTS to a higher degree than with individual analgesic pretreatment regimens. Fentanyl TTS is a promising option for chronic pain control in children. An approximate conversion factor of 45 mg/day oral morphine to 12.5 mu g/h fentanyl TTS is used for initial therapy dose estimation in children receiving long-term morphine therapy. This is conservatively low to avoid respiratory depression. Daily oral morphine equivalent dose should be at least 30 mg/d before fentanyl TTS therapy is started with 12.5 mu g/h. Evidence for superiority of fentanyl TTS treatment above conventional opioid administration is both scarce and of low quality. Perspective: The article gives a comprehensive overview of all pediatric data concerning the fentanyl TTS. Children may take longer to reach steady-state fentanyl serum concentrations than adults, and younger children may require higher doses referenced to body weight than older children or adults. Consequently, there is a need to provide sufficient medication in the phase of therapy initiation to prevent breakthrough pain. The 72-hour dosing schedule recommended by the manufacturers may not be applicable to children because of poor patch adhesiveness. The authors suggest to ensure firm fixation of the fentanyl TTS with additional medical tape if necessary and to change the fentanyl TTS after 48 hours. Transdermal fentanyl in children may exhibit fewer side effects when compared with other opioids, especially constipation. Randomized studies are urgently needed to definitively answer this question. (C) 2007 by the American Pain Society.	Univ Witten Herdecke, Childrens Hosp Datteln, Vodafone Fdn Inst Childrens Pain Theray & Pediat, D-45711 Datteln, Germany; Childrens Hosp Konstanz, Constance, Germany; Univ Childrnes Hosp Munster, Dept Pediat Hematol & Oncol, Munster, Germany; Univ Auckland, Dept Anaesthesiol, Auckland 1, New Zealand	Zernikow, B (reprint author), Univ Witten Herdecke, Childrens Hosp Datteln, Vodafone Fdn Inst Childrens Pain Theray & Pediat, Dr Friedrich Steiner Str 5, D-45711 Datteln, Germany.	Boris.Zernikow@t-online.de					Anderson BJ, 1997, CLIN PHARMACOKINET, V33, P313, DOI 10.2165/00003088-199733050-00001; Christensen ML, 1996, J PEDIAT HEMATOL ONC, V18, P372, DOI 10.1097/00043426-199611000-00007; Clark AJ, 2004, CURR MED RES OPIN, V20, P1419, DOI 10.1185/030079904X2114; Collins JJ, 1999, J PEDIATR-US, V134, P319, DOI 10.1016/S0022-3476(99)70457-9; Finkel JC, 2005, CANCER-AM CANCER SOC, V104, P2847, DOI 10.1002/cncr.21497; Freynhagen R, 2005, J PAIN SYMPTOM MANAG, V30, P289, DOI 10.1016/j.jpainsymman.2005.03.015; GOLDMAN A, 2000, [No title captured], V342, P1997; Gourlay G K, 2001, Lancet Oncol, V2, P165, DOI 10.1016/S1470-2045(00)00258-8; GUPTA SK, 1992, J PAIN SYMPTOM MAN S, V73, pS17; Hunt A, 2001, PALLIATIVE MED, V15, P405, DOI 10.1191/026921601680419456; IRVING H, 1995, 4 C EUR ASS PALL CAR; JOHNSON K L, 1984, Anesthesiology (Hagerstown), V61, pA441, DOI 10.1097/00000542-198409001-00441; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; LANDGRAF JM, 2000, CHQ USERS MANUAL; LANSKY LL, 1985, CANCER S, V567, P1837; LEVRON JC, 1992, INT J CLIN PHARM TH, P199; LIPMAN AG, 2000, EVIDENCE BASED SYMPT; Ljungman G, 1999, ACTA PAEDIATR, V88, P623, DOI 10.1080/08035259950169279; Ljungman G, 1996, PAIN, V68, P385, DOI 10.1016/S0304-3959(96)03193-4; Ljungman G, 2000, PEDIATR HEMAT ONCOL, V17, P211, DOI 10.1080/088800100276389; MANNERKOSKI MK, 2001, EUR J PAEDIAT NEU SA, V5, pA175; Marier JF, 2006, J CLIN PHARMACOL, V46, P642, DOI 10.1177/0091270006286901; Mercadante S, 2005, J CLIN ONCOL, V23, P5229, DOI 10.1200/JCO.2005.13.128; Noyes M, 2001, Am J Hosp Palliat Care, V18, P411, DOI 10.1177/104990910101800612; NUNN T, 2004, PAEDIAT PERINATAL DR, V6, P1; PATT RB, 1993, J PAIN SYMPTOM MANAG, V8, P317, DOI 10.1016/0885-3924(93)90161-N; Paut O, 2000, ANAESTHESIA, V55, P1202, DOI 10.1046/j.1365-2044.2000.01615-3.x; Radbruch L, 2001, PALLIATIVE MED, V15, P309, DOI 10.1191/026921601678320296; Radbruch Lukas, 2004, Keio J Med, V53, P23, DOI 10.2302/kjm.53.23; Sasson M, 2006, J PAIN SYMPTOM MANAG, V31, P389, DOI 10.1016/j.jpainsymman.2005.12.015; Sathyan G, 2005, CURR MED RES OPIN, V21, P1961, DOI 10.1185/030079905X65259; Sirkia K, 1998, J PAIN SYMPTOM MANAG, V15, P220, DOI 10.1016/S0885-3924(98)00366-2; Tobias JD., 1992, AM J PAIN MANAGEMENT, V2, P30; Wolfe J, 2000, NEW ENGL J MED, V342, P326, DOI 10.1056/NEJM200002033420506; Zernikow B, 2001, MED PEDIATR ONCOL, V36, P451, DOI 10.1002/mpo.1109	35	22	22	0	8	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	1526-5900			J PAIN	J. Pain	MAR	2007	8	3					187	207		10.1016/j.jpain.2006.11.008			21	Clinical Neurology; Neurosciences	Neurosciences & Neurology	151XG	WOS:000245323800001	17350554				2020-06-30	J	Passik, SD; Kirsh, KL				Passik, Steven D.; Kirsh, Kenneth L.			Weighing in on the off-label use of Actiq (TM) for noncancer-related pain: A recipe for success or a recipe for disaster?	PAIN MEDICINE			English	Article						opioids; off-label; pain; Actiq (TM)	OPIOID-TREATED PATIENTS; BREAKTHROUGH PAIN; UNIVERSAL PRECAUTIONS; MEDICAL USE; ANALGESICS; TRENDS; ABUSE	Objective. An editorial is provided based in part upon a recent Wall Street Journal article by John Carreyrou, which cast the off-label use of opioids, in this case, Actiq(TM) (oral transmucosal fentanyl citrate), in an extremely negative light from the viewpoint of contributing to addiction. As in the past, this article seems to follow a "recipe" used to demonize opioids, the pharmaceutical industry and the physicians who prescribe pain medications. Specifically, the case is made that using oral transmucosal fentanyl citrate in noncancer patients, for whom there is no current indication, is contributing to the prescription drug abuse problem. Conclusions. We discuss the faulty logic in parsing the use of opioids between malignant and non-malignant pain patients. A call is made to pain professionals to begin discussion of the common use of pharmaceuticals in off-label ways to treat pain issues as well as a discussion of the dangers of not addressing this practice openly.	Mem Sloan Kettering Canc Ctr, Dept Psychiat & Behav Sci, New York, NY 10022 USA	Passik, SD (reprint author), Mem Sloan Kettering Canc Ctr, Dept Psychiat & Behav Sci, 641 Lexington Ave, New York, NY 10022 USA.	passiks@mskcc.org					CARREYROU J, 2006, [No title captured]; *CEPH, 2006, [No title captured]; *CEPH INC, 2006, [No title captured]; Cicero TJ, 2005, J PAIN, V6, P662, DOI 10.1016/j.jpain.2005.05.004; Davies AN, 2006, BRIT J HOSP MED, V67, P414, DOI 10.12968/hmed.2006.67.8.21960; Gilson AM, 2004, J PAIN SYMPTOM MANAG, V28, P176, DOI 10.1016/j.jpainsymman.2004.01.003; Gourlay D, 2006, PAIN MED, V7, P210, DOI 10.1111/j.1526-4637.2006.00114.x; Gourlay DL, 2005, PAIN MED, V6, P107, DOI 10.1111/j.1526-4637.2005.05031.x; Heit Howard A, 2003, J Pain Palliat Care Pharmacother, V17, P15; Hojsted J, 2006, ACTA ANAESTH SCAND, V50, P1290, DOI 10.1111/j.1399-6576.2006.01154.x; Mystakidou K, 2006, DRUG DELIV, V13, P269, DOI 10.1080/10717540500394661; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Portenoy RK, 2006, J PAIN, V7, P583, DOI 10.1016/j.jpain.2006.02.003; Savage SR, 2003, J PAIN SYMPTOM MANAG, V26, P655, DOI 10.1016/S0885-3924(03)00219-7; Webster LR, 2006, EXPERT OPIN INV DRUG, V15, P1469, DOI 10.1517/13543784.15.11.1469	15	8	9	0	3	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1526-2375	1526-4637		PAIN MED	Pain Med.	MAR	2007	8	2					130	133		10.1111/j.1526-4637.2006.00295.x			4	Anesthesiology; Medicine, General & Internal	Anesthesiology; General & Internal Medicine	136TG	WOS:000244246400003	17305684	Bronze			2020-06-30	J	MacLaren, R; Forrest, LK; Kiser, TH				MacLaren, Robert; Forrest, Laurel K.; Kiser, Tyree H.			Adjunctive dexmedetomidine therapy in the intensive care unit: A retrospective assessment of impact on sedative and analgesic requirements, levels of sedation and analgesia, and ventilatory and hemodynamic parameters	PHARMACOTHERAPY			English	Article; Proceedings Paper	Spring Practice and Research Forum of the American-College-of-Clinical-Pharmacy	APR 09-12, 2006	Monterey, CA	Amer Coll Clin Pharm		dexmedetomidine; sedation; analgesia; critical care; intensive care; propofol; lorazepam; fentanyl; ventilatory support; hemodynamic support	CRITICALLY-ILL PATIENTS; MECHANICAL VENTILATION; PHASE-II; PROPOFOL; MIDAZOLAM; PATIENT; LORAZEPAM; INFUSION; EFFICACY; SURGERY	Study Objective. To determine if adjunctive dexmedetomidine therapy in intensive care patients alters requirements for and levels of sedation and analgesia, and to describe hemodynamic and ventilatory parameters. Design. Retrospective, noncontrolled, descriptive study of clinical practice. Setting. Four intensive care units (ICUs; medical, surgical, neurosurgical, or burn) in a university-affiliated medical center. Patients. Forty patients who were already receiving sustained use of propofol, lorazepam, or fentanyl when dexmedetomidine was started. Measurements and Main Results. Medical records were identified by searching the pharmacy database for patients who had received continuous-infusion dexmedetomidine from January 2000-January 2003 while in one of the four ICUs. Primary end points were discontinuation or dosage reduction of other sedatives or fentanyl from the hour before to 6 hours after starting dexmedetomidine. Other outcomes included levels of sedation and analgesia before and after dexmedetomidine and description of ventilatory and hemodynamic parameters. The initial dexmedetomidine rate of 0.4 +/- 0.25 mu g/kg/hour changed minimally through 47.4 +/- 61.1 infusion hours. At 6 hours, 11 of 13 patients receiving propofol, 14 of 23 receiving lorazepam, and 4 of 30 receiving fentanyl had the respective agent discontinued. With dexmedetomidine, the hourly rates and cumulative daily doses were reduced only for propofol. Adequate sedation occurred at rates of 64.6% and 47.9% during the 24-hour periods before and after dexmedetomidine was started, respectively (p=0.001). Four and 12 patients had severe agitation before and after, respectively (p=0.05). One and 12 patients had severe pain before and after, respectively (p=0.02). Nine patients experienced hypotension or bradycardia. Twenty-two patients were successfully extubated within 24 hours of starting dexmedetomidine. Conclusions. Adjunctive dexmedetomidine reduces sedative requirements but does not alter analgesic requirements. However, dexmedetomidine was associated with enhanced agitation, severe pain, and hemodynamic compromise. Transitioning to dexmedetomidine from other sedatives and analgesics may not provide optimal sedation and analgesia. Future studies are needed to evaluate dexmedetomidine as a bridge to extubation.	Univ Colorado, Hlth Sci Ctr, Sch Pharm, Dept Clin Pharm, Denver, CO 80262 USA	MacLaren, R (reprint author), Univ Colorado, Hlth Sci Ctr, Sch Pharm, Dept Clin Pharm, C238,4200 E 9th Ave, Denver, CO 80262 USA.	rob.maclaren@uchsc.edu		Kiser, Tyree/0000-0001-7415-3999			AHO M, 1992, ANESTH ANALG, V75, P940; Arain SR, 2004, ANESTH ANALG, V98, P153, DOI 10.1213/01.ANE.0000093225.39866.75; Arroliga A, 2005, CHEST, V128, P496, DOI 10.1378/chest.128.2.496; Bol CJJG, 2000, J PHARMACOL EXP THER, V294, P347; Chrysostomou C, 2005, PEDIATR CARDIOL, V26, P651, DOI 10.1007/s00246-005-0683-3; Corbett SM, 2005, CRIT CARE MED, V33, P940, DOI 10.1097/01.CCM.0000162565.18193.E5; Dasta JF, 2004, ANN PHARMACOTHER, V38, P1130, DOI 10.1345/aph.1D615; Dasta JF, 2006, PHARMACOTHERAPY, V26, P798, DOI 10.1592/phco.26.6.798; Dutta S, 2001, J PHARM SCI-US, V90, P172, DOI 10.1002/1520-6017(200102)90:2<172::AID-JPS8>3.0.CO;2-J; Elbaradie Samia, 2004, J Egypt Natl Canc Inst, V16, P153; Finkel JC, 2005, CRIT CARE MED, V33, P2110, DOI 10.1097/01.CCM.0000178183.21883.23; HORVATH G, 1992, LIFE SCI, V50, P215; Jacobi J, 2002, CRIT CARE MED, V30, P119, DOI 10.1097/00003246-200201000-00020; Kent CD, 2005, ANESTHESIOLOGY, V103, P439, DOI 10.1097/00000542-200508000-00028; Kress JP, 2002, AM J RESP CRIT CARE, V166, P1024, DOI 10.1164/rccm.200204-270CC; Lawrence CJ, 1997, ANAESTHESIA, V52, P736, DOI 10.1111/j.1365-2044.1997.169-az0303.x; MacLaren R, 2005, PHARMACOTHERAPY, V25, P1319, DOI 10.1592/phco.2005.25.10.1319; Martin Eike, 2003, J Intensive Care Med, V18, P29, DOI 10.1177/0885066602239122; Mehta S, 2006, CRIT CARE MED, V34, P374, DOI 10.1097/01.CCM.0000196830.61965.F1; Ostermann ME, 2000, JAMA-J AM MED ASSOC, V283, P1451, DOI 10.1001/jama.283.11.1451; Pandharipande P, 2006, ANESTHESIOLOGY, V104, P21, DOI 10.1097/00000542-200601000-00005; Rodrigues MG, 2003, CRIT CARE MED, V31, pA138; Saito M, 2003, ANESTH ANALG, V96, P834, DOI 10.1213/01.ANE.0000048714.01230.75; SALONEN M, 1992, PSYCHOPHARMACOLOGY, V108, P229, DOI 10.1007/BF02245313; SEGAL IS, 1988, ANESTHESIOLOGY, V69, P818, DOI 10.1097/00000542-198812000-00004; Shehabi Y, 2004, INTENS CARE MED, V30, P2188, DOI 10.1007/s00134-004-2417-z; Siobal MS, 2006, RESP CARE, V51, P492; Soliman HM, 2001, BRIT J ANAESTH, V87, P186, DOI 10.1093/bja/87.2.186; Triltsch AE, 2002, CRIT CARE MED, V30, P1007, DOI 10.1097/00003246-200205000-00009; Vender Jeffery S, 2004, Crit Care Med, V32, pS554, DOI 10.1097/01.CCM.0000145907.86298.12; Venn RM, 2001, BRIT J ANAESTH, V87, P684, DOI 10.1093/bja/87.5.684; Venn RM, 1999, ANAESTHESIA, V54, P1136, DOI 10.1046/j.1365-2044.1999.01114.x; Venn RM, 2000, CRIT CARE, V4, P302, DOI 10.1186/cc712; Venn RM, 2003, INTENS CARE MED, V29, P201, DOI 10.1007/s00134-002-1579-9; Walder B, 2001, ANESTH ANALG, V92, P975, DOI 10.1097/00000539-200104000-00033; Walker J, 2006, J BURN CARE RES, V27, P206, DOI 10.1097/01.BCR.0000200910.76019.CF; Young C, 2000, CRIT CARE MED, V28, P854, DOI 10.1097/00003246-200003000-00041	37	27	31	0	2	PHARMACOTHERAPY PUBLICATIONS INC	BOSTON	NEW ENGLAND MEDICAL CENTER, 806, 750 WASHINGTON ST, BOSTON, MA 02111 USA	0277-0008			PHARMACOTHERAPY	Pharmacotherapy	MAR	2007	27	3					351	359		10.1592/phco.27.3.351			9	Pharmacology & Pharmacy	Pharmacology & Pharmacy	141YY	WOS:000244616400004	17316147				2020-06-30	J	Burlacu, CL; Frizelle, HP; Moriarty, DC				Burlacu, Crina L.; Frizelle, Henry P.; Moriarty, Denis C.			Pharmacokinetics of levobupivacaine, fentanyl, and clonidine after administration in thoracic paravertebral analgesia	REGIONAL ANESTHESIA AND PAIN MEDICINE			English	Article						clonidine; fentanyl; levobupivacaine; paravertebral; pharmacokinetics	BRACHIAL-PLEXUS BLOCK; INTERCOSTAL NERVE BLOCK; POSTTHORACOTOMY PAIN; HUMAN SKIN; BUPIVACAINE; LIDOCAINE; EPINEPHRINE; MECHANISMS; ANESTHESIA; PROLONGS	Background and Objectives: There is little knowledge of the pharmacokinetics of local anesthetics and adjunctive analgesics after paravertebral blockade. We evaluated the pharmacokinetics of low-dose levobupivacaine, fentanyl, and clonidine after paravertebral analgesia for breast surgery. Methods: Thirty-eight patients receiving paravertebral analgesia for breast surgery received a 19-mL paravertebral bolus of levobupivacaine 0.25% combined with a 1-mL volume of saline (group L, 13 patients), fentanyl 50 jig (group LF, 13 patients), or clonidine 150 mu g (group LC, 12 patients) followed I hour later by infusion of levobupivacaine 0.1% (L), levobupivacaine 0.05% with fentanyl 4 mu g/mL (LF), or levobupivacaine 0.05% with clonidine 3 mu g/mL (LC), respectively. Plasma concentrations of study drugs were determined at intervals up to 24 hours after bolus injection. Results: There was rapid absorption of levobupivacaine after bolus with mean (standard deviation) maximum plasma concentration (Cpmax) of 0.51(0.24) mu g/mL in a median time to maximum concentration tCpmax of 15 minutes. Mean Cpmax fentanyl and clonidine after bolus were 0.62 (0.37) and 0.79 (0.23) ng/mL, in a median tCpmax of 15 and 22.5 minutes, respectively. Mean Cpmax levobupivacaine after infusion was 0.47 (0.41) mu g/mL in a median tCpmax of 24 hours. There was progressive accumulation of fentanyl and clonidine at 24 hours with a mean Cpmax of 0.72 (0.33) and 1.74 (0.70) ng/mL, respectively. Conclusions: After paravertebral bolus and infusion administration, Cpmax levobupivacaine was within the safe range. Cpmax fentanyl and clonidine were less than the effective levels after IV administration, suggesting that their analgesic effect may be partly attributed to a peripheral mechanism of action.	Mater Misericordiae Univ Hosp, Dept Anaesthesia Intens Care & Pain Med, Dublin 7, Ireland; Outcomes Res Inst, Cleveland, OH USA	Burlacu, CL (reprint author), Mater Misericordiae Univ Hosp, Dept Anaesthesia Intens Care & Pain Med, Eccles St, Dublin 7, Ireland.	crina@ireland.com		Buggy, Donal/0000-0003-3922-4397			Altermatt F, 2006, ANESTH ANALG, V102, P1597, DOI 10.1213/01.ANE.0000215120.90857.55; Bardsley H, 1998, BRIT J CLIN PHARMACO, V46, P245, DOI 10.1046/j.1365-2125.1998.00775.x; BERNARD JM, 1995, ANESTH ANALG, V81, P706, DOI 10.1097/00000539-199510000-00009; BERRISFORD RG, 1993, BRIT J ANAESTH, V70, P201, DOI 10.1093/bja/70.2.201; Bimston DN, 1999, SURGERY, V126, P650, DOI 10.1016/S0039-6060(99)70118-2; Burlacu CL, 2006, ANAESTHESIA, V61, P932, DOI 10.1111/j.1365-2044.2006.04793.x; Crews JC, 2002, ANESTH ANALG, V95, P219, DOI 10.1097/00000539-200207000-00039; Eisenach JC, 1996, ANESTHESIOLOGY, V85, P655, DOI 10.1097/00000542-199609000-00026; GAUMANN D, 1992, ANESTH ANALG, V75, P69; GAUMANN DM, 1992, ANESTH ANALG, V74, P719; GISSEN AJ, 1987, ANESTH ANALG, V66, P1272; GOURLAY GK, 1988, ANESTH ANALG, V67, P329; Hermann D, 2005, J APPL PHYSIOL, V99, P2266, DOI 10.1152/japplphysiol.00271.2005; KHASAR SG, 1995, NEUROSCIENCE, V66, P427, DOI 10.1016/0306-4522(94)00562-J; Kopacz DJ, 1999, ANESTH ANALG, V89, P1027, DOI 10.1097/00000539-199910000-00038; McLeod GA, 2001, ANAESTHESIA, V56, P331, DOI 10.1046/j.1365-2044.2001.01964.x; Newton DJ, 2005, BRIT J ANAESTH, V94, P662, DOI 10.1093/bja/aei095; Nishikawa K, 2000, ANESTH ANALG, V91, P384, DOI 10.1097/00000539-200008000-00028; PERTTUNEN K, 1995, BRIT J ANAESTH, V75, P541, DOI 10.1093/bja/75.5.541; Reinhart DJ, 1996, ANESTH ANALG, V83, P760, DOI 10.1097/00000539-199610000-00018; Rosenberg PH, 2004, REGION ANESTH PAIN M, V29, P564, DOI 10.1016/j.rapm.2004.08.003; Sahin AE, 2005, J CARDIOTHOR VASC AN, V19, P197, DOI 10.1053/j.jvca.2005.01.031; SINGELYN FJ, 1992, REGION ANESTH, V17, P148; STEIN C, 1995, NEW ENGL J MED, V332, P1685, DOI 10.1056/NEJM199506223322506; Tschernko EM, 1998, ANESTH ANALG, V87, P107, DOI 10.1097/00000539-199807000-00023	25	22	23	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1098-7339			REGION ANESTH PAIN M	Region. Anesth. Pain Med.	MAR-APR	2007	32	2					136	145		10.1016/j.rapm.2006.11.011			10	Anesthesiology	Anesthesiology	150MZ	WOS:000245222200008	17350525				2020-06-30	J	Luo, WH; Li, PC; Chen, SB; Zeng, SQ; Luo, QM				Luo, Weihua; Li, Pencheng; Chen, Shangbin; Zeng, Shaoqun; Luo, Qingmin			Differentiating hemodynamic responses in rat primary somatosensory cortex during non-noxious and noxious electrical stimulation by optical imaging	BRAIN RESEARCH			English	Article						intrinsic signal; nociception; somatosensory cortex; optical imaging; cerebral blood volume	CEREBRAL-BLOOD-FLOW; SCIATIC-NERVE STIMULATION; ANTERIOR PARIETAL CORTEX; NEURONAL-ACTIVITY; VISUAL-CORTEX; FLUTTER STIMULATION; SURROUND INHIBITION; COLUMNAR RESOLUTION; INTRINSIC SIGNALS; BRAIN ACTIVATION	Nociception in the primary somatosensory (S1) cortex remains in need of further elucidation. The spatiotemporal comparison on changes of the cerebral blood volume evoked by graded peripheral electrical stimulation was performed in rat contralateral somatosensory cortex with optical intrinsic signal imaging (OISI, optical reflectance at 550 nm). Non-noxious electrical stimulus was applied with 5 Hz pulses (0.5 ms peak duration) for 2 s at the threshold current for muscle twitch, while noxious stimulus was delivered at currents of 10x and 20x amplitude of the predetermined threshold. Although the dimensions of peak response defined in the spatial domain (cerebral blood volume increase) in the S1 cortex presented no significant difference under non-/noxious stimuli, its early response component (about 1 s after stimulation onset) revealed by OISI technique was suggested to differentiate the loci of activated cortical region due to different stimulation in this study. The magnitude and duration of the optical intrinsic signal (OIS) response was found increasing with the varying stimulus intensity. Regions activated by the delivery of a noxious stimulus were surrounded by a ring of inverted optical intrinsic signal, the amplitude of that was inversely proportional to the strength of the optical signal attributable to activation. Intense stimuli significantly augmented the inverted optical signal in magnitude and spatial extent. These results indicated that noxious stimulation evoked different response patterns in the contralateral Sl cortex. The magnitude-dependent inverted optical signal might contribute to the differentiation of nociceptive input in the S1 cortex. (c) 2006 Published by Elsevier B.V.	Huazhong Univ Sci & Technol, Wuhan Natl Lab Optoelect, Minist Educ, Key Lab Biomed Photon, Wuhan 430074, Peoples R China	Luo, QM (reprint author), Huazhong Univ Sci & Technol, Wuhan Natl Lab Optoelect, Minist Educ, Key Lab Biomed Photon, Wuhan 430074, Peoples R China.	qluo@mail.hust.edu.cn					Bingel U, 2004, NEUROIMAGE, V23, P224, DOI 10.1016/j.neuroimage.2004.05.021; Blood AJ, 2002, J NEUROPHYSIOL, V88, P422, DOI 10.1152/jn.2002.88.1.422; BONHOEFFER T, 1991, NATURE, V353, P429, DOI 10.1038/353429a0; Bushnell MC, 1999, P NATL ACAD SCI USA, V96, P7705, DOI 10.1073/pnas.96.14.7705; Casey KL, 2000, J NEUROPHYSIOL, V84, P525; Chang C, 2001, BRAIN RES, V897, P71, DOI 10.1016/S0006-8993(01)02094-7; Chen-Bee CH, 2000, J NEUROSCI METH, V97, P157, DOI 10.1016/S0165-0270(00)00180-1; Creac'h C, 2000, AM J NEURORADIOL, V21, P1402; Culver JP, 2005, NEUROIMAGE, V27, P947, DOI 10.1016/j.neuroimage.2005.05.052; de Tommaso M, 2002, NEUROSCI LETT, V333, P29, DOI 10.1016/S0304-3940(02)00967-9; Derdikman D, 2003, J NEUROSCI, V23, P3100; Devor A, 2005, P NATL ACAD SCI USA, V102, P3822, DOI 10.1073/pnas.0407789102; Erdos B, 2003, BRAIN RES, V960, P219, DOI 10.1016/S0006-8993(02)03890-8; Erinjeri JP, 2002, J CEREBR BLOOD F MET, V22, P353, DOI 10.1097/00004647-200203000-00013; Favorov OV, 2006, BRAIN RES, V1071, P81, DOI 10.1016/j.brainres.2005.11.073; Fayuk D, 2002, J NEUROPHYSIOL, V87, P1924, DOI 10.1152/jn.00231.2001; Firestone LL, 1996, ANESTH ANALG, V82, P1247, DOI 10.1097/00000539-199606000-00025; Friedman RM, 2004, P NATL ACAD SCI USA, V101, P12724, DOI 10.1073/pnas.0404884101; GRINVALD A, 1986, NATURE, V324, P361, DOI 10.1038/324361a0; Hendrich KS, 2001, MAGNET RESON MED, V46, P202, DOI 10.1002/mrm.1178; Ichimi K, 1999, NEUROL RES, V21, P579, DOI 10.1080/01616412.1999.11740980; Ji RR, 2003, TRENDS NEUROSCI, V26, P696, DOI 10.1016/j.tins.2003.09.017; KALLIOMAKI J, 1993, BRAIN RES, V622, P262, DOI 10.1016/0006-8993(93)90827-A; LAMOUR Y, 1983, EXP BRAIN RES, V49, P35; Le Bars D, 2001, PHARMACOL REV, V53, P597; Li PC, 2003, J BIOMED OPT, V8, P629, DOI 10.1117/1.1609199; Liu GB, 2003, BRAIN RES, V985, P13, DOI 10.1016/S0006-8993(03)03049-X; Moulton EA, 2005, J NEUROPHYSIOL, V93, P2183, DOI 10.1152/jn.01025.2004; Nemoto M, 1999, J CEREBR BLOOD F MET, V19, P246, DOI 10.1097/00004647-199903000-00002; NGAI AC, 1988, AM J PHYSIOL, V254, pH133; Nielsen AN, 2001, J PHYSIOL-LONDON, V533, P773, DOI 10.1111/j.1469-7793.2001.00773.x; Paxinos G., 1998, RAT BRAIN STEREOTAXI; Rubin BD, 1999, NEURON, V23, P499, DOI 10.1016/S0896-6273(00)80803-X; Schuett S, 2002, J NEUROSCI, V22, P6549; Schwartz TH, 2004, NEUROREPORT, V15, P1527, DOI 10.1097/01.wnr.0000131006.59315.2f; Schwartz TH, 2001, NAT MED, V7, P1063, DOI 10.1038/nm0901-1063; Sheth SA, 2004, J NEUROSCI, V24, P634, DOI 10.1523/JNEUROSCI.4526-03.2004; Sheth SA, 2004, NEURON, V42, P347, DOI 10.1016/S0896-6273(04)00221-1; Sheth SA, 2005, J CEREBR BLOOD F MET, V25, P830, DOI 10.1038/sj.jcbfm.9600091; Silva AC, 1999, J CEREBR BLOOD F MET, V19, P871, DOI 10.1097/00004647-199908000-00006; Simons SB, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-43; Stucky CL, 2001, P NATL ACAD SCI USA, V98, P11845, DOI 10.1073/pnas.211373398; Suh M, 2005, J NEUROSCI, V25, P68, DOI 10.1523/JNEUROSCI.2823-04.2005; Takashima I, 2001, NEUROREPORT, V12, P2889, DOI 10.1097/00001756-200109170-00027; Tommerdahl M, 1996, J NEUROPHYSIOL, V75, P2662; Tommerdahl M, 1998, J NEUROPHYSIOL, V80, P3272; Tommerdahl M, 1999, J NEUROPHYSIOL, V82, P16; Ureshi M, 2005, NEUROSCI RES, V51, P139, DOI 10.1016/j.neures.2004.10.008; Vanzetta I, 2004, NEURON, V42, P843, DOI 10.1016/j.neuron.2004.04.004; Yaksh TL, 1997, ACTA ANAESTH SCAND, V41, P94, DOI 10.1111/j.1399-6576.1997.tb04623.x; Zhao FQ, 2005, NEUROIMAGE, V27, P416, DOI 10.1016/j.neuroimage.2005.04.011	51	11	12	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	FEB 16	2007	1133	1					67	77		10.1016/j.brainres.2006.09.111			11	Neurosciences	Neurosciences & Neurology	138NA	WOS:000244368100009	17196176				2020-06-30	J	Mutoh, T				Mutoh, T.			Effects of premedication with fentanyl and midazolam on mask induction of anaesthesia of dogs with sevoflurane	VETERINARY RECORD			English	Article							SPONTANEOUSLY BREATHING DOGS; RAPID INHALATION INDUCTION; ANESTHETIZED DOGS; VOLATILE ANESTHETICS; RESPIRATORY REFLEXES; ACEPROMAZINE-BUTORPHANOL; MEDETOMIDINE-MIDAZOLAM; NITROUS-OXIDE; ISOFLURANE; HALOTHANE	Fourteen beagles were used to determine the effects of fentanyl and midazolam as a premedicant for mask induction of anaesthesia with sevoflurane. The drugs were administered to each dog in a randomised cross-over design with a seven-day washout period between experiments. After a 15-minute equilibration period, a treatment consisting of fentanyl (10 mu g/kg bodyweight) and midazolam (0-2 mg/kg) was given either intravenously or intramuscularly. Anaesthesia was then induced by the use of a facemask with sevoflurane in 100 per cent oxygen at a flow rate of 4 l/minute. Vaporiser settings were increased by 0.8 per cent at 15-second intervals until the value corresponding to 4-8 per cent sevoflurane was achieved. The time to the onset and cessation of involuntary movements, loss of the palpebral reflex, negative response to tail-clamp stimulation, and endotracheal intubation and cardiopulmonary variables were measured. Both the treatments with tentanyl and midazolam resulted in a shorter and smoother induction of anaesthesia than treatment with saline, and the cardiopulmonary changes were smaller and milder.	Univ Tokyo, Lab Vet Surg, Grad Sch Agr & Life Sci, Bunkyo Ku, Tokyo, Japan	Mutoh, T (reprint author), Teine Keijinkai Med Ctr, Dept Neurosurg, Teine Ku, 1-40 Maeda 1 Jyo, Sapporo, Hokkaido 0068555, Japan.						EGER EI, 1994, ANESTHESIOLOGY, V80, P906, DOI 10.1097/00000542-199404000-00024; FLACKE JW, 1985, ANESTH ANALG, V64, P1053; Gross JB, 1996, ANESTHESIOLOGY, V85, P713, DOI 10.1097/00000542-199610000-00005; Hall AP, 1999, BRIT J ANAESTH, V82, P857; HALL RI, 1988, ANESTHESIOLOGY, V68, P862, DOI 10.1097/00000542-198806000-00005; HARVEY RC, 1992, VET CLIN N AM-SMALL, V22, P310, DOI 10.1016/S0195-5616(92)50616-7; Hellyer PW, 2001, AM J VET RES, V62, P555, DOI 10.2460/ajvr.2001.62.555; Johnson RA, 1998, AM J VET RES, V59, P478; Kojima K, 2002, AM J VET RES, V63, P1671, DOI 10.2460/ajvr.2002.63.1671; Lerche P, 2002, J SMALL ANIM PRACT, V43, P12, DOI 10.1111/j.1748-5827.2002.tb00003.x; MCCULLOCH TM, 1992, ANN OTO RHINOL LARYN, V101, P583, DOI 10.1177/000348949210100707; Mutoh T, 1997, AM J VET RES, V58, P885; Mutoh T, 1999, J VET MED SCI, V61, P1033, DOI 10.1292/jvms.61.1033; Mutoh T, 1995, J VET MED SCI, V57, P1007, DOI 10.1292/jvms.57.1007; Mutoh T, 2000, AM J VET RES, V61, P260, DOI 10.2460/ajvr.2000.61.260; Mutoh T, 2003, AM J RESP CRIT CARE, V167, P557, DOI 10.1164/rccm.200207-768BC; Mutoh T, 2002, AM J VET RES, V63, P1022, DOI 10.2460/ajvr.2002.63.1022; Mutoh T, 1998, RESP PHYSIOL, V111, P113, DOI 10.1016/S0034-5687(97)00123-0; Mutoh T, 1998, RESP PHYSIOL, V112, P253, DOI 10.1016/S0034-5687(98)00028-0; Mutoh T, 1998, LUNG, V176, P181, DOI 10.1007/PL00007601; Mutoh T, 2001, AM J VET RES, V62, P1727, DOI 10.2460/ajvr.2001.62.1727; Mutoh T, 1995, J VET MED SCI, V57, P1121, DOI 10.1292/jvms.57.1121; Mutoh T, 2001, J VET MED A, V48, P223, DOI 10.1046/j.1439-0442.2001.00350.x; Mutoh T, 2001, AM J VET RES, V62, P311, DOI 10.2460/ajvr.2001.62.311; Mutoh T, 2001, VET SURG, V30, P87, DOI 10.1053/jvet.2001.20329; Muzi M, 1997, ANESTH ANALG, V85, P1143, DOI 10.1097/00000539-199711000-00034; NISHINO T, 1993, RESP PHYSIOL, V91, P247, DOI 10.1016/0034-5687(93)90103-H; PADDLEFORD RR, 1992, VET CLIN N AM-SMALL, V22, P308, DOI 10.1016/S0195-5616(92)50615-5; Sawyer D. C., 1982, PRACTICE SMALL ANIMA, P13; TerRiet MF, 2000, BRIT J ANAESTH, V85, P305, DOI 10.1093/bja/85.2.305; THURMON JC, 1996, LUMB JONES VET ANEST, P5	31	4	4	0	1	BRITISH VETERINARY ASSOC	LONDON	7 MANSFIELD ST, LONDON W1M 0AT, ENGLAND	0042-4900			VET REC	Vet. Rec.	FEB 3	2007	160	5					152	+		10.1136/vr.160.5.152			6	Veterinary Sciences	Veterinary Sciences	137GL	WOS:000244280900011	17277297				2020-06-30	J	Bauer, C; Kreuer, S; Ketter, R; Grundmann, U; Wilhelm, W				Bauer, C.; Kreuer, S.; Ketter, R.; Grundmann, U.; Wilhelm, W.			Remifentanil-propofol versus fentanyl-midazolam combinations for intracranial surgery. Influence of anaesthesia technique and intensive sedation on ventilation times and duration of stay in the ICU	ANAESTHESIST			German	Article						neurosurgery; anaesthesia technique; ventilation time; sedation technique; intensive care unit stay	CRITICALLY-ILL PATIENTS; CARE-UNIT; ANALGESIA; PNEUMONIA	Introduction After neurosurgery patients often need to be sedated and ventilated in the intensive care unit (ICU). However, rapid postoperative recovery and neurological examination are particularly important for the early recognition of complications. In this retrospective study two different strategies of anaesthesia technique and ICU sedation (fentanyl-midazolam versus remifentanil-propofol) were compared. Methods Intraoperatively, patients received continuous infusions of either fentanyl (0.2-1.0 mg/h) and midazolam (2-10 mg/h) or remifentanil (0.2-0.5 mu g/kg body weight/min) and propofol (3-6 mg/kg body weight/h). After arrival in the ICU fentanyl (0.03-0.2 mg/h) and midazolam (2-12 mg/h) or remifentanil (0.1-0.2 mu g/kg body weight/min) and propofol (0.5-3 mg/kg body weight/h) were infused to reach a Ramsay score of 4. The times between termination of infusion and extubation and the length of stay in the ICU were examined. Results A total of 60 patients (n=30 each group) undergoing supratentorial brain tumour surgery were enrolled. The groups were comparable for age, weight, ASA status (American Society of Anesthesiologists) and duration of drug administration (remifentanil-propofol 528 +/- 382 min versus fentanyl-midazolam 548 +/- 360 min). Extubation times were significantly shorter after remifentanil-propofol (47 min) than after fentanyl-midazolam (481 min), and the length of stay in the ICU was also significantly reduced (1.8 days versus 3.7 days). As a result of prolonged unconsciousness and impaired neurological assessability, a brain CT scan was necessary in 3 patients after fentanyl-midazolam to exclude neurosurgical complications. Conclusions This retrospective study demonstrates that remifentanil-propofol anaesthesia and ICU sedation are superior to the combination of fentanyl and midazolam in terms of ventilation time and length of ICU stay. Moreover, the use of fentanyl-midazolam may lead to unnecessary CT scans.	Univ Klinikum Saarlandes, Klin Anaesthesiol Intens Med & Schmerztherapie, D-66421 Homburg, Germany; Univ Klinikum Saarlandes, Neurochirurg Klin, D-66421 Homburg, Germany	Bauer, C (reprint author), Univ Klinikum Saarlandes, Klin Anaesthesiol Intens Med & Schmerztherapie, D-66421 Homburg, Germany.	clemens.bauer@uniklinikum-saarland.de					BarrientosVega R, 1997, CRIT CARE MED, V25, P33, DOI 10.1097/00003246-199701000-00009; Breen D, 2005, CRIT CARE, V9, pR200, DOI 10.1186/cc3495; Casati A, 2000, ANESTH ANALG, V91, P1269, DOI 10.1097/00000539-200011000-00040; Chastre J, 2002, AM J RESP CRIT CARE, V165, P867, DOI 10.1164/ajrccm.165.7.2105078; Dahaba AA, 2004, ANESTHESIOLOGY, V101, P640, DOI 10.1097/00000542-200409000-00012; EGAN TD, 1993, ANESTHESIOLOGY, V79, P881, DOI 10.1097/00000542-199311000-00004; Evans TN, 1997, ANAESTHESIA, V52, P800; GLASS PS, 1999, ANESTH ANALG, V89, P7; LANGER M, 1989, AM REV RESPIR DIS, V140, P302, DOI 10.1164/ajrccm/140.2.302; Martin J, 2005, ANASTH INTENSIVMED, V46, P1; Ostermann ME, 2000, JAMA-J AM MED ASSOC, V283, P1451, DOI 10.1001/jama.283.11.1451; RAMSAY MA, 1974, [No title captured], V22, P656; Schaffrath E, 2004, ANAESTHESIST, V53, P1111, DOI 10.1007/s00101-004-0773-2; Wilhelm W, 2003, ANAESTHESIST, V52, P473, DOI 10.1007/s00101-003-0540-9; Wilhelm W, 1999, ANAESTHESIST, V48, P625, DOI 10.1007/s001010050762	15	8	9	0	1	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013 USA	0003-2417			ANAESTHESIST	Anaesthesist	FEB	2007	56	2					128	132		10.1007/s00101-006-1130-4			5	Anesthesiology	Anesthesiology	139SN	WOS:000244453000003	17235542				2020-06-30	J	Martin, TJ; Kim, SA; Buechler, NL; Porreca, F; Eisenach, JC				Martin, Thomas J.; Kim, Susy A.; Buechler, Nancy L.; Porreca, Frank; Eisenach, James C.			Opioid self-administration in the nerve-injured rat	ANESTHESIOLOGY			English	Article							RECEPTOR-LIKE IMMUNOREACTIVITY; G-PROTEIN ACTIVATION; NEUROPATHIC PAIN; ANTIALLODYNIC EFFICACY; REINFORCING EFFICACY; EXPERIMENTAL-MODEL; AXIS FUNCTION; SPINAL-CORD; MORPHINE; HEROIN	Background: Neuropathic pain is associated with several sensory abnormalities, including allodynia as well as spontaneous pain. Opioid intake in neuropathic pain patients is motivated by alleviation of both pain and allodynia. However, laboratory animal studies rely almost exclusively on reflexive withdrawal measures of allodynia. The authors examined the pharmacology of self-regulated intake of opioids; in rats with or without nerve injury and compared the rate of drug intake to reversal of allodynia. Methods: Rats were implanted with intravenous catheters, and the L5 and L6 spinal nerves were ligated in half of these animals. Rats were then trained to self-administer a commonly abused opioid (heroin) and commonly prescribed opioids (morphine, fentanyl, hydromorphone, and methadone). in addition, rats trained to self-administer heroin were given either clonidine or adenosine spinally before self-administration sessions to assess opioid-sparing effects. Results: Nerve injury significantly decreased the reinforcing effects of low doses of opioids, and only doses of each opioid that reduced mechanical hypersensitivity maintained self-administration after spinal nerve ligation. The rate of drug consumption was correlated with the duration of the antiallodynic effect for each dose of opioid. Intrathecal administration of clonidine or adenosine reversed mechanical hypersensitivity, but only clonidine reduced heroin self-administration in rats with spinal nerve ligation. Conclusion: Opioid self-administration is significantly altered by nerve injury, with rate of drug intake being correlated with reversal of allodynia. Intrathecal clonidine, but not adenosine, produces opioid-sparing effects in self-administering rats. The neurobiologic mechanisms that regulate opioid consumption in rats therefore seem to be altered after nerve injury.	Wake Forest Univ, Sch Med, Dept Anesthesiol, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Physiol & Pharmacol, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Ctr Study Pharmacol Plast Presence Pain, Winston Salem, NC 27157 USA; Univ Arizona, Dept Pharmacol, Sch Med, Tucson, AZ USA	Martin, TJ (reprint author), Wake Forest Univ, Sch Med, Dept Anesthesiol, Med Cr Blvd, Winston Salem, NC 27157 USA.	tjmartin@wfubmc.edu			NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [GM48085]; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS41386, NS38231]		Aston-Jones G, 2004, NEUROPHARMACOLOGY, V47, P167, DOI 10.1016/j.neuropharm.2004.06.020; Ator NA, 2003, DRUG ALCOHOL DEPEN, V70, pS55, DOI 10.1016/S0376-8716(03)00099-1; Backonja MM, 2004, J PAIN, V5, P491, DOI 10.1016/j.jpain.2004.09.001; BIAN D, 1995, NEUROREPORT, V6, P1981, DOI 10.1097/00001756-199510010-00007; Bickel WK, 2000, PSYCHOPHARMACOLOGY, V153, P44, DOI 10.1007/s002130000589; Blackburn-Munro G, 2001, J NEUROENDOCRINOL, V13, P1009, DOI 10.1046/j.0007-1331.2001.00727.x; Bomholt SF, 2005, BRAIN RES, V1044, P216, DOI 10.1016/j.brainres.2005.03.005; BROWN ZW, 1976, PHARMACOL BIOCHEM BE, V5, P363, DOI 10.1016/0091-3057(76)90090-3; Chaplan SR, 1997, J PHARMACOL EXP THER, V280, P829; CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9; COLPAERT FC, 1982, LIFE SCI, V31, P67, DOI 10.1016/0024-3205(82)90402-7; Colpaert FC, 2001, PAIN, V91, P33, DOI 10.1016/S0304-3959(00)00413-9; Compton WM, 2006, DRUG ALCOHOL DEPEN, V81, P103, DOI 10.1016/j.drugalcdep.2005.05.009; EBERT B, 1995, NEUROSCI LETT, V187, P165, DOI 10.1016/0304-3940(95)11364-3; EISENACH JC, 1995, PAIN, V61, P391, DOI 10.1016/0304-3959(94)00209-W; Eisenach JC, 2003, PAIN, V105, P65, DOI 10.1016/S0304-3959(03)00158-1; FINC PG, 2002, J PAIN PALLIAT CARE, V16, P77; KIM SH, 1992, PAIN, V50, P355; King T, 2006, J PAIN, V7, P513, DOI 10.1016/j.jpain.2006.02.001; Lavand'homme PM, 1999, PAIN, V80, P31, DOI 10.1016/S0304-3959(98)00193-6; Leung A, 2001, PAIN, V91, P177, DOI 10.1016/S0304-3959(00)00433-4; Lu L, 2003, NEUROSCI BIOBEHAV R, V27, P457, DOI 10.1016/S0149-7634(03)00073-3; LYNESS WH, 1989, LIFE SCI, V45, P2217, DOI 10.1016/0024-3205(89)90062-3; Martin TJ, 2001, J PHARMACOL EXP THER, V299, P811; Martin TJ, 1998, EUR J PHARMACOL, V357, P25, DOI 10.1016/S0014-2999(98)00531-7; Martin TJ, 1996, DRUG ALCOHOL DEPEN, V41, P93, DOI 10.1016/0376-8716(96)01245-8; McCleane G, 2003, CNS DRUGS, V17, P1031, DOI 10.2165/00023210-200317140-00003; Mercadante S, 1999, J CLIN ONCOL, V17, P3307, DOI 10.1200/JCO.1999.17.10.3307; Mogil JS, 2004, PAIN, V112, P12, DOI 10.1016/j.pain.2004.09.028; Narita M, 2006, NEUROPSYCHOPHARMACOL, V31, P739, DOI 10.1038/sj.npp.1300858; Nichols ML, 1995, J PHARMACOL EXP THER, V275, P1339; Ozaki S, 2003, NEUROSCIENCE, V116, P89, DOI 10.1016/S0306-4522(02)00699-1; Ozaki S, 2002, J NEUROCHEM, V82, P1192, DOI 10.1046/j.1471-4159.2002.01071.x; Pertovaara A, 2003, PAIN, V101, P237, DOI 10.1016/S0304-3959(02)00320-2; Portenoy RK, 2000, J PAIN SYMPTOM MANAG, V19, pS16; Przewlocki R, 2005, CURR PHARM DESIGN, V11, P3013, DOI 10.2174/1381612054865055; Rocha A, 2004, PSYCHOPHARMACOLOGY, V174, P203, DOI 10.1007/s00213-003-1742-1; Rosin DL, 1996, J COMP NEUROL, V372, P135; Selley DE, 1998, J PHARMACOL EXP THER, V285, P496; Selley DE, 2001, BIOCHEM PHARMACOL, V62, P447, DOI 10.1016/S0006-2952(01)00689-X; SHAHAM Y, 1994, PSYCHOPHARMACOLOGY, V114, P523, DOI 10.1007/BF02249346; Shaham Y, 2000, EUR J NEUROSCI, V12, P292, DOI 10.1046/j.1460-9568.2000.00899.x; Siddall PJ, 2000, ANESTH ANALG, V91, P1493, DOI 10.1097/00000539-200012000-00037; Sizemore GM, 2000, PSYCHOPHARMACOLOGY, V153, P57, DOI 10.1007/s002130000611; Sullivan M, 2005, J PAIN, V6, P2, DOI 10.1016/j.jpain.2004.10.006; Talley EM, 1996, J COMP NEUROL, V372, P111, DOI 10.1002/(SICI)1096-9861(19960812)372:1<111::AID-CNE8>3.0.CO;2-6; TSILBUSKY VL, 1999, BRAIN RES, V839, P85; Ulrich-Lai YM, 2006, PHYSIOL BEHAV, V88, P67, DOI 10.1016/j.physbeh.2006.03.012; WAY EL, 1965, B NARCOTICS, V17, P25; WEEKS JR, 1962, SCIENCE, V138, P143, DOI 10.1126/science.138.3537.143; YAKSH TL, 1995, J PHARMACOL EXP THER, V272, P207; Yaksh TL, 1976, PHYSIOL BEHAV, V7, P1032	52	73	75	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-3022			ANESTHESIOLOGY	Anesthesiology	FEB	2007	106	2					312	322		10.1097/00000542-200702000-00020			11	Anesthesiology	Anesthesiology	132CH	WOS:000243919200018	17264726				2020-06-30	J	Guedj, MP				Guedj, M. P.			Sudden deflation of a tourniquet caused by lowering of the operating table	ANNALES FRANCAISES D ANESTHESIE ET DE REANIMATION			English	Letter						intravenous regional anesthesia; local anesthetic; tourniquet; operating table			Univ Hosp Hadassa Ein Karem, Dept Anesthesia & Crit Care, IL-91120 Jerusalem, Israel	Guedj, MP (reprint author), Univ Hosp Hadassa Ein Karem, Dept Anesthesia & Crit Care, Kiryat Hadassah,POB 12000, IL-91120 Jerusalem, Israel.	Pierre@hadassah.org.il					ABDULLA WY, 1992, ANESTH ANALG, V75, P597; DAUBIGNE RM, 1995, MEM ACAD CHIR PARIS, V91, P532	2	0	0	0	0	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0750-7658	1769-6623		ANN FR ANESTH	Ann. Fr. Anest. Reanim.	FEB	2007	26	2					174	174		10.1016/j.annfar.2006.10.003			1	Anesthesiology	Anesthesiology	141XT	WOS:000244613100012	17174519				2020-06-30	J	Bannwarth, B				Bannwarth, Bernard			Transdermal fentanyl in patients with osteoarthritis: comment on the article by Langford et al	ARTHRITIS AND RHEUMATISM			English	Letter							CONTROLLED TRIAL; NONCANCER PAIN; OPIOIDS; MANAGEMENT; KNEE		Univ Hosp Bordeaux, Bordeaux, France	Bannwarth, B (reprint author), Univ Hosp Bordeaux, Bordeaux, France.						Bannwarth B, 1999, DRUG SAFETY, V21, P283, DOI 10.2165/00002018-199921040-00004; Jordan KM, 2003, ANN RHEUM DIS, V62, P1145, DOI 10.1136/ard.2003.011742; Kalso E, 2005, BRIT MED J, V330, P156, DOI 10.1136/bmj.330.7484.156; Kornick CA, 2003, DRUG SAFETY, V26, P951, DOI 10.2165/00002018-200326130-00004; Langford R, 2006, ARTHRITIS RHEUM-US, V54, P1829, DOI 10.1002/art.21884; McKenna F, 2001, SCAND J RHEUMATOL, V30, P11; Simonnet G, 2005, PAIN, V118, P8, DOI 10.1016/j.pain.2005.07.021; Truitt KE, 2001, AGING-CLIN EXP RES, V13, P112, DOI 10.1007/BF03351533	8	0	0	0	1	WILEY-LISS	HOBOKEN	DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA	0004-3591			ARTHRITIS RHEUM	Arthritis Rheum.	FEB	2007	56	2					697	698		10.1002/art.22396			2	Rheumatology	Rheumatology	135HS	WOS:000244145300041	17265512				2020-06-30	J	Mousa, SA; Cheppudira, BP; Shaqura, M; Fischer, O; Hofmann, J; Hellweg, R; Schafer, M				Mousa, Shaaban A.; Cheppudira, Bopaiah P.; Shaqura, Mohammed; Fischer, Oliver; Hofmann, Julia; Hellweg, Rainer; Schaefer, Michael			Nerve growth factor governs the enhanced ability of opioids to suppress inflammatory pain	BRAIN			English	Article						opioid receptors; sensory neuron; nerve growth factor; pain; antinociception	PRIMARY SENSORY NEURONS; PRIMARY AFFERENT NEURONS; GENE-RELATED PEPTIDE; DORSAL-ROOT GANGLIA; INFLAMED TISSUE; RETROGRADE TRANSPORT; AXONAL-TRANSPORT; SUBSTANCE-P; SPINAL-CORD; IMMUNOCYTOCHEMICAL LOCALIZATION	Nerve growth factor (NGF) regulates sensory neuron phenotype by elevated expression of ion channels and receptors contributing to pain. Peripheral opioid antinociception is dependent on sensory neuron mu opioid receptor (MOR) expression, coupling and efficacy. This study investigates the role of NGF in the upregulation of the number and efficacy of sensory MORs rendering sites of painful inflammation more susceptible to opioids. We identified co-localization of MOR with calcitonin gene-related peptides (CGRP) and with the NGF receptors tyrosine receptor kinase (TrkA) and p75(NTR) within rat dorsal root ganglia (DRG). We showed that unilateral hind paw inflammation induced with Freund's complete adjuvant (FCA) or intraplantar (i.pl.) NGF increased NGF's retrograde transport and MOR expression in TrkA positive DRG which was prevented by the disruption of this NGF transport. MOR upregulation in DRG was followed by enhanced axonal MOR transport towards peripheral nerve terminals and subsequent increase of MOR-ir nerve fibres within skin. Furthermore, peripheral antinociception elicited by i.pl. fentanyl was naloxone reversible and potentiated exclusively in inflamed and NGF-treated paws. Both FCA- and NGF-induced effects occurring through DRG to peripheral nerve fibres and the potentiation of antinociception were abrogated by NGF neutralization. Therefore, our results suggest that NGF not only contributes to inflammatory pain but also governs the upregulation in the number and efficacy of sensory neuron MOR, resulting in enhanced opioid susceptibility towards better pain control. This suggests the potential to overcome the unresponsiveness to opioids of certain neuropathic pain states.	Univ Med Berlin, Charite, Klin Anaesthesiol & Operat Intens Med, D-12200 Berlin, Germany; Univ Med Berlin, Charite, Klin Hsch Ambulanz Psychiat & Psychotherapie, D-12200 Berlin, Germany	Schafer, M (reprint author), Univ Med Berlin, Charite, Klin Anaesthesiol & Operat Intens Med, Campus Benjamin Franklin,Hindenburgdamm 30, D-12200 Berlin, Germany.	micha.schaefer@charite.de	Schafer, Michael/AAB-1395-2020				ANDREEV NY, 1995, PAIN, V63, P109, DOI 10.1016/0304-3959(95)00024-M; ANTONIJEVIC I, 1995, J NEUROSCI, V15, P165; AVERILL S, 1995, EUR J NEUROSCI, V7, P1484, DOI 10.1111/j.1460-9568.1995.tb01143.x; Barbacid M, 1995, ANN NY ACAD SCI, V766, P442, DOI 10.1111/j.1749-6632.1995.tb26693.x; Brack A, 2004, PAIN, V108, P67, DOI 10.1016/j.pain.2003.12.008; Bussmann KAV, 1999, NEUROSCIENCE, V91, P273, DOI 10.1016/S0306-4522(98)00562-4; Cahill CM, 2003, NEUROPHARMACOLOGY, V45, P543, DOI 10.1016/S0028-3908(03)00192-8; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; CHAO MV, 1995, TRENDS NEUROSCI, V18, P321, DOI 10.1016/0166-2236(95)93922-K; Chen JJ, 1997, MOL PHARMACOL, V51, P666; Cho HJ, 1997, BRAIN RES, V749, P358, DOI 10.1016/S0006-8993(97)00048-6; Delcroix JD, 2003, NEURON, V39, P69, DOI 10.1016/S0896-6273(03)00397-0; DONNERER J, 1992, NEUROSCIENCE, V49, P693, DOI 10.1016/0306-4522(92)90237-V; Dyck PJ, 1997, NEUROLOGY, V48, P501, DOI 10.1212/WNL.48.2.501; Frank AJ, 2003, EXP CELL RES, V283, P127, DOI 10.1016/S0014-4827(02)00026-5; FRIZELL M, 1975, BRAIN RES, V86, P67, DOI 10.1016/0006-8993(75)90638-1; GREENE LA, 1995, CURR OPIN NEUROBIOL, V5, P579, DOI 10.1016/0959-4388(95)80062-X; HASSAN AHS, 1993, NEUROSCIENCE, V55, P185, DOI 10.1016/0306-4522(93)90465-R; Hellweg R, 2001, BRAIN RES, V907, P100, DOI 10.1016/S0006-8993(01)02611-7; HELLWEG R, 1989, TECHNIQUE, V1, P43; INOUE N, 1982, J BIOL CHEM, V257, P9238; JEANJEAN AP, 1995, NEUROSCIENCE, V68, P151, DOI 10.1016/0306-4522(95)00106-S; Ji RR, 1995, J NEUROSCI, V15, P8156; Ji RR, 2002, NEURON, V36, P57, DOI 10.1016/S0896-6273(02)00908-X; JOHNSON EM, 1978, BRAIN RES, V150, P319, DOI 10.1016/0006-8993(78)90283-4; LADURON PM, 1984, BRAIN RES, V294, P157, DOI 10.1016/0006-8993(84)91322-2; Lee YJ, 2002, MOL CELL NEUROSCI, V19, P186, DOI 10.1006/mcne.2001.1073; LEWIN GR, 1994, EUR J NEUROSCI, V6, P1903, DOI 10.1111/j.1460-9568.1994.tb00581.x; Li JL, 1998, BRAIN RES, V794, P347, DOI 10.1016/S0006-8993(98)00332-1; Mamet J, 2002, J NEUROSCI, V22, P10662; McDowell TS, 2004, NEUROSCIENCE, V125, P1029, DOI 10.1016/j.neuroscience.2004.03.009; MCMAHON SB, 1995, NAT MED, V1, P774, DOI 10.1038/nm0895-774; Molliver DC, 2005, PAIN, V113, P277, DOI 10.1016/j.pain.2004.10.025; Mousa SA, 2001, J NEUROIMMUNOL, V115, P71, DOI 10.1016/S0165-5728(01)00271-5; Mousa SA, 2002, J NEUROIMMUNOL, V126, P5, DOI 10.1016/S0165-5728(02)00049-8; Mousa SA, 2004, ENDOCRINOLOGY, V145, P1331, DOI 10.1210/en.2003-1287; NINKOVIC M, 1982, BRAIN RES, V241, P197, DOI 10.1016/0006-8993(82)91056-3; Pezet S, 2001, PAIN, V90, P113, DOI 10.1016/S0304-3959(00)00393-6; Puehler W, 2004, NEUROSCIENCE, V129, P473, DOI 10.1016/j.neuroscience.2004.06.086; RAIVICH G, 1991, NEURON, V7, P151, DOI 10.1016/0896-6273(91)90083-C; RICHARDSON PM, 1984, J NEUROSCI, V4, P1683; Rittner HL, 2001, ANESTHESIOLOGY, V95, P500, DOI 10.1097/00000542-200108000-00036; SAFIEHGARABEDIAN B, 1995, BRIT J PHARMACOL, V115, P1265, DOI 10.1111/j.1476-5381.1995.tb15035.x; SCHAFER M, 1994, P NATL ACAD SCI USA, V91, P4219, DOI 10.1073/pnas.91.10.4219; Shaqura MA, 2004, J PHARMACOL EXP THER, V308, P712, DOI 10.1124/jpet.103.057257; Stein C, 2003, NAT MED, V9, P1003, DOI 10.1038/nm908; STEIN C, 1988, [No title captured], V31, P455; Wallin HJ, 2001, EUR J NEUROSCI, V14, P267, DOI 10.1046/j.0953-816x.2001.01641.x; Walsh GS, 1999, J NEUROSCI, V19, P258; Woolf CJ, 1996, PHILOS T ROY SOC B, V351, P441, DOI 10.1098/rstb.1996.0040; Woolf CJ, 1999, P NATL ACAD SCI USA, V96, P7723, DOI 10.1073/pnas.96.14.7723; ZHOU L, 1998, J PHARMACOL EXP THER, V286, P1; Zollner C, 2003, MOL PHARMACOL, V64, P202, DOI 10.1124/mol.64.2.202; Zwick M, 2003, PAIN, V106, P491, DOI 10.1016/j.pain.2003.09.016	54	78	84	0	6	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950			BRAIN	Brain	FEB	2007	130		2				502	513		10.1093/brain/awl330			12	Clinical Neurology; Neurosciences	Neurosciences & Neurology	130PC	WOS:000243810500025	17142830	Bronze			2020-06-30	J	Vasudevan, A; Snowman, CE; Sundar, S; Sarge, TW; Hess, PE				Vasudevan, A.; Snowman, C. E.; Sundar, S.; Sarge, T. W.; Hess, P. E.			Intrathecal morphine reduces breakthrough pain during labour epidural analgesia	BRITISH JOURNAL OF ANAESTHESIA			English	Article						analgesia, obstetric; analgesia regional, epidural; anaesthetics local, bupivacaine; analgesics opioid, fentanyl; analgesics opioid, morphine	SPINAL ANALGESIA; BUPIVACAINE; FENTANYL; ANESTHESIA	Background. When using the combined spinal-epidural (CSE) technique for labour analgesia, parturients often experience breakthrough pain after the spinal medication has receded. We tested the hypothesis that a small dose of intrathecal morphine would reduce breakthrough pain. Methods. This was a randomized, double-blind, placebo-controlled trial. Subjects were randomized to receive either 100 mu g of morphine (MS) or placebo (PLCB) with the spinal injection of bupivacaine and fentanyl. Assessments included need for supplementation during labour analgesia, use of pain medications for 24 h after delivery, and side-effects. The primary endpoint was the rate of breakthrough pain. Results. Sixty subjects were enrolled, 55 subjects completed the trial. The MS group had a significantly lower rate of breakthrough pain than the PLCB group (0.6 (0.6) vs 1.1 (0.8) episodes per patient; P < 0.01), and longer time to first episode of breakthrough pain (300 vs 180 min; P=0.03). The MS group used 75% less opioid medications during the subsequent 24 h, but had a 17% incidence of nausea. Conclusions. The addition of small dose of morphine to the spinal component of the CSE technique improved the effectiveness of epidural labour analgesia and reduced the need for pain medications over 24 h, but resulted in a small increase in nausea.	Beth Israel Deaconess Med Ctr, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02215 USA	Hess, PE (reprint author), Beth Israel Deaconess Med Ctr, Dept Anesthesia Crit Care & Pain Med, 330 Brookline Ave, Boston, MA 02215 USA.	phess@bidmc.harvard.edu	Hess, Philip/A-8577-2013	Hess, Philip/0000-0002-1206-0102			Beilin Y, 2002, ANESTH ANALG, V94, P927, DOI 10.1097/00000539-200204000-00029; Birnbach DJ, 1999, ANESTH ANALG, V88, P971, DOI 10.1097/00000539-199905000-00001; BREEN TW, 1993, ANESTH ANALG, V77, P919; Cohen SE, 2000, ANESTHESIOLOGY, V92, P387, DOI 10.1097/00000542-200002000-00019; Gaiser RR, 2000, REGION ANESTH PAIN M, V25, P223, DOI 10.1016/S1098-7339(00)90002-6; Hess PE, 2006, INT J OBSTET ANESTH, V15, P195, DOI 10.1016/j.ijoa.2005.12.006; Hess PE, 2003, ANESTH ANALG, V97, P247, DOI 10.1213/01.ANE.0000066520.30763.B8; LEIGHTON BL, 1989, ANESTH ANALG, V69, P122; Palmer CM, 1999, ANESTHESIOLOGY, V90, P437, DOI 10.1097/00000542-199902000-00018; Takiguchi T, 1997, ANESTH ANALG, V85, P1097, DOI 10.1097/00000539-199711000-00024; Yeh HM, 2001, ANESTH ANALG, V92, P665, DOI 10.1097/00000539-200103000-00022	11	17	17	0	2	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0007-0912			BRIT J ANAESTH	Br. J. Anaesth.	FEB	2007	98	2					241	245		10.1093/bja/ael346			5	Anesthesiology	Anesthesiology	138FY	WOS:000244349700014	17210732	Bronze			2020-06-30	J	Larson, MD; Berry, PD; May, J; Bjorksten, A; Sessler, DI				Larson, M. D.; Berry, P. D.; May, J.; Bjorksten, A.; Sessler, D. I.			Autonomic effects of epidural and intravenous fentanyl	BRITISH JOURNAL OF ANAESTHESIA			English	Article						anaesthetic techniques, epidural; analgesics, opioids, fentanyl; pain; parasympathetic nervous system; pupils, pupillary reflex dilation; sympathetic nervous system	REFLEX PUPILLARY DILATION; NOXIOUS-STIMULATION; POSTOPERATIVE PAIN; ALFENTANIL; VOLUNTEERS; ANESTHESIA; MANAGEMENT; SURGERY; HUMANS; SITE	Background. We tested the hypothesis that there is greater suppression of autonomic reflexes during general anaesthesia when fentanyl is administered epidurally than when it is given intravenously. Methods. Ten volunteers were anaesthetized with desflurane. Noxious stimuli of variable intensity were then delivered by tetanic electrical stimuli. Heart rate, arterial pressure, and pupillary dilation in response to these stimuli defined nociception. Seven of these volunteers participated twice using a crossover design: they received i.v. fentanyl on one study day and epidurally on the other. Autonomic responses to alternative tetanic stimuli at L4 and C5 dermatomes were measured every 5 min for 3 h after fentanyl administration. Results. After a brief redistribution period, plasma fentanyl concentrations were virtually identical on both days. After stimulation of the L4 dermatome only, block of pupillary reflex dilation was greater by 47 (22)% after epidural fentanyl compared with i.v. fentanyl. Time to maximal depression of reflex dilation after L4 stimulation was 41 (13) min. Arterial pressure and heart rate decreased after fentanyl by either route but there were no differences observed between L4 and C5 stimulations. Conclusion. We conclude that during general anaesthesia, epidural fentanyl enhances antinociception by a spinal mechanism which can be detected by pupillary dilation but not by changes in arterial pressure or heart rate.	Univ Calif San Francisco, Dept Anesthesia & Perioperat Care, San Francisco, CA 94143 USA; Royal Free Hosp, London NW3 2QG, England; Royal Melbourne Hosp, Dept Anaesthesia, Parkville, Vic 3050, Australia; Univ Louisville, Dept Outcomes Res, Cleveland Clin, Outcomes Res Inst, Louisville, KY 40292 USA	Larson, MD (reprint author), Univ Calif San Francisco, Dept Anesthesia & Perioperat Care, Box 0648, San Francisco, CA 94143 USA.	larsonm@anesthesia.ucsf.edu	Sessler, Daniel/D-3504-2011	Sessler, Daniel/0000-0001-9932-3077	NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [GM 061655]		BJORKMAN S, 1988, J CHROMATOGR-BIOMED, V433, P95, DOI 10.1016/S0378-4347(00)80588-5; Brennum J, 1996, Acta Physiol Scand Suppl, V634, P1; CODA BA, 1994, ANESTHESIOLOGY, V81, P1149, DOI 10.1097/00000542-199411000-00008; Constant I, 2006, BRIT J ANAESTH, V96, P614, DOI 10.1093/bja/ael073; George MJ, 2006, ANAESTHESIA, V61, P659, DOI 10.1111/j.1365-2044.2006.04713.x; Ginosar Y, 2003, ANESTH ANALG, V97, P1428, DOI 10.1213/01.ANE.0000081793.60059.10; Guignard B, 2000, ANESTHESIOLOGY, V93, P409, DOI 10.1097/00000542-200008000-00019; GUINARD JP, 1995, ANESTHESIOLOGY, V82, P377, DOI 10.1097/00000542-199502000-00008; HARUKUNI I, 1995, ANESTH ANALG, V81, P1169, DOI 10.1097/00000539-199512000-00009; INAGAKI Y, 1992, ANESTH ANALG, V74, P856; Kehlet H, 2005, ANESTHESIOLOGY, V102, P1083, DOI 10.1097/00000542-200506000-00004; KITAHATA LM, 1974, ANESTHESIOLOGY, V41, P39, DOI 10.1097/00000542-197407000-00008; LARSELL O, 1953, NERVOUS SYSTEM SPINA, P1252; Larson MD, 2004, J APPL PHYSIOL, V97, P725, DOI 10.1152/japplphysiol.00098.2004; Larson MD, 1997, ANESTHESIOLOGY, V87, P849, DOI 10.1097/00000542-199710000-00019; Larson MD, 1996, ANESTHESIOLOGY, V85, P748, DOI 10.1097/00000542-199610000-00009; LARSON MD, 1993, ANESTH ANALG, V76, P1072; Li XQ, 2001, ANESTH ANALG, V93, P204; Liu SS, 1996, ANESTH ANALG, V82, P98, DOI 10.1097/00000539-199601000-00017; LOEWENFELD IE, 1958, DOC OPTHALMOL, V12, P184; LOEWY AD, 1973, BRAIN RES, V60, P65, DOI 10.1016/0006-8993(73)90851-2; Sabbe M B, 1990, J Pain Symptom Manage, V5, P191, DOI 10.1016/0885-3924(90)90009-9; Steinlechner B, 2006, BRIT J ANAESTH, V96, P444, DOI 10.1093/bja/ael037; WETZEL RC, 1985, ANESTH ANALG, V64, P125; Yang LL, 2003, ANESTHESIOLOGY, V99, P1281, DOI 10.1097/00000542-200312000-00008; Zhang R, 2004, NEUROSCIENCE, V125, P777, DOI 10.1016/j.neuroscience.2004.01.055	26	9	9	0	1	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0007-0912			BRIT J ANAESTH	Br. J. Anaesth.	FEB	2007	98	2					263	269		10.1093/bja/ael335			7	Anesthesiology	Anesthesiology	138FY	WOS:000244349700018	17210735	Bronze			2020-06-30	J	Nitahara, K; Sugi, Y; Shono, S; Hamada, T; Higa, K				Nitahara, K.; Sugi, Y.; Shono, S.; Hamada, T.; Higa, K.			Risk factors for nausea and vomiting following vitrectomy in adults	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article						anaesthesia, general; postoperative nausea and vomiting; postoperative period, complications; vitrectomy; surgery ophthalmic	POSTOPERATIVE NAUSEA; GENETIC POLYMORPHISMS; CAUCASIANS; DROPERIDOL; PREVENTION; ANESTHESIA	Background and objective: Postoperative nausea and vomiting (PONV) after ophthalmic surgery under general anaesthesia remains a complex and perturbing complication associated with several factors. Little information is available regarding the risk factors for nausea and vomiting after vitrectomy in adults. In this study, we evaluated the potential risk factors for PONV after vitrectomy in adult patients. Methods: Univariate and multivariate analyses of clinical factors associated with PONV were undertaken in a retrospective case-control series of 247 adult patients undergoing vitrectomy under general anaesthesia. We examined PONV for the first 48 h. Factors examined were age, body mass index (BMI), smoking status, H(2)-blocker as premedication, type of general anaesthesia (sevoflurane and fentanyl or total intravenous (i.v.) anaesthesia with propofol and fentanyl), duration of surgery, and intraoperative fentanyl dose. Results: Fifty-nine patients (24%) reported one or more episodes of PONV during the study period. Female gender (P < 0.01), lower BMI (P < 0.01) and general anaesthesia with inhalational anaesthetics (P < 0.01) were significantly related to nausea during the first 2 h post-operatively. Female gender (P < 0.01) was significantly related to nausea and vomiting throughout the study period. Other factors, including smoking status, did not alter the risk for nausea and/or vomiting. Conclusions: We conclude that female gender, lower BMI and inhalation anaesthesia are the main risk factors for PONV after vitrectomy in adults. Smoking status did not reduce the incidence of PONV in our patients.	Fukuoka Univ, Sch Med, Dept Anesthesiol, Jonan Ku, Fukuoka 8140180, Japan	Nitahara, K (reprint author), Fukuoka Univ, Sch Med, Dept Anesthesiol, Jonan Ku, 7-45-1 Nanakuma, Fukuoka 8140180, Japan.	nitahara@fukuoka-u.ac.jp					Apfel CC, 2002, BRIT J ANAESTH, V88, P659, DOI 10.1093/bja/88.5.659; Apfel CC, 1998, ACTA ANAESTH SCAND, V42, P495, DOI 10.1111/j.1399-6576.1998.tb05157.x; Chimbira W, 2000, ANAESTHESIA, V55, P540, DOI 10.1046/j.1365-2044.2000.01474.x; COHEN MM, 1994, ANESTH ANALG, V78, P7; Eberhart LHJ, 2004, OPHTHALMOLOGY, V111, P1569, DOI 10.1016/j.ophtha.2004.01.031; Inoue K, 2000, ARCH TOXICOL, V73, P532, DOI 10.1007/s002040050005; IWAMOTO K, 1978, ARCH OPHTHALMOL-CHIC, V96, P1378; Kim K, 2004, J CLIN PHARMACOL, V44, P1083, DOI 10.1177/0091270004268128; Koivuranta M, 1997, ANAESTHESIA, V52, P443, DOI 10.1111/j.1365-2044.1997.117-az0113.x; Kranke P, 2001, ACTA ANAESTH SCAND, V45, P160, DOI 10.1034/j.1399-6576.2001.450205.x; LARSSON S, 1995, ACTA ANAESTH SCAND, V39, P539, DOI 10.1111/j.1399-6576.1995.tb04115.x; Pavlin DJ, 1998, ANESTH ANALG, V87, P816, DOI 10.1097/00000539-199810000-00014; QUINN AC, 1994, ANAESTHESIA, V49, P62, DOI 10.1111/j.1365-2044.1994.tb03316.x; Sinclair DR, 1999, ANESTHESIOLOGY, V91, P109, DOI 10.1097/00000542-199907000-00018; Stadler M, 2003, ANESTHESIOLOGY, V98, P46, DOI 10.1097/00000542-200301000-00011; Tramer M, 1997, BRIT J ANAESTH, V78, P247; VANDENBERG AA, 1989, ANAESTHESIA, V44, P110; WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023	18	5	5	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0265-0215			EUR J ANAESTH	Eur. J. Anaesth.	FEB	2007	24	2					166	170		10.1017/S0265021506001360			5	Anesthesiology	Anesthesiology	135LP	WOS:000244155400010	16978442				2020-06-30	J	Turan, R; Yagmurdur, H; Kavutcu, M; Dikmen, B				Turan, R.; Yagmurdur, H.; Kavutcu, M.; Dikmen, B.			Propofol and tourniquet induced ischaemia reperfusion injury in lower extremity operations	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article						anaesthetics intravenous, propofol; reperfusion injury; tourniquets; antioxidants; lipid peroxidation; surgery, lower limbs	FREE-RADICAL PRODUCTION; GLUTATHIONE-PEROXIDASE; SPINAL-ANESTHESIA; SUPEROXIDE-DISMUTASE; GENERAL-ANESTHESIA; OXIDATIVE STRESS; XANTHINE-OXIDASE; SKELETAL-MUSCLE; RAT-BRAIN; ANTIOXIDANT	Background and objective: Extremity surgery with tourniquet to provide a bloodless field may be a good human model for ischaemia reperfusion (IR) injury. The aim of this study was to investigate the effects of three different modes of propofol use on tourniquet induced IR injury in lower extremity operations. Methods: Thirty-three consecutive ASA Grade I and 11 patients were randomized into three groups of I I patients each. In the spinal group (Group S), after intrathecal anaesthesia, sedation was given with a propofol infusion at 2 mg kg(-1) h(-1) after a 0.2 mg kg(-1) bolus dose and fentanyl 100 mu g. In the general (Group G) and TIVA (Group T) groups, general anaesthesia was induced with propofol 2 mg kg(-1) with fentanyl 100 mu g and maintained with inhalation of halothane or infusion of propofol respectively. Venous blood samples were obtained at different time points for measurements of plasma malondialdehyde (MDA), superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx) levels. Results: Plasma MDA levels were increased significantly in the Group G at I min before tourniquet release and 5 and 20 min after tourniquet release compared with before induction of general anaesthesia (baseline). Before intrathecal anaesthesia and before induction of general anaesthesia significantly decreased levels of MDA were observed both before and after tourniquet release compared to baseline. Plasma SOD and CAT concentrations were decreased significantly only at tourniquet release in the Group G compared with baseline. In the Groups S and T these enzymes were not changed significantly. Plasma GPx levels were not altered in any groups. Conclusion: Propofol administration may inhibit lipid peroxidation and restore antioxidant enzyme levels in extremity surgery requiring tourniquet application.	Ankara Res & Training Hosp, Minist Hlth, Clin Anaesthesiol & Reanimat, Ankara, Turkey; Gazi Univ, Sch Med, Dept Biochem, Ankara, Turkey	Yagmurdur, H (reprint author), Esat Cad 102-10 Kucukesat, TR-06660 Ankara, Turkey.	hyagmurdur@yahoo.com					Aabdallah DM, 2004, J BIOCHEM MOL TOXIC, V18, P273, DOI 10.1002/jbt.20037; AEBI H, 1984, METHOD ENZYMOL, V105, P121; Aldemir O, 2001, ACTA ANAESTH SCAND, V45, P1221, DOI 10.1034/j.1399-6576.2001.451008.x; Anaya-Prado R, 2002, J SURG RES, V105, P248, DOI 10.1006/jsre.2002.6385; BULKLEY GB, 1993, SURGERY, V113, P479; Bushell A, 1996, ACTA ORTHOP SCAND, V67, P393, DOI 10.3109/17453679609002338; CHAN PH, 1988, BRAIN RES, V439, P388, DOI 10.1016/0006-8993(88)91500-4; Cheng YJ, 2002, ANESTH ANALG, V94, P1617, DOI 10.1097/00000539-200206000-00047; CONCANNON MJ, 1992, PLAST RECONSTR SURG, V89, P846, DOI 10.1097/00006534-199205000-00012; Demiryurek AT, 1998, BRIT J ANAESTH, V80, P649; ERSKINE R, 1992, CAN J ANAESTH, V39, P905, DOI 10.1007/BF03008337; ERSKINE R, 1994, CAN J ANAESTH, V41, P632, DOI 10.1007/BF03010005; FRIEDL HP, 1991, KLIN WOCHENSCHR, V69, P1109, DOI 10.1007/BF01645168; GRANGER DN, 1988, AM J PHYSIOL, V255, pH1269; GREEN TR, 1994, TOXICOL APPL PHARM, V129, P163, DOI 10.1006/taap.1994.1240; Grisham MB, 1989, SPLANCHNIC ISCHEMIA, P135; HALLIWELL B, 1992, J LAB CLIN MED, V119, P598; Kahraman S, 1997, BRIT J ANAESTH, V78, P279; Kato R, 2002, CAN J ANAESTH, V49, P777, DOI 10.1007/BF03017409; KINUTA Y, 1989, NIPPON GEKA HOKAN, V8, P59; LINDSAY TF, 1990, J VASC SURG, V12, P8, DOI 10.1067/mva.1990.19946; McCord JM, 2000, AM J MED, V108, P652, DOI 10.1016/S0002-9343(00)00412-5; Mohler LR, 1996, J SURG RES, V60, P23, DOI 10.1006/jsre.1996.0005; MURPHY PG, 1992, BRIT J ANAESTH, V68, P613, DOI 10.1093/bja/68.6.613; NG A, 1995, ANAESTH INTENS CARE, V23, P543, DOI 10.1177/0310057X9502300502; PAGLIA DE, 1967, J LAB CLIN MED, V70, P158; Runzer TD, 2002, ANESTH ANALG, V94, P89, DOI 10.1097/00000539-200201000-00017; Schlack W, 1998, BRIT J ANAESTH, V81, P913; SUN Y, 1988, CLIN CHEM, V34, P497; VALENZUELA A, 1991, LIFE SCI, V48, P301, DOI 10.1016/0024-3205(91)90550-U; Wakai A, 2001, J TRAUMA, V51, P922, DOI 10.1097/00005373-200111000-00016; YOSHIOKA T, 1979, AM J OBSTET GYNECOL, V135, P372, DOI 10.1016/0002-9378(79)90708-7; ZHANG LP, 1989, BIOCHIM BIOPHYS ACTA, V1006, P140, DOI 10.1016/0005-2760(89)90336-6	33	28	28	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0265-0215			EUR J ANAESTH	Eur. J. Anaesth.	FEB	2007	24	2					185	189		10.1017/S0265021506001347			5	Anesthesiology	Anesthesiology	135LP	WOS:000244155400013	16938161				2020-06-30	J	Dumont, H; Guntz, E; Sosnowski, M; Talla, G; Roman, A; Segers, B				Dumont, H.; Guntz, E.; Sosnowski, M.; Talla, G.; Roman, A.; Segers, B.			Opioid-induced hyperalgesia	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Letter							D-ASPARTATE RECEPTOR; REMIFENTANIL; TOLERANCE; MORPHINE; KETAMINE; RAT		Free Univ Brussels, Dept Anesthesiol, Ctr Hosp Univ St Pierre, B-1000 Brussels, Belgium; Free Univ Brussels, Dept Intens Care Unit, Ctr Hosp Univ St Pierre, B-1000 Brussels, Belgium; Free Univ Brussels, Dept Vasc Surg, Ctr Hosp Univ St Pierre, Brussels, Belgium	Guntz, E (reprint author), Free Univ Brussels, Dept Anesthesiol, Ctr Hosp Univ St Pierre, Rue Haute 322, B-1000 Brussels, Belgium.	eguntz@ulb.ac.be					Guignard B, 2000, ANESTHESIOLOGY, V93, P409, DOI 10.1097/00000542-200008000-00019; Guignard B, 2002, ANESTH ANALG, V95, P103, DOI 10.1097/00000539-200207000-00018; Guntz E, 2005, ANESTHESIOLOGY, V102, P1235, DOI 10.1097/00000542-200506000-00025; Hahnenkamp K, 2004, ANESTHESIOLOGY, V100, P1531, DOI 10.1097/00000542-200406000-00028; Laulin JP, 2002, ANESTH ANALG, V94, P1263, DOI 10.1097/00000539-200205000-00040; Rivat C, 2002, ANESTHESIOLOGY, V96, P381, DOI 10.1097/00000542-200202000-00025; SOSNOWSKI M, 1990, ANESTHESIOLOGY, V73, P1141, DOI 10.1097/00000542-199012000-00012	7	12	25	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0265-0215			EUR J ANAESTH	Eur. J. Anaesth.	FEB	2007	24	2					205	207		10.1017/S0265021506001700			3	Anesthesiology	Anesthesiology	135LP	WOS:000244155400020	17038211				2020-06-30	J	Heimel, JA; Hartman, RJ; Hermans, JM; Levelt, CN				Heimel, J. Alexander; Hartman, Robin J.; Hermans, Josephine M.; Levelt, Christiaan N.			Screening mouse vision with intrinsic signal optical imaging	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						acuity; ocular dominance plasticity; temporal frequency; visual cortex	OCULAR DOMINANCE PLASTICITY; PRIMARY VISUAL-CORTEX; EXPERIENCE-DEPENDENT PLASTICITY; CRITICAL PERIOD; STRIATE CORTEX; MONOCULAR DEPRIVATION; POSTNATAL-DEVELOPMENT; RECEPTIVE-FIELDS; WILD-TYPE; MICE	The introduction of forward genetic screens in the mouse asks for techniques that make rapid screening of visual function possible. Transcranial imaging of intrinsic signal is suitable for this purpose and could detect the effects of retinal degeneration, and the increased predominance of the contralateral eye in albino animals. We quantified visual response properties of the cortex by introducing a normalization method to reduce the impact of biological noise. In addition, the presentation of a 'reset'-stimulus shortly after the probing stimulus at a different visual location could reduce the interstimulus time necessary for the decay of the response. Applying these novel methods, we found that acuity of C57Bl/6J mice rises from 0.35 cycles per degree (cpd) at postnatal day 25 to 0.56 cpd in adults. Temporal resolution was lower in adults than in juvenile animals. There was no patchy organization of spatial or temporal frequency preference at the intrinsic signal resolution. Monocular deprivation, a model for amblyopia and critical period plasticity, led to a loss in acuity and a shift towards the nondeprived eye in juvenile animals. Short deprivation did not lead to increased acuity of the nondeprived eye. In adults, a small ocular dominance shift was detectable with urethane anaesthesia. This was not observed when the combination of the opiate fentanyl, fluanisone with a benzodiazepine was used, adding evidence to the hypothesis that enhancing GABA(A)-receptor function masks an adult shift. Together, these novel applications confirm that noninvasive screening of many functional properties of the visual cortex is possible.	Netherlands Inst Neurosci, Amsterdam, Netherlands	Heimel, JA (reprint author), Netherlands Inst Neurosci, Amsterdam, Netherlands.	heimel@nin.knaw.nl	Heimel, J.Alexander/F-5782-2012				Airey DC, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-18; Antonini A, 1999, J NEUROSCI, V19, P4388; BALKEMA GW, 1991, VISUAL NEUROSCI, V6, P577, DOI 10.1017/S095252380000256X; Bence M, 2005, PROG BRAIN RES, V147, P125, DOI 10.1016/S0079-6123(04)47010-1; Berardi N, 2003, TRENDS NEUROSCI, V26, P369, DOI 10.1016/S0166-2236(03)00168-1; Cang JH, 2005, VISUAL NEUROSCI, V22, P685, DOI 10.1017/S0952523805225178; Clapp WC, 2006, NEUROREPORT, V17, P511, DOI 10.1097/01.wnr.0000209004.63352.10; Dalke C, 2004, INVEST OPHTH VIS SCI, V45, P601, DOI 10.1167/iovs.03-0561; DEANGELIS GC, 1993, J NEUROPHYSIOL, V69, P1091; DRAGER UC, 1975, J COMP NEUROL, V160, P269, DOI 10.1002/cne.901600302; DRAGER UC, 1980, J COMP NEUROL, V191, P383, DOI 10.1002/cne.901910306; FAGIOLINI M, 1994, VISION RES, V34, P709, DOI 10.1016/0042-6989(94)90210-0; FREEMAN DN, 1975, NATURE, V254, P614, DOI 10.1038/254614a0; Frenkel MY, 2006, NEURON, V51, P339, DOI 10.1016/j.neuron.2006.06.026; Gianfranceschi L, 1999, VISION RES, V39, P569, DOI 10.1016/S0042-6989(98)00169-2; Gordon JA, 1996, J NEUROSCI, V16, P3274; Gresh J, 2003, VISUAL NEUROSCI, V20, P211, DOI 10.1017/S0952523803202108; GRINVALD A, 1986, NATURE, V324, P361, DOI 10.1038/324361a0; Grubb MS, 2003, J NEUROPHYSIOL, V90, P3594, DOI 10.1152/jn.00699.2003; Hensch TK, 2005, NAT REV NEUROSCI, V6, P877, DOI 10.1038/nrn1787; Hensch TK, 1998, SCIENCE, V282, P1504, DOI 10.1126/science.282.5393.1504; Hofer SB, 2006, NAT NEUROSCI, V9, P127, DOI 10.1038/nn1610; Huang ZJ, 1999, CELL, V98, P739, DOI 10.1016/S0092-8674(00)81509-3; HUBEL DH, 1977, PHILOS T ROY SOC B, V278, P377, DOI 10.1098/rstb.1977.0050; Iny K, 2006, J NEUROSCI, V26, P7368, DOI 10.1523/JNEUROSCI.0124-06.2006; Issa NP, 1999, J NEUROSCI, V19, P6965, DOI 10.1523/JNEUROSCI.19-16-06965.1999; *JACKS LAB, 2002, JAX NOTES, V485, P2; Kalatsky VA, 2003, NEURON, V38, P529, DOI 10.1016/S0896-6273(03)00286-1; LUND RD, 1965, SCIENCE, V149, P1506, DOI 10.1126/science.149.3691.1506; McGee AW, 2005, SCIENCE, V309, P2222, DOI 10.1126/science.1114362; METIN C, 1988, EXP BRAIN RES, V69, P594; MITCHELL DE, 1988, J PHYSIOL-LONDON, V395, P639, DOI 10.1113/jphysiol.1988.sp016939; Mitchell Donald E, 2002, Clin Exp Optom, V85, P5; NORCIA AM, 1985, VISION RES, V25, P1399, DOI 10.1016/0042-6989(85)90217-2; Ohki K, 2005, NATURE, V433, P597, DOI 10.1038/nature03274; Pham TA, 2004, LEARN MEMORY, V11, P738, DOI 10.1101/lm.75304; Pinto LH, 2004, VISION RES, V44, P3335, DOI 10.1016/j.visres.2004.07.025; POLC P, 1988, PROG NEUROBIOL, V31, P349, DOI 10.1016/0301-0082(88)90014-7; Porciatti V, 1999, VISION RES, V39, P3071, DOI 10.1016/S0042-6989(99)00022-X; Prusky GT, 2000, VISION RES, V40, P2201, DOI 10.1016/S0042-6989(00)00081-X; Prusky GT, 2004, VISION RES, V44, P3411, DOI 10.1016/j.visres.2004.09.001; Prusky GT, 2003, EUR J NEUROSCI, V17, P167, DOI 10.1046/j.1460-9568.2003.02420.x; REMTULLA S, 1985, VISION RES, V25, P21, DOI 10.1016/0042-6989(85)90076-8; Rust NC, 2002, J NEUROSCI, V22, P10519; Saunders P A, 1990, Prog Drug Res, V34, P261; Sawtell NB, 2003, NEURON, V38, P977, DOI 10.1016/S0896-6273(03)00323-4; Schuett S, 2002, J NEUROSCI, V22, P6549; Shoham D, 1997, NATURE, V385, P529, DOI 10.1038/385529a0; SIEGHART W, 1994, J PSYCHIATR NEUROSCI, V19, P24; Tagawa Y, 2005, NAT NEUROSCI, V8, P380, DOI 10.1038/nn1410; Taha SA, 2005, PROG BRAIN RES, V147, P103, DOI 10.1016/S0079-6123(04)47008-3; Tropea D, 2006, NAT NEUROSCI, V9, P660, DOI 10.1038/nn1689; Van Hooser SD, 2005, J NEUROSCI, V25, P19, DOI 10.1523/JNEUROSCI.4042-04.2005; WAGOR E, 1980, J COMP NEUROL, V193, P187, DOI 10.1002/cne.901930113; Wang KH, 2006, CELL, V126, P389, DOI 10.1016/j.cell.2006.06.038; Webber Ann L, 2005, Clin Exp Optom, V88, P365; Weliky M, 1996, NATURE, V379, P725, DOI 10.1038/379725a0; WIESEL TN, 1963, J NEUROPHYSIOL, V26, P1003; WIESEL TN, 1965, J NEUROPHYSIOL, V28, P1029; Zhou GM, 1999, OPTOMETRY VISION SCI, V76, P408, DOI 10.1097/00006324-199906000-00021	60	50	51	0	7	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0953-816X			EUR J NEUROSCI	Eur. J. Neurosci.	FEB	2007	25	3					795	804		10.1111/j.1460-9568.2007.05333.x			10	Neurosciences	Neurosciences & Neurology	137DS	WOS:000244273800019	17328775				2020-06-30	J	Mamula, P; Markowitz, JE; Neiswender, K; Zimmerman, A; Wood, S; Garofolo, M; Nieberle, M; Trautwein, A; Lombardi, S; Sargent-Harkins, L; Lachewitz, G; Farace, L; Morgan, V; Puma, A; Cook-Sather, SD; Liacouras, CA				Mamula, Petar; Markowitz, Jonathan E.; Neiswender, Kristin; Zimmerman, Ann; Wood, Stephanie; Garofolo, Michael; Nieberle, Megan; Trautwein, Andria; Lombardi, Susan; Sargent-Harkins, Lynn; Lachewitz, Greta; Farace, Lisa; Morgan, Verita; Puma, Anita; Cook-Sather, Scott D.; Liacouras, Chris A.			Safety of intravenous midazolam and fentanyl for pediatric GI endoscopy: prospective study of 1578 endoscopies	GASTROINTESTINAL ENDOSCOPY			English	Article							UPPER GASTROINTESTINAL ENDOSCOPY; DEEP SEDATION; OXYGEN DESATURATION; CONSCIOUS SEDATION; GENERAL-ANESTHESIA; CHILDREN; PROPOFOL; COLONOSCOPY; MEPERIDINE; AGENT	Background: Data on safety of intravenous sedation in pediatric GI endoscopy are sparse. Objective: To evaluate safety of intravenous sedation for GI endoscopy. Design/Setting: Single-center prospective series of outpatient GI endoscopies performed from February 2003 to February 2004 at The Children's Hospital of Philadelphia. The recorded information included demographic, medication, and adverse event data. Patients: A total of 1226 patients were studied. Main Outcome Measurements: Description of adverse events relating to intravenous sedation. Results: A total of 2635 endoscopies were performed, of which 1717 were outpatient procedures with the patient under intravenous sedation. Sedation data were available on 1578 procedures (92%, M/F 674/552): 758 esophagogastroduodenoscopies (EGD) alone, 116 colonoscopies (COL) alone, and 352 combined EGD and COL. The median dose of fentanyl was 2.77 mu g/kg (SD 0.97, range 0-6.73), and of midazolam was 0.11 mg/kg (SD 0.06, range 0-0.39). The mean recovery time was 118 minutes (SD 47.3, range 31-375). Ten patients (0.8%) failed intravenous sedation. Serious adverse events (apnea) were noted in 2 patients (0.2%). Mild or moderate adverse events included desaturation below 92% for less than 20 seconds (100 patients, 9%), vomiting (64 patients, 5%), agitation (15 patients, 1%), desaturation below 92% for greater than 20 seconds (12 patients, 0.7%), and rash (8 patients, 0.7%). No cardiopulmonary resuscitation or sedation reversal was necessary. No patients required hospitalization. Patients younger than 6 years were more likely to develop respiratory adverse event (P < .01). Conclusions: Intravenous sedation with midazolam and fentanyl is safe for pediatric GI endoscopy. Serious adverse events are rare and no patient required hospitalization.	Univ Penn, Div GI & Nutr, Sch Med, Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; Univ Penn, Kohls GI & Nutr Diagnost Suite Endoscopy Unit, Sch Med, Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; Univ Penn, Dept Anesthesiol & Crit Care Med, Sch Med, Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA	Mamula, P (reprint author), Univ Penn, Div GI & Nutr, Sch Med, Childrens Hosp Philadelphia, 34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA.						Aggarwal A, 1998, Indian Pediatr, V35, P1211; ALATRAKCHI HA, 1989, GASTROINTEST ENDOSC, V35, P79, DOI 10.1016/S0016-5107(89)72712-7; Ali S, 2004, DIGEST DIS SCI, V49, P888, DOI 10.1023/B:DDAS.0000030106.01928.b4; AMENT ME, 1995, GASTROINTEST ENDOSC, V41, P173, DOI 10.1016/S0016-5107(05)80607-8; Balsells F, 1997, GASTROINTEST ENDOSC, V45, P375, DOI 10.1016/S0016-5107(97)70147-0; Barbi E, 2003, ARCH PEDIAT ADOL MED, V157, P1097, DOI 10.1001/archpedi.157.11.1097; Bishop PR, 2002, GASTROINTEST ENDOSC, V55, P624, DOI 10.1067/mge.2002.123417; CASTEEL HB, 1990, GASTROINTEST ENDOSC, V36, P489, DOI 10.1016/S0016-5107(90)71122-4; Chuang E, 2001, Gastrointest Endosc Clin N Am, V11, P569; CHUANG E, 1995, GASTROINTEST ENDOSC, V42, P156, DOI 10.1016/S0016-5107(95)70073-0; Elitsur Y, 2000, ENDOSCOPY, V32, P788, DOI 10.1055/s-2000-7713; Gilger MA, 2004, GASTROINTEST ENDOSC, V59, P659, DOI 10.1016/S0016-5107(04)00180-4; GILGER MA, 1993, GASTROINTEST ENDOSC, V39, P392, DOI 10.1016/S0016-5107(93)70112-1; Gorman R, 2002, PEDIATRICS, V110, P836; GREENBLATT DJ, 1989, CLIN PHARMACOL THER, V45, P356, DOI 10.1038/clpt.1989.41; Gross JB, 2002, ANESTHESIOLOGY, V96, P1004; HANLEY JA, 1983, JAMA-J AM MED ASSOC, V249, P1743, DOI 10.1001/jama.249.13.1743; HASSALL E, 1984, PEDIATRICS, V73, P594; Heuss LT, 2004, DIGESTION, V69, P20, DOI 10.1159/000076543; ISRAEL DM, 1994, J PEDIATR GASTR NUTR, V19, P283, DOI 10.1097/00005176-199410000-00004; Kaddu R, 2002, GASTROINTEST ENDOSC, V55, P27, DOI 10.1067/mge.2002.120386; Khoshoo V, 2003, J PEDIATR GASTR NUTR, V37, P146, DOI 10.1097/00005176-200308000-00012; Koh TL, 2001, J PEDIATR GASTR NUTR, V33, P314, DOI 10.1097/00005176-200109000-00016; Lightdale Jenifer R, 2004, Gastrointest Endosc Clin N Am, V14, P385, DOI 10.1016/j.giec.2004.01.004; Michaud L, 2005, ENDOSCOPY, V37, P167, DOI 10.1055/s-2004-826144; Montes RG, 2000, J PEDIATR GASTR NUTR, V31, P41, DOI 10.1097/00005176-200007000-00010; Motas D, 2004, PEDIATR ANESTH, V14, P256, DOI 10.1046/j.1460-9592.2003.01184.x; PAYNE K, 1989, EUR J CLIN PHARMACOL, V37, P267, DOI 10.1007/BF00679782; Radaelli Franco, 2004, Gastrointest Endosc Clin N Am, V14, P335, DOI 10.1016/j.giec.2004.01.008; SALONEN M, 1987, ANESTH ANALG, V66, P625; SCHREINER MS, 1992, ANESTHESIOLOGY, V76, P528, DOI 10.1097/00000542-199204000-00007; SQUIRES RH, 1995, GASTROINTEST ENDOSC, V41, P99, DOI 10.1016/S0016-5107(05)80589-9; Stringer MD, 1999, ACTA PAEDIATR, V88, P199, DOI 10.1080/08035259950170394; Tolia V, 2000, J PEDIATR GASTR NUTR, V30, P477, DOI 10.1097/00005176-200005000-00003; TOLIA V, 1991, J PEDIATR-US, V119, P467, DOI 10.1016/S0022-3476(05)82066-9; Verhage Jan, 2003, Rom J Gastroenterol, V12, P273; Wilcox Charles M, 2004, Gastrointest Endosc Clin N Am, V14, P647, DOI 10.1016/j.giec.2004.04.004; ZAHAVI I, 1994, ISRAEL J MED SCI, V30, P664	38	30	31	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0016-5107	1097-6779		GASTROINTEST ENDOSC	Gastrointest. Endosc.	FEB	2007	65	2					203	210		10.1016/j.gie.2006.05.002			8	Gastroenterology & Hepatology	Gastroenterology & Hepatology	133VL	WOS:000244041900005	17258977				2020-06-30	J	Rattan, V; Arora, S; Grover, VK				Rattan, V.; Arora, S.; Grover, V. K.			Assessment of the effectiveness of peripheral administration of fentanyl with lidocaine in inflamed dentoalveolar tissues	INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY			English	Article						peripheral opioid analgesia; local anaesthesia; dental extraction; inflammation; Opioids	MORPHINE ANALGESIA; OPIOID RECEPTORS; DENTAL SURGERY; INFLAMMATION; PAIN; EFFICACY; PULP; RATS	Peripheral action of opioids for pain control, for which local inflammation has been shown to be crucial, is being increasingly used in clinical practice. The aim of this study was to evaluate the hypothesis that addition of fentanyl to lidocaine, when injected into inflamed dentoalveolar tissues, can improve the quality of analgesia during surgery. Seventy-one patients reporting with pain and tenderness in the maxillary tooth were assigned into the experimental (LAF) or control (LA) group in a prospective, randomized double-blind trial. The LAF group (n = 36) was injected submucosally with a mixture of 40 mu g of fentanyl (0.8 ml) and 2% lidocaine hydrochloride with 1:200000 adrenaline (2 ml). In the LA group (n = 35) 0.9% of saline (0.8 ml) was added instead of fentanyl. The pain scores were recorded before injecting, 5 min after injection, and immediately after surgery using a visual analogue scale. The mean pain scores were not significantly different at all time intervals. Twelve patients in the LAF group (2.75 +/- 0.72 ml) and ten patients in the LA (2.90 +/- 0.70 ml) group required additional local anaesthetic to achieve pain control. In conclusion, there was no improvement in quality of intraoperative analgesia on addition of fentanyl to lidocaine in inflamed dentoalveolar tissues.	Postgrad Inst Med Educ & Res, Oral Hlth Sci Ctr, Unit Oral & Maxillofacial Surg, Chandigarh 160012, India; Postgrad Inst Med Educ & Res, Dept Anaesthesia & Intens Care, Chandigarh 160012, India	Rattan, V (reprint author), Postgrad Inst Med Educ & Res, Oral Hlth Sci Ctr, Unit Oral & Maxillofacial Surg, Chandigarh 160012, India.	drvidyarattan@sancharnet.in		Rattan, Vidya/0000-0002-6313-5098			Amir R, 2006, J PAIN, V7, pS1, DOI 10.1016/j.jpain.2006.01.444; Bileviciute-Ljungar I, 2006, J PHARMACOL EXP THER, V317, P220, DOI 10.1124/jpet.105.096032; BULLINGHAM R, 1983, ANESTH ANALG, V62, P164; Dionne RA, 2001, CLIN PHARMACOL THER, V70, P66, DOI 10.1067/mcp.2001.116443; Fristad I, 2006, ARCH ORAL BIOL, V51, P273, DOI 10.1016/j.archoralbio.2005.08.007; Jaber L, 2003, J ENDODONT, V29, P108, DOI 10.1097/00004770-200302000-00005; Kaczmarzyk T, 2005, PAIN, V115, P348, DOI 10.1016/j.pain.2005.03.036; Likar R, 2005, SCHMERZ, V19, P195, DOI 10.1007/s00482-004-0334-2; Likar R, 1998, PAIN, V76, P145, DOI 10.1016/S0304-3959(98)00036-0; Likar R, 2001, J PAIN SYMPTOM MANAG, V21, P330, DOI 10.1016/S0885-3924(01)00251-2; Oeltjenbruns J, 2005, SCHMERZ, V19, P447, DOI 10.1007/s00482-005-0431-x; Picard PR, 1997, PAIN, V72, P309, DOI 10.1016/S0304-3959(97)00040-7; Pol O, 2004, CURR TOP MED CHEM, V4, P51, DOI 10.2174/1568026043451519; STEIN C, 1995, NEW ENGL J MED, V332, P1685, DOI 10.1056/NEJM199506223322506	14	5	5	0	0	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0901-5027			INT J ORAL MAX SURG	Int. J. Oral Maxillofac. Surg.	FEB	2007	36	2					128	131		10.1016/j.ijom.2006.09.007			4	Dentistry, Oral Surgery & Medicine; Surgery	Dentistry, Oral Surgery & Medicine; Surgery	141PP	WOS:000244591500005	17101259				2020-06-30	J	Van Nimmen, NFJ; Veulemans, HAF				Van Nimmen, Nadine F. J.; Veulemans, Hendrik A. F.			Validated GC-MS analysis for the determination of residual fentanyl in applied Durogesic (R) reservoir and Durogesic (R) D-Trans (R) matrix transdermal fentanyl patches	JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES			English	Article						fentanyl; transdermal patch; reservoir type; matrix type; method validation; GC-MS	CANCER PAIN PATIENTS; PHARMACOKINETICS; ABSORPTION	The method development and validation characteristics are described of a simple gas chromatographic-mass spectrometric (GC-MS) analytical procedure to determine residual fentanyl in used Durogesic (R) reservoir patches and Durogesic (R) D-Trans (R) matrix technology based systems to estimate the actual rate of transdermal fentanyl delivered in individual patients. The sample preparation protocol constituting a saline based extraction of sets of new patches of each nominal dose available, resulted in fentanyl extraction recoveries to increase steadily as a function of. increasing extraction time. For the reservoir type transdermal therapeutic system (TTS), fentanyl extraction efficiencies at equilibrium (16h) ranged from approximately 60% (100-mu g/h TTS) to 95% (25-mu g/h TTS), whereas for the matrix type system considerable lower recoveries were demonstrated for the highest nominal dose rates (35%-52%), while reaching 90% for the 25-mu g/h system. For the latter type of fentanyl TTS, an optimized methanol based extraction protocol yielded virtually quantitative fentanyl recoveries for each matrix patch nominal dose level at substantially shorter extraction periods (15 min). The GC-MS analytical method using selected ion monitoring (SIM) and deuterated fentanyl as internal standard was shown to be adequately selective with regard to the presence of other compounds in the Durogesic (R) patches. It was further demonstrated that the developed analytical protocols provided highly reproducible and accurate estimates of the initial fentanyl content of each patch type at all available nominal doses, with coefficients of variation and relative errors generally below 10%. These advantageous assay validation characteristics can be further transposed to the application of residual fentanyl level estimates in used patches, provided that with each batch of samples also a set of new TTSs with equal dose is assayed to perfectly mimic extraction phenomena. Finally, the presented GC-MS analytical protocol was successfully applied for the determination of residual fentanyl in a subset of 57 reservoir type patches obtained from four palliative patients. (c) 2006 Elsevier B.V. All rights reserved.	Catholic Univ Louvain, Dept Occupat Environm & Isurance Med, Lab Occupat Hyg & Toxicol, B-3000 Louvain, Belgium	Van Nimmen, NFJ (reprint author), Catholic Univ Louvain, Dept Occupat Environm & Isurance Med, Lab Occupat Hyg & Toxicol, Kapucijnenvoer 35,6th Floor, B-3000 Louvain, Belgium.	nadine.vannimmen@med.kuleuven.be					[Anonymous], 2003, DUR FENT TRANSD SYST; Freynhagen R, 2005, J PAIN SYMPTOM MANAG, V30, P289, DOI 10.1016/j.jpainsymman.2005.03.015; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; *JOHNS JOHNS, 2004 ANN REP; Karst M, 2001, PAIN MED, V2, P225, DOI 10.1046/j.1526-4637.2001.01028.x; Kornick CA, 2003, DRUG SAFETY, V26, P951, DOI 10.2165/00002018-200326130-00004; Larsen RH, 2003, PHARMACOL TOXICOL, V93, P244, DOI 10.1046/j.1600-0773.2003.pto930508.x; MARQUARDT KA, 1995, ANN PHARMACOTHER, V29, P969, DOI 10.1177/106002809502901001; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; PORTENOY RK, 1993, ANESTHESIOLOGY, V78, P36, DOI 10.1097/00000542-199301000-00007; Solassol I, 2005, ONCOL REP, V14, P1029; Solassol I, 2005, THER DRUG MONIT, V27, P491, DOI 10.1097/01.ftd.0000160717.50704.42; VARVEL JR, 1989, ANESTHESIOLOGY, V70, P928, DOI 10.1097/00000542-198906000-00008	13	15	15	0	13	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1570-0232			J CHROMATOGR B	J. Chromatogr. B	FEB 1	2007	846	1-2					264	272		10.1016/j.jchromb.2006.09.002			9	Biochemical Research Methods; Chemistry, Analytical	Biochemistry & Molecular Biology; Chemistry	137GN	WOS:000244281100035	17030157				2020-06-30	J	Nishikawa, K; Yoshida, S; Shimodate, Y; Igarashi, M; Namiki, A				Nishikawa, Kohki; Yoshida, Shinichiro; Shimodate, Yuki; Igarashi, Motohiko; Namiki, Akiyoshi			A comparison of spinal anesthesia with small-dose lidocaine and general anesthesia with fentanyl and propofol for ambulatory prostate biopsy procedures in elderly patients	JOURNAL OF CLINICAL ANESTHESIA			English	Article						age factors; analgesics, opioid : fentanyl; anesthesia : day-case; anesthetics, intravenous : propofol; anesthetics, local : lidocaine	PERIPROSTATIC LOCAL-ANESTHESIA; PAIN	Study Objective: To compare operating conditions, intraoperative adverse events, recovery profiles, postoperative adverse effects, patient satisfaction, and costs of small-dose lidocaine spinal anesthesia with those of general anesthesia using fentanyl and propofol for elderly outpatient prostate biopsy. Design: Prospective, randomized, blind study. Setting: Outpatient anesthesia unit at a municipal hospital. Patients: 80 ASA physical status I and II patients, aged 65 to 80 years, scheduled for outpatient prostate biopsy. Interventions: Patients were assigned to receive either spinal anesthesia with 10 mg of hyperbaric 1% lidocaine (L group, n = 40) or anesthetic induction with fentanyl 1 mu g . kg(-1) IV and 1.0 mg . kg(-1) propofol injected at 90 mg . kg(-1) . h(-1), followed by continuous infusion at 6 mg kg(-1) . h(-1) (F/P group, n = 40). Measurements and Main Results: Both anesthetic techniques provided acceptable operating conditions for the surgeon. However, a significantly higher frequency of intraoperative hypotension was found in the F/P group than in the L group (P < 0.05). Time to home readiness was shorter in the F/P group (P < 0.05). Both techniques had no major postoperative adverse effects and resulted in a high rate of patient satisfaction. Total costs were significantly lower in the L group than in the F/P group (P < 0.01). Conclusions: Spinal anesthesia with 10 mg of hyperbaric 1% lidocaine maybe a more suitable alternative to general anesthesia with fentanyl and propofol for ambulatory elderly prostate biopsy in terms of safety and costs. (C) 2007 Elsevier Inc. All rights reserved.	Sapporo Med Univ, Sch Med, Dept Anesthesiol, Sapporo, Hokkaido 0608543, Japan	Nishikawa, K (reprint author), Muroran City Gen Hosp, Dept Anesthesia, Muroran, Hokkaido 0518512, Japan.	nkouki@sapmed.ac.jp					Buckenmaier CC, 2002, ANESTH ANALG, V95, P1253, DOI 10.1097/00000539-200211000-00028; Chung SW, 2005, SMALL, V1, P64, DOI 10.1002/smll.200400005; GOLDMAN L, 1979, ANESTHESIOLOGY, V50, P285, DOI 10.1097/00000542-197904000-00002; Jones JS, 2003, PROSTATE CANCER P D, V6, P53, DOI 10.1038/sj.pcan.4500630; Liguori GA, 1998, ANESTHESIOLOGY, V88, P619, DOI 10.1097/00000542-199803000-00010; Luscombe CJ, 2004, LANCET, V363, P1840, DOI 10.1016/S0140-6736(04)16392-7; Nishikawa K, 2004, ANAESTHESIA, V59, P948, DOI 10.1111/j.1365-2044.2004.03798.x; OMOTE K, 1992, ANAESTHESIA, V47, P24, DOI 10.1111/j.1365-2044.1992.tb01947.x; Soloway MS, 2000, J UROLOGY, V163, P172, DOI 10.1016/S0022-5347(05)67997-9; Tong D, 1997, ANESTHESIOLOGY, V87, P856, DOI 10.1097/00000542-199710000-00020; Turker G, 2003, ACTA ANAESTH SCAND, V47, P986, DOI 10.1034/j.1399-6576.2003.00194.x; White PF, 1999, ANESTH ANALG, V88, P1069, DOI 10.1097/00000539-199905000-00018	12	11	12	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	FEB	2007	19	1					25	29		10.1016/j.jclinane.2006.05.017			5	Anesthesiology	Anesthesiology	145PN	WOS:000244877100006	17321923				2020-06-30	J	Feld, J; Hoffman, WE; Paisansathan, C; Park, H; Ananda, RC				Feld, James; Hoffman, William E.; Paisansathan, Chanannait; Park, Hans; Ananda, Ranga C.			Autonomic activity during dexmedetomidine or fentanyl infusion with desflurane anesthesia	JOURNAL OF CLINICAL ANESTHESIA			English	Article; Proceedings Paper	Annual Meeting of the American-Society-of-Anesthesiologists	OCT 22-26, 2005	Atlanta, GA	Amer Soc Anesthesiologists		desflurane anesthesia; dexmedetomidine; response entropy; sympathetic	HEART-RATE-VARIABILITY; TONE-ENTROPY ANALYSIS; BARIATRIC SURGERY; PREMEDICATION; HYSTERECTOMY	Study Objective: To evaluate autonomic activity with dexmedetomidine or fentanyl infusion and desflurane anesthesia during laparoscopic gastric banding. Study Design: Randomized, single-blinded, open-label study. Setting: Operating rooms at a university hospital. Subjects: 40 patients scheduled for laparoscopic gastric banding with a mean body mass index of 50 kg/m(2). Interventions: Patients received either dexmedetomidine (0.5 mu g/kg given intravenously over 10 minutes, 0.4 mu g . kg(-1) . h(-1), n = 20) or fentanyl (0.5 pg . kg (-1) bolus, 1 mu g . kg(-1) . h(-1), n = 20) during anesthesia. Response entropy of the electroencephalogram was maintained at 45 +/- 5 by adjusting end-tidal desflurane concentration. Measurements: In the operating room, blood pressure, heart rate (HR), response entropy, end-tidal desflurane concentration, tone entropy, and power-spectral analysis of HR were measured with the patient awake; 20, 40, and 60 minutes from intubation and the start of drug infusion; and at extubation. Main Results: The mean end-tidal desflurane concentration during anesthesia was 4.0% +/- 0.6% with dexmedetomidine and 4.1% +/- 0.7% with fentanyl, indicating a similar anesthetic requirement in both groups. Autonomic activity, determined by tone entropy and spectral analysis of HR, decreased by 50% during anesthesia in both groups. The dexmedetomidine group showed a greater decrease in sympathovagal balance during anesthesia. Conclusion: Both dexmedetomidine and fentanyl facilitated anesthesia and attenuated autonomic activity. Dexmedetomidine produced a greater decrease in sympathovagal balance than fentanyl. (C) 2007 Elsevier Inc. All rights reserved.	Univ Illinois, Dept Anesthesiol, Chicago, IL 60612 USA	Hoffman, WE (reprint author), Univ Illinois, Dept Anesthesiol, Chicago, IL 60612 USA.						AHO M, 1992, ANESTH ANALG, V75, P940; Amano M, 2005, EUR J APPL PHYSIOL, V94, P602, DOI 10.1007/s00421-005-1364-x; Angrisani L, 2001, OBES SURG, V11, P232, DOI 10.1381/096089201321577965; Feld JM, 2006, J CLIN ANESTH, V18, P24, DOI 10.1016/j.jclinane.2005.05.009; FLACKE JW, 1983, ANESTH ANALG, V62, P305; GAUTRET B, 1985, J CARDIOVASC PHARM, V7, P649, DOI 10.1097/00005344-198507000-00006; Hofer RE, 2005, CAN J ANAESTH, V52, P176, DOI 10.1007/BF03027725; Hogue CW, 2002, ANESTHESIOLOGY, V97, P592, DOI 10.1097/00000542-200209000-00012; Hsu YW, 2004, ANESTHESIOLOGY, V101, P1066, DOI 10.1097/00000542-200411000-00005; JAAKOLA ML, 1994, ACTA ANAESTH SCAND, V38, P238, DOI 10.1111/j.1399-6576.1994.tb03881.x; JAAKOLA ML, 1994, J CLIN ANESTH, V6, P204, DOI 10.1016/0952-8180(94)90060-4; Kanaya N, 2003, ANESTHESIOLOGY, V98, P34, DOI 10.1097/00000542-200301000-00009; Lawrence CJ, 1997, ANAESTHESIA, V52, P736, DOI 10.1111/j.1365-2044.1997.169-az0303.x; McDonald T, 2001, J NEUROSURG ANESTH, V13, P74, DOI 10.1097/00008506-200104000-00002; O'Keeffe T, 2004, OBES SURG, V14, P23, DOI 10.1381/096089204772787248; Oida E, 1999, ACTA PHYSIOL SCAND, V165, P129; Oida E, 1997, J APPL PHYSIOL, V82, P1794; Penttila J, 2004, CAN J PHYSIOL PHARM, V82, P359, DOI 10.1139/Y04-028; Piccirillo G, 1999, ARCH GERONTOL GERIAT, V28, P159, DOI 10.1016/S0167-4943(99)00003-5; Storella RJ, 1999, J CARDIOTHOR VASC AN, V13, P451, DOI 10.1016/S1053-0770(99)90219-7; Tanaka M, 2004, ANESTH ANALG, V99, P924, DOI 10.1213/01.ANE.0000131966.61686.66; Weaver W., 1949, MATH THEORY COMMUNIC, P48; Widmark C, 1998, ACTA ANAESTH SCAND, V42, P204; Wong S. K. H., 2005, Hong Kong Medical Journal, V11, P20	24	21	27	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180			J CLIN ANESTH	J. Clin. Anesth.	FEB	2007	19	1					30	36		10.1016/j.jclinane.2006.05.019			7	Anesthesiology	Anesthesiology	145PN	WOS:000244877100007	17321924				2020-06-30	J	Yeh, CC; Wu, CT; Huh, BK; Lee, MS; Lin, SL; Sheen, MJ; Wong, CS				Yeh, Chun-Chang; Wu, Ching-Tang; Huh, Bilty K.; Lee, Meei-Shyuan; Lin, Shinn-Long; Sheen, Michaet J.; Wong, Chih-Shung			Premedication with intravenous low-dose ketamine suppresses fentanyl-induced cough	JOURNAL OF CLINICAL ANESTHESIA			English	Article						ketamine; NMDA receptor; fentanyl; cough	TRACHEAL SMOOTH-MUSCLE; D-ASPARTATE RECEPTORS; BOLUS; ANESTHESIA; MANAGEMENT; INJECTION; LIDOCAINE; PROPOFOL; PAIN	Study Objective: To evaluate the effect of low-dose ketamine on fentanyl-induced cough. Design: Prospective, randomized, double-blind, placebo-controlled clinical trial. Setting: Medical center hospital. Patients: 360 ASA physical status I-II patients aged 18 to 65 years, weighing between 40 and 80 kg, and scheduled for elective surgery during general anesthesia. Interventions and Measurements: Patients were randomly assigned to receive either ketamine 0.15 mg/kg or placebo (equal volume of 0.9% saline) given intravenously over 10 seconds, one minute before administration of fentanyl (1.5 mu g/kg IV, injected within 5 seconds), during induction of general anesthesia. Any episode of cough was classified as coughing and the onset time of cough (the time of the first episode of cough) was observed for one minute after fentanyl administration by a blinded observer. Severity of coughing was graded based on the number of episodes of coughing (mild, 1-2; moderate, 3-5; and severe, >5). Blood pressure, heart rate, and pulse oximetry oxygen saturation (Spo(2)) were recorded before giving ketamine or 0.9% saline and I minute after fentanyl injections. Main Results: After the intravenous injection of fentanyl bolus, patients in the placebo group showed significantly higher frequency cough than those in the ketamine pretreatment group (21.6% vs 7.2%, P < 0.05), and onset time of the ketamine group was significantly longer than that of the control group (20 +/- 8 vs 15 +/- 10 seconds, P < 0.01). However, no difference in cough severity was observed between the two groups. Conclusion: Low-dose ketamine (0.15 mg/kg IV) effectively reduces fentanyl-induced cough and delays the onset time of cough. (C) 2007 Elsevier Inc. All rights reserved.	Triserv Gen Hosp, Dept Anesthesiol, Taipei 114, Taiwan; Natl Def Med Ctr, Taipei 114, Taiwan; Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27710 USA; Natl Def Med Ctr, Sch Publ Hlth, Taipei, Taiwan	Wong, CS (reprint author), Triserv Gen Hosp, Dept Anesthesiol, Taipei 114, Taiwan.	w82556@ndmctsgh.edu.tw					Agarwal A, 2003, CAN J ANAESTH, V50, P297, DOI 10.1007/BF03017801; Ambalavanar R, 2002, J NEUROPHYSIOL, V87, P1252, DOI 10.1152/jn.00595.2001; BOHRER H, 1990, ANAESTHESIA, V45, P18, DOI 10.1111/j.1365-2044.1990.tb14496.x; BOVILL JG, 1984, ANESTHESIOLOGY, V61, P731; Brown RH, 1999, ANESTHESIOLOGY, V90, P822, DOI 10.1097/00000542-199903000-00025; Cheng EY, 1996, ANESTH ANALG, V83, P162, DOI 10.1097/00000539-199607000-00028; CORSSEN G, 1972, ANESTH ANAL CURR RES, V51, P588; DURIEUX ME, 1995, ANESTH ANALG, V81, P57, DOI 10.1097/00000539-199507000-00012; Elia N, 2005, PAIN, V113, P61, DOI 10.1016/j.pain.2004.09.036; GRELL FL, 1970, ANESTH ANAL CURR RES, V49, P523; HAXHIU MA, 1987, J APPL PHYSIOL, V63, P1268; Himmelseher S, 2005, ANESTHESIOLOGY, V102, P211, DOI 10.1097/00000542-200501000-00030; KAMEI J, 1989, EUR J PHARMACOL, V168, P153; Lin CS, 2004, CAN J ANAESTH, V51, P654, DOI 10.1007/BF03018421; Lin JA, 2005, ANESTH ANALG, V101, P670, DOI 10.1213/01.ANE.0000159161.31276.DB; Lui PW, 1996, CAN J ANAESTH, V43, P1216; LUNDY PM, 1974, BRIT J ANAESTH, V46, P333, DOI 10.1093/bja/46.5.333; Pandey CK, 2004, ANESTH ANALG, V99, P1696, DOI 10.1213/01.ANE.0000136967.82197.82; PHUA WT, 1991, CAN J ANAESTH, V38, P330, DOI 10.1007/BF03007623; Robertson BS, 1998, NEUROSCI LETT, V244, P77, DOI 10.1016/S0304-3940(98)00130-X; SAID SI, 1995, NEUROSCIENCE, V65, P943, DOI 10.1016/0306-4522(95)00021-A; Sato T, 1998, ANESTH ANALG, V87, P1383, DOI 10.1097/00000539-199812000-00033; Sato T, 1997, ANESTH ANALG, V84, P641, DOI 10.1097/00000539-199703000-00033; Tweed WA, 2001, ANESTH ANALG, V92, P1442	24	30	42	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	FEB	2007	19	1					53	56		10.1016/j.jclinane.2006.05.021			4	Anesthesiology	Anesthesiology	145PN	WOS:000244877100011	17321928				2020-06-30	J	Kaymak, C; Yilmaz, E; Basar, H; Ozcakir, S; Apan, A; Batislam, E				Kaymak, Cetin; Yilmaz, Erdal; Basar, Hulya; Ozcakir, Sibel; Apan, Alpaslan; Batislam, Ertan			Use of the NMDA antagonist magnesium sulfate during monitored anesthesia care for shockwave lithotripsy	JOURNAL OF ENDOUROLOGY			English	Article							ANALGESIC TECHNIQUES; MIDAZOLAM; RECEPTOR; FENTANYL; REQUIREMENTS; INFUSION; PAIN	Purpose: To assess whether intravenous magnesium sulfate infusion affects analgesic requirements during monitored anesthesia care (MAC) for shockwave lithotripsy (SWL). Patients and Methods: Fifty patients in ASA class I or II undergoing SWL with MAC were randomized into two groups. Induction of MAC was produced by bolus doses of midazolam 0.03 mg/kg(-1) and fentanyl 0.5 mu g/kg(-1) followed by intravenous infusion of midazolam 0.015 to 0.06 mg/kg(-1)/hr(-1) with fentanyl supplementation 0.2 mu g/kg(-1). In addition, group I patients received magnesium sulfate 30 mg/kg(-1) intravenously as a bolus dose followed by a continuous infusion of 10 mg/kg(-1) /hr(-1) beginning 15 minutes before induction of sedation. The midazolam infusion rate and additional fentanyl doses were adjusted by verbal analog scale (VAS) measurements, observer assessment sedation score (OAA/S), and achieving a target bispectral index (BIS) in a range of 70 to 90. At the end of SWL, the total midazolam and total fentanyl consumptions were recorded, and the serum magnesium concentration was measured. Results: Magnesium caused significant decreases in the total consumption of midazolam (P = 0.001) and fentanyl (P = 0.001). The VAS values at the 15th, 20th, and 25th minute in group I were significantly lower than in group II. In group I, hemodynamic and arterial oxygen parameters were better than in group II. Conclusion: A magnesium bolus and infusion can be utilized to reduce analgesic requirements under MAC during SWL.	Kirikkale Univ, Dept Anesthesiol & Reanimatol, TR-71100 Kirikkale, Turkey; Kirikkale Univ, Fac Med, Dept Urol, TR-71100 Kirikkale, Turkey	Yilmaz, E (reprint author), Kirikkale Univ, Tip Fak Urol ABD, Dept Urol, TR-71100 Kirikkale, Turkey.	erdaly69@mynet.com	Batislam, Ertan/E-2892-2016	Batislam, Ertan/0000-0002-7493-4573			Apan A, 2004, EUR J ANAESTH, V21, P766, DOI 10.1017/S026502150400002X; Basar H, 2003, J ENDOUROL, V17, P3, DOI 10.1089/089277903321196706; Begum R, 2000, EUR J OBSTET GYN R B, V92, P223, DOI 10.1016/S0301-2115(99)00274-2; CHAUSSY C, 1980, LANCET, V2, P1265; Cortinez LI, 2005, EUR J ANAESTH, V22, P56, DOI 10.1017/S0265021505000128; DICKENSON AH, 1990, TRENDS PHARMACOL SCI, V11, P307, DOI 10.1016/0165-6147(90)90228-Z; DUNDEE JW, 1984, DRUGS, V28, P519, DOI 10.2165/00003495-198428060-00002; Fawcett WJ, 1999, BRIT J ANAESTH, V83, P302, DOI 10.1093/bja/83.2.302; Gesztesi Z, 2000, ANESTH ANALG, V90, P567, DOI 10.1097/00000539-200003000-00013; Ghisi D, 2005, Minerva Anestesiol, V71, P533; Koinig H, 1998, ANESTH ANALG, V87, P206, DOI 10.1097/00000539-199807000-00042; Liu J, 1996, ANESTHESIOLOGY, V84, P64, DOI 10.1097/00000542-199601000-00007; MARRANNES R, 1988, BRAIN RES, V457, P226, DOI 10.1016/0006-8993(88)90690-7; MASON BA, 1994, AM J OBSTET GYNECOL, V171, P999, DOI 10.1016/0002-9378(94)90022-1; Memis D, 2003, CRIT CARE, V7, pR123, DOI 10.1186/cc2365; MONK TG, 1991, ANESTH ANALG, V72, P616; MONK TG, 1991, ANESTHESIOLOGY, V74, P1023, DOI 10.1097/00000542-199106000-00009; Rao M. Prasad, 2005, International Urology and Nephrology, V37, P219, DOI 10.1007/s11255-004-7969-x; Richardson MG, 1998, ANESTH ANALG, V86, P1214; Salinas AS, 1999, UROL INT, V63, P92, DOI 10.1159/000030425; Telci L, 2002, BRIT J ANAESTH, V89, P594, DOI 10.1093/bja/aef238; Tramer MR, 1996, ANESTHESIOLOGY, V84, P340, DOI 10.1097/00000542-199602000-00011; Wilder-Smith OHG, 1998, ANESTH ANALG, V86, P95, DOI 10.1097/00000539-199801000-00019; WOOLF CJ, 1991, PAIN, V44, P293, DOI 10.1016/0304-3959(91)90100-C	24	5	6	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0892-7790	1557-900X		J ENDOUROL	J. Endourol.	FEB	2007	21	2					145	150		10.1089/end.2006.0195			6	Urology & Nephrology	Urology & Nephrology	146DN	WOS:000244914800038	17338610				2020-06-30	J	Elsharrawy, EA; Elbaghdady, YM				Elsharrawy, Ernan A.; Elbaghdady, Yehia M.			A double-blind comparison of a supplemental interligamentary injection of fentanyl and mepivacaine with 1 : 200,000 epinephrine for irreversible pulpitis	JOURNAL OF PAIN AND SYMPTOM MANAGEMENT			English	Article						fentanyl; mepivacaine; acute pulpitis; interligamentary injection	ANESTHETIC EFFICACY; SPINAL-ANESTHESIA; BUPIVACAINE; SURGERY; OPIOIDS	The analgesic efficacy of supplemental interligamentary fentanyl injection for management of endodontic debridement patients was investigated through a randomized, double-blind study. Forty patients who presented with acute symptomatic irreversible pulpitis of the upper first molar tooth participated in the study. Patients were scheduled for endodontic debridement, for which infiltration anesthesia with 1.8 ml of 2% mepivacaine with epinephrine 1:200, 000 was the standard primary anesthetic technique. Patients were randomly divided into two equal groups. The first g-roup received supplemental interligamentary injection with 0.4 fentanyl 0.05 mg/ml, while the second group received supplemental interligamentary injection with 0.4 ml mepivacaine with epinephrine 1:200,000. The intraligamental-injected drug was given as 0.2 ml on the mesial and 0.2 ml on the distal aspect of the tooth. Results indicated that fentanyl provided relatively greater analgesia, yielding satisfactory relief during different stages of the procedure, including access cavity preparation, pulpotomy, and pulp extirpation. Fentanyl is effective when used in conjunction with local anesthetics to provide adequate analgesia during endodontic debridement, and this finding provides strong evidence that, peripheral actions are involved in the analgesia produced by opioid drugs in inflammatory pain.	October 6 Univ, Dept Anesthesiol, Fac Dent, Nasr City, Cairo, Egypt	Elsharrawy, EA (reprint author), October 6 Univ, Dept Anesthesiol, Fac Dent, 19 Mohamed Elmakref St, Nasr City, Cairo, Egypt.	elsharrawy@hotmail.com					Ballas SK, 2002, BLOOD, V99, P1096, DOI 10.1182/blood.V99.3.1096; Choi DH, 2000, REGION ANESTH PAIN M, V25, P240, DOI 10.1016/S1098-7339(00)90005-1; Goel S, 2003, EUR J ANAESTH, V20, P294, DOI 10.1097/00003643-200304000-00004; Goodell GG, 2000, ORAL SURG ORAL MED O, V90, P88, DOI 10.1067/moe.2000.107365; HARGREAVES K, 1991, Journal of Dental Research, V70, P445; JAFFE J H, 1990, P485; JORIS JL, 1987, ANESTH ANALG, V66, P1277; Keiser Karl, 2003, Tex Dent J, V120, P250; Kuusniemi KS, 2000, ANESTH ANALG, V91, P1452, DOI 10.1097/00000539-200012000-00029; Langeland K, 1981, J Endod, V7, P169, DOI 10.1016/S0099-2399(81)80231-2; Lantz GC, 2003, J VET DENT, V20, P181, DOI 10.1177/089875640302000306; LULLMANN H, 1985, BRIT J ANAESTH, V57, P1012, DOI 10.1093/bja/57.10.1012; Machelska H, 2002, J NEUROSCI, V22, P5588; Meechan JG, 2002, INT ENDOD J, V35, P885, DOI 10.1046/j.1365-2591.2002.00592.x; Nettis E, 2001, ORAL SURG ORAL MED O, V91, P402, DOI 10.1067/moe.2001.113348; Norholt SE, 1998, INT J ORAL MAX SURG, V27, P7; Stabile P, 2000, ORAL SURG ORAL MED O, V89, P407, DOI 10.1016/S1079-2104(00)70120-X; Tetzlaff JE, 1999, REGION ANESTH PAIN M, V24, P220, DOI 10.1016/S1098-7339(99)90131-1; Twillman RK, 1999, J PAIN SYMPTOM MANAG, V17, P288, DOI 10.1016/S0885-3924(98)00140-7; Uhle R A, 1997, Anesth Prog, V44, P90; Wong J K, 2001, J Can Dent Assoc, V67, P391; Yonchak T, 2001, ORAL SURG ORAL MED O, V92, P132, DOI 10.1067/moe.2001.115720	22	6	6	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0885-3924	1873-6513		J PAIN SYMPTOM MANAG	J. Pain Symptom Manage.	FEB	2007	33	2					203	207		10.1016/j.jpainsymman.2006.07.020			5	Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology	Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology	137BW	WOS:000244268800011	17280925	Bronze			2020-06-30	J	Hagen, NA; Fisher, K; Victorino, C; Farrar, JT				Hagen, Neil A.; Fisher, Kim; Victorino, Charlemaigne; Farrar, John T.			A titration strategy is needed to manage breakthrough cancer pain effectively: Observations from data pooled from three clinical trials	JOURNAL OF PALLIATIVE MEDICINE			English	Article							TRANSMUCOSAL FENTANYL CITRATE; OPIOID RESPONSIVENESS; DOSE-TITRATION; AGE; MORPHINE; PHARMACOKINETICS; PREVALENCE; THERAPY	Background: Breakthrough pain is a prevalent and serious problem in patients with cancer. However, it is not known how best to predict the effective dose of breakthrough opioid for any given patient. Methods: Data were pooled and reanalyzed from three large, randomized clinical trials of the rapidly absorbed oral transmucosal fentanyl citrate lozenges (OTFC) in which patients were carefully titrated to an optimal OTFC dose. The relationships between the optimal OTFC dose, patients' previous opioid dose, 24-hour total opioid, and patient characteristics were explored to determine whether the optimal OTFC dose can be predicted based on pretreatment clinical factors. Results: The cohort included 188 patients within the three trials whose breakthrough pain was effectively managed with OTFC. Prior to entry into the trial, the average breakthrough opioid dose in the 188 patients was 12% of the daily dose of scheduled opioid but strikingly, ranged from 1%-72%. The optimal OTFC dose was poorly correlated with patients' scheduled or previous breakthrough opioid doses. The only clinically meaningful correlation was that the average final OTFC dose significantly decreased with increasing age. Overall, there was enormous interindividual variability in patients' dose requirements for breakthrough pain. Conclusions: This is the largest study to date of the relationship between clinical variables and the effective dose of OTFC when titrated to effect for breakthrough cancer pain. These results suggest that use of breakthrough medication should routinely be individualized with a titration strategy separate from the around-the-clock medication, according to each patient's response to their breakthrough opioid.	Tom Baker Canc Clin, Dept Med, Calgary, AB T2N 4N2, Canada; Pain Res Consulting, Calgary, AB, Canada; Alberta Canc Board, Div Populat Hlth & Informat, Calgary, AB, Canada; Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA	Hagen, NA (reprint author), Tom Baker Canc Clin, Dept Med, 1331 29 St NW, Calgary, AB T2N 4N2, Canada.	neilha@cancerboard.ab.ca	Farrar, John/A-1037-2007	Farrar, John/0000-0001-8656-5157			*AG HLTH CAR POL R, 1994, [No title captured]; Benedetti F, 1998, PAIN, V74, P205, DOI 10.1016/S0304-3959(97)00172-3; BENTLEY JB, 1982, ANESTH ANALG, V61, P968; Caraceni A, 2004, PALLIATIVE MED, V18, P177, DOI 10.1191/0269216304pm890oa; CHERNY NI, 1993, CANCER-AM CANCER SOC, V72, P3393, DOI 10.1002/1097-0142(19931201)72:11+<3393::AID-CNCR2820721606>3.0.CO;2-O; CHERNY NI, 1994, NEUROLOGY, V44, P857, DOI 10.1212/WNL.44.5.857; Christie JM, 1998, J CLIN ONCOL, V16, P3238, DOI 10.1200/JCO.1998.16.10.3238; COLLIN E, 1993, PAIN, V55, P319, DOI 10.1016/0304-3959(93)90007-C; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Farrar JT, 1998, JNCI-J NATL CANCER I, V90, P611, DOI 10.1093/jnci/90.8.611; Ferrante FM, 1996, ANESTHESIOLOGY, V84, P1243; Hall S, 2003, PAIN MED, V4, P125, DOI 10.1046/j.1526-4637.2003.03020.x; Hanks GW, 1997, ACTA ANAESTH SCAND, V41, P154, DOI 10.1111/j.1399-6576.1997.tb04630.x; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; Kharasch ED, 2004, ANESTHESIOLOGY, V101, P738, DOI 10.1097/00000542-200409000-00023; Mercadante S, 1998, EUR J CANCER, V34, P627, DOI 10.1016/S0959-8049(97)10053-3; Mercadante S, 1997, J PAIN SYMPTOM MANAG, V13, P204, DOI 10.1016/S0885-3924(96)00302-8; Mercadante S, 2004, J PAIN SYMPTOM MANAG, V28, P505, DOI 10.1016/j.jpainsymman.2004.02.024; Mercadante S, 2002, CANCER, V94, P832, DOI 10.1002/cncr.10249; Miaskowski C, 2002, J PAIN, V3, P12, DOI 10.1054/jpai.2002.27002; *NAT COMPR CANC NE, 2000, ONCOLOGY, V14, P135; Patt RB, 1998, ONCOLOGY-NY, V12, P1035; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, PAIN, V79, P303, DOI 10.1016/S0304-3959(98)00179-1; SCOTT JC, 1987, J PHARMACOL EXP THER, V240, P159; *SPSS INC, 1998, SPSS GRAD PACK 9 0 W; World Health Organization, 1996, CANC PAIN REL; Zeppetela G, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004311.pub2	28	47	50	0	0	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1096-6218			J PALLIAT MED	J. Palliat. Med.	FEB	2007	10	1					47	55		10.1089/jpm.2006.0151			9	Health Care Sciences & Services	Health Care Sciences & Services	135DU	WOS:000244135100013	17298253				2020-06-30	J	Scott, DJ; Domino, EF; Heitzeg, MM; Koeppe, RA; Ni, LS; Guthrie, S; Zubieta, JK				Scott, David J.; Domino, Edward F.; Heitzeg, Mary M.; Koeppe, Robert A.; Ni, Lisong; Guthrie, Sally; Zubieta, Jon-Kar			Smoking modulation of mu-opioid and dopamine D2 receptor-mediated neurotransmission in humans	NEUROPSYCHOPHARMACOLOGY			English	Article						nicotine; mu-opioid receptors; positron emission tomography; dopamine; opioids; craving	NUCLEUS-ACCUMBENS; ENDOGENOUS OPIOIDS; CIGARETTE-SMOKING; PREFRONTAL CORTEX; NICOTINE; NALOXONE; BRAIN; ADDICTION; BEHAVIOR; RELEASE	This is a pilot examination of the hypothesis that some of the effects of smoking cigarettes in humans are mediated through nicotine activation of opioid and dopamine (DA) neurotransmission. Neuroimaging was performed using positron emission tomography and the radiotracers [C-11] carfentanil and [C-11] raclopride, labeling mu-opioid and DA D2 receptors, respectively. Six healthy male smokers were abstinent overnight. After radiotracer administration, subjects smoked two denicotinized cigarettes, followed 45 min later by two average nicotine cigarettes. Dynamic data were acquired over 90 min, and transformed into parametric maps of receptor availability in vivo (binding potential, BP), corresponding to low and high nicotine smoking periods and analyzed on a voxel-by-voxel basis using SPM'99 and correction for multiple comparisons. Significant activation of m-opioid receptor-mediated neurotransmission from denicotinized to average nicotine conditions was observed in the right anterior cingulate cortex. DA D2 neurotransmission was activated in the ventral basal ganglia, correlating with Fagerstrom scale nicotine dependence scores. Lower m-opioid receptor BP was also detected during the denicotinized smoking condition in the smoker group, compared to baseline scans in non-smokers, in the cingulate cortex, thalamus, ventral basal ganglia, and amygdala. These reductions were reversed during the average nicotine condition in the thalamus, ventral basal ganglia and amygdala. These data point to both the feasibility of simultaneously examining opioid and DA neurotransmission responses to smoking in humans, as well as to the need to examine non-nicotine aspects of smoking to more fully understand the behavioral effects of this drug.	Univ Michigan, Dept Psychiat, Mol & Behav Neurosci Inst, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Radiol, Ann Arbor, MI 48109 USA; Univ Michigan, Coll Pharm, Dept Clin Pharm, Ann Arbor, MI 48109 USA	Zubieta, JK (reprint author), Univ Michigan, Dept Psychiat, Mol & Behav Neurosci Inst, 205 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.	zubieta@umich.edu	Heitzeg, Mary/M-7154-2017	Heitzeg, Mary/0000-0002-6737-2971	NCCIH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine [R01 AT 001415]; NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [R01 DA 016423]		ACETO MD, 1993, EUR J PHARM-ENVIRON, V248, P333, DOI 10.1016/0926-6917(93)90009-F; ANGULO JA, 1994, BRAIN RES REV, V19, P1, DOI 10.1016/0165-0173(94)90002-7; Benedetti F, 2005, J NEUROSCI, V25, P10390, DOI 10.1523/JNEUROSCI.3458-05.2005; Berridge KC, 2003, TRENDS NEUROSCI, V26, P507, DOI 10.1016/S0166-2236(03)00233-9; Borras MC, 2004, J NEUROPHYSIOL, V91, P2723, DOI 10.1152/jn.00249.2003; Brody AL, 2002, ARCH GEN PSYCHIAT, V59, P1162, DOI 10.1001/archpsyc.59.12.1162; Carboni E, 2000, DRUG ALCOHOL DEPEN, V58, P93, DOI 10.1016/S0376-8716(99)00064-2; Carboni E, 2000, J NEUROSCI, V20; DAVENPORT KE, 1990, NEUROSCI LETT, V113, P40, DOI 10.1016/0304-3940(90)90491-Q; de la Fuente-Fernandez R, 2001, SCIENCE, V293, P1164, DOI 10.1126/science.1060937; Di Chiara G, 2000, EUR J PHARMACOL, V393, P295, DOI 10.1016/S0014-2999(00)00122-9; Domino EF, 2002, PROG NEURO-PSYCHOPH, V26, P1071, DOI 10.1016/S0278-5846(02)00224-5; EIDEN LE, 1984, NATURE, V312, P661, DOI 10.1038/312661a0; First M.B., 1995, STRUCTURED CLIN INTE; Friston K J, 1994, Hum Brain Mapp, V1, P210, DOI 10.1002/hbm.460010306; Gestreau C, 2000, J COMP NEUROL, V427, P285, DOI 10.1002/1096-9861(20001113)427:2<285::AID-CNE9>3.0.CO;2-T; Gorelick D A, 1988, J Subst Abuse, V1, P153, DOI 10.1016/S0899-3289(88)80018-X; HEATHERTON TF, 1991, BRIT J ADDICT, V86, P1119; HOUDI AA, 1991, PEPTIDES, V12, P161, DOI 10.1016/0196-9781(91)90183-P; HURD YL, 1993, SYNAPSE, V13, P357, DOI 10.1002/syn.890130408; Jewett DM, 2001, NUCL MED BIOL, V28, P733, DOI 10.1016/S0969-8051(01)00226-8; KARRAS A, 1980, LIFE SCI, V27, P1541, DOI 10.1016/0024-3205(80)90562-7; Kilts CD, 2001, ARCH GEN PSYCHIAT, V58, P334, DOI 10.1001/archpsyc.58.4.334; Knutson B, 2003, NEUROIMAGE, V18, P263, DOI 10.1016/S1053-8119(02)00057-5; Koob GF, 2001, NEUROPSYCHOPHARMACOL, V24, P97, DOI 10.1016/S0893-133X(00)00195-0; Kraus MA, 1996, BRAIN RES, V724, P33, DOI 10.1016/0006-8993(96)00263-6; Laruelle M, 2000, J CEREBR BLOOD F MET, V20, P423, DOI 10.1097/00004647-200003000-00001; Logan J, 1996, J CEREBR BLOOD F MET, V16, P834, DOI 10.1097/00004647-199609000-00008; MALIN DH, 1993, PSYCHOPHARMACOLOGY, V112, P339, DOI 10.1007/BF02244930; MINOSHIMA S, 1993, J NUCL MED, V34, P322; Moles A, 2004, SCIENCE, V304, P1983, DOI 10.1126/science.1095943; Narendran R, 2004, SYNAPSE, V52, P188, DOI 10.1002/syn.20013; NEMETHCOSLETT R, 1986, PSYCHOPHARMACOLOGY, V89, P261; Nestler EJ, 2005, NAT NEUROSCI, V8, P1445, DOI 10.1038/nn1578; Pomerleau OF, 1998, PSYCHONEUROENDOCRINO, V23, P115, DOI 10.1016/S0306-4530(97)00074-7; Pruessner JC, 2004, J NEUROSCI, V24, P2825, DOI 10.1523/JNEUROSCI.3422-03.2004; Rainville P, 1997, SCIENCE, V277, P968, DOI 10.1126/science.277.5328.968; Schroeder BE, 2001, NEUROSCIENCE, V105, P535, DOI 10.1016/S0306-4522(01)00221-4; Steiner H, 1998, EXP BRAIN RES, V123, P60, DOI 10.1007/s002210050545; SUTHERLAND G, 1995, PSYCHOPHARMACOLOGY, V120, P418, DOI 10.1007/BF02245813; Tanda GL, 1998, EUR J NEUROSCI, V10, P1179, DOI 10.1046/j.1460-9568.1998.00135.x; Unterwald EM, 2001, ANN NY ACAD SCI, V937, P74; Volkow ND, 2004, MOL PSYCHIATR, V9, P557, DOI 10.1038/sj.mp.4001507; Walters CL, 2005, NEURON, V46, P933, DOI 10.1016/j.neuron.2005.05.005; Wewers ME, 1999, BRAIN RES, V822, P107, DOI 10.1016/S0006-8993(99)01095-1; WORSLEY KJ, 1992, J CEREBR BLOOD F MET, V12, P900, DOI 10.1038/jcbfm.1992.127; Zald DH, 2004, J NEUROSCI, V24, P4105, DOI 10.1523/JNEUROSCI.4643-03.2004; Zangen A, 1999, J NEUROCHEM, V73, P2569, DOI 10.1046/j.1471-4159.1999.0732569.x; Zubieta JK, 2005, J NEUROSCI, V25, P7754, DOI 10.1523/JNEUROSCI.0439-05.2005; Zubieta JK, 2003, SCIENCE, V299, P1240, DOI 10.1126/science.1078546; Zubieta JK, 1996, NAT MED, V2, P1225, DOI 10.1038/nm1196-1225; Zubieta JK, 2001, SCIENCE, V293, P311, DOI 10.1126/science.1060952	52	87	88	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0893-133X	1740-634X		NEUROPSYCHOPHARMACOL	Neuropsychopharmacology	FEB	2007	32	2					450	457		10.1038/sj.npp.1301238			8	Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	128EH	WOS:000243640500020	17091130	Bronze			2020-06-30	J	Meakin, GH; Meretoja, OA; Perkins, RJ; Waite, I; Taivainen, T; Wirtavuori, K; Murphy, AK; Raiha, L				Meakin, George H.; Meretoja, Olli A.; Perkins, Russell J.; Waite, Ian; Taivainen, Tomi; Wirtavuori, Kari; Murphy, Anthony K.; Raiha, Leena			Tracheal intubating conditions and pharmacodynamics following cisatracurium in infants and children undergoing halothane and thiopental-fentanyl anesthesia	PEDIATRIC ANESTHESIA			English	Article						anesthesia; intubation; tracheal; neuromuscular block; cisatracurium; anesthetics i.v.; thiopental; anesthetics inhaled; halothane; analgesics; fentanyl	OPIOID BARBITURATE ANESTHESIA; LOW-DOSE ROCURONIUM; MUSCLE-RELAXANTS; 51W89; VECURONIUM; SAFETY; PANCURONIUM; ALFENTANIL; ATRACURIUM; DEPENDENCE	Background: The aims of the present study were to determine the tracheal intubating conditions, onset time, duration of action, and hemodynamic responses following the administration of cisatracurium 0.15 mg.kg(-1) to infants and children. Methods: One hundred and eighty-one infants and children aged 1 month to 12 years were randomized to two groups to receive anesthesia with nitrous oxide-oxygen-halothane (group H) or nitrous oxide-oxygen-thiopental-fentanyl (group TF). Intubation conditions were assessed 120 s after cisatracurium administration using a 4-part scale. Neuromuscular transmission was monitored by recording the evoked compound electromyogram of the adductor pollicis. Results: The proportion of patients with excellent or good intubating conditions was similar in both groups (88 of 90, 98% in group H; 85 of 90, 94% in group TF). However, there was a significantly greater proportion of excellent intubating conditions in group H (79 of 90, 88%) compared with group TF (65 of 90, 72%) (P = 0.01) and recovery time was significantly longer in group H compared with group TF (P < 0.001). There was also a higher proportion of excellent intubating conditions in infants compared with older subjects (P = 0.02) and a shorter onset time (P < 0.001) and longer recovery time (P < 0.001) in younger compared with older patients. Changes in heart rate and arterial pressure were negligible 1 min following the cisatracurium administration. Conclusions: Cisatracurium 0.15 mg.kg(-1) produces acceptable intubating conditions at 120 s in the great majority of infants and children. Anesthesia background and age have significant effects on intubating conditions and duration of action of cisatracurium.	Royal Manchester Childrens Hosp, Dept Anaesthesia, Manchester M27 4HA, Lancs, England; Univ Helsinki, Childrens Hosp, Dept Anaesthesia, Helsinki, Finland; Bolton Royal Infirm, Dept Anaesthesia, Bolton, England	Meakin, GH (reprint author), Royal Manchester Childrens Hosp, Dept Anaesthesia, Manchester M27 4HA, Lancs, England.	george.meakin@manchester.ac.uk					Barclay K, 1997, BRIT J ANAESTH, V78, P92; BELMONT MR, 1995, ANESTHESIOLOGY, V82, P1139, DOI 10.1097/00000542-199505000-00008; Bluestein LS, 1996, CAN J ANAESTH, V43, P925, DOI 10.1007/BF03011806; BOWMAN WC, 1988, ANESTHESIOLOGY, V69, P57, DOI 10.1097/00000542-198807000-00009; de Ruiter J, 2001, ANESTHESIOLOGY, V94, P790, DOI 10.1097/00000542-200105000-00016; Doenicke A, 1997, ANESTH ANALG, V84, P623, DOI 10.1097/00000539-199703000-00030; Donati F, 2003, CAN J ANAESTH, V50, P99, DOI 10.1007/BF03017838; Eikermann M, 2001, ACTA ANAESTH SCAND, V45, P1036, DOI 10.1034/j.1399-6576.2001.450819.x; FRIISHA.B, 1961, PEDIATRICS, V28, P169; Imbeault K, 2006, ANESTH ANALG, V102, P738, DOI 10.1213/01.ane.0000195342.29133.ce; KALLI I, 1989, BRIT J ANAESTH, V62, P188, DOI 10.1093/bja/62.2.188; Kenaan CA, 2000, J CLIN ANESTH, V12, P173, DOI 10.1016/S0952-8180(00)00132-X; KONSTADT SN, 1995, ANESTH ANALG, V81, P1010, DOI 10.1097/00000539-199511000-00020; Lepage JY, 1996, ANESTH ANALG, V83, P823; LIEN CA, 1995, ANESTHESIOLOGY, V82, P1131, DOI 10.1097/00000542-199505000-00007; LITTLEJOHN IH, 1995, ANAESTHESIA, V50, P499, DOI 10.1111/j.1365-2044.1995.tb06038.x; MAEKIN GH, 1988, BRIT J ANAESTH, V60, P171; Meakin GH, 2001, EUR J ANAESTH, V18, P47, DOI 10.1046/j.1365-2346.2001.00002.x; MERETOJA OA, 1988, ANESTH ANALG, V67, P21; MERETOJA OA, 1995, BRIT J ANAESTH, V74, P6, DOI 10.1093/bja/74.1.6; MILLER RD, 1972, ANESTHESIOLOGY, V37, P573, DOI 10.1097/00000542-197212000-00001; RIMANIOL JM, 1997, ANAESTHESIA, V52, P988; RUDOLPH A, 1974, CONGENITAL DIS HEART; SCHELLER MS, 1992, ANESTH ANALG, V75, P788; Soltesz S, 2002, ANAESTHESIST, V51, P374, DOI 10.1007/s00101-002-0304-y; SORVA R, 1984, ACTA PAEDIATR SCAND, V73, P527, DOI 10.1111/j.1651-2227.1984.tb09965.x; STEYN MP, 1994, BRIT J ANAESTH, V72, P403, DOI 10.1093/bja/72.4.403; Taivainen T, 2000, ANAESTHESIA, V55, P1047, DOI 10.1046/j.1365-2044.2000.01623.x; WAREHAM AC, 1994, BRIT J ANAESTH, V72, P205, DOI 10.1093/bja/72.2.205; WAUD BE, 1979, ANESTHESIOLOGY, V50, P103, DOI 10.1097/00000542-197902000-00006	30	9	15	0	0	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	1155-5645			PEDIATR ANESTH	Pediatr. Anesth.	FEB	2007	17	2					113	120		10.1111/j.1460-9592.2006.02042.x			8	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	124XL	WOS:000243405600004	17238881				2020-06-30	J	Rajamani, A; Kamat, V; Rajavel, VP; Murthy, J; Hussain, SA				Rajamani, Arvind; Kamat, Vijaylakshmi; Rajavel, Vardaraja Ponnambalam; Murthy, Jyotsna; Hussain, Syed Altaf			A comparison of bilateral infraorbital nerve block with intravenous fentanyl for analgesia following cleft lip repair in children	PEDIATRIC ANESTHESIA			English	Article						cleft lip repair; infraorbital nerve block; pediatric anaesthesia	INFANTS	Background: The efficacy of analgesia with bilateral infraorbital nerve block and intravenous (i.v.) fentanyl were compared for cleft lip surgery in children. Methods: Eighty-two children aged 3 months to 10 years undergoing cleft lip repair were prospectively randomized to one of two groups: bilateral infraorbital nerve block (Group B), or i.v. fentanyl (Group F). Group B (n = 41) received bilateral infraorbital injection of 1 ml 0.25% bupivacaine and 2 ml i.v. saline as control. Group F (n = 41) received 2 mu g.kg(-1) i.v. fentanyl, and bilateral infraorbital injection of 1 ml saline as control. Pain was evaluated by the incidence of tachycardia, hypertension, and/or modified pain score >= 4. The time to awakening, time to first cry and time to feeding were noted. Results: Thirty four children (82.9%) in Group B had adequate analgesia compared with 15 (36.6%) in Group F (P < 0.0001, RR of failure 0.27 for Group B). Group B had a mean time to awakening of 5.65 +/- 2.52 min (Group F: 9.37 +/- 4.50 min; P < 0.0001), time to first cry 32.14 +/- 18.22 min (Group F: 28.00 +/- 16.27 min; P = 0.3), time to feed 62.05 +/- 20.06 min (Group F: 72.44 +/- 17.72; P = 0.015), and pain score 2.81 +/- 1.38 (Group F: 4.71 +/- 1.89; P < 0.0001). There were no major complications. Conclusions: Bilateral infraorbital block is superior to fentanyl in terms of analgesia, and time to awakening and feeding.	Sri Ramachandra Med Coll & Res Inst, Dept Anaesthesiol & Crit Care, Madras, Tamil Nadu, India; Sri Ramachandra Med Coll & Res Inst, Dept Plast Surg, Madras, Tamil Nadu, India	Rajamani, A (reprint author), Dept Anesthesiol & Crit Care Saranam, Plot 174,Chitrai St,Chinmaya Nagar Stage 2, Madras 600092, Tamil Nadu, India.	rrarvind@yahoo.com					AHUJA S, 1994, ANAESTHESIA, V49, P441; BLASS EM, 1989, ANN NY ACAD SCI, V575, P292; BOSENBERG AT, 1995, BRIT J ANAESTH, V74, P506, DOI 10.1093/bja/74.5.506; Buttner W, 2000, PAEDIATR ANAESTH, V10, P303, DOI 10.1046/j.1460-9592.2000.00530.x; Doyle E, 1992, PAEDIATR ANAESTH, V2, P139; Gunawardana RH, 2000, ANAESTHESIA, V55, P197, DOI 10.1046/j.1365-2044.2000.055002197.x; Lynch M T, 1994, Acad Emerg Med, V1, P514; Mayer M. N., 1997, Revue de Stomatologie et de Chirurgie Maxillo-Faciale, V98, P246; NICODEMUS HF, 1991, SCAND J PLAST RECONS, V25, P253, DOI 10.3109/02844319109020629; Prabhu KPK, 1999, SCAND J PLAST RECONS, V33, P83, DOI 10.1080/02844319950159668; SCOTT DB, 1989, TECHNIQUES REGIONAL, P64; Suresh Santhanam, 2002, Anesthesiol Clin North Am, V20, P83, DOI 10.1016/S0889-8537(03)00056-7; Warner MA, 1999, ANESTHESIOLOGY, V90, P896	13	33	33	0	2	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	1155-5645			PEDIATR ANESTH	Pediatr. Anesth.	FEB	2007	17	2					133	139		10.1111/j.1460-9592.2006.02032.x			7	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	124XL	WOS:000243405600007	17238884				2020-06-30	J	Wallenborn, J; Kluba, K; Olthoff, D				Wallenborn, Jan; Kluba, Karsten; Olthoff, Derk			Comparative evaluation of Bispectral Index and Narcotrend Index in children below 5 years of age	PEDIATRIC ANESTHESIA			English	Article						anesthesia; monitoring; Bispectral Index; Narcotrend	TIDAL SEVOFLURANE CONCENTRATION; ELECTROENCEPHALOGRAPHIC PARAMETERS; HEMODYNAMIC PARAMETERS; PEDIATRIC ANESTHESIA; INFANTS; MONITOR; DEPTH; BIS; EEG; PERFORMANCE	Background: The use of electroencephalogram (EEG) monitoring devices for assessing the depth of hypnosis is most difficult in children under 5 years of age. Methods: Forty five children aged 0-60 months were included in a prospective observational study. A direct comparison of the processed EEG variables Bispectral Index(TM) (BIS, version 3.4) and Narcotrend (R) Index (NI, version 2.0AF) was to be achieved by simultaneous recording. The ability of these parameters to differentiate between various clinical states was evaluated by using the prediction probability (P-k). Age-related effects on the BIS and NI were analyzed by dividing the children into three age groups: 0-6, 7-18 and 19-60 months. Results: The preanesthesia, conscious children were differentiated from anesthetized patients by the BIS and NI with no overlap (P-k = 1.0). In the awake period the BIS was superior to the NI (P-k to differentiate 'end of anesthesia' from 'awakening' was 0.97 vs 0.73 respectively; P = 0.002). Patients aged 7-18 months showed higher BIS and NI values in the course of anesthesia than the younger and older children (P = 0.001). On awakening, children aged 0-6 months showed the lowest mean BIS (n.s.) and NI (P = 0.006) values. Conclusions: The BIS currently seems to be superior to the NI, but age-related processing algorithms of the raw EEG must be implemented in both BIS and NI in order to be useful in children younger than 5 years of age.	Univ Leipzig, Dept Anaesthesiol & Intens Care Med, D-04103 Leipzig, Germany	Wallenborn, J (reprint author), Univ Leipzig, Dept Anaesthesiol & Intens Care Med, Liebigstr 20, D-04103 Leipzig, Germany.	jan.wallenborn@medizin.uni-leipzig.de					Bannister CF, 2001, ANESTH ANALG, V92, P877; Davidson AJ, 2006, PEDIATR ANESTH, V16, P374, DOI 10.1111/j.1460-9592.2006.01877.x; Davidson AJ, 2005, BRIT J ANAESTH, V95, P674, DOI 10.1093/bja/aei247; Davidson AJ, 2001, ANESTH ANALG, V93, P326, DOI 10.1097/00000539-200108000-00017; Denman WT, 2000, ANESTH ANALG, V90, P872, DOI 10.1213/00000539-200004000-00018; Kim HS, 2005, BRIT J ANAESTH, V95, P362, DOI 10.1093/bja/aei196; Kreuer S, 2004, BRIT J ANAESTH, V93, P235, DOI 10.1093/bja/aeh182; Murat I, 2005, PEDIATR ANESTH, V15, P177, DOI 10.1111/j.1460-9592.2004.01564.x; Pilge S, 2006, ANESTHESIOLOGY, V104, P488, DOI 10.1097/00000542-200603000-00016; Rampil IJ, 1998, ANESTHESIOLOGY, V89, P980, DOI 10.1097/00000542-199810000-00023; Reimann B, 2001, ANASTH INTENSIV NOTF, V36, P664, DOI 10.1055/s-2001-18051; Rodriguez RA, 2004, CAN J ANAESTH, V51, P472, DOI 10.1007/BF03018310; Schmidt GN, 2003, ANESTHESIOLOGY, V99, P1072, DOI 10.1097/00000542-200311000-00012; Schneider G, 2004, ANESTHESIOLOGY, V101, P1105, DOI 10.1097/00000542-200411000-00009; Schultz B, 2003, ANAESTHESIST, V52, P1143, DOI 10.1007/s00101-003-0603-y; Smith WD, 1996, ANESTHESIOLOGY, V84, P38, DOI 10.1097/00000542-199601000-00005; Wallenborn J, 2002, KLIN NEUROPHYSIOL, V33, P213, DOI 10.1055/s-2002-36005; Watcha MF, 2001, ANESTH ANALG, V92, P805; Weber F, 2005, PEDIATR ANESTH, V15, P727, DOI 10.1111/j.1460-9592.2004.01546.x; Weber F, 2005, PEDIATR ANESTH, V15, P378, DOI 10.1111/j.1460-9592.2005.01465.x; Weber F, 2004, CAN J ANAESTH, V51, P855, DOI 10.1007/BF03018471; Wodey E, 2005, BRIT J ANAESTH, V94, P810, DOI 10.1093/bja/aei140	22	22	26	0	1	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	1155-5645			PEDIATR ANESTH	Pediatr. Anesth.	FEB	2007	17	2					140	147		10.1111/j.1460-9592.2006.02036.x			8	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	124XL	WOS:000243405600008	17238885				2020-06-30	J	Canbay, O; Kose, EA; Celebi, N; Karagoz, AH; Ozgen, S				Canbay, Ozgur; Kose, Emine Arzu; Celebi, Nalan; Karagoz, Ayse Heves; Ozgen, Saadet			Anesthesia for congenital insensitivity to pain with anhidrosis	PEDIATRIC ANESTHESIA			English	Letter							MANAGEMENT		Hacettepe Univ, Sch Med, Dept Anesthesiol & Reanimat, Ankara, Turkey	Canbay, O (reprint author), Hacettepe Univ, Sch Med, Dept Anesthesiol & Reanimat, Ankara, Turkey.	arzukose@hacettepe.edu.tr					BROWN JH, 1996, GOODMAN GILMANS PHAR, V153; Indo Y, 1996, NAT GENET, V13, P485, DOI 10.1038/ng0896-485; Ku ASW, 2005, J ORAL MAXIL SURG, V63, P848, DOI 10.1016/j.joms.2005.02.023; Okuda K, 2000, PAEDIATR ANAESTH, V10, P545, DOI 10.1046/j.1460-9592.2000.00542.x; ROSEMBERG S, 1994, PEDIATR NEUROL, V11, P50, DOI 10.1016/0887-8994(94)90091-4; Rozentsveig V, 2004, PEDIATR ANESTH, V14, P344, DOI 10.1046/j.1460-9592.2003.01235.x; Tomioka T, 2002, ANESTH ANALG, V94, P271, DOI 10.1097/00000539-200202000-00008	7	5	5	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645	1460-9592		PEDIATR ANESTH	Pediatr. Anesth.	FEB	2007	17	2					190	192		10.1111/j.1460-9592.2006.02033.x			4	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	124XL	WOS:000243405600019	17238896				2020-06-30	J	Graf, G; Likar, R; Schalk, HV; Kager, I; Jabarzadeh, H				Graf, G.; Likar, R.; Schalk, H. -V.; Kager, I.; Jabarzadeh, H.			Spinal epidural abscess after long-term epidural catheterization	SCHMERZ			German	Article						spinal epidural abscess; long-term epidural catheterization; complications; conservative treatment; predispositions	OF-THE-LITERATURE; CONSERVATIVE TREATMENT; EXTRADURAL ABSCESS; MANAGEMENT; ANESTHESIA	This case report describes a 63-year-old male patient with considerably impaired postoperative wound healing in the region of the lower extremities. After initial drug therapy for the pain was ineffectual, the patient was treated repeatedly through an epidural catheter. In the further course, an extensive spinal epidural abscess was diagnosed as an incidental finding without neurological symptoms. After taking into consideration the patient's age and the risk factors present as well as inclusion of the subspecialties involved for an interdisciplinary assessment, the patient was successfully treated with a conservative approach. Our contribution concludes with a detailed discussion and comparison of the literature.	Landeskrankenhaus, Abt Anasthesiol & Intens Med, A-9020 Klagenfurt, Austria	Graf, G (reprint author), Landeskrankenhaus, Abt Anasthesiol & Intens Med, St Veiter Str 47, A-9020 Klagenfurt, Austria.	Gudrun.Graf@lkh-klu.at					Beland B, 1997, ANAESTHESIST, V46, P536, DOI 10.1007/s001010050435; Ben-David Bruce, 2002, Anesthesiol Clin North Am, V20, P669; CHAO D, 2002, AM FAM PHYSICIAN, V65, P7; DANNER RL, 1987, REV INFECT DIS, V9, P265; Dysart RH, 1997, BRIT J ANAESTH, V78, P591; Grieve JP, 2000, EUR SPINE J, V9, P67, DOI 10.1007/s005860050012; HANIGAN WC, 1990, SURG NEUROL, V34, P408, DOI 10.1016/0090-3019(90)90245-K; HLAVIN ML, 1990, NEUROSURGERY, V27, P177, DOI 10.1227/00006123-199008000-00001; HOLT HM, 1995, J HOSP INFECT, V30, P253, DOI 10.1016/0195-6701(95)90259-7; HUNT JR, 1977, ANESTH ANALG, V56, P222; Kindler CH, 1998, ACTA ANAESTH SCAND, V42, P609; Kurokawa Y, 1989, No To Shinkei, V41, P513; Michel H, 1997, Anaesthesiol Reanim, V22, P69; NUSSBAUM ES, 1992, SURG NEUROL, V38, P225, DOI 10.1016/0090-3019(92)90173-K; Okano K, 1999, JPN J CLIN ONCOL, V29, P49, DOI 10.1093/jjco/29.1.49; RONG KL, 2002, NEUROSURGERY, V51, P509; SCOTT DB, 1990, BRIT J ANAESTH, V64, P537, DOI 10.1093/bja/64.5.537; Siddiq F, 2004, ARCH INTERN MED, V164, P2409, DOI 10.1001/archinte.164.22.2409; Sorensen P, 2003, BRIT J NEUROSURG, V17, P513, DOI 10.1080/02688690310001627731; TEMAN AJ, 1992, ARCH NEUROL-CHICAGO, V49, P743, DOI 10.1001/archneur.1992.00530310091017; Wang JS, 1996, ANESTH ANALG, V82, P1069, DOI 10.1097/00000539-199605000-00034; Wessling H, 2003, NEUROCIRUGIA, V14, P529; WHEELER D, 1992, CLIN INFECT DIS, V15, P22, DOI 10.1093/clinids/15.1.22	23	1	1	0	0	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013 USA	0932-433X			SCHMERZ	Schmerz	FEB	2007	21	1					68	72		10.1007/s00482-006-0489-0			5	Anesthesiology; Clinical Neurology	Anesthesiology; Neurosciences & Neurology	138WG	WOS:000244393400009	16850305				2020-06-30	J	Corso, OH; Morris, RG; Hewett, PJ; Karatassas, A				Corso, Olivia H.; Morris, Raymond G.; Hewett, Peter J.; Karatassas, Alex			Safety of 96-hour incision-site continuous infusion of ropivacaine for postoperative analgesia after bowel cancer resection	THERAPEUTIC DRUG MONITORING			English	Article						ropivacaine; postoperative pain; local anesthetic	CONTINUOUS WOUND INSTILLATION; REGIONAL BLOOD-FLOW; EPIDURAL INFUSION; CLINICAL-TRIAL; PAIN RELIEF; 2 MG/ML; BUPIVACAINE; PHARMACOKINETICS; SURGERY; ABSORPTION	The aim of this study was to examine the safety of ropivacaine given to patients as a continuous infusion [0.2% (2 mg/mL), 5 mL/h for 96 hours] into a right lateral transverse incision using a portable elastomeric infusion pump after colon cancer resection. Blood samples were collected throughout the infusion and up to 12 hours after infusion and were analyzed by highperformance liquid chromatography (HPLC) for total and unbound ropivacaine concentrations in plasma. Alpha, acid glycoprotein (AAG) concentrations were measured at 0 and 48 hours to assess possible changes in ropivacaine protein binding after surgery. Postoperative pain control was assessed using 12 hour visual analog scale (VAS) scores. Patient-controlled analgesia (PCA) using fentanyl was freely available in parallel for breakthrough pain, with usage and consumption compared with a historical cohort. The mean +/- SD C-max total plasma ropivacaine concentration (n = 5) from 12 hours to the end of the infusion was 4.5 +/- 2.6 mg/L, comparable with the previously published threshold for CNS toxicity in the most sensitive patient studied (3.4 mg/L). However, the corresponding maximum unbound ropivacaine concentration (ie, the pharmacologically active moiety) of 0.07 +/- 0.01 mg/L ranged from four- to sevenfold below the reported toxicity threshold (0.34 mg/L). The apparently greater safety margin seen with unbound ropivacaine may have resulted from a significant increase (mean 63%, P < 0.05) in AAG concentrations measured at 48 hours after surgery. This reduction resulted from the known AAG reaction after surgical intervention, resulting in a reducing unbound ropivacaine fraction throughout the 96 hour infusion in all patients. Mean subjective 12 hour pain scale scores at rest and on movement showed large variability between patients. No signs or symptoms of ropivarcaine toxicity were observed or reported on questioning. In this limited sample, extending the infusion period from the presently approved 48 hours to 96 hours seems to be a safe alternative and/or adjunct to standard opiate analgesia after colorectal surgery using a right lateral transverse incision, hence reducing the incidence of opiate adverse effects and enhancing recovery. Unbound ropivacaine concentrations suggest there is scope for testing elevated doses to enhance efficacy further.	Queen Elizabeth Hosp, Dept Cardiol & Clin Pharmacol, Woodville, SA 5011, Australia; Univ Adelaide, Fac Hlth Sci, Discipline Pharmacol, Adelaide, SA, Australia; Queen Elizabeth Hosp, Dept Surg, Woodville, SA 5011, Australia	Morris, RG (reprint author), Queen Elizabeth Hosp, Dept Cardiol & Clin Pharmacol, 28 Woodville Rd, Woodville, SA 5011, Australia.						Bianconi M, 2003, BRIT J ANAESTH, V91, P830, DOI 10.1093/bja/aeg277; Burm AGL, 2000, ANESTHESIOLOGY, V93, P395, DOI 10.1097/00000542-200008000-00017; Cheong WK, 2001, BRIT J SURG, V88, P357, DOI 10.1046/j.1365-2168.2001.01717.x; Dickenson AH, 2002, BRIT J ANAESTH, V88, P755, DOI 10.1093/bja/88.6.755; Dowling R, 2003, J THORAC CARDIOV SUR, V126, P1271, DOI 10.1016/S0022-5223(03)00585-3; Ekatodramis G, 2003, ANESTHESIOLOGY, V98, P143, DOI 10.1097/00000542-200301000-00023; Erichsen CJ, 1996, ANESTHESIOLOGY, V84, P834, DOI 10.1097/00000542-199604000-00010; Kampe S, 2003, BRIT J PLAST SURG, V56, P478, DOI 10.1016/S0007-1226(03)00180-2; KARATASSAS A, 1993, AUST NZ J SURG, V63, P766, DOI 10.1111/j.1445-2197.1993.tb00338.x; Knudsen K, 1997, BRIT J ANAESTH, V78, P507; LEE A, 1989, ANESTH ANALG, V69, P736; LUZZI FA, 1984, J CHROMATOGR, V311, P291, DOI 10.1016/S0378-4347(00)84722-2; MELZACK R, 1965, SCIENCE, V150, P971, DOI 10.1126/science.150.3699.971; MORRIS RG, 1993, J PHARMACOL TOXICOL, V30, P39, DOI 10.1016/1056-8719(93)90006-Z; NATION RL, 1979, J CHROMATOGR, V162, P466, DOI 10.1016/S0378-4347(00)81538-8; SAEDEN MR, 2003, BEST PRACT RES CLIN, V17, P191; SCOTT DB, 1989, ANESTH ANALG, V69, P563, DOI 10.1213/00000539-198911000-00003; SECHZER PH, 1963, ANESTHESIOLOGY, V24, P779, DOI 10.1097/00000542-196311000-00005; Shah V P, 2000, Pharm Res, V17, P1551, DOI 10.1023/A:1007669411738; VEERING BT, 1987, ANESTH ANALG, V66, P589; VEERING BT, 1991, ANESTHESIOLOGY, V74, P250, DOI 10.1097/00000542-199102000-00010; Wiedemann D, 2000, BRIT J ANAESTH, V85, P830, DOI 10.1093/bja/85.6.830; Wulf H, 1999, ANESTH ANALG, V89, P1471, DOI 10.1097/00000539-199912000-00029	23	12	12	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0163-4356	1536-3694		THER DRUG MONIT	Ther. Drug Monit.	FEB	2007	29	1					57	63		10.1097/FTD.0b013e31802c59ec			7	Medical Laboratory Technology; Pharmacology & Pharmacy; Toxicology	Medical Laboratory Technology; Pharmacology & Pharmacy; Toxicology	132PM	WOS:000243954700009	17304151				2020-06-30	J	van Oostrom, H; Stienen, PJ; van den Bos, R; de Groot, HNM				van Oostrom, Hugo; Stienen, Peter J.; van den Bos, Ruud; de Groot, Harry N. M.			Somatosensory-evoked potentials indicate increased unpleasantness of noxious stimuli in response to increasing stimulus intensities in the rat	BRAIN RESEARCH BULLETIN			English	Article						somatosensory-evoked potential; fear-conditioning; pain; analgesia	BRAIN POTENTIALS; PAIN SYSTEM; CORTEX; VERTEX; RECEPTORS; AWAKE; NOCICEPTION; TEMPERATURE; SENSITIVITY; SUPPRESSES	Recently, it has been shown in rats that specific characteristics of somatosensory-evoked potentials (SEPs) recorded from different sites on the scalp correlate differently to the amount of unpleasantness experienced by the animal following noxious stimulation. It was shown that the SEP recorded from vertex (Vx-SEP) did correlate with the unpleasantness, whereas the SEP recorded from the primary somatosensory cortex (SI-SEP) did not. In the present study, we further investigated the relationship between the Vx-SEP, SI-SEP and the unpleasantness of noxious stimuli. Therefore, different groups of rats were subjected to a SEP fear-conditioning paradigm in which the unconditioned stimulus (US), represented by noxious stimuli applied to evoke SEPs, was paired to a conditioned stimulus (CS) represented by a tone. Different stimulus intensities of the US were applied in the different groups. After CS-US presentation, CS-induced fear-conditioned behaviour was analysed in relation to the characteristics of the Vx- and SI-SEP during CS-US presentation. Results showed that increasing stimulus intensities led to increased SEP amplitudes, which were paralleled by an increased amount of CS-induced fear-conditioned behaviour. No differences between Vx-SEP and SI-SEP were found. The increase in the SEPs in parallel with the increased amount of fear-induced behaviour further supports the SEP to be a potentially valuable tool for studying acute pain and analgesia in animals. (c) 2006 Elsevier Inc. All rights reserved.	Univ Utrecht, Fac Vet Med, Div Anesthesiol & Neurophysiol, Dept Clin Sci Compan Anim, NL-3508 TD Utrecht, Netherlands; Univ Utrecht, Fac Vet Med, Div Anesthesiol, Dept Equine Sci, NL-3508 TD Utrecht, Netherlands; Univ Utrecht, Fac Vet Med, Div Ethol & Welf, Dept Anim Sci & Soc, NL-3508 TD Utrecht, Netherlands; Univ Utrecht, Rudolf Magnus Inst Neurosci, Utrecht, Netherlands	van Oostrom, H (reprint author), Univ Utrecht, Fac Vet Med, Div Anesthesiol & Neurophysiol, Dept Clin Sci Compan Anim, POB 80-154,Yalelaan 8, NL-3508 TD Utrecht, Netherlands.	H.vanOostrom@vet.uu.nl					Anagnostaras SG, 2000, LEARN MEMORY, V7, P58, DOI 10.1101/lm.7.1.58; Arendt-Nielsen L, 1994, Acta Anaesthesiol Scand Suppl, V101, P7; ATWEH SF, 1983, BRIT MED BULL, V39, P47, DOI 10.1093/oxfordjournals.bmb.a071789; Beydoun A, 1997, PAIN, V72, P319, DOI 10.1016/S0304-3959(97)00056-0; BJERRING P, 1988, J NEUROL NEUROSUR PS, V51, P43, DOI 10.1136/jnnp.51.1.43; Bromm B, 1998, ELECTROEN CLIN NEURO, V107, P227, DOI 10.1016/S0013-4694(98)00075-3; BROMM B, 1991, ELECTROEN CLIN NEURO, V80, P284, DOI 10.1016/0168-5597(91)90111-A; BROMM B, 1984, METHOD FIND EXP CLIN, V6, P405; Casey KL, 2000, J NEUROPHYSIOL, V84, P525; Davies MF, 2004, NEUROPSYCHOPHARMACOL, V29, P229, DOI 10.1038/sj.npp.1300324; Djouhri L, 2004, BRAIN RES REV, V46, P131, DOI 10.1016/j.brainresrev.2004.07.015; FANSELOW MS, 1979, J COMP PHYSIOL PSYCH, V93, P736, DOI 10.1037/h0077609; Haberham ZL, 2000, BRAIN RES, V873, P287, DOI 10.1016/S0006-8993(00)02504-X; Iannetti GD, 2004, CLIN NEUROPHYSIOL, V115, P2629, DOI 10.1016/j.clinph.2004.05.023; Inui K, 2002, PAIN, V96, P247, DOI 10.1016/S0304-3959(01)00453-5; JONES AK, 1991, NEUROSCI LETT, V26, P25; Kakigi R, 2000, J CLIN NEUROPHYSIOL, V17, P295, DOI 10.1097/00004691-200005000-00007; Kalliomaki J, 1998, PAIN, V77, P323, DOI 10.1016/S0304-3959(98)00115-8; Kanda M, 2002, CLIN NEUROPHYSIOL, V113, P1013, DOI 10.1016/S1388-2457(02)00125-6; Kandel L, 1996, ANESTH ANALG, V82, P321, DOI 10.1097/00000539-199602000-00019; KOLPAKOV VG, 1977, BEHAVIOUR, V62, P190, DOI 10.1163/156853977X00108; Le Bars D, 2001, PHARMACOL REV, V53, P597; Lefaucheur JP, 2004, J NEUROL NEUROSUR PS, V75, P417, DOI 10.1136/jnnp.2003.019208; Liu EHC, 2005, BRIT J ANAESTH, V94, P193, DOI 10.1093/bja/aei003; Logginidou HG, 2003, ANESTH ANALG, V97, P1784, DOI 10.1213/01.ANE.0000090318.16879.A8; Lorenz J, 1996, EVOKED POTENTIAL, V100, P165, DOI 10.1016/0013-4694(95)00259-6; Lorenz J, 1996, J NEUROL NEUROSUR PS, V61, P107, DOI 10.1136/jnnp.61.1.107; Maes JHR, 1997, PHARMACOL BIOCHEM BE, V58, P305, DOI 10.1016/S0091-3057(97)00240-2; Mantzaridis H, 1997, ANAESTHESIA, V52, P1030, DOI 10.1111/j.1365-2044.1997.185-az0327.x; Overton DA, 1985, CONTEXT LEARNING, P357; Pietersen CY, 2006, PROG NEURO-PSYCHOPH, V30, P1209, DOI 10.1016/j.pnpbp.2006.02.019; Price DD, 2000, SCIENCE, V288, P1769, DOI 10.1126/science.288.5472.1769; Pypendop B, 1999, RES VET SCI, V67, P35, DOI 10.1053/rvsc.1998.0273; Sewards TV, 2002, BRAIN RES BULL, V59, P163, DOI 10.1016/S0361-9230(02)00864-X; Shi L, 2004, ANESTH ANALG, V99, P159, DOI 10.1213/01.ANE.0000114552.20268.7F; Silbert SC, 2003, J NEUROSCI, V23, P34; Spiegel J, 2000, CLIN NEUROPHYSIOL, V111, P725, DOI 10.1016/S1388-2457(99)00297-7; Spiegel J, 2003, CLIN NEUROPHYSIOL, V114, P992, DOI 10.1016/S1388-2457(03)00069-5; Stienen PJ, 2006, BRAIN RES BULL, V70, P203, DOI 10.1016/j.brainresbull.2006.06.003; Stienen PJ, 2005, BRAIN RES BULL, V67, P269, DOI 10.1016/j.brainresbull.2005.06.038; Stienen PJ, 2004, BRAIN RES, V1030, P256, DOI 10.1016/j.brainres.2004.10.014; Stienen PJ, 2003, J NEUROSCI METH, V126, P79, DOI 10.1016/S0165-0270(03)00070-0; van Oostrom H, 2005, BRAIN RES PROTOC, V15, P14, DOI 10.1016/j.brainresprot.2005.02.001; Willis WD, 1997, J CLIN NEUROPHYSIOL, V14, P2, DOI 10.1097/00004691-199701000-00002; Zarrindast MR, 2004, EUR J PHARMACOL, V497, P197, DOI 10.1016/j.ejphar.2004.06.041	45	10	10	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0361-9230	1873-2747		BRAIN RES BULL	Brain Res. Bull.	JAN 9	2007	71	4					404	409		10.1016/j.brainresbull.2006.10.009			6	Neurosciences	Neurosciences & Neurology	131HJ	WOS:000243859300011	17208658	Green Published			2020-06-30	J	Kisli, E; Agargun, MY; Tekin, M; Selvi, Y; Karaayvaz, M				Kisli, Erol; Agargun, M. Yucel; Tekin, Murat; Selvi, Yavuz; Karaayvaz, Muammer			Effects of spinal anesthesia and laryngeal mask anesthesia on mood states during hemorrhoidectomy	ADVANCES IN THERAPY			English	Article						hemorrhoidectomy; spinal anesthesia; laryngeal mask anesthesia; mood states	PROPOFOL ANESTHESIA; GENERAL-ANESTHESIA; COGNITIVE FUNCTION; URINARY RETENTION; CONTROLLED-TRIAL; RECOVERY; DESFLURANE; ISOFLURANE; SEDATION; SURGERY	The present study was undertaken to compare the effects of laryngeal mask anesthesia (LMA) and spinal anesthesia on mood states in patients undergoing hemorrhoidectomy. A total of 46 patients who underwent hemorrhoidectomy for grade III and IV hemorrhoids were included in this study. LMA with fentanyl plus propofol was given to 23 patients, and spinal anesthesia with bupivacaine was administered to 23 patients. Mood changes were assessed preoperatively and 2 h postoperatively with the Profile of Mood States (POMS), which consists of 65 questions that are designed to measure 6 identifiable mood states (tension, depression, anger, vigor, fatigue, and confusion). No significant differences were noted between the 2 groups in terms of baseline POMS global and subscale scores, except for scores regarding vigor. No significant mood changes were observed after hemorrhoidectomy in patients who were given LMA; however, an increase in total POMS score was reported in patients given spinal anesthesia. These findings suggest that mood score is affected by spinal anesthesia but not by LMA in patients who are about to undergo hemorrhoidectomy.	Yuzuncu Yil Univ, Sch Med, Dept Gen Surg, Van, Turkey; Yuzuncu Yil Univ, Sch Med, Dept Psychiat, Van, Turkey; Yuzuncu Yil Univ, Sch Med, Dept Anesthesiol, Van, Turkey	Kisli, E (reprint author), Tip Fak Arastirma Hastanesi, Genel Cerrahi Anabilim Dali, Maras Caddesi, TR-65200 Van, Turkey.	erolkisli@yahoo.com					Apfelbaum JL, 1996, ANESTH ANALG, V83, P721, DOI 10.1097/00000539-199610000-00010; COVINO BG, 1981, J DENT RES, V60, P1454, DOI 10.1177/00220345810600080903; DING Y, 1993, J CLIN ANESTH, V5, P443; FINLEY RK, 1991, AM SURGEON, V57, P486; FLEISCHER M, 1994, AM SURGEON, V60, P812; Fredman B, 1999, J CLIN ANESTH, V11, P635, DOI 10.1016/S0952-8180(99)00108-7; Gencosmanoglu R, 2002, DIS COLON RECTUM, V45, P70, DOI 10.1007/s10350-004-6116-1; GHOURI AF, 1991, ANESTHESIOLOGY, V74, P419, DOI 10.1097/00000542-199103000-00005; ILAHI OA, 1994, [No title captured], V299, P44; Joshi GP, 1997, ANESTH ANALG, V85, P573, DOI 10.1097/00000539-199709000-00016; Juvin P, 1997, ANESTH ANALG, V85, P647, DOI 10.1097/00000539-199709000-00029; Klein SM, 1999, REGION ANESTH PAIN M, V24, P175, DOI 10.1016/S1098-7339(99)90081-0; KORTTILA K, 1975, ACTA ANAESTH SCAND, V19, P384, DOI 10.1111/j.1399-6576.1975.tb05200.x; Kudoh A, 2002, NEUROPSYCHOBIOLOGY, V46, P22, DOI 10.1159/000063572; Leitch JA, 2004, ANAESTHESIA, V59, P853, DOI 10.1111/j.1365-2044.2004.03761.x; MACKENZIE N, 1987, ANAESTHESIA, V42, P3, DOI 10.1111/j.1365-2044.1987.tb02936.x; MARSHALL CA, 1992, ANAESTHESIA, V47, P461, DOI 10.1111/j.1365-2044.1992.tb02265.x; MAWJI FA, 1971, AMBULATORY ANORECTAL; McNair DM, 1971, EITS MANUAL POMS PRO; MORGAN GE, 2002, CLIN ANAESTHESIOL, P268; Pavlin DJ, 1999, ANESTH ANALG, V89, P90, DOI 10.1097/00000539-199907000-00016; Randel G I, 1992, J Clin Anesth, V4, P185, DOI 10.1016/0952-8180(92)90062-6; Rasmussen LS, 2001, ACTA ANAESTH SCAND, V45, P275, DOI 10.1034/j.1399-6576.2001.045003275.x; Rohm KD, 2006, ACTA ANAESTH SCAND, V50, P14, DOI 10.1111/j.1399-6576.2006.00905.x; Schaer H, 1998, ANAESTHESIST, V47, P469, DOI 10.1007/s001010050584; STRICKER K, 1991, ANAESTHESIST, V40, P287; VAN HJ, 1991, ANESTHESIOLOGY, V75, P197; WHITE PF, 1992, ANAESTHESIA ANALG S4, V75, P47; WHITE PF, 1988, ANESTHESIA CLIN N AM, P297	29	1	2	0	2	HEALTH COMMUNICATIONS INC	EDISON	292 FERNWOOD AVE, EDISON, NJ 08837 USA	0741-238X			ADV THER	Adv. Ther.	JAN-FEB	2007	24	1					171	177		10.1007/BF02850005			7	Medicine, Research & Experimental; Pharmacology & Pharmacy	Research & Experimental Medicine; Pharmacology & Pharmacy	164JL	WOS:000246229900019	17526474				2020-06-30	J	Cho, NS; Ha, JH; Rhee, YG				Cho, Nam Su; Ha, Jeong Han; Rhee, Yong Girl			Patient-controlled analgesia after arthroscopic rotator cuff repair - Subacromial catheter versus intravenous injection	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						shoulder; rotator cuff tear; patient-controlled analgesia	CRUCIATE LIGAMENT RECONSTRUCTION; POSTOPERATIVE PAIN-CONTROL; INTRAARTICULAR MORPHINE; SHOULDER SURGERY; KNEE SURGERY; BUPIVACAINE; INFUSION; NARCOTICS; BLOCK	Background: No study has compared pain control results between patient-controlled subacromial infusion and intravenous injection after arthroscopic shoulder surgery. Hypothesis: Subacromial infusion of analgesics are more effective in pain alleviation than intravenous injection. Study Design: Randomized controlled clinical trial; Level of evidence, 2. Methods: The authors prospectively analyzed 40 cases of arthroscopic rotator cuff repair that received patient-controlled analgesia. They divided the 40 cases into 2 groups: subacromial infusion group with 0.5% bupivacaine (group 1, 20 cases) and intravenous injection group with fentanyl and ketorolac tromethamine (group 2, 20 cases). The visual analog scale was used to record the patient's level of pain every 12 hours until postoperative 72 hours and the following 48 hours after the suspension of patient-controlled analgesia. Results: The mean preoperative visual analog scale score during motions was 6.8 in group 1 and 5.8 in group 2. The immediate postoperative visual analog scale score was 7.6 and 7.4, respectively, for each group. At postoperative time periods, most of the scores of subacromial infusion at rest and during motions were lower than those of intravenous injection, but significant differences were not found between groups 1 and 2. Conclusion: Patient-controlled analgesia after arthroscopic rotator cuff repair showed that both subacromial infusion of bupivacaine and intravenous injection of fentanyl and ketorolac tromethamine were equally effective and clinically equivalent pain control methods.	Kyung Hee Univ, Dept Orthopaed Surg, Coll Med, Shoulder & Elbow Clin, Seoul 130702, South Korea; Hallym Univ, Sacred Heart Hosp, Dept Orthopaed Surg, Anyang, South Korea	Rhee, YG (reprint author), Kyung Hee Univ, Dept Orthopaed Surg, Coll Med, Shoulder & Elbow Clin, 1 Hoegi Dong, Seoul 130702, South Korea.	shoulderrhee@hanmail.net	Cho, Nam Su/S-3188-2017	Cho, Nam Su/0000-0003-1643-1641			Barber FA, 1998, ARTHROSCOPY, V14, P130, DOI 10.1016/S0749-8063(98)70030-1; Barber FA, 2002, ARTHROSCOPY, V18, P76, DOI 10.1053/jars.2002.25976; Berde C, 2000, LOCAL ANESTHETICS, P491; BODEN BP, 1994, ARTHROSCOPY, V10, P104, DOI 10.1016/S0749-8063(05)80301-9; DEORIO JK, 1984, J BONE JOINT SURG AM, V66A, P563, DOI 10.2106/00004623-198466040-00011; EDKIN BS, 1995, ARTHROSCOPY, V11, P404, DOI 10.1016/0749-8063(95)90191-4; EGBERT AM, 1990, ARCH INTERN MED, V150, P1897, DOI 10.1001/archinte.150.9.1897; HARRISON DM, 1988, ANESTHESIOLOGY, V68, P454, DOI 10.1097/00000542-198803000-00025; Harvey GP, 2004, ARTHROSCOPY, V20, P451, DOI 10.1016/j.arthro.2004.03.004; Jackson D, 1989, J Intraven Nurs, V12, P42; JAUREGUITO JW, 1995, AM J SPORT MED, V23, P350, DOI 10.1177/036354659502300318; JOSHI GP, 1992, ANAESTHESIA, V47, P627, DOI 10.1111/j.1365-2044.1992.tb02350.x; KHOURY GF, 1992, ANESTHESIOLOGY, V77, P263, DOI 10.1097/00000542-199208000-00007; MATHENY JM, 1993, ARTHROSCOPY, V9, P87, DOI 10.1016/S0749-8063(05)80350-0; Muittari PA, 1999, J CLIN ANESTH, V11, P11, DOI 10.1016/S0952-8180(98)00122-6; Savoie FH, 2000, ARTHROSCOPY, V16, P339, DOI 10.1016/S0749-8063(00)90076-8; Singelyn FJ, 1999, ANESTH ANALG, V89, P1216, DOI 10.1213/00000539-199911000-00024; Speer K P, 1996, J Shoulder Elbow Surg, V5, P62, DOI 10.1016/S1058-2746(96)80032-2; STEIN C, 1991, NEW ENGL J MED, V325, P1123, DOI 10.1056/NEJM199110173251602; Tauro JC, 2004, ARTHROSCOPY, V20, P13, DOI 10.1016/j.arthro.2003.10.013; Tetzlaff JE, 2000, REGION ANESTH PAIN M, V25, P611, DOI 10.1053/rapm.2000.8573; Wolf EM, 2004, ARTHROSCOPY, V20, P5, DOI 10.1016/j.arthro.2003.11.001	22	29	31	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465			AM J SPORT MED	Am. J. Sports Med.	JAN	2007	35	1					75	79		10.1177/0363546506291632			5	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	126EA	WOS:000243493800010	16923824				2020-06-30	J	Sugiura, S; Seki, S; Hidaka, K; Masuoka, M; Tsuchida, H				Sugiura, Soichiro; Seki, Sumihiko; Hidaka, Kohji; Masuoka, Miharu; Tsuchida, Hideaki			The hemodynamic effects of landiolol, an ultra-short-acting beta(1)-selective blocker, on endotracheal intubation in patients with and without hypertension	ANESTHESIA AND ANALGESIA			English	Article							BETA-BLOCKER; TRACHEAL INTUBATION; NONCARDIAC SURGERY; VASCULAR-SURGERY; CARDIAC EVENTS; ONO-1101; ANESTHESIA; INDUCTION; MORTALITY; ATENOLOL	BACKGROUND: The ultra-short-acting beta-selective blocker, landiolol, is widely used in Japan. We investigated the effects of landiolol on intubation-induced adrenergic response in 88 patients. METHODS: General anesthesia was induced and maintained with target-controlled infusion of propofol at an effect-site concentration of 5 mu g/mL. Muscle relaxation was obtained with 0.1 mg/kg vecuronium, and endotracheal intubation was performed 4 min after vecuronium injection. We first investigated the optimal time point for landiolol to be administered before intubation in 43 normotensive patients. Then we examined whether landiolol was as effective as fentanyl to prevent tachycardia after intubation in 45 hypertensive patients. RESULTS: Landiolol at 0.1 mg/kg was most effective against intubation-induced tachycardia when infused 4 min before intubation in normotensive patients. However, 0.2 mg/kg landiolol was necessary to prevent tachycardia after intubation in hypertensive patients. Landiolol had no significant effects on arterial blood pressure or bispectral. index at any dose throughout the study period. In contrast, 2 mu g/kg fentanyl frequently caused hypotension just before and 5 min after intubation. CONCLUSION: Low doses of landiolol can effectively prevent tachycardia after intubation without significant effects on arterial blood pressure.	Kanazawa Med Univ, Dept Anesthesiol & Perioperat Med, Uchinada, Ishikawa 9200293, Japan	Sugiura, S (reprint author), Kanazawa Med Univ, Dept Anesthesiol & Perioperat Med, Daigaku 1-1, Uchinada, Ishikawa 9200293, Japan.	s-sugi@kanazawa-med.ac.jp					Auerbach AD, 2002, JAMA-J AM MED ASSOC, V287, P1435, DOI 10.1001/jama.287.11.1435; BILLARD V, 1994, ANESTHESIOLOGY, V81, P1384, DOI 10.1097/00000542-199412000-00013; Boersma E, 2001, JAMA-J AM MED ASSOC, V285, P1865, DOI 10.1001/jama.285.14.1865; CHAUDHRI S, 1992, ANAESTHESIA, V47, P551, DOI 10.1111/j.1365-2044.1992.tb02321.x; Dzimiri N, 1999, PHARMACOL REV, V51, P465; Esler M, 2000, J CARDIOVASC PHARM, V35, pS1, DOI 10.1097/00005344-200000004-00001; Hirota Kazuyoshi, 2005, J Anesth, V19, P17, DOI 10.1007/s00540-004-0281-1; Hoffman D.J., 2001, GOODMAN GILMANS PHAR, P215; IGUCHI S, 1992, CHEM PHARM BULL, V40, P1462; JENNINGS GL, 1998, J HYPERTENS       S3, V16, P35; Kitamura A, 1997, EUR J CLIN PHARMACOL, V51, P467, DOI 10.1007/s002280050232; Kubo Kozue, 2005, J Anesth, V19, P174, DOI 10.1007/s00540-005-0302-8; LAUBIE M, 1977, N-S ARCH PHARMACOL, V296, P255, DOI 10.1007/BF00498691; Mangano DT, 1996, NEW ENGL J MED, V335, P1713, DOI 10.1056/NEJM199612053352301; Muraki K, 1996, J PHARMACOL EXP THER, V278, P555; Oda Y, 2005, ANESTH ANALG, V100, P733, DOI 10.1213/01.ANE.0000154441.22654.11; Poldermans D, 1999, NEW ENGL J MED, V341, P1789, DOI 10.1056/NEJM199912093412402; Sugiyama A, 1999, J CARDIOVASC PHARM, V34, P70, DOI 10.1097/00005344-199907000-00012; Tsuchida Hideaki, 2003, J Anesth, V17, P154; VANAKEN H, 1988, ANESTHESIOLOGY, V68, P157; Wallace A, 1998, ANESTHESIOLOGY, V88, P7, DOI 10.1097/00000542-199801000-00005; WHITE PF, 1996, ANESTHESIA DRUG MANU; Yamazaki A, 2005, CAN J ANAESTH, V52, P254, DOI 10.1007/BF03016059	23	25	26	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	JAN	2007	104	1					124	129		10.1213/01.ane.0000249044.40819.e5			6	Anesthesiology	Anesthesiology	119US	WOS:000243040100025	17179256				2020-06-30	J	Rashid, RM; Ibrahim, S; Patel, V				Rashid, Rashid M.; Ibrahim, Shariq; Patel, Vikram			Painful pemphigus vulgaris	ANESTHESIA AND ANALGESIA			English	Letter									Loyola Univ, Med Ctr, MD PhD Program, Chicago, IL 60611 USA; Loyola Univ, Med Ctr, Div Pain Management, Dept Anesthesia, Chicago, IL 60611 USA	Rashid, RM (reprint author), Loyola Univ, Med Ctr, MD PhD Program, Chicago, IL 60611 USA.	Rrashid@lumc.edu					Bystryn JC, 2005, LANCET, V366, P61, DOI 10.1016/S0140-6736(05)66829-8; NISENGARD RJ, 1975, ORAL SURG ORAL MED O, V40, P365, DOI 10.1016/0030-4220(75)90421-1; Tirado-Sanchez A, 2006, Allergol Immunopathol (Madr), V34, P10, DOI 10.1157/13084220	3	2	2	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	JAN	2007	104	1					233	233		10.1213/01.ane.0000248172.00969.35			1	Anesthesiology	Anesthesiology	119US	WOS:000243040100090	17179306				2020-06-30	J	Deitch, K; Chudnofsky, CR; Dominici, P				Deitch, Kenneth; Chudnofsky, Carl R.; Dominici, Paul			The utility of supplemental oxygen during emergency department procedural sedation and analgesia with midazolam and fentanyl: A randomized, controlled trial	ANNALS OF EMERGENCY MEDICINE			English	Article; Proceedings Paper	Research Forum of the American-College-of-Emergency-Physicians (ACEP)	SEP 27-28, 2005	Washington, DC	Amer Coll Emergency Phys (ACEP)			TIDAL CARBON-DIOXIDE; CONSCIOUS SEDATION; CLINICAL-TRIAL; CAPNOGRAPHY; PROPOFOL	Study objective: To determine whether supplemental oxygen reduces the incidence of hypoxia by 20% in study patients receiving midazolam and fentanyl for emergency department procedural sedation and analgesia. Methods: Patients were randomized to receive either supplemental oxygen or compressed air by nasal cannula at 2 L per minute. Physicians were blinded to the gas used and end-tidal carbon dioxide (ETCO2) data. Respiratory depression was defined a priori as oxygen saturation less than 90%, ETCO2 level greater than 50 mm Hg, an absolute change from baseline of 10 mm Hg, or loss of the ETCO2 waveform. Results: Of the 80 patients analyzed, 44 received supplemental oxygen and 36 received compressed air. Twenty supplemental oxygen patients and 19 compressed air patients met at least 1 criterion for respiratory depression. Six supplemental oxygen patients and 5 compressed air patients experienced hypoxia (P=.97; effect size 0%; 95% confidence interval -15% to +15%). Fourteen patients in each group met ETCO2 criteria for respiratory depression but were not hypoxic. Physicians identified respiratory depression in 8 of 11 patients who became hypoxic and 0 of 28 patients who met ETCO2 criteria for respiratory depression but who did not become hypoxic. There were no adverse events. Conclusion: Supplemental oxygen did not reduce (or trend toward reducing) the incidence of hypoxia in patients moderately sedated with midazolam and fentanyl. However, our lower-than-expected rate of hypoxia limits the power of this comparison. Blinded capnography frequently identified respiratory depression undetected by the treating physicians.	Albert Einstein Med Ctr, Dept Emergency Med, Philadelphia, PA 19141 USA	Deitch, K (reprint author), Albert Einstein Med Ctr, Dept Emergency Med, Korman B-6,5501 Old York Rd, Philadelphia, PA 19141 USA.	deitchk@einstein.edu		Dominici, Paul/0000-0002-3096-4367			Abramo TJ, 1997, CRIT CARE MED, V25, P1242, DOI 10.1097/00003246-199707000-00029; BOSE EA, 1989, J CLIN MONITOR, V5, P105; Chudnofsky CR, 2006, ROSENS EMERGENCY MED, P2938; De Jonghe B, 2000, INTENS CARE MED, V26, P275, DOI 10.1007/s001340051150; Friesen RH, 1996, J CLIN MONITOR, V12, P155, DOI 10.1007/BF02078136; Gross JB, 2002, ANESTHESIOLOGY, V96, P1004; Hart LS, 1997, PEDIATR EMERG CARE, V13, P189, DOI 10.1097/00006565-199706000-00004; Havel CJ, 1999, ACAD EMERG MED, V6, P989, DOI 10.1111/j.1553-2712.1999.tb01180.x; Hunt GS, 2005, AM J EMERG MED, V23, P299, DOI 10.1016/j.ajem.2005.02.042; Kennedy RM, 1998, PEDIATRICS, V102, P956, DOI 10.1542/peds.102.4.956; MCNULTY SE, 1990, J CLIN MONITOR, V6, P93, DOI 10.1007/BF02828284; Miner JR, 2003, ACAD EMERG MED, V10, P931, DOI 10.1197/S1069-6563(03)00310-5; Miner JR, 2003, ACAD EMERG MED, V10, P638, DOI 10.1197/aemj.10.6.638; Miner JR, 2002, ACAD EMERG MED, V9, P275, DOI 10.1197/aemj.9.4.275; Poirier MP, 1998, AM J EMERG MED, V16, P350, DOI 10.1016/S0735-6757(98)90125-5; PRSTOJEVICH SJ, 1992, J ORAL MAXIL SURG, V50, P37, DOI 10.1016/0278-2391(92)90192-3; SANTHI PB, 1994, SOLVENT EXTR ION EXC, V12, P633, DOI 10.1080/07366299408918229; Symington L, 2006, EMERG MED J, V23, P89, DOI 10.1136/emj.2005.023713; WEINGARTEN M, 1988, PEDIAT DENT, V10, P94; WRIGHT SW, 1992, ANN EMERG MED, V21, P551, DOI 10.1016/S0196-0644(05)82523-5	20	62	63	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644	1097-6760		ANN EMERG MED	Ann. Emerg. Med.	JAN	2007	49	1					1	8		10.1016/j.annemergmed.2006.06.013			8	Emergency Medicine	Emergency Medicine	125NH	WOS:000243448300001	16978741				2020-06-30	J	Greenwald, M; Johanson, CE; Bueller, J; Chang, Y; Moody, DE; Kilbourn, M; Koeppe, R; Zubieta, JK				Greenwald, Mark; Johanson, Chris-Ellyn; Bueller, Joshua; Chang, Yan; Moody, David E.; Kilbourn, Michael; Koeppe, Robert; Zubieta, Jon-Kar			Buprenorphine duration of action: Mu-opioid receptor availability and pharmacokinetic and behavioral indices	BIOLOGICAL PSYCHIATRY			English	Article; Proceedings Paper	65th Annual Meeting of the College-on-Problems-of-Drug-Dependence	JUN 14-19, 2003	Bal Harbour, FL	Coll Problems Drug Dependence		buprenorphine; carfentanil; hydromorphone; mu-opioid receptor; PET; pharmacokinetics	POSITRON-EMISSION-TOMOGRAPHY; HEROIN-DEPENDENT VOLUNTEERS; MAINTAINED RHESUS-MONKEYS; RAT-BRAIN; VENTILATORY RESPONSE; MORPHINE-DEPENDENCE; OPIATE RECEPTORS; SEEKING BEHAVIOR; DOSING REGIMENS; BINDING	Background: Buprenorphine (BUP) is effective in the treatment of opioid dependence when given on alternating days, probably as a result of long-lasting occupation of mu opioid receptors (mu ORs). This study examined the duration of action of BUP at mu CRs and correlations with pharmacokinetic and pharmacodynamic outcomes in 10 heroin-dependent volunteers. Methods: Availability of mu OR (measured with positron emission tomography and [C-11]-carfentanil), plasma BUP concentration, opioid withdrawal symptoms, and blockade of hydromorphone (HYD; heroin-like agonist) effects were measured at 4, 28, 52, and 76 hours after omitting the 16 mg/d dose of BUP in a study reported elsewhere. Results: Relative to heroin-dependent volunteers maintained on BUP placebo, wbole-brain mu OR availability was 30%, 54%, 67%, and 82% at 4, 28, 52, and 76 hours after BUP. Regions of interest showed similar effects. Plasma concentrations of BUP were time dependent, as were withdrawal symptoms, carbon dioxide sensitivity and extent of HYD blockade. Availability of mu OR was also correlated with BUP plasma concentration, withdrawal symptoms, and HYD blockade. Conclusions. Together with our previous findings, it appears that mu OR availability predicts changes in pharmacokinetic and pharmacodynamic measures and that about 50%-60% BUP occupancy is required for adequate withdrawal symptom suppression (in the absence of other opioids) and HYD blockade.	Wayne State Univ, Subst Abuse Res Div, Dept Psychiat & Behav Neurosci, Detroit, MI 48207 USA; Univ Michigan, Mol & Behav Neurosci Inst, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Radiol, Ann Arbor, MI 48109 USA; Univ Utah, Ctr Human Toxicol, Dept Pharmacol & Toxicol, Salt Lake City, UT 84112 USA	Greenwald, M (reprint author), Wayne State Univ, Subst Abuse Res Div, Dept Psychiat & Behav Neurosci, 2761 E Jefferson Ave, Detroit, MI 48207 USA.	mgreen@med.wayne.edu			NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [R01 DA10100, P50 DA00254]		AMASS L, 1994, LIFE SCI, V54, P1215, DOI 10.1016/0024-3205(94)00848-5; BELCHEVA MM, 1993, MOL PHARMACOL, V44, P173; Bencherif B, 2004, BIOL PSYCHIAT, V55, P255, DOI 10.1016/j.biopsych.2003.07.007; Bickel WK, 1999, PSYCHOPHARMACOLOGY, V146, P111, DOI 10.1007/s002130051096; BOLGER GT, 1988, FEBS LETT, V234, P22, DOI 10.1016/0014-5793(88)81294-8; CHEN ZR, 1991, LIFE SCI, V48, P2165, DOI 10.1016/0024-3205(91)90150-A; DANNALS RF, 1985, INT J APPL RADIAT IS, V36, P303, DOI 10.1016/0020-708X(85)90089-4; DAVENPORT KE, 1990, NEUROSCI LETT, V113, P40, DOI 10.1016/0304-3940(90)90491-Q; Eissenberg T, 1997, DRUG ALCOHOL DEPEN, V45, P81, DOI 10.1016/S0376-8716(97)01347-1; First M., 1996, STRUCTURED CLIN INTE; FUDALA PJ, 1990, CLIN PHARMACOL THER, V47, P525, DOI 10.1038/clpt.1990.67; Gorelick DA, 2005, BIOL PSYCHIAT, V57, P1573, DOI 10.1016/j.biopsych.2005.02.026; Greenwald MK, 2006, EXP CLIN PSYCHOPHARM, V14, P52, DOI 10.1037/1064-1297.14.1.52; Greenwald MK, 2005, EXP CLIN PSYCHOPHARM, V13, P3, DOI 10.1037/1064-1297.13.1.3; Greenwald MK, 2004, PHARMACOL BIOCHEM BE, V77, P39, DOI 10.1016/j.pbb.2003.10.003; Greenwald MK, 2002, EXP CLIN PSYCHOPHARM, V10, P39, DOI 10.1037//1064-1297.10.1.39; Greenwald MK, 2003, NEUROPSYCHOPHARMACOL, V28, P2000, DOI 10.1038/sj.npp.1300251; Greenwald MK, 2002, PSYCHOPHARMACOLOGY, V160, P344, DOI 10.1007/s00213-001-0975-0; Greenwald MK, 1999, DRUG ALCOHOL DEPEN, V56, P191, DOI 10.1016/S0376-8716(99)00032-0; GREENWALD MK, IN PRESS HEROIN ADDI; Gross A, 2001, DRUG ALCOHOL DEPEN, V64, P111, DOI 10.1016/S0376-8716(00)00227-1; Hawkinson JE, 2000, EUR J PHARMACOL, V389, P107, DOI 10.1016/S0014-2999(99)00904-8; Heinz A, 2005, ARCH GEN PSYCHIAT, V62, P57, DOI 10.1001/archpsyc.62.1.57; Huang P, 2001, J PHARMACOL EXP THER, V297, P688; JASINSKI DR, 1968, CLIN PHARMACOL THER, V9, P215; JASINSKI DR, 1978, ARCH GEN PSYCHIAT, V35, P501; Jewett DM, 2001, NUCL MED BIOL, V28, P733, DOI 10.1016/S0969-8051(01)00226-8; Johnson RE, 2003, DRUG ALCOHOL DEPEN, V70, pS59, DOI 10.1016/S0376-8716(03)00060-7; JOHNSON RE, 1995, DRUG ALCOHOL DEPEN, V40, P27, DOI 10.1016/0376-8716(95)01189-7; Kling MA, 2000, J PHARMACOL EXP THER, V295, P1070; Kuhlman JJ, 1998, ADDICTION, V93, P549, DOI 10.1080/09652149835747; Lee KO, 1999, EUR J PHARMACOL, V378, P323, DOI 10.1016/S0014-2999(99)00460-4; Lewis JW, 2004, CURR PHARM DESIGN, V10, P717, DOI 10.2174/1381612043453027; Logan J, 1996, J CEREBR BLOOD F MET, V16, P834, DOI 10.1097/00004647-199609000-00008; MARTIN WR, 1969, J PSYCHIAT RES, V7, P9, DOI 10.1016/0022-3956(69)90007-7; Meyer C R, 1997, Med Image Anal, V1, P195, DOI 10.1016/S1361-8415(97)85010-4; MINOSHIMA S, 1992, J NUCL MED, V33, P1579; Moody DE, 2002, ANAL BIOCHEM, V306, P31, DOI 10.1006/abio.2002.5673; Negus SS, 2002, BEHAV PHARMACOL, V13, P557, DOI 10.1097/00008877-200211000-00005; Paronis CA, 1997, J PHARMACOL EXP THER, V282, P355; Paronis CA, 1997, J PHARMACOL EXP THER, V282, P348; Petry NM, 1999, CLIN PHARMACOL THER, V66, P306, DOI 10.1016/S0009-9236(99)70039-1; Petry NM, 2001, ADDICTION, V96, P823, DOI 10.1046/j.1360-0443.2001.9668234.x; READ DJC, 1967, AUSTRALAS ANN MED, V16, P20; REBUCK AS, 1976, CHEST, V70, P118, DOI 10.1378/chest.70.1_Supplement.118; REISINE T, 1996, [No title captured], P521; RICHARDS ML, 1985, EUR J PHARMACOL, V114, P343, DOI 10.1016/0014-2999(85)90379-6; ROSEN MI, 1994, DRUG ALCOHOL DEPEN, V35, P141, DOI 10.1016/0376-8716(94)90121-X; Schuh KJ, 1999, PSYCHOPHARMACOLOGY, V145, P162, DOI 10.1007/s002130051045; Schuster CR, 1995, EXP CLIN PSYCHOPHARM, V3, P424, DOI 10.1037/1064-1297.3.4.424; SCOTT DJ, IN PRESS NEUROPSYCHO; TAO PL, 1987, J PHARMACOL EXP THER, V240, P809; TEMPEL A, 1988, DEV BRAIN RES, V41, P129, DOI 10.1016/0165-3806(88)90176-9; TITELER M, 1989, EUR J PHARMACOL, V167, P221, DOI 10.1016/0014-2999(89)90582-7; ULIBARRI I, 1987, N-S ARCH PHARMACOL, V336, P530; Volkow ND, 1996, P NATL ACAD SCI USA, V93, P10388, DOI 10.1073/pnas.93.19.10388; Wewers ME, 1999, BRAIN RES, V822, P107, DOI 10.1016/S0006-8993(99)01095-1; Wnendt S, 1999, MOL PHARMACOL, V56, P334; Yamamoto T, 2006, J PHARMACOL EXP THER, V318, P206, DOI 10.1124/jpet.105.100859; Zachary RA, 1991, SHIPLEY I LIVING SCA; Zaki PA, 2000, J PHARMACOL EXP THER, V292, P1127; Zubieta JK, 2000, NEUROPSYCHOPHARMACOL, V23, P326, DOI 10.1016/S0893-133X(00)00110-X; Zubieta JK, 1996, NAT MED, V2, P1225, DOI 10.1038/nm1196-1225	63	55	56	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0006-3223	1873-2402		BIOL PSYCHIAT	Biol. Psychiatry	JAN 1	2007	61	1					101	110		10.1016/j.biopsych.2006.04.043			10	Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	120AQ	WOS:000243056200015	16950210				2020-06-30	J	Power, I				Power, I.			Fentanyl HCl iontophoretic transdermal system (ITS): clinical application of iontophoretic technology in the management of acute postoperative pain	BRITISH JOURNAL OF ANAESTHESIA			English	Review						analgesia, patient-controlled; analgesics opioid, fentanyl; iontophoresis, transdermal; pain, postoperative	PATIENT-CONTROLLED ANALGESIA; PLACEBO-CONTROLLED TRIAL; PHARMACOLOGICAL-PROPERTIES; THERAPEUTIC-EFFICACY; LOCAL-ANESTHESIA; DELIVERY; PHARMACOKINETICS; SAFETY; MORPHINE; GUIDELINES	The fentanyl HCl iontophoretic transdermal system (fentanyl ITS) is a novel patient-controlled analgesia (PCA) system that has been approved in the USA and Europe for the management of acute, moderate-to-severe postoperative pain. This system extends the applicability of transdermal drug delivery to acute pain management, allowing patients to self-administer pre-programmed doses of fentanyl non-invasively through the use of iontophoretic technology. Iontophoresis is the process by which an electric current is used to drive ionized drug molecules across the skin and into the systemic circulation. Results of a recent US clinical trial found the fentanyl ITS to provide pain control equivalent to a standard regimen of morphine i.v. PCA, with a similar incidence of opioid-related adverse events. The fentanyl ITS may offer a number of clinical advantages over existing PCA modalities. Its method of drug delivery avoids the risk of complications from needle-related injuries and infection, and its pre-programmed electronics eliminate the potential for manual programming errors and excessive dosing. In addition, the compact size of the system could enable greater patient mobility following surgery. The fentanyl ITS has the potential to become a valuable option in the management of acute postoperative pain.	Univ Edinburgh, Royal Infirm, Edinburgh EH16 4SA, Midlothian, Scotland	Power, I (reprint author), Univ Edinburgh, Royal Infirm, Little France, Edinburgh EH16 4SA, Midlothian, Scotland.	ian.power@ed.ac.uk					ABBOTT PCA, 1997, HLTH DEVICES, V26, P389; *AM PAIN SOC, 2003, [No title captured]; Apfelbaum JL, 2003, ANESTH ANALG, V97, P534, DOI 10.1213/01.ANE.0000068822.10113.9E; ASHBURN MA, 1995, ANESTHESIOLOGY, V82, P1146, DOI 10.1097/00000542-199505000-00009; ASHBURN MA, 1992, J PAIN SYMPTOM MANAG, V7, P27, DOI 10.1016/0885-3924(92)90104-P; Ashburn MA, 2004, ANESTHESIOLOGY, V100, P1573; *AUSTR NEW ZEAL CO, 2005, ACUT PAIN MAN SCI EV; BALLANTYNE JC, 1993, J CLIN ANESTH, V5, P182, DOI 10.1016/0952-8180(93)90013-5; Barry BW, 2001, EUR J PHARM SCI, V14, P101, DOI 10.1016/S0928-0987(01)00167-1; Bertolucci L E, 1982, J Orthop Sports Phys Ther, V4, P103; BEZZANT JL, 1988, J AM ACAD DERMATOL, V19, P869, DOI 10.1016/S0190-9622(88)70247-9; BROOME IJ, 1995, ANAESTHESIA, V50, P300, DOI 10.1111/j.1365-2044.1995.tb04603.x; BROWN CR, 1998, 17 ANN SCI M AM PAIN, P192; Camu F, 1998, ANESTH ANALG, V87, P890, DOI 10.1097/00000539-199810000-00027; Chelly JE, 2005, EXPERT OPIN PHARMACO, V6, P1205, DOI 10.1517/14656566.6.7.1205; Chelly JE, 2004, ANESTH ANALG, V98, P427, DOI 10.1213/01.ANE.0000093314.13848.7E; Curdy C, 2001, J PHARM PHARMACOL, V53, P769, DOI 10.1211/0022357011776117; Dolin SJ, 2002, BRIT J ANAESTH, V89, P409, DOI 10.1093/bja/aef207; DUTHIE DJR, 1988, BRIT J ANAESTH, V60, P614, DOI 10.1093/bja/60.6.614; Francesca F, 2003, EUR UROL, V44, P383, DOI 10.1016/S0302-2838(03)00321-X; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; Gupta SK, 2005, CLIN PHARMACOKINET, V44, P25, DOI 10.2165/00003088-200544001-00005; Gupta SK, 1998, J CLIN PHARMACOL, V38, P951, DOI 10.1002/j.1552-4604.1998.tb04392.x; HOLLEY FO, 1988, BRIT J ANAESTH, V60, P608, DOI 10.1093/bja/60.6.608; *INT ASS STUD PAIN, 1992, MAN ACUT PAIN PRACT; IRSFELD S, 1993, BRIT J ANAESTH, V71, P375, DOI 10.1093/bja/71.3.375; Jeal W, 1997, DRUGS, V53, P109, DOI 10.2165/00003495-199753010-00011; Kalia YN, 2004, ADV DRUG DELIVER REV, V56, P619, DOI 10.1016/j.addr.2003.10.026; Kearns GL, 2003, PEDIATRICS, V112, P578, DOI 10.1542/peds.112.3.578; KILBRIDE M, 1994, DIS COLON RECTUM, V37, P1070, DOI 10.1007/BF02049805; Lehmann LJ, 1997, REGION ANESTH, V22, P24, DOI 10.1016/S1098-7339(06)80052-0; Macintyre PE, 2001, BRIT J ANAESTH, V87, P36, DOI 10.1093/bja/87.1.36; McDonnell A, 2003, J CLIN NURS, V12, P387, DOI 10.1046/j.1365-2702.2003.00748.x; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; Nirschl RP, 2003, AM J SPORT MED, V31, P189; Nolli M, 2000, Minerva Anestesiol, V66, P585; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; *PICK I EUR, 2002, IMPR QUAL HLTH CAR T; Pikal MJ, 2001, ADV DRUG DELIVER REV, V46, P281, DOI 10.1016/S0169-409X(00)00138-1; PLEZIA PM, 1989, PHARMACOTHERAPY, V9, P2; Rawal N, 1999, REGION ANESTH PAIN M, V24, P68, DOI 10.1016/S1098-7339(99)90168-2; Ready LB, 1999, REGION ANESTH PAIN M, V24, P499, DOI 10.1016/S1098-7339(99)90038-X; Rose JB, 2002, ANESTH ANALG, V94, P867, DOI 10.1097/00000539-200204000-00017; ROY SD, 1989, PHARM RES-DORDR, V6, P825, DOI 10.1023/A:1015944018555; Sadler PJ, 1999, BRIT J ANAESTH, V82, P432, DOI 10.1093/bja/82.3.432; Sathyan G, 2005, CLIN PHARMACOKINET, V44, P7, DOI 10.2165/00003088-200544001-00003; Sathyan S, 2005, CLIN PHARMACOKINET, V44, P17, DOI 10.2165/00003088-200544001-00004; Stamer U, 2002, ANAESTHESIST, V51, P248, DOI 10.1007/s00101-002-0288-7; STEPHEN R, 1994, ARTIF ORGANS, V18, P461, DOI 10.1111/j.1525-1594.1994.tb02233.x; Stomberg Margareta Warren, 2003, Pain Manag Nurs, V4, P11, DOI 10.1053/jpmn.2003.3; VARVEL JR, 1989, ANESTHESIOLOGY, V70, P928, DOI 10.1097/00000542-198906000-00008; *VET HLTH ADM, 2004, CLIN PRACT GUID MAN; Vicente KJ, 2003, CAN J ANAESTH, V50, P328, DOI 10.1007/BF03021027; Viscusi ER, 2006, ANESTH ANALG, V102, P188, DOI 10.1213/01.ane.0000183649.58483.77; Viscusi ER, 2004, AM J HEALTH-SYST PH, V61, pS11, DOI 10.1093/ajhp/61.suppl_1.S11; Viscusi ER, 2004, JAMA-J AM MED ASSOC, V291, P1333, DOI 10.1001/jama.291.11.1333; Walder B, 2001, ACTA ANAESTH SCAND, V45, P795, DOI 10.1034/j.1399-6576.2001.045007795.x; Wheatley RG, 2001, BRIT J ANAESTH, V87, P47, DOI 10.1093/bja/87.1.47; 2002, [No title captured], V31, P342	59	35	38	0	5	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0007-0912	1471-6771		BRIT J ANAESTH	Br. J. Anaesth.	JAN	2007	98	1					4	11		10.1093/bja/ael314			8	Anesthesiology	Anesthesiology	117RC	WOS:000242889600003	17158126	Bronze			2020-06-30	J	Marier, JF; Lor, M; Morin, J; Roux, L; Di Marco, M; Morelli, G; Saedder, EA				Marier, Jean-Francois; Lor, Mary; Morin, Josee; Roux, Lionel; Di Marco, Marika; Morelli, Gaetano; Saedder, Eva Aggerholm			Comparative bioequivalence study between a novel matrix transdermal delivery system of fentanyl and a commercially available reservoir formulation	BRITISH JOURNAL OF CLINICAL PHARMACOLOGY			English	Article						fentanyl; matrix transdermal delivery system; performance; pharmacokinetics; safety	PAIN	Aim: To determine the pharmacokinetics, safety and performance of a novel matrix formulation of fentanyl. Methods: Transdermal fentanyl was administered as the novel matrix and the Durogesic((R)) reservoir formulations (24 subjects, 100 mu g h(-1)) in a randomized, fully replicate, four-way crossover study. Serum concentrations of fentanyl were assayed by LC/MS/MS. Pharmacokinetic parameters of fentanyl and performance (adherence and skin irritability) were evaluated. Results: Test/reference ratio (90% confidence intervals) for AUC(0-t), AUC(inf) and C-max were 105.5% (99.4, 112.0), 105.3% (99.3, 111.6) and 111.4% (100.4, 123.6), respectively. Adherence and skin irritability results of the two formulations were similar. Conclusion: The two formulations are expected to result in similar efficacy for the management of severe pain.	NYCOMED, Int Med Affairs, DK-4000 Roskilde, Denmark	Saedder, EA (reprint author), NYCOMED, Int Med Affairs, Langebjerg 1,Postbox 88, DK-4000 Roskilde, Denmark.	amgr@nycomed.com	Saedder, Eva Aggerholm/AAI-8590-2020	Saedder, Eva/0000-0003-4905-1004			FISET P, 1995, ANESTHESIOLOGY, V83, P459, DOI 10.1097/00000542-199509000-00004; Freynhagen R, 2005, J PAIN SYMPTOM MANAG, V30, P289, DOI 10.1016/j.jpainsymman.2005.03.015; Jeal W, 1997, DRUGS, V53, P109, DOI 10.2165/00003495-199753010-00011; Lambropoulos J, 1999, J PHARMACEUT BIOMED, V20, P705, DOI 10.1016/S0731-7085(99)00077-1; Marier JF, 2006, J CLIN PHARMACOL, V46, P642, DOI 10.1177/0091270006286901; MARQUARDT KA, 1995, ANN PHARMACOTHER, V29, P969, DOI 10.1177/106002809502901001; Tan HS, 1999, PHARM SCI TECHNOL TO, V2, P60, DOI 10.1016/S1461-5347(99)00119-4; *US DEP HHS, 1999, SKIN IRR SENS TEST G; *US FOOD DRUG ADM, 2004, SAF AL DRUGS BIOL ME; *US FOOD DRUG ADM, 2005, SAF AL DRUGS BIOL ME; Woodroffe MA, 1997, CAN FAM PHYSICIAN, V43, P268	11	21	23	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0306-5251	1365-2125		BRIT J CLIN PHARMACO	Br. J. Clin. Pharmacol.	JAN	2007	63	1					121	124		10.1111/j.1365-2125.2006.02758.x			4	Pharmacology & Pharmacy	Pharmacology & Pharmacy	113ZU	WOS:000242637300017	16939522	Green Published			2020-06-30	J	Preston, R				Preston, Roanne			The role of combined spinal epidural analgesia for labour: is there still a question?	CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Editorial Material							NEUROLOGICAL COMPLICATIONS; INTRATHECAL SUFENTANIL; BUPIVACAINE; RISK		Univ British Columbia, Dept Anesthesia, BC Womens Hosp, Vancouver, BC V6H 3N1, Canada; Univ British Columbia, Ctr Hlth, Vancouver, BC V6H 3N1, Canada; Univ British Columbia, Dept Anesthesiol Pharmacol & Therapeut, Vancouver, BC V6H 3N1, Canada	Preston, R (reprint author), Univ British Columbia, Dept Anesthesia, BC Womens Hosp, Rm 1Q72,4500 Oak St, Vancouver, BC V6H 3N1, Canada.	rpreston@cw.bc.ca					ABOULEISH A, 1994, CAN J ANAESTH, V41, P575, DOI 10.1007/BF03009995; COLLIS RE, 1995, LANCET, V345, P1413, DOI 10.1016/S0140-6736(95)92602-X; Ferouz F, 1997, ANESTH ANALG, V85, P1088; HARDING SA, 1994, BRIT J ANAESTH, V73, P545, DOI 10.1093/bja/73.4.545; Leighton BL, 1996, ANESTH ANALG, V83, P526, DOI 10.1097/00000539-199609000-00015; Loo CC, 2000, INT J OBSTET ANESTH, V9, P99, DOI 10.1054/ijoa.1999.0347; Lu JK, 1997, ANESTHESIOLOGY, V87, P170, DOI 10.1097/00000542-199707000-00025; MacArthur C, 2002, ANESTHESIOLOGY, V97, P1567; Mardirosoff C, 2002, BJOG-INT J OBSTET GY, V109, P274, DOI 10.1016/S1470-0328(02)01380-0; Moen V, 2004, ANESTHESIOLOGY, V101, P950, DOI 10.1097/00000542-200410000-00021; Norris MC, 2000, INT J OBSTET ANESTH, V9, P3, DOI 10.1054/ijoa.1999.0301; Rofaeel A, 2007, CAN J ANAESTH, V54, P15, DOI 10.1007/BF03021894; Sia A. T., 2003, SMJ Singapore Medical Journal, V44, P464; Simmons SW, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003401.pub3; Van de Velde M, 2004, ANESTH ANALG, V98, P1153, DOI 10.1213/01.ANE.0000101980.34587.66; Wong CA, 2005, NEW ENGL J MED, V352, P655, DOI 10.1056/NEJMoa042573; Wong CA, 2000, ANESTHESIOLOGY, V92, P1553, DOI 10.1097/00000542-200006000-00011	17	11	18	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0832-610X			CAN J ANAESTH	Can. J. Anaesth.-J. Can. Anesth.	JAN	2007	54	1					9	14		10.1007/BF03021893			6	Anesthesiology	Anesthesiology	125VR	WOS:000243471900002	17197462	Bronze			2020-06-30	J	Rofaeel, A; Lilker, S; Fallah, S; Goldszmidt, E; Carvalho, J				Rofaeel, Ayman; Lilker, Suzanne; Fallah, Shafagh; Goldszmidt, Eric; Carvalho, Jose			Intrathecal plain vs hyperbaric bupivacaine for labour analgesia: efficacy and side effects	CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Article; Proceedings Paper	Annual Meeting of the American-Society-of-Anesthesiologists	OCT 22-26, 2005	Atlanta, GA	Amer Soc Anesthesiologists			SPINAL-EPIDURAL ANALGESIA; HEART-RATE CHANGES; FETAL BRADYCARDIA; ANESTHETIC SOLUTIONS; CEREBROSPINAL-FLUID; RATE ABNORMALITIES; SUFENTANIL; FENTANYL; DENSITY; OPIOIDS	Purpose: Baricity is an important determinant of block characteristics of the spinal component of a combined spinal epidural (CSE) for labour analgesia. This study compares the analgesic efficacy and side effects of intrathecally administered plain and hyperbaric bupivacaine (both with fentanyl) during active labour. Methods: Sixty-two women in active labour (cervical dilatation >= 5 cm and pain score > 5) were randomized in a prospective, single-blinded fashion to receive 2.5 mg of either hyperbaric or plain bupivacaine both combined with 15 mu g of fentanyl as the spinal component of a CSE. The primary outcome was failure of satisfactory analgesia within ten minutes of the intrathecal injection as defined by a verbal pain score > 3. Secondary outcomes included need for rescue analgesia, hypotension, respiratory depression, nausea and vomiting, pruritus and sustained fetal bradycardia. Results: Sixty patients were analyzed. The failure rates were 20% in the hyperbaric group vs 0% in the plain group (P = 0.024). The plain solution provided faster onset, higher sensory levels and less motor block at all times during the first 30 min. The incidence of both pruritus and sustained fetal bradycardia was 33% in the plain group and 10% in the hyperbaric group (P = 0.03). Conclusion: A plain rather than hyperbaric solution of bupivacaine 2.5 mg with fentanyl 15 mu g provides a faster onset of analgesia, higher sensory levels and less motor block, while demonstrating an increased incidence of pruritus and sustained fetal bradycardia.	Mt Sinai Hosp, Dept Anesthesia & Pain Management, Toronto, ON M5G 1X5, Canada	Goldszmidt, E (reprint author), Mt Sinai Hosp, Dept Anesthesia & Pain Management, 600 Univ Ave,Suite 1514, Toronto, ON M5G 1X5, Canada.	e.goldszmidt@utoronto.ca					BALLANTYNE JC, 1988, PAIN, V33, P149, DOI 10.1016/0304-3959(88)90085-1; BLOMQVIST H, 1989, REGION ANESTH, V14, P195; CAMPBELL DC, 1995, ANESTH ANALG, V81, P305, DOI 10.1097/00000539-199508000-00017; CLARKE VT, 1994, ANESTHESIOLOGY, V81, P1083, DOI 10.1097/00000542-199410000-00041; COHEN SE, 1993, ANESTH ANALG, V77, P1155; Connolly C, 2001, BRIT J ANAESTH, V86, P805, DOI 10.1093/bja/86.6.805; Cook TM, 2000, ANAESTHESIA, V55, P42, DOI 10.1046/j.1365-2044.2000.01157.x; CRISP T, 1992, GEN PHARMACOL, V23, P1087, DOI 10.1016/0306-3623(92)90291-Q; DAngelo R, 1997, ANESTHESIOLOGY, V87, P166, DOI 10.1097/00000542-199707000-00023; Eisenach JC, 1999, ANESTHESIOLOGY, V91, P299, DOI 10.1097/00000542-199907000-00038; Eltzschig HK, 2003, NEW ENGL J MED, V348, P319, DOI 10.1056/NEJMra021276; Ferouz F, 1997, ANESTHESIOLOGY, V86, P592, DOI 10.1097/00000542-199703000-00010; Gage JC, 1997, ANESTH ANALG, V85, P826, DOI 10.1097/00000539-199710000-00020; Gambling DR, 1998, ANESTHESIOLOGY, V89, P1336, DOI 10.1097/00000542-199812000-00010; GOURLAY GK, 1989, PAIN, V38, P253, DOI 10.1016/0304-3959(89)90210-8; GREENE NM, 1985, ANESTH ANALG, V64, P715; Hallworth SP, 2002, ANESTH ANALG, V94, P1621, DOI 10.1097/00000539-200206000-00048; HAMILTON CL, 1995, ANESTHESIOLOGY, V83, P1118, DOI 10.1097/00000542-199511000-00028; Hocking G, 2004, BRIT J ANAESTH, V93, P568, DOI 10.1093/bja/aeh204; Lui ACP, 1998, CAN J ANAESTH, V45, P297, DOI 10.1007/BF03012018; Mardirosoff C, 2002, BJOG-INT J OBSTET GY, V109, P274, DOI 10.1016/S1470-0328(02)01380-0; McLeod GA, 2004, BRIT J ANAESTH, V92, P547, DOI 10.1093/bja/aeh094; Nielsen PE, 1996, ANESTH ANALG, V83, P742, DOI 10.1097/00000539-199610000-00014; Norris MC, 2000, INT J OBSTET ANESTH, V9, P264, DOI 10.1054/ijoa.2000.0746; PAEZ JC, 2003, ANESTHESIOLOGY, V99, pA1198; Palmer CM, 1999, ANESTH ANALG, V88, P577, DOI 10.1097/00000539-199903000-00021; Rawal N, 2000, Anesthesiol Clin North Am, V18, P267, DOI 10.1016/S0889-8537(05)70164-4; Richardson MG, 1997, ANESTH ANALG, V84, P95, DOI 10.1097/00000539-199701000-00018; Richardson MG, 1996, ANESTHESIOLOGY, V85, P326, DOI 10.1097/00000542-199608000-00014; Schiffer E, 2002, ANESTHESIOLOGY, V96, P1325, DOI 10.1097/00000542-200206000-00010; Segal S, 1998, ANESTH ANALG, V87, P864, DOI 10.1097/00000539-199810000-00022; SHENNAN A, 1995, BRIT J OBSTET GYNAEC, V102, P192, DOI 10.1111/j.1471-0528.1995.tb09093.x; STIENSTRA R, 1988, ANESTH ANALG, V67, P272; Teoh WHL, 2003, ANESTH ANALG, V97, P873, DOI 10.1213/01.ANE.0000076388.17223.37; THOMAS DA, 1993, ANESTHESIOLOGY, V79, P548, DOI 10.1097/00000542-199309000-00019; Van de Velde M, 2004, ANESTH ANALG, V98, P1153, DOI 10.1213/01.ANE.0000101980.34587.66; Van de Velde M, 2001, REGION ANESTH PAIN M, V26, P257, DOI 10.1053/rapm.2001.22258	37	19	20	0	0	CANADIAN ANESTHESIOLOGISTS SOC	TORONTO	1 EGLINTON AVE EAST, SUITE 208, TORONTO, ONTARIO M4P 3A1, CANADA	0832-610X			CAN J ANAESTH	Can. J. Anaesth.-J. Can. Anesth.	JAN	2007	54	1					15	20		10.1007/BF03021894			6	Anesthesiology	Anesthesiology	125VR	WOS:000243471900003	17197463	Bronze			2020-06-30	J	Ugur, B; Ogurlu, M; Gezer, E; Aydin, ON; Gursoy, F				Ugur, Bakiye; Ogurlu, Mustafa; Gezer, Erdal; Aydin, Osman Nuri; Gursoy, Feray			Effects of esmolol, lidocaine and fentanyl on haemodynamic responses to endotracheal intubation - A comparative study	CLINICAL DRUG INVESTIGATION			English	Article							LOW-DOSE FENTANYL; TRACHEAL INTUBATION; CARDIOVASCULAR-RESPONSE; INTRAVENOUS LIDOCAINE; GERIATRIC-PATIENTS; PRESSOR-RESPONSE; STRESS-RESPONSE; LARYNGOSCOPY; INDUCTION	Background and objective: Predicting the haemodynamic changes that may result in myocardial ischaemia for patients undergoing laryngoscopy and tracheal intubation will help to avoid events that trigger ischaemia and allow immediate treatment. The objective of this study was to compare the effects of esmolol with those of lidocaine (lignocaine) and fentanyl on prevention of tachycardia and hypertension caused by endotracheal intubation. Methods: This was a prospective, randomised, double-blind study. The study was conducted at the Adnan Menderes University Hospital in Aydin, Turkey and involved 120 patients of American Society of Anesthesiologists physical status I or II aged 20-50 years. The patients were randomised into four equal groups. The control group (group C) received dextrose 5% 5mL, the esmolol group (group E) received esmolol 1.5 mg/kg, the fentanyl group (group F) received fentanyl 1 mu g/kg and the lidocaine group (group C) received lidocaine 1.5 mg/kg 2 minutes before endotracheal intubation. Heart rate (HR), mean arterial pressure (MAP) and rate-pressure product (RPP) were recorded before and after induction of anaesthesia, immediately after intubation, and 1, 3, 5, 7 and 10 minutes after intubation. Results: Compared with control, HR decreased significantly in group E after induction, immediately after intubation and I minute after intubation (p < 0.0083). In group F there was an increase in MAP immediately after intubation, but the increase was less than in other groups. Compared with control, RPP decreased significantly in groups E and F after induction, immediately after intubation and 1 minute after intubation (p < 0.0083). RPP was significantly lower in group E than in controls and group L3 minutes after intubation (p < 0.0083), and it was significantly lower in group F than in controls 10 minutes after intubation (p < 0.0083). Conclusion: It can be concluded that administration of esmolol 1.5 mg/kg 2 minutes before intubation prevents tachycardia and an increase in RPP caused by laryngoscopy and tracheal intubation, and can be beneficial when administered before laryngoscopy and tracheal intubation in patients with tachyeardia.	Adnan Menderes Univ, Tip Fak, Anesteziyoloji & Reanimasyon Anabilim Dali, TR-09100 Aydin, Turkey	Ogurlu, M (reprint author), Adnan Menderes Univ, Tip Fak, Anesteziyoloji & Reanimasyon Anabilim Dali, TR-09100 Aydin, Turkey.	drmustafaogurlu@yahoo.com					ABOUMADI MN, 1977, CAN ANAESTH SOC J, V24, P12; Adachi YU, 2002, ANESTH ANALG, V95, P233, DOI 10.1097/00000539-200207000-00043; Barak M, 2003, J CLIN ANESTH, V15, P132, DOI 10.1016/S0952-8180(02)00514-7; BARASH PG, 1997, HDB CLIN ANESTHESIA, P115; BEDFORD RF, 1984, ACTA ANAESTH SCAND, V28, P563, DOI 10.1111/j.1399-6576.1984.tb02120.x; Bensky K P, 2000, AANA J, V68, P437; CHRAEMMERJORGENSEN B, 1986, ANESTH ANALG, V65, P1037; CHUNG F, 1985, CAN ANAESTH SOC J, V32, P622, DOI 10.1007/BF03011409; DAHLGREN N, 1981, ANAESTHESIA, V36, P1022, DOI 10.1111/j.1365-2044.1981.tb08676.x; Ebert T J, 1990, J Clin Anesth, V2, P243; Feng C K, 1996, Acta Anaesthesiol Sin, V34, P61; FOX EJ, 1977, ANESTHESIOLOGY, V47, P524, DOI 10.1097/00000542-197712000-00013; HABBERG J, 1999, ANESTHESIA PERIOPERA, P4; HELFMAN SM, 1991, ANESTH ANALG, V72, P482; HIMES RS, 1977, ANESTHESIOLOGY, V47, P437, DOI 10.1097/00000542-197711000-00010; KAPLAN JA, 1987, CARDIAC ANESTHESIA, P261; KAUTTO UM, 1982, ACTA ANAESTH SCAND, V26, P217, DOI 10.1111/j.1399-6576.1982.tb01757.x; KAYHAN Z, 2004, Z ENDOTRAKEAL ENTUBA; Kim NS, 2002, ANAESTHESIA, V57, P227, DOI 10.1046/j.0003-2409.2001.02407.x; Korpinen R, 1998, Acta Anaesthesiol Belg, V49, P123; Kumar S, 2003, INDIAN J ANAESTH, V47, P41; LARSON CP, 2002, CLIN ANAESTHESIOL, P50; MARTIN DE, 1982, ANESTH ANALG, V61, P680; MESSERLI FH, 1996, CARDIOVASCULAR DRUG; MILLER CD, 1990, BRIT J ANAESTH, V65, P216, DOI 10.1093/bja/65.2.216; Parnass S M, 1990, J Clin Anesth, V2, P232, DOI 10.1016/0952-8180(90)90102-9; Pathak D, 1990, J Clin Anesth, V2, P81, DOI 10.1016/0952-8180(90)90058-B; Rathore A, 2002, INDIAN J ANAESTH, V46, P449; REICH DL, 1999, CARDIAC ANESTHESIA, P321; REVES JG, 2002, CLIN ANAESTHESIOL, P193; ROY WL, 1979, ANESTHESIOLOGY, V51, P393, DOI 10.1097/00000542-197911000-00005; Samaha T, 1996, ANN FR ANESTH, V15, P36, DOI 10.1016/0750-7658(96)89400-7; SINGH H, 1995, J CLIN ANESTH, V7, P5, DOI 10.1016/0952-8180(94)00013-T; SINTETOS AL, 1987, CLIN PHARMACOL THER, V41, P112, DOI 10.1038/clpt.1987.19; SPLINTER WM, 1989, CAN J ANAESTH, V36, P370, DOI 10.1007/BF03005332; TAM S, 1987, ANESTH ANALG, V66, P1036; Tan PH, 2002, ANAESTHESIA, V57, P1207, DOI 10.1046/j.1365-2044.2002.02624_4.x; THOMSON IR, 1989, CAN J ANAESTH, V36, P367, DOI 10.1007/BF03005331; Zalunardo MP, 2001, ANAESTHESIST, V50, P21, DOI 10.1007/s001010050958	39	24	33	0	4	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	1173-2563	1179-1918		CLIN DRUG INVEST	Clin. Drug Invest.		2007	27	4					269	277		10.2165/00044011-200727040-00006			9	Pharmacology & Pharmacy	Pharmacology & Pharmacy	161YB	WOS:000246051900006	17358099				2020-06-30	J	Darwish, M; Kirby, M; Robertson, P; Tracewell, W; Jiang, JG				Darwish, Mona; Kirby, Mary; Robertson, Philmore; Tracewell, William; Jiang, John G.			Absorption of fentanyl from fentanyl buccal tablet in cancer patients with or without oral mucositis - A pilot study	CLINICAL DRUG INVESTIGATION			English	Article							BREAKTHROUGH PAIN; CHEMOTHERAPY; VOLUNTEERS; THERAPY	Background and objectives: Patients with cancer, particularly those undergoing chemotherapy or radiotherapy, may develop oral mucositis. This is the first study to investigate the absorption profile of fentanyl buccal tablet (FBT) - an effervescent formulation of fentanyl indicated for the management of breakthrough pain in opioid-tolerant cancer patients - in patients with or without oral mucositis. Methods: In this open-label study, patients with or without oral mucositis self-administered a single 200 mu g dose of FBT by placing the tablet between the upper gum and cheek above a molar tooth. Venous blood samples for measurement of plasma fentanyl concentrations were collected at regular intervals up to 8 hours following FBT administration. Parameters of interest included maximum plasma concentration (C-max), time to reach Cmax (t(max)), area under the plasma concentration-time curve from time zero to 8 hours (AUC(8)), and AUC from time zero to the median tmax (AUC(tmax')). Adverse events were monitored throughout the study. Oral mucosal examinations and measurements of vital signs were performed at intervals up to 8 hours following FBT administration. Results: Sixteen patients, 8 with and 8 without oral mucositis, received FBT and completed the study. The severity of oral mucositis was mild in the patients exhibiting this condition. Median Cmax values were comparable: 1.14 ng/mL (range 0.26-2.69 ng/mL) in patients with mucositis, and 1.21 ng/mL (range 0.21-2.34 ng/mL) in patients without mucositis. The tmax was not significantly different in the two groups: median tmax was 25.0 min (range 15-45 min) in patients with mucositis and 22.5 min (range 10-121 min) in patients without mucositis. Median AUCtmax' values were 0.17ng center dot h/mL (range 0.04-0.52 ng center dot h/mL) in patients with mucositis, and 0.20 ng center dot h/mL (range 0.00-0.65 ng 9 h/mL) in patients without mucositis. The corresponding AUC8 values were 2.05 ng center dot h/mL (range 1.16-3.83 ng center dot h/mL) and 1.55 ng center dot h/mL (range 0.74-3.07 ng 9 h/mL), respectively. FBT was generally well tolerated in this small group. No application site adverse events or changes in oral mucosal assessments were reported. Conclusion: The absorption profile of a single dose of FBT 200 mu g was similar in patients with or without mild oral mucositis. The compound was generally well tolerated.	Cephalon Inc, Frazer, PA 19355 USA; Cephalon Inc, W Chester, PA USA	Darwish, M (reprint author), Cephalon Inc, Frazer, PA 19355 USA.	mdarwish@cephalon.com					BENNETT D, 2005, [No title captured], V30, P296; BERGER A, 1995, J PAIN SYMPTOM MANAG, V10, P243, DOI 10.1016/0885-3924(94)00130-D; Berger A M, 1998, Oncol Nurs Forum, V25, P1623; Borbasi Sally, 2002, Oncol Nurs Forum, V29, P1051, DOI 10.1188/02.ONF.1051-1057; *CTCAE, 2003, [No title captured]; Darwish M, 2006, CLIN THER, V28, P707, DOI 10.1016/j.clinthera.2006.05.015; Darwish M, 2005, CLIN PHARMACOKINET, V44, P1279, DOI 10.2165/00003088-200544120-00006; Durfee S, 2006, AM J DRUG DELIV, V4, P1, DOI DOI 10.2165/00137696-200604010-00001; GIBALDI M, 1982, PHARMACOKINETICS, pCH11; Kwong KKF, 2004, CANCER NURS, V27, P183, DOI 10.1097/00002820-200405000-00003; Lesage, 1999, Cancer Control, V6, P136; Ohrn KEO, 2001, SUPPORT CARE CANCER, V9, P247, DOI 10.1007/s005200000214; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Sonis ST, 1998, ORAL ONCOL, V34, P39, DOI 10.1016/S1368-8375(97)00053-5; Wardley AM, 2000, BRIT J HAEMATOL, V110, P292, DOI 10.1046/j.1365-2141.2000.02202.x	16	23	27	0	2	ADIS INT LTD	AUCKLAND	41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW ZEALAND	1173-2563			CLIN DRUG INVEST	Clin. Drug Invest.		2007	27	9					605	611		10.2165/00044011-200727090-00002			7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	209AC	WOS:000249359500002	17705569				2020-06-30	J	Yassen, A; Ofsen, E; Romberg, R; Sarton, E; Teppema, L; Danhof, M; Dahan, A				Yassen, A.; Ofsen, E.; Romberg, R.; Sarton, E.; Teppema, L.; Danhof, M.; Dahan, A.			Mechanism-based PK/PD modeling of the respiratory depressant effect of buprenorphine and fentanyl in healthy volunteers	CLINICAL PHARMACOLOGY & THERAPEUTICS			English	Article							COMPARATIVE PHARMACODYNAMICS; RATS; BINDING; NORBUPRENORPHINE; HUMANS; BRAIN; PHARMACOLOGY; ANALGESIA; KINETICS; MORPHINE	The objective of this study was to characterize the pharmacokinetic/pharmacodynamic (PK/PD) relationship of buprenorphine and fentanyl for the respiratory depressant effect in healthy volunteers. Data on the time course of the ventilatory response at a fixed PETCO2 of 50 mm Hg and PETO2 Of 110 mm Hg following intravenous administration of buprenorphine and fentanyl were obtained from two phase I studies (50 volunteers received buprenorphine: 0.05-0.6 mg/70 kg and 24 volunteers received fentanyl: 0.075-0.5 mg/70 kg). The PK/PD correlations were analyzed using nonlinear mixed effects modeling. A two- and three-compartment pharmacokinetic model characterized the time course of fentanyl and buprenorphine concentration, respectively. Three structurally different PK/PD models were evaluated for their appropriateness to describe the time course of respiratory depression: (1) a biophase distribution model with a fractional sigmoid Ea. pharmacodynamic model, (2) a receptor association/dissociation model with a linear transduction function, and (3) a combined biophase distribution-receptor association/dissociation model with a linear transduction function. The results show that for fentanyl hysteresis is entirely determined by the biophase distribution kinetics, whereas for buprenorphine hysteresis is caused by a combination of biophase distribution kinetics and receptor association/dissociation kinetics. The half-time values of biophase equilibration (t(1/2,keo)) were 16.4 and 75.3 min for fentanyl and buprenorphine, respectively. In addition, for buprenorphine, the value of k(on) was 0.246 ml/ng/min and the value of k(off) was 0.0102 min(-1). The concentration-effect relationship of buprenorphine was characterized by a ceiling effect at higher concentrations (intrinsic activity alpha = 0.56, 95% confidence interval (CI): 0.50-0.62), whereas fentanyl displayed full respiratory depressant effect (alpha = 0.91, 915% CI: 0.19-1.62).	Leiden Amsterdam Ctr Drug Res, Dept Pharmacol, Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Anesthesiol, NL-2300 RA Leiden, Netherlands	Danhof, M (reprint author), Leiden Amsterdam Ctr Drug Res, Dept Pharmacol, Leiden, Netherlands.	m.danhof@chem.leidenuniv.nl	Dahan, Albert/B-8845-2008	Dahan, Albert/0000-0003-3161-3945			ARIENS EJ, 1954, ARCH INT PHARMACOD T, V99, P32; BAXTER AD, 1994, CAN J ANAESTH, V41, P87, DOI 10.1007/BF03009796; BEAL SL, 1999, NONMEM USERS GUIDE; BJORKMAN S, 1990, ANESTHESIOLOGY, V72, P865, DOI 10.1097/00000542-199005000-00017; BLACK JW, 1983, PROC R SOC SER B-BIO, V220, P141, DOI 10.1098/rspb.1983.0093; BOAS RA, 1985, BRIT J ANAESTH, V57, P192, DOI 10.1093/bja/57.2.192; CLARK AJ, 1937, HEFFNERS HDB EXPT PH, V4, P38; COWAN A, 1977, BRIT J PHARMACOL, V60, P547, DOI 10.1111/j.1476-5381.1977.tb07533.x; Dahan A, 2001, ANESTHESIOLOGY, V94, P824, DOI 10.1097/00000542-200105000-00021; DAHAN A, 1990, J PHYSIOL-LONDON, V428, P485, DOI 10.1113/jphysiol.1990.sp018223; Dahan A, 1998, ANESTHESIOLOGY, V88, P903, DOI 10.1097/00000542-199804000-00009; Dahan A, 2005, BRIT J ANAESTH, V94, P825, DOI 10.1093/bja/aei145; Dutta S, 1998, BRIT J ANAESTH, V81, P422, DOI 10.1093/bja/81.3.422; Ette EL, 2003, J CLIN PHARMACOL, V43, P610, DOI 10.1177/0091270003253624; GAL TJ, 1989, CLIN PHARMACOL THER, V45, P66, DOI 10.1038/clpt.1989.10; Galynker I, 1996, NUCL MED BIOL, V23, P325, DOI 10.1016/0969-8051(95)02087-X; Henthorn TK, 1999, J PHARMACOL EXP THER, V289, P1084; Huang P, 2001, J PHARMACOL EXP THER, V297, P688; Jonsson EN, 1999, COMPUT METH PROG BIO, V58, P51; Lee KO, 1999, EUR J PHARMACOL, V378, P323, DOI 10.1016/S0014-2999(99)00460-4; LING GSF, 1985, J PHARMACOL EXP THER, V232, P149; MANDEMA JW, 1992, J PHARMACOKINET BIOP, V20, P511, DOI 10.1007/BF01061469; Meert TF, 2005, PHARMACOL BIOCHEM BE, V80, P309, DOI 10.1016/j.pbb.2004.12.002; OHTANI M, 1995, J PHARMACOL EXP THER, V272, P505; Ohtani M, 1997, J PHARMACOL EXP THER, V281, P428; *PHARM PRESS, 2006, CLARK AN DRUG POIS; Radbruch L, 2003, INT J CLIN PRACT, P19; SCOTT JC, 1991, ANESTHESIOLOGY, V74, P34, DOI 10.1097/00000542-199101000-00007; Selley DE, 1997, MOL PHARMACOL, V51, P87; SHEINER LB, 1979, CLIN PHARMACOL THER, V25, P358; Shimada S, 1996, BIOL PHARM BULL, V19, P430; VILLIGER JW, 1982, J NEUROCHEM, V38, P1771, DOI 10.1111/j.1471-4159.1982.tb06662.x; WALSH SL, 1994, CLIN PHARMACOL THER, V55, P569, DOI 10.1038/clpt.1994.71; Yassen A, 2005, J PHARMACOL EXP THER, V313, P1136, DOI 10.1124/jpet.104.082560; Yassen A, 2006, J PHARMACOL EXP THER, V319, P682, DOI 10.1124/jpet.106.107953; Yassen A, 2006, ANESTHESIOLOGY, V104, P1232, DOI 10.1097/00000542-200606000-00019	36	56	57	1	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0009-9236	1532-6535		CLIN PHARMACOL THER	Clin. Pharmacol. Ther.	JAN	2007	81	1					50	58		10.1038/sj.clpt.6100025			9	Pharmacology & Pharmacy	Pharmacology & Pharmacy	117LI	WOS:000242874200017	17185999				2020-06-30	J	Ray, DC; McKeown, DW				Ray, David Charles; McKeown, Dermot William			Effect of induction agent on vasopressor and steroid use, and outcome in patients with septic shock	CRITICAL CARE			English	Article							RELATIVE ADRENAL INSUFFICIENCY; RAPID-SEQUENCE INTUBATION; MULTIPLE TRAUMA PATIENTS; INTENSIVE-CARE-UNIT; ENDOTRACHEAL INTUBATION; AIRWAY MANAGEMENT; CORTISOL-LEVELS; SEVERE SEPSIS; RISK-FACTORS; ILL PATIENTS	Introduction In seriously ill patients, etomidate gives cardiovascular stability at induction of anaesthesia, but there is concern over possible adrenal suppression. Etomidate could reduce steroid synthesis and increase the need for vasopressor and steroid therapy. The outcome could be worse than in patients given other induction agents. Methods We reviewed 159 septic shock patients admitted to our intensive care unit ( ICU) over a 40-month period to study the association between induction agent and clinical outcome, including vasopressor, inotrope, and steroid therapy. From our records, we retrieved induction agent use; vasopressor administration at induction; vasopressor, inotrope, and steroid administration in the ICU; and hospital outcome. Results Hospital mortality was 65%. The numbers of patients given an induction agent were 74, etomidate; 25, propofol; 26, thiopental; 18, other agent; and 16, no agent. Vasopressor, inotrope, or steroid administration and outcome were not related to the induction agent chosen. Corticosteroid therapy given to patients who received etomidate did not affect outcome. Vasopressor therapy was required less frequently and in smaller doses when etomidate was used to induce anaesthesia. We found no evidence that either clinical outcome or therapy was affected when etomidate was used. Etomidate caused less cardiovascular depression than other induction agents in patients with septic shock. Conclusion Etomidate use for critically ill patients should consider all of these issues and not simply the possibility of adrenal suppression, which may not be important when steroid supplements are used.	Royal Infirm, Dept Anaesthesia Crit Care & Pain Med, Edinburgh EH16 4SA, Midlothian, Scotland	Ray, DC (reprint author), Royal Infirm, Dept Anaesthesia Crit Care & Pain Med, Little France Crescent, Edinburgh EH16 4SA, Midlothian, Scotland.	david.ray@luht.scot.nhs.uk		Ray, David/0000-0002-4739-6773			Absalom A, 1999, ANAESTHESIA, V54, P861; Angus DC, 2001, CRIT CARE MED, V29, P1303, DOI 10.1097/00003246-200107001-00035; Annane D, 2003, AM J RESP CRIT CARE, V168, P165, DOI 10.1164/rccm.2201087; Annane D, 2005, INTENS CARE MED, V31, P1454, DOI 10.1007/s00134-005-2755-5; Annane D, 2005, INTENS CARE MED, V31, P325, DOI 10.1007/s00134-005-2560-1; Annane D, 2004, BRIT MED J, V329, P480, DOI 10.1136/bmj.38181.482222.55; Annane D, 2000, JAMA-J AM MED ASSOC, V283, P1038, DOI 10.1001/jama.283.8.1038; Annane D, 2002, JAMA-J AM MED ASSOC, V288, P862, DOI 10.1001/jama.288.7.862; Arbous MS, 2001, ANAESTHESIA, V56, P1141, DOI 10.1046/j.1365-2044.2001.02051.x; Benson M, 2000, J CLIN MONITOR COMP, V16, P183, DOI 10.1023/A:1009937510028; Bergen Joseph M., 1997, Journal of Emergency Medicine, V15, P221, DOI 10.1016/S0736-4679(96)00350-2; Bloomfield R, 2006, BRIT J ANAESTH, V97, P116, DOI 10.1093/bja/ael124; Bloomfield R, 2006, CRIT CARE, V10, DOI 10.1186/cc5020; Cooper MS, 2003, NEW ENGL J MED, V348, P727, DOI 10.1056/NEJMra020529; Dellinger RP, 2003, CRIT CARE MED, V31, P946, DOI 10.1097/01.CCM.0000057403.73299.A6; den Brinker M, 2005, J CLIN ENDOCR METAB, V90, P5110, DOI 10.1210/jc.2005-1107; DIAGO MC, 1988, ANAESTHESIA, V43, P644, DOI 10.1111/j.1365-2044.1988.tb04148.x; DUTHIE DJR, 1985, BRIT J ANAESTH, V57, P156, DOI 10.1093/bja/57.2.156; Friedman G, 1998, CRIT CARE MED, V26, P2078, DOI 10.1097/00003246-199812000-00045; Jaber S, 2006, CRIT CARE MED, V34, P2355, DOI 10.1097/01.CCM.0000233879.58720.87; Jackson WL, 2005, CHEST, V127, P1031, DOI 10.1378/chest.127.3.1031; KEH D, 2006, [No title captured], V5, P138; LEDINGHAM IM, 1983, LANCET, V1, P1270; Leibowitz AB, 2006, CRIT CARE MED, V34, P2497, DOI 10.1097/01.CCM.0000235993.47514.8F; Malerba G, 2005, INTENS CARE MED, V31, P388, DOI 10.1007/s00134-004-2550-8; Marik PE, 2003, CRIT CARE MED, V31, P141, DOI 10.1097/00003246-200301000-00022; MCCOLLUM JSC, 1986, ANAESTHESIA, V41, P995, DOI 10.1111/j.1365-2044.1986.tb12740.x; Mohammad Z, 2006, CRIT CARE, V10, DOI 10.1186/cc4979; Morris C, 2005, ANAESTHESIA, V60, P737, DOI 10.1111/j.1365-2044.2005.04325.x; Murray H, 2005, CHEST, V127, P707, DOI 10.1378/chest.127.3.707; Oglesby AJ, 2004, EMERG MED J, V21, P655, DOI 10.1136/emj.2003.009043; Pizarro CF, 2005, CRIT CARE MED, V33, P855, DOI 10.1097/01.CCM.0000159854.23324.84; Reich DL, 2005, ANESTH ANALG, V101, P622, DOI 10.1213/01.ANE.0000175214.38450.91; Reynolds SF, 2005, CHEST, V127, P1397, DOI 10.1378/chest.127.4.1397; SCHWARTZ DE, 1995, ANESTHESIOLOGY, V82, P367, DOI 10.1097/00000542-199502000-00007; Siraux V, 2005, CRIT CARE MED, V33, P2479, DOI 10.1097/01.CCM.0000185641.87051.7C; Sprung J, 2000, ANESTH ANALG, V91, P68, DOI 10.1097/00000539-200007000-00014; WAGNER RL, 1984, NEW ENGL J MED, V310, P1415, DOI 10.1056/NEJM198405313102202; WATT I, 1984, ANAESTHESIA, V39, P973, DOI 10.1111/j.1365-2044.1984.tb08885.x; YOUNG SP, 2005, ANAESTHESIA, V60, P737	40	60	62	0	1	BIOMED CENTRAL LTD	LONDON	MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND	1466-609X			CRIT CARE	Crit. Care		2007	11	3							R58	10.1186/cc5916			8	Critical Care Medicine	General & Internal Medicine	185PM	WOS:000247722900005	17506873	DOAJ Gold, Green Published			2020-06-30	J	Portenoy, RK; Messina, J; Xie, F; Peppin, J				Portenoy, Russell K.; Messina, John; Xie, Fang; Peppin, John			Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study	CURRENT MEDICAL RESEARCH AND OPINION			English	Article; Proceedings Paper	ASRA Annual Pain Medicine Meeting and Workshop	NOV 16-19, 2006	San Francisco, CA	ASRA		breakthrough pain; fentanyl buccal tablet (FBT); low back pain; nonmalignant chronic pain; opioids	HEALTHY ADULT VOLUNTEERS; CANCER PAIN; DOSE PROPORTIONALITY; ORAL MORPHINE; OPEN-LABEL; MU-G; CITRATE; PREVALENCE; DISEASES; TRIAL	Background: Short-acting opioids are commonly used to treat breakthrough pain ( BTP) and rapid-onset formulations are being developed to improve the effectiveness of this approach. Fentanyl buccal tablet ( FBT) is a new formulation of fentanyl that enhances transbuccal drug delivery via an effervescent reaction and may provide relatively rapid-onset analgesia. FBT was evaluated for BTP in opioid-treated patients with chronic low back pain - the first such study in a population with chronic non-cancer pain. Design: Randomized, double-blind, placebo-controlled. Patients and setting: Patients with chronic low back pain receiving long-term opioid therapy at 16 pain treatment centers in the United States. Procedures: Following open-label titration to identify an effective FBT dose, patients were randomly assigned to one of three double-blind dose sequences ( six doses of FBT, three placebo) to treat nine BTP episodes. Pain intensity ( PI), measured on an 11-point scale ( 0 = no pain; 10 = worst pain), and other outcomes were assessed for 2 h after dosing. Data analysis: The primary efficacy measure was the sum of pain intensity differences ( PIDs) for the first 60 min ( SPID60); secondary efficacy measures included PIDs at other time points, pain relief ( PR), meaningful PR, time to meaningful PR, use of supplementary BTP medication, and self/investigator-reported adverse events. Results: Of the 124 patients screened, 10 patients were enrolled, 84 identified an effective FBT dose, and 77 entered the double-blind phase. SPID60 significantly favored FBT ( p < 0.0001). All secondary measures also favored FBT, with PIDs and PR showing significant differences versus placebo as early as 10 and 1 min, respectively. An improvement in PI score of >= 33% occurred in a significantly larger proportion of FBT-treated episodes versus placebo from 1 min ( 20% vs. 11%, p < 0.01) through 2 h ( 65% vs. 28%, p < 0.0001). Patients were approximately four times more likely to require supplemental opioids for BTP episodes following administration of placebo compared with episodes treated with FBT. AEs were typical for opioids, and were mostly reported during dose titration. Limitations of this study may be related to its open-label dose-titration phase ( which has the potential to compromise blinding) and the recruitment of patients from pain clinics, which could potentially yield a study population that is not representative of the general population with BTP. Conclusions: FBT was efficacious and well tolerated in the treatment of BTP in opioid-treated patients with chronic low back pain.	Beth Israel Med Ctr, Dept Pain Med & Palliat Care, New York, NY 10003 USA; Cephalon Inc, Frazer, PA USA; Iowa Pain Management Clin, W Des Moines, IA USA	Portenoy, RK (reprint author), Beth Israel Med Ctr, Dept Pain Med & Palliat Care, 1st Ave,16th St, New York, NY 10003 USA.	rportenoy@chpnet.org					Allan L, 2005, SPINE, V30, P2484, DOI 10.1097/01.brs.0000186860.23078.a8; Caraceni A, 2004, PALLIATIVE MED, V18, P177, DOI 10.1191/0269216304pm890oa; Collins SL, 1998, J PAIN SYMPTOM MANAG, V16, P388, DOI 10.1016/S0885-3924(98)00094-3; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Darwish M, 2006, CLIN THER, V28, P707, DOI 10.1016/j.clinthera.2006.05.015; Darwish M, 2006, CLIN THER, V28, P715, DOI 10.1016/j.clinthera.2006.05.016; Darwish M, 2005, CLIN PHARMACOKINET, V44, P1279, DOI 10.2165/00003088-200544120-00006; DARWISH M, 2006, AM PAIN SOC ANN M MA; DAUT RL, 1983, PAIN, V17, P197, DOI 10.1016/0304-3959(83)90143-4; Durfee S, 2006, AM J DRUG DELIV, V4, P1, DOI DOI 10.2165/00137696-200604010-00001; Fairbank JCT, 2000, SPINE, V25, P2940, DOI 10.1097/00007632-200011150-00017; Farrar JT, 1998, JNCI-J NATL CANCER I, V90, P611, DOI 10.1093/jnci/90.8.611; Fine PG, 1998, J PAIN SYMPTOM MANAG, V16, P179, DOI 10.1016/S0885-3924(98)00045-1; Hanks GW, 2004, PALLIATIVE MED, V18, P698, DOI 10.1191/0269216304pm966oa; Hwang SS, 2003, PAIN, V101, P55, DOI 10.1016/S0304-3959(02)00293-2; ICH Expert Working Group, ICH HARM TRIP GUID G; Mercadante S, 2002, CANCER, V94, P832, DOI 10.1002/cncr.10249; MIASKOWSKI C, 2005, [No title captured], V3; Murray A, 2005, J PAIN SYMPTOM MANAG, V29, pS57, DOI 10.1016/j.jpainsymman.2005.01.007; Payne R, 2001, J PAIN SYMPTOM MANAG, V22, P575, DOI 10.1016/S0885-3924(01)00306-2; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Portenoy RK, 2006, J PAIN, V7, P583, DOI 10.1016/j.jpain.2006.02.003; Prommer E, 2006, SUPPORT CARE CANCER, V14, P109, DOI 10.1007/s00520-005-0917-1; Svendsen KB, 2005, EUR J PAIN, V9, P195, DOI 10.1016/j.ejpain.2004.06.001; Trescot Andrea M, 2006, Pain Physician, V9, P1	27	72	75	1	9	LIBRAPHARM	NEWBURY	29-35  VENTURE WEST, NEW GREENHAM PARK, NEWBURY RG19 6HX, BERKSHIRE, ENGLAND	0300-7995			CURR MED RES OPIN	Curr. Med. Res. Opin.	JAN	2007	23	1					222	232		10.1185/030079906X162818			11	Medicine, General & Internal; Medicine, Research & Experimental	General & Internal Medicine; Research & Experimental Medicine	122VY	WOS:000243256500023	17207304				2020-06-30	J	Thomasy, SM; Mama, KR; Whitley, K; Steffey, ER; Stanley, SD				Thomasy, S. M.; Mama, K. R.; Whitley, K.; Steffey, E. R.; Stanley, S. D.			Influence of general anaesthesia on the pharmacokinetics of intravenous fentanyl and its primary metabolite in horses	EQUINE VETERINARY JOURNAL			English	Article						horse; analgesia; opioids; isoflurane; anaesthesia; pharmacokinetics	ISOFLURANE; HALOTHANE; AWAKE	Reasons for performing study: In order to evaluate its potential as an adjunct to inhalant anaesthesia in horses, the pharmacokinetics of fentanyl must first be determined. Objectives: To describe the pharmacokinetics of fentanyl and its metabolite, N-[1-(2-phenethyl-4-piperidinyl)maloanilinic acid (PMA), after i.v. administration of a single dose to horses that were awake in Treatment I and anaesthetised with isoflurane in Treatment 2. Methods: A balanced crossover design was used (n = 4/group). During Treatment 1, horses received a single dose of fentanyl (4 mu g/kg bwt, i.v.) and during Treatment 2, they were anaesthetised with isoflurane and maintained at 1.2 x minimum alveolar anaesthetic concentration. After a 30 min equilibration period, a single dose of fentanyl (4 mu g/kg bwt, i.v.) was administered to each horse. Plasma fentanyl and PMA concentrations were measured at various time points using liquid chromatography-mass spectrometry. Results: Anaesthesia with isoflurane significantly decreased mean fentanyl clearance (P < 0.05). The fentanyl elimination half-life, in awake and anaesthetised horses, was I h and volume of distribution at steady state was 0.37 and 0.26 l/kg bwt, respectively. Anaesthesia with isoflurane also significantly decreased PMA apparent clearance and volume of distribution. The elimination half-life of PMA was 2 and 1.5 h in awake and anaesthetised horses, respectively. Conclusions and potential relevance: Pharmacokinetics of fentanyl and PMA in horses were substantially altered in horses anaesthetised with isoflurane. These pharmacokinetic parameters provide information necessary for determination of suitable fentanyl loading and infusion doses in awake and isoflurane-anaesthetised horses.	Univ Calif Davis, KL Maddy Equine Analyt Chem Lab, Calif Anim Hlth & Food Safety Lab, Sch Vet Med, Davis, CA 95616 USA; Colorado State Univ, Coll Vet Med & Biomed Sci, Dept Clin Sci, Ft Collins, CO 80523 USA; Univ Calif Davis, Sch Vet Med, Dept Surg & Radiol Sci, Davis, CA 95616 USA	Stanley, SD (reprint author), Univ Calif Davis, KL Maddy Equine Analyt Chem Lab, Calif Anim Hlth & Food Safety Lab, Sch Vet Med, Davis, CA 95616 USA.						FRINCKE JM, 1980, DRUG METAB DISPOS, V8, P425; FUNG DL, 1980, J CLIN PHARMACOL, V20, P652, DOI 10.1002/j.1552-4604.1980.tb01682.x; HUDSON RJ, 1986, ANESTHESIOLOGY, V64, P334, DOI 10.1097/00000542-198603000-00006; Ilkiw JE, 1999, CLIN TECH SMALL AN P, V14, P27, DOI 10.1016/S1096-2867(99)80024-3; Kyles AE, 1998, COMP CONT EDUC PRACT, V20, P721; LEHMANN K A, 1988, Acta Anaesthesiologica Belgica, V39, P11; MANOHAR M, 1987, AM J VET RES, V48, P1504; Maxwell LK, 2003, EQUINE VET J, V35, P484, DOI 10.2746/042516403775600415; MCCLAIN DA, 1980, CLIN PHARMACOL THER, V28, P106, DOI 10.1038/clpt.1980.138; MURPHY MR, 1983, ANESTHESIOLOGY, V59, P537, DOI 10.1097/00000542-198312000-00009; PASCOE PJ, 1993, AM J VET RES, V54, P1327; Russo C. I., 2002, P 14 INT C RAC AN VE, P413; STEFFEY EP, 1987, J VET PHARMACOL THER, V10, P290, DOI 10.1111/j.1365-2885.1987.tb00104.x; STEFFEY EP, 1987, AM J VET RES, V48, P7; STEFFEY EP, 1980, AM J VET RES, V41, P821; STEFFEY EP, 1977, AM J VET RES, V38, P1833; Steffey EP, 2003, AM J VET RES, V64, P166, DOI 10.2460/ajvr.2003.64.166; Thomasy SM, 2006, BRIT J ANAESTH, V97, P232, DOI 10.1093/bja/ael116; Thomasy SM, 2004, J VET INTERN MED, V18, P550, DOI 10.1892/0891-6640(2004)18&lt;550:TFCWNA&gt;2.0.CO;2; YAMAOKA K, 1978, J PHARMACOKINET BIOP, V6, P165, DOI 10.1007/BF01117450	20	25	25	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0425-1644	2042-3306		EQUINE VET J	Equine Vet. J.	JAN	2007	39	1					54	58		10.2746/042516407X153011			5	Veterinary Sciences	Veterinary Sciences	128YV	WOS:000243696500013	17228596				2020-06-30	J	Freye, E; Levy, JV				Freye, E.; Levy, J. V.			Reflex activity caused by laryngoscopy and intubation is obtunded differently by meptazinol, nalbuphine and fentanyl	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article						anaesthesia intravenous; opioid analgesics, fentanyl, meptazinol, nalbuphine; laryngoscopy; intubation intratracheal; electroencephalogram; bispectral index; haemodynamic phenomena, blood pressure, heart rate	OPIOID RECEPTOR-BINDING; TRACHEAL INTUBATION; ANESTHESIA; INDUCTION; MORPHINE; PROPOFOL; THIOPENTONE; ANALGESIA; RESPONSES; SUFENTANIL	Background and objective: To evaluate the different potencies of several opioids in obtunding reflex mechanisms of laryngoscopy and intubation. Methods: Three groups of patients (each n = 25, ASA 1-2) undergoing elective plastic surgery were randomly given meptazinol (2.5 mg kg(-1)), nalbuphine (0.3 mg kg(-1)) or fentanyl (5 mu g kg(-1)) in a blinded fashion prior to laryngoscopy and intubation. This was followed by a standardized bolus induction of a barbiturate and a muscle relaxant. The response to laryngoscopy and intubation was studied, using blood pressure, heart rate and bispectral index. Results: With fentanyl, there was an increase of heart rate by 17%, and systolic blood pressure by 7% when compared to control. Bispectral index dropped an additional 8% when compared to 1 min after barbiturate induction. In the nalbuphine group there was a 16% increase in systolic blood pressure, and a 16% increase in heart rate when compared to control. Also, bispectral index increased by 18% when compared to 1 min after barbiturate injection. The group receiving meptazinol demonstrated no cardiovascular changes although bispectral index dropped by an additional 19% when compared to 1 min after barbiturate injection. Conclusion: Meptazinol, appears to depress cardiovascular stimulatory effects and electroencephalogram arousal induced by laryngoscopy and intubation better than nalbuphine or fentanyl.	Univ Dusseldorf, Clin Vasc Surg, D-4000 Dusseldorf, Germany; Univ Dusseldorf, Clin Renal Transplantat, D-4000 Dusseldorf, Germany; Univ Pacific, Dept Physiol & Pharmacol, San Francisco, CA 94115 USA	Freye, E (reprint author), Deichstr 3A, D-41468 Neuss Uedesheim, Germany.	enno.freye@uni-duesseldorf.de					Beilin B, 2005, ACTA ANAESTH SCAND, V49, P78, DOI 10.1111/j.1399-6576.2004.00548.x; BILL DJ, 1983, BRIT J PHARMACOL, V79, P191, DOI 10.1111/j.1476-5381.1983.tb10512.x; BORGEAT A, 1993, J CLIN ANESTH, V5, P12, DOI 10.1016/0952-8180(93)90081-O; BOWDLE TA, 1989, ANESTHESIOLOGY, V70, P26, DOI 10.1097/00000542-198901000-00007; CHIANG CY, 1989, BRAIN RES, V478, P293, DOI 10.1016/0006-8993(89)91509-6; CORBETT D, 1993, OPIOIDS, V1, P645; CORK RC, 1983, ANESTHESIOLOGY, V59, pA334; DESOUZA EB, 1988, J PHARMACOL EXP THER, V244, P391; DRAY A, 1986, NEUROPHARMACOLOGY, V25, P343, DOI 10.1016/0028-3908(86)90228-5; DUMAS PA, 1984, 7 WORLD C AN MAN PHI, P43; Freye E, 1999, Acta Anaesthesiol Belg, V50, P71; FREYE E, 2004, OPIOIDE MED; FREYE E, 1986, ANESTH ANALG, V65, P551; FREYE E, 1987, PAIN CLINIC, V1, P225; GAL TJ, 1982, ANESTHESIOLOGY, V57, P367, DOI 10.1097/00000542-198211000-00004; GILLBERG PG, 1988, NEUROSCI LETT, V90, P197, DOI 10.1016/0304-3940(88)90811-7; Gurses E, 2004, ANESTH ANALG, V98, P128, DOI 10.1213/01.ANE.0000090314.43496.1D; Hardman J, 1996, GOODMAN GILMANS PHAR; HARGREAVES J, 1985, ANAESTHESIA, V40, P490; Harris C E, 1988, Anaesthesia, V43 Suppl, P32, DOI 10.1111/j.1365-2044.1988.tb09065.x; HOLMES B, 1985, DRUGS, V30, P285, DOI 10.2165/00003495-198530040-00001; Hood DD, 1997, J PHARMACOL EXP THER, V282, P86; IYER V, 1988, ANAESTH INTENS CARE, V16, P411, DOI 10.1177/0310057X8801600405; JORDAN C, 1979, BRIT J ANAESTH, V51, P497, DOI 10.1093/bja/51.6.497; KAY B, 1987, ANAESTHESIA, V42, P382, DOI 10.1111/j.1365-2044.1987.tb03979.x; Lauretti GR, 1996, ANESTH ANALG, V82, P617, DOI 10.1097/00000539-199603000-00033; LEVY WJ, 1984, ANESTHESIOLOGY, V60, P430, DOI 10.1097/00000542-198405000-00007; LINDGREN L, 1993, BRIT J ANAESTH, V70, P306, DOI 10.1093/bja/70.3.306; Lu CC, 2003, ANAESTHESIA, V58, P951, DOI 10.1046/j.1365-2044.2003.03346.x; MCCAMMON RL, 1984, ANESTH ANALG, V63, P139; MORUZZI G, 1949, ELECTROEN CLIN NEURO, V1, P455, DOI 10.1016/0013-4694(49)90066-8; Omais M, 2002, ANESTH ANALG, V95, P1698, DOI 10.1097/00000539-200212000-00042; PASTERNAK GW, 1985, POSTGRAD MED J, V61, P5; RAMPIL IJ, 1987, ANESTHESIOLOGY, V67, P139, DOI 10.1097/00000542-198707000-00033; RANDEL GI, 1994, ANESTHESIOLOGY, V81, pA375; ROBSON PJ, 1983, POSTGRAD MED J, V59, P85; ROMAGNOLI A, 1980, CLIN PHARMACOL THER, V27, P478, DOI 10.1038/clpt.1980.67; SCHMIDT WK, 1985, DRUG ALCOHOL DEPEN, V14, P339, DOI 10.1016/0376-8716(85)90066-3; SHAH NK, 1990, MEMORY AWARENESS ANA, P378; SPIEGEL K, 1984, J PHARMACOL EXP THER, V228, P414; SPLINTER WM, 1989, CAN J ANAESTH, V36, P370, DOI 10.1007/BF03005332; STOELTING RK, 1977, ANESTHESIOLOGY, V47, P381, DOI 10.1097/00000542-197710000-00012; Tolksdorf W, 1990, Anasth Intensivther Notfallmed, V25, P198, DOI 10.1055/s-2007-1001048; Tolksdorf W, 1987, Anasth Intensivther Notfallmed, V22, P171, DOI 10.1055/s-2007-1002530; VATASHSKY E, 1985, CURR THER RES CLIN E, V37, P95; WILDERSMITH OHG, 1995, BRIT J ANAESTH, V75, P441, DOI 10.1093/bja/75.4.441	46	5	7	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0265-0215			EUR J ANAESTH	Eur. J. Anaesth.	JAN	2007	24	1					53	58		10.1017/S0265021506001086			6	Anesthesiology	Anesthesiology	162VX	WOS:000246118700009	16834791				2020-06-30	J	Komurcu, S; Turhal, S; Altundag, K; Atahan, L; Turna, HS; Manavoglu, O; Yavuz, AA; Ozkok, S; Aliustaoglu, M; Altinbas, M; Pak, Y; Cooper, R; Yaylaci, M; Demirkan, B; Sarihan, S; Ozdemir, F				Komurcu, S.; Turhal, S.; Altundag, K.; Atahan, L.; Turna, H. S.; Manavoglu, O.; Yavuz, A. A.; Oezkoek, S.; Aliustaoglu, M.; Altinbas, M.; Pak, Y.; Cooper, R.; Yaylaci, M.; Demirkan, B.; Sarihan, S.; Oezdemir, F.			Safety and efficacy of transdermal fentanyl in patients with cancer pain: phase IV, Turkish oncology group trial	EUROPEAN JOURNAL OF CANCER CARE			English	Article						transdermal fentanyl; cancer pain; opioids	MORPHINE; RELEASE	We have performed a prospective evaluation of the efficacy, safety and convenience of the transdermal therapeutic system - fentanyl (TTS-F) in Turkish cancer patients when it was newly available in Turkey. Ninety-nine patients with historically confirmed malignancy and pain entered the study; the mean age was 55.1 (16-58) years. The study duration was 28 days. Transdermal therapeutic system - fentanyl was used in opioid-naive or pre-treated patients. Most patients reported a decrease in pain severity. Use of rescue medication decreased from day 4 to day 28. The majority of patients rated patch convenience of use as excellent. A total of 22.2% of patients experienced adverse events that were either probably related or very likely to be related to the study drug. The majority of the adverse events mentioned were related to the digestive system. Eighteen serious adverse events were reported by 13 patients. Six events were doubtfully related, and 12 events were not related to the study drug. Four patients died during the trial. None of these deaths was attributed to the study drug. In conclusion, the trial showed that TTS-F is easily managed, effective and will help to enable the appropriate opioid administration to patients who are suffering from cancer pain in Turkey.	Gulhane Askeri Tip Akad, Dept Med Oncol, Ankara, Turkey; Marmara Univ, Sch Med, Dept Med Oncol, Istanbul, Turkey; Hacettepe Univ, Sch Med, Dept Med Oncol, Ankara, Turkey; Hacettepe Univ, Sch Med, Dept Radiat Oncol, Ankara, Turkey; Istanbul Univ, Cerrahpasa Med Sch, Dept Med Oncol, Istanbul, Turkey; Uludag Univ, Sch Med, Dept Med Oncol, Bursa, Turkey; Karadeniz Teknik Univ, Sch Med, Dept Radiat Oncol, Trabzon, Turkey; Ege Univ, Sch Med, Dept Radiat Oncol, Izmir, Turkey; Erciyes Univ, Sch Med, Dept Med Oncol, Kayseri, Turkey; Gulhane Askeri Tip Akad, Dept Radiat Oncol, Ankara, Turkey; Dokuz Eylul Univ, Sch Med, Dept Radiat Oncol, Izmir, Turkey; Gulhane Askeri Tip Akad, Div Med Oncol, Istanbul, Turkey; Dokuz Eylul Univ, Sch Med, Dept Med Oncol, Izmir, Turkey; Uludag Univ, Sch Med, Dept Radiat Oncol, Bursa, Turkey; Karadeniz Teknik Univ, Sch Med, Dept Med Oncol, Trabzon, Turkey	Komurcu, S (reprint author), GATA Med Oncol, TR-06018 Ankara, Turkey.	skomurcu@gata.edu.tr	yavuz, ali aydin/C-3154-2016	Aliustaoglu, Mehmet/0000-0003-0287-0766			AHMEDZAI S, 1994, J DRUG DEV, V6, P93; AUSTIN KL, 1980, PAIN, V8, P47, DOI 10.1016/0304-3959(80)90089-5; FINCH JS, 1964, J CLIN PHARMACOL, V7, P46; Foley K M, 1981, NIDA Res Monogr, V36, P169; HALL GM, 1980, BRIT J ANAESTH, V52, P561, DOI 10.1093/bja/52.6.561; HOMESLEY HD, 1986, AM J CLIN ONCOL-CANC, V9, P449, DOI 10.1097/00000421-198610000-00018; Huynh NH, 2005, J PHARMACEUT BIOMED, V37, P1095, DOI 10.1016/j.jpba.2004.09.024; Joranson DE, 2000, JAMA-J AM MED ASSOC, V283, P1710, DOI 10.1001/jama.283.13.1710; Lorvidhaya Vicharn, 2004, Journal of the Medical Association of Thailand, V87, P319; Markman Maurie, 2005, Cancer Chemother Biol Response Modif, V22, P677; MCGIVNEY WT, 1984, JAMA-J AM MED ASSOC, V251, P1182; Morita T, 2005, J PAIN SYMPTOM MANAG, V30, P96, DOI 10.1016/j.jpainsymman.2004.12.010; Mystakidou K, 2004, J PAIN, V5, P119, DOI 10.1016/j.jpain.2003.12.003; Tawfik MO, 2004, CURR MED RES OPIN, V20, P259, DOI 10.1185/030079903125003026; van Seventer R, 2003, CURR MED RES OPIN, V19, P457, DOI 10.1185/030079903125002045; Vielvoye-Kerkmeer APE, 2000, J PAIN SYMPTOM MANAG, V19, P185, DOI 10.1016/S0885-3924(99)00152-9; WUSTER M, 1980, LIFE SCI, V27, P163, DOI 10.1016/0024-3205(80)90459-2; Yeo W, 1997, PALLIATIVE MED, V11, P233, DOI 10.1177/026921639701100308; Yu Shi-ying, 2005, Zhonghua Zhongliu Zazhi, V27, P369	19	7	7	1	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0961-5423	1365-2354		EUR J CANCER CARE	Eur. J. Cancer Care	JAN	2007	16	1					67	73		10.1111/j.1365-2354.2006.00707.x			7	Oncology; Health Care Sciences & Services; Nursing; Rehabilitation	Oncology; Health Care Sciences & Services; Nursing; Rehabilitation	124WU	WOS:000243403500009	17227355				2020-06-30	J	Mystakidou, K; Tsilika, E; Tsiatas, M; Vlahos, L				Mystakidou, Kyriaki; Tsilika, Eleni; Tsiatas, Marinos; Vlahos, Lambros			Oral transmucosal fentanyl citrate in cancer pain management: a practical application of nanotechnology	INTERNATIONAL JOURNAL OF NANOMEDICINE			English	Review						oral transmucosal fentanyl citrate; cancer pain; breakthrough pain	BREAKTHROUGH PAIN; TRANSDERMAL FENTANYL; DOSE-TITRATION; PHARMACOKINETICS; PREVALENCE; TRIAL	Pain is experienced by most cancer patients and represents an important issue in the clinical setting. Breakthrough pain is a transitory flare of pain that occurs in most cancer patients on a background of otherwise controlled persistent pain. Treatment of breakthrough pain is a challenging phenomenon. Oral transmucosal fentanyl citrate (OTFC; Actiq (R), Cephalon, UK), a new opioid formulation with a unique delivery system, utilizing the advantages that nanotechnology offers, reflects the characteristics of breakthrough pain (rapid onset of action and short duration), which makes it an effective treatment to cancer patients who are already receiving opioids and continue to experience such flares of pain. Oral transmueosal fentanyl citrate is specifically developed and approved for the management of breakthrough pain in cancer patients and it has the potential to be a useful tool for clinicians.	[Mystakidou, Kyriaki; Tsilika, Eleni; Vlahos, Lambros] Univ Athens, Arete Hosp, Pain Relief & Palliat Care Unit,Sch Med, Dept Radiol, Athens 11526, Greece; [Tsiatas, Marinos] Univ Athens, Dept Clin Therapeut, Alexandra Hosp, Athens, Greece	Mystakidou, K (reprint author), Univ Athens, Arete Hosp, Pain Relief & Palliat Care Unit,Sch Med, Dept Radiol, 27 Korinthias St, Athens 11526, Greece.	mistakidou@yahoo.com					Burton AW, 2004, CLIN J PAIN, V20, P195, DOI 10.1097/00002508-200405000-00011; CARTWRIGHT P, 1983, ANESTH ANALG, V62, P966; *CEP INC, 2003, ACT SUMM PROD CHAR; Christie JM, 1998, J CLIN ONCOL, V16, P3238, DOI 10.1200/JCO.1998.16.10.3238; COHEN MR, 1982, PSYCHIAT RES, V6, P7, DOI 10.1016/0165-1781(82)90032-4; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Csaba Noemi, 2006, Expert Opin Drug Deliv, V3, P463, DOI 10.1517/17425247.3.4.463; Cuenca AG, 2006, CANCER-AM CANCER SOC, V107, P459, DOI 10.1002/cncr.22035; DAUT RL, 1982, CANCER-AM CANCER SOC, V50, P1913, DOI 10.1002/1097-0142(19821101)50:9<1913::AID-CNCR2820500944>3.0.CO;2-R; Farrar JT, 1998, JNCI-J NATL CANCER I, V90, P611, DOI 10.1093/jnci/90.8.611; Foley KM, 1999, ARCH NEUROL-CHICAGO, V56, P413, DOI 10.1001/archneur.56.4.413; Hwang SS, 2003, PAIN, V101, P55, DOI 10.1016/S0304-3959(02)00293-2; Lee M, 2003, J PAIN SYMPTOM MANAG, V26, P743, DOI 10.1016/S0885-3924(03)00241-0; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; McMenamin Erin, 2002, Expert Rev Neurother, V2, P625, DOI 10.1586/14737175.2.5.625; MEULDERMANS WEG, 1982, ARCH INT PHARMACOD T, V257, P4; Mystakidou K, 2006, DRUG DELIV, V13, P269, DOI 10.1080/10717540500394661; Mystakidou Kyriaki, 2005, Am J Hosp Palliat Care, V22, P228, DOI 10.1177/104990910502200313; Mystakidou Kyriaki, 2002, Curr Opin Investig Drugs, V3, P463; Payne R, 2001, J PAIN SYMPTOM MANAG, V22, P575, DOI 10.1016/S0885-3924(01)00306-2; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; PORTENOY RK, 1993, ANESTHESIOLOGY, V78, P36, DOI 10.1097/00000542-199301000-00007; Portenoy RK, 1999, PAIN, V79, P303, DOI 10.1016/S0304-3959(98)00179-1; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Simmonds MA, 1999, ONCOLOGY-NY, V13, P1103; Sprintz M, 2005, Minerva Anestesiol, V71, P419; Streisand JB, 1998, ANESTHESIOLOGY, V88, P305, DOI 10.1097/00000542-199802000-00006; STREISAND JB, 1991, ANESTHESIOLOGY, V75, P223, DOI 10.1097/00000542-199108000-00009; TAMSEN A, 1982, PAIN, V13, P171, DOI 10.1016/0304-3959(82)90027-6; TWYCROSS RG, 1982, PAIN, V14, P303, DOI 10.1016/0304-3959(82)90137-3	30	13	13	1	8	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1178-2013			INT J NANOMED	Int. J. Nanomed.		2007	2	1					49	54		10.2147/nano.2007.2.1.49			6	Nanoscience & Nanotechnology; Pharmacology & Pharmacy	Science & Technology - Other Topics; Pharmacology & Pharmacy	247AD	WOS:000252048600009	17722512	DOAJ Gold, Green Published			2020-06-30	J	Ko, JS; Kim, CS; Cho, HS; Choi, DH				Ko, J-S.; Kim, C-S.; Cho, H-S.; Choi, D-H.			A randomized trial of crystalloid versus colloid solution for prevention of hypotension during spinal or low-dose combined spinal-epidural anesthesia for elective cesarean delivery	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Article; Proceedings Paper	24th World Congress of the European-Society-of-Regional-Anaethesia-and-Pain-Therapy	2005	Berlin, GERMANY	European Soc Reg Anaesthesia & Pain Therapy		cesarean delivery; spinal anesthesia; combined spinal-epidural anesthesia; preload; crystalloid; colloid	RINGERS SOLUTION; SECTION; PRELOAD; VOLUME; BUPIVACAINE; FENTANYL	Background: Spinal anesthesia for cesarean delivery is commonly associated with hypotension and nausea and vomiting, and preload with crystalloid or colloid solution is widely recommended. Low-dose spinal via the combined spinal-epidural technique appears to cause less hypotension and nausea and vomiting. The aim of this study was to investigate whether the combined use of colloid preload and combined spinal-epidural technique might further reduce the rates of these symptoms. Methods: Women undergoing elective cesarean delivery were randomly allocated to one of four groups (50 in each) to receive crystalloid preload before spinal anesthesia, colloid preload before spinal anesthesia, crystalloid preload before combined spinal-epidural anesthesia, and colloid preload before combined spinal-epidural anesthesia. The incidences of hypotension and nausea and vomiting were compared. Spinal anesthesia was performed with 0.5% hyperbaric bupivacaine 9 mg and fentanyl 20 mu g, and combined spinal-epidural anesthesia with 0.5% hyperbaric bupivacaine 6 mg + fentanyl 20 mu g followed by epidural injection of 0.25% bupivacaine 10 mL. Results: The frequencies of hypotension were 44%, 18%, 24%, and 20% in crystalloid preload-spinal anesthesia, colloid preload-spinal anesthesia, crystalloid preload-combined spinal epidural anesthesia, and colloid preload-combined spinal epidural anesthesia groups, respectively. The frequencies of nausea and vomiting were 20%, 2%, 8%, and 4% in respective groups. Conclusion: Colloid preload and low-dose spinal anesthesia alone or in combination lowered the incidences of hypotension and nausea. However, the combination of two methods failed to demonstrate further decreases in the incidence of the symptoms compared to the colloid-spinal anesthesia or crystalloid-combined spinal-epidural anesthesia groups. (c) 2006 Elsevier Ltd. All rights reserved.	Sungkyunkwan Univ, Dept Anesthesiol & Pain Med, Samsung Med Ctr, Sch Med, Seoul 135710, South Korea	Choi, DH (reprint author), Sungkyunkwan Univ, Dept Anesthesiol & Pain Med, Samsung Med Ctr, Sch Med, 50 Ilwon Dong, Seoul 135710, South Korea.	dhchoi@smc.samsung.co.kr					Ben-David B, 2000, REGION ANESTH PAIN M, V25, P235, DOI 10.1016/S1098-7339(00)90004-X; BenDavid B, 1997, ANESTH ANALG, V85, P560, DOI 10.1097/00000539-199709000-00014; Choi DH, 2006, INT J OBSTET ANESTH, V15, P13, DOI 10.1016/j.ijoa.2005.05.009; Choi DH, 2000, REGION ANESTH PAIN M, V25, P240, DOI 10.1016/S1098-7339(00)90005-1; CLARK RB, 1976, ANESTHESIOLOGY, V45, P670, DOI 10.1097/00000542-197612000-00018; CULLEN MJ, 1990, ANAESTHESIA, V45, P1041, DOI 10.1111/j.1365-2044.1990.tb14883.x; Dahlgren G, 2005, ACTA ANAESTH SCAND, V49, P1200, DOI 10.1111/j.1399-6576.2005.00730.x; Emmett RS, 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002251; FINUCANE BT, 1995, REGION ANESTH, V20, P87; FISHER MM, 1990, DRUG SAFETY, V5, P86, DOI 10.2165/00002018-199005020-00002; French GWG, 1999, BRIT J ANAESTH, V83, P475; JACKSON R, 1995, BRIT J ANAESTH, V75, P262, DOI 10.1093/bja/75.3.262; Kee WDN, 2005, ANESTHESIOLOGY, V103, P744, DOI 10.1097/00000542-200510000-00012; MACLENNAN FM, 1987, ANAESTHESIA, V42, P141, DOI 10.1111/j.1365-2044.1987.tb02986.x; MARX GF, 1969, ANESTH ANAL CURR RES, V48, P986; Park GE, 1996, ANESTH ANALG, V83, P299, DOI 10.1097/00000539-199608000-00017; RAWAL N, 1988, ACTA ANAESTH SCAND, V32, P61, DOI 10.1111/j.1399-6576.1988.tb02689.x; Rawal N, 1997, REGION ANESTH, V22, P406, DOI 10.1016/S1098-7339(97)80026-0; Rawal N, 2000, Anesthesiol Clin North Am, V18, P267, DOI 10.1016/S0889-8537(05)70164-4; RILEY ET, 1995, ANESTH ANALG, V81, P838, DOI 10.1097/00000539-199510000-00031; Rout C, 1999, ANESTHESIOLOGY, V91, P1565, DOI 10.1097/00000542-199912000-00004; ROUT CC, 1992, BRIT J ANAESTH, V68, P394, DOI 10.1093/bja/68.4.394; ROUT CC, 1993, ANESTHESIOLOGY, V79, P262, DOI 10.1097/00000542-199308000-00011; Siddik SM, 2000, CAN J ANAESTH, V47, P616, DOI 10.1007/BF03018992; Ueyama H, 1999, ANESTHESIOLOGY, V91, P1571, DOI 10.1097/00000542-199912000-00006; Vercauteren MP, 2000, ANESTH ANALG, V90, P324, DOI 10.1097/00000539-200002000-00016; WOLLMAN SB, 1968, ANESTHESIOLOGY, V29, P374, DOI 10.1097/00000542-196803000-00024	27	34	39	0	9	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-289X	1532-3374		INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	JAN	2007	16	1					8	12		10.1016/j.ijoa.2006.07.004			5	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	136JE	WOS:000244217600003	17125995				2020-06-30	J	Dunstan, CR; Walpole, R				Dunstan, C. R.; Walpole, R.			Change from continuous epidural infusion to patient-controlled epidural analgesia on the labour ward of a large district general hospital	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Letter									Royal Gwent Hosp, Dept Anaesthet, Newport NP20 2UP, Gwent, Wales	Dunstan, CR (reprint author), Royal Gwent Hosp, Dept Anaesthet, Newport NP20 2UP, Gwent, Wales.	cdunstan@doctors.net.uk					GAMBLING DR, 1988, CAN J ANAESTH, V35, P249, DOI 10.1007/BF03010618; Graham AC, 2001, ANAESTHESIA, V56, P470, DOI 10.1046/j.1365-2044.2001.01524-6.x; van der Vyver M, 2002, BRIT J ANAESTH, V89, P459, DOI 10.1093/bja/aef217	3	0	0	0	0	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0959-289X			INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	JAN	2007	16	1					93	94		10.1016/j.ijoa.2006.09.002			2	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	136JE	WOS:000244217600021	17126546				2020-06-30	J	Almeida, TF; Fantoni, DT; Mastrocinque, S; Tatarunas, AC; Imagawa, VH				Almeida, Tatiana F.; Fantoni, Denise T.; Mastrocinque, Sandra; Tatarunas, Angelica C.; Imagawa, Viviane H.			Epidural anesthesia with bupivacaine, bupivacaine and fentanyl, or bupivacaine and sufentanil during intravenous administration of propofol for ovariohysterectomy in dogs	JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION			English	Article							GENERALIZED LINEAR-MODELS; POSTOPERATIVE ANALGESIA; LABOR; CATS; PAIN; MORPHINE; SURGERY; CARPROFEN; CHILDREN	Objective-To compare cardiovascular and systemic effects and analgesia during the postoperative period of epidural anesthesia performed with bupivacaine alone or with fentanyl or sufentanil in bitches maintained at a light plane of anesthesia with continuous infusion of propofol. Study Design-Prospective randomized masked clinical trial. Animals-30 female dogs of various breeds. Procedures-Dogs were allocated into 3 groups of 10 each. One group received fentanyl (2 mu g/kg [0.91 mu g/lb]) and bupivacaine (1 mg/kg [0.45 mg/lb]), 1 group received sufentanil (1 mu g/kg) and bupivacaine (1 mg/kg), and 1 group received bupivacaine (1 mg/kg). All dogs received acepromazine (0.1 mg/kg [0.045 mg/lb]) and continuous infusion of propofol for sedation. The agents were administered into the lumbosacral space and diluted in saline (0.9% NaCl) solution to a total volume of 0.36 mL/kg (0.164 mL/lb). Cardiac and respiratory rates, arterial blood pressures, pH, and blood gases were evaluated. Analgesia, sedation level, serum cortisol concentrations, and plasma catecholamine concentrations were measured regularly for 6 hours. Results-No important changes in cardiovascular, respiratory, or sedation variables were observed. Degree of analgesia in the postoperative period was higher in the sufentanil group, although use of fentanyl and bupivacaine also resulted in a sufficient level of analgesia. Conclusions and Clinical Relevance-Use of the 3 anesthetic techniques permitted ovariohysterectomy with sufficient analgesia and acceptable neuroendocrine modulation of pain with minimal adverse effects.	Univ Sao Paulo, Dept Surg, Sch Vet Med & Zootechn, Sao Paulo, Brazil	Fantoni, DT (reprint author), Univ Sao Paulo, Dept Surg, Sch Vet Med & Zootechn, Sao Paulo, Brazil.		Holtet, Astrid/B-9316-2012; Fantoni, Denise/C-8761-2012; Fantoni, Denise T/C-5602-2012	Fantoni, Denise T/0000-0002-8452-2038			Ackerman B, 1988, ANESTH ANALG, V67, P943; Aguiar Antonio Ja, 2001, Vet Anaesth Analg, V28, P220, DOI 10.1046/j.1467-2987.2001.00048.x; BONATH KH, 1985, P 2 INT C VET AN OCT, P7; BRAZ JRC, 1998, REV BRAS ANESTESIOL, V48, P455; Capogna G, 2003, ANESTH ANALG, V96, P1178, DOI 10.1213/01.ANE.0000054003.03645.CF; CHRISTOPHERSON R, 1993, ANESTHESIOLOGY, V79, P422, DOI 10.1097/00000542-199309000-00004; COHEN SE, 1988, ANESTHESIOLOGY, V68, P129, DOI 10.1097/00000542-198801000-00023; Connelly NR, 2000, ANESTH ANALG, V91, P374, DOI 10.1097/00000539-200008000-00026; COUSINS MJ, 1984, ANESTHESIOLOGY, V61, P276; DECASTRO J, 1979, ACTA ANAESTH BELG, V30, P95; Gozzane J.L., 1997, ANESTESIA OBSTET, P33; HANSEN B, 1993, J AM VET MED ASSOC, V202, P1485; Hellyer PW, 1998, COMP CONT EDUC PRACT, V20, P140; Herman NL, 1998, J CLIN ANESTH, V10, P670, DOI 10.1016/S0952-8180(98)00113-5; Hopkins D, 1998, CAN J ANAESTH, V45, P435, DOI 10.1007/BF03012579; Johnson C, 1989, J Clin Anesth, V1, P440, DOI 10.1016/0952-8180(89)90008-1; KANEKO M, 1994, ANESTHESIOLOGY, V80, P137, DOI 10.1097/00000542-199401000-00021; KLIDE AM, 1968, J AM VET MED ASSOC, V153, P165; LASCELLES BDX, 1994, VET REC, V134, P187, DOI 10.1136/vr.134.8.187; Lascelles BDX, 1998, VET SURG, V27, P568, DOI 10.1111/j.1532-950X.1998.tb00533.x; Lejus C, 2000, BRIT J ANAESTH, V85, P615, DOI 10.1093/bja/85.4.615; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; LLOYDTHOMAS AR, 1990, BRIT J ANAESTH, V64, P85, DOI 10.1093/bja/64.1.85; Massone F, 1999, ANESTESIOLOGIA VET F, P225; NELDER JA, 1972, J R STAT SOC SER A-G, V135, P370, DOI 10.2307/2344614; Neter J., 1996, APPL LINEAR STAT MOD, P1408; Palmer CM, 1998, ANESTHESIOLOGY, V88, P355, DOI 10.1097/00000542-199802000-00014; Rolfseng OK, 2002, EUR J ANAESTH, V19, P812, DOI 10.1017/S026502150200131X; Scott NB, 2003, PRINCIPLES PRACTICE, P9; Smith JD, 1999, AM J VET RES, V60, P432; TAYLOR PM, 1984, J SMALL ANIM PRACT, V25, P437, DOI 10.1111/j.1748-5827.1984.tb03416.x; URBAN MK, 1994, REGION ANESTH, V19, P175; WEAVER BMQ, 1990, VET REC, V126, P617; WOOD CE, 1994, CAN J ANAESTH, V41, P613, DOI 10.1007/BF03010002	34	20	20	0	3	AMER VETERINARY MEDICAL ASSOC	SCHAUMBURG	1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173-4360 USA	0003-1488			JAVMA-J AM VET MED A	JAVMA-J. Am. Vet. Med. Assoc.	JAN 1	2007	230	1					45	51		10.2460/javma.230.1.45			7	Veterinary Sciences	Veterinary Sciences	124AX	WOS:000243340400011	17199491				2020-06-30	J	Ishida, R; Shido, A; Kishimoto, T; Sakura, S; Saito, Y				Ishida, Ryosuke; Shido, Akemi; Kishimoto, Tomomune; Sakura, Shinichi; Saito, Yon			Prolonged cardiac arrest unveiled silent sick sinus syndrome during general and epidural anesthesia	JOURNAL OF ANESTHESIA			English	Article						sick sinus syndrome; epidural anesthesia; cardiac arrest; intravenous anesthetics	SPINAL-ANESTHESIA; BRADYCARDIA; PROPOFOL; VECURONIUM; INDUCTION; ASYSTOLE; FENTANYL	Patients who have silent sick sinus syndrome (SSS) can show various unexpected arrhythmias during surgery. The severity of these bradyarrythmias is affected by anesthetic methods. We report a unique case of a patient with silent SSS who developed 40s of asystole under combined general and epidural anesthesia. A 40-year-old woman with no apparent cardiac disease underwent abdominal hysterectomy. General anesthesia was induced and maintained with propofol, fentanyl, and vecuronium combined with thoracic epidural anesthesia. During surgery, severe bradycardia, triggered by peritoneal manipulation, occurred, leading to 40s of asystole. She was diagnosed as having SSS by a postoperative 24-h Holler electrocardiogram. We propose that the possible existence of SSS should be kept in mind even in a patient who shows no abnormalities on routine preoperative examination, especially in those in whom vagomimetic anesthetic methods are used.	[Ishida, Ryosuke; Shido, Akemi; Kishimoto, Tomomune; Sakura, Shinichi; Saito, Yon] Shimane Univ, Sch Med, Dept Anesthesiol, Izumo, Shimane 6938501, Japan	Ishida, R (reprint author), Shimane Univ, Sch Med, Dept Anesthesiol, 89-1 Enya Cho, Izumo, Shimane 6938501, Japan.						BURT DER, 1982, ANAESTHESIA, V37, P1108, DOI 10.1111/j.1365-2044.1982.tb01756.x; COHEN LI, 1988, ANESTHESIOLOGY, V68, P787, DOI 10.1097/00000542-198805000-00019; COLSON P, 1988, ANESTH ANALG, V67, P906; COZANITIS DA, 1989, ANAESTHESIA, V44, P303, DOI 10.1111/j.1365-2044.1989.tb11282.x; EBERT TJ, 1994, ANESTH ANALG, V78, P369, DOI 10.1213/00000539-199402000-00029; EGAN TD, 1991, ANESTH ANALG, V73, P818; Gregoratos G, 1998, J AM COLL CARDIOL, V31, P1175; Hirata A, 1994, Masui, V43, P1048; INOUE K, 1988, BRIT J ANAESTH, V60, P10, DOI 10.1093/bja/60.1.10; Ishiyama T, 2000, J Anesth, V14, P102, DOI 10.1007/s005400050075; Kabutan K, 2000, Masui, V49, P60; MCCONACHIE I, 1987, ANAESTHESIA, V42, P636, DOI 10.1111/j.1365-2044.1987.tb03089.x; Murakawa T, 2001, Masui, V50, P65; STOWE DF, 1988, ANESTHESIOLOGY, V68, P887, DOI 10.1097/00000542-198806000-00009; UNDERWOOD SM, 1988, ANAESTHESIA, V43, P307	15	7	7	0	1	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.		2007	21	1					62	65		10.1007/s00540-006-0450-5			4	Anesthesiology	Anesthesiology	275TQ	WOS:000254094900012	17285416				2020-06-30	J	Iyilikci, L; Akarsu, M; Kocaayan, E; Topalak, O				Iyilikci, Leyla; Akarsu, Mesut; Kocaayan, Emine; Topalak, Omer			Sedation for endoscopic retrograde cholangiopancreatography (ERCP) in a pregnant patient	JOURNAL OF ANESTHESIA			English	Article						ERCP; pregnancy		Anesthesiology management of endoscopic retrograde cholangiopancreatography (ERCP) in the twenty-first week of pregnancy of a woman patient is reported. The patient gave birth to a healthy male baby at 40 weeks of gestation.	[Iyilikci, Leyla; Kocaayan, Emine] Dokuz Eylul Univ, Sch Med, Dept Anesthesiol, TR-35340 Izmir, Turkey; [Akarsu, Mesut; Topalak, Omer] Dokuz Eylul Univ, Sch Med, Div Gastroenterol, TR-35340 Izmir, Turkey	Iyilikci, L (reprint author), Dokuz Eylul Univ, Sch Med, Dept Anesthesiol, TR-35340 Izmir, Turkey.		iyilikci, leyla/Q-1633-2019; AKPINAR, HALE/Q-2507-2019				Amornyotin Somchai, 2004, Journal of the Medical Association of Thailand, V87, P1491; [Anonymous], 2004, OBSTET GYNECOL, V104, P647; Bagci Sait, 2003, Archives of Gynecology and Obstetrics, V267, P239; Cappell Mitchell S, 2006, Gastrointest Endosc Clin N Am, V16, P1, DOI 10.1016/j.giec.2006.01.007; GLOSTEN B, 2000, ANESTHESIA, P2025; Gupta Rajesh, 2005, Indian J Gastroenterol, V24, P161; McGrath BA, 2005, INT J OBSTET ANESTH, V14, P172, DOI 10.1016/j.ijoa.2004.10.006; Menees Stacy, 2006, Gastrointest Endosc Clin N Am, V16, P41; MORGAN GE, 2002, CLIN ANAESTHESIOL, P819; Schmit A, 2005, ENDOSCOPY, V37, P695, DOI 10.1055/s-2005-870137; Simmons DC, 2004, AM J OBSTET GYNECOL, V190, P1467, DOI 10.1016/j.ajog.2004.02.030	11	3	3	0	1	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.		2007	21	1					69	71		10.1007/s00540-006-0448-z			3	Anesthesiology	Anesthesiology	275TQ	WOS:000254094900014	17285418				2020-06-30	J	Sasano, N; Fujita, Y; So, MH; Sobue, K; Sasano, H; Katsuya, H				Sasano, Nobuko; Fujita, Yoshihito; So, Min Hye; Sobue, Kazuya; Sasano, Hiroshi; Katsuya, Hirotada			Anesthetic management of a patient with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) during laparotomy	JOURNAL OF ANESTHESIA			English	Article						MELAS; bicarbonated Ringer's solution; normothermia; mitochondria		A 53-year-old man with mitochondrial myopathy, encephalopathy. lactic acidosis, and stroke-like episodes (MELAS) underwent a gastrectomy. We administered bicarbonated Ringer's solution, which has a physiological concentration of bicarbonate. The level of serum lactate did not increase significantly, and metabolic acidosis did not occur throughout surgery or for 3h after surgery. Aggressive warming was needed to maintain normothermia, presumably because the mitochondrial respiratory chain, which is responsible for thermogenesis, is impaired in MELAS patients. It is important to maintain normothermia in MELAS patients in order to avoid further mitochondrial metabolic depression.	[Sasano, Nobuko; Fujita, Yoshihito; So, Min Hye; Sobue, Kazuya; Sasano, Hiroshi; Katsuya, Hirotada] Nagoya City Univ, Grad Sch Med Sci, Dept Anesthesiol & Med Crisis Management, Mizuho Ku, Nagoya, Aichi 4678622, Japan	Sasano, N (reprint author), Nagoya City Univ, Grad Sch Med Sci, Dept Anesthesiol & Med Crisis Management, Mizuho Ku, 1 Kawasumi Mizuho Cho, Nagoya, Aichi 4678622, Japan.						Bolton P, 2003, PAEDIATR ANAESTH, V13, P453, DOI 10.1046/j.1460-9592.2003.01001.x; Cholley F, 2001, NEUROPEDIATRICS, V32, P104, DOI 10.1055/s-2001-13878; Farag E, 2002, CAN J ANAESTH, V49, P958, DOI 10.1007/BF03016883; GOU R, 1987, J CLIN ANESTH, V11, P57; Hashimoto K, 2001, J THORAC CARDIOV SUR, V121, P1179, DOI 10.1067/mtc.2001.113599; HIRANO M, 1994, J CHILD NEUROL, V9, P4, DOI 10.1177/088307389400900102; Maeda Y, 2001, Masui, V50, P299; McKenzie M, 2004, NEUROCHEM RES, V29, P589, DOI 10.1023/B:NERE.0000014829.42364.dd; NELSON DL, 2005, PRINCIPLES BIOCH, P690; OHTANI Y, 1985, BRAIN DEV-JPN, V7, P249; PARK R, 1982, J CLIN INVEST, V70, P853, DOI 10.1172/JCI110682; Satoh K, 2005, EUR J ANAESTH, V22, P624, DOI 10.1017/S0265021505001043; Thambisetty M, 2004, EXPERT REV MOL DIAGN, V4, P631, DOI 10.1586/14737159.4.5.631; Thompson VA, 1997, ANESTH ANALG, V85, P1404, DOI 10.1097/00000539-199712000-00041	14	19	19	0	3	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.		2007	21	1					72	75		10.1007/s00540-006-0449-y			4	Anesthesiology	Anesthesiology	275TQ	WOS:000254094900015	17285419				2020-06-30	J	Hudcova, J; Schumann, R				Hudcova, Jana; Schumann, Roman			Undiagnosed catecholamine-secreting paraganglioma and coexisting carcinoid in a patient with MH susceptibility: an unusual anesthetic challenge	JOURNAL OF ANESTHESIA			English	Article						undiagnosed pheochromocytoma; carcinoid neuroendocrine tumors; dexmedetomidine; propofol infusion syndrome	PROPOFOL INFUSION SYNDROME; LARGE PHEOCHROMOCYTOMA; DEXMEDETOMIDINE; RESECTION; ADULT	The management of a patient with two undiagnosed neuroendocrine tumors and possible malignant hyperthermia (MH) susceptibility poses a unique challenge to the anesthesiologist. We describe a total intravenous anesthetic including an alpha 2-agonist infusion combined with epidurally administered bupivacaine for intra- and postoperative pain management. Alpha 2-agonists may offer improved intraoperative hemodynamic management in patients with catecholamine-secreting tumors and reduce the total dose needed for intravenous anesthetics such as propofol. The latter mechanism may be useful to avert the risk of the propofol infusion syndrome occurring as a consequence of a high cumulative dose following its prolonged administration.	[Hudcova, Jana; Schumann, Roman] Tufts Univ, Sch Med, Tufts New England Med Ctr, Dept Anesthesia, Boston, MA 02111 USA	Hudcova, J (reprint author), Beth Israel Deaconess Med Ctr, Dept Anesthesia Crit Care & Pain Med, 1 Deaconess Rd CC-470, Boston, MA 02215 USA.						Arain SR, 2002, ANESTH ANALG, V95, P461, DOI 10.1097/00000539-200208000-00042; Barakat MT, 2004, ENDOCR-RELAT CANCER, V11, P1, DOI 10.1677/erc.0.0110001; Ernest D, 2003, ANAESTH INTENS CARE, V31, P316; GRAHAM GW, 2000, INT ANESTHESIOL CLIN, V4, P31; JORDEN VSB, 2002, SEMIN ANESTH PERIO M, V21, P265, DOI DOI 10.1053/sane.2002.34195; Kang TM, 2002, ANN PHARMACOTHER, V36, P1453; Koch M, 2004, INTENS CARE MED, V30, P522, DOI 10.1007/s00134-003-2130-3; Liolios A, 2005, ANESTH ANALG, V100, P1804, DOI 10.1213/01.ANE.0000153017.93666.BF; Oberg Kjell, 2003, Expert Rev Anticancer Ther, V3, P863, DOI 10.1586/14737140.3.6.863; Ramsay MAE, 2004, ANESTHESIOLOGY, V101, P787; Schumann R, 2003, J CLIN ANESTH, V15, P540, DOI 10.1016/j.jclinane.2003.02.006; Short Timothy G, 2003, Best Pract Res Clin Anaesthesiol, V17, P77, DOI 10.1053/bean.2002.0266; SPRUNG J, 2002, SEMIN ANESTH PERIO M, V21, P35, DOI DOI 10.1053/sane.2002.30379; Vasile B, 2003, INTENS CARE MED, V29, P1417, DOI 10.1007/s00134-003-1905-x; VOROS DC, 1995, EUR J SURG, V162, P985; Wong AYC, 2004, BRIT J ANAESTH, V93, P873, DOI 10.1093/bja/aeh634	16	1	1	0	2	SPRINGER TOKYO	TOKYO	3-3-13, HONGO, BUNKYO-KU, TOKYO, 113-0033, JAPAN	0913-8668			J ANESTH	J. Anesth.		2007	21	1					80	82		10.1007/s00540-006-0462-1			3	Anesthesiology	Anesthesiology	275TQ	WOS:000254094900017	17285421				2020-06-30	J	Bedirli, N; Boyaci, A; Akin, A; Esmaoglu, A				Bedirli, Nurdan; Boyaci, Adem; Akin, Aynur; Esmaoglu, Aliye			Comparison of the effects of fentanyl and remifentanil on splanchnic tissue perfusion during cardiac surgery	JOURNAL OF ANESTHESIA			English	Article						cardiopulmonary bypass; remifentanil; fentanyl; splanchnic perfusion	GASTRIC INTRAMUCOSAL PH; CARDIOPULMONARY BYPASS; EARLY EXTUBATION; OXYGENATION; TONOMETRY; FAILURE; SEPSIS; FLOW	The purpose of this study was to compare the effects of fentanyl and remifentanil on splanchnic perfusion during coronary artery bypass graft (CABG) surgery. Fifty patients were randomized to receive either fentanyl (10 mu g.kg(-1) at induction and 5 mu g.kg(-1).h(-1) infusion for maintenance) or remifentanil (3 mu g.kg(-1) at induction and 1 mu g.kg(-1).min(-1) infusion for maintenance). Patients in both groups were comparable with regard to demographics. Intraoperative volume management and inotropic therapy were similiar in both groups. Regarding heart rate, there were no significant differences between the groups at any measurement time (P > 0.05). Compared to the fentanyl group, the remifentanil group showed a significant decrease in mean arterial pressure during induction. Also, the gastric intramucosal CO, pressure (Pg(CO2)) and the Pg(CO2) gap, defined as the difference between Pg(CO2) and Pg(CO2) were significantly increased and the gastric mucosal pH (pHi) was significantly decreased in the remifentanil group in the postinduction period (P < 0.05). However, there were no statistically significant differences in respiratory data at any time between the two groups (P > 0.05). Both fentanyl and remifentanil seemed to be effective and well tolerated in this CABG population. Episodes of hypotension and transient reduction in splanchnic perfusion were more common in patients treated with remifentanil when compared to those receiving the fentanyl opioid regimen.	[Bedirli, Nurdan; Boyaci, Adem; Akin, Aynur; Esmaoglu, Aliye] Erciyes Univ, Fac Med, Dept Anesthesiol, TR-38039 Kayseri, Turkey	Bedirli, N (reprint author), Mesa Koru Sit Fulya Blok 85-39, TR-06810 Ankara, Turkey.			Bedirli, Nurdan/0000-0003-2624-0259			ANDRITSCH RF, 1981, ANESTHESIOLOGY, V55, P311, DOI 10.1097/00000542-198109000-00022; Bennett-Guerrero E, 2000, ANESTHESIOLOGY, V92, P38, DOI 10.1097/00000542-200001000-00012; Biffl WL, 1996, BRIT J ANAESTH, V77, P59; Chapman M V, 2000, Intensive Care Med, V26, P613, DOI 10.1007/s001340051212; FIDDIANGREEN RG, 1995, BRIT J ANAESTH, V74, P591, DOI 10.1093/bja/74.5.591; GARDEBACK M, 1995, ACTA ANAESTH SCAND, V39, P1066, DOI 10.1111/j.1399-6576.1995.tb04231.x; Gerhardt MA, 1998, J CLIN ANESTH, V10, P249, DOI 10.1016/S0952-8180(98)00017-8; HamiltonDavies C, 1997, INTENS CARE MED, V23, P276, DOI 10.1007/s001340050328; Holland J, 2005, AM J SURG, V190, P393, DOI 10.1016/j.amjsurg.2005.03.038; Howie MB, 2001, ANESTH ANALG, V92, P1084; Lebuffe G, 1999, ANESTH ANALG, V89, P1084, DOI 10.1213/00000539-199911000-00003; MARIK PE, 1993, CHEST, V104, P225, DOI 10.1378/chest.104.1.225; Martinez-Pellus AE, 1997, INTENS CARE MED, V23, P1251, DOI 10.1007/s001340050494; Myles PS, 2002, ANESTH ANALG, V95, P805, DOI 10.1097/00000539-200210000-00004; Ohri SK, 1997, ANN THORAC SURG, V64, P163, DOI 10.1016/S0003-4975(97)00290-7	15	5	5	0	0	SPRINGER TOKYO	TOKYO	3-3-13, HONGO, BUNKYO-KU, TOKYO, 113-0033, JAPAN	0913-8668			J ANESTH	J. Anesth.		2007	21	1					94	98		10.1007/s00540-006-0457-y			5	Anesthesiology	Anesthesiology	275TQ	WOS:000254094900021	17285425				2020-06-30	J	Saito, O; Yamamoto, T; Mizuno, Y				Saito, Osamu; Yamamoto, Tatsuo; Mizuno, Yuko			Epidural anesthetic management using ropivacaine in a parturient with multi-minicore disease and susceptibility to malignant hyperthermia	JOURNAL OF ANESTHESIA			English	Letter									[Saito, Osamu] Univ Calif San Diego, Anesthesia Res Lab, La Jolla, CA 92093 USA; [Saito, Osamu; Mizuno, Yuko] Chiba Univ, Grad Sch Med, Dept Anesthesiol, Chuo Ku, Chiba 2608670, Japan	Saito, O (reprint author), Univ Calif San Diego, Anesthesia Res Lab, CTF C-312,9500 Gilman Dr,Dept 0818, La Jolla, CA 92093 USA.						Ferreiro A, 2002, ANN NEUROL, V51, P750, DOI 10.1002/ana.10231; Halpern SH, 2003, ANESTHESIOLOGY, V98, P1431, DOI 10.1097/00000542-200306000-00020; Maemura Yumi, 2002, Japanese Journal of Anesthesiology, V51, P19; Osada H, 2004, GYNECOL OBSTET INVES, V58, P32, DOI 10.1159/000077658	4	6	6	0	0	SPRINGER TOKYO	TOKYO	3-3-13, HONGO, BUNKYO-KU, TOKYO, 113-0033, JAPAN	0913-8668			J ANESTH	J. Anesth.		2007	21	1					113	113		10.1007/s00540-006-0467-9			1	Anesthesiology	Anesthesiology	275TQ	WOS:000254094900028	17285432				2020-06-30	J	Gulhas, N; Erdil, FA; Sagir, O; Gedik, E; Togal, T; Begec, Z; Ersoy, MO				Gulhas, Nurcin; Erdil, Feray Akgul; Sagir, Ozlem; Gedik, Ender; Togal, Turkan; Begec, Zekine; Ersoy, M. Ozcan			Lornoxicam and ondansetron for the prevention of intrathecal fentanyl-induced pruritus	JOURNAL OF ANESTHESIA			English	Article						intrathecal; fentanyl; pruritus; ondansetron; lornoxicam	PROPHYLACTIC ONDANSETRON; CESAREAN DELIVERY; BUPIVACAINE; TENOXICAM; NSAID	Purpose. In this randomized, double-blind study, we aimed to compare the effectiveness of lornoxicam and ondansetron for the prevention of intrathecal fentanyl-induced pruritus in patients undergoing cesarean section. Methods. One hundred and eight parturients (American Society of Anesthesiologists [ASA] I-II status) requesting neuraxial analgesia by a combined spinal-epidural (CSE) technique were recruited for this study. A CSE technique was performed and anesthesia was achieved with fentanyl 25 mu g and hyperbaric bupivacaine 12mg. Patients were randomly allocated to three groups, each with 36 participants. Immediately following delivery, patients received either lornoxicam 8 mg IV (group L; n = 36), ondansetron 8 mg IV (group O; n = 36), or normal saline 2ml IV (group P; n = 36). Pruritus, pain, and nausea and vomiting scores were recorded during the initial 24h postoperatively. Results. The incidence of pruritus was significantly lower in group O from 4 to 12 h postoperatively when compared to that in group L and group P. According to the pruritus grading system we used, the number of patients without pruritus was significantly higher in group O when compared to that in group L and group P. The number of patients experiencing moderate pruritus was significantly lower in group O when compared to that in group P. Conclusion. We observed that the administration of 8mg IV lornoxicam failed to prevent intrathecal fentanyl-induced pruritus in parturients. Also, our data confirmed that ondansetron is likely to attenuate intrathecal fentanyl-induced pruritus.	[Gulhas, Nurcin; Erdil, Feray Akgul; Sagir, Ozlem; Gedik, Ender; Togal, Turkan; Begec, Zekine; Ersoy, M. Ozcan] Inonu Univ, Sch Med, Dept Anesthesiol, Malatya, Turkey	Gulhas, N (reprint author), Turgut Ozal Tip Merkezi Anesteziyol Bolumu, TR-44315 Malatya, Turkey.						Anderson GD, 2005, CLIN PHARMACOKINET, V44, P989, DOI 10.2165/00003088-200544100-00001; BOGRA J, 2005, BMC ANESTHESIOLOGY, V5, P1; Carvalho B, 2005, ANESTHESIOLOGY, V103, P606, DOI 10.1097/00000542-200509000-00025; Charuluxananan S, 2000, REGION ANESTH PAIN M, V25, P535, DOI 10.1053/rapm.2000.7809; Colbert S, 1999, ANAESTHESIA, V54, P76, DOI 10.1046/j.1365-2044.1999.00610.x; Colbert S, 1999, ANAESTHESIA, V54, P948, DOI 10.1046/j.1365-2044.1999.01066.x; CONKLN KA, 1999, OBSTET ANESTHESIA, P25; ELHAKIM M, 1995, BRIT J ANAESTH, V74, P643, DOI 10.1093/bja/74.6.643; Gurkan Y, 2002, ANESTH ANALG, V95, P1763, DOI 10.1213/01.ANE.0000033097.30674.02; Kimoto Michiyo, 2005, Masui, V54, P864; Korhonen AM, 2003, ACTA ANAESTH SCAND, V47, P1292, DOI 10.1046/j.1399-6576.2003.00206.x; Radhofer-Welte S, 2000, DRUG TODAY, V36, P55, DOI 10.1358/dot.2000.36.1.566627; Rosenow DE, 1996, CLIN DRUG INVEST, V11, P11, DOI 10.2165/00044011-199611010-00002; Sarvela PJ, 2006, ACTA ANAESTH SCAND, V50, P239, DOI 10.1111/j.1399-6576.2006.00934.x; Szarvas S, 2003, J CLIN ANESTH, V15, P234, DOI 10.1016/S0952-8180(02)00501-9; Teoh WHL, 2006, INT J OBSTET ANESTH, V15, P273, DOI 10.1016/j.ijoa.2006.03.004; Waxler B, 2005, ANESTHESIOLOGY, V103, P168, DOI 10.1097/00000542-200507000-00025; Yazigi A, 2002, J CLIN ANESTH, V14, P183, DOI 10.1016/S0952-8180(01)00381-6; Yeh HM, 2000, ANESTH ANALG, V91, P172, DOI 10.1097/00000539-200007000-00032	19	8	12	1	3	SPRINGER JAPAN KK	TOKYO	SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.		2007	21	2					159	163		10.1007/s00540-007-0503-4			5	Anesthesiology	Anesthesiology	281PB	WOS:000254509300007	17458644				2020-06-30	J	Adachi, YU; Sano, H; Doi, M; Sato, S				Adachi, Yushi U.; Sano, Hideki; Doi, Matsuyuki; Sato, Shigehito			Central neurogenic hyperventilation treated with intravenous fentanyl followed by transdermal application	JOURNAL OF ANESTHESIA			English	Article						central neurogenic hyperventilation; fentanyl patch; Durotep	BRAIN; PATHOPHYSIOLOGY; LYMPHOMA; PH	Central neurogenic hyperventilation (CNH) is a rare clinical condition that is sometimes difficult to treat. We report a 51-year-old female patient who was successfully treated with intravenous fentanyl followed by transdermal fentanyl. She had a transient epileptic episode with a temporary loss of consciousness. Immediately before her admission to the intensive care unit (ICU), her Pa(CO2) and pH were 6.7mmHg and 7.64, respectively. Rebreathing from a paper bag and the intravenous administration of diazepam failed to improve the decreased PaCO(2). Therefore, we administered intravenous fentanyl, at the rate of 50 mu g(.)h(-1). Two days after her admission to the ICU, the PaCO(2) had increased gradually to 22.9 mmHg, and the pH to 7.50. Although infiltration of recurrent lymphoma to the brain became apparent, she remained active, without epilepsy or loss of consciousness, in a general ward for 1 month with transdermal fentanyl, treatment until she again became drowsy; she died on hospital day 58. Transdermal fentanyl seems to be a good palliative measure to treat CNH in patients who have advanced neoplasms.	[Adachi, Yushi U.; Sano, Hideki; Doi, Matsuyuki; Sato, Shigehito] Hamamatsu Univ Sch Med, Intens Care Unit, Univ Hosp, Hamamatsu, Shizuoka 4313192, Japan	Adachi, YU (reprint author), Hamamatsu Univ Sch Med, Intens Care Unit, Univ Hosp, 1-20-1 Handayama, Hamamatsu, Shizuoka 4313192, Japan.						Gaviani P, 2005, NEUROLOGY, V64, P166, DOI 10.1212/01.WNL.0000148579.80486.F1; JAECKLE KA, 1990, NEUROLOGY, V40, P1715, DOI 10.1212/WNL.40.11.1715; Johnston SC, 2001, NEUROLOGY, V57, P2131, DOI 10.1212/WNL.57.11.2131; PAUZNER R, 1989, ARCH NEUROL-CHICAGO, V46, P510, DOI 10.1001/archneur.1989.00520410044021; PLUM F, 1959, ARCH NEURO PSYCHIATR, V81, P535, DOI 10.1001/archneurpsyc.1959.02340170001001; ROTTENBERG DA, 1985, ANN NEUROL, V17, P70, DOI 10.1002/ana.410170116; Sakamoto T, 2001, Radiat Med, V19, P209; Shahar E, 2004, PEDIATR NEUROL, V30, P287, DOI 10.1016/j.pediatrneurol.2003.10.003; SHIBATA Y, 1992, J NEUROSURG, V76, P696, DOI 10.3171/jns.1992.76.4.0696; SOMJEN GG, 1987, CAN J PHYSIOL PHARM, V65, P1078, DOI 10.1139/y87-169; SUNDERRAJAN EV, 1984, CHEST, V86, P634, DOI 10.1378/chest.86.4.634; Tarulli AW, 2005, ARCH NEUROL-CHICAGO, V62, P1632, DOI 10.1001/archneur.62.10.1632	12	6	6	0	1	SPRINGER TOKYO	TOKYO	1-11-11 KUDAN-KITA, CHIYODA-KU, TOKYO, 102-0073, JAPAN	0913-8668			J ANESTH	J. Anesth.		2007	21	3					417	419		10.1007/s00540-007-0526-x			3	Anesthesiology	Anesthesiology	310LN	WOS:000256531200021	17680198				2020-06-30	J	Doi, K; Yamanaka, M; Shono, A; Fukuda, N; Saito, Y				Doi, Katsushi; Yamanaka, Manami; Shono, Atsuko; Fukuda, Noriko; Saito, Yoji			Preoperative epidural fentanyl reduces postoperative pain after upper abdominal surgery	JOURNAL OF ANESTHESIA			English	Article						postoperative analgesia; epidural analgesia; bupivacaine; fentanyl	PREEMPTIVE ANALGESIA; BUPIVACAINE; MORPHINE; INFUSION; EXPERIENCE; RELIEF	Forty patients, American Society of Anesthesiology (ASA) physical status 1-2, undergoing subtotal gastrectomy were enrolled in this study. The patients were allocated to two groups with or (group P) and without (group C) preoperative epidural fentanyl 100 mu g. Postoperatively, all patients received continuous infusion of the study solution, containing fentanyl 30 mu g.ml(-1) and 2mg/ml bupivacaine, at a rate of 0.7ml.h(-1) for 72h. The scores on the Prince Henry Hospital self-assessed pain scale (PHPS) were recorded at 0, 4, 12, 24, 48, and 72h after the surgery. We compared the total rescue doses of analgesics during each period of 24h until 72h postoperatively. Although the total rescue doses of analgesics were not different between the groups, the median PHPS score was lower in group P than in group C, except at Oh after the surgery. Preoperative epidural fentanyl 100 mu g may increase the analgesic potency of postoperative epidural low-dose infusion of bupivacaine with fentanyl.	[Doi, Katsushi; Saito, Yoji] Shimane Univ, Sch Med, Dept Anesthesiol, Izumo, Shimane 6938501, Japan; [Doi, Katsushi; Yamanaka, Manami; Shono, Atsuko; Fukuda, Noriko] Miyoshi Gen Hosp, Dept Anesthesiol, Miyoshi, Japan	Doi, K (reprint author), Shimane Univ, Sch Med, Dept Anesthesiol, 89-1 Enya Cho, Izumo, Shimane 6938501, Japan.						Aida S, 2000, ANESTHESIOLOGY, V92, P1624, DOI 10.1097/00000542-200006000-00020; CHIEN BB, 1991, ARCH SURG-CHICAGO, V126, P692; CHISAKUTA AM, 1995, ANAESTHESIA, V50, P72, DOI 10.1111/j.1365-2044.1995.tb04518.x; COOPER DW, 1993, BRIT J ANAESTH, V70, P503, DOI 10.1093/bja/70.5.503; DALL JB, 1992, ANESTH ANALG, V74, P362; deLeonCasasola OA, 1996, ANESTH ANALG, V83, P867, DOI 10.1097/00000539-199610000-00038; Gedney JA, 1998, ANAESTHESIA, V53, P1148, DOI 10.1046/j.1365-2044.1998.00636.x; GEORGE KA, 1994, ACTA ANAESTH SCAND, V38, P808, DOI 10.1111/j.1399-6576.1994.tb04009.x; Hurford W E, 1993, J Cardiothorac Vasc Anesth, V7, P521, DOI 10.1016/1053-0770(93)90306-6; Katz J, 2003, ANESTHESIOLOGY, V98, P1449, DOI 10.1097/00000542-200306000-00023; Liu SS, 1998, ANESTHESIOLOGY, V88, P688, DOI 10.1097/00000542-199803000-00020; PYBUS DA, 1982, BRIT J ANAESTH, V54, P1259, DOI 10.1093/bja/54.12.1259; Rockemann MG, 1996, ANESTHESIOLOGY, V84, P1027, DOI 10.1097/00000542-199605000-00003; SAITO Y, 1994, ACTA ANAESTH SCAND, V38, P398, DOI 10.1111/j.1399-6576.1994.tb03915.x; SCOTT DA, 1995, ANESTHESIOLOGY, V83, P727, DOI 10.1097/00000542-199510000-00012; THOMSON CA, 1995, ANESTH ANALG, V81, P973, DOI 10.1097/00000539-199511000-00014	16	3	5	0	1	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0913-8668			J ANESTH	J. Anesth.		2007	21	3					439	441		10.1007/s00540-007-0519-9			3	Anesthesiology	Anesthesiology	310LN	WOS:000256531200027	17680204				2020-06-30	J	Darwish, M; Kirby, M; Robertson, P; Hellriegel, E; Jiang, JG				Darwish, Mona; Kirby, Mary; Robertson, Philmore, Jr.; Hellriegel, Edward; Jiang, John G.			Single-dose and steady-state pharmacokinetics of fentanyl buccal tablet in healthy volunteers	JOURNAL OF CLINICAL PHARMACOLOGY			English	Article						fentanyl buccal tablet; opioid; transmucosal; healthy volunteers; pharmacokinetics		This study evaluated the single-dose and steady-state pharmacokinetics of fentanyl buccal tablet 400 mu g in healthy adult volunteers. After receiving naltrexone 50 mg to block opioid receptor-mediated effects of fentanyl, subjects received fentanyl buccal tablet 400 mu g on day 1, then every 6 hours from day 4 to day 9 (21 doses). Naltrexone 50 mg was administered every 12 hours throughout the study. Plasma fentanyl concentrations were determined for 72 hours after administration of fentanyl buccal tablet 400 mu g on day 1 and the last dose of fentanyl buccal tablet 400 mu g on day 9. Following single- and multiple-dose administration of fentanyl buccal tablet, the median time to maximum concentration (t(max)) was 52.2 and 49.8 minutes, respectively. Peak plasma concentration of fentanyl (C-max was 0.88 ng/mL for the single-dose regimen and 1.77 ng/mL for the multiple-dose regimen. Steady state was reached within 5 days, consistent with the observed median half-life of approximately 22 hours following multiple doses. Observed accumulation of fentanyl after multiple doses of fentanyl buccal tablet was slightly greater than would be expected based on the single-dose data. This was attributed to the redistribution of fentanyl from a deep tissue compartment into the plasma. This study indicates that fentanyl buccal tablet has predictable pharmacokinetics following multiple-dose administration.	Cephalon Inc, Clin Pharmacol, Frazer, PA USA; Cephalon Inc, Drug Safety & Disposit, Frazer, PA USA	Darwish, M (reprint author), 41 Moores Rd, Frazer, PA 19355 USA.	mdarwish@cephalon.com					Darwish M, 2005, CLIN PHARMACOKINET, V44, P1279, DOI 10.2165/00003088-200544120-00006; Durfee S, 2006, AM J DRUG DELIV, V4, P1, DOI DOI 10.2165/00137696-200604010-00001; Eichman JD, 1998, PHARM RES-DORDR, V15, P925, DOI 10.1023/A:1011936901638; Eichman JD, 1997, EUR J PHARM BIOPHARM, V44, P33, DOI 10.1016/S0939-6411(97)00099-4; GIBALDI M, 1982, PHARMACOKINETICS; GUTSTEIN H, 2006, [No title captured]; HUDSON RJ, 1986, ANESTHESIOLOGY, V64, P334, DOI 10.1097/00000542-198603000-00006; HUG CC, 1981, ANESTHESIOLOGY, V55, P369, DOI 10.1097/00000542-198110000-00006; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Stanley TH, 2005, J PAIN SYMPTOM MANAG, V29, pS67, DOI 10.1016/j.jpainsymman.2005.01.009	10	23	23	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0091-2700	1552-4604		J CLIN PHARMACOL	J. Clin. Pharmacol.	JAN	2007	47	1					56	63		10.1177/0091270006294129			8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	122LC	WOS:000243227500007	17192502				2020-06-30	J	Naja, MZ; El-Rajab, M; Kabalan, W; Itani, MT; Kharma, K; Al Tannir, MA; Ziade, MF				Naja, M. Z.; El-Rajab, M.; Kabalan, W.; Itani, M. T.; Kharma, K.; Al Tannir, M. A.; Ziade, M. F.			Effectiveness of local anaesthesia (clonidine and fentanyl) infiltration for post-submucosal resection pain relief: a randomized, double-blinded clinical trial	JOURNAL OF LARYNGOLOGY AND OTOLOGY			English	Article						nasal Septum; Perioperative pain; otorhinolaryngologic surgical procedures; anaesthesia; local	GENERAL-ANESTHESIA; TONSILLECTOMY; SURGERY; BUPIVACAINE	Background: Submucosal resection is accompanied by significant post-operative pain and discomfort. The aim of this randomized, double-blinded clinical trial was to study the efficacy of a local block anaesthetic, delivered after induction of general anaesthesia, in reducing post-operative pain. Methods: Patients aged 16 years and over who were scheduled for elective submucosal resection were randomly assigned to receive either standardized general anaesthesia, general anaesthesia with local anaesthetic infiltration or general anaesthesia with placebo infiltration. Haemodynamic stability, intra-operative blood loss, post-operative pain (over a seven day follow-up period), analgesics consumption, hospital stay, and the patient's and surgeon's levels of satisfaction were assessed. Results: We found significantly lower results for pack removal pain score, volume of intra-operative blood loss, number of patients suffering from headache, altered dental sensation or nasal pain, number of patients who consumed analgesics, and length of hospital stay, comparing the infiltration group with the general anaesthesia and placebo groups (p < 0.05). Conclusion: This clinical trial showed that infiltration with the local anaesthetics fentanyl and clonidine substantially reduced post-operative pain and shortened patients' hospital stay.	Makassed Gen Hosp, Dept Anesthesia, Beirut 11072210, Lebanon; Makassed Gen Hosp, Dept Pediat, Beirut, Lebanon; Makassed Gen Hosp, Dept Ear Nose & Throat, Beirut, Lebanon; Makassed Gen Hosp, Res Unit, Beirut, Lebanon; Lebanese Univ, Fac Publ Hlth, Beirut, Lebanon	Naja, MZ (reprint author), Makassed Gen Hosp, Dept Anesthesia, POB 11-6301, Beirut 11072210, Lebanon.	zouhnaja@yahoo.com		Al-Tannir, Mohamad/0000-0002-7739-8446			ANDERSSON JE, 1983, GRANTS ATLAS ANATOMY; BUCKLEY JG, 1991, J LARYNGOL OTOL, V105, P544, DOI 10.1017/S0022215100116561; Giannoni C, 2001, ARCH OTOLARYNGOL, V127, P1265, DOI 10.1001/archotol.127.10.1265; Ho W, 2004, ARCH OTOLARYNGOL, V130, P324, DOI 10.1001/archotol.130.3.324; JEBELES JA, 1993, INT J PEDIATR OTORHI, V25, P149, DOI 10.1016/0165-5876(93)90048-8; Johansen M, 1996, ARCH OTOLARYNGOL, V122, P261; Lavand'homme PM, 2003, PAIN, V105, P247, DOI 10.1016/S0304-3959(03)00221-5; MACDOUGALL G, 1993, J LARYNGOL OTOL, V107, P1011, DOI 10.1017/S0022215100125125; Naja MZ, 2005, INT J PEDIATR OTORHI, V69, P35, DOI 10.1016/j.ijporl.2004.07.024; Naja MZ, 2003, ANAESTHESIA, V58, P1007, DOI 10.1046/j.1365-2044.2003.03401.x; NAJA MZ, 2000, [No title captured], V16, P201; Naja Z, 2002, EUR J ANAESTH, V19, P197, DOI 10.1017/S0265021502000352; Naja Z, 2001, ANAESTHESIA, V56, P1184; SANCHEZ R, 1984, ANAESTHESIA, V39, P788, DOI 10.1111/j.1365-2044.1984.tb06525.x; Singelyn FJ, 1996, ANESTH ANALG, V83, P1046, DOI 10.1097/00000539-199611000-00025; SRINIVASAN V, 1995, J LARYNGOL OTOL, V109, P614, DOI 10.1017/S0022215100130853	16	2	2	0	2	CAMBRIDGE UNIV PRESS	CAMBRIDGE	EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND	0022-2151	1748-5460		J LARYNGOL OTOL	J. Laryngol. Otol.	JAN	2007	121	1					19	24		10.1017/S0022215106003306			6	Otorhinolaryngology	Otorhinolaryngology	224YM	WOS:000250484300005	17059616				2020-06-30	J	Morii, H; Chiba, M; Konishi, H; Endo, Y; Yamaji, A				Morii, Hiroaki; Chiba, Mikio; Konishi, Hiroki; Endo, Yoshihiro; Yamaji, Akira			Failure of pain control using transdermal fentanyl during rifampicin treatment	JOURNAL OF PAIN AND SYMPTOM MANAGEMENT			English	Letter							DISPOSITION		Shiga Univ Med Sci, Otsu, Shiga 52021, Japan	Morii, H (reprint author), Shiga Univ Med Sci, Otsu, Shiga 52021, Japan.						Donner B, 1996, PAIN, V64, P527, DOI 10.1016/0304-3959(95)00180-8; Kharasch ED, 2004, ANESTHESIOLOGY, V101, P729, DOI 10.1097/00000542-200409000-00022; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154; Takane H, 2005, ANN PHARMACOTHER, V39, P2139, DOI 10.1345/aph.1G370	5	7	7	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0885-3924			J PAIN SYMPTOM MANAG	J. Pain Symptom Manage.	JAN	2007	33	1					5	6		10.1016/j.jpainsymman.2006.08.005			2	Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology	Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology	127AG	WOS:000243556300003	17196900	Bronze			2020-06-30	J	Worrich, S; Schuler, G; Janicki, PK				Worrich, Scott; Schuler, Gregg; Janicki, Piotr K.			Effect of local administration of transdermal fentanyl on peripheral opioid analgesia	PAIN MEDICINE			English	Article						fentanyl; transdermal; quantitative sensory testing; pain threshold	HEAT/CAPSAICIN SENSITIZATION MODEL; MU-OPIATE RECEPTOR; INDUCED THERMAL NOCICEPTION; POSTOPERATIVE PAIN; HYPERALGESIA; CAPSAICIN; REMIFENTANIL; PHARMACOKINETICS; PREDICTION; ALLODYNIA	Objective. Transdermal fentanyl is a commonly used analgesic for the treatment of severe chronic pain. Recent investigations have shown the presence of mu-opioid receptors in the skin and opioid analgesic efficacy with alternative routes of administration of narcotics. This placebo-controlled, double-blind prospective study assessed whether transdermal fentanyl administration produces local peripheral opioid analgesia at the site of application. Design. Baseline pain threshold and supra-threshold pain intensity assessments were measured using Quantitative Sensory Testing in 12 healthy volunteers. Placebo and fentanyl containing patches (Duragesic(R), 25 mu g/h) were applied to opposite forearms for 2 h. After patch removal, pain threshold, supra-threshold pain response, and the area of secondary hyperalgesia were evaluated for both forearms. Results. No statistically significant differences in pain threshold, supra-threshold pain intensity, or area of hyperalgesia in fentanyl- versus placebo-treated forearms were detected in the study subjects. Conclusion. These results suggest that the application of transdermal fentanyl patch for a period of 2 h does not produce local peripheral opioid analgesia at the site of patch application.	Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Anesthesiol, Hershey, PA 17033 USA	Janicki, PK (reprint author), Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Anesthesiol, 500 Univ Dr,H187, Hershey, PA 17033 USA.	pjanicki@psu.edu			NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR10732]		Bigliardi PL, 2003, J INVEST DERMATOL, V120, P145, DOI 10.1046/j.1523-1747.2003.12018.x; Bigliardi PL, 2002, J RECEPT SIGNAL TR R, V22, P191, DOI 10.1081/RRS-120014595; Bigliardi-Qi M, 1999, ANN NY ACAD SCI, V885, P368; Compton P, 2001, DRUG ALCOHOL DEPEN, V63, P139, DOI 10.1016/S0376-8716(00)00200-3; DeHaven-Hudkins DL, 2003, CURR OPIN ANESTHESIO, V16, P541, DOI 10.1097/00001503-200310000-00016; Dirks J, 2000, ANESTH ANALG, V91, P967, DOI 10.1097/00000539-200010000-00037; Dirks J, 2003, J PAIN, V4, P122, DOI 10.1054/jpai.2003.10; Dirks J, 2002, ANESTHESIOLOGY, V97, P102, DOI 10.1097/00000542-200207000-00015; Dirks J, 2001, REGION ANESTH PAIN M, V26, P414, DOI 10.1097/00115550-200109000-00005; Drummond PD, 2003, INFLAMM RES, V52, P366, DOI 10.1007/s00011-003-1188-2; Eisenach JC, 1997, ANESTHESIOLOGY, V86, P1279, DOI 10.1097/00000542-199706000-00008; Granot M, 2003, ANESTHESIOLOGY, V98, P1422, DOI 10.1097/00000542-200306000-00018; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; Guignard B, 2000, ANESTHESIOLOGY, V93, P409, DOI 10.1097/00000542-200008000-00019; Hood DD, 2003, ANESTH ANALG, V97, P810, DOI 10.1213/01.ANE.0000078811.80093.88; Ko MC, 1999, J PHARMACOL EXP THER, V289, P378; Ko MC, 1998, J PHARMACOL EXP THER, V286, P150; Ko MCH, 2000, EUR J PHARMACOL, V402, P69, DOI 10.1016/S0014-2999(00)00503-3; LEHMANN K A, 1988, Acta Anaesthesiologica Belgica, V39, P11; Mikkelsen S, 2001, BRIT J ANAESTH, V86, P871, DOI 10.1093/bja/86.6.871; Petersen KL, 2001, ANESTHESIOLOGY, V94, P15, DOI 10.1097/00000542-200101000-00008; Schiff E, 2003, ANESTH ANALG, V97, P828, DOI 10.1213/01.ANE.0000078583.47735.69; Slominski A, 2003, J INVEST DERMATOL, V120, pXII, DOI 10.1046/j.1523-1747.2003.12258.x; Smith MA, 1997, ANESTH ANALG, V84, pS335; Stander S, 2002, REGUL PEPTIDES, V110, P75, DOI 10.1016/S0167-0115(02)00159-3; STEIN C, 1995, ANN MED, V27, P219, DOI 10.3109/07853899509031962; STEIN C, 1995, NEW ENGL J MED, V332, P1685, DOI 10.1056/NEJM199506223322506; Thompson JP, 1998, BRIT J ANAESTH, V81, P152; Werner MU, 2004, ANESTHESIOLOGY, V100, P115, DOI 10.1097/00000542-200401000-00020; Woodhouse A, 2000, REGION ANESTH PAIN M, V25, P259, DOI 10.1016/S1098-7339(00)90008-7	30	1	1	0	3	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1526-2375	1526-4637		PAIN MED	Pain Med.	JAN-FEB	2007	8	1					41	47		10.1111/j.1526-4637.2007.00144.x			7	Anesthesiology; Medicine, General & Internal	Anesthesiology; General & Internal Medicine	138UY	WOS:000244390000009	17244103	Bronze			2020-06-30	J	Kim, TW; Chan, CC				Kim, Tae W.; Chan, Calvin C.			Local anesthetic infiltration of the wound for supplemental postoperative pain management in a pediatric liver transplant patient	PEDIATRIC ANESTHESIA			English	Letter							MORPHINE		Texas Childrens Hosp, Baylor Coll Med, Dept Anesthesiol & Pediat, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Houston, TX USA	Kim, TW (reprint author), Texas Childrens Hosp, Baylor Coll Med, Dept Anesthesiol & Pediat, Houston, TX 77030 USA.	twkim@bcm.tmc.edu	Chan, Chun-Kit/A-6904-2010	Chan, Chun-Kit/0000-0002-7046-5335			Djurberg H, 2002, J CLIN ANESTH, V14, P564, DOI 10.1016/S0952-8180(02)00446-4; Kim TW, 2004, ANESTH ANALG, V99, P373, DOI 10.1213/01.ANE.0000122822.58156.48; Moretti EW, 2002, J CLIN ANESTH, V14, P416, DOI 10.1016/S0952-8180(02)00390-2; Ulukaya S, 2003, PEDIATR TRANSPLANT, V7, P381, DOI 10.1034/j.1399-3046.2003.00072.x	4	1	1	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645	1460-9592		PEDIATR ANESTH	Pediatr. Anesth.	JAN	2007	17	1					87	88		10.1111/j.1460-9592.2006.01963.x			2	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	132YT	WOS:000243979500018	17184441				2020-06-30	J	Yildiz, TS; Yumuk, NO; Baykal, D; Solak, M; Toker, K				Yildiz, Tulay S.; Yumuk, Nurcan O.; Baykal, Duygu; Solak, Mine; Toker, Kamil			Alagille syndrome and anesthesia management	PEDIATRIC ANESTHESIA			English	Letter							ARTERIOHEPATIC DYSPLASIA; PROPOFOL		Univ Kocaeli, Sch Med, Dept Anesthesiol, Kocaeli, Turkey	Yildiz, TS (reprint author), Univ Kocaeli, Sch Med, Dept Anesthesiol, Kocaeli, Turkey.	tulaysahin00@yahoo.com					ALAGILLE D, 1987, J PEDIATR-US, V110, P195, DOI 10.1016/S0022-3476(87)80153-1; ALAGILLE D, 1975, J PEDIATR-US, V86, P63, DOI 10.1016/S0022-3476(75)80706-2; Choudhry DK, 1998, PAEDIATR ANAESTH, V8, P79, DOI 10.1046/j.1460-9592.1998.00668.x; Emerick KM, 1999, HEPATOLOGY, V29, P822, DOI 10.1002/hep.510290331; HARPER MH, 1982, ANESTH ANALG, V61, P79; MORGAN GE, 2002, CLIN ANAESTHESIOL, P193; MURRAY JM, 1992, BRIT J ANAESTH, V69, P643, DOI 10.1093/bja/69.6.643; Oda T, 1997, NAT GENET, V16, P235, DOI 10.1038/ng0797-235; ROBINSON FP, 1985, POSTGRAD MED J, V61, P160; WATSON GH, 1973, ARCH DIS CHILD, V48, P459, DOI 10.1136/adc.48.6.459	10	0	0	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645	1460-9592		PEDIATR ANESTH	Pediatr. Anesth.	JAN	2007	17	1					91	92		10.1111/j.1460-9592.2006.02022.x			2	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	132YT	WOS:000243979500021	17184444				2020-06-30	J	Seewal, R; Shende, D; Kashyap, L; Mohan, V				Seewal, Rahul; Shende, Dilip; Kashyap, Lokesh; Mohan, Virender			Effect of addition of various doses of fentanyl intrathecally to 0.5% hyperbaric bupivacaine on perioperative analgesia and subarachnoid-block characteristics in lower abdominal surgery: A dose-response study	REGIONAL ANESTHESIA AND PAIN MEDICINE			English	Article						subarachnoid block; hernia repair; fentanyl; bupivacaine	CESAREAN-SECTION; LABOR ANALGESIA; ANESTHESIA	Background: The purpose of this randomized, double-blind, placebo-con trolled trial is to study the effect of adding various doses of fentanyl to 2.2 mL of bupivacaine (0.5% hyperbaric), for spinal anesthetic in nonobstetric population undergoing Superficial lower abdominal surgery (hernia repair). Methods: A population of 60 patients belonging to ASA classes I and II, scheduled for elective inguinal hernia repair, were randomized to receive a spinal anesthetic with 2.2 mL of bupivacaine (0.5% hyperbaric) and saline (control group), or fentanyl 10, 20, 30, or 40 mu g. The volume of injected drug was kept constant at 3 mL by adding preservative-free saline for blinding purposes. Subarachnoid block characteristics, drug-related side effects, and postoperative analgesia requirements were assessed and recorded. Results: Significant improvement in quality and duration of analgesia ocurred in treatment groups (receiving fentanyl and bupivacaine) compared with the control group (saline and bupivacaine) (P < .05). However, no improvement in analgesia occurred when the dose of fentanyl added was increased from 10 to 20, 30, or 40 mu g. Conclusions: The data suggest that in a nonobstetric population receiving spinal anesthetic for superficial lower abdominal surgery (hernia repair), addition of 10 ttg fentanyl to bupivacame 0.5% (hyperbaric) signihcantly improves the quality and duration of analgesia. No further advantage occurs if the dose of fentanyl is increased up to 40 mu g.	Brompton & Harefield NHS Trust, London SE13 6UH, England	Seewal, R (reprint author), Brompton & Harefield NHS Trust, 49 Lullingstone Lane, London SE13 6UH, England.	seewalrul@hotmail.com					BELZARENA SD, 1992, ANESTH ANALG, V74, P653; BenDavid B, 1997, ANESTH ANALG, V85, P560, DOI 10.1097/00000539-199709000-00014; Chu C C, 1995, Acta Anaesthesiol Sin, V33, P149; Herman NL, 1999, ANESTH ANALG, V89, P378, DOI 10.1097/00000539-199908000-00024; Kuusniemi KS, 2000, ANESTH ANALG, V91, P1452, DOI 10.1097/00000539-200012000-00029; Palmer CM, 1998, ANESTHESIOLOGY, V88, P355, DOI 10.1097/00000542-199802000-00014; Roussel J R, 1999, AANA J, V67, P337; Shende D, 1998, ANAESTHESIA, V53, P706, DOI 10.1046/j.1365-2044.1998.329-az0482.x; Stocks GM, 2001, ANESTHESIOLOGY, V94, P593, DOI 10.1097/00000542-200104000-00011; Wong CA, 2004, INT J OBSTET ANESTH, V13, P19, DOI 10.1016/S0959-289X(03)00106-7	10	10	10	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1098-7339	1532-8651		REGION ANESTH PAIN M	Region. Anesth. Pain Med.	JAN-FEB	2007	32	1					20	26		10.1016/j.rapm.2006.09.007			7	Anesthesiology	Anesthesiology	123QT	WOS:000243311100005	17196488				2020-06-30	J	Schmiedt, CW; Bjorling, DE				Schmiedt, Chad W.; Bjorling, Dale E.			Accidental prehension and suspected transmucosal or oral absorption of fentanyl from a transdermal patch in a dog	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article						dog; fentanyl; fentanyl patch; overdose; transdermal	ADMINISTERED FENTANYL; PHARMACOKINETICS; ANALGESIA; ABUSE	A 100-mu g hour(-1) transdermal fentanyl patch was applied to a 29-kg, 6-year-old, intact male mixed breed dog to help manage postoperative pain after total ear canal ablation and lateral bulla osteotomy. Two days later, the dog was found extremely sedated, and the reservoir of the transdermal patch was open. It was suspected that the dog ingested the contents of the reservoir of the transdermal patch and absorbed the fentanyl across its oral mucosa or through the gastrointestinal tract resulting in an overdose. The patch was removed, blood was drawn to determine serum fentanyl levels, and the dog recovered without incident. This clinical case documents the potential for neurologic sequelae, and bradycardia when fentanyl patches are used in animals to relieve postoperative pain.	Univ Wisconsin, Sch Vet Med, Dept Surg Sci, Madison, WI 53706 USA	Schmiedt, CW (reprint author), Univ Wisconsin, Sch Vet Med, Dept Surg Sci, 2015 Linden Dr, Madison, WI 53706 USA.	schmiedtc@svm.vetmed.wisc.edu					Barrueto F, 2004, VET HUM TOXICOL, V46, P30; Egger CM, 1998, VET SURG, V27, P159, DOI 10.1111/j.1532-950X.1998.tb00114.x; Frolich M, 2001, ANESTH ANALG, V93, P647; Gilberto DB, 2003, CONTEMP TOP LAB ANIM, V42, P21; GUYTON AC, 2000, TXB MED PHYSL, P738; Hofmeister EH, 2004, J AM ANIM HOSP ASSOC, V40, P468, DOI 10.5326/0400468; HOLLEY FO, 1988, BRIT J ANAESTH, V60, P608, DOI 10.1093/bja/60.6.608; Kramer Christopher, 1998, Journal of the American Osteopathic Association, V98, P385; Kyles AE, 1998, RES VET SCI, V65, P245, DOI 10.1016/S0034-5288(98)90151-5; Kyles AE, 1996, AM J VET RES, V57, P715; MURPHY MR, 1983, ANESTHESIOLOGY, V59, P537, DOI 10.1097/00000542-198312000-00009; PLUMB DC, 2005, VET DRUG HDB, P470; Purucker M, 2000, ANN EMERG MED, V35, P314, DOI 10.1016/S0196-0644(00)70091-6; Reeves MD, 2002, MED J AUSTRALIA, V177, P552, DOI 10.5694/j.1326-5377.2002.tb04951.x; Robinson TM, 1999, J AM ANIM HOSP ASSOC, V35, P95, DOI 10.5326/15473317-35-2-95; STREISAND JB, 1995, ANESTHESIOLOGY, V82, P759, DOI 10.1097/00000542-199503000-00018; STREISAND JB, 1991, ANESTHESIOLOGY, V75, P223, DOI 10.1097/00000542-199108000-00009; Tharp AM, 2004, AM J FOREN MED PATH, V25, P178, DOI 10.1097/01.paf.0000127398.67081.11; VARVEL JR, 1989, ANESTHESIOLOGY, V70, P928, DOI 10.1097/00000542-198906000-00008; WIGGS RB, 1997, VET DENT PRINCIPLES, P55	20	15	15	1	12	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	1467-2987			VET ANAESTH ANALG	Vet. Anaesth. Analg.	JAN	2007	34	1					70	73		10.1111/j.1467-2995.2006.00302.x			4	Veterinary Sciences	Veterinary Sciences	125ZI	WOS:000243481600011	17238966				2020-06-30	J	Oztekin, I; Gokdogan, S; Oztekin, DS; Issever, H; Goksel, O; Canik, S				Oztekin, Ilhan; Gokdogan, Sumeyye; Oztekin, Deniz S.; Issever, Halim; Goksel, Onur; Canik, Sevim			Effects of propofol and midazolam on lipids, glucose, and plasma osmolality during and in the early postoperative period following coronary artery bypass graft surgery: A randomized trial	YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN			English	Article						propofol; midazolam; fentanyl; serum lipids; glucose; plasma osmolality	LONG-TERM SEDATION; CRITICALLY-ILL PATIENTS; CARDIOPULMONARY BYPASS; MYOCARDIAL-METABOLISM; FATTY-ACIDS; ANESTHESIA; ISCHEMIA; FENTANYL; INSULIN	It is not clear how levels of serum lipids and glucose and plasma osmolality change during propofol infusion in the pre- and postoperative period of coronary artery bypass graft surgery (CABG). This prospective, randomized, controlled trial evaluated changes in these parameters during propofol or midazolam infusion during and in the early postoperative period following surgery. Twenty patients undergoing CABG were randomized preoperatively into two groups: 10 patients received propofol (induction 1.5 mg/kg, maintenance 1.5 mg kg(-1) h(-1)) and 10 patients received midazolam (induction 0.5 mg/kg, maintenance 0.1 mg kg(-1) h(-1)). Both groups also received fentanyl (induction 20 mu g/kg, maintenance 10 mu g kg(-1)). Serum lipids, glucose, and plasma osmolality were measured preinduction, precardiopulmonary bypass, at the end of cardiopulmonary bypass, at the end of surgery, and 4 and 24 h postoperatively. In the propofol group, we observed a significant increase in triglycerides and very low-density lipoprotein levels 4 h postoperatively. In the midazolam group, we observed a significant decrease in low-density lipoprotein, cholesterol at the end of cardiopulmonary bypass, end of surgery, and 4 and 24 h postoperatively and significant increase in osmolality at the end of cardiovascular bypass. Changes in glucose levels did not differ significantly different between the two groups. In patients with normal serum lipids, glucose, and plasma osmolality undergoing CABG, propofol infusion for maintenance anesthesia is not associated with dangerous changes in serum lipids, glucose, and plasma osmolality compared with midazolam. A propofol infusion technique for maintenance of anesthesia for cardiac surgery where serum lipids and glucose may be of concern could be recommended as an alternative to midazolam.	Siyami Ersek Thorac & Cardiovas Surg Hosp, Istanbul, Turkey; Istanbul Univ, Florence Nightingale Coll Nursing, Istanbul, Turkey; Istanbul Univ, Fac Med, Dept Publ Hlth, Istanbul, Turkey; Istanbul Univ, Fac Med, Dept Cardiovasc Surg, Istanbul, Turkey	Oztekin, DS (reprint author), Siyami Ersek Thorac & Cardiovas Surg Hosp, Istanbul, Turkey.	oztekin.deniz@gmail.com	Oztekin, Seher Deniz/C-9708-2019	Oztekin, Seher Deniz/0000-0001-5215-7913			CARRASCO G, 1993, CHEST, V103, P557, DOI 10.1378/chest.103.2.557; DEWANDRE J, 1994, ANAESTHESIA, V49, P8, DOI 10.1111/j.1365-2044.1994.tb03303.x; FAUST RJ, 1994, ANAESTHESIOLOGY REV, P35; GOTTARDIS M, 1989, BRIT J ANAESTH, V62, P393, DOI 10.1093/bja/62.4.393; Gottschling S, 2005, ANAESTHESIA, V60, P660, DOI 10.1111/j.1365-2044.2005.04231.x; Inoue S, 2001, EUR J ANAESTH, V18, P113, DOI 10.1046/j.0265-0215.2000.00789.x; Johnson JH., 1996, PERIOPERATIVE NURSIN, P467; KIMURA T, 2001, MASUI, V9, P1009; Knibbe CAJ, 2004, ACTA ANAESTH SCAND, V48, P302, DOI 10.1111/j.1399-6576.2004.0339.x; Knibbe CAJ, 2002, CLIN PHARMACOL THER, V72, P670, DOI 10.1067/mcp.2002.129500; KUNTSCHEN FR, 1985, J THORAC CARDIOV SUR, V89, P97; KUNTSCHEN FR, 1986, J THORAC CARDIOV SUR, V91, P451; Mateu J, 1996, INTENS CARE MED, V22, P834, DOI 10.1007/BF01709533; MYLES PS, 1995, J CARDIOTHOR VASC AN, V9, P373, DOI 10.1016/S1053-0770(05)80090-4; NAGAOKA H, 1989, ANN THORAC SURG, V48, P798, DOI 10.1016/0003-4975(89)90673-5; OLIVER MF, 1968, LANCET, V1, P710; OLIVER MF, 1994, LANCET, V343, P155, DOI 10.1016/S0140-6736(94)90939-3; Piper SN, 2001, ANAESTHESIA, V56, P836, DOI 10.1046/j.1365-2044.2001.02175.x; REILLY RA, 1985, GOODMAN GILMANS PHAR, P1338; ROGERS RN, 1970, THERMOCHIM ACTA, V1, P1; Sanchez-Izquierdo-Riera JA, 1998, ANESTH ANALG, V86, P1219, DOI 10.1097/00000539-199806000-00016; SEARLE NR, 1993, CAN J ANAESTH, V40, P730, DOI 10.1007/BF03009770; SEIFERT P, 1996, PERIOPERATIVE NURSIN, P318; SMITH RC, 1991, ANESTHESIOLOGY, V74, P464, DOI 10.1097/00000542-199103000-00013; STEPHAN H, 1986, BRIT J ANAESTH, V58, P969, DOI 10.1093/bja/58.9.969; Theilen HJ, 2002, ANESTH ANALG, V95, P923, DOI 10.1097/00000539-200210000-00024; VERMEYEN KM, 1987, BRIT J ANAESTH, V59, P1115, DOI 10.1093/bja/59.9.1115; VERMEYEN KM, 1991, BRIT J ANAESTH, V66, P504, DOI 10.1093/bja/66.4.504; YOKOTA H, 1977, J THORAC CARDIOV SUR, V73, P543; Zamacona MK, 1998, ANESTH ANALG, V87, P1147, DOI 10.1097/00000539-199811000-00032	30	4	5	0	1	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0031-6903	1347-5231		YAKUGAKU ZASSHI	Yakugaku Zasshi-J. Pharm. Soc. Jpn.		2007	127	1					173	182		10.1248/yakushi.127.173			10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	132SV	WOS:000243963400020	17202798	Bronze			2020-06-30	J	Koltzenburg, M; Pokorny, R; Gasser, UE; Richarz, U				Koltzenburg, Martin; Pokorny, Rolf; Gasser, Urs E.; Richarz, Ute			Differential sensitivity of three experimental pain models in detecting the analgesic effects of transdermal fentanyl and buprenorphine	PAIN			English	Article						transdermal opioid delivery system; fentanyl; buprenorphine; dose effectiveness; acute pain models; healthy volunteers; double-blind cross-over study	CHRONIC NONCANCER PAIN; RELEASE ORAL MORPHINE; LOW-BACK-PAIN; DOUBLE-BLIND; OPEN-LABEL; SECONDARY HYPERALGESIA; INTRADERMAL CAPSAICIN; INTRAVENOUS KETAMINE; PHASE-III; ALFENTANIL	This is the first randomized controlled trial that tests the analgesic efficacy of transdermally delivered opioids in healthy volunteers and that assesses the sensitivity of different experimental pain tests to detect analgesia in this setting. Transdermal application of the full agonist fentanyl (TDF: 12.5 or 25 mu g/h) and the partial agonist buprenorphine (TDB: 35 mu g/h) was compared in three experimental models of acute pain (heat pain, painful electrical stimulation, cold pressor) in a double-blind, randomized, placebo-controlled. 4-arm crossover study with 20 healthy subjects (15 men, 5 women). Patches were administered for 72 h and pain levels measured at baseline and 24 and 72 h, with an 11-day wash-out. The cold pressor test was most sensitive to analgesic effects, with significant reductions in area under the pain intensity curve for all active compounds at 24 It (average reductions: 14% TDF 12.5 mu g/h 35% TDF 25 mu g/h 43% TDB 35 mu g/h). There were significant increases in heat pain threshold for TDF 25 mu g/h and TDB 35 mu g/h. Painful electrical stimulation failed to demonstrate an analgesic effect. The magnitude of analgesia in the cold pressor model showed some correlation with TDF dosage and comparable effects for the full agonist fentanyl and the partial agonist buprenorphine. We conclude that the cold pressor test was most sensitive to analgesic effects in healthy subjects and that a transdermal dose of 12.5 mu g/h fentanyl achieved significant pain reduction compared with placebo. Subjects experienced opioid-typical AEs including dizziness, nausea and vomiting. No serious AEs occurred. (c) 2006 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.	Janssen Cilag AG, CH-6341 Baar, Switzerland; Univ Coll, Inst Child Hlth, Neural Plastic Unit, London, England; Swiss Pharma Contract Ltd, Allschwil, Switzerland; ClinRes GmbH, Aesch, Switzerland	Richarz, U (reprint author), Janssen Cilag AG, Shilbruggstr 111, CH-6341 Baar, Switzerland.	urichar1@jacch.jnj.com	Koltzenburg, Martin/C-1349-2008	Koltzenburg, Martin/0000-0001-9181-5966			Allan L, 2005, SPINE, V30, P2484, DOI 10.1097/01.brs.0000186860.23078.a8; Allan L, 2001, BRIT MED J, V322, P1154, DOI 10.1136/bmj.322.7295.1154; Angst MS, 2001, ANESTHESIOLOGY, V94, P63, DOI 10.1097/00000542-200101000-00014; ArendtNielsen L, 1996, BRIT J ANAESTH, V77, P625; BLACK JR, 1999, 17406 INV CLIN RES; Caldwell JR, 2002, J PAIN SYMPTOM MANAG, V23, P278, DOI 10.1016/S0885-3924(02)00383-4; Enggaard TP, 2001, CLIN PHARMACOL THER, V69, P245, DOI 10.1067/mcp.2001.114873; FRUHSTORFER H, 1976, J NEUROL NEUROSUR PS, V39, P1071, DOI 10.1136/jnnp.39.11.1071; Graven-Nielsen Thomas, 2003, Curr Pain Headache Rep, V7, P443, DOI 10.1007/s11916-003-0060-y; Hale ME, 2005, J PAIN, V6, P21, DOI 10.1016/j.jpain.2004.09.005; JONES SF, 1988, PAIN, V34, P117, DOI 10.1016/0304-3959(88)90156-X; Koppert W, 1999, ANESTH ANALG, V89, P1521, DOI 10.1097/00000539-199912000-00039; Le Loet X, 2005, BMC MUSCULOSKEL DIS, V6, DOI 10.1186/1471-2474-6-31; Leung A, 2001, PAIN, V91, P177, DOI 10.1016/S0304-3959(00)00433-4; Luginbuhl M, 2001, ANESTHESIOLOGY, V95, P22, DOI 10.1097/00000542-200107000-00009; Milligan K, 2001, J PAIN, V2, P197, DOI 10.1054/jpai.2001.25352; Muriel C, 2005, CLIN THER, V27, P451, DOI 10.1016/j.clinthera.2005.04.007; Naef M, 2003, PAIN, V105, P79, DOI 10.1016/S0304-3959(03)00163-5; Otis JAD, 2005, ANN RHEUM DIS, V64, P528; PARK KM, 1995, PAIN, V63, P163, DOI 10.1016/0304-3959(95)00029-R; Park R, 2001, J PERIPHER NERV SYST, V6, P232, DOI 10.1046/j.1529-8027.2001.01025.x; Pavelka K, 2004, CURR MED RES OPIN, V20, P1967, DOI 10.1185/030079904X14120; Petersen KL, 2003, J PAIN, V4, P400, DOI 10.1016/S1526-5900(03)00718-1; Petersen KL, 2001, ANESTHESIOLOGY, V94, P15, DOI 10.1097/00000542-200101000-00008; Petersen-Felix S, 1998, BRIT J ANAESTH, V81, P742, DOI 10.1093/bja/81.5.742; PETERSENFELIX S, 1994, BRIT J ANAESTH, V73, P326, DOI 10.1093/bja/73.3.326; Price DD, 1999, PAIN, V83, P147, DOI 10.1016/S0304-3959(99)00081-0; Sethna NF, 1998, ANESTH ANALG, V86, P1250, DOI 10.1097/00000539-199806000-00022; SINDRUP SH, 1993, PAIN, V53, P335, DOI 10.1016/0304-3959(93)90229-I; Sittl R, 2003, CLIN THER, V25, P150, DOI 10.1016/S0149-2918(03)90019-1; Sorge J, 2004, CLIN THER, V26, P1808, DOI 10.1016/j.clinthera.2004.11.008; Staahl C, 2004, BASIC CLIN PHARMACOL, V95, P97; VANSTRIEN GA, 1994, CONTACT DERMATITIS, V31, P95, DOI 10.1111/j.1600-0536.1994.tb01925.x	33	51	51	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0304-3959			PAIN	Pain	DEC 15	2006	126	1-3					165	174		10.1016/j.pain.2006.06.028			10	Anesthesiology; Clinical Neurology; Neurosciences	Anesthesiology; Neurosciences & Neurology	119KW	WOS:000243012200021	16901645				2020-06-30	J	Haeseler, G; Foadi, N; Ahrens, J; Dengler, R; Hecker, H; Leuwer, M				Haeseler, Gertrud; Foadi, Nilufar; Ahrens, Joerg; Dengler, Reinhard; Hecker, Hartmut; Leuwer, Martin			Tramadol, fentanyl and sufentanil but not morphine block voltage-operated sodium channels	PAIN			English	Article						sodium channels; voltage-operated; opioids; local anesthetic-like action	GATED NA+ CHANNELS; FAST-INACTIVATION GATE; STATE-DEPENDENT BLOCK; SLOW INACTIVATION; LOCAL-ANESTHETICS; NEUROPATHIC PAIN; OPIOID RECEPTOR; LIDOCAINE BLOCK; NEURONS; MEPERIDINE	Lidocaine-like sodium channel blocking drugs provide pain relief either by interrupting impulse conduction in neurons when applied locally in high concentrations or, when given systemically, by suppressing high-frequency ectopic discharges due to preferential drug binding to inactivated channel states. Lidocaine-like actions of opioids have frequently been demonstrated clinically. However, drug binding to resting and inactivated channel conformations has been studied systematically only in the case of meperidine. The aim of this in vitro study was to investigate the effects of four currently used opioids on heterologously expressed neuronal (NaV1.2) voltage-gated sodium channels. Block of sodium currents was studied at hyperpolarized holding potentials and at depolarized potentials inducing either fast- or slow-inactivation. Sufentanil, fentanyl and tramadol but not morphine reversibly suppressed sodium inward currents at high concentrations (half-maximum blocking concentrations (IC50) 49 +/- 4, 141 6 and 103 +/- 8 mu M) when depolarizations were started from hyperpolarized holding potentials. Short depolarizations inducing fast-inactivation and long prepulses inducing slow-inactivation significantly (*p <= 0.001) increased the blocking potency for these opioids. 15% slow inactivated channels reduced the respective IC50 values to 5 +/- 3, 12 +/- 12 and 21 +/- 2 mu M. These results show that: (1) Sufentanil, fentanyl and tramadol block voltage-gated sodium channels with half-maximum inhibitory concentrations similar to the IC50 reported for meperidine. (2) Slow inactivation - a physiological mechanism to suppress ectopic activity in response to slow shifts in membrane potential - increases binding affinity for sufentanil, fentanyl and tramadol. (3) Morphine has no such effects. (c) 2006 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.	Hannover Med Sch, Dept Anesthesiol, D-3000 Hannover, Germany; Hannover Med Sch, Dept Neurol & Clin Neurophysiol, D-3000 Hannover, Germany; Hannover Med Sch, Dept Biometr, D-3000 Hannover, Germany; Univ Liverpool, Div Clin Sci, Liverpool L69 3BX, Merseyside, England	Haeseler, G (reprint author), Hannover Med Sch, Dept Anesthesiol, D-3000 Hannover, Germany.	Haeseler.Gertrud@MH-Hannover.de					Acalovschi I, 2001, ANESTH ANALG, V92, P209; Balser JR, 1996, J GEN PHYSIOL, V107, P643, DOI 10.1085/jgp.107.5.643; BEAN BP, 1983, J GEN PHYSIOL, V81, P613, DOI 10.1085/jgp.81.5.613; Bernards CM, 2003, ANESTHESIOLOGY, V99, P455, DOI 10.1097/00000542-200308000-00029; Blake AD, 1997, J BIOL CHEM, V272, P782, DOI 10.1074/jbc.272.2.782; Brau ME, 2000, ANESTHESIOLOGY, V92, P147; Brau ME, 2001, ANESTHESIOLOGY, V94, P137; Carr DB, 2003, NEURON, V39, P793, DOI 10.1016/S0896-6273(03)00531-2; CHAHINE M, 1994, PFLUG ARCH EUR J PHY, V427, P136, DOI 10.1007/BF00585952; DUGGAN AW, 1983, PHARMACOL REV, V35, P219; Eichenberger U, 2003, BRIT J ANAESTH, V90, P467, DOI 10.1093/bja/aeg100; FRANK GB, 1985, CAN J PHYSIOL PHARM, V63, P1023, DOI 10.1139/y85-168; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Haeseler G, 2000, ANESTHESIOLOGY, V92, P1385, DOI 10.1097/00000542-200005000-00029; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hammarstrom AKM, 1998, J PHYSIOL-LONDON, V510, P735, DOI 10.1111/j.1469-7793.1998.735bj.x; HILLE B, 1992, IONIC CHANNELS EXCIT, P390; HODGKIN AL, 1959, J PHYSIOL-LONDON, V148, P127, DOI 10.1113/jphysiol.1959.sp006278; Jaffe RA, 1996, ANESTH ANALG, V83, P776, DOI 10.1097/00000539-199610000-00021; Joris JL, 2003, ANESTH ANALG, V97, P1446, DOI 10.1213/01.ANE.0000082251.85534.84; Ju YK, 1996, J PHYSIOL-LONDON, V497, P337, DOI 10.1113/jphysiol.1996.sp021772; KAYA K, 1992, ACTA NEUROL SCAND, V85, P337; KLEMM WR, 1981, PROG NEURO-PSYCHOPHA, V5, P1, DOI 10.1016/0364-7722(81)90002-3; Lai J, 2004, ANNU REV PHARMACOL, V44, P371, DOI 10.1146/annurev.pharmtox.44.101802.121627; Leuwer M, 2004, BRIT J PHARMACOL, V141, P47, DOI 10.1038/sj.bjp.0705594; Mert T, 2003, PHARMACOLOGY, V69, P68, DOI 10.1159/000072358; MITROVIC N, 1994, J PHYSIOL-LONDON, V478, P395, DOI 10.1113/jphysiol.1994.sp020260; NORTH RA, 1979, LIFE SCI, V24, P1527, DOI 10.1016/0024-3205(79)90014-6; OLSEN H, 2000, MEYLERS SIDE EFFECTS, V1, P198; Petaja-Repo UE, 2000, J BIOL CHEM, V275, P13727, DOI 10.1074/jbc.275.18.13727; RAGSDALE DS, 1994, SCIENCE, V265, P1724, DOI 10.1126/science.8085162; Rogawski MA, 2004, NAT MED, V10, P685, DOI 10.1038/nm1074; SARKAR SN, 1995, J PHYSIOL-LONDON, V488, P633, DOI 10.1113/jphysiol.1995.sp020996; Scholz A, 1998, J NEUROPHYSIOL, V79, P1746; SCHUG SA, 2000, MEYLERS SIDE EFFECTS, V1, P339; Takahashi Masahiko, 2004, J Anesth, V18, P1, DOI 10.1007/s00540-003-0214-4; UKOMADU C, 1992, NEURON, V8, P663, DOI 10.1016/0896-6273(92)90088-U; Vedantham V, 1998, J GEN PHYSIOL, V111, P83, DOI 10.1085/jgp.111.1.83; Vedantham V, 1999, J GEN PHYSIOL, V113, P7, DOI 10.1085/jgp.113.1.7; Vilin YY, 2001, CELL BIOCHEM BIOPHYS, V35, P171, DOI 10.1385/CBB:35:2:171; Wang DW, 1996, BIOPHYS J, V70, P238, DOI 10.1016/S0006-3495(96)79566-8; Wang GK, 2004, PAIN, V110, P166, DOI 10.1016/j.pain.2004.03.018; WANG HL, 2005, J NEUROCHEM, P92; Wolff M, 2004, ANESTHESIOLOGY, V100, P947, DOI 10.1097/00000542-200404000-00027	44	68	71	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0304-3959			PAIN	Pain	DEC 15	2006	126	1-3					234	244		10.1016/j.pain.2006.07.003			11	Anesthesiology; Clinical Neurology; Neurosciences	Anesthesiology; Neurosciences & Neurology	119KW	WOS:000243012200027	16949748				2020-06-30	J	Ojanpera, I; Gergov, M; Rasanen, I; Lunetta, P; Toivonen, S; Tiainen, E; Vuori, E				Ojanpera, Ilkka; Gergov, Merja; Rasanen, Ilpo; Lunetta, Philippe; Toivonen, Sauli; Tiainen, Erkki; Vuori, Erkki			Blood levels of 3-methylfentanyl in 3 fatal poisoning cases	AMERICAN JOURNAL OF FORENSIC MEDICINE AND PATHOLOGY			English	Article						3-methylfentanyl; designer drug; fatal poisoning; LC-MS/MS	FENTANYL-RELATED DEATHS; TOXICOLOGY; DRUGS	Three fatal poisoning cases due to 3-methylfentanyl are described. In each case, the death was accidental and occurred after injection of the opioid combined with amphetamine, heroin, or other drugs. The victims' ages, ranging from 30 to 41 years, were higher than those typically found in heroin poisonings in Finland. The blood concentrations of cis-3-methylfentanyl, measured here for the first time by a specific tandem mass spectrometric method, ranged from 0.3 to 0.9 mu g/L (mean 0.5 mu g/L). These values are significantly lower than the levels reported for a-methylfentanyl and fentanyl in fatal poisonings. Repeated seizures of fentanyl and its analogs have been reported in Europe close to the Russian border.	Univ Helsinki, Dept Forens Med, FI-00014 Helsinki, Finland; State Prov Off So Finland, Helsinki, Finland	Ojanpera, I (reprint author), Univ Helsinki, Dept Forens Med, POB 40, FI-00014 Helsinki, Finland.	ilkka.ojanpera@helsinki.fi		Ojanpera, Ilkka/0000-0001-5790-1473			BASELT RC, 2004, DISPOSITION TOXIC DR; *EUR MON CTR DRUGS, 2004, [No title captured]; Gergov M, 2001, FORENSIC SCI INT, V121, P108, DOI 10.1016/S0379-0738(01)00460-1; GILLESPIE TJ, 1982, J ANAL TOXICOL, V6, P139, DOI 10.1093/jat/6.3.139; HAMMARGREN WR, 1988, J ANAL TOXICOL, V12, P183, DOI 10.1093/jat/12.4.183; HENDERSON GL, 1983, P W PHARMACOL SOC, V26, P287; HENDERSON GL, 1988, J FORENSIC SCI, V33, P569; HENDERSON GL, 1991, J FORENSIC SCI, V36, P422; HIBBS J, 1991, JAMA-J AM MED ASSOC, V265, P1011, DOI 10.1001/jama.265.8.1011; Kronstrand R, 1997, FORENSIC SCI INT, V88, P185, DOI 10.1016/S0379-0738(97)00068-6; Kuhlman JJ, 2003, J ANAL TOXICOL, V27, P499, DOI 10.1093/jat/27.7.499; MARTIN M, 1991, ANN EMERG MED, V20, P158, DOI 10.1016/S0196-0644(05)81216-8; Sorokin VI SE, 1994, MICROGRAM, V27, P221; TALU A, 2004, 2004 NAT REP EMCDDA; VANBEVER WF, 1974, J MED CHEM, V17, P1047, DOI 10.1021/jm00256a003; Vuori E, 2003, ADDICTION, V98, P365, DOI 10.1046/j.1360-0443.2003.00292.x; Wax PM, 2003, ANN EMERG MED, V41, P700, DOI 10.1067/mem.2003.148	17	23	24	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-7910	1533-404X		AM J FOREN MED PATH	Am. J. Forensic Med. Pathol.	DEC	2006	27	4					328	331		10.1097/01.paf.0000188097.78132.e5			4	Medicine, Legal; Pathology	Legal Medicine; Pathology	112LD	WOS:000242526500011	17133031				2020-06-30	J	Kennedy, RR; Sakowska, MM				Kennedy, R. R.; Sakowska, M. M.			The relationship between calculated effect-site sevoflurane levels and awakening from anaesthesia	ANAESTHESIA AND INTENSIVE CARE			English	Article; Proceedings Paper	National Scientific Congress of the Australian-Society-of-Anaesthetists	OCT, 2005	Gold Coast, AUSTRALIA	Australian Soc Anaesthetists		anaesthesia; inhalation; pharmacokinetics; anaesthesia recovery period; sevoflurane effect-site	MINIMUM ALVEOLAR CONCENTRATION; END-TIDAL SEVOFLURANE; DYNAMIC RELATIONSHIP; ISOFLURANE; REMIFENTANIL; AGE; FENTANYL; MAC; PROPOFOL; RECOVERY	We have previously described a system that displays real-time estimates of effect-site sevoflurane concentrations. Estimates of effect-site levels should be similar to minimum alveolar concentration (MAC) values, which are determined after allowing time for equilibrium. This study aimed to determine estimated effect-site sevoflurane concentrations at awakening from routine anaesthesia and to compare this with published estimates of MAC-awake. If these values were similar, this would validate our approach to the calculation of effect-site concentration. Sixty-five patients undergoing a variety of surgical procedures were observed. Prior to disconnection from the breathing circuit, forward estimates of effect-site sevoflurane were recorded. Patients were observed in the post-anaesthesia care unit and the time at which they responded to command was recorded. Age-adjusted effect-site sevoflurane at the time of awakening was determined. Correlation with patient, surgical and anaesthetic factors including age, gender, ASA status and intraoperative opioid usage were explored. Mean age-adjusted calculated effect-site concentration at awakening was 0.59 (SD 0.27) vol%. This value is within the range of values determined for MAC-awake of sevoflurane. There was no con-elation with any of the demographic or anaesthetic factors, but patients undergoing major surgery woke at a significantly lower mean sevoflurane level. These results support the use of effect-site sevoflurane concentration to guide administration of anaesthesia.	Christchurch Hosp, Dept Anaesthesia, Christchurch, New Zealand; Christchurch Sch Med & Hlth Sci, Christchurch, New Zealand	Kennedy, RR (reprint author), Christchurch Hosp, Dept Anaesthesia, Christchurch, New Zealand.						Absalom AR, 2003, BRIT J ANAESTH, V90, P737, DOI 10.1093/bja/aeg137; Albertin A, 2004, ANESTHESIOLOGY, V100, P255, DOI 10.1097/00000542-200402000-00012; Buchanan FF, 2006, ANESTH ANALG, V102, P291, DOI 10.1213/01.ane.0000181321.55422.C6; Eger EI, 2003, ANESTHESIOLOGY, V99, P1059, DOI 10.1097/00000542-200311000-00009; Eger EI, 2002, ANESTHESIOLOGY, V96, P238, DOI 10.1097/00000542-200201000-00037; Eger EI, 2001, ANESTH ANALG, V93, P947, DOI 10.1097/00000539-200110000-00029; GROSS JB, 1988, ANESTH ANALG, V67, P27; KATOH T, 1992, BRIT J ANAESTH, V69, P259, DOI 10.1093/bja/69.3.259; KATOH T, 1993, CAN J ANAESTH, V40, P825, DOI 10.1007/BF03009252; Katoh T, 1998, ANESTHESIOLOGY, V88, P18, DOI 10.1097/00000542-199801000-00006; KATOH T, 1994, BRIT J ANAESTH, V73, P322, DOI 10.1093/bja/73.3.322; KATOH T, 1993, ANESTH ANALG, V77, P1012; KATOH T, 1993, ANESTH ANALG, V76, P348; Kennedy RR, 2005, ANESTH ANALG, V101, P1023, DOI 10.1213/01.ane.0000168337.88469.9c; Kennedy RR, 2004, ANESTH ANALG, V99, P1159, DOI 10.1213/01.ANE.0000131507.65132.7F; Kennedy RR, 2002, ANESTH ANALG, V95, P1616, DOI 10.1097/00000539-200212000-00027; KENNEDY RR, 2005, EUR J ANAESTHESI S34, V22, pA489; Mapleson WW, 1996, BRIT J ANAESTH, V76, P179; Minto CF, 1997, ANESTHESIOLOGY, V86, P10, DOI 10.1097/00000542-199701000-00004; Monk TG, 2005, ANESTH ANALG, V100, P4, DOI 10.1213/01.ANE.0000147519.82841.5E; Morley AP, 2002, ANESTH ANALG, V95, P1412, DOI 10.1097/00000539-200211000-00057; Munoz HR, 2005, ANESTH ANALG, V101, P371, DOI 10.1213/01.ANE.0000156950.21292.1A; Olofsen E, 1999, ANESTHESIOLOGY, V90, P1345, DOI 10.1097/00000542-199905000-00019; Olofsen E, 2002, ANESTHESIOLOGY, V96, P555, DOI 10.1097/00000542-200203000-00009; Satas S, 1996, ACTA ANAESTH SCAND, V40, P452, DOI 10.1111/j.1399-6576.1996.tb04468.x; SCOTT JC, 1987, J PHARMACOL EXP THER, V240, P159; Struys M, 1998, ANAESTHESIA, V53, P4, DOI 10.1046/j.1365-2044.1998.00279.x; Struys MMRF, 2000, ANESTHESIOLOGY, V92, P399, DOI 10.1097/00000542-200002000-00021; Syroid ND, 2002, ANESTHESIOLOGY, V96, P565, DOI 10.1097/00000542-200203000-00010; van Delden PG, 2002, ANAESTHESIA, V57, P212, DOI 10.1046/j.0003-2409.2001.02465.x; VITEZ TS, 1974, ANESTHESIOLOGY, V41, P80, DOI 10.1097/00000542-197407000-00020; Wakeling HG, 1999, ANESTHESIOLOGY, V90, P92, DOI 10.1097/00000542-199901000-00014	32	5	5	0	0	AUSTRALIAN SOC ANAESTHETISTS	EDGECLIFF	P O BOX 600, EDGECLIFF, NSW 2021, AUSTRALIA	0310-057X			ANAESTH INTENS CARE	Anaesth. Intensive Care	DEC	2006	34	6					713	718		10.1177/0310057X0603400632			6	Anesthesiology; Critical Care Medicine	Anesthesiology; General & Internal Medicine	124AH	WOS:000243338700004	17183887	Bronze			2020-06-30	J	Hua, S; Hermanussen, S; Tang, L; Monteith, GR; Cabot, PJ				Hua, Susan; Hermanussen, Siobhan; Tang, Linda; Monteith, Greg R.; Cabot, Peter J.			The neural cell adhesion molecule antibody blocks cold water swim stress-induced analgesia and cell adhesion between lymphocytes and cultured dorsal root ganglion neurons	ANESTHESIA AND ANALGESIA			English	Article							INFLAMMATORY PAIN; BETA-ENDORPHIN; IMMUNE CELLS; INFLAMED TISSUE; OPIOID-PEPTIDES; ANTINOCICEPTION; L1; INHIBITION; EXPRESSION; INTEGRINS	BACKGROUND: Opioid-containing immune cells migrate in a site-directed manner into inflamed tissue and adhere to sensory nerve fibers. These cells release opioid peptides in close proximity to these fibers, thereby avoiding localized degradation by pepticlases, and delivering opioid peptides proximal to opioid receptors to provide antinociception. METHODS: The effects of the anti-neural-cell-adhesion molecule (anti-NCAM) were assessed on cold water swim stress-induced antinociception in Wistar rats with Freund's adjuvant-induced inflammation of one hindpaw. Algesiometry was assessed for both thermal and mechanical stimuli. Cell adhesion experiments examining the effects of beta-endorphin and antibodies to NCAM and intercellular cell adhesion molecule-1 and were performed on cultured dorsal root ganglion neurons and isolated lymphocytes. Lymphocyte binding was determined by fluorescence using calcein AM loaded into freshly isolated lymphocytes. RESULTS: The direct adhesion between lymphocytes and cultured sensory neurons was inhibited by anti-NCAM. This adhesion was also demonstrated to be opioid dependent, with lymphocyte adhesion to cultured sensory neurons reduced in the presence of 1 mu M beta-endorphin, which was reversed by 100 mu M naloxone. Moreover, anti-NCAM blocked cold-water-swim-induced analgesia in inflamed paws both to thermal and mechanical stimuli. However, anti-NCAM did not affect fentanyl-induced antinociception. CONCLUSIONS: This study provides insight into the role of cell adhesion molecules in lymphocyte adhesion to sensory neurons and a link to immune-derived antinociceptim.	Univ Queensland, Sch Pharm, Brisbane, Qld 4072, Australia	Cabot, PJ (reprint author), Univ Queensland, Sch Pharm, Brisbane, Qld 4072, Australia.	pcabot@pharmacy.uq.edu.au	Cabot, Peter John/B-2424-2013; Monteith, Gregory/B-1626-2008	Cabot, Peter John/0000-0003-1778-3753; Monteith, Gregory/0000-0002-4345-530X			Biroc SL, 2001, ARTHRITIS RHEUM, V44, P703, DOI 10.1002/1529-0131(200103)44:3<703::AID-ANR120>3.0.CO;2-2; Cabot PJ, 1997, J CLIN INVEST, V100, P142, DOI 10.1172/JCI119506; Curran DR, 2002, CURR OPIN PHARMACOL, V2, P243, DOI 10.1016/S1471-4892(02)00155-8; Dustin ML, 2002, SCIENCE, V298, P785, DOI 10.1126/science.1076386; FELTEN DL, 1987, IMMUNOL REV, V100, P225, DOI 10.1111/j.1600-065X.1987.tb00534.x; Gahmberg CG, 1997, CURR OPIN CELL BIOL, V9, P643, DOI 10.1016/S0955-0674(97)80117-2; Hermanussen S, 2004, ANESTH ANALG, V98, P723; Itoh K, 1997, J NEUROBIOL, V33, P735, DOI 10.1002/(SICI)1097-4695(19971120)33:6<735::AID-NEU3>3.0.CO;2-A; JACOBUS WE, 1977, NATURE, V265, P756, DOI 10.1038/265756a0; JIVEGARD L, 1989, CLIN SCI, V77, P49, DOI 10.1042/cs0770049; Kanai M, 2002, EUR J PHARMACOL, V453, P53, DOI 10.1016/S0014-2999(02)02392-0; Kasper C, 2000, NAT STRUCT BIOL, V7, P389; Kos FJ, 2002, IMMUNOL CELL BIOL, V80, P364, DOI 10.1046/j.1440-1711.2002.01098.x; KOWITZ A, 1992, EUR J IMMUNOL, V22, P1199, DOI 10.1002/eji.1830220514; Liu RY, 2002, MOL CELL NEUROSCI, V20, P2, DOI 10.1006/mcne.2002.1107; Machelska H, 1998, NAT MED, V4, P1425, DOI 10.1038/4017; Machelska H, 2002, J NEUROSCI, V22, P5588; Machelska H, 2004, BRIT J PHARMACOL, V142, P772, DOI 10.1038/sj.bjp.0705837; Mousa SA, 2000, J NEUROIMMUNOL, V108, P160, DOI 10.1016/S0165-5728(00)00284-8; Mousa SA, 2003, ADV EXP MED BIOL, V521, P77; PARSONS CG, 1990, J PHARMACOL EXP THER, V255, P795; PIRCIO AW, 1966, J PHARMACOL EXP THER, V154, P103; PRZEWLOCKI R, 1992, NEUROSCIENCE, V48, P491, DOI 10.1016/0306-4522(92)90509-Z; Ruppert M, 1995, J CELL BIOL, V131, P1881, DOI 10.1083/jcb.131.6.1881; SCHAFER M, 1994, P NATL ACAD SCI USA, V91, P4219, DOI 10.1073/pnas.91.10.4219; Song BB, 2003, J NEUROSCI, V23, P1847; STEIN C, 1990, PROG CLIN BIOL RES, V328, P425; Tian L, 2000, EUR J IMMUNOL, V30, P810, DOI 10.1002/1521-4141(200003)30:3<810::AID-IMMU810>3.3.CO;2-O	28	23	23	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	DEC	2006	103	6					1558	1564		10.1213/01.ane.0000243410.61451.c1			7	Anesthesiology	Anesthesiology	109DW	WOS:000242289100041	17122239				2020-06-30	J	Mayes, S; Ferrone, M				Mayes, Stacey; Ferrone, Marcus			Fentanyl HCl patient-controlled iontophoretic transdermal system for the management of acute postoperative pain	ANNALS OF PHARMACOTHERAPY			English	Article						cutaneous analgesia; fentanyl; IONSYS; patient-controlled analgesia	ANALGESIA; PHARMACOKINETICS; DELIVERY; EFFICACY; MORPHINE; PCTS	OBJECTIVE: To summarize the pharmaceutics, pharmacokinetics, development, and clinical application of IONSYS, the fentanyl HCI patient-controlled iontophoretic transdermal system for the management of acute postoperative pain. DATA SOURCES: Clinical literature including both primary sources and review articles was accessed through a search of the MEDLINE databases (1980-October 2006). Key search terms included cutaneous analgesia, fentanyl, IONSYS, opioid, postoperative pain, and patient-controlled analgesia (PCA). Additional clinical trial and drug data were supplied by the manufacturer, the ALZA Corporation. STUDY SELECTION AND DATA EXTRACTION: Review articles, abstracts, and clinical studies related to patient-controlled iontophoretic transdermal fentanyl and postoperative pain management were analyzed. An evaluation of the research exploring IONSYS for the management of acute postoperative pain was conducted. Relevant information was then selected and is provided in this article. DATA SYNTHESIS: IONSYS is the first iontophoretic transdermal drug delivery system that utilizes low-level electrical energy to actively transport ionized fentanyl HCI through intact skin. Research has revealed that use of IONSYS for patients with acute postoperative pain is safe, effective, and well tolerated. Phase I-III trials have demonstrated an appropriate dosing range leading to effective analgesia, with minimal adverse effects. The analgesia provided by this system was found to be superior to that of analgesia placebo and equivalent to that of an intravenous morphine PCA. CONCLUSIONS: Data from clinical trials indicated that IONSYS is successful in controlling acute postoperative pain that circumvents the limitations of intravenous patient-controlled analgesia. The use of this system may serve as an alternative modality for the management of acute pain without increasing such adverse effects as bleeding, intravenous catheter infiltration, or manual pump malfunction.	Baptist Med Ctr Downtown, Emergency Dept Clin Pharm, Jacksonville, FL 32207 USA; Wolfson Childrens Hosp, Jacksonville, FL USA; Univ Calif San Francisco, Drug Prod Serv Lab, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Clin Pharm, San Francisco, CA 94143 USA	Mayes, S (reprint author), Baptist Med Ctr Downtown, Emergency Dept Clin Pharm, 800 Prudential Dr, Jacksonville, FL 32207 USA.	Stacy.Mayes@bmcjax.com					*ALZA, 2005, PACK INS DUR FENT; Andrews C, 1983, CLIN ANAESTHESIOL, V1, P97; [Anonymous], 2006, PACK INS IONSYS FENT; ASHBURN MA, 1995, ANESTHESIOLOGY, V82, P1146, DOI 10.1097/00000542-199505000-00009; ASHBURN MA, 1992, J PAIN SYMPTOM MANAG, V7, P27, DOI 10.1016/0885-3924(92)90104-P; Bastani B, 1997, NEPHROL DIAL TRANSPL, V12, P2802, DOI 10.1093/ndt/12.12.2802; Bertolucci L E, 1982, J Orthop Sports Phys Ther, V4, P103; Breivik H, 1998, EUR J ANAESTH, V15, P748, DOI 10.1097/00003643-199811000-00022; Carr DB, 1999, LANCET, V353, P2051, DOI 10.1016/S0140-6736(99)03313-9; Chelly JE, 2004, ANESTH ANALG, V98, P427, DOI 10.1213/01.ANE.0000093314.13848.7E; Eade D M, 1997, Nurs Manage, V28, P38; Etches RC, 1999, SURG CLIN N AM, V79, P297, DOI 10.1016/S0039-6109(05)70384-4; GLASS JM, 1980, INT J DERMATOL, V19, P519, DOI 10.1111/j.1365-4362.1980.tb00380.x; Gupta SK, 2005, CLIN PHARMACOKINET, V44, P25, DOI 10.2165/00003088-200544001-00005; Gupta SK, 1998, J CLIN PHARMACOL, V38, P951, DOI 10.1002/j.1552-4604.1998.tb04392.x; Halliburton J. R., 1988, AANA J, V56, P299; HUDSON RJ, 1986, ANESTHESIOLOGY, V64, P334, DOI 10.1097/00000542-198603000-00006; HULL CJ, 1982, BRIT J ANAESTH, V54, P871; Joh J, 1998, ANESTH ANALG, V86, P447, DOI 10.1097/00000539-199802000-00049; *JOINT COMM ACCR H, 2000, PAIN ASS MAN ORG APP; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; MAX MB, 1995, JAMA-J AM MED ASSOC, V274, P1874, DOI 10.1001/jama.1995.03530230060032; Miaskowski Christine, 2005, J Perianesth Nurs, V20, P255, DOI 10.1016/j.jopan.2005.05.005; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; *PHSAHCPR, 1992, CLIN PRACT GUID, V1; Rawal N, 2001, Minerva Anestesiol, V67, P200; READY LB, 1995, ANESTHESIOLOGY, V82, P1071; READY LB, 1992, MANAGEMENT ACTUE PAI; Sathyan G, 2005, CLIN PHARMACOKINET, V44, P7, DOI 10.2165/00003088-200544001-00003; Sathyan S, 2005, CLIN PHARMACOKINET, V44, P17, DOI 10.2165/00003088-200544001-00004; Shang AB, 2003, DRUGS, V63, P855, DOI 10.2165/00003495-200363090-00002; Sinatra R, 2005, CLIN PHARMACOKINET, V44, P1; STANLEY TH, 1992, J PAIN SYMPTOM MANAG, V7, pS3, DOI 10.1016/0885-3924(92)90047-L; Striebel HW, 1996, ANESTH ANALG, V83, P548, DOI 10.1097/00000539-199609000-00019; Striebel HW, 1996, CAN J ANAESTH, V43, P749, DOI 10.1007/BF03017961; STRIEBEL HW, 1999, ACUTE PAIN, V2, P36; VARVEL JR, 1989, ANESTHESIOLOGY, V70, P928, DOI 10.1097/00000542-198906000-00008; Viscusi ER, 2006, ANESTH ANALG, V102, P188, DOI 10.1213/01.ane.0000183649.58483.77; Viscusi ER, 2004, AM J HEALTH-SYST PH, V61, pS11, DOI 10.1093/ajhp/61.suppl_1.S11; Viscusi ER, 2004, JAMA-J AM MED ASSOC, V291, P1333, DOI 10.1001/jama.291.11.1333; WARFIELD CA, 1995, ANESTHESIOLOGY, V83, P1090, DOI 10.1097/00000542-199511000-00023; WILLENS JS, 1993, HEART LUNG, V22, P239; Woolf CJ, 2004, ANN INTERN MED, V140, P441, DOI 10.7326/0003-4819-140-8-200404200-00010	43	37	38	1	8	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1060-0280	1542-6270		ANN PHARMACOTHER	Ann. Pharmacother.	DEC	2006	40	12					2178	2186		10.1345/aph.1H135			9	Pharmacology & Pharmacy	Pharmacology & Pharmacy	117OA	WOS:000242881400012	17164395				2020-06-30	J	Kawaraguchi, Y; Otomo, T; Ota, C; Uchida, N; Taniguchi, A; Inoue, S				Kawaraguchi, Y.; Otomo, T.; Ota, C.; Uchida, N.; Taniguchi, A.; Inoue, S.			A prospective, double-blind, randomized trial of caudal block using ropivacaine 0.2% with or without fentanyl 1 mu g kg(-1) in children	BRITISH JOURNAL OF ANAESTHESIA			English	Article						analgesia; postoperative; analgesics opioid; fentanyl; anaesthesia; paediatric; anaesthetic techniques; regional; caudal; anaesthetics local; ropivacaine	POSTOPERATIVE ANALGESIA; BUPIVACAINE; CLONIDINE; DURATION	Background. It has been reported that ropivacaine produces vasoconstriction in contrast to vasodilation produced by bupivacaine. It is possible that additives to ropivacaine can provide further analgesic advantages compared with bupivacaine. We thus evaluated whether the addition of fentanyl to ropivacaine prolonged the duration of analgesia after a single shot caudal block. Methods. A total of 36 children undergoing surgical procedures below the umbilicus were randomly allocated to one of two groups: Group F received ropivacaine 0.2%, 1 ml kg(-1) with fentanyl 1 mu g kg(-1) and Group S received ropivacaine 0.2%, 1 ml kg(-1) with saline. The analgesic effect of the caudal block was evaluated using the Children's Hospital of Eastern Ontario Pain Scale (CHEOPS) and sedation was assessed using the Steward score at 30 min after extubation and at 1, 2, 4, 6, 12 and 24 h. The first analgesic requirement time and side-effects in a 24 h period were also recorded. Results. There were no differences in characteristics between the groups. The end-tidal concentration of sevoflurane at extubation in Group F was significantly lower than in Group S. However, there was no significant difference in time from discontinuation of the volatile anaesthetics to tracheal extubation. No statistical differences were found in the CHEOPS and Steward score, and the time to first analgesia. The incidence of postoperative vomiting was not significantly different. Conclusion. We found that the addition of fentanyl 1 mu g kg(-1) to ropivacaine 0.2% for caudal analgesia provides no further analgesic advantages over ropivacaine 0.2% alone.	Nara Med Univ, Dept Anaesthesiol, Kashihara, Nara 6348522, Japan; Miyagi Childrens Hosp, Dept Anaesthesia & Crit Care, Sendai, Miyagi, Japan	Kawaraguchi, Y (reprint author), Nara Med Univ, Dept Anaesthesiol, 840 Shijo Cho, Kashihara, Nara 6348522, Japan.	kawaraguchi@bea.hi-ho.ne.jp					Baris S, 2003, PAEDIATR ANAESTH, V13, P126, DOI 10.1046/j.1460-9592.2003.00979.x; Bosenberg A, 2002, PAEDIATR ANAESTH, V12, P53, DOI 10.1046/j.1460-9592.2002.00769.x; Burmester MD, 2005, ANESTH ANALG, V100, P707, DOI 10.1213/01.ANE.0000146511.79069.01; Constant I, 1998, BRIT J ANAESTH, V80, P294; De Mey JC, 2000, EUR J ANAESTH, V17, P379, DOI 10.1046/j.1365-2346.2000.00690.x; Gaitini LA, 2000, ANESTH ANALG, V90, P1029, DOI 10.1097/00000539-200005000-00006; Iida H, 1997, ANESTHESIOLOGY, V87, P75, DOI 10.1097/00000542-199707000-00011; Iida H, 2001, ANESTH ANALG, V93, P1552, DOI 10.1097/00000539-200112000-00046; Katoh T, 1998, ANESTHESIOLOGY, V88, P18, DOI 10.1097/00000542-199801000-00006; Knudsen K, 1997, BRIT J ANAESTH, V78, P507; Markham A, 1996, DRUGS, V52, P429, DOI 10.2165/00003495-199652030-00012; Martindale SJ, 2004, BRIT J ANAESTH, V92, P344, DOI 10.1093/bja/aeh076; MATHEWS JR, 1993, PAIN INFANTS CHILDRE, P97; Sanders JC, 2002, BRIT J ANAESTH, V89, P707, DOI 10.1093/bja/aef263; SCOTT DB, 1989, ANESTH ANALG, V69, P563, DOI 10.1213/00000539-198911000-00003; STEWARD DJ, 1975, CAN ANAESTH SOC J, V22, P111, DOI 10.1007/BF03004827; Turan A, 2003, ANESTHESIOLOGY, V98, P719, DOI 10.1097/00000542-200303000-00021; Wheeler M, 2005, PEDIATR ANESTH, V15, P476, DOI 10.1111/j.1460-9592.2005.01481.x	18	14	15	2	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0007-0912	1471-6771		BRIT J ANAESTH	Br. J. Anaesth.	DEC	2006	97	6					858	861		10.1093/bja/ael249			4	Anesthesiology	Anesthesiology	108NP	WOS:000242246800017	16973647	Bronze			2020-06-30	J	Van Elstracte, AC; Sitbon, P; Mazoit, JX; Conti, M; Benhamou, D				Van Elstracte, Alain C.; Sitbon, Philippe; Mazoit, Jean-Xavier; Conti, Marc; Benhamou, Dan			Protective effect of prior administration of magnesium on delayed hyperalgesia induced by fentanyl in rats	CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Article							PROTEIN-KINASE-C; MORPHINE-TOLERANCE; NEUROPATHIC PAIN; INTRAVENOUS MAGNESIUM; CEREBROSPINAL-FLUID; SULFATE; SENSITIVITY; HEROIN; SENSITIZATION; POTENTIATION	Purpose: Magnesium exerts a physiological block of the ion channel on the N-methyl-D-aspartate receptor, and may therefore prevent the induction of central sensitization. The purpose of this study was to assess whether systemic magnesium can prevent long-lasting hyperalgesia induced by sc fentanyl administration in uninjured rats. Methods: Long-lasting hyperalgesia was induced in male Sprague Dawley rats with sc fentanyl (four injections, 60 mu g(.)kg(-1) per injection at 15-min intervals). Magnesium sulphate (100 mg(.)kg(-1)) was injected ip 30 min prior to the first sc fentanyl injection. Sensitivity to nociceptive stimuli (paw-pressure test) was assessed for several days after injections. Results: Subcutaneous fentanyl led to delayed hyperalgesia associated with a decrease in the nociceptive threshold lasting two days (35% decrease for the maximum effect). Intraperitoneal magnesium sulphate partially but significantly (P < 0.05) prevented the delayed decrease in the nociceptive threshold following sc administration of fentanyl. Conclusions: This study shows that magnesium may prevent the delayed and prolonged hyperalgesia following fentanyl administration in rats.	Hop Bicetre, AP HP, Dept Anesthesiol, Le Kremlin Bicetre, France; Hop Bicetre, AP HP, Biochem Lab, Le Kremlin Bicetre, France; Univ Paris Sud, Fac Med Kremlin Bicetre, Anesthesia Lab, UPRES EA 3540, F-94275 Le Kremlin Bicetre, France	Van Elstracte, AC (reprint author), Hop Bicetre, Serv Anesthesie Reanimat, F-94275 Le Kremlin Bicetre, France.	alainvanel@hotmail.com		Sitbon, Philippe/0000-0003-0520-9180			Begon S, 2000, BRAIN RES, V887, P436, DOI 10.1016/S0006-8993(00)03028-6; BENELIYAHU S, 1992, BRAIN RES, V575, P304, DOI 10.1016/0006-8993(92)90094-P; Brill S, 2002, BRIT J ANAESTH, V89, P711, DOI 10.1093/bja/aef266; Celerier E, 2000, ANESTHESIOLOGY, V92, P465, DOI 10.1097/00000542-200002000-00029; Celerier E, 2001, J NEUROSCI, V21, P4074, DOI 10.1523/JNEUROSCI.21-11-04074.2001; CHEN L, 1992, NATURE, V356, P521, DOI 10.1038/356521a0; CHEN L, 1991, NEURON, V7, P319, DOI 10.1016/0896-6273(91)90270-A; Crosby V, 2000, J PAIN SYMPTOM MANAG, V19, P35, DOI 10.1016/S0885-3924(99)00135-9; Fawcett WJ, 1999, BRIT J ANAESTH, V83, P302, DOI 10.1093/bja/83.2.302; Gentili ME, 1999, ANESTH ANALG, V89, P979, DOI 10.1097/00000539-199910000-00029; Karasawa S, 1998, ANAESTHESIA, V53, P879, DOI 10.1046/j.1365-2044.1998.00518.x; Ko SH, 2001, ANESTHESIOLOGY, V95, P640, DOI 10.1097/00000542-200109000-00016; Laulin JP, 2002, ANESTH ANALG, V94, P1263, DOI 10.1097/00000539-200205000-00040; Laulin JP, 1999, NEUROSCIENCE, V89, P631, DOI 10.1016/S0306-4522(98)00652-6; Laulin JP, 1998, EUR J NEUROSCI, V10, P782, DOI 10.1046/j.1460-9568.1998.00083.x; Mao JR, 2002, PAIN, V100, P213, DOI 10.1016/S0304-3959(02)00422-0; MAO JR, 1995, PAIN, V62, P259, DOI 10.1016/0304-3959(95)00073-2; Mayer DJ, 1999, P NATL ACAD SCI USA, V96, P7731, DOI 10.1073/pnas.96.14.7731; MAYER DJ, 1995, PAIN, V61, P365, DOI 10.1016/0304-3959(95)00023-L; McCarthy RJ, 1998, ANESTH ANALG, V86, P830, DOI 10.1097/00000539-199804000-00028; Mochizuki Masahiro, 1998, Journal of Toxicological Sciences, V23, P31; OPPELT WW, 1963, AM J PHYSIOL, V205, P959; RANDALL LO, 1957, ARCH INT PHARMACOD T, V111, P409; Takano Y, 2000, PAIN, V84, P175, DOI 10.1016/S0304-3959(99)00207-9; THURNAU GR, 1987, AM J OBSTET GYNECOL, V157, P1435, DOI 10.1016/S0002-9378(87)80239-9; WOOLF CJ, 1991, PAIN, V44, P293, DOI 10.1016/0304-3959(91)90100-C; XIAO WH, 1994, BRAIN RES, V666, P168, DOI 10.1016/0006-8993(94)90768-4; ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4	28	12	12	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0832-610X			CAN J ANAESTH	Can. J. Anaesth.-J. Can. Anesth.	DEC	2006	53	12					1180	1185		10.1007/BF03021578			6	Anesthesiology	Anesthesiology	120NB	WOS:000243090500003	17142651	Bronze			2020-06-30	J	Culp, WC; McCowan, TC; DeValdenebro, M; Wright, LB; Workman, JL; Culp, WC				Culp, William C.; McCowan, Timothy C.; DeValdenebro, Miguel; Wright, Lonnie B.; Workman, James L.; Culp, William C., Jr.			Paravertebral block: An improved method of pain control in percutaneous transhepatic biliary drainage	CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY			English	Article						analgesia; biliary drainage; paravertebral anesthesia	HEPATIC ARTERIAL EMBOLIZATION; CELIAC PLEXUS BLOCK; INTERVENTIONAL RADIOLOGY; NERVE BLOCK; ANESTHESIA; SEDATION; BUPIVACAINE; EXPERIENCE; MANAGEMENT; ANALGESIA	Background: Percutaneous transhepatic biliary drainage remains a painful procedure in many cases despite the routine use of large amounts of intravenous sedation. We present a feasibility study of thoracic paravertebral blocks in an effort to reduce pain during and following the procedure and reduce requirements for intravenous sedation. Methods: Ten consecutive patients undergoing biliary drainage procedures received fluoroscopically guided paravertebral blocks and then had supplemental intravenous sedation as required to maintain patient comfort. Levels T8-T9 and T9-T10 on the right were targeted with 10-20 ml of 0.5% bupivacaine. Sedation requirements and pain levels were recorded. Results: Ten biliary drainage procedures in 8 patients were performed for malignancy in 8 cases and for stones in 2. The mean midazolam use was 1.13 mg IV, and the mean fentanyl requirement was 60.0 mu g IV in the block patients. Two episodes of hypotension, which responded promptly to volume replacement, may have been related to the block. No serious complications were encountered. The mean pain score when traversing the chest wall, liver capsule, and upon entering the bile ducts was 0.1 on a scale of 0 to 10, with 1 patient reporting a pain level of 1 and 9 reporting 0. The mean peak pain score, encountered when manipulating at the common bile duct level or when addressing stones there, was 5.4 and ranged from 0 to 10. Conclusions: Thoracic paravertebral block with intravenous sedation supplementation appears to be a feasible method of pain control during biliary interventions.	Univ Arkansas Med Sci, Dept Radiol, Little Rock, AR 72205 USA; Univ Texas, Med Branch, Dept Anesthesiol, Galveston, TX 77550 USA; Texas A&M Univ, Coll Med, Scott & White Clin & Mem Hosp, Dept Anesthesiol,Syst Hlth Sci Ctr, Temple, TX 76508 USA	Culp, WC (reprint author), Univ Arkansas Med Sci, Dept Radiol, 4301 W Markham St,Slot 556, Little Rock, AR 72205 USA.	culpwilliamc@uams.edu; culpwilliamc@uams.edu					Arepally A, 2001, CARDIOVASC INTER RAD, V24, P185, DOI 10.1007/s002700002549; BAILEY PL, 1990, ANESTHESIOLOGY, V73, P826, DOI 10.1097/00000542-199011000-00005; COLDWELL DM, 1989, RADIOLOGY, V172, P1039, DOI 10.1148/172.3.1039; CONACHER ID, 1983, ANAESTHESIA, V38, P546; Coveney E, 1998, ANN SURG, V227, P496, DOI 10.1097/00000658-199804000-00008; Culp WC, 2005, J VASC INTERV RADIOL, V16, P1397, DOI 10.1097/01.RVI.0000174285.84995.7F; GASNER RR, 1998, PRINCIPLES PRACTICE, P140; Grass JA, 1999, ANN THORAC SURG, V67, P828; HARSHFIELD DL, 1993, AM J ROENTGENOL, V161, P1057, DOI 10.2214/ajr.161.5.7903843; Hatsiopoulou O, 2003, J VASC INTERV RADIOL, V14, P1373, DOI 10.1097/01.RVI.0000085769.63355.24; HOFFMAN B, 2001, PHARMACOL BASIS THER, P140; KAMAKAR MK, 2001, ANESTHESIOLOGY, V95, P771; Kopacz DJ, 1998, NEURAL BLOCKADE CLIN, P451; LIEBERMAN RP, 1988, SEMIN INTERVENT RAD, V5, P213, DOI 10.1055/s-2008-1075957; LIEBERMAN RP, 1990, RADIOLOGY, V175, P274, DOI 10.1148/radiology.175.1.2315494; LIEBERMAN RP, 1988, RADIOLOGY, V167, P562, DOI 10.1148/radiology.167.2.3357975; LOPER KA, 1989, ANESTH ANALG, V69, P398; Lubenow Timothy R., 1997, P1305; Naja AZ, 2004, EUR J ANAESTH, V21, P489; Naja Z, 2001, ANAESTHESIA, V56, P1184; PURCELLJONES G, 1989, ANESTH ANALG, V68, P32; Razzaq R, 2000, CLIN RADIOL, V55, P131, DOI 10.1053/crad.1999.0325; Richardson J, 1999, BRIT J ANAESTH, V83, P387; Richardson J, 1998, BRIT J ANAESTH, V81, P230; Savader S J, 1993, J Vasc Interv Radiol, V4, P539, DOI 10.1016/S1051-0443(93)71917-X; TANAKA N, 1985, EUR SURG RES, V17, P237, DOI 10.1159/000128472; TENICELA R, 1990, CLIN J PAIN, V6, P227, DOI 10.1097/00002508-199009000-00010	27	7	8	0	1	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013 USA	0174-1551			CARDIOVASC INTER RAD	Cardiovasc. Interv. Radiol.	DEC	2006	29	6					1015	1021		10.1007/s00270-005-0273-z			7	Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging	Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging	099OY	WOS:000241606000013	16988878				2020-06-30	J	Unlugenc, H; Ozalevli, M; Gunes, Y; Olguner, S; Evruke, C; Ozcengiz, D; Akman, H				Unlugenc, H.; Ozalevli, M.; Gunes, Y.; Olguner, S.; Evruke, C.; Ozcengiz, D.; Akman, H.			A double-blind comparison of intrathecal S(+) ketamine and fentanyl combined with bupivacaine 0.5% for Caesarean delivery	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article						anaesthetics, intravenous, ketamine; local anaesthetics, bupivacaine; analgesics, opioid, fentanyl; spinal anaesthesia	REDUCES POSTOPERATIVE PAIN; SPINAL-ANESTHESIA; KNEE ARTHROPLASTY; MORPHINE; SURGERY; ANTINOCICEPTION; ROPIVACAINE; RECEPTOR; BLOCK; RATS	Background, In this prospective, randomized, double-blind, controlled study, we investigated the sensory, motor and analgesic block characteristics of S(+) ketamine, fentanyl and saline given intrathecally (IT) in addition to 0.5% plain bupivacaine (10mg) for spinal analgesia. Methods: Ninety ASA I or II adult patients undergoing Caesarean section were randomly allocated to receive 1.0 mL of 0.9% saline in Group S (n = 30), 0.05 mg kg(-1) of S(+) ketamine (1.0 mL) in Group K (n = 30) or 25 mu g (1.0 mL) of fentanyl in Group F (n = 30) following 10 mg of plain bupivacaine 0.5% IT. We recorded onset and duration of sensory and motor block, time to reach the maximal dermatomal level of sensory block and duration of spinal analgesia. Results: The onset time of sensory and motor block was significantly shorter in Groups K and F than in Group S (P < 0.014). Their duration was significantly longer in Group F than in Groups K and S (P < 0.009). The time to reach the maximal dermatomal level of sensory block was significantly shorter in Groups K and F than in Group S (P < 0.001). The duration of spinal analgesia was significantly longer in Group F than in Groups K and S (P < 0.001). Conclusion: In patients undergoing Caesarean section with spinal analgesia, the addition of S(+) ketamine (0.05 mg kg(-1)) IT to 10 mg of spinal plain bupivacaine (0.5%) led to rapid onset of both sensory and motor blockade and enhanced the segmental spread of spinal block without prolonging the duration of spinal analgesia, whereas fentanyl provided prolonged analgesia.	Cukurova Univ, Fac Med, Dept Anaesthesiol, TR-01330 Adana, Turkey; Cukurova Univ, Fac Med, Dept Gynecol & Obstet, TR-01330 Adana, Turkey	Unlugenc, H (reprint author), Cukurova Univ, Fac Med, Dept Anaesthesiol, TR-01330 Adana, Turkey.	unlugenc@cu.edu.tr	Unlugenc, Hakki/W-9586-2018	Unlugenc, Hakki/0000-0003-0164-8258			ArendtNielsen L, 1996, BRIT J ANAESTH, V77, P625; BACIGALUPO G, 1990, J PERINAT MED, V18, P289, DOI 10.1515/jpme.1990.18.4.289; BION JF, 1984, ANAESTHESIA, V39, P1023, DOI 10.1111/j.1365-2044.1984.tb08895.x; CALVEY TN, 1995, ACTA ANAESTH SCAND, V39, P83, DOI 10.1111/j.1399-6576.1995.tb04316.x; Chia YY, 1998, ANESTH ANALG, V86, P1245, DOI 10.1097/00000539-199806000-00021; Choi DH, 2000, REGION ANESTH PAIN M, V25, P240, DOI 10.1016/S1098-7339(00)90005-1; Danelli G, 2004, REGION ANESTH PAIN M, V29, P221, DOI 10.1016/j.rapm.2004.02.003; DHASMANA KM, 1986, ARCH INT PHARMACOD T, V280, P97; Gantenbein M, 1997, LIFE SCI, V61, P2027, DOI 10.1016/S0024-3205(97)00861-8; Hao JX, 1998, ACTA ANAESTH SCAND, V42, P435, DOI 10.1111/j.1399-6576.1998.tb05138.x; Himmelseher S, 2001, ANESTH ANALG, V92, P1290; Hirota K, 1996, BRIT J ANAESTH, V77, P441, DOI 10.1093/bja/77.4.441; Kathirvel S, 2000, ANAESTHESIA, V55, P899, DOI 10.1046/j.1365-2044.2000.01472.x; Klimscha W, 1998, ANESTH ANALG, V86, P561, DOI 10.1097/00000539-199803000-00023; Kroin JS, 2000, ANESTH ANALG, V90, P913, DOI 10.1213/00000539-200004000-00025; Kuusniemi KS, 2000, ANESTH ANALG, V91, P1452, DOI 10.1097/00000539-200012000-00029; MATHISEN LC, 1995, PAIN, V61, P215, DOI 10.1016/0304-3959(94)00170-J; Morgan GE, 2002, CLIN ANAESTHESIOL, P233; PALMER CM, 1995, REGION ANESTH, V20, P389; RAVAT F, 1987, ANESTHESIOLOGY, V66, P819, DOI 10.1097/00000542-198706000-00019; Sarton E, 2001, ANESTH ANALG, V93, P1495, DOI 10.1097/00000539-200112000-00031; Shende D, 1998, ANAESTHESIA, V53, P706, DOI 10.1046/j.1365-2044.1998.329-az0482.x; Strumper D, 2004, ANESTH ANALG, V98, P497, DOI 10.1213/01.ANE.0000096243.74182.5E; SUMIHISA A, 2000, ANESTHESIOLOGY, V92, P1624; Togal T, 2004, EUR J ANAESTH, V21, P193, DOI 10.1017/S0265021504003059; Tomemori T, 2001, CLIN IMAG, V25, P355, DOI 10.1016/S0899-7071(01)00332-1; Weir PS, 1998, BRIT J ANAESTH, V80, P299; Wong CS, 1996, REGION ANESTH, V21, P534; Yanli Y, 1996, ANAESTHESIA, V51, P84, DOI 10.1111/j.1365-2044.1996.tb07662.x	29	13	15	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0265-0215	1365-2346		EUR J ANAESTH	Eur. J. Anaesth.	DEC	2006	23	12					1018	1024		10.1017/S0265021506000950			7	Anesthesiology	Anesthesiology	109JI	WOS:000242303600006	16824240				2020-06-30	J	Siddik-Sayyid, SM; Taha, SK; Aouad, MT; Daaboul, DG; Deeb, PG; El Khatib, MF; Baraka, AS				Siddik-Sayyid, Sahar M.; Taha, Samar K.; Aouad, Marie T.; Daaboul, Dima G.; Deeb, Patricia G.; El Khatib, Mohamed F.; Baraka, Anis S.			The effect of injection of two vs 10 mL saline on the subsequent spread and quality of epidural analgesia in parturients	JOURNAL OF CLINICAL ANESTHESIA			English	Article						anesthesia, obstetrical; analgesia, epidural; loss-of-resistance technique, saline	SPACE; IDENTIFICATION; RESISTANCE; PUNCTURE; VOLUME; NEEDLE; AIR	Objective: To determine whether two vs 10 mL of saline injected into the epidural space affects the subsequent spread and quality of epidural analgesia in parturients. Design: Randomized, double-blinded, placebo-controlled study. Setting: Delivery room. Patients: 105 ASA physical status I and II parturients requesting epidural analgesia. Interventions: After identification of the epidural space by the loss-of-resistance technique using normal saline, two mL of saline was then injected into the epidural space in the 2-mL group (n = 53) and 10 mL in the 10-mL group (n = 52). Five minutes after the test dose, patients received 10 mL of bupivacaine (0.1%) with fentanyl two mu g mL(-1). Measurements: 25 minutes after the initial bolus of bupivacaine and fentanyl, spread of block, subsequent pain relief, and influence of the volume of the injected saline on the ease of epidural catheter insertion and on the incidence of blood vessel trauma and paresthesia, were evaluated. Results: The total number of dermatomes blocked for cold and pinprick sensation in the 10-mL group was significantly more than in the 2-mL group (19 [6-29] vs 15 [4-27] for cold sensation, P = 0.000; and 15 [3-29] vs 11.5 [3-26] for pinprick sensation, P = 0.001). However, the visual analog pain scale and need for supplemental analgesia were similar between the two groups. The epidural catheter was easily inserted in 94.2% of the 2-mL group and 100% of the 10-mL group. The incidence of blood vessel trauma was low and the incidence of paresthesia was high without any significant difference between the two groups. Conclusions: 10 mL saline was associated with a higher total number of dermatomes blocked for both cold and pinprick sensation than the two mL saline. However, the pain relief was adequate in both groups, and two mL saline was as effective as the 10 mL in the ease of catheter insertion and prevention of intravascular cannulation. (C) 2006 Elsevier Inc. All rights reserved.	Amer Univ Beirut, Med Ctr, Dept Anesthesiol, Beirut, Lebanon	Baraka, AS (reprint author), Amer Univ Beirut, Med Ctr, Dept Anesthesiol, POB 11-0236, Beirut, Lebanon.	abaraka@aub.edu.lb					Beilin Y, 2000, REGION ANESTH PAIN M, V25, P596, DOI 10.1053/rapm.2000.9535; BLOMBERG RG, 1989, ANAESTHESIA, V44, P742, DOI 10.1111/j.1365-2044.1989.tb09260.x; BROMAGE PR, 1983, ANESTHESIOLOGY, V58, P257, DOI 10.1097/00000542-198303000-00010; BROMAGE PR, 1962, BRIT J ANAESTH, V34, P161, DOI 10.1093/bja/34.3.161; BROMAGE PR, 1978, EPIDURAL ANALGESIA, P218; Cheek TG, 2002, SHNIDER LEVINSONS AN, P3; Evron S, 2004, ANESTH ANALG, V99, P245, DOI 10.1213/01.ane.0000120084.56136.15; Gadalla F, 2003, CAN J ANAESTH, V50, P382, DOI 10.1007/BF03021036; Iwama H, 1997, ANESTHESIOLOGY, V86, P507, DOI 10.1097/00000542-199702000-00032; JAUCOT J, 1986, Acta Anaesthesiologica Belgica, V37, P187; MANNION D, 1991, ANAESTHESIA, V46, P585, DOI 10.1111/j.1365-2044.1991.tb09665.x; Okutomi T, 1998, CAN J ANAESTH, V45, P1091, DOI 10.1007/BF03012397; Okutomi T, 1999, CAN J ANAESTH, V46, P930, DOI 10.1007/BF03013126; ROLBIN SH, 1987, CAN J ANAESTH, V34, P459, DOI 10.1007/BF03014349; ROLBIN SH, 1990, CAN J ANAESTH, V37, P337, DOI 10.1007/BF03005586; ROSEN R, 2002, [No title captured], P123; VERNIQUET AJW, 1980, ANAESTHESIA, V35, P660, DOI 10.1111/j.1365-2044.1980.tb03880.x	17	9	9	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	DEC	2006	18	8					575	579		10.1016/j.jclinane.2006.03.015			5	Anesthesiology	Anesthesiology	121WY	WOS:000243188900004	17175425				2020-06-30	J	Maddali, MM; Kurian, E; Fahr, J				Maddali, Madan Mohan; Kurian, Elizabeth; Fahr, Jutta			Extubation time, hemodynamic stability, and postoperative pain control in patients undergoing coronary artery bypass surgery: an evaluation of fentanyl, remifentanil, and nonsteroidal antiinflammatory drugs with propofol for perioperative and postoperative management	JOURNAL OF CLINICAL ANESTHESIA			English	Article						anesthesia; intravenous; coronary artery bypass graft surgery; nonsteroidal antiinflammatory drugs; opioids; NSAID	INTENSIVE-CARE-UNIT; GRAFT-SURGERY; SEDATION; EFFICACY; TRIAL	Study Objective: To compare three anesthetic strategies with respect to the time of extubation after coronary artery bypass graft (CABG) surgery and to assess patient satisfaction with the procedure. Design: Prospective, randomized, clinical study. Setting: Tertiary-care referral center. Participants: 180 cardiac surgical patients undergoing primary CABG from January through June 2004. Interventions: After induction of general anesthesia, patients were allocated to one of three groups. All three groups received a continuous infusion of intravenous (IV) propofol perioperatively and postoperatively. Group 1 (fentanyl infusion group, n = 60) received continuous IV fentanyl infusion perioperatively and postoperatively for analgesia. Group 2 (diclofenac group, n = 60) received fentanyl bolus doses intraoperatively and diclofenac suppository postoperatively. Group 3 (remifentanil group, n = 60) received continuous infusion of IV remifentanil perioperatively and IV fentanyl as an immediate postoperative bolus followed by continuous fentanyl infusion. Duration of postoperative ventilation up to the time of extubation, inotrope requirement, time at which analgesic infusion was discontinued, postextubation arterial blood gas analysis, pain evaluation via visual analog scale, need for rescue analgesia, awareness during surgery, and length of postcardiac surgical unit stay, were evaluated in each patient. Main Results: The diclofenac group exhibited the shortest time to extubation, the least inotrope use, and the fewest rescue doses of analgesic than did patients of the other two groups. Conclusion: Intravenous propofol with bolus doses of W fentanyl intraoperatively in combination with postoperative nonsteroidal antiinflammatory drugs had the best recovery profile in patients undergoing primary CABG than did the other two regimens studied. (C) 2006 Elsevier Inc. All rights reserved.	Royal Hosp, Dept Anesthesia, Muscat 131111, Oman	Maddali, MM (reprint author), Royal Hosp, Dept Anesthesia, Muscat 131111, Oman.	madan@omantel.net.om	Maddali, Madan/D-8501-2016	Maddali, Madan/0000-0003-0435-6111			BARR J, 1995, CRIT CARE CLIN, V11, P827; Cheng DCH, 2001, ANESTH ANALG, V92, P1094; Elliott P, 2000, ANESTH ANALG, V91, P58, DOI 10.1097/00000539-200007000-00011; Engoren M, 2001, ANESTH ANALG, V93, P859, DOI 10.1097/00000539-200110000-00011; Herr DL, 2003, J CARDIOTHOR VASC AN, V17, P576, DOI 10.1016/S1053-0770(03)00200-3; Howie MB, 2001, ANESTH ANALG, V92, P1084; Kollef MH, 1998, CHEST, V114, P541, DOI 10.1378/chest.114.2.541; Mollhoff T, 2001, BRIT J ANAESTH, V87, P718, DOI 10.1093/bja/87.5.718; Myles PS, 2002, ANESTH ANALG, V95, P805, DOI 10.1097/00000539-200210000-00004; Young C, 2000, CRIT CARE MED, V28, P854, DOI 10.1097/00003246-200003000-00041	10	24	26	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	DEC	2006	18	8					605	610		10.1016/j.jclinane.2006.03.022			6	Anesthesiology	Anesthesiology	121WY	WOS:000243188900010	17175431				2020-06-30	J	Kanamori, C; Kanamori, T; Hayashi, M; Yorioka, H; Kanzaki, H				Kanamori, Chiharu; Kanamori, Takanobu; Hayashi, Michiharu; Yorioka, Hirokazu; Kanzaki, Haruhide			Three-cycle fentanyl patch system significantly improves pain control in gynecologic cancer	JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH			English	Article						cancer pain; opioid rotation; opioid therapy; pain control; transdermal fentanyl	TRANSDERMAL FENTANYL; PHARMACOLOGICAL-PROPERTIES; THERAPEUTIC-EFFICACY; MANAGEMENT; MORPHINE; PATIENT	Pain affects many cancer patients, and in advanced stages of the disease it can significantly affect the quality of their lives. Morphine has long been the 'gold standard' for the treatment of cancer pain. However, its side-effects, particularly sedation and cognitive impairment at high doses, have encouraged the use of 'opioid rotation'. The transdermal fentanyl patch has advantages over oral morphine, with reduced side-effects and increased convenience in practical usage. The side-effects were reduced in patients who changed to the fentanyl patch, but rescue analgesia was often needed because of the decrease of fentanyl release from the patch, especially on the patch replacement day. We have developed a three-cycle fentanyl patch system that provided an appropriate pain control, and this system should be considered for pain relief in cancer patients.	Kansai Med Univ, Dept Obstet & Gynecol, Osaka 5708507, Japan; Tenri Hosp, Dept Obstet & Gynecol, Nara, Japan	Kanamori, C (reprint author), Kansai Med Univ, Dept Obstet & Gynecol, Osaka 5708507, Japan.	goldwoodchiharu@yahoo.co.jp					AHMEDZAI S, 1994, J DRUG DEV, V6, P93; AHMEDZAI S, 1997, EUR J CANC S6, V33, P8; Allan L, 2001, BRIT MED J, V322, P1154, DOI 10.1136/bmj.322.7295.1154; BOSEK V, 1992, J CLIN ANESTH, V4, P480, DOI 10.1016/0952-8180(92)90223-N; CALIS KA, 1992, CLIN PHARMACY, V11, P22; CHEN JC, 1993, LIFE SCI, V52, P389, DOI 10.1016/0024-3205(93)90152-S; Cherny N, 2000, J Oncol Manag, V9, P8; HAYS H, 1995, AM PAIN SOC 14 ANN M, P17; *JANSS PHARM, 1995, 1097592 JANSS PHARM; Jeal W, 1997, DRUGS, V53, P109, DOI 10.2165/00003495-199753010-00011; Konishi H, 2005, PHARM WORLD SCI, V27, P353, DOI 10.1007/s11096-005-5972-7; LEVY S, 1988, P AM SOC CLIN PHARM, V7, P292; LUKUS R, 2000, PALLIATIVE MED, V14, P111; MAVES TJ, 1992, J PAIN SYMPTOM MAN S, V7, P58; MEGANS AAH, 1996, R004263 JANSS RES FD; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; Mystakidou K, 2003, INT J CANCER, V107, P486, DOI 10.1002/ijc.11416; Radbruch L, 2001, PALLIATIVE MED, V15, P309, DOI 10.1191/026921601678320296; SIMMONDS MA, 1989, P AN M AM SOC CLIN, V8, P324; SKAER TL, 1993, CLIN THER, V15, P638; Sloan PA, 1998, J PAIN SYMPTOM MANAG, V16, P102, DOI 10.1016/S0885-3924(98)00044-X; SOUTHAM MA, 1995, ANTI-CANCER DRUG, V6, P29, DOI 10.1097/00001813-199504003-00005; World Health Organization, 1990, CANC PAIN REL PALL C; ZECH DFJ, 1992, PAIN, V50, P293, DOI 10.1016/0304-3959(92)90034-9	24	3	3	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1341-8076	1447-0756		J OBSTET GYNAECOL RE	J. Obstet. Gynaecol. Res.	DEC	2006	32	6					605	609		10.1111/j.1447-0756.2006.00457.x			5	Obstetrics & Gynecology	Obstetrics & Gynecology	104IC	WOS:000241951100011	17100824				2020-06-30	J	Orsini, JA; Moate, PJ; Kuersten, K; Soma, LR; Boston, RC				Orsini, J. A.; Moate, P. J.; Kuersten, K.; Soma, L. R.; Boston, R. C.			Pharmacokinetics of fentanyl delivered transdermally in healthy adult horses - variability among horses and its clinical implications	JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS			English	Article							ANALGESIA; DOGS; DISPOSITION; CATS	The safety and pharmacokinetics of fentanyl, delivered transdermally at a dosage of 60-67 mu g/kg, were investigated in six healthy adult horses. Three transdermal fentanyl patches (Duragesic (R)), each containing 10 mg of fentanyl citrate, were applied to the mid-dorsal thorax of each horse and left in place for 72 h. Plasma fentanyl concentrations were periodically measured throughout this period and for 12 h after patch removal. After an initial delay of approximately 2 h, the plasma fentanyl concentration rose rapidly in a fairly linear fashion, reaching a peak at around 12 h; thereafter, it gradually declined in a roughly linear manner over the next 72 h. There was much individual variation, however. The initial delay ranged from 0 to 5.1 h (mean, 1.91 +/- 2.0 h), T-cmax ranged from 8.5 to 14.5 h (mean, 11.4 +/- 2.7 h) and C-max ranged from 0.67 to 5.12 ng/mL (mean, 2.77 +/- 1.92 ng/mL). In two horses, the plasma fentanyl concentration failed to reach even 1 ng/mL, whereas in the other four horses it was > 1 ng/mL for at least 40 h and for at least 72 h in two of these horses. No adverse effects attributable to fentanyl were observed in any of the horses, indicating that this dosage is safe in systemically healthy adult horses. However, it failed to achieve plasma fentanyl concentrations generally considered to be analgesic (>= 1 ng/mL) in about one-third of horses.	Univ Penn, Sch Vet Med, Dept Clin Studies, New Bolton Ctr, Kennett Sq, PA 19348 USA	Orsini, JA (reprint author), Univ Penn, Sch Vet Med, Dept Clin Studies, New Bolton Ctr, Kennett Sq, PA 19348 USA.	orsini@vet.upenn.edu	Moate, Peter/AAE-1555-2019	Moate, Peter/0000-0003-4598-2047			*AHFS DRUG INF, 2006, FENT CITR, P2102; Boston RC, 2005, MAGN RESON IMAGING, V23, P591, DOI 10.1016/j.mri.2005.02.006; Harkins JD, 1997, J VET PHARMACOL THER, V20, P396, DOI 10.1046/j.1365-2885.1997.00089.x; KAMERLING SG, 1985, GEN PHARMACOL, V16, P253, DOI 10.1016/0306-3623(85)90078-3; Kyles AE, 1996, AM J VET RES, V57, P715; Lee DD, 2000, AM J VET RES, V61, P672, DOI 10.2460/ajvr.2000.61.672; LEHMANN KA, 1992, J PAIN SYMPTOM MANAG, V7, P8; MATTHEWS NS, 1997, P 6 INT C VET AN THE, P116; Maxwell LK, 2003, EQUINE VET J, V35, P484, DOI 10.2746/042516403775600415; MICHIELS M, 1977, EUR J CLIN PHARMACOL, V12, P153, DOI 10.1007/BF00645137; Mills PC, 2004, AM J VET RES, V65, P1697, DOI 10.2460/ajvr.2004.65.1697; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; Robertson SA, 2005, J VET PHARMACOL THER, V28, P87, DOI 10.1111/j.1365-2885.2004.00628.x; Stefanovski D, 2003, METABOLISM, V52, P1153, DOI 10.1016/S0026-0495(03)00144-6; Thomasy SM, 2004, J VET INTERN MED, V18, P550, DOI 10.1892/0891-6640(2004)18&lt;550:TFCWNA&gt;2.0.CO;2; Wegner K., 2002, Proceedings of the 48th Annual Convention of the American Association of Equine Practitioners, Orlando, Florida, USA, 4-8 December 2002, P291	16	27	27	0	13	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0140-7783			J VET PHARMACOL THER	J. Vet. Pharmacol. Ther.	DEC	2006	29	6					539	546		10.1111/j.1365-2885.2006.00796.x			8	Pharmacology & Pharmacy; Veterinary Sciences	Pharmacology & Pharmacy; Veterinary Sciences	101JS	WOS:000241737700011	17083458				2020-06-30	J	Smith, KM; Powell, DM; James, SB; Calle, PP; Moore, RP; Zurawka, HS; Goscilo, S; Raphael, BL				Smith, Kristine M.; Powell, David M.; James, Stephanie B.; Calle, Paul P.; Moore, Robert P.; Zurawka, Heidi S.; Goscilo, Sabrina; Raphael, Bonnie L.			Anesthesia of male axis deer (Axis axis): Evaluation of thiafentanil, medetomidine, and ketamine versus medetomidine and ketamine	JOURNAL OF ZOO AND WILDLIFE MEDICINE			English	Article						Axis axis; axis deer; anesthesia; ketamine; medetomidine; thiafentanil oxalate	MULE DEER; IMMOBILIZATION; COMBINATION; CARFENTANIL; XYLAZINE; A3080	Thiafentanil oxalate, previously known as A-3080, is a synthetic opioid used for chemical immobilization of a variety of nondomestic hoofstock species. (1-4.8.10.12) This Study compared the combination of thiafentanil oxalate, medetomidine, and ketamine (TMK: 0.09 +/- 0.02 mg/kg, 0.01 +/- 0.003 mg/kg, and 1.36 +/- 0.33 mg/kg, respectively) with the combination of medetomidine and ketamine (MK; 0.09 +/- 0.02 mg/kg and 3.48 +/- 0.55 mg/kg, respectively) for anesthetization of 17 captive male axis deer (Axis axis) for vasectomy. Nine deer received TMK and eight deer received MK via projectile syringe during the months of January and February, 2005. Mean induction and arousal times, vital signs, and arterial blood gas values were monitored and compared. All animals received Supplemental oxygen during the surgical procedure. Animals receiving TMK were reversed with naltrexone (100 mg/mg, thiafentanil) and atipamazole (5 mg/mg medetomidine). Animals receiving MK were reversed with atipamazole (5 mg/mg medetomidine). Two MK animals and three TMK animals required supplementation with ketamine i.v. immediately upon handling. Six of the nine animals immobilized with TMK required intubation for positive-pressure ventilation. Two of these six animals also required isoflurane to maintain anesthesia. Mean induction time was 3.5 +/- 2.0 min in the TMK group, and 9.8 +/- 6.7 min in the MK group. Despite shorter mean induction times, animals anesthetized with TMK experienced unpredictable inductions, apnea, muscle rigidity, limb movement, and significant respiratory and metabolic lactic acidosis. MK resulted in smoother inductions, better respiratory function, and less adverse metabolic disturbances, and thus Was considered superior to TMK for anesthesia in captive axis deer at the dosages tested.	Wildlife Conservat Soc, Dept Mammal, Bronx, NY 10460 USA	Smith, KM (reprint author), Wildlife Conservat Soc, Dept Mammal, Bronx, NY 10460 USA.						Citino SB, 2002, J WILDLIFE DIS, V38, P457, DOI 10.7589/0090-3558-38.2.457; Citino SB, 2001, J S AFR VET ASSOC, V72, P29; Grobler D, 2001, J S AFR VET ASSOC, V72, P81; JANSSEN DL, 1991, PROCEEDINGS : AMERICAN ASSOCIATION OF ZOO VETERINARIANS - ANNUAL MEETING 1991, P340; JESSUP DA, 1984, J ZOO ANIM MED, V15, P8, DOI 10.2307/20094672; KARESH WB, 1986, J ZOO WILDLIFE MED, V17, P58, DOI 10.2307/20094795; KLEIN L, 1996, P AM ASS ZOO VET ANN, P376; MCJAMES SW, 1993, P AM ASS ZOO VET, P365; Moresco A, 2001, J ZOO WILDLIFE MED, V32, P81, DOI 10.1638/1042-7260(2001)032[0081:UONTRC]2.0.CO;2; Pye Geoffrey W., 2001, P226; Smith I.L., 1993, P AM ASS ZOO VET, P367; STANLEY TH, 1989, P C AM ASS ZOO VET, P13; THURMON JC, 1996, LUMB JONES VET ANEST, P741; Wolfe LL, 2004, J WILDLIFE DIS, V40, P282, DOI 10.7589/0090-3558-40.2.282	14	15	15	0	1	AMER ASSOC ZOO VETERINARIANS	MEDIA	6 NORTH PENNELL ROAD, MEDIA, PA 19063 USA	1042-7260			J ZOO WILDLIFE MED	J. Zoo Wildl. Med.	DEC	2006	37	4					513	517		10.1638/06-027.1			5	Veterinary Sciences	Veterinary Sciences	124KS	WOS:000243367300009	17315436				2020-06-30	J	Macey, TA; Lowe, JD; Chavkin, C				Macey, Tara A.; Lowe, Janet D.; Chavkin, Charles			Mu opioid receptor activation of ERK1/2 is GRK3 and arrestin dependent in striatal neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DESENSITIZATION; KINASE; MORPHINE; PHOSPHORYLATION; INTERNALIZATION; EFFICACY; RESENSITIZATION; ENDOCYTOSIS; EXPRESSION; TOLERANCE	In this study we investigated the mechanisms responsible for MAP kinase ERK1/2 activation following agonist activation of endogenous mu opioid receptors (MOR) normally expressed in cultured striatal neurons. Treatment with the MOR agonist fentanyl caused significant activation of ERK1/2 in neurons derived from wild type mice. Fentanyl effects were blocked by the opioid antagonist naloxone and were not evident in neurons derived from MOR knock-out (-/-) mice. In contrast, ERK1/2 activation by fentanyl was not evident in neurons from GRK3(-/-) mice or neurons pretreated with small inhibitory RNA for arrestin3. Consistent with this observation, treatment with the opiate morphine (which is less able to activate arrestin) did not elicit ERK1/2 activation in wild type neurons; however, transfection of arrestin3-(R170E) (a dominant positive form of arrestin that does not require receptor phosphorylation for activation) enabled morphine activation of ERK1/2. In addition, activation of ERK1/2 by fentanyl and morphine was rescued in GRK3(-/-) neurons following transfection with dominant positive arrestin3(R170E). The activation of ERK1/2 appeared to be selective as p38 MAP kinase activation was not increased by either fentanyl or morphine treatment in neurons from wild type, MOR-/-, or GRK3(-/-) mice. In addition, U0126 (a selective inhibitor of MEK kinase responsible for ERK phosphorylation) blocked ERK1/2 activation by fentanyl. These results support the hypothesis that MOR activation of ERK1/2 requires opioid receptor phosphorylation by GRK3 and association of arrestin3 to initiate the cascade resulting in ERK1/2 phosphorylation in striatal neurons.	Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA	Chavkin, C (reprint author), Box 357280,1959 Pacific Ave NE, Seattle, WA 98195 USA.	cchavkin@u.washington.edu	Chavkin, Charles/G-2797-2010		NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [R37 DA011672, R01 DA016898, R01DA11672, R01 DA016898-05, R37 DA011672-07, R01 DA011672, R37 DA011672-08, R37 DA011672-06]; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32 NS007332, T32NS07332]		Beaulieu JM, 2005, CELL, V122, P261, DOI 10.1016/j.cell.2005.05.012; Belcheva MM, 1998, J NEUROCHEM, V70, P635; Bohn LM, 2004, MOL PHARMACOL, V66, P106, DOI 10.1124/mol.66.1.106; Bruchas MR, 2006, J BIOL CHEM, V281, P18081, DOI 10.1074/jbc.M513640200; Celver J, 2002, J BIOL CHEM, V277, P9043, DOI 10.1074/jbc.M107400200; Celver J, 2004, MOL PHARMACOL, V65, P528, DOI 10.1124/mol.65.3.528; Clark MJ, 2004, J PHARMACOL EXP THER, V310, P215, DOI 10.1124/jpet.103.064824; Dang VC, 2005, MOL PHARMACOL, V68, P1127, DOI 10.1124/mol.105.013185; Debic HH, 2005, J NEUROSCI, V25, P7847, DOI 10.1523/JNEUROSCI.5045-04.2005; Dheda K, 2004, BIOTECHNIQUES, V37, P112, DOI 10.2144/04371RR03; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; Koch T, 2001, J BIOL CHEM, V276, P31408, DOI 10.1074/jbc.M100305200; Kovoor A, 1999, J BIOL CHEM, V274, P6831, DOI 10.1074/jbc.274.11.6831; Kovoor A, 1998, MOL PHARMACOL, V54, P704; KOVOOR A, 1995, J BIOL CHEM, V270, P589, DOI 10.1074/jbc.270.2.589; Kovoor A, 1997, J BIOL CHEM, V272, P27605, DOI 10.1074/jbc.272.44.27605; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Ma WY, 2001, EUR J NEUROSCI, V14, P1091, DOI 10.1046/j.0953-816x.2001.01731.x; Macey TA, 2004, MOL PHARMACOL, V66, P1635, DOI 10.1124/mol.104.001495; McDonald PH, 2001, CELL SIGNAL, V13, P683, DOI 10.1016/S0898-6568(01)00203-0; Narita M, 2002, NEUROSCI LETT, V324, P97, DOI 10.1016/S0304-3940(02)00141-6; Peppel K, 1997, J BIOL CHEM, V272, P25425, DOI 10.1074/jbc.272.41.25425; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; Schuller AGP, 1999, NAT NEUROSCI, V2, P151; Schulz R, 2004, EUR J PHARMACOL, V500, P487, DOI 10.1016/j.ejphar.2004.07.010; Shenoy SK, 2006, J BIOL CHEM, V281, P1261, DOI 10.1074/jbc.M506576200; Terman GW, 2004, BRIT J PHARMACOL, V141, P55, DOI 10.1038/sj.bjp.0705595; Tsao PI, 2000, J BIOL CHEM, V275, P11130, DOI 10.1074/jbc.275.15.11130; Wang XW, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng154; Whistler JL, 1999, NEURON, V23, P737, DOI 10.1016/S0896-6273(01)80032-5; Yu YK, 1997, J BIOL CHEM, V272, P28869, DOI 10.1074/jbc.272.46.28869; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157	32	55	56	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34515	34524		10.1074/jbc.M604278200			10	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	101UZ	WOS:000241767600072	16982618	Green Accepted, Bronze			2020-06-30	J	Sunder, RA; Agarwal, A				Sunder, R. A.; Agarwal, A.			Anaesthetic management of a patient with ornithine transcarbamylase deficiency	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Letter							UREA CYCLE DISORDERS		All India Inst Med Sci, Dept Anaesthesiol & Crit Care, New Delhi 110092, India	Sunder, RA (reprint author), All India Inst Med Sci, Dept Anaesthesiol & Crit Care, Ansari Nagar, New Delhi 110092, India.	rani_kannan2000@yahoo.com					Batshaw ML, 2001, J PEDIATR-US, V138, pS46, DOI 10.1067/mpd.2001.111836; Berry GT, 2001, J PEDIATR-US, V138, pS56, DOI 10.1067/mpd.2001.111837; BRUSILOW SW, 2001, [No title captured], P1909; Schmidt J, 2006, PEDIATR ANESTH, V16, P333, DOI 10.1111/j.1460-9592.2005.01695.x; Summar M, 2001, J PEDIATR-US, V138, pS30, DOI 10.1067/mpd.2001.111834	5	1	1	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	NOV	2006	50	10					1310	1311		10.1111/j.1399-6576.2006.01111.x			2	Anesthesiology	Anesthesiology	104JL	WOS:000241954600028	17067337				2020-06-30	J	Hyvarinen, A; Kokki, H; Heinonen, S; Silvola, J; Valtonen, H				Hyvarinen, A.; Kokki, H.; Heinonen, S.; Silvola, J.; Valtonen, H.			Sensorineural hearing loss after epidural block for labor analgesia: a case report	ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA			English	Article						cerebrospinal fluid leakage; epidural anesthesia; sensorineural hearing loss	SPINAL-ANESTHESIA; PRESSURE; HEADACHE; PUNCTURE		Kuopio Univ Hosp, Dept Otorhinolaryngol, FIN-70211 Kuopio, Finland; Kuopio Univ Hosp, Dept Anesthesiol & Intens Care, FIN-70211 Kuopio, Finland; Kuopio Univ Hosp, Dept Obstet & Gynecol, FIN-70211 Kuopio, Finland	Hyvarinen, A (reprint author), Kuopio Univ Hosp, Dept Otorhinolaryngol, POB 1777, FIN-70211 Kuopio, Finland.	antti.hyvarinen@kuh.fi					CARLBORG BIR, 1983, AM J OTOLARYNG, V4, P273, DOI 10.1016/S0196-0709(83)80071-4; Finegold H, 2002, ANESTH ANALG, V95, P198, DOI 10.1097/00000539-200207000-00035; Gultekin S, 2002, ANESTH ANALG, V94, P1318; LYBECKER H, 1995, J CLIN ANESTH, V7, P457, DOI 10.1016/0952-8180(95)00053-K; MICHEL O, 1992, ANN OTO RHINOL LARYN, V101, P390, DOI 10.1177/000348949210100503; VANDAM LD, 1956, JAMA-J AM MED ASSOC, V161, P586, DOI 10.1001/jama.1956.02970070018005; WANG LP, 1986, ACTA ANAESTH SCAND, V30, P412, DOI 10.1111/j.1399-6576.1986.tb02441.x	7	1	1	0	0	TAYLOR & FRANCIS AS	OSLO	PO BOX 12 POSTHUSET, NO-0051 OSLO, NORWAY	0001-6349			ACTA OBSTET GYN SCAN	Acta Obstet. Gynecol. Scand.	NOV	2006	85	11					1403	1405		10.1080/00016340600617619			4	Obstetrics & Gynecology	Obstetrics & Gynecology	108BF	WOS:000242214200024	17091427				2020-06-30	J	Gupta, K; Vohra, V; Sood, J				Gupta, K.; Vohra, V.; Sood, J.			The role of magnesium as an adjuvant during general anaesthesia	ANAESTHESIA			English	Article							SULFATE; REQUIREMENTS; PROPOFOL; MAINTENANCE; SALTS; PART	Magnesium sulphate is used extensively in the treatment of eclampsia, and is also used to treat refractory arrhythmias, asthma, myocardial ischaemia and acute respiratory failure. We studied the interaction between magnesium sulphate and the anaesthetic agents propofol, rocuronium bromide and fentanyl citrate. This randomised, double blind study was conducted in 50 patients. The magnesium group A (n = 25) received 30 mg.kg(-1) magnesium sulphate before induction of anaesthesia and 10 mg.kg(-1) continuously intra-operatively until the end of surgery. Group B (n = 25) received the same volume of isotonic saline. Propofol, rocuronium and fentanyl infusions were started and the patients lungs' were ventilated with 33% oxygen in nitrous oxide. Anaesthetic depth was maintained at a bispectral index value of between 40 and 60. Muscle relaxation was maintained at a train-of-four count of 1 throughout surgery using neuromuscular monitoring. The fentanyl infusion was titrated to haemodynamic variables: heart rate and blood pressure. We concluded that magnesium sulphate has anaesthetic, analgesic and muscle relaxation effects and significantly reduces the drug requirements of propofol, rocuronium and fentanyl during anaesthesia.	Sir Ganga Ram Hosp, Dept Anaesthesiol Pain & Perioperat Med, New Delhi 110060, India	Vohra, V (reprint author), Sir Ganga Ram Hosp, Dept Anaesthesiol Pain & Perioperat Med, New Delhi 110060, India.	vohra361@hotmail.com	garcia, waynice np/K-3914-2015				ALDRETE JA, 1968, ANESTH ANAL CURR RES, V47, P428; BUDER TF, 1995, BRIT J ANAESTH, V74, P405; CHESLEY LC, 1979, AM J OBSTET GYNECOL, V133, P1; Choi JC, 2002, ANESTHESIOLOGY, V97, P1137, DOI 10.1097/00000542-200211000-00017; COUNTINHO ELSIMAR METZKER, 1966, J GEN PHYSIOL, V49, P845; Fawcett WJ, 1999, BRIT J ANAESTH, V83, P302, DOI 10.1093/bja/83.2.302; FERIA M, 1993, PAIN, V53, P287, DOI 10.1016/0304-3959(93)90225-E; Glass PS, 1997, ANESTHESIOLOGY, V86, P836, DOI 10.1097/00000542-199704000-00014; ISERI LT, 1984, AM HEART J, V108, P188, DOI 10.1016/0002-8703(84)90572-6; JAMES MFM, 1992, ANESTH ANALG, V74, P129; Koinig H, 1998, ANESTH ANALG, V87, P206, DOI 10.1097/00000539-199807000-00042; Kussman B, 1997, BRIT J ANAESTH, V79, P122; LUI J, 1997, ANESTH ANALG, V84, P185; Meltzer SJ, 1906, AM J PHYSIOL, V16, P233; Meltzer SJ, 1906, AM J PHYSIOL, V15, P387; Peck CH, 1916, J AMER MED ASSOC, V67, P1131; SAVARENESE JJ, 2000, ANAESTHESIA, P463; Schulz-Stubner S, 2001, EUR J ANAESTH, V18, P723, DOI 10.1046/j.1365-2346.2001.00921.x; SOMJEN G, 1966, J PHARMACOL EXP THER, V154, P652; Telci L, 2002, BRIT J ANAESTH, V89, P594, DOI 10.1093/bja/aef238; Thompson SW, 1988, ANESTH ANALG, V20, P1273; Tramer MR, 1996, ANESTHESIOLOGY, V84, P340, DOI 10.1097/00000542-199602000-00011; WOOLF CJ, 1991, PAIN, V44, P293, DOI 10.1016/0304-3959(91)90100-C	23	36	44	1	1	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0003-2409			ANAESTHESIA	Anaesthesia	NOV	2006	61	11					1058	1063		10.1111/j.1365-2044.2006.04801.x			6	Anesthesiology	Anesthesiology	094IM	WOS:000241233100007	17042843				2020-06-30	J	Kennedy, SE; Koeppe, RA; Young, EA; Zubieta, JK				Kennedy, Susan E.; Koeppe, Robert A.; Young, Elizabeth A.; Zubieta, Jon-Kar			Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women	ARCHIVES OF GENERAL PSYCHIATRY			English	Article; Proceedings Paper	57th Annual Meeting of the Society-of-Biological-Psychiatry	MAY 16-18, 2002	PHILADELPHIA, PA	Soc Biol Psychiat			CORTICOTROPIN-RELEASING HORMONE; POSITRON-EMISSION-TOMOGRAPHY; SUICIDE VICTIMS; INDUCED ANALGESIA; MICE LACKING; HUMAN BRAIN; PARAVENTRICULAR NUCLEUS; ANTERIOR CINGULATE; GENDER-DIFFERENCES; OPIATE MODULATION	Context: There is extensive evidence implicating dysfunctions in stress responses and adaptation to stress in the pathophysiological mechanism of major depressive disorder (MDD) in humans. Endogenous opioid neurotransmission activating mu-opioid receptors is involved in stress and emotion regulatory processes and has been further implicated in MDD. Objective: To examine the involvement of mu-opioid neurotransmission in the regulation of affective states in volunteers with MDD and its relationship with clinical response to antidepressant treatment. Design: Measures of mu-opioid receptor availability in vivo ( binding potential [BP]) were obtained with positron emission tomography and the mu-opioid receptor selective radiotracer carbon 11-labeled carfentanil during a neutral state. Changes in BP during a sustained sadness challenge were obtained by comparing it with the neutral state, reflecting changes in endogenous opioid neurotransmission during the experience of that emotion. Setting: Clinics and neuroimaging facilities at a university medical center. Participants: Fourteen healthy female volunteers and 14 individually matched patient volunteers diagnosed with MDD were recruited via advertisement and through outpatient clinics. Interventions: Sustained neutral and sadness states, randomized and counterbalanced in order, elicited by the cued recall of an autobiographical event associated with that emotion. Following imaging procedures, patients underwent a 10-week course of treatment with 20 to 40 mg of fluoxetine hydrochloride. Main Outcome Measures: Changes in mu-opioid receptor BP during neutral and sustained sadness states, negative and positive affect ratings, plasma cortisol and corticotropin levels, and clinical response to antidepressant administration. Results: The sustained sadness condition was associated with a statistically significant decrease in mu-opioid receptor BP in the left inferior temporal cortex of patients with MDD and correlated with negative affect ratings experienced during the condition. Conversely, a significant increase in mu-opioid receptor BP was observed in healthy control subjects in the rostral region of the anterior cingulate. In this region, a significant decrease in mu-opioid receptor BP during sadness was observed in patients with MDD who did not respond to antidepressant treatment. Comparisons between patients with MDD and controls showed significantly lower neutral-state mu-opioid receptor BP in patients with MDD in the posterior thalamus, correlating with corticotropin and cortisol plasma levels. Larger reductions in mu-opioid system BP during sadness were obtained in patients with MDD in the anterior insular cortex, anterior and posterior thalamus, ventral basal ganglia, amygdala, and periamygdalar cortex. The same challenge elicited larger increases in the BP measure in the control group in the anterior cingulate, ventral basal ganglia, hypothalamus, amygdala, and periamygdalar cortex. Conclusions: The results demonstrate differences between women with MDD and control women in mu-opioid receptor availability during a neutral state, as well as opposite responses of this neurotransmitter system during the experimental induction of a sustained sadness state. These data demonstrate that endogenous opioid neurotransmission on mu-opioid receptors, a system implicated in stress responses and emotional regulation, is altered in patients diagnosed with MDD.	Univ Michigan, Sch Med, Dept Psychiat, Mol & Behav Neurosci Inst, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Radiol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Mol & Behav, Neurol Inst, Ann Arbor, MI 48109 USA	Zubieta, JK (reprint author), Univ Michigan, Sch Med, Dept Psychiat, Mol & Behav Neurosci Inst, 205 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.	zubieta@umich.edu			NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R21 MH 069612]		AKIL H, 1984, ANNU REV NEUROSCI, V7, P223, DOI 10.1146/annurev.ne.07.030184.001255; Anderson AK, 2003, NEURON, V39, P581, DOI 10.1016/S0896-6273(03)00504-X; BECK AT, 1987, [No title captured]; Bencherif B, 2002, PAIN, V99, P589, DOI 10.1016/S0304-3959(02)00266-X; Borras MC, 2004, J NEUROPHYSIOL, V91, P2723, DOI 10.1152/jn.00249.2003; Casey KL, 2000, J NEUROPHYSIOL, V84, P525; CORYELL W, 1990, J AFFECT DISORDERS, V19, P163, DOI 10.1016/0165-0327(90)90086-N; Drevets WC, 1997, NATURE, V386, P824, DOI 10.1038/386824a0; Eisenberger NI, 2003, SCIENCE, V302, P290, DOI 10.1126/science.1089134; Filliol D, 2000, NAT GENET, V25, P195, DOI 10.1038/76061; First M.B., 1995, STRUCTURED CLIN INTE; Friston K J, 1994, Hum Brain Mapp, V1, P210, DOI 10.1002/hbm.460010306; Friston KJ, 1994, HUMAN BRAIN MAPPING, V2, P189, DOI DOI 10.1002/HBM.460020402; GABILONDO AM, 1995, BRAIN RES, V682, P245, DOI 10.1016/0006-8993(95)00333-L; GEAR RW, 1995, J NEUROSCI, V15, P3154; Gear RW, 1999, J NEUROSCI, V19, P7175, DOI 10.1523/JNEUROSCI.19-16-07175.1999; George MS, 1996, BIOL PSYCHIAT, V40, P859, DOI 10.1016/0006-3223(95)00572-2; GEORGE MS, 1995, AM J PSYCHIAT, V152, P341; GROSSISSEROFF R, 1990, BRAIN RES, V530, P312, DOI 10.1016/0006-8993(90)91301-V; Guy W., 1976, ECDEU ASSESSMENT MAN, P218, DOI DOI 10.1016/J.BIOPHA.2016.11.034; HALBREICH U, 1985, ARCH GEN PSYCHIAT, V42, P904; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; HERMAN BH, 1978, PHARMACOL BIOCHEM BE, V9, P213, DOI 10.1016/0091-3057(78)90167-3; Horvitz JC, 2000, NEUROSCIENCE, V96, P651, DOI 10.1016/S0306-4522(00)00019-1; Jones AKP, 1999, J CEREBR BLOOD F MET, V19, P803, DOI 10.1097/00004647-199907000-00011; Kalin NH, 1995, PSYCHONEUROENDOCRINO, V20, P735, DOI 10.1016/0306-4530(95)00023-2; KALIN NH, 1988, BRAIN RES, V440, P285, DOI 10.1016/0006-8993(88)90997-3; Kerns JG, 2004, SCIENCE, V303, P1023, DOI 10.1126/science.1089910; Koob GF, 2001, NEUROPSYCHOPHARMACOL, V24, P97, DOI 10.1016/S0893-133X(00)00195-0; Kraus MA, 1996, BRAIN RES, V724, P33, DOI 10.1016/0006-8993(96)00263-6; LEVINE JD, 1984, BRAIN RES, V304, P265, DOI 10.1016/0006-8993(84)90329-9; Liberzon I, 2002, P NATL ACAD SCI USA, V99, P7084, DOI 10.1073/pnas.102174799; Logan J, 1996, J CEREBR BLOOD F MET, V16, P834, DOI 10.1097/00004647-199609000-00008; LOPEZ JF, 1992, NEUROENDOCRINOLOGY, V56, P491, DOI 10.1159/000126266; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; Mayberg HS, 1999, AM J PSYCHIAT, V156, P675; Mayberg HS, 1997, NEUROREPORT, V8, P1057, DOI 10.1097/00001756-199703030-00048; MEUCCI E, 1989, EUR J PHARMACOL, V171, P167, DOI 10.1016/0014-2999(89)90105-2; MINOSHIMA S, 1993, J NUCL MED, V34, P322; Moles A, 2004, SCIENCE, V304, P1983, DOI 10.1126/science.1095943; Morris JS, 1998, BRAIN, V121, P47, DOI 10.1093/brain/121.1.47; Napier TC, 1999, ANN NY ACAD SCI, V877, P176, DOI 10.1111/j.1749-6632.1999.tb09268.x; Narendran R, 2004, SYNAPSE, V52, P188, DOI 10.1002/syn.20013; NEMEROFF CB, 1988, ARCH GEN PSYCHIAT, V45, P577; NEMEROFF CB, 1984, AM J PSYCHIAT, V141, P247; PFOHL B, 1985, BIOL PSYCHIAT, V20, P1055, DOI 10.1016/0006-3223(85)90004-6; Phan KL, 2002, NEUROIMAGE, V16, P331, DOI 10.1006/nimg.2002.1087; PLOTSKY PM, 1986, REGUL PEPTIDES, V16, P235, DOI 10.1016/0167-0115(86)90022-4; Price DD, 2000, SCIENCE, V288, P1769, DOI 10.1126/science.288.5472.1769; Quirarte GL, 1998, BRAIN RES, V808, P134, DOI 10.1016/S0006-8993(98)00795-1; RAADSHEER FC, 1995, AM J PSYCHIAT, V152, P1372; RAADSHEER FC, 1994, NEUROENDOCRINOLOGY, V60, P436, DOI 10.1159/000126778; RIBEIRO SCM, 1993, AM J PSYCHIAT, V150, P1618; ROY A, 1987, PSYCHIAT RES, V20, P229, DOI 10.1016/0165-1781(87)90083-7; ROY A, 1992, BIOL PSYCHIAT, V32, P812, DOI 10.1016/0006-3223(92)90084-D; Rubinstein M, 1996, P NATL ACAD SCI USA, V93, P3995, DOI 10.1073/pnas.93.9.3995; Schneider F, 2000, HUM BRAIN MAPP, V9, P226, DOI 10.1002/(SICI)1097-0193(200004)9:4<226::AID-HBM4>3.0.CO;2-K; Singer T, 2004, SCIENCE, V303, P1157, DOI 10.1126/science.1093535; Smith YR, 2006, J NEUROSCI, V26, P5777, DOI 10.1523/JNEUROSCI.5223-05.2006; Smith YR, 1998, J CLIN ENDOCR METAB, V83, P4498, DOI 10.1210/jc.83.12.4498; SPANAGEL R, 1992, P NATL ACAD SCI USA, V89, P2046, DOI 10.1073/pnas.89.6.2046; Steiner H, 1998, EXP BRAIN RES, V123, P60, DOI 10.1007/s002210050545; Unterwald EM, 2001, ANN NY ACAD SCI, V937, P74; WATKINS LR, 1982, SCIENCE, V216, P1185, DOI 10.1126/science.6281891; WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063; WORSLEY KJ, 1992, J CEREBR BLOOD F MET, V12, P900, DOI 10.1038/jcbfm.1992.127; Young EA, 2004, PSYCHONEUROENDOCRINO, V29, P1198, DOI 10.1016/j.psyneuen.2004.02.002; Zubieta JK, 1999, AM J PSYCHIAT, V156, P842, DOI 10.1176/ajp.156.6.842; Zubieta JK, 2003, ARCH GEN PSYCHIAT, V60, P1145, DOI 10.1001/archpsyc.60.11.1145; Zubieta JK, 2002, J NEUROSCI, V22, P5100, DOI 10.1523/JNEUROSCI.22-12-05100.2002; Zubieta JK, 2003, SCIENCE, V299, P1240, DOI 10.1126/science.1078546; Zubieta JK, 2001, SCIENCE, V293, P311, DOI 10.1126/science.1060952	72	178	182	1	22	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0003-990X	1538-3636		ARCH GEN PSYCHIAT	Arch. Gen. Psychiatry	NOV	2006	63	11					1199	1208		10.1001/archpsyc.63.11.1199			10	Psychiatry	Psychiatry	102HQ	WOS:000241802000005	17088500	Bronze			2020-06-30	J	Portenoy, RK; Taylor, D; Messina, J; Tremmel, L				Portenoy, Russell K.; Taylor, Donald; Messina, John; Tremmel, Lothar			A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer	CLINICAL JOURNAL OF PAIN			English	Article						fentanyl buccal tablet; rapid-onset opioid; breakthrough pain; cancer pain	DOSE-TITRATION; CITRATE; MULTICENTER; PREVALENCE; PERMEABILITY; TRIAL	Objectives: Cancer-related breakthrough pain (BTP) is typically managed with a short-acting oral opioid, taken as needed during a fixed-schedule opioid regimen. The conventional approach may not provide the onset of analgesia required for BTP for many patients, because the onset of analgesia with short-acting opioids lags behind the time course of the majority of episodes of BTP. The fentanyl buccal tablet (FBT) employs a novel delivery system that enhances the rate and extent of absorption of fentanyl through the buccal mucosa. This double-blind, randomized, placebo-controlled study evaluated the efficacy, safety, and tolerability of FBT in opioid-treated patients with cancer-related BTP. Methods: After an open-label titration (N = 123) to identify an effective FBT dose to treat BTP episodes, 77 patients were randomly assigned to 1 of 18 prespecified dose sequences of 10 tablets (7 FBT and 3 placebo). Pain intensity, pain relief (PR), and global performance of the medication were recorded at regular time intervals between 15 and 60 minutes. Pain intensity differences (PID), the summed PID (SPID), and summed total PR were calculated. The SPID at 30 minutes (SPID30) was the primary efficacy variable. Adverse events were reported. Results: Sixty-five percent (80/123) of patients were titrated to an effective dose. The mean (SE) SPID30 for FBT was 3.0 +/- 0.12 versus 1.8 +/- 0.18 for placebo (P < 0.0001). Measures of PR, PID, SPID, summed total PR, and patient ratings of global performance of medication significantly favored FBT over placebo at all time points. Adverse events were typical of opioid drugs. Poor oral tolerability was noted in 2 patients. Conclusions: FBT is efficacious and safe in the treatment of cancer-related BTP.	Beth Israel Med Ctr, Dept Pain Med & Palliat Care, New York, NY 10003 USA; Comprehens Pain Care PC, Marietta, GA USA; Cephalon Inc, Frazer, PA USA	Portenoy, RK (reprint author), Beth Israel Med Ctr, Dept Pain Med & Palliat Care, 1st Ave & 16th St, New York, NY 10003 USA.	rportenoy@chpnet.org					BENNETT D, 2005, [No title captured], V30, P296; BENNETT D, 2005, [No title captured], V30, P354; BRUERA E, 1995, J PAIN SYMPTOM MANAG, V10, P348, DOI 10.1016/0885-3924(95)00052-Z; Caraceni A, 2004, PALLIATIVE MED, V18, P177, DOI 10.1191/0269216304pm890oa; Christie JM, 1998, J CLIN ONCOL, V16, P3238, DOI 10.1200/JCO.1998.16.10.3238; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; DARWISH M, 2006, J PAIN S1, V7, P35; Durfee S, 2006, AM J DRUG DELIV, V4, P1, DOI DOI 10.2165/00137696-200604010-00001; Eichman JD, 1998, PHARM RES-DORDR, V15, P925, DOI 10.1023/A:1011936901638; Eichman JD, 1997, EUR J PHARM BIOPHARM, V44, P33, DOI 10.1016/S0939-6411(97)00099-4; Farrar JT, 1998, JNCI-J NATL CANCER I, V90, P611, DOI 10.1093/jnci/90.8.611; Farrar JT, 2003, J PAIN SYMPTOM MANAG, V25, P406, DOI 10.1016/S0885-3924(03)00162-3; Fine PG, 1998, J PAIN SYMPTOM MANAG, V16, P179, DOI 10.1016/S0885-3924(98)00045-1; Fortner BV, 2002, J PAIN, V3, P38, DOI 10.1054/jpai.2002.27136; Goudas LC, 2005, CANCER INVEST, V23, P182, DOI 10.1081/CNV-200050482; Hanks GW, 2004, PALLIATIVE MED, V18, P698, DOI 10.1191/0269216304pm966oa; Hwang SS, 2003, PAIN, V101, P55, DOI 10.1016/S0304-3959(02)00293-2; MCQUAY HJ, 1994, CANCER SURV, V21, P17; MERCADANTE S, 1992, PAIN, V50, P151, DOI 10.1016/0304-3959(92)90155-5; Mercadante S, 2002, CANCER, V94, P832, DOI 10.1002/cncr.10249; National Cancer Institute, 2019, COMM TERM CRIT ADV E; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Payne R, 2001, J PAIN SYMPTOM MANAG, V22, P575, DOI 10.1016/S0885-3924(01)00306-2; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, PAIN, V79, P303, DOI 10.1016/S0304-3959(98)00179-1; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Portenoy RK, 2006, J PAIN, V7, P583, DOI 10.1016/j.jpain.2006.02.003; Svendsen KB, 2005, EUR J PAIN, V9, P195, DOI 10.1016/j.ejpain.2004.06.001	28	152	160	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0749-8047			CLIN J PAIN	Clin. J. Pain	NOV-DEC	2006	22	9					805	811		10.1097/01.ajp.0000210932.27945.4a			7	Anesthesiology; Clinical Neurology	Anesthesiology; Neurosciences & Neurology	101XD	WOS:000241773700009	17057563				2020-06-30	J	Allen, RH; Kumar, D; Fitzmaurice, G; Lifford, KL; Goldberg, AB				Allen, Rebecca H.; Kumar, Divya; Fitzmaurice, Garrett; Lifford, Karen Loeb; Goldberg, Alisa B.			Pain management of first-trimester surgical abortion: effects of selection of local anesthesia with and without lorazepam or intravenous sedation	CONTRACEPTION			English	Article; Proceedings Paper	29th Annual Meeting of the National-Aborition-Federation	APR 16-19, 2005	Montreal, CANADA	Natl Aborit Federat		pain; induced abortion; conscious sedation; anxiolytics; paracervical block		Objective: This prospective observational study compared the effectiveness and acceptability of three commonly used regimens to reduce pain during first-trimester surgical abortion with local anesthesia. Method: Women undergoing suction curettage at less than 14 weeks gestation received preoperative ibuprofen and an intraoperative paracervical block. Participants then selected (1) no additional medication (local arm), (2) sublingual lorazepam (0.5 to 1 mg, approximately 20 min preoperatively) or (3) intravenous sedation with fentanyl and midazolam (doses from 50 to 125 mu g of fentanyl and 1-2 mg of midazolam). Our primary outcome was intraoperative pain as measured on an 11-pointverbal rating scale (0=no pain and 10=worst pain ever). Results: Three-hundred thirty women were enrolled, 105 chose local, 106 opt for lorazepam and 119 picked intravenous sedation. Mean pain scores were 6.2 for local, 6.8 for lorazepam and 5.7 for intravenous sedation. Increased preoperative anxiety, depression and expected pain and a lower volume of local anesthesia used (10 mL vs. 20 mL) were positive predictors of intraoperative pain. Using multivariable analyses to control for these confounders, plus gestational age, alcohol use and body mass index, intravenous sedation was associated with a 0.86 point lower pain score (p <.005), and the local and lorazepam groups were not significantly different. Compared with the referent group (local), participants who received lorazepam were significantly less satisfied with pain control (23.8% vs. 6% unsatisfied; OR = 1.93, 95% CI = 1.13 to 3.26). Conclusion: In women who self-selected their type of anesthesia, intravenous sedation using fentanyl and midazolam decreased pain with suction curettage under local anesthesia. Sublingual lorazepam as studied did not decrease pain compared with local anesthesia alone and was associated with more dissatisfaction with pain control. (c) 2006 Elsevier Inc. All rights reserved.	Brigham & Womens Hosp, Div Womens Hlth, Dept Obstet Gynecol & Reprod Biol, Boston, MA 02120 USA; Planned Parenthood League Massachusetts, Boston, MA 02215 USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Div Gen Med, Boston, MA 02115 USA	Allen, RH (reprint author), Brigham & Womens Hosp, Div Womens Hlth, Dept Obstet Gynecol & Reprod Biol, 1620 Tremont St,3rd Floor, Boston, MA 02120 USA.	rallen@partners.org					BELANGER E, 1989, PAIN, V36, P339, DOI 10.1016/0304-3959(89)90094-8; Borgatta L, 1997, J REPROD MED, V42, P287; Herndon Joy, 2002, MMWR Surveill Summ, V51, P1; Jensen MP, 1998, CLIN J PAIN, V14, P343, DOI 10.1097/00002508-199812000-00012; JENSEN MP, 1994, PAIN, V58, P387, DOI 10.1016/0304-3959(94)90133-3; Jones RK, 2002, PERSPECT SEX REPRO H, V34, P226, DOI 10.2307/3097821; Lichtenberg ES, 2001, CONTRACEPTION, V64, P345, DOI 10.1016/S0010-7824(01)00279-7; PAUL M, 1999, [No title captured]; PETERSON HB, 1981, AM J OBSTET GYNECOL, V141, P763, DOI 10.1016/0002-9378(81)90701-8; Rawling MJ, 1998, INT J GYNECOL OBSTET, V60, P293, DOI 10.1016/S0020-7292(97)00254-3; Rawling MJ, 2001, AM J OBSTET GYNECOL, V185, P103, DOI 10.1067/mob.2001.115860; SMITH GM, 1979, AM J OBSTET GYNECOL, V133, P489, DOI 10.1016/0002-9378(79)90282-5; Wiebe E, 2003, CONTRACEPTION, V67, P219, DOI 10.1016/S0010-7824(02)00516-4; WIEBE ER, 1992, AM J OBSTET GYNECOL, V167, P131, DOI 10.1016/S0002-9378(11)91645-7; WIEBE ER, 1995, INT J GYNECOL OBSTET, V50, P41, DOI 10.1016/0020-7292(95)02416-A; Wong CYG, 2002, HUM REPROD, V17, P1222, DOI 10.1093/humrep/17.5.1222	16	30	30	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0010-7824			CONTRACEPTION	Contraception	NOV	2006	74	5					407	413		10.1016/j.contraception.2006.06.002			7	Obstetrics & Gynecology	Obstetrics & Gynecology	099DI	WOS:000241572300009	17046383				2020-06-30	